PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bromberg, KD; Burgin, AB; Osheroff, N				Bromberg, KD; Burgin, AB; Osheroff, N			A two-drug model for etoposide action against human topoisomerase II alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE RELIGATION REACTION; MEDIATED DNA CLEAVAGE; ANTICANCER DRUGS; TARGETED DRUGS; SACCHAROMYCES-CEREVISIAE; GENOMIC BREAKPOINT; MECHANISM; ENZYME; BREAKAGE; STRAND	The widely used anticancer drug etoposide kills cells by increasing levels of topoisomerase II-mediated DNA breaks. While it is known that the drug acts by inhibiting the ability of topoisomerase II to ligate cleaved DNA molecules, the precise mechanism by which it accomplishes this action is not well understood. Because there are two scissile bonds per enzyme-mediated double-stranded DNA break, it has been assumed that there are two sites for etoposide in every cleavage complex. However, it is not known whether the action of etoposide at only one scissile bond is sufficient to stabilize a double-stranded DNA break or whether both drug sites nee to be occupied. An oligonucleotide system was utilized to address this important issue. Results of DNA cleavage and ligation assays support a two-drug model for the action of etoposide against human topoisomerase IIalpha. This model postulates that drug interactions at both scissile bonds are required in order to increase enzyme-mediated double-stranded DNA breaks. Etoposide actions at either of the two scissile bonds appear to be independent of one another, with each individual drug molecule stabilizing a strand-specific nick rather than a double-stranded DNA break. This finding suggests (at least in the presence of drug) that there is little or no communication between the two promoter active sites of topoisomerase II. The two-drug model has implications for cancer chemotherapy, the cellular processing of etoposide-stabilized enzyme-DNA cleavage complexes, and the catalytic mechanism of eukaryotic topoisomerase II.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA; deCODE Genet, BioStruct Grp, Bainbridge Isl, WA 98110 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Robinson Res Bldg, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944, R01GM058596] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33944, GM58596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Baguley BC, 1998, BBA-GENE STRUCT EXPR, V1400, P213, DOI 10.1016/S0167-4781(98)00137-7; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; Berger JM, 1998, BBA-GENE STRUCT EXPR, V1400, P3, DOI 10.1016/S0167-4781(98)00124-9; Bromberg KD, 2002, J BIOL CHEM, V277, P31201, DOI 10.1074/jbc.M204741200; Bromberg KD, 2001, BIOCHEMISTRY-US, V40, P8410, DOI 10.1021/bi010681q; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Capranico G, 1998, BBA-GENE STRUCT EXPR, V1400, P185, DOI 10.1016/S0167-4781(98)00135-3; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CORBETT AH, 1992, J BIOL CHEM, V267, P683; Felix C A, 1999, Oncologist, V4, P225; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; GOTO T, 1984, J BIOL CHEM, V259, P422; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kingma PS, 1999, BIOCHEMISTRY-US, V38, P3457, DOI 10.1021/bi982855i; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; LIU LF, 1983, J BIOL CHEM, V258, P5365; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; Liu QY, 1999, P NATL ACAD SCI USA, V96, P881, DOI 10.1073/pnas.96.3.881; LONG BH, 1986, CANCER RES, V46, P3809; LONG BH, 1985, CANCER RES, V45, P3106; Marians KJ, 1997, J BIOL CHEM, V272, P9401; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Raffini LJ, 2002, P NATL ACAD SCI USA, V99, P4568, DOI 10.1073/pnas.062066799; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; Ross JA, 1998, INT J CANCER, V78, P26; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; SANDER M, 1983, J BIOL CHEM, V258, P8421; Slater DJ, 2002, ONCOGENE, V21, P4706, DOI 10.1038/sj.onc.1205572; Tennyson RB, 1997, BIOCHEMISTRY-US, V36, P6107, DOI 10.1021/bi970152f; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; van Hille B, 1999, ANTI-CANCER DRUG, V10, P551, DOI 10.1097/00001813-199907000-00007; Walker JV, 2002, CANCER INVEST, V20, P570, DOI 10.1081/CNV-120002156; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WARING MJ, 1965, J MOL BIOL, V13, P269, DOI 10.1016/S0022-2836(65)80096-1; WASSERMAN RA, 1993, CANCER RES, V53, P3591; Wilstermann AM, 2001, J BIOL CHEM, V276, P17727, DOI 10.1074/jbc.M100197200; WILSTERMANN AM, 2002, CURR TOP MED CHEM, V3, P1349; WOZNIAK AJ, 1983, CANCER RES, V43, P120; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	62	116	118	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7406	7412		10.1074/jbc.M212056200	http://dx.doi.org/10.1074/jbc.M212056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12473657	hybrid			2022-12-25	WOS:000181195100100
J	Chang, SH; Low, PS				Chang, SH; Low, PS			Identification of a critical ankyrin-binding loop on the cytoplasmic domain of erythrocyte membrane band 3 by crystal structure analysis and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CA2+ RELEASE; ANION-EXCHANGER; CELL-ADHESION; 2 DISTINCT; PROTEIN; KIDNEY; SPECTRIN; PHOSPHORYLATION; LOCALIZATION; ASSOCIATION	The cytoplasmic domain of erythrocyte membrane band 3 (cdb3) serves as a center of membrane organization, interacting with such proteins as ankyrin, protein 4.1, protein 4.2, hemoglobin, several glycolytic enzymes, a tyrosine phosphatase, and a tyrosine kinase, p72(syk). The crystallographic structure of the cdb3 dimer has revealed that residues 175-185 assume a beta-hairpin loop similar to a putative ankyrin-binding motif at the cytoplasmic surface of the Na+/K+-ATPase. To test whether this hairpin loop constitutes an ankyrin-binding site on cdb3, we have deleted amino acids 175-185 and substituted the 11-residue loop with a Gly-Gly dipeptide that bridges the deletion without introducing strain into the structure. Although the deletion mutant undergoes the same native conformational changes exhibited by wild type cdb3 and binds other peripheral proteins normally, the mutant exhibits no affinity for ankyrin. This suggests that the exposed beta-hairpin turn indeed constitutes a major ankyrin-binding site on cdb3. Other biochemical studies suggest that ankyrin also docks at the NH2 terminus of band 3. Thus, antibodies to the NH2 terminus of cdb3 block ankyrin binding to the cdb3, and ankyrin binding to cdb3 prevents p72(syk) phosphorylation of cdb3 at its NH2 terminus (predominantly at Tyr-8). However, a truncation mutant of cdb3 lacking the NH2-terminal 50 residues displays the same binding affinity as wild type cdb3. These data thus suggest that the NH2 terminus of cdb3 is proximal to but not required for the cdb3-ankyrin interaction.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	plow@purdue.edu		Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024417, R37GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELL KC, 1981, J BIOL CHEM, V256, P1104; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; Chen JH, 1998, J BIOL CHEM, V273, P1038, DOI 10.1074/jbc.273.2.1038; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; Ding Y, 1996, J BIOL CHEM, V271, P22494, DOI 10.1074/jbc.271.37.22494; DING Y, 1994, J BIOL CHEM, V269, P32201; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARRISON ML, 1994, J BIOL CHEM, V269, P955; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KOOB R, 1988, EUR J CELL BIOL, V45, P230; LI ZP, 1993, J BIOL CHEM, V268, P11489; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1984, J BIOL CHEM, V259, P3070; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; TSAI LH, 1982, J BIOL CHEM, V157, P1438; Van Dort HM, 2001, J BIOL CHEM, V276, P46968, DOI 10.1074/jbc.M107855200; Van Dort HM, 1998, J BIOL CHEM, V273, P14819, DOI 10.1074/jbc.273.24.14819; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WANG CC, 1995, J BIOL CHEM, V270, P17892, DOI 10.1074/jbc.270.30.17892; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1061, P253, DOI 10.1016/0005-2736(91)90291-F; Zhang DC, 2000, BLOOD, V96, P2925; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681	43	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6879	6884		10.1074/jbc.M211137200	http://dx.doi.org/10.1074/jbc.M211137200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482869	hybrid			2022-12-25	WOS:000181195100033
J	Rajebhosale, M; Greenwood, S; Vidugiriene, J; Jeromin, A; Hilfiker, S				Rajebhosale, M; Greenwood, S; Vidugiriene, J; Jeromin, A; Hilfiker, S			Phosphatidylinositol 4-OH kinase is a downstream target of neuronal calcium sensor-1 in enhancing exocytosis in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; PHOSPHOLIPASE-C; PC12 CELLS; CA2+-BINDING PROTEIN; MEMBRANE-PROTEIN; BINDING-PROTEIN; CA2+ CHANNELS; FREQUENIN; SECRETION; FAMILY	Neuronal calcium sensor-1 (NCS-1), the mammalian orthologue of frequenin, belongs to a family of EF-handcontaining Ca2+ sensors. NCS-1/frequenin has been shown to enhance synaptic transmission in PC12 cells and Drosophila and Xenopus, respectively. However, the precise molecular mechanism for the enhancement of exocytosis is largely unknown. In PC12 cells, NCS-1 potentiated exocytosis evoked by ATP, an agonist to phospholipase C-linked receptors, but had no effect on depolarization-evoked release. NCS-1 also enhanced exocytosis triggered by ionomycin, a Ca2+ ionophore that bypasses K+ and Ca2+ channels. Overexpression of NCS-1 caused a shift in the dose-response curve of inhibition of ATP-evoked secretion using phenylarsine oxide, an inhibitor of phosphatidylinositol 4-OH kinase (P14K). Plasma membrane phosphatidylinositol 4,5bisphosphate pools were increased upon NCS-1 transfection as visualized using a phospholipase C-delta pleckstrin homology domain-green fluorescent protein construct. NCS-1-transfected cell extracts displayed increased phosphatidylinositol-4-phosphate biosynthesis, indicating an increase in P14K activity. Mutations in NCS-1 equivalent to those that abolish the interaction of recoverin, another EF-hand-containing Ca2+ sensor, with its downstream target rhodopsin kinase, lost their ability to enhance exocytosis. Taken together, the present data indicate that NCS-1 modulates the activity of P14K, leading to increased levels of phosphoinositides and concomitant enhancement of exocytosis.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Promega Corp, Res & Dev, Madison, WI 53711 USA	University of Manchester; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Promega Corporation	Hilfiker, S (corresponding author), Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England.	sabine.hilfiker@man.ac.uk	Hilfiker, Sabine N/L-6369-2014	Hilfiker, Sabine N/0000-0002-5167-7682				Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Balla A, 2002, J BIOL CHEM, V277, P20041, DOI 10.1074/jbc.M111807200; BARRY VA, 1994, J CELL SCI, V107, P451; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgoyne RD, 2001, BIOCHEM J, V353, P1; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chen XL, 2001, J PHYSIOL-LONDON, V532, P649, DOI 10.1111/j.1469-7793.2001.0649e.x; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Cremona O, 2001, J CELL SCI, V114, P1041; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Gomez M, 2001, NEURON, V30, P241, DOI 10.1016/S0896-6273(01)00276-8; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Iacovelli L, 1999, FASEB J, V13, P1; Khvotchev M, 1998, J BIOL CHEM, V273, P21451, DOI 10.1074/jbc.273.34.21451; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Koizumi S, 2002, J BIOL CHEM, V277, P30315, DOI 10.1074/jbc.M201132200; Loyet KM, 1998, J BIOL CHEM, V273, P8337, DOI 10.1074/jbc.273.14.8337; Martin TFJ, 1997, BIOCHEM SOC T, V25, P1137, DOI 10.1042/bst0251137; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Micheva KD, 2001, J CELL BIOL, V154, P355, DOI 10.1083/jcb.200102098; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Osborne SL, 2001, NEURON, V32, P9, DOI 10.1016/S0896-6273(01)00455-X; Pan CY, 2002, J NEUROSCI, V22, P2427, DOI 10.1523/JNEUROSCI.22-07-02427.2002; PAPINI E, 1995, J BIOL CHEM, V270, P1332, DOI 10.1074/jbc.270.3.1332; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; POULAIN C, 1994, PFLUG ARCH EUR J PHY, V427, P71, DOI 10.1007/BF00585944; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tachibanaki S, 2000, J BIOL CHEM, V275, P3313, DOI 10.1074/jbc.275.5.3313; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weiss JL, 2001, J BIOL CHEM, V276, P44804, DOI 10.1074/jbc.M103262200; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Werle MJ, 2000, NEUROSCI LETT, V284, P33, DOI 10.1016/S0304-3940(00)01004-1; WICK PF, 1993, J BIOL CHEM, V268, P10983; Wiedemann C, 1998, J NEUROSCI, V18, P5594; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zimmerberg J, 1999, ADV DRUG DELIVER REV, V38, P197, DOI 10.1016/S0169-409X(99)00029-0; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	63	57	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6075	6084		10.1074/jbc.M204702200	http://dx.doi.org/10.1074/jbc.M204702200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471042	hybrid			2022-12-25	WOS:000181129400074
J	Tohgo, A; Choy, EW; Gesty-Palmer, D; Pierce, KL; Laporte, S; Oakley, RH; Caron, MG; Lefkowitz, RJ; Luttrell, LM				Tohgo, A; Choy, EW; Gesty-Palmer, D; Pierce, KL; Laporte, S; Oakley, RH; Caron, MG; Lefkowitz, RJ; Luttrell, LM			The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ACTIVATION; BETA(2)-ADRENERGIC RECEPTOR; SUBSTANCE-P; MAP KINASE; B-RAF; SIGNAL; TRANSACTIVATION; BETA-ARRESTIN1; ENDOCYTOSIS; DESENSITIZATION	By binding to agonist-activated G protein-coupled receptors (GPCRs), beta-arrestins mediate homologous receptor desensitization and endocytosis via clathrin-coated pits. Recent data suggest that beta-arrestins also contribute to GPCR signaling by acting as scaffolds for components of the ERK mitogen-activated protein kinase cascade. Because of these dual functions, we hypothesized that the stability of the receptor-beta-arrestin interaction might affect the mechanism and functional consequences of GPCR-stimulated ERK activation. In transfected COS-7 cells, we found that angiotensin AT1a and vasopressin V2 receptors, which form stable receptor-beta-arrestin complexes, activated a beta-arrestin-bound pool of ERK2 more efficiently than alpha1b and 132 adrenergic receptors, which form transient receptor-beta-arrestin complexes. We next studied chimeric receptors in which the pattern of beta-arrestin binding was reversed by exchanging the C-terminal tails of the beta2 and V2 receptors. The ability of the V2beta2 and beta2V2 chimeras to activate beta-arrestin-bound ERK2 corresponded to the pattern of beta-arrestin binding, suggesting that the stability of the receptor-beta-arrestin complex determined the mechanism of ERK2 activation. Analysis of covalently cross-linked detergent lysates and cellular fractionation revealed that wild type V2 receptors generated a larger pool of cytosolic phospho-ERK1/2 and less nuclear phospho-ERK1/2 than the chimeric V2beta2 receptor, consistent with the cytosolic retention of beta-arrestin-bound ERK. In stably transfected HEK-293 cells, the V2beta2 receptor increased ERK1/2-mediated, Elk-l-driven transcription of a luciferase reporter to a greater extent than the wild type V2 receptor. Furthermore, the V2beta2, but not the V2 receptor, was capable of eliciting a mitogenic response. These data suggest that the C-terminal tail of a GPCR, by determining the stability of the receptor-beta-arrestin complex, controls the extent of beta-arrestin-bound ERK activation, and influences both the subcellular localization of activated ERK and the physiologic consequences of ERK activation.	Durham Vet Affairs Med Ctr, GRECC, Durham, NC 27705 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Luttrell, LM (corresponding author), Durham Vet Affairs Med Ctr, GRECC, N3019,5058 Fulton St, Durham, NC 27705 USA.	luttrell@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021; Laporte, Stephane A/F-3282-2012; Laporte, Stephane/ABC-4228-2021	Laporte, Stephane/0000-0002-0633-543X; Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK055524, R01DK055524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK55524] Funding Source: Medline; NINDS NIH HHS [NS19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	39	283	289	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6258	6267		10.1074/jbc.M212231200	http://dx.doi.org/10.1074/jbc.M212231200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12473660	hybrid			2022-12-25	WOS:000181129400097
J	den Engelsman, J; Keijsers, V; de Jong, WW; Boelens, WC				den Engelsman, J; Keijsers, V; de Jong, WW; Boelens, WC			The small heat-shock protein alpha B-crystallin promotes FBX4-dependent ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEINS; SIGNAL-TRANSDUCTION; MISSENSE MUTATION; BODY FORMATION; PHOSPHORYLATION; DISEASE; PATHWAY; SYSTEM; STRESS; CELLS	alphaB-Crystallin is a small heat-shock protein in which three serine residues (positions 19, 45, and 59) can be phosphorylated under various conditions. We describe here the interaction of alphaB-crystallin with FBX4, an F-box-containing protein that is a component of the ubiquitin-protein isopeptide ligase SCF (SKP1/CUL1/F-box). The interaction with FBX4 was enhanced by mimicking phosphorylation of alphaB-crystallin at both Ser-19 and Ser-45 (S19D/S45D), but not at other combinations. Ser-19 and Ser-45 are preferentially phosphorylated during the mitotic phase of the cell cycle. Also alphaB-crystallin R120G, a mutant found to co-segregate with a desmin-related myopathy, displayed increased interaction with FBX4. Both alphaB-crystallin S19D/S45D and R120G specifically translocated FBX4 to the detergent-insoluble fraction and stimulated the ubiquitination of one or a few yet unknown proteins. These findings implicate the involvement of alphaB-crystallin in the ubiquitin/ proteasome pathway in a phosphorylation- and cell cycle-dependent manner and may provide new insights into the alphaB-crystallin-induced aggregation in desmin-related myopathy.	Univ Nijmegen, Dept Biochem, NCMLS, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Boelens, WC (corresponding author), Univ Nijmegen, Dept Biochem, NCMLS, POB 9101,161, NL-6500 HB Nijmegen, Netherlands.		Boelens, Wilbert/D-8877-2012					AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Boelens WC, 2001, BBA-PROTEIN STRUCT M, V1544, P311, DOI 10.1016/S0167-4838(00)00243-0; Brachmann CB, 1997, J VIROL, V71, P812, DOI 10.1128/JVI.71.1.812-817.1997; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chiaur DS, 2000, CYTOGENET CELL GENET, V88, P255, DOI 10.1159/000015532; Chung KKK, 2001, TRENDS NEUROSCI, V24, pS7, DOI 10.1016/S0166-2236(00)01998-6; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Ciechanover A, 2001, NAT MED, V7, P1108, DOI 10.1038/nm1001-1108; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Djabali K, 1997, J CELL SCI, V110, P2759; Eaton P, 2001, J MOL CELL CARDIOL, V33, P1659, DOI 10.1006/jmcc.2001.1418; Finley D, 2002, NAT CELL BIOL, V4, pE121, DOI 10.1038/ncb0502-e121; Head MW, 2000, NEUROPATH APPL NEURO, V26, P304, DOI 10.1046/j.1365-2990.2000.00269.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Inaguma Y, 2001, EUR J CELL BIOL, V80, P741, DOI 10.1078/0171-9335-00203; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KAPPE G, 2003, IN PRESS CELL STRESS; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; Kato K, 2002, FASEB J, V16, P1432, DOI 10.1096/fj.02-0129fje; Kato K, 2001, J NEUROCHEM, V76, P730, DOI 10.1046/j.1471-4159.2001.00038.x; Kipreos ET, 2000, GENOME BIOL, V1; Layfield R, 2001, PROTEOMICS, V1, P773, DOI 10.1002/1615-9861(200106)1:6<773::AID-PROT773>3.0.CO;2-0; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Nakashima A, 2002, J NEUROCHEM, V82, P202, DOI 10.1046/j.1471-4159.2002.00921.x; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Perng MD, 1999, J CELL SCI, V112, P2099; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; TAMAOKA A, 1995, J NEUROL SCI, V129, P192, DOI 10.1016/0022-510X(94)00275-S; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Verschuure P, 2002, J MOL CELL CARDIOL, V34, P117, DOI 10.1006/jmcc.2001.1493; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4	43	109	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4699	4704		10.1074/jbc.M211403200	http://dx.doi.org/10.1074/jbc.M211403200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468532	hybrid			2022-12-25	WOS:000180968900045
J	Galetic, I; Maira, SM; Andjelkovic, M; Hemmings, BA				Galetic, I; Maira, SM; Andjelkovic, M; Hemmings, BA			Negative regulation of ERK and Elk by protein kinase B modulates c-fos transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DUAL PHOSPHORYLATION; SIGNALING PATHWAY; AKT; ACTIVATION; RAS; APOPTOSIS; UBIQUITINATION; AKT/PKB; TARGET	In this study, we have identified novel regulatory steps involved in the cross-talk between protein kinase B (PKB) and MAPK signaling pathways. We found that PKB down-regulates the Ras-Raf-MEK-ERK pathway by reducing the activity of ERK, which leads to inactivation of the transcription factor Elk1. In addition, PKB is able to reduce protein levels of Elk1. Both events lead to suppression of serum response element (SRE)-dependent transcription and a consequent decrease in the transcription of SRE-containing genes, such as c-fos. Because activation of the Ras/MAPK cascade is reported to increase c-fos transcription before apoptosis, our results are consistent with a specific role for PKB in promoting cell survival. Decrease in c-Fos protein levels in glioblastoma cells with constitutively active PKB provides further support for our observations. Therefore, our findings delineate a novel mechanism regulating immediate-early transcription, which may be involved in the initial steps in PKB-induced oncogenic transformation.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.							Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; Guan KL, 2000, J BIOL CHEM, V275, P27354; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kops GJPL, 2000, J ANAT, V197, P571, DOI 10.1046/j.1469-7580.2000.19740571.x; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; RAO VN, 1992, ONCOGENE, V7, P2335; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	46	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4416	4423		10.1074/jbc.M210578200	http://dx.doi.org/10.1074/jbc.M210578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468535	hybrid			2022-12-25	WOS:000180968900009
J	Ni, CY; Yuan, HP; Carpenter, G				Ni, CY; Yuan, HP; Carpenter, G			Role of the ErbB-4 carboxyl terminus in gamma-secretase cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR RECEPTOR; NUCLEAR-LOCALIZATION; ALZHEIMERS-DISEASE; PRESENILIN-1; NOTCH; SYNAPSES; KINASE	The ErbB-4 receptor tyrosine kinase has a PDZ domain recognition motif at its carboxyl terminus. The first step in ErbB-4 proteolytic processing is a metalloprotease-dependent cleavage of the receptor ectodomain, which is not influenced by deletion of this motif. Metalloprotease cleavage of ErbB-4 produces a membrane-associated 80-kDa fragment that is a substrate for subsequent gamma-secretase cleavage, which releases the cytoplasmic domain from the membrane and allows nuclear translocation of this fragment. Deletion of the PDZ domain recognition motif does abrogate the gamma-secretase cleavage of ErbB-4. The wild-type 80-kDa ErbB-4 fragment forms an association complex with presenilin, thought to be the catalytic moiety of gamma-secretase activity. However, this association is significantly impaired by loss of the PDZ domain recognition motif from ErbB-4. Deletion of this ErbB-4 motif prevents the nuclear localization of the ErbB-4 cytoplasmic domain. Data also show that the basal cleavage of wild-type ErbB-4 by this proteolytic system can produce a sufficient level of ErbB-4 processing to negatively influence cell growth and that loss of the PDZ domain recognition motif abrogates this response.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.				NCI NIH HHS [CA97456, CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097456, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baulida J, 1996, J BIOL CHEM, V271, P5251; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xu XM, 1999, J BIOL CHEM, V274, P32543, DOI 10.1074/jbc.274.46.32543; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	24	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4561	4565		10.1074/jbc.M210504200	http://dx.doi.org/10.1074/jbc.M210504200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12454007	hybrid			2022-12-25	WOS:000180968900028
J	Shirasawa, T; Izumizaki, M; Suzuki, Y; Ishihara, A; Shimizu, T; Tamaki, M; Huang, F; Koizumi, K; Iwase, M; Sakai, H; Tsuchida, E; Ueshima, K; Inoue, H; Koseki, H; Senda, T; Kuriyama, T; Homma, I				Shirasawa, T; Izumizaki, M; Suzuki, Y; Ishihara, A; Shimizu, T; Tamaki, M; Huang, F; Koizumi, K; Iwase, M; Sakai, H; Tsuchida, E; Ueshima, K; Inoue, H; Koseki, H; Senda, T; Kuriyama, T; Homma, I			Oxygen affinity of hemoglobin regulates O-2 consumption, metabolism, and physical activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE-DEHYDROGENASE ACTIVITY; TIBIALIS ANTERIOR; VARIANTS; BETA-108; FIBERS; MUSCLE; SPERM; SIZE; MICE	The oxygen affinity of hemoglobin is critical for gas exchange in the lung and O-2 delivery in peripheral tissues. In the present study, we generated model mice that carry low affinity hemoglobin with the Titusville mutation in the alpha-globin gene or Presbyterian mutation in the beta-globin gene. The mutant mice showed increased O-2 consumption and CO2 production in tissue metabolism, suggesting enhanced O-2 delivery by mutant Hbs. The histology of muscle showed a phenotypical conversion from a fast glycolytic to fast oxidative type. Surprisingly, mutant mice spontaneously ran twice as far as controls despite mild anemia. The oxygen affinity of hemoglobin may control the basal level of erythropoiesis, tissue O-2 consumption, physical activity, and behavior in mice.	Tokyo Metropolitan Inst Gerontol, Dept Mol Gerontol, Itabahi Ku, Tokyo 1730015, Japan; Showa Univ, Sch Med, Dept Physiol, Tokyo 1428555, Japan; Chiba Univ, Grad Sch Med, Dept Chest Med, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Mol Embryol, Chiba 2608670, Japan; Kyoto Univ, Fac Integrated Human Studies, Lab Neurochem, Kyoto 6068501, Japan; Waseda Univ, Dept Polymer Chem, Shinjuku Ku, Tokyo 1698555, Japan; Iwate Med Univ, Dept Internal Med, Morioka, Iwate 0208505, Japan; AIST, Japan Biol Informat Res Ctr, Struct Genom Grp, Koto Ku, Tokyo 1350064, Japan	Tokyo Metropolitan Institute of Gerontology; Showa University; Chiba University; Chiba University; Kyoto University; Waseda University; Iwate Medical University; National Institute of Advanced Industrial Science & Technology (AIST)	Shirasawa, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Mol Gerontol, Itabahi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan.	sirasawa@tmig.or.jp	Koseki, Haruhiko/I-3825-2014; Sakai, Hiromi/J-2529-2019	Koseki, Haruhiko/0000-0001-8424-5854; Sakai, Hiromi/0000-0002-0681-3032; Senda, Toshiya/0000-0002-5153-928X				ATHA DH, 1979, J BIOL CHEM, V254, P2390; BONAVENTURA J, 1968, J BIOL CHEM, V243, P980; Chui DHK, 1998, BLOOD, V91, P2643; FAIRBANKS VF, 1971, MAYO CLIN PROC, V46, P721; Giordano PC, 1996, ANN HEMATOL, V73, P183, DOI 10.1007/s002770050225; GRACE RJ, 1992, CLIN LAB HAEMATOL, V14, P195; HARANO K, 1984, HEMOGLOBIN, V8, P407, DOI 10.3109/03630268408991725; Hirofuji C, 2000, ACTA HISTOCHEM CYTOC, V33, P295, DOI 10.1267/ahc.33.295; ISHIHARA A, 1995, NEUROSCIENCE, V68, P813, DOI 10.1016/0306-4522(95)00165-F; Ishihara A, 1998, J APPL PHYSIOL, V84, P2183, DOI 10.1152/jappl.1998.84.6.2183; Izumizaki M, 2000, J APPL PHYSIOL, V89, P770, DOI 10.1152/jappl.2000.89.2.770; JONES RT, 1967, J CLIN INVEST, V46, P1840, DOI 10.1172/JCI105674; KELMAN GR, 1966, J APPL PHYSIOL, V21, P1484, DOI 10.1152/jappl.1966.21.5.1484; KOHNE E, 1979, HEMOGLOBIN, V3, P365, DOI 10.3109/03630267908997542; KOMIYAMA NH, 1995, NATURE, V373, P244, DOI 10.1038/373244a0; Lahiri S, 1995, BIOL SIGNAL, V4, P257; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MOOPENN WF, 1978, FEBS LETT, V92, P53, DOI 10.1016/0014-5793(78)80720-0; NAGY ZP, 1993, HUM REPROD, V8, P2180, DOI 10.1093/oxfordjournals.humrep.a138000; ODONNELL JK, 1994, J BIOL CHEM, V269, P27692; PERUTZ MF, 1978, SCI AM, V239, P92, DOI 10.1038/scientificamerican1278-92; RIGGS A, 1973, P NATL ACAD SCI USA, V70, P1718, DOI 10.1073/pnas.70.6.1718; SCHNEIDER RG, 1975, BIOCHIM BIOPHYS ACTA, V400, P365, DOI 10.1016/0005-2795(75)90192-0; SCHNEIDER RG, 1976, BLOOD, V48, P629; Shimizu T, 1997, BIOCHEMISTRY-US, V36, P12071, DOI 10.1021/bi970922n; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Suzuki Y, 2002, BIOCHEM BIOPH RES CO, V295, P869, DOI 10.1016/S0006-291X(02)00752-0; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; VILLEGAS A, 1986, ACTA HAEMATOL-BASEL, V76, P161, DOI 10.1159/000206043; Weiss RG, 1999, J CLIN INVEST, V103, P739, DOI 10.1172/JCI6030	31	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5035	5043		10.1074/jbc.M211110200	http://dx.doi.org/10.1074/jbc.M211110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458204	hybrid			2022-12-25	WOS:000180968900089
J	Tworkowski, KA; Salghetti, SE; Tansey, WP				Tworkowski, KA; Salghetti, SE; Tansey, WP			Stable and unstable pools of Myc protein exist in human cells	ONCOGENE			English	Article						Myc; Max; ubiquitin-mediated proteolysis	UBIQUITIN-MEDIATED PROTEOLYSIS; C-MYC; IN-VIVO; BURKITTS-LYMPHOMA; CDK INHIBITOR; DNA-BINDING; DEGRADATION; PATHWAY; DOMAIN; TRANSCRIPTION	The oncoprotein transcription factor Myc plays a crucial role in the control of cell growth and proliferation. Consistent with its potent growth-promoting properties, cells have evolved a number of mechanisms to limit the activity and accumulation of the Myc protein. One of the most striking of these mechanisms is ubiquitin (Ub)-mediated proteolysis, which typically destroys Myc within minutes of its synthesis. Here we show that, despite the extreme instability of the Myc protein, cells contain a pool of Myc that is metabolically stable. Entry of Myc into the stable pool is signaled by an element within the carboxy-terminus of the protein, and is a cell-specific process that is regulated during mitosis and by interaction with Max. These data demonstrate that even for a rapidly turned-over protein such as Myc metabolically stable and unstable forms of a protein can co-exist in cells, and suggest that the rate of destruction of Myc molecules is linked to their specific functions.	SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA; Cold Spring Harbor Lab, New York, NY 11724 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory	Tansey, WP (corresponding author), SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P30CA045508, P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008468] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106, CA45508] Funding Source: Medline; NIGMS NIH HHS [1T32-GM08468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Hancock R, 2000, CHROMOSOMA, V109, P219, DOI 10.1007/s004120000077; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Niklinski J, 2000, MOL CELL BIOL, V20, P5276, DOI 10.1128/MCB.20.14.5276-5284.2000; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; Rudolph C, 1999, ANAL BIOCHEM, V269, P66, DOI 10.1006/abio.1999.3095; Sacco-Bubulya P, 2002, J CELL BIOL, V156, P425, DOI 10.1083/jcb.200107017; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	25	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8515	8520		10.1038/sj.onc.1205976	http://dx.doi.org/10.1038/sj.onc.1205976			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466972				2022-12-25	WOS:000179480100015
J	Kraus, J; Borner, C; Hollt, V				Kraus, J; Borner, C; Hollt, V			Distinct palindromic extensions of the 5 '-TTC...GAA-3 ' motif allow STAT6 binding in vivo	FASEB JOURNAL			English	Article						transcription regulation; cytokine; cytokine response element; interleukin-4	INTERLEUKIN-4-INDUCED TRANSCRIPTION FACTOR; GERMLINE EPSILON-PROMOTER; NF-KAPPA-B; GENE-EXPRESSION; DNA-BINDING; FACTOR DECOY; SITES; IL-4; ACTIVATION; ELEMENTS	STATs (signal transducers and activators of transcription) are transcription factors downstream of cytokine and growth factor signals. All of the seven different STATs bind to regulatory promoter elements with the common core motif 5'-TTC(N)(2-4)GAA-3'. A key question is how the different STAT factors recognize "their" response elements, that is, what distinguishes for example STAT1 from STAT6 binding sites. In vivo, binding of the different STATs to DNA elements is highly specific and disruption of the genes for the different STAT factors is accompanied with distinct, non-overlaping phenotypical effects. As a first step towards discrimination of target sequences for the various STATs, we determined requirements for binding sites for STAT6. In functional assays, six sequences were identified. These have palindromic extensions of the core motif in common (underlined): 5'-TTTCNNNGAAA-3', 5'-CTTCNNNGAAG-3', 5'-TTTCNNNNGAAA-3', 5'-CTTCNNNNGAAG-3', 5'-TTCCNNGGAA3' and 5'-TTCANNTGAA-3'. Different approaches and mutational analysis demonstrated the functionality of these sequences and high specific binding to STAT6. (I) These elements mediate transcriptional induction by interleukin-(IL)-4, IL-13, IL-15, and platelet-derived growth factor. (II) When used as "decoy" oligonucleotides, they bind STAT6 and disrupt its function in vivo, attenuating (a) STAT6/IL-4-mediated reporter gene transcription and (b) STAT6/IL-4-mediated induction of mu-opioid receptor mRNA of Raji cells.	Univ Magdeburg, Inst Pharmacol & Toxicol, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Kraus, J (corresponding author), Univ Magdeburg, Inst Pharmacol & Toxicol, Dept Pharmacol & Toxicol, 44 Leipzigerstr, D-39120 Magdeburg, Germany.	juergen.kraus@medizin.uni-magdeburg.de						Bianchi M, 1999, EUR J NEUROSCI, V11, P1501, DOI 10.1046/j.1460-9568.1999.00563.x; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Conrad DJ, 2000, AM J RESP CELL MOL, V22, P226, DOI 10.1165/ajrcmb.22.2.3786; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; KANG C, 1993, BIOTECHNIQUES, V15, P659; Khew-Goodall Y, 1999, ARTERIOSCL THROM VAS, V19, P1421, DOI 10.1161/01.ATV.19.6.1421; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; Kraus J, 2001, J BIOL CHEM, V276, P43901, DOI 10.1074/jbc.M107543200; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Matsukura S, 1999, J IMMUNOL, V163, P6876; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Morishita R, 1998, CIRC RES, V82, P1023, DOI 10.1161/01.RES.82.10.1023; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Ohmori Y, 1996, J IMMUNOL, V157, P2058; Richards ML, 1997, J IMMUNOL, V158, P263; Schaffer A, 1999, J IMMUNOL, V162, P5327; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x	27	39	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					304	+		10.1096/fj.02-0482fje	http://dx.doi.org/10.1096/fj.02-0482fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475891				2022-12-25	WOS:000180574300024
J	Stead, E; White, J; Faast, R; Conn, S; Goldstone, S; Rathjen, J; Dhingra, U; Rathjen, P; Walker, D; Dalton, S				Stead, E; White, J; Faast, R; Conn, S; Goldstone, S; Rathjen, J; Dhingra, U; Rathjen, P; Walker, D; Dalton, S			Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities	ONCOGENE			English	Article						cell cycle; pluripotent; stem cell	EMBRYONIC STEM-CELLS; DIFFERENTIATION INHIBITING ACTIVITY; RETINOIC ACID; MOUSE EMBRYOS; BREAST-CANCER; ES CELLS; RETINOBLASTOMA PROTEIN; REGULATED EXPRESSION; GERM-CELLS; IN-VITRO	Pluripotent cells of embryonic origin proliferate at unusually rapid rates and have a characteristic cell cycle structure with truncated gap phases. To define the molecular basis for this we have characterized the cell cycle control of murine embryonic stem cells and early primitive ectoderm-like cells. These cells display precocious Cdk2, cyclin A and cyclin E kinase activities that are conspicuously cell cycle independent. Suppression of Cdk2 activity significantly decreased cycling times of pluripotent cells, indicating it to be rate-limiting for rapid cell division, although this had no impact on cell cycle structure and the establishment of extended gap phases. Cdc2-cyclin B was the only Cdk activity that was identified to be cell cycle regulated in pluripotent cells. Cell cycle regulation of cyclin B levels and Y-15 regulation of Cdc2 contribute to the temporal changes in Cdc2-cyclin B activity. E2F target genes are constitutively active throughout the cell cycle, reflecting the low activity of pocket proteins such as p107 and pRb and constitutive activity of pRb-kinases. These results show that rapid cell division cycles in primitive cells of embryonic origin are driven by extreme levels of Cdk activity that lack normal cell cycle periodicity.	Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia; Univ Adelaide, BresaGen Luminis Cell Therapy Program, Adelaide, SA 5005, Australia; Hoffmann La Roche, Nutley, NJ 07110 USA	University of Adelaide; University of Adelaide; University of Adelaide; Roche Holding	Dalton, S (corresponding author), Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia.	Stephen.Dalton@adelaide.edu.au	Conn, Simon/G-1191-2012	Conn, Simon/0000-0002-1376-4515; Wright, Josephine/0000-0003-4588-8827				BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHISHOLM JC, 1985, J EMBRYOL EXP MORPH, V86, P311; DHINGRA UH, 1998, Patent No. 5811420; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GARDNER RL, 1988, J CELL SCI, P11; GARDNER RL, 1979, J EMBRYOL EXP MORPH, V52, P141; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Harwell RM, 2000, CANCER RES, V60, P481; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HOGAN B, 1989, MANIPULATING MOUSE E; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KRANENBURG O, 1995, ONCOGENE, V10, P87; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lake JA, 2000, J CELL SCI, V113, P555; MACAULEY A, 1993, DEVELOPMENT, V117, P873; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Mumberg D, 1996, ONCOGENE, V13, P2493; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; MUMMERY CL, 1987, CELL DIFFER DEV, V20, P153, DOI 10.1016/0045-6039(87)90429-5; MURRAY A, 1993, CELL CYCLE; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; PEDERSEN RA, 1994, REPROD FERT DEVELOP, V6, P543, DOI 10.1071/RD9940543; Pelton TA, 1998, REPROD FERT DEVELOP, V10, P535, DOI 10.1071/RD98084; POWER MA, 1993, ANAT EMBRYOL, V187, P493; Rathjen J, 1999, J CELL SCI, V112, P601; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Smith C.S., 1999, Biological Invasions, V1, P89, DOI 10.1023/A:1010091918466; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SOLTER D, 1971, EXP CELL RES, V64, P331, DOI 10.1016/0014-4827(71)90084-X; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sweeney C, 1996, DEVELOPMENT, V122, P53; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WIMMEL A, 1994, ONCOGENE, V9, P995; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yarden A, 1996, DEV DYNAM, V206, P1	75	286	295	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8320	8333		10.1038/sj.onc.1206015	http://dx.doi.org/10.1038/sj.onc.1206015			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447695				2022-12-25	WOS:000179323900010
J	Iannaccone, P; Morley, S; Skimina, T; Mullins, J; Landini, G				Iannaccone, P; Morley, S; Skimina, T; Mullins, J; Landini, G			Cord-like mosaic patches in the adrenal cortex are fractal: Implications for growth and development	FASEB JOURNAL			English	Article						organogenesis; chimeras; mosaic pattern; adrenal cortex; fractals	EXCHANGE FACTOR; EXPRESSION; GEOMETRY; LIVER; MIGRATION; PATTERNS; BUD5	Organogenesis proceeds rapidly and faithfully during fetal development. The process includes generation of parenchyma, followed by organization into functional tissues. The method by which the growth of organ parenchyma is regulated is not known, but insight into this regulation has been obtained by studying mosaic tissues of experimental chimeras and transgenic mosaics. The patterns revealed by this procedure offer an indication of how the parenchyma was generated. In the liver, the pattern appears as islands of one cell type in a sea of the other cell type, while in the adrenal cortex the pattern is one of alternating cords of one cell type adjacent to the other cell type. We have established previously that mosaic patches in the liver are fractal. The fractal dimensions of patches in the liver are consistent with an iterative, recursive growth model with simple stereotypical division rules. Here we report that the patches in mosaic adrenal cortex of the mouse and rat are also fractal and that the fractal dimension of the surface of the patches is lower than that in the liver. Fetal development and fractal dimensions of adrenal cortical mosaic patches are consistent with an algorithmic cell division model in which parenchymal growth is constrained to edges of growth centers forcing cord structures to form. Fractal analysis of the geometry of mosaic patches in tissues of experimental chimeras is helpful in constructing hypotheses of organ growth.	Northwestern Univ, Sch Med, Dept Pediat, Childrens Mem Inst Educ & Res, Evanston, IL 60201 USA; Univ Edinburgh, Royal Infirm NHS Trust, Dept Reprod & Dev Sci, Clin Biochem Sect, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Sch Med, Mol Physiol Grp, Edinburgh, Midlothian, Scotland; Univ Birmingham, Sch Dent, Oral Pathol Unit, Birmingham, W Midlands, England	Northwestern University; University of Edinburgh; University of Edinburgh; University of Birmingham	Iannaccone, P (corresponding author), Northwestern Univ, Sch Med, Dept Pediat, Childrens Mem Inst Educ & Res, 2300 Childrens Plaza,No 204, Evanston, IL 60201 USA.	pmi@nwu.edu	Morley, Steve/AAY-9985-2020	Landini, Gabriel/0000-0002-9689-0989; Morley, Steven/0000-0002-7355-3349				Bass WT, 1998, HISTOCHEM J, V30, P657, DOI 10.1023/A:1003597010707; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; IANNACCONE PM, 1987, DEVELOPMENT, V99, P187; IANNACCONE PM, 1987, J EXP ZOOL, V243, P217, DOI 10.1002/jez.1402430207; IANNACCONE PM, 1990, FASEB J, V4, P1508, DOI 10.1096/fasebj.4.5.2307328; KHOKHA MK, 1994, DEV BIOL, V165, P545, DOI 10.1006/dbio.1994.1274; Landini G, 2000, FASEB J, V14, P823, DOI 10.1096/fasebj.14.5.823; MANDELBROT B, 1967, SCIENCE, V156, P636, DOI 10.1126/science.156.3775.636; Marston AL, 2001, CURR BIOL, V11, P803, DOI 10.1016/S0960-9822(01)00230-5; MICHAELS L, 1991, AM J ANAT, V191, P280, DOI 10.1002/aja.1001910307; Mitani F, 1999, ENDOCRINOLOGY, V140, P3342, DOI 10.1210/en.140.7.3342; Mitani F, 1998, ENDOCR RES, V24, P983, DOI 10.3109/07435809809032721; Morley SD, 1996, ENDOCR RES, V22, P631, DOI 10.1080/07435809609043757; Morley SD, 1996, MOL ENDOCRINOL, V10, P585, DOI 10.1210/me.10.5.585; NG YK, 1992, DEV BIOL, V151, P419, DOI 10.1016/0012-1606(92)90182-G; WEINBERG WC, 1985, SCIENCE, V227, P524, DOI 10.1126/science.3966159; WEINBERG WC, 1985, HYBRIDOMA, V4, P27, DOI 10.1089/hyb.1985.4.27	17	20	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					41	+		10.1096/fj.02-0451fje	http://dx.doi.org/10.1096/fj.02-0451fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475906				2022-12-25	WOS:000180218500028
J	Guan, L; Sahin-Toth, M; Kalai, T; Hideg, M; Kaback, HR				Guan, L; Sahin-Toth, M; Kalai, T; Hideg, M; Kaback, HR			Probing the mechanism of a membrane transport protein with affinity inactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROCHEMICAL PROTON GRADIENT; SUBSTRATE-BINDING SITE; LAC CARRIER PROTEIN; CYSTEINE-SCANNING MUTAGENESIS; LACTOSE PERMEASE; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; MOLECULAR-BIOLOGY; HELIX-IV; VESICLES	Affinity inactivators are useful for probing catalytic mechanisms. Here we describe the synthesis and properties of methanethiosulfonyl (MTS) galactose or glucose derivatives with respect to a well studied membrane transport protein, the lactose permease of Escherichia coli. The MTS-galactose derivatives behave as affinity inactivators of a functional mutant with Ala(122)-->Cys in a background otherwise devoid of Cys residues. A proton electrochemical gradient (Delta<(mu)over bar>(H+)) markedly increases the rate of reaction between Cys(122) and MTS-galactose derivatives; nonspecific labeling with the corresponding MTS-glucose derivatives is unaffected. When the Ala(122)-->Cys mutation is combined with a mutation (Cys(154)-->Gly) that blocks transport but increases binding affinity, discrimination between the MTS-galactose and MTS-glucose derivatives is abolished, and Delta<(mu)over bar>(H+) has no effect. The results provide strong confirmation that the non-galactosyl moiety of permease substrates abuts Ala(122) in helix IV. In addition, the findings demonstrate that the MTS-galactose derivatives do not react with the Cys residue at position 122 upon binding per se but at a subsequent step in the overall transport mechanism. Thus, these inactivators behave as unique suicide substrates.	Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Mol Biol Inst, Los Angeles, CA 90095 USA; Univ Pecs, Inst Organ & Med Chem, H-7643 Pecs, Hungary	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of Pecs	Kaback, HR (corresponding author), Macdonald Res Labs, Box 951662, Los Angeles, CA 90095 USA.	RonaldK@HHMI.UCLA.edu	Guan, Lan/B-5288-2010	Sahin-Toth, Miklos/0000-0003-4513-9922	NIDDK NIH HHS [DK51131-07] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; COHN DE, 1981, BIOCHEMISTRY-US, V20, P3308, DOI 10.1021/bi00514a050; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; Davis BG, 2000, TETRAHEDRON-ASYMMETR, V11, P245, DOI 10.1016/S0957-4166(99)00497-8; FOSTER DL, 1983, J BIOL CHEM, V258, P31; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P3950, DOI 10.1021/bi952601m; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P5333, DOI 10.1021/bi953068d; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Guan L, 2003, BIOCHEMISTRY-US, V42, P1377, DOI 10.1021/bi027152m; Guan L, 2002, P NATL ACAD SCI USA, V99, P3475, DOI 10.1073/pnas.052703699; Guan L, 2002, P NATL ACAD SCI USA, V99, P6613, DOI 10.1073/pnas.102178299; JUNG H, 1994, BIOCHEMISTRY-US, V33, P12160, DOI 10.1021/bi00206a019; Kaback H R, 1974, Methods Enzymol, V31, P698; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; KABACK HR, 1983, J MEMBRANE BIOL, V76, P95; KABACK HR, 1976, J CELL PHYSIOL, V89, P575, DOI 10.1002/jcp.1040890414; KABACK HR, 1974, ARCH BIOCHEM BIOPHYS, V160, P215, DOI 10.1016/S0003-9861(74)80028-7; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; Kwaw I, 2001, BIOCHEMISTRY-US, V40, P10491, DOI 10.1021/bi010866x; MENICK DR, 1985, BIOCHEM BIOPH RES CO, V132, P162, DOI 10.1016/0006-291X(85)91002-2; MINTEL R, 1966, J BIOL CHEM, V241, P3381; OLSEN SG, 1989, J BIOL CHEM, V264, P15982; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; RAMOS S, 1976, P NATL ACAD SCI USA, V73, P1892, DOI 10.1073/pnas.73.6.1892; RAMOS S, 1977, BIOCHEMISTRY-US, V16, P848, DOI 10.1021/bi00624a006; RAMOS S, 1977, BIOCHEMISTRY-US, V16, P854, DOI 10.1021/bi00624a007; ROBERTSON DE, 1980, BIOCHEMISTRY-US, V19, P5692, DOI 10.1021/bi00566a005; RUDNICK G, 1976, BIOCHEMISTRY-US, V15, P5126, DOI 10.1021/bi00668a028; Sahin-Toth M, 2000, BIOCHEMISTRY-US, V39, P5097, DOI 10.1021/bi0000263; Sahin-Toth M, 2001, BIOCHEMISTRY-US, V40, P13015, DOI 10.1021/bi011233l; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; SANDERMANN H, 1977, EUR J BIOCHEM, V80, P507, DOI 10.1111/j.1432-1033.1977.tb11906.x; SHORT SA, 1974, P NATL ACAD SCI USA, V71, P1461, DOI 10.1073/pnas.71.4.1461; SMIRNOVA I, 2003, IN PRESS BIOCHEMISTR; Sorgen PL, 2002, P NATL ACAD SCI USA, V99, P14037, DOI 10.1073/pnas.182552199; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; VANIWAARDEN PR, 1993, BIOCHEMISTRY-US, V32, P5419, DOI 10.1021/bi00071a017; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; WEINGLASS AB, 2003, IN PRESS EMBO J; Wolin CD, 2000, BIOCHEMISTRY-US, V39, P6130, DOI 10.1021/bi0001269; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	50	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10641	10648		10.1074/jbc.M211355200	http://dx.doi.org/10.1074/jbc.M211355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12471022	hybrid			2022-12-25	WOS:000181777500085
J	Goto, H; Yasui, Y; Kawajiri, A; Nigg, EA; Terada, Y; Tatsuka, M; Nagata, K; Inagaki, M				Goto, H; Yasui, Y; Kawajiri, A; Nigg, EA; Terada, Y; Tatsuka, M; Nagata, K; Inagaki, M			Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; HISTONE H3 PHOSPHORYLATION; INTERMEDIATE FILAMENT DYNAMICS; CHROMOSOME CONDENSATION; LIVING CELLS; PROTEIN; SEGREGATION; MITOSIS; SITES; DOMAIN	Aurora-B is an evolutionally conserved protein kinase that regulates several mitotic events including cytokinesis. We previously demonstrated the possible existence of a protein kinase that phosphorylates at least Ser-72 on vimentin, the most widely expressed intermediate filament protein, in the cleavage furrow-specific manner. Here we showed that vimentin-Ser-72 phosphorylation occurred specifically at the border of the Aurora-B-localized area from anaphase to telophase. Expression of a dominant-negative mutant of Aurora-B led to a reduction of this vimentin-Ser-72 phosphorylation. In vitro analyses revealed that Aurora-B phosphorylates vimentin at similar to2 mol phosphate/mol of substrate for 30 min and that this phosphorylation dramatically inhibits vimentin filament formation. We further identified eight Aurora-B phosphorylation sites, including Ser-72 on vimentin, and then constructed the mutant vimentin in which these identified sites are changed into Ala. Cells expressing this mutant formed an unusually long bridge-like intermediate filament structure between unseparated daughter cells. We then identified important phosphorylation sites for the bridge phenotype. Our findings indicate that Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation and controls vimentin filament segregation in cytokinetic process.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Pathol, Nagoya, Aichi 4668550, Japan; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Hiroshima Univ, Res Inst Radiat Biol & Med, Hiroshima 7348553, Japan	Aichi Cancer Center; Nagoya University; Max Planck Society; University of Minnesota System; University of Minnesota Twin Cities; Hiroshima University	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan.	minagaki@aichi-cc.jp	Inagaki, Masaki/B-9920-2016	nigg, erich/0000-0003-4835-5719; Goto, Hidemasa/0000-0002-6796-4467; Terada, Yasuhiko/0000-0003-4784-5273				Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FURUHASHI K, 1992, J BIOL CHEM, V267, P9326; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Ho CL, 1998, J CELL SCI, V111, P1767; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Kosako H, 1997, J BIOL CHEM, V272, P10333; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WOOD L, 1989, GENE, V76, P171, DOI 10.1016/0378-1119(89)90020-6; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yasui Y, 2001, ONCOGENE, V20, P2868, DOI 10.1038/sj.onc.1204407; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125	34	154	168	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8526	8530		10.1074/jbc.M210892200	http://dx.doi.org/10.1074/jbc.M210892200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12458200	hybrid			2022-12-25	WOS:000181466800101
J	Gupta, RA; Sarraf, P; Brockman, JA; Shappell, SB; Raftery, LA; Willson, TM; DuBois, RN				Gupta, RA; Sarraf, P; Brockman, JA; Shappell, SB; Raftery, LA; Willson, TM; DuBois, RN			Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; TGF-BETA; STIMULATED CLONE-22; COLORECTAL-CANCER; HUMAN-COLON; IN-VIVO; DIFFERENTIATION; GENE; EXPRESSION; MOUSE	Peroxisome proliferator-activated receptor gamma(PPARgamma) and transforming growth factor-beta (TGF-beta) are key regulators of epithelial cell biology. However, the molecular mechanisms by which either pathway induces growth inhibition and differentiation are incompletely understood. We have identified transforming growth factor-simulated clone-22 (TSC-22) as a target gene of both pathways in intestinal epithelial cells. TSC-22 is member of a family of leucine zipper containing transcription factors with repressor activity. Although little is known regarding its function in mammals, the Drosophila homolog of TSC-22, bunched, plays an essential role in fly development. The ability of PPARgamma to induce TSC-22 was not dependent on an intact TGF-beta1 signaling pathway and was specific for the gamma isoform. Localization studies revealed that TSC-22 mRNA is enriched in the postmitotic epithelial compartment of the normal human colon. Cells transfected with wild-type TSC-22 exhibited reduced growth rates and increased levels of p21 compared with vector-transfected cells. Furthermore, transfection with a dominant negative TSC-22 in which both repressor domains were deleted was able to reverse the p21 induction and growth inhibition caused by activation of either the PPARgamma or TGF-beta pathways. These results place TSC-22 as an important downstream component of PPARgamma and TGF-beta signaling during intestinal epithelial cell differentiation.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cellular & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Psychiat Genom Inc, Gaithersburg, MD 20878 USA; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; GlaxoSmithKline	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104,1161 21st Ave S, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020; feinstein, doug/M-9414-2019; Raftery, Laurel/H-1406-2012	Raftery, Laurel/0000-0003-4797-4163	NCI NIH HHS [P01CA-77839] Funding Source: Medline; NIDDK NIH HHS [R01DK 47279] Funding Source: Medline; NIEHS NIH HHS [P030 ES-00267-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVERY A, 1993, BRIT J CANCER, V68, P137, DOI 10.1038/bjc.1993.301; Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Brown PJ, 2001, BIOORG MED CHEM LETT, V11, P1225, DOI 10.1016/S0960-894X(01)00188-3; CALNEK D, 1993, DIFFERENTIATION, V53, P95, DOI 10.1111/j.1432-0436.1993.tb00649.x; Chang TH, 2000, CANCER RES, V60, P1129; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Cobb JE, 1998, J MED CHEM, V41, P5055, DOI 10.1021/jm980414r; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dobens LL, 2000, DEVELOPMENT, V127, P745; Dobens LL, 1997, MECH DEVELOP, V65, P197, DOI 10.1016/S0925-4773(97)00080-4; Dohrmann CE, 2002, DEV DYNAM, V223, P85, DOI 10.1002/dvdy.1236; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Grady WM, 1999, CANCER RES, V59, P320; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jay P, 1996, BIOCHEM BIOPH RES CO, V222, P821, DOI 10.1006/bbrc.1996.0825; Kester HA, 1999, J BIOL CHEM, V274, P27439, DOI 10.1074/jbc.274.39.27439; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kubota T, 1998, CANCER RES, V58, P3344; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVINE AE, 1985, CANCER RES, V45, P2248; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; MULDER KM, 1988, CANCER RES, V48, P7120; Nakashiro K, 1998, CANCER RES, V58, P549; Omotehara F, 2000, ONCOL REP, V7, P737; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Seidel G, 1997, J BIOL CHEM, V272, P30918, DOI 10.1074/jbc.272.49.30918; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Tian JQ, 1999, AM J PHYSIOL-GASTR L, V276, pG1094, DOI 10.1152/ajpgi.1999.276.5.G1094; Tian JQ, 1999, AM J PHYSIOL-CELL PH, V276, pC1245, DOI 10.1152/ajpcell.1999.276.6.C1245; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	49	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7431	7438		10.1074/jbc.M208076200	http://dx.doi.org/10.1074/jbc.M208076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12468551	hybrid			2022-12-25	WOS:000181195100103
J	Gusterson, RJ; Jazrawi, E; Adcock, IM; Latchman, DS				Gusterson, RJ; Jazrawi, E; Adcock, IM; Latchman, DS			The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-TRANSFERASE-ACTIVITY; RUBINSTEIN-TAYBI SYNDROME; ATRIAL-NATRIURETIC-FACTOR; GENE-EXPRESSION; MYOCYTES; GATA-4; PHOSPHORYLATION; ABNORMALITIES; DEACETYLASES; ACTIVATION	The CBP and p300 proteins are transcriptional coactivators that are involved in a variety of transcriptional pathways in development and in response to specific signaling pathways. We have previously demonstrated that the ability of both these factors to stimulate transcription is greatly enhanced by treatment of cardiac cells with the hypertrophic agent phenylephrine (PE). Here, we show that inhibition of either CBP or p300 with antisense or dominant negative mutant constructs inhibits PE-induced hypertrophy as assayed by atrial naturetic protein production, cardiac cell protein: DNA ratio and cell size. Furthermore, we show that overexpression of CBP or p300 can induce hypertrophy and that this effect requires their histone acetyltransferase (HAT) activity. Moreover, we show that PE can directly enhance CBP HAT activity and that artificial enhancement of HAT activity is sufficient to induce hypertrophy. Hence, CBP and p300 play an essential role in hypertrophy induced by PE, and this effect is mediated via PE-induced enhancement of their HAT activity. This is the first time a role for these factors, and their HAT activity, in hypertrophy has been directly demonstrated.	UCL, Inst Child Hlth, London WC1N 1EH, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	University of London; University College London; Imperial College London	Latchman, DS (corresponding author), UCL, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	d.latchman@ich.ucl.ac.uk	Adcock, Ian/L-3217-2019	Adcock, Ian/0000-0003-2101-8843				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Bishopric NH, 1997, J BIOL CHEM, V272, P20584, DOI 10.1074/jbc.272.33.20584; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fukuzawa J, 2000, HYPERTENSION, V35, P1191, DOI 10.1161/01.HYP.35.6.1191; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Gusterson R, 2002, J BIOL CHEM, V277, P2517, DOI 10.1074/jbc.M104626200; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; HENNEKAM RCM, 1990, AM J MED GENET, P17; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; Mascareno E, 1998, P NATL ACAD SCI USA, V95, P5590, DOI 10.1073/pnas.95.10.5590; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; MORIMOTO T, 2000, ABSTR AM HEART ASS A, V1060, P219; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000; Rossow KL, 2001, CANCER RES, V61, P2690; RUBINSTEIN JH, 1963, AM J DIS CHILD, V105, P588, DOI 10.1001/archpedi.1963.02080040590010; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STEVENS CA, 1995, AM J MED GENET, V59, P346, DOI 10.1002/ajmg.1320590313; VANBILSEN M, 1993, CARDIOVASC RES, V27, P1140; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	37	134	146	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6838	6847		10.1074/jbc.M211762200	http://dx.doi.org/10.1074/jbc.M211762200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12477714	hybrid			2022-12-25	WOS:000181195100028
J	Sharma, DK; Choudhury, A; Singh, RD; Wheatley, CL; Marks, DL; Pagano, RE				Sharma, DK; Choudhury, A; Singh, RD; Wheatley, CL; Marks, DL; Pagano, RE			Glycosphingolipids internalized via caveolar-related endocytosis rapidly merge with the clathrin pathway in early endosomes and form microdomains for recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PLASMA-MEMBRANE; SPECTRAL PROPERTIES; GOLGI-APPARATUS; RAB PROTEINS; TRANSPORT; CHOLESTEROL; ANALOG; TRAFFICKING; INHIBITION	We have previously demonstrated that glycosphingolipids are internalized from the plasma membrane of human skin fibroblasts by a clathrin-independent, caveolar-related mechanism and are subsequently transported to the Golgi apparatus by a process that is dependent on microtubules, phosphatidylinositol 3-kinase, Rab7, and Rab9. Here we characterized the early steps of intracellular transport of a fluorescent glycosphingolipid analog, BODIPY-lactosylceramide (LacCer), and compared this to fluorescent transferrin (Tfn), a well established marker for the clathrin pathway. Although these two markers were initially internalized into separate vesicles by distinct mechanisms, they became co-localized in early endosomes within 5 min. These results demonstrate that glycosphingolipid-containing vesicles derived from caveolar-related endocytosis fuse with the classical endosomal system. However, in contrast to Tfn, internalization and trafficking of LacCer was independent of Rab5a, a key regulator of transport to early endosomes. By taking advantage of the monomer/excimer properties of the fluorescent lipid analog, we were also able to visualize LacCer segregation into distinct microdomains of high (red emission) and low (green emission) concentrations in the early endosomes of living cells. Interestingly, the high concentration "red" microdomains co-localized with fluorescent Tfn upon exit from early endosomes and passed through Rab11-positive "recycling endosomes" prior to being transported back to the plasma membrane. These results together with our previous studies suggest that glycosphingolipids internalized by caveolar endocytosis are rapidly delivered to early endosomes where they are fractionated into two major pools, one that is transported via late endosomes to the Golgi apparatus and the other that is returned to the plasma membrane via the recycling compartment.	Mayo Clin & Mayo Fdn, Thorac Dis Res Unit, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Thorac Dis Res Unit, Dept Biochem & Mol Biol, Stabile 8,200 1st St SW, Rochester, MN 55905 USA.	pagano.richard@mayo.edu	Takhter, Ramandeep/AAG-8977-2019	Takhter, Ramandeep/0000-0002-1441-2722	NIGMS NIH HHS [GM-22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022942, R37GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Benmerah A, 1999, J CELL SCI, V112, P1303; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GHOSH RN, 1994, J CELL SCI, V107, P2177; Gleizes PE, 1996, EUR J CELL BIOL, V71, P144; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; KAUPPL M, 2001, J CELL SCI, V115, P899; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Miaczynska M, 2002, EXP CELL RES, V272, P8, DOI 10.1006/excr.2001.5401; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pol A, 2000, J BIOL CHEM, V275, P30566, DOI 10.1074/jbc.M001131200; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Prevostel C, 2000, J CELL SCI, V113, P2575; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; RODGERS W, 1993, BIOCHEMISTRY-US, V32, P12591, DOI 10.1021/bi00210a007; Schapiro FB, 1998, AM J PHYSIOL-CELL PH, V274, pC319, DOI 10.1152/ajpcell.1998.274.2.C319; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Woodman PG, 2000, TRAFFIC, V1, P695, DOI 10.1034/j.1600-0854.2000.010902.x; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	38	184	187	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7564	7572		10.1074/jbc.M210457200	http://dx.doi.org/10.1074/jbc.M210457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482757	hybrid			2022-12-25	WOS:000181195100119
J	Van Petegem, F; Collins, T; Meuwis, MA; Gerday, C; Feller, G; Van Beeumen, J				Van Petegem, F; Collins, T; Meuwis, MA; Gerday, C; Feller, G; Van Beeumen, J			The structure of a cold-adapted family 8 xylanase at 1.3 angstrom resolution - Structural adaptations to cold and investigation of the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; CITRATE SYNTHASE; ENZYMES; SEQUENCE; MUTAGENESIS; MOLSCRIPT; INSIGHTS; PROGRAM; COMPLEX	Enzymes from psychrophilic organisms differ from their mesophilic counterparts in having a lower thermo-stability and a higher specific activity at low and moderate temperatures. The current consensus is that they have an increased flexibility, enhancing accommodation and transformation of the substrates at low energy costs. Here we describe the structure of the xylanase from the Antarctic bacterium Pseudoalteromonas haloplanktis at 1.3 Angstrom resolution. Xylanases are usually grouped into glycosyl hydrolase families 10 and 11, but this enzyme belongs to family 8. The fold differs from that of other known xylanases and can be described as an (alpha/alpha)(6) barrel. Various parameters that may explain the cold-adapted properties were examined and indicated that the protein has a reduced number of salt bridges and an increased exposure of hydrophobic residues. The crystal structures of a complex with xylobiose and of mutant D144N were obtained at 1.2 and 1.5 A resolution, respectively. Analysis of the various substrate binding sites shows that the +3 and -3 subsites are rearranged as compared to those of a family 8 homolog, while the xylobiose complex suggests the existence of a +4 subsite. A decreased acidity of the substrate binding cleft and an increased flexibility of aromatic residues lining the subsites may enhance the rate at which substrate is bound.	Univ Ghent, Lab Eiwitbiochem Eiwitengineering, B-9000 Ghent, Belgium; Univ Liege, Inst Chem, Biochim Lab, B-4000 Liege, Belgium	Ghent University; University of Liege	Van Beeumen, J (corresponding author), Univ Ghent, Lab Eiwitbiochem Eiwitengineering, Ledeganckstr 35, B-9000 Ghent, Belgium.	Jozef.Van-Beeumen@rug.ae.be	Collins, Tony/A-3484-2012; Van Petegem, Filip/M-6061-2016	Collins, Tony/0000-0002-4167-973X; Van Petegem, Filip/0000-0003-2728-8537				Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; AGHAJARI N, 2003, IN PRESS PROTEINS; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Alvarez M, 1998, J BIOL CHEM, V273, P2199, DOI 10.1074/jbc.273.4.2199; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEGUIN P, 1985, J BACTERIOL, V162, P102; Collins T, 2002, J BIOL CHEM, V277, P35133, DOI 10.1074/jbc.M204517200; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Feller G, 1997, COMP BIOCHEM PHYS A, V118, P495, DOI 10.1016/S0300-9629(97)00011-X; Gerday C, 2000, TRENDS BIOTECHNOL, V18, P103, DOI 10.1016/S0167-7799(99)01413-4; Gerike U, 2001, PROTEIN ENG, V14, P655, DOI 10.1093/protein/14.9.655; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; Kim SY, 1999, J BIOL CHEM, V274, P11761, DOI 10.1074/jbc.274.17.11761; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lackner P, 2000, PROTEIN ENG, V13, P745, DOI 10.1093/protein/13.11.745; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li KC, 2000, ENZYME MICROB TECH, V27, P89; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OZAKI K, 1994, BBA-PROTEIN STRUCT M, V1207, P159, DOI 10.1016/0167-4838(94)00060-3; Parsiegla G, 1998, EMBO J, V17, P5551, DOI 10.1093/emboj/17.19.5551; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PETRE J, 1981, BIOCHIMIE, V63, P629, DOI 10.1016/S0300-9084(81)80061-2; ROUSSEL A, 1992, SILICON GRAPHICS GEO, V86; Russell NJ, 2000, EXTREMOPHILES, V4, P83, DOI 10.1007/s007920050141; Russell RJM, 1998, STRUCTURE, V6, P351, DOI 10.1016/S0969-2126(98)00037-9; Schmidt RK, 1996, J AM CHEM SOC, V118, P541, DOI 10.1021/ja951066a; SMALAS AO, 1994, PROTEINS, V20, P149, DOI 10.1002/prot.340200205; SMALAS AO, 2002, BIOTECHNOL ANN REV, V6, P1; Sunna A, 1997, CRIT REV BIOTECHNOL, V17, P39, DOI 10.3109/07388559709146606; TORRONEN A, 1994, EMBO J, V13, P2493, DOI 10.1002/j.1460-2075.1994.tb06536.x; Van Petegem F, 2002, ACTA CRYSTALLOGR D, V58, P1494, DOI 10.1107/S0907444902011666; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Zecchinon L, 2001, EXTREMOPHILES, V5, P313, DOI 10.1007/s007920100207	39	110	113	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7531	7539		10.1074/jbc.M206862200	http://dx.doi.org/10.1074/jbc.M206862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12475991	Green Published, hybrid			2022-12-25	WOS:000181195100115
J	Adisa, A; Rug, M; Klonis, N; Foley, M; Cowman, AF; Tilley, L				Adisa, A; Rug, M; Klonis, N; Foley, M; Cowman, AF; Tilley, L			The signal sequence of exported protein-1 directs the green fluorescent protein to the parasitophorous vacuole of transfected malaria parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SURFACE-MEMBRANE; PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; BINDING PROTEIN; TRAFFICKING; TRANSPORT; ANTIGEN; IDENTIFICATION; LOCALIZATION; CYTOPLASM	The malaria parasite, Plasmodium falciparum, spends part of its life cycle inside the erythrocytes of its human host. In the mature stages of intraerythrocytic growth, the parasite undertakes extensive remodeling of its adopted cellular home by exporting proteins beyond the confines of its own plasma membrane. To examine the signals involved in export of parasite proteins, we have prepared transfected parasites expressing a chimeric protein comprising the N-terminal region of the Plasmodium falciparum exported protein-1 appended to green fluorescent protein. The majority of the population of the chimeric protein appears to be correctly processed and trafficked to the parasito-phorous vacuole, indicating that this is the default destination for protein secretion. Some of the protein is redirected to the parasite food vacuole and further degraded. Photobleaching studies reveal that the parasitophorous vacuole contains subcompartments that are only partially interconnected. Dual labeling with the lipid probe, BODIPY-TR-ceramide, reveals the presence of membrane-bound extensions that can bleb from the parasitophorous vacuole to produce double. membrane-bound compartments. We also observed regions and extensions of the parasitophorous vacuole, where there is segregation of the lumenal chimera from the lipid components. These regions may represent sites for the sorting of proteins destined for the trafficking to sites beyond the parasitophorous vacuole membrane.	La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia; La Trobe Univ, Cooperat Res Ctr Diagnost, Bundoora, Vic 3086, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia	La Trobe University; La Trobe University; Walter & Eliza Hall Institute	Tilley, L (corresponding author), La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia.	L.Tilley@LaTrobe.edu.au	Tilley, Leann/AAU-5281-2020; Cowman, Alan F/C-7642-2013; Rug, Melanie/A-9504-2011; Rug, Melanie/B-5417-2015	Cowman, Alan F/0000-0001-5145-9004; Foley, Michael/0000-0003-1349-4698; Tilley, Leann/0000-0001-9910-0199				Adisa A, 2001, J CELL SCI, V114, P3377; Albano F R, 1999, Novartis Found Symp, V226, P157; Albano FR, 1999, EUR J CELL BIOL, V78, P453, DOI 10.1016/S0171-9335(99)80072-7; ALEY SB, 1986, PARASITOLOGY, V92, P511, DOI 10.1017/S0031182000065410; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; Baumeister S, 2001, MOL BIOCHEM PARASIT, V112, P133, DOI 10.1016/S0166-6851(00)00343-1; BEHARI R, 1994, EXP PARASITOL, V79, P250, DOI 10.1006/expr.1994.1088; BENTING J, 1994, BIOCHEM J, V300, P821, DOI 10.1042/bj3000821; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Burghaus PA, 2001, J BIOL CHEM, V276, P26838, DOI 10.1074/jbc.M100111200; COPPEL RL, 1985, P NATL ACAD SCI USA, V82, P5121, DOI 10.1073/pnas.82.15.5121; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; CULVENOR JG, 1990, J PROTOZOOL, V37, P59, DOI 10.1111/j.1550-7408.1990.tb01117.x; DeRocher A, 2000, J CELL SCI, V113, P3969; ELFORD BC, 1995, BIOCHEM J, V308, P361, DOI 10.1042/bj3080361; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Foley M, 1998, INT J PARASITOL, V28, P1671, DOI 10.1016/S0020-7519(98)00132-5; GORMLEY JA, 1992, J CELL BIOL, V119, P1481, DOI 10.1083/jcb.119.6.1481; GUNTHER K, 1991, MOL BIOCHEM PARASIT, V46, P149, DOI 10.1016/0166-6851(91)90208-N; HALDAR K, 1991, MOL BIOCHEM PARASIT, V49, P143, DOI 10.1016/0166-6851(91)90137-U; Hayashi M, 2001, J BIOL CHEM, V276, P15249, DOI 10.1074/jbc.M011709200; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; HINTERBERG K, 1994, EXP PARASITOL, V79, P279, DOI 10.1006/expr.1994.1091; HOPE IA, 1985, NUCLEIC ACIDS RES, V13, P369, DOI 10.1093/nar/13.2.369; Howard R. J., 1988, The biology of parasitism. A molecular and immunological approach., P111; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; KARA U, 1990, MOL BIOCHEM PARASIT, V38, P19, DOI 10.1016/0166-6851(90)90200-6; KILEJIAN A, 1986, P NATL ACAD SCI USA, V83, P7938, DOI 10.1073/pnas.83.20.7938; Klonis N, 2002, EUR BIOPHYS J BIOPHY, V31, P36, DOI 10.1007/s00249-001-0202-2; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; LaGreca N, 1997, MOL BIOCHEM PARASIT, V89, P283, DOI 10.1016/S0166-6851(97)00134-5; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Mattei Denise, 1999, Novartis Foundation Symposium, V226, P215; MIURA S, 1992, J BIOL CHEM, V267, P14405; Nacer A, 2001, INT J PARASITOL, V31, P1371, DOI 10.1016/S0020-7519(01)00253-3; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; O'Donnell RA, 2002, EMBO J, V21, P1231, DOI 10.1093/emboj/21.5.1231; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Papalexis V, 2001, MOL BIOCHEM PARASIT, V115, P77, DOI 10.1016/S0166-6851(01)00271-7; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Saliba KJ, 1998, J BIOL CHEM, V273, P10190, DOI 10.1074/jbc.273.17.10190; Sam-Yellowe TY, 2001, PARASITOL RES, V87, P173, DOI 10.1007/PL00008572; Schwartzbach SD, 1998, PLANT MOL BIOL, V38, P247, DOI 10.1023/A:1006029919283; SIMMONS D, 1987, EMBO J, V6, P485, DOI 10.1002/j.1460-2075.1987.tb04779.x; Taraschi TF, 2001, INT J PARASITOL, V31, P1381, DOI 10.1016/S0020-7519(01)00256-9; van Dooren GG, 2000, PARASITOL TODAY, V16, P421, DOI 10.1016/S0169-4758(00)01792-0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Wickham Mark E., 2001, EMBO (European Molecular Biology Organization) Journal, V20, P5636, DOI 10.1093/emboj/20.20.5636; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973	55	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6532	6542		10.1074/jbc.M207039200	http://dx.doi.org/10.1074/jbc.M207039200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12456681	hybrid			2022-12-25	WOS:000181129400130
J	Le Rumeur, E; Fichou, Y; Pottier, S; Gaboriau, F; Rondeau-Mouro, C; Vincent, M; Gallay, J; Bondon, A				Le Rumeur, E; Fichou, Y; Pottier, S; Gaboriau, F; Rondeau-Mouro, C; Vincent, M; Gallay, J; Bondon, A			Interaction of dystrophin rod domain with membrane phospholipids - Evidence of a close proximity between tryptophan residues and lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; GLYCOPROTEIN COMPLEX; INTRINSIC FLUORESCENCE; CYTOSKELETAL PROTEINS; PENETRATION DEPTH; HELICAL PEPTIDES; TERMINAL DOMAINS; SKELETAL-MUSCLE; WATER INTERFACE; BINDING-SITES	Dystrophin is assumed to act via the central rod domain as a flexible linker between the amino-terminal actin binding domain and carboxyl-terminal proteins associated with the membrane. The rod domain is made up of 24 spectrin-like repeats and has been shown to modify the physical properties of lipid membranes. The nature of this association still remains unclear. Tryptophan residues tend to cluster at or near to the waterlipid interface of the membrane. To assess dystrophin rod domain-membrane interactions, tryptophan residues properties of two recombinant proteins of the rod domain were examined by H-1 NMR and fluorescence techniques in the presence of membrane lipids. F114 (residues 439-553) is a partly folded protein as inferred from 1H NMR, tryptophan fluorescence emission intensity, and the excited state lifetime. By contrast, F125 (residues 439-564) is a folded compact protein. Tryptophan fluorescence quenching shows that both proteins are characterized by structural fluctuations with their tryptophan residues only slightly buried from the surface. In the presence of negatively charged small vesicles, the fluorescence characteristics of F125 change dramatically, indicating that tryptophan residues are in a more hydrophobic environment. Interestingly, these modifications are not observed with F114. Fluorescence quenching experiments confirm that tryptophan residues are shielded from the solvent in the complex F125 lipids by a close contact with lipids. The use of membrane-bound quenchers allowed us to conclude that dystrophin rod domain lies along the membrane surface and may be involved in a structural array comprising membrane and cytoskeletal proteins as well as membrane lipids.	Fac Med, Unite Propre Rech Enseignement Super EA 2230, Lab Resonance Magnet Nucl Biol & Med, F-35043 Rennes, France; CNRS, FRE 2261, Fac Med, Grp Rech Therapeut Anticancereuse, F-35043 Rennes, France; CNRS, UMR 6509, Lab Chim Organomet & Biol, F-35042 Rennes, France; Ctr Univ Paris Sud, Utilisat Rayonnement Electromagnet Lab, CNRS, UMR 130, F-91898 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Le Rumeur, E (corresponding author), Fac Med, Unite Propre Rech Enseignement Super EA 2230, Lab Resonance Magnet Nucl Biol & Med, CS 34317, F-35043 Rennes, France.		Fichou, Yann/AAJ-9179-2020; Rondeau-Mouro, Corinne/ABD-4514-2021; Corinne, Rondeau-Mouro/T-8285-2017	Fichou, Yann/0000-0002-5104-9125; Corinne, Rondeau-Mouro/0000-0002-8573-1050; POTTIER, Sandrine/0000-0002-7367-946X; bondon, arnaud/0000-0002-9229-6317				ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; BROWN SC, 1993, BIOESSAYS, V15, P413, DOI 10.1002/bies.950150608; Calvert R, 1996, BIOPHYS J, V71, P1605, DOI 10.1016/S0006-3495(96)79363-3; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Clayton AHA, 2000, BIOPHYS J, V79, P1066, DOI 10.1016/S0006-3495(00)76360-0; CROSS RA, 1990, FEBS LETT, V262, P87, DOI 10.1016/0014-5793(90)80160-K; de Foresta B, 1999, BIOPHYS J, V77, P3071, DOI 10.1016/S0006-3495(99)77138-9; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; Dempsey CE, 2001, PROG NUCL MAG RES SP, V39, P135, DOI 10.1016/S0079-6565(01)00032-2; DeWolf C, 1997, BIOPHYS J, V72, P2599, DOI 10.1016/S0006-3495(97)78903-3; Diakowski W, 1999, BIOCHEM J, V338, P83, DOI 10.1042/0264-6021:3380083; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; EFTINK MR, 1977, BIOCHIM BIOPHYS ACTA, V491, P473, DOI 10.1016/0005-2795(77)90290-2; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ervasti JM, 1997, SOC GEN PHY, V52, P31; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; HELLIWELL TR, 1992, AM J HUM GENET, V50, P508; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1991, ANN NEUROL, V30, P605, DOI 10.1002/ana.410300414; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; KAHANA E, 1995, BIOCHEMISTRY-US, V34, P8110, DOI 10.1021/bi00025a017; KAHANA E, 1992, BIOCHEM J, V282, P75, DOI 10.1042/bj2820075; KAUREL O, 1998, BIOCHEMISTRY-US, V37, P1407; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Manno S, 2002, P NATL ACAD SCI USA, V99, P1943, DOI 10.1073/pnas.042688399; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; Niggli V, 2001, TRENDS BIOCHEM SCI, V26, P604, DOI 10.1016/S0968-0004(01)01927-2; O'Toole PJ, 2000, BBA-BIOMEMBRANES, V1466, P39, DOI 10.1016/S0005-2736(00)00168-1; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; RECAN D, 1992, J CLIN INVEST, V89, P712, DOI 10.1172/JCI115640; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; Schmitz AAP, 2000, ARCH BIOCHEM BIOPHYS, V380, P380, DOI 10.1006/abbi.2000.1925; SIKORSKI AF, 1987, STUD BIOPHYS, V121, P183; Sopkova J, 1999, BIOCHEMISTRY-US, V38, P5447, DOI 10.1021/bi982760g; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; VINCENT M, 1995, J PHYS CHEM-US, V99, P14931, DOI 10.1021/j100041a006; Vogt TCB, 1999, J BIOL CHEM, V274, P29115, DOI 10.1074/jbc.274.41.29115; Wimley WC, 2000, BIOCHEMISTRY-US, V39, P161, DOI 10.1021/bi991836l; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Yuen CTK, 2000, BIOCHEMISTRY-US, V39, P16155, DOI 10.1021/bi0016117; Zargarian L, 1999, BIOCHEMISTRY-US, V38, P1921, DOI 10.1021/bi981199j	56	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5993	6001		10.1074/jbc.M207321200	http://dx.doi.org/10.1074/jbc.M207321200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480947	Green Published, hybrid			2022-12-25	WOS:000181129400064
J	Crucitti, P; Abril, AM; Salas, M				Crucitti, P; Abril, AM; Salas, M			Bacteriophage Phi 29 early protein p17 - Self-association and hetero-association with the viral histone-like protein p6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS PHAGE PHI-29; COLI NUCLEOID PROTEIN; DNA-BINDING PROTEINS; ESCHERICHIA-COLI; H-NS; BACILLUS-SUBTILIS; INVITRO TRANSCRIPTION; LEUCINE ZIPPER; COILED-COIL; CURVED DNA	Gene 17 of the Bacillus subtilis phage Phi29 is expressed early after infection, and it has been shown to be required at the very beginning of phage replication under conditions of low but not high multiplicity of infection. It has been proposed that, at the beginning of the infection, protein p17 could be recruiting limiting amounts of initiation factors at the viral origins. Once the infection process is established and the replication proteins reach optimal concentration, protein p17 becomes dispensable. In this paper we focused, on the one hand, on the study of protein p17 dimerization and the role of a putative coiled-coil region. On the other hand, we focused on its interaction with the viral origin-binding protein p6. Based on our results we propose that protein p17 function is to optimize binding of protein p6 at the viral DNA ends, thus favoring the initiation of replication and negatively modulating its own transcription.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Canto Blanco, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01 GM27242-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abril AM, 1997, BIOCHEMISTRY-US, V36, P11901, DOI 10.1021/bi970994e; Abril AM, 1999, J MOL BIOL, V292, P581, DOI 10.1006/jmbi.1999.3078; Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; BAILONE A, 1978, VIROLOGY, V84, P547, DOI 10.1016/0042-6822(78)90273-8; Balandina A, 2001, MOL MICROBIOL, V39, P1069, DOI 10.1046/j.1365-2958.2001.02305.x; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; BARTHELEMY I, 1989, J VIROL, V63, P460, DOI 10.1128/JVI.63.1.460-462.1989; BETERMIER M, 1995, J MOL BIOL, V249, P332, DOI 10.1006/jmbi.1995.0300; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Camacho A, 2001, J BIOL CHEM, V276, P28927, DOI 10.1074/jbc.M103738200; Camacho A, 2001, EMBO J, V20, P6060, DOI 10.1093/emboj/20.21.6060; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; Crucitti P, 1998, GENE, V223, P135, DOI 10.1016/S0378-1119(98)00167-X; Elias-Arnanz M, 1999, GENE DEV, V13, P2502, DOI 10.1101/gad.13.19.2502; FALCONI M, 1993, MOL MICROBIOL, V10, P273, DOI 10.1111/j.1365-2958.1993.tb01953.x; FLASHNER Y, 1988, CELL, V54, P713, DOI 10.1016/S0092-8674(88)80016-3; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARVEY KJ, 1985, GENE, V40, P301, DOI 10.1016/0378-1119(85)90053-8; GUTIERREZ C, 1994, EMBO J, V13, P269, DOI 10.1002/j.1460-2075.1994.tb06257.x; JIMENEZ F, 1977, EUR J BIOCHEM, V73, P57, DOI 10.1111/j.1432-1033.1977.tb11291.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lewis DEA, 1999, MOL MICROBIOL, V31, P451, DOI 10.1046/j.1365-2958.1999.01186.x; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MELLADO RP, 1976, J VIROL, V19, P495, DOI 10.1128/JVI.19.2.495-500.1976; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Morales P, 2002, J BACTERIOL, V184, P1565, DOI 10.1128/JB.184.6.1565-1570.2002; MORENO F, 1974, VIROLOGY, V62, P1, DOI 10.1016/0042-6822(74)90298-0; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Petersen C, 2002, J BIOL CHEM, V277, P31373, DOI 10.1074/jbc.M204268200; Polaczek P, 1998, PLASMID, V39, P77, DOI 10.1006/plas.1997.1328; PRIETO I, 1988, P NATL ACAD SCI USA, V85, P314, DOI 10.1073/pnas.85.2.314; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J., 2002, MOL CLONING LAB MANU; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; TALAVERA A, 1971, VIROLOGY, V46, P586, DOI 10.1016/0042-6822(71)90062-6; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; WHITELEY HR, 1986, VIROLOGY, V155, P392, DOI 10.1016/0042-6822(86)90202-3; Williams RM, 1997, FEMS MICROBIOL LETT, V156, P175, DOI 10.1016/S0378-1097(97)00397-2; ZUBER F, 1994, MOL MICROBIOL, V12, P231, DOI 10.1111/j.1365-2958.1994.tb01012.x	46	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4906	4911		10.1074/jbc.M210289200	http://dx.doi.org/10.1074/jbc.M210289200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12480935	hybrid			2022-12-25	WOS:000180968900073
J	Czarny, M; Liu, J; Oh, P; Schnitzer, JE				Czarny, M; Liu, J; Oh, P; Schnitzer, JE			Transient mechanoactivation of neutral sphingomyelinase in caveolae to generate ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Annual Meeting of the Federation-of-American-Societies-for-Experimental-Biology	APR 15-18, 2000	SAN DIEGO, CA	Federat Amer Soc Exptl Biol			FLUID SHEAR-STRESS; NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; HUMAN ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; VASCULAR ENDOTHELIUM; POTASSIUM CHANNEL; IN-SITU; PURIFICATION; LOCALIZATION	The vascular endothelium acutely autoregulates blood flow in vivo in part through unknown mechano-sensing mechanisms. Here, we report the discovery of a new acute mechanotransduction pathway. Hemodynamic stressors from increased vascular flow and pressure in situ rapidly and transiently induce the activity of neutral sphingomyelinase but not that acid sphingomyelinase in a time- and flow rate-dependent manner, followed by the generation of ceramides. This acute mechanoactivation occurs directly at the luminal endothelial cell surface primarily in caveolae enriched in sphingomyelin and neutral sphingomyelinase, but not acid sphingomyelinase. Scyphostatin, which specifically blocks neutral but not acid sphingomyelinase, inhibits mechano-induced neutral sphingomyelinase activity as well as downstream activation of extracellular signal-regulated kinase 1 and 2 (ERK1 and ERK2) by increased flow in situ. We postulate a novel physiological function for neutral sphingomyelinase as a new mechanosensor initiating the ERK cascade and possibly other mechanotransduction pathways.	Sidney Kimmel Canc Ctr, Div Vasc Biol & Angiogenesis, San Diego, CA 92121 USA		Schnitzer, JE (corresponding author), Sidney Kimmel Canc Ctr, Div Vasc Biol & Angiogenesis, 10835 Altman Row, San Diego, CA 92121 USA.	jschnitzer@skcc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067386] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67386] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN D, 1988, BIOCHEM J, V254, P765, DOI 10.1042/bj2540765; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; Bernardo K, 2000, J BIOL CHEM, V275, P7641, DOI 10.1074/jbc.275.11.7641; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chatterjee S, 1999, CHEM PHYS LIPIDS, V102, P79, DOI 10.1016/S0009-3084(99)00077-8; Chatterjee S, 1999, J BIOL CHEM, V274, P37407, DOI 10.1074/jbc.274.52.37407; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; Ghosh N, 1998, MOL CELL BIOCHEM, V189, P161, DOI 10.1023/A:1006910200656; Gimbrone MA, 1999, AM J PATHOL, V155, P1, DOI 10.1016/S0002-9440(10)65090-0; Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515; Gudi SRP, 1996, CIRC RES, V79, P834, DOI 10.1161/01.RES.79.4.834; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hida H, 1998, J NEUROSCI, V18, P8712; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; HOSTETLER KY, 1979, J LIPID RES, V20, P456; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Jin JS, 1999, CHINESE J PHYSIOL, V42, P47; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Jung SY, 2000, J NEUROCHEM, V75, P1004, DOI 10.1046/j.1471-4159.2000.0751004.x; Katsuyama K, 1998, ENDOCRINOLOGY, V139, P4506, DOI 10.1210/en.139.11.4506; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KUCHAN MJ, 1994, AM J PHYSIOL, V267, pC753, DOI 10.1152/ajpcell.1994.267.3.C753; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu B, 2000, METHOD ENZYMOL, V311, P156; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Liu J, 1999, METH MOL B, V116, P61; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Martin SF, 2001, J BIOENERG BIOMEMBR, V33, P143, DOI 10.1023/A:1010704715979; MARUYAMA EN, 1989, J NEUROCHEM, V52, P611, DOI 10.1111/j.1471-4159.1989.tb09163.x; Mizutani Y, 2001, J CELL SCI, V114, P3727; Mizutani Y, 2000, BBA-MOL CELL BIOL L, V1485, P236, DOI 10.1016/S1388-1981(00)00059-7; Nusrat A, 2000, J CELL SCI, V113, P1771; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Oh P, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P34; OHNO M, 1993, CIRCULATION, V88, P193, DOI 10.1161/01.CIR.88.1.193; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Rizzo V, 1999, NATO ADV SCI I A-LIF, V308, P97; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; Romiti E, 2001, FEBS LETT, V506, P163, DOI 10.1016/S0014-5793(01)02878-2; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schnitzer J. E., 1997, VASCULAR ENDOTHELIUM, P77; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1995, ANN BIOMED ENG, V23, pS34; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Su XH, 1999, AM J PHYSIOL-GASTR L, V276, pG853, DOI 10.1152/ajpgi.1999.276.4.G853; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Tanaka M, 1999, J ANTIBIOT, V52, P827, DOI 10.7164/antibiotics.52.827; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Topper JN, 1999, MOL MED TODAY, V5, P40, DOI 10.1016/S1357-4310(98)01372-0; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	69	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4424	4430		10.1074/jbc.M210375200	http://dx.doi.org/10.1074/jbc.M210375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	645GY	12473648	hybrid			2022-12-25	WOS:000180968900010
J	Lee, EB; Skovronsky, DM; Abtahian, F; Doms, RW; Lee, VMY				Lee, EB; Skovronsky, DM; Abtahian, F; Doms, RW; Lee, VMY			Secretion and intracellular generation of truncated A beta in beta-Site Amyloid-beta precursor protein-cleaving enzyme expressing human neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; ALZHEIMERS-DISEASE; SENILE PLAQUES; CELL-LINE; IN-VITRO; PRESENILIN-1 MUTATIONS; ENDOPLASMIC-RETICULUM; PEPTIDE VARIANTS; NTERA-2 CELLS; HUMAN BRAIN	Insoluble pools of the amyloid-beta peptide (Abeta) in brains of Alzheimer's disease patients exhibit considerable Nand C-terminal heterogeneity. Mounting evidence suggests that both C-terminal extensions and N-terminal truncations help precipitate amyloid plaque formation. Although mechanisms underlying the increased generation of C-terminally extended peptides have been extensively studied, relatively little is known about the cellular mechanisms underlying production of N-terminally truncated Abeta. Thus, we used human NT2N neurons to investigate the production of Abeta11-40/42 from amyloid-beta precursor protein (APP) by beta-site APP-cleaving enzyme (BACE). When comparing undifferentiated human embryonal carcinoma NT2- cells and differentiated NT2N neurons, the secretion of sAPP and A,6 correlated with BACE expression. To study the effects of BACE expression on endogenous APP metabolism in human cells, we overexpressed BACE in undifferentiated NT2- cells and NT2N neurons. Whereas NT2N neurons produced both full-length and truncated Abeta as a result of normal processing of endogenous APP, BACE overexpression increased the secretion of Abeta1-40/42 and Abeta11-40/42 in both NT2- cells and NT2N neurons. Furthermore, BACE overexpression resulted in increased intracellular Abeta1-40/42 and Abeta11-40/42. Therefore, we conclude that Abeta11-40/42 is generated prior to deposition in senile plaques and that N-terminally truncated Abeta peptides may contribute to the downstream effects of amyloid accumulation in Alzheimer's disease.	Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Lee, VMY (corresponding author), Hosp Univ Penn, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Maloney 3, Philadelphia, PA 19104 USA.		Lee, Edward/AAU-8436-2021		NIA NIH HHS [AG11542, T32 AG00255] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011542, T32AG000255] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1984, LAB INVEST, V50, P147; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Bodendorf U, 2001, J BIOL CHEM, V276, P12019, DOI 10.1074/jbc.M008861200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; Ginsberg SD, 1999, ANN NEUROL, V45, P174, DOI 10.1002/1531-8249(199902)45:2<174::AID-ANA7>3.0.CO;2-E; Gouras GK, 1998, J NEUROCHEM, V71, P1920; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; GOWING E, 1994, J BIOL CHEM, V269, P10987; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; He WL, 1999, BIOCHEMISTRY-US, V38, P10871, DOI 10.1021/bi990563r; Higgins LS, 1996, AM J PATHOL, V149, P585; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Lalowski M, 1996, J BIOL CHEM, V271, P33623, DOI 10.1074/jbc.271.52.33623; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; Masliah E, 1996, J NEUROSCI, V16, P5795; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCDONALD JK, 1986, MAMMALIAN PROTEASES, V3, P305; Mochizuki A, 2000, LANCET, V355, P42, DOI 10.1016/S0140-6736(99)04937-5; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI N, 1994, AM J PATHOL, V145, P452; Tabira T, 2002, FRONT BIOSCI-LANDMRK, V7, pA44, DOI 10.2741/tabira; Tanahashi H, 2001, NEUROSCI LETT, V307, P9, DOI 10.1016/S0304-3940(01)01912-7; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; Walsh DM, 2001, BIOCHEM J, V355, P869, DOI 10.1042/bj3550869; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wiltfang J, 2002, J NEUROCHEM, V81, P481, DOI 10.1046/j.1471-4159.2002.00818.x; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748	69	69	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4458	4466		10.1074/jbc.M210105200	http://dx.doi.org/10.1074/jbc.M210105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12480937	hybrid			2022-12-25	WOS:000180968900015
J	Schmidt, U; Wochnik, GM; Rosenhagen, MC; Young, JC; Hartl, FU; Holsboer, F; Rein, T				Schmidt, U; Wochnik, GM; Rosenhagen, MC; Young, JC; Hartl, FU; Holsboer, F; Rein, T			Essential role of the unusual DNA-binding motif of BAG-1 for inhibition of the glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALTERNATIVE TRANSLATION INITIATION; HSP90-BASED CHAPERONE MACHINERY; VITAMIN-D-RECEPTOR; MAMMALIAN-CELLS; NEGATIVE REGULATOR; MOLECULAR CHAPERONES; INDUCED APOPTOSIS; DOWN-REGULATION; CANCER-CELLS	The co-chaperone BAG-1 is involved in the regulation of steroid hormone receptors, including the glucocorticoid receptor (GR). More recently, BAG-1 was found in the nucleus where it decreases GR transactivation. Moreover, nonspecific DNA binding of BAG-1 has been reported. We discovered that of the N-terminal part of BAG-1M, the first 8 amino acids are sufficient for DNA binding, containing a stretch of three lysines and a stretch of three arginines. Changing the spacing between these stretches had no effect on DNA binding. Surprisingly, this small, nonsequence-specific DNA binding domain was nonetheless necessary for the inhibitory function of BAG-1 for GR-dependent transcription, whereas the following serine- and threonine-rich E2X4 repeat domain was not. Mutational analysis of these two domains revealed that only mutants retaining DNA binding capability were able to down-regulate GR-mediated transactivation. Intriguingly, lack of DNA binding could not be functionally rescued by BAG-1M harboring a point mutation abolishing interaction with hsp70. Thus, DNA binding and hsp70 interaction are required in cis. We propose that the nonsequence-specific DNA-binding protein BAG-1 acts at specific chromosomal loci by interacting with other proteins.	Max Planck Inst Psychiat, D-80804 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society	Rein, T (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 10, D-80804 Munich, Germany.		Hartl, F. Ulrich/Y-8206-2019	Rein, Theo/0000-0003-2850-4289				Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Chen J, 2002, ONCOGENE, V21, P7050, DOI 10.1038/sj.onc.1205845; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Cutress RI, 2002, BRIT J CANCER, V87, P834, DOI 10.1038/sj.bjc.6600538; DeFranco DB, 1998, J STEROID BIOCHEM, V65, P51, DOI 10.1016/S0960-0760(97)00177-5; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; DOMM K, 1994, METHODS NEUROSCIENCE, P265; Feng L, 2000, MOL BIOL CELL, V11, P1673, DOI 10.1091/mbc.11.5.1673; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Freeman BC, 2000, GENE DEV, V14, P422; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Guzey M, 2000, J BIOL CHEM, V275, P40749, DOI 10.1074/jbc.M004977200; Herr AS, 2000, MOL PHARMACOL, V57, P732, DOI 10.1124/mol.57.4.732; Hofman K, 2000, MOL CELL ENDOCRINOL, V168, P21, DOI 10.1016/S0303-7207(00)00311-7; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Kanelakis KC, 1999, J BIOL CHEM, V274, P34134, DOI 10.1074/jbc.274.48.34134; Kanelakis KC, 2000, BIOCHEMISTRY-US, V39, P14314, DOI 10.1021/bi001671c; Kermer P, 2002, CELL DEATH DIFFER, V9, P405, DOI 10.1038/sj.cdd.4400972; Knee DA, 2001, J BIOL CHEM, V276, P12718, DOI 10.1074/jbc.M010841200; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Liu JM, 1999, MOL ENDOCRINOL, V13, P355, DOI 10.1210/me.13.3.355; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; Niyaz Y, 2001, J CELL SCI, V114, P1839; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pratt WB, 1998, TRENDS ENDOCRIN MET, V9, P244, DOI 10.1016/S1043-2760(98)00059-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schneikert J, 2000, EMBO J, V19, P6508, DOI 10.1093/emboj/19.23.6508; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; Sondermann H, 2002, J BIOL CHEM, V277, P33220, DOI 10.1074/jbc.M204624200; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thress K, 2001, EMBO J, V20, P1033, DOI 10.1093/emboj/20.5.1033; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang B, 1999, J BIOL CHEM, V274, P8291, DOI 10.1074/jbc.274.12.8291; Witcher M, 2001, EXP CELL RES, V265, P167, DOI 10.1006/excr.2001.5176; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	61	48	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4926	4931		10.1074/jbc.M212000200	http://dx.doi.org/10.1074/jbc.M212000200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12482863	hybrid			2022-12-25	WOS:000180968900076
J	Gudlavalleti, SK; Forsberg, LS				Gudlavalleti, SK; Forsberg, LS			Structural characterization of the lipid a component of Sinorhizobium sp NGR234 rough and smooth form lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; RHIZOBIUM-LEGUMINOSARUM; ESCHERICHIA-COLI; FATTY-ACIDS; K-ANTIGENS; BRADYRHIZOBIUM-JAPONICUM; CAPSULAR POLYSACCHARIDES; SURFACE POLYSACCHARIDE; SALMONELLA-TYPHIMURIUM; INFECTION THREAD	A broad-host-range endosymbiont, Sinorhizobium sp. NGR234 is a component of several legume-symbiont model systems; however, there is little structural information on the cell surface glycoconjugates. NGR234 cells in free-living culture produce a major rough lipopolysaccharide (LPS, lacking O-chain) and a minor smooth LPS (containing O-chain), and the structure of the lipid A components was investigated by chemical analyses, mass spectrometry, and NMR spectroscopy of the underivatized lipids A. The lipid A from rough LPS is heterogeneous and consists of six major bisphosphorylated species that differ in acylation. Pentaacyl species (52%) are acylated at positions 2, 3, 2', and 3', and tetraacyl species (46%) lack an acyl group at C-3 of the proximal glucosamine. In contrast to Rhizobium etli and Rhizobium leguminosarum; the NGR234 lipid A contains a bisphosphorylated beta-(1'-->6)-glucosamine disaccharide, typical of enterobacterial lipid A. However, NGR234 lipid A retains the unusual acylation pattern of R. etli lipid A, including the presence of a distal, amide-linked acyloxyacyl residue containing a long chain fatty acid (LCFA) (e.g. 29-hydroxytriacontanoate) attached as the secondary fatty acid. As in R. etli, a 4-carbon fatty acid, beta-hydroxybutyrate, is esterified to (omega - 1) of the LCFA forming an acyloxyacyl residue at that location. The NGR234 lipid A lacks all other ester-linked acyloxyacyl,residues and shows extensive heterogeneity of the amide-linked fatty acids. The N-acyl heterogeneity, including unsaturation, is localized mainly to the proximal glucosamine. The lipid A from smooth LPS contains unique triacyl species (20%) that lack ester-linked fatty acids but retain bisphosphorylation and the LCFA-acyloxyacyl moiety. The unusual structural features shared with R. etli/R. leguminosarum lipid A may be essential for symbiosis.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Forsberg, LS (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.							Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1992, GLYCOBIOLOGY, V2, P535, DOI 10.1093/glycob/2.6.535; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; BHAT UR, 1987, FEMS MICROBIOL LETT, V40, P189; Broughton WJ, 2000, J BACTERIOL, V182, P5641, DOI 10.1128/JB.182.20.5641-5652.2000; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; CARLSON RW, 1984, J BACTERIOL, V158, P1012, DOI 10.1128/JB.158.3.1012-1017.1984; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CARRION M, 1990, J BACTERIOL, V172, P1725, DOI 10.1128/jb.172.4.1725-1731.1990; DEMAAGD RA, 1989, J BACTERIOL, V171, P1143, DOI 10.1128/jb.171.2.1143-1150.1989; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Forsberg LS, 1997, J BACTERIOL, V179, P5366, DOI 10.1128/jb.179.17.5366-5371.1997; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; FUKUOKA S, 1992, ARCH MICROBIOL, V157, P311, DOI 10.1007/BF00248674; Gudlavalleti S. K., 2002, P525; Jabbouri S, 1996, BIOLOGY OF PLANT-MICROBE INTERACTIONS, P319; Kannenberg EL, 2001, MOL MICROBIOL, V39, P379, DOI 10.1046/j.1365-2958.2001.02225.x; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003-2697(78)90260-9; KRAUSS JH, 1988, INT J SYST BACTERIOL, V38, P157, DOI 10.1099/00207713-38-2-157; LOPEZLARA IM, 1995, MICROBIOL-UK, V141, P573, DOI 10.1099/13500872-141-3-573; LOWRY OH, 1954, J BIOL CHEM, V207, P1; Niehaus K, 1998, MOL PLANT MICROBE IN, V11, P906, DOI 10.1094/MPMI.1998.11.9.906; Noel KD, 2000, PROKARYOTIC NITROGEN FIXATION, P415; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; Noel KD, 2000, J BACTERIOL, V182, P5317, DOI 10.1128/JB.182.19.5317-5324.2000; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PETROVICS G, 1993, MOL MICROBIOL, V8, P1083, DOI 10.1111/j.1365-2958.1993.tb01653.x; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Pueppke SG, 1999, MOL PLANT MICROBE IN, V12, P293, DOI 10.1094/MPMI.1999.12.4.293; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; REUHS BL, 1994, MOL PLANT MICROBE IN, V7, P240, DOI 10.1094/MPMI-7-0240; REUHS BL, 1993, J BACTERIOL, V175, P3570, DOI 10.1128/jb.175.11.3570-3580.1993; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Reuhs BL, 1999, APPL ENVIRON MICROB, V65, P5186; REUHS BL, 1995, J BACTERIOL, V177, P4289, DOI 10.1128/jb.177.15.4289-4296.1995; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RUSSA R, 1991, FEMS MICROBIOL LETT, V84, P337, DOI 10.1111/j.1574-6968.1991.tb04620.x; Russa R, 1996, ARCH MICROBIOL, V165, P26, DOI 10.1007/s002030050292; STACEY G, 1991, MOL PLANT MICROBE IN, V4, P332, DOI 10.1094/MPMI-4-332; STEVENSON TT, 1991, CARBOHYD RES, V210, P277, DOI 10.1016/0008-6215(91)80129-B; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WILLIAMS MNV, 1990, J BACTERIOL, V172, P2622, DOI 10.1128/jb.172.5.2622-2632.1990; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	57	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3957	3968		10.1074/jbc.M210491200	http://dx.doi.org/10.1074/jbc.M210491200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12456672	hybrid			2022-12-25	WOS:000180869700057
J	Drake, PMW; Chargelegue, D; Vine, ND; Van Dolleweerd, CJ; Obregon, P; Ma, JKC				Drake, PMW; Chargelegue, D; Vine, ND; Van Dolleweerd, CJ; Obregon, P; Ma, JKC			Transgenic plants expressing antibodies: a model for phytoremediation	FASEB JOURNAL			English	Article						hydroponic medium; recombinant antibody; transgenic plants	MONOCLONAL-ANTIBODIES; TOBACCO PLANTS; IMMUNOGLOBULIN; DOMAINS; PROTEIN; CHAINS; GENE	The feasibility of using antibody expressing transgenic plants either to neutralize bioactive molecules in the rhizosphere, or to accumulate and concentrate the molecules in leaves has been demonstrated in a model system consisting of hydroponic Nicotiana plant cultures expressing a murine monoclonal IgG1. Two transgenic plant types were used; in the first, functional antibody was rhizosecreted and shown to bind with antigen in the surrounding medium to form an immune complex. In the second, a transmembrane sequence retained monoclonal antibody in the plants, on the plasma membrane. Antigen added to the nutrient medium around the roots of mIgG plants was transported within 24 h to the topmost leaves of the plant where it was sequestered as an immune complex by binding to antibody on the cell membrane. Concentration of immune complex in the leaf tissue remained constant over a 72 h period after removal of antigen from nutrient medium. Free antigen was not detected in the leaves of wild-type plants. The two strategies of rhizosecretion-mediated binding and sequestration in leaf tissue could potentially be used in the phytoremediation of any pollutant for which it is possible to generate a monoclonal antibody.	Guys Hosp, GKT Dent Inst, Dept Oral Med & Pathol, Immunol Unit, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Ma, JKC (corresponding author), Guys Hosp, GKT Dent Inst, Dept Oral Med & Pathol, Immunol Unit, 28th Floor,Guys Tower,London Bridge, London SE1 9RT, England.	julian.ma@kcl.ac.uk		Ma, Julian/0000-0003-0767-0042; Drake, Pascal/0000-0002-6181-0600; van Dolleweerd, Craig/0000-0002-1380-6930				BENVENUTO E, 1991, PLANT MOL BIOL, V17, P865, DOI 10.1007/BF00037067; BILES CL, 1991, PLANT PHYSIOL, V96, P597, DOI 10.1104/pp.96.2.597; DENEVE M, 1993, TRANSGENIC RES, V2, P227, DOI 10.1007/BF01977353; Frigerio L, 2000, PLANT PHYSIOL, V123, P1483, DOI 10.1104/pp.123.4.1483; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Kramer U, 1996, NATURE, V379, P635, DOI 10.1038/379635a0; Kramer U, 2001, APPL MICROBIOL BIOT, V55, P661, DOI 10.1007/s002530100631; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; MAITI IB, 1989, PLANT PHYSIOL, V91, P1020, DOI 10.1104/pp.91.3.1020; Meagher RB, 2000, CURR OPIN PLANT BIOL, V3, P153, DOI 10.1016/S1369-5266(99)00054-0; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OWEN M, 1992, BIO-TECHNOL, V10, P790, DOI 10.1038/nbt0792-790; PAN AH, 1994, MOL GEN GENET, V242, P666, DOI 10.1007/BF00283421; Ryland JR, 2000, J MICROBIOL BIOTECHN, V10, P449; SMITH R, 1989, ORAL MICROBIOL IMMUN, V4, P153, DOI 10.1111/j.1399-302X.1989.tb00243.x; Vine ND, 2001, PLANT MOL BIOL, V45, P159, DOI 10.1023/A:1006477231006; Vonier PM, 1996, ENVIRON HEALTH PERSP, V104, P1318, DOI 10.2307/3432968; Wongsamuth R, 1997, BIOTECHNOL BIOENG, V54, P401, DOI 10.1002/(SICI)1097-0290(19970605)54:5&lt;401::AID-BIT1&gt;3.0.CO;2-I; YAMAWAKIKATAOKA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2623, DOI 10.1073/pnas.79.8.2623	20	18	18	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1855	1860		10.1096/fj.02-0148com	http://dx.doi.org/10.1096/fj.02-0148com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468448				2022-12-25	WOS:000180574300004
J	Liu, YQ; Jovanovic, B; Pins, M; Lee, C; Bergan, RC				Liu, YQ; Jovanovic, B; Pins, M; Lee, C; Bergan, RC			Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion	ONCOGENE			English	Article						adhesion; motility; transforming growth factor beta; carcinogenesis	GROWTH-FACTOR-BETA; FOCAL ADHESION KINASE; HEMORRHAGIC TELANGIECTASIA TYPE-1; BINDING PROTEIN ENDOGLIN; HUMAN ENDOTHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; IN-VITRO; INTEGRIN; INHIBITION; TGF-BETA-1	The regulation of cell adhesion and motility in human prostate is not well understood. We have previously shown that the endoglin gene is differently expressed during changes in prostate cell adhesion. Endoglin is a transmembrane transforming growth factor beta binding protein typically expressed by endothelial cells. In this report we demonstrate that endoglin over expression increases prostate cell attachment, while decreasing migration and invasion. Engineered decreases in endoglin expression have opposite effects. While endoglin exerted only relatively small effects upon cell adhesion, large effects upon cell migration and invasion were observed. Endoglin was shown to localize to focal adhesion plaques, consistent with its role in regulating cell adhesion and motility. Loss of endoglin expression in cancer, as compared to normal prostate, was seen in human prostate cell lines. Suppression of endoglin expression in a panel of normal human prostate cell lines led to cell detachment. Endoglin is identified as a regulator of cell adhesion, motility and invasion in human prostate. Loss of endoglin expression appears to be associated with prostate cancer progression, at least in vitro.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; Northwestern University	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Olson 8524,710 N Fairbanks, Chicago, IL 60611 USA.	r-bergan@northwestern.edu	Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634	NCI NIH HHS [CA90386] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090386] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albo D, 1997, SURGERY, V122, P493, DOI 10.1016/S0039-6060(97)90043-X; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; BERGAN R, 1993, NUCLEIC ACIDS RES, V21, P3567, DOI 10.1093/nar/21.15.3567; BERGAN R, 1994, NUCLEIC ACIDS RES, V22, P2150, DOI 10.1093/nar/22.11.2150; Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; Bright RK, 1997, CANCER RES, V57, P995; Cai T, 2000, BIOCHEM BIOPH RES CO, V274, P519, DOI 10.1006/bbrc.2000.3177; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Dakhama A, 1996, J HISTOCHEM CYTOCHEM, V44, P1205, DOI 10.1177/44.10.8813086; Eckstein F, 1996, ANTISENSE NUCLEIC A, V6, P149, DOI 10.1089/oli.1.1996.6.149; Festuccia C, 1999, INT J CANCER, V81, P395, DOI 10.1002/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.0.CO;2-V; Fornaro M, 1996, AM J PATHOL, V149, P765; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Games P. A., 1976, J EDUCATIONAL STATIS, V1, P113, DOI [10.3102/10769986001002113, DOI 10.2307/1164979]; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goldfinger LE, 1999, J CELL SCI, V112, P2615; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jovanovic B D, 2001, Am J Pharmacogenomics, V1, P145, DOI 10.2165/00129785-200101020-00007; JOVANOVIC BD, 2002, ANAL GENE ARRAY DATA; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; LIU YQ, 2001, PROSTATIC DIS, V4, P1; Loganadane LD, 1999, CELL ADHES COMMUN, V7, P57, DOI 10.3109/15419069909034392; Luo Jan, 1997, Pathol Oncol Res, V3, P264; MCALLISTER KA, 1995, HUM MOL GENET, V4, P1983, DOI 10.1093/hmg/4.10.1983; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MERZAK A, 1994, BRIT J CANCER, V70, P199, DOI 10.1038/bjc.1994.280; NAGLE RB, 1994, J CELL BIOCHEM, P232; Pece-Barbara N, 1999, HUM MOL GENET, V8, P2171, DOI 10.1093/hmg/8.12.2171; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; Schwartz GN, 1998, ANTISENSE NUCLEIC A, V8, P329, DOI 10.1089/oli.1.1998.8.329; Sharma N, 2002, PROSTATE, V50, P189, DOI 10.1002/pros.10048; Takahashi N, 2001, CLIN CANCER RES, V7, P524; Teti A, 1997, INT J CANCER, V72, P1013; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; WITKOWSKI CM, 1993, J CANCER RES CLIN, V119, P637, DOI 10.1007/BF01215981; Yamada KM, 1997, MATRIX BIOL, V16, P137, DOI 10.1016/S0945-053X(97)90001-9	49	87	94	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8272	8281		10.1038/sj.onc.1206117	http://dx.doi.org/10.1038/sj.onc.1206117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447690				2022-12-25	WOS:000179323900005
J	Yuan, JP; Eckerdt, F; Bereiter-Hahn, J; Kurunci-Csacsko, E; Kaufmann, M; Strebhardt, K				Yuan, JP; Eckerdt, F; Bereiter-Hahn, J; Kurunci-Csacsko, E; Kaufmann, M; Strebhardt, K			Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1	ONCOGENE			English	Article						phosphorylation; cyclin B1; mitotic kinases; polo-like kinase; cell cycle	PROTEIN-KINASE; CELL-CYCLE; NUCLEAR-LOCALIZATION; PROMOTING FACTOR; XENOPUS; P34CDC2; MATURATION; ACTIVATION; CDC2; PLK	The cyclin-dependent kinase 1 (Cdc2)/cyclin B1 complex performs cardinal roles for eukaryotic mitotic progression. Phosphorylation of four serine residues within cyclin B1 promotes the rapid nuclear translocation of Cdc2/cyclin B1 at the G(2)/M transition. Still, the role of individual phosphorylation sites and their corresponding kinases remain to be elucidated. Polo-like kinase I (Plk1) shows a spatial and temporal distribution which makes it a candidate kinase for the phosphorylation of cyclin B1. We could demonstrate the interaction of both proteins in mammalian cells. Plk1 phosphorylated wildtype cyclin 111 expressed in bacteria and in mammalian cells. Ser-133 within the cytoplasmic retention signal (CRS) of cyclin B1, which regulates the nuclear entry of the heterodimeric complex during prophase, is a target of Plk1. In contrast, MAPK (Erk2) and MPF phosphorylate Ser-126 and Ser-128 within the CRS. Phosphorylation of CRS by MAPK (Erk2) prior to Plk1 treatment induced enhanced phosphorylation of cyclin 131 by Plk1 suggesting a synergistic action of both enzymes towards cyclin B1. In addition, pretreatment of cyclin B1 by MAPK (Erk2) altered the phosphorylation pattern of Plk 1. Mutation of Ser-133 to Ala decreased the phosphorylation of cyclin 131 in vivo. An immunofluorescence study revealed that a mutation of Ser-133 reduced the nuclear import rate of cyclin B1. Still, multiple serine mutations are required to prevent nuclear translocation completely indicating that orchestrated phosphorylation within the CRS triggers rapid import of cyclin B1.	Univ Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany; Univ Frankfurt, Dept Biol, D-60439 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Strebhardt, K (corresponding author), Univ Frankfurt, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Yuan JP, 1997, AM J PATHOL, V150, P1165	37	108	112	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8282	8292		10.1038/sj.onc.1206011	http://dx.doi.org/10.1038/sj.onc.1206011			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447691				2022-12-25	WOS:000179323900006
J	Lynn, FC; Thompson, SA; Pospisilik, JA; Ehses, JA; Hinke, SA; Pamir, N; McIntosh, CHS; Pederson, RA				Lynn, FC; Thompson, SA; Pospisilik, JA; Ehses, JA; Hinke, SA; Pamir, N; McIntosh, CHS; Pederson, RA			A novel pathway for regulation of glucose-dependent insulinotropic polypeptide receptor expression in beta-cells	FASEB JOURNAL			English	Article						PPAR alpha; type 2 diabetes; Zucker rats; INS(832/13) cells; gastric inhibitory polypeptide	GASTRIC-INHIBITORY POLYPEPTIDE; RAT; GIP; ALPHA; STIMULATION; RELEASE; GENE; DESENSITIZATION; INTOLERANCE; ANTAGONIST	Glucose-dependent insulinotropic polypeptide (GIP) is secreted postprandially and acts in concert with glucose to stimulate insulin secretion from the pancreas. Here, we describe a novel pathway for the regulation of GIP receptor (GIPR) expression within clonal beta-cell lines, pancreatic islets, and in vivo. High (25 mM) glucose was able to significantly reduce GIPR mRNA levels in INS(832/13) cells after only 6 h. In contrast, palmitic acid (2 mM) and WY 14643 (100 muM) stimulated approximate doublings of GIPR expression in INS(832/13) cells under low (5.5 mM), but not high (25 mM), glucose conditons, suggesting that fat can regulate GIPR expression via PPARalpha in a glucose-dependent manner. Both MK-886, an antagonist of PPARalpha, and a dominant negative form of PPARalpha transfected into INS(832/13) cells caused a significant reduction in GIPR expression in low, but not high, glucose conditions. Finally, in hyperglycemic clamped rats, there was a 70% reduction in GIPR expression in the islets and a 71% reduction in GIP-stimulated insulin secretion from the perfused pancreas. Thus, evidence is presented that the GIPR is controlled at normoglycemia by the fatty acid load on the islet; however, when exposed to hyperglycemic conditions, the GIPR is down-regulated, which may contribute to the decreased responsiveness to GIP that is observed in type 2 diabetes.	Univ British Columbia, Fac Med, Dept Physiol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Pederson, RA (corresponding author), Univ British Columbia, Fac Med, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	pederson@interchange.ubc.ca	Hinke, Simon/R-7120-2019; Ehses, Jan/AAK-1635-2020; Pamir, Nathalie/H-5234-2013	Ehses, Jan/0000-0001-9066-7607; Pamir, Nathalie/0000-0002-2074-888X; Lynn, Francis/0000-0001-9318-1063				AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; BECK B, 1983, REGUL PEPTIDES, V7, P3, DOI 10.1016/0167-0115(83)90276-8; Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; BLAKE AD, 1987, BIOCHEM J, V245, P357, DOI 10.1042/bj2450357; DAlessio D, 1997, HORM METAB RES, V29, P297, DOI 10.1055/s-2007-979039; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Ding WG, 1997, DIABETES, V46, P615, DOI 10.2337/diabetes.46.4.615; Ehses JA, 2001, J BIOL CHEM, V276, P23667, DOI 10.1074/jbc.M103023200; Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; Hinke SA, 2000, J ENDOCRINOL, V165, P281, DOI 10.1677/joe.0.1650281; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Holst JJ, 1997, DIABETOLOGIA, V40, P984, DOI 10.1007/s001250050779; HSU MH, 1995, MOL PHARMACOL, V48, P559; Kehrer JP, 2001, BIOCHEM J, V356, P899, DOI 10.1042/0264-6021:3560899; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Laybutt R, 2001, DIABETES, V50, pS180, DOI 10.2337/diabetes.50.2007.S180; Lynn FC, 2001, DIABETES, V50, P1004, DOI 10.2337/diabetes.50.5.1004; McClenaghan NH, 1996, DIABETES, V45, P1132, DOI 10.2337/diabetes.45.8.1132; McIntosh CHS, 1996, ACTA PHYSIOL SCAND, V157, P361, DOI 10.1046/j.1365-201X.1996.44267000.x; McIntosh CHS, 1999, ENDOCRINOLOGY, V140, P398, DOI 10.1210/en.140.1.398; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; NAUCK M, 1986, DIABETOLOGIA, V29, P46, DOI 10.1007/BF02427280; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; OBEN J, 1991, J ENDOCRINOL, V130, P267, DOI 10.1677/joe.0.1300267; PEDERSON RA, 1975, DIABETES, V24, P1050, DOI 10.2337/diabetes.24.12.1050; PEDERSON RA, 1976, ENDOCRINOLOGY, V99, P780, DOI 10.1210/endo-99-3-780; PEDERSON RA, 1982, REGUL PEPTIDES, V5, P53, DOI 10.1016/0167-0115(82)90075-1; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Roduit R, 2000, J BIOL CHEM, V275, P35799, DOI 10.1074/jbc.M006001200; Schinner S, 2002, J BIOL CHEM, V277, P1941, DOI 10.1074/jbc.M109718200; Schirra J, 1998, J CLIN INVEST, V101, P1421, DOI 10.1172/JCI1349; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; Tseng CC, 1996, J CLIN INVEST, V98, P2440, DOI 10.1172/JCI119060; Tseng CC, 1999, AM J PHYSIOL-ENDOC M, V276, pE1049, DOI 10.1152/ajpendo.1999.276.6.E1049; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898	41	71	78	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					91	+		10.1096/fj.02-0243fje	http://dx.doi.org/10.1096/fj.02-0243fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475913				2022-12-25	WOS:000180218500017
J	Lima, WF; Wu, HJ; Nichols, JG; Manalili, SM; Drader, JJ; Hofstadler, SA; Crooke, ST				Lima, WF; Wu, HJ; Nichols, JG; Manalili, SM; Drader, JJ; Hofstadler, SA; Crooke, ST			Human RNase H1 activity is regulated by a unique redox switch formed between adjacent cysteines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ION-CYCLOTRON RESONANCE; RIBONUCLEASE-H; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; MOLECULAR-CLONING; PURIFICATION; RNA; RESIDUES	Human RNase HI is active only under reduced conditions. Oxidation as well as N-ethylmaleimide (NEM) treatment of human RNase HI ablates the cleavage activity. The oxidized and NEM alkylated forms of human RNase H1 exhibited binding affinities for the heteroduplex substrate comparable with the reduced form of the enzyme. Mutants of human RNase H1 in which the cysteines were either deleted or substituted with alanine exhibited cleavage rates comparable with the reduced form of the enzyme, suggesting that the cysteine residues were not required for catalysis. The cysteine residues responsible for the observed redox-dependent activity of human RNase H1 were determined by site-directed mutagenesis to involve Cys(147) and Cys(148). The redox states of the Cys(147) and Cys(148) residues were determined by digesting the reduced, oxidized, and NEM-treated forms of human RNase H1 with trypsin and analyzing the cysteine containing tryptic fragments by mu high performance liquid chromatography-electrospray ionization-Fourier transform ion cyclotron mass Spectrometry. The tryptic fragment Asp(131)-Arg(153) containing Cys(147) and Cys(148) was identified. The mass spectra for the Asp(131)-Arg(153) peptides from the oxidized and reduced forms of human RNase H1 in the presence and absence of NEM showed peptide masses consistent with the formation of a disulfide bond between Cys(147) and Cys(148). These data show that the formation of a disulfide bond between adjacent Cys(147) and Cys(148) residues results in an inactive enzyme conformation and provides further insights into the interaction between human RNase H1 and the heteroduplex substrate.	ISIS Pharmaceut, Dept Mol & Struct Biol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Lima, WF (corresponding author), ISIS Pharmaceut, Dept Mol & Struct Biol, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	wlima@isisph.com						Ausubel FM., 1988, CURRENT PROTOCOLS MO; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; Blazquez M, 1996, J BIOL CHEM, V271, P18638, DOI 10.1074/jbc.271.31.18638; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; CAPASSO S, 1977, ACTA CRYSTALLOGR B, V33, P2080, DOI 10.1107/S0567740877007778; Cerritelli SM, 1998, GENOMICS, V53, P300, DOI 10.1006/geno.1998.5497; CERRITELLI SM, 1995, RNA, V1, P246; Crouch R. J., 1982, NUCLEASES, P211; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; EDER PS, 1991, J BIOL CHEM, V266, P6472; Evans SP, 1999, J MOL BIOL, V291, P661, DOI 10.1006/jmbi.1999.2971; FRANK P, 1994, NUCLEIC ACIDS RES, V22, P5247, DOI 10.1093/nar/22.24.5247; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; GHOSH M, 1995, STRUCTURE, V3, P177, DOI 10.1016/S0969-2126(01)00148-4; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; Kim BM, 1999, PROTEIN SCI, V8, P430; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Marshall AG, 1998, MASS SPECTROM REV, V17, P1, DOI 10.1002/(SICI)1098-2787(1998)17:1<1::AID-MAS1>3.0.CO;2-K; MILLER SM, 1989, BIOCHEMISTRY-US, V28, P1194, DOI 10.1021/bi00429a037; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; Park C, 2001, PROTEIN ENG, V14, P939, DOI 10.1093/protein/14.11.939; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; Sambrook J, 1989, MOL CLONING LAB MANU, P431; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; Smith RD, 2000, INT J MASS SPECTROM, V200, P509, DOI 10.1016/S1387-3806(00)00352-3; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; SUKUMARAN DK, 1991, J AM CHEM SOC, V113, P706, DOI 10.1021/ja00002a067; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 2001, J BIOL CHEM, V276, P23547, DOI 10.1074/jbc.M009676200; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	43	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14906	14912		10.1074/jbc.M211279200	http://dx.doi.org/10.1074/jbc.M211279200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12473655	hybrid			2022-12-25	WOS:000182516100043
J	Yan, Z; Choi, SD; Liu, XB; Zhang, M; Schageman, JJ; Lee, SY; Hart, R; Lin, L; Thurmond, FA; Williams, RS				Yan, Z; Choi, SD; Liu, XB; Zhang, M; Schageman, JJ; Lee, SY; Hart, R; Lin, L; Thurmond, FA; Williams, RS			Highly coordinated gene regulation in mouse skeletal muscle regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-DEPENDENT KINASE; STEM-CELL FUNCTION; MYOGENIC DIFFERENTIATION; SATELLITE CELLS; DIRECT BINDING; UP-REGULATION; MYOD PROTEIN; CYCLIN-D; EXPRESSION; E2F	Mammalian skeletal muscles are capable of regeneration after injury. Quiescent satellite cells are activated to reenter the cell cycle and to differentiate for repair, recapitulating features of myogenesis during embryonic development. To understand better the molecular mechanism involved in this process in vivo, we employed high density cDNA microarrays for gene expression profiling in mouse tibialis anterior muscles after a cardiotoxin injection. Among 16,267 gene elements surveyed, 3,532 elements showed at least a 2.5-fold change at one or more time points during a 14-day time course. Hierarchical cluster analysis and semiquantitative reverse transcription-PCR showed induction of genes important for cell cycle control and DNA replication during the early phase of muscle regeneration. Subsequently, genes for myogenic regulatory factors, a group of imprinted genes and genes with functions to inhibit cell cycle progression and promote myogenic differentiation, were induced when myogenic stem cells started to differentiate. Induction of a majority of these genes, including E2f1 and E2f2, was abolished in muscles lacking satellite cell activity after gamma radiation. Regeneration was severely compromised in E2f1 null mice but not affected in E2f2 null mice. This study identifies novel genes potentially important for muscle regeneration and reveals highly coordinated myogenic cell proliferation and differentiation programs in adult skeletal muscle regeneration in vivo.	Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27710 USA; CALTECH, Dept Biol, Pasadena, CA 91125 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	Duke University; California Institute of Technology; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yan, Z (corresponding author), Duke Univ, Med Ctr, Div Cardiol, Dept Med, 201C MSRB,Res Dr,MC 2635, Durham, NC 27710 USA.	zhen.yan@duke.edu		Yan, Zhen/0000-0002-4826-9813	NIAMS NIH HHS [AR40849] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040849, R56AR040849] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson JE, 1998, BIOCHEM CELL BIOL, V76, P13, DOI 10.1139/bcb-76-1-13; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Bischoff R., 1994, MYOLOGY, VVolume 1, P97; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; Campbell WG, 2001, AM J PHYSIOL-CELL PH, V280, pC763, DOI 10.1152/ajpcell.2001.280.4.C763; Carson JA, 2001, FASEB J, V15, P207, DOI 10.1096/fj.01-0544fje; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; Cooper RN, 1999, J CELL SCI, V112, P2895; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Cornelison DDW, 2000, DEV BIOL, V224, P122, DOI 10.1006/dbio.2000.9682; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Coutelle O, 2001, DEV BIOL, V236, P136, DOI 10.1006/dbio.2001.0193; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EDMONDSON DG, 1990, GENE DEV, V4, P1450, DOI 10.1101/gad.4.8.1450; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El Kharroubi A, 2001, J BIOL CHEM, V276, P8674, DOI 10.1074/jbc.M009392200; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Garry DJ, 2000, P NATL ACAD SCI USA, V97, P5416, DOI 10.1073/pnas.100501197; Grounds M D, 1993, Mol Cell Biol Hum Dis Ser, V3, P210; Haslett JN, 2002, INT J DEV NEUROSCI, V20, P359, DOI 10.1016/S0736-5748(02)00041-2; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRSCH S, 1983, IMMUNOGENETICS, V18, P229, DOI 10.1007/BF00952962; KATO J, 1993, GENE DEV, V7, P331; KOISHI K, 1995, DEV DYNAM, V202, P244, DOI 10.1002/aja.1002020304; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; LEIBOVITCH MP, 1995, ONCOGENE, V10, P251; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin Q, 1998, DEVELOPMENT, V125, P4565; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PEARCE GW, 1962, J PATHOL BACTERIOL, V83, P535, DOI 10.1002/path.1700830228; PEARSON CM, 1962, BRAIN, V85, P109, DOI 10.1093/brain/85.1.109; Phelan JN, 1997, ANAT REC, V247, P179, DOI 10.1002/(SICI)1097-0185(199702)247:2<179::AID-AR4>3.0.CO;2-T; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; Roth SM, 2002, PHYSIOL GENOMICS, V10, P181, DOI 10.1152/physiolgenomics.00028.2002; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Stewart CEH, 1996, J CELL PHYSIOL, V169, P23, DOI 10.1002/(SICI)1097-4652(199610)169:1<23::AID-JCP3>3.0.CO;2-G; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Urashima M, 1999, BRIT J CANCER, V79, P1032, DOI 10.1038/sj.bjc.6690165; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Wittwer M, 2002, FASEB J, V16, P884, DOI 10.1096/fj.01-0792fje; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yang X, 2002, DIABETOLOGIA, V45, P1584, DOI 10.1007/s00125-002-0905-7; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	70	201	209	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8826	8836		10.1074/jbc.M209879200	http://dx.doi.org/10.1074/jbc.M209879200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12477723	hybrid, Green Accepted			2022-12-25	WOS:000181466800139
J	Elvert, G; Kappel, A; Heidenreich, R; Englmeier, U; Lanz, S; Acker, T; Rauter, M; Plate, K; Sieweke, M; Breier, G; Flamme, I				Elvert, G; Kappel, A; Heidenreich, R; Englmeier, U; Lanz, S; Acker, T; Rauter, M; Plate, K; Sieweke, M; Breier, G; Flamme, I			Cooperative interaction of hypoxia-inducible factor-2 alpha (HIF-2 alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAS DOMAIN PROTEIN-1; TYROSINE KINASE; DNA-BINDING; FACTOR 1-ALPHA; CELL DIFFERENTIATION; VEGF RECEPTOR-2; TRANSGENIC MICE; GENE-EXPRESSION; UP-REGULATION; FACTOR-I	Interactions between Ets family members and a variety of other transcription factors serve important functions during development and differentiation processes, e.g. in the hematopoietic system. Here we show that the endothelial basic helix-loop-helix PAS domain transcription factor, hypoxia-inducible factor-2alpha (HIF-2alpha) (but not its close relative HIF-1alpha), cooperates with Ets-1 in activating transcription of the vascular endothelial growth factor receptor-2 (VEGF-2) gene (Flk-1). The receptor tyrosine kinase Flk-1 is indispensable for angiogenesis, and its expression is closely regulated during development. Consistent with the hypothesis that HIF-2alpha controls the expression of Flk-1 in vivo, we show here that HIF-2alpha and Flk-1 are co-regulated in postnatal mouse brain capillaries. A tandem HIF-2alpha/Ets binding site was identified within the Flk-1 promoter that acted as a strong enhancer element. Based on the analysis of transgenic mouse embryos, these motifs are essential for endothelial cell-specific reporter gene expression. A single HIF-2alpha/Ets element conferred strong cooperative induction by HIF-2alpha and Ets-1 when fused to a heterologous promoter and was most active in endothelial cells. The physical interaction of HIF-2alpha with Ets-1 was demonstrated and localized to the HIF-2alpha carboxyl terminus and the autoinhibitory exon VII domain of Ets-1, respectively. The deletion of the DNA binding and carboxyl-terminal transactivation domains of HIF-2alpha, respectively, created dominant negative mutants that suppressed transactivation by the wild type protein and failed to synergize with Ets-1. These results suggest that the interaction between HIF-2alpha and endothelial Ets factors is required for the full transcriptional activation of Flk-1 in endothelial cells and may therefore represent a future target for the manipulation of angiogenesis.	Univ Cologne, Zentrum Mol Med, D-50931 Cologne, Germany; Max Planck Inst Physiol & Clin Res, Abt Mol Zellbiol, D-61231 Bad Nauheim, Germany; CNRS, INSERM, Ctr Immunol, F-13288 Marseille 9, France; Univ Erlangen Nurnberg, Abt Neuropathol, D-91052 Nurnberg, Germany	University of Cologne; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Erlangen Nuremberg	Flamme, I (corresponding author), Bayer AG, Herz Kreislauf Forsch 2, Aprather Weg 18A, D-42096 Wuppertal, Germany.	ingo.flamme.if@bayer-ag.de	Sieweke, Michael/AAR-7515-2020; Breier, Georg/E-3580-2016	Sieweke, Michael/0000-0002-3228-9537; Breier, Georg/0000-0002-9467-780X; Acker, Till/0000-0001-6357-7227				Ausubel FM, 1998, CURRENT PROTOCOLS MO; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Breier G, 1997, THROMB HAEMOSTASIS, V78, P678; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Elvert G, 1999, MECH DEVELOP, V87, P193, DOI 10.1016/S0925-4773(99)00144-6; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Heidenreich R, 2000, CANCER RES, V60, P6142; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kappel A, 2000, BLOOD, V96, P3078; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kremer C, 1997, CANCER RES, V57, P3852; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Liao EC, 1998, GENE DEV, V12, P621, DOI 10.1101/gad.12.5.621; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PLATE KH, 1995, GLIA, V15, P339, DOI 10.1002/glia.440150313; Porcher C, 1999, DEVELOPMENT, V126, P4603; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTSON PL, 1985, DEV BRAIN RES, V23, P219, DOI 10.1016/0165-3806(85)90044-6; Ronicke V, 1996, CIRC RES, V79, P277, DOI 10.1161/01.RES.79.2.277; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Semenza GL, 2001, J CLIN INVEST, V108, P39, DOI 10.1172/JCI13374; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Wenger RH, 1997, BIOL CHEM, V378, P609; WERNERT N, 1992, AM J PATHOL, V140, P119; WHITE RJ, 1989, BIOCHEMISTRY-US, V28, P6259, DOI 10.1021/bi00441a018; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	67	220	231	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7520	7530		10.1074/jbc.M211298200	http://dx.doi.org/10.1074/jbc.M211298200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12464608	hybrid			2022-12-25	WOS:000181195100114
J	Denis, GV; Yu, Q; Deeds, PH; Faller, DV; Chen, CY				Denis, GV; Yu, Q; Deeds, PH; Faller, DV; Chen, CY			Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; FAS-INDUCED APOPTOSIS; PROTEIN-KINASE-C; CYTOCHROME-C; B-CELLS; T-CELLS; H-RAS; X-L; MEMBRANE; ACTIVATION	Bcl-2 protects cells against Ras-mediated apoptosis; this protection coincides with its binding to Ras. However, the protection mechanism has remained enigmatic. Here, we demonstrate that, upon apoptotic stimulation, newly synthesized Bcl-2 redistributes to mitochondria, interacts there with activated Ras, and blocks Ras-mediated apoptotic signaling. We also show, by employing bcl-2 mutants, that the BH4 domain of Bcl-2 binds to Ras and regulates its anti-apoptotic activity. Experiments with a C-terminal-truncated Ras or a farnesyltransferase inhibitor demonstrate that the CAAX motif of Ras is essential for apoptotic signaling and Bcl-2 association. The results indicate a potential mechanism by which Bcl-2 protects cells against Ras-mediated apoptotic signaling.	Boston Univ, Sch Med, Ctr Canc Res, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Chen, CY (corresponding author), Boston Univ, Sch Med, Ctr Canc Res, 80 E Concord St,Rm R908, Boston, MA 02118 USA.			Denis, Gerald/0000-0001-9886-0401				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAVID CS, 2000, CELL, V103, P839; Deschenes RJ, 1990, CURR OPIN CELL BIOL, V2, P1108, DOI 10.1016/0955-0674(90)90164-A; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLER M, 1995, J CLIN INVEST, V95, P2633; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gulbahar MY, 2000, AUST VET J, V78, P247, DOI 10.1111/j.1751-0813.2000.tb11744.x; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERRY D, 1991, NATURE, V348, P334; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; KOVACS B, 1995, J IMMUNOL, V155, P5543; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Liou JS, 2000, J BIOL CHEM, V275, P39001, DOI 10.1074/jbc.M007154200; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PARIJS LV, 1998, J IMMUNOL, V160, P2065; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rebollo A, 1999, ONCOGENE, V18, P4930, DOI 10.1038/sj.onc.1202875; REED CJ, 1997, NATURE, V387, P773; SALMON M, 1994, EUR J IMMUNOL, V24, P892, DOI 10.1002/eji.1830240417; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TANAKA S, 1993, J BIOL CHEM, V268, P10920; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	59	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5775	5785		10.1074/jbc.M210202200	http://dx.doi.org/10.1074/jbc.M210202200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12477721	hybrid			2022-12-25	WOS:000181129400038
J	Spessotto, P; Cervi, M; Mucignat, MT; Mungiguerra, G; Sartoretto, I; Doliana, R; Colombatti, A				Spessotto, P; Cervi, M; Mucignat, MT; Mungiguerra, G; Sartoretto, I; Doliana, R; Colombatti, A			beta 1 integrin-dependent cell adhesion to EMILIN-1 is mediated by the gC1q domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELL; LIGAND-BINDING; GLOBULAR DOMAIN; COMPLEMENT C1Q; LATE ANTIGEN-4; GLYCOPROTEIN; ALPHA(4)BETA(1); PROTEIN; FIBRONECTIN; RECEPTOR	EMILIN-1 (Elastin Microfibril Interface Located ProteIN), the prototype of the EMILIN family, consists of a cysteine-rich domain (EMI domain) at the N terminus, an extended region with a high potential coiled-coil structure, a short collagenous stalk, and a self-interacting globular gC1q-1 domain. EMILIN-1 is an adhesive extracellular matrix constituent associated with elastic fibers, detected also in the proximity of cell surfaces. To localize the cell attachment site(s), monoclonal antibodies (mAbs) against EMILIN-1 or the gC1q-1 domain were used to inhibit cell attachment to EMILIN-1. Thus, one mAb mapping to the gC1q-1 domain caused complete inhibition of cell attachment. EMILIN-1 and gC1q-1 displayed a comparable dose-dependent ability to promote cell adhesion. Adhesion kinetics was similar to that of fibronectin (FN), reaching the maximum level of attachment at 20 min, but in the absence of cations adhesion was negligible. The relative adhesion strength to detach 50% of the cells was similar for EMILIN-1 and gC1q-1 (250-270 x g) but lower than that for FN (much greater than500). Cell adhesion to EMILIN-1 or gC1q-1 was completely blocked by a function-blocking beta(1) integrin subunit mAb. In contrast, adhesion to the complement C1q component was totally unaffected. Among the various function-blocking mAbs against the alpha integrin subunits only the anti-alpha(4) fully abrogated cell adhesion to gC1q-1 and up to 70% to EMILIN-1. Furthermore, only K562 cells transfected with the alpha(4) integrin chain, but not wild type K562, were able to adhere to EMILIN-1 and were specifically inhibited by anti-alpha(4) function-blocking mAb. Finally, cells attached to EMILIN-1 or gC1q-1, compared with cells plated on FN or vitronectin, which appeared well spread out on the substrate with prominent stress fibers and focal contacts, were much smaller with wide ruffles and a different organization status of the actin cytoskeleton along the cell periphery. This pattern was in accord with the ability of EMILIN-1 to promote cell movement.	Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-35100 Udine, Italy; Univ Udine, Micrograv Ageing Training & Immobil Ctr Excellenc, I-35100 Udine, Italy	IRCCS Aviano (CRO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Udine	Colombatti, A (corresponding author), Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy.	acolombatti@cro.it	Spessotto, Paola/K-5005-2012; Mucignat, Maria Teresa/AAY-3908-2020; Doliana, Roberto/AAA-1479-2019	Spessotto, Paola/0000-0002-3033-404X; Mucignat, Maria Teresa/0000-0002-9601-054X; Doliana, Roberto/0000-0002-8324-7564; colombatti, alfonso/0000-0002-3676-2379	Telethon [E.1256] Funding Source: Medline	Telethon(Fondazione Telethon)		AOTA S, 1991, J BIOL CHEM, V266, P15938; Bayless KJ, 1998, J CELL SCI, V111, P1165; Bogetto L, 2000, BLOOD, V95, P2397, DOI 10.1182/blood.V95.7.2397.007k07_2397_2406; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; BRESSAN GM, 1983, J BIOL CHEM, V258, P3262; Bridges LC, 2002, J BIOL CHEM, V277, P3784, DOI 10.1074/jbc.M109538200; Christian S, 2001, J BIOL CHEM, V276, P48588, DOI 10.1074/jbc.M106152200; Cleary E. G., 1996, EXTRACELLULAR MATRIX, V2, P95; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; COLOMBATTI A, 1985, COLLAGEN REL RES, V5, P181; COLOMBATTI A, 1988, J BIOL CHEM, V263, P17534; COLOMBATTI A, 1985, J CELL BIOL, V100, P18, DOI 10.1083/jcb.100.1.18; COLOMBATTI A, 1987, COLLAGEN REL RES, V7, P259; D'Arrigo C, 1998, CONNECT TISSUE RES, V37, P29, DOI 10.3109/03008209809028898; DAGAGORDINI D, 1987, HISTOCHEM J, V19, P623, DOI 10.1007/BF01676168; Davis GE, 1997, J LEUKOCYTE BIOL, V62, P318, DOI 10.1002/jlb.62.3.318; Decker S, 2002, BIOCHEM BIOPH RES CO, V293, P86, DOI 10.1016/S0006-291X(02)00180-8; Dedio J, 1998, J IMMUNOL, V160, P3534; Doliana R, 1999, J BIOL CHEM, V274, P16773, DOI 10.1074/jbc.274.24.16773; Doliana R, 2001, J BIOL CHEM, V276, P12003, DOI 10.1074/jbc.M011591200; Doliana R, 2000, FEBS LETT, V484, P164, DOI 10.1016/S0014-5793(00)02140-2; Duplaa C, 1997, CIRC RES, V80, P159; Eggleton P, 2000, CLIN EXP IMMUNOL, V120, P406, DOI 10.1046/j.1365-2249.2000.01218.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Feng XD, 2002, J IMMUNOL, V168, P2441, DOI 10.4049/jimmunol.168.5.2441; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GATTEI V, 1992, J CELL BIOL, V116, P437, DOI 10.1083/jcb.116.2.437; GHEBREHIWET B, 1995, J IMMUNOL, V155, P2614; Ghebrehiwet B, 2001, IMMUNOL REV, V180, P65, DOI 10.1034/j.1600-065X.2001.1800106.x; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Giacomello E, 1999, BIOTECHNIQUES, V26, P758, DOI 10.2144/99264pf01; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GORDINI DD, 1990, CELL TISSUE RES, V260, P137, DOI 10.1007/BF00297499; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; Hou GP, 2000, AM J PATHOL, V156, P467, DOI 10.1016/S0002-9440(10)64751-7; IIDA J, 1995, CANCER RES, V55, P2177; Isobe T, 1997, J BIOL CHEM, V272, P8447, DOI 10.1074/jbc.272.13.8447; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kuna P, 1996, CLIN IMMUNOL IMMUNOP, V81, P48, DOI 10.1006/clin.1996.0156; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mongiat M, 2000, J BIOL CHEM, V275, P25471, DOI 10.1074/jbc.M001426200; Munoz M, 1996, J BIOL CHEM, V271, P2696, DOI 10.1074/jbc.271.5.2696; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Newham P, 1998, J IMMUNOL, V160, P4508; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Peerschke EIB, 1996, J IMMUNOL, V157, P4154; Pfaff M, 1996, FEBS LETT, V384, P247, DOI 10.1016/0014-5793(96)00325-0; Pinco KA, 2002, MOL BIOL CELL, V13, P3203, DOI 10.1091/mbc.02-05-0086; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAELMAN EUM, 1994, BLOOD, V83, P1244; Saini A, 1997, INT J CANCER, V73, P264, DOI 10.1002/(SICI)1097-0215(19971009)73:2<264::AID-IJC17>3.3.CO;2-V; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; Solito E, 2000, J IMMUNOL, V165, P1573, DOI 10.4049/jimmunol.165.3.1573; Spessotto P, 2000, METH MOL B, V139, P321; Spring FA, 2001, BLOOD, V98, P458, DOI 10.1182/blood.V98.2.458; Tan XX, 1998, CLIN IMMUNOL IMMUNOP, V87, P193, DOI 10.1006/clin.1997.4485; Tozer EC, 1996, BIOCHEM CELL BIOL, V74, P785, DOI 10.1139/o96-085; Waitkus-Edwards KR, 2002, CIRC RES, V90, P473, DOI 10.1161/hh0402.105899; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yin ZN, 1997, CELL GROWTH DIFFER, V8, P1339	67	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6160	6167		10.1074/jbc.M208322200	http://dx.doi.org/10.1074/jbc.M208322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12456677	hybrid			2022-12-25	WOS:000181129400084
J	Valiakhmetov, A; Perlin, DS				Valiakhmetov, A; Perlin, DS			Molecular architecture of the phosphorylation region of the yeast plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; ENERGY TRANSDUCTION MECHANISM; CATALYZED OXIDATIVE CLEAVAGE; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC DOMAINS; SECRETORY VESICLES; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; MG2+ BINDING	The molecular architecture of the yeast plasma membrane H+-ATPase phosphorylation region was explored by Fe2+-catalyzed cleavage. An ATP-Mg2+.Fe2+ Complex was found to act as an affinity cleavage reagent in the presence of dithiothreitol/H2O2. Selective enzyme cleavage required bound adenine nucleotide, either ATP or ADP, in the presence of Mg2+. The fragment profile included a predominant N-terminal 61-kDa fragment, a minor 37-kDa fragment, and three prominent C-terminal fragments of 39, 36, and 30 kDa. The 61-kDa N-terminal and 39-kDa C-terminal fragments were predicted to originate from cleavage within the conserved MLT(558)GDAVG sequence. The 37-kDa fragment was consistent with cleavage within the S4/M4 sequence PVGLPA(340)V, while the 30-kDa and 36-kDa C-terminal fragments appeared to originate from cleavage in or around sequences D(646)TGIAVE and DMPGS(595)ELADF, respectively. The latter are spatially close to the highly conserved motif GD(634)GVND(638)APSL and conserved residues Thr(558) and Lys(615), which have been implicated in coordinating Mg2+ and ATP. Overall, these results demonstrate that Fe2+ associated with ATP and Mg2+ acts as an affinity cleavage agent of the H+-ATPase with backbone cleavage occurring in conserved regions known to coordinate metal-nucleotide complexes. This study provides support for a three-dimensional organization of the phosphorylation region of the yeast plasma membrane H+-ATPase that is consistent with, but not identical to, typical P-type enzymes.	Publ Hlth Res Inst, Newark, NJ 07103 USA		Perlin, DS (corresponding author), Publ Hlth Res Inst, 225 Warren St, Newark, NJ 07103 USA.	perlin@phri.org	Perlin, David S/K-4013-2015; Valiakhmetov, Airat/AAN-1307-2020	Valiakhmetov, Airat/0000-0002-4739-0806	NIGMS NIH HHS [GM 38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Borchers C, 2000, ANAL CHEM, V72, P1163, DOI 10.1021/ac990937m; Breaux GA, 2000, ANAL CHEM, V72, P1169, DOI 10.1021/ac9907282; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Goldshleger R, 2001, J BIOENERG BIOMEMBR, V33, P387, DOI 10.1023/A:1010615422932; Goldshleger R, 1998, ACTA PHYSIOL SCAND, V163, P89; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; Hasper A, 1999, BBA-BIOMEMBRANES, V1420, P214, DOI 10.1016/S0005-2736(99)00100-5; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; Hua SM, 2002, BIOCHEMISTRY-US, V41, P2264, DOI 10.1021/bi015684h; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pedersen PA, 2000, J BIOL CHEM, V275, P37588, DOI 10.1074/jbc.M005610200; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Scarborough GA, 1999, CURR OPIN CELL BIOL, V11, P517, DOI 10.1016/S0955-0674(99)80075-1; SETOYOUNG D, 1992, BIOCHIM BIOPHYS ACTA, V1102, P213, DOI 10.1016/0167-4838(92)90512-C; Soteropoulos P, 2001, J BIOL CHEM, V276, P16265, DOI 10.1074/jbc.M011115200; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Wang GF, 1997, ARCH BIOCHEM BIOPHYS, V344, P309, DOI 10.1006/abbi.1997.0213	29	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6330	6336		10.1074/jbc.M208927200	http://dx.doi.org/10.1074/jbc.M208927200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480942	hybrid			2022-12-25	WOS:000181129400106
J	Gupta, S; Chatterji, D				Gupta, S; Chatterji, D			Bimodal protection of DNA by Mycobacterium smegmatis DNA-binding protein from stationary phase cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-STRESS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; DPS; TUBERCULOSIS; SEQUENCES; DEFENSES; SURVIVAL; HOMOLOG	Some members of the DNA-binding protein from stationary phase cells (Dps) family of proteins have been shown to play an important role in protecting microorganisms from oxidative or nutritional stress. Dps homologs have been identified in various bacteria such as Escherichia coli, Bacillus subtilis, and Listeria innocua. Recently we have reported the presence of a Dps homolog, Ms-Dps, in Mycobacterium smegmatis. Ms-Dps was found to have a nonspecific DNA binding ability. Here we have detected two stable oligomeric forms of Ms-Dps in vitro, a trimeric and a dodecameric form. Interestingly, the conversion of Dps from a trimeric to a dodecameric form takes place upon incubation at 37 degreesC for 12 h. These two oligomeric forms differ in their DNA binding properties. The dodecameric form is capable of DNA binding and forming large crystalline arrays with DNA, whereas the trimeric form cannot do so. However, even in the absence of DNA binding, the trimeric form has the capacity to protect the DNA against Fenton's mediated damage. The protection is afforded by the ferroxidase activity of the trimer. However, the trimeric form cannot protect DNA from DNaseI attack, for which a direct physical shielding of DNA by the dodecamer is required. Thus we suggest that Ms-Dps provides a bimodal protection of DNA by its two different oligomeric forms.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Chatterji, D (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	dipankar@mbu.iise.ernet.in		Chatterji, Dipankar/0000-0002-9985-0632				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; CHEN L, 1995, MOL MICROBIOL, V18, P295, DOI 10.1111/j.1365-2958.1995.mmi_18020295.x; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Ferguson GP, 1998, J BACTERIOL, V180, P1030, DOI 10.1128/JB.180.5.1030-1036.1998; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Gupta S, 2002, PROTEIN ENG, V15, P503, DOI 10.1093/protein/15.6.503; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; Ilari A, 2002, J BIOL CHEM, V277, P37619, DOI 10.1074/jbc.M206186200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMOVSKAYA OL, 1994, J BACTERIOL, V176, P3928, DOI 10.1128/JB.176.13.3928-3935.1994; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Ojha AK, 2000, INFECT IMMUN, V68, P4084, DOI 10.1128/IAI.68.7.4084-4091.2000; Papinutto E, 2002, J BIOL CHEM, V277, P15093, DOI 10.1074/jbc.M112378200; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; ROSZAK DB, 1987, MICROBIOL REV, V51, P365, DOI 10.1128/MMBR.51.3.365-379.1987; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; Wolf SG, 1999, NATURE, V400, P83, DOI 10.1038/21918; Yamamoto Y, 2002, J BACTERIOL, V184, P2931, DOI 10.1128/JB.184.11.2931-2939.2002; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	26	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5235	5241		10.1074/jbc.M208825200	http://dx.doi.org/10.1074/jbc.M208825200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466274	hybrid			2022-12-25	WOS:000180968900112
J	Kobrinsky, E; Schwartz, E; Abernethy, DR; Soldatov, NM				Kobrinsky, E; Schwartz, E; Abernethy, DR; Soldatov, NM			Voltage-gated mobility of the Ca2+ channel cytoplasmic tails and its regulatory role	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; SHAKER POTASSIUM CHANNEL; CALCIUM-CHANNEL; ALPHA(1C) SUBUNIT; FUNCTIONAL EXPRESSION; CARBOXYL-TERMINUS; LIVING CELLS; BETA-SUBUNIT; INACTIVATION; CALMODULIN	Transient increase in intracellular free Ca2+ concentration generated by the voltage-gated Ca(v)1.2 channels acts as an important intracellular signal. By using fluorescence resonance energy transfer combined with patch clamp in living cells, we present evidence for voltage-gated mobility of the cytoplasmic tails of the Ca(v)1.2 channel and for its regulatory role in intracellular signaling. Anchoring of the C-terminal tail to the plasma membrane caused an inhibition of its state-dependent mobility, channel inactivation, and CREB-dependent transcription. Release of the tail restored these functions suggesting a direct role for voltage-gated mobility of the C-terminal tail in Ca2+ signaling.	NIA, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Soldatov, NM (corresponding author), NIA, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [Z01AG000294, ZIAAG000294] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Fan JS, 1998, PFLUG ARCH EUR J PHY, V436, P1021, DOI 10.1007/PL00008086; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kepplinger KJF, 2000, FEBS LETT, V477, P161, DOI 10.1016/S0014-5793(00)01791-9; Kepplinger KJF, 2000, J PHYSIOL-LONDON, V529, P119, DOI 10.1111/j.1469-7793.2000.00119.x; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Mermelstein PG, 2001, P NATL ACAD SCI USA, V98, P15342, DOI 10.1073/pnas.211563998; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; SALGADO VL, 1985, BIOPHYS J, V47, P567, DOI 10.1016/S0006-3495(85)83952-7; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; WEI XY, 1994, J BIOL CHEM, V269, P1635; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xia ZP, 2001, J BIOL CHEM, V276, P1766, DOI 10.1074/jbc.M008741200; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zal T, 2002, IMMUNITY, V16, P521, DOI 10.1016/S1074-7613(02)00301-1; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	43	48	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5021	5028		10.1074/jbc.M211254200	http://dx.doi.org/10.1074/jbc.M211254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473653	hybrid			2022-12-25	WOS:000180968900087
J	Rizos, H; Diefenbach, E; Badhwar, P; Woodruff, S; Becker, TM; Rooney, RJ; Kefford, RF				Rizos, H; Diefenbach, E; Badhwar, P; Woodruff, S; Becker, TM; Rooney, RJ; Kefford, RF			Association of p14(ARF) with the p120(E4F) transcriptional repressor enhances cell cycle inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P19(ARF) TUMOR-SUPPRESSOR; NUCLEOLAR LOCALIZATION; P53-DEPENDENT APOPTOSIS; GERMLINE MUTATIONS; MELANOMA FAMILIES; P53 STABILIZATION; BINDING PROTEIN; ARF-P53 PATHWAY; ARF; MDM2	The p14(ARF) tumor suppressor is a key regulator of cellular proliferation and is frequently inactivated in human cancer. This tumor suppressor functions in the p53 and pRb cell cycle regulatory pathways and can effectively activate both pathways to induce growth arrest or cell death. We now report that p14(ARF) forms a complex with the E1A-regulated transcriptional repressor, p120(E4F). p120(E4F) contacts p14(ARF) and p53 to form a ternary complex in vivo and enhances p14(ARF)-induced G(2) cell cycle arrest in a p53-dependent manner. We suggest that the interaction of p14(ARF) and p120(E4F) forms an important link between the p14(ARF) and p53 tumor suppressor proteins, both of which exhibit enhanced cell cycle inhibitory activity in the presence of this transcriptional repressor.	Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia; Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead, NSW 2145, Australia; Duke Univ, Ctr Med, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	University of Sydney; University of Sydney; Westmead Institute for Medical Research; Duke University	Rizos, H (corresponding author), Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.	helen_rizos@wmi.usyd.edu.au	Rizos, Helen/AAE-5010-2020	Rizos, Helen/0000-0002-2094-9198; Becker, Therese/0000-0002-5636-9902; Kefford, Richard/0000-0001-9251-9229				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DURO D, 1995, ONCOGENE, V11, P21; Esteller M, 2000, CANCER RES, V60, P129; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Fernandes ER, 1999, MOL CELL BIOL, V19, P4739; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; FOGNANI C, 1993, EMBO J, V12, P4985, DOI 10.1002/j.1460-2075.1993.tb06192.x; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Hasan MK, 2002, J BIOL CHEM, V277, P37765, DOI 10.1074/jbc.M204177200; Hashemi J, 2001, GENE CHROMOSOME CANC, V31, P107, DOI 10.1002/gcc.1124; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Holland EA, 1999, GENE CHROMOSOME CANC, V25, P339, DOI 10.1002/(SICI)1098-2264(199908)25:4<339::AID-GCC5>3.0.CO;2-H; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; LIN JY, 1995, ONCOGENE, V10, P2387; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Mason SL, 2002, ONCOGENE, V21, P4220, DOI 10.1038/sj.onc.1205524; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 1999, MELANOMA RES, V9, P10, DOI 10.1097/00008390-199902000-00003; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Rooney RJ, 2001, CELL GROWTH DIFFER, V12, P505; Rooney RJ, 1998, NUCLEIC ACIDS RES, V26, P1681, DOI 10.1093/nar/26.7.1681; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugihara T, 2001, J BIOL CHEM, V276, P18649, DOI 10.1074/jbc.C100011200; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	63	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4981	4989		10.1074/jbc.M210978200	http://dx.doi.org/10.1074/jbc.M210978200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12446718	hybrid			2022-12-25	WOS:000180968900083
J	Sijbrandi, R; Urbanus, ML; ten Hagen-Jongman, CM; Bernstein, HD; Oudega, B; Otto, BR; Luirink, J				Sijbrandi, R; Urbanus, ML; ten Hagen-Jongman, CM; Bernstein, HD; Oudega, B; Otto, BR; Luirink, J			Signal recognition particle (SRP)-mediated targeting and sec-dependent translocation of an extracellular Escherichia coli protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; INNER MEMBRANE; EXPORT; YIDC; SECRETION	Hemoglobin protease (Hbp) is a hemoglobin-degrading protein that is secreted by a human pathogenic Escherichia coli strain via the autotransporter mechanism. Little is known about the earliest steps in autotransporter secretion, i.e. the targeting to and translocation across the inner membrane. Here, we present evidence that Hbp interacts with the signal recognition particle (SRP) and the Sec-translocon early during biogenesis. Furthermore, Hbp requires a functional SRP targeting pathway and Sec-translocon for optimal translocation across the inner membrane. SecB is not required for targeting of Hbp but can compensate to some extent for the lack of SRP. Hbp is synthesized with an unusually long signal peptide that is remarkably conserved among a subset of autotransporters. We propose that these autotransporters preferentially use the co-translational SRP/Sec route to avoid adverse effects of the exposure of their mature domains in the cytoplasm.	Vrije Univ Amsterdam, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands; NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	Vrije Universiteit Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Luirink, J (corresponding author), Vrije Univ Amsterdam, Dept Mol Microbiol, Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	luirink@bio.vu.nl	Luirink, Joen/AAB-8658-2021	Luirink, J./0000-0001-8431-0804	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052022, ZIADK052022] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Bernstein KD, 2001, J BACTERIOL, V183, P2187, DOI 10.1128/JB.183.7.2187-2197.2001; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Grass S, 2000, MOL MICROBIOL, V36, P55, DOI 10.1046/j.1365-2958.2000.01812.x; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Kim J, 2001, FEBS LETT, V505, P245, DOI 10.1016/S0014-5793(01)02784-3; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUSTERS R, 1995, FEBS LETT, V372, P253, DOI 10.1016/0014-5793(95)00997-N; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MILLER JH, 1992, SHORT COURSE BACTERI, P437; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; Otto BR, 1998, J EXP MED, V188, P1091, DOI 10.1084/jem.188.6.1091; Otto BR, 2002, INFECT IMMUN, V70, P5, DOI 10.1128/IAI.70.1.5-10.2002; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Sarker S, 2000, J BACTERIOL, V182, P5592, DOI 10.1128/JB.182.19.5592-5595.2000; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; van Dooren SJM, 2001, FEMS MICROBIOL LETT, V205, P147, DOI 10.1016/S0378-1097(01)00454-2; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122	31	102	107	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4654	4659		10.1074/jbc.M211630200	http://dx.doi.org/10.1074/jbc.M211630200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466262	hybrid, Green Submitted			2022-12-25	WOS:000180968900040
J	Xu, YZ; Ji, Y; Zipser, B; Jellies, J; Johansen, KM; Johansen, J				Xu, YZ; Ji, Y; Zipser, B; Jellies, J; Johansen, KM; Johansen, J			Proteolytic cleavage of the ectodomain of the L1 CAM family member tractin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE L1; CELL-ADHESION; DIFFERENTIAL GLYCOSYLATION; NERVOUS-SYSTEM; PROTEINS; EXTENSION; RECEPTOR; MEMBRANE; NOTCH; FURIN	Tractin is a member of the L1 family of cell adhesion molecules in leech. Immunoblot analysis suggests that Tractin is constitutively cleaved in vivo at a proteolytic site with the sequence RKRRSR. This sequence conforms to the consensus sequence for cleavage by members of the furin family of convertases, and this proteolytic site is shared by a majority of other L1 family members. We provide evidence with furin-specific inhibitor experiments, by site-specific mutagenesis of Tractin constructs expressed in S2 cells, as well as by Tractin expression in furin-deficient LoVo cells that a furin convertase is the likely protease mediating this processing. Cross-immunoprecipitations with Tractin domain-specific antibodies suggest that the resulting NH2- and COOH-terminal cleavage fragments interact with each other and that this interaction provides a means for the NH2-terminal fragment to be tethered to the membrane. Furthermore, in S2 cell aggregation assays we show that the NH2-terminal fragment is necessary for homophilic adhesion and that cells expressing only the transmembrane COOH-terminal fragment are non-adhesive. However, tethering of exogeneously provided Tractin NH2-terminal fragment to S2 cells expressing only the COOH-terminal fragment can functionally restore the adhesive properties of Tractin.	Iowa State Univ Sci & Technol, Dept Zool & Genet, Ames, IA 50011 USA; Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Western Michigan Univ, Dept Biol Sci, Kalamazoo, MI 49008 USA	Iowa State University; Michigan State University; Western Michigan University	Johansen, J (corresponding author), Iowa State Univ Sci & Technol, Dept Zool & Genet, 3156 Mol Biol Bldg, Ames, IA 50011 USA.		Ji, Yun/B-7245-2009; Waldmann, Thomas/AAT-5972-2021	Ji, Yun/0000-0001-6340-7009; Waldmann, Thomas/0000-0003-4500-6660	NINDS NIH HHS [NS28857] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028857, R29NS028857] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Brummendorf T, 2001, CURR OPIN CELL BIOL, V13, P611, DOI 10.1016/S0955-0674(00)00259-3; Chen LS, 2001, J CELL BIOL, V154, P841, DOI 10.1083/jcb.200009004; COHEN NR, 1997, CURR BIOL, V7, P26; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Demyanenko GP, 1999, J NEUROSCI, V19, P4907; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FLASTER MS, 1983, BRAIN RES, V277, P196, DOI 10.1016/0006-8993(83)90927-7; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Hall SG, 1997, J NEUROBIOL, V32, P325, DOI 10.1002/(SICI)1097-4695(199703)32:3<325::AID-NEU6>3.3.CO;2-N; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLM J, 1995, J NEUROSCI RES, V42, P9, DOI 10.1002/jnr.490420103; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hortsch M, 1998, CELL ADHES COMMUN, V5, P61, DOI 10.3109/15419069809005599; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; Huang YQ, 1997, J CELL BIOL, V138, P143, DOI 10.1083/jcb.138.1.143; Jie CF, 2000, BBA-PROTEIN STRUCT M, V1479, P1, DOI 10.1016/S0167-4838(00)00030-3; Johansen J, 1997, CRIT REV EUKAR GENE, V7, P95, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.60; JOHANSEN KM, 1992, NEURON, V8, P559, DOI 10.1016/0896-6273(92)90283-J; Kamiguchi H, 1998, ANNU REV NEUROSCI, V21, P97, DOI 10.1146/annurev.neuro.21.1.97; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; MCKAY RDG, 1983, SCIENCE, V222, P788, DOI 10.1126/science.6356361; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nayeem N, 1999, J CELL SCI, V112, P4739; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; SADOUL K, 1988, J NEUROCHEM, V50, P510, DOI 10.1111/j.1471-4159.1988.tb02941.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6	38	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4322	4330		10.1074/jbc.M210775200	http://dx.doi.org/10.1074/jbc.M210775200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446717	Green Published, hybrid			2022-12-25	WOS:000180869700100
J	Hannon, R; Croxtall, JD; Getting, SJ; Roviezzo, F; Yona, S; Paul-Clark, MJ; Gavins, FNE; Perretti, M; Morris, JF; Buckingham, JC; Flower, RJ				Hannon, R; Croxtall, JD; Getting, SJ; Roviezzo, F; Yona, S; Paul-Clark, MJ; Gavins, FNE; Perretti, M; Morris, JF; Buckingham, JC; Flower, RJ			Aberrant inflammation and resistance to glucocorticoids in Annexin 1(-/-) Mouse	FASEB JOURNAL			English	Article						neutrophil activation; cell adhesion molecules; phagocytosis; cytokines; edema	LIPOCORTIN-I; RECOMBINANT LIPOCORTIN-1; GENE-EXPRESSION; LAVAGE FLUID; PAW EDEMA; MECHANISM; AUTOANTIBODIES; DEXAMETHASONE; PHAGOCYTOSIS; MACROPHAGES	The 37-kDa protein annexin 1 (Anx-1; lipocortin 1) has been implicated in the regulation of phagocytosis, cell signaling, and proliferation and is postulated to be a mediator of glucocorticoid action in inflammation and in the control of anterior pituitary hormone release. Here, we report that mice lacking the Anx-1 gene exhibit a complex phenotype that includes an altered expression of other annexins as well as of COX-2 and cPLA(2). In carrageenin- or zymosan-induced inflammation, Anx-1(-/-) mice exhibit an exaggerated response to the stimuli characterized by an increase in leukocyte emigration and IL-1beta generation and a partial or complete resistance to the antiinflammatory effects of glucocorticoids. Anx-1(-/-) polymorphonuclear leucocytes exhibited increased spontaneous migratory behavior in vivo whereas in vitro, leukocytes from Anx-1(-/-) mice had reduced cell surface CD 11b (MAC-1) but enhanced CD62L (L-selectin) expression and Anx-1(-/-) macrophages exhibited anomalies in phagocytosis. There are also gender differences in activated leukocyte behavior in the Anx-1(-/-) mice that are not seen in the wild-type animals, suggesting an interaction between sex hormones and inflammation in Anx-1(-/-) animals.	Univ London, Queen Mary, William Harvey Res Inst, Dept Biochem Pharmacol, London EC1M 6BQ, England; Univ Naples Federico II, Dipartimento Farmacol Sperimentale Federico II, Naples, Italy; Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England; Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W12 0NN, England	University of London; Queen Mary University London; University of Naples Federico II; University of Oxford; Imperial College London	Flower, RJ (corresponding author), Univ London, Queen Mary, William Harvey Res Inst, Dept Biochem Pharmacol, Charterhouse Sq, London EC1M 6BQ, England.	r.j.flower@qmul.ac.uk	Yona, Simon/ABE-6572-2020; Gavins, Felicity N. E./AAU-6010-2020	Gavins, Felicity N. E./0000-0001-7008-5423; Yona, Simon/0000-0002-3984-2008				Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Ajuebor MN, 1999, J IMMUNOL, V162, P1685; Akama Hideto, 1995, Materia Medica Polona, V27, P75; Barnes PJ, 2001, ALLERGY, V56, P928, DOI 10.1034/j.1398-9995.2001.00001.x; Bastian Boris C., 1993, Journal of Dermatological Science, V6, P225, DOI 10.1016/0923-1811(93)90043-O; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; Collins HL, 1997, J CELL SCI, V110, P191; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; CROXTALL JD, 1992, P NATL ACAD SCI USA, V89, P3571, DOI 10.1073/pnas.89.8.3571; Croxtall JD, 2002, BRIT J PHARMACOL, V135, P511, DOI 10.1038/sj.bjp.0704474; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; DASILVA JAP, 1993, J ENDOCRINOL, V136, P389, DOI 10.1677/joe.0.1360389; DAVIDSON J, 1991, BRIT J PHARMACOL, V102, P7, DOI 10.1111/j.1476-5381.1991.tb12122.x; DECATERINA R, 1993, J APPL PHYSIOL, V75, P2368, DOI 10.1152/jappl.1993.75.6.2368; Diakonova M, 1997, J CELL SCI, V110, P1199; EBERHARD DA, 1994, AM J PATHOL, V145, P640; ELDERFIELD AJ, 1992, J NEUROIMMUNOL, V39, P91, DOI 10.1016/0165-5728(92)90178-N; Ferreira SH, 1997, BRIT J PHARMACOL, V121, P883, DOI 10.1038/sj.bjp.0701211; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GARCIAGONZALEZ A, 1992, SEMIN ARTHRITIS RHEU, V22, P139, DOI 10.1016/0049-0172(92)90014-5; Getting SJ, 1997, BRIT J PHARMACOL, V120, P1075, DOI 10.1038/sj.bjp.0701029; GOULDING NJ, 1990, LANCET, V335, P1416, DOI 10.1016/0140-6736(90)91445-G; GOULDING NJ, 1989, ANN RHEUM DIS, V48, P843, DOI 10.1136/ard.48.10.843; Goulding NJ, 1998, INFLAMM RES, V47, pS158; GunteskiHamblin AM, 1996, AM J PHYSIOL-HEART C, V270, pH1091, DOI 10.1152/ajpheart.1996.270.3.H1091; Harricane MC, 1996, CELL BIOL INT, V20, P193, DOI 10.1006/cbir.1996.0024; Hawkins TE, 1999, MOL CELL BIOL, V19, P8028; HENRIQUES MGMO, 1987, BRAZ J MED BIOL RES, V20, P243; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Hogan B, 1994, MANIPULATING MOUSE E; HORLICK KR, 1991, GENOMICS, V10, P365, DOI 10.1016/0888-7543(91)90321-5; KITAJIMA Y, 1991, J INVEST DERMATOL, V97, P1032, DOI 10.1111/1523-1747.ep12492494; Kusumawati A, 2001, CELL BIOL INT, V25, P809, DOI 10.1006/cbir.2000.0704; La M, 2001, FASEB J, V15, P2247, DOI 10.1096/fj.01-0196com; Le Cabec V, 2000, INFECT IMMUN, V68, P4736, DOI 10.1128/IAI.68.8.4736-4745.2000; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Lindahl M, 1999, ELECTROPHORESIS, V20, P881, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<881::AID-ELPS881>3.0.CO;2-6; MEERS P, 1992, BIOCHEMISTRY-US, V31, P6372, DOI 10.1021/bi00143a003; MEERS P, 1993, BIOCHEMISTRY-US, V32, P1390, DOI 10.1021/bi00056a026; Mikuniya T, 1998, SARCOIDOSIS VASC DIF, V15, P38; MULLA A, 2001, IN PRESS J ENDOCRINO; Newman SP, 1997, ADV EXP MED BIOL, V407, P249; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; Philip JG, 2001, BRIT J PHARMACOL, V134, P887, DOI 10.1038/sj.bjp.0704324; PODGORSKI MR, 1992, J RHEUMATOL, V19, P1668; Rand JH, 1999, NEW ENGL J MED, V340, P1035, DOI 10.1056/NEJM199904013401310; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RELTON JK, 1991, J EXP MED, V174, P305, DOI 10.1084/jem.174.2.305; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHOHAT M, 1989, AM J MED GENET, V34, P163, DOI 10.1002/ajmg.1320340205; SMITH FB, 1995, J VASC INVEST, V1, P79; SMITH SF, 1990, ENVIRON HEALTH PERSP, V85, P135, DOI 10.2307/3430676; Srivastava M, 2000, CELL BIOL INT, V24, P475, DOI 10.1006/cbir.2000.0511; STEVENS TRJ, 1993, CLIN SCI, V84, P381, DOI 10.1042/cs0840381; Strausbaugh HJ, 2001, J IMMUNOL, V166, P6294, DOI 10.4049/jimmunol.166.10.6294; Sun HT, 2001, AM J MED GENET, V103, P81, DOI 10.1002/1096-8628(20010915)103:1<81::AID-AJMG1505>3.0.CO;2-T; TAYLOR AD, 1993, NEUROENDOCRINOLOGY, V58, P430, DOI 10.1159/000126572; TAYLOR AD, 1995, J ENDOCRINOL, V147, P533, DOI 10.1677/joe.0.1470533; TAYLOR AD, 1995, NEUROENDOCRINOLOGY, V62, P19, DOI 10.1159/000126984; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; VIOLETTE SM, 1990, J CELL PHYSIOL, V142, P70, DOI 10.1002/jcp.1041420110; VISHWANATH BS, 1993, J CLIN INVEST, V92, P1974, DOI 10.1172/JCI116791; Yang YH, 1999, ARTHRITIS RHEUM, V42, P1538, DOI 10.1002/1529-0131(199907)42:7<1538::AID-ANR29>3.0.CO;2-3	66	292	306	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					253	+		10.1096/fj.02-0239fje	http://dx.doi.org/10.1096/fj.02-0239fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475898				2022-12-25	WOS:000180574300020
J	Kwong, KY; Zou, YY; Day, CP; Hung, MC				Kwong, KY; Zou, YY; Day, CP; Hung, MC			The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway	ONCOGENE			English	Article						APC; beta-catenin; Tcf; colon cancer; adenovirus; thymidine kinase	CYCLIN D1; MUTATIONS; EXPRESSION; TUMOR; GENE; APC	The adenomatous polyposis coli (APC) or beta-catenin genes are frequently mutated in colorectal cancers, leading to activation of downstream genes with beta-catenin/T-cell factor (Tcf)-responsive promoters. We have developed a gene therapy approach selectively targeting colorectal cancer cells in which beta-catenin/Tcf4 pathway is activated by using a recombinant adenovirus AdTOP-CMV-TK, which carries a herpes simplex virus thymidine kinase gene (HSV TK) under the control of a beta-catenin/Tcf-response promoter linking to a minimum CMV promoter. AdTOP-CMV-TK and ganciclovir (GCV) treatment significantly suppressed the growth of human DLD-1 colon cancer cells in nude mice. Furthermore, no significant tumor suppression effect was observed in human hepatoma cell line SK-HEP-1, in which the beta-catenin/Tcf pathway is not activated, as a control experiment. In summary, we demonstrated the selective targeting of colorectal cancers with activated beta-catenin by AdTOP-CMV-TK and GCV treatment in animal models, as well as its therapeutic potential for colon cancer metastasized to liver.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen RH, 2001, CANCER RES, V61, P4445; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MELTON RG, 1999, ENZYME PRODRUG STRAT, P216; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884	15	32	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8340	8346		10.1038/sj.onc.1206050	http://dx.doi.org/10.1038/sj.onc.1206050			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447697				2022-12-25	WOS:000179323900012
J	Klarmann, GJ; Chen, X; North, TW; Preston, BD				Klarmann, GJ; Chen, X; North, TW; Preston, BD			Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FELINE IMMUNODEFICIENCY VIRUS; POLYPURINE TRACT; IN-VITRO; REPAIR ENZYME; RNASE-H; REPLICATION; DUTPASE; SEQUENCE; RECOGNITION; BINDING	Many retroviruses either encode dUTP pyrophosphatase (dUTPase) or package host-derived uracil DNA glycosylase as a means to limit the accumulation of uracil in DNA strands, suggesting that uracil is detrimental to one or more steps in the viral life cycle. In the present study, the effects of DNA uracilation on (-) strand DNA synthesis, RNase H activity, and (+) strand DNA synthesis were investigated in a cell-free system. This system uses the activities of purified human immunodeficiency virus type 1 (HIV-1) reverse transcriptase to convert single-stranded RNA to double-stranded DNA in a single reaction mixture. Substitution of dUTP for dTTP had no effect on (-) strand synthesis but significantly decreased yields of (+) strand DNA. Mapping of nascent (+) strand 5' ends revealed that this was due to decreased initiation from polypurine tracts with a concomitant increase in initiation at non-polypurine tract sites. Aberrant initiation correlated with a change in RNase H cleavage specificity when assayed on preformed RNA-DNA duplexes containing uracilated DNA, suggesting that appropriate "selection" of the (+) strand primer is affected. Collectively, these data suggest that accumulation of uracil in retroviral DNA may disrupt the viral life cycle by altering the specificity of (+) strand DNA synthesis initiation during reverse transcription.	Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of California System; University of California Davis	Klarmann, GJ (corresponding author), NCI, HIV Drug Resistant Program, POB B, Frederick, MD 21702 USA.	gklarmann@ncifcrf.gov			NCI NIH HHS [P30 CA42014] Funding Source: Medline; NIAID NIH HHS [R01 AI28189, R01 AI38755, R01 AI34834] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038755, R01AI028189, R01AI034834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Bailly C, 1999, J MOL BIOL, V291, P561, DOI 10.1006/jmbi.1999.2979; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; Brown HEV, 1999, J VIROL, V73, P9011, DOI 10.1128/JVI.73.11.9011-9020.1999; BROYLES SS, 1993, VIROLOGY, V195, P863, DOI 10.1006/viro.1993.1446; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Coffin JM, 1996, FIELDS VIROLOGY, P1767; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; ELDER JH, 1992, J VIROL, V66, P1791, DOI 10.1128/JVI.66.3.1791-1794.1992; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; GOULIAN M, 1980, J BIOL CHEM, V255, P630; HARRIS JD, 1981, VIROLOGY, V113, P573, DOI 10.1016/0042-6822(81)90185-9; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUNGNES O, 1992, VIROLOGY, V190, P440, DOI 10.1016/0042-6822(92)91230-R; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; Klarmann GJ, 2000, J BIOL CHEM, V275, P359, DOI 10.1074/jbc.275.1.359; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KORNBERG A, 1995, DNA REPLICATION; Kvaratskhelia M, 2002, J BIOL CHEM, V277, P16689, DOI 10.1074/jbc.M109914200; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LICHTENSTEIN DL, 1995, J VIROL, V69, P2881, DOI 10.1128/JVI.69.5.2881-2888.1995; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; NORTH TW, 1990, J BIOL CHEM, V265, P5121; Oliveros M, 1999, J VIROL, V73, P8934, DOI 10.1128/JVI.73.11.8934-8943.1999; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; Powell MD, 1999, J BIOL CHEM, V274, P19885, DOI 10.1074/jbc.274.28.19885; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Preston BD, 1997, SCIENCE, V275, P228, DOI 10.1126/science.275.5297.228; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; STEAGALL WK, 1995, VIROLOGY, V210, P302, DOI 10.1006/viro.1995.1347; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; TAPPER DP, 1981, NUCLEIC ACIDS RES, V9, P6787, DOI 10.1093/nar/9.24.6787; Telesnitsky A., 1997, P121; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; Turelli P, 1996, J VIROL, V70, P1213, DOI 10.1128/JVI.70.2.1213-1217.1996; Tuteja N, 2001, CRIT REV BIOCHEM MOL, V36, P261, DOI 10.1080/20014091074192; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775; Wang T, 1999, BIOCHEMISTRY-US, V38, P3624, DOI 10.1021/bi982124i; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999	54	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7902	7909		10.1074/jbc.M207223200	http://dx.doi.org/10.1074/jbc.M207223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12458216	hybrid			2022-12-25	WOS:000181466800022
J	Tansey, JT; Huml, AM; Vogt, R; Davis, KE; Jones, JM; Fraser, KA; Brasaemle, DL; Kimmel, AR; Londos, C				Tansey, JT; Huml, AM; Vogt, R; Davis, KE; Jones, JM; Fraser, KA; Brasaemle, DL; Kimmel, AR; Londos, C			Functional studies on native and mutated forms of perilipins - A role in protein kinase A-mediated lipolysis of triacylglycerols in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ACYL-COA SYNTHETASE; STORAGE; BLOCKS; INHIBITION; INFECTION; DROPLETS; DNA	Perilipin A coats the lipid storage droplets in adipocytes and is polyphosphorylated by protein kinase A (PKA); the fact that PKA activates lipolysis in adipocytes suggests a role for perilipins in this process. To assess whether perilipins participate directly in PKA-mediated lipolysis, we have expressed constructs coding for native and mutated forms of the two major splice variants of the perilipin gene, perilipins A and B, in Chinese hamster ovary fibroblasts. Perilipins localize to lipid droplet surfaces and displace the adipose differentiation-related protein that normally coats the droplets in these cells. Perilipin A inhibits triacylglycerol hydrolysis by 87% when PKA is quiescent, but activation of PKA and phosphorylation of perilipin A engenders a 7-fold lipolytic activation. Mutation of PKA sites within the N-terminal region of perilipin abrogates the PKA-mediated lipolytic response. In contrast, perilipin B exerts only minimal protection against lipolysis and is unresponsive to PKA activation. Since Chinese hamster ovary cells contain no PKA-activated lipase, we conclude that the expression of perilipin A alone is sufficient to confer PKA-mediated lipolysis in these cells. Moreover, the data indicate that the unique C-terminal portion of perilipin A is responsible for its protection against lipolysis and that phosphorylation at the N-terminal PKA sites attenuates this protective effect.	NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Londos, C (corresponding author), NIDDK, Cellular & Dev Biol Lab, NIH, Bldg 50,Rm 3140, Bethesda, MD 20892 USA.	DeanL@intra.niddk.nih.gov		Brasaemle, Dawn/0000-0002-8553-8285	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503, ZIADK015505, Z01DK015505] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1908, BIOMETRIKA, V6, P1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; LEVACHER C, 1985, REPROD NUTR DEV, V25, P169, DOI 10.1051/rnd:19850204; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; MILLER DG, 1992, J VIROL, V66, P78, DOI 10.1128/JVI.66.1.78-84.1992; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Osuga J, 1997, BIOCHEM BIOPH RES CO, V233, P655, DOI 10.1006/bbrc.1997.6518; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SLATIEL AR, 2002, P NATL ACAD SCI USA, V97, P535; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; WILSON CA, 1991, J VIROL, V65, P5975, DOI 10.1128/JVI.65.11.5975-5982.1991	27	178	185	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8401	8406		10.1074/jbc.M211005200	http://dx.doi.org/10.1074/jbc.M211005200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12477720	hybrid			2022-12-25	WOS:000181466800086
J	Gu, YJ; Chen, FS; Sanjo, N; Kawarai, T; Hasegawa, H; Duthie, M; Li, WP; Ruan, XY; Luthra, A; Mount, HTJ; Tandon, A; Fraser, PE; St George-Hyslop, P				Gu, YJ; Chen, FS; Sanjo, N; Kawarai, T; Hasegawa, H; Duthie, M; Li, WP; Ruan, XY; Luthra, A; Mount, HTJ; Tandon, A; Fraser, PE; St George-Hyslop, P			APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin-nicastrin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE CLEAVAGE; FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; BETA-APP; NOTCH; ACCUMULATION; DROSOPHILA; GENE; FRAGMENTS	APH-1 and PEN-2 genes modulate the function of nicastrin and the presenilins in Caenorhabditis elegans. Preliminary studies in transfected mammalian cells overexpressing tagged APH-1 proteins suggest that this genetic interaction is mediated by a direct physical interaction. Using the APH-1 protein encoded on human chromosome 1 (APH-1(1)L; also known as APH-1a) as an archetype, we report here that endogenous forms of APH-1 are predominantly expressed in intracellular membrane compartments, including the endoplasmic reticulum and cis-Golgi. APH-1 proteins directly interact with immature and mature forms of the presenilins and nicastrin within high molecular weight complexes that display gamma- and is an element of-secretase activity. Indeed APH-1 proteins can bind to the nicastrin Delta312-369 loss of function mutant, which does not undergo glycosylation maturation and is not trafficking beyond the endoplasmic reticulum. The levels of expression of endogenous APH-1(1)L can be suppressed by overexpression of any other members of the APH-1 family, suggesting that their abundance is coordinately regulated. Finally, although the absence of APH-1 destabilizes the presenilins, in contrast to nicastrin and PEN-2, APH-1 itself is only modestly destabilized in cells lacking functional expression of presenilin I or presenilin 2. Taken together, our data suggest that APH-1 proteins, and APH-1(1) in particular, may have a role in the initial assembly and maturation of presenilin-nicastrin complexes.	Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Toronto Western Hosp, Dept Med, Div Neurol,Univ Hlth Network, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.		Mount, Howard/B-4097-2013; Kawarai, Toshitaka/C-2822-2013	Kawarai, Toshitaka/0000-0003-4547-8131; Sanjo, Nobuo/0000-0002-1226-2425				ARAWAKA S, 2002, J NERUOCHEM, V275, P36794; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TAKESHITA I, 1990, ACTA NEUROPATHOL, V79, P506, DOI 10.1007/BF00296110; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	29	139	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7374	7380		10.1074/jbc.M209499200	http://dx.doi.org/10.1074/jbc.M209499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12471034	hybrid			2022-12-25	WOS:000181195100096
J	Salsi, V; Caretti, G; Wasner, M; Reinhard, W; Haugwitz, U; Engeland, K; Mantovani, R				Salsi, V; Caretti, G; Wasner, M; Reinhard, W; Haugwitz, U; Engeland, K; Mantovani, R			Interactions between p300 and multiple NF-Y trimers govern cyclin B2 promoter function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-ALPHA PROMOTER; TRANSCRIPTION FACTOR; CCAAT BOXES; P300/CBP-ASSOCIATED FACTOR; HISTONE ACETYLTRANSFERASE; GENE-TRANSCRIPTION; B1 GENE; IN-VIVO; BINDING; ACETYLATION	The CCAAT box is one of the most common elements in eukaryotic promoters and is activated by NF-Y, a conserved trimeric transcription factor with histone-like subunits. Usually one CCAAT element is present in promoters at positions between -60 and -100, but an emerging class of promoters harbor multiple NF-Y sites. In the triple CCAAT-containing cyclin B2 cell-cycle promoter, all CCAAT boxes, independently from their NF-Y affinities, are important for function. We investigated the relationships between NF-Y and p300. Chromatin immunoprecipitation analysis found that NF-Y and p300 are bound to the cyclin B2 promoter in vivo and that their binding is regulated during the cell cycle, positively correlating with promoter function. Cotransfection experiments determined that the coactivator acts on all CCAAT boxes and requires a precise spacing between the three elements. We established the order of in vitro binding of the three NF-Y complexes and find decreasing affinities from the most distal Y1 to the proximal Y3 site. Binding of two or three NF-Y trimers with or without p300 is not cooperative, but association with the Y1 and Y2 sites is extremely stable. p300 favors the binding of NF-Y to the weak Y3 proximal site, provided that a correct distance between the three CCAAT is respected. Our data indicate that the precise spacing of multiple CCAAT boxes is crucial for coactivator function. Transient association to a weak site might be a point of regulation during the cell cycle and a general theme of multiple CCAAT box promoters.	Univ Modena & Reggio, Dipartimento Biol Anim, I-41100 Modena, Italy; Univ Leipzig, Med Klin 2, Max Burger Forschungszentrum, D-04103 Leipzig, Germany	Universita di Modena e Reggio Emilia; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Mantovani, R (corresponding author), Univ Modena & Reggio, Dipartimento Biol Anim, Via Campi 213-D, I-41100 Modena, Italy.		Engeland, Kurt/AAW-9965-2020	Engeland, Kurt/0000-0003-3525-0440; SALSI, Valentina/0000-0002-7133-0360				Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; ARCOT SS, 1989, J BIOL CHEM, V264, P2343; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Caretti G, 1999, MOL CELL BIOL, V19, P8591; Coustry F, 2001, J BIOL CHEM, V276, P40621, DOI 10.1074/jbc.M106918200; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Dohna CLZ, 2000, FEBS LETT, V484, P77, DOI 10.1016/S0014-5793(00)02133-5; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; Goodman RH, 2000, GENE DEV, V14, P1553; Harton JA, 2001, J BIOL CHEM, V276, P38715, DOI 10.1074/jbc.M106652200; Haugwitz U, 2002, NUCLEIC ACIDS RES, V30, P1967, DOI 10.1093/nar/30.9.1967; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Korner K, 2000, J BIOL CHEM, V275, P18676, DOI 10.1074/jbc.M001110200; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Liberati C, 1999, J MOL BIOL, V285, P1441, DOI 10.1006/jmbi.1998.2384; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Park JB, 2000, BIOCHEM BIOPH RES CO, V267, P651, DOI 10.1006/bbrc.1999.1980; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suzuki Y, 2001, GENOME RES, V11, P677, DOI 10.1101/gr.GR-1640R; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zemzoumi K, 1999, J MOL BIOL, V286, P327, DOI 10.1006/jmbi.1998.2496; Zeng XY, 2001, J BIOL CHEM, V276, P48, DOI 10.1074/jbc.C000722200; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	49	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6642	6650		10.1074/jbc.M210065200	http://dx.doi.org/10.1074/jbc.M210065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482752	Green Published, hybrid			2022-12-25	WOS:000181195100004
J	Abdollahi, A; Pisarcik, D; Roberts, D; Weinstein, J; Cairns, P; Hamilton, TC				Abdollahi, A; Pisarcik, D; Roberts, D; Weinstein, J; Cairns, P; Hamilton, TC			LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NEONATAL DIABETES-MELLITUS; SURFACE EPITHELIAL-CELLS; DNA METHYLATION; HISTONE DEACETYLASE; CHROMATIN STRUCTURE; SPONTANEOUS TRANSFORMATION; IMPRINTED GENES; CPG METHYLATION; ACETYLATION	LOT1 is a zinc-finger nuclear transcription factor, which possesses anti-proliferative effects and is frequently silenced in ovarian and breast cancer cells. The LOT1 gene is localized at chromosome 6q24-25, a chromosomal region maternally imprinted and linked to growth retardation in several organs and progression of disease states such as transient neonatal diabetes mellitus. Toward understanding the molecular mechanism underlying the loss of LOT1 expression in cancer, we have characterized the genomic structure and analyzed its epigenetic regulation. Genome mapping of LOT1 in comparison with the other splice variants, namely ZAC1 and PLAGL1, revealed that its mRNA (similar to4.7 kb; GenBank(TM) accession number U72621) is potentially spliced using six exons spanning at least 70 kb of the human genome. 5'-RACE (rapid amplification of cDNA ends) data indicate the presence of at least two transcription start sites. We found that in vitro methylation of the LOTI promoter causes a significant loss in its ability to drive luciferase transcription. To determine the nature of in vivo methylation of LOTI, we used bisulfite-sequencing strategies on genomic DNA. We show that in the ovarian and breast cancer cell lines and/or tumors the 5'-CpG island of LOT1 is a differentially methylated region. In these cell lines the ratio of methylated to unmethylated CpG dinucleotides in this region ranged from 31 to 99% and the ovarian tumors have relatively higher cytosine methylation than normal tissues. Furthermore, we show that trichostatin A, a specific inhibitor of histone deacetylase, relieves transcriptional silencing of LOT1 mRNA in malignantly transformed cells. It appears that, unlike DNA methylation, histone deacetylation does not target the promoter, and rather it is indirect and may be elicited by a mechanism upstream of the LOT1 regulatory pathway. Taken together, the data suggest that expression of LOT1 is under the control of two epigenetic modifications and that, in the absence of loss of heterozygosity, the biallelic (two-hit) or maximal silencing of LOT1 requires both processes.	Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Abdollahi, A (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	A_Abdollahi@fccc.edu			NCI NIH HHS [CA56916, CA83638, CA84242, CA51228] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084242, R01CA056916, P50CA083638, R01CA051228] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Arima T, 2001, HUM MOL GENET, V10, P1475, DOI 10.1093/hmg/10.14.1475; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; El Kharroubi A, 2001, J BIOL CHEM, V276, P8674, DOI 10.1074/jbc.M009392200; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gardner RJ, 2000, HUM MOL GENET, V9, P589, DOI 10.1093/hmg/9.4.589; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kamiya M, 2000, HUM MOL GENET, V9, P453, DOI 10.1093/hmg/9.3.453; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; MARUYAMA K, 1994, GENE, V138, P171; NAN X, 1998, NATURE, V393; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; SAKAI T, 1991, AM J HUM GENET, V48, P880; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Singal R, 2002, J BIOL CHEM, V277, P1897, DOI 10.1074/jbc.M105580200; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; TESTA JR, 1994, CANCER RES, V54, P2778; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; Varrault A, 2001, J BIOL CHEM, V276, P18653, DOI 10.1074/jbc.C100095200; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; ZHANG YH, 1993, AM J HUM GENET, V53, P113	51	88	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6041	6049		10.1074/jbc.M210361200	http://dx.doi.org/10.1074/jbc.M210361200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12473647	hybrid			2022-12-25	WOS:000181129400070
J	Bouvard, D; Vignoud, L; Dupe-Manet, S; Abed, N; Fournier, HN; Vincent-Monegat, C; Retta, SF; Fassler, R; Block, MR				Bouvard, D; Vignoud, L; Dupe-Manet, S; Abed, N; Fournier, HN; Vincent-Monegat, C; Retta, SF; Fassler, R; Block, MR			Disruption of focal adhesions by integrin cytoplasmic domain-associated protein-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; MUSCLE CELL-MIGRATION; EMBRYONIC STEM-CELLS; DEPENDENT PROTEIN; BETA(1) INTEGRIN; R-RAS; ALPHA-5-BETA-1 INTEGRIN; INTRACELLULAR CALCIUM; MONOCLONAL-ANTIBODY; BINDING-SITE	Regulation of integrin affinity and clustering plays a key role in the control of cell adhesion and migration. The protein ICAP-1alpha (integrin cytoplasmic domain-associated protein-1alpha) binds to the cytoplasmic domain of the beta(1A) integrin and controls cell spreading on fibronectin. Here, we demonstrate that, despite its ability to interact with beta(1A) integrin, ICAP-1alpha is not recruited in focal adhesions, whereas it is colocalized with the integrin at the ruffling edges of the cells. ICAP-1alpha induced a rapid disruption of focal adhesions, which may result from the ability of ICAP-1alpha to inhibit the association of beta(1A) integrin with talin, which is crucial for the assembly of these structures. ICAP-1alpha-mediated dispersion of beta(1A) integrins is not observed with beta(1D) integrins that do not bind ICAP. This strongly suggests that ICAP-1alpha action depends on a direct interaction between ICAP-1alpha and the cytoplasmic domain of the beta(1) chains. Altogether, these results suggest that ICAP-1alpha plays a key role in cell adhesion by acting as a negative regulator of beta(1) integrin avidity.	Fac Med Grenoble, Inst Albert Bonniot, UMR UJR CNRS 5538, Lab Etud Differenciat & Adherence Cellulaires, F-38706 La Tronche, France; Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Max Planck Society; University of Turin	Block, MR (corresponding author), Fac Med Grenoble, Inst Albert Bonniot, UMR UJR CNRS 5538, Lab Etud Differenciat & Adherence Cellulaires, F-38706 La Tronche, France.		Retta, Saverio Francesco/Q-4770-2019; Block, Marc R/M-2740-2013; Vincent-Monégat, Carole/G-7287-2011; Bouvard, Daniel/M-2727-2013; Bouvard, Daniel/B-1260-2017	Retta, Saverio Francesco/0000-0001-9761-2959; Block, Marc R/0000-0003-2214-9706; Bouvard, Daniel/0000-0002-0845-6681				ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; Bouvard D, 1998, J CELL SCI, V111, P657; Bouvard D, 1998, BIOCHEM BIOPH RES CO, V252, P46, DOI 10.1006/bbrc.1998.9592; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; CATTELINO A, 1995, J CELL SCI, V108, P3067; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; Chang DD, 2002, J BIOL CHEM, V277, P8140, DOI 10.1074/jbc.M109031200; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Degani S, 2002, J CELL BIOL, V156, P377, DOI 10.1083/jcb.200108030; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Faisst AM, 1998, DEV DYNAM, V212, P293, DOI 10.1002/(SICI)1097-0177(199806)212:2<293::AID-AJA14>3.0.CO;2-5; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Fournier HN, 2002, J BIOL CHEM, V277, P20895, DOI 10.1074/jbc.M200200200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hendey B, 1996, BLOOD, V87, P2038; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; PAULY RR, 1995, CIRCULATION, V91, P1107, DOI 10.1161/01.CIR.91.4.1107; POMIES P, 1995, BIOCHEMISTRY-US, V34, P5104, DOI 10.1021/bi00015a022; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; Takahashi K, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-23; Tang SQ, 1999, J CELL BIOL, V147, P1073, DOI 10.1083/jcb.147.5.1073; Valmu L, 1999, BIOCHEM J, V339, P119, DOI 10.1042/0264-6021:3390119; Vignoud L, 1997, J CELL SCI, V110, P1421; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wennerberg K, 1998, J CELL SCI, V111, P1117; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	46	69	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6567	6574		10.1074/jbc.M211258200	http://dx.doi.org/10.1074/jbc.M211258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12473654	Green Published, hybrid			2022-12-25	WOS:000181129400134
J	Datta, K; LiCata, VJ				Datta, K; LiCata, VJ			Salt dependence of DNA binding by Thermus aquaticus and Escherichia coli DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID POLYMERASE; LARGE FRAGMENT; RAPID PURIFICATION; KLENOW FRAGMENT; TAQ POLYMERASE; PROTEIN-DNA; I KLENOW; MECHANISM; EXPRESSION; SITE	DNA binding properties of the Type 1 DNA polymerases from Thermus aquaticus (Taq, Klentaq) and Escherichia coli (Klenow) have been examined as a function of [KCl] and [MgCl2]. Full-length Taq and its Klentaq "large fragment" behave similarly in all assays. The two different species of polymerases bind DNA with submicromolar affinities in very different salt concentration ranges. Consequently, at similar [KCl] the binding of Klenow is similar to 3 kcal/mol (150x) tighter than that of Taq/Klentaq to the same DNA. Linkage analysis reveals a net release of 2-3 ions upon DNA binding of Taq/Klentaq and 4-5 ions upon binding of Klenow. DNA binding of Taq at a higher temperature (60 degreesC) slightly decreases the ion release. Linkage analysis of binding versus ion upon [MgCl2] reports the ultimate release of similar to 1 Mg2+, complex formation. However, the MgCl2 dependence for Klenow, but not Klentaq, shows two distinct phases. In 10 mm EDTA, both polymerase species still bind DNA, but their binding affinity is significantly diminished, Klenow more than Klentaq. In summary, the two polymerase species, when binding to identical DNA, differ substantially in their sensitivity to the salt concentration range, bind with very different affinities when compared under similar conditions, release different numbers of ions upon binding, and differ in their interactions with divalent cations.	Louisiana State Univ, Dept Sci Biol, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	LiCata, VJ (corresponding author), Louisiana State Univ, Dept Sci Biol, Baton Rouge, LA 70803 USA.	licata@lsu.edu						BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3842, DOI 10.1021/bi00516a027; BARNES WM, 1992, GENE, V112, P29, DOI 10.1016/0378-1119(92)90299-5; BARNES WM, 1995, Patent No. 5436149; BATTISTA JR, 2001, BERGEYS MANUAL SYSTE, V1, P395; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK TD, 1974, BERGEYS MANUAL DETER, P285; CHIEN A, 1976, J BACTERIOL, V127, P1550, DOI 10.1128/JB.127.3.1550-1557.1976; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; Dabrowski S, 1998, ACTA BIOCHIM POL, V45, P661, DOI 10.18388/abp.1998_4204; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; DENMAN S, 1991, FEMS MICROBIOL LETT, V82, P73; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ENGELKE DR, 1990, ANAL BIOCHEM, V191, P396, DOI 10.1016/0003-2697(90)90238-5; ENGLUND PT, 1969, J BIOL CHEM, V244, P3038; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; GELFAND DH, 1989, Patent No. 4889818; GELFAND DH, 1989, Patent No. 5079352; GRIMM E, 1995, NUCLEIC ACIDS RES, V23, P4518, DOI 10.1093/nar/23.21.4518; Heyduk E, 2001, J BIOL CHEM, V276, P44598, DOI 10.1074/jbc.M107760200; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; INGLESE J, 1989, J MED CHEM, V32, P937, DOI 10.1021/jm00125a002; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; KALEDIN A S, 1980, Biokhimiya, V45, P644; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KLENOW H, 1970, FEBS LETT, V6, P25, DOI 10.1016/0014-5793(70)80032-1; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Lawyer F C, 1993, PCR Methods Appl, V2, P275; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEELAYUWAT C, 1997, J MED ASS THAIL S1, V80, P129; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; Lundback T, 1996, J PHYS CHEM-US, V100, P17690, DOI 10.1021/jp9614613; MADIGAN MT, 1997, BROCK BIOL MICROORGA, P170; MINKLEY EG, 1984, J BIOL CHEM, V259, P386; Morales JC, 2000, BIOCHEMISTRY-US, V39, P12979, DOI 10.1021/bi001578o; MULLEN GP, 1990, J BIOL CHEM, V265, P14327; Nord K, 2000, J BIOTECHNOL, V80, P45, DOI 10.1016/S0168-1656(00)00232-7; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; Patel PH, 2001, NAT STRUCT BIOL, V8, P656, DOI 10.1038/90344; Perler FB, 1996, ADV PROTEIN CHEM, V48, P377; PLUTHERO FG, 1993, NUCLEIC ACIDS RES, V21, P4850, DOI 10.1093/nar/21.20.4850; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; Record MT, 1998, ADV PROTEIN CHEM, V51, P281; SLATER JP, 1972, J BIOL CHEM, V247, P6784; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; SULLIVAN MA, 2000, Patent No. 6083686; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Yadav Prem N. S., 1994, Journal of Molecular Recognition, V7, P207, DOI 10.1002/jmr.300070308	52	51	64	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5694	5701		10.1074/jbc.M208133200	http://dx.doi.org/10.1074/jbc.M208133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12466277	Green Published, hybrid			2022-12-25	WOS:000181129400028
J	Iida, R; Yasuda, T; Tsubota, E; Takatsuka, H; Masuyama, M; Matsuki, T; Kishi, K				Iida, R; Yasuda, T; Tsubota, E; Takatsuka, H; Masuyama, M; Matsuki, T; Kishi, K			M-LP, Mpv17-like protein, has a peroxisomal membrane targeting signal comprising a transmembrane domain and a positively charged loop and up-regulates expression of the manganese superoxide dismutase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SACCHAROMYCES-CEREVISIAE; MOUSE MODEL; IMPORT; MICE; BIOGENESIS; TERMINUS; CLONING; PROLIFERATION; FIBROBLASTS	M-LP (Mpv17-like protein) has been identified as a new protein that has high sequence homology with Mpv17 protein, a peroxisomal membrane protein involved in the development of early onset glomerulosclerosis. In this study, we verified the peroxisomal localization of M-LP by performing dual-color confocal analysis of COS-7 cells cotransfected with green fluorescent protein-tagged M-LP and DsRED2-PTS1, a red fluorescent peroxisomal marker. To characterize the peroxisomal membrane targeting signal, we examined the intracellular localizations of several green fluorescent protein-tagged deletion mutants and demonstrated that, of the three transmembrane segments predicted, the first near the NH2 terminus and NH2-terminal half of the following loop region, which is abundant in positively charged amino acids, were necessary and sufficient for peroxisomal targeting. To elucidate the function of M-LP, we examined the activities of several enzymes involved in reactive oxygen species metabolism in COS-7 cells and found that transfection with M-LP increased the superoxide dismutase activity significantly. Quantitative real-time PCR analysis revealed that the manganese SOD (SOD2) mRNA level of COS-7 cells transfected with M-LP was elevated. These results indicate that M-LP participates in reactive oxygen species metabolism.	Fukui Med Sch, Dept Forens Med, Fukui 9101193, Japan; Fukui Med Sch, Dept Biol, Fukui 9101193, Japan; Gunma Univ, Sch Med, Dept Legal Med, Gunma 3718511, Japan	University of Fukui; University of Fukui; Gunma University	Iida, R (corresponding author), Fukui Med Sch, Dept Forens Med, Fukui 9101193, Japan.	ireiko@fmsrsa.fukui-med.ac.jp						AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; ALLEN RG, 1995, J CELL PHYSIOL, V165, P576; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Binder CJ, 1999, AM J PATHOL, V154, P1067, DOI 10.1016/S0002-9440(10)65359-X; BRYANT DD, 1995, BIOCHEM MOL MED, V55, P22, DOI 10.1006/bmme.1995.1027; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Iida R, 2000, MECH AGEING DEV, V113, P135, DOI 10.1016/S0047-6374(99)00104-9; Iida R, 2002, EXP GERONTOL, V37, P1121, DOI 10.1016/S0531-5565(02)00066-9; Iida R, 2001, BIOCHEM BIOPH RES CO, V283, P292, DOI 10.1006/bbrc.2001.4769; Imanaka T, 1996, J BIOL CHEM, V271, P3706; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; Maria CS, 1996, FREE RADICAL RES, V25, P401, DOI 10.3109/10715769609149062; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Pause B, 2000, FEBS LETT, V471, P23, DOI 10.1016/S0014-5793(00)01332-6; Przedborski S, 1998, NAT GENET, V18, P99, DOI 10.1038/ng0298-99; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; VANDENBOSCH H, 1982, ANNU REV BIOCHEM, V61, P157; Wagner G, 2001, BIOL CHEM, V382, P1019, DOI 10.1515/BC.2001.128; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; WEIHER H, 1990, CELL, V62, P425, DOI 10.1016/0092-8674(90)90008-3; Wiemer EAC, 1997, J CELL BIOL, V136, P71, DOI 10.1083/jcb.136.1.71; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; zumGottesberge AMM, 1996, EUR ARCH OTO-RHINO-L, V253, P470, DOI 10.1007/BF00179952	38	36	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6301	6306		10.1074/jbc.M210886200	http://dx.doi.org/10.1074/jbc.M210886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471025	hybrid			2022-12-25	WOS:000181129400102
J	Teufel, M; Saudek, V; Ledig, JP; Bernhardt, A; Boularand, S; Carreau, A; Cairns, NJ; Carter, C; Cowley, DJ; Duverger, D; Ganzhorn, AJ; Guenet, C; Heintzelmann, B; Laucher, V; Sauvage, C; Smirnova, T				Teufel, M; Saudek, V; Ledig, JP; Bernhardt, A; Boularand, S; Carreau, A; Cairns, NJ; Carter, C; Cowley, DJ; Duverger, D; Ganzhorn, AJ; Guenet, C; Heintzelmann, B; Laucher, V; Sauvage, C; Smirnova, T			Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM CARNOSINASE; HUMAN-TISSUE CARNOSINASE; FLUOROMETRIC ASSAY; AMINO-ACIDS; RAT-BRAIN; HOMOCARNOSINE; PURIFICATION; CELLS; LOCALIZATION; INHIBITION	Carnosine (beta-alanyl-L-histidine) and homocarnosine (gamma-aminobutyric acid-L-histidine) are two naturally occurring dipeptides with potential neuroprotective and neurotransmitter functions in the brain. Peptidase activities degrading both carnosine and homocarnosine have been described previously, but the genes linked to these activities were unknown. Here we present the identification of two novel cDNAs named CN1 and CN2 coding for two proteins of 56.8 and 52.7 kDa and their classification as members of the M20 metalloprotease family. Whereas human CN1 mRNA and protein are brain-specific, CN2 codes for a ubiquitous protein. In contrast, expression of the mouse and rat CN1 orthologues was detectable only in kidney. The recombinant CN1 and CN2 proteins were expressed in Chinese hamster ovary cells and purified to homogeneity. CN1 was identified as a homodimeric dipeptidase with a narrow substrate specificity for Xaa-His dipeptides including those with Xaa = betaAla (carnosine, K-m 1.2 mm), N-methyl betaAla, Ala, Gly, and gamma-aminobutyric acid (homocarnosine, K-m 200 mum), an isoelectric point of pH 4.5, and maximal activity at pH 8.5. CN2 protein is a dipeptidase not limited to Xaa-His dipeptides, requires Mn2+ for full activity, and is sensitive to inhibition by bestatin (IC50 7 nm). This enzyme does not degrade homocarnosine and hydrolyzes carnosine only at alkaline pH with an optimum at pH 9.5. Based on their substrate specificity and biophysical and biochemical properties CN1 was identified as human carnosinase (EC 3.4.13.20), whereas CN2 corresponds to the cytosolic nonspecific dipeptidase (EC 3.4.13.18).	Sanofi Synthelabo Rech, Dept Exploratory Res, F-67080 Strasbourg, France; Kings Coll London, Inst Psychiat, Dept Neuropathol, London SE5 8AF, England; Dept Exploratoire, Labs Fournier, F-21121 Daix, France; Aventis Pharma, Paris Res Ctr, F-94400 Vitry Sur Seine, France; Sanofi Synthelabo Rech, Dept Neurosci, F-92200 Bagneux, France	Sanofi-Aventis; Sanofi France; University of London; King's College London; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Teufel, M (corresponding author), Sanofi Synthelabo Rech, Dept Exploratory Res, 16 Rue Ankara, F-67080 Strasbourg, France.	michael.teufel@sanofi-synthelabo.com	Cairns, Nigel/AAB-9713-2020; Carter, Christopher J/C-5452-2011	Cairns, Nigel/0000-0001-9858-3344; Carter, Christopher J/0000-0003-1368-4205				Abe H, 2000, BIOCHEMISTRY-MOSCOW+, V65, P757; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALESMITH EC, 1938, J PHYSL, V92, P336; BANDO K, 1984, ANN CLIN BIOCHEM, V21, P510, DOI 10.1177/000456328402100613; Baran EJ, 2000, BIOCHEMISTRY-MOSCOW+, V65, P789; CLARKE R, 1994, BASIC CELL CULTURE P, P223; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; FERRARO TN, 1985, BRAIN RES, V338, P53, DOI 10.1016/0006-8993(85)90247-1; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; Gulewitsch W, 1900, BER DTSCH CHEM GES, V33, P1902, DOI 10.1002/cber.19000330275; HANSON HT, 1949, J BIOL CHEM, V179, P789; Hipkiss AR, 1998, INT J BIOCHEM CELL B, V30, P863, DOI 10.1016/S1357-2725(98)00060-0; Hipkiss AR, 1997, NEUROSCI LETT, V238, P135, DOI 10.1016/S0304-3940(97)00873-2; HORINISHI H, 1978, J NEUROCHEM, V31, P909, DOI 10.1111/j.1471-4159.1978.tb00127.x; JACKSON MC, 1991, CLIN CHIM ACTA, V196, P193, DOI 10.1016/0009-8981(91)90073-L; KISH SJ, 1979, J NEUROCHEM, V32, P1629, DOI 10.1111/j.1471-4159.1979.tb02272.x; Koppensteiner WA, 2000, J MOL BIOL, V296, P1139, DOI 10.1006/jmbi.1999.3501; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNZE N, 1986, EUR J BIOCHEM, V160, P605, DOI 10.1111/j.1432-1033.1986.tb10081.x; LENNEY JF, 1985, BIOCHEM J, V228, P653, DOI 10.1042/bj2280653; LENNEY JF, 1990, BIOL CHEM H-S, V371, P167, DOI 10.1515/bchm3.1990.371.1.167; LENNEY JF, 1982, CLIN CHIM ACTA, V123, P221, DOI 10.1016/0009-8981(82)90166-8; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; MANNION AF, 1992, EUR J APPL PHYSIOL O, V64, P47, DOI 10.1007/BF00376439; MARGOLIS FL, 1983, BIOCHIM BIOPHYS ACTA, V744, P237, DOI 10.1016/0167-4838(83)90196-6; MCFARLAND G, 1994, EXP CELL RES, V167, P175; MURPHEY WH, 1972, CLIN CHIM ACTA, V42, P309, DOI 10.1016/0009-8981(72)90094-0; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; PEPPERS SC, 1988, BIOL CHEM H-S, V369, P1281, DOI 10.1515/bchm3.1988.369.2.1281; PERRY TL, 1968, J NEUROCHEM, V15, P1203, DOI 10.1111/j.1471-4159.1968.tb06838.x; PERRY TL, 1968, LANCET, V8, P1229; Petroff OAC, 1999, NEUROLOGY, V52, P473, DOI 10.1212/WNL.52.3.473; Petroff OAC, 2001, NEUROLOGY, V56, P709, DOI 10.1212/WNL.56.6.709; POLLACK SJ, 1994, P NATL ACAD SCI USA, V91, P5766, DOI 10.1073/pnas.91.13.5766; QUINN PJ, 1992, MOL ASPECTS MED, V13, P379, DOI 10.1016/0098-2997(92)90006-L; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rowsell S, 1997, STRUCTURE, V5, P337, DOI 10.1016/S0969-2126(97)00191-3; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; Tabakman R, 2002, J NEUROSCI RES, V68, P463, DOI 10.1002/jnr.10228; Trombley PQ, 2000, BIOCHEMISTRY-MOSCOW+, V65, P807; VANHEIJNE G, 1997, PROTEIN ENG, V10, P1; WOLOS A, 1978, INT J BIOCHEM, V9, P57, DOI 10.1016/0020-711X(78)90139-8; WOOD T, 1957, NATURE, V180, P39, DOI 10.1038/180039a0; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019; ZOCH E, 1971, ENZYMOLOGIA, V40, P199	46	243	258	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6521	6531		10.1074/jbc.M209764200	http://dx.doi.org/10.1074/jbc.M209764200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12473676	hybrid			2022-12-25	WOS:000181129400129
J	Bai, JX; Cederbaum, AI				Bai, JX; Cederbaum, AI			Catalase protects HepG2 cells from apoptosis induced by DNA-damaging agents by accelerating the degradation of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COMPARTMENT PROTECTS; OXIDATIVE STRESS; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; POTENTIAL MEDIATOR; DEATH; OVEREXPRESSION; INHIBITOR; INJURY; CANCER	Oxidants such as H2O2 play a role in the toxicity of certain DNA-damaging agents, a process that often involves the tumor suppressor p53. H2O2 is rapidly degraded by catalase, which protects cells against oxidant injury. To study the effect of catalase on apoptosis induced by DNA-damaging agents, HepG2 cells were infected with adenovirus containing the cDNA of catalase (Ad-Cat). Forty-eight hours after infection, catalase protein and activity was increased 7-10-fold compared with control cells infected with Ad-LacZ. After treatment with Vp16 or mitomycin C, control cells underwent apoptosis in a p53-dependent manner; however, overexpression of catalase inhibited this apoptosis. Basal levels as well as Vp16- or mitomycin C-stimulated levels of p53 and p21 protein were decreased in the catalase-overexpressing cells as compared with control cells; however, p53 mRNA levels were not decreased by catalase. There was no difference in p53 protein synthesis between catalase-overexpressing cells and control cells. However, pulse-chase experiments indicated that p53 protein degradation was enhanced in the catalase-overexpressing cells. Proteasome inhibitors but not calpeptin prevented the catalase-mediated decrease of p53 content. Whereas Vp16 increased, catalase overexpression decreased the phosphorylation of p53. The protein phosphatase inhibitor okadaic acid did not prevent the catalase-mediated down-regulation of p53 or phosphorylated p53. These results demonstrate that catalase protects HepG2 cells from apoptosis induced by DNA-damaging agents in association with decreasing p53 phosphorylation; the latter may lead to an acceleration in the degradation of p53 protein by the proteasome, complex. This suggests that the level of catalase may play a critical role in cell-induced resistance to the effects of anti-cancer drugs which up-regulate p53.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.	Arthur.Cederbaum@mssm.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006610, R37AA006610, R01AA012757] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06610, AA12757] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bagchi D, 2001, MOL CELL BIOCHEM, V222, P149, DOI 10.1023/A:1017958028256; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Bai JX, 2001, BIOL SIGNAL RECEPT, V10, P189; Bai JX, 2001, J BIOL CHEM, V276, P4315, DOI 10.1074/jbc.M008895200; Bilski P, 2002, FREE RADICAL BIO MED, V33, P938, DOI 10.1016/S0891-5849(02)00982-6; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; FRITSCHE M, 1993, ONCOGENE, V8, P307; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; Sato N, 2000, ANTICANCER RES, V20, P837; Senturker S, 2002, ARCH BIOCHEM BIOPHYS, V397, P262, DOI 10.1006/abbi.2001.2681; Siitonen T, 1999, ANN ONCOL, V10, P1361, DOI 10.1023/A:1008382912096; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	32	79	82	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4660	4667		10.1074/jbc.M206273200	http://dx.doi.org/10.1074/jbc.M206273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468545	hybrid			2022-12-25	WOS:000180968900041
J	Cervelli, M; Polticelli, F; Federico, R; Mariottini, P				Cervelli, M; Polticelli, F; Federico, R; Mariottini, P			Heterologous expression and characterization of mouse spermine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIZE POLYAMINE OXIDASE; CELL-WALL; PROTEIN; LOCALIZATION; PURIFICATION; ACANTHAMOEBA; TISSUES; BARLEY; LIVER	Polyamine oxidases are key enzymes responsible of the polyamine interconversion metabolism in animal cells. Recently, a novel enzyme belonging to this class of enzymes has been characterized for its capability to oxidize preferentially spermine and designated as spermine oxidase. This is a flavin adenine dinucleotide-containing enzyme, and it has been expressed both in vitro and in vivo systems. The primary structure of mouse spermine oxidase (mSMO) was deduced from a cDNA clone (Image Clone 264769) recovered by a data base search utilizing the human counterpart of polyamine oxidases, PAOh1. The open reading frame predicts a 555-amino acid protein with a calculated M-r of 61,852.30, which shows a 95.1% identity with PAOh1. To understand the biochemical properties of mSMO and its structure/function relationship, the mSMO cDNA has been subcloned and expressed in secreted and secreted-tagged forms into Escherichia coli BL21 DE3 cells. The recombinant enzyme shows an optimal pH value of 8.0 and is able to oxidize rapidly spermine to spermidine and 3-aminopropanal and fails to act upon spermidine and N-acetylpolyamines. The purified recombinant-tagged form enzyme (Mr. similar to68,000) has K. and k(cat) values of 90 mum and 4.5 s(-1), respectively, using spermine as substrate at pH 8.0. Molecular modeling of mSMO protein based on maize polyamine oxidase three-dimensional structure suggests that the general features of maize polyamine oxidase active site are conserved in mSMO.	Univ Roma Tor Vergata, Dipartimento Biol, I-00146 Rome, Italy	University of Rome Tor Vergata	Mariottini, P (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Viale Guglielmo Marconi 446, I-00146 Rome, Italy.		Cervelli, Manuela/ABC-6913-2020; OLIVERIO, MARCO/F-2229-2010; Polticelli, Fabio/A-4573-2009	Cervelli, Manuela/0000-0001-8535-8279; OLIVERIO, MARCO/0000-0002-0316-4364; Polticelli, Fabio/0000-0002-7657-2019				ANGELINI R, 1995, J PLANT PHYSIOL, V145, P686, DOI 10.1016/S0176-1617(11)81282-4; Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; Binda C, 2002, J BIOL CHEM, V277, P23973, DOI 10.1074/jbc.R200005200; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; BOLKENIUS FN, 1985, BIOCHIM BIOPHYS ACTA, V838, P69, DOI 10.1016/0304-4165(85)90251-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cervelli M, 2000, PLANT PHYSIOL BIOCH, V38, P667, DOI 10.1016/S0981-9428(00)01170-0; Cervelli M, 2001, EUR J BIOCHEM, V268, P3816, DOI 10.1046/j.1432-1327.2001.02296.x; Cohen S. S., 1998, GUIDE POLYAMINES, P82; DENMUNCKHOF RJM, 1995, J HISTOCHEM CYTOCHEM, V43, P1155; FEDERICO R, 1989, PHYTOCHEMISTRY, V28, P45, DOI 10.1016/0031-9422(89)85004-6; FEDERICO R, 1991, BIOCHEM PHYSIOL PFL, V187, P113, DOI 10.1016/S0015-3796(11)80110-1; FLORES HE, 1982, SCIENCE, V217, P1259, DOI 10.1126/science.217.4566.1259; GASPARYAN V K, 1990, Biokhimiya, V55, P1632; Geha RM, 2002, J BIOL CHEM, V277, P17209, DOI 10.1074/jbc.M110920200; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; KIM BG, 1987, J PROTOZOOL, V34, P278, DOI 10.1111/j.1550-7408.1987.tb03175.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laurenzi M, 1999, PLANTA, V208, P146, DOI 10.1007/s004250050544; LIBBY PR, 1987, BIOCHEM BIOPH RES CO, V144, P528, DOI 10.1016/S0006-291X(87)80541-7; McIntire W. S., 1993, COPPER CONTAINING AM, P97; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishikawa M, 2000, FEBS LETT, V476, P150, DOI 10.1016/S0014-5793(00)01708-7; PEGG AE, 1995, CANCER LETT, V95, P247, DOI 10.1016/0304-3835(95)03897-6; Rost B, 1996, METHOD ENZYMOL, V266, P525; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 2002, MOL CLONING LAB MANU; Sebela M, 2001, PLANT SCI, V160, P197, DOI 10.1016/S0168-9452(00)00380-0; Seiler N, 1995, PROG BRAIN RES, V106, P333; SHUKLA OP, 1992, MOL BIOCHEM PARASIT, V51, P91, DOI 10.1016/0166-6851(92)90204-W; Smith T A, 1988, Adv Exp Med Biol, V250, P573; SMITH TA, 1976, PHYTOCHEMISTRY, V15, P633, DOI 10.1016/S0031-9422(00)94408-X; SUZUKI O, 1984, EXPERIENTIA, V40, P838, DOI 10.1007/BF01951981; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tavladoraki P, 1998, FEBS LETT, V426, P62, DOI 10.1016/S0014-5793(98)00311-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUKADA T, 1988, INT J BIOCHEM, V20, P695, DOI 10.1016/0020-711X(88)90164-4; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Wang YL, 2001, CANCER RES, V61, P5370	40	79	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5271	5276		10.1074/jbc.M207888200	http://dx.doi.org/10.1074/jbc.M207888200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458219	hybrid			2022-12-25	WOS:000180968900117
J	Jiang, DW; Xiao, BL; Li, XL; Chen, SRW				Jiang, DW; Xiao, BL; Li, XL; Chen, SRW			Smooth muscle tissues express a major dominant negative splice variant of the type 3 Ca2+ release channel (Ryanodine receptor)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CELLS; BRAIN; RYR3; MYOCYTES; PROTEINS; ISOFORMS; CLONING	It is well known that the type 3 Ca2+ release channel (ryanodine receptor, RyR3) exhibits strikingly different pharmacological and functional properties depending on the tissues in which it resides. To investigate the molecular basis for this tissue-dependent heterogeneity, we examined the primary structure of RyR3 from various tissues by reverse transcription polymerase chain reaction and DNA sequence analysis. As many as seven alternatively spliced variants of RyR3 were detected. Ribonuclease protection assays revealed that one of these splice variants, RyR3 (AS-8a), which lacks a 29-amino acid fragment (His(4406)-Lys(4434)) encompassing a predicted transmembrane helix, was highly expressed in smooth muscle tissues, but not in skeletal muscle, the heart, or the brain. Although the RyR3 (AS-8a) splice variant did not form a functional Ca2+ release channel when expressed alone in HEK293 cells, it was able to form functional heteromeric channels with reduced caffeine sensitivity when co-expressed with the wild type RyR3. Interestingly, this RyR3 splice variant was also able to form heteromeric channels with and suppress the activity of the type 2 ryanodine receptor (RyR2). Tissue-specific expression of RyR3 splice variants is therefore likely to account for some of the pharmacological and functional heterogeneities of RyR3. These observations also reveal a novel mechanism by which a splice variant of one RyR isoform (RyR3) can suppress the activity of another RyR isoform (RyR2) via a dominant negative effect.	Univ Calgary, Cardiovasc Res Grp, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Cardiovasc Res Grp, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Chen, SRW (corresponding author), Univ Calgary, Cardiovasc Res Grp, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada.		Xiao, Bailong/B-6187-2012					Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; Fleischer S, 1988, Prog Clin Biol Res, V273, P435; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Lohn M, 2001, CIRC RES, V89, P1051, DOI 10.1161/hh2301.100250; LYNN S, 1993, FEBS LETT, V330, P227, DOI 10.1016/0014-5793(93)80279-4; LYNN S, 1995, FEBS LETT, V372, P6, DOI 10.1016/0014-5793(95)00924-X; Masumiya H, 2003, J BIOL CHEM, V278, P3786, DOI 10.1074/jbc.M210962200; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mironneau J, 2002, J PHYSIOL-LONDON, V538, P707, DOI 10.1113/jphysiol.2001.013046; Murayama T, 1996, J BIOL CHEM, V271, P5079; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Xiao BL, 2002, J BIOL CHEM, V277, P41778, DOI 10.1074/jbc.M208210200; Yang DM, 2001, J BIOL CHEM, V276, P40210, DOI 10.1074/jbc.M106944200; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	29	58	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4763	4769		10.1074/jbc.M210410200	http://dx.doi.org/10.1074/jbc.M210410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12471029	hybrid			2022-12-25	WOS:000180968900054
J	Loomis, WH; Namiki, S; Ostrom, RS; Insel, PA; Junger, WG				Loomis, WH; Namiki, S; Ostrom, RS; Insel, PA; Junger, WG			Hypertonic stress increases T cell interleukin-2 expression through a mechanism that involves ATP release, P2 receptor, and p38 MAPK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN-KINASE P38; OSMOTIC-STRESS; GENE-TRANSCRIPTION; ADENOSINE; ISCHEMIA; FAMILIES; PATHWAYS; SHOCK	Hypertonic stress (HS) can alter the function of mammalian cells. We have reported that HS enhances differentiated responses of T cells by increasing their ability to produce interleukin (IL)-2, a finding of clinical interest because hypertonic infusions may modulate immune function in patients. HS shrinks cells and mechanically deforms membranes, which results in ATP release from many cell types. Here we investigate if ATP release is an underlying mechanism through which HS augments T cell function. We found that mechanical stress and HS induced rapid ATP release from Jurkat T cells. HS and exogenous ATP mobilized intracellular Ca2+, activated p38 MAPK and increased IL-2 expression. Ca2+ mobilization was attenuated in the presence of EGTA or by removal of extracellular ATP with apyrase. Adenosine did not increase IL-2 expression, as did ATP. Apyrase, inhibition of P2 receptors, or inhibition of p38 MAPK with SB203580 reduced the stimulatory effects of HS, indicating that HS enhances IL-2 expression through a mechanism that involves ATP release, P2 (perhaps P2X7) receptors, and p38 MAPK activation. We conclude that release of and response to ATP plays a key role in the mechanism through which hypertonic stress regulates the function of T cells.	Univ Calif San Diego, Ctr Med, Dept Trauma Surg, San Diego, CA 92103 USA; Univ Calif San Diego, Ctr Med, Dept Pharmacol, San Diego, CA 92103 USA; Univ Calif San Diego, Ctr Med, Dept Med, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Junger, WG (corresponding author), Univ Calif San Diego, Ctr Med, Dept Surg, Div Trauma, 200 W Arbor Dr, San Diego, CA 92103 USA.		Junger, Wolfgang G/I-1932-2013	Junger, Wolfgang G/0000-0003-3350-8452; Ostrom, Rennolds/0000-0002-7204-0357	NHLBI NIH HHS [1U01 HL69758] Funding Source: Medline; NIGMS NIH HHS [R29 GM-51477, R01 GM-60475] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL069758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051477, R29GM051477, R01GM060475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/j.1600-065X.1995.tb00680.x; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bouma MG, 1997, SHOCK, V8, P313, DOI 10.1097/00024382-199711000-00001; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Dubyak GR, 2002, AM J PHYSIOL-CELL PH, V282, pC242, DOI 10.1152/ajpcell.00522.2001; Dubyak GR, 2000, J AUTONOM NERV SYST, V81, P64, DOI 10.1016/S0165-1838(00)00155-7; FIRESTEIN GS, 1994, J IMMUNOL, V152, P5853; GREENLEAF JE, 1995, MED SCI SPORT EXER, V27, P194; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; HARKEMA JM, 1992, CRIT CARE MED, V20, P263, DOI 10.1097/00003246-199202000-00015; HENROTTE JG, 1966, FED PROC, V25, P1375; Junger WG, 1997, SHOCK, V8, P235, DOI 10.1097/00024382-199710000-00001; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; Junger WG, 1997, J TRAUMA, V42, P437, DOI 10.1097/00005373-199703000-00011; Kultz D, 1998, J EXP BIOL, V201, P3015; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Loomis WH, 2001, AM J PHYSIOL-CELL PH, V281, pC840, DOI 10.1152/ajpcell.2001.281.3.C840; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MCLEAN KA, 1992, AGE AGEING, V21, P56, DOI 10.1093/ageing/21.1.56; Nguyen HT, 2000, AM J PHYSIOL-CELL PH, V279, pC1155, DOI 10.1152/ajpcell.2000.279.4.C1155; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Pedersen S, 1999, BBA-BIOMEMBRANES, V1416, P271, DOI 10.1016/S0005-2736(98)00228-4; Ralevic V, 1998, PHARMACOL REV, V50, P413; Roman RM, 1999, AM J PHYSIOL-GASTR L, V277, pG1222, DOI 10.1152/ajpgi.1999.277.6.G1222; Sauer H, 2000, AM J PHYSIOL-CELL PH, V279, pC295, DOI 10.1152/ajpcell.2000.279.2.C295; Sawada Y, 2001, J CELL SCI, V114, P1221; Schwiebert ER, 2001, CLIN EXP PHARMACOL P, V28, P340, DOI 10.1046/j.1440-1681.2001.03451.x; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; Shapiro L, 1997, EXP CELL RES, V231, P354, DOI 10.1006/excr.1997.3476; SURGENOR S, 1994, AM J EMERG MED, V12, P441, DOI 10.1016/0735-6757(94)90057-4; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Zimmermann H, 1999, TRENDS PHARMACOL SCI, V20, P231, DOI 10.1016/S0165-6147(99)01293-6	40	90	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4590	4596		10.1074/jbc.M207868200	http://dx.doi.org/10.1074/jbc.M207868200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12464620	hybrid			2022-12-25	WOS:000180968900032
J	Mikhailov, V; Mikhailova, M; Degenhardt, K; Venkatachalam, MA; White, E; Saikumar, P				Mikhailov, V; Mikhailova, M; Degenhardt, K; Venkatachalam, MA; White, E; Saikumar, P			Association of Bax and Bak homo-oligomers in mitochondria - Bax requirement for Bak reorganization and cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGE; BCL-2 FAMILY; APOPTOSIS; MEMBRANE; PROTEIN; REDISTRIBUTION; ACTIVATION; TERMINUS; MEMBERS; CELLS	ATP depletion induced by hypoxia or mitochondrial inhibitors results in Bax translocation from cytosol to mitochondria and release of cytochrome c from mitochondria into cytosol in cultured rat proximal tubule cells. Translocated Bax undergoes further conformational changes to oligomerize into high molecular weight complexes (Mikhailov, V., Mikhailova, M., Pulkrabek, D. J., Dong, Z., Venkatachalam, M. A., and Saikumar, P. (2001) J. Biol. Chem. 276, 18361-18374). Here we report that following Bax translocation in ATP-depleted rat proximal tubule cells, Bak, a proapoptotic molecule that normally resides in mitochondria, also reorganizes to form homo-oligomers. Oligomerization of both Bax and Bak occurred independently of Bid cleavage and/or translocation. Western blots of chemically cross-linked membrane extracts showed nonoverlapping "ladders" of Bax and Bak complexes in multiples of similar to21 and similar to23 kDa, respectively, consistent with molecular homogeneity within each ladder. This indicated that Bax and Bak complexes were homo-oligomeric. Nevertheless, each oligomer could be co-immunoprecipitated with the other, suggesting a degree of affinity between Bax and Bak that permitted co-precipitation but not cross-linking. Furthermore, dissociation of cross-linked complexes by SDS and renaturation prior to immunoprecipitation did not prevent reassociation of the two oligomeric species. Notably, expression of Bcl-2 prevented not only the oligomerization of Bax and Bak, but also the association between these two proteins in energy-deprived cells. Using Bax-deficient HCT116 and BMK cells, we show that there is stringent Bax requirement for Bak homo-oligomerization and for cytochrome c release during energy deprivation. Using Bak-deficient BMK cells we further show that Bak deficiency is associated with delayed kinetics of Bax translocation but does not affect either the oligomerization of translocated Bax or the leakage of cytochrome c. These results suggest a degree of functional cooperation between Bax and Bak in this form of cell injury, but also demonstrate an absolute requirement of Bax for mitochondrial permeabilization.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Rutgers State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA	University of Texas System; University of Texas Health San Antonio; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Saikumar, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	saikumar@uthscsa.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NIDDK NIH HHS [DK 37139, DK-54472] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037139, R01DK054472, R01DK037139] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Cuconati A, 2002, J VIROL, V76, P4547, DOI 10.1128/JVI.76.9.4547-4558.2002; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dong Z, 2000, BIOCHEM J, V347, P669, DOI 10.1042/0264-6021:3470669; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fan HB, 2001, J COMP NEUROL, V436, P82; Griffin DE, 1997, ANNU REV MICROBIOL, V51, P565, DOI 10.1146/annurev.micro.51.1.565; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tanner VA, 1996, J HISTOCHEM CYTOCHEM, V44, P1481, DOI 10.1177/44.12.8985140; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WEINBERG JM, 1991, AM J PHYSIOL, V260, pF410, DOI 10.1152/ajprenal.1991.260.3.F410; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	40	185	194	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5367	5376		10.1074/jbc.M203392200	http://dx.doi.org/10.1074/jbc.M203392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12454021	hybrid			2022-12-25	WOS:000180968900129
J	Moseley, AE; Lieske, SP; Wetzel, RK; James, PF; He, SW; Shelly, DA; Paul, RJ; Boivin, GP; Witte, DP; Ramirez, JM; Sweadner, KJ; Lingrel, JB				Moseley, AE; Lieske, SP; Wetzel, RK; James, PF; He, SW; Shelly, DA; Paul, RJ; Boivin, GP; Witte, DP; Ramirez, JM; Sweadner, KJ; Lingrel, JB			The Na,K-ATPase alpha 2 isoform is expressed in neurons, and its absence disrupts neuronal activity in newborn mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; CENTRAL-NERVOUS-SYSTEM; GENE-EXPRESSION; INVITRO DEVELOPMENT; SUBUNIT ISOFORMS; MESSENGER-RNAS; BETA-SUBUNITS; CELLS; BRAIN; ISOZYMES	Na,K-ATPase is an ion transporter that impacts neural and glial physiology by direct electrogenic activity and the modulation of ion gradients. Its three isoforms in brain have cell-type and development-specific expression patterns. Interestingly, our studies demonstrate that in late gestation, the alpha2 isoform is widely expressed in neurons, unlike in the adult brain, in which alpha2 has been shown to be expressed primarily in astrocytes. This unexpected distribution of alpha2 isoform expression in neurons is interesting in light of our examination of mice lacking the alpha2 isoform which fail to survive after birth. These animals showed no movement; however, defects in gross brain development, muscle contractility, neuromuscular transmission, and lung development were ruled out. Akinesia suggests a primary neuronal defect and electrophysiological recordings in the pre-Botzinger complex, the brainstem breathing center, showed reduction of respiratory rhythm activity, with less regular and smaller population bursts. These data demonstrate that the Na,K-ATPase alpha2 isoform could be important in the modulation of neuronal activity in the neonate.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Massachusetts Gen Hosp, Ctr Neurosci, Lab Membrane Biol, Charlestown, MA 02129 USA; Miami Univ, Dept Zool, Oxford, OH 45056 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA; Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Childrens Hosp, Med Ctr, Dept Pathol, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Harvard University; Massachusetts General Hospital; University System of Ohio; Miami University; University of Chicago; University of Chicago; Cincinnati Children's Hospital Medical Center	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way,MSB Bldg,ML 0524, Cincinnati, OH 45267 USA.			Ramirez, Jan-Marino/0000-0002-5626-3999	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066062, R01HL028573, R01HL060120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66062, HL28573, HL 60120] Funding Source: Medline; NINDS NIH HHS [NS27653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BRINES ML, 1993, BRAIN RES, V631, P1, DOI 10.1016/0006-8993(93)91179-V; CAMERON R, 1994, MOL BRAIN RES, V21, P333, DOI 10.1016/0169-328X(94)90264-X; CORTHESYTHEULAZ I, 1990, AM J PHYSIOL, V258, pC1062, DOI 10.1152/ajpcell.1990.258.6.C1062; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; CRUMP RG, 1995, AM J PHYSIOL-LUNG C, V269, pL299, DOI 10.1152/ajplung.1995.269.3.L299; D'Ambrosio R, 2002, J NEUROPHYSIOL, V87, P87, DOI 10.1152/jn.00240.2001; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GOLOVINA VA, 2003, IN PRESS AM J PHYSL; Habiba A, 2000, BRAIN RES, V875, P1, DOI 10.1016/S0006-8993(00)02541-5; Harding R, 1996, J APPL PHYSIOL, V81, P209, DOI 10.1152/jappl.1996.81.1.209; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; He SW, 2001, AM J PHYSIOL-REG I, V281, pR917, DOI 10.1152/ajpregu.2001.281.3.R917; HERRERA VLM, 1994, AM J PHYSIOL, V266, pC1301, DOI 10.1152/ajpcell.1994.266.5.C1301; Ingbar DH, 1996, AM J PHYSIOL-LUNG C, V270, pL619, DOI 10.1152/ajplung.1996.270.4.L619; INOUE N, 1990, BRAIN RES, V534, P309, DOI 10.1016/0006-8993(90)90146-3; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Juhaszova M, 1997, P NATL ACAD SCI USA, V94, P1800, DOI 10.1073/pnas.94.5.1800; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li S, 2001, NEUROSCIENCE, V107, P675, DOI 10.1016/S0306-4522(01)00385-2; Lieske SP, 2000, NAT NEUROSCI, V3, P600, DOI 10.1038/75776; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Moseley AE, 1996, INVEST OPHTH VIS SCI, V37, P1502; Muller-Ehmsen J, 2001, AM J PHYSIOL-CELL PH, V281, pC1355, DOI 10.1152/ajpcell.2001.281.4.C1355; OBRODOVICH H, 1993, AM J PHYSIOL, V264, pC1137, DOI 10.1152/ajpcell.1993.264.5.C1137; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; Pacholczyk T, 1997, PROTEIN SCI, V6, P1537, DOI 10.1002/pro.5560060718; Pellerin L, 1997, J NEUROCHEM, V69, P2132; Peng L, 1997, J NEUROSCI, V17, P3488; Peng L, 1998, GLIA, V24, P257, DOI 10.1002/(SICI)1098-1136(199811)24:3<257::AID-GLIA1>3.0.CO;2-#; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; Ransom CB, 2000, J PHYSIOL-LONDON, V522, P427, DOI 10.1111/j.1469-7793.2000.00427.x; Ridge KM, 1997, AM J PHYSIOL-LUNG C, V273, pL246, DOI 10.1152/ajplung.1997.273.1.L246; ROTHMAN S, 1981, J COMP NEUROL, V195, P141, DOI 10.1002/cne.901950108; Rozzo A, 2002, J NEUROPHYSIOL, V88, P676, DOI 10.1152/jn.2002.88.2.676; Segall L, 2001, J BIOL CHEM, V276, P31535, DOI 10.1074/jbc.M103720200; SHAMRAJ OI, 1994, P NATL ACAD SCI USA, V91, P12952, DOI 10.1073/pnas.91.26.12952; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; Soga TM, 2001, NEUROREPORT, V12, P829, DOI 10.1097/00001756-200103260-00041; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Tang YM, 2000, J NEUROCHEM, V74, P702, DOI 10.1046/j.1471-4159.2000.740702.x; Telgkamp P, 1999, J NEUROPHYSIOL, V82, P2163, DOI 10.1152/jn.1999.82.5.2163; Vaillancourt C, 1999, EXP NEUROL, V160, P142, DOI 10.1006/exnr.1999.7201; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425; Wetzel RK, 1999, J NEUROSCI, V19, P9878	48	120	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5317	5324		10.1074/jbc.M211315200	http://dx.doi.org/10.1074/jbc.M211315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458206	hybrid			2022-12-25	WOS:000180968900123
J	Rajendran, RR; Nye, AC; Frasor, J; Balsara, RD; Martini, PGV; Katzenellenbogen, BS				Rajendran, RR; Nye, AC; Frasor, J; Balsara, RD; Martini, PGV; Katzenellenbogen, BS			Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; BREAST-CANCER-CELLS; HORMONE RECEPTORS; THYROID-HORMONE; N-COR; CONFORMATIONAL-CHANGES; PROGESTERONE-RECEPTOR; EUKARYOTIC RIBOSOMES; HISTONE DEACETYLASE; COACTIVATOR PGC-1	We have identified a novel DEAD box RNA helicase (97 kDa, DP97) from a breast cancer cDNA library that interacts in a hormone-dependent manner with nuclear receptors and represses their transcriptional activity. DP97 has RNA-dependent ATPase activity, and mapping studies localize the interacting regions of DP97 and nuclear receptors to the C-terminal region of DP97 and the hormone binding/activation function-2 region of estrogen receptors (ER), as well as several other nuclear receptors. Repression by DP97 maps to a small region (amino acids 589-631) that has homology to a repression domain in the corepressor protein NCoR2/SMRTe. This region of DP97 is necessary and sufficient for its intrinsic repression activity. The N-terminal helicase region of DP97 is, however, dispensable for its transcriptional repressor activity. The knockdown of endogenous cellular DP97 by antisense DP97 or RNA interference (siRNA for DP97) results in significant enhancement of the expression of estradiol-ER-stimulated genes and attenuation of the repression of genes inhibited by the estradiol-ER. This implies that endogenous DP97 normally dampens stimulation and intensifies repression of estradiol-ER-regulated genes. Our findings add to the growing evidence that RNA helicases can associate with nuclear receptors and function as coregulators to modulate receptor transcriptional activity.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 407 S Goodwin Ave,524 Burrill Hall, Urbana, IL 61801 USA.	katzenel@life.uiuc.edu	Carpenter, Anne/C-4982-2008	Carpenter, Anne/0000-0003-1555-8261	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089652] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Askjaer P, 2000, J BIOL CHEM, V275, P11561, DOI 10.1074/jbc.275.16.11561; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Chen TC, 2000, CANCER LETT, V153, P169, DOI 10.1016/S0304-3835(00)00366-9; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Gamble MJ, 2002, TRENDS BIOCHEM SCI, V27, P165, DOI 10.1016/S0968-0004(02)02076-5; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; HIRAOKA Y, 1991, MOL CELL ENDOCRINOL, V81, P147, DOI 10.1016/0303-7207(91)90213-C; Honig A, 2002, MOL CELL BIOL, V22, P5698, DOI 10.1128/MCB.22.16.5698-5707.2002; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Ikeda K, 1998, MOL CELL BIOL, V18, P10, DOI 10.1128/MCB.18.1.10; Inadera H, 2002, BIOCHEM BIOPH RES CO, V294, P602, DOI 10.1016/S0006-291X(02)00530-2; Inadera H, 2000, BIOCHEM BIOPH RES CO, V275, P108, DOI 10.1006/bbrc.2000.3276; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; KRAUS WL, 1993, MOL ENDOCRINOL, V7, P1603, DOI 10.1210/me.7.12.1603; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Linder P, 2000, NAT STRUCT BIOL, V7, P97, DOI 10.1038/72464; Linder P, 2000, CURR BIOL, V10, pR887, DOI 10.1016/S0960-9822(00)00857-5; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; READ LD, 1990, CANCER RES, V50, P3947; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REESE JC, 1991, J BIOL CHEM, V266, P10880; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Schulz M, 2001, BIOCHEM BIOPH RES CO, V280, P476, DOI 10.1006/bbrc.2000.4141; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; WEAVER CA, 1988, MOL ENDOCRINOL, V2, P936, DOI 10.1210/mend-2-10-936; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200	71	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4628	4638		10.1074/jbc.M210066200	http://dx.doi.org/10.1074/jbc.M210066200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466272	hybrid			2022-12-25	WOS:000180968900037
J	Muscarella, DE; Bloom, SE				Muscarella, DE; Bloom, SE			Cross-linking of surface IgM in the Burkitt's lymphoma cell line ST486 provides protection against arsenite- and stress-induced apoptosis that is mediated by ERK and phosphoinositide 3-kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; FOLLICULAR DENDRITIC CELLS; RECEPTOR-INDUCED APOPTOSIS; CENTER B-CELLS; ANTIGEN RECEPTOR; DIFFERENTIAL ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; INHIBITORY PROTEIN; BCL-2 FAMILY; DEATH	The ST486 cell line, derived from a human Burkitt's lymphoma, is a model for antigen-induced clonal deletion in germinal center B-lymphocytes, with apoptosis induced upon cross-linking of surface IgM. Moreover, this cell line is highly sensitive to the induction of apoptosis by many chemicals, including sodium arsenite, a significant environmental contaminant with immunotoxic activity. In contrast to arsenite and other chemicals, surface IgM cross-linking induces apoptosis in ST486 cells with delayed kinetics. Moreover, the initial signaling events following IgM stimulation are associated with cell survival and proliferation and include activation of the extracellular-signal regulated kinase (ERK) and the phosphoinositide 3-kinase (PI3K) pathways. We examined the question of whether IgM-mediated activation of the ERK and PI3K pathways can influence the apoptotic response of ST486 cells following exposure to arsenite and selected drugs with different molecular targets, including cycloheximide, etoposide, and camptothecin, and a physical stress, hyperthermia. Our findings show that IgM-stimulated cells are significantly protected against arsenite and drug-induced apoptosis during a window of several hours after surface IgM cross-linking, as evidenced by an inhibition of cleavage of poly(ADP-ribose) polymerase and lack of morphological changes indicative of apoptosis. Significantly, surface IgM cross-linking also protects against arsenite-induced mitochondrial depolarization as well as caspase-9 cleavage. Furthermore, we demonstrate that this IgM-mediated protection requires the activation of the ERK and PI3K pathways, because inhibition of either pathway blocks the ability of antigen receptor activation to protect against apoptosis. Our study also provides evidence for p90(S6) ribosomal kinase as a point of convergence between the two signaling pathways resulting in the phosphorylation of the pro-apoptotic Bcl-2 family member Bad at serine 112. This investigation demonstrates, for the first time, that specific signals transduced by activation of the B-cell receptor protect cells at a common point of regulation in the apoptotic pathways for diverse stresses.	Cornell Univ, Vet Med Ctr C4101, Dept Microbiol & Immunol, Ithaca, NY 14853 USA	Cornell University	Muscarella, DE (corresponding author), Cornell Univ, Vet Med Ctr C4101, Dept Microbiol & Immunol, Ithaca, NY 14853 USA.	dem10@cornell.edu			NIEHS NIH HHS [R01ES010815] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010815] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; BARGOU RC, 1995, EUR J IMMUNOL, V25, P770, DOI 10.1002/eji.1830250322; Berard R, 1999, J IMMUNOL, V163, P4655; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; Bouchon A, 2000, EUR J IMMUNOL, V30, P69, DOI 10.1002/1521-4141(200001)30:1<69::AID-IMMU69>3.0.CO;2-#; Brennan P, 2002, ONCOGENE, V21, P1263, DOI 10.1038/sj.onc.1205182; Carey GB, 2001, J IMMUNOL, V166, P1618, DOI 10.4049/jimmunol.166.3.1618; Craxton A, 2000, CELL IMMUNOL, V200, P56, DOI 10.1006/cimm.2000.1616; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Descotes J., 1988, IMMUNOTOXICOLOGY DRU, V2nd, P444; FAN SJ, 1994, CANCER RES, V54, P5824; FODRIN M, 1999, MOL CELL ENDOCRINOL, V151, P65; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gauld SB, 2002, J IMMUNOL, V168, P3855, DOI 10.4049/jimmunol.168.8.3855; Gold MR, 1999, J IMMUNOL, V163, P1894; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hennino A, 2001, J EXP MED, V193, P447, DOI 10.1084/jem.193.4.447; Herold MJ, 2002, J IMMUNOL, V168, P3902, DOI 10.4049/jimmunol.168.8.3902; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Huang CS, 1999, CANCER RES, V59, P3053; Jacob A, 2002, J BIOL CHEM, V277, P23420, DOI 10.1074/jbc.M202485200; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025; Kaptein JS, 1996, J BIOL CHEM, V271, P18875, DOI 10.1074/jbc.271.31.18875; Kashiwada M, 1996, EUR J IMMUNOL, V26, P1451, DOI 10.1002/eji.1830260708; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; Koopman G, 1997, EUR J IMMUNOL, V27, P1, DOI 10.1002/eji.1830270102; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee YJ, 1997, BLOOD, V89, P4480, DOI 10.1182/blood.V89.12.4480; Lens SMA, 1998, J IMMUNOL, V160, P6083; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; Lin CKE, 1998, EXP CELL RES, V244, P1, DOI 10.1006/excr.1998.4158; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MacKichan ML, 1999, J BIOL CHEM, V274, P1767, DOI 10.1074/jbc.274.3.1767; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Muscarella DE, 1998, EXP CELL RES, V238, P155, DOI 10.1006/excr.1997.3832; Muscarella DE, 2002, TOXICOL SCI, V68, P82, DOI 10.1093/toxsci/68.1.82; NING ZQ, 1995, BIOCHEM BIOPH RES CO, V215, P23, DOI 10.1006/bbrc.1995.2429; Nordstrom DK, 2002, SCIENCE, V296, P2143, DOI 10.1126/science.1072375; O'Brien KA, 2001, TOXICOL APPL PHARM, V174, P245, DOI 10.1006/taap.2001.9215; Oberholzer A, 2001, IMMUNOL LETT, V75, P221, DOI 10.1016/S0165-2478(00)00307-2; Oberholzer C, 2001, FASEB J, V15, P879, DOI 10.1096/fj.00-058rev; Park E, 1996, EXP CELL RES, V226, P1, DOI 10.1006/excr.1996.0196; PARRY SL, 1994, J IMMUNOL, V152, P2821; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Sakata N, 1999, EUR J IMMUNOL, V29, P2999, DOI 10.1002/(SICI)1521-4141(199909)29:09<2999::AID-IMMU2999>3.0.CO;2-L; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schwarz YX, 1999, J IMMUNOL, V163, P6442; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Su L, 1999, J IMMUNOL, V162, P6317; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; TORDAI A, 1994, J BIOL CHEM, V269, P7538; TOSHIMURA S, 1998, J BIOL CHEM, V273, P6921; van Eijk M, 2001, TRENDS IMMUNOL, V22, P677, DOI 10.1016/S1471-4906(01)02086-5; van Eijk M, 2001, J IMMUNOL, V166, P6473, DOI 10.4049/jimmunol.166.11.6473; Walker A, 1997, CANCER RES, V57, P1939; Weinmann P, 1997, EUR J IMMUNOL, V27, P2466, DOI 10.1002/eji.1830270947; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	74	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4358	4367		10.1074/jbc.M208779200	http://dx.doi.org/10.1074/jbc.M208779200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12464623	hybrid			2022-12-25	WOS:000180869700105
J	Carey, KD; Watson, RT; Pessin, JE; Stork, PJS				Carey, KD; Watson, RT; Pessin, JE; Stork, PJS			The requirement of specific membrane domains for Raf-1 phosphorylation and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-DEPENDENT ACTIVATION; PROTEIN-KINASE; PLASMA-MEMBRANE; HA-RAS; B-RAF; PHOSPHATIDYLINOSITOL 3-KINASE; CHOLESTEROL DEPLETION; CAVEOLAE MEMBRANE; LIPID RAFTS; MAP KINASE	Activation of Raf-1 by Ras requires recruitment to the membrane as well as additional phosphorylations, including phosphorylation at serine 338 (Ser-338) and tyrosine 341 (Tyr-341). In this study we show that Tyr-341 participates in the recruitment of Raf-1 to specialized membrane domains called "rafts," which are required for Raf-1 to be phosphorylated on Ser-338. Raf-1 is also thought to be recruited to the small G protein Rap1 upon GTP loading of Rap1. However, this does not result in Raf-1 activation. We propose that this is because Raf-1 is not phosphorylated on Tyr-341 upon recruitment to Rap1. Redirecting Rapl to Ras-containing membranes or mimicking Tyr-341 phosphorylation of Raf-1 by mutation converts Rapl into an activator of Raf-1. In contrast to Raf-1, B-Raf is activated by Rapl. We suggest that this is because B-Raf activation is independent of tyrosine phosphorylation. Moreover, mutants that render B-Raf dependent on tyrosine phosphorylation are no longer activated by Rap1.	Oregon Hlth & Sci Univ, Vollum Inst, Dept Cell & Dev Biol, Portland, OR 97201 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Oregon Health & Science University; University of Iowa	Stork, PJS (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, Dept Cell & Dev Biol, L-474,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	stork@ohsu.edu			NATIONAL CANCER INSTITUTE [R01CA072971] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA72971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Carey KD, 2000, MOL CELL BIOL, V20, P8409, DOI 10.1128/MCB.20.22.8409-8419.2000; Carozzi AJ, 2002, J BIOL CHEM, V277, P17944, DOI 10.1074/jbc.M110879200; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Jaumot M, 2002, J BIOL CHEM, V277, P272, DOI 10.1074/jbc.M108423200; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Okada T, 1999, MOL CELL BIOL, V19, P6057; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; PIZON V, 1994, J CELL SCI, V107, P1661; Prior IA, 2001, J CELL SCI, V114, P1603; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; White MA, 2001, NAT CELL BIOL, V3, pE172, DOI 10.1038/35087098; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Woodman SE, 2002, J BIOL CHEM, V277, P38988, DOI 10.1074/jbc.M205511200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	65	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3185	3196		10.1074/jbc.M207014200	http://dx.doi.org/10.1074/jbc.M207014200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446733	hybrid			2022-12-25	WOS:000180915000054
J	Sheffield, PJ; Oliver, CJ; Kremer, BE; Sheng, ST; Shao, ZF; Macara, IG				Sheffield, PJ; Oliver, CJ; Kremer, BE; Sheng, ST; Shao, ZF; Macara, IG			Borg/septin interactions and the assembly of mammalian septin heterodimers, trimers, and filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA SEPTINS; YEAST; GTPASE; PROTEINS; FAMILY; CDC42; COMPARTMENTALIZATION; CYTOKINESIS; CDCREL-1; DIVISION	Septins constitute a family of guanine nucleotide-binding proteins that were first discovered in the yeast Saccharomyces cerevisiae but are also present in many other eukaryotes. In yeast they congregate at the bud neck and are required for cell division. Their function in metazoan cells is uncertain, but they have been implicated in exocytosis and cytokinesis. Septins have been purified from cells as hetero-oligomeric filaments, but their mechanism of assembly is unknown. Further studies have been limited by the difficulty in expressing functional septin proteins in bacteria. We now show that stable, soluble septin heterodimers can be produced by co-expression from bicistronic vectors in bacteria and that the co-expression of three septins results in their assembly into filaments. Pre-assembled dimers and trimers bind guanine nucleotide and show a slow GTPase activity. The assembly of a heterodimer from monomers in vitro is accompanied by GTP hydrolysis. Borg3, a downstream effector of the Cdc42 GTPase, binds specifically to a septin heterodimer composed of Sept6 and Sept7 and to the Sept2/6/7 trimer, but not to septin monomers or to other heterodimers. Septins associate through their C-terminal coiled-coil domains, and Borg3 appears to recognize the interface between these domains in Sept6 and Sept7.	Univ Virginia, Ctr Cell Signaling, Sch Med, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Sch Med, Charlottesville, VA 22908 USA; Univ Virginia, Dept Physiol & Biophys, Sch Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Macara, IG (corresponding author), Univ Virginia, Ctr Cell Signaling, Sch Med, Box 800577,MSB,HSC, Charlottesville, VA 22908 USA.		Shao, Zhifeng/B-6075-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam JC, 2000, MOL BIOL CELL, V11, P3123, DOI 10.1091/mbc.11.9.3123; Barral Y, 2000, MOL CELL, V5, P841, DOI 10.1016/S1097-2765(00)80324-X; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Dent J, 2002, P NATL ACAD SCI USA, V99, P3064, DOI 10.1073/pnas.052715199; FARES H, 1995, MOL BIOL CELL, V6, P1843, DOI 10.1091/mbc.6.12.1843; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; Gladfelter AS, 2002, J CELL BIOL, V156, P315, DOI 10.1083/jcb.200109062; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Joberty G, 2001, NAT CELL BIOL, V3, P861, DOI 10.1038/ncb1001-861; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; Mendoza M, 2002, CURR BIOL, V12, P1858, DOI 10.1016/S0960-9822(02)01258-7; Peng XR, 2002, MOL CELL BIOL, V22, P378, DOI 10.1128/MCB.22.1.378-387.2002; Richman TJ, 1999, J BIOL CHEM, V274, P16861, DOI 10.1074/jbc.274.24.16861; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Takizawa PA, 2000, SCIENCE, V290, P341, DOI 10.1126/science.290.5490.341; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519	25	126	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3483	3488		10.1074/jbc.M209701200	http://dx.doi.org/10.1074/jbc.M209701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446710	hybrid			2022-12-25	WOS:000180915000090
J	Huang, M; Dorsey, JF; Epling-Burnette, PK; Nimmanapalli, R; Landowski, TH; Mora, LB; Niu, GL; Sinibaldi, D; Bai, FQ; Kraker, A; Yu, H; Moscinski, L; Wei, S; Djeu, J; Dalton, WS; Bhalla, K; Loughran, TP; Wu, J; Jove, R				Huang, M; Dorsey, JF; Epling-Burnette, PK; Nimmanapalli, R; Landowski, TH; Mora, LB; Niu, GL; Sinibaldi, D; Bai, FQ; Kraker, A; Yu, H; Moscinski, L; Wei, S; Djeu, J; Dalton, WS; Bhalla, K; Loughran, TP; Wu, J; Jove, R			Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells	ONCOGENE			English	Article						Stat5; Bcr-Abl; CML; PD180970; apoptosis; cell cycle	DNA-BINDING ACTIVITY; MYELOGENOUS LEUKEMIA-CELLS; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCER; BCL-2 FAMILY; SH2 DOMAINS	Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the BCR-ABL genetic translocation and constitutive activation of the Abl tyrosine kinase. Among members of the Signal Transducers and Activators of Transcription (STAT) family of transcription factors, Stat5 is activated by the Ber-Abl kinase and is implicated in the pathogenesis of CML. We recently identified PD180970 as a new and highly potent inhibitor of Bcr-Abl kinase. In this study, we show that blocking Bcr-Abl kinase activity using PD180970 in the human K562 CML cell line resulted in inhibition of Stat5 DNA-binding activity with an IC50 of 5 nM. Furthermore, abrogation of Abl kinase-mediated Stat5 activation suppressed cell proliferation and induced apoptosis in K562 cells, but not in the Ber-Abl-negative myeloid cell lines, HEL 92.1.7 and HL-60. Dominant-negative Stat5 protein expressed from a vaccinia virus vector also induced apoptosis of K562 cells, consistent with earlier studies that demonstrated an essential role of Stat5 signaling in growth and survival of CML cells. RNA and protein analyses revealed several candidate target genes of Stat5, including Bcl-x, Mcl-1, c-Myc and cyclin D2, which were down-regulated after treatment with PD180970. In addition, PD180970 inhibited Stat5 DNA-binding activity in cultured primary leukemic cells derived from CML patients. To detect activated Stat5 in CML patient specimens, we developed an immunocytochemical assay that can be used as a molecular end-point assay to monitor inhibition of Bcr-Abl signaling. Moreover, PD180970 blocked Stat5 signaling and induced apoptosis of STI-571 (Gleevec, Imatinib)-resistant Bcr-Abl-positive cells. Together, these results suggest that the mechanism of action of PD180970 involves inhibition of Bcr-Abl-mediated Stat5 signaling and provide further evidence that compounds in this structural class may represent potential therapeutic agents for CML.	Univ S Florida, H Lee Moffitt Canc Ctr, Res Inst, Mol Oncol Program, Tampa, FL 33682 USA; Pfizer Global Res & Dev, Dept Canc Res, Ann Arbor, MI 48106 USA; Univ Arizona, Hlth Sci Ctr, Dept Med, Tucson, AZ 85724 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Pfizer; University of Arizona; University of Arizona Health Sciences; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Jove, R (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.	richjove@moffitt.usf.edu	Wu, Jie/R-2404-2019; Herrmann, Eva/E-8215-2010	Wu, Jie/0000-0002-2864-1606; YU, Hua/0000-0003-0931-1000; Bhalla, Kapil/0000-0001-5209-5126	NATIONAL CANCER INSTITUTE [P01CA082533, R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA82533, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cortez D, 1996, ONCOGENE, V13, P2589; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Dorsey JF, 2000, CANCER RES, V60, P3127; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Frank DA, 1996, LEUKEMIA, V10, P1724; Gelfanov VM, 2001, BLOOD, V98, P2508, DOI 10.1182/blood.V98.8.2508; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ibrado AM, 1996, CANCER RES, V56, P4743; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jain SK, 1996, BLOOD, V88, P1542; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Jonuleit T, 1998, BRIT J HAEMATOL, V100, P295, DOI 10.1046/j.1365-2141.1998.00564.x; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Nagar B, 2002, CANCER RES, V62, P4236; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NIMMANAPALLI R, 2002, IN PRESS CANC RES; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Porosnicu M, 2001, LEUKEMIA, V15, P772, DOI 10.1038/sj.leu.2402104; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wei S, 2000, J IMMUNOL, V165, P3811, DOI 10.4049/jimmunol.165.7.3811; Wisniewski D, 2002, CANCER RES, V62, P4244; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	74	116	131	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8804	8816		10.1038/sj.onc.1206028	http://dx.doi.org/10.1038/sj.onc.1206028			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483533	Bronze			2022-12-25	WOS:000179734400014
J	Shivapurkar, N; Reddy, J; Matta, H; Sathyanarayana, UG; Huang, CX; Toyooka, S; Minna, JD; Chaudhary, PM; Gazdar, AF				Shivapurkar, N; Reddy, J; Matta, H; Sathyanarayana, UG; Huang, CX; Toyooka, S; Minna, JD; Chaudhary, PM; Gazdar, AF			Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification	ONCOGENE			English	Article						CASP8; DISC; MYC; TRAIL	NF-KAPPA-B; CASPASE 8; C-MYC; APOPTOSIS; ACTIVATION; ONCOGENE	We have previously reported that the key apoptosis related gene caspase 8 (CASP8) is frequently silenced in small cell lung cancer (SCLC) tumors and cell lines usually, but not always, by aberrant promoter methylation. Because CASP8 is a key component of the death-inducing signaling complex (DISC) when specific death receptors (including DR4, DR5, FAS) are activated by their specific ligands (TRAIL/FASL), we examined expression of the components of the DISC complex in lung cancer cell lines. MYC family members are frequently amplified (MYC+ve) in SCLC, and MYC is a potent inducer of apoptosis. We examined 34 SCLC tines (12 of which were MYC+ve) and 22 NSCLC lines. CASP8 gene expression was frequently lost (79%) at message and protein levels in SCLC but not in non-SCLC (NSCLC). MYC amplification was present in 45% of SCLC cell lines, which had lost CASP8 expression, but not in any of the CASP8 positive lines. The frequency of CASP8 loss was significantly higher in MYC+ve SCLC compared to MYC-ve SCLC or in NSCLC. Analyses of other DISC components showed significantly higher rates of loss of expression of CASP10, DR5, FAS and FASL in SCLC compared to NSCLC. The loss of expression of proapoptotic DISC components was significantly higher in MYC+ve SCLC cell lines and these lines were completely resistant to TRAIL. Expression of CASP10 (a caspase closely related to CASP8) was frequently absent at the protein level in both SCLC and NSCLC lines. Expression of c-FLIP (proteolytically inactive homolog of CASP8) was inversely related to expression of CASP8. Our major conclusions are: (a) The death receptor pathway is differently inactivated at multiple levels in lung cancer cell lines; and (b) MYC amplification in SCLC is associated with inactivation of most components of the DISC complex, with resistance to TRAIL and with expression of c-FLIP. These findings may have considerable clinical and therapeutic implications.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, NB8 106,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	adi.gazdar@UTSouthwestern.edu	Chaudhary, Preet/E-1970-2018		NCI NIH HHS [P50-CA70907] Funding Source: Medline; NIAID NIH HHS [AI/AR47230-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BROERS JLV, 1993, AM J RESP CELL MOL, V9, P33, DOI 10.1165/ajrcmb/9.1.33; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hopkins-Donaldson S, 2000, MED PEDIATR ONCOL, V35, P608; Johnson BE, 1996, J CELL BIOCHEM, P210; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kumar A, 2001, ONCOGENE, V20, P1010, DOI 10.1038/sj.onc.1204154; MORSTYN G, 1984, JNCI-J NATL CANCER I, V73, P801; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Ozkara HA, 1999, TUMORI J, V85, P508; Phelps RM, 1996, J CELL BIOCHEM, P32; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Wang XD, 2001, GENE DEV, V15, P2922; Zajac-Kaye M, 2001, LUNG CANCER-J IASLC, V34, pS43, DOI 10.1016/S0169-5002(01)00343-9; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	23	64	67	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8510	8514		10.1038/sj.onc.1205941	http://dx.doi.org/10.1038/sj.onc.1205941			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466971	Bronze			2022-12-25	WOS:000179480100014
J	Yin, D; Xie, D; Hofmann, WK; Miller, CW; Black, KL; Koeffler, HP				Yin, D; Xie, D; Hofmann, WK; Miller, CW; Black, KL; Koeffler, HP			Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors	ONCOGENE			English	Article						Methylation; p14(ARF); p15(INK4B); p16(INK4A); RB; brain tumors; p53 mutation	HOMOZYGOUS DELETION; SUPPRESSOR GENE; CPG ISLAND; P16 GENE; SOMATIC MUTATIONS; FAMILIAL MELANOMA; P16(INK4A) GENES; DNA METHYLATION; STABILIZES P53; HUMAN CANCERS	Methylation status of the p(15INK4B), p16(INK4A), p14(ARF) and retinoblastoma (RB) genes was studied using methylation specific polymerase chain reaction (MSP) in 85 human brain tumors of various subtypes and four normal brain samples. These genes play an important role in the control of the cell cycle. Twenty-four out of 85 cases (28%) had at least one of these genes methylated. The frequency of p14ARF methylation was 15 out of 85 (18%) cases, and the expression of p14(ARF) in methylated gliomas was significantly lower than in unmethylated gliomas. The incidence of methylation of p15(INK4B), p16(INK4A) and RB gene was 4%, 7%, and 4%, respective . Samples with p14(ARF) methylation did not have p16(INK4A) methylation even though both genes physically overlap. None of the target genes was methylated in the normal brain samples. In addition, the p53 gene was mutated in 19 out of 85 (22%) samples as determined by single strand conformation polymorphism (SSCP) analysis and DNA sequencing. Thirty out of 85 (35%) brain tumors had either a p53 mutation or methylation of p14(ARF). Also, the p14(ARF) expression in p53 wild-type gliomas was lower than levels in p53 mutated gliomas. This finding is consistent with wild-type p53 being able to autoregulate its levels by down-regulating expression of p14(ARF). In summary, inactivation of the apoptosis pathway that included the p14(ARF) and p53 genes by hypermethylation and mutation, respectively, occurred frequently in human brain tumors. Down-regulation of p14(ARF) in gliomas was associated with hypermethylation of its promoter and the presence of a wild-type p53 in these samples.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yin, D (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, 8700 Beverly Blvd,Suite BM-1,Room 109, Los Angeles, CA 90048 USA.			Black, Keith/0000-0002-0546-4934; Xie, Dong/0000-0002-1150-8657				BARTSCH D, 1995, GENE CHROMOSOME CANC, V14, P189, DOI 10.1002/gcc.2870140306; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Costello JF, 1996, CANCER RES, V56, P2405; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Duro D, 1996, CANCER RES, V56, P848; Esteller M, 2000, CANCER RES, V60, P129; GREGER V, 1994, HUM GENET, V94, P491; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; IMAI Y, 1994, MODERN PATHOL, V7, P766; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LIU L, 1995, ONCOGENE, V11, P405; LIU QY, 1995, ONCOGENE, V10, P619; LOUIS DN, 1994, J NEUROPATH EXP NEUR, V53, P11, DOI 10.1097/00005072-199401000-00002; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nakamura M, 2001, CANCER RES, V61, P6335; Nakamura M, 2001, BRAIN PATHOL, V11, P159; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SAKAI T, 1991, AM J HUM GENET, V48, P880; Schmidt EE, 1997, BRIT J CANCER, V75, P2, DOI 10.1038/bjc.1997.2; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simon M, 1999, ACTA NEUROPATHOL, V98, P444, DOI 10.1007/s004010051107; Simpson DJ, 2000, CANCER RES, V60, P1211; Stirzaker C, 1997, CANCER RES, V57, P2229; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	49	41	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8372	8378		10.1038/sj.onc.1206031	http://dx.doi.org/10.1038/sj.onc.1206031			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447702				2022-12-25	WOS:000179323900017
J	Chantret, I; Dancourt, J; Dupre, T; Delenda, C; Bucher, S; Vuillaumier-Barrot, S; de Baulny, HO; Peletan, C; Danos, O; Seta, N; Durand, G; Oriol, R; Codogno, P; Moore, SEH				Chantret, I; Dancourt, J; Dupre, T; Delenda, C; Bucher, S; Vuillaumier-Barrot, S; de Baulny, HO; Peletan, C; Danos, O; Seta, N; Durand, G; Oriol, R; Codogno, P; Moore, SEH			A deficiency in dolichyl-P-glucose : Glc(1)Man(9)GlcNAc(2)-PP-dolichyl alpha 3-glucosyltransferase defines a new subtype of congenital disorders of glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; PHOSPHOMANNOSE ISOMERASE DEFICIENCY; POLYMANNOSE-TYPE OLIGOSACCHARIDES; MESSENGER-RNA DECAY; SYNDROME TYPE-I; GLYCOPROTEIN SYNDROME; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; SUCRASE-ISOMALTASE; GENE-EXPRESSION	The underlying causes of type 1 congenital disorders of glycosylation (CDG 1) have been shown to be mutations in genes encoding proteins involved in the biosynthesis of the dolichyl-linked oligosaccharide (Glc(3)Man(9)GIcNAC(2)-PP-dolichyl) that is required for protein glycosylation. Here we describe a CDG 1 patient displaying gastrointestinal problems but no central nervous system deficits. Fibroblasts from this patient accumulate mainly Man(9)GleNAC(2)-PP-dolichyl, but in the presence of castanospermine, an endoplasmic reticulum glucosidase inhibitor Glc(1)Man(9)GlcNAc(2)-PP-dolichyl predominates, suggesting inefficient addition of the second glucose residue onto lipid-linked oligosaccharide. Northern blot analysis revealed the cells from the patient to possess only 10-20% normal amounts of mRNA encoding the enzyme, dolichyl-P-glucose:Glc(1)Man(9)GlcNAC(2)-pp-dolichyl alpha3-glucosyltransferase (hALG8p), which catalyzes this reaction. Sequencing of hALG8 genomic DNA revealed exon 4 to contain a base deletion in one allele and a base insertion in the other. Both mutations give rise to premature stop codons predicted to generate severely truncated proteins, but because the translation inhibitor emetine was shown to stabilize the hALG8 mRNA from the patient to normal levels, it is likely that both transcripts undergo nonsense-mediated mRNA decay. As the cells from the patient were successfully complemented with wild type hALG8 cDNA, we conclude that these mutations are the underlying cause of this new CDG 1 subtype that we propose be called CDG 1h.	INSERM, U504, Unite Glycobiol & Signalisat Cellulaire, F-94807 Villejuif, France; Hop Bichat, F-91002 Evry, France; CNRS, URA 1923, F-91002 Evry, France; Hop Robert Debre, Assistance Publ Hop Paris, F-75004 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Moore, SEH (corresponding author), INSERM, U504, Unite Glycobiol & Signalisat Cellulaire, Batiment INSERM,16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Dancourt, Julia/U-1533-2017; Moore, Stuart/AAF-3920-2021; CHANTRET, Isabelle/AAF-7134-2021; Codogno, Patrice/G-1384-2013; Seta, Nathalie S/F-1824-2018	Dancourt, Julia/0000-0002-6237-1566; Moore, Stuart/0000-0002-1020-2242; CHANTRET, Isabelle/0000-0002-0896-1274; Codogno, Patrice/0000-0002-5492-3180; Seta, Nathalie S/0000-0002-9240-8630				Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; AW TY, 1984, BIOCHEM J, V219, P707, DOI 10.1042/bj2190707; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P115; Barnier A, 2002, CLIN CHEM, V48, P934; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; CHANTRET I, 1994, J CELL SCI, V107, P213; Chantret I, 2002, J BIOL CHEM, V277, P25815, DOI 10.1074/jbc.M203285200; CHAO KM, 1992, COMPUT APPL BIOSCI, V8, P481; Chatelut M, 1997, CLIN CHIM ACTA, V262, P61, DOI 10.1016/S0009-8981(97)06527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; D'SOUZA-SCHOREY C, 1993, J BIOL CHEM, V268, P4720; de Koning TJ, 2000, VIRCHOWS ARCH, V437, P101, DOI 10.1007/s004280000185; de Lonlay P, 2001, J MED GENET, V38, P14, DOI 10.1136/jmg.38.1.14; DEIANNINO NI, 1988, ARCH BIOCHEM BIOPHYS, V260, P139, DOI 10.1016/0003-9861(88)90434-1; ELTING JJ, 1980, J BIOL CHEM, V255, P2325; Freeze HH, 2001, BIOCHIMIE, V83, P791, DOI 10.1016/S0300-9084(01)01292-5; Freeze HH, 1999, BIOCHEM BIOPH RES CO, V255, P189, DOI 10.1006/bbrc.1998.9945; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; Grubenmann CE, 2002, HUM MOL GENET, V11, P2331, DOI 10.1093/hmg/11.19.2331; Grunewald S, 2000, ANN NEUROL, V47, P776; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; Imbach T, 1999, P NATL ACAD SCI USA, V96, P6982, DOI 10.1073/pnas.96.12.6982; Jaeken J, 1996, PEDIATR RES, V40, P764, DOI 10.1203/00006450-199611000-00017; JAEKEN J, 1993, J INHERIT METAB DIS, V16, P813, DOI 10.1007/BF00714272; Kim S, 2000, J CLIN INVEST, V105, P191, DOI 10.1172/JCI7302; Korner C, 1998, GLYCOBIOLOGY, V8, P165, DOI 10.1093/glycob/8.2.165; Korner C, 1999, EMBO J, V18, P6816, DOI 10.1093/emboj/18.23.6816; Korner C, 1998, P NATL ACAD SCI USA, V95, P13200, DOI 10.1073/pnas.95.22.13200; Kornfeld S, 1998, J CLIN INVEST, V101, P1293, DOI 10.1172/JCI3140; Kranz C, 2001, J CLIN INVEST, V108, P1613, DOI 10.1172/JCI200113635; KUKURUZINSKA MA, 1994, GLYCOBIOLOGY, V4, P437, DOI 10.1093/glycob/4.4.437; Kukuruzinska MA, 1999, BBA-GEN SUBJECTS, V1426, P359, DOI 10.1016/S0304-4165(98)00136-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LENNON K, 1995, GLYCOBIOLOGY, V5, P633, DOI 10.1093/glycob/5.6.633; Matthijs G, 1997, NAT GENET, V16, P88, DOI 10.1038/ng0597-88; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; Moore SEH, 1998, GLYCOBIOLOGY, V8, P373, DOI 10.1093/glycob/8.4.373; MOORE SEH, 1995, EMBO J, V14, P6034, DOI 10.1002/j.1460-2075.1995.tb00292.x; MURPHY LA, 1981, J BIOL CHEM, V256, P7487; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; OGIERDENIS E, 1994, J BIOL CHEM, V269, P4285; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; Panneerselvam K, 1997, J BIOL CHEM, V272, P23123, DOI 10.1074/jbc.272.37.23123; Reiss G, 1996, GLYCOBIOLOGY, V6, P493, DOI 10.1093/glycob/6.5.493; ROUSSET M, 1989, J CELL PHYSIOL, V141, P627, DOI 10.1002/jcp.1041410322; Saint-Pol A, 1999, J BIOL CHEM, V274, P13547, DOI 10.1074/jbc.274.19.13547; Schachter H, 2001, CELL MOL LIFE SCI, V58, P1085, DOI 10.1007/PL00000923; Schenk B, 2001, J CLIN INVEST, V108, P1687, DOI 10.1172/JCI200113419; Seta N, 1996, CLIN CHIM ACTA, V254, P131, DOI 10.1016/0009-8981(96)06379-6; SPIRO MJ, 1986, J BIOL CHEM, V261, P4725; SPIRO RG, 1983, J BIOL CHEM, V258, P9469; SPIRO RG, 1976, J BIOL CHEM, V251, P6409; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; Thiel C, 2002, BIOCHEM J, V367, P195, DOI 10.1042/BJ20020794; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WICE BM, 1985, J BIOL CHEM, V260, P139	61	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9962	9971		10.1074/jbc.M211950200	http://dx.doi.org/10.1074/jbc.M211950200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12480927	hybrid			2022-12-25	WOS:000181524000144
J	Swietnicki, W; Barnie, AM; Dyas, BK; Ulrich, RG				Swietnicki, W; Barnie, AM; Dyas, BK; Ulrich, RG			Zinc binding and dimerization of Streptococcus pyogenes pyrogenic exotoxin C are not essential for T-cell stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL-ENTEROTOXIN-A; CLASS-II MHC; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; BETA-CHAINS; SUPERANTIGENS; RECEPTOR; RECOGNITION; SUGGEST; TOXIN	Streptococcal pyrogenic enterotoxin C (Spe-C) is a superantigen virulence factor produced by Streptococcus pyogenes that activates T-cells polyclonally. The biologically active form of Spe-C is thought to be a homodimer containing an essential zinc coordination site on each subunit, consisting of the residues His(167), HiS(201), and Asp(203). Crystallographic data suggested that receptor specificity is dependent on contacts between the zinc coordination site of Spe-C and the beta-chain of the major histocompatibility complex type H (MHCII) molecule. Our results indicate that only a minor fraction of dimer is present at T-cell stimulatory concentrations of Spe-C following mutation of the unpaired side chain of cysteine at residue 27 to serine. Mutations of amino acid residues His(167), HiS(201), or Asp(203) had only minor effects on protein stability but resulted in greatly diminished MHCII binding, as measured by surface plasmon resonance with isolated receptor/ligand pairs and flow cytometry with MHCII-expressing cells. However, with the exception of the mutants D203A and D203N, mutation of the zinc-binding site of Spe-C did not significantly impact T-cell activation. The mutation Y76A, located in a polar pocket conserved among most superantigens, resulted in significant loss of T-cell stimulation, although no effect was observed on the overall binding to human MHCII molecules, perhaps because of the masking of this lower affinity interaction by the dominant zinc-dependent binding. To a lesser extent, mutations of side chains found in a second conserved MHCII alpha-chain-binding site consisting of a hydrophobic surface loop decreased T-cell stimulation. Our results demonstrate that dimerization and zinc coordination are not essential for biological activity of Spe-C and suggest the contribution of an alternative MHCII binding mode to T-cell activation.	USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA		Swietnicki, W (corresponding author), USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA.	wes.swietnicki@amedd.army.mil; ulrich@nciferf.gov	Swietnicki, Wieslaw/AAU-1536-2020; Swietnicki, Wieslaw/GOP-2576-2022; Swietnicki, Wieslaw/AAL-2452-2021	Swietnicki, Wieslaw/0000-0002-9354-8184; 				Arcus VL, 2000, J MOL BIOL, V299, P157, DOI 10.1006/jmbi.2000.3725; Bachmann MF, 1999, IMMUNOL TODAY, V20, P568, DOI 10.1016/S0167-5699(99)01543-1; BAVARI S, 1995, INFECT IMMUN, V63, P423, DOI 10.1128/IAI.63.2.423-429.1995; Bertelli M, 2001, J COMPUT AID MOL DES, V15, P465, DOI 10.1023/A:1011196508214; Cavallin A, 2000, J BIOL CHEM, V275, P1665, DOI 10.1074/jbc.275.3.1665; Chi YI, 2002, J BIOL CHEM, V277, P22839, DOI 10.1074/jbc.M201932200; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Dhar A, 1999, J MED CHEM, V42, P3602, DOI 10.1021/jm9900974; Dowd JE, 1996, MOL IMMUNOL, V33, P1267, DOI 10.1016/S0161-5890(96)00085-5; Fagin U, 1997, INFECT IMMUN, V65, P4725, DOI 10.1128/IAI.65.11.4725-4733.1997; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; Meegan MJ, 2001, J MED CHEM, V44, P1072, DOI 10.1021/jm001119l; Nilsson H, 1999, J IMMUNOL, V163, P6686; Papageorgiou AC, 1999, EMBO J, V18, P9, DOI 10.1093/emboj/18.1.9; Petersson K, 2001, EMBO J, V20, P3306, DOI 10.1093/emboj/20.13.3306; Proft T, 1999, J EXP MED, V189, P89, DOI 10.1084/jem.189.1.89; Proft T, 2001, J IMMUNOL, V166, P6711, DOI 10.4049/jimmunol.166.11.6711; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; Roussel A, 1997, NAT STRUCT BIOL, V4, P635, DOI 10.1038/nsb0897-635; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Sundberg E, 1999, NAT STRUCT BIOL, V6, P123; Sundberg EJ, 2002, STRUCTURE, V10, P687, DOI 10.1016/S0969-2126(02)00759-1; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; ULRICH RG, 1995, NAT STRUCT BIOL, V2, P554, DOI 10.1038/nsb0795-554; Willett P, 1995, TRENDS BIOTECHNOL, V13, P516, DOI 10.1016/S0167-7799(00)89015-0	33	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9885	9895		10.1074/jbc.M206957200	http://dx.doi.org/10.1074/jbc.M206957200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12473669	hybrid			2022-12-25	WOS:000181524000135
J	Harper, CC; Berg, JM; Gould, SJ				Harper, CC; Berg, JM; Gould, SJ			PEX5 binds the PTS1 independently of Hsp70 and the peroxin PEX12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING SIGNAL RECEPTOR; PROTEIN IMPORT; BIOGENESIS DISORDERS; PICHIA-PASTORIS; MATRIX PROTEIN; DOCKING SITE; MEMBRANE; GENE; IDENTIFICATION; DOMAIN	Most peroxisomal enzymes are targeted to peroxisomes by virtue of a type-1 peroxisomal targeting signal (PTS1) at their extreme C terminus. PEX5 binds the PTS1 through its C-terminal 40-kDa tetratricopeptide repeat domain and is essential for import of PTS1-contining proteins into peroxisomes. Here we examined the PTS1-binding activity of purified, recombinant, full-length PEX5 using a fluorescence anisotropy-based assay. Like its C-terminal fragment, full-length tetrameric PEX5 exhibits high intrinsic affinity for the PTS1, with a K-d of 35 nm for the peptide lissamine-Tyr-Gln-Ser-Lys-Leu-COO-. The specificity of this interaction was demonstrated by the fact that PEX5 had no detectable affinity for a peptide in which the Lys was replaced with Glu, a substitution that inactivates PTS1 signals in vivo. Hsp70 has been found to regulate the affinity of PEX5 for a PTS1-containing protein, but we found that the kinetics of PEX5-PTSI binding was unaffected by Hsp70, Hsp70 plus ATP, or Hsp70 plus ADP. In addition, we found that another protein known to interact with the PTS1-binding domain of PEX5, the PEX12 zinc RING domain, also had no discernable effect on PEX5-PTS1 binding kinetics. Taken together, these results suggest that the initial step in peroxisomal protein import, the recognition of enzymes by PEX5, is a relatively simple process and that Hsp70 most probably stimulates this process by catalyzing the folding of newly synthesized peroxisomal enzymes and/or enhancing the accessibility of their PTS1.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.		Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Berg, Jeremy/0000-0003-3022-0963				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dodt G, 2001, J BIOL CHEM, V276, P41769, DOI 10.1074/jbc.M106932200; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; Harano T, 2001, BIOCHEM J, V357, P157, DOI 10.1042/0264-6021:3570157; Horovitz A, 2001, J STRUCT BIOL, V135, P104, DOI 10.1006/jsbi.2001.4377; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIU H, 1995, J BIOL CHEM, V270, P10940, DOI 10.1074/jbc.270.18.10940; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; SWINKELS BW, 1991, EMBO J, V10, P3244; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; Will GK, 1999, MOL CELL BIOL, V19, P2265	35	26	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7897	7901		10.1074/jbc.M206651200	http://dx.doi.org/10.1074/jbc.M206651200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12456682	hybrid			2022-12-25	WOS:000181466800021
J	Mattila, PK; Salminen, M; Yamashiro, T; Lappalainen, P				Mattila, PK; Salminen, M; Yamashiro, T; Lappalainen, P			Mouse MIM, a tissue-specific regulator of cytoskeletal dynamics, interacts with ATP-actin monomers through its C-terminal WH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; DEPOLYMERIZING FACTOR; FILAMENT TURNOVER; ARP2/3 COMPLEX; PROFILIN; THYMOSIN-BETA-4; POLYMERIZATION; PURIFICATION; ADF/COFILIN; INTEGRATION	The WH2 (WASP homology domain-2) is a small actin monomer-binding motif and is found in many proteins that regulate the actin cytoskeleton, including the beta-thymosins, ciboulot, WASP, and verprolin/WIP (WASP-interacting protein). In sequence database searches we identified a novel mouse protein containing a WH2 domain in its C-terminal region. This mouse gene also shows strong sequence homology to human MIM (Missing in Metastasis), a cDNA fragment that is present in non-metastatic but absent in metastatic bladder cancer cell lines. Northern blot and in situ hybridizations show that MIM is strongly expressed in the developing neurons and skeletal and cardiac muscles in mouse embryos. In adult mice, the strongest expression of MIM mRNA is in liver, outer layers of the kidney, and in the Purkinje cells of the brain. Recombinant MIM protein interacts with actin monomers and inhibits actin filament nucleation in vitro. However, the MIM/ATP-G-actin complex can participate in actin filament assembly at the barbed end. MIM binds ATP-G-actin with a higher affinity (K-D = 0.06 muM) than ADP-G-actin (K-D = 0.3 muM) and inhibits the nucleotide exchange on actin monomers. Site-directed mutagenesis demonstrates that the actin monomer-binding site resides in the C-terminal WH2 domain of MIM. Overexpression of mouse MIM in NIH 3T3 cells results in the disappearance of actin stress fibers and appearance of abnormal actin filament structures. These data show that MIM is an ATP-G-actin binding protein that regulates cytoskeletal dynamics in specialized mammalian cell-types.	Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Program Dev Biol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Lappalainen, P (corresponding author), Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, POB 56, FIN-00014 Helsinki, Finland.		Mattila, Pieta K/G-6815-2013; Yamashiro, Takashi/Y-6411-2019; Yamashiro, Takashi/S-6010-2019; YAMASHIRO, Takashi/B-2026-2011	Mattila, Pieta K/0000-0003-2805-0686; Yamashiro, Takashi/0000-0002-4419-9643; Lappalainen, Pekka/0000-0001-6227-0354; Salminen, Marjo/0000-0003-0696-6845				Amann KJ, 2001, NAT CELL BIOL, V3, P306, DOI 10.1038/35060104; Anadon R, 2001, BRAIN RES, V894, P255, DOI 10.1016/S0006-8993(01)02024-8; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; Boquet I, 2000, CELL, V102, P797, DOI 10.1016/S0092-8674(00)00068-4; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; DETMERS P, 1981, J BIOL CHEM, V256, P99; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Goode BL, 1998, J CELL BIOL, V142, P723, DOI 10.1083/jcb.142.3.723; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; Hertzog M, 2002, J BIOL CHEM, V277, P14786, DOI 10.1074/jbc.M112064200; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Ojala PJ, 2002, MOL BIOL CELL, V13, P3811, DOI 10.1091/mbc.E02-03-0157; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Paunola E, 2002, FEBS LETT, V513, P92, DOI 10.1016/S0014-5793(01)03242-2; Peranen J, 2001, METHOD ENZYMOL, V329, P188; Peri S, 2001, TRENDS GENET, V17, P685, DOI 10.1016/S0168-9525(01)02493-3; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rice DPC, 2000, DEVELOPMENT, V127, P1845; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Takenawa T, 2001, J CELL SCI, V114, P1801; Thanabalu T, 2001, EMBO J, V20, P6979, DOI 10.1093/emboj/20.24.6979; Van Troys M, 1999, BBA-MOL CELL RES, V1448, P323, DOI 10.1016/S0167-4889(98)00152-9; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; Vartiainen M, 2000, MOL CELL BIOL, V20, P1772, DOI 10.1128/MCB.20.5.1772-1783.2000; WEEDS AG, 1986, EUR J BIOCHEM, V161, P77, DOI 10.1111/j.1432-1033.1986.tb10126.x; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Yarar D, 2002, MOL BIOL CELL, V13, P4045, DOI 10.1091/mbc.E02-05-0294	40	125	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8452	8459		10.1074/jbc.M212113200	http://dx.doi.org/10.1074/jbc.M212113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12482861	Green Published, hybrid			2022-12-25	WOS:000181466800092
J	Whiteman, M; Siau, JL; Halliwell, B				Whiteman, M; Siau, JL; Halliwell, B			Lack of tyrosine nitration by hypochlorous acid in the presence of physiological concentrations of nitrite - Implications for the role of nitryl chloride in tyrosine nitration in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXYNITRITE-TREATED PROTEINS; OXIDE PRODUCTION; 3-NITROTYROSINE; LOCALIZATION; MECHANISM; PLASMA; MYELOPEROXIDASE; DENITRATION; NITRATASES; DNA	Elevated levels of reactive nitrogen species (RNS) such as peroxynitrite have been implicated in over 50 diverse human diseases as measured by the formation of the RNS biomarker 3-nitrotyrosine. Recently, an additional RNS was postulated to contribute to 3-nitrotyrosine formation in vivo; nitryl chloride formed from the reaction of nitrite and neutrophil myeloperoxidase-derived hypochlorous acid (HOCI). Whether nitryl chloride nitrates intracellular protein is unknown. Therefore, we exposed intact human HepG2 and SW1353 cells or cell lysates to HOCI and nitrite and examined each for 3-nitrotyrosine formation by: 1) Western blotting, 2) using a commercial 3-nitrotyrosine enzyme-linked immunosorbent assay kit, 3) flow cytometric analysis, and 4) confocal microscopic analysis. With each approach, no significant 3-nitrotyrosine formation was observed in either whole cells or cell lysates. However, substantial 3-nitrotyrosine was observed when peroxynitrite (100 pm) was added to cells or cell lysates. These data suggest that nitryl chloride formed from the reaction of nitrite with HOCI does not contribute to the elevated levels of 3-nitrotyrosine observed in human diseases.	Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 117597, Singapore	National University of Singapore	Whiteman, M (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, 8 Med Dr, Singapore 117597, Singapore.	bchwml@nus.edu.sg	Halliwell, Barry/C-8318-2009; Whiteman, Matthew/C-6079-2009	Whiteman, Matthew/0000-0002-6583-6779; Halliwell, Barry/0000-0002-3560-7123				Ahn B, 1999, CARCINOGENESIS, V20, P1337, DOI 10.1093/carcin/20.7.1337; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Choi JJ, 2002, GLIA, V39, P37, DOI 10.1002/glia.10084; Clement MV, 1998, BLOOD, V92, P996; Davies CA, 1999, ELECTROPHORESIS, V20, P2111; Duguet A, 2001, AM J RESP CRIT CARE, V164, P1119, DOI 10.1164/ajrccm.164.7.2010085; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Ellis G, 1998, CLIN BIOCHEM, V31, P195, DOI 10.1016/S0009-9120(98)00015-0; Greenacre SAB, 1999, BIOCHEM BIOPH RES CO, V262, P781, DOI 10.1006/bbrc.1999.1309; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Grzelak A., 1997, BIOCHIM BIOPHYS ACTA, V1528, P97; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; Helaleh MIH, 2000, J CHROMATOGR B, V744, P433, DOI 10.1016/S0378-4347(00)00264-4; JOHNSON DW, 1991, INORG CHEM, V30, P4845, DOI 10.1021/ic00025a031; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; Kono Y, 1995, BIOCHEM MOL BIOL INT, V36, P275; Konttinen YT, 1997, ARTHRITIS RHEUM-US, V40, P875, DOI 10.1002/art.1780400515; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Kuo WN, 1999, MOL CELL BIOCHEM, V201, P11, DOI 10.1023/A:1007024126947; Kuo WN, 1999, BIOCHEM MOL BIOL INT, V47, P1061; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V200, P951, DOI 10.1006/bbrc.1994.1542; Mapp PI, 2001, ARTHRITIS RHEUM, V44, P1534, DOI 10.1002/1529-0131(200107)44:7<1534::AID-ART276>3.0.CO;2-#; Marcinkiewicz J, 2000, INFLAMM RES, V49, P280, DOI 10.1007/PL00000208; McKnight GM, 1999, BRIT J NUTR, V81, P349, DOI 10.1017/S000711459900063X; MONCADA S, 2001, VERH K ACAD GENEESKD, V62, P171; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Panasenko OM, 1997, ARCH BIOCHEM BIOPHYS, V343, P254, DOI 10.1006/abbi.1997.0171; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Spencer JPE, 2000, FREE RADICAL BIO MED, V28, P1039, DOI 10.1016/S0891-5849(00)00190-8; Sud A, 2000, NITRIC OXIDE-BIOL CH, V4, P615, DOI 10.1006/niox.2000.0309; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; UEDA T, 1995, ELECTROPHORESIS, V16, P1002, DOI 10.1002/elps.11501601167; Ueki Y, 1996, J RHEUMATOL, V23, P230; Wanchu A, 1998, RHEUMATOL INT, V18, P41, DOI 10.1007/s002960050055; Wanchu A, 1996, INDIAN J MED RES, V104, P263; Weitzberg E, 1998, NITRIC OXIDE-BIOL CH, V2, P1, DOI 10.1006/niox.1997.0162; Whiteman M, 1999, BIOCHEM BIOPH RES CO, V258, P168, DOI 10.1006/bbrc.1999.0564; Whiteman M, 1999, BIOCHEM BIOPH RES CO, V257, P572, DOI 10.1006/bbrc.1999.0448; Whiteman M, 2002, P NATL ACAD SCI USA, V99, P12061, DOI 10.1073/pnas.152462399; ZUBER M, 1994, PORTL PR P, V8, P503	42	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8380	8384		10.1074/jbc.M211086200	http://dx.doi.org/10.1074/jbc.M211086200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12475975	hybrid			2022-12-25	WOS:000181466800083
J	Chen, F; Chang, R; Trivedi, M; Capetanaki, Y; Cryns, VL				Chen, F; Chang, R; Trivedi, M; Capetanaki, Y; Cryns, VL			Caspase proteolysis of desmin produces a dominant-negative inhibitor of intermediate filaments and promotes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN 1-BETA-CONVERTING ENZYME; LAMIN-A; SKELETAL MYOPATHY; I KERATINS; ROCK-I; CLEAVAGE; MUSCLE; GENE; SUBSTRATE; PROTEASES	Caspase cleavage of key cytoskeletal proteins, including several intermediate filament proteins, triggers the dramatic disassembly of the cytoskeleton that characterizes apoptosis. Here we describe the muscle-specific intermediate filament protein desmin as a novel caspase substrate. Desmin is cleaved selectively at a conserved Asp residue in its L1-L2 linker domain (VEMD down arrow M-264) by caspase-6 in vitro and in myogenic cells undergoing apoptosis. We demonstrate that caspase cleavage of desmin at Asp 263 has important functional consequences, including the production of an amino-terminal cleavage product, N-desmin, which is unable to assemble into intermediate filaments, instead forming large intracellular aggregates. Moreover, N-desmin functions as a dominant-negative inhibitor of filament assembly, both for desmin and the structurally related intermediate filament protein vimentin. We also show that stable expression of a caspase cleavage-resistant desmin D263E mutant partially protects cells from tumor necrosis factor-alpha-induced apoptosis. Taken together, these results indicate that caspase proteolysis of desmin at Asp(263) produces a dominant-negative inhibitor of intermediate filaments and actively participates in the execution of apoptosis. In addition, these findings provide further evidence that the intermediate filament cytoskeleton has been targeted systematically for degradation during apoptosis.	Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Dept Med, Chicago, IL 60611 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Northwestern University; Feinberg School of Medicine; Baylor College of Medicine	Cryns, VL (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Endocrinol, Tarry 15-755,303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031957] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31957] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Capetanaki Y, 1998, Subcell Biochem, V31, P463; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; Ku NO, 2001, J BIOL CHEM, V276, P26792, DOI 10.1074/jbc.M103315200; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lee JC, 2002, J CELL BIOL, V158, P1051, DOI 10.1083/jcb.200112124; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Milner DJ, 1999, J MOL CELL CARDIOL, V31, P2063, DOI 10.1006/jmcc.1999.1037; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; Munoz-Marmol AM, 1998, P NATL ACAD SCI USA, V95, P11312, DOI 10.1073/pnas.95.19.11312; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Quinlan R, 1999, NAT MED, V5, P25, DOI 10.1038/4704; RAATS JMH, 1991, EUR J CELL BIOL, V56, P84; Raats JMH, 1996, EUR J CELL BIOL, V71, P221; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; SCHULTHEISS T, 1991, J CELL BIOL, V114, P953, DOI 10.1083/jcb.114.5.953; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Thornell LE, 1997, J MOL CELL CARDIOL, V29, P2107, DOI 10.1006/jmcc.1997.0446; Tolstonog GV, 2002, DNA CELL BIOL, V21, P213, DOI 10.1089/10445490252925459; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; YU KR, 1994, P NATL ACAD SCI USA, V91, P2497, DOI 10.1073/pnas.91.7.2497	49	83	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6848	6853		10.1074/jbc.M212021200	http://dx.doi.org/10.1074/jbc.M212021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12477713	hybrid			2022-12-25	WOS:000181195100029
J	Garnett, AP; Viles, JH				Garnett, AP; Viles, JH			Copper binding to the octarepeats of the prion protein - Affinity, specificity, folding, and cooperativity: Insights from circular dichroism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE ACTIVITY; OCTAPEPTIDE REPEAT REGION; ANTIOXIDANT FUNCTION; TERMINAL DOMAIN; SCRAPIE ISOFORM; METAL-BINDING; IN-VIVO; DISEASE; SITES; MANGANESE	The prion protein (PrP) is a Cu2+ binding cell surface glycoprotein. There is increasing evidence that PrP functions as a copper transporter. In addition, strains of prion disease have been linked with copper binding. We present here CD spectroscopic studies of Cu2+ binding to various fragments of the octarepeat region of the prion protein. We show that glycine and L-histidine will successfully compete for all Cu2+ ions bound to the PrP octapeptide region, suggesting Cu2+ coordinates with a lower affinity for PrP than the f(M) dissociation constant reported previously. We show that each of the octarepeats do not form an isolated Cu2+ binding motif but fold up cooperatively within multiple repeats. In addition to the coordinating histidine side chain residues, we show that the glycine residues and the proline within each octarepeat are also necessary to maintain the coordination geometry. The highly conserved octarepeat region in mammals is a hexarepeat in birds that also binds copper but with different coordination geometry. Finally, in contrast to other reports, we show that Mn2+ does not bind to the octarepeat region of PrP.	Univ London Queen Mary, Sch Biol Sci, London E1 4NS, England	University of London; Queen Mary University London	Viles, JH (corresponding author), Univ London Queen Mary, Sch Biol Sci, Mile End Rd, London E1 4NS, England.							Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; Bonomo RP, 2000, CHEM-EUR J, V6, P4195, DOI 10.1002/1521-3765(20001117)6:22<4195::AID-CHEM4195>3.0.CO;2-2; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1998, J NEUROCHEM, V70, P1686; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; Brown DR, 2001, BRAIN RES BULL, V55, P165, DOI 10.1016/S0361-9230(01)00453-1; Brown DR, 2000, BIOCHEM J, V352, P511, DOI 10.1042/0264-6021:3520511; BRYCE GF, 1966, J BIOL CHEM, V241, P122; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; Dawson R.M.C., 1986, DATA BIOCH RES, P399; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; GABRIEL JM, 1992, P NATL ACAD SCI USA, V89, P9097, DOI 10.1073/pnas.89.19.9097; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gustiananda M, 2002, FEBS LETT, V512, P38, DOI 10.1016/S0014-5793(01)03298-7; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Marcotte EM, 1999, BIOCHEMISTRY-US, V38, P667, DOI 10.1021/bi981487f; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Purdey M, 2001, MED HYPOTHESES, V57, P29, DOI 10.1054/mehy.2001.1305; Purdey M, 2000, MED HYPOTHESES, V54, P278, DOI 10.1054/mehy.1999.0836; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; RICK R, 1996, NATURE, V382, P180; Ruiz FH, 2000, BIOCHEM BIOPH RES CO, V269, P491, DOI 10.1006/bbrc.2000.2270; Shiraishi N, 2000, BIOCHEM BIOPH RES CO, V267, P398, DOI 10.1006/bbrc.1999.1944; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Thackray AM, 2002, BIOCHEM J, V362, P253, DOI 10.1042/0264-6021:3620253; TSANGARIS JM, 1970, J AM CHEM SOC, V92, P4255, DOI 10.1021/ja00717a020; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; Wong BS, 2000, BIOCHEM BIOPH RES CO, V273, P136, DOI 10.1006/bbrc.2000.2911; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	56	185	186	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6795	6802		10.1074/jbc.M209280200	http://dx.doi.org/10.1074/jbc.M209280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12454014	hybrid			2022-12-25	WOS:000181195100022
J	Jodo, S; Kung, JT; Xiao, S; Chan, DV; Kobayashi, S; Tateno, M; Lafyatis, R; Ju, ST				Jodo, S; Kung, JT; Xiao, S; Chan, DV; Kobayashi, S; Tateno, M; Lafyatis, R; Ju, ST			Anti-CD95-induced lethality requires radioresistant Fc gamma RII+ cells - A novel mechanism for fulminant hepatic failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-FAS ANTIBODY; TUMOR NECROSIS FACTOR; PROTECTS MICE; HEPATOCELLULAR APOPTOSIS; LIVER DESTRUCTION; KUPFFER CELLS; TNF-ALPHA; IN-VIVO; RECEPTORS; LIGAND	The Jo2 anti-mouse CD95 monoclonal antibody induces lethality in mice characterized by hepatocyte death and liver hemorrhage. Mice bearing a defect in Fas expression or in the Fas-mediated apoptotic pathway are resistant to Jo2. Here we show that FcgammaRII knockout mice or mice with monoclonal antibody-blocked FcgammaRII are also resistant to Jo2. The critical FcgammaRII(+) cells are radioresistant and could not be reconstituted with splenic cells. Death of sinusoidal lining cells and destruction of sinusoids were observed, consistent with the characteristic liver hemorrhage and the selective FcgammaRII expression in sinusoidal lining cells but not hepatocytes. Hemorrhage developed coincident with hepatocyte death and the sharp rise of serum alanine aminotransferase and alanine aminotransferase. Invariably, moribund mice showed severe liver hemorrhage and destruction of sinusoids. The data demonstrate a novel mechanism by which the destruction of liver sinusoids, induced by the Jo2-mediated co-engagement of Fas and FcgammaRII, leads to severe hemorrhage and lethal fulminant hepatitis.	Univ Virginia, Dept Internal Med, Div Rheumatol & Immunol, Charlottesville, VA 22908 USA; Boston Univ, Sch Med, Arthrit Ctr, Dept Med, Boston, MA 02118 USA; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Hokkaido Univ, Coll Med Technol, Dept Lab Technol, Sapporo, Hokkaido 060, Japan; Sapporo City Gen Hosp, Dept Pathol, Sapporo, Hokkaido, Japan	University of Virginia; Boston University; Academia Sinica - Taiwan; Boston University; Hokkaido University; Sapporo City General Hospital	Ju, ST (corresponding author), Univ Virginia, Dept Internal Med, Div Rheumatol & Immunol, POB 800412, Charlottesville, VA 22908 USA.	sj8r@virginia.edu	Kobayashi, Seiichi/D-6499-2012; Kung, John T/AAZ-8354-2021	Kobayashi, Seiichi/0000-0002-5867-6076; Kung, John T/0000-0001-9052-1392; Lafyatis, Robert/0000-0002-9398-5034	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES010244] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36938] Funding Source: Medline; NIEHS NIH HHS [ES-10244] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAUJOJORGE T, 1993, INFECT IMMUN, V61, P4925, DOI 10.1128/IAI.61.11.4925-4928.1993; Bahjat FR, 2000, J IMMUNOL, V165, P6559, DOI 10.4049/jimmunol.165.11.6559; Bobe P, 1997, J IMMUNOL, V159, P4197; DeLeve LD, 1997, BIOCHEM PHARMACOL, V53, P1339, DOI 10.1016/S0006-2952(97)00048-8; DeLeve LD, 2002, SEMIN LIVER DIS, V22, P27, DOI 10.1055/s-2002-23204; Feng GP, 2000, J CLIN INVEST, V105, P329, DOI 10.1172/JCI7398; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; HUBSCHER SG, 1989, J CLIN PATHOL, V42, P360, DOI 10.1136/jcp.42.4.360; Jodo S, 2000, J IMMUNOL, V165, P5487, DOI 10.4049/jimmunol.165.10.5487; Jodo S, 2001, J BIOL CHEM, V276, P39938, DOI 10.1074/jbc.M107005200; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LEIST M, 1995, AM J PATHOL, V146, P1220; Morikawa A, 1996, INFECT IMMUN, V64, P734, DOI 10.1128/IAI.64.3.734-738.1996; MURO H, 1993, AM J PATHOL, V143, P105; Natori S, 1999, TRANSPLANTATION, V68, P89, DOI 10.1097/00007890-199907150-00018; Nishimura Y, 1997, INT IMMUNOL, V9, P307, DOI 10.1093/intimm/9.2.307; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Onda M, 2000, J IMMUNOL, V165, P7150, DOI 10.4049/jimmunol.165.12.7150; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; TAKEZAWA R, 1995, J BIOCHEM, V118, P1175, DOI 10.1093/oxfordjournals.jbchem.a125004; Tanaka M, 1997, J IMMUNOL, V158, P2303; TIEGS G, 1989, BIOCHEM PHARMACOL, V38, P627, DOI 10.1016/0006-2952(89)90208-6; Wanner GA, 1999, FASEB J, V13, P1239, DOI 10.1096/fasebj.13.10.1239; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Woo M, 1999, J IMMUNOL, V163, P4909; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	31	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7553	7557		10.1074/jbc.M211229200	http://dx.doi.org/10.1074/jbc.M211229200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12477718	hybrid			2022-12-25	WOS:000181195100117
J	Adam, PJ; Boyd, R; Tyson, KL; Fletcher, GC; Stamps, A; Hudson, L; Poyser, HR; Redpath, N; Griffiths, M; Steers, G; Harris, AL; Patel, S; Berry, J; Loader, JA; Townsend, RR; Daviet, L; Legrain, P; Parekh, R; Terrett, JA				Adam, PJ; Boyd, R; Tyson, KL; Fletcher, GC; Stamps, A; Hudson, L; Poyser, HR; Redpath, N; Griffiths, M; Steers, G; Harris, AL; Patel, S; Berry, J; Loader, JA; Townsend, RR; Daviet, L; Legrain, P; Parekh, R; Terrett, JA			Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; S100A4 P9KA; METASTASIS; GENE; EXPRESSION; CALNUC	Proteins associated with cancer cell plasma membranes are rich in known drug and antibody targets as well as other proteins known to play key roles in the abnormal signal transduction processes required for carcinogenesis. We describe here a proteomics process that comprehensively annotates the protein content of breast tumor cell membranes and defines the clinical relevance of such proteins. Tumor-derived cell lines were used to ensure an enrichment for cancer cell-specific plasma membrane proteins because it is difficult to purify cancer cells and then obtain good membrane preparations from clinical material. Multiple cell lines with different molecular pathologies were used to represent the clinical heterogeneity of breast cancer. Peptide tandem mass spectra were searched against a comprehensive data base containing known and conceptual proteins derived from many public data bases including the draft human genome sequences. This plasma membrane-enriched proteome analysis created a data base of more than 500 breast cancer cell line proteins, 27% of which were of unknown function. The value of our approach is demonstrated by further detailed analyses of three previously uncharacterized proteins whose clinical relevance has been defined by their unique cancer expression profiles and the identification of protein-binding partners that elucidate potential functionality in cancer.	The Forum, Oxford Glyocosci, Abingdon OX14 4RY, Oxon, England; John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res United Kingdom Mol Oncol Labs, Oxford OX3 9DS, England; Hybrigen, F-75014 Paris, France	University of Oxford	Terrett, JA (corresponding author), The Forum, Oxford Glyocosci, 86 Milton Pk, Abingdon OX14 4RY, Oxon, England.	jon.terrett@ogs.co.uk	Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5; Abicht A, 2000, CURR OPIN MOL THER, V2, P593; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Brenner T L, 1999, J Am Pharm Assoc (Wash), V39, P236; Catimel B, 1996, J BIOL CHEM, V271, P25664, DOI 10.1074/jbc.271.41.25664; Davies MPA, 1996, ONCOGENE, V13, P1631; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FLETCHER GC, 2003, IN PRESS BR J CANC; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Koller A, 2002, P NATL ACAD SCI USA, V99, P11969, DOI 10.1073/pnas.172183199; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Lin P, 2000, P NATL ACAD SCI USA, V97, P674, DOI 10.1073/pnas.97.2.674; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Pasquali C, 1999, J CHROMATOGR B, V722, P89, DOI 10.1016/S0378-4347(98)00314-4; Petek E, 2000, CYTOGENET CELL GENET, V89, P141, DOI 10.1159/000015594; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Ranson Malcolm, 2002, Expert Rev Anticancer Ther, V2, P161, DOI 10.1586/14737140.2.2.161; Rosel M, 1998, ONCOGENE, V17, P1989, DOI 10.1038/sj.onc.1202079; Rudland PS, 2000, CANCER RES, V60, P1595; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Simpson RJ, 2000, ELECTROPHORESIS, V21, P1707, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1707::AID-ELPS1707>3.0.CO;2-Q; Stradal TB, 1999, J BIOL CHEM, V274, P31593, DOI 10.1074/jbc.274.44.31593; Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Zhou HL, 2002, NAT BIOTECHNOL, V20, P512, DOI 10.1038/nbt0502-512; 2001, EXPERT REV ANTICANCE, V1, P3	31	174	191	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6482	6489		10.1074/jbc.M210184200	http://dx.doi.org/10.1074/jbc.M210184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12477722	hybrid			2022-12-25	WOS:000181129400123
J	Fluhrer, R; Multhaup, G; Schlicksupp, A; Okochi, M; Takeda, M; Lammich, S; Willem, M; Westmeyer, G; Bode, W; Walter, J; Haass, C				Fluhrer, R; Multhaup, G; Schlicksupp, A; Okochi, M; Takeda, M; Lammich, S; Willem, M; Westmeyer, G; Bode, W; Walter, J; Haass, C			Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; PROTEIN-CLEAVING ENZYME; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; THYMOCYTE DEVELOPMENT; CELL-LINES; A-BETA; CLEAVAGE; GAMMA; SITE	The beta-amyloid precursor protein (betaAPP) is proteolytically processed by two secretase activities to produce the pathogenic amyloid beta-peptide (Abeta). N-terminal cleavage is mediated by beta-secretase (BACE) whereas C-terminal intramembraneous cleavage is exerted by the presenilin (PS) gamma-secretase complex. The Abeta-generating,gamma-secretase cleavage principally occurs after amino acid 40 or 42 and results in secretion of A/beta-(1-40) or Abeta-(1-42). Upon overexpression of BACE in cultured cells we unexpectedly noticed a reduction of secreted Abeta-(1-40/ 42). However, mass spectrometry revealed a truncated Abeta species, which terminates at amino acid 34 (Abeta-(1-34)) suggesting an alternative gamma-secretase cut. Indeed, expression of a loss-of-function variant of PS1 inhibited not only the production of Abeta-(1-40) and Abeta-(1-42) but also that of Abeta-(1-34). However, expression levels of BACE correlate with the amount of Abeta-(1-34), and Abeta(1-34) is produced at the expense of Abeta-(1-40) and Abeta(1-42). Since this suggested that BACE is involved in a C-teriminal truncation of Abeta, we incubated purified BACE with Abeta-(1-40) in vitro. Under these conditions Abeta-(1-34) was generated. Moreover, when conditioned media containing Abeta-(1-40) and Abeta-(1-42) were incubated with cells expressing a loss-of-function PS1 variant together with BACE, Abeta-(1-34) was efficiently produced in vivo. These data demonstrate that an apparently gamma-secretase-dependent Abeta derivative is produced after the generation of the non-truncated Abeta via an additional and unexpected activity of BACE.	Univ Munich, Dept Biochem, Adolf Butenandt Inst, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Univ Heidelberg, ZMBH, Ctr Biol Mol, D-6900 Heidelberg, Germany; Osaka Univ, Grad Sch Med, Div Psychiat & Behav Prote, Dept Postgeonomics & Dis, Osaka 5650871, Japan; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Munich; Ruprecht Karls University Heidelberg; Osaka University; Max Planck Society	Walter, J (corresponding author), Univ Munich, Dept Biochem, Adolf Butenandt Inst, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.		Walter, Jochen/B-3677-2014; Fluhrer, Regina/F-2642-2011; Wang, Caihong/T-5837-2019	Wang, Caihong/0000-0002-6808-3709; Walter, Jochen/0000-0002-4678-2912; Okochi, Masayasu/0000-0002-2318-7651; Westmeyer, Gil Gregor/0000-0001-7224-8919				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Beher D, 2002, J NEUROCHEM, V82, P563, DOI 10.1046/j.1471-4159.2002.00985.x; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Capell A, 2002, J BIOL CHEM, V277, P5637, DOI 10.1074/jbc.M109119200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; FAN W, 1999, SCIENCE, V286, P1255; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Pinnix I, 2001, FASEB J, V15, P1810, DOI 10.1096/fj.00-0891fje; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saunders AJ, 1999, SCIENCE, V286; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Vandermeeren M, 2001, NEUROSCI LETT, V315, P145, DOI 10.1016/S0304-3940(01)02369-2; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	69	60	62	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5531	5538		10.1074/jbc.M211485200	http://dx.doi.org/10.1074/jbc.M211485200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471021	Green Published, hybrid			2022-12-25	WOS:000181129400009
J	Hill, DM; Kasliwal, T; Schwarz, E; Hebert, AM; Chen, T; Gubina, E; Zhang, L; Kozlowski, S				Hill, DM; Kasliwal, T; Schwarz, E; Hebert, AM; Chen, T; Gubina, E; Zhang, L; Kozlowski, S			A dominant negative mutant beta 2-microglobulin blocks the extracellular folding of a major histocompatibility complex class I heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; INDUCED CONFORMATIONAL CHANGE; CELL-SURFACE EXPRESSION; T-CELL; HUMAN BETA(2)-MICROGLOBULIN; ANTIGEN PRESENTATION; CRYSTAL-STRUCTURE; PEPTIDE BINDING; ALPHA-3 DOMAIN; MOLECULES	The major histocompatibility complex class I (MHC1) molecule plays a crucial role in cytotoxic lymphocyte function. beta2-Microglobutin (beta2m) has been demonstrated to be both a structural component of the MHC1 complex and a chaperone-like molecule for MHC1 folding. beta2m binding to an isolated alpha3 domain of MHC1 heavy chain at micromolar concentrations has been shown to accurately model the biochemistry and thermodynamics of beta2m-driven MHC1 folding. These results suggested a model in which the chaperone-like role of beta2m is dependent on initial binding to the alpha3 domain interface of MHC1 with beta2m. Such a model predicts that a mutant beta2m molecule with an intact MHC1 alpha3 domain interaction but a defective MHC1 alpha1alpha2 domain interaction would block beta2m-driven folding of MHC1. In this study we generated such a beta2m mutant and demonstrated that it blocks MHC1 folding by normal beta2m at the expected micromolar concentrations. Our data support an initial interaction of beta2m with the MHC1 alpha3 domain in MHC I folding. In addition, the dominant negative mutant beta2m can block T-cell functional responses to antigenic peptide and MHC1.	US FDA, Ctr Biol Evaluat & Res, Div Monoclonal Antibodies, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Kozlowski, S (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Monoclonal Antibodies, 29 Lincoln Dr,Bldg 29B-3NN08,HFM-561, Bethesda, MD 20892 USA.							ABASTADO JP, 1993, J IMMUNOL, V151, P3569; Achour A, 1998, IMMUNITY, V9, P199, DOI 10.1016/S1074-7613(00)80602-0; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; ANDERSON KS, 1993, J IMMUNOL, V151, P3407; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1997, DOI 10.1002/eji.1830210905; BIX M, 1992, J EXP MED, V176, P829, DOI 10.1084/jem.176.3.829; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Chen WS, 1999, J EXP MED, V189, P1757, DOI 10.1084/jem.189.11.1757; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALO LD, 1992, P NATL ACAD SCI USA, V89, P8347, DOI 10.1073/pnas.89.17.8347; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FUKAZAWA T, 1994, J IMMUNOL, V153, P3543; GARBOCZI DN, 1994, J MOL BIOL, V239, P581, DOI 10.1006/jmbi.1994.1398; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glick M, 2002, J BIOL CHEM, V277, P20840, DOI 10.1074/jbc.M201819200; Hebert AM, 2001, BIOCHEMISTRY-US, V40, P5233, DOI 10.1021/bi002392s; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOCHMAN JH, 1988, J IMMUNOL, V140, P2322; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HYAFIL F, 1979, P NATL ACAD SCI USA, V76, P5834, DOI 10.1073/pnas.76.11.5834; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jones EY, 1998, IMMUNOL REV, V163, P121, DOI 10.1111/j.1600-065X.1998.tb01191.x; KANE KP, 1991, EUR J IMMUNOL, V21, P2289, DOI 10.1002/eji.1830210945; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; KOZLOWSKI S, 1993, J IMMUNOL, V151, P4033; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; Li HM, 1998, J MOL BIOL, V283, P179, DOI 10.1006/jmbi.1998.2091; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Ljunggren HG, 1996, HISTOL HISTOPATHOL, V11, P267; Michaelsson J, 2001, J IMMUNOL, V166, P7327, DOI 10.4049/jimmunol.166.12.7327; Noun G, 1996, J IMMUNOL, V157, P2455; OTTEN GR, 1992, J IMMUNOL, V148, P3723; OZATO K, 1983, P NATL ACAD SCI-BIOL, V80, P2040, DOI 10.1073/pnas.80.7.2040; PARKER KC, 1985, BIOCHEMISTRY-US, V24, P5543, DOI 10.1021/bi00341a039; PEDERSEN LO, 1994, SCAND J IMMUNOL, V39, P64, DOI 10.1111/j.1365-3083.1994.tb03341.x; Perlmutter RM, 1996, CURR OPIN IMMUNOL, V8, P285, DOI 10.1016/S0952-7915(96)80069-0; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; RIBAUDO RK, 1995, J IMMUNOL, V155, P3481; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; SALTER RD, 1992, HUM IMMUNOL, V35, P40, DOI 10.1016/0198-8859(92)90093-3; SANTOSAGUADO J, 1987, MOL CELL BIOL, V7, P982, DOI 10.1128/MCB.7.3.982; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SEONG RH, 1988, J EXP MED, V167, P288, DOI 10.1084/jem.167.2.288; SHERMAN LA, 1992, J EXP MED, V175, P1221, DOI 10.1084/jem.175.5.1221; Shields MJ, 1998, J IMMUNOL, V160, P2297; Shields MJ, 1998, J BIOL CHEM, V273, P28010, DOI 10.1074/jbc.273.43.28010; Shields MJ, 1998, MOL IMMUNOL, V35, P919, DOI 10.1016/S0161-5890(98)00083-2; Shields MJ, 1999, MOL IMMUNOL, V36, P561, DOI 10.1016/S0161-5890(99)00077-2; SMITH JD, 1992, P NATL ACAD SCI USA, V89, P7767, DOI 10.1073/pnas.89.16.7767; SMITH MH, 1990, MOL IMMUNOL, V27, P169, DOI 10.1016/0161-5890(90)90112-D; Solheim JC, 1999, IMMUNOL REV, V172, P11, DOI 10.1111/j.1600-065X.1999.tb01352.x; SOLHEIM JC, 1995, EUR J IMMUNOL, V25, P3011, DOI 10.1002/eji.1830251104; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TAKESHITA T, 1995, J IMMUNOL, V154, P1973; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; Wang J, 2002, J BIOL CHEM, V277, P1433, DOI 10.1074/jbc.M110316200; Whitman MC, 2000, MOL IMMUNOL, V37, P141, DOI 10.1016/S0161-5890(00)00034-1; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	68	19	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5630	5638		10.1074/jbc.M208381200	http://dx.doi.org/10.1074/jbc.M208381200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12454016	hybrid			2022-12-25	WOS:000181129400020
J	Ludidi, N; Gehring, C				Ludidi, N; Gehring, C			Identification of a novel protein with guanylyl cyclase activity in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; NATRIURETIC PEPTIDES; CATALYTIC MECHANISM; GENE-EXPRESSION; CYCLIC-GMP; BINDING; ADENYLYL; PHYTOCHROME; GTPASE; CGMP	Guanylyl cyclases (GCs) catalyze the formation of the second messenger guanosine 3',5'-cyclic monophosphate (cGMP) from guanosine 5'-triphosphate (GTP). While many cGMP-mediated processes in plants have been reported, no plant molecule with GC activity has been identified. When the Arabidopsis thaliana genome is queried with GC sequences from cyanobacteria, lower and higher eukaryotes no unassigned proteins with significant similarity are found. However, a motif search of the A. thaliana genome based on conserved and functionally assigned amino acids in the catalytic center of annotated GCs returns one candidate that also contains the adjacent glycine-rich domain typical for GCs. In this molecule, termed AtGC1, the catalytic domain is in the N-terminal part. AtGC1 contains the arginine or lysine that participates in hydrogen bonding with guanine and the cysteine that confers substrate specificity for GTP. When AtGC1 is expressed in Escherichia coli, cell extracts yield >2.5 times more cGMP than control extracts and this increase is not nitric oxide dependent. Furthermore, purified recombinant AtGC1 has Mg2+-dependent GC activity in vitro and >3 times less adenylyl cyclase activity when assayed with ATP as substrate in the absence of GTP. Catalytic activity in vitro proves that AtGC1 can function either as a monomer or homo-oligomer. AtGC1 is thus not only the first functional plant GC but also, due to its unusual domain organization, a member of a new class of GCs.	Univ Western Cape, Dept Biotechnol, ZA-7535 Bellville, South Africa	University of the Western Cape	Gehring, C (corresponding author), Univ Western Cape, Dept Biotechnol, Private Bag X17, ZA-7535 Bellville, South Africa.	cgehring@uwc.ac.za	Ludidi, Ndiko/W-4796-2019	Gehring, Christoph/0000-0003-4355-4591				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOWLER C, 1994, GENE DEV, V8, P2188, DOI 10.1101/gad.8.18.2188; Bowler C, 1997, ACTA PHYSIOL PLANT, V19, P475, DOI 10.1007/s11738-997-0044-3; Chamovitz DA, 1996, CRIT REV PLANT SCI, V15, P455, DOI 10.1080/07352689609382367; Durner J, 1998, P NATL ACAD SCI USA, V95, P10328, DOI 10.1073/pnas.95.17.10328; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; Hurley JH, 1998, CURR OPIN STRUC BIOL, V8, P770, DOI 10.1016/S0959-440X(98)80097-3; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KOESLING D, 1991, FEBS LETT, V280, P301, DOI 10.1016/0014-5793(91)80317-V; Koglin M, 2001, J BIOL CHEM, V276, P30737, DOI 10.1074/jbc.M102549200; Lawson DM, 2000, EMBO J, V19, P5661, DOI 10.1093/emboj/19.21.5661; Leng Q, 1999, PLANT PHYSIOL, V121, P753, DOI 10.1104/pp.121.3.753; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Lucas KA, 2000, PHARMACOL REV, V52, P375; Ludidi NN, 2002, J MOL EVOL, V54, P587, DOI 10.1007/s00239-001-0055-4; Maathuis FJM, 2001, PLANT PHYSIOL, V127, P1617, DOI 10.1104/pp.010502; McCue LA, 2000, GENOME RES, V10, P204, DOI 10.1101/gr.10.2.204; Neuhaus G, 1997, EMBO J, V16, P2554, DOI 10.1093/emboj/16.10.2554; Neun R, 1996, FEBS LETT, V390, P69, DOI 10.1016/0014-5793(96)00628-X; Nighorn A, 1999, J BIOL CHEM, V274, P2525, DOI 10.1074/jbc.274.4.2525; Nighorn A, 2001, J EXP BIOL, V204, P305; Penson SP, 1996, PLANT CELL, V8, P2325, DOI 10.1105/tpc.8.12.2325; Pharmawati M, 1998, PLANT SCI, V137, P107, DOI 10.1016/S0168-9452(98)00135-6; Pharmawati M, 1998, CELL MOL LIFE SCI, V54, P272, DOI 10.1007/s000180050149; Pharmawati M, 2001, PLANT PHYSIOL BIOCH, V39, P385, DOI 10.1016/S0981-9428(01)01252-9; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Roelofs J, 2001, EMBO J, V20, P4341, DOI 10.1093/emboj/20.16.4341; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; Simpson PJ, 1999, J BIOL CHEM, V274, P4440, DOI 10.1074/jbc.274.7.4440; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; THOMPSON DK, 1995, J BIOL CHEM, V270, P425, DOI 10.1074/jbc.270.1.425; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THORPE DS, 1990, J BIOL CHEM, V265, P14717; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Volotovski ID, 1998, PLANT PHYSIOL, V117, P1023, DOI 10.1104/pp.117.3.1023; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; Wedel BJ, 1997, FEBS LETT, V410, P29, DOI 10.1016/S0014-5793(97)00358-X; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	41	122	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6490	6494		10.1074/jbc.M210983200	http://dx.doi.org/10.1074/jbc.M210983200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482758	hybrid			2022-12-25	WOS:000181129400124
J	Natsch, A; Gfeller, H; Gygax, P; Schmid, J; Acuna, G				Natsch, A; Gfeller, H; Gygax, P; Schmid, J; Acuna, G			A specific bacterial aminoacylase cleaves odorant precursors secreted in the human axilla	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEBACTERIUM SULFOLOBUS-SOLFATARICUS; GENE; PHEROMONE; CARBOXYPEPTIDASE; AMIDOHYDROLASE; PURIFICATION; EXPRESSION; SEQUENCE; PROTEINS; BINDING	Human axillary odor is known to be formed upon the action of Corynebacteria sp. on odorless axilla secretions. The known axilla odor determinant 3-methyl-2-hexenoic acid was identified in hydrolyzed axilla secretions along with a chemically related compound, 3-hydroxy-3-methylhexanoic acid. The natural precursors of both these acids were purified from non-hydrolyzed axilla secretions. From liquid chromatography/ mass spectrometry analysis, it appeared that the acids are covalently linked to a glutamine residue in fresh axilla secretions, and the corresponding conjugates were synthesized for confirmation. Bacterial isolates obtained from the human axilla and belonging to the Corynebacteria were found to release the acids from these odorless precursors in vitro. A Zn2+-dependent aminoacylase mediating this cleavage was purified from Corynebacterium striatum Ax20, and the corresponding gene agaA was cloned and heterologously expressed in Escherichia coli. The enzyme is highly specific for the glutamine residue but has a low specificity for the acyl part of the substrate. agaA is closely related to many genes coding for enzymes involved in the cleavage of N-terminal acyl and aryl substituents from amino acids. This is the first report of the structure elucidation of precursors for human body odorants and the isolation of the bacterial enzyme involved in their cleavage.	Givaudan Dubendorf Ltd, CH-8600 Dubendorf, Switzerland	Givaudan SA	Natsch, A (corresponding author), Givaudan Dubendorf Ltd, Ueberlandstr 138, CH-8600 Dubendorf, Switzerland.		natsch, andreas/AAM-7042-2020	Natsch, Andreas/0000-0003-2231-2489				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMOORE JE, 1977, CHEM SENS FLAV, V2, P267, DOI 10.1093/chemse/2.3.267; BARTEL B, 1995, SCIENCE, V268, P1745, DOI 10.1126/science.7792599; BIRD S, 1981, J STEROID BIOCHEM, V14, P213, DOI 10.1016/0022-4731(81)90176-X; Briand L, 2000, FEBS LETT, V476, P179, DOI 10.1016/S0014-5793(00)01719-1; BROOKSBA.BW, 1974, EXPERIENTIA, V30, P864, DOI 10.1007/BF01938327; CASEY JE, 2000, Patent No. 0001353; CLAUS R, 1976, J ENDOCRINOL, V68, P483, DOI 10.1677/joe.0.0680483; COLOMBO S, 1992, EUR J BIOCHEM, V206, P349, DOI 10.1111/j.1432-1033.1992.tb16934.x; COLOMBO S, 1995, J BACTERIOL, V177, P5561, DOI 10.1128/jb.177.19.5561-5566.1995; Davies RT, 1999, PLANT CELL, V11, P365, DOI 10.1105/tpc.11.3.365; FROEBE C, 1990, J SOC COSMET CHEM, V41, P173; HANI EK, 1995, J BACTERIOL, V177, P2396, DOI 10.1128/jb.177.9.2396-2402.1995; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Ishikawa K, 2001, APPL ENVIRON MICROB, V67, P673, DOI 10.1128/AEM.67.2.673-679.2001; JACKMAN PJH, 1983, CLIN EXP DERMATOL, V8, P259, DOI 10.1111/j.1365-2230.1983.tb01778.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYDEN JJ, 1981, J INVEST DERMATOL, V77, P413, DOI 10.1111/1523-1747.ep12494624; LYON SB, 1997, Patent No. 9105541; MCCLINTOCK MK, 1978, HORM BEHAV, V10, P264, DOI 10.1016/0018-506X(78)90071-5; Moore DD, 1995, GLOB MOB SURV; POWERS EM, 1995, APPL ENVIRON MICROB, V61, P3756, DOI 10.1128/AEM.61.10.3756-3758.1995; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; Rodriguez I, 2000, NAT GENET, V26, P18, DOI 10.1038/79124; SAKANYAN V, 1993, APPL ENVIRON MICROB, V59, P3878, DOI 10.1128/AEM.59.11.3878-3888.1993; Shehadeh N, 1963, J INVEST DERMATOL, V41, P1; SHELLEY WB, 1953, AMA ARCH DERM SYPH, V68, P430, DOI 10.1001/archderm.1953.01540100070012; SMITH K, 1969, SCIENCE, V166, P398, DOI 10.1126/science.166.3903.398; SPIELMAN AI, 1995, EXPERIENTIA, V51, P40; WEDEKIND C, 1995, P ROY SOC B-BIOL SCI, V260, P245, DOI 10.1098/rspb.1995.0087; Zeng CH, 1996, P NATL ACAD SCI USA, V93, P6626, DOI 10.1073/pnas.93.13.6626; ZENG XN, 1992, J CHEM ECOL, V18, P1039, DOI 10.1007/BF00980061; ZENG XN, 1991, J CHEM ECOL, V17, P1469, DOI 10.1007/BF00983777	33	114	127	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5718	5727		10.1074/jbc.M210142200	http://dx.doi.org/10.1074/jbc.M210142200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12468539	hybrid			2022-12-25	WOS:000181129400031
J	Palka, HL; Park, M; Tonks, NK				Palka, HL; Park, M; Tonks, NK			Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRB2 BINDING-SITE; BETA-CATENIN; MOLECULAR-CLONING; EPITHELIAL MORPHOGENESIS; CELL-TRANSFORMATION; THYROID-CELLS; IN-VIVO; EXPRESSION; GAB1; MOTILITY	The receptor protein-tyrosine phosphatase (PTP) DEP-1 (CD148/PTP-eta) has been implicated in the regulation of cell growth, differentiation, and transformation, and most recently has been identified as a potential tumor suppressor gene mutated in colon, lung, and breast cancers. We have generated constructs comprising the cytoplasmic segment of DEP-1 fused to the maltose-binding protein to identify potential substrates and thereby suggest a physiological function for DEP-1. We have shown that the substrate-trapping mutant form of DEP-1 interacted with a small subset of tyrosine-phosphorylated proteins from lysates of the human breast tumor cell lines MDA-MB-231, T-47D, and T-47D/Met and have identified the hepatocyte growth factor/scatter factor receptor Met, the adapter protein Gab1, and the junctional component p120 catenin as potential substrates. Following ligand stimulation, phosphorylation of specific tyrosyl residues in Met induces mitogenic, motogenic, and morphogenic responses. When co-expressed in 293 cells, the full-length substrate-trapping mutant form of DEP-1 formed a stable complex with the chimeric receptor colony stimulating factor 1 (CSF)-Met and wild type DEP-1 dephosphorylated CSF-Met. Furthermore, we observed that DEP-1 preferentially dephosphorylated a Gab1 binding site (Tyr(1349)) and a COOH-terminal tyrosine implicated in morphogenesis (Tyr(1365)), whereas tyrosine residues in the activation loop of Met (Tyr(1230), Tyr(1234), and Tyr(1235)) were not preferred targets of the PTP. The ability of DEP-1 preferentially to dephosphorylate particular tyrosine residues that are required for Met-induced signaling suggests that DEP-1 may function in controlling the specificity of signals induced by this PTK, rather than as a simple "off-switch" to counteract PTK activity.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Cold Spring Harbor Laboratory; McGill University	Tonks, NK (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.				NCI NIH HHS [T32-CA09311] Funding Source: Medline; NIGMS NIH HHS [R01-GM55989] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; FIXMAN ED, 1995, ONCOGENE, V10, P237; Florio T, 1997, ENDOCRINOLOGY, V138, P3756, DOI 10.1210/en.138.9.3756; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Keane MM, 1996, CANCER RES, V56, P4236; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; KOMADA M, 1993, ONCOGENE, V8, P2381; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Kuramochi S, 1996, FEBS LETT, V378, P7, DOI 10.1016/0014-5793(95)01415-2; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Osborne JM, 1998, J LEUKOCYTE BIOL, V64, P692, DOI 10.1002/jlb.64.5.692; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palou E, 1997, IMMUNOL LETT, V57, P101, DOI 10.1016/S0165-2478(97)00069-2; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Tangye SG, 1998, J IMMUNOL, V161, P3249; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	50	145	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5728	5735		10.1074/jbc.M210656200	http://dx.doi.org/10.1074/jbc.M210656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12475979	hybrid			2022-12-25	WOS:000181129400032
J	Roda, O; Valero, ML; Peiro, S; Andreu, D; Realt, FX; Navarro, P				Roda, O; Valero, ML; Peiro, S; Andreu, D; Realt, FX; Navarro, P			New insights into the tPA-Annexin A2 interaction - Is annexin A2 CYS8 the sole requirement for this association?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; ENDOTHELIAL-CELL RECEPTOR; TYROSINE KINASE SUBSTRATE; T-PA; BINDING PROTEINS; CALPACTIN-I; MONOCLONAL-ANTIBODIES; ANTICOAGULANT PROTEIN; MATRIX VESICLES; PANCREAS CANCER	Annexin A2 has been described as an important receptor for tissue-type plasminogen activator in endothelium and other cell types. Interaction between tissue-type plasminogen activator and its cellular receptor is critical for many of the functions of this protease. The annexin A2 motif that mediates tissue plasminogen activator interaction has been assigned to the hexapeptide LCKLSL in the amino-terminal domain of the protein, and it has been proposed that Cys(8) of this sequence is essential for tPA binding. In an attempt to identify other amino acids critical for tPA-annexin A2 interaction, we have analyzed a set of peptides containing several modifications of the original hexapeptide, including glycine scans, alanine scans, D-amino acid scans, conservative mutations, cysteine blocking, and enantiomer and retroenantiomer sequences. Using a non-radioactive competitive binding assay, we have found that all cysteine-containing peptides, independently of their sequence, compete the interaction between tPA and annexin A2. Cysteine-containing peptides also inhibit tPA binding to the surface of cultured human umbilical vein endothelial cells (HUVEC). Mass spectrometry demonstrates that the peptides bind through a disulfide bond to a cysteine residue of annexin A2, the same mechanism that has been suggested for the inhibition mediated by homocysteine. These data call for a revision of the role of the LCKLSL sequence as the sole annexin A2 structural region required to bind tPA and indicate that further studies are necessary to better define the annexin A2-tPA interaction.	Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain; Univ Pomeu Fabra, Fac Ciencies Salut & Vida, Dept Ciencies Expt & Salut, Barcelona 08003, Spain		Navarro, P (corresponding author), Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Dr Aiguader 80, E-08003 Barcelona, Spain.		Andreu, David/I-4359-2014; Navarro, Pilar/A-2122-2010; Navarro, Pilar/ABF-2728-2020; Arribas, Francisco X Real/H-5275-2015	Andreu, David/0000-0002-6317-6666; Navarro, Pilar/0000-0003-4314-4584; Navarro, Pilar/0000-0003-4314-4584; Arribas, Francisco X Real/0000-0001-9501-498X				ANDREE HAM, 1992, J BIOL CHEM, V267, P17907; BARNATHAN ES, 1988, FIBRINOLYSIS, V2, P58; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BEEBE DP, 1989, BLOOD, V74, P2034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1994, ANN NY ACAD SCI, V710, P333, DOI 10.1111/j.1749-6632.1994.tb26640.x; CARRENO C, 1992, INT J PEPT PROT RES, V39, P41; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; DAngelo A, 1997, BLOOD, V90, P1; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; Hajjar KA, 1999, TRENDS CARDIOVAS MED, V9, P128, DOI 10.1016/S1050-1738(99)00020-1; Hajjar KA, 2001, J CLIN INVEST, V107, P663, DOI 10.1172/JCI12369; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HARDER T, 1993, J CELL SCI, V104, P1109; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; KONDO S, 1987, THROMB RES, V48, P449, DOI 10.1016/0049-3848(87)90402-6; Konig J, 1998, J BIOL CHEM, V273, P19679, DOI 10.1074/jbc.273.31.19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LEUNG MF, 1992, CANCER RES, V52, P3063; LIOTTA LA, 1983, LAB INVEST, V49, P636; MA ASP, 1994, J CELL SCI, V107, P1973; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MORGAN A, 1993, BIOCHEM SOC T, V21, P401, DOI 10.1042/bst0210401; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Paciucci R, 1996, FEBS LETT, V385, P72, DOI 10.1016/0014-5793(96)00352-3; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; POLLARD HB, 1992, BIOPHYS J, V62, P15, DOI 10.1016/S0006-3495(92)81764-2; REDLITZ A, 1995, BAILLIERE CLIN HAEM, V8, P313, DOI 10.1016/S0950-3536(05)80270-7; ROJAS E, 1992, BONE MINER, V17, P214, DOI 10.1016/0169-6009(92)90739-Z; ROMISCH J, 1990, THROMB RES, V60, P355, DOI 10.1016/0049-3848(90)90218-2; Sinniger V, 1999, J BIOL CHEM, V274, P12414, DOI 10.1074/jbc.274.18.12414; SUN J, 1993, THROMB RES, V69, P279, DOI 10.1016/0049-3848(93)90025-J; THIEL C, 1992, J CELL SCI, V103, P733; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; TRESSLER RJ, 1992, J CELL BIOCHEM, V48, P162, DOI 10.1002/jcb.240480208; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; VISHWANATHA JK, 1993, J CELL SCI, V105, P533; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WU LNY, 1991, J BIOL CHEM, V266, P1195; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	63	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5702	5709		10.1074/jbc.M207605200	http://dx.doi.org/10.1074/jbc.M207605200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12468550	hybrid			2022-12-25	WOS:000181129400029
J	Shang, YL; Bodero, AJ; Chen, PL				Shang, YL; Bodero, AJ; Chen, PL			NFBD1, a novel nuclear protein with signature motifs of FRA and BRCT, and an internal 41-amino acid repeat sequence, is an early participant in DNA damage response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; RETINOBLASTOMA GENE-PRODUCT; BUDDING YEAST RAD9; ATAXIA-TELANGIECTASIA; HISTONE H2AX; BREAST-CANCER; GENOMIC INSTABILITY; CRYSTAL-STRUCTURE; FHA DOMAIN; IN-VIVO	Efficient repair of DNA double-strand breaks depends on the intact signaling cascade, comprising molecules involved in DNA damage signal pathways and checkpoints. Budding yeast Rad9 (scRad9) is required for activation of scRad53 (mammalian homolog Chk2) and transduction of the signal further downstream in this pathway. In the search for a mammalian homolog, three proteins in the human data base, including BRCA1, 53BP1, and nuclear factor with BRCT domains protein 1 (NFBD1), were found to share significant homology with the BRCT motifs of scRad9. Because BRCA1 and 53BP1 are involved in DNA damage responses, a similar role for NFBD1 was tested. We show that NFBD1 is a 250-kDa nuclear protein containing a forkhead-associated motif at its N terminus, two BRCT motifs at its C terminus, and 13 internal repetitions of a 41-amino acid sequence. Five minutes after gamma-irradiation, NFBD1 formed nuclear foci that colocalized with the phosphorylated form of H2AX and Chk2, two phosphorylation events known to be involved in early DNA damage response. NFBD1 foci are also detected in response to camptothecin, etoposide, and methylmethanesulfonate treatments. Deletion of the forkhead-associated motif or the internal repeats of NFBD1 has no effect on DNA damage-induced NFBD1 foci formation. Conversely, deletion of the BRCT motifs abrogates damage-induced NFBD1 foci. Ectopic expression of the BRCT motifs reduced damage-induced NFBD1 foci and compromised phosphorylated Chk2- and phosphorylated H2AX-containing foci. These results suggest that NFBD1, like BRCA1 and 53BP1, participates in the early response to DNA damage.	Univ Texas, Ctr Hlth Sci, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Ctr Hlth Sci, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Chen, PL (corresponding author), Univ Texas, Ctr Hlth Sci, Dept Mol Med, 15255 Lambda Dr, San Antonio, TX 78245 USA.	chenp0@uthscsa.edu		Chen, Phang-Lang/0000-0002-0357-9017	NCI NIH HHS [CA85605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2000, CANCER RES, V60, P5934; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Liu QH, 2000, GENE DEV, V14, P1448; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Ozaki T, 2000, DNA CELL BIOL, V19, P475, DOI 10.1089/10445490050128403; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Post S, 2001, P NATL ACAD SCI USA, V98, P13102, DOI 10.1073/pnas.231364598; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schramke V, 2001, GENE DEV, V15, P1845, DOI 10.1101/gad.193901; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; WANG B, 2002, UNPUB SCIENCE; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	76	70	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6323	6329		10.1074/jbc.M210749200	http://dx.doi.org/10.1074/jbc.M210749200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12475977	hybrid			2022-12-25	WOS:000181129400105
J	Andersen, JF; Francischetti, IMB; Valenzuela, JG; Schuck, P; Ribeiro, JMC				Andersen, JF; Francischetti, IMB; Valenzuela, JG; Schuck, P; Ribeiro, JMC			Inhibition of hemostasis by a high affinity biogenic amine-binding protein from the saliva of a blood-feeding insect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; HISTAMINE-BINDING; RHODNIUS-PROLIXUS; BLOODSUCKING BUG; HEME PROTEIN; PURIFICATION; NITROPHORIN; LIPOCALIN; CLONING; SEROTONIN	The saliva of the blood-feeding insect Rhodnius prolixus contains numerous pharmacologically active substances. Included among these are a number of lipocalin proteins that bind various ligands important in hemostasis and inflammation. One such protein is a biogenic amine-binding protein (ABP) that binds serotonin, epinephrine, and norepinephrine. Based on amino acid alignments, it is most similar to the nitrophorin group of lipocalins found in the same insect species. Physiologically, this protein appears to act as both a vasodilator and platelet aggregation inhibitor. This protein inhibits smooth muscle contraction of the rat uterus in response to serotonin and of the rabbit aorta in response to norepinephrine. Platelet aggregation induced by a combination of low concentrations of ADP and either serotonin or epinephrine is inhibited because of the binding of serotonin and epinephrine. Potentiation of aggregation induced by low concentrations of collagen along with serotonin or epinephrine is also inhibited. Dissociation constants for biogenic amines were measured using isothermal titration calorimetry and the Hummel-Dreyer method of equilibrium gel filtration. In this manner, K-d values of 102, 24, and 345 nM were found for serotonin, norepinephrine, and epinephrine, respectively. Molecular modeling of AEP suggests that ligand binding is mediated by interaction with the side chains of aromatic amino acids and charged residues that line the binding pocket.	NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; NIH, Div Bioengn & Phys Sci, Off Res Serv, Off Director, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Andersen, JF (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, Rm 126,Bldg 4,4 Ctr Dr, Bethesda, MD 20892 USA.	jandersen@niaid.nih.gov	Schuck, Peter/AAA-6888-2020	Schuck, Peter/0000-0002-8859-6966; Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000810, Z01AI000810] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andersen JF, 2000, BIOCHEMISTRY-US, V39, P10118, DOI 10.1021/bi000766b; Andersen JF, 2000, J BIOL CHEM, V275, P30496, DOI 10.1074/jbc.M002857200; BOND RF, 1985, FED PROC, V44, P281; Flower DR, 1996, BIOCHEM J, V318, P1; Francischetti IMB, 2000, J BIOL CHEM, V275, P12639, DOI 10.1074/jbc.275.17.12639; Francischetti IMB, 2002, BIOCHEMISTRY-US, V41, P3810, DOI 10.1021/bi011015s; Francischetti IMB, 2002, J EXP BIOL, V205, P2429; GADDUM JH, 1949, J PHYSIOL-LONDON, V108, P467, DOI 10.1113/jphysiol.1949.sp004350; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lopez Maria M, 2002, Methods Mol Biol, V173, P121; MONTFORT WR, 2000, BIOCHIM BIOPHYS ACTA, V18, P110; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Paesen GC, 1999, MOL CELL, V3, P661, DOI 10.1016/S1097-2765(00)80359-7; PAESEN GC, 2000, BIOCHIM BIOPHYS ACTA, V18, P92; RIBEIRO JMC, 1982, J INSECT PHYSIOL, V28, P69, DOI 10.1016/0022-1910(82)90024-5; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1994, J EXP MED, V180, P2251, DOI 10.1084/jem.180.6.2251; Ribeiro JMC, 1999, J EXP BIOL, V202, P809; RIBEIRO JMC, 1981, J EXP BIOL, V94, P219; Ribeiro JMC, 1998, J MED ENTOMOL, V35, P599, DOI 10.1093/jmedent/35.4.599; RIBEIRO JMC, 1995, BIOCHEM J, V308, P243, DOI 10.1042/bj3080243; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Sangamnatdej S, 2002, INSECT MOL BIOL, V11, P79, DOI 10.1046/j.0962-1075.2001.00311.x; SARKIS JJF, 1986, BIOCHEM J, V233, P885, DOI 10.1042/bj2330885; Valenzuela JG, 2002, INSECT BIOCHEM MOLEC, V32, P1101, DOI 10.1016/S0965-1748(02)00047-4; WEBSTER ME, 1970, METHOD ENZYMOL, V19, P681; Weichsel A, 1998, NAT STRUCT BIOL, V5, P304, DOI 10.1038/nsb0498-304; Weichsel A, 2000, NAT STRUCT BIOL, V7, P551, DOI 10.1038/76769	30	69	71	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4611	4617		10.1074/jbc.M211438200	http://dx.doi.org/10.1074/jbc.M211438200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12464610	hybrid			2022-12-25	WOS:000180968900035
J	Araya, N; Hirota, K; Shimamoto, Y; Miyagishi, M; Yoshida, E; Ishida, J; Kaneko, S; Kaneko, M; Nakajima, T; Fukamizu, A				Araya, N; Hirota, K; Shimamoto, Y; Miyagishi, M; Yoshida, E; Ishida, J; Kaneko, S; Kaneko, M; Nakajima, T; Fukamizu, A			Cooperative interaction of EWS with CREB-binding protein selectively activates hepatocyte nuclear factor 4-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; COACTIVATOR PGC-1; TERMINAL DOMAIN; DNA-BINDING; GENE; FAMILY; FUSION; CBP/P300; TUMORS; PHOSPHORYLATION	The EWS gene when fused to transcription factors such as the ETS family ATF-1, Wilms' tumor-1, and nuclear orphan receptors upon chromosomal translocation is thought to contribute the development of Ewing sarcoma and several malignant tumors. Although EWS is predicted to be an RNA-binding protein, an inherent EWS nuclear function has not yet been elucidated. In this study, we found that EWS associates with a transcriptional co-activator CREB-binding protein (CBP) and the hypophosphorylated RNA polymerase II, which are included preferentially in the transcription preinitiation complex. These interactions suggest the potential involvement of EWS in gene transcription, leading to the hypothesis that EWS may function as a co-activator of CBP-dependent transcription factors. Based on this hypothesis, we investigated the effect of EWS on the activation of nuclear receptors that are activated by CBP. Of nuclear receptors examined, hepatocyte nuclear factor 4-dependent transcription was selectively enhanced by EWS but not by an EWS mutant defective for CBP binding. These results suggest that EWS as a co-activator requires CBP for hepatocyte nuclear factor 4-mediated transcriptional activation.	Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Clin Med, Dept Pediat Surg, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.		Miyagishi, Makoto/L-8174-2016; fukamizu, akiyoshi/J-5350-2012	Miyagishi, Makoto/0000-0001-7654-3616; fukamizu, akiyoshi/0000-0002-8786-6020				Alliegro MC, 1996, DEV BIOL, V174, P288, DOI 10.1006/dbio.1996.0074; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chansky HA, 2001, CANCER RES, V61, P3586; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Goodman RH, 2000, GENE DEV, V14, P1553; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li JX, 2000, GENE DEV, V14, P464; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; OHNO T, 1994, ONCOGENE, V9, P3087; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; RAO VN, 1993, ONCOGENE, V8, P2167; Rossow KL, 2001, CANCER RES, V61, P2690; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Yanai K, 1999, J BIOL CHEM, V274, P34605, DOI 10.1074/jbc.274.49.34605; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086	32	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5427	5432		10.1074/jbc.M210234200	http://dx.doi.org/10.1074/jbc.M210234200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12459554	hybrid			2022-12-25	WOS:000180968900135
J	Dorin, D; Bonnet, MC; Bannwarth, S; Gatignol, A; Meurs, EF; Vaquero, C				Dorin, D; Bonnet, MC; Bannwarth, S; Gatignol, A; Meurs, EF; Vaquero, C			The TAR RNA-binding protein, TRBP, stimulates the expression of TAR-containing RNAs in vitro and in vivo independently of its ability to inhibit the dsRNA-dependent kinase PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 TAR; SECONDARY STRUCTURE; TRANSLATIONAL CONTROL; PREVENT ACTIVATION; MESSENGER-RNA; INITIATION; REGION; MOTIF; TRANSACTIVATION	TRBP (HIV-1 transactivating response (TAR) RNA-binding protein) and PKR, the interferon-induced dsRNA-regulated protein kinase, contain two dsRNA binding domains. They both bind to HIV-1 TAR RNAs through different sites. Binding to dsRNA activates PKR that phosphorylates the eukaryotic initiation factor eIF-2alpha leading to protein synthesis inhibition. TRBP and PKR can heterodimerize, which inhibits the kinase function of PKR and has a positive effect on HIV-1 expression. In this study, an in vitro reticulocyte assay revealed the poor expression of TAR containing CAT RNAs compared with CAT RNAs. Addition of TRBP restored translation efficiency of TAR-CAT RNA and decreased the phosphorylation status of eIF-2alpha, confirm ing its role as a PKR inhibitor. Unexpectedly, eIF-2alpha was phosphorylated in the presence of TAR-CAT as well as CAT RNA devoid of the TAR structure. TRBP inhibited eIF-2alpha phosphorylation in both cases, suggesting that it restores the translation of TAR-CAT RNA independently and in addition to its ability to inhibit PKR. TRBP activity on gene expression was then analyzed in a PKR-free environment using PKR-deficient murine embryo fibroblasts. In a transient reporter gene assay, TRBP stimulated the expression of a TAR-containing luciferase 3.8-fold whereas the reporter gene with mutated TAR structures or devoid of TAR was stimulated 1.5- to 2.4-fold. Overall, the activity of TRBP2 was higher when the 5'-end of the mRNA was structured and was mediated independently by each dsRBD in TRBP. Increasing concentrations of TRBP showed no significant modification of the luciferase RNA levels, suggesting that TRBP stimulates translation of TAR-containing RNAs Therefore, TRBP is an important cellular factor for efficient translation of dsRNA containing transcripts, both by inhibiting PKR and in a PKR-independent pathway.	Hop La Pitie Salpetriere, INSERM U511, F-75643 Paris 13, France; Inst Pasteur, Unite Hepacivirus, F-75724 Paris, France; Lady Davis Inst Med Res, McGill AIDS Ctr, Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Lady Davis Institute; McGill University; McGill University	Meurs, EF (corresponding author), Hop La Pitie Salpetriere, INSERM U511, F-75643 Paris 13, France.		Gatignol, Anne/AAA-6501-2020; Bonnet, Marion C/C-5612-2014	Gatignol, Anne/0000-0002-4553-0836; Bonnet, Marion C/0000-0002-7559-2413				Bannwarth S, 2001, J BIOL CHEM, V276, P48803, DOI 10.1074/jbc.M104645200; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Daher A, 2001, J BIOL CHEM, V276, P33899, DOI 10.1074/jbc.M103584200; Daviet L, 2000, EUR J BIOCHEM, V267, P2419, DOI 10.1046/j.1432-1327.2000.01256.x; Duarte M, 2000, J BIOMED SCI, V7, P494; Eckmann CR, 1997, J CELL BIOL, V138, P239, DOI 10.1083/jcb.138.2.239; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; ELLERBROK H, 1993, EUR J BIOCHEM, V216, P459, DOI 10.1111/j.1432-1033.1993.tb18164.x; Erard M, 1998, J MOL BIOL, V279, P1085, DOI 10.1006/jmbi.1998.1831; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Francois C, 2000, J VIROL, V74, P5587, DOI 10.1128/JVI.74.12.5587-5596.2000; Gatignol A, 1996, GENE EXPRESSION, V5, P217; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GEBALLE AP, 1992, NUCLEIC ACIDS RES, V20, P4291, DOI 10.1093/nar/20.16.4291; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; James MC, 1999, EUR J BIOCHEM, V266, P151, DOI 10.1046/j.1432-1327.1999.00839.x; Lee K, 1996, MOL CELL BIOL, V16, P3023; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Nekhai S, 1996, VIROLOGY, V222, P193, DOI 10.1006/viro.1996.0410; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; ROY S, 1991, J VIROL, V65, P632, DOI 10.1128/JVI.65.2.632-640.1991; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684; Zuker M, 2000, CURR OPIN STRUC BIOL, V10, P303, DOI 10.1016/S0959-440X(00)00088-9	35	74	80	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4440	4448		10.1074/jbc.M208954200	http://dx.doi.org/10.1074/jbc.M208954200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12475984	hybrid			2022-12-25	WOS:000180968900013
J	Granas, C; Ferrer, J; Loland, CJ; Javitch, JA; Gether, U				Granas, C; Ferrer, J; Loland, CJ; Javitch, JA; Gether, U			N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BIOGENIC-AMINE TRANSPORTERS; TACHYKININ NK1 RECEPTOR; SEROTONIN TRANSPORTERS; STRIATAL SYNAPTOSOMES; FUNCTIONAL REGULATION; PHARMACOLOGICAL CHARACTERIZATION; NOREPINEPHRINE TRANSPORTER; SURFACE EXPRESSION; ACTIVATION	The structural basis of phosphorylation and its putative role in internalization were investigated in the human dopamine transporter (hDAT). Activation of protein kinase C (PKC) was achieved either directly by treatment with 4-alpha-phorbol 12-myristate 13-acetate (PMA) or by activating the Galpha(q)-coupled human substance P receptor (hNK-1) co-expressed with hDAT in HEK293 cells and in N2A neuroblastoma cells. In both cell lines, activation of the hNK-1 receptor by substance P reduced the V-max for [H-3]dopamine uptake to the same degree as did PMA (similar to50 and similar to20% in HEK293 and N2A cells, respectively). In HEK293 cells, the reduction in transport capacity could be accounted for by internalization of the transporter, as assessed by cell surface biotinylation experiments, and by fluorescence microscopy using enhanced green fluorescent protein-tagged hDAT. In HEK293 cells, hNK-1 receptor activation, as well as direct PKC activation by PMA, was accompanied by a marked increase in transporter phosphorylation. However, truncation of the first 22 N-terminal residues almost abolished detectable phosphorylation without affecting the SP- or PMA-induced reduction in transport capacity and internalization. In this background truncation construct, systematic mutation of all the phosphorylation consensus serines and threonines in hDAT, alone and in various combinations, did also not alter the effect of hNK-1 receptor activation or PMA treatment in either HEK293 or N2A cells. Mutation of a dileucine and of two tyrosine-based motifs in hDAT was similarly without effect. We conclude that the major phosphorylation sites in hDAT are within the distal N terminus, which contains several serines. Moreover, the present data strongly suggest that neither this phosphorylation, nor the phosphorylation of any other sites within hDAT, is required for either receptor-mediated or direct PKC-mediated internalization of the hDAT.	Univ Copenhagen, Panum Inst, Dept Pharmacol 18 6, Mol Neuropharmacol Grp, DK-2200 Copenhagen N, Denmark; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol & Psychiat, New York, NY 10032 USA	University of Copenhagen; Columbia University; Columbia University	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol 18 6, Mol Neuropharmacol Grp, DK-2200 Copenhagen N, Denmark.	gether@mfi.ku.dk	Loland, Claus/E-5975-2014	Loland, Claus/0000-0002-1773-1446; Gether, Ulrik/0000-0002-0020-3807; Javitch, Jonathan/0000-0001-7395-2967	NIDA NIH HHS [DA 11495] Funding Source: Medline; NIMH NIH HHS [MH 57324] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011495] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; Bauman AL, 2000, J NEUROSCI, V20, P7571; Beckman ML, 1999, J NEUROSCI, V19; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Chang MY, 2001, J NEUROCHEM, V77, P754, DOI 10.1046/j.1471-4159.2001.00284.x; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; Futami T, 1998, MOL BRAIN RES, V54, P183, DOI 10.1016/S0169-328X(97)00307-0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; GITTER BD, 1995, J PHARMACOL EXP THER, V275, P737; GOMEZA J, 1995, BBA-BIOMEMBRANES, V1233, P41, DOI 10.1016/0005-2736(94)00249-O; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Holst B, 1998, MOL PHARMACOL, V53, P166, DOI 10.1124/mol.53.1.166; Huff RA, 1997, J NEUROCHEM, V68, P225; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JENSEN CJ, 1994, MOL PHARMACOL, V45, P294; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Melikian HE, 1999, J NEUROSCI, V19, P7699; Norregaard L, 2001, Curr Opin Drug Discov Devel, V4, P591; Page G, 2001, J NEUROCHEM, V76, P1282, DOI 10.1046/j.1471-4159.2001.00179.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Percy E, 1999, BRIT J PHARMACOL, V128, P774, DOI 10.1038/sj.bjp.0702831; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quartara L, 1997, NEUROPEPTIDES, V31, P537, DOI 10.1016/S0143-4179(97)90001-9; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Rees S, 1996, BIOTECHNIQUES, V20, P102; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; SATO K, 1995, J NEUROCHEM, V65, P1967; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Stout SC, 2001, ANNU REV PHARMACOL, V41, P877, DOI 10.1146/annurev.pharmtox.41.1.877; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; TREMBLAY L, 1992, P NATL ACAD SCI USA, V89, P11214, DOI 10.1073/pnas.89.23.11214; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	46	133	133	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4990	5000		10.1074/jbc.M205058200	http://dx.doi.org/10.1074/jbc.M205058200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12464618	hybrid			2022-12-25	WOS:000180968900084
J	Huttner, IG; Strahl, T; Osawa, M; King, DS; Ames, JB; Thorner, J				Huttner, IG; Strahl, T; Osawa, M; King, DS; Ames, JB; Thorner, J			Molecular interactions of yeast frequenin (Frq1) with the phosphatidylinositol 4-kinase isoform, Pik1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CALCIUM SENSOR-1; SACCHAROMYCES-CEREVISIAE; SIGNALING REACTIONS; ESCHERICHIA-COLI; BINDING; PROTEIN; KINASE; FAMILY; SECRETION; PHOSPHOINOSITIDES	Frq1, a 190-residue N-myristoylated calcium-binding protein, associates tightly with the N terminus of Pik1, a 1066-residue phosphatidylinositol 4-kinase. Deletion analysis of an Frq1-binding fragment, Pik1-(10-192), showed that residues within 80-192 are necessary and sufficient for Frq1 association in vitro. A synthetic peptide (residues 151-199) competed for binding of [S-35]Pik1-(10-192) to bead-immobilized Frq1, whereas shorter peptides (164-199 and 174-199) did not. Correspondingly, a deletion mutant, Pik1(Delta152-191), did not co-immunoprecipitate efficiently with Frq1 and did not support growth at elevated temperature. Site-directed mutagenesis of Pik1-(10-192) suggested that recognition determinants lie over an extended region. Titration calorimetry demonstrated that binding of an 83-residue fragment, Pik1-(110-192), or the 151-199 peptide to Frq1 shows high affinity (K-d similar to 100 nM) and is largely entropic, consistent with hydrophobic interaction. Stoichiometry of Pik1-(110-192) binding to Frq1 was 1:1, as judged by titration calorimetry, by changes in NMR spectrum and intrinsic tryptophan fluorescence, and by light scattering. In cell extracts, Pik1 and Frq1 exist mainly in a heterodimeric complex, as shown by size exclusion chromatography. Cys-15 in Frq1 is not S-palmitoylated, as assessed by mass spectrometry; a Frq1(C15A) mutant and even a non-myristoylated Frq1(G2AC15A) double mutant rescued the inviability of frq1Delta cells. This study defines the segment of Pik1 required for high affinity binding of Frq1.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Thorner, J (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA.	jeremy@socrates.berkeley.edu	Osawa, Masanori/GRS-5726-2022; Strahl, Thomas/E-4315-2010; THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Osawa, Masanori/0000-0002-1285-4316; Martin, Inken/0000-0002-8790-092X	NEI NIH HHS [EY12347] Funding Source: Medline; NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R01GM021841] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; Barry WT, 2002, J BIOL CHEM, V277, P28877, DOI 10.1074/jbc.M202983200; BENTON BM, 1990, MOL CELL BIOL, V10, P353, DOI 10.1128/MCB.10.1.353; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; FREIFELDER D, 1982, PHYSICAL BIOCH, P537; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P182; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; JONES EW, 1991, METHOD ENZYMOL, V194, P428; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Meyers R E, 1998, Methods Mol Biol, V105, P99; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNIEDERS EA, 1996, THESIS U CALIFORNIA; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; Simonsen A, 2001, NAT CELL BIOL, V3, pE179, DOI 10.1038/35087112; Takimoto K, 2002, J BIOL CHEM, V277, P26904, DOI 10.1074/jbc.M203651200; Tanaka T, 1998, J BIOMOL NMR, V11, P135, DOI 10.1023/A:1008212316986; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Tolias KF, 1999, CHEM PHYS LIPIDS, V98, P69, DOI 10.1016/S0009-3084(99)00019-5; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; WINGFIELD PT, 1995, CURRENT PROTOCOLS PR, V1; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WONG K, 1994, J BIOL CHEM, V269, P28878; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; Zhang XL, 1998, SEMIN CELL DEV BIOL, V9, P153, DOI 10.1006/scdb.1997.0220; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200	59	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4862	4874		10.1074/jbc.M207920200	http://dx.doi.org/10.1074/jbc.M207920200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12477731	hybrid			2022-12-25	WOS:000180968900068
J	Iwabuchi, M; Kohno-Murase, J; Imamura, J				Iwabuchi, M; Kohno-Murase, J; Imamura, J			Delta 12-Oleate Desaturase-related Enzymes Associated with Formation of Conjugated trans-Delta 11, cis-Delta 13 double bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIENOIC FATTY-ACIDS; LINOLEIC-ACID; OLEATE 12-HYDROXYLASE; BIOSYNTHETIC ORIGIN; GENE; SEED; TUMOR; IDENTIFICATION; ACCUMULATION; HYDROXYLASE	Conjugated linolenic acids are present as major seed oils in several plant species. Punicic acid (or trichosanic acid) is a conjugated linolenic acid isomer containing cis-Delta9, trans-Delta11, cis-Delta13 double bonds in the C-18 carbon chain. Here we report cDNAs, TkFac and PgFac, isolated from Trichosanthes kirilowii and Punica granatum, that encode a class of conjugases associated with the formation of trans-Delta11, cis-Delta13 double bonds. Expression of TkFac and PgFac in Arabidopsis seeds under transcriptional control of the seed-specific napin promoter resulted in accumulation of punicic acid up to similar to10% (w/w) of the total seed oils. In contrast, no punicic acid was found in lipids from leaves even when the conjugases were driven under control of the cauliflower mosaic virus 35S promoter. In yeast cells grown without exogenous fatty acids in the culture medium, TkFac and PgFac expression resulted in punicic acid accumulation accompanied by 16:2Delta(9cis), (12cis) and 18:2Delta(9cis), (12cis). production. Thus, TkFac and PgFac are defined as bifunctional enzymes having both conjugase and Delta12-oleate desaturase activity. Furthermore, we demonstrate that 16: 2Delta(9cis), (12cis) and 18:3Delta(9cis), (12cis), (15cis) as well as 18:2Delta(9cis), (12cis) are potential substrates for the conjugases to form trans-Delta11 and cis-Delta13 double bonds.	Plantech Res Inst, Aoba Ku, Yokohama, Kanagawa 2270033, Japan		Iwabuchi, M (corresponding author), Plantech Res Inst, Aoba Ku, 1000 Kamoshida Cho, Yokohama, Kanagawa 2270033, Japan.	5505276@cc.m-kagaku.co.jp						BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Blankson H, 2000, J NUTR, V130, P2943, DOI 10.1093/jn/130.12.2943; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; Broun P, 1997, PLANT PHYSIOL, V113, P933, DOI 10.1104/pp.113.3.933; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Cahoon EB, 1999, P NATL ACAD SCI USA, V96, P12935, DOI 10.1073/pnas.96.22.12935; Cahoon EB, 2001, J BIOL CHEM, V276, P2637, DOI 10.1074/jbc.M009188200; Carpenter CD, 1998, METH MOL B, V82, P85; Delany JP, 1999, AM J PHYSIOL-REG I, V276, pR1172, DOI 10.1152/ajpregu.1999.276.4.R1172; Durgam VR, 1997, CANCER LETT, V116, P121, DOI 10.1016/S0304-3835(97)00192-4; HOOD EE, 1986, J BACTERIOL, V168, P1291, DOI 10.1128/jb.168.3.1291-1301.1986; Hornung E, 2002, EUR J BIOCHEM, V269, P4852, DOI 10.1046/j.1432-1033.2002.03184.x; Igarashi M, 2000, CANCER LETT, V148, P173, DOI 10.1016/S0304-3835(99)00332-8; Igarashi M, 2000, BIOCHEM BIOPH RES CO, V270, P649, DOI 10.1006/bbrc.2000.2484; IP C, 1991, CANCER RES, V51, P6118; JAMES DW, 1995, PLANT CELL, V7, P309, DOI 10.2307/3869853; JOH YG, 1995, J AM OIL CHEM SOC, V72, P1037, DOI 10.1007/BF02660718; JOSEFSSON LG, 1987, J BIOL CHEM, V262, P12196; KOBA K, 2002, J AM OIL CHEM SOC, V37, P343; KOHNOMURASE J, 1994, PLANT MOL BIOL, V26, P1115, DOI 10.1007/BF00040693; Lee M, 1998, SCIENCE, V280, P915, DOI 10.1126/science.280.5365.915; Liu LS, 1997, PLANT PHYSIOL, V113, P1343, DOI 10.1104/pp.113.4.1343; MATSUSHITA M, 1995, J BIOCHEM-TOKYO, V117, P447, DOI 10.1093/jb/117.2.447; Millar AA, 1998, PLANT CELL, V10, P1889, DOI 10.1105/tpc.10.11.1889; Millar AA, 1997, PLANT J, V12, P121, DOI 10.1046/j.1365-313X.1997.12010121.x; Moore DD, 1995, GLOB MOB SURV; Qiu X, 2001, PLANT PHYSIOL, V125, P847, DOI 10.1104/pp.125.2.847; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; SHULTZ TD, 1992, CANCER LETT, V63, P125, DOI 10.1016/0304-3835(92)90062-Z; Singh S, 2001, PLANTA, V212, P872, DOI 10.1007/s004250000456; Smith C. R. Jr., 1970, Progress in the Chemistry of Fats and other Lipids, V11, P137; Suzuki R, 2001, LIPIDS, V36, P477, DOI 10.1007/s11745-001-0746-0; TAKAGI T, 1981, LIPIDS, V16, P546, DOI 10.1007/BF02535054; UEMATSU C, 1991, PLANT CELL REP, V10, P286, DOI 10.1007/BF00193143; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743; West DB, 1998, AM J PHYSIOL-REG I, V275, pR667; Zambell KL, 2000, LIPIDS, V35, P777, DOI 10.1007/s11745-000-0585-z	37	54	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4603	4610		10.1074/jbc.M210748200	http://dx.doi.org/10.1074/jbc.M210748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12464604	hybrid			2022-12-25	WOS:000180968900034
J	Kitta, K; Day, RM; Kim, Y; Torregroza, I; Evans, T; Suzuki, YJ				Kitta, K; Day, RM; Kim, Y; Torregroza, I; Evans, T; Suzuki, YJ			Hepatocyte growth factor induces GATA-4 phosphorylation and cell survival in cardiac muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; ACTIVATED PROTEIN-KINASE; C-MET; MOLECULAR-CLONING; INDUCED APOPTOSIS; RAT HEPATOCYTES; FACTOR HGF; IN-VITRO; GENE; EXPRESSION	Hepatocyte growth factor (HGF) is released in response to myocardial infarction and may play a role in regulating cardiac remodeling. Recently, HGF was found to inhibit the apoptosis of cardiac muscle cells. Because GATA-4 can induce cell survival, the effects of HGF on GATA-4 activity were investigated. Treatment of HL-1 cells or primary adult rat cardiac myocytes with HGF, at concentrations that can be detected in the human serum after myocardial infarction, rapidly enhances GATA-4 DNA-binding activity. The enhanced DNA-binding activity is associated with the phosphorylation of GATA-4. HGF-induced phosphorylation and activation of GATA-4 is abolished by MEK inhibitors or the mutation of the ERK phosphorylation site (S105A), suggesting that HGF activates GATA-4 via MEK-ERK pathway-dependent phosphorylation. HGF enhances the expression of anti-apoptotic Bcl-X-L, and this is blocked by dominant negative mutants of MEK or GATA-4. Forced expression of wild-type GATA-4, but not the GATA-4 mutant (S105A) increases the expression of Bcl-X-L. Furthermore, expression of the GATA-4 mutant (S105A) suppresses HGF-mediated protection of cells against daunorubicin-induced apoptosis. These results demonstrate that HGF protects cardiac muscle cells against apoptosis via a signaling pathway involving MEK/ERK-dependent phosphorylation of GATA-4.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, Div Pulm & Crit Care, Dept Med, Boston, MA 02111 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; Yeshiva University; Albert Einstein College of Medicine	Suzuki, YJ (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	yuichiro.suzuki@tufts.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG016121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64282] Funding Source: Medline; NIA NIH HHS [AG16121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Blobel GA, 1996, MOL CELL BIOL, V16, P1687, DOI 10.1128/mcb.16.4.1687; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Ghatpande S, 2000, DEV BIOL, V219, P59, DOI 10.1006/dbio.1999.9601; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Heikinheimo M, 1997, ENDOCRINOLOGY, V138, P3505, DOI 10.1210/en.138.8.3505; Keinanen R, 1999, GENE, V234, P297, DOI 10.1016/S0378-1119(99)00196-1; Kim Y, 2003, MOL PHARMACOL, V63, P368, DOI 10.1124/mol.63.2.368; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; Kitta K, 2001, BIOCHEM J, V359, P375, DOI 10.1042/0264-6021:3590375; Kitta K, 2001, FREE RADICAL BIO MED, V31, P902, DOI 10.1016/S0891-5849(01)00663-3; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Liu YH, 1999, AM J PHYSIOL-RENAL, V277, pF624, DOI 10.1152/ajprenal.1999.277.4.F624; Liu YH, 1998, BIOCHEM BIOPH RES CO, V246, P821, DOI 10.1006/bbrc.1998.8676; Matsumori A, 1996, BIOCHEM BIOPH RES CO, V221, P391, DOI 10.1006/bbrc.1996.0606; MICHALOPOULOS G, 1982, CANCER RES, V42, P4673; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; MORITA M, 1995, HEPATOLOGY, V21, P1585, DOI 10.1016/0270-9139(95)90463-8; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; Ono K, 1997, CIRCULATION, V95, P2552, DOI 10.1161/01.CIR.95.11.2552; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; REVOLTELLA RP, 1993, CYTOTECHNOLOGY, V13, P13, DOI 10.1007/BF00749971; Sato T, 1997, HEART VESSELS, V12, P241, DOI 10.1007/BF02766790; Schaper W, 1997, CIRCULATION, V95, P2471, DOI 10.1161/01.CIR.95.11.2471; STRAIN AJ, 1982, IN VITRO CELL DEV B, V18, P108; Suzuki YJ, 1998, FREE RADICAL BIO MED, V24, P318, DOI 10.1016/S0891-5849(97)00227-X; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; Tanaka T., 1998, Clinical and Experimental Obstetrics and Gynecology, V25, P125; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Ueda H, 2001, CARDIOVASC RES, V51, P41, DOI 10.1016/S0008-6363(01)00272-3; Ueda H, 1999, ANN THORAC SURG, V67, P1726, DOI 10.1016/S0003-4975(99)00279-9; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Yo Y, 1998, KIDNEY INT, V54, P1128, DOI 10.1046/j.1523-1755.1998.00092.x; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	50	98	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4705	4712		10.1074/jbc.M211616200	http://dx.doi.org/10.1074/jbc.M211616200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468531	hybrid			2022-12-25	WOS:000180968900046
J	Colombo, C; Haluzik, M; Cutson, JJ; Dietz, KR; Marcus-Samuels, B; Vinson, C; Gavrilova, O; Reitman, ML				Colombo, C; Haluzik, M; Cutson, JJ; Dietz, KR; Marcus-Samuels, B; Vinson, C; Gavrilova, O; Reitman, ML			Opposite effects of background genotype on muscle and liver insulin sensitivity of lipoatrophic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; DIABETES-MELLITUS; LIPOPROTEIN-LIPASE; SKELETAL-MUSCLE; GLUCOSE-UPTAKE; MOUSE; RESISTANCE; PROTEIN; EXPRESSION; LEPTIN	The metabolic phenotype of the A-ZIP/F-1 (AZIP) lipoatrophic mouse is different depending on its genetic background. On both the FVB/N (FVB) and C57BL/6J (B6) backgrounds, AZIP mice have a similarly severe lack of white adipose tissue and comparably increased insulin levels and triglyceride secretion rates. However, on the B6 background, the AZIP mice have less hyperglycemia, lower circulating triglyceride and fatty acid levels, and lower mortality. AZIP characteristics that are more severe on the B6 background include increased liver size and liver triglyceride content. A unifying hypothesis is that the B6 strain has higher triglyceride clearance into the liver, with lower triglyceride levels elsewhere. This may account for the observation that the B6 AZIP mice have less insulin-resistant muscles and more insulin-resistant livers, than do the FVB AZIP mice. B6 wild type, as well as B6 AZIP, mice have increased triglyceride clearance relative to FVB, which may be explained in part by higher serum lipase levels and liver CD36/fatty acid translocase mRNA levels. Thus, it is likely that increased triglyceride clearance in B6, as compared with FVB, mice contributes to the strain differences in insulin resistance and lipid metabolism.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reitman, ML (corresponding author), Merck Res Labs, POB 2000,RY80M-213, Rahway, NJ 07065 USA.		Dietz, Kelly/AAE-3074-2021; Reitman, Marc/B-4448-2013; Haluzik, Martin/I-8190-2017	Reitman, Marc/0000-0002-0426-9475; Haluzik, Martin/0000-0002-0201-6888; Dietz, Kelly/0000-0003-3670-2912	NATIONAL CANCER INSTITUTE [Z01BC005271, ZIABC005271] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BORENSZTAJN J, 1976, BIOCHEM J, V156, P539, DOI 10.1042/bj1560539; BRADLEY DC, 1989, ANAL BIOCHEM, V180, P11, DOI 10.1016/0003-2697(89)90081-X; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Chua S, 2002, DIABETOLOGIA, V45, P976, DOI 10.1007/s00125-002-0880-z; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; Colombo C, 2002, DIABETES, V51, P2727, DOI 10.2337/diabetes.51.9.2727; Comuzzie AG, 1998, SCIENCE, V280, P1374, DOI 10.1126/science.280.5368.1374; Dansky HM, 1999, ARTERIOSCL THROM VAS, V19, P1960, DOI 10.1161/01.ATV.19.8.1960; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; FOSTER DW, 1998, HARRISONS PRINCIPLES, P2209; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Gavrilova O, 2000, NATURE, V403, P850, DOI 10.1038/35002663; Haluzik M, 2002, DIABETES, V51, P2113, DOI 10.2337/diabetes.51.7.2113; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; HUMMEL KP, 1972, BIOCHEM GENET, V7, P1, DOI 10.1007/BF00487005; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Knowles JW, 2000, ARTERIOSCL THROM VAS, V20, P2336, DOI 10.1161/01.ATV.20.11.2336; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; LEITER EH, 1981, DIABETES, V30, P1035, DOI 10.2337/diabetes.30.12.1035; LEITER EH, 1980, DIABETOLOGIA, V19, P58, DOI 10.1007/BF00258313; Lutz EP, 2001, J CLIN INVEST, V107, P1183, DOI 10.1172/JCI11774; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; PETERS LL, 2002, 6224 MPD; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Tietge UJF, 1999, J LIPID RES, V40, P2134; Virkamaki A, 2001, DIABETES, V50, P2337, DOI 10.2337/diabetes.50.10.2337; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; YOUN JH, 1994, DIABETES, V43, P564, DOI 10.2337/diabetes.43.4.564	54	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3992	3999		10.1074/jbc.M207665200	http://dx.doi.org/10.1074/jbc.M207665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12456680	hybrid			2022-12-25	WOS:000180869700061
J	Kimura, S; Kawamura, M; Iyanagi, T				Kimura, S; Kawamura, M; Iyanagi, T			Role of Thr(66) in porcine NADIR-cytochrome b(5) reductase in catalysis and control of the rate-limiting step in electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHTHALATE DIOXYGENASE REDUCTASE; HEPATIC NADH-CYTOCHROME-B5 REDUCTASE; FLAVIN-DEPENDENT REDUCTASES; SITE-DIRECTED MUTAGENESIS; B5 REDUCTASE; ADENINE DINUCLEOTIDE; LIVER MICROSOMES; FERREDOXIN-NADP(+) REDUCTASE; FLAVOPROTEIN REDUCTASES; 3-DIMENSIONAL STRUCTURE	Site-directed mutagenesis of Thr(66) in porcine liver NADH-cytochrome b(5) reductase demonstrated that this residue modulates the semiquinone form of FAD and the rate-limiting step in the catalytic sequence of electron transfer. The absorption spectrum of the T66V mutant showed a typical neutral blue semiquinone intermediate during turnover in the electron transfer from NADH to ferricyanide but showed an anionic red semiquinone form during anaerobic photoreduction. The apparent k(cat) values of this mutant were similar to10% of that of the wild type enzyme (WT). These data suggest that the T66V mutation stabilizes the neutral blue semiquinone and that the conversion of the neutral blue to the anionic red semiquinone form is the rate-limiting step. In the WT, the value of the rate constant of FAD reduction (k(red)) was consistent with the k(cat) values, and the oxidized enzyme-NADH complex was observed during the turnover with ferricyanide. This indicates that the reduction of FAD by NADH in the WT-NADH complex is the rate-limiting step. In the T66A mutant, the k(red) value was larger than the k(cat) values, but the kred value in the presence of NAD(+) was consistent with the k(cat) values. The spectral shape of this mutant observed during turnover was similar to that during the reduction with NADH in the presence of NAD(+). These data suggest that the oxidized T66A-NADH-NAD(+) ternary complex is a major intermediate in the turnover and that the release of NAD(+) from this complex is the rate-limiting step. These results substantiate the important role of Thr66 in the one-electron transfer reaction catalyzed by this enzyme. On the basis of these data, we present a new kinetic scheme to explain the mechanism of electron transfer from NADH to one-electron acceptors including cytochrome b(5).	Himeji Inst Technol, Grad Sch Sci, Dept Life Sci, Kamigori, Hyogo 6781297, Japan	University of Hyogo	Kimura, S (corresponding author), Himeji Inst Technol, Grad Sch Sci, Dept Life Sci, Kouto 3-2-1, Kamigori, Hyogo 6781297, Japan.	s-kimura@sci.himeji-tech.ac.jp						ABE K, 1985, J BIOCHEM, V97, P1659, DOI 10.1093/oxfordjournals.jbchem.a135224; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; Aliverti A, 1997, BIOCHEMISTRY-US, V36, P14771, DOI 10.1021/bi971791t; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Bewley MC, 2001, BIOCHEMISTRY-US, V40, P13574, DOI 10.1021/bi0106336; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; CRISTIANO RJ, 1989, NUCLEIC ACIDS RES, V17, P799, DOI 10.1093/nar/17.2.799; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Fazekar A. G., 1971, METHODS ENZYMOL    B, V18B, P385; GASSNER G, 1994, BIOCHEMISTRY-US, V33, P12184, DOI 10.1021/bi00206a022; GASSNER GT, 1995, BIOCHEMISTRY-US, V34, P13460, DOI 10.1021/bi00041a025; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; IYANAGI T, 1984, BIOCHEMISTRY-US, V23, P1418, DOI 10.1021/bi00302a013; IYANAGI T, 1977, BIOCHEMISTRY-US, V16, P2725, DOI 10.1021/bi00631a021; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KEYES SR, 1980, J BIOL CHEM, V255, P1357; Kimura S, 2001, J BIOCHEM, V130, P481, DOI 10.1093/oxfordjournals.jbchem.a003010; Kimura S, 1999, BBA-PROTEIN STRUCT M, V1430, P290, DOI 10.1016/S0167-4838(99)00008-4; KOBAYASHI K, 1988, J BIOL CHEM, V263, P7493; KYTE J, 1995, MECH PROTEIN CHEM, P72; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; Marohnic CC, 2001, ARCH BIOCHEM BIOPHYS, V389, P223, DOI 10.1006/abbi.2001.2340; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MEYER TE, 1995, ARCH BIOCHEM BIOPHYS, V318, P457, DOI 10.1006/abbi.1995.1254; MIKI K, 1987, J BIOL CHEM, V262, P11801; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Murataliev MB, 1999, FEBS LETT, V453, P201, DOI 10.1016/S0014-5793(99)00723-1; Murataliev MB, 2000, BIOCHEMISTRY-US, V39, P5066, DOI 10.1021/bi992917k; NISHIDA H, 1995, FEBS LETT, V361, P97, DOI 10.1016/0014-5793(95)00161-2; Nishida H, 1996, PROTEINS, V26, P32, DOI 10.1002/(SICI)1097-0134(199609)26:1<32::AID-PROT3>3.0.CO;2-I; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; OKAYASU T, 1981, ARCH BIOCHEM BIOPHYS, V206, P21, DOI 10.1016/0003-9861(81)90061-8; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; OZOLS J, 1974, BIOCHEMISTRY-US, V13, P426, DOI 10.1021/bi00700a005; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; Shirabe K, 1994, FLAVINS AND FLAVOPROTEINS 1993, P405; SPATZ L, 1973, J BIOL CHEM, V248, P793; STRITTMATTER P, 1963, J BIOL CHEM, V238, P2213; STRITTMATTER P, 1962, J BIOL CHEM, V237, P3250; STRITTMATTER P, 1965, J BIOL CHEM, V240, P4481; STRITTMATTER P, 1963, ENZYMES, V8, P113; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; TAKANO T, 1987, J MOL BIOL, V195, P749, DOI 10.1016/0022-2836(87)90195-1; Takano T, 1994, FLAVINS AND FLAVOPROTEINS 1993, P409; TRIMBOLI AJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P48, DOI 10.1006/abbi.1994.1469; VanDerMark PK, 1997, BIOCHEM BIOPH RES CO, V240, P80, DOI 10.1006/bbrc.1997.7599; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411	54	33	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3580	3589		10.1074/jbc.M209838200	http://dx.doi.org/10.1074/jbc.M209838200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12459552	hybrid			2022-12-25	WOS:000180869700011
J	Lesort, M; Lee, M; Tucholski, J; Johnson, GVW				Lesort, M; Lee, M; Tucholski, J; Johnson, GVW			Cystamine inhibits caspase activity - Implications for the treatment of polyglutamine disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; TRANSGENIC MOUSE MODEL; TISSUE TRANSGLUTAMINASE; HUNTINGTONS-DISEASE; APOPTOSIS; AGGREGATION; GLUTATHIONE; DYSFUNCTION; INCREASES; CREATINE	Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an abnormally expended polyglutamine domain. There is no effective treatment for HD; however, inhibition of caspase activity or prevention of mitochondria dysfunction delays disease progression in HD mouse models. Similarly administration of cystamine, which can inhibit transglutaminase, prolonged survival of HD mice, suggesting that inhibition of transglutaminase might provide a new treatment strategy. However, it has been suggested that cystamine may inhibit other thiol-dependent enzymes in addition to transglutaminase. In this study we show that cystamine inhibits recombinant active caspase-3 in a concentration-dependent manner. At low concentrations cystamine is an uncompetitive inhibitor of caspase-3 activity, becoming a non-competitive inhibitor at higher concentrations. The IC50 for cystamine-mediated inhibition of caspase-3 activity in vitro was 23.6 mum. In situ cystamine inhibited in a concentration-dependent manner the activation of caspase-3 by different pro-apoptotic agents. Additionally, cystamine inhibited caspase-3 activity to the same extent in cell lines stably overexpressing wild type tissue transglutaminase (tTG), a mutant inactive tTG, or an antisense for tTG, demonstrating that cystamine inhibits caspase activity independently of any effects it may have on the transamidating activity of tTG. Finally, treatment with cystamine resulted in a robust increase in the levels of glutathione. These findings demonstrate that cystamine may prolong neuronal survival and delay the onset of HD by inhibiting caspases and increasing the level of antioxidants such as glutathione.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Lesort, M (corresponding author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720,7th Ave S,SC1079, Birmingham, AL 35294 USA.	mlesort@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012396] Funding Source: NIH RePORTER; NIA NIH HHS [AG12396] Funding Source: Medline; NINDS NIH HHS [R01 NS041552-02, R01 NS041552, NS41552] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Andreassen OA, 2001, NEUROBIOL DIS, V8, P479, DOI 10.1006/nbdi.2001.0406; BEAL MF, 1994, NEUROBIOL AGING, V15, P275; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Browne SE, 1999, BRAIN PATHOL, V9, P147; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chun WJ, 2001, J CELL BIOL, V153, P25, DOI 10.1083/jcb.153.1.25; Cooper AJL, 1999, J NEUROCHEM, V72, P889, DOI 10.1046/j.1471-4159.1999.0720889.x; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DJURHUUS R, 1991, CARCINOGENESIS, V12, P241, DOI 10.1093/carcin/12.2.241; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; GREEN H, 1993, CELL, V74, P955, DOI 10.1016/0092-8674(93)90718-6; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; JOKAY I, 1998, LIFE SCI, V62, P27; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Karpuj MV, 2002, NAT MED, V8, P143, DOI 10.1038/nm0202-143; Lesort M, 2000, J NEUROCHEM, V75, P1951, DOI 10.1046/j.1471-4159.2000.0751951.x; Lesort M, 1999, J NEUROCHEM, V73, P2018; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Lorand L, 1998, NAT GENET, V20, P231, DOI 10.1038/3033; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mastroberardino P, 2002, CELL DEATH DIFFER, V9, P873, DOI 10.1038/sj.cdd.4401093; Naujokat C, 2000, EUR J HAEMATOL, V65, P221, DOI 10.1034/j.1600-0609.2000.065004221.x; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	38	142	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3825	3830		10.1074/jbc.M205812200	http://dx.doi.org/10.1074/jbc.M205812200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458211	hybrid			2022-12-25	WOS:000180869700040
J	Miura, S; Zhang, JL; Boros, J; Karnik, SS				Miura, S; Zhang, JL; Boros, J; Karnik, SS			TM2-TM7 interaction in coupling movement of transmembrane helices to activation of the angiotensin II type-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN; DOMAIN	Agonist-induced rigid body motion of transmembrane (TM) helices has been established as a unifying mechanism in the activation of the G protein-coupled receptors. In attempts to measure specific conformational transitions during the activation of the type 1 receptor for angiotensin II (AT(1)), we found a decrease in accessibility of Cys(76) in the second TM helix, suggesting that the orientation of TM2 is altered (Miura, S., and Karnik, S. S. (2002) J. Biol. Chem. 277, 24299-24305). Now we provide evidence that the TM2 helical movement plays a role in regulating the activated state of the AT, receptor, and this role may involve an interaction between TM2 and TM7. Alanine substitution of native Cys296 in TM7 leads to increased accessibility of Cys2ss and diminished response to bound agonist. Both effects of the C296A mutation are suppressed when combined with F77A and N111G mutants. The TM7 conformation and the sensitivity of Cys(289) altered by C296A mutation are suppressed by the F77A mutation in TM2 to salvage function. We show that the F77A mutant alters orientation of both TM2 and TM7 but does not induce constitutive activity in suppressing the C296A mutant effects. Thus, interaction of TM2 and TM7 is important for transmembrane signal transduction in the AT(1) receptor.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Karnik, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.	karniks@ccf.org	Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057470] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL057470, HL57470, R01 HL064845] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Hunyady L, 2001, J RENIN-ANGIO-ALDO S, V2, pS16, DOI 10.1177/14703203010020010301; Karnik SS, 2000, V CH MO CAR, V1, P117; MARIE J, 1994, J BIOL CHEM, V269, P20815; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Miura S, 2002, J BIOL CHEM, V277, P24299, DOI 10.1074/jbc.M202743200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Perodin J, 2002, BIOCHEMISTRY-US, V41, P14348, DOI 10.1021/bi0258602; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091	16	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3720	3725		10.1074/jbc.M211338200	http://dx.doi.org/10.1074/jbc.M211338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446719	hybrid			2022-12-25	WOS:000180869700027
J	Norum, JH; Hart, K; Levy, FO				Norum, JH; Hart, K; Levy, FO			Ras-dependent ERK activation by the human G(s)-coupled serotonin receptors 5-HT4(b) and 5-HT7(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NUCLEOTIDE-EXCHANGE FACTOR; KINASE SIGNALING PATHWAY; LONG-TERM FACILITATION; BETA-GAMMA-SUBUNITS; SMOOTH-MUSCLE CELLS; MAP KINASE; ADENYLYL-CYCLASE; MEDIATED SIGNALS; TYROSINE KINASE	Receptor tyrosine kinases activate mitogen-activated protein (MAP) kinases through Ras, Raf-1, and MEK. Receptor tyrosine kinases can be transactivated by G protein-coupled receptors coupling to G(i) and G(q). The human G protein-coupled serotonin receptors 5-HT4(b) and 5-HT7(a) couple to G(s) and elevate intracellular cAMP. Certain G.-coupled receptors have been shown to activate MAP kinases through a protein kinase A- and Rap1-dependent pathway. We report the activation of the extracellular signal-regulated kinases (ERKs) 1 and 2 (p44 and p42 ALAP kinase) through the human serotonin receptors 5-HT4(b) and 5-HT7(a) in COS-7 and human embryonic kidney HEK293 cells. In transfected HEK293 cells, 5-HT-induced activation of ERK1/2 is sensitive to H89, which indicates a role for protein kinase A. The observed activation of ERK1/2 does not require transactivation of epidermal growth factor receptors. Furthermore, 5-HT induced activation of both Ras and Rap1. Whereas the presence of Rap1GAP1 did not influence the 5-HT-mediated activation of ERK1/2, the activation of ERK1/2 was abolished in the presence of dominant negative Ras (RasN17). ERK1/2 activation was reduced in the presence of "dominant negative" Raf1 (RafS621A) and slightly reduced by dominant negative B-Raf, indicating the involvement of one or more Raf isoforms. These findings suggest that activation of ERK1/2 through the human G(s)-coupled serotonin receptors 5-HT4(b) and 5-HT7(a) in HEK293 cells is dependent on Ras, but independent of Rap1.	Univ Oslo, Merck Sharp & Dohme Cardiovac Res ctr, Inst Surg Res, N-0316 Oslo, Norway; Univ Oslo, Rikshosp, Dept Pharmacol, N-0316 Oslo, Norway	University of Oslo; University of Oslo; National Hospital Norway	Levy, FO (corresponding author), Univ Oslo, Dept Pharmacol, POB 1057 Blindern, N-0316 Oslo, Norway.							Ambrosini A, 2000, MOL BRAIN RES, V75, P54, DOI 10.1016/S0169-328X(99)00294-6; Bach T, 2001, N-S ARCH PHARMACOL, V363, P146, DOI 10.1007/s002100000299; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Bender E, 2000, J NEUROCHEM, V74, P478, DOI 10.1046/j.1471-4159.2000.740478.x; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Errico H, 2001, NEUROSCIENCE, V102, P361, DOI 10.1016/S0306-4522(00)00460-7; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Heidmann DEA, 1997, J NEUROCHEM, V68, P1372; HOYER D, 1994, PHARMACOL REV, V46, P157; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Krobert KA, 2001, N-S ARCH PHARMACOL, V363, P620, DOI 10.1007/s002100000369; Leserer M, 2000, IUBMB LIFE, V49, P405; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Markstein R, 1999, N-S ARCH PHARMACOL, V359, P454, DOI 10.1007/PL00005375; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Michael D, 1998, P NATL ACAD SCI USA, V95, P1864, DOI 10.1073/pnas.95.4.1864; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; Thomas DR, 1999, BRIT J PHARMACOL, V128, P158, DOI 10.1038/sj.bjp.0702759; VAN BT, 1995, NATURE, V376, P781; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; Zippel R, 1996, ONCOGENE, V12, P2697	60	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3098	3104		10.1074/jbc.M206237200	http://dx.doi.org/10.1074/jbc.M206237200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446729	hybrid			2022-12-25	WOS:000180915000043
J	Witowsky, JA; Johnson, GL				Witowsky, JA; Johnson, GL			Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; GENE DISRUPTION; CELL-MIGRATION; UBIQUITIN; KINASE; C-CBL/SLI-1; APOPTOSIS; REQUIRES; PROTEINS; COMPLEX	MEKK1 is a MAPK kinase kinase that is activated in response to stimuli that alter the cytoskeleton and cell shape. MEKK1 phosphorylates and activates MKK1 and MKK4, leading to ERK1/2 and JNK activation. MEKK1 has a plant homeobox domain (PHD) that has been shown to have E3 ligase activity. (Lu, Z., Xu, S., Joazeiro, C., Cobb, M. H., and Hunter, T. (2002) Mol. Cell 9, 945956). MEKK1 kinase activity is required for ubiquitylation of MEKK1. MEKK1 ubiquitylation is inhibited by mutation of cysteine 441 to alanine (C441A) within the PHD. The functional consequence of MEKK1 ubiquitylation. is the inhibition of MEKK1 catalyzed phosphorylation of MKK1 and MKK4 resulting in inhibition of ERK1/2 and JNK activation. The C441A mutation within the PHD of MEKK1 prevents ubiquitylation and preserves the ability of MEKK1 to catalyze MKK1 and MKK4 phosphorylation. MEKK1 ubiquitylation represents a mechanism for inhibiting the ability of a protein kinase to phosphorylate substrates and regulate downstream signaling pathways.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Johnson, GL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave,Rm 2809,SOM, Denver, CO 80262 USA.				NIDDK NIH HHS [DK37871] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Esch RK, 2002, P NATL ACAD SCI USA, V99, P9160, DOI 10.1073/pnas.142034399; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Heasley LE, 1996, MOL CELL BIOL, V16, P648; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Marx J, 2002, SCIENCE, V297, P1792, DOI 10.1126/science.297.5588.1792; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	23	72	77	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1403	1406		10.1074/jbc.C200616200	http://dx.doi.org/10.1074/jbc.C200616200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12456688	hybrid			2022-12-25	WOS:000180462200005
J	Baar, K; Wende, AR; Jones, TE; Marison, M; Nolte, LA; Chen, M; Kelly, DP; Holloszy, JO				Baar, K; Wende, AR; Jones, TE; Marison, M; Nolte, LA; Chen, M; Kelly, DP; Holloszy, JO			Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1	FASEB JOURNAL			English	Article						GLUT4; mitochondrial biogenesis; NRF-1; NRF-2	GLUCOSE-TRANSPORT CAPACITY; NUCLEAR RESPIRATORY FACTORS; MITOCHONDRIAL BIOGENESIS; BIOCHEMICAL ADAPTATIONS; ENDURANCE EXERCISE; ENERGY-METABOLISM; GENE-EXPRESSION; MESSENGER-RNA; ACTIVATION; GLUT-4	Endurance exercise induces increases in mitochondria and the GLUT4 isoform of the glucose transporter in muscle. Although little is known about the mechanisms underlying these adaptations, new information has accumulated regarding how mitochondrial biogenesis and GLUT4 expression are regulated. This includes the findings that the transcriptional coactivator PGC-1 promotes mitochondrial biogenesis and that NRF-1 and NRF-2 act as transcriptional activators of genes encoding mitochondrial enzymes. We tested the hypothesis that increases in PGC-1, NRF-1, and NRF-2 are involved in the initial adaptive response of muscle to exercise. Five daily bouts of swimming induced increases in mitochondrial enzymes and GLUT4 in skeletal muscle in rats. One exercise bout resulted in similar to twofold increases in full-length muscle PGC-1 mRNA and PGC-1 protein, which were evident 18 h after exercise. A smaller form of PGC-1 increased after exercise. The exercise induced increases in muscle NRF-1 and NRF-2 that were evident 12 to 18 h after one exercise bout. These findings suggest that increases in PGC-1, NRF-1, and NRF-2 represent key regulatory components of the stimulation of mitochondrial biogenesis by exercise and that PGC-1 mediates the coordinated increases in GLUT4 and mitochondria.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jhollosz@im.wustl.edu	Wende, Adam/AFG-8878-2022; Kelly, Daniel/ABG-2056-2021	Wende, Adam/0000-0002-5536-4675; Baar, Keith/0000-0001-9337-6186	NIA NIH HHS [AG00425, AG00078] Funding Source: Medline; NIDDK NIH HHS [DK45416] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045416, R29DK045416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG000425, R01AG000425, R56AG000425] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARNARD RJ, 1970, J APPL PHYSIOL, V28, P762, DOI 10.1152/jappl.1970.28.6.762; Booth F, 1977, Ann N Y Acad Sci, V301, P431, DOI 10.1111/j.1749-6632.1977.tb38219.x; BOOTH FW, 1997, HDB PHYSL 12, P1075; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; CASLA A, 1990, BIOCHEM BIOPH RES CO, V171, P182, DOI 10.1016/0006-291X(90)91374-2; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CHI MMY, 1983, AM J PHYSIOL, V244, pC276, DOI 10.1152/ajpcell.1983.244.3.C276; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CONSTABLE SH, 1987, AM J PHYSIOL, V253, pC316, DOI 10.1152/ajpcell.1987.253.2.C316; COYLE EF, 1985, J APPL PHYSIOL, V59, P853, DOI 10.1152/jappl.1985.59.3.853; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; FRIEDMAN JE, 1990, FEBS LETT, V268, P13, DOI 10.1016/0014-5793(90)80960-Q; GOODYEAR LJ, 1992, DIABETES, V41, P1091, DOI 10.2337/diabetes.41.9.1091; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HOLLOSZY JO, 1979, AM J PHYSIOL, V236, pR180, DOI 10.1152/ajpregu.1979.236.3.R180; HOLLOSZY JO, 1970, BIOCHEM BIOPH RES CO, V40, P1368, DOI 10.1016/0006-291X(70)90017-3; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Hood D A, 2000, Exerc Sport Sci Rev, V28, P68; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; HOPPELER H, 1973, PFLUG ARCH EUR J PHY, V344, P217, DOI 10.1007/BF00588462; Kakuma T, 2000, ENDOCRINOLOGY, V141, P4576, DOI 10.1210/en.141.12.4576; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730; MURAKAMI S, 1998, J PLASMA FUSION RES, V1, P122; Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PLOUG T, 1990, AM J PHYSIOL, V259, pE778, DOI 10.1152/ajpendo.1990.259.6.E778; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; REN JM, 1994, J BIOL CHEM, V269, P14396; Scarpulla RC, 1996, TRENDS CARDIOVAS MED, V6, P39, DOI 10.1016/1050-1738(95)00129-8; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WATSON JD, 1995, GENE, V158, P275, DOI 10.1016/0378-1119(95)00029-6; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185; WINDER WW, 1974, EUR J BIOCHEM, V47, P461, DOI 10.1111/j.1432-1033.1974.tb03713.x; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; YAN Z, 1995, AM J PHYSIOL-ENDOC M, V268, pE277, DOI 10.1152/ajpendo.1995.268.2.E277	54	739	770	3	83	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1879	1886		10.1096/fj.02-0367com	http://dx.doi.org/10.1096/fj.02-0367com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468452				2022-12-25	WOS:000180574300008
J	Bruton, JD; Lemmens, R; Shi, CL; Persson-Sjogren, S; Westerblad, H; Ahmed, M; Pyne, NJ; Frame, M; Furman, BL; Islam, MS				Bruton, JD; Lemmens, R; Shi, CL; Persson-Sjogren, S; Westerblad, H; Ahmed, M; Pyne, NJ; Frame, M; Furman, BL; Islam, MS			Ryanodine receptors of pancreatic-cells mediate a distinct context-dependent signal for insulin secretion	FASEB JOURNAL			English	Article						calcium signaling; islets of Langerhans; calcium-induced calcium release; diabetes	CA2+-INDUCED CA2+ RELEASE; ADENOSINE 3'-5'-CYCLIC MONOPHOSPHATE; BETA-CELLS; ENDOPLASMIC-RETICULUM; CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; PHOSPHODIESTERASE ACTIVITY; SMOOTH-MUSCLE; K+ CHANNELS; CAFFEINE	The ryanodine (RY) receptors in beta-cells amplify signals by Ca(2+)-induced Ca(2+) release (CICR). The role of CICR in insulin secretion remains unclear in spite of the fact that caffeine is known to stimulate secretion. This effect of caffeine is attributed solely to the inhibition of cAMP-phosphodiesterases (cAMP-PDEs). We demonstrate that stimulation of insulin secretion by caffeine is due to a sensitization of the RY receptors. The dose-response relationship of caffeine-induced inhibition of cAMP-PDEs was not correlated with the stimulation of insulin secretion. Sensitization of the RY receptors stimulated insulin secretion in a context-dependent manner, that is, only in the presence of a high concentration of glucose. This effect of caffeine depended on an increase in [Ca(2+)](i). Confocal images of beta-cells demonstrated an increase in [Ca(2+)](i) induced by caffeine but not by forskolin. 9-Methyl-7-bromoeudistomin D (MBED), which sensitizes RY receptors, did not inhibit cAMP-PDEs, but it stimulated secretion in a glucose-dependent manner. The stimulation of secretion by caffeine and MBED involved both the first and the second phases of secretion. We conclude that the RY receptors of beta-cells mediate a distinct glucose-dependent signal for insulin secretion and may be a target for developing drugs that will stimulate insulin secretion only in a glucose-dependent manner.	Karolinska Inst, Karolinska Hosp, Dept Mol Med, Dept Endocrinol, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Physiol, S-10401 Stockholm, Sweden; Umea Univ, Dept Integrat Med Biol, Sect Histol & Cell Biol, Umea, Sweden; Univ Strathclyde, Dept Physiol & Pharmacol, Strathclyde Inst Biomed Sci, Glasgow G1 1XW, Lanark, Scotland	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Umea University; University of Strathclyde	Islam, MS (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Mol Med, Dept Endocrinol, L6B-01, S-17176 Stockholm, Sweden.	Shahidul.Islam@molmed.ki.se	Islam, Shahidul/K-3295-2019	Islam, Shahidul/0000-0002-9016-1881; Westerblad, Hakan/0000-0002-8180-3029; Bruton, Joseph/0000-0002-6985-099X; Pyne, Nigel/0000-0002-5657-4578				Ahmad M, 2000, BRIT J PHARMACOL, V129, P1228, DOI 10.1038/sj.bjp.0703165; Alonso MT, 1999, J CELL BIOL, V144, P241, DOI 10.1083/jcb.144.2.241; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; CAPITO K, 1976, BIOCHEM J, V158, P335, DOI 10.1042/bj1580335; Cavallaro RA, 1999, J MED CHEM, V42, P2527, DOI 10.1021/jm980469t; COOPER RH, 1973, BIOCHEM J, V134, P599, DOI 10.1042/bj1340599; DONOSO P, 1994, BRIT J PHARMACOL, V111, P455, DOI 10.1111/j.1476-5381.1994.tb14757.x; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Gamberucci A, 1999, FEBS LETT, V446, P309, DOI 10.1016/S0014-5793(99)00220-3; HernandezCruz A, 1997, J GEN PHYSIOL, V109, P147, DOI 10.1085/jgp.109.2.147; HILLAIREBUYS D, 1987, EUR J PHARMACOL, V136, P109, DOI 10.1016/0014-2999(87)90786-2; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679; Islam MS, 1998, DIABETOLOGIA, V41, pA37; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; ISLAM MS, 1993, BIOCHEM J, V293, P423, DOI 10.1042/bj2930423; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; Kermode H, 1998, FEBS LETT, V431, P59, DOI 10.1016/S0014-5793(98)00725-X; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; Maechler P, 2000, IUBMB LIFE, V50, P27, DOI 10.1080/15216540050176557; MCNULTY TJ, 1993, BIOCHEM J, V291, P799, DOI 10.1042/bj2910799; Mears D, 1999, DIABETES, V48, pA443; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; MULLER CE, 1993, BIOCHEM PHARMACOL, V46, P1825, DOI 10.1016/0006-2952(93)90589-O; Ohi Y, 2001, JPN J PHARMACOL, V85, P382, DOI 10.1254/jjp.85.382; Porta M, 2002, BIOPHYS J, V82, p82A; Pyne NJ, 1997, BIOCHEM J, V328, P689; Qian WJ, 2001, BIOCHEM BIOPH RES CO, V286, P315, DOI 10.1006/bbrc.2001.5379; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SAMS DJ, 1972, BIOCHEM J, V129, P945, DOI 10.1042/bj1290945; Seino-Umeda A, 1998, EUR J PHARMACOL, V357, P261, DOI 10.1016/S0014-2999(98)00589-5; Shi CL, 1997, CELL TRANSPLANT, V6, P33, DOI 10.1016/S0963-6897(96)00181-9; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TANIGUCHI T, 1996, ENDOCRINOL METAB, V3, P135; Tengholm A, 1999, J BIOL CHEM, V274, P36883, DOI 10.1074/jbc.274.52.36883; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Varadi A, 2002, DIABETES, V51, pS190, DOI 10.2337/diabetes.51.2007.S190; Wissing F, 2002, BIOCHEM J, V361, P605, DOI 10.1042/0264-6021:3610605; Yu GY, 2000, BASIC RES CARDIOL, V95, P137, DOI 10.1007/s003950050175; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	44	48	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					301	+		10.1096/fj.02-0481fje	http://dx.doi.org/10.1096/fj.02-0481fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475892				2022-12-25	WOS:000180574300016
J	Mazzucato, M; Cozzi, MR; Pradella, P; Perissinotto, D; Malmstrom, A; Morgelin, M; Spessotto, P; Colombatti, A; De Marco, L; Perris, R				Mazzucato, M; Cozzi, MR; Pradella, P; Perissinotto, D; Malmstrom, A; Morgelin, M; Spessotto, P; Colombatti, A; De Marco, L; Perris, R			Vascular PG-M/versican variants promote platelet adhesion at low shear rates and cooperate with collagens to induce aggregation	FASEB JOURNAL			English	Article						proteoglycan; hemostasis; shear stress	VON-WILLEBRAND-FACTOR; HUMAN ATHEROSCLEROTIC LESIONS; SMOOTH-MUSCLE CELLS; SULFATE PROTEOGLYCAN; THROMBUS FORMATION; BOVINE AORTA; FLOW CONDITIONS; VI COLLAGEN; I COLLAGEN; FIBRINOGEN	We have identified a novel von Willebrand factor/fibrinogen/selectin-independent, platelet adhesion-promoting function of vascular PG-M/versicans that may be relevant in normal venous thrombosis and critical in atherosclerotic conditions. A purification scheme was devised to obtain vascular versicans, which by biochemical, immunochemical, and ultrastructural means were asserted to be 1) composed primarily of isoforms V1 and V2; 2) free of contaminants; 3) prevalently substituted with chondroitin-4-sulfate and dermatan sulfate (DS) chains; and 4) capable of binding hyaluronan to form link protein-stabilized ternary complexes. Real-time analysis of human platelet perfused under diverse shear forces showed that they largely failed to bind to several vascular and nonvascular proteoglycans (PGs). In contrast, they bound in a dose- and shear rate-dependent manner to vascular versicans, exhibiting a unique attachment-detachment kinetics and establishing a firm substrate tethering characterized with no significant aggregation. Digestion of these PGs with lyases and competition experiments with purified glycosaminoglycans revealed that platelet adhesion to vascular versicans was primarily mediated by their DS chains. Incorporation of the versicans into fibrillar collagen substrates augmented their adhesive activity and strongly promoted platelet aggregation at low and high shear rates. Affinity chromatography of platelet surfaces on DS columns identified a 120-140 kDa polypeptide complex that behaved as a specific vascular versican binding membrane ligand in solid-phase binding assays. These findings indicate that selective versican variants of the subendothelium may serve as ancillary GPIbalpha/integrin/selectin-independent platelet ligands in healthy and diseased vascular beds and may be directly responsible for the platelet accruing after rupture of atherosclerotic plaques., versican variants promote platelet adhesion at low shear rates and cooperate with collagens to induce aggregation.	Univ Parma, Dept Evolutionary & Funct Biol, I-43100 Parma, Italy; IRCCS, CRO, Natl Canc Inst, Div Expt Oncol 2, I-33081 Aviano, PN, Italy; Lund Univ, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Univ Udine, MATI Ctr Excellence, I-35100 Udine, Italy	University of Parma; IRCCS Aviano (CRO); Lund University; University of Udine	De Marco, L (corresponding author), Univ Parma, Dept Evolutionary & Funct Biol, Viale Sci 11-A, I-43100 Parma, Italy.	ldemarco@cro.it; rperris@cro.it	Spessotto, Paola/K-5005-2012; Mazzucato, Mario/ABF-5472-2020; Cozzi, Maria Rita/ABD-7970-2020	Spessotto, Paola/0000-0002-3033-404X; Mazzucato, Mario/0000-0001-8319-053X; Cozzi, Maria Rita/0000-0001-6841-2632; colombatti, alfonso/0000-0002-3676-2379; Malmstrom, Anders/0000-0002-6691-146X				AKIYAMA F, 1987, ARCH BIOCHEM BIOPHYS, V252, P574, DOI 10.1016/0003-9861(87)90065-8; Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Barnes M J, 1998, Curr Opin Hematol, V5, P314, DOI 10.1097/00062752-199809000-00002; Baumann H, 1997, SEMIN THROMB HEMOST, V23, P203, DOI 10.1055/s-2007-996092; Bennett JS, 1997, J BIOL CHEM, V272, P8137, DOI 10.1074/jbc.272.13.8137; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; CADROY Y, 1993, ARTERIOSCLER THROMB, V13, P1213, DOI 10.1161/01.ATV.13.8.1213; Cerletti C, 1999, THROMB HAEMOSTASIS, V82, P787; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; Clemetson KJ, 1999, CURR BIOL, V9, pR110, DOI 10.1016/S0960-9822(99)80063-3; DALFERES ER, 1987, EXP MOL PATHOL, V47, P363, DOI 10.1016/0014-4800(87)90019-0; DAVIES CA, 2001, OXIDAT STRESS DIS, V7, P17; Eriksen GV, 1999, BIOCHEM J, V340, P613, DOI 10.1042/0264-6021:3400613; Evanko SP, 1998, AM J PATHOL, V152, P533; FABRIS F, 1992, THROMB RES, V66, P409, DOI 10.1016/0049-3848(92)90290-Q; Fay WP, 1999, BLOOD, V93, P1825, DOI 10.1182/blood.V93.6.1825.406k37_1825_1830; FRANSSON LA, 1979, BIOCHIM BIOPHYS ACTA, V586, P179, DOI 10.1016/0304-4165(79)90416-1; Geberhiwot T, 1999, EXP CELL RES, V253, P723, DOI 10.1006/excr.1999.4653; Godyna S, 1996, BLOOD, V88, P2569, DOI 10.1182/blood.V88.7.2569.bloodjournal8872569; Ismail NAE, 1997, INT J EXP PATHOL, V78, P71, DOI 10.1046/j.1365-2613.1997.d01-242.x; ISOGAI Z, 2001, IN PRESS J BIOL CHEM; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; KAPOOR R, 1986, BIOCHEM J, V240, P575, DOI 10.1042/bj2400575; Kauhanen P, 2000, ARTERIOSCL THROM VAS, V20, pE113, DOI 10.1161/01.ATV.20.11.e113; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; KEHREL B, 1993, BLOOD, V82, P3364; Kroll MH, 1996, BLOOD, V88, P1525; KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x; LARK MW, 1988, J HISTOCHEM CYTOCHEM, V36, P1211, DOI 10.1177/36.10.3047228; Lemire JM, 1999, ARTERIOSCL THROM VAS, V19, P1630, DOI 10.1161/01.ATV.19.7.1630; Lethias C, 1996, INT ANGIOL, V15, P104; Matsuura R, 1996, J PATHOL, V180, P311, DOI 10.1002/(SICI)1096-9896(199611)180:3<311::AID-PATH657>3.0.CO;2-B; Mazzucato M, 1999, J BIOL CHEM, V274, P3033, DOI 10.1074/jbc.274.5.3033; MCMURTREY J, 1979, J BIOL CHEM, V254, P1621; Merten M, 2000, CIRCULATION, V102, P1931, DOI 10.1161/01.CIR.102.16.1931; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; Moroi M, 1997, BLOOD, V90, P4413; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; NAKASHIMA Y, 1992, ARTERY, V19, P256; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; OEGEMA TR, 1979, J BIOL CHEM, V254, P1312; Perissinotto D, 2000, DEVELOPMENT, V127, P2823; RADHAKRISHNAMURTHY B, 1986, BIOCHIM BIOPHYS ACTA, V882, P85, DOI 10.1016/0304-4165(86)90059-0; RICHARDSON M, 1993, EXP MOL PATHOL, V58, P77, DOI 10.1006/exmp.1993.1007; Ruggeri ZM, 2000, J CLIN INVEST, V105, P699, DOI 10.1172/JCI9604; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; SRINIVASAN SR, 1988, ATHEROSCLEROSIS, V72, P1, DOI 10.1016/0021-9150(88)90056-1; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; TSAO CH, 1981, LAB INVEST, V45, P450; Tsuji S, 1999, BLOOD, V94, P968, DOI 10.1182/blood.V94.3.968.415a13_968_975; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; vanZanten GH, 1996, BLOOD, V88, P3862, DOI 10.1182/blood.V88.10.3862.bloodjournal88103862; Vasudevan S, 2000, J BIOL CHEM, V275, P12763, DOI 10.1074/jbc.275.17.12763; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; Zaidi TN, 1996, BLOOD, V88, P2967, DOI 10.1182/blood.V88.8.2967.bloodjournal8882967	60	30	32	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1903	1916		10.1096/fj.02-0382com	http://dx.doi.org/10.1096/fj.02-0382com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468455				2022-12-25	WOS:000180574300011
J	Brachat, A; Pierrat, B; Xynos, A; Brecht, K; Simonen, M; Brungger, A; Heim, J				Brachat, A; Pierrat, B; Xynos, A; Brecht, K; Simonen, M; Brungger, A; Heim, J			A microarray-based, integrated approach to identify novel regulators of cancer drug response and apoptosis	ONCOGENE			English	Article						apoptosis; microarray; hemoglobin; camptothecin; methotrexate; cisplatin	GP49B INHIBITORY RECEPTOR; GENE-EXPRESSION; ADENYLATE KINASE; DNA-DAMAGE; IDENTIFICATION; PROTEIN; SENSITIVITY; CYCLOPHILIN; CLONING; STRESS	DNA microarrays are powerful tools for the analysis of gene expression on a genomic scale. The importance of individual regulatory events for the process under study can however not be deduced unequivocally without additional experiments. We devised a strategy to identify central regulators of cancer drug responses by combining the results of microarray experiments with efficient methods for phenotypic testing of candidate genes. We exposed murine FL5.12 pro-B cells to cisplatin, camptothecin, methotrexate or paclitaxel, respectively and analysed the patterns of gene expression with cDNA microarrays. Drug-specific regulatory events as well as intersections between different apoptotic pathways, including previously studied responses to staurosporine and interleukin-3 (IL-3) deprivation, were identified. Genes shared by at least three pathways were chosen for further analysis. Ectopic expression of three such genes, TEAP, GP49B, and Lipin1 was found to have an anti-proliferative effect on pro-B cells. Interestingly, we identified hemoglobin alpha as a strong pro-apoptotic regulator. While hemoglobin-expressing cells were growing normally in the presence of IL-3, they displayed accelerated apoptosis with similar kinetics as Bax overexpressing cells upon IL-3 removal. The proapoptotic effect of hemoglobin was suppressed by Bcl-2 and was characterized by enhanced stimulation of caspase activity.	Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland; Novartis Pharma AG, Mol & Cellular Biol Sr Sci Expert Lab, CH-4002 Basel, Switzerland	Novartis; Novartis	Heim, J (corresponding author), Novartis Pharma AG, Oncol Res, K-125-13-16, CH-4002 Basel, Switzerland.	jutta.heim@pharma.novartis.com		Brachat, Arndt/0000-0001-5768-3429				Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Beinert T, 2000, J LEUKOCYTE BIOL, V67, P369, DOI 10.1002/jlb.67.3.369; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Brachat A, 2000, ONCOGENE, V19, P5073, DOI 10.1038/sj.onc.1203882; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Carrier A, 1999, IMMUNOGENETICS, V50, P255, DOI 10.1007/s002510050601; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Dunn SE, 1997, CANCER RES, V57, P2687; Ferrante K, 1999, CANCER CHEMOTH PHARM, V43, pS61, DOI 10.1007/s002800051100; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lehar SM, 1996, ONCOGENE, V12, P1181; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Matsuda S, 1996, ONCOGENE, V12, P705; Matsumoto Y, 2001, J IMMUNOL, V166, P781, DOI 10.4049/jimmunol.166.2.781; Meguro T, 2001, J NEUROCHEM, V77, P1128, DOI 10.1046/j.1471-4159.2001.00313.x; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; SWIFT S, 1999, CUR PROTO IMMUNOL S, V28; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang LL, 2000, J IMMUNOL, V164, P5215, DOI 10.4049/jimmunol.164.10.5215; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; Yoneda T, 1998, MOL BRAIN RES, V62, P187, DOI 10.1016/S0169-328X(98)00249-6	32	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8361	8371		10.1038/sj.onc.1206016	http://dx.doi.org/10.1038/sj.onc.1206016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447701				2022-12-25	WOS:000179323900016
J	Guo, WH; Weng, LQ; Ito, K; Chen, LF; Nakanishi, H; Tatematsu, M; Ito, Y				Guo, WH; Weng, LQ; Ito, K; Chen, LF; Nakanishi, H; Tatematsu, M; Ito, Y			Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor	ONCOGENE			English	Article						Runx3; tumor suppressor; methylation; gastric cancer	METHYL-N-NITROSOUREA; P53 GENE-MUTATIONS; HISTONE DEACETYLASE; INDUCTION; PROMOTER; LINES; MECP2	We reported recently that the silencing of RUNX3 is causally related to gastric cancer in humans. Here we report that in three of four cell tines derived from N-methyl-N-nitrosourea-induced mouse glandular stomach carcinomas, Runx3 is silenced due to hypermethylation of CpG islands in the promoter region, as we also observed for human gastric cancer cells. Although two of the sites we tested in the promoter of the fourth line were not methylated, in all four cases the silencing of Runx3 could be reversed by treatment of the cells with 5'-azacytidine and trichostatin A. Interestingly, the exogenous expression of RUNX3 in cell lines that do not express the endogenous gene caused an inhibition of growth in soft agar, suggesting that anchorage-independent growth could be used as an assay of RUNX3 activity in vitro. These observations suggest that the mouse system described here may be useful as a model for the study of human gastric carcinogenesis.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Aichi Canc Ctr, Res Inst, Pathol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Kyoto University; Aichi Cancer Center	Ito, Y (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							AMY SY, 1998, FRONT BIOSCI, V3, P532; Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515; Furihata C, 1997, JPN J CANCER RES, V88, P363, DOI 10.1111/j.1349-7006.1997.tb00390.x; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ichinose M, 1998, JPN J CANCER RES, V89, P516, DOI 10.1111/j.1349-7006.1998.tb03292.x; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; TAMURA G, 1991, CANCER RES, V51, P3056; TATEMATSU M, 1993, JPN J CANCER RES, V84, P1258, DOI 10.1111/j.1349-7006.1993.tb02831.x; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6	16	78	90	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8351	8355		10.1038/sj.onc.1206037	http://dx.doi.org/10.1038/sj.onc.1206037			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447699	Green Submitted			2022-12-25	WOS:000179323900014
J	Shah, RNH; Ibbitt, JC; Alitalo, K; Hurst, HC				Shah, RNH; Ibbitt, JC; Alitalo, K; Hurst, HC			FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1 alpha	ONCOGENE			English	Article						FGFR4; pancreatic cancer; HNF1; intronic enhancer	FIBROBLAST GROWTH-FACTORS; TRANSCRIPTION FACTORS; MULTIGENE FAMILY; FACTOR RECEPTORS; GENE; EXPRESSION; HOMEOPROTEIN; MUTATIONS; PROMOTERS; DIVERSITY	Fibroblast growth factor receptor 4 (FGFR4) is expressed in 50-70% of pancreatic carcinomas (PC) and a similar proportion of derived cell tines. Here we determine the sites of FGFR4 transcriptional initiation which show a pattern characteristic of genes with GC-rich, TATA-less promoters. We have examined the chromatin structure around the FGFR4 gene in a panel of expressing and non-expressing PC tines using the DNase I hypersensitive site assay. One region of hypersensitivity, located largely within intron 1, was found to be greatly extended in expressing cells. Subsequent functional analyses using reporter assays demonstrated that this region was able to act as a cell-specific enhancer, only showing significant activity in PC tines expressing endogenous FGFR4. Transcription factors able to bind to the enhancer were investigated using footprinting and mobility shift assays and two binding sites for Sp1 proteins and two sites able to bind hepatic nuclear factor 1 (HNF1) proteins were identified. Further reporter assays using constructs mutated in each binding site demonstrated that HNF1 binding was essential for enhancer activity in expressing cells, an observation that correlated with the increased abundance of HNF1alpha in these same cells as measured by Western blotting. Finally we show that exogenous expression of HNF1 factors in an FGFR4 non-expressing line led to an induction of enhancer activity in reporter assays and also activated expression of the endogenous gene. We conclude that HNF1alpha is a major determinant of FGFR4 expression in PC.	Hammersmith Hosp, ICSM, Canc Res UK Mol Oncol Unit, London W12 0NN, England; Biomedicum Helsinki, Helsinki 00014, Finland	Cancer Research UK; Imperial College London; University of Helsinki	Hurst, HC (corresponding author), Hammersmith Hosp, ICSM, Canc Res UK Mol Oncol Unit, London W12 0NN, England.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				ARMSTRONG E, 1992, GENE CHROMOSOME CANC, V4, P94, DOI 10.1002/gcc.2870040116; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bange J, 2002, CANCER RES, V62, P840; Becker M, 2000, BIOCHEM BIOPH RES CO, V276, P493, DOI 10.1006/bbrc.2000.3483; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; Jang JH, 2001, CANCER RES, V61, P3541; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; KOBRIN MS, 1993, CANCER RES, V53, P937; Kostrzewa M, 1998, MAMM GENOME, V9, P131, DOI 10.1007/s003359900703; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; Le Bras S, 1998, DIABETES, V47, P1236, DOI 10.2337/diabetes.47.8.1236; LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515; Li JX, 2000, GENE DEV, V14, P464; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Miralles F, 1999, P NATL ACAD SCI USA, V96, P6267, DOI 10.1073/pnas.96.11.6267; OHATA T, 1995, BRIT J CANCER, V72, P824; Ornitz DM, 2001, GENOME BIOL, V2; Parakati R, 2002, J BIOL CHEM, V277, P9278, DOI 10.1074/jbc.M108411200; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Wagner M, 1998, GASTROENTEROLOGY, V114, P798, DOI 10.1016/S0016-5085(98)70594-3; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264	37	51	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8251	8261		10.1038/sj.onc.1206020	http://dx.doi.org/10.1038/sj.onc.1206020			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447688				2022-12-25	WOS:000179323900003
J	Issa, R; Zhou, XY; Trim, N; Millward-Sadler, H; Krane, S; Benyon, C; Iredale, J				Issa, R; Zhou, XY; Trim, N; Millward-Sadler, H; Krane, S; Benyon, C; Iredale, J			Mutation in collagen-I that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration	FASEB JOURNAL			English	Article						apoptosis; metalloproteinase (MMP); tissue inhibitor of metalloproteinase (TIMP); hepatic regeneration	TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE-2; LIPOCYTES SYNTHESIZE; GENE-EXPRESSION; RAT; APOPTOSIS; CLEAVAGE; MECHANISMS; MICE	Collagen-I, which predominates in the neomatrix of fibrotic liver, regulates hepatocyte and hepatic stellate cell (HSC) phenotypes. Recovery from liver fibrosis is accompanied by hepatocyte regeneration, matrix degradation, and HSC apoptosis. Using mice bearing a mutated collagen-I gene (r/r mice), which confers resistance to collagenase degradation, we have investigated the hypothesis that collagen-I degradation is critical to HSC apoptosis and hepatocyte regeneration during recovery from liver fibrosis. During a 28-day recovery period after 8 wk of CCl4 treatment, wild-type (WT) livers had significantly (43%) decreased hydroxyproline (OHP) content. In r/r livers, however, OHP content remained elevated at peak fibrosis levels. Expressed markers of activated HSC (alpha-smooth muscle actin, collagen-I), elevated at peak fibrosis, dropped to control levels in WT livers after 28 days but remained raised in the r/r livers. Moreover, relative to WT livers, r/r livers had significantly reduced stellate cell apoptosis and hepatocyte regeneration during the recovery period. Using extracted collagen-I from each genotype as culture substrata, relative to r/r, we show that WT collagen-I promotes hepatocyte proliferation via stimulation of integrin alphavbeta(3). Failure to degrade collagen-I critically impairs HSC apoptosis and may prevent the effective restoration of hepatocyte mass in liver fibrosis.	Univ Southampton, Southampton Gen Hosp, Liver Res Grp, Southampton SO19 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Dept Histopathol Infect Inflammat & Repair, Southampton SO19 6YD, Hants, England; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA	University of Southampton; University of Southampton; Harvard University; Harvard Medical School; Massachusetts General Hospital	Iredale, J (corresponding author), Univ Southampton, Southampton Gen Hosp, Mail Point 811,Level D,S Block, Southampton SO19 6YD, Hants, England.	jpi@soton.ac.uk		Iredale, John/0000-0003-2174-5127	Medical Research Council [G9900297] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Alcolado R, 1997, CLIN SCI, V92, P103, DOI 10.1042/cs0920103; ARTHUR MJP, 1989, J CLIN INVEST, V84, P1076, DOI 10.1172/JCI114270; ARTHUR MJP, 1992, BIOCHEM J, V287, P701, DOI 10.1042/bj2870701; Benyon RC, 1996, GASTROENTEROLOGY, V110, P821, DOI 10.1053/gast.1996.v110.pm8608892; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; BURT AD, 1993, J PATHOL, V170, P105, DOI 10.1002/path.1711700203; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; HASTY KA, 1993, MATRIX, V13, P181, DOI 10.1016/S0934-8832(11)80001-6; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hovell C. J., 1995, Hepatology, V22, p369A; Iimuro Y, 1999, HEPATOLOGY, V30, p299A; IREDALE JP, 1994, GUT, V35, P729, DOI 10.1136/gut.35.6.729; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; IREDALE JP, 1992, J CLIN INVEST, V90, P282, DOI 10.1172/JCI115850; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; Issa R, 2001, GUT, V48, P548, DOI 10.1136/gut.48.4.548; Iwamoto H, 1999, J LAB CLIN MED, V134, P83, DOI 10.1016/S0022-2143(99)90057-4; Iwamoto H, 1999, DIGEST DIS SCI, V44, P1038, DOI 10.1023/A:1026633302985; Iwamoto H, 1998, J HEPATOL, V29, P752, DOI 10.1016/S0168-8278(98)80256-0; Krane SM, 1996, J BIOL CHEM, V271, P28509, DOI 10.1074/jbc.271.45.28509; Leyland H, 1996, HEPATOLOGY, V24, P1172, DOI 10.1002/hep.510240532; LIU ML, 1994, HEPATOLOGY, V19, P1521; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MARS WM, 1995, HEPATOLOGY, V21, P1695, DOI 10.1016/0270-9139(95)90477-8; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Preaux AM, 1999, HEPATOLOGY, V30, P944, DOI 10.1002/hep.510300432; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; Thompson KC, 1998, HEPATOLOGY, V28, P1518, DOI 10.1002/hep.510280611; UKEI T, 1999, NAT MED, V5, P226; VYAS SK, 1995, GASTROENTEROLOGY, V109, P889, DOI 10.1016/0016-5085(95)90399-2; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	45	158	167	2	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					47	+		10.1096/fj.02-0494fje	http://dx.doi.org/10.1096/fj.02-0494fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475903				2022-12-25	WOS:000180218500026
J	Berardi, P; Meyyappan, M; Riabowol, KT				Berardi, P; Meyyappan, M; Riabowol, KT			A novel transcriptional inhibitory element differentially regulates the cyclin D1 gene in senescent cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; DNA-SYNTHESIS; REPLICATIVE SENESCENCE; INCREASED EXPRESSION; CELLULAR SENESCENCE; ANDROGEN RECEPTOR; RESPONSE ELEMENT; GROWTH ARREST; IN-VIVO; OVEREXPRESSION	Senescent human diploid fibroblasts are unable to initiate DNA synthesis following mitogenic stimulation and adopt a unique gene expression profile distinct from young or quiescent cells. In this study, a novel transcriptional regulatory element was identified in the 5'-untranslated region of the cyclin D1 gene. We show that this element differentially suppresses cyclin D1 expression in young versus senescent fibroblasts. Electrophoretic mobility shift assays revealed abundant complexes forming with young cell nuclear extracts compared with senescent cell nuclear extracts. Binding was maintained in young quiescent cells, showing that loss of this activity was specific to senescent cells a not an effect of cell cycle arrest. Site-directed mutage-esis within this cyclin D1 inhibitory element (DIE) abolished binding activity and selectively increased cyclin D1 promoter activity in young but not in senescent cells. Sequences with homology to the DIE were found in the 5'-untranslated regions of other genes known to be up-regulated during cellular aging, suggesting that protein(s) that bind the DIE might be responsible for the coordinate increase in transcription of many genes during cellular aging. This study provides evidence that loss of transcriptional repressor activity contributes to the up-regulation of cyclin D1, and possibly additional age-regulated genes, during cellular senescence.	Univ Calgary, So Alberta Canc Res Ctr, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Incyte Genom, Beverly, MA 01915 USA	University of Calgary; Incyte	Riabowol, KT (corresponding author), Univ Calgary, So Alberta Canc Res Ctr, Dept Biochem & Mol Biol, Canc Biol Res Grp, Hertiage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	karl@ucalgary.ca		Berardi, Philip/0000-0002-2302-6145				ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; ATADJA PW, 1994, MOL CELL BIOL, V14, P4991, DOI 10.1128/MCB.14.7.4991; BURGER C, 1994, J CELL SCI, V107, P2047; Cristofalo VJ, 1998, CRIT REV EUKAR GENE, V8, P43, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.30; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FUKAMI J, 1995, MECH AGEING DEV, V81, P139, DOI 10.1016/0047-6374(95)93703-6; Fukami-Kobayashi J, 1998, EXP CELL RES, V241, P435, DOI 10.1006/excr.1998.4079; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSMANN ME, 1994, MOL ENDOCRINOL, V8, P448, DOI 10.1210/me.8.4.448; HAN EKH, 1995, ONCOGENE, V10, P953; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hara E, 1996, MOL CELL BIOL, V16, P859; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HERBER, 1994, ONCOGENE, V9, P2105; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOERMAN EJ, 1993, EXP GERONTOL, V28, P361, DOI 10.1016/0531-5565(93)90063-J; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Parr E, 1998, CURR SCI INDIA, V74, P878; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SMITH JR, 1989, GENOME, V31, P386, DOI 10.1139/g89-058; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; vanGrunsven LA, 1996, ONCOGENE, V12, P855; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; West MD, 1996, EXP GERONTOL, V31, P175, DOI 10.1016/0531-5565(95)02013-6; WILHIDE CC, 1995, BLOOD, V86, P294, DOI 10.1182/blood.V86.1.294.bloodjournal861294; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; YAN GZ, 1995, J NEUROSCI, V15, P6200	47	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7510	7519		10.1074/jbc.M210864200	http://dx.doi.org/10.1074/jbc.M210864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12464605	hybrid			2022-12-25	WOS:000181195100113
J	Kurepa, J; Walker, JM; Smalle, J; Gosink, MM; Davis, SJ; Durham, TL; Sung, DY; Vierstra, RD				Kurepa, J; Walker, JM; Smalle, J; Gosink, MM; Davis, SJ; Durham, TL; Sung, DY; Vierstra, RD			The small ubiquitin-like modifier (SUMO) protein modification system in Arabidopsis - Accumulation of SUMO1 and -2 conjugates is increased by stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; TRANSCRIPTION FACTOR; IN-VIVO; NUCLEAR-BODIES; ENZYME; YEAST; GENE; FAMILY; THERMOTOLERANCE; EXPRESSION	Small ubiquitin-like modifier (SUMO) is a member of the superfamily of ubiquitin-like polypeptides that become covalently attached to various intracellular target proteins as a way to alter their function, location, and/or half-life. Here we show that the SUMO conjugation system operates in plants through a characterization of the Arabidopsis SUMO pathway. An eight-gene family encoding the SUMO tag was discovered as were genes encoding the various enzymes required for SUMO processing, ligation, and release. A diverse array of conjugates could be detected, some of which appear to be SUMO isoform-specific. The levels of SUMO1 and -2 conjugates but not SUMO3 conjugates increased substantially following exposure of seedlings to stress conditions, including heat shock, H2O2, ethanol, and the amino acid analog canavanine. The heat-induced accumulation could be detected within 2 min from the start of a temperature upshift, suggesting that SUMO1/2 conjugation is one of the early plant responses to heat stress. Overexpression of SUMO2 enhanced both the steady state levels of SUMO2 conjugates under normal growth conditions and the subsequent heat shock-induced accumulation. This accumulation was dampened in an Arabidopsis line engineered for increased thermotolerance by overexpressing the cytosolic isoform of the HSP70 chaperonin. Taken together, the SUMO conjugation system appears to be a complex and functionally heterogeneous pathway for protein modification in plants with initial data indicating that one important function may be in stress protection and/or repair.	Univ Wisconsin, Dept Hort, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Florida, Inst Food & Agr Sci, Dept Environm Hort, Gainesville, FL 32611 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; State University System of Florida; University of Florida	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Hort, 1575 Linden Dr, Madison, WI 53706 USA.			Durham Brooks, Tessa/0000-0002-8699-6253; Gosink, Mark/0000-0003-3009-3941				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Azuma Y, 2001, FASEB J, V15, P1825, DOI 10.1096/fj.00-0818fje; Bates PW, 1999, PLANT J, V20, P183, DOI 10.1046/j.1365-313x.1999.00590.x; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Callis J, 2000, CURR OPIN PLANT BIOL, V3, P381, DOI 10.1016/S1369-5266(00)00100-X; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Doelling JH, 2002, J BIOL CHEM, V277, P33105, DOI 10.1074/jbc.M204630200; Eloranta JJ, 2002, J BIOL CHEM, V277, P30798, DOI 10.1074/jbc.M202780200; Feder ME, 1996, J EXP BIOL, V199, P1837; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Gagne JM, 2002, P NATL ACAD SCI USA, V99, P11519, DOI 10.1073/pnas.162339999; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Hanania U, 1999, PLANT J, V19, P533, DOI 10.1046/j.1365-313X.1999.00547.x; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hong SW, 2001, PLANT J, V27, P25, DOI 10.1046/j.1365-313x.2001.01066.x; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Howe K, 1998, GENOMICS, V47, P92, DOI 10.1006/geno.1997.5091; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lynn K, 1999, DEVELOPMENT, V126, P469; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Never L, 1996, CELL STRESS CHAPERON, V1, P215, DOI 10.1379/1466-1268(1996)001<0215:THWCAP>2.3.CO;2; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Queitsch C, 2000, PLANT CELL, V12, P479, DOI 10.1105/tpc.12.4.479; Rao-Naik C, 1998, J BIOL CHEM, V273, P34976, DOI 10.1074/jbc.273.52.34976; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rose A, 2001, P NATL ACAD SCI USA, V98, P15377, DOI 10.1073/pnas.261459698; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; SCHIRMER EC, 1994, PLANT CELL, V6, P1899, DOI 10.1105/tpc.6.12.1899; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Smalle J, 2002, PLANT CELL, V14, P17, DOI 10.1105/tpc.010381; Sung DY, 2001, PLANT PHYSIOL, V126, P789, DOI 10.1104/pp.126.2.789; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Vierstra RD, 1999, PLANT MOL BIOL, V41, P435, DOI 10.1023/A:1006323317890; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; WETTERN M, 1990, EUR J BIOCHEM, V191, P571, DOI 10.1111/j.1432-1033.1990.tb19159.x	60	342	378	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6862	6872		10.1074/jbc.M209694200	http://dx.doi.org/10.1074/jbc.M209694200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482876	hybrid			2022-12-25	WOS:000181195100031
J	Olsen, O; Bredt, DS				Olsen, O; Bredt, DS			Functional analysis of the nucleotide binding domain of membrane-associated guanylate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-SUPPRESSOR; SH3 DOMAIN; INTRAMOLECULAR INTERACTION; POSTSYNAPTIC DENSITY; SCAFFOLDING PROTEINS; TIGHT JUNCTIONS; MAGUK FAMILY; PDZ DOMAIN; PSD-95; SRC	Membrane-associated guanylate kinases (MAGUKs) regulate cellular adhesion and signal transduction at sites of cell-cell contact. MAGUKs are composed of modular protein-protein interaction motifs including L27, PDZ, Src homology (SH) 3, and guanylate kinase domains that aggregate adhesion molecules and receptors. Genetic analyses reveal that lethal mutations of MAGUKs often occur in the guanylate kinase domain, indicating a critical role for this domain. Here, we explored whether GMP binding to the guanylate kinase domain regulates MAGUK function. Surprisingly, and in contrast to previously published studies, we failed to detect GMP binding to the MAGUKs postsynaptic density-95 (PSD-95) and CASK. Two amino acid residues in the GMP. binding pocket that differ between MAGUKs and authentic guanylate kinase explain this lack of binding, as swapping these residues largely prevent GMP binding to yeast guanylate kinase. Conversely, these mutations restore GMP binding but not catalytic activity to PSD-95. Protein ligands for the PSD-95 guanylate kinase domain, guanylate kinase-associated protein (GKAP) and MAP1A, appear not to interact with the canonical GMP binding pocket, and GMP binding does not influence the intramolecular SH3/guanylate kinase (GK) interaction within PSD-95. These studies indicate that MAGUK proteins have lost affinity for GMP but may have retained the guanylate kinase structure to accommodate a related regulatory ligand.	Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.	bredt@itsa.ucsf.edu						Agarwal K C, 1978, Methods Enzymol, V51, P483; Brenman JE, 1998, J NEUROSCI, V18, P8805; Brenman JE, 1996, J NEUROSCI, V16, P7407; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hoskins R, 1996, DEVELOPMENT, V122, P97; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; Li YH, 2002, J BIOL CHEM, V277, P4159, DOI 10.1074/jbc.M110792200; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Mayer BJ, 2001, J CELL SCI, V114, P1253; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	43	30	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6873	6878		10.1074/jbc.M210165200	http://dx.doi.org/10.1074/jbc.M210165200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482754	hybrid			2022-12-25	WOS:000181195100032
J	Daly, NL; Clark, RJ; Craik, DJ				Daly, NL; Clark, RJ; Craik, DJ			Disulfide folding pathways of cystine knot proteins - Tying the knot within the circular backbone of the cyclotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN COUPLING-CONSTANTS; TORSION ANGLE DYNAMICS; TRYPSIN-INHIBITOR; PLANT CYCLOTIDES; MACROCYCLIC PEPTIDES; STRUCTURAL MOTIF; BETA-SHEET; NMR; SQUASH; POLYPEPTIDE	The plant cyclotides are a fascinating family of circular proteins that contain a cyclic cystine knot motif. The knotted topology and cyclic nature of the cyclotides pose interesting questions about folding mechanisms and how the knotted arrangement of disulfide bonds is formed. In the current study we have examined the oxidative refolding and reductive unfolding of the prototypic cyclotide, kalata B1. A stable two-disulfide intermediate accumulated during oxidative refolding but not in reductive unfolding. Mass spectrometry and NMR spectroscopy were used to show that the intermediate contained a native-like structure with two native disulfide bonds topologically similar to the intermediate isolated for the related cystine knot protein EETI-II (LeNguyen, D., Heitz, A., Chiche, L., El Hajji, M., and Castro B. (1993) Protein Sci. 2, 165-174). However, the folding intermediate observed for kalata B1 is not the immediate precursor of the three-disulfide native peptide and does not accumulate in the reductive unfolding process, in contrast to the intermediate observed for EETI-II. These alternative pathways of linear and cyclic cystine knot proteins appear to be related to the constraints imposed by the cyclic backbone of kalata B1 and the different ring size of the cystine knot. The three-dimensional structure of a synthetic version of the two-disulfide intermediate of kalata B1 in which Ala residues replace the reduced Cys residues provides a structural insight into why the two-disulfide intermediate is a kinetic trap on the folding pathway.	Univ Queensland, Australian Res Council, Ctr Funct & Appl Genom, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland		d.craik@imb.uq.edu.au	Daly, Norelle L/D-4302-2013; Craik, David/B-1695-2010; Clark, Richard J/G-8848-2012	Daly, Norelle L/0000-0002-4697-6602; Craik, David/0000-0003-0007-6796; Clark, Richard J/0000-0002-6807-5426				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODE W, 1989, FEBS LETT, V242, P285, DOI 10.1016/0014-5793(89)80486-7; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Chang JY, 2001, J BIOL CHEM, V276, P4845, DOI 10.1074/jbc.M005160200; Chang JY, 2000, J BIOL CHEM, V275, P8287, DOI 10.1074/jbc.275.12.8287; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P1809, DOI 10.1016/S0041-0101(01)00129-5; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Craik DJ, 2001, LETT PEPT SCI, V8, P119, DOI 10.1007/BF02446507; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Daly NL, 2000, J BIOL CHEM, V275, P19068, DOI 10.1074/jbc.M000450200; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276; Darling RJ, 2001, BIOCHEMISTRY-US, V40, P577, DOI 10.1021/bi002046a; Derua R, 1996, BIOCHEM BIOPH RES CO, V228, P632, DOI 10.1006/bbrc.1996.1708; English BP, 2002, J AM CHEM SOC, V124, P4995, DOI 10.1021/ja012634r; FAVEL A, 1989, INT J PEPT PROT RES, V33, P202; Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200; GRAN L, 1973, ACTA PHARMACOL TOX, V33, P400; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; HEITZ A, 1989, BIOCHEMISTRY-US, V28, P2392, DOI 10.1021/bi00432a009; Heitz A, 2001, BIOCHEMISTRY-US, V40, P7973, DOI 10.1021/bi0106639; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LENGUYEN D, 1993, PROTEIN SCI, V2, P165; LI YJ, 1995, NAT STRUCT BIOL, V2, P489, DOI 10.1038/nsb0695-489; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; ROSENGREN KJ, 2002, J BIOL CHEM     1212, DOI DOI 10.1074/JBCM211147200; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; Skjeldal L, 2002, ARCH BIOCHEM BIOPHYS, V399, P142, DOI 10.1006/abbi.2002.2769; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Tam James P., 2001, P215; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; van den Berg P, 1999, EMBO J, V18, P4794, DOI 10.1093/emboj/18.17.4794; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WIECZOREK M, 1985, BIOCHEM BIOPH RES CO, V126, P646, DOI 10.1016/0006-291X(85)90233-5; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002; WUTHRICK K, 1986, NMR PROTEINS NUCL AC	52	110	113	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6314	6322		10.1074/jbc.M210492200	http://dx.doi.org/10.1074/jbc.M210492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482862	hybrid			2022-12-25	WOS:000181129400104
J	Chandrasekar, B; Melby, PC; Sarau, HM; Raveendran, M; Perla, RP; Marelli-Berg, FM; Dulin, NO; Singh, IS				Chandrasekar, B; Melby, PC; Sarau, HM; Raveendran, M; Perla, RP; Marelli-Berg, FM; Dulin, NO; Singh, IS			Chemokine-cytokine cross-talk - The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; POLY(ADP-RIBOSE) POLYMERASE-1; INTERLEUKIN-8 RECEPTORS; MYOCARDIAL-ISCHEMIA; KINASE COMPLEX; GRO-ALPHA; INDUCED TRANSCRIPTION; REPERFUSION INJURY; DEFICIENT MICE	It is well established that cytokines can induce the production of chemokines, but the role of chemokines in the regulation of cytokine expression has not been fully investigated. Exposure of rat cardiac-derived endothelial cells (CDEC) to lipopolysaccharide-induced CXC chemokine (LIX), and to a lesser extent to KC and MIP-2, activated NF-kappaB and induced kappaB-driven promoter activity. LIX did not activate Oct-1. LIX-induced interleukin-1beta and tumor necrosis factor-alpha promoter activity, and up-regulated mRNA expression. Increased transcription and mRNA stability both contributed to cytokine expression. LIX-mediated cytokine gene transcription was inhibited by interleukin-10. Transient overexpression of kinase-deficient NF-kappaB-inducing kinase (NIK) and IkappaB kinase (IKK), and dominant negative IkappaB significantly inhibited LIX-mediated NF-kappaB activation in rat CDEC. Inhibition of Gi protein-coupled signal transduction, poly(ADP-ribose) polymerase, phosphatidylinositol 3-kinase, and the 26 S proteasome significantly inhibited LIX-mediated NF-kappaB activation and cytokine gene transcription. Blocking CXCR2 attenuated LIX-mediated kappaB activation and kappaB-driven promoter activity in rat CDEC that express both CXCR1 and -2, and abrogated its activation in mouse CDEC that express only CXCR2. These results indicate that LIX activates NF-kappaB and induces kappaB-responsive proinflammatory cytokines via either CXCR1 or CXCR2, and involved phosphatidylinositol 3-kinase, NIK, IKK, and IkappaB. Thus, in addition to attracting and activating neutrophils, the ELR+ CXC chemokines amplify the inflammatory cascade, stimulating local production of cytokines that have negative inotropic and proapoptotic effects.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; GlaxoSmithKline Beecham, Ctr Excellence Drug Discovery, King Of Prussia, PA 19406 USA; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Immunol, London W12 0NN, England; Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	University of Texas System; University of Texas Health San Antonio; GlaxoSmithKline; Imperial College London; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Maryland; University of Maryland Baltimore	Chandrasekar, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chandraseka@uthscsa.edu			NHLBI NIH HHS [HL68020] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; BOYLE MP, 1993, CIRCULATION, V88, P2872, DOI 10.1161/01.CIR.88.6.2872; Chandrasekar B, 2001, CIRCULATION, V103, P2296; Chandrasekar B, 1999, CIRCULATION, V99, P427, DOI 10.1161/01.CIR.99.3.427; Clark RA, 2002, J BIOL CHEM, V277, P32369, DOI 10.1074/jbc.M205269200; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Damaj BB, 1996, J BIOL CHEM, V271, P20540, DOI 10.1074/jbc.271.34.20540; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; DIGLIO CA, 1988, TISSUE CELL, V20, P477, DOI 10.1016/0040-8166(88)90051-1; Dulin NO, 2001, J BIOL CHEM, V276, P20827, DOI 10.1074/jbc.C100195200; Dunstan CAN, 1996, J BIOL CHEM, V271, P32770, DOI 10.1074/jbc.271.51.32770; ENGLER RL, 1983, AM J PATHOL, V111, P98; ENTMAN ML, 1994, CARDIOVASC RES, V28, P1301, DOI 10.1093/cvr/28.9.1301; ENTMAN ML, 1992, J CLIN INVEST, V90, P1335, DOI 10.1172/JCI115999; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Frangogiannis N G, 1996, EXS, V76, P263; Frangogiannis NG, 1998, J MOL CELL CARDIOL, V30, P2567, DOI 10.1006/jmcc.1998.0829; Fridovich I, 1998, J EXP BIOL, V201, P1203; Gobl AE, 1997, BBA-BIOMEMBRANES, V1326, P171, DOI 10.1016/S0005-2736(97)00065-5; GODAMBE SA, 1994, J IMMUNOL, V153, P143; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hall DA, 1999, BRIT J PHARMACOL, V126, P810, DOI 10.1038/sj.bjp.0702329; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kelly RA, 1997, CIRCULATION, V95, P778; Kuhnle S, 1999, BIOCHEM BIOPH RES CO, V263, P433, DOI 10.1006/bbrc.1999.1393; KUKIELKA GL, 1995, J CLIN INVEST, V95, P89, DOI 10.1172/JCI117680; LE JM, 1987, LAB INVEST, V56, P234; Liaudet L, 2002, AM J RESP CRIT CARE, V165, P372, DOI 10.1164/ajrccm.165.3.2106050; Lukacs N W, 1999, Chem Immunol, V72, P102, DOI 10.1159/000058729; Maekawa T, 2000, INTERNAL MED, V39, P90, DOI 10.2169/internalmedicine.39.90; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Murray DR, 2000, CIRCULATION, V101, P2338, DOI 10.1161/01.CIR.101.20.2338; Nguyen D, 2001, DEV BRAIN RES, V128, P77, DOI 10.1016/S0165-3806(01)00128-6; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rovai LE, 1998, J LEUKOCYTE BIOL, V64, P494, DOI 10.1002/jlb.64.4.494; Sarau HM, 2001, PROG R RES, V31, P293; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Simonini A, 2000, CIRCULATION, V101, P1519, DOI 10.1161/01.CIR.101.13.1519; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Williams FM, 1996, PHARMACOL THERAPEUT, V72, P1, DOI 10.1016/S0163-7258(96)00090-3; Wolf M, 1998, EUR J IMMUNOL, V28, P164, DOI 10.1002/(SICI)1521-4141(199801)28:01<164::AID-IMMU164>3.0.CO;2-S; Yang M, 2001, J IMMUNOL, V166, P6885, DOI 10.4049/jimmunol.166.11.6885; Ye RD, 2001, J LEUKOCYTE BIOL, V70, P839; Youker KA, 1997, ANN NY ACAD SCI, V832, P243, DOI 10.1111/j.1749-6632.1997.tb46252.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	66	83	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4675	4686		10.1074/jbc.M207006200	http://dx.doi.org/10.1074/jbc.M207006200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468547	hybrid			2022-12-25	WOS:000180968900043
J	Nagasako, T; Sugiyama, T; Mizushima, T; Miura, Y; Kato, M; Asaka, M				Nagasako, T; Sugiyama, T; Mizushima, T; Miura, Y; Kato, M; Asaka, M			Up-regulated smad5 mediates apoptosis of gastric epithelial cells induced by Helicobacter pylori infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; FACTOR-KAPPA-B; PATHOGENICITY ISLAND; VIRULENCE; PROTEINS; CYTOTOXIN; MEMBRANE; GENE; CAG	The gastric pathogen Helicobacter pylori activates epithelial cell signaling pathways, and its infection induces changes in the expression of several genes in infected human gastric tissues. Recent studies have indicated that the ability of H. pylori to regulate epithelial cell responses depends on the presence of an intact cag pathogenicity island (cagPAI). We investigated altered mRNA expression of gastric epithelial cells after infection with H. pylori, both cagPAI-positive and cagPAI-negative strains, by cDNA microarray, reverse transcription PCR, and Northern blot analysis. Our results indicated that cagPAI-positive H. pylori strains (ATCC 43504 and clinical isolated strains) significantly activated Smad5 mRNA expression of human gastric epithelial cells (AGS, KATOIII, MKN28, and MEN45). We further examined whether the up-regulated Smad5 was related to apoptosis of gastric epithelial cells induced by H. pylori. Smad5 RNA interference completely inhibited H. pylori-induced apoptosis. These results suggest that Smad5 is up-regulated in gastric epithelial cells through the presence of cagPAI of H. pylori and that Smad5 mediates apoptosis of gastric epithelial cells induced by H. pylori infection.	Hokkaido Univ, Grad Sch Med, Dept Gastroenterol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University	Sugiyama, T (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Gastroenterol, Kita Ku, Kita 15,Nishi 17, Sapporo, Hokkaido 0608638, Japan.		Kato, Mototsugu/A-6736-2012; Asaka, Masahiro/A-5948-2012					Ando T, 2002, CANCER RES, V62, P2385; Bruno E, 1998, BLOOD, V91, P1917, DOI 10.1182/blood.V91.6.1917.1917_1917_1923; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hennig EE, 2001, BIOCHEM BIOPH RES CO, V289, P103, DOI 10.1006/bbrc.2001.5950; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Howe JR, 2002, AM J HUM GENET, V70, P1357, DOI 10.1086/340258; Kawahara T, 2001, INFECT IMMUN, V69, P4382, DOI 10.1128/IAI.69.7.4382-4389.2001; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; Maeda S, 2002, GUT, V50, P771, DOI 10.1136/gut.50.6.771; Maeda S, 1999, GUT, V44, P336, DOI 10.1136/gut.44.3.336; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Mizushima T, 2002, HELICOBACTER, V7, P22, DOI 10.1046/j.1523-5378.2002.00052.x; Mizushima T, 2001, J CLIN MICROBIOL, V39, P2463, DOI 10.1128/JCM.39.7.2463-2465.2001; Morbiato L, 2001, FEBS LETT, V508, P479, DOI 10.1016/S0014-5793(01)03133-7; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; Ogura K, 1998, DIGEST DIS SCI, V43, P2738, DOI 10.1023/A:1026671815512; Satin B, 2000, J EXP MED, V191, P1467, DOI 10.1084/jem.191.9.1467; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Sharma SA, 1998, J IMMUNOL, V160, P2401; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Taketo M M, 2000, Hum Cell, V13, P85; Wagner S, 1997, GASTROENTEROLOGY, V113, P1836, DOI 10.1016/S0016-5085(97)70003-9; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yamaoka Y, 2002, GASTROENTEROLOGY, V123, P414, DOI 10.1053/gast.2002.34781; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	31	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4821	4825		10.1074/jbc.M211143200	http://dx.doi.org/10.1074/jbc.M211143200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473652	hybrid			2022-12-25	WOS:000180968900062
J	Tatton, L; Morley, GM; Chopra, R; Khwaja, A				Tatton, L; Morley, GM; Chopra, R; Khwaja, A			The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL-FACTOR; BASOPHILIC LEUKEMIA-CELLS; RECEPTOR C-KIT; FAMILY KINASES; HEMATOPOIETIC-CELLS; HUMAN MASTOCYTOSIS; MAST-CELLS; GROWTH; MUTATIONS; ACTIVATION	4-Amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1) was identified as an Src-selective tyrosine kinase inhibitor and has been used extensively to investigate signaling pathways involving Src kinases, including events downstream of the stem cell factor (SCF) receptor c-Kit. While investigating the role of Src kinases in SCF signaling, we found that PP1 completely abrogated the proliferation of M07e cells in response to SCF. PP1 inhibited SCF-induced c-Kit autophosphorylation in intact cells and blocked the activation of mitogen-activated protein kinase and Akt. In vitro kinase assays using immunoprecipitated c-Kit confirmed direct inhibition by PPL SCF-induced c-Kit phosphorylation was also inhibited by the related inhibitor 4-amino-5(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP2) and by STI571 but not by the Src inhibitor SU6656. PP1 inhibited the activity of mutant constitutively active forms of c-Kit (D814V and D814Y) found in mast cell disorders, and triggered apoptosis in the rat basophilic leukemia cell line RBL-2113 that expresses mutant c-Kit. In addition, PPI (and PP2) inhibited the in vitro kinase activity and autophosphorylation in whole cells of p210 Bcr-Abl. PP1 reduced the constitutive activation of signal transducer and activators of transcription 5 and mitogen-activated protein kinase and triggered apoptosis in FDCP1 cells expressing Bcr-Abl. These results have implications for the use of PPI in investigating intracellular signaling and suggest that PPI or related compounds may be useful in the treatment of malignant diseases associated with dysregulated c-Kit or Abl tyrosine kinase activity.	UCL Royal Free & Univ Coll, Sch Med, Dept Haematol, London WC1E 6HX, England; Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Christie Hosp, Dept Expt Haematol, Manchester M20 4BX, Lancs, England; Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England	University of London; University College London; UCL Medical School; Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Khwaja, A (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England.	a.khwaja@ucl.ac.uk	Khwaja, Asim/C-1509-2008					Abassi YA, 2000, DEV BIOL, V218, P206, DOI 10.1006/dbio.1999.9582; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Boissan M, 2000, J LEUKOCYTE BIOL, V67, P135, DOI 10.1002/jlb.67.2.135; Bondzi C, 2000, CELL GROWTH DIFFER, V11, P305; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; BRANFORD S, 2002, CANC CELL, V99, P3472; Broudy VC, 1999, BLOOD, V94, P1979; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Carlomagno F, 2002, CANCER RES, V62, P1077; Dahl ME, 2000, GENES CELLS, V5, P143, DOI 10.1046/j.1365-2443.2000.00312.x; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hines SJ, 1999, BREAST CANCER RES TR, V58, P1, DOI 10.1023/A:1006272527435; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Kilic T, 2000, CANCER RES, V60, P5143; Krystal GW, 1996, CANCER RES, V56, P370; Krystal GW, 1998, CANCER RES, V58, P4660; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Ma YS, 2000, J INVEST DERMATOL, V114, P392, DOI 10.1046/j.1523-1747.2000.00888.x; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mocsai A, 1999, J IMMUNOL, V162, P1120; MORITA Y, 1981, J IMMUNOL, V127, P1339; Mou S, 1999, BIOCHEM J, V342, P163, DOI 10.1042/0264-6021:3420163; Nagata H, 1997, INT ARCH ALLERGY IMM, V113, P184, DOI 10.1159/000237541; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; Price DJ, 1999, BIOCHEM BIOPH RES CO, V259, P611, DOI 10.1006/bbrc.1999.0840; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; Valent P, 1999, INT ARCH ALLERGY IMM, V120, P1, DOI 10.1159/000024214; Waltenberger J, 1999, CIRC RES, V85, P12; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505	42	155	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4847	4853		10.1074/jbc.M209321200	http://dx.doi.org/10.1074/jbc.M209321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12475982	hybrid			2022-12-25	WOS:000180968900066
J	Hawke, TJ; Jiang, N; Garry, DJ				Hawke, TJ; Jiang, N; Garry, DJ			Absence of p21(CIP) rescues myogenic progenitor cell proliferative and regenerative capacity in Foxk1 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTORS; MUSCLE SATELLITE CELLS; WINGED HELIX PROTEINS; KINASE INHIBITOR P21; STEM-CELLS; SKELETAL-MUSCLE; EXPRESSION; GROWTH; BETA; HEAD	Foxk1 is a forkhead/winged helix transcription factor that is restricted to myogenic progenitor cells in adult skeletal muscle. Mice lacking Foxk1 (Foxk1-/-) display growth retardation and a severe impairment in skeletal muscle regeneration following injury. Here we show that myogenic progenitor cells from Foxk1-/- mice are reduced in number and have perturbed cell cycle progression (G(0)/G(1) arrest). Molecular analysis of Foxk1-/-myogenic progenitor cells revealed increased expression of the cyclin-dependent kinase inhibitor, p21(CIP), independent of changes in other cell cycle inhibitors, including p53. Combinatorial mating of Foxk1-/- mice with p21(CIP)-/- mice, to generate double mutant progeny, resulted in a complete restoration of the growth deficit, skeletal muscle regeneration, myogenic progenitor cell number, and cell cycle progression that characterized the Foxk1-/- mice. We conclude that Foxk1 is essential for regulating cell cycle progression in the myogenic progenitor cell and that the cyclin-dependent kinase inhibitor, p21(CIP), may be a downstream target of Foxk1.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garry, DJ (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Hawke, Thomas/0000-0003-4974-4820	NIAMS NIH HHS [AR47850] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047850] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Bockhold KJ, 1998, MUSCLE NERVE, V21, P173, DOI 10.1002/(SICI)1097-4598(199802)21:2<173::AID-MUS4>3.0.CO;2-8; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; FELDMAN JL, 1992, DEV BIOL, V153, P217, DOI 10.1016/0012-1606(92)90107-R; Freyaldenhoven BS, 1997, CANCER RES, V57, P123; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Garry DJ, 2000, P NATL ACAD SCI USA, V97, P5416, DOI 10.1073/pnas.100501197; Garry DJ, 1997, DEV BIOL, V188, P280, DOI 10.1006/dbio.1997.8657; Grounds MD, 2002, J HISTOCHEM CYTOCHEM, V50, P589, DOI 10.1177/002215540205000501; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Kaestner KH, 2000, GENE DEV, V14, P142; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Miller JB, 1999, CURR TOP DEV BIOL, V43, P191; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Partridge T, 2000, NEUROL SCI, V21, pS939; Pavlath Grace K., 1996, P307; ROSENBLATT JD, 1995, IN VITRO CELL DEV-AN, V31, P773; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Yang Q, 1997, MOL CELL BIOL, V17, P5236, DOI 10.1128/MCB.17.9.5236; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	37	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4015	4020		10.1074/jbc.M209200200	http://dx.doi.org/10.1074/jbc.M209200200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446708	hybrid			2022-12-25	WOS:000180869700064
J	Liao, WX; Moore, RK; Otsuka, F; Shimasaki, S				Liao, WX; Moore, RK; Otsuka, F; Shimasaki, S			Effect of intracellular interactions on the processing and secretion of bone morphogenetic protean-15 (BMP-15) and growth and differentiation factor-9 - Implication of the aberrant ovarian phentype of BMP-15 mutant sheep	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNITS; VG1 PROTEIN; GENE; EXPRESSION; INHIBIN; GDF-9; FSH; INFERTILITY; MUTATIONS	Bone morphogenetic protein-15 (BMP-15) and growth and differentiation factor-9 (GDF-9) are members of the transforming growth factor-beta superfamily. Both molecules are closely related in their primary structures and share a nearly identical spatiotemporal expression pattern in the oocyte during folliculogenesis in mammals. Here we have established a series of cell lines, which express recombinant BMP-15, GDF-9, or both, and investigated whether they form homodimers and/or heterodimers. We demonstrate the first evidence that both BMP-15 and GDF-9 can form non-covalent homodimers when expressed individually, while when both are coexpressed BMP-15/GDF-9 heterodimers are produced. Interestingly, when GDF-9 and BMP-15 are co-expressed the processing of both proproteins are significantly impaired as compared with that of the singly expressed proproteins, suggesting that the proprotein heterodimer is less susceptible to proteolytic cleavage than the individual homodimers. Since BMP-15 mutant sheep, called Inverdale, exhibit severe defects in ovarian function we have also established stable transformants expressing the mutant BMW-15 (InvBMP-15) alone or together with GDF-9. Although InvBMP-15 was previously predicted to be unable to form homodimers, we show here that it does form non-covalent dimers; however, the processing efficiency of InvBMP-15 proprotein is significantly lower than wild-type BMW-15. Surprisingly, when GDF-9 is co-expressed, the processing and secretion of InvBMP-15 is abolished, and the processing of GDF-9 is also severely impaired, suggesting that the heterodimers of InvBMP-15/GDF-9 proproteins are not susceptible to proteolytic cleavage and thus degrade in the cells. Based on these findings we propose a novel hypothesis that a decrease in GDF-9 secretion may be involved in causing infertility in homozygous Inverdale ewes.	Univ Calif San Diego, Sch Med, Dept Reprod Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Shimasaki, S (corresponding author), Univ Calif San Diego, Sch Med, Dept Reprod Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sshimasaki@ucsd.edu			NICHD NIH HHS [U54HD12303, R01 HD41494, F32 HD41320] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD012303, R01HD041494] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD041320] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALY DL, 1993, ENDOCRINOLOGY, V132, P2099, DOI 10.1210/en.132.5.2099; Bodensteiner KJ, 2000, BIOL REPROD, V62, P1479, DOI 10.1095/biolreprod62.6.1479; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; Davis G. H., 2001, Proceedings of the Fourteenth Conference of the Association for the Advancement of Animal Breeding and Genetics, Queenstown, New Zealand, 30 July-2 August 2001, P175; DAVIS GH, 1992, BIOL REPROD, V46, P636, DOI 10.1095/biolreprod46.4.636; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Galloway SM, 2002, MOL CELL ENDOCRINOL, V191, P15, DOI 10.1016/S0303-7207(02)00047-3; Hayashi M, 1999, ENDOCRINOLOGY, V140, P1236, DOI 10.1210/en.140.3.1236; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Israel DI, 1992, GROWTH FACTORS, V7, P139, DOI 10.3109/08977199209046403; Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229; Laitinen M, 1998, MECH DEVELOP, V78, P135, DOI 10.1016/S0925-4773(98)00161-0; LAMBERTMESSERLIAN GM, 1994, J CLIN ENDOCR METAB, V79, P45, DOI 10.1210/jc.79.1.45; LING N, 1986, BIOCHEM BIOPH RES CO, V138, P1129, DOI 10.1016/S0006-291X(86)80400-4; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; NAKAMURA T, 1992, J BIOL CHEM, V267, P16385; Otsuka F, 2000, J BIOL CHEM, V275, P39523, DOI 10.1074/jbc.M007428200; Otsuka F, 2001, J BIOL CHEM, V276, P11387, DOI 10.1074/jbc.M010043200; Otsuka F, 2002, P NATL ACAD SCI USA, V99, P8060, DOI 10.1073/pnas.122066899; SHACKELL GH, 1993, BIOL REPROD, V48, P1150, DOI 10.1095/biolreprod48.5.1150; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854	31	121	135	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3713	3719		10.1074/jbc.M210598200	http://dx.doi.org/10.1074/jbc.M210598200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446716	hybrid			2022-12-25	WOS:000180869700026
J	McCulloch, SD; Gu, LY; Li, GM				McCulloch, SD; Gu, LY; Li, GM			Bi-directional processing of DNA loops by mismatch repair-dependent and -independent pathways in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-DIRECTED REPAIR; SMALL HETEROLOGOUS SEQUENCES; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; HETERODUPLEX DNA; MICROSATELLITE INSTABILITY; REPLICATION FIDELITY; NUCLEAR EXTRACTS; TUMOR-CELLS; HETERODIMER	Previous work has shown that small DNA loop heterologies are repaired not only through the mismatch repair (MMR) pathway but also via an MMR-independent pathway in human cells. However, how DNA loop repair is partitioned between these pathways and how the MMR-independent repair is processed are not clear. Using a novel construct that completely and specifically inhibits MMR in HeLa extracts, we demonstrate here that although MMR is capable of bi-directionally processing DNA loops of 2, 4, 5, 8, 10, or 12 nucleotides in length, the repair activity decreases with the increase of the loop size. Evidence is presented that the largest loop that the MMR system can process is 16 nucleotides. We also show that strand-specific MMR-independent loop repair occurs for all looped substrates tested and rigorously demonstrate that this repair is bi-directional. Analysis of repair intermediates generated by the MMR-independent pathway revealed that although the processing of looped substrates with a strand break 5' to the heterology occurred similarly to MMR (i.e. excision is conducted by exonucleases from the pre-existing strand break to the heterology), the processing of the heterology in substrates with a 3' strand break is consistent with the involvement of endonucleases.	Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Li, GM (corresponding author), Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, 800 Rose St, Lexington, KY 40536 USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NCI NIH HHS [CA85377, CA72956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072956, R01CA085377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; Corrette-Bennett SE, 2001, NUCLEIC ACIDS RES, V29, P4134, DOI 10.1093/nar/29.20.4134; Corrette-Bennett SE, 1999, J BIOL CHEM, V274, P17605, DOI 10.1074/jbc.274.25.17605; DOHET C, 1987, MOL GEN GENET, V206, P181, DOI 10.1007/BF00326556; DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714; FANG WH, 1993, COLD SPRING HARB SYM, V58, P597, DOI 10.1101/SQB.1993.058.01.066; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P317; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gu LY, 2002, ONCOGENE, V21, P5758, DOI 10.1038/sj.onc.1205695; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LEARN BA, 1989, J BACTERIOL, V171, P6473, DOI 10.1128/jb.171.12.6473-6481.1989; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Miret JJ, 1996, NUCLEIC ACIDS RES, V24, P721, DOI 10.1093/nar/24.4.721; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SU SS, 1988, J BIOL CHEM, V263, P6829; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Wierdl M, 1997, GENETICS, V146, P769; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; Wu JX, 1999, MOL CELL BIOL, V19, P8292	37	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3891	3896		10.1074/jbc.M210687200	http://dx.doi.org/10.1074/jbc.M210687200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458199	hybrid			2022-12-25	WOS:000180869700049
J	Kamihira, M; Oshiro, Y; Tuzi, S; Nosaka, AY; Saito, H; Naito, A				Kamihira, M; Oshiro, Y; Tuzi, S; Nosaka, AY; Saito, H; Naito, A			Effect of electrostatic interaction on fibril formation of human calcitonin as studied by high resolution solid state C-13 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE; CHEMICAL-SHIFTS; CONFORMATIONAL CHARACTERIZATION; SECONDARY STRUCTURE; PEPTIDES; FIBRILLOGENESIS; SPECTROSCOPY; TRANSITIONS; AMYLOIDOSIS; MECHANISM	Fibrillation of a human calcitonin mutant (hCT) at the position of Asp(15) (D15N-hCT) was examined to reveal the effect of the electrostatic interaction of Asp(15) with charged side chains. The secondary structures of fibrils and soluble monomers in the site-specific C-13-labeled D15N-hCTs were determined using C-13 cross-polarization magic angle spinning and dipolar decoupled magic angle spinning NMR approaches, sensitive to detect C-13 signals from the fibril and the soluble monomer, respectively. The local conformations and structures of D15-NhCT fibrils at pH 7.5 and 3.2 were found to be similar to each other and those of hCT at pH 3.3 and were interpreted as a mixture of antiparallel and parallel beta-sheets, whereas they were different from the hCT fibril at pH 7.5 whose structure is proposed to be antiparallel beta-sheets. Thus the negatively charged Asp5 in the hCT molecule turned out to play an essential role in determining the structures and orientations of the hCT molecules. Fibrillation kinetics of D15N-hCT was analyzed using a two-step autocatalytic reaction mechanism. The results indicated that the replacement of Asp(15) with Asn(15) did not reduce the rate constants of the fibril formation but rather increased the rate constants at neutral pH.	Yokohama Natl Univ, Grad Sch Engn, Hodogaya Ku, Yokohama, Kanagawa 2408501, Japan; Himeji Inst Technol, Dept Life Sci, Grad Sch Sci, Kamigori, Hyogo 6781297, Japan; Niigata Univ Management, Niigata 9591321, Japan	Yokohama National University; University of Hyogo; Niigata University	Naito, A (corresponding author), Yokohama Natl Univ, Grad Sch Engn, Hodogaya Ku, 79-5 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.	natio@ynu.ac.jp	Naito, Akira/AAC-7843-2019					ARVINTE T, 1993, J BIOL CHEM, V268, P6415; AUSTIN LA, 1981, NEW ENGL J MED, V304, P269, DOI 10.1056/NEJM198101293040505; BERGER G, 1988, VIRCHOWS ARCH A, V412, P543, DOI 10.1007/BF00844290; Branden C. I., 1999, INTRO PROTEIN STRUCT, P35; BYARD R W, 1990, Pediatric Pathology, V10, P581; COPP DH, 1962, ENDOCRINOLOGY, V70, P638, DOI 10.1210/endo-70-5-638; EPAND RM, 1990, EUR J BIOCHEM, V188, P633, DOI 10.1111/j.1432-1033.1990.tb15444.x; EPAND RM, 1983, BIOCHEMISTRY-US, V22, P5074, DOI 10.1021/bi00291a005; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; Hijirida DH, 1996, BIOPHYS J, V71, P3442, DOI 10.1016/S0006-3495(96)79539-5; ISHIDA M, 1990, MACROMOLECULES, V23, P88, DOI 10.1021/ma00203a017; JEON YH, 1998, 13 INT C MAGN RES BI, P61; Kamihira M, 2000, PROTEIN SCI, V9, P867, DOI 10.1110/ps.9.5.867; KANAORI K, 1995, BIOCHEMISTRY-US, V34, P12138, DOI 10.1021/bi00038a006; Kazantzis A, 2002, EUR J BIOCHEM, V269, P780, DOI 10.1046/j.0014-2956.2001.02689.x; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; KUMAR MA, 1963, LANCET, V2, P480; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; MOE GR, 1985, BIOCHEMISTRY-US, V24, P1971, DOI 10.1021/bi00329a026; Orpiszewski J, 1999, J MOL BIOL, V289, P413, DOI 10.1006/jmbi.1999.2768; SAITO H, 1984, MACROMOLECULES, V17, P1405, DOI 10.1021/ma00137a018; Saito H, 1998, ANNU REP NMR SPECTRO, V36, P79, DOI 10.1016/S0066-4103(08)60006-X; SAITO H, 1986, MAGN RESON CHEM, V24, P835, DOI 10.1002/mrc.1260241002; Saituo H., 1989, ANNU REP NMR SPECTRO, V21, P209, DOI DOI 10.1016/S0066-4103(08)60124-6; Sieber P, 1970, Helv Chim Acta, V53, P2135, DOI 10.1002/hlca.19700530826; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; TORCHIA DA, 1974, BIOPOLYMERS, V13, P97, DOI 10.1002/bip.1974.360130106; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133	32	32	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					2859	2865		10.1074/jbc.M205285200	http://dx.doi.org/10.1074/jbc.M205285200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446725	hybrid			2022-12-25	WOS:000180915000014
J	Kino, T; Chrousos, GP				Kino, T; Chrousos, GP			Tumor necrosis factor alpha receptor- and Fas-associated FLASH inhibit transcriptional activity of the glucocorticoid receptor by binding to and interfering with its interaction with p160 type nuclear receptor coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; INDUCED APOPTOSIS; PROTEIN-1 GRIP1; CELLS; ESTROGEN; SENSITIVITY; LYMPHOCYTES; BIOLOGY; GROWTH; TNF	Tumor necrosis factor alpha (TNFalpha) and its downstream transcription factor nuclear factor kappaB (NF-kappaB) suppress glucocorticoid action, contributing to tissue resistance to glucocorticoids in several pathologic inflammatory states. p160 nuclear receptor coactivators on the other hand, contribute to the transcriptional signal of the glucocorticoid receptor (GR) through interaction with it via LXXLL motifs in their nuclear receptor-binding (NRB) domain. To discover TNFalpha-induced factors that regulate GR activity at the coactivator level, we performed yeast two-hybrid screening using the NRB domain of the glucocorticoid receptor-interacting protein 1 (GRIP1) as bait. We found that FLICE-associated huge protein (FLASH), which transduces, TNFalpha and Fas ligand signals, bound the NRB domain of GRIP1 at a region between the second and third LXXLL motifs. FLASH suppressed both GR transactivation and GRIP1 enhancement of the glucocorticoid signal and inhibited the physical interaction between GR and the GRIP1 NRB domain. Transfected green fluorescent protein-fused FLASH was located in both the cytoplasm and nucleus, while endogenous FLASH shifted its subcellular localization from the cytoplasm into the nucleus in response to TNFalpha. FLASH antisense and super-repressor IkappaBalpha inhibited the action of TNFalpha independently of each other and additively. These findings indicate that FLASH participates in TNFalpha-induced blockade of GR transactivation at the nuclear receptor coactivator level, upstream and independently of NF-kappaB.	NICHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kino, T (corresponding author), NICHD, Pediat & Reprod Endocrinol Branch, NIH, Bldg 10,Rm 9D42,10 Ctr Dr,MSC 1583, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD008732, ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000618, Z01HD008732, Z01HD000615] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CHROUSOS GP, 1993, ANN INTERN MED, V119, P1113, DOI 10.7326/0003-4819-119-11-199312010-00009; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Eisen Andrea, 1998, Current Opinion in Oncology, V10, P486, DOI 10.1097/00001622-199811000-00002; Evans-Storms RB, 2000, ENDOCRINOLOGY, V141, P1854, DOI 10.1210/en.141.5.1854; Franchimont D, 1999, J CLIN ENDOCR METAB, V84, P2834, DOI 10.1210/jc.84.8.2834; Franchimont D, 1999, DIGEST DIS SCI, V44, P1208, DOI 10.1023/A:1026644711530; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Huang STJ, 1999, FASEB J, V13, P467, DOI 10.1096/fasebj.13.3.467; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Kino T, 2002, J BIOL CHEM, V277, P2396, DOI 10.1074/jbc.M106312200; Kino T, 2002, J ALLERGY CLIN IMMUN, V109, P609, DOI 10.1067/mai.2002. 123708; Kino T, 2001, J ENDOCRINOL, V169, P437, DOI 10.1677/joe.0.1690437; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Maruo T, 2000, STEROIDS, V65, P585, DOI 10.1016/S0039-128X(00)00171-9; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Meduri GU, 2002, AM J RESP CRIT CARE, V165, P983, DOI 10.1164/ajrccm.165.7.2106014; Moran TJ, 2000, CANCER RES, V60, P867; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Riccardi C, 2000, THERAPIE, V55, P165; Rosenfeld CS, 2001, REPRODUCTION, V122, P215, DOI 10.1530/rep.0.1220215; Rothwarf D.M., 1999, SCI STKE, V1999, pRE1; Santamaria P, 2001, CURR OPIN IMMUNOL, V13, P663, DOI 10.1016/S0952-7915(01)00276-X; SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; VAN AD, 1996, SCIENCE, V274, P787; Vottero A, 2002, J CLIN ENDOCR METAB, V87, P2658, DOI 10.1210/jc.87.6.2658; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002	46	51	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3023	3029		10.1074/jbc.M209234200	http://dx.doi.org/10.1074/jbc.M209234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12477726	hybrid			2022-12-25	WOS:000180915000034
J	Kadakia, M; Brown, TL; McGorry, MM; Berberich, SJ				Kadakia, M; Brown, TL; McGorry, MM; Berberich, SJ			MdmX inhibits Smad transactivation	ONCOGENE			English	Article						MdmX; Mdm2; Smad; TGF-beta	GROWTH-FACTOR-BETA; P53; EXPRESSION; PROTEIN; DIFFERENTIATION; DEGRADATION; INTERACTS; PROMOTES; PATHWAY; ARREST	Mdm2 overexpression confers a growth promoting activity upon cells primarily by downregulating the p53 tumor suppressor protein. Nevertheless, Mdm2 deregulation has also been implicated in inhibiting TGF-beta growth repression in a p53 independent manner. Our goal in this study was to examine whether overexpression of Mdm2 or MdmX, a Mdm2-related protein, could affect Smad-induced transactivation. As downstream signaling elements of the TGF-beta pathway, Smads represent one potential target for Mdm2 and MdmX. Here we show that MdmX but not Mdm2 is capable of inhibiting Smad induced transactivation. Based on deletion mutant analysis, MdmX inhibition of Smad transactivation was independent of the p53 and Mdm2 interaction domains, yet required amino acid residues 128-444. Using TGF-beta sensitive HepG2 cells, MdmX overexpression was shown to inhibit TGF-beta induced Smad transactivation. Additionally, mouse embryo fibroblasts (MEFs) lacking p53 and MdmX showed enhanced Smad transactivation when compared to MEFs lacking either p53 or p53 and Mdm2. Interestingly, the inhibition of Smad transactivation by MdmX could be reversed by p300, a functional co-activator of Smads and a necessary factor for Mdm2 nuclear export and did not result from altered Smad localization. In vitro studies demonstrate that MdmX binds to p300 as well as Smad3 and Smad4. Taken together, these results suggest that inhibition of Smad-induced transactivation by MdmX occurs by altering Smad interaction with its coactivator p300.	Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA; Wright State Univ, Dept Physiol & Biophys, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton	Berberich, SJ (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA.	steven.berberich@wright.edu			NATIONAL CANCER INSTITUTE [R29CA064430, R01CA064430] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA064430, CA64430, R01 CA064430-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Blain SW, 2000, J BIOL CHEM, V275, P32066, DOI 10.1074/jbc.M006496200; Brown TL, 1998, CELL GROWTH DIFFER, V9, P869; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Finch RA, 2002, CANCER RES, V62, P3221; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; JACKSON MW, 2001, J BIOL CHEM, V10, P10; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kim RH, 2000, GENE DEV, V14, P1605; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Luna RMD, 1997, NAT GENET, V16, P336; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; TERUEL T, 1995, FEBS LETT, V364, P193, DOI 10.1016/0014-5793(95)00385-M; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yam CH, 1999, CANCER RES, V59, P5075; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	41	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8776	8785		10.1038/sj.onc.1205993	http://dx.doi.org/10.1038/sj.onc.1205993			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483531				2022-12-25	WOS:000179734400012
J	Karahalil, B; Hogue, BA; De Souza-Pinto, NC; Bohr, VA				Karahalil, B; Hogue, BA; De Souza-Pinto, NC; Bohr, VA			Base excision repair capacity in mitochondria and nuclei: tissue-specific variations	FASEB JOURNAL			English	Article						BER; repair activity; mouse tissues; oxidative stress; nucleus	DNA-REPAIR; EXPRESSION; DAMAGE; ENDONUCLEASE; BRAIN; LIVER; HEART; YOUNG; GENE; MICE	Base excision repair is the main pathway for repair of oxidative base lesions in DNA. Mammalian cells must maintain genomic stability in their nuclear and mitochondrial genomes, which have different degrees of vulnerability to DNA damage. This study quantifies DNA glycosylase activity in mitochondria and nucleus from C57/BL6 mouse tissues including brain, liver, heart, muscle, kidney, and testis. The activities of oxoguanine DNA glycosylase (OGG1), uracil DNA glycosylase, and endonuclease III homologue 1 (NTH1) were measured using oligonucleotide substrates with DNA lesions specific for each glycosylase. Mitochondrial content was normalized to citrate synthase activity and mitochondrial function was assessed by measuring cytochrome c oxidase (COX) activity. In nuclear and mitochondrial extracts, the highest DNA glycosylase activities were in testis. Brain and heart, tissues with the highest oxidative load, did not have higher levels of OGG1 or NTH1 activity than muscle or kidney, which are more glycolytic tissues. In general, mitochondrial extracts have lower DNA glycosylase activity than nuclear extracts. There was no correlation between glycosylase activities in the mitochondrial extracts and COX activity, suggesting that DNA repair enzymes may be regulated by a mechanism different from this mitochondrial enzyme.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Gazi Univ, Fac Pharm, Dept Toxicol, TR-06330 Ankara, Turkey	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Gazi University	Bohr, VA (corresponding author), 5600 Nathan Shock Dr,Box 1, Baltimore, MD 21224 USA.	bohrv@grc.nia.nih.gov	Karahalil, Bensu/AFU-8097-2022; Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019; Bohr, Vilhelm/AAP-5931-2020	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X; 	NATIONAL INSTITUTE ON AGING [Z01AG000733, ZIAAG000733] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOHR VA, 1995, MUTAT RES-DNAGING G, V338, P25, DOI 10.1016/0921-8734(95)00008-T; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; CHAN AC, 1976, J CELL BIOL, V70, P685, DOI 10.1083/jcb.70.3.685; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Dantzer F, 2002, NUCLEIC ACIDS RES, V30, P2349, DOI 10.1093/nar/30.11.2349; de Souza-Pinto NC, 2001, FREE RADICAL BIO MED, V30, P916, DOI 10.1016/S0891-5849(01)00483-X; Gillardon F, 1997, MOL BRAIN RES, V52, P194, DOI 10.1016/S0169-328X(97)00237-4; Hamilton ML, 2001, NUCLEIC ACIDS RES, V29, P2117, DOI 10.1093/nar/29.10.2117; HANSKI I, 1982, ANN BOT FENN, V19, P1; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; JONES JS, 1991, NUCLEIC ACIDS RES, V19, P893, DOI 10.1093/nar/19.4.893; Kanoh M, 1999, CIRCULATION, V99, P2757, DOI 10.1161/01.CIR.99.21.2757; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Korr H, 2001, CHEM-BIOL INTERACT, V134, P217, DOI 10.1016/S0009-2797(01)00154-5; Laposa RR, 2001, P NATL ACAD SCI USA, V98, P12860, DOI 10.1073/pnas.241519498; Li YY, 2001, CIRCULATION, V104, P2492, DOI 10.1161/hc4501.098944; Lin LH, 2000, J NEUROCHEM, V74, P1098; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MarinGarcia J, 1997, BIOCHEM CELL BIOL, V75, P137, DOI 10.1139/bcb-75-2-137; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; NILSEN H, 1997, NUCLEIC ACIDS RES, V21, P2579; PETERSON C, 1985, J NEUROCHEM, V45, P1779, DOI 10.1111/j.1471-4159.1985.tb10534.x; Rasmussen HN, 1997, ANAL BIOCHEM, V252, P153, DOI 10.1006/abio.1997.2304; Richardson LL, 2000, BIOL REPROD, V62, P789, DOI 10.1095/biolreprod62.3.789; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Schmerold I, 2001, EXP GERONTOL, V36, P1375, DOI 10.1016/S0531-5565(01)00103-6; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Tan YS, 1996, ACTA MED OKAYAMA, V50, P53; Walter CA, 1998, P NATL ACAD SCI USA, V95, P10015, DOI 10.1073/pnas.95.17.10015; Wilson TM, 1996, MUTAT RES-DNA REPAIR, V362, P237, DOI 10.1016/0921-8777(95)00053-4; Zahn RK, 1996, MECH AGEING DEV, V89, P79, DOI 10.1016/0047-6374(96)01738-1	34	96	103	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1895	1902		10.1096/fj.02-0463com	http://dx.doi.org/10.1096/fj.02-0463com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468454				2022-12-25	WOS:000180574300010
J	Lee, C; Kim, SJ; Jeong, DG; Lee, SM; Ryu, SE				Lee, C; Kim, SJ; Jeong, DG; Lee, SM; Ryu, SE			Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA; PROTEIN; BINDING; ALPHA; VHL; HYDROXYLATION; HIF-1-ALPHA; FAMILY; 2-OXOGLUTARATE; UBIQUITYLATION	The master switch of cellular hypoxia responses, hypoxia-inducible factor 1 (HIF-1), is hydroxylated by factor inhibiting HIF-1 (FIH-1) at a conserved asparagine residue under normoxia, which suppresses transcriptional activity of HIF-1 by abrogating its interaction with transcription coactivators. Here we report the crystal structure of human FIH-1 at 2.8-Angstrom resolution. The structural core of FIH-1 consists of a jellyroll-like beta-barrel containing the conserved ferrous-binding triad residues, confirming that FIH-1 is a member of the 2-oxoglutarate-dependent dioxygenase family. Except for the core structure and triad residues, FIH-1 has many structural deviations from other family members including N- and C-terminal insertions and various deletions in the middle of the structure. The ferrous-binding triad region is highly exposed to the solvent, which is connected to a prominent groove that may bind to a helix near the hydroxylation site of HIF-1. The structure, which is in a dimeric state, also reveals the putative von Hippel-Lindau-binding site that is distinctive to the putative HIF-1-binding site, supporting the formation of the ternary complex by FIH-1, HIF-1, and von Hippel-Lindau. The unique environment of the active site and cofactor-binding region revealed in the structure should allow design of selective drugs that can be used in ischemic diseases to promote hypoxia responses.	Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Yuseong Gu, Taejon 305806, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Ryu, SE (corresponding author), Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Yuseong Gu, 52 Euh Eun Dong, Taejon 305806, South Korea.	ryuse@kribb.re.kr						Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Aravind L, 2001, GENOME BIOL, V2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barlow JN, 1997, BIOCHEM SOC T, V25, P86, DOI 10.1042/bst0250086; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Clifton IJ, 2001, EUR J BIOCHEM, V268, P6625, DOI 10.1046/j.0014-2956.2001.02617.x; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	39	109	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7558	7563		10.1074/jbc.M210385200	http://dx.doi.org/10.1074/jbc.M210385200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482756	hybrid			2022-12-25	WOS:000181195100118
J	Pei, Y; Schwer, B; Shuman, S				Pei, Y; Schwer, B; Shuman, S			Interactions between fission yeast Cdk9, its cyclin partner Pch1, and mRNA capping enzyme Pct1 suggest an elongation checkpoint for mRNA quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II ELONGATION; CARBOXYL-TERMINAL DOMAIN; P-TEFB; TRANSCRIPTION; PHOSPHORYLATION; ACTIVATION; COMPLEX; DSIF; TRIPHOSPHATASE; RECRUITMENT	RNA polymerase II (pol II) is subject to an early elongation delay induced by negative factors Spt5/Spt4 and NELF, which is overcome by the positive factor P-TEFb (Cdk9/cyclin T), a protein kinase that phosphorylates the pol II C-terminal domain (CTD) and the transcription elongation factor Spt5. Although the rationale for this arrest and restart is unclear, recent studies suggest a connection to mRNA capping, which is coupled to transcription elongation via physical and functional interactions between the cap-forming enzymes, the CTD-PO4, and Spt5. Here we identify a novel interaction between fission yeast RNA triphosphatase Pct1, the enzyme that initiates cap formation, and Schizosaccharomyces pombe Cdk9. The C-terminal segment of SpCdk9 comprises a Pct1-binding domain distinct from the N-terminal Cdk domain. We show that the Cdk domain interacts with S. pombe Pch1, a homolog of cyclin T, and that the purified recombinant SpCdk9/Pch1 heterodimer can phosphorylate both the pol II CTD and the C-terminal domain of S. pombe Spt5. We provide genetic evidence that SpCdk9 and Pch1 are functional orthologs of the Saccharomyces cerevisiae CTD kinase Bur1/Bur2, a putative yeast P-TEFb. Mutations of the kinase active site and the regulatory T-loop of SpCdk9 abolish its activity in vivo. Deleting the C-terminal domain of SpCdk9 causes a severe growth defect. We suggest a model whereby Spt5-induced arrest of early elongation ensures a temporal window for recruitment of the capping enzymes, which in turn attract Cdk9 to alleviate the arrest. This elongation checkpoint may avoid wasteful rounds of transcription of uncapped pre-mRNAs.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Pei, Yi/D-8998-2011	Pei, Yi/0000-0002-3466-760X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Brogna S, 2002, MOL CELL, V10, P93, DOI 10.1016/S1097-2765(02)00565-8; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Chiu YL, 2002, MOL CELL, V10, P585, DOI 10.1016/S1097-2765(02)00630-5; Chiu YL, 2001, J BIOL CHEM, V276, P12959, DOI 10.1074/jbc.M007901200; Furnari BA, 1997, J BIOL CHEM, V272, P12100, DOI 10.1074/jbc.272.18.12100; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lee KM, 1999, CURR BIOL, V9, P441, DOI 10.1016/S0960-9822(99)80194-8; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Pei Y, 2002, J BIOL CHEM, V277, P19639, DOI 10.1074/jbc.M200015200; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yao S, 2000, MOL CELL BIOL, V20, P7080, DOI 10.1128/MCB.20.19.7080-7087.2000; Yao S, 2002, MOL CELL BIOL, V22, P6750, DOI 10.1128/MCB.22.19.6750-6758.2002; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	34	57	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7180	7188		10.1074/jbc.M211713200	http://dx.doi.org/10.1074/jbc.M211713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12475973	hybrid			2022-12-25	WOS:000181195100071
J	Pereira, T; Zheng, XW; Ruas, JL; Tanimoto, K; Poellinger, L				Pereira, T; Zheng, XW; Ruas, JL; Tanimoto, K; Poellinger, L			Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; CREB-BINDING PROTEIN; FACTOR 1-ALPHA; PROLYL HYDROXYLATION; HIF-ALPHA; TRANSCRIPTIONAL ACTIVITY; PROLINE HYDROXYLATION; DEGRADATION DOMAIN; ACTIVATION; COMPLEX	Under normoxic conditions the hypoxia-inducible factor-1alpha (HIF-1alpha) protein is targeted for degradation by the von Hippel-Lindau (pVHL) tumor suppressor protein acting as an E3 ubiquitin ligase. Binding of pVHL to HIF-1alpha is dependent on hydroxylation of specific proline residues by O-2-dependent prolyl 4-hydroxylases. Upon exposure to hypoxia the hydroxylase activity is inhibited, resulting in stabilization of HIF-1alpha protein levels and activation of transcription of target genes. One of the two critical proline residues, Pro 563 in mouse HIF-1a, is located within a bifunctional domain, the N-terminal transactivation domain (N-TAD), which mediates both pVHL-dependent degradation at normoxia and transcriptional activation at hypoxia. Here we have identified two N-TAD residues, Tyr(564) and He 565, which, in addition to Pro(563), were critical for pVHL-mediated degradation at normoxia. We have also identified D568A/D569A/D570A, F571A, and L573A as mutations of the N-TAD that abrogated binding to pVHL both in vitro and in vivo, and constitutively stabilized N-TAD against degradation. Moreover, the mutations Y564G, L556A/L558A, and F571A/L573A drastically reduced the transactivation function of either the isolated N-TAD or full-length HIF-1alpha in hypoxic cells. Interestingly, the P563A mutant exhibited a constitutively active and potent transactivation function that was enhanced by functional interaction with the transcriptional coactivator protein CREB-binding protein. In conclusion, we have identified by mutation analysis several residues that are critical for either one or both of the interdigitated and conditionally regulated degradation and transactivation functions of the N-TAD of HIF-1alpha.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.		Pereira, Teresa/AAP-8197-2020; Keiji, Tanimoto/U-1839-2019; Ruas, Jorge/AAE-6094-2019	Pereira, Teresa/0000-0001-8654-2385; Keiji, Tanimoto/0000-0003-4912-4197; Ruas, Jorge/0000-0002-1110-2606; Zheng, Xiaowei/0000-0002-2648-1119				Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yu F, 2001, CANCER RES, V61, P4136	37	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6816	6823		10.1074/jbc.M209297200	http://dx.doi.org/10.1074/jbc.M209297200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12468553	hybrid			2022-12-25	WOS:000181195100025
J	Du, M; Yeh, HC; Berka, V; Wang, LH; Tsai, AL				Du, M; Yeh, HC; Berka, V; Wang, LH; Tsai, AL			Redox properties of human endothelial nitric-oxide synthase oxygenase and reductase domains purified from yeast expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE; RADICAL FORMATION; HEME DOMAIN; FLAVIN; PTERIN; TETRAHYDROBIOPTERIN; BINDING; IDENTIFICATION; RECONSTITUTION; PURIFICATION	Characterization of the redox properties of endothelial nitric-oxide synthase (eNOS) is fundamental to understanding the complicated reaction mechanism of this important enzyme participating in cardiovascular function. Yeast overexpression of both the oxygenase and reductase domains of human eNOS, i.e. eNOS(ox) and eNOS(red), has been established to accomplish this goal. UV-visible and electron paramagnetic resonance (EPR) spectral characterization for the resting eNOS(ox). and its complexes with various ligands indicated a standard NOS heme structure as a thiolate hemeprotein. Two low spin imidazole heme complexes but not the isolated eNOS(ox). were resolved by EPR indicating slight difference in heme geometry of the dimeric eNOS(ox). domain. Stoichiometric titration of eNOS(ox) demonstrated that the heme has a capacity for a reducing equivalent of 1-1.5. Additional 1.5-2.5 reducing equivalents were consumed before heme reduction occurred indicating the presence of other unknown high potential redox centers. There is no indication for additional metal centers that could explain this extra electron capacity of eNOS(ox). Ferrous eNOS(ox), in the presence of L-arginine, is fully functional in forming the tetrahydrobiopterin radical upon mixing with oxygen as demonstrated by rapid-freeze EPR measurements. Calmodulin binds eNOS(red) at 1:1 stoichiometry and high affinity. Stoichiometric titration and computer simulation enabled the determination for three redox potential separations between the four half-reactions of FMN and FAD. The extinction coefficient could also be resolved for each flavin for its semiquinone, oxidized, and reduced forms at multiple wavelengths. This first redox characterization on both eNOS domains by stoichiometric titration and the generation of a high quality EPR spectrum for the BH4 radical intermediate illustrated the usefulness of these tools in future detailed investigations into the reaction mechanism of eNOS.	Univ Texas, Hlth Sci Ctr, Div Hematol, Dept Internal Med, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Div Hematol, Dept Internal Med, POB 20708, Houston, TX 77225 USA.	Ah-lim.Tsai@uth.tmc.edu			NHLBI NIH HHS [HL60625] Funding Source: Medline; NIGMS NIH HHS [GM56818] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056818] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ARCHER MC, 1972, CAN J BIOCHEM CELL B, V50, P1174, DOI 10.1139/o72-160; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berka V, 1998, BIOCHEMISTRY-US, V37, P6136, DOI 10.1021/bi980133l; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FOUST GP, 1969, ANAL BIOCHEM, V27, P530, DOI 10.1016/0003-2697(69)90066-9; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Gorren ACF, 2001, NITRIC OXIDE-BIOL CH, V5, P176, DOI 10.1006/niox.2001.0332; GRASSETTI DR, 1969, J CHROMATOGR, V41, P121, DOI 10.1016/0021-9673(64)80109-6; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2002, BIOCHEMISTRY-US, V41, P3439, DOI 10.1021/bi012002h; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; Leber A, 1999, J BIOL CHEM, V274, P37658, DOI 10.1074/jbc.274.53.37658; LUNTE CE, 1983, ANAL BIOCHEM, V129, P377, DOI 10.1016/0003-2697(83)90565-1; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MAYER B, 1996, METH NEUROSCI, V31, P130; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Perry JM, 1998, CHEM BIOL, V5, P355, DOI 10.1016/S1074-5521(98)90069-2; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROMAN CS, 2000, PORPHYRIN HDB, P293; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Rusche KM, 2001, J BIOL CHEM, V276, P421, DOI 10.1074/jbc.M006860200; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Tsai AL, 1998, ANAL BIOCHEM, V264, P165, DOI 10.1006/abio.1998.2774; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Zeghouf M, 1998, BIOCHEMISTRY-US, V37, P6114, DOI 10.1021/bi9728699; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	45	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6002	6011		10.1074/jbc.M209606200	http://dx.doi.org/10.1074/jbc.M209606200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480940	hybrid			2022-12-25	WOS:000181129400065
J	Gencic, S; Grahame, DA				Gencic, S; Grahame, DA			Nickel in subunit beta of the acetyl-CoA decarbonylase/synthase multienzyme complex in methanogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; CLOSTRIDIUM-THERMOACETICUM; METHANOSARCINA-THERMOPHILA; ENZYME COMPLEX; ALPHA-METALLOSUBUNIT; CLEAVAGE; METHYLATION; MECHANISM; CATALYSIS; BINDING	The acetyl-CoA decarbonylase/synthase (ACDS) complex catalyzes the central reaction of acetyl C-C bond cleavage in methanogens growing on acetate and is also responsible for synthesis of acetyl units during growth on C-1 substrates. The ACDS beta subunit contains nickel and an Fe/S center and reacts with acetyl-CoA forming an acetyl-enzyme intermediate presumably directly involved in acetyl C-C bond activation. To investigate the role of nickel in this process two forms of the Methanosarcina thermophila 13 subunit were overexpressed in anaerobically grown Escherichia coli. Both contained an Fe/S center but lacked nickel and were inactive in acetyl-enzyme formation in redox-dependent acetyltransferase assays. However, high activity developed during incubation with NiCl2. The native and nickel-reconstituted proteins both contained iron and nickel in a 2:1 ratio, with insignificant levels of other metals, including copper. Binding of nickel elicited marked changes in the UV-visible spectrum, with intense charge transfer bands indicating multiple thiolate ligation to nickel. The kinetics of nickel incorporation matched the time course for enzyme activation. Other divalent metal ions could not substitute for nickel in yielding catalytic activity. Acetyl-CoA was formed in reactions with CoA, CO, and methylcobalamin, directly demonstrating C-C bond activation by the 13 subunit in the absence of other ACDS subunits. Nickel was indispensable in this process too and was needed to form a characteristic EPR-detectable enzyme-carbonyl adduct in reactions with CO. In contrast to enzyme activation, EPR signal formation did not require addition of reducing agent, indicating indirect catalytic involvement of the paramagnetic species. Site-directed mutagenesis indicated that Cys-278 and Cys-280 coordinate nickel, with Cys-189 essential for Fe/S cluster formation. The results are consistent with an Ni-2[Fe4S4] arrangement at the active site. A mechanism for C-C bond activation is proposed that includes a specific role for the Fe4S4 center and accounts for the absolute requirement for nickel.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Grahame, DA (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.							Barondeau DP, 1997, J AM CHEM SOC, V119, P3959, DOI 10.1021/ja963597k; Bhaskar B, 1998, BIOCHEMISTRY-US, V37, P14491, DOI 10.1021/bi9812423; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; Doukov TI, 2002, SCIENCE, V298, P567, DOI 10.1126/science.1075843; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Gencic S, 2001, BIOCHEMISTRY-US, V40, P13068, DOI 10.1021/bi0112917; Grahame DA, 1996, BIOCHEMISTRY-US, V35, P593, DOI 10.1021/bi9511494; Grahame DA, 1996, J BIOL CHEM, V271, P8352, DOI 10.1074/jbc.271.14.8352; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; Loke HK, 2002, J AM CHEM SOC, V124, P8667, DOI 10.1021/ja025924w; MaupinFurlow JA, 1996, J BACTERIOL, V178, P6849, DOI 10.1128/jb.178.23.6849-6856.1996; Murakami E, 2000, J BIOL CHEM, V275, P4699, DOI 10.1074/jbc.275.7.4699; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; RAGSDALE SW, 1985, P NATL ACAD SCI USA, V82, P6811, DOI 10.1073/pnas.82.20.6811; Russell WK, 1998, J AM CHEM SOC, V120, P7502, DOI 10.1021/ja981165z; Seravalli J, 2002, BIOCHEMISTRY-US, V41, P1807, DOI 10.1021/bi011687i; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; TERLESKY KC, 1987, J BIOL CHEM, V262, P15392; XIA JQ, 1995, BIOCHEMISTRY-US, V34, P6037, DOI 10.1021/bi00018a005; XIA JQ, 1995, J AM CHEM SOC, V117, P7065, DOI 10.1021/ja00132a004; Xia JQ, 1996, J AM CHEM SOC, V118, P483, DOI 10.1021/ja952845u	23	70	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6101	6110		10.1074/jbc.M210484200	http://dx.doi.org/10.1074/jbc.M210484200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12464601	hybrid			2022-12-25	WOS:000181129400077
J	Nair, R; Shaha, C				Nair, R; Shaha, C			Diethylstilbestrol induces rat spermatogenic cell apoptosis in vivo through increased expression of spermatogenic cell Fas/FasL system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE REPRODUCTIVE HEALTH; ADULT-RATS; FAS LIGAND; IN-SITU; TESTIS; DEATH; ESTROGEN; RECEPTOR; GLUTATHIONE; MECHANISMS	The significant role that estrogens play in spermatogenesis has opened up an exciting area of research in male reproductive biology. The realization that estrogens are essential for proper maintenance of spermatogenesis, as well as growing evidence pointing to the deleterious effects of estrogen-like chemicals on male reproductive health, has made it imperative to dissect the role estrogens play in the male. Using a model estrogen, diethylstilbestrol (DES), to induce spermatogenic cell apoptosis in vivo in the male rat, we provide a new insight into an estrogen-dependent regulation of the Fas-FasL system specifically in spermatogenic cells. We show a distinct increase in Fas-FasL expression in spermatogenic cells upon exposure to diethylstilbestrol. This increase is confined to the spermatid population, which correlates with increased apoptosis seen in the haploid cells. Testosterone supplementation is able to prevent DES-induced Fas-FasL up-regulation,and apoptosis in the spermatogenic cells. DES-induced germ cell apoptosis does not occur in Fas-deficient lpr mice. One other important finding is that spermatogenic cells are type II cells, as the increase in Fas-FasL expression in the spermatogenic cells is followed by the cleavage of caspase-8 to its active form, following which Bax translocates to the mitochondria and precipitates the release of cytochrome c that is accompanied by a drop in mitochondrial potential. Subsequent to this, activation of caspase-9 occurs that in turn activates caspase-3 leading to the cleavage of poly(ADP-ribose) polymerase. Taken together, the data indicate that estrogen-like chemicals can precipitate apoptotic death in spermatogenic cells by increasing the expression of spermatogenic cell Fas-FasL, thus initiating apoptosis in the same lineage of cells through the activation of the apoptotic pathway chosen by type II cells.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Shaha, C (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Rd, New Delhi 110067, India.	cshaha@nii.res.in		Nair, Radhika/0000-0002-6585-3384				Akingbemi BT, 2001, ANN MED, V33, P391, DOI 10.3109/07853890108995952; AMADOR AG, 1989, REV ESP FISIOL, V45, P245; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BLANCHARD Y, 1991, MOL REPROD DEV, V30, P275, DOI 10.1002/mrd.1080300316; BlancoRodriguez J, 1997, J REPROD FERTIL, V110, P61, DOI 10.1530/jrf.0.1100061; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; D'Alessio A, 2001, P NATL ACAD SCI USA, V98, P3316, DOI 10.1073/pnas.051566098; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Eguchi Y, 1997, CANCER RES, V57, P1835; Eid NAS, 2002, INT J ANDROL, V25, P159, DOI 10.1046/j.1365-2605.2002.00341.x; Goyal HO, 2001, BIOL REPROD, V64, P927, DOI 10.1095/biolreprod64.3.927; GRAHAM JC, 1993, METHODS MOL BIOL; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Hikim APS, 1999, REV REPROD, V4, P38; HIKIM APS, 1995, ENDOCRINOLOGY, V136, P2770, DOI 10.1210/en.136.6.2770; KONONEN J, 1994, ENDOCRINOLOGY, V135, P2291, DOI 10.1210/en.135.5.2291; KRICKA LJ, 1998, ANAL BIOCHEM, V175, P14; Li X, 2000, EXP CELL RES, V255, P125, DOI 10.1006/excr.1999.4796; Lombardi G, 2001, MOL CELL ENDOCRINOL, V178, P51, DOI 10.1016/S0303-7207(01)00420-8; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Meachem SJ, 1999, J ANDROL, V20, P756; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; Miura M, 2002, FERTIL STERIL, V77, P787, DOI 10.1016/S0015-0282(01)03255-1; Moline JM, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3434987; Nonclercq D, 1996, BIOL REPROD, V55, P1368, DOI 10.1095/biolreprod55.6.1368; O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289; Rao AVSK, 2002, FEBS LETT, V527, P133, DOI 10.1016/S0014-5793(02)03196-4; Rao AVSK, 2000, FREE RADICAL BIO MED, V29, P1015, DOI 10.1016/S0891-5849(00)00408-1; Russell LD, 2002, BIOL REPROD, V66, P950, DOI 10.1095/biolreprod66.4.950; RUSSELL LD, 1990, AM J ANAT, V188, P21, DOI 10.1002/aja.1001880104; Sapi E, 2002, J SOC GYNECOL INVEST, V9, P243, DOI 10.1016/S1071-5576(02)00162-4; Saunders PTK, 2002, J CLIN ENDOCR METAB, V87, P2706, DOI 10.1210/jc.87.6.2706; Saunders PTK, 1998, REV REPROD, V3, P164, DOI 10.1530/ror.0.0030164; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SELAM B, 2002, J CLIN ENDOCR METAB, V87, P3821; Senft AP, 2000, ANAL BIOCHEM, V280, P80, DOI 10.1006/abio.2000.4498; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; SUFI SB, 1994, WHO MATCHED REAGENTS, P74; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Williams K, 2000, MOL CELL ENDOCRINOL, V164, P117, DOI 10.1016/S0303-7207(00)00231-8; Woolveridge L, 1999, BIOL REPROD, V60, P461, DOI 10.1095/biolreprod60.2.461; Xu JP, 1999, AM J REPROD IMMUNOL, V42, P381; Yamamoto CM, 2000, BIOL REPROD, V63, P1683, DOI 10.1095/biolreprod63.6.1683; Yin YZ, 1998, DEV BIOL, V204, P165, DOI 10.1006/dbio.1998.9074; Yin YZ, 2002, J ANDROL, V23, P64, DOI 10.1002/jand.2002.23.1.64; Yu XZ, 2001, TOXICOL APPL PHARM, V174, P35, DOI 10.1006/taap.2001.9187; Zimmermann KC, 2001, J ALLERGY CLIN IMMUN, V108, pS99, DOI 10.1067/mai.2001.117819	54	99	115	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6470	6481		10.1074/jbc.M209319200	http://dx.doi.org/10.1074/jbc.M209319200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12477725	hybrid			2022-12-25	WOS:000181129400122
J	Bagga, S; Seth, D; Batra, JK				Bagga, S; Seth, D; Batra, JK			The cytotoxic activity of ribosome-inactivating protein saporin-6 is attributed to its rRNA N-glycosidase and internucleosomal DNA fragmentation activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; POKEWEED ANTIVIRAL PROTEIN; POLYNUCLEOTIDE-ADENOSINE GLYCOSIDASE; SITE-DIRECTED MUTAGENESIS; SAPONARIA-OFFICINALIS; ENZYMATIC-ACTIVITY; SENSITIVE METHOD; IN-VITRO; RNA; PLANTS	Saporin-6 produced by the plant Saponaria officinalis belongs to the family of single chain ribosome-inactivating proteins. It potently inhibits protein synthesis in eukaryotic cells, by cleaving the N-glycosidic bond of a specific adenine in 28 S rRNA, which results in the cell death. Saporin-6 has also been shown to be active on DNA and induces apoptosis. In the current study, we have investigated the roles of rRNA depurination and the activity of saporin-6 on genomic DNA in its cytotoxic activity. The role of putative active site residues, Tyr(72), Tyr(120), Glu(176), Arg(179), and Trp(208), and two invariant residues, Tyr(16) and Are, proposed to be important for structural stability of saporin-6, has been investigated in its catalytic and cytotoxic activity. These residues were mutated to alanine to generate seven mutants, Y16A, R24A, Y72A, Y120A, E176A, R179A, and W208A. We show that for the RNA N-glycosidase activity of sa saporin-6, residues Tyr(16), Tyr(72), and Arg(179) are absolutely critical; Tyr(120) and Glu(176) can be partially dispensed with, whereas Trp(208) and Arg(24) do not appear to be involved in this activity. The residues Tyr(72), Tyr(120), Glu(176), Arg(179), and Trp(208) were found to be essential for the genomic DNA fragmentation activity, whereas residues Tyr(16) and Arg(24) do not appear to be required for the DNA fragmentation. The study shows that saporin-6 possesses two catalytic activities, namely RNA N-glycosidase and genomic DNA fragmentation activity, and for its complete cytotoxic activity both activities are required.	Natl Inst Immunol, Immunochem Lab, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Batra, JK (corresponding author), Natl Inst Immunol, Immunochem Lab, Aruna Asaf Ali Rd, New Delhi 110067, India.	janendra@nii.res.in	Batra, Janendra/GWQ-8031-2022	Batra, Janendra/0000-0003-2206-3398				Barbieri L, 1998, MOL MICROBIOL, V29, P661, DOI 10.1046/j.1365-2958.1998.00911.x; Barbieri L, 2000, BBA-PROTEIN STRUCT M, V1480, P258, DOI 10.1016/S0167-4838(00)00077-7; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Brigotti M, 2001, TOXICON, V39, P341, DOI 10.1016/S0041-0101(00)00135-5; Brigotti M, 1998, NUCLEIC ACIDS RES, V26, P4306, DOI 10.1093/nar/26.18.4306; Brigotti M, 2002, FASEB J, V16, DOI 10.1096/fj.01-0521com; Brigotti M, 2000, LIFE SCI, V68, P331, DOI 10.1016/S0024-3205(00)00941-3; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; CARNICELLI D, 1992, BIOCHEM BIOPH RES CO, V182, P579, DOI 10.1016/0006-291X(92)91771-H; Chen JK, 1997, PROTEIN ENG, V10, P827, DOI 10.1093/protein/10.7.827; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Fong WP, 2000, INT J BIOCHEM CELL B, V32, P571, DOI 10.1016/S1357-2725(99)00149-1; FRANKEL A, 1990, MOL CELL BIOL, V10, P6257, DOI 10.1128/MCB.10.12.6257; HARLOW E, 1988, ANTIBODIES LABORATOR, P332; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; Helmy M, 1999, BIOCHEM BIOPH RES CO, V258, P252, DOI 10.1006/bbrc.1999.0618; Hudak KA, 2000, RNA, V6, P369, DOI 10.1017/S1355838200991337; Irvin JD, 1995, ANTIVIRAL PROTEINS H, P65; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; KIM YS, 1992, BIOCHEMISTRY-US, V31, P3294, DOI 10.1021/bi00127a035; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Li XD, 1996, BIOL CHEM, V377, P825, DOI 10.1515/bchm3.1996.377.12.825; LING J, 1994, FEBS LETT, V345, P143, DOI 10.1016/0014-5793(94)00421-8; MARCHANT A, 1995, J MOL BIOL, V254, P848, DOI 10.1006/jmbi.1995.0660; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; MORRIS KN, 1992, P NATL ACAD SCI USA, V89, P4869, DOI 10.1073/pnas.89.11.4869; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Rajamohan F, 2000, J BIOL CHEM, V275, P3382, DOI 10.1074/jbc.275.5.3382; READY MP, 1991, PROTEINS, V10, P270, DOI 10.1002/prot.340100311; ROBERTUS JD, 1992, GENETICALLY ENG TOXI, P133; Roncuzzi L, 1996, FEBS LETT, V392, P16, DOI 10.1016/0014-5793(96)00776-4; Sambrook J, 1989, MOL CLONING LAB MANU, V3; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santanche S, 1997, BIOCHEM BIOPH RES CO, V234, P129, DOI 10.1006/bbrc.1997.6597; Savino C, 2000, FEBS LETT, V470, P239, DOI 10.1016/S0014-5793(00)01325-9; Shaw PC, 1997, EUR J BIOCHEM, V245, P423, DOI 10.1111/j.1432-1033.1997.00423.x; Shih NR, 1997, PLANT SCI, V130, P145, DOI 10.1016/S0168-9452(97)00229-X; STIRPE F, 1988, NUCLEIC ACIDS RES, V16, P1349, DOI 10.1093/nar/16.4.1349; STIRPE F, 1983, BIOCHEM J, V216, P617, DOI 10.1042/bj2160617; Suzuki A, 2000, GENE DEV, V14, P1734; Wang P, 1999, NUCLEIC ACIDS RES, V27, P1900, DOI 10.1093/nar/27.8.1900; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; YANG JT, 1986, METHOD ENZYMOL, V130, P208	49	61	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4813	4820		10.1074/jbc.M207389200	http://dx.doi.org/10.1074/jbc.M207389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466280	hybrid			2022-12-25	WOS:000180968900061
J	Robbe, K; Otto-Bruc, A; Chardin, P; Antonny, B				Robbe, K; Otto-Bruc, A; Chardin, P; Antonny, B			Dissociation of GDP dissociation inhibitor and membrane translocation are required for efficient activation of Rac by the Dbl homology-pleckstrin homology region of Tiam	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE; RHO-FAMILY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN; BINDING; DOMAIN; CDC42; COMPLEX; GTPASES	Small G proteins of the Rho/Rac/Cdc42 family are associated with lipid membranes through their prenylated C termini. Alternatively, these proteins form soluble complexes with GDI proteins. To assess how this membrane partitioning influences the activation of Rac by guanine nucleotide exchange factors, GDP-to-GTP exchange reactions were performed in the presence of liposomes using different forms of Rac-GDP. We show that both non-prenylated Rac-GDP and the soluble complex between prenylated Rac-GDP and GDI are poorly activated by the Dbl homology-pleckstrin homology (DH-PH) domain of the exchange factor Tiam1, whereas prenylated Rac-GDP bound to liposomes is activated about 10 times more rapidly. Sedimentation experiments with liposomes reveal that the DH-PH region of Tiam1 forms, with nucleotide-free prenylated Rac, a membrane-bound complex from which GDI is excluded. Taken together, these experiments demonstrate that the dissociation of Rac-GDP from GDI and its translocation to membrane lipids favor DH-PH-catalyzed nucleotide exchange because the steric hindrance caused by GDI is relieved and because the membrane environment favors functional interaction between the DH-PH domain and the small G protein.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Antonny, B (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	antonny@ipmc.cnrs.fr	Robbe-Sermesant, Karine/Q-2253-2016; Antonny, Bruno/ABH-7434-2020	Robbe-Sermesant, Karine/0000-0003-0580-3817; Antonny, Bruno/0000-0002-9166-8668				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Buchwald G, 2002, EMBO J, V21, P3286, DOI 10.1093/emboj/cdf329; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Gao Y, 2001, J BIOL CHEM, V276, P47530, DOI 10.1074/jbc.M108865200; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; HORI Y, 1991, ONCOGENE, V6, P515; ISOMURA M, 1991, ONCOGENE, V6, P119; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Read PW, 2000, PROTEIN SCI, V9, P376; Read PW, 2000, METHOD ENZYMOL, V325, P15; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; SASAKI T, 1993, J BIOL CHEM, V268, P23959; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116	37	64	70	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4756	4762		10.1074/jbc.M210412200	http://dx.doi.org/10.1074/jbc.M210412200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12471028	hybrid			2022-12-25	WOS:000180968900053
J	Xu, GZ; Rich, RL; Steegborn, C; Min, TP; Huang, YH; Myszka, DG; Wu, H				Xu, GZ; Rich, RL; Steegborn, C; Min, TP; Huang, YH; Myszka, DG; Wu, H			Mutational analyses of the p35-caspase interaction - A bowstring kinetic model of caspase inhibition by p35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC PROTEIN P35; REACTIVE-SITE LOOP; BACULOVIRUS P35; CELL-DEATH; CRYSTAL-STRUCTURE; CAENORHABDITIS-ELEGANS; EXPRESSION; CLEAVAGE; COMPLEX; MECHANISM	Apoptosis is a highly regulated multistep process for programmed cellular destruction. It is centered on the activation of a group of intracellular cysteine proteases known as caspases. The baculoviral p35 protein effectively blocks apoptosis through its broad spectrum caspase inhibition. It harbors a caspase recognition sequence within a highly protruding reactive site loop (RSL), which gets cleaved by a target caspase before the formation of a tight complex. The crystal structure of the post-cleavage complex between p35 and caspase-8 shows that p35 forms a thioester bond with the active site cysteine of the caspase. The covalent bond is prevented from hydrolysis by the N terminus of p35, which repositions into the active site of the caspase to eliminate solvent accessibility of the catalytic residues. Here, we report mutational analyses of the pre-cleavage and post-cleavage p35/caspase interactions using surface plasmon resonance biosensor measurements, pull-down assays and kinetic inhibition experiments. The experiments identify important structural elements for caspase inhibition by p35, including the strict requirement for a Cys at the N terminus of p35 and the rigidity of the RSL. A bowstring kinetic model for p35 function is derived in which the tension generated in the bowstring system during the pre-cleavage interaction is crucial for the fast post-cleavage conformational changes required for inhibition.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Univ Utah, Sch Med, Ctr Biomol Interact Anal, Salt Lake City, UT 84132 USA	Cornell University; Utah System of Higher Education; University of Utah	Wu, H (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, Whitney 2,1300 York Ave, New York, NY 10021 USA.				NIAID NIH HHS [AI50872] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050872] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Araki T, 2000, CELL DEATH DIFFER, V7, P485, DOI 10.1038/sj.cdd.4400674; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; dela Cruz WP, 2001, J BIOL CHEM, V276, P32933, DOI 10.1074/jbc.M103930200; Eddins MJ, 2002, ACTA CRYSTALLOGR D, V58, P299, DOI 10.1107/S0907444901018753; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hisahara S, 2000, EMBO J, V19, P341, DOI 10.1093/emboj/19.3.341; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Morishima N, 1998, FEBS LETT, V427, P144, DOI 10.1016/S0014-5793(98)00389-5; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Snipas SJ, 2001, BIOCHEM J, V357, P575, DOI 10.1042/0264-6021:3570575; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zoog SJ, 1999, J BIOL CHEM, V274, P25995, DOI 10.1074/jbc.274.37.25995	34	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5455	5461		10.1074/jbc.M211607200	http://dx.doi.org/10.1074/jbc.M211607200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458208	hybrid			2022-12-25	WOS:000180968900138
J	Kim, SW; Hayashi, M; Lo, JF; Yang, Y; Yoo, JS; Lee, JD				Kim, SW; Hayashi, M; Lo, JF; Yang, Y; Yoo, JS; Lee, JD			ADP-ribosylation factor 4 small GTPase mediates epidermal growth factor receptor-dependent phospholipase D2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; SIGNALING NETWORK; ARF PROTEINS; AP-1; BMK1/ERK5; PATHWAY; MEMBERS; FAMILY; KINASE; FUSION	The epidermal growth factor receptor (EGFR) plays a critical role in the development, proliferation, and differentiation of cells of epithelial and mesenchymal origin. These EGFR-dependent cellular processes are mediated by a repertoire of intracellular signaling pathways triggered by the activation of the EGFR cytoplasmic domain, which originates from ligand binding of its extracellular domain. To understand the molecular mechanisms by which the intracellular domain of EGFR transmits mitogenic messages to the downstream signaling pathways, we used the, cytoplasmic region of EGFR as bait in yeast two-hybrid screening. We found that ADP-ribosylation factor 4 (ARF4) interacts with the intracellular part of EGFR and mediates the EGF-dependent cellular activation of phospholipase D2 (PLD2) but does not mediate the activation of PLD1. In addition, ARF4-mediated PLD2 activation leads to dramatic activation of the transcription factor activator protein 1 (AP-1), and, importantly, ARF4 activity is required for EGF-induced activation of cellular AP-1. Our findings indicate that ARF4 is a critical molecule that directly regulates cellular PLD2 activity and that this ARF4-mediated PLD2 activation stimulates AP-1-dependent transcription in the EGF-induced cellular response.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.		Lo, Jeng-Fan/ABB-2820-2020; Lo, Jeng-Fan/AAE-9626-2020	Lo, Jeng-Fan/0000-0001-7188-9140; Lo, Jeng-Fan/0000-0001-7188-9140	NATIONAL CANCER INSTITUTE [R21CA095353, R01CA079871] Funding Source: NIH RePORTER; NCI NIH HHS [CA079871, CA095353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FLINT KJ, 1991, ONCOGENE, V6, P2019; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; KAHN RA, 1988, J BIOL CHEM, V263, P8282; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Shome K, 1998, J BIOL CHEM, V273, P30836, DOI 10.1074/jbc.273.46.30836; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	32	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2661	2668		10.1074/jbc.M205819200	http://dx.doi.org/10.1074/jbc.M205819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12446727	hybrid			2022-12-25	WOS:000180562000078
J	Chau, CH; Chen, KY; Deng, HT; Kim, KJ; Hosoya, K; Terasaki, T; Shih, HM; Ann, DK				Chau, CH; Chen, KY; Deng, HT; Kim, KJ; Hosoya, K; Terasaki, T; Shih, HM; Ann, DK			Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation	ONCOGENE			English	Article						Etk; VEGF; autocrine; survival; proliferation	ENDOTHELIAL GROWTH-FACTOR; FOCAL ADHESION KINASE; BMX TYROSINE KINASE; PROSTATE-CANCER CELLS; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL-TRANSDUCTION; FAMILY KINASES; PH-DOMAIN; EXPRESSION	Etk/Bmx, a member of the Tee family of non-receptor tyrosine kinase, is characterized by an N-terminal PH domain and has recently been shown to be involved in the regulation of various cellular processes, including proliferation, differentiation, motility and apoptosis. Since VEGF and the activation of its signaling pathway have been implicated in modulating a variety of biological responses, we characterized the role of Etk-dependent signaling pathways involved in the upregulation of VEGF expression, and explored the functional implications of this enhancement in sustaining cell proliferation and survival. Using Northern and Western analyses, transient transfections, and pharmacological agents, we demonstrate that Elk activation alone is sufficient to transcriptionally induce VEGF expression, independent of the previously identified hypoxia response element (HRE), in both Pa-4 epithelial and TR-BBB endothelial cells under normoxia. In addition, Elk utilizes both MEK/ERK and PI3-K/Pak1 signaling pathways in concert to activate VEGF transcription. Functionally, Etk activation elicits a profound stimulatory effect on TR-BBB cell proliferation and formation of capillary-like networks in Matrigel containing reduced levels of growth factors. Finally, antisense oligonucleotides against either endogenous VEGF or Etk abrogate the proliferation of Elk-activated TR-BBB cells, and exogenous VEGF treatment stimulates endogenous Elk tyrosine phosphorylation in HUVECs. Taken together, these results indicate that VEGF is both an Etk downstream target gene and an Elk upstream activator, constituting a reciprocal Etk-VEGF autoregulatory loop. These findings, to our knowledge, are the first delineation of a network of positive feedforward signaling pathways that converge on the Etk-VEGF axis, causally associating Elk-mediation of VEGF induction with enhanced cellular processes in both epithelial and endothelial cells.	Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Mol Biopharm & Genet, Aoba Ku, Sendai, Miyagi 9808578, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Natl Hlth Res Inst, Div Mol & Genomic Med, Taipei 11529, Taiwan; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90033 USA; Univ So Calif, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Univ So Calif, Dept Med, Los Angeles, CA 90033 USA	University of Southern California; Tohoku University; University of Toyama; National Health Research Institutes - Taiwan; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Ann, DK (corresponding author), Univ So Calif, Dept Mol Pharmacol & Toxicol, Hlth Sci Campus,PSC-210B,1985 Zonal Ave, Los Angeles, CA 90033 USA.		Shih, Hsiu-Ming/S-7023-2018; Terasaki, Tetsuya/K-6730-2012	Terasaki, Tetsuya/0000-0002-6332-7575	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064365, R01HL038658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 64365, R01 HL 38658] Funding Source: Medline; NIDCR NIH HHS [R01 DE 14183, DE 07211, R01 DE 10742] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Dunk C, 2001, AM J PATHOL, V158, P265, DOI 10.1016/S0002-9440(10)63965-X; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hamm-Alvarez SF, 2001, AM J PHYSIOL-CELL PH, V280, pC1657, DOI 10.1152/ajpcell.2001.280.6.C1657; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; Kanellis J, 2000, AM J PHYSIOL-RENAL, V278, pF905, DOI 10.1152/ajprenal.2000.278.6.F905; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Parrizas M, 1997, J BIOL CHEM, V272, P154; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rajantie I, 2001, MOL CELL BIOL, V21, P4647, DOI 10.1128/MCB.21.14.4647-4655.2001; RAK J, 1995, CANCER RES, V55, P4575; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Terasaki T, 2001, BIOL PHARM BULL, V24, P111, DOI 10.1248/bpb.24.111; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Vega-Diaz B, 2001, J INVEST DERMATOL, V116, P525, DOI 10.1046/j.1523-1747.2001.01294.x; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Wen X, 2000, Adv Dent Res, V14, P76; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	57	49	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8817	8829		10.1038/sj.onc.1206032	http://dx.doi.org/10.1038/sj.onc.1206032			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483534				2022-12-25	WOS:000179734400015
J	Konduri, SD; Yanamandra, N; Siddique, K; Joseph, A; Dinh, DH; Olivero, WC; Gujrati, M; Kouraklis, G; Swaroop, A; Kyritsis, AP; Rao, JS				Konduri, SD; Yanamandra, N; Siddique, K; Joseph, A; Dinh, DH; Olivero, WC; Gujrati, M; Kouraklis, G; Swaroop, A; Kyritsis, AP; Rao, JS			Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells	ONCOGENE			English	Article						glioma; invasion; cathepsin B; cystatin C	INHIBITORS STEFIN-A; CYSTEINE PROTEINASE-INHIBITORS; HUMAN COLORECTAL-CARCINOMA; HUMAN COLON-CARCINOMA; HUMAN BREAST-CANCER; CATHEPSIN-B; PROGNOSTIC-SIGNIFICANCE; ENDOGENOUS INHIBITORS; PROTEASE INHIBITORS; MOLECULAR-CLONING	Increases in the abundance of cathepsin B transcript and protein with increased tumor grade and changes in subcellular localization and activity of this enzyme. We observed progressive reductions in levels of the protease inhibitor cystatin C, an inhibitor of cathepsin B with corresponding increases in the malignancy of glioma cell lines, implying an inverse correlation between cystatin C and tumor grade. To investigate the role of cystatin C in the invasion of brain tumor cells, we stably transfected SNB19 glioblastoma cells with either a 0.4-kb cDNA construct of human cystatin C in the sense orientation or an empty vector. Clones expressing sense-cystatin C cDNA had higher cystatin C mRNA and protein levels than did control cells. Sense-transfected cells were also markedly less invasive than control cells in a Matrigel invasion assay and in a coculture assay of SNB19 spheroids and fetal rat brain aggregates. Finally, the sense-transfected cells did not form tumors in nude mice upon intracerebral injection. These results strongly implicate cystatin C in the invasiveness of human glioblastoma cells and suggest that sense transcripts of cystatin C may prove useful in cancer therapy.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Ioannina, Sch Med, Dept Neurol, GR-45110 Ioannina, Greece; Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci & Human Genet, Ann Arbor, MI 48109 USA; Univ Athens, Sch Med, Dept Propedeut Surg, GR-11527 Athens, Greece; Univ Illinois, Dept Neuropathol, Peoria, IL USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA	University of Illinois System; University of Illinois Peoria; University of Ioannina; University of Michigan System; University of Michigan; Athens Medical School; National & Kapodistrian University of Athens; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Swaroop, Anand/0000-0002-1975-1141	NCI NIH HHS [CA 76350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BOBEK LA, 1992, CRIT REV ORAL BIOL M, V3, P307, DOI 10.1177/10454411920030040101; Calkins CC, 1998, J HISTOCHEM CYTOCHEM, V46, P745, DOI 10.1177/002215549804600607; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTICCHIATO O, 1992, INT J CANCER, V52, P645; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Cox JL, 1999, MELANOMA RES, V9, P369, DOI 10.1097/00008390-199908000-00005; Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013; Gaumann A, 2001, PATHOL RES PRACT, V197, P257, DOI 10.1078/0344-0338-00044; HAWLEYNELSON P, 1988, MOL CARCINOGEN, V1, P202, DOI 10.1002/mc.2940010309; HEIDTMANN HH, 1992, BRIT J CANCER, V65, P154, DOI 10.1038/bjc.1992.33; HEIDTMANN HH, 1989, CANCER RES, V49, P6960; Hirai K, 1999, HUM PATHOL, V30, P680, DOI 10.1016/S0046-8177(99)90094-1; Huh CG, 1999, J CLIN PATHOL-MOL PA, V52, P332, DOI 10.1136/mp.52.6.332; KEPPLER D, 1994, BBA-MOL BASIS DIS, V1226, P117, DOI 10.1016/0925-4439(94)90018-3; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Kos J, 1997, CLIN CANCER RES, V3, P1815; Kos J, 2000, INT J BIOL MARKER, V15, P84, DOI 10.1177/172460080001500116; Kos J, 1998, CLIN CANCER RES, V4, P1511; Kos J, 2000, CLIN CANCER RES, V6, P505; Krepela E, 1998, NEOPLASMA, V45, P318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAH TT, 1992, CANCER LETT, V61, P243, DOI 10.1016/0304-3835(92)90295-7; Lah TT, 2000, CLIN CANCER RES, V6, P578; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Mangge H, 2000, CLIN CHIM ACTA, V300, P195, DOI 10.1016/S0009-8981(00)00322-3; Merz GS, 1997, J CELL PHYSIOL, V173, P423; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MORT JS, 1980, BIOCHIM BIOPHYS ACTA, V614, P134, DOI 10.1016/0005-2744(80)90174-6; MURNANE MJ, 1991, CANCER RES, V51, P1137; Pavlova A, 2000, FEBS LETT, V487, P156, DOI 10.1016/S0014-5793(00)02337-1; PEDERSEN PH, 1993, CANCER RES, V53, P5158; QIAN F, 1989, CANCER RES, V49, P4870; Randers E, 1999, CLIN CHEM LAB MED, V37, P389, DOI 10.1515/CCLM.1999.064; SCHMITT M, 1992, FIBRINOLYSIS, V6, P3; Sexton PS, 1997, MELANOMA RES, V7, P97, DOI 10.1097/00008390-199704000-00002; SHEAHAN K, 1989, CANCER RES, V49, P3809; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SLOANE BF, 1990, CANCER METAST REV, V9, P333, DOI 10.1007/BF00049523; SLOANE BF, 1994, BIOCH MOL ASPECTS SE, V2, P411; Stabuc B, 2000, CLIN CHEM, V46, P193; Strojan P, 2000, CLIN CANCER RES, V6, P1052; Strojnik T, 1999, CLIN CANCER RES, V5, P559; SUKOH N, 1994, VIRCHOWS ARCH, V424, P33; TERADA T, 1995, HUM PATHOL, V26, P746, DOI 10.1016/0046-8177(95)90222-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE M, 1989, BIOCHEM MED METAB B, V42, P21, DOI 10.1016/0885-4505(89)90037-6; Werle B, 1999, BRIT J CANCER, V81, P510, DOI 10.1038/sj.bjc.6690723; Yano M, 2001, SURG TODAY, V31, P385, DOI 10.1007/s005950170126; Yoshimura K, 2000, ONCOL REP, V7, P27	53	64	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8705	8712		10.1038/sj.onc.1205949	http://dx.doi.org/10.1038/sj.onc.1205949			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483523				2022-12-25	WOS:000179734400004
J	Wang, S; Fusaro, G; Padmanabhan, J; Chellappan, SP				Wang, S; Fusaro, G; Padmanabhan, J; Chellappan, SP			Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression	ONCOGENE			English	Article						prohibitin; Rb; histone deacetylase 1; IgM; marked box	RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; TUMOR-SUPPRESSOR; ACUTE-LEUKEMIA; CELL-CYCLE; E2F; INTERACTS; RECEPTOR; COMPLEXES; TARGET	The potential tumor suppressor protein prohibitin can prevent cell proliferation and this required its binding to the Rb protein. Prohibitin could repress the transcriptional activity of E2F family members and this required a part of the marked box region of E2F. The sub-cellular localization of prohibitin has been variously attributed to the mitochondria as well as the inner cell membrane. Here we show that a subset of probibitin molecules are present in the nucleus where it co-localizes with the Rb protein. Deletion of a putative amino-terminal membrane-docking domain of prohibitin had no effect on its ability to suppress cell proliferation or inhibit E2F activity. Our experiments show that a 53 amino-acid stretch of E2F1 is sufficient for being targeted by prohibitin; fusion of this region to GAL4-VP16 construct could make it susceptible to prohibitin-mediated, but not Rb-mediated repression. Prohibitin, like Rb, could repress transcription from SV40 and major late promoters when recruited directly to DNA. Prohibitin mediated transcriptional repression required histone-deacetylase activity, but unlike Rb, additional co-repressors like N-CoR are also involved. Repression by prohibitin correlates with histone deacetylation on promoters and this was reversed by IgM stimulation of cells; IgM did not affect Rb-mediated repression or deacetylation of the promoters. Prohibitin thus appears to repress E2F-mediated transcription utilizing different molecular mediators and facilitate channeling of specific signaling pathways to the cell cycle machinery.	Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Chellappan, SP (corresponding author), Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Chellasp@moffitt.usf.edu	Padmanabhan, Jaya/A-4226-2012	Padmanabhan, Jaya/0000-0003-2019-5135	NCI NIH HHS [CA 77301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Steglich G, 1999, MOL CELL BIOL, V19, P3435; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Thompson WE, 1999, ANAT REC, V256, P40, DOI 10.1002/(SICI)1097-0185(19990901)256:1<40::AID-AR6>3.0.CO;2-X; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHANG YH, 1995, ONCOGENE, V10, P2085	46	175	186	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8388	8396		10.1038/sj.onc.1205944	http://dx.doi.org/10.1038/sj.onc.1205944			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466959				2022-12-25	WOS:000179480100002
J	Thiriet, N; Ladenheim, B; McCoy, MT; Cadet, JL				Thiriet, N; Ladenheim, B; McCoy, MT; Cadet, JL			Analysis of ecstasy (MDMA)-induced transcriptional responses in the rat cortex	FASEB JOURNAL			English	Article						MDMA; cortex; gene expression; cDNA arrays; SYBR green PCR	SEROTONIN-DOPAMINE INTERACTIONS; ACTIVATED PROTEIN-KINASES; C-FOS EXPRESSION; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; METHYLENEDIOXYMETHAMPHETAMINE MDMA; SUPEROXIDE-DISMUTASE; TRANSGENIC MICE; GENE-EXPRESSION; 5-HT3 RECEPTORS; OXIDATIVE STRESS	3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a popular drug of abuse. MDMA is pharmacologically classified as an entactogen because of its affinities to classical hallucinogens and stimulants. Oral ingestion of a single dose of the drug is associated with euphoria, elevated self-confidence, and heightened sensory awareness in humans. Evidence for neurotoxicity in the human serotonin (5-HT) system has been provided. In rats, a single injection of MDMA induces hyperthermia and formation of reactive oxygen species. These effects may cause MDMA-associated, long-term 5-HT depletion, with the cortex being quite sensitive to the biochemical effects of MDMA. It has been suggested that these MDMA effects may be associated with molecular changes in this brain region. To test these ideas, we have made use of the cDNA array analysis, which can provide a more global view of the molecular changes secondary to MDMA injections. Our results show that the genes regulated by MDMA encode proteins that belong to signaling pathways, transcription regulators, or xenobiotic metabolism. Our observations indicate that cortical cells respond to the acute administration of MDMA by modulating transcription of several genes that might lead to long-term changes in the brain.	NIDA, Mol Neuropsychiat Sect, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Sect, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	jcadet@intra.nida.nih.gov		THIRIET, Nathalie/0000-0002-0076-4946	NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000153] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Aguirre N, 1997, J NEUROCHEM, V68, P1099; Aguirre N, 1999, NEUROREPORT, V10, P3675, DOI 10.1097/00001756-199911260-00039; Bai FJ, 2001, CHEM RES TOXICOL, V14, P863, DOI 10.1021/tx010011l; Bai FJ, 1999, CHEM RES TOXICOL, V12, P1150, DOI 10.1021/tx990084t; Bankson MG, 2001, J PHARMACOL EXP THER, V297, P846; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; Berry MD, 2000, J NEUROSCI RES, V60, P150, DOI 10.1002/(SICI)1097-4547(20000415)60:2<150::AID-JNR3>3.0.CO;2-4; CADET JL, 1995, SYNAPSE, V21, P169, DOI 10.1002/syn.890210210; CADET JL, 1994, BRAIN RES, V655, P259, DOI 10.1016/0006-8993(94)91624-1; Cadet JL, 2002, SYNAPSE, V44, P211, DOI 10.1002/syn.10074; Colado MI, 1997, BRIT J PHARMACOL, V121, P889, DOI 10.1038/sj.bjp.0701213; COLADO MJ, 1994, BRIT J PHARMACOL, V111, P131, DOI 10.1111/j.1476-5381.1994.tb14034.x; DAFTERS RI, 1994, PSYCHOPHARMACOLOGY, V114, P505, DOI 10.1007/BF02249342; Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Granoff MI, 1998, NEUROPSYCHOBIOLOGY, V37, P36, DOI 10.1159/000026474; Gudelsky GA, 1996, J NEURAL TRANSM, V103, P1397, DOI 10.1007/BF01271253; Gudelsky GA, 1996, J NEUROCHEM, V66, P243; Gurd JW, 1997, NEUROCHEM INT, V31, P635, DOI 10.1016/S0197-0186(97)00022-3; Hegadoren KM, 1999, NEUROSCI BIOBEHAV R, V23, P539, DOI 10.1016/S0149-7634(98)00046-3; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HIRAMATSU M, 1990, J PHARMACOL EXP THER, V254, P521; Hoyer D, 1997, NEUROPHARMACOLOGY, V36, P419, DOI 10.1016/S0028-3908(97)00036-1; Iwakura Y, 2001, J BIOL CHEM, V276, P40025, DOI 10.1074/jbc.M103125200; Jayanthi S, 1999, NEUROSCIENCE, V91, P1379, DOI 10.1016/S0306-4522(98)00698-8; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KUMAGAI Y, 1991, CHEM RES TOXICOL, V4, P330, DOI 10.1021/tx00021a012; Lee SA, 2000, MOL BRAIN RES, V75, P16, DOI 10.1016/S0169-328X(99)00280-6; LEONARDI ETK, 1994, NEUROPSYCHOPHARMACOL, V10, P231, DOI 10.1038/npp.1994.26; Liechti ME, 2000, NEUROPSYCHOPHARMACOL, V22, P513, DOI 10.1016/S0893-133X(99)00148-7; Marcotte ER, 2001, TRENDS PHARMACOL SCI, V22, P426, DOI 10.1016/S0165-6147(00)01741-7; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; MATTHEWS RT, 1989, PHARMACOL BIOCHEM BE, V33, P741, DOI 10.1016/0091-3057(89)90464-4; MCKENNA DJ, 1990, J NEUROCHEM, V54, P14, DOI 10.1111/j.1471-4159.1990.tb13277.x; MILLER FD, 1987, J CELL BIOL, V105, P3065, DOI 10.1083/jcb.105.6.3065; Morales M, 1996, BRAIN RES, V731, P199, DOI 10.1016/S0006-8993(96)00557-4; MORATALLA R, 1992, J NEUROSCI, V12, P2609; Morgan MJ, 2000, PSYCHOPHARMACOLOGY, V152, P230, DOI 10.1007/s002130000545; Paillart C, 1996, J CELL BIOL, V134, P499, DOI 10.1083/jcb.134.2.499; PATTERSON PH, 1995, CURR OPIN NEUROBIOL, V5, P642, DOI 10.1016/0959-4388(95)80070-0; Portas CM, 2000, PROG NEUROBIOL, V60, P13, DOI 10.1016/S0301-0082(98)00097-5; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; ROBINSON TE, 1982, BRAIN RES, V253, P231, DOI 10.1016/0006-8993(82)90690-4; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHEFFEL U, 1992, NEUROPHARMACOLOGY, V31, P881, DOI 10.1016/0028-3908(92)90126-A; SCHMIDT CJ, 1990, ANN NY ACAD SCI, V600, P665, DOI 10.1111/j.1749-6632.1990.tb16917.x; SCHMIDT CJ, 1987, J PHARMACOL EXP THER, V240, P1; Shankaran H, 1999, EUR J PHARMACOL, V385, P103, DOI 10.1016/S0014-2999(99)00728-1; Shirayama Y, 2000, EUR J PHARMACOL, V402, P215, DOI 10.1016/S0014-2999(00)00521-5; Simantov R, 1997, FASEB J, V11, P141, DOI 10.1096/fasebj.11.2.9039956; Stephenson CP, 1999, NEUROSCIENCE, V92, P1011, DOI 10.1016/S0306-4522(99)00049-4; STONE DM, 1987, NEUROPHARMACOLOGY, V26, P1677, DOI 10.1016/0028-3908(87)90117-1; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; SUGITA S, 1992, NEURON, V8, P199, DOI 10.1016/0896-6273(92)90121-S; Urade Y, 1996, J LIPID MEDIAT CELL, V14, P71, DOI 10.1016/0929-7855(96)01511-8; VACCARINO FM, 1993, MOL BRAIN RES, V19, P76, DOI 10.1016/0169-328X(93)90151-E; van Hooft JA, 2000, TRENDS NEUROSCI, V23, P605, DOI 10.1016/S0166-2236(00)01662-3; White SR, 1996, PROG NEUROBIOL, V49, P455, DOI 10.1016/0301-0082(96)00027-5; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; YAKEL JL, 1988, NEURON, V1, P615, DOI 10.1016/0896-6273(88)90111-0; Yau JLW, 1997, NEUROSCIENCE, V78, P111, DOI 10.1016/S0306-4522(96)00497-6; Yeh SY, 1997, PHARMACOL BIOCHEM BE, V58, P701, DOI 10.1016/S0091-3057(97)90010-1	68	27	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1887	1894		10.1096/fj.02-0502com	http://dx.doi.org/10.1096/fj.02-0502com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468453				2022-12-25	WOS:000180574300009
J	Philip, S; Kundu, GC				Philip, S; Kundu, GC			Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; ALPHA-V-BETA-3 INTEGRIN; TUMOR INVASION; MOUSE SKIN; CELLS; TRANSCRIPTION; INDUCTION; CANCER	We have recently reported that osteopontin (OPN) stimulates tumor growth and activation of promatrix metalloproteinase-2 (pro-MMP-2) through nuclear factor kappaB (NFkappaB)-mediated induction of membrane type 1 matrix metalloproteinase (MT1-MMP) in murine melanoma cells (Philip, S., Bulbule, A., and Kundu, G. C. (2001) J. BioL Chem. 276, 44926-44935). However, the molecular mechanism by which OPN activates NFkappaB and regulates pro-MMP-2 activation in murine melanoma (B16F10) cells is not well defined. We also investigated the mechanism of action of curcumin (diferulolylmethane) on OPN-induced NFkappaB-mediated activation of pro-MMP-2 in B16F10 cells. Here we report that OPN induces phosphorylation and degradation of the inhibitor of nuclear factor kappaB (IkappaBalpha) by inducing the activity of IkappaB kinase (IKK) in these cells. OPN also induces the nuclear accumulation of NFkappaB p65, NFkappaB-DNA binding, and transactivation. However, curcumin a known antiinflammatory and anticarcinogenic agent suppressed OPN-induced IkappaBalpha phosphorylation and degradation by inhibiting the IKK activity. Moreover, our data revealed that curcumin inhibited the OPN-induced translocation of p65, NFkappaB-DNA binding, and NFkappaB transcriptional activity. The OPN-induced pro-MMP-2 activation and MT1-MMP expression were also drastically reduced by curcumin. Curcumin also inhibited OPN-induced cell proliferation, cell migration, extracellular matrix invasion, and synergistically induced apoptotic morphology with OPN in these cells. Most importantly, curcumin suppressed the OPN-induced tumor growth in nude mice, and the levels of pro-MMP-2 expression and activation in OPN-induced tumor were inhibited by curcumin. To our knowledge, this is the first report that OPN induces NFkappaB activity through phosphorylation and degradation of lkappaBalpha by activating IKK that ultimately triggers the activation of pro-MMP-2 and further demonstrates that curcumin potently suppresses OPN-induced cell migration, tumor growth, and NFkappaB-mediated pro-MMP-2 activation by blocking the IKK/IkappaBalpha signaling pathways.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOPRA RN, 1958, CHOPRAS INDIGENOUS D, P325; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Commandeur JNM, 1996, XENOBIOTICA, V26, P667, DOI 10.3109/00498259609046741; COTTAM DW, 1993, INT J ONCOL, V2, P861; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Han YP, 2001, J CELL SCI, V114, P131; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HUANG MT, 1988, CANCER RES, V48, P5941; Jobin C, 1999, J IMMUNOL, V163, P3474; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NADKARNI KM, 1976, MATERIA MEDICA, P414; Nagabhushan M, 1986, Nutr Cancer, V8, P201; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RITTER NM, 1992, J BONE MINER RES, V7, P877; SATOSKAR RR, 1986, INT J CLIN PHARM TH, V24, P651; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHANNON AG, 1980, FIBONACCI QUART, V18, P73; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Sun Y, 1996, ANTICANCER RES, V16, P1; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang WX, 1999, CLIN CANCER RES, V5, P119; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486	51	211	237	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14487	14497		10.1074/jbc.M207309200	http://dx.doi.org/10.1074/jbc.M207309200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12473670	hybrid			2022-12-25	WOS:000182405000116
J	Qin, KF; Coomaraswamy, J; Mastrangelo, P; Yang, Y; Lugowski, S; Petromilli, C; Prusiner, SB; Fraser, PE; Goldberg, JM; Chakrabartty, A; Westaway, D				Qin, KF; Coomaraswamy, J; Mastrangelo, P; Yang, Y; Lugowski, S; Petromilli, C; Prusiner, SB; Fraser, PE; Goldberg, JM; Chakrabartty, A; Westaway, D			The PrP-like protein doppel binds copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRION PROTEIN; TERMINAL DOMAIN; DISEASE; GENE; NEURONS; CELLS; SITES; IDENTIFICATION; ENDOCYTOSIS; RECOMBINANT	Doppel (Dp1) is a glycosylphosphatidylinositol-anchored protein expressed in the testis. It exhibits 26% sequence identity with the prion protein (PrP) but lacks the octarepeat region implicated as the major copperbinding domain. Contrary to expectations, Cu(II) induced a 26% reduction in the intrinsic fluorescence of Dpl(27-154) and a calculated K-d for a single-site model of 0.16 +/- 0.08 muM. Other metals had minimal effects on fluorescence quenching. Matrix-assisted laser desorption ionization mass spectrometry of a Dpl peptide revealed binding of copper (but not other metals) to the helical alphaB/B'-Ioop-alphaC subregion of Dpl. Fluorescence quenching and equilibrium dialysis analyses of this Dpl(101-145) peptide were compatible with a binding site of K-d = 0.4 muM. Diethylpyrocarbonate footprinting (Qin, K., Yang, Y., Mastrangelo, P., and Westaway, D. (2002) J. BioL Chem. 277, 1981-1990) of Dpl(27-154) defined one residue/molecule was protected by copper from diethylpyrocarbonate adduct formation, and reiteration of this analysis with Dpl(101-145) suggested that His(131) may contribute to Cu(II) binding. Taken together, our data indicate that the alpha-helical region of mouse Dpl possesses a selective copper-binding site with a submicromolar Kd and perhaps one or more lower affinity sites. Although metallated forms of Dpl might exist in vivo, analyses of Tg(Dpl)10329 mice were inconsistent with reports that Dpl expression is associated with increased carbonylation and nitrosylation of brain proteins. Thus, rather than comprising an important source of free radical damage, copper binding may serve to modulate the activity, stability, or localization of the Dpl protein.	Univ Toronto, CRND, Toronto, ON M5S 3H2, Canada; Univ Toronto, Mol Med Res Ctr, Mass Spectrometry Lab, Toronto, ON M5S 3H2, Canada; Univ Toronto, Inst Biomat & Biomech Engn, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of California System; University of California San Francisco; Boston Biomedical Research Institute	Westaway, D (corresponding author), Univ Toronto, CRND, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	david.westaway@utoronto.ca		Chakrabartty, Avi/0000-0001-7002-8381				Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; Beck JA, 2001, NEUROLOGY, V57, P354, DOI 10.1212/WNL.57.2.354; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Capellari S, 2002, NEUROLOGY, V59, P1628, DOI 10.1212/01.WNL.0000035533.86833.28; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; LAU SJ, 1971, J BIOL CHEM, V246, P5938; Li AM, 2000, AM J PATHOL, V157, P1447, DOI 10.1016/S0002-9440(10)64782-7; Linder MC, 1996, AM J CLIN NUTR, V63, P797; Mastrangelo P, 2002, FEBS LETT, V532, P21, DOI 10.1016/S0014-5793(02)03614-1; Mastrangelo P, 2001, GENE, V275, P1, DOI 10.1016/S0378-1119(01)00627-8; Mo HP, 2001, P NATL ACAD SCI USA, V98, P2352, DOI 10.1073/pnas.051627998; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moore RC, 2001, P NATL ACAD SCI USA, V98, P15288, DOI 10.1073/pnas.251550798; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Silverman GL, 2000, J BIOL CHEM, V275, P26834; Spiro TG, 1969, STRUCT BOND, V6, P117; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wong BS, 2001, MOL CELL NEUROSCI, V17, P768, DOI 10.1006/mcne.2001.0963; Wong WY, 2001, REPROD TOXICOL, V15, P131, DOI 10.1016/S0890-6238(01)00113-7	44	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8888	8896		10.1074/jbc.M210875200	http://dx.doi.org/10.1074/jbc.M210875200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12482851	hybrid			2022-12-25	WOS:000181524000005
J	Grziwa, B; Grimm, MOW; Masters, CL; Beyreuther, K; Hartmann, T; Lichtenthaler, SF				Grziwa, B; Grimm, MOW; Masters, CL; Beyreuther, K; Hartmann, T; Lichtenthaler, SF			The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; STAPHYLOCOCCAL ALPHA-HEMOLYSIN; ALZHEIMERS-DISEASE; BETA-PROTEIN; INTRAMEMBRANE CLEAVAGE; INTRACELLULAR DOMAIN; SCANNING MUTAGENESIS; GOLGI-APPARATUS; KEY RESIDUES; NOTCH	The amyloid precursor protein is cleaved within its ectodomain by beta-amyloid-converting enzyme (BACE) yielding C99, which is further cleaved by gamma-secretase within its putative transmembrane domain (TMD). Because it is difficult to envisage how a protease may cleave within the membrane, alternative mechanisms have been proposed for gamma-cleavage in which the TMD is shorter than predicted or positioned such that the gamma-cleavage site is accessible to cytosolic proteases. Here, we have biochemically determined the length of the TMD of C99 in microsomal membranes. Using a single cysteine mutagenesis scan of C99 combined with cysteine modification with a membrane-impermeable labeling reagent, we identified which residues are accessible to modification and thus located outside of the membrane. We find that in endoplasmic reticulum-derived microsomes the TMD of C99 consists of 12 residues that span from residues 37 to 48, which is N- and C-terminally shorter than predicted. Thus, the gamma-cleavage sites are positioned around the middle of the lipid bilayer and are unlikely to be accessible to cytosolic proteases. Moreover, the center of the TMD is positioned at the gamma-cleavage site at residue 42. Our data are consistent with a model in which gamma-secretase is a membrane protein that cleaves at the center of the membrane.	Univ Heidelberg, Ctr Mol Biol, D-69120 Heidelberg, Germany; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA	Ruprecht Karls University Heidelberg; University of Melbourne; Harvard University; Harvard Medical School; Massachusetts General Hospital	Grziwa, B (corresponding author), Univ Heidelberg, Ctr Mol Biol, INF 282, D-69120 Heidelberg, Germany.		Hartmann, Tobias/AAB-8297-2022; Lichtenthaler, Stefan F/B-6587-2016; Grimm, Marcus O. W./F-8134-2011	Lichtenthaler, Stefan F/0000-0003-2211-2575; Grimm, Marcus O. W./0000-0002-4160-6506; Hartmann, Tobias/0000-0001-7481-6430				BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 2000, J CELL SCI, V113, P1857; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lichtenthaler SF, 2002, P NATL ACAD SCI USA, V99, P1365, DOI 10.1073/pnas.032395699; Lichtenthaler SF, 1999, FEBS LETT, V453, P288, DOI 10.1016/S0014-5793(99)00730-9; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; MARUYAMA K, 1994, BIOCHEM BIOPH RES CO, V202, P1517, DOI 10.1006/bbrc.1994.2103; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; van Geest M, 2000, BBA-BIOMEMBRANES, V1466, P328, DOI 10.1016/S0005-2736(00)00185-1; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200	47	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6803	6808		10.1074/jbc.M210047200	http://dx.doi.org/10.1074/jbc.M210047200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12454010	hybrid			2022-12-25	WOS:000181195100023
J	Schmidt, EE; Bondareva, AA; Radke, JR; Capecchi, MR				Schmidt, EE; Bondareva, AA; Radke, JR; Capecchi, MR			Fundamental cellular processes do not require vertebrate-specific sequences within the TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MESSENGER-RNA; ARCHAEAL TRANSCRIPTION; HUMAN TBP; NF-Y; MOUSE; GENE; EXPRESSION; PROMOTER; CDNA	The 180-amino acid core of the TATA-binding protein (TBPCORE) is conserved from Archae bacteria to man. Vertebrate TBPs contain, in addition, a large and highly conserved N-terminal region that is not found in other phyla. We have generated a line of mice in which the tbp allele is replaced with a version, tbp(DeltaN), which lacks 111 of 135 N-terminal amino acid residues. Most tbp(DeltaN/DeltaN) fetuses die in midgestation. To test whether a disruption of general cellular processes contributed to this fetal loss, primary fibroblast cultures were established from +/+, DeltaN/+, and DeltaN/DeltaN fetuses. The cultures exhibited no genotype-dependent differences in proliferation or in expression of the proliferative markers dihydrofolate reductase (DHFR) mRNA (S phase-specific) and cdc25B mRNA (G(2)-specific). The mutation had no effect on transcription initiation site fidelity by either RNA polymerase H (pol 11) or pol III. Moreover, the mutation did not cause differences in levels of U6 RNA, a pol III-dependent component of the splicing machinery, in mRNA splicing efficiency, in expression of housekeeping genes from either TATA-containing or TATA-less promoters, or in global gene expression. Our results indicated that general eukaryotic cell functions are unaffected by deletion of these vertebrate-specific sequences from TBP. Thus, all activities of this polypeptide domain must either be compensated for by redundant activities or be restricted to situations that are not represented by primary fibroblasts.	Montana State Univ, Marsh Labs, Dept Vet Mol Biol, Bozeman, MT 59717 USA; Univ Utah, Howard Hughes Med Inst, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA	Montana State University System; Montana State University Bozeman; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Schmidt, EE (corresponding author), Montana State Univ, Marsh Labs, Dept Vet Mol Biol, Bozeman, MT 59717 USA.	eschmidt@montana.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD039242, R03HD035824] Funding Source: NIH RePORTER; NICHD NIH HHS [R03 HD039242-01, R03 HD039242-02, R03 HD035824-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P365, DOI 10.1128/MCB.6.2.365; HASHIMOTO S, 1992, NUCLEIC ACIDS RES, V20, P3788, DOI 10.1093/nar/20.14.3788; Hausner W, 2001, J BACTERIOL, V183, P3025, DOI 10.1128/JB.183.10.3025-3031.2001; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hernandez S, 1998, CANCER RES, V58, P1762; Hobbs NK, 2002, CELL, V110, P43, DOI 10.1016/S0092-8674(02)00806-1; Hoshiyama D, 2001, GENE, V280, P169, DOI 10.1016/S0378-1119(01)00766-1; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P1598, DOI 10.1128/MCB.3.9.1598; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LI XY, 1992, J BIOL CHEM, V267, P8984; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; Meir E, 2002, CURR BIOL, V12, P778, DOI 10.1016/S0960-9822(02)00839-4; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; NAKASHIMA K, 1995, GENE, V152, P209, DOI 10.1016/0378-1119(94)00681-H; NUDEL U, 1982, P NATL ACAD SCI-BIOL, V79, P2763, DOI 10.1073/pnas.79.9.2763; Ohbayashi T, 1999, BIOCHEM BIOPH RES CO, V255, P137, DOI 10.1006/bbrc.1999.0159; Ohbayashi T, 1999, NUCLEIC ACIDS RES, V27, P750, DOI 10.1093/nar/27.3.750; Ohbayashi T, 1996, BIOCHEM BIOPH RES CO, V225, P275, DOI 10.1006/bbrc.1996.1166; Qureshi SA, 1997, EMBO J, V16, P2927, DOI 10.1093/emboj/16.10.2927; Rabenstein MD, 1999, P NATL ACAD SCI USA, V96, P4791, DOI 10.1073/pnas.96.9.4791; REDDY R, 1987, J BIOL CHEM, V262, P75; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Schmidt EE, 1997, DEV BIOL, V184, P138, DOI 10.1006/dbio.1997.8514; Schmidt EE, 1997, J BIOL CHEM, V272, P5326, DOI 10.1074/jbc.272.8.5326; SCHMIDT EE, 1989, J BIOL CHEM, V264, P21247; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; SHARP PA, 1988, JAMA-J AM MED ASSOC, V260, P3035, DOI 10.1001/jama.260.20.3035; Shimada M, 1999, NUCLEIC ACIDS RES, V27, P3146, DOI 10.1093/nar/27.15.3146; SUZUKI N, 1993, NUCLEIC ACIDS RES, V21, P245, DOI 10.1093/nar/21.2.245; Takada S, 2000, CELL, V101, P459, DOI 10.1016/S0092-8674(00)80857-0; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; Um M, 2001, MOL CELL BIOL, V21, P2435, DOI 10.1128/MCB.21.7.2435-2448.2001; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Zhao XM, 2002, CELL, V108, P615, DOI 10.1016/S0092-8674(02)00648-7	52	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6168	6174		10.1074/jbc.M211205200	http://dx.doi.org/10.1074/jbc.M211205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471023	hybrid			2022-12-25	WOS:000181129400085
J	Singh, DK; Mokashi, V; Elmore, CL; Porter, TD				Singh, DK; Mokashi, V; Elmore, CL; Porter, TD			Phosphorylation of supernatant protein factor enhances its ability to stimulate microsomal squalene monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOCOPHEROL-ASSOCIATED PROTEIN; RAT OLFACTORY EPITHELIUM; KINASE-C; EPOXIDASE ACTIVITY; LIVER; CHOLESTEROL; EXPRESSION; HEPATOCYTES; INHIBITORS; CELLS	Supernatant protein factor is a 46-kDa cytosolic protein that stimulates squalene monooxygenase, a downstream enzyme in the cholesterol biosynthetic pathway. The mechanism of stimulation is poorly understood, although supernatant protein factor belongs to a family of lipid-binding proteins that includes Sec14p and a-tocopherol transfer protein. Because recombinant human supernatant protein factor purified from Escherichia coli exhibited a relatively weak ability to activate microsomal squalene monooxygenase, we investigated the possibility that cofactors or post-translational modifications were necessary for full activity. Addition of ATP to rat liver cytosol increased supernatant protein factor activity by more than 2-fold and could be prevented by the addition of inhibitors of protein kinases A and C. Incubation of purified recombinant supernatant protein factor with ATP and protein kinases A or Cdelta similarly increased activity by more than 2-fold. Addition of protein phosphatase lgamma, a serine/threonine phosphatase, to rat liver cytosol reduced activity by 50%, suggesting that supernatant protein factor is partially phosphorylated in vivo. To determine whether dietary cholesterol influenced the phosphorylation state, cytosols were prepared from livers of rats fed a high fat diet. Although supernatant protein factor activity was reduced by more than one-half, it could not be restored by the addition of ATP or protein kinase CS with ATP, suggesting that dietary cholesterol reduced the expression of this protein. Supernatant protein factor thus appears to be regulated both post-translationally through phosphorylation and at the level of expression. Phosphorylation may provide a means for the rapid short term modulation of cholesterol synthesis.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Porter, TD (corresponding author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007266] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES-07266] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; BEG ZH, 1985, J BIOL CHEM, V260, P1682; CARAS IW, 1980, J BIOL CHEM, V255, P3575; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Ducher L, 1995, BIOCHEM BIOPH RES CO, V217, P546, DOI 10.1006/bbrc.1995.2810; EASOM RA, 1984, BIOCHEM J, V220, P733, DOI 10.1042/bj2200733; EILENBERG H, 1987, J LIPID RES, V28, P1398; FERGUSON JB, 1977, J BIOL CHEM, V252, P5381; FRIEDLANDER EJ, 1980, J BIOL CHEM, V255, P8042; FUKSHOLMBERG D, 1983, J LIPID RES, V24, P402; GLASS DB, 1989, J BIOL CHEM, V264, P8802; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; Hernandez ML, 1997, BBA-LIPID LIPID MET, V1349, P233, DOI 10.1016/S0005-2760(97)00141-0; Laden BP, 2000, ARCH BIOCHEM BIOPHYS, V374, P381, DOI 10.1006/abbi.1999.1629; Lange Y, 2002, BIOCHEM BIOPH RES CO, V290, P488, DOI 10.1006/bbrc.2001.6156; Lange Y, 1999, J LIPID RES, V40, P2264; Lu ZX, 1996, BIOL CHEM H-S, V377, P373; Mehta KD, 2002, MOL CELL BIOL, V22, P3783, DOI 10.1128/MCB.22.11.3783-3793.2002; Merkulova MI, 1999, FEBS LETT, V450, P126, DOI 10.1016/S0014-5793(99)00470-6; Nagai M, 2002, BIOCHEM BIOPH RES CO, V295, P74, DOI 10.1016/S0006-291X(02)00623-X; NAGUMO A, 1995, J LIPID RES, V36, P1489; Nakamura P, 1996, J BIOL CHEM, V271, P8053, DOI 10.1074/jbc.271.14.8053; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NOVOSELOV VI, 1994, FEBS LETT, V353, P286, DOI 10.1016/0014-5793(94)01051-X; ONO T, 1975, J BIOL CHEM, V250, P1571; Porter TD, 2003, J NUTR BIOCHEM, V14, P3, DOI 10.1016/S0955-2863(02)00262-0; Ricciarelli R, 2000, CIRCULATION, V102, P82, DOI 10.1161/01.CIR.102.1.82; SATOH T, 1990, J LIPID RES, V31, P2095; Sayed SB, 1997, J ENDOCRINOL, V154, P449, DOI 10.1677/joe.0.1540449; Sekar N, 2001, ENDOCRINOLOGY, V142, P2921, DOI 10.1210/en.142.7.2921; SENJO M, 1985, ARCH BIOCHEM BIOPHYS, V238, P584, DOI 10.1016/0003-9861(85)90203-6; Shibata N, 2001, P NATL ACAD SCI USA, V98, P2244, DOI 10.1073/pnas.041620398; Stocker A, 2002, STRUCTURE, V10, P1533, DOI 10.1016/S0969-2126(02)00884-5; Teupser D, 1999, ATHEROSCLEROSIS, V144, P109, DOI 10.1016/S0021-9150(99)00040-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WAGNER M, 1995, J NEUROCHEM, V64, P2169; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V285, P295, DOI 10.1006/bbrc.2001.5162; ZAMMIT VA, 1990, BIOCHEM J, V269, P373, DOI 10.1042/bj2690373; Zimmer S, 2000, J BIOL CHEM, V275, P25672, DOI 10.1074/jbc.M000851200	39	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5646	5651		10.1074/jbc.M211750200	http://dx.doi.org/10.1074/jbc.M211750200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12454003	hybrid			2022-12-25	WOS:000181129400022
J	Weston, C; Gordon, C; Teressa, G; Hod, E; Ren, XD; Prives, J				Weston, C; Gordon, C; Teressa, G; Hod, E; Ren, XD; Prives, J			Cooperative regulation by Rac and Rho of agrin-induced acetylcholine receptor clustering in muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; SRC FAMILY KINASES; NEUROMUSCULAR-JUNCTION; FOCAL ADHESIONS; SUBSTRATE CONTACT; GENE-PRODUCT; GTPASES; PHOSPHORYLATION; CYTOSKELETON	A key aspect of neuromuscular synapse formation is the clustering of muscle acetylcholine receptors (AChR) at synaptic sites in response to neurally secreted agrin. Agrin-induced AChR clustering in cultured myotubes proceeds via the initial formation of small microclusters, which then aggregate to form AChR clusters. Here we show that the coupling of agrin signaling to AChR clustering is dependent on the coordinated activities of Rac and Rho GTPases. The addition of agrin induces the sequential activation of Rac and Rho in C2 muscle cells. The activation of Rac is rapid and transient and constitutes a prerequisite for the subsequent activation of Rho. This temporal pattern of agrin-induced Rac and Rho activation reflects their respective roles in AChR cluster formation. Whereas agrin-induced activation of Rac is necessary for the initial phase of AChR cluster formation, which involves the aggregation of diffuse AChR into microclusters, Rho activation is crucial for the subsequent condensation of these microclusters into full-size AChR clusters. Co-expression of constitutively active forms of Rac and Rho is sufficient to induce the formation of mature AChR clusters in the absence of agrin. These results establish that Rac and Rho play distinct but complementary roles in the mechanism of agrin-induced AChR clustering.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Dermatol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Prives, J (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.				NIGMS NIH HHS [T32 GM008444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BLOCH RJ, 1980, CELL, V21, P25, DOI 10.1016/0092-8674(80)90111-7; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; Borges LS, 2002, J NEUROBIOL, V50, P69, DOI 10.1002/neu.10020; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Colledge M, 1998, P NATL ACAD SCI USA, V95, P3341, DOI 10.1073/pnas.95.7.3341; Dai ZS, 2000, J CELL BIOL, V150, P1321, DOI 10.1083/jcb.150.6.1321; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Fuhrer C, 1996, J BIOL CHEM, V271, P32474, DOI 10.1074/jbc.271.50.32474; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hoch W, 1999, EUR J BIOCHEM, V265, P1, DOI 10.1046/j.1432-1327.1999.00765.x; HOCH W, 1994, J CELL BIOL, V126, P1, DOI 10.1083/jcb.126.1.1; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Kunkel DD, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-19; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo ZG, 2002, NEURON, V35, P489, DOI 10.1016/S0896-6273(02)00783-3; LUTHER PW, 1994, CELL MOTIL CYTOSKEL, V28, P179, DOI 10.1002/cm.970280209; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Marangi PA, 2001, EMBO J, V20, P7060, DOI 10.1093/emboj/20.24.7060; Mittaud P, 2001, J BIOL CHEM, V276, P14505, DOI 10.1074/jbc.M007024200; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Nimnual AS, 1998, BIOCHEMISTRY-US, V37, P14823, DOI 10.1021/bi9802824; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Phillips WD, 1995, CLIN EXP PHARMACOL P, V22, P961, DOI 10.1111/j.1440-1681.1995.tb02333.x; PUMPLIN DW, 1987, J CELL BIOL, V104, P97, DOI 10.1083/jcb.104.1.97; RAPUANO M, 1989, DEV BIOL, V134, P271, DOI 10.1016/0012-1606(89)90099-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; ROSS A, 1988, J CELL BIOL, V107, P1139, DOI 10.1083/jcb.107.3.1139; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Smith CL, 2001, J NEUROSCI, V21, P3151, DOI 10.1523/JNEUROSCI.21-09-03151.2001; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Weston C, 2000, J CELL BIOL, V150, P205, DOI 10.1083/jcb.150.1.205; Wilde C, 2001, TOXICON, V39, P1647, DOI 10.1016/S0041-0101(01)00152-0	52	99	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6450	6455		10.1074/jbc.M210249200	http://dx.doi.org/10.1074/jbc.M210249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12473646	hybrid			2022-12-25	WOS:000181129400119
J	Yedavalli, VSRK; Benkirane, M; Jeang, KT				Yedavalli, VSRK; Benkirane, M; Jeang, KT			Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; P-TEFB KINASE; POLYMERASE-II; TRANSCRIPTIONAL ELONGATION; IN-VIVO; DNA-BINDING; TYPE-1; DOMAIN; PROTEIN; COMPLEX	P-TEFb, cyclin T1 + CDK9, is needed for the expression of cellular promoters and primate lentiviral long terminal repeats (LTRs). Curiously, cellular and lentiviral promoters differ dramatically in the requirements for positive transcriptional elongation factor (P-TEF) b activity. Lentiviral LTRs, but not cellular promoters, need an RNA-associated P-TEFb/Tat/TAR (trans-activation-responsive) RNA ternary complex. Ternary complex defective murine cycT1 is apparently inactive for lentiviral transcription. Why P-TEFb requires Tat/TAR for LTRs but not for cellular promoters remains unknown. To explore this question, we sought to determine whether DNA targeting of murine and human cyclin T1 can reconstitute a Tat/TAR-independent activity to the HIV-1 LTR. In the absence of Tat and TAR, we found that both HuCycT1 and MuCycT1 can robustly activate the HIV-1 LTR. We further showed that Sp1 is necessary and sufficient for this DNA-targeted activity. Thus, like cellular promoters, HIV-1 LTR can use P-TEFb function without a Tat/TAR RNA complex. This activity could explain recent findings of robust HIV-1 replication in rat cells that cannot form a P-TEFb/Tat/TAR moiety.	NIAID, Mol Microbiol Lab, Mol Virol Sect, Bethesda, MD 20892 USA; CNRS, Unite Propre Rech, Inst Genet Humaine, Lab Virol Mol & Transfert Gene, F-34296 Montpellier, France	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Jeang, KT (corresponding author), Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Bieniasz PD, 2000, J VIROL, V74, P9868, DOI 10.1128/JVI.74.21.9868-9877.2000; Chen D, 1999, MOL CELL BIOL, V19, P2863; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Fraldi A, 2001, J CELL BIOCHEM, P247; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Herrmann CH, 2001, J CELL SCI, V114, P1491; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Ivanov D, 1999, J MOL BIOL, V288, P41, DOI 10.1006/jmbi.1999.2663; JACKSON DA, 1993, J CELL SCI, V105, P1143; Jeang K T, 1994, Curr Top Microbiol Immunol, V188, P123; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Keppler OT, 2001, J VIROL, V75, P8063, DOI 10.1128/JVI.75.17.8063-8073.2001; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Lin X, 2002, J BIOL CHEM, V277, P16873, DOI 10.1074/jbc.M200117200; Lis JT, 2000, GENE DEV, V14, P792; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marcello A, 2001, J BIOL CHEM, V276, P39220, DOI 10.1074/jbc.M104830200; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Reid W, 2001, P NATL ACAD SCI USA, V98, P9271, DOI 10.1073/pnas.161290298; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; West MJ, 1999, EMBO J, V18, P1378, DOI 10.1093/emboj/18.5.1378; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	58	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6404	6410		10.1074/jbc.M209162200	http://dx.doi.org/10.1074/jbc.M209162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12458222	hybrid			2022-12-25	WOS:000181129400113
J	Daltrop, O; Ferguson, SJ				Daltrop, O; Ferguson, SJ			Cytochrome c maturation - The in vitro reactions of horse heart apocytochrome c and Paracoccus denitrificans apocytochrome c(550) with heme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL THIOREDOXIN SYSTEM; BINDING; BIOGENESIS; PROTEINS; COMPLEX; IDENTIFICATION; EXPRESSION; C(552); IMPORT; FORMS	C-type cytochromes are characterized by having the heme moiety covalently attached via thioether bonds between the heme vinyl groups and the thiols of conserved cysteine residues of the polypeptide chain. Previously, we have shown the in vitro formation of Hydrogenobacter thermophilus cytochrome c(552) (Daltrop, O., Allen, J. W. A., Willis, A. C., and Ferguson, S. J. (2002) Proc. Natl Acad. Sci. U. S. A. 99, 7872-7876). In this work we report that thioether bonds can form spontaneously in vitro between heme and the apocytochromes c from horse heart and Paracoccus denitrificans via b-type cytochrome intermediates. Both apocytochromes, but not the holo forms, bind 8-anilino-1-naphthalenesulfonate, indicating that the apoproteins each have an affinity for a hydrophobic ligand. Furthermore, for both apocytochromes c an intramolecular disulfide can form between the cysteines of the CXXCH motif that is characteristic of c-type cytochromes. In vitro reaction of these apocytochromes c with heme to yield holocytochromes c, and the tendency to form a disulfide, have implications for the different systems responsible for cytochrome c maturation in vivo in various organisms.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	stuart.ferguson@bioch.ox.ac.uk						Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; Ferguson SJ, 2001, BIOCHEM SOC T, V29, P629, DOI 10.1042/0300-5127:0290629; FISHER WR, 1973, J BIOL CHEM, V248, P3188; Goldberg ME, 1999, J BIOL CHEM, V274, P16052, DOI 10.1074/jbc.274.23.16052; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; HULSE CL, 1988, ANAL BIOCHEM, V172, P420, DOI 10.1016/0003-2697(88)90464-2; Kang XS, 1999, BIOCHEMISTRY-US, V38, P15944, DOI 10.1021/bi9919089; KOPPENHOFER A, 1998, THESIS U OXFORD; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; LADOKHIN AS, 2000, ENCY ANAL CHEM, P5762; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; McRee DE, 2001, J BIOL CHEM, V276, P6537, DOI 10.1074/jbc.M008421200; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Patel CN, 2001, PROTEIN EXPRES PURIF, V22, P220, DOI 10.1006/prep.2001.1438; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Richter CD, 2002, J BIOL CHEM, V277, P3093, DOI 10.1074/jbc.M108944200; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; Sanders C, 2000, BBA-BIOENERGETICS, V1459, P131, DOI 10.1016/S0005-2728(00)00122-5; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; SCOTT RA, 1995, CYTOCHROME C MULTIDI; Sinha N, 1998, FEMS MICROBIOL LETT, V161, P1; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; Tong JC, 1998, J BIOL CHEM, V273, P25695, DOI 10.1074/jbc.273.40.25695; VESTWEBER D, 1988, J CELL BIOL, V107, P2045, DOI 10.1083/jcb.107.6.2045; Wain R, 2001, J BIOL CHEM, V276, P45813, DOI 10.1074/jbc.M107572200	39	35	35	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4404	4409		10.1074/jbc.M211124200	http://dx.doi.org/10.1074/jbc.M211124200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458205	hybrid			2022-12-25	WOS:000180968900007
J	Liu, M; Liu, MC; Magoulas, C; Priestley, JV; Willmott, NJ				Liu, M; Liu, MC; Magoulas, C; Priestley, JV; Willmott, NJ			Versatile regulation of cytosolic Ca2+ by vanilloid receptor I in rat dorsal root ganglion neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; ACTIVATED ION-CHANNEL; PROTEIN-KINASE-C; CAPSAICIN-RECEPTOR; SENSORY NEURONS; XENOPUS OOCYTES; DESENSITIZATION; THAPSIGARGIN; DEPLETION; STORES	Analysis of small dorsal root ganglion (DRG) neurons revealed novel functions for vanilloid receptor 1 (VR1) in the regulation of cytosolic Ca2+. The VR1 agonist capsaicin induced Ca2+ mobilization from intracellular stores in the absence of extracellular Ca2+, and this release was inhibited by the VR1 antagonist capsazepine but was unaffected by the phospholipase C inhibitor xestospongins, indicating that Ca2+ mobilization was dependent on capsaicin receptor binding and was not due to intracellular inositol-1,4,5-trisphosphate generation. Confocal microscopy revealed extensive expression of VR1 on endoplasmic reticulum, consistent with VR1 operating as a Ca2+ release receptor. The main part of the capsaicin-releasable Ca2+ store was insensitive to thapsigargin, a selective endoplasmic reticulum Ca2+- ATPase inhibitor, suggesting that VR1 might be predominantly localized to a thapsigargin-insensitive endoplasmic reticulum Ca2+ store. In addition, VR1 was observed to behave as a store-operated Ca2+ influx channel. In DRG neurons, capsazepine attenuated Ca2+ influx following thapsigargin-induced Ca2+ store depletion and inhibited thapsigargin-induced inward currents. Conversely, transfected HEK-293 cells expressing VR1 showed enhanced Ca2+ influx and inward currents following Ca2+ store depletion. Combined data support topographical and functional diversity for VR1 in the regulation of cytosolic Ca2+ with the plasma membrane-associated form behaving as a store-operated Ca2+ influx channel and endoplasmic reticulum-associated VR1 possibly functioning as a Ca2+ release receptor in sensory neurons.	Univ London, St Bartholomews & Royal London Sch Med & Dent, Dept Neurosci, London EC1 4NS, England; Univ London, St Bartholomews & Royal London Sch Med & Dent, Dept Neurosurg, London EC1 4NS, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Willmott, NJ (corresponding author), Univ London, St Bartholomews & Royal London Sch Med & Dent, Dept Neurosci, Med Sci Bldg,Mile End Rd, London EC1 4NS, England.			Magoulas, Charalambos/0000-0002-4396-7700				Bevan S., 1993, CAPSAICIN STUDY PAIN, P27; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; CHOLEWINSKI A, 1993, NEUROSCIENCE, V55, P1015, DOI 10.1016/0306-4522(93)90315-7; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; Eun SY, 2001, BIOCHEM BIOPH RES CO, V285, P1114, DOI 10.1006/bbrc.2001.5272; Feher JJ, 1998, MOL CELL BIOCHEM, V189, P9, DOI 10.1023/A:1006800328118; Fierro L, 2000, J PHYSIOL-LONDON, V522, P247, DOI 10.1111/j.1469-7793.2000.t01-1-00247.x; GAVAZZI S, 2000, NEUROREPORT, V11, P1607; HOLZER P, 1991, PHARMACOL REV, V43, P143; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; HYLDEN JLK, 1992, J NEUROSCI, V12, P1716; JANCSO G, 1984, BRAIN RES, V295, P211, DOI 10.1016/0006-8993(84)90969-7; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; Jung J, 1999, J NEUROSCI, V19, P529; KIRALY E, 1991, BRAIN RES, V540, P279, DOI 10.1016/0006-8993(91)90518-Z; LUPUMEIRI M, 1993, CELL CALCIUM, V14, P101, DOI 10.1016/0143-4160(93)90080-P; MARSH SJ, 1987, NEUROSCIENCE, V23, P275, DOI 10.1016/0306-4522(87)90289-2; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Missiaen L, 2002, J BIOL CHEM, V277, P6898, DOI 10.1074/jbc.M110939200; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Putney JW, 2001, NATURE, V410, P648, DOI 10.1038/35070704; Putney JW, 1999, BIOESSAYS, V21, P38; SANTICIOLI P, 1987, NEUROSCI LETT, V80, P167, DOI 10.1016/0304-3940(87)90648-3; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	37	88	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5462	5472		10.1074/jbc.M209111200	http://dx.doi.org/10.1074/jbc.M209111200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12454015	hybrid			2022-12-25	WOS:000180968900139
J	Sigal, N; Gorzalczany, Y; Sarfstein, R; Weinbaum, C; Zheng, Y; Pick, E				Sigal, N; Gorzalczany, Y; Sarfstein, R; Weinbaum, C; Zheng, Y; Pick, E			The guanine nucleotide exchange factor trio activates the phagocyte NADPH oxidase in the absence of GDP to GTP exchange on Rac - "The emperor's new clothes"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; BINDING PROTEINS; SUPEROXIDE PRODUCTION; CRYSTAL-STRUCTURE; FACTOR DOMAINS; IN-VITRO; P67(PHOX); COMPONENT; COMPLEX	The superoxide-generating NADPH oxidase complex of phagocytes consists of a membrane-associated flavocytochrome b(559) and four cytosolic components as follows: p47(phox), p67(phox), p40(phox), and the small GTPase Rac (1 or 2). Activation of the oxidase is the result of assembly of the cytosolic components with cytochrome b(559) and can be mimicked in vitro by mixtures of membrane and cytosolic components exposed to an anionic amphiphile, serving as activator. We reported that prenylation of Rac1 endows it with the ability to support oxidase activation in conjunction with p67(phox) but in the absence of amphiphile and p47ph,. We now show the following 6 points. 1) The Rac guanine nucleotide exchange factor Trio markedly potentiates oxidase activation by prenylated Rac1-GDP. 2) This occurs in the absence of exogenous GTP or any other source of GTP generation, demonstrating that the effect of Trio does not involve GDP to GTP exchange on Rac1. 3) Trio does not potentiate oxidase activation by prenylated Rac1-GTP, by nonprenylated Rac1-GDP in the presence or absence of amphiphile, and by a prenylated [p67(phox)-Rac1] chimera in GDP-bound form. 4) Rac1 mutants defective in the ability to bind Trio or to respond to Trio by nucleotide exchange fail to respond to Trio by enhanced oxidase activation. 5) A Trio mutant with conserved Rac1-binding ability but lacking nucleotide exchange activity fails to enhance oxidase activation. 6) The effect of Trio is mimicked by displacement of Mg2+ from Rac1-GDP. These results reveal the existence of a novel mechanism of Rac activation by a guanine nucleotide exchange factor and suggest that the induction by Trio of a conformational change in Rac1, in the absence of nucleotide exchange, is sufficient for enhancing its effector function.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Ela Kodesz Inst Host Def Infect Dis, IL-69978 Tel Aviv, Israel; Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Duke University	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel.		Zheng, Yi/J-7235-2015; Pick, Edgar/B-1795-2008	Zheng, Yi/0000-0001-7089-6074; Pick, Edgar/0000-0003-4625-3233	NIGMS NIH HHS [GM60523, GM46372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523, R01GM046372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1992, J BIOL CHEM, V267, P16767; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cross AR, 1999, BIOCHEM J, V338, P229, DOI 10.1042/0264-6021:3380229; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Gao Y, 2001, J BIOL CHEM, V276, P47530, DOI 10.1074/jbc.M108865200; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HARTWICK RA, 1975, J CHROMATOGR, V112, P651, DOI 10.1016/S0021-9673(00)99994-1; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Leto TL., 1999, INFLAMMATION BASIC P, P769; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Shimizu T, 2000, J BIOL CHEM, V275, P18311, DOI 10.1074/jbc.M910274199; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SUNYER T, 1984, J BIOL CHEM, V259, P5447; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; XU XM, 1994, J BIOL CHEM, V269, P23569; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	42	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4854	4861		10.1074/jbc.M211011200	http://dx.doi.org/10.1074/jbc.M211011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12475976	hybrid			2022-12-25	WOS:000180968900067
J	Sun, SY; Shamoo, Y				Sun, SY; Shamoo, Y			Biochemical characterization of interactions between DNA polymerase and single-stranded DNA-binding protein in bacteriophage RB69	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-DESTABILIZING PROTEIN; GENE 32 PROTEIN; REPLICATION FORK; T4 GENE-32; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; KLENOW FRAGMENT; COOH TERMINUS; COMPLEX; PURIFICATION	The organization and proper assembly of proteins to the primer-template junction during DNA replication is essential for accurate and processive DNA synthesis. DNA replication in RB69 (a T4-like bacteriophage) is similar to those of eukaryotes and archaea and has been a prototype for studies on DNA replication and assembly of the functional replisome. To examine protein-protein interactions at the DNA replication fork, we have established solution conditions for the formation of a discrete and homogeneous complex of RB69 DNA polymerase (gp43), primer-template DNA, and RB69 single-stranded DNA-binding protein (gp32) using equilibrium fluorescence and light scattering. We have characterized the interaction between DNA polymerase and single-stranded DNA-binding protein and measured a 60-fold increase in the overall affinity of RB69 single-stranded DNA-binding protein (SSB) for template strand DNA in the presence of DNA polymerase that is the result of specific protein-protein interactions. Our data further suggest that the cooperative binding of the RB69 DNA polymerase and SSB to the primer-template junction is a simple but functionally important means of regulatory assembly of replication proteins at the site of action. We have also shown that a functional domain of RB69 single-stranded DNA-binding protein suggested previously to be the site of RB69 DNA polymerise-SSB interactions is dispensable. The data from these studies have been used to model the RB69 DNA polymerise-SSB interaction at the primer-template junction.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Rice University	Shamoo, Y (corresponding author), Rice Univ, Dept Biochem & Cell Biol, 6100 S Main St,MS140, Houston, TX 77005 USA.			Shamoo, Yousif/0000-0001-9241-8962				Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; BRUCK I, 2001, GENOME BIOL, V2; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Davey MJ, 2000, CURR OPIN CHEM BIOL, V4, P581, DOI 10.1016/S1367-5931(00)00134-4; Folta-Stogniew E, 1999, J Biomol Tech, V10, P51; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P8759, DOI 10.1021/bi00100a007; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1980, BIOPHYS J, V32, P403, DOI 10.1016/S0006-3495(80)84964-2; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; KRISCH HM, 1982, P NATL ACAD SCI-BIOL, V79, P4937, DOI 10.1073/pnas.79.16.4937; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4665, DOI 10.1021/bi00315a023; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; MUNN MM, 1991, J BIOL CHEM, V266, P20034; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; Smith WR, 1982, CHEM REACTION EQUILI; SPICER EK, 1979, J BIOL CHEM, V254, P6433; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; SUBBARAO NK, 1993, ANALYST, V118, P913, DOI 10.1039/an9931800913; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Yeh LS, 1998, J BACTERIOL, V180, P2005, DOI 10.1128/JB.180.8.2005-2013.1998; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	42	22	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3876	3881		10.1074/jbc.M210497200	http://dx.doi.org/10.1074/jbc.M210497200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458197	hybrid			2022-12-25	WOS:000180869700047
J	Osterod, M; Larsen, E; Le Page, F; Hengstler, JG; van der Horst, GT; Boiteux, S; Klungland, A; Epe, B				Osterod, M; Larsen, E; Le Page, F; Hengstler, JG; van der Horst, GT; Boiteux, S; Klungland, A; Epe, B			A global DNA repair mechanism involving the Cockayne syndrome B (CSB) gene product can prevent the in vivo accumulation of endogenous, oxidative DNA base damage	ONCOGENE			English	Article						OGG1; CSB; DNA repair; 7,8-dihydro-8oxoguanine (8-oxoG)	TRANSCRIPTION-COUPLED REPAIR; MAMMALIAN-CELLS; EXCISION-REPAIR; 8-OXOGUANINE; CANCER; 8-HYDROXYGUANINE; OGG1; MICE; MUTAGENESIS; GENOME	The Cockayne syndrome B (CSB) gene product is involved in the repair of various types of base modifications in actively transcribed DNA sequences. To investigate its significance for the repair of endogenous oxidative DNA damage, homozygous csb(-/-)/ogg1(-/-) double knockout mice were generated. These combine the deficiency of CSB with that of OGG1, a gene coding for the mammalian repair glycosylase that initiates the base excision repair of 7,8-dihydro-8-oxoguanine (8-oxoG). Compared to ogg1(-/-) mice, csb(-/-)/ogg1(-/-) mice were found to accumulate with age severalfold higher levels of oxidited purine modifications in hepatocytes, splenocytes and kidney cells. In contrast, the basal (steady-state) levels of oxidative DNA modifications in cells from csb(-/-) mice were not different from those in wild-type mice and did not increase with age. The analysis of the repair rates of additional oxidative DNA base modifications induced by photosensitization in immortalized embryonic fibroblasts was in accordance with these findings: compared to wild-type cells, the global repair was only slightly affected in csb(-/-) cells, more compromised in ogg1(-/-) cells, but virtually absent in csb(-/-)/ogg1(-/-) cells. An inhibition of transcription by a-amanitin did not block the Csb-dependent repair in ogg1(-/-) fibroblasts. The influence of Csb on the global repair of 8-oxoG was not detectable in assays with total protein extracts and in a shuttle vector system. The data indicate a role for Csb in the removal of 8-oxoG from the overall genome that is independent of both Ogg1-mediated base excision repair and regular transcription.	Univ Mainz, Inst Pharm, D-55099 Mainz, Germany; Univ Oslo, Ctr Mol Biol & Neurosci, Natl Hosp, N-0027 Oslo, Norway; Univ Oslo, Inst Med Microbiol, Natl Hosp, N-0027 Oslo, Norway; CEA, UMR 217 CNRS, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France; Univ Mainz, Inst Toxicol, D-55099 Mainz, Germany; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Johannes Gutenberg University of Mainz; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; CEA; Johannes Gutenberg University of Mainz; Erasmus University Rotterdam	Epe, B (corresponding author), Univ Mainz, Inst Pharm, Staudingerweg 5, D-55099 Mainz, Germany.		Klungland, Arne/X-1233-2019; van der Horst, Gijsbertus TJ/E-3661-2015; Hengstler, Jan G./O-1415-2013	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Hengstler, Jan/0000-0002-1427-5246; Klungland, Arne/0000-0001-7274-3661				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CHENG KC, 1992, J BIOL CHEM, V267, P166; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; HAZRA TK, 1998, NUCLEIC ACIDS RES, V27, P4001; Hengstler JG, 2000, DRUG METAB REV, V32, P81, DOI 10.1081/DMR-100100564; Hollenbach S, 1999, CARCINOGENESIS, V20, P1863, DOI 10.1093/carcin/20.9.1863; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CANCER RES, V60, P5548; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Le Page F, 1998, NUCLEIC ACIDS RES, V26, P1276, DOI 10.1093/nar/26.5.1276; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sunesen M, 2002, ONCOGENE, V21, P3571, DOI 10.1038/sj.onc.1205443; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Thorslund T, 2002, DNA REPAIR, V1, P261, DOI 10.1016/S1568-7864(02)00003-4; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tomatis L., 1990, IARC SCI PUBLICATION; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Will O, 1999, MUTAT RES-DNA REPAIR, V435, P89, DOI 10.1016/S0921-8777(99)00039-7; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	44	120	124	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8232	8239		10.1038/sj.onc.1206027	http://dx.doi.org/10.1038/sj.onc.1206027			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447686				2022-12-25	WOS:000179323900001
J	Zippin, JH; Chen, YQ; Nahirney, P; Kamenetsky, M; Wuttke, MS; Fischman, DA; Levin, LR; Buck, J				Zippin, JH; Chen, YQ; Nahirney, P; Kamenetsky, M; Wuttke, MS; Fischman, DA; Levin, LR; Buck, J			Compartmentalization of bicarbonate-sensitive adenylyl cyclase in distinct signaling microdomains	FASEB JOURNAL			English	Article						G-protein; cAMP; transmembrane spanning domains	DEPENDENT PROTEIN-KINASE; C-OXIDASE ACTIVITY; REGULATORY SUBUNIT; ANCHOR PROTEIN; CAMP; CENTROSOME; PHOSPHORYLATION; LOCALIZATION; MITOCHONDRIA; EXPRESSION	Intracellular targets of the ubiquitous second messenger cAMP are located at great distances from the most widely studied source of cAMP, the G protein responsive transmembrane adenylyl cyclases. We previously identified an alternative source of cAMP in mammalian cells lacking transmembrane spanning domains, the "soluble" adenylyl cyclase (sAC). We now demonstrate that sAC is distributed in specific subcellular compartments: mitochondria, centrioles, mitotic spindles, mid-bodies, and nuclei, all of which contain cAMP targets. Distribution at these intracellular sites proves that adenylyl cyclases are in close proximity to all cAMP effectors, suggesting a model in which local concentrations of cAMP are regulated by individual adenylyl cyclases targeted to specific microdomains throughout the cell.	Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Tri Inst MD PhD Program, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Cell Biol, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Levin, LR (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.	llevin@med.cornell.edu		Levin, Lonny/0000-0002-5204-6356				BEAVO JA, 1994, MOL PHARMACOL, V46, P399; Bender E, 2000, FEBS LETT, V466, P130, DOI 10.1016/S0014-5793(99)01773-1; BEVENSEE MO, 2000, KIDNEY, V1; BRAUN T, 1975, P NATL ACAD SCI USA, V72, P1097, DOI 10.1073/pnas.72.3.1097; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; Diviani D, 2001, J CELL SCI, V114, P1431; Feliciello A, 1998, J BIOL CHEM, V273, P23361, DOI 10.1074/jbc.273.36.23361; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; JAISWAL BS, 2001, J BIOL CHEM, V21, P21; JUNGMANN RA, 1988, METHOD ENZYMOL, V159, P225; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; KUETTEL MR, 1985, J CELL BIOL, V101, P965, DOI 10.1083/jcb.101.3.965; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; QIAO J, 2002, IN PRESS J BIOL CHEM, V8; Rich TC, 2000, J GEN PHYSIOL, V116, P147, DOI 10.1085/jgp.116.2.147; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; SHMYREV II, 1990, MOL CELL BIOCHEM, V93, P47; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; SQUINTO SP, 1989, BIOCHEM J, V260, P673, DOI 10.1042/bj2600673; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Wuttke M S, 2001, JOP, V2, P154; Yang WL, 1998, BIOCHEMISTRY-US, V37, P14175, DOI 10.1021/bi981402a; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zippin JH, 2001, TRENDS ENDOCRIN MET, V12, P366, DOI 10.1016/S1043-2760(01)00454-4	40	218	231	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					82	+		10.1096/fj.02-0598fje	http://dx.doi.org/10.1096/fj.02-0598fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475901				2022-12-25	WOS:000180218500020
J	Chen, F; Ma, L; Dawson, PA; Sinal, CJ; Sehayek, E; Gonzalez, FJ; Breslow, J; Ananthanarayanan, M; Shneider, BL				Chen, F; Ma, L; Dawson, PA; Sinal, CJ; Sehayek, E; Gonzalez, FJ; Breslow, J; Ananthanarayanan, M; Shneider, BL			Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; BINDING-PROTEIN; SERUM-CHOLESTEROL; MESSENGER-RNA; RAT ILEUM; IDENTIFICATION; INHIBITION; RABBITS; GENE; HYPERCHOLESTEROLEMIA	Intestinal reclamation of bile salts is mediated in large part by the apical sodium-dependent bile acid transporter (ASBT). The bile acid responsiveness of ASBT is controversial. Bile acid feeding in mice results in decreased expression of ASBT protein and mRNA. Mouse but not rat ASBT promoter activity was repressed in Caco-2, but not IEC-6, cells by chenodeoxycholic acid. A potential liver receptor homologue-1 (LRH-1) cis-acting element was identified in the bile acid-responsive region of the mouse but not rat promoter. The mouse, but not rat, promoter was activated by LRH-1, and this correlated with nuclear protein binding to the mouse but not rat LRH-1 element. The short heterodimer partner diminished the activity of the mouse promoter and could partially offset its activation by LRH-1. Interconversion of the potential LRH-1 cis-elements between the mouse and rat ASBT promoters was associated with an interconversion of LRH-1 and bile acid responsiveness. LRH-1 protein was found in Caco-2 cells and mouse ileum, but not IEC-6 cells or rat ileum. Bile acid response was mediated by the farnesoid X receptor, as shown by the fact that overexpression of a dominant-negative farnesoid X-receptor eliminated the bile acid mediated down-regulation of ASBT. In addition, ASBT expression in farnesoid X receptor null mice was unresponsive to bile acid feeding. In summary cell line- and species-specific negative feedback regulation of ASBT by bile acids is mediated by farnesoid X receptor via small heterodimer partner-dependent repression of LRH-1 activation of the ASBT promoter.	Mt Sinai Med Ctr, Mt Sinai Sch Med, New York, NY 10029 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC 27157 USA; NIH, Bethesda, MD 20892 USA; Rockefeller Univ, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Wake Forest University; Wake Forest Baptist Medical Center; National Institutes of Health (NIH) - USA; Rockefeller University	Shneider, BL (corresponding author), Mt Sinai Med Ctr, Mt Sinai Sch Med, Box 1656,1 Gustave L Levy Pl, New York, NY 10029 USA.		Breslow, Jan L/B-7544-2008	Sinal, Christopher/0000-0001-8301-3349	NIDDK NIH HHS [DK 54165, DK 20632, R01 DK047987, DK 02076] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002076, R01DK047987, R01DK020632, R01DK054165] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Arrese M, 1998, HEPATOLOGY, V28, P1081, DOI 10.1002/hep.510280424; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen F, 2001, J BIOL CHEM, V276, P38703, DOI 10.1074/jbc.M104511200; Chen FY, 1997, P NATL ACAD SCI USA, V94, P4348, DOI 10.1073/pnas.94.9.4348; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; DUMSWALA R, 1996, HEPATOLOGY, V23, P623; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; HARA S, 1997, LIFE SCI, V60, P365; Higaki J, 1998, ARTERIOSCL THROM VAS, V18, P1304, DOI 10.1161/01.ATV.18.8.1304; HIGGINS JV, 1994, AM J PHYSIOL-GASTR L, V267, pG501, DOI 10.1152/ajpgi.1994.267.4.G501; Hofmann AF, 1999, HEPATOLOGY, V29, P1335, DOI 10.1002/hep.510290430; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Lee J, 2001, GASTROENTEROLOGY, V121, P1473, DOI 10.1053/gast.2001.29608; LEWIS MC, 1995, J LIPID RES, V36, P1098; LILLIENAU J, 1993, GASTROENTEROLOGY, V104, P38, DOI 10.1016/0016-5085(93)90833-X; LILLINAU J, 1995, GASTROENTEROLOGY, V108, pA637; Love MW, 1998, CURR OPIN LIPIDOL, V9, P225, DOI 10.1097/00041433-199806000-00007; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo Y, 2001, J BIOL CHEM, V276, P24767, DOI 10.1074/jbc.M100912200; Ma L, 2000, GASTROENTEROLOGY, V118, pA934, DOI 10.1016/S0016-5085(00)85873-4; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pawlikowska L, 2001, HEPATOLOGY, V34, p240A; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; Sauer P, 2000, J HEPATOL, V33, P2, DOI 10.1016/S0168-8278(00)80152-X; Schwarz M, 1998, J LIPID RES, V39, P1833; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Shneider BL, 2001, J PEDIATR GASTR NUTR, V32, P407, DOI 10.1097/00005176-200104000-00002; Shneider BL, 1997, PEDIATR RES, V42, P189, DOI 10.1203/00006450-199708000-00010; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stravitz RT, 1997, GASTROENTEROLOGY, V113, P1599, DOI 10.1053/gast.1997.v113.pm9352862; Torchia EC, 1996, BIOCHEM BIOPH RES CO, V225, P128, DOI 10.1006/bbrc.1996.1141; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; Xu GR, 2001, J LIPID RES, V42, P1438; Xu GR, 2000, J LIPID RES, V41, P298	40	180	194	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19909	19916		10.1074/jbc.M207903200	http://dx.doi.org/10.1074/jbc.M207903200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12456679	hybrid			2022-12-25	WOS:000183078000045
J	Pratt, MAC; Niu, MY				Pratt, MAC; Niu, MY			Bcl-2 controls caspase activation following a p53-dependent cyclin D1-induced death signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; MITOCHONDRIAL PERMEABILITY TRANSITION; ECTOPIC EXPRESSION; FAMILY-MEMBERS; APOPTOSIS; BAX; PROTEIN; CANCER; D1; P53	MCF-7 and ZR-75 breast cancer cells infected with an adenovirus constitutively expressing high levels of cyclin D1 demonstrated widespread mitochondrial translocation of Bax and cytochrome c release that was approximately doubled after the addition of all-trans retinoic acid (RA) or Bcl-2 antisense oligonucleotide. By comparison, the percentage of cells in Lac Z virus-infected cultures containing translocated Bax and cytoplasmic cytochrome c was markedly less even after RA treatment. Despite this, RA-treated Lac Z and untreated cyclin D1 virus-infected cultures contained similarly low proportions of cells with active caspase or cells that were permeable to propidium iodide. Bax activation was p53-,dependent and accompanied by arrest in G(2) phase. Although constitutive Bcl-2 expression prevented Bax activation, it did not alter cyclin D1-induced cell cycle arrest, illustrating the independence of these events. Both RA and antisense Bcl-2 oligonucleotide decreased Bcl-2 protein levels and markedly increased caspase activity and apoptosis in cyclin D1-infected cells. Thus amplified cyclin D1 expression initiates an apoptotic signal inhibited by different levels of cellular Bcl-2 at two points. Whereas high cellular levels of Bcl-2 prevent mitochondrial Bax translocation, lower levels can prevent apoptosis by inhibition of caspase activation.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Pratt, MAC (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	cpratt@uottawa.ca						Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; DAHLSEID JN, 1994, MOL BIOL CELL, V5, P1265, DOI 10.1091/mbc.5.11.1265; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hansen LK, 1999, J CELL SCI, V112, P2971; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Katayama K, 2001, FEBS LETT, V509, P382, DOI 10.1016/S0014-5793(01)03200-8; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; MIYASHITA T, 1995, CELL, V80, P293; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	53	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14219	14229		10.1074/jbc.M209650200	http://dx.doi.org/10.1074/jbc.M209650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12480939	hybrid			2022-12-25	WOS:000182405000084
J	Edman, M; Berg, S; Storm, P; Wikstrom, M; Vikstrom, S; Ohman, A; Wieslander, A				Edman, M; Berg, S; Storm, P; Wikstrom, M; Vikstrom, S; Ohman, A; Wieslander, A			Structural features of glycosyltransferases synthesizing major bilayer and nonbilayer-prone membrane lipids in Acholeplasma laidlawii and Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 1,2-DIACYLGLYCEROL 3-GLUCOSYLTRANSFERASE; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ENZYMATIC-SYNTHESIS; STRAIN; PROTEINS; SEQUENCE; GLYCOLIPIDS; CURVATURE	In membranes of Acholeplasma laidlawii two consecutively acting glucosyltransferases, the (i) alpha-monoglucosyl-diacylglycerol. (MGlcDAG) synthase (aIMGS) (EC 2.4.1.157) and the (ii) alpha-diglucosyl-DAG (DGlcDAG) synthase (alDGS) (EC 2.4.1.208), are involved in maintaining (i) a certain anionic lipid surface charge density and (ii) constant nonbilayer/bilayer conditions (curvature packing stress), respectively. Cloning of the aIDGS gene revealed related uncharacterized sequence analogs especially in several Gram-positive pathogens, thermophiles and archaea, where the encoded enzyme function of a potential Streptococcus pneumoniae DGS gene (cpoA) was verified. A strong stimulation of aIDGS by phosphatidylglycerol (PG), cardiolipin, or nonbilayer-prone 1,3-DAG was observed, while only PG stimulated CpoA. Several secondary structure prediction and fold recognition methods were used together with SWISS-MODEL to build three-dimensional model structures for three MGS and two DGS lipid glycosyltransferases. Two Escherichia coli proteins with known structures were identified as the best templates, the membrane surface-associated two-domain glycosyltransferase MurG and the soluble GlcNAc epimerase. Differences in electrostatic surface potential between the different models and their individual domains suggest that electrostatic interactions play a role for the association to membranes. Further support for this was obtained when hybrids of the N- and C-domain, and full size alMGS with green fluorescent protein were localized to different regions of the E. coli inner membrane and cytoplasm in vivo. In conclusion, it is proposed that the varying abilities to bind, and sense lipid charge and curvature stress, are governed by typical differences in charge (pI values), amphiphilicity, and hydrophobicity for the N- and (catalytic) C-domains of these structurally similar membrane-associated enzymes.	Univ Stockholm, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Umea Univ, Dept Biochem, S-90187 Umea, Sweden; Umea Univ, Dept Odontol, S-90187 Umea, Sweden	Stockholm University; Umea University; Umea University	Wieslander, A (corresponding author), Univ Stockholm, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	ake@dbb.su.se	Berg, Stefan O/D-3847-2011; Berg, Stefan/AAU-6463-2020	Berg, Stefan/0000-0002-3470-7579				Abdian PL, 2000, J BIOL CHEM, V275, P40568, DOI 10.1074/jbc.M007496200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson AS, 1998, BBA-LIPID LIPID MET, V1389, P43, DOI 10.1016/S0005-2760(97)00091-X; Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Berg S, 2001, J BIOL CHEM, V276, P22056, DOI 10.1074/jbc.M102576200; Booth PJ, 2001, CRIT REV BIOCHEM MOL, V36, P501, DOI 10.1080/20014091074246; Botelho AV, 2002, BIOCHEMISTRY-US, V41, P6354, DOI 10.1021/bi011995g; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; BRUNDISH DE, 1965, BIOCHEM J, V97, P158; BRUNDISH DE, 1967, BIOCHEM J, V104, P205; Bujnicki JM, 2001, BIOINFORMATICS, V17, P750, DOI 10.1093/bioinformatics/17.8.750; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; DAHLQVIST A, 1992, BIOCHIM BIOPHYS ACTA, V1105, P131, DOI 10.1016/0005-2736(92)90171-H; DAHLQVIST A, 1995, BIOCHEMISTRY-US, V34, P13381, DOI 10.1021/bi00041a015; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; Dormann P, 2002, TRENDS PLANT SCI, V7, P112, DOI 10.1016/S1360-1385(01)02216-6; EFRATI H, 1986, ARCH BIOCHEM BIOPHYS, V248, P282, DOI 10.1016/0003-9861(86)90425-X; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fischer W, 1998, J BACTERIOL, V180, P2950, DOI 10.1128/JB.180.11.2950-2957.1998; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; Grebe T, 1997, J BACTERIOL, V179, P3342, DOI 10.1128/jb.179.10.3342-3349.1997; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; HAUKSSON JB, 1995, BBA-LIPID LIPID MET, V1258, P1, DOI 10.1016/0005-2760(95)00074-M; Herrmann Richard, 1992, P157; Ho C, 2001, BIOCHEMISTRY-US, V40, P10334, DOI 10.1021/bi002839x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hu ZL, 2002, P NATL ACAD SCI USA, V99, P6761, DOI 10.1073/pnas.102059099; Hu ZL, 2001, MOL CELL, V7, P1337, DOI 10.1016/S1097-2765(01)00273-8; Karlsson OP, 1997, J BIOL CHEM, V272, P929, DOI 10.1074/jbc.272.2.929; KARLSSON OP, 1994, J BIOL CHEM, V269, P23484; KAUFAM B, 1965, BIOCHEM BIOPH RES CO, V18, P312, DOI 10.1016/0006-291X(65)90705-9; Koppelman CM, 2001, J BACTERIOL, V183, P6144, DOI 10.1128/JB.183.20.6144-6147.2001; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P16198; Lundstrom J, 2001, PROTEIN SCI, V10, P2354, DOI 10.1110/ps.08501; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MADDEN TD, 1982, BIOCHIM BIOPHYS ACTA, V684, P149, DOI 10.1016/0005-2736(82)90061-X; MANCA MC, 1992, BIOCHIM BIOPHYS ACTA, V1124, P249, DOI 10.1016/0005-2760(92)90136-J; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; Mulichak AM, 2001, STRUCTURE, V9, P547, DOI 10.1016/S0969-2126(01)00616-5; OSTERBERG F, 1995, BBA-LIPID LIPID MET, V1257, P18, DOI 10.1016/0005-2760(95)00042-B; Pascarella S, 1998, PROTEINS, V32, P190, DOI 10.1002/(SICI)1097-0134(19980801)32:2<190::AID-PROT5>3.0.CO;2-P; Schwartz R, 2001, GENOME RES, V11, P703, DOI 10.1101/gr.GR-1587R; SHAW N, 1968, BIOCHEM J, V107, P329, DOI 10.1042/bj1070329; SHAW N, 1970, Bacteriological Reviews, V34, P365; STEINICK LE, 1980, J BACTERIOL, V143, P1200, DOI 10.1128/JB.143.3.1200-1207.1980; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; THURMOND RL, 1991, BIOPHYS J, V60, P728, DOI 10.1016/S0006-3495(91)82103-8; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Urbanus ML, 2002, J BIOL CHEM, V277, P12718, DOI 10.1074/jbc.M200311200; Videira P, 2001, BIOCHEM J, V358, P457, DOI 10.1042/0264-6021:3580457; Vikstrom S, 1999, BIOCHEMISTRY-US, V38, P5511, DOI 10.1021/bi982532m; Vikstrom S, 2000, J BIOL CHEM, V275, P9296, DOI 10.1074/jbc.275.13.9296; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wieslander A, 1997, CURR TOP MEMBR, V44, P517; WIESLANDER A, 1986, BIOCHEMISTRY-US, V25, P7511, DOI 10.1021/bi00371a038; Wilkinson S., 1988, MICROBIAL LIPIDS; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Wrabl JO, 2001, J MOL BIOL, V314, P365, DOI 10.1006/jmbi.2001.5151	65	63	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8420	8428		10.1074/jbc.M211492200	http://dx.doi.org/10.1074/jbc.M211492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12464611	hybrid			2022-12-25	WOS:000181466800088
J	Nishi, T; Kawasaki-Nishi, S; Forgac, M				Nishi, T; Kawasaki-Nishi, S; Forgac, M			The first putative transmembrane segment of subunit c '' (Vma16p) of the yeast V-ATPase is not necessary for function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; MUTATIONAL ANALYSIS; ROTARY MOTOR; SACCHAROMYCES-CEREVISIAE; LUMINAL ACIDIFICATION; CATALYTIC SUBUNIT; GENE DUPLICATION; CDNA SEQUENCE; IN-VIVO	The yeast vacuolar ATPase (V-ATPase) contains three proteolipid subunits: c (Vma3p), c' (Vma11p), and c" (Vma16p). Each subunit contains a buried glutamate residue that is essential for function, and these subunits are not able to substitute for each other in supporting activity. Subunits c and c' each contain four putative transmembrane segments (TM1-4), whereas subunit c" is predicted to contain five. To determine whether TM1 of subunit c" serves an essential function, a deletion mutant of Vma16p was constructed lacking TM1 (Vma16p-DeltaTM1). Although this construct does not complement the loss of Vma3p or Vma11p, it does complement the loss of full-length Vma16p. Vacuoles isolated from the strain expressing Vma16p-DeltaTM1 showed V-ATPase activity and proton transport greater than 80% relative to wild type and displayed wild type levels of subunits A and a, suggesting normal assembly of the V-ATPase complex. These results suggest that TM1 of Vma16p is dispensable for both activity and assembly of the V-ATPase. To obtain information about the topology of Vma16p, labeling of single cysteine-containing mutants using the membrane-permeable reagent 3-(N-maleimidylpropionyl)biocytin (MPB) and the -impermeable reagent 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid (AMS) was tested. Both the Cys-less form of Vma16p and eight single cysteine-containing mutants retained greater than 80% of wild type levels of activity. Of the eight mutants tested, two (S5C and S178C) were labeled by MPB. MPB-labeling of S5C was blocked by AMS in intact vacuoles, whereas S178C was blocked by AMS only in the presence of permeabilizing concentrations of detergent. In addition, a hemagglutinin epitope tag introduced into the C terminus of Vma16p was recognized by an anti-hemagglutinin antibody in intact vacuolar membranes, suggesting a cytoplasmic orientation for the C terminus. These results suggest that subunit c" contains four rather than five transmembrane segments with both the N and C terminus on the cytoplasmic side of the membrane.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34928] Funding Source: Medline; NIGMS NIH HHS [R37 GM034478, GM34478, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI H, 1988, J BIOL CHEM, V263, P8796; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brown D, 2000, J EXP BIOL, V203, P137; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Gibson LCD, 2002, BIOCHEM J, V366, P911, DOI 10.1042/BJ20020171; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Graham LA, 2000, J EXP BIOL, V203, P61; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2001, J BIOL CHEM, V276, P34122, DOI 10.1074/jbc.M104682200; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	51	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5821	5827		10.1074/jbc.M209875200	http://dx.doi.org/10.1074/jbc.M209875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482875	hybrid			2022-12-25	WOS:000181129400043
J	Quiel, JA; Bender, J				Quiel, JA; Bender, J			Glucose conjugation of anthranilate by the Arabidopsis UGT74F2 glucosyltransferase is required for tryptophan mutant blue fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; METHYLATION; METABOLISM; IDENTIFICATION; BIOSYNTHESIS; MAINTENANCE; EXPRESSION; ACID	Plant mutants with defects in intermediate enzymes of the tryptophan biosynthetic pathway often display a blue fluorescent phenotype. This phenotype results from the accumulation of the fluorescent tryptophan precursor anthranilate, the bulk of which is found in a glucose-conjugated form. To elucidate factors that control fluorescent tryptophan metabolites, we conducted a genetic screen for suppressors of blue fluorescence in the Arabidopsis trp1-100 mutant, which has a defect in the second enzymatic step of the tryptophan pathway. This screen yielded loss-of-function mutations in the UDP-glucosyltransferase gene UGT74F2. The bacterially expressed UGT74F2 enzyme catalyzed a conjugation reaction, with free anthranilate and UDP-glucose as substrates, that yielded the same fluorescent glucose ester compound as extracted from the trp1-100 mutant. These results indicate that sugar conjugation of anthranilate by UGT74F2 allows its stable accumulation in plant tissues. A highly related Arabidopsis enzyme UGT74F1 could also catalyze this reaction in vitro and could complement the ugt74F2 mutation when overexpressed in vivo. However, the UGT74F1 gene is expressed at a lower level than the UGT74F2 gene. Therefore, even though UGT74F1 and UGT74F2 have redundant conjugating activities toward anthranilate, UGT74F2 is the major source of this activity in the plant.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bender, J (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 N Wolfe St, Baltimore, MD 21205 USA.	jbender@mail.jhmi.edu						Bartee L, 2001, GENE DEV, V15, P1753, DOI 10.1101/gad.905701; Bartee L, 2001, NUCLEIC ACIDS RES, V29, P2127, DOI 10.1093/nar/29.10.2127; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Bender J, 1998, P NATL ACAD SCI USA, V95, P5655, DOI 10.1073/pnas.95.10.5655; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; Hull AK, 2000, P NATL ACAD SCI USA, V97, P2379, DOI 10.1073/pnas.040569997; Jackson RG, 2001, J BIOL CHEM, V276, P4350, DOI 10.1074/jbc.M006185200; Jeddeloh JA, 1998, GENE DEV, V12, P1714, DOI 10.1101/gad.12.11.1714; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAST RL, 1988, SCIENCE, V240, P305, DOI 10.1126/science.240.4850.305; LEE HI, 1995, P NATL ACAD SCI USA, V92, P4076, DOI 10.1073/pnas.92.10.4076; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 2002, J BIOL CHEM, V277, P586, DOI 10.1074/jbc.M109287200; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; Malagnac F, 2002, EMBO J, V21, P6842, DOI 10.1093/emboj/cdf687; Melquist S, 1999, GENETICS, V153, P401; Neff MM, 1998, PLANT J, V14, P387, DOI 10.1046/j.1365-313X.1998.00124.x; NIYOGI KK, 1993, PLANT CELL, V5, P1011, DOI 10.1105/tpc.5.9.1011; RADWANSKI ER, 1995, PLANT CELL, V7, P921, DOI 10.1105/tpc.7.7.921; ROSE AB, 1992, PLANT PHYSIOL, V100, P582, DOI 10.1104/pp.100.2.582; Rose AB, 1997, GENETICS, V145, P197; RYALS J, 1995, P NATL ACAD SCI USA, V92, P4202, DOI 10.1073/pnas.92.10.4202; SINGH M, 1975, BIOCHEM GENET, V13, P357, DOI 10.1007/BF00485821; Smolen G, 2002, GENETICS, V160, P323; vanHoof A, 1996, PLANT J, V10, P415, DOI 10.1046/j.1365-313x.1996.10030415.x; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; ZHAO JM, 1995, J BIOL CHEM, V270, P6081, DOI 10.1074/jbc.270.11.6081	31	46	55	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6275	6281		10.1074/jbc.M211822200	http://dx.doi.org/10.1074/jbc.M211822200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12475971	hybrid			2022-12-25	WOS:000181129400099
J	Ellison, PA; DePew, ZS; Cremo, CR				Ellison, PA; DePew, ZS; Cremo, CR			Both heads of tissue-derived smooth muscle heavy meromyosin bind to actin in the presence of ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; LIGHT-CHAIN; ADENOSINE-TRIPHOSPHATASE; GIZZARD MYOSIN; DOMAIN; CONFORMATION; SUBFRAGMENT-1; TROPOMYOSIN; PROTEOLYSIS; ASYMMETRY	The effect of ADP and phosphorylation upon the actin binding properties of heavy meromyosin was investigated using three fluorescence methods that monitor the number of heavy meromyosin heads that bind to pyrene-actin: (i) amplitudes of ATP-induced dissociation, (ii) amplitudes of ADP-induced dissociation of the pyrene-actin-heavy meromyosin complex, and (iii) amplitudes of the association of heavy meromyosin with pyrene-actin. Both heads bound to pyrene-actin, irrespective of regulatory light chain phosphorylation or the presence of ADP. This behavior was found for native regulated heavy meromyosin prepared by proteolytic digestion of chicken gizzard myosin with between 5 and 95% heavy chain cleavage at the actin-binding loop, showing that two-head binding is a property of heavy meromyosin with uncleaved heavy chains. These data are in contrast to a previous study using an uncleaved expressed preparation (Berger, C. E., Fagnant, P. M., Heizmann, S., Trybus, K. M., and Geeves, M. A. (2001) J. Biol. Chem. 276,23240-23245), which showed that one head of the unphosphorylated heavy meromyosin-ADP complex bound to actin and that the partner head either did not bind or bound weakly. Possible explanations for the differences between the two studies are discussed. We have shown that unphosphorylated heavy meromyosin appears to adopt a special state in the presence of ADP based upon analysis of actin-heavy meromyosin association rate constants. Data were consistent with one head binding rapidly and the second head binding more slowly in the presence of ADP. Both heads bound to actin at the same rate for all other states.	Univ Nevada, Dept Biochem 330, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Cremo, CR (corresponding author), Univ Nevada, Dept Biochem 330, 1664 N Virginia St, Reno, NV 89557 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040917, R01AR040917] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40917] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Berger CEM, 2001, J BIOL CHEM, V276, P23240, DOI 10.1074/jbc.M100524200; BONET A, 1987, J BIOL CHEM, V262, P16524; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; Dantzig JA, 1999, BIOPHYS J, V77, P386, DOI 10.1016/S0006-3495(99)76897-9; DASH PK, 1991, BIOCHEM INT, V25, P1013; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; Gollub J, 1999, BIOCHEMISTRY-US, V38, P10107, DOI 10.1021/bi990267e; Hartshorne DJ, 1987, PHYSL GASTROINTESTIN, P423; IKEBE M, 1993, J BIOL CHEM, V268, P25948; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1986, BIOCHEMISTRY-US, V25, P6177, DOI 10.1021/bi00368a052; JACKSON AP, 1988, BIOCHEM J, V251, P515, DOI 10.1042/bj2510515; Konishi K, 1998, J BIOCHEM-TOKYO, V124, P163, DOI 10.1093/oxfordjournals.jbchem.a022075; Konishi K, 2001, J BIOCHEM-TOKYO, V129, P365, DOI 10.1093/oxfordjournals.jbchem.a002866; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; Sellers J. R., 1999, MYOSINS; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SELLERS JR, 1995, MOTOR PROTEIN 2, V2; SELLERS JR, 1982, J BIOL CHEM, V257, P12880; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098	32	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4410	4415		10.1074/jbc.M211016200	http://dx.doi.org/10.1074/jbc.M211016200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12464606	hybrid			2022-12-25	WOS:000180968900008
J	Zhang, ZS; Shen, K; Lu, W; Cole, PA				Zhang, ZS; Shen, K; Lu, W; Cole, PA			The role of C-terminal tyrosine phosphorylation in the regulation of SHP-1 explored via expressed protein ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; KINASE CSK; BINDING; SH-PTP1; INHIBITORS; SIGNALS; SHPTP1	The protein-tyrosine phosphatase SHP-1 plays a variety of roles in the "negative" regulation of cell signaling. The molecular basis for the regulation of SHP-1 is incompletely understood. Whereas SHP-1 has previously been shown to be phosphorylated on two tail tyrosine residues (Tyr(536) and Tyr(564)) by several protein-tyrosine kinases, the effects of these phosphorylation events have been difficult to address because of the intrinsic instability of the linkages within a protein-tyrosine phosphatase. Using expressed protein ligation, we have generated semisynthetic SHP-1 proteins containing phosphotyrosine mimetics at the Tyr(536) and Tyr(564) sites. Two phosphonate analogues were installed, phosphonomethylenephenylalanine (Pmp) and difluorophosphonomethylenephenylalanine (F(2)pMP). Incorporation of Pmp at the 536 site led to 4-fold stimulation of the SHP-1 tyrosine phosphatase activity whereas incorporation at the 564 site led to no effect. Incorporation of F(2)Pmp at the 536 site led to 8-fold stimulation of the SHP-1 tyrosine phosphatase activity and 1.6-fold at the 564 site. A combination of size exclusion chromatography, phosphotyrosine peptide stimulation studies, and site-directed mutagenesis led to the structural model in which tyrosine phosphorylation at the 536 site engages the N-Src homology 2 domain in an intramolecular fashion relieving basal inhibition. In contrast, tyrosine phosphorylation at the 564 site has the potential to engage the C-Src homology 2 domain intramolecularly, which can modestly and indirectly influence catalytic activity. The finding that phosphonate modification at each of the 536 and 564 sites can promote interaction with the Grb2 adaptor protein indicates that the intramolecular interactions fostered by post-translational modifications of tyrosine are not energetically strong and susceptible to intermolecular competition.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.				NCI NIH HHS [CA74305] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074305, R01CA074305] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beebe KD, 2000, BIOCHEMISTRY-US, V39, P13251, DOI 10.1021/bi0014397; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, V503, DOI [10.1016/0307-4412(81)90143-6, DOI 10.1016/0307-4412(81)90143-6]; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Chiang GG, 2001, J BIOL CHEM, V276, P23173, DOI 10.1074/jbc.M101219200; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; Eklund EA, 2002, J BIOL CHEM, V277, P36878, DOI 10.1074/jbc.M203917200; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; Guo XL, 2002, J BIOL CHEM, V277, P41014, DOI 10.1074/jbc.M207347200; Kant AM, 2002, BLOOD, V100, P1852; Kautz B, 2001, J BIOL CHEM, V276, P37868; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Mizuno K, 2002, J IMMUNOL, V169, P778, DOI 10.4049/jimmunol.169.2.778; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Otipoby KL, 2001, J BIOL CHEM, V276, P44315, DOI 10.1074/jbc.M105446200; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; Wang DX, 2001, J AM CHEM SOC, V123, P8883, DOI 10.1021/ja010540b; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; YEUNG YG, 1992, J BIOL CHEM, V265, P14777; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	34	110	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4668	4674		10.1074/jbc.M210028200	http://dx.doi.org/10.1074/jbc.M210028200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468540	hybrid			2022-12-25	WOS:000180968900042
J	Danielli, A; Kafatos, FC; Loukeris, TG				Danielli, A; Kafatos, FC; Loukeris, TG			Cloning and characterization of four Anopheles gambiae serpin isoforms, differentially induced in the midgut by Plasmodium berghei invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-SITE LOOP; MALARIA VECTOR; MANDUCA-SEXTA; IMMUNE-RESPONSES; INNATE IMMUNITY; PROTEINASE-INHIBITORS; HYPHANTRIA-CUNEA; FALL WEBWORM; MOSQUITO; HEMOLYMPH	The genomic locus SRPN10 of the malaria vector Anopheles gambiae codes for four alternatively spliced serine protease inhibitors of the serpin superfamily. The four 40- to 42-kDa isoforms differ only at their C terminus, which bears the reactive site loop, and exhibit protein sequence similarity with other insect serpins and mammalian serpins of the ovalbumin family. Inhibition experiments with recombinant purified SRPN10 serpins reveal distinct and specific inhibitory activity of three isoforms toward different proteases. All isoforms are mainly expressed in the midgut but also in pericardial cells and hemocytes of the mosquito. The cellular localization of SRPN10 serpins is nucleocytoplasmic in pericardial cells, in hemocytes and in a hemocyte-like mosquito cell line, but in the gut the proteins are mostly localized in the nucleus. Although the transcript levels of all SRPN10 isoforms are marginally affected by bacterial challenge, the transcripts of two isoforms (KRAL and RCM) are induced in female mosquitoes in response to midgut invasion by Plasmodium berghei ookinetes. The KRAL and RCM SRPN10 isoforms represent new potential markers to study the ookinete midgut invasion process in anopheline mosquitoes.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Kafatos, FC (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	dg-office@embl-heidelberg.de	DANIELLI, ALBERTO/AFQ-1474-2022	DANIELLI, ALBERTO/0000-0002-9414-9898	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044220] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI44220-2] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atchley WR, 2001, MOL BIOL EVOL, V18, P1502, DOI 10.1093/oxfordjournals.molbev.a003936; Barillas-Mury C, 2000, INSECT BIOCHEM MOLEC, V30, P429, DOI 10.1016/S0965-1748(00)00018-7; BENSAADIMERCHERMEK N, 1994, GENETICA, V93, P139, DOI 10.1007/BF01435246; Bergner A, 1997, BIOL CHEM, V378, P283, DOI 10.1515/bchm.1997.378.3-4.283; Bird P I, 1998, Results Probl Cell Differ, V24, P63; Bird PI, 1999, IMMUNOL CELL BIOL, V77, P47, DOI 10.1046/j.1440-1711.1999.00787.x; Bonnet S, 2001, CELL MICROBIOL, V3, P449, DOI 10.1046/j.1462-5822.2001.00128.x; Chitnis CE, 2000, PARASITOL TODAY, V16, P411, DOI 10.1016/S0169-4758(00)01756-7; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Dahlen JR, 1998, BIOCHEM BIOPH RES CO, V244, P172, DOI 10.1006/bbrc.1998.8225; Dahlen JR, 1997, BIOCHEM BIOPH RES CO, V238, P329, DOI 10.1006/bbrc.1997.7282; Danielli A, 2000, P NATL ACAD SCI USA, V97, P7136, DOI 10.1073/pnas.97.13.7136; Dimopoulos G, 1998, EMBO J, V17, P6115, DOI 10.1093/emboj/17.21.6115; Dimopoulos G, 2000, P NATL ACAD SCI USA, V97, P6619, DOI 10.1073/pnas.97.12.6619; Dimopoulos G, 2001, CURR OPIN IMMUNOL, V13, P79, DOI 10.1016/S0952-7915(00)00186-2; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Forch P, 2001, APOPTOSIS, V6, P463, DOI 10.1023/A:1012441824719; Gan H, 2001, INSECT BIOCHEM MOLEC, V31, P887, DOI 10.1016/S0965-1748(01)00034-0; Green C, 2000, GENETICS, V156, P1117; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Han JH, 2000, FEBS LETT, V468, P194, DOI 10.1016/S0014-5793(00)01224-2; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Iwanaga S, 1998, J BIOCHEM, V123, P1; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P693, DOI 10.1016/S0965-1748(97)00045-3; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; Kanost MR, 2001, ADV EXP MED BIOL, V484, P319; Kanost MR, 1999, DEV COMP IMMUNOL, V23, P291, DOI 10.1016/S0145-305X(99)00012-9; Kenneth KR, 1998, J BIOL CHEM, V273, P20802, DOI 10.1074/jbc.273.33.20802; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kruger O, 2002, GENE, V293, P97, DOI 10.1016/S0378-1119(02)00697-2; Kumar V., 1994, Insect Molecular Biology, V3, P41, DOI 10.1111/j.1365-2583.1994.tb00149.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Luckhart S, 1998, P NATL ACAD SCI USA, V95, P5700, DOI 10.1073/pnas.95.10.5700; Muller HM, 1999, J BIOL CHEM, V274, P11727, DOI 10.1074/jbc.274.17.11727; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Oduol F, 2000, P NATL ACAD SCI USA, V97, P11397, DOI 10.1073/pnas.180060997; Park DS, 2000, MOL CELLS, V10, P186, DOI 10.1007/s10059-000-0186-2; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; Schick C, 1998, P NATL ACAD SCI USA, V95, P13465, DOI 10.1073/pnas.95.23.13465; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; VERNICK KD, 1995, EXP PARASITOL, V80, P583, DOI 10.1006/expr.1995.1074; Zieler H, 2000, P NATL ACAD SCI USA, V97, P11516, DOI 10.1073/pnas.97.21.11516	51	74	76	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4184	4193		10.1074/jbc.M208187200	http://dx.doi.org/10.1074/jbc.M208187200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12456678	hybrid			2022-12-25	WOS:000180869700086
J	Deshane, J; Garner, CC; Sontheimer, H				Deshane, J; Garner, CC; Sontheimer, H			Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM DISINTEGRIN; CENTRAL-NERVOUS-SYSTEM; HUMAN BRAIN-TUMORS; INTEGRIN ALPHA-V-BETA-3; GELATINASE-A; TYROSINE PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; TISSUE INHIBITOR	Primary brain tumors (gliomas) have the unusual ability to diffusely infiltrate the normal brain thereby evading surgical treatment. Chlorotoxin is a scorpion toxin that specifically binds to the surface of glioma cells and impairs their ability to invade. Using a recombinant His-Cltx we isolated and identified the principal Cltx receptor on the surface of glioma cells as matrix metalloproteinase-2 (MMP-2). MMP-2 is specifically upregulated in gliomas and related cancers, but is not normally expressed in brain. We demonstrate that Cltx specifically and selectively interacts with MMP-2 isoforms, but not with MMP-1, -3, and -9, which are also expressed in malignant glioma cells. Importantly, we show that the anti-invasive effect of Cltx on glioma cells can be explained by its interactions with MMP-2. Cltx exerts a dual effect on MMP-2: it inhibits the enzymatic activity of MMP-2 and causes a reduction in the surface expression of MMP-2. These findings suggest that Cltx is a specific MMP-2 inhibitor with significant therapeutic potential for gliomas and other diseases that invoke the activity of MMP-2.	Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama, Civitan Int Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Sontheimer, H (corresponding author), 1719 6th Ave,S CIRC 589, Birmingham, AL 35294 USA.			Garner, Craig/0000-0003-1970-5417; Sontheimer, Harald/0000-0002-5843-9871	NINDS NIH HHS [2R01-NS-36692] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036692] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bello L, 2001, CANCER RES, V61, P8730; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cameron PL, 2002, GLIA, V37, P275, DOI 10.1002/glia.10036; DEBIN JA, 1991, TOXICON, V29, P1403, DOI 10.1016/0041-0101(91)90128-E; DEBIN JA, 1993, AM J PHYSIOL, V264, P361; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 1997, J CELL SCI, V110, P2473; Deryugina EI, 1998, CANCER RES, V58, P3743; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; FRIDMAN R, 1995, CANCER RES, V55, P2548; Friedberg MH, 1998, CANCER, V82, P923, DOI 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Giese A, 1998, ANTICANCER RES, V18, P2435; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Haugland HK, 1997, ANTICANCER RES, V17, P1035; Hidalgo M, 2001, Adv Intern Med, V47, P159; Hofmann UB, 2000, J INVEST DERMATOL, V115, P625, DOI 10.1046/j.1523-1747.2000.00114.x; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Kachra Z, 1999, CLIN EXP METASTAS, V17, P555, DOI 10.1023/A:1006760632766; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Linskey ME, 1997, J NEURO-ONCOL, V34, P5, DOI 10.1023/A:1005751018617; Lyons SA, 2002, GLIA, V39, P162, DOI 10.1002/glia.10083; MacFarlane SN, 2000, J NEUROSCI, V20, P5245, DOI 10.1523/JNEUROSCI.20-14-05245.2000; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Oh LYS, 1999, J NEUROSCI, V19, P8464; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Planchenault T, 2001, NEUROSCI LETT, V299, P140, DOI 10.1016/S0304-3940(00)01787-0; Pol A, 2000, J BIOL CHEM, V275, P30566, DOI 10.1074/jbc.M001131200; Prados Michael D., 2000, Seminars in Oncology, V27, P1; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Ritter MR, 2000, J CELL BIOCHEM, V79, P28, DOI 10.1002/1097-4644(2000)79:1<28::AID-JCB40>3.0.CO;2-Y; Rooprai HK, 2000, BRIT J CANCER, V82, P52, DOI 10.1054/bjoc.1999.0876; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Sawicki G, 1997, NATURE, V386, P616, DOI 10.1038/386616a0; Schmitmeier S, 2000, ANTICANCER RES, V20, P4227; Sheu JR, 1997, BBA-GEN SUBJECTS, V1336, P445, DOI 10.1016/S0304-4165(97)00057-3; Skretting G, 1999, J CELL SCI, V112, P3899; Soroceanu L, 1998, CANCER RES, V58, P4871; Soroceanu L, 1999, J NEUROSCI, V19, P5942, DOI 10.1523/JNEUROSCI.19-14-05942.1999; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tonn JC, 1998, ANTICANCER RES, V18, P2599; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Ullrich N, 1996, AM J PHYSIOL-CELL PH, V270, pC1511; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999; Ye ZC, 1996, NEUROREPORT, V7, P2181, DOI 10.1097/00001756-199609020-00025	55	325	353	2	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4135	4144		10.1074/jbc.M205662200	http://dx.doi.org/10.1074/jbc.M205662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12454020	hybrid			2022-12-25	WOS:000180869700080
J	Ikeda, K; Emoto, N; Matsuo, M; Yokoyama, M				Ikeda, K; Emoto, N; Matsuo, M; Yokoyama, M			Molecular identification and characterization of a novel nuclear protein whose expression is up-regulated in insulin-resistant animals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-REPEAT PROTEIN; MEMBRANE-BOUND METALLOPROTEASE; HUMAN SKELETAL-MUSCLE; GENE-EXPRESSION; METABOLISM; CARP; TRIGLYCERIDE; GAMMA; CELLS; HEART	Energy metabolism is the most fundamental capacity for mammals, impairment of which causes a variety of diseases such as type 2 diabetes and insulin resistance. Here, we identified a novel gene, termed diabetes-related ankyrin repeat protein (DARP) that is up-regulated in the heart of KKA(y) mouse, a type 2 diabetes and insulin resistance model animal. DARP contains putative nuclear localization signals and four tandem ankyrin-like repeats. Its expression is restricted in heart, skeletal muscle, and brown adipose. Western blot analysis and immunocytochemistry of DARP-transfected Chinese hamster ovary (CHO) and COS-7 cells reveal that DARP is a nuclear protein. When DARP is expressed in CHO cells, [1-C-14]palmitate uptake is significantly decreased, whereas the palmitate oxidation does not show significant change. Furthermore, DARP expression is altered by the change of energy supply induced by excess fatty acid treatment of skeletal myo-tube in vitro and fasting treatment of C57 mouse in vivo. We confirmed that DARP expression is also altered in Zucker fatty rat, another insulin resistance model animal. Taken together, these data suggest that DARP is a novel nuclear protein potentially involved in the energy metabolism. Detailed analysis of DARP may provide new insights in the energy metabolism.	Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc & Resp Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Int Ctr Med Res, Div Mol Med, Kobe, Hyogo 6500017, Japan	Kobe University; Kobe University	Emoto, N (corresponding author), Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc & Resp Med,Chuo Ku, 7-5-1 Kusunoki, Kobe, Hyogo 6500017, Japan.			Emoto, Noriaki/0000-0001-6673-2616; ikeda, Koji/0000-0002-9972-7255				Ahuja HS, 2001, MOL PHARMACOL, V59, P765, DOI 10.1124/mol.59.4.765; Belke DD, 2000, AM J PHYSIOL-ENDOC M, V279, pE1104, DOI 10.1152/ajpendo.2000.279.5.E1104; Bezaire V, 2001, AM J PHYSIOL-ENDOC M, V281, pE975, DOI 10.1152/ajpendo.2001.281.5.E975; Brunmair B, 2001, DIABETES, V50, P2309, DOI 10.2337/diabetes.50.10.2309; Cha BS, 2001, DIABETOLOGIA, V44, P444, DOI 10.1007/s001250051642; Chatham JC, 1997, AM J PHYSIOL-HEART C, V273, pH52, DOI 10.1152/ajpheart.1997.273.1.H52; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Kanai H, 2001, CIRC RES, V88, P30, DOI 10.1161/01.RES.88.1.30; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kelley DE, 2001, DIABETES CARE, V24, P933, DOI 10.2337/diacare.24.5.933; Kemp TJ, 2000, GENOMICS, V66, P229, DOI 10.1006/geno.2000.6213; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS516; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Luiken JJFP, 1997, J LIPID RES, V38, P745; Mackem S, 2001, J BIOL CHEM, V276, P45501, DOI 10.1074/jbc.C100269200; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Moriyama M, 2001, BIOCHEM BIOPH RES CO, V285, P715, DOI 10.1006/bbrc.2001.5216; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; Taylor DA, 1997, P ASSOC AM PHYSICIAN, V109, P245; Van der Lee KAJM, 2001, J LIPID RES, V42, P1752; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a; Zou YM, 1997, DEVELOPMENT, V124, P793	28	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3514	3520		10.1074/jbc.M204563200	http://dx.doi.org/10.1074/jbc.M204563200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12456686	hybrid			2022-12-25	WOS:000180869700003
J	Shumway, SD; Li, Y; Xiong, Y				Shumway, SD; Li, Y; Xiong, Y			14-3-3 beta binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; RAF-1 KINASE; PROLIFERATION; 14-3-3-ZETA; PROTEIN	TSC2, or tuberin, is the product of the tuberous sclerosis tumor suppressor gene TSC2 and acts downstream of the phosphatidylinositol 3-kinase-Akt signaling pathway to negatively regulate cellular growth. One mechanism underlying its function is to assemble into a heterodimer with the TSC1 gene product TSC1, or hamartin, resulting in a reduction in phosphorylation, and hence activation, of the ribosomal subunit S6 kinase (S6K). We identified a novel interaction between TSC2 and 14-3-3beta. We found that 14-3-3beta does not interfere with TSC1-TSC2 binding and can form a ternary complex with these two proteins. Association between 14-3-3beta and TSC2 requires phosphorylation of TSC2 at a unique residue that is not a known Akt phosphorylation site. The overexpression of 14-3-3beta compromises the ability of the TSC1-TSC2 complex to reduce S6K phosphorylation. The antagonistic activity of 14-3-3beta toward TSC is dependent on the 14-3-3beta-TSC2 interaction, since a mutant of TSC2 that is not recognized by 14-3-3beta is refractory to 14-3-3beta. We suggest that 14-3-3 proteins interact with the TSC1-TSC2 complex and negatively regulate the function of the TSC proteins.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	yxiong@email.unc.edu			NCI NIH HHS [CA65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	18	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2089	2092		10.1074/jbc.C200499200	http://dx.doi.org/10.1074/jbc.C200499200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12468542	hybrid			2022-12-25	WOS:000180562000003
J	Astrinidis, A; Cash, TP; Hunter, DS; Walker, CL; Chernoff, J; Henske, EP				Astrinidis, A; Cash, TP; Hunter, DS; Walker, CL; Chernoff, J; Henske, EP			Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration	ONCOGENE			English	Article						tuberous sclerosis complex; TSC2; tuberin; RhoA; cell migration; cell attachment	TSC1 GENE; EKER RAT; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; KINASE GENE; GTPASE-RHO; HAMARTIN; PROLIFERATION; EXPRESSION; CANCER	Tuberous sclerosis complex (TSC) is a tumor suppressor gene syndrome characterized by seizures, mental retardation, autism, and tumors of the brain, kidney, heart, retina, and skin. TSC is caused by mutations in either TSC1 or TSC2, both of which are tumor suppressor genes. Hamartin, the protein product of TSC1, was found to interact with the ezrin-radixin-moesin family of cytoskeletal proteins and to activate the small GTPase Rho. To determine whether tuberin, the TSC2 product, can also activate Rho, we stably expressed full-length human tuberin in two cell types: MDCK cells and ELT3 cells. ELT3 cells lack endogenous tuberin expression. We found that expression of human tuberin in both MDCK and ELT3 cells was associated with an increase in the amount of Rho-GTP, but not in Rac1-GTP or cdc42-GTP. Tuberin expression increased cell adhesion in both cell types, and decreased chemotactic cell migration in ELT3 cells. In MDCK cells, there was a decrease in the amount of total Focal Adhesion Kinase (FAK) and an increase in the fraction of phosphorylated FAK. These findings demonstrate for the first time that tuberin activates Rho and regulates cell adhesion and migration. Pathways involving Rho activation may have relevance to the clinical manifestations of TSC, including pulmonary lymphangioleiomyomatosis.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Texas, MD Anderson Canc Ctr, Smithville, TX 78957 USA	Fox Chase Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Henske, EP (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Astreinidis, Aristotelis/AAK-5137-2020; Chernoff, Jonathan/I-7631-2014; Astreinidis, Aristotelis/ABA-6715-2021; Astrinidis, Aristotelis/A-1396-2010	Chernoff, Jonathan/0000-0002-4803-7836; Astrinidis, Aristotelis/0000-0001-7098-1391	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051052, R01DK051052] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60746] Funding Source: Medline; NIDDK NIH HHS [DK 51052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BONIFACINO JS, 2001, CURRENT PROTOCOLS CE; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Flinn HM, 1996, J CELL SCI, V109, P1133; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; HOWE SR, 1995, AM J PATHOL, V146, P1568; Ilic D, 1997, J CELL SCI, V110, P401; Irani C, 2002, AM J PHYSIOL-LUNG C, V282, pL854, DOI 10.1152/ajplung.00291.2001; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; NELLIST M, 1993, CELL, V75, P1305; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Sullivan EJ, 1998, CHEST, V114, P1689, DOI 10.1378/chest.114.6.1689; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1995, MOL CARCINOGEN, V14, P28, DOI 10.1002/mc.2940140107; Yu J, 2001, AM J RESP CRIT CARE, V164, P1537, DOI 10.1164/ajrccm.164.8.2104095	44	116	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8470	8476		10.1038/sj.onc.1205962	http://dx.doi.org/10.1038/sj.onc.1205962			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466966				2022-12-25	WOS:000179480100009
J	Leheste, JR; Melsen, F; Wellner, M; Jansen, P; Schlichting, U; Renner-Muller, I; Andreassen, TT; Wolf, E; Bachmann, S; Nykjaer, A; Willnow, TE				Leheste, JR; Melsen, F; Wellner, M; Jansen, P; Schlichting, U; Renner-Muller, I; Andreassen, TT; Wolf, E; Bachmann, S; Nykjaer, A; Willnow, TE			Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect	FASEB JOURNAL			English	Article						Cre recombinase; endocytosis; LDL receptor gene family; osteomalacia; vitamin D	D-BINDING PROTEIN; VITAMIN-D; CYTOSOLIC ADAPTER; PROXIMAL TUBULE; RECEPTOR; GP330; CLONING; FAMILY; CELLS; MODEL	Megalin is an endocytic receptor highly expressed in the proximal tubules of the kidney. Recently, we demonstrated that this receptor is essential for the renal uptake and conversion of 25-OH vitamin D(3) to 1,25-(OH)(2) vitamin D(3), a central step in vitamin D and bone metabolism. Unfortunately, the perinatal lethality of the conventional megalin knockout mouse model precluded the detailed analysis of the significance of megalin for calcium homeostasis and bone turnover in vivo. Here, we have generated a new mouse model with conditional inactivation of the megalin gene in the kidney by using Cre recombinase. Animals with a renal-specific receptor gene defect were viable and fertile. However, lack of receptor expression in the kidney results in plasma vitamin D deficiency, in hypocalcemia and in severe bone disease, characterized by a decrease in bone mineral content, an increase in osteoid surfaces, and a lack of mineralizing activity. These features are consistent with osteomalacia (softening of the bones) as a consequence of hypovitaminosis D and demonstrate the crucial importance of the megalin pathway for systemic calcium homeostasis and bone metabolism.	Free Univ Berlin, Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Free Univ Berlin, Fac Med, D-1000 Berlin, Germany; Humboldt Univ, Franz Volhard Clin, Berlin, Germany; Univ Munich, Gene Ctr, Munich, Germany; Aarhus Univ, Dept Biochem Med, Aarhus, Denmark; Aarhus Univ, Inst Anat, Dept Connect Tissue Biol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus, Denmark	Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Franz-Volhard Clinical Research Center; Humboldt University of Berlin; University of Munich; Aarhus University; Aarhus University; Aarhus University	Willnow, TE (corresponding author), Free Univ Berlin, Max Delbruck Ctr Mol Med, Robert Roessle Str 10, D-13125 Berlin, Germany.	willnow@mdc-berlin.de		Willnow, Thomas/0000-0001-9515-7921; Wolf, Eckhard/0000-0002-0430-9510; Nykjaer, Anders/0000-0001-6422-6736				Biemesderfer D, 1999, J BIOL CHEM, V274, P17518, DOI 10.1074/jbc.274.25.17518; Birn H, 2002, AM J PHYSIOL-RENAL, V282, pF408, DOI 10.1152/ajprenal.00206.2000; Bland R, 2001, KIDNEY INT, V60, P1277, DOI 10.1046/j.1523-1755.2001.00966.x; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; Christensen EI, 1999, J AM SOC NEPHROL, V10, P2224; DELUCA HF, 1976, CLIN ENDOCRINOL, V5, pS97, DOI 10.1111/j.1365-2265.1976.tb03819.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HADDAD JG, 1995, J STEROID BIOCHEM, V53, P1; HILPERT J, 2002, IN PRESS KIDNEY INT; Hjalm G, 1996, EUR J BIOCHEM, V239, P132, DOI 10.1111/j.1432-1033.1996.0132u.x; Holick MF, 2000, CLIN LAB MED, V20, P569; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Rader K, 2000, J AM SOC NEPHROL, V11, P2167, DOI 10.1681/ASN.V11122167; Safadi FF, 1999, J CLIN INVEST, V103, P239, DOI 10.1172/JCI5244; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Schmitz C, 2002, J BIOL CHEM, V277, P618, DOI 10.1074/jbc.M109959200; Theilig F, 2001, J AM SOC NEPHROL, V12, P2209, DOI 10.1681/ASN.V12112209; White P, 2000, TRENDS ENDOCRIN MET, V11, P320, DOI 10.1016/S1043-2760(00)00317-9; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Willnow TE, 2002, CURR OPIN LIPIDOL, V13, P255, DOI 10.1097/00041433-200206000-00004; Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888	30	127	138	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					247	+		10.1096/fj.02-0578fje	http://dx.doi.org/10.1096/fj.02-0578fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475886				2022-12-25	WOS:000180574300013
J	Muller, FU; Lewin, G; Matus, M; Neumann, J; Riemann, B; Wistuba, J; Schutz, G; Schmitz, W				Muller, FU; Lewin, G; Matus, M; Neumann, J; Riemann, B; Wistuba, J; Schutz, G; Schmitz, W			Impaired cardiac contraction and relaxation and decreased expression of sarcoplasmic Ca2+-ATPase in mice lacking the CREM gene	FASEB JOURNAL			English	Article						transcription factor; cAMP response element modulator (CREM) knockout ventricular function; SERCA beta-adrenoreceptor	CONGESTIVE-HEART-FAILURE; TRANSCRIPTIONAL REGULATION; DILATED CARDIOMYOPATHY; BETA-ADRENOCEPTORS; TRANSGENIC MICE; CAMP; PROTEINS; BETA-2-ADRENOCEPTORS; ISOFORM; BETA-1-ADRENOCEPTORS	Congestive heart failure is the common endpoint of various cardiac diseases representing a leading cause of cardiovascular mortality in Western countries. Characteristic functional alterations of the failing heart are explained by expressional changes of myocardial regulatory proteins; however, little is known about underlying mechanisms regulating cardiac gene expression in the failing heart. Here, we address the specific role of transcription factor CREM for cardiac function in CREM mutant mice with complete inactivation of the CREM gene. We show that CREM mutant mice display distinct alterations of cardiac function resembling characteristic functional defects of the failing heart. Left ventricular hemodynamic assessment of CREM mutant mice revealed impairment of both cardiac contraction and relaxation in basal state, as well as a decreased responsiveness to beta-adrenergic stimulation. The diminished cardiac contractile performance was associated with a selective down-regulation of beta(1)-adrenergic receptors and a decreased ventricular expression of SERCA, the Ca2+-ATPase of the sarcoplasmic reticulum. The cardiac phenotype of CREM mutant mice provides the first evidence that CREM represents an important key regulator of cardiac gene expression, which is essential for normal left ventricular contractile performance and response to beta-adrenoreceptor stimulation.	Univ Munster, Inst Pharmacol & Toxicol, D-48149 Munster, Germany; Univ Munster, Dept Nucl Med, D-48149 Munster, Germany; Univ Munster, Inst Reprod Med, D-48149 Munster, Germany; German Canc Res Ctr, Mol Biol Cell Div 1, D-6900 Heidelberg, Germany	University of Munster; University of Munster; University of Munster; Helmholtz Association; German Cancer Research Center (DKFZ)	Muller, FU (corresponding author), Univ Munster, Inst Pharmacol & Toxicol, Domagkstr 12, D-48149 Munster, Germany.	mullerf@uni-muenster.de						[Anonymous], 1990, Lancet, V336, P1; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BRODDE OE, 1991, PHARMACOL REV, V43, P203; Cho MC, 1999, J BIOL CHEM, V274, P22251, DOI 10.1074/jbc.274.32.22251; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; Colucci WS., 1997, HEART DIS TXB CARDIO, P394; DOOLEY DJ, 1986, EUR J PHARMACOL, V130, P137, DOI 10.1016/0014-2999(86)90193-7; ENGEL G, 1981, N-S ARCH PHARMACOL, V317, P277, DOI 10.1007/BF00501307; ESCHENHAGEN T, 1992, MOL PHARMACOL, V42, P773; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luss I, 1999, J MOL CELL CARDIOL, V31, P1299, DOI 10.1006/jmcc.1999.0962; Mehrhof FB, 2001, CIRCULATION, V104, P2088, DOI 10.1161/hc4201.097133; Mittmann C, 1998, CARDIOVASC RES, V39, P267, DOI 10.1016/S0008-6363(98)00139-4; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Moriscot AS, 1997, ENDOCRINOLOGY, V138, P26, DOI 10.1210/en.138.1.26; MOTOMURA S, 1990, BRIT J PHARMACOL, V101, P363, DOI 10.1111/j.1476-5381.1990.tb12715.x; MULLER FU, 1995, CIRCULATION, V92, P2041, DOI 10.1161/01.CIR.92.8.2041; Muller FU, 2000, MOL CELL BIOCHEM, V212, P11, DOI 10.1023/A:1007176030884; Muller FU, 1998, FASEB J, V12, P1191; MULLER FU, 1993, CIRC RES, V72, P696, DOI 10.1161/01.RES.72.3.696; Muller FU, 2001, CARDIOVASC RES, V52, P95, DOI 10.1016/S0008-6363(01)00361-3; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIMOMURA H, 1990, NUCLEIC ACIDS RES, V18, P4591, DOI 10.1093/nar/18.15.4591; Sigmund M, 1996, EUR J CLIN PHARMACOL, V51, P127, DOI 10.1007/s002280050172; STEINFATH M, 1992, J MOL CELL CARDIOL, V24, P1189, DOI 10.1016/0022-2828(92)93182-J; Zhang L, 2001, J MOL CELL CARDIOL, V33, P233, DOI 10.1006/jmcc.2000.1295	36	35	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					103	+		10.1096/fj.02-0486fje	http://dx.doi.org/10.1096/fj.02-0486fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475904				2022-12-25	WOS:000180218500013
J	Li, RA; Ennis, IL; Xue, T; Nguyen, HM; Tomaselli, GF; Goldin, AL; Marban, E				Li, RA; Ennis, IL; Xue, T; Nguyen, HM; Tomaselli, GF; Goldin, AL; Marban, E			Molecular basis of isoform-specific mu-conotoxin block of cardiac, skeletal muscle, and brain Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT SODIUM-CHANNELS; BINDING-SITE; RAT SKELETAL; OUTER VESTIBULE; GIIIA; MUTANT; PORE; LOCALIZATION; DISCRIMINATE; DETERMINANTS	mu-Conotoxins (mu-CTXs) block skeletal muscle Na+ channels with an affinity 1-2 orders of magnitude higher than cardiac and brain Na+ channels. Although a number of conserved pore residues are recognized as critical determinants of mu-CTX block, the molecular basis of isoform-specific toxin sensitivity remains unresolved. Sequence comparison of the domain II (DII) S5-S6 loops of rat skeletal muscle (mu1, Na(v)1.4), human heart (hhl, Na(v)1.5), and rat brain (rb1, Na(v)1.1) Na+ channels reveals substantial divergence in their N-terminal S5-P linkers even though the P-S6 and C-terminal P segments are almost identical. We used Na(v)1.4 as the backbone and systematically converted these DII S5-P isoform. variants to the corresponding residues in Nav1.1 and Na(v)1.5. The Na(v)1.4-->Na-v 1.5 variant substitutions V724R, C725S, A728S, D730S, and C731S (Na-v 1.4 numbering) reduced block of Na(v)1.4 by 4-, 86-, 12-, 185-, and 55-fold respectively, rendering the skeletal muscle isoform more "cardiac-like." Conversely, an Na(v)1.5--> Na(v)1.4 chimeric construct in which the Na(v)1.4 DII S5-P linker replaces the analogous segment in Na(v)1.5 showed enhanced mu-CTX block. However, these variant determinants are conserved between Na(v)1.1 and Na(v)1.4 and thus cannot explain their different sensitivities to mu-CTX. Comparison of their sequences reveals two variants at Na(v)1.4 positions 729 and 732: Ser and Asn in Nav1.4 compared with Thr and Lys in Nav1.1, respectively. The double mutation S729T/N732K rendered Na(v)1.4 more "brain-like" (30-fold down arrow in block), and the converse mutation T925S/K928N in Nav1.1 reproduced the high affinity blocking phenotype of Na(v)1.4. We conclude that the DII S5-P linker, although lying outside the conventional ion-conducting pore, plays a prominent role in mu-CTX binding, thus shaping isoform-specific toxin sensitivity.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Johns Hopkins University; University of California System; University of California Irvine	Li, RA (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.	ronaldli@jhmi.edu	Xue, Tian/G-9009-2018; Li, Ronald/E-9833-2010; Marban, Eduardo/GWC-8514-2022; Goldin, Alan/A-8385-2015	Ennis, Irene/0000-0003-3510-7302; Goldin, Alan/0000-0001-7159-0288	NHLBI NIH HHS [R01 HL-50411, R01 HL-52768] Funding Source: Medline; NINDS NIH HHS [R01 NS-26729] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050411, R01HL052768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026729] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; Chahine M, 1998, BIOPHYS J, V75, P236, DOI 10.1016/S0006-3495(98)77510-1; Chang NS, 1998, BIOCHEMISTRY-US, V37, P4407, DOI 10.1021/bi9724927; CHEN LQ, 1992, FEBS LETT, V309, P253, DOI 10.1016/0014-5793(92)80783-D; CRUZ LJ, 1989, BIOCHEMISTRY-US, V28, P3437, DOI 10.1021/bi00434a043; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Cummins TR, 2002, MOL PHARMACOL, V61, P1192, DOI 10.1124/mol.61.5.1192; Dudley SC, 2000, J GEN PHYSIOL, V116, P679, DOI 10.1085/jgp.116.5.679; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GRAY WR, 1983, J BIOL CHEM, V258, P2247; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN SH, 1992, PFLUG ARCH EUR J PHY, V422, P90, DOI 10.1007/BF00381519; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Hui KY, 2002, J GEN PHYSIOL, V119, P45, DOI 10.1085/jgp.119.1.45; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Li RA, 2002, FEBS LETT, V511, P159, DOI 10.1016/S0014-5793(01)03316-6; Li RA, 1999, CIRC RES, V85, P88; Li RA, 1997, BIOPHYS J, V73, P1874, DOI 10.1016/S0006-3495(97)78218-3; Li RA, 2000, J GEN PHYSIOL, V115, P81, DOI 10.1085/jgp.115.1.81; Li RA, 2001, CIRCULATION, V104, P309; Li RA, 2001, BIOCHEMISTRY-US, V40, P6002, DOI 10.1021/bi010077f; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Li RK, 2000, J BIOL CHEM, V275, P27551; LI Y, 1991, J BIOL CHEM, V266, P15481; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; MOCZYDLOWSKI E, 1986, ANN NY ACAD SCI, V479, P269, DOI 10.1111/j.1749-6632.1986.tb15575.x; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; NAKAMURA H, 1983, EXPERIENTIA, V39, P590, DOI 10.1007/BF01971110; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Pardo-Lopez L, 2002, J BIOL CHEM, V277, P16403, DOI 10.1074/jbc.M200460200; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SATO K, 1991, J BIOL CHEM, V266, P16989; Smith RD, 1998, J NEUROSCI, V18, P811; STARMER CF, 1984, BIOPHYS J, V46, P15, DOI 10.1016/S0006-3495(84)83994-6; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; Xue T, 2002, J BIOL CHEM, V277, P46233, DOI 10.1074/jbc.M204915200; YANAGAWA Y, 1986, NEUROSCI LETT, V64, P7, DOI 10.1016/0304-3940(86)90654-3	41	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8717	8724		10.1074/jbc.M210882200	http://dx.doi.org/10.1074/jbc.M210882200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12471026	hybrid, Green Published			2022-12-25	WOS:000181466800124
J	Odunuga, OO; Hornby, JA; Bies, C; Zimmermann, R; Pugh, DJ; Blatch, GL				Odunuga, OO; Hornby, JA; Bies, C; Zimmermann, R; Pugh, DJ; Blatch, GL			Tetratricopeptide repeat motif-mediated Hsc70-mSTI1 interaction - Molecular characterization of the critical contacts for successful binding and specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; STRESS-INDUCIBLE GENE; SACCHAROMYCES-CEREVISIAE; TPR MOTIF; IDENTIFICATION; CLONING; DOMAIN; COMPLEXES; HSP90; EXPRESSION	Murine stress-inducible protein 1 (mSTI1) is a cochaperone that is homologous with the human Hsp70/ Hsp90-organizing protein (Hop). Guided by Hop structural data and sequence alignment analyses, we have used site-directed mutagenesis, co-precipitation assays, circular dichroism spectroscopy, steady-state fluorescence, and surface plasmon resonance spectroscopy to both qualitatively and quantitatively characterize the contacts necessary for the N-terminal tetratricopeptide repeat domain (TPR1) of mSTI1 to bind to heat shock cognate protein 70 (Hsc70) and to discriminate between Hsc70 and Hsp90. We have shown that substitutions in the first TPR motif of Lys(8) or Asn(12) did not affect binding of mSTI1 to Hsc70, whereas double substitution of these residues abrogated binding. A substitution in the second TPR motif of Asn(43) lowered but did not abrogate binding. Similarly, a deletion in the second TPR motif coupled with a substitution of Lys(8) or Asn(12) reduced but did not abrogate binding. These results suggest that mSTI1.Hsc70 interaction requires a network of interactions not only between charged residues in the TPR1 domain of mSTI1 and the EEVD motif of Hsc70 but also outside the TPR domain. We propose that the electrostatic interactions in the first TPR motif made by Lys(8) or Asn(12) define part of the minimum interactions required for successful mSTI1-Hsc70 interaction. Using a truncated derivative of mSTI1 incapable of binding to Hsp90, we substituted residues on TPR1 potentially involved in hydrophobic contacts with Hsc70. The modified protein had reduced binding to Hsc70 but now showed significant binding capacity for Hsp90. In contrast, topologically equivalent substitutions on a truncated derivative of mSTI1 incapable of binding to Hsc70 did not confer Hsc70 specificity on TPR2A. Our results suggest that binding of Hsc70 to TPR1 is more specific than binding of Hsp90 to TPR2A with serious implications for the mechanisms of mSTI1 interactions with Hsc70 and Hsp90 in vivo.	Rhodes Univ, Dept Biochem Microbiol & Biotechnol, ZA-6140 Grahamstown, South Africa; Univ Saarland, D-66421 Homburg, Germany; Univ Western Cape, Dept Biotechnol, ZA-7535 Cape Town, South Africa	Rhodes University; Saarland University; University of the Western Cape	Blatch, GL (corresponding author), Rhodes Univ, Dept Biochem Microbiol & Biotechnol, ZA-6140 Grahamstown, South Africa.		Blatch, Gregory Lloyd/Q-5900-2019; Odunuga, Odutayo/W-2141-2019	Blatch, Gregory Lloyd/0000-0003-0778-8577; 				Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Blatch GL, 1997, GENE, V194, P277, DOI 10.1016/S0378-1119(97)00206-0; Blecher O, 1996, PLANT MOL BIOL, V32, P493, DOI 10.1007/BF00019101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; HOHFELD J, 1995, CELL, V83, P589; HONORE B, 1992, J BIOL CHEM, V267, P8485; Irmer H, 1997, J BIOL CHEM, V272, P2230; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Sambrook J., 1989, MOL CLONING, pA1; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Smith DF, 1998, BIOL CHEM, V379, P283; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TORRES JH, 1995, PLANT MOL BIOL, V27, P1221, DOI 10.1007/BF00020896; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van der Spuy J, 2000, BIOCHEM J, V345, P645, DOI 10.1042/0264-6021:3450645; Wallace LA, 1998, BIOCHEMISTRY-US, V37, P5320, DOI 10.1021/bi972936z; Webb JR, 1996, J IMMUNOL, V157, P5034	33	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6896	6904		10.1074/jbc.M206867200	http://dx.doi.org/10.1074/jbc.M206867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482845	hybrid			2022-12-25	WOS:000181195100035
J	Bando, M; Hasegawa, M; Tsuboi, Y; Miyake, Y; Shiina, M; Ito, M; Handa, H; Nagai, K; Kataoka, T				Bando, M; Hasegawa, M; Tsuboi, Y; Miyake, Y; Shiina, M; Ito, M; Handa, H; Nagai, K; Kataoka, T			The mycotoxin penicillic acid inhibits fas ligand-induced apoptosis by blocking self-processing of caspase-8 in death-inducing signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CELL-DEATH; ACTIVATION; LYMPHOCYTE; PROTEASES; CYTOTOXICITY; RECEPTORS; SURVIVAL; CASCADE; ENZYME	Upon engagement with Fas ligand (FasL), Fas rapidly induces recruitment and self-processing of caspase-8 via the adaptor protein Fas-associated death domain (FADD), and activated caspase-8 cleaves downstream substrates such as caspase-3. We have found that penicillic acid (PCA) inhibits FasL-induced apoptosis and concomitant loss of cell viability in Burkitt's lymphoma Raji cells. PCA prevented activation of caspase-8 and caspase-3 upon treatment with FasL. However, PCA did not affect active caspase-3 in FasL-treated cells, suggesting that PCA primarily blocks early signaling events upstream of caspase-8 activation. FasL-induced processing of caspase-8 was severely impaired in the death-inducing signaling complex, although FasL-induced recruitment of FADD and caspase-8 occurred normally in PCA-treated cells. Although PCA inhibited the enzymatic activities of active recombinant caspase-3, caspase-8, and caspase-9 at similar concentrations, PCA exerted weak inhibitory effects on activation of caspase-9 and caspase-3 in staurosporine-treated cells but strongly inhibited caspase-8 activation in FasL-treated cells. Glutathione and cysteine neutralized an inhibitory effect of PCA on caspase-8, and PCA bound directly to the active center cysteine in the large subunit of caspase-8. Thus, our present results demonstrate that PCA inhibits FasL-induced apoptosis by targeting self-processing of caspase-8.	Tokyo Inst Technol, Res Ctr Expt Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Dept Bioengn, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology; Tokyo Institute of Technology	Kataoka, T (corresponding author), Tokyo Inst Technol, Res Ctr Expt Biol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.							Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bando M, 2002, BIOCHEM BIOPH RES CO, V290, P268, DOI 10.1006/bbrc.2001.6199; Blanchard H, 2000, J MOL BIOL, V302, P9, DOI 10.1006/jmbi.2000.4041; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dittel BN, 1999, J IMMUNOL, V162, P6392; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Okuda Y, 1998, MOL IMMUNOL, V35, P317, DOI 10.1016/S0161-5890(98)00049-2; OSADA H, 1988, J ANTIBIOT, V41, P925, DOI 10.7164/antibiotics.41.925; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276	45	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5786	5793		10.1074/jbc.M204178200	http://dx.doi.org/10.1074/jbc.M204178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482880	hybrid			2022-12-25	WOS:000181129400039
J	Kim, S; Ko, J; Shin, H; Lee, JR; Lim, C; Han, JH; Altrock, WD; Garner, CC; Gundelfinger, ED; Premont, RT; Kaang, BK; Kim, E				Kim, S; Ko, J; Shin, H; Lee, JR; Lim, C; Han, JH; Altrock, WD; Garner, CC; Gundelfinger, ED; Premont, RT; Kaang, BK; Kim, E			The GIT family of proteins forms multimers and associates with the presynaptic cytomatrix protein Piccolo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; RECEPTOR-BINDING PROTEIN; TYROSINE-PHOSPHATASE; INTERACTING PROTEINS; POSTSYNAPTIC DENSITY; MEMBRANE-TRANSPORT; AMPA RECEPTORS; NERVOUS-SYSTEM; ACTIVE ZONES; BETA-PIX	The cytoskeletal matrix assembled at active zones (CAZ) is implicated in defining neurotransmitter release sites. However, little is known about the molecular mechanisms by which the CAZ is organized. Here we report a novel interaction between Piccolo, a core component of the CAZ, and GIT proteins, multidomain signaling integrators with GTPase-activating protein activity for ADP-ribosylation factor small GTPases. A small region (similar to150 amino acid residues) in Piccolo, which is not conserved in the closely related CAZ protein Bassoon, mediates a direct interaction with the Spa2 homology domain (SHD) domain of GIT1. Piccolo and GIT1 colocalize at synaptic sites in cultured neurons. In brain, Piccolo forms a complex with GIT1 and various GIT-associated proteins, including betaPIX, focal adhesion kinase, liprin-alpha, and paxillin. Point mutations in the SHD of GIT1 differentially interfere with the association of GIT1 with Piccolo, betaPIX, and focal adhesion kinase, suggesting that these proteins bind to the SHD by different mechanisms. Intriguingly, GIT proteins form homo- and heteromultimers through their C-terminal G-protein-coupled receptor kinase-binding domain in a tail-to-tail fashion. This multimerization enables GIT1 to simultaneously interact with multiple SHD-binding proteins including Piccolo and betaPIX. These results suggest that, through their multimerization and interaction with Piccolo, the GIT family proteins are involved in the organization of the CAZ.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Seoul Natl Univ, Coll Nat Sci, Sch Biol Sci,Inst Mol Biol & Genet, Mol Neurobiol Lab, Seoul 151742, South Korea; Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; Stanford Univ, Nancy Pritzer Lab, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Duke Univ, Med Ctr, Dept Med Gastroenterol, Durham, NC 27710 USA	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Leibniz Institut fur Neurobiologie (LIN); Stanford University; Duke University	Kim, E (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	kime@mail.kaist.ac.kr	Han, Jin-Hee/C-2069-2011; Lim, Chunghun/AAB-1253-2020; Kim, Eunjoon/C-1566-2011	Lim, Chunghun/0000-0001-8473-9272; Garner, Craig/0000-0003-1970-5417; Premont, Richard/0000-0002-8053-5026; Han, Jin-Hee/0000-0002-2139-5596	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER; NIA NIH HHS [P01-AG06569] Funding Source: Medline; NINDS NIH HHS [R01-NS39471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; Andreev J, 1999, MOL CELL BIOL, V19, P2338; Ashery U, 1999, P NATL ACAD SCI USA, V96, P1094, DOI 10.1073/pnas.96.3.1094; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Banker G., 1991, CULTURING NERVE CELL; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Clandinin TR, 2001, NEURON, V32, P237, DOI 10.1016/S0896-6273(01)00474-3; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Fujimoto K, 2002, J BIOL CHEM, V277, P50497, DOI 10.1074/jbc.M210146200; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Hernandez-Deviez DJ, 2002, NAT NEUROSCI, V5, P623, DOI 10.1038/nn865; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim S, 2000, BIOCHEM BIOPH RES CO, V272, P721, DOI 10.1006/bbrc.2000.2845; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Koh CG, 2001, J CELL SCI, V114, P4239; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; LANDIS DMD, 1988, J ELECTRON MICR TECH, V10, P129, DOI 10.1002/jemt.1060100203; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Manabe R, 2002, J CELL SCI, V115, P1497; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Maurel-Zaffran C, 2001, NEURON, V32, P225, DOI 10.1016/S0896-6273(01)00471-8; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Parnas D, 2001, NEURON, V32, P415, DOI 10.1016/S0896-6273(01)00485-8; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Song J, 1998, J CELL SCI, V111, P2257; Srivastava S, 1999, ANN NY ACAD SCI, V868, P561, DOI 10.1111/j.1749-6632.1999.tb11329.x; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2002, P NATL ACAD SCI USA, V99, P14464, DOI 10.1073/pnas.182532999; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	65	103	105	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6291	6300		10.1074/jbc.M212287200	http://dx.doi.org/10.1074/jbc.M212287200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12473661	hybrid			2022-12-25	WOS:000181129400101
J	Yang, J; Liu, LJ; He, DD; Song, X; Liang, XS; Zhao, ZZJ; Zhou, GW				Yang, J; Liu, LJ; He, DD; Song, X; Liang, XS; Zhao, ZZJ; Zhou, GW			Crystal structure of human protein-tyrosine phosphatase SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN; SIGNAL-TRANSDUCTION; CATALYTIC DOMAIN; SPECIFICITY; RECEPTOR; BINDING; SH-PTP2; CELLS	SHP-1 is a cytosolic protein-tyrosine phosphatase that behaves as a negative regulator in eukaryotic cellular signaling pathways. To understand its regulatory mechanism, we have determined the crystal structure of the C-terminal truncated human SHP-1 in the inactive conformation at 2.8-Angstrom resolution and refined the structure to a crystallographic R-factor of 24.0%. The three-dimensional structure shows that the ligand-free SHP-1 has an auto-inhibited conformation. Its N-SH2 domain blocks the catalytic domain and keeps the enzyme in the inactive conformation, which supports that the phosphatase activity of SHP-1 is primarily regulated by the N-SH2 domain. In addition, the C-SH2 domain of SHP-1 has a different orientation from and is more flexible than that of SHP-2, which enables us to propose an enzymatic activation mechanism in which the C-SH2 domains of SHPs could be involved in searching for phosphotyrosine activators.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	University of Massachusetts System; University of Massachusetts Worcester; Vanderbilt University	Zhou, GW (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christensen MD, 2000, SCAND J IMMUNOL, V51, P557; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Famiglietti SJ, 1999, IMMUNOL LETT, V68, P35, DOI 10.1016/S0165-2478(99)00027-9; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Huyer G, 1998, BIOCHEMISTRY-US, V37, P2741, DOI 10.1021/bi9722913; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Liang XS, 1997, J STRUCT BIOL, V120, P201, DOI 10.1006/jsbi.1997.3927; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; Shakespeare WC, 2001, CURR OPIN CHEM BIOL, V5, P409, DOI 10.1016/S1367-5931(00)00222-2; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Wang LL, 1999, J IMMUNOL, V162, P1318; WIELIGMANN K, 2002, SILICO BIOL, V2, P28; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; Yang J, 2001, J CELL BIOCHEM, V83, P14, DOI 10.1002/jcb.1195; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; [No title captured]	34	130	137	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6516	6520		10.1074/jbc.M210430200	http://dx.doi.org/10.1074/jbc.M210430200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482860	hybrid			2022-12-25	WOS:000181129400128
J	Beloin, C; Jeusset, J; Revet, B; Mirambeau, G; Le Hegarat, F; Le Cam, E				Beloin, C; Jeusset, J; Revet, B; Mirambeau, G; Le Hegarat, F; Le Cam, E			Contribution of DNA conformation and topology in right-handed DNA wrapping by the Bacillus subtilis LrpC protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATOR; NUCLEOPROTEIN COMPLEXES; BINDING PROPERTIES; SEQUENCE; CURVATURE; GENE; HU; RECOGNITION	The Bacillus subtilis LrpC protein belongs to the Lrp/AsnC family of transcriptional regulators. It binds the upstream region of the lrpC gene and autoregulates its expression. In this study, we have dissected the mechanisms that govern the interaction of LrpC with DNA by electrophoretic mobility shift assay, electron microscopy, and atomic force microscopy. LrpC is a structure-specific DNA binding protein that forms stable complexes with curved sequences containing phased A tracts and wraps DNA to form spherical, nucleosome-like structures. Formation of such wraps, initiated by cooperative binding of LrpC to DNA, results from optimal protein/protein interactions specified by the DNA conformation. In addition, we have demonstrated that LrpC constrains positive supercoils by wrapping the DNA in a right-handed superhelix, as visualized by electron microscopy.	Univ Paris 11, UMR 8621, Inst Genet & Microbiol, F-91405 Orsay, France; Inst Gustave Roussy, UMR 8126, Lab Microscopie Cellulaire & Mol, F-94805 Villejuif, France	UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Le Hegarat, F (corresponding author), Univ Paris 11, UMR 8621, Inst Genet & Microbiol, Batiment 360, F-91405 Orsay, France.		BELOIN, Christophe/F-9284-2012	BELOIN, Christophe/0000-0002-0344-3443; Mirambeau, Gilles/0000-0001-8308-4948; Le cam, Eric/0000-0002-6832-6117				Aki T, 1997, EMBO J, V16, P3666, DOI 10.1093/emboj/16.12.3666; ALONSO JC, 1995, MOL MICROBIOL, V18, P471, DOI 10.1111/j.1365-2958.1995.mmi_18030471.x; Azam TA, 1999, J BIOL CHEM, V274, P33105, DOI 10.1074/jbc.274.46.33105; Belitsky BR, 1997, J BACTERIOL, V179, P5448, DOI 10.1128/jb.179.17.5448-5457.1997; Beloin C, 2000, J BACTERIOL, V182, P4414, DOI 10.1128/JB.182.16.4414-4424.2000; Beloin C, 1997, MOL GEN GENET, V256, P63, DOI 10.1007/s004380050546; BIANCHI ME, 1994, MOL MICROBIOL, V14, P1, DOI 10.1111/j.1365-2958.1994.tb01261.x; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; Dartois V, 1997, MOL MICROBIOL, V25, P39, DOI 10.1046/j.1365-2958.1997.4491805.x; DELAIN E, 1992, MICROSC MICROANAL M, V3, P457, DOI 10.1051/mmm:0199200306045700; Delain E, 1995, VISUALIZATION NUCL A, P35; DESANTIS P, 1990, BIOCHEMISTRY-US, V29, P9269, DOI 10.1021/bi00491a023; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; FLASHNER Y, 1988, CELL, V54, P713, DOI 10.1016/S0092-8674(88)80016-3; GOOSEN N, 1995, MOL MICROBIOL, V16, P1, DOI 10.1111/j.1365-2958.1995.tb02386.x; Grove A, 1996, J MOL BIOL, V260, P120, DOI 10.1006/jmbi.1996.0386; Hamiche A, 1996, P NATL ACAD SCI USA, V93, P7588, DOI 10.1073/pnas.93.15.7588; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; Jafri S, 1999, J MOL BIOL, V288, P811, DOI 10.1006/jmbi.1999.2715; JOANICOT M, 1987, BIOPOLYMERS, V26, P315, DOI 10.1002/bip.360260211; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LARQUET E, 1995, J BIOMOL STRUCT DYN, V12, P134; LECAM E, 1995, VISUALIZATION NUCL A, P333; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; Mary J, 1999, J MOL BIOL, V286, P121, DOI 10.1006/jmbi.1998.2464; Musgrave D, 2000, MOL MICROBIOL, V35, P341, DOI 10.1046/j.1365-2958.2000.01689.x; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; MUZARD G, 1990, EMBO J, V9, P1289, DOI 10.1002/j.1460-2075.1990.tb08238.x; NADEAU JG, 1989, P NATL ACAD SCI USA, V86, P2622, DOI 10.1073/pnas.86.8.2622; Napoli A, 2001, J BIOL CHEM, V276, P10745, DOI 10.1074/jbc.M010611200; Ozoline ON, 1999, J BIOMOL STRUCT DYN, V16, P825, DOI 10.1080/07391102.1999.10508295; PerezMartin J, 1997, ANNU REV MICROBIOL, V51, P593, DOI 10.1146/annurev.micro.51.1.593; PREOBRAJENSKAYA O, 1994, MOL MICROBIOL, V13, P459, DOI 10.1111/j.1365-2958.1994.tb00440.x; PUTNAM CD, 1994, MOL CELL BIOL, V14, P6476, DOI 10.1128/MCB.14.10.6476; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Reeves R, 2000, MOL CELL BIOL, V20, P4666, DOI 10.1128/MCB.20.13.4666-4679.2000; REVET B, 1995, P NATL ACAD SCI USA, V92, P7535, DOI 10.1073/pnas.92.16.7535; Shin BS, 1997, J BACTERIOL, V179, P7394, DOI 10.1128/jb.179.23.7394-7402.1997; Tapias A, 2000, NUCLEIC ACIDS RES, V28, P552, DOI 10.1093/nar/28.2.552; TRAVERS A, 1987, NATURE, V327, P280, DOI 10.1038/327280a0; TRIFONOV EN, 1991, TRENDS BIOCHEM SCI, V16, P467; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	46	73	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5333	5342		10.1074/jbc.M207489200	http://dx.doi.org/10.1074/jbc.M207489200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458218	hybrid			2022-12-25	WOS:000180968900125
J	Lemercier, C; Legube, G; Caron, C; Louwagie, M; Garin, J; Trouche, D; Khochbin, S				Lemercier, C; Legube, G; Caron, C; Louwagie, M; Garin, J; Trouche, D; Khochbin, S			Tip60 acetyltransferase activity is controlled by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-ACETYLTRANSFERASE; SUBSTRATE-SPECIFICITY; DEPENDENT KINASES; PROTEIN; TRANSCRIPTION; COMPLEX; INTERACTS; RECEPTOR; TRANSACTIVATOR; ACETYLATION	Here we show that the phosphorylation of histone acetyltransferase Tip60, a target of human immunodeficiency virus, type 1-encoded transactivator Tat, plays a crucial role in the control of its catalytic activity. Baculovirus-based expression and purification of Tip60 combined with mass spectrometry allowed the identification of serines 86 and 90 as two major sites of phosphorylation in vivo. The phosphorylation of Tip60 was found to modulate its histone acetyltransferase activity. One of the identified phosphorylated serines, Ser-90, was within a consensus cyclin B/Cdc2 site. Ser-90 was specifically phosphorylated in vitro by the cyclin B/Cdc2 complex. Accordingly, the phosphorylation of Tip60 was enhanced after drug-induced arrest of cells in G(2)/M. This G(2)/M-dependent phosphorylation of Tip60 was abolished by treating cells with a specific inhibitor of the cyclin-dependent kinase, roscovitin. All together, these results strongly suggest a G(2)/M-dependent control of Tip60 activity.	INSERM, U309, Inst Albert Bonniot, Fac Med,Lab Biol Mol & Cellulaire Differenciat, F-38706 La Tronche, France; CEA Grenoble, Lab Chim Prot, F-38054 Grenoble, France; CNRS, Lab Biol Mol Eucaryote, UPR 9006, F-31062 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Khochbin, S (corresponding author), INSERM, U309, Inst Albert Bonniot, Fac Med,Lab Biol Mol & Cellulaire Differenciat, Domaine Merci, F-38706 La Tronche, France.		Caron, Cecile/M-3485-2013; Khochbin, Saadi/M-8090-2013; LEGUBE, Gaelle/AAX-9772-2021; Lemercier, Claudie/F-6759-2015; Trouche, Didier/B-2854-2008	Khochbin, Saadi/0000-0002-0455-0857; Trouche, Didier/0000-0003-1398-6481				Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Caron C, 2003, BIOESSAYS, V25, P58, DOI 10.1002/bies.10202; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; John S, 2000, GENE DEV, V14, P1196; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	29	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4713	4718		10.1074/jbc.M211811200	http://dx.doi.org/10.1074/jbc.M211811200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468530	Green Submitted, hybrid			2022-12-25	WOS:000180968900047
J	Lu, Q; Surks, HK; Ebling, H; Baur, WE; Brown, D; Pallas, DC; Karas, RH				Lu, Q; Surks, HK; Ebling, H; Baur, WE; Brown, D; Pallas, DC; Karas, RH			Regulation of estrogen receptor alpha-mediated transcription by a direct interaction with protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; KINASE; GROWTH; CLONING; EXPRESSION; LIGAND; OCCURS; BETA	Estrogen receptor a (ERalpha) mediates the effects of estrogen by altering gene expression following hormone binding. It has recently been shown that kinase-mediated phosphorylation of ERalpha also transcriptionally activates the receptor in the absence of estrogen. We now report that ERalpha-dependent gene expression also is regulated by protein phosphatase 2A (PP2A). ERalpha co-immunoprecipitates with enzymatically active PP2A. ERalpha binds directly to the catalytic subunit of PP2A, which dephosphorylates serine 118 of the receptor. Amino acids 176-182 in the A/B domain of ERalpha are required for the interaction between PP2A and the receptor. Phosphatase inhibition disrupts the ERalpha-PP2A complex and induces formation of an ERalpha-activated mitogen-activated protein kinase complex, phosphorylation of ERalpha on serine 118, and transcriptional activation. These findings demonstrate that estrogen receptors exist in complexes with phosphatases as well as kinases. We propose a new model of ligand-independent activation of estrogen receptors in which the level of phosphorylation of ERalpha, and hence its transcriptional activation, is determined by the net effect of these counterregulatory pathways.	Tufts Univ, Sch Med, New England Med Ctr Hosp Inc, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Med Ctr Hosp Inc, Mol Cardiol Res Inst, Boston, MA 02111 USA; Emory Univ, Sch Med, Rollins Res Ctr, Dept Biochem, Atlanta, GA 30322 USA; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA	Tufts University; Tufts University; Emory University; Tufts University	Karas, RH (corresponding author), Tufts Univ, New England Med Ctr, Mol Cardiol Res Ctr, 750 Washington St,Box 80, Boston, MA 02111 USA.				NCI NIH HHS [R01 CA057327] Funding Source: Medline; NHLBI NIH HHS [HL61290] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061290] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; BRUNO C, 1999, TEM, V10, P41; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; GREENE GL, 1986, J STEROID BIOCHEM, V24, P1, DOI 10.1016/0022-4731(86)90024-5; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IgnarTrowbridge DM, 1996, ENDOCRINOLOGY, V137, P1735, DOI 10.1210/en.137.5.1735; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Karas RH, 1998, J CLIN INVEST, V101, P2851, DOI 10.1172/JCI1416; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LI X, 2002, EMBO, V20, P4122; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MUARATA K, 1997, P NATL ACAD SCI USA, V94, P10624; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	34	54	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4639	4645		10.1074/jbc.M210949200	http://dx.doi.org/10.1074/jbc.M210949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466266	hybrid			2022-12-25	WOS:000180968900038
J	Zhang, KZ; Kurachi, S; Kurachi, K				Zhang, KZ; Kurachi, S; Kurachi, K			Limitation in use of heterologous reporter genes for gene promoter analysis - Silencer activity associated with the chloramphenicol acetyltransferase reporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; AGE REGULATION; PROTEIN-C; MECHANISMS; REGION; ORGANIZATION; EXPRESSION	Various heterologous reporter genes have been widely used for the functional characterization of gene promoters. Many such studies often found weak to very strong silencer activities to be associated with specific parts of the basal promoter or further upstream regions. In this study, we carried out a systematic study on human blood coagulation factor IX (hFIX) and anti-coagulant protein C (hPC) genes, previously shown to have silencer activities associated with their 5'-flanking regions containing promoter sequences. With newly constructed chloramphenicol acetyltransferase (CAT) reporter vectors carrying hFIX or hPC gene promoter sequences, we confirmed the strong silencer activities associated with the regions nt -1895 through nt -416 of the hFIX gene or with the region nt -802 through nt -82 of the hPC gene. However, no such silencer activities associated with the specific regions were found when autologous hFIX cDNA, hFIX minigenes, or hPC minigenes were used as reporters in the expression vector system. Relative levels of CAT, hFM and hPC proteins produced in the transient assays correlated well with their mRNA levels. Human FIX minigene constructs containing a simian virus 40 (SV40) 3'-untranslated region (UTR) taken from the CAT reporter gene showed no silencer activity, indicating that SV40 3'-UTR sequence of the CAT reporter gene does not contribute to the silencer activity. Expression vectors constructed with the beta-galactosidase gene under the control of hFIX gene promoter sequences also showed no silencer activity associated with the region nt -1895 through nt -416. These findings indicate that silencer activities associated with specific regions of promoter sequences as analyzed with CAT reporter genes may represent artifacts specific to the CAT reporter genes. Our findings strongly suggest a need for re-examination of promoter characterizations of many eukaryotic genes, which have been studied to date with CAT reporter genes.	Age Dimens Res Ctr, Natl Inst Adv Ind Sci & Technol, AIST Tsukuba Cent 4th Site,Higashi 1-1-1, Tsukuba, Ibaraki 3058562, Japan; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	National Institute of Advanced Industrial Science & Technology (AIST); University of Michigan System; University of Michigan	Kurachi, K (corresponding author), Age Dimens Res Ctr, Natl Inst Adv Ind Sci & Technol, AIST Tsukuba Cent 4th Site,Higashi 1-1-1, Tsukuba, Ibaraki 3058562, Japan.	kkurachi@umich.edu		Zhang, Kezhong/0000-0002-6062-235X	National Institutes of Health [HL64522, HL38644]; University of Michigan [NIH 5-P60-AR-20557]; Michigan Diabetes Research and Training Center [NIH 5P60 DK20572]; University of Michigan General Clinical Research Center [NIH MO1-RR-00042]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038644, R01HL064522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan(University of Michigan System); Michigan Diabetes Research and Training Center; University of Michigan General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by Grants HL64522 and HL38644(to K. K.) from the National Institutes of Health, Grant NIH 5-P60-AR-20557 from the Multipurpose Arthritis Center of the University ofMichigan, Grant NIH 5P60 DK20572 from the Michigan Diabetes Re-search and Training Center, and Grant NIH MO1-RR-00042 from theUniversity of Michigan General Clinical Research Center.	Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; GOODBOURN S, 1990, BIOCHIM BIOPHYS ACTA, V1032, P53, DOI 10.1016/0304-419X(90)90012-P; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hsu W, 1999, THROMB HAEMOSTASIS, V82, P1782, DOI 10.1055/s-0037-1614923; Jain VK, 1996, METHOD ENZYMOL, V273, P319; JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x; Kurachi S, 1999, SCIENCE, V285, P739, DOI 10.1126/science.285.5428.739; KURACHI S, 1995, J BIOL CHEM, V270, P5276, DOI 10.1074/jbc.270.10.5276; KURACHI S, 1998, BIOCHEMICA, V3, P43; Lewis JC, 1998, ANAL CHEM, V70, p579A, DOI 10.1021/ac9819638; Miao CH, 1996, J BIOL CHEM, V271, P9587, DOI 10.1074/jbc.271.16.9587; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Ogbourne S, 1998, BIOCHEM J, V331, P1; PLUTZKY J, 1986, P NATL ACAD SCI USA, V83, P546, DOI 10.1073/pnas.83.3.546; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Zhang KZ, 2002, J BIOL CHEM, V277, P4532, DOI 10.1074/jbc.M109524200	23	9	9	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4826	4830		10.1074/jbc.M211361200	http://dx.doi.org/10.1074/jbc.M211361200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473656	hybrid			2022-12-25	WOS:000180968900063
J	Zhao, XH; Lamphear, BJ; Xiong, DD; Knowlton, K; Rhoads, RE				Zhao, XH; Lamphear, BJ; Xiong, DD; Knowlton, K; Rhoads, RE			Protection of cap-dependent protein synthesis in vivo and in vitro with an eIF4G-1 variant highly resistant to cleavage by coxsackievirus 2A protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4G; INFECTED HELA-CELLS; MESSENGER-RNA TRANSLATION; AMINO-ACID-SEQUENCE; BINDING-PROTEIN; POLIOVIRUS INFECTION; IN-VITRO; POLY(A)-BINDING PROTEIN; INDEPENDENT TRANSLATION; PROTEOLYTIC CLEAVAGE	The shutoff of host protein synthesis by certain picornaviruses is mediated, at least in part, by proteolytic cleavage of eIF4G-1. Previously, we developed a cleavage site variant of eIF4G-1, termed eIF4G-1(SM), that was 100-fold more resistant to in vitro cleavage by Coxsackievirus 2A protease (2A(Pro)) than wild-type eIF4G-1 (eIF4G-1(WT)), but it was still digested at high protease concentrations. Here we identified a secondary cleavage site upstream of the primary site. We changed Gly at the P1'-position of the secondary site to Ala to produce eIF4G-1(DM). eIF4G-1(DM) was 1,000-10,000-fold more resistant to cleavage in vitro than eIF4G-1(WT). Full functional activity of eIF4G-1(DM) was demonstrated in vitro by its ability to restore cap-dependent translation to a 2A(Pro)- pretreated rabbit reticulocyte system. An isoform containing the binding site for poly(A)-binding protein, eIF4G-1e(DM), was more active in this assay than an isoform lacking it, eIF4G-1a(DM), but only with polyadenylated mRNA. Functional activity was also demonstrated in vivo with stably transfected HeLa cells expressing eIF4G-1(DM) from a tetracycline-regulated promoter. Cap-dependent green fluorescent protein synthesis was drastically inhibited by 2A(Pro) expression, but synthesis was almost fully restored by induction of either eIF4G-1a(DM) or eIF4G-1e(DM). By contrast, encephalomyocarditis virus internal ribosome entry site-dependent green fluorescent protein synthesis was stimulated by 2A(Pro); stimulation was suppressed by eIF4G-1e(DM) but not eIF4G-1a(DM).	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of California System; University of California San Diego	Rhoads, RE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.				NHLBI NIH HHS [R01 HL57365] Funding Source: Medline; NIGMS NIH HHS [R01 GM20818] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020818] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badorff C, 2000, CIRCULATION, V102, P2276; Blom N, 1996, PROTEIN SCI, V5, P2203, DOI 10.1002/pro.5560051107; BONNEAU AM, 1987, J VIROL, V61, P986, DOI 10.1128/JVI.61.4.986-991.1987; Borman AM, 1997, RNA, V3, P186; Bradley CA, 2002, J BIOL CHEM, V277, P12559, DOI 10.1074/jbc.M111134200; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; CHU LY, 1980, BIOCHEMISTRY-US, V19, P184, DOI 10.1021/bi00542a028; Clark BFC, 1996, BIOCHIMIE, V78, P1119, DOI 10.1016/S0300-9084(97)86738-7; DAVIES MV, 1991, J BIOL CHEM, V266, P14714; EDERY I, 1983, J BIOL CHEM, V258, P1398; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; HELENTJARIS T, 1979, J BIOL CHEM, V254, P973; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; IRURZUN A, 1995, J VIROL, V69, P7453, DOI 10.1128/JVI.69.12.7453-7460.1995; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; JOSHI B, 1994, J BIOL CHEM, V269, P2048; Keiper BD, 1997, NUCLEIC ACIDS RES, V25, P395, DOI 10.1093/nar/25.2.395; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; MACADAM AJ, 1994, EMBO J, V13, P924, DOI 10.1002/j.1460-2075.1994.tb06336.x; Novoa I, 1999, MOL CELL BIOL, V19, P2445; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PEREZ L, 1992, VIROLOGY, V189, P178, DOI 10.1016/0042-6822(92)90693-J; ROSE JK, 1978, P NATL ACAD SCI USA, V75, P2732, DOI 10.1073/pnas.75.6.2732; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; YAN RQ, 1995, GENOMICS, V26, P394, DOI 10.1016/0888-7543(95)80227-D; YAN RQ, 1992, J BIOL CHEM, V267, P23226	48	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4449	4457		10.1074/jbc.M212393200	http://dx.doi.org/10.1074/jbc.M212393200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12475969	hybrid			2022-12-25	WOS:000180968900014
J	Gendron, L; Oligny, JF; Payet, MD; Gallo-Payet, N				Gendron, L; Oligny, JF; Payet, MD; Gallo-Payet, N			Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT(2) receptor signaling pathway in NG108-15 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NUCLEOTIDE-EXCHANGE FACTOR; ACTIVATED PROTEIN-KINASE; FETAL ADRENAL-GLAND; SMOOTH-MUSCLE CELL; TYPE-2 RECEPTOR; MAP KINASE; TYROSINE-PHOSPHATASE; PC12W CELLS; MEDIATED APOPTOSIS	The angiotensin II (Ang II) type 2 (AT(2)) receptor is an atypical seven-transmembrane domain receptor. Controversy surrounding this receptor concerns both the nature of the second messengers produced as well as its associated signaling mechanisms. Using the neuronal cell line NG108-15, we have reported previously that activation of the AT2 receptor induced morphological differentiation in a p21(ras)-independent, but p42/p44(mapk)-dependent mechanism. The activation of p42/p44(mapk) was delayed, sustained, and had been shown to be essential for neurite elongation. In the present report, we demonstrate that activation of the AT2 receptor rapidly, but transiently, activated the Rap1/B-Raf complex of signaling proteins. In RapN17- and Rap1GAP-transfected cells, the effects induced by Ang II were abolished, demonstrating that activation of these proteins was responsible for the observed p42/p44(mapk) phosphorylation and for morphological differentiation. To assess whether cAMP was involved in the activation of Rap1B-Raf and neuronal differentiation induced by Ang II, NG108-15 cells were treated with stimulators or inhibitors of the cAMP pathway. We found that dibutyryl cAMP and forskolin did not stimulate Rap1 or p42/p44(mapk) activity. Furthermore, adding H-89, an inhibitor of protein kinase A, or Rp-8-Br-cAMP-S, an inactive cAMP analog, failed to impair p42/p44(mapk) activity and neurite outgrowth induced by Ang II. The present observations clearly indicate that cAMP, a well known stimulus of neuronal differentiation, did not participate in the AT2 receptor signaling pathways in the NG108-15 cells. Therefore, the AT2 receptor of Ang II activates the signaling modules of Rap1B-Raf and p42/p44(mapk) via a cAMP-independent pathway to induce morphological differentiation of NG108-15 cells.	Univ Sherbrooke, Fac Med, Serv Endocrinol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Gallo-Payet, N (corresponding author), Univ Sherbrooke, Fac Med, Serv Endocrinol, 3001 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	Nicole.Gallo_Payet@USherbrooke.ca		Gendron, Louis/0000-0002-2058-8863				Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Allen AM, 1999, REGUL PEPTIDES, V79, P1, DOI 10.1016/S0167-0115(98)00138-4; BEAMANHALL CM, 1993, J NEUROBIOL, V24, P1500, DOI 10.1002/neu.480241105; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Breault L, 1996, J CLIN ENDOCR METAB, V81, P3914, DOI 10.1210/jc.81.11.3914; Brinkmann T, 2002, J BIOL CHEM, V277, P12525, DOI 10.1074/jbc.M109176200; BUISSON B, 1992, FEBS LETT, V309, P161, DOI 10.1016/0014-5793(92)81086-2; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; Chamoux E, 1999, J CLIN ENDOCR METAB, V84, P4722, DOI 10.1210/jc.84.12.4722; Cote F, 1999, J BIOL CHEM, V274, P31686, DOI 10.1074/jbc.274.44.31686; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cui TX, 2001, CARDIOVASC RES, V49, P863, DOI 10.1016/S0008-6363(00)00299-6; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Elbaz N, 2000, MOL ENDOCRINOL, V14, P795, DOI 10.1210/me.14.6.795; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GALLOPAYET N, 1989, J ENDOCRINOL, V120, P409, DOI 10.1677/joe.0.1200409; Ge JA, 1996, EUR J PHARMACOL, V297, P299, DOI 10.1016/0014-2999(95)00762-8; Gendron L, 1999, MOL ENDOCRINOL, V13, P1615, DOI 10.1210/me.13.9.1615; Gendron L, 2002, NEUROENDOCRINOLOGY, V75, P70, DOI 10.1159/000048222; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P316; Hansen JL, 2000, CIRC RES, V87, P753, DOI 10.1161/01.RES.87.9.753; Haywood GA, 1997, CIRCULATION, V95, P1201; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Horiuchi M, 1999, HYPERTENSION, V33, P613, DOI 10.1161/01.HYP.33.2.613; Horiuchi M, 1998, ENDOCR RES, V24, P307, DOI 10.3109/07435809809032610; Huang XC, 1996, J BIOL CHEM, V271, P15635, DOI 10.1074/jbc.271.26.15635; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; Johnson MC, 1997, MOL HUM REPROD, V3, P663, DOI 10.1093/molehr/3.8.663; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; Moritz KM, 1999, MOL CELL ENDOCRINOL, V157, P153, DOI 10.1016/S0303-7207(99)00148-3; NAHMIAS C, 1995, BIOCHEM J, V306, P87, DOI 10.1042/bj3060087; Nouet S, 2000, TRENDS ENDOCRIN MET, V11, P1, DOI 10.1016/S1043-2760(99)00205-2; Okuyama S, 1999, JPN J PHARMACOL, V81, P259, DOI 10.1254/jjp.81.259; Ouali R, 1997, ENDOCRINOLOGY, V138, P725, DOI 10.1210/en.138.2.725; OUALI R, 1993, ENDOCRINOLOGY, V133, P2766, DOI 10.1210/en.133.6.2766; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; REAGAN LP, 1993, J NEUROCHEM, V60, P24, DOI 10.1111/j.1471-4159.1993.tb05818.x; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sanchez S, 2001, J NEUROCHEM, V78, P468, DOI 10.1046/j.1471-4159.2001.00453.x; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Schutz S, 1996, AM J PATHOL, V149, P2067; Smith RD, 1999, ENDOCRINOLOGY, V140, P1385, DOI 10.1210/en.140.3.1385; SPETH R C, 1989, Peptide Research, V2, P232; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Stroth U, 2000, MOL BRAIN RES, V78, P175, DOI 10.1016/S0169-328X(00)00093-0; TALLANT EA, 1991, HYPERTENSION, V17, P1135, DOI 10.1161/01.HYP.17.6.1135; TANAKA M, 1995, BIOCHEM BIOPH RES CO, V207, P593, DOI 10.1006/bbrc.1995.1229; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; Tsuzuki S, 1996, BIOCHEM BIOPH RES CO, V228, P825, DOI 10.1006/bbrc.1996.1739; Unger T, 2000, AM HEART J, V139, pS2, DOI 10.1067/mhj.2000.102901; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vervoort VS, 2002, SCIENCE, V296, P2401; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yamada H, 1999, HYPERTENSION, V33, P1414, DOI 10.1161/01.HYP.33.6.1414; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yoshimura Y, 1996, ENDOCRINOLOGY, V137, P1204, DOI 10.1210/en.137.4.1204; Zhang JS, 1996, J BIOL CHEM, V271, P15026, DOI 10.1074/jbc.271.25.15026; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	74	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3606	3614		10.1074/jbc.M202446200	http://dx.doi.org/10.1074/jbc.M202446200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12464615	hybrid			2022-12-25	WOS:000180869700014
J	Karten, B; Vance, DE; Campenot, RB; Vance, JE				Karten, B; Vance, DE; Campenot, RB; Vance, JE			Trafficking of cholesterol from cell bodies to distal axons in Niemann pick C1-deficient neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY LIPOPROTEIN-CHOLESTEROL; INTRACELLULAR-TRANSPORT; C1 PROTEIN; SYNTHESIZED CHOLESTEROL; ENDOPLASMIC-RETICULUM; SYMPATHETIC NEURONS; ENDOCYTIC PATHWAYS; APOLIPOPROTEIN-E; MEMBRANE-LIPIDS; PLASMA-MEMBRANE	Niemann Pick type C (NPC) disease is a progressive neurodegenerative disorder. In cells lacking functional NPC1 protein, endocytosed cholesterol accumulates in late endosomes/lysosomes. We utilized primary neuronal cultures in which cell bodies and distal axons reside in separate compartments to investigate the requirement of NPC1 protein for transport of cholesterol from cell bodies to distal axons. We have recently observed that in NPC1-deficient neurons compared with wildtype neurons, cholesterol accumulates in cell bodies but is reduced in distal axons (Karten, B., Vance, D. E., Campenot, R. B., and Vance, J. E. (2002) J. Neurochem. 83, 1154-1163). We now show that NPC1 protein is expressed in both cell bodies and distal axons. In NPC1-deficient neurons, cholesterol delivered to cell bodies from low density lipoproteins (LDLs), high density lipoproteins, or cyclodextrin complexes was transported into axons in normal amounts, whereas transport of endogenously synthesized cholesterol was impaired. Inhibition of cholesterol synthesis with pravastatin in wildtype and NPC1-deficient neurons reduced axonal growth. However, LDLs restored a normal rate of growth to wild-type but not NPC1-deficient neurons treated with pravastatin. Thus, although LDL cholesterol is transported into axons of NPC1-deficient neurons, this source of cholesterol does not sustain normal axonal growth. Over the lifespan of NPC1-deficient neurons, these defects in cholesterol transport might be responsible for the observed altered distribution of cholesterol between cell bodies and axons and, consequently, might contribute to the neurological dysfunction in NPC disease.	Univ Alberta, Heritage Med Res Ctr 332, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Heritage Med Res Ctr 332, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca		Karten, Barbara/0000-0003-2395-3333				BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Campenot R B, 1979, Methods Enzymol, V58, P302; Campenot RB, 1996, J CELL BIOL, V135, P701, DOI 10.1083/jcb.135.3.701; CAMPENOT RB, 1982, DEV BIOL, V93, P1, DOI 10.1016/0012-1606(82)90232-9; CAMPENOT RB, 1992, CELL CELL INTERACTIO, P275; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHAM BE, 1976, J LIPID RES, V17, P176; Christian AE, 1997, J LIPID RES, V38, P2264; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DANIK M, 1993, J COMP NEUROL, V334, P209, DOI 10.1002/cne.903340205; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; de Chaves EIP, 2000, J BIOL CHEM, V275, P19883, DOI 10.1074/jbc.275.26.19883; de Chaves EP, 2001, J BIOL CHEM, V276, P36207, DOI 10.1074/jbc.M104282200; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; EDMOND J, 1991, J NUTR, V121, P1323, DOI 10.1093/jn/121.9.1323; Fan QW, 2002, J NEUROCHEM, V80, P178, DOI 10.1046/j.0022-3042.2001.00686.x; Garver WS, 2000, J LIPID RES, V41, P673; GOODRUM JF, 1990, J NEUROCHEM, V54, P1709, DOI 10.1111/j.1471-4159.1990.tb01225.x; Goodrum JF, 1997, J NEUROSCI RES, V49, P389, DOI 10.1002/(SICI)1097-4547(19970801)49:3<389::AID-JNR14>3.0.CO;2-V; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; HIGASHI Y, 1993, ACTA NEUROPATHOL, V85, P175; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Karten B, 2002, J NEUROCHEM, V83, P1154, DOI 10.1046/j.1471-4159.2002.01220.x; KARTEN B, 2002, APOPTOSIS METHODS TE, V37, P163; Keller P, 1997, J CELL SCI, V110, P3001; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Koch S, 2001, J LIPID RES, V42, P1143; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; OVERLY CC, 1995, P NATL ACAD SCI USA, V92, P3156, DOI 10.1073/pnas.92.8.3156; Overly CC, 1996, J NEUROSCI, V16, P6056; PARTON RG, 1993, J NEUROSCI RES, V36, P1, DOI 10.1002/jnr.490360102; PARTON RG, 1992, J CELL BIOL, V119, P123, DOI 10.1083/jcb.119.1.123; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; PATEL SC, 1995, NEUROREPORT, V6, P653, DOI 10.1097/00001756-199503000-00017; Pentchev P., 1995, METABOLIC MOL BASES, P2625; PITAS RE, 1987, J BIOL CHEM, V262, P14352; ROFF CF, 1992, AM J MED GENET, V42, P593, DOI 10.1002/ajmg.1320420433; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Sawamura N, 2001, J BIOL CHEM, V276, P10314, DOI 10.1074/jbc.M009733200; SEXTON RC, 1983, BIOCHEMISTRY-US, V22, P5687, DOI 10.1021/bi00294a001; SOKOL J, 1988, J BIOL CHEM, V263, P3411; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Turley SD, 1996, J LIPID RES, V37, P1953; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; URBANI L, 1990, J BIOL CHEM, V265, P1919; VANCE JE, 1994, J NEUROCHEM, V62, P329; VANCE JE, 1995, NEUROBIOL AGING, V16, P493, DOI 10.1016/0197-4580(94)00180-9; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; WEISGRABER KH, 1980, J LIPID RES, V21, P316; Zakharenko S, 2000, NEUROSCIENCE, V97, P185, DOI 10.1016/S0306-4522(00)00022-1; Zakharenko S, 1998, J CELL BIOL, V143, P1077, DOI 10.1083/jcb.143.4.1077	72	84	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4168	4175		10.1074/jbc.M205406200	http://dx.doi.org/10.1074/jbc.M205406200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458210	hybrid			2022-12-25	WOS:000180869700084
J	Subramanian, VS; Marchant, JS; Parker, I; Said, HM				Subramanian, VS; Marchant, JS; Parker, I; Said, HM			Cell biology of the human thiamine transporter-1 (hTHTR1) - Intracellular trafficking and membrane targeting mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCED FOLATE CARRIER; PLASMA-MEMBRANE; RESPONSIVE ANEMIA; PROTEIN; SLC19A2; GENE; LOCALIZATION; MICROSCOPE; EXPRESSION; MUTATIONS	The human thiamine transporter hTHTR1 is involved in the cellular accumulation of thiamine (vitamin 131) in many tissues. Thiamine deficiency disorders, such as thiamine-responsive megaloblastic anemia (TRMA), which is associated with specific mutations within hTHTR1, likely impairs the functionality and/or intracellular targeting of hTHTR1. Unfortunately, nothing is known about the mechanisms that control the intracellular trafficking or membrane targeting of hTHTR1. To identify molecular determinants involved in hTHTR1 targeting, we generated a series of hTHTR1 truncations fused with the green fluorescent protein and imaged the targeting and trafficking dynamics of each construct in living duodenal epithelial cells. Whereas the full-length fusion protein was functionally expressed at the plasma membrane, analysis of the truncated mutants demonstrated an essential role for both NH2-terminal sequence and the integrity of the backbone polypeptide for cell surface expression. Most notably, truncation of hTHTR1 within a region where several TRMA truncations are clustered resulted in intracellular retention of the mutant protein. Finally, confocal imaging of the dynamics of intracellular hTHTR1 vesicles revealed a critical role for microtubules, but not microfilaments, in hTHTR1 trafficking. Taken together, these results correlate hTHTR1 structure with cellular expression profile and reveal a critical dependence on hTHTR1 backbone integrity and microtubule-based trafficking processes for functional expression of hTHTR1.	Dept Vet Affairs Med Ctr, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities	Said, HM (corresponding author), Dept Vet Affairs Med Ctr, Long Beach, CA 90822 USA.	hmsaid@uci.edu	Marchant, Jonathan/Q-5484-2019; MARCHANT, Jonathan/B-8051-2009	Marchant, Jonathan/0000-0001-6592-0877; MARCHANT, Jonathan/0000-0001-6592-0877	NIDDK NIH HHS [DK-58057, F32DK063750-01, DK-56061] Funding Source: Medline; NIGMS NIH HHS [GM-48071] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK056061, R01DK058057, F32DK063750, R01DK056061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048071, R01GM048071] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balamurugan K, 2002, AM J PHYSIOL-GASTR L, V283, pG37, DOI 10.1152/ajpgi.00547.2001; Berdanier CD, 1998, ADV NUTR MICRONUTRIE, P80; Callamaras N, 1999, CELL CALCIUM, V26, P271, DOI 10.1054/ceca.1999.0085; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; Dutta B, 1999, J BIOL CHEM, V274, P31925, DOI 10.1074/jbc.274.45.31925; Eudy JD, 2000, MOL GENET METAB, V71, P581, DOI 10.1006/mgme.2000.3112; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Janecki AJ, 2000, J HISTOCHEM CYTOCHEM, V48, P1479, DOI 10.1177/002215540004801105; Kumar CK, 1998, AM J PHYSIOL-CELL PH, V274, pC289, DOI 10.1152/ajpcell.1998.274.1.C289; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; Lalioti V, 2001, MOL MEMBR BIOL, V18, P257, DOI 10.1080/09687680110090780; MANDEL H, 1984, NEW ENGL J MED, V311, P836, DOI 10.1056/NEJM198409273111307; Marchant JS, 2002, J BIOL CHEM, V277, P33325, DOI 10.1074/jbc.M205955200; Marchant JS, 2001, BRIT J PHARMACOL, V132, P1396, DOI 10.1038/sj.bjp.0703922; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Neufeld EJ, 2001, BLOOD CELL MOL DIS, V27, P135, DOI 10.1006/bcmd.2000.0356; Oishi K, 2001, MOL GENET METAB, V73, P149, DOI 10.1006/mgme.2001.3184; Parker I, 1997, CELL CALCIUM, V21, P441, DOI 10.1016/S0143-4160(97)90055-5; PARKS GD, 1993, J BIOL CHEM, V268, P19101; Rajgopal A, 2001, BBA-MOL BASIS DIS, V1537, P175, DOI 10.1016/S0925-4439(01)00073-4; Raz T, 2000, HUM MUTAT, V16, P37, DOI 10.1002/1098-1004(200007)16:1<37::AID-HUMU7>3.0.CO;2-9; Reidling JC, 2002, BBA-BIOMEMBRANES, V1561, P180, DOI 10.1016/S0005-2736(02)00341-3; Rindi G, 2000, P SOC EXP BIOL MED, V224, P246, DOI 10.1046/j.1525-1373.2000.22428.x; ROGERS LE, 1969, J PEDIATR-US, V74, P494, DOI 10.1016/S0022-3476(69)80031-4; Said HM, 2001, AM J PHYSIOL-GASTR L, V281, pG144, DOI 10.1152/ajpgi.2001.281.1.G144; SAID HM, 2000, INTESTINAL ABSORPTIO, P37; Scharfe C, 2000, J MED GENET, V37, P669, DOI 10.1136/jmg.37.9.669; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; Subramanian VS, 2001, AM J PHYSIOL-GASTR L, V281, pG1477, DOI 10.1152/ajpgi.2001.281.6.G1477; Sun AQ, 2001, J BIOL CHEM, V276, P6825, DOI 10.1074/jbc.M008797200; Suzuki T, 2001, EUR J CELL BIOL, V80, P765, DOI 10.1078/0171-9335-00204; Sweet DH, 2000, AM J PHYSIOL-RENAL, V279, pF826, DOI 10.1152/ajprenal.2000.279.5.F826; Tanphaichitr V., 1994, MODERN NUTR HLTH DIS, P359; Trinczek B, 1999, J CELL SCI, V112, P2355; Victor M., 1989, WERNICKE KORSAKOFF S, V2nd	41	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3976	3984		10.1074/jbc.M210717200	http://dx.doi.org/10.1074/jbc.M210717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12454006	hybrid			2022-12-25	WOS:000180869700059
J	Polager, S; Ginsberg, D				Polager, S; Ginsberg, D			E2F mediates sustained G(2) arrest and down-regulation of stathmin and AIM-1 expression in response to genotoxic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; S-PHASE ENTRY; TRANSCRIPTION FACTOR E2F-1; HUMAN CANCER-CELLS; DNA-DAMAGE; SUBCELLULAR-LOCALIZATION; NUCLEAR-LOCALIZATION; CHECKPOINT CONTROL; GAMMA-IRRADIATION; FAMILY MEMBERS	Exposure of cells to genotoxic agents results in activation of checkpoint pathways leading to cell cycle arrest. These arrest pathways allow repair of damaged DNA before its replication and segregation, thus preventing accumulation of mutations. The tumor suppressor retinoblastoma, (RB) is required for the G(1)/S checkpoint function. In addition, regulation of the G, checkpoint by the tumor suppressor p53 is RB-dependent. However, the molecular mechanism underlying the involvement of RB and its related proteins p107 and p130 in the G(2) checkpoint is not fully understood. We show here that sustained G(2)/M arrest induced by the genotoxic agent doxorubicin is E217-dependent and involves a decrease in expression of two mitotic regulators, Stathmin and AIM-1. Abrogation of E2F function by dominant negative E2F abolishes the doxorubicin-induced down-regulation of Stathmin and AIM-1 and leads to premature exit from G(2). Expression of the E7 papilloma virus protein, which dissociates complexes containing E2F and RB family members, also prevents the down-regulation of these mitotic genes and leads to premature exit from G(2) after genotoxic stress. Furthermore, genotoxic stress increases the levels of nuclear E2F-4 and p130 as well as their in vivo binding to the Stathinin promoter. Thus, functional complexes containing E2F and RB family members appear to be essential for repressing expression of critical mitotic regulators and maintaining the G(2)/M checkpoint.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			ginsberg, doron/0000-0002-1257-4920				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARPER JW, 1993, CELL, V75, P805; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Huang YY, 1997, CANCER RES, V57, P3640; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kawasaki A, 2001, J CELL BIOL, V152, P275, DOI 10.1083/jcb.152.2.275; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lin WC, 2001, GENE DEV, V15, P1833; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUO XN, 1994, J BIOL CHEM, V269, P10312; Magae J, 1996, J CELL SCI, V109, P1717; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Muller H, 1997, MOL CELL BIOL, V17, P5508; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Park M, 2000, CANCER RES, V60, P542; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; ROWLANDS DC, 1995, LAB INVEST, V72, P100; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Takahashi Y, 2000, GENE DEV, V14, P804; Tatsuka M, 1998, CANCER RES, V58, P4811; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WALDMAN T, 1995, CANCER RES, V55, P5187; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	64	55	60	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1443	1449		10.1074/jbc.M210327200	http://dx.doi.org/10.1074/jbc.M210327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12446714	hybrid			2022-12-25	WOS:000180462200011
J	Jackson, RJ; Adnane, J; Coppola, D; Cantor, A; Sebti, SM; Pledger, WJ				Jackson, RJ; Adnane, J; Coppola, D; Cantor, A; Sebti, SM; Pledger, WJ			Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models	ONCOGENE			English	Article						p21(Cip1); p27(Kip1); urethane; tumors; MMTV/v-Ha-ras mice	MAMMARY-CANCER MODEL; TRANSGENIC MICE; HA-RAS; BREAST-CANCER; GROWTH-FACTOR; SKIN CARCINOGENESIS; LACKING P27(KIP1); TUMOR SUPPRESSION; ONCOGENIC RAS; DIFFERENTIATION	Events that contribute to tumor formation include mutations in the ras gene and loss or inactivation of cell cycle inhibitors such as p21(Cip1) and p27(Kip1). In our previous publication, we showed that mice expressing the MMTV/v-Ha-ras transgene developed tumors earlier and at higher multiplicities in the absence than in the presence of p21(Cip1). To further evaluate the combinatorial role of genetic alterations and loss of cell cycle inhibitors in tumorigenesis, we performed two companion studies. In the first study, wild type and p21(Cip1)-null mice were exposed to the chemical carcinogen, urethane. Similar to its effects in v-Ha-ras mice, loss of p21(Cip1) accelerated tumor onset and increased tumor multiplicity in urethane-treated mice. Lung tumors were the predominant tumor type in urethane-treated mice regardless of p21(Cip1) status. In the second study, tumor formation was monitored in v-Ha-ras mice expressing or lacking p27(Kip1). Unlike p21(Cip1), the absence of p27(Kip1) had no effect on the timing or multiplicity of tumor formation, which was largely restricted to mammary and salivary glands. However, once tumors appeared, they grew faster in p27(Kip1)-null mice than in p27(Kip1)-wild type mice. Increases in growth rate were particularly striking for salivary tumors in ras/p27(-/-) mice. Loss of p21(Cip1) on the other hand, had no effect on tumor growth rate in v-Ha-ras mice. Collectively, our data suggest that p21(Cip1) suppresses tumor formation elicited by multiple agents and that p21(Cip1) and p27(Kip1) suppress tumor formation in different ways.	H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffit Canc Ctr & Res Inst, Pathol Serv, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [U19CA067771, P01CA078038, R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA78038, CA67771, CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; BOS JL, 1989, CANCER RES, V49, P4682; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Davis R W, 1980, Methods Enzymol, V65, P404; Della Ragione F, 1999, ADV EXP MED BIOL, V472, P73; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DRAGANI TA, 1991, ONCOGENE, V6, P333; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Mirvish S S, 1968, Adv Cancer Res, V11, P1; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NUZUM EO, 1990, MOL CARCINOGEN, V3, P287, DOI 10.1002/mc.2940030509; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Quaroni A, 2000, AM J PHYSIOL-CELL PH, V279, pC1045, DOI 10.1152/ajpcell.2000.279.4.C1045; SANDGREN EP, 1989, ONCOGENE, V4, P715; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shiohara M, 1997, LEUKEMIA LYMPHOMA, V26, P35, DOI 10.3109/10428199709109155; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Winston JT, 1996, ONCOGENE, V12, P127; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; Yang WC, 2001, CANCER RES, V61, P565; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L	56	66	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8486	8497		10.1038/sj.onc.1205946	http://dx.doi.org/10.1038/sj.onc.1205946			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466968				2022-12-25	WOS:000179480100011
J	Jurd, R; Arras, M; Lambert, S; Drexler, B; Siegwart, R; Crestani, F; Zaugg, M; Vogt, KE; Ledermann, B; Antkowiak, B; Rudolph, U				Jurd, R; Arras, M; Lambert, S; Drexler, B; Siegwart, R; Crestani, F; Zaugg, M; Vogt, KE; Ledermann, B; Antkowiak, B; Rudolph, U			General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta 3 subunit	FASEB JOURNAL			English	Article						anesthesia; animal model; knock-in; gene targeting	AMINOBUTYRIC ACID(A) RECEPTOR; SUBUNIT MESSENGER-RNAS; RAT SPINAL-CORD; A RECEPTOR; INTRAVENOUS ANESTHETICS; SYNAPTIC TRANSMISSION; BETA(3) SUBUNIT; MICE LACKING; ETOMIDATE; BINDING	General anesthetics are widely used in clinical practice. On the molecular level, these compounds have been shown to modulate the activity of various neuronal ion channels. However, the functional relevance of identified sites in mediating essential components of the general anesthetic state, such as immobility and hypnosis, is still unknown. Using gene-targeting technology, we generated mice harboring a subtle point mutation (N265M) in the second transmembrane region of the beta3 subunit of the GABA(A) receptor. In these mice, the suppression of noxious-evoked movements in response to the intravenous anesthetics etomidate and propofol is completely abolished, while only slightly decreased with the volatile anesthetics enflurane and halothane. 3(N265M) mice also display a profound reduction in the loss of righting reflex duration in response to intravenous but not volatile anesthetics. In addition, electrophysiological recordings revealed that anesthetic agents were significantly less effective in enhancing GABA(A) receptor-mediated currents, and in decreasing spontaneous action potential firing in cortical brain slices derived from mutant mice. Taken together, our results demonstrate that a single molecular target, and indeed a specific residue (N265) located within the GABA(A) receptor beta3 subunit, is a major determinant of behavioral responses evoked by the intravenous anesthetics etomidate and propofol, whereas volatile anesthetics appear to act via a broader spectrum of molecular targets.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Lab Anim Sci, CH-8057 Zurich, Switzerland; Univ Tubingen, Dept Anesthesiol, D-72076 Tubingen, Germany	University of Zurich; University of Zurich; Eberhard Karls University of Tubingen	Rudolph, U (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	rudolph@pharma.unizh.ch	Zaugg, Michael/G-4287-2016; Drexler, Berthold/AAF-8358-2020; Siegwart, Roland/A-4495-2008	Vogt, Kaspar/0000-0002-0859-876X; Zaugg, Michael/0000-0002-2016-8973; Siegwart, Roland/0000-0002-2760-7983; Drexler, Berthold/0000-0001-7202-1511; Arras, Margarete/0000-0003-3864-9879				Antkowiak B, 1998, ANESTHESIOLOGY, V88, P1592, DOI 10.1097/00000542-199806000-00024; Antognini JF, 2001, SLEEP, V24, P26, DOI 10.1093/sleep/24.1.26; ARRAS M, 2001, COMPARATIVE MED, V51, P436; Barnard EA, 1998, PHARMACOL REV, V50, P291; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Benke D, 1997, J NEUROCHEM, V69, P806; BENKE D, 1994, J BIOL CHEM, V269, P27100; Benson JA, 1998, FEBS LETT, V431, P400, DOI 10.1016/S0014-5793(98)00803-5; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Carlson BX, 2000, MOL PHARMACOL, V57, P474, DOI 10.1124/mol.57.3.474; Cheng G, 2000, ANESTHESIOLOGY, V93, P1075, DOI 10.1097/00000542-200010000-00032; Collinson N, 2002, J NEUROSCI, V22, P5572; DildyMayfield JE, 1996, J PHARMACOL EXP THER, V276, P1058; Eckenhoff RG, 1998, MOL PHARMACOL, V54, P610; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Friederich P, 1999, ANESTHESIOLOGY, V91, P1853, DOI 10.1097/00000542-199912000-00040; Fritschy JM, 1998, J COMP NEUROL, V390, P194; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; Guertin PA, 1999, NEUROSCIENCE, V88, P353, DOI 10.1016/S0306-4522(98)00371-6; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Homanics GE, 1997, MOL PHARMACOL, V51, P588, DOI 10.1124/mol.51.4.588; Homanics GE, 1997, P NATL ACAD SCI USA, V94, P4143, DOI 10.1073/pnas.94.8.4143; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; Jones A, 1997, J NEUROSCI, V17, P1350; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lingamaneni R, 2001, ANESTHESIOLOGY, V95, P1460, DOI 10.1097/00000542-200112000-00027; Low K, 2000, SCIENCE, V290, P131, DOI 10.1126/science.290.5489.131; MA W, 1993, J COMP NEUROL, V338, P337, DOI 10.1002/cne.903380303; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miralles CP, 1999, J COMP NEUROL, V413, P535; MOHLER H, 2001, HANDB EXP PHARM, V150, P101; Moody EJ, 1997, J NEUROCHEM, V69, P1310; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; PERSOHN E, 1991, NEUROSCIENCE, V42, P497, DOI 10.1016/0306-4522(91)90392-2; Pistis M, 1999, J PHYSIOL-LONDON, V515, P3, DOI 10.1111/j.1469-7793.1999.003ad.x; Quinlan JJ, 1998, ANESTHESIOLOGY, V88, P775, DOI 10.1097/00000542-199803000-00030; RAMPIL IJ, 1994, ANESTHESIOLOGY, V80, P606, DOI 10.1097/00000542-199403000-00017; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; Sanna E, 1997, MOL PHARMACOL, V51, P484; Siegwart R, 2002, J NEUROCHEM, V80, P140, DOI 10.1046/j.0022-3042.2001.00682.x; Sur C, 2001, J NEUROSCI, V21, P3409, DOI 10.1523/JNEUROSCI.21-10-03409.2001; Tomlin SL, 1998, ANESTHESIOLOGY, V88, P708, DOI 10.1097/00000542-199803000-00022; Ugarte SD, 2000, NEUROSCIENCE, V95, P795; Vicini S, 2001, J NEUROSCI, V21, P3009, DOI 10.1523/JNEUROSCI.21-09-03009.2001; Vogt KE, 2001, J NEUROSCI, V21, P75, DOI 10.1523/JNEUROSCI.21-01-00075.2001; WAUD DR, 1972, J PHARMACOL EXP THER, V183, P577; WONG SM, ANESTHESIOLOGY, V95, P154; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23; Zhang L, 1997, BRIT J PHARMACOL, V120, P353, DOI 10.1038/sj.bjp.0700934	54	451	465	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					250	+		10.1096/fj.02-0611fje	http://dx.doi.org/10.1096/fj.02-0611fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475885				2022-12-25	WOS:000180574300019
J	Maytum, R; Westerdorf, B; Jaquet, K; Geeves, MA				Maytum, R; Westerdorf, B; Jaquet, K; Geeves, MA			Differential regulation of the actomyosin interaction by skeletal and cardiac troponin isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN FILAMENT; MYOSIN SUBFRAGMENT-1; ESCHERICHIA-COLI; TAIL DOMAIN; MUSCLE; TROPOMYOSIN; ACTIN; PHOSPHORYLATION; COMPLEX; BINDING	There are significant isoform differences between the skeletal and cardiac troponin complexes. Studies of the regulatory properties of these proteins have previously shown only significant differences in the calcium dependence of their regulation. Using a sensitive myosin subfragment 1 (S1) binding assay we show that in the presence of calcium, thin filaments reconstituted with either skeletal or cardiac troponin produce virtually identical S1 binding curves. However in the absence of calcium the S1 binding curves differ considerably. Combined with kinetic measurements, curve fitting to the three-state thin filament regulatory model shows the main difference is that calcium produces a 4-fold change in K-T (the closed-open equilibrium) for the skeletal system but little change in the cardiac system. The results show a significant difference in the range of regulatory effect between the cardiac and skeletal systems that we interpret as effects upon actin-troponin (Tn)I-TnC binding equilibria. As structural data show that the Ca2+ bound TnC structures differ, the additional counter-intuitive result here is that with respect to myosin binding the +Ca2+ state of the two systems is similar whereas the -Ca2+ state differs. This shows the regulatory tuning of the troponin complex produced by isoform variation is the net result of a complex series of interactions among all the troponin components.	Univ Kent, Canterbury CT2 7NJ, Kent, England; Univ Bochum, St Josef Hosp, Clin Ruhr, D-44791 Bochum, Germany	University of Kent; Ruhr University Bochum	Maytum, R (corresponding author), Univ Kent, Canterbury CT2 7NJ, Kent, England.	rmm@ukc.ac.uk	Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898; Maytum, Robin/0000-0003-0395-403X				Ardelt P, 1998, BIOL CHEM, V379, P341, DOI 10.1515/bchm.1998.379.3.341; BEIER N, 1988, EUR J BIOCHEM, V176, P327, DOI 10.1111/j.1432-1033.1988.tb14285.x; Chen YD, 2001, BIOPHYS J, V80, P2338, DOI 10.1016/S0006-3495(01)76204-2; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HEAD JG, 1995, EUR J BIOCHEM, V227, P694, DOI 10.1111/j.1432-1033.1995.tb20190.x; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERZBERG O, 1984, J MOL BIOL, V172, P345, DOI 10.1016/S0022-2836(84)80030-3; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; Lohmann K, 2001, PROTEIN EXPRES PURIF, V21, P49, DOI 10.1006/prep.2000.1328; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; Maytum R, 2002, J BIOL CHEM, V277, P29774, DOI 10.1074/jbc.M201761200; Maytum R, 2001, BIOCHEMISTRY-US, V40, P7334, DOI 10.1021/bi010072i; Maytum R, 2001, BIOPHYS J, V80, p87A; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MIKI M, 2002, CELL DIFFER, V36, P191; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Reiffert S, 1999, EUR J BIOCHEM, V261, P40, DOI 10.1046/j.1432-1327.1999.00261.x; Reiffert SU, 1996, FEBS LETT, V384, P43, DOI 10.1016/0014-5793(96)00274-8; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWIDEREK K, 1988, EUR J BIOCHEM, V176, P335, DOI 10.1111/j.1432-1033.1988.tb14286.x; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; Tobacman LS, 2002, J BIOL CHEM, V277, P27636, DOI 10.1074/jbc.M201768200; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; Ward DG, 2001, EUR J BIOCHEM, V268, P179, DOI 10.1046/j.1432-1327.2001.01871.x; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	43	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6696	6701		10.1074/jbc.M210690200	http://dx.doi.org/10.1074/jbc.M210690200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12475978	hybrid			2022-12-25	WOS:000181195100010
J	Adams, TE; Mason, AB; He, QY; Halbrooks, PJ; Briggs, SK; Smith, VC; MacGillivray, RTA; Everse, SJ				Adams, TE; Mason, AB; He, QY; Halbrooks, PJ; Briggs, SK; Smith, VC; MacGillivray, RTA; Everse, SJ			The position of arginine 124 controls the rate of iron release from the N-lobe of human serum transferrin - A structural study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANION-BINDING; LACTOFERRIN; SITE; OVOTRANSFERRIN; RECOMBINANT; MECHANISM; MUTANTS; PYROPHOSPHATE; RESOLUTION	Human serum transferrin (hTF) is a bilobal iron-binding and transport protein that carries iron in the blood stream for delivery to cells by a pH-dependent mechanism. Two iron atoms are held tightly in two deep clefts by coordination to four amino acid residues in each cleft (two tyrosines, a histidine, and an aspartic acid) and two oxygen atoms from the "synergistic" carbonate anion. Other residues in the binding pocket, not directly coordinated to iron, also play critical roles in iron uptake and release through hydrogen bonding to the liganding residues. The original crystal structures of the iron-loaded N-lobe of hTF (pH 5.75 and 6.2) revealed that the synergistic carbonate is stabilized by interaction with Arg-124 and that both the arginine and the carbonate adopt two conformations (MacGillivray, R. T. A., Moore, S. A., Chen, J., Anderson, B. F., Baker, H., Luo, Y. G., Bewley, M., Smith, C. A., Murphy, M. E., Wang, Y., Mason, AL B., Woodworth, R. C., Brayer, G. D., and Baker, E. N. (1998) Biochemistry 37, 7919-7928). In the present study, we show that the two conformations are also found for a structure at pH 7.7, indicating that this finding was not strictly a function of pH. We also provide structures for two single point mutants (Y45E and L66W) designed to force Arg-124 to adopt each of the previously observed conformations. The structures of each mutant show that this goal was accomplished, and functional studies confirm the hypothesis that access to the synergistic anion dictates the rate of iron release. These studies highlight the importance of the arginine/carbonate movement in the mechanism of iron release in the N-lobe of hTF. Access to the carbonate via a water channel allows entry of protons and anions, enabling the attack on the iron.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of Vermont; University of British Columbia	Everse, SJ (corresponding author), Univ Vermont, Coll Med, Dept Biochem, 89 Beaumont Ave, Burlington, VT 05405 USA.		He, Qing-Yu/H-7078-2014; Mason, Anne B/A-6754-2008	He, Qing-Yu/0000-0003-0503-9492; 	NIDDK NIH HHS [DK 21739] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021739, R56DK021739] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdallah FB, 2000, J MOL BIOL, V303, P255, DOI 10.1006/jmbi.2000.4101; Abdallah FB, 1999, EUR J BIOCHEM, V263, P912, DOI 10.1046/j.1432-1327.1999.00596.x; AISEN P, 1973, BIOCHIM BIOPHYS ACTA, V304, P797, DOI 10.1016/0304-4165(73)90226-2; Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Baker EN, 1998, ADV EXP MED BIOL, V443, P1; Baker EN, 2002, BIOCHEM CELL BIOL, V80, P27, DOI 10.1139/o01-153; BALI PK, 1989, J AM CHEM SOC, V111, P4457, DOI 10.1021/ja00194a047; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAHINE JME, 1994, EUR J BIOCHEM, V223, P581; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Evans RW, 1999, IRON INFECT MOL PHYS, P27; Faber HR, 1996, BIOCHEMISTRY-US, V35, P14473, DOI 10.1021/bi961729g; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; He QY, 2000, BIOCHEM J, V350, P909, DOI 10.1042/0264-6021:3500909; He QY, 1999, BIOCHEMISTRY-US, V38, P9704, DOI 10.1021/bi990134t; He QY, 2001, BIOCHEM J, V354, P423, DOI 10.1042/0264-6021:3540423; HE QY, 2002, MOL CELLULAR IRON TR, P95; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; Li YJ, 1998, BIOCHEMISTRY-US, V37, P14157, DOI 10.1021/bi9810454; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; MARQUES HM, 1995, J INORG BIOCHEM, V57, P11, DOI 10.1016/0162-0134(94)00009-Y; Mason A B, 1991, Protein Expr Purif, V2, P214, DOI 10.1016/1046-5928(91)90074-S; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORGAN EH, 1979, BIOCHIM BIOPHYS ACTA, V580, P312, DOI 10.1016/0005-2795(79)90144-2; Muralidhara BK, 2000, J BIOL CHEM, V275, P12463, DOI 10.1074/jbc.275.17.12463; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATCH MG, 1981, INORG CHIM A-BIOINOR, V56, pL71, DOI 10.1016/S0020-1693(00)88536-9; Peterson NA, 2000, BIOCHEMISTRY-US, V39, P6625, DOI 10.1021/bi0001224; WILLIAMS J, 1982, TRENDS BIOCHEM SCI, V7, P394, DOI 10.1016/0968-0004(82)90183-9; Zak O, 2002, BIOCHEMISTRY-US, V41, P7416, DOI 10.1021/bi0160258; Zak O, 1997, BIOCHEMISTRY-US, V36, P11036, DOI 10.1021/bi970628v; ZAK O, 1995, BIOCHEMISTRY-US, V34, P14428, DOI 10.1021/bi00044a020; ZUCCOLA HJ, 1993, THESIS GEORGIA I TEC	40	49	51	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6027	6033		10.1074/jbc.M210349200	http://dx.doi.org/10.1074/jbc.M210349200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12458193	hybrid			2022-12-25	WOS:000181129400068
J	Baek, SJ; Wilson, LC; Hsi, LC; Eling, TE				Baek, SJ; Wilson, LC; Hsi, LC; Eling, TE			Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma - A novel mechanism for its anti-tumorigenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; SMOOTH-MUSCLE CELLS; COLON-CANCER CELLS; MESSENGER-RNA; CARCINOMA CELLS; RICH ELEMENT; IN-VITRO; APOPTOSIS; DIFFERENTIATION; EXPRESSION	Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma (PPARgamma) ligand that has pro-apoptotic activity in human colon cancer. Although TGZ binds to PPARgamma transcription factors as an agonist, emerging evidence suggests that TGZ acts independently of PPARgamma in many functions, including apoptosis. Early growth response-1 (Egr-1) transcription factor has been linked to apoptosis and shown to be activated by extracellular signal-regulated kinase (ERK). We investigated whether TGZ-induced apoptosis may be related to Egr-1 induction, because TGZ has been known to induce ERK activity. Our results show that Egr-1 is induced dramatically by TGZ but not by other PPARgamma ligands. TGZ affects Egr-1 induction at least by two mechanisms; TGZ increases Egr-1 promoter activity by 2-fold and prolongs Egr-1 mRNA stability by 3-fold. Inhibition of ERK phosphorylation in HCT-116 cells abolishes the Egr-1 induction by TGZ, suggesting its ERK-dependent manner. Further, the TGZ-induced Egr-1 expression results in increased promoter activity using a reporter system containing four copies of Egr-1 binding sites, and TGZ induces Egr-1 binding activity to Egr-1 consensus sites as assessed by gel shift assay. In addition, TGZ induces ERK-dependent phosphorylation of PPARgamma, resulting in the down-regulation of PPARgamma activity. The fact that TGZ-induced apoptosis is accompanied by the biosynthesis of Egr-1 suggests that Egr-1 plays a pivotal role in TGZ-induced apoptosis in HCT-116 cells. Our results suggest that Egr-1 induction is a unique property of TGZ compared with other PPARgamma ligands and is independent of PPARgamma activation. Thus, the up-regulation of Egr-1 may provide an explanation for the anti-tumorigenic properties of TGZ.	NIEHS, Eicosanoids Biochem Sect, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eling, TE (corresponding author), NIEHS, Eicosanoids Biochem Sect, Mol Carcinogenesis Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.			Baek, Seung/0000-0001-7866-7778	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES010016, Z01ES050143, ZIAES050144, Z01ES050144, Z01ES010016] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Chang TH, 2000, CANCER RES, V60, P1129; CHENG T, 1994, J BIOL CHEM, V269, P30848; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Cibelli G, 2002, J NEUROSCI RES, V67, P450, DOI 10.1002/jnr.10141; Davies GF, 2001, BIOCHEM PHARMACOL, V62, P1071, DOI 10.1016/S0006-2952(01)00764-X; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fehlberg S, 2002, BIOCHEM J, V362, P573, DOI 10.1042/0264-6021:3620573; Gouni-Berthold I, 2001, N-S ARCH PHARMACOL, V363, P215; Hattori Y, 1999, HYPERTENSION, V33, P943, DOI 10.1161/01.HYP.33.4.943; Hsi LC, 2001, J BIOL CHEM, V276, P34545, DOI 10.1074/jbc.M100280200; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135; Kausch C, 2001, BIOCHEM BIOPH RES CO, V280, P664, DOI 10.1006/bbrc.2000.4216; Kim JA, 2002, CANCER LETT, V179, P185, DOI 10.1016/S0304-3835(01)00869-2; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kubota T, 1998, CANCER RES, V58, P3344; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu J, 2001, INT J ONCOL, V18, P863; Masamune A, 2002, PANCREAS, V24, P130, DOI 10.1097/00006676-200203000-00003; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Okura T, 2000, EUR J PHARMACOL, V407, P227, DOI 10.1016/S0014-2999(00)00758-5; Palakurthi SS, 2001, CANCER RES, V61, P6213; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sakaue M, 2001, CELL DEATH DIFFER, V8, P411, DOI 10.1038/sj.cdd.4400818; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Satoh T, 2002, ONCOGENE, V21, P2171, DOI 10.1038/sj.onc.1205279; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Sugimura A, 1999, BIOCHEM BIOPH RES CO, V261, P833, DOI 10.1006/bbrc.1999.1049; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; Wang MH, 1999, DIABETES, V48, P254, DOI 10.2337/diabetes.48.2.254; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Zhang WH, 2001, EXP CELL RES, V266, P21, DOI 10.1006/excr.2001.5196; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117	58	175	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5845	5853		10.1074/jbc.M208394200	http://dx.doi.org/10.1074/jbc.M208394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12475986	hybrid			2022-12-25	WOS:000181129400046
J	Chang, VK; Fitch, MJ; Donato, JJ; Christensen, TW; Merchant, AM; Tye, BK				Chang, VK; Fitch, MJ; Donato, JJ; Christensen, TW; Merchant, AM; Tye, BK			Mcm1 binds replication origins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; TRANSCRIPTION FACTORS; MADS-BOX; FUNCTIONAL ELEMENTS; NUCLEAR ANTIGEN-1; ESCHERICHIA-COLI; S-CEREVISIAE; CELL-CYCLE	Mcm1 is an essential protein required for the efficient replication of minichromosomes and the transcriptional regulation of early cell cycle genes in Saccharomyces cerevisiae. In this study, we report that Mcm1 is an abundant protein that associates globally with chromatin in a punctate pattern. We show that Mcm1 is localized at replication origins and plays an important role in the initiation of DNA synthesis at a chromosomal replication origin in vivo. Using purified Mcm1 protein, we show that Mcm1 binds cooperatively to multiple sites at autonomously replicating sequences. These results suggest that, in addition to its role as a transcription factor for the expression of replication genes, Mcm1 may influence the local structure of replication origins by direct binding.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Drew Univ, Dept Chem, Madison, NJ 07940 USA	Cornell University; Drew University	Tye, BK (corresponding author), Cornell Univ, Dept Mol Biol & Genet, 325 Biotechnol Bldg, Ithaca, NY 14853 USA.	bt16@cornell.edu			NIGMS NIH HHS [GM34190, GM07616, GM07273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034190] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton TB, 1997, MOL CELL BIOL, V17, P1881, DOI 10.1128/MCB.17.4.1881; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bielinsky AK, 1999, MOL CELL, V3, P477, DOI 10.1016/S1097-2765(00)80475-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHAN CSM, 1980, P NATL ACAD SCI-BIOL, V77, P6329, DOI 10.1073/pnas.77.11.6329; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; Doran KS, 1999, J BIOL CHEM, V274, P17918, DOI 10.1074/jbc.274.25.17918; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; Gavin IM, 2000, EMBO J, V19, P5875, DOI 10.1093/emboj/19.21.5875; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Kumar R, 2000, CURR BIOL, V10, P896, DOI 10.1016/S0960-9822(00)00618-7; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; Mai B, 2002, MOL CELL BIOL, V22, P430, DOI 10.1128/MCB.22.2.430-441.2002; MAINE GT, 1984, GENETICS, V106, P365; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; NEWLON CS, 1996, DNA REPLICATION EUKA; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; Polaczek P, 1997, MOL MICROBIOL, V26, P261, DOI 10.1046/j.1365-2958.1997.5701931.x; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; Raychaudhuri S, 1997, NUCLEIC ACIDS RES, V25, P5057, DOI 10.1093/nar/25.24.5057; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; Schepers A, 2001, EMBO J, V20, P4588, DOI 10.1093/emboj/20.16.4588; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; Theis JF, 2001, MOL CELL BIOL, V21, P2790, DOI 10.1128/MCB.21.8.2790-2801.2001; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; VENDITTI P, 1994, BBA-GENE STRUCT EXPR, V1219, P677, DOI 10.1016/0167-4781(94)90227-5; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WALKER SS, 1989, MOL CELL BIOL, V9, P2914, DOI 10.1128/MCB.9.7.2914; West AG, 1999, J MOL BIOL, V286, P1311, DOI 10.1006/jmbi.1999.2576; Wu C, 1998, GENE DEV, V12, P1726, DOI 10.1101/gad.12.11.1726; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; Young MR, 1997, GENES CELLS, V2, P631, DOI 10.1046/j.1365-2443.1997.1510349.x	61	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6093	6100		10.1074/jbc.M209827200	http://dx.doi.org/10.1074/jbc.M209827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12473677	hybrid			2022-12-25	WOS:000181129400076
J	Kapoor, M; Srinivas, H; Kandiah, E; Gemma, E; Ellgaard, L; Oscarson, S; Helenius, A; Surolia, A				Kapoor, M; Srinivas, H; Kandiah, E; Gemma, E; Ellgaard, L; Oscarson, S; Helenius, A; Surolia, A			Interactions of substrate with calreticulin, an endoplasmic reticulum chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MOLECULAR CHAPERONE; QUALITY-CONTROL; COMBINING SITE; SARCOPLASMIC-RETICULUM; LEGUME LECTINS; CALNEXIN; OLIGOSACCHARIDE; GLYCOPROTEINS; CARBOHYDRATE	Calreticulin is a molecular chaperone found in the endoplasmic reticulum in eukaryotes, and its interaction with N-glycosylated polypeptides is mediated by the glycan Glc(1)Man(7-9)GlcNAc(2) present on the target glycoproteins. Here, we report the thermodynamic parameters of its interaction with di-, tri-, and tetrasaccharide, which are truncated versions of the glucosylated arm of Glc(1)Man(7-9)GlcNAc(2), determined by the quantitative technique of isothermal titration calorimetry. This method provides a direct estimate of the binding constants (K-b) and changes in enthalpy of binding (DeltaH(b)degrees) as well as the stoichiometry of the reaction. Unlike past speculations, these studies demonstrate unambiguously that calreticulin has only one site per molecule for binding its complementary glucosylated ligands. Although the binding of glucose by itself is not detectable, a binding constant of 4.19 X 10(4) m(-1) at 279 K is obtained when glucose occurs in alpha-1,3 linkage to ManalphaMe as in Glcalpha1-3ManalphaMe. The binding constant increases by 25-fold from di- to trisaccharide and doubles from tri- to tetrasaccharide, demonstrating that the entire Glcalpha1-3Manalpha1-2Manalpha1-ManalphaMe structure of the oligosaccharide is recognized by calreticulin. The thermodynamic parameters thus obtained were supported by modeling studies, which showed that increased number of hydrogen bonds and van der Waals interactions occur as the size of the oligosaccharide is increased. Also, several novel findings about the recognition of saccharide ligands by calreticulin vis 6 vis legume lectins, which have the same fold as this chaperone, are discussed.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Univ Stockholm, Arrhenius Lab, Dept Organ Chem, S-10691 Stockholm, Sweden; Swiss Fed Inst Technol, Inst Biochem, CH-8093 Hoenggerberg, Switzerland	Indian Institute of Science (IISC) - Bangalore; Stockholm University	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		Ellgaard, Lars/I-9034-2014; Kandiah, Eaazhisai/D-2354-2010; SUROLIA, AVADESHA/C-5442-2009	Ellgaard, Lars/0000-0002-7018-0137; Kandiah, Eaazhisai/0000-0002-9877-7621; Oscarson, Stefan/0000-0002-8273-4918				Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; Brandl M, 2001, J MOL BIOL, V307, P357, DOI 10.1006/jmbi.2000.4473; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chandra NR, 2001, PROTEIN ENG, V14, P857, DOI 10.1093/protein/14.11.857; Cherif S, 2002, J CARBOHYD CHEM, V21, P123, DOI 10.1081/CAR-120003743; Cherif S, 1998, J CARBOHYD CHEM, V17, P1203, DOI 10.1080/07328309808001894; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hamelryck TW, 1996, J BIOL CHEM, V271, P20479, DOI 10.1074/jbc.271.34.20479; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Jeyaprakash AA, 2002, J MOL BIOL, V321, P637, DOI 10.1016/S0022-2836(02)00674-5; KAIN RK, 1995, CARBOHYD RES, V271, P185; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Loss A, 2002, NUCLEIC ACIDS RES, V30, P405, DOI 10.1093/nar/30.1.405; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; *MICR CAL, 1998, VP ITC MICR US MAN; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OSTWALD TJ, 1974, J BIOL CHEM, V249, P5867; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Parodi AJ, 1999, BBA-GEN SUBJECTS, V1426, P287, DOI 10.1016/S0304-4165(98)00130-5; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; Peterson JR, 1999, J CELL SCI, V112, P2775; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Prabu MM, 1999, PROTEINS, V35, P58, DOI 10.1002/(SICI)1097-0134(19990401)35:1<58::AID-PROT6>3.0.CO;2-A; Ravishankar R, 2001, PROTEINS, V43, P260, DOI 10.1002/prot.1037; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; Sharma V, 1996, J BIOL CHEM, V271, P21209, DOI 10.1074/jbc.271.35.21209; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Srinivas VR, 2001, BBA-GEN SUBJECTS, V1527, P102, DOI 10.1016/S0304-4165(01)00153-2; Steiner T, 2001, J MOL BIOL, V305, P535, DOI 10.1006/jmbi.2000.4301; Surolia A, 1996, J BIOL CHEM, V271, P17697, DOI 10.1074/jbc.271.30.17697; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	53	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6194	6200		10.1074/jbc.M209132200	http://dx.doi.org/10.1074/jbc.M209132200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12464625	hybrid			2022-12-25	WOS:000181129400089
J	Koizumi, T; Hikiji, H; Shin, WS; Takato, T; Fukuda, S; Abe, T; Koshikiya, N; Iwasawa, K; Toyo-oka, T				Koizumi, T; Hikiji, H; Shin, WS; Takato, T; Fukuda, S; Abe, T; Koshikiya, N; Iwasawa, K; Toyo-oka, T			Cell density and growth-dependent down-regulation of both intracellular calcium responses to agonist stimuli and expression of smooth-surfaced endoplasmic reticulum in MC3T3-E1 osteoblast-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELLS; PARATHYROID-HORMONE; OSTEOSARCOMA CELLS; ENDOTHELIAL-CELLS; CYTOSOLIC CALCIUM; CA2+; RELEASE; ATP; HETEROGENEITY; MECHANISMS	A two-dimensional intracellular Ca2+ ([Ca2+](i)) imaging system was used to examine the relationship between [Ca2+](i) handling and the proliferation of MC3T3-E1 osteoblast-like cells. The resting [Ca2+](i) level in densely cultured cells was 1.5 times higher than the [Ca2+](i) level in sparsely cultured cells or in other cell types (mouse fibroblasts, rat vascular smooth muscle cells, and bovine endothelial cells). A high resting [Ca2+](i) level may be specific for MC3T3-E1 cells. MC3T3-E1 cells were stimulated with ATP (10 mum), caffeine (10 mm), thapsigargin (1 mum), or ionomycin (10 mum), and the effect on the [Ca2+](i) level of MC3T3-E1 cells was studied. The percentage of responding cells and the degree of [Ca2+](i) elevation were high in the sparsely cultured cells and low in densely cultured cells. The rank order for the percentage of responding cells and magnitude of the Ca2+ response to the stimuli was ionomycin > thapsigargin = ATP > caffeine and suggests the existence of differences among the various [Ca2+](i) channels. All Ca2+ responses in the sparsely cultured MC3T3-E1 cells, unlike in other cell types, disappeared after the cells reached confluence. Heptanol treatment of densely cultured cells restored the Ca2+ response, suggesting that cell-cell contact is involved with the confluence-dependent disappearance of the Ca2+ response. Immunohistological analysis of type 1 inositol trisphosphate receptors and electron microscopy showed distinct expression of inositol trisphosphate receptor proteins and smooth-surfaced endoplasmic reticulum in sparsely cultured cells but reduced levels in densely cultured cells. These results indicate that the underlying basis of confluence-dependent [Ca2+](i) regulation is down-regulation of smooth-surfaced endoplasmic reticulum by cell-cell contacts.	Univ Tokyo, Dept Oral & Maxillofacial Surg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Pathol, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Organ Pathol & Internal Med, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Hlth Serv Ctr, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Hikiji, H (corresponding author), Univ Tokyo, Dept Oral & Maxillofacial Surg, Bunkyo Ku, 7-3-1,Hongo, Tokyo 1138655, Japan.							Chen J, 2000, J BIOL CHEM, V275, P28739, DOI 10.1074/jbc.M000910200; CIVITELLI R, 1992, ENDOCRINOLOGY, V130, P2392, DOI 10.1210/en.130.4.2392; GOLDWIN SL, 2002, BONE, V30, P559; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; Ilvesaro J, 2000, J BONE MINER RES, V15, P919, DOI 10.1359/jbmr.2000.15.5.919; Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497; KUMAGAI H, 1991, J BONE MINER RES, V6, P697; KUMAGAI H, 1989, CALCIFIED TISSUE INT, V45, P251, DOI 10.1007/BF02556045; Leis HJ, 1997, J BONE MINER RES, V12, P541, DOI 10.1359/jbmr.1997.12.4.541; LJUNGGREN O, 1991, J BONE MINER RES, V6, P443; MASUO M, 1991, CIRC RES, V69, P1327, DOI 10.1161/01.RES.69.5.1327; MESZAROS JG, 1995, J BONE MINER RES, V10, P704; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; Saunders MM, 2001, AM J PHYSIOL-CELL PH, V281, pC1917, DOI 10.1152/ajpcell.2001.281.6.C1917; Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732; SHIN WS, 1992, J BIOL CHEM, V267, P20377; SHIN WS, 1991, CIRC RES, V69, P551, DOI 10.1161/01.RES.69.2.551; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Wang YP, 2001, CIRC RES, V88, P202; WILTINK A, 1993, CELL CALCIUM, V14, P591, DOI 10.1016/0143-4160(93)90059-F; Zach D, 2001, BONE, V28, P595, DOI 10.1016/S8756-3282(01)00461-6	21	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6433	6439		10.1074/jbc.M210243200	http://dx.doi.org/10.1074/jbc.M210243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471030	hybrid			2022-12-25	WOS:000181129400117
J	Kong, M; Mounier, C; Dumas, V; Posner, BI				Kong, M; Mounier, C; Dumas, V; Posner, BI			Epidermal growth factor-induced DNA synthesis - Key role for Src phosphorylation of the docking protein Gab2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; EPITHELIAL MORPHOGENESIS DOWNSTREAM; OVEREXPRESSING C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; EGF-RECEPTOR; T-CELL; MITOGENIC RESPONSIVENESS; RAT HEPATOCYTES; FAMILY KINASES; SH3 DOMAINS	We have previously demonstrated that phosphatidylinositol 3-kinase (PI3-kinase) is necessary and sufficient to account for epidermal growth factor (EGF)-induced mitogenesis in rat primary hepatocytes. A cytosolic Gab2-containing complex accounts for >80% of the total EGF-induced PI3-kinase activity (Kong, M., Mounier, C., Wu, J., and Posner, B. I. (2000) J. Biol. Chem. 275, 3603536042), suggesting a key role for Gab2 in EGF-induced mitogenesis. Here, we demonstrate that PP1, a selective inhibitor of Src family kinases, blocks the EGF-induced Gab2 tyrosine phosphorylation without inhibiting EGF-induced phosphorylation of the EGF receptor, ErbB3, or Shc. We also show that Gab2 phosphorylation is increased in Csk knockout cells in which Src family kinases are constitutively activated. Furthermore, PP1 blocks Gab2-associated downstream events including EGF-induced PI3-kinase activation, Akt phosphorylation, and DNA synthesis. We demonstrate that Gab2 and Src are constitutively associated. Since this association involves the proline-rich sequences of Gab2, it probably involves the Src homology 3 domain of Src kinase. Mutation of the proline-rich sequences in Gab2 prevented EGF-induced Gab2 phosphorylation, PI3-kinase/Akt activation, and DNA synthesis, demonstrating that Gab2 phosphorylation is critical for EGF-induced mitogenesis and is not complemented by ErbB3 or Shc phosphorylation. We also found that overexpression of a Gab2 mutant lacking SHP2 binding sites increased EGF-induced Gab2 phosphorylation and the activation of PI3-kinase but blocked activation of MAPK. In addition, we demonstrated that the Src-induced response was down-regulated by Gab2-associated SHP2. In summary, our results have defined the role for Src activation in EGF-induced hepatic mitogenesis through the phosphorylation of Gab2 and the activation of the PI3-kinase cascade.	McGill Univ, Polypeptide Hormone Lab, Fac Med, Montreal, PQ H3A 2B2, Canada	McGill University	Posner, BI (corresponding author), McGill Univ, Polypeptide Hormone Lab, Fac Med, Strathcona Anat Bldg,3640 Univ St, Montreal, PQ H3A 2B2, Canada.	barry.posner@staff.mcgill.ca	Mounier, Catherine/D-3690-2011; Posner, Barry/B-6733-2008	Mounier, Catherine/0000-0003-3608-4229				Band CJ, 1999, ENDOCRINOLOGY, V140, P5626, DOI 10.1210/en.140.12.5626; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Brockdorff JL, 2001, EXP CLIN IMMUNOGENET, V18, P86, DOI 10.1159/000049187; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Kameda H, 2001, CELL GROWTH DIFFER, V12, P307; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kim J, 2002, J BIOL CHEM, V277, P32116, DOI 10.1074/jbc.M204895200; Kong M, 2000, J BIOL CHEM, V275, P36035, DOI 10.1074/jbc.M005621200; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1992, ONCOGENE, V7, P2429; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; Pellicena P, 2002, FRONT BIOSCI-LANDMRK, V7, pD256, DOI 10.2741/pellicen; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Winnay JN, 2000, J BIOL CHEM, V275, P10545, DOI 10.1074/jbc.275.14.10545; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamasaki S, 2001, J BIOL CHEM, V276, P45175, DOI 10.1074/jbc.M105384200; Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5837	5844		10.1074/jbc.M208286200	http://dx.doi.org/10.1074/jbc.M208286200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12464621	hybrid			2022-12-25	WOS:000181129400045
J	Noga, AA; Stead, LM; Zhao, Y; Brosnan, ME; Brosnan, JT; Vance, DE				Noga, AA; Stead, LM; Zhao, Y; Brosnan, ME; Brosnan, JT; Vance, DE			Plasma homocysteine is regulated by phospholipid methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ENDOTHELIUM-DEPENDENT VASODILATION; CYSTATHIONINE BETA-SYNTHASE; VASCULAR-DISEASE; MICE DEFICIENT; RISK FACTOR; RAT-LIVER; PHOSPHATIDYLETHANOLAMINE; EXPRESSION; HYPERHOMOCYSTEINEMIA	Mild hyperhomocysteinemia is an independent risk factor for cardiovascular disease. Homocysteine, a nonprotein amino acid, is formed from S-adenosylhomocysteine and partially secreted into plasma. A potential source for homocysteine is methylation of the lipid phosphatidylethanolamine to phosphatidylcholine by phosphatidylethanolamine N-methyltransferase in the liver. We show that mice that lack phosphatidylethanolamine N-methyltransferase have plasma levels of homocysteine that are similar to50% of those in wild-type mice. Hepatocytes isolated from methyltransferase-deficient mice secrete similar to50% less homocysteine. Rat hepatoma cells transfected with phosphatidylethanolamine N-methyltransferase secrete more homocysteine than wild-type cells. Thus, phosphatidylethanolamine N-methyltransferase is an important source of plasma homocysteine and a potential therapeutic target for hyperhomocysteinemia.	Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst, Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Mem Univ Newfoundland, Dept Biochem, St Johns, NF A1B 3X9, Canada	University of Alberta; University of Alberta; Memorial University Newfoundland	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.							Agellon LB, 1999, HEPATOLOGY, V30, P725, DOI 10.1002/hep.510300305; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Chao CL, 2000, CIRCULATION, V101, P485, DOI 10.1161/01.CIR.101.5.485; CHEEMA SK, 1997, J LIPID RES, V38, P157; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; CUI Z, 1993, J BIOL CHEM, V268, P16655; Dalton ML, 1997, FASEB J, V11, P703, DOI 10.1096/fasebj.11.8.9240971; DAVIS RA, 1979, J BIOL CHEM, V266, P497; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Desai A, 2001, INFLAMMATION, V25, P179, DOI 10.1023/A:1011088431191; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; GORNALL AG, 1949, J BIOL CHEM, V177, P751; KOBLIN DD, 1981, ANESTHESIOLOGY, V54, P318, DOI 10.1097/00000542-198104000-00012; LOO G, 1986, J NUTR, V116, P2403, DOI 10.1093/jn/116.12.2403; Majors A, 1997, ARTERIOSCL THROM VAS, V17, P2074, DOI 10.1161/01.ATV.17.10.2074; MUDD SH, 1965, J BIOL CHEM, V240, P4382; MUDD SH, 1980, METABOLISM, V29, P707, DOI 10.1016/0026-0495(80)90192-4; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; MURRAY CE, 1981, CLIN SCI, V61, P737, DOI 10.1042/cs0610737; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Poddar R, 2001, CIRCULATION, V103, P2717; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; Robinson K, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P371; Selhub J, 2000, AM J CLIN NUTR, V71, p614S; Stead LM, 2001, AM J PHYSIOL-ENDOC M, V281, pE1095, DOI 10.1152/ajpendo.2001.281.5.E1095; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Tawakol A, 1997, CIRCULATION, V95, P1119; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE JE, 1988, J BIOL CHEM, V263, P5898; Verhoef P, 1997, ATHEROSCLEROSIS, V132, P105, DOI 10.1016/S0021-9150(97)00084-1; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WALKEY CJ, 1997, THESIS U ALBERTA; WANG J, 1991, CLIN CHIM ACTA, V204, P239, DOI 10.1016/0009-8981(91)90235-5; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585	38	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5952	5955		10.1074/jbc.M212194200	http://dx.doi.org/10.1074/jbc.M212194200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482759	hybrid			2022-12-25	WOS:000181129400058
J	Pavlov, D; Gerson, JH; Yu, TW; Tobacman, LS; Homsher, E; Reisler, E				Pavlov, D; Gerson, JH; Yu, TW; Tobacman, LS; Homsher, E; Reisler, E			The regulation of subtilisin-cleaved actin by tropomyosin/troponin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN FILAMENT REGULATION; MYOSIN SUBFRAGMENT-1; SKELETAL-MUSCLE; SMOOTH-MUSCLE; 3-DIMENSIONAL RECONSTRUCTION; TROPONIN-TROPOMYOSIN; MUTATIONAL ANALYSIS; SLIDING MOVEMENT; BINDING; MODEL	Vertebrate striated muscle contraction is regulated in a Ca2+-dependent fashion by tropomyosin (Tm) and troponin (Tn). This regulation involves shifts in the position of Tin and Tn on actin filaments and may include conformational changes in actin that are then communicated to myosin subfragment 1 (S1). To determine whether subdomain 2 of actin plays a role in this regulation, the DNase-I loop 38-52 of this subdomain was cleaved by subtilisin between residues Met(47) and Gly(48). Despite impaired unregulated function, the potentiation and regulation of cleaved actin movement in the in vitro motility assay was not significantly different from that of uncleaved actin. Stopped-flow measurements of ADP release from regulated and unregulated cleaved acto-S1 showed a marked increase in ADP release from acto-S1 in the presence of the regulatory complex. The enhancement of the actin affinity for S1 in the presence of regulatory proteins was greater for uncleaved than for cleaved F-actin. Finally, both cleaved and uncleaved actins protect myosin loop 1 from papain cleavage equally well. Our results suggest that the potentiation of actin function in the in vitro motility assay by regulatory proteins stems from changes in cross-bridge cycle kinetics. In addition, the unimpaired calcium-sensitive regulation of cleaved actin indicates that subdomain 2 conformation does not play an essential role in the regulation process.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Iowa, Dept Internal Med & Biochem, Iowa City, IA 52242 USA; Univ Calif Los Angeles, Geffen Sch Med, Dept Physiol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Reisler, E (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	reisler@mbi.ucla.edu		Yu, Tianwei/0000-0003-2502-1628	NHLBI NIH HHS [HL 38834, HL 63774] Funding Source: Medline; NIAMS NIH HHS [R01 AR022031, AR 22031, AR 30988] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038834, R01HL038834, R01HL063774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030988, R01AR022031] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		APPLEGATE D, 1983, P NATL ACAD SCI-BIOL, V80, P7109, DOI 10.1073/pnas.80.23.7109; Bing W, 1997, BIOCHEM J, V327, P335, DOI 10.1042/bj3270335; Bing W, 1998, J BIOL CHEM, V273, P15016, DOI 10.1074/jbc.273.24.15016; BONAFE N, 1994, BIOCHEMISTRY-US, V33, P2594, DOI 10.1021/bi00175a031; Craig R, 2001, J MOL BIOL, V311, P1027, DOI 10.1006/jmbi.2001.4897; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; GEEVES MA, 1986, PROC R SOC SER B-BIO, V229, P85, DOI 10.1098/rspb.1986.0076; Gerson JH, 2001, J BIOL CHEM, V276, P18442, DOI 10.1074/jbc.M011070200; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; Gordon AM, 1997, BIOPHYS J, V72, P1295, DOI 10.1016/S0006-3495(97)78776-9; Homsher E, 2000, J PHYSIOL-LONDON, V524, P233, DOI 10.1111/j.1469-7793.2000.00233.x; HOMSHER E, 1992, AM J PHYSIOL, V262, P714; Khaitlina SY, 2002, BIOPHYS J, V82, P321, DOI 10.1016/S0006-3495(02)75397-6; Kim E, 2000, BIOPHYS CHEM, V86, P191, DOI 10.1016/S0301-4622(00)00143-5; Korman VL, 2000, J BIOL CHEM, V275, P22470, DOI 10.1074/jbc.M002939200; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; Lehman W, 2001, J MOL BIOL, V307, P739, DOI 10.1006/jmbi.2001.4514; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Luo Y, 2002, J MOL BIOL, V316, P429, DOI 10.1006/jmbi.2001.5358; MIKI M, 1991, BIOCHEMISTRY-US, V30, P5625, DOI 10.1021/bi00236a042; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P3670, DOI 10.1021/bi952645v; Narita A, 2001, J MOL BIOL, V308, P241, DOI 10.1006/jmbi.2001.4598; Orlova A, 1997, J MOL BIOL, V271, P235, DOI 10.1006/jmbi.1997.1163; PATE E, 1989, J MUSCLE RES CELL M, V10, P181, DOI 10.1007/BF01739809; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1920; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9994; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Sweeney HL, 1996, ANNU REV PHYSIOL, V58, P751, DOI 10.1146/annurev.ph.58.030196.003535; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; WILLIAMS DL, 1983, BIOCHEMISTRY-US, V22, P2770, DOI 10.1021/bi00280a027; Xu C, 1999, BIOPHYS J, V77, P985, DOI 10.1016/S0006-3495(99)76949-3	43	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5517	5522		10.1074/jbc.M210889200	http://dx.doi.org/10.1074/jbc.M210889200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12468534	hybrid			2022-12-25	WOS:000181129400007
J	Sweetman, D; Smith, T; Farrell, ER; Chantry, A; Munsterberg, A				Sweetman, D; Smith, T; Farrell, ER; Chantry, A; Munsterberg, A			The conserved glutamine-rich region of chick csal1 and csal3 mediates protein interactions with other spalt family members - Implications for Townes-Brocks syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOTIC GENE SPALT; ZINC-FINGER PROTEIN; MOLECULAR-CLONING; DROSOPHILA EMBRYO; SALL1; EXPRESSION; HOMOLOG; SYSTEM; HEAD	Members of the spalt family of zinc finger-containing proteins have been implicated in development and disease. However, very little is known about the molecular function of spalt proteins. We have used biochemical approaches to characterize functional domains of two chick spalt homologs, csa11 and csal3. We show that csall and csal3 proteins repress transcription and that they can interact with each other. Furthermore, we found that truncated chick spalt proteins, similar to the truncated spalt protein expressed in the human congenital disorder Townes-Brocks syndrome, affect the nuclear localization of full-length spalt. Our findings have implications for the understanding of Townes-Brocks syndrome and the role of spalt genes in normal development. We propose that truncated spalt can exert a dominant negative effect and is able to interfere with the correct function of full-length protein, by causing its displacement from the nucleus. This could affect the transcriptional repressor activity of spalt and DNA binding. Spalt protein truncations could also affect the function of other spalt family members in various tissues.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Dundee, Wellcome Trust Bioctr, Div Cell & Dev Biol, Dundee DD1 5EH, Scotland	University of East Anglia; University of Dundee	Munsterberg, A (corresponding author), Univ E Anglia, Sch Biol Sci, Earlham Rd, Norwich NR4 7TJ, Norfolk, England.		Munsterberg, Andrea E/E-2205-2011	Munsterberg, Andrea E/0000-0002-4577-4240; Sweetman, Dylan/0000-0002-9561-8035				Anderson LA, 2002, J BIOL CHEM, V277, P29550, DOI 10.1074/jbc.M200513200; Barrio R, 1996, DEV GENES EVOL, V206, P315, DOI 10.1007/s004270050058; Buck A, 2000, CYTOGENET CELL GENET, V89, P150, DOI 10.1159/000015598; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen CK, 1998, DEVELOPMENT, V125, P4959; de Celis JF, 1999, DEVELOPMENT, V126, P2653; Engels S, 2000, J MED GENET, V37, P458, DOI 10.1136/jmg.37.6.458; Farrell ER, 2001, MECH DEVELOP, V102, P227, DOI 10.1016/S0925-4773(01)00296-9; Farrell ER, 2000, DEV BIOL, V225, P447, DOI 10.1006/dbio.2000.9852; Galant R, 2002, DEVELOPMENT, V129, P3115; Gould AP, 2001, J ANAT, V199, P25, DOI 10.1017/S0021878201008317; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HARLOW E, 1998, ANTIBODIES LAB MANUA, P447; Hollemann T, 1996, MECH DEVELOP, V55, P19, DOI 10.1016/0925-4773(95)00485-8; JURGENS G, 1988, EMBO J, V7, P189, DOI 10.1002/j.1460-2075.1988.tb02799.x; Kiefer SM, 2002, J BIOL CHEM, V277, P14869, DOI 10.1074/jbc.M200052200; Kohlhase J, 1999, GENOMICS, V62, P216, DOI 10.1006/geno.1999.6005; Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81; Kohlhase J, 1996, GENOMICS, V38, P291, DOI 10.1006/geno.1996.0631; Koster R, 1997, DEVELOPMENT, V124, P3147; Kuhnlein RP, 1996, DEVELOPMENT, V122, P2215; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Netzer C, 2001, HUM MOL GENET, V10, P3017, DOI 10.1093/hmg/10.26.3017; Nishinakamura R, 2001, DEVELOPMENT, V128, P3105; Onuma Y, 1999, BIOCHEM BIOPH RES CO, V264, P151, DOI 10.1006/bbrc.1999.1479; Ott T, 2001, MECH DEVELOP, V101, P203, DOI 10.1016/S0925-4773(00)00552-9; Ott T, 1996, MECH DEVELOP, V56, P117, DOI 10.1016/0925-4773(96)00516-3; Sturtevant MA, 1997, DEVELOPMENT, V124, P21; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002	30	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6560	6566		10.1074/jbc.M209066200	http://dx.doi.org/10.1074/jbc.M209066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482848	hybrid			2022-12-25	WOS:000181129400133
J	Babwah, AV; Dale, LB; Ferguson, SSG				Babwah, AV; Dale, LB; Ferguson, SSG			Protein kinase C isoform-specific differences in the spatial temporal regulation and decoding of metabotropic glutamate receptor1a-stimulated second messenger responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM OSCILLATIONS; CA2+ OSCILLATIONS; PHOSPHORYLATION; RECEPTORS; ACTIVATION; MEMBRANE; ALPHA; DESENSITIZATION; TRANSLOCATION	Metabotropic glutamate receptors (mGluRs) coupled via Gq to the hydrolysis of phosphoinositides stimulate Ca2+ and PKCbetaII oscillations in both excitable and non-excitable cells. In the present study, we show that mGluR1a activation stimulates the repetitive plasma membrane translocation of each of the conventional and novel, but not atypical, PKC isozymes. However, despite similarities in sequence and cofactor regulation by diacy-glycerol and Ca2+, conventional PKCs exhibit isoform-specific oscillation patterns. PKCalpha and PKCbetaI display three distinct patterns of activity: 1) agonist-independent oscillations, 2) agonist-stimulated oscillations, and 3) persistent plasma membrane localization in response to mGluR1a activation. In contrast, only agonist-stimulated PKCbetaII translocation responses are observed in mGluR1a-expressing cells. PKCbetaI expression also promotes persistent increases in intracellular diacyglycerol concentrations in response to mGluR1a stimulation without affecting PKCbetaII oscillation patterns in the same cell. PKCbetaII isoform-specific translocation patterns are regulated by specific amino acid residues localized within the C-terminal PKC V5 domain. Specifically, Asn-625 and Lys-668 localized within the V5 domain of PKCbetaII cooperatively suppress PKCbetaI-like response patterns for PKCbetaII. Thus, redundancy in PKC isoform expression and differential decoding of second messenger response provides a novel mechanism for generating cell type-specific responses to the same signal.	John P Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Ferguson, SSG (corresponding author), John P Robarts Res Inst, Cell Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.							Angenstein F, 1999, NEUROSCIENCE, V93, P1289, DOI 10.1016/S0306-4522(99)00315-2; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Flint AC, 1999, P NATL ACAD SCI USA, V96, P12144, DOI 10.1073/pnas.96.21.12144; GILON P, 1993, J BIOL CHEM, V268, P22265; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; KANASHIRO CA, 1998, CLIN EXP PHARM PHYSL, V25, P874; Kawabata S, 1998, J BIOL CHEM, V273, P17381, DOI 10.1074/jbc.273.28.17381; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Nakahara K, 1997, J NEUROCHEM, V69, P1467; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SPITZER NC, 1995, J NEUROBIOL, V26, P316, DOI 10.1002/neu.480260304; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P156; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200	35	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5419	5426		10.1074/jbc.M211053200	http://dx.doi.org/10.1074/jbc.M211053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12454004	hybrid			2022-12-25	WOS:000180968900134
J	Baliga, BC; Colussi, PA; Read, SH; Dias, MM; Jans, DA; Kumar, S				Baliga, BC; Colussi, PA; Read, SH; Dias, MM; Jans, DA; Kumar, S			Role of prodomain in importin-mediated nuclear localization and activation of caspase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; APOPTOSIS; OLIGOMERIZATION; RECOGNITION; PRECURSOR; TRANSPORT; SEQUENCE; SIGNAL; RAIDD	Caspase-2 is unique among mammalian caspases because it localizes to the nucleus in a prodomain-dependent manner. The caspase-2 prodomain also regulates caspase-2 activity via a caspase recruitment domain that mediates oligomerization of procaspase-2 molecules and their subsequent autoactivation. In this study we sought to map specific functional regions in the caspase-2 prodomain that regulate its nuclear transport and also its activation. Our data indicate that caspase-2 contains a classical nuclear localization signal (NLS) at the C terminus of the prodomain which is recognized by the importin alpha/beta heterodimer. The mutation of a conserved Lys residue in the NLS abolishes nuclear localization of caspase-2 and binding to the importin alpha/beta heterodimer. Although caspase-2 is imported into the nucleus, mutants lacking the NLS were still capable of inducing apoptosis upon overexpression in transfected cells. We define a region in the prodomain that regulates the ability of caspase-2 to form dot- and filament-like structures when ectopically expressed, which in turn promotes cell killing. Our data provides a mechanism for caspase-2 nuclear import and demonstrate that association of procaspase-2 into higher order structures, rather than its nuclear localization, is required for caspase-2 activation and its ability to induce apoptosis.	Hanson Inst, Adelaide, SA 5000, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia	Hanson Institute; Monash University; University of Adelaide	Kumar, S (corresponding author), Hanson Inst, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814				Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Dowds TA, 2001, CELL DEATH DIFFER, V8, P640, DOI 10.1038/sj.cdd.4400855; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Forwood JK, 2001, J BIOL CHEM, V276, P46575, DOI 10.1074/jbc.M101668200; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shearwin-Whyatt L, 2001, BIOCHEM BIOPH RES CO, V282, P1114, DOI 10.1006/bbrc.2001.4699; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; WANG X, 2000, GENE DEV, V15, P1060; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	34	86	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4899	4905		10.1074/jbc.M211512200	http://dx.doi.org/10.1074/jbc.M211512200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12477715	hybrid			2022-12-25	WOS:000180968900072
J	Jung, S; Muhle, A; Schaefer, M; Strotmann, R; Schultz, G; Plant, TD				Jung, S; Muhle, A; Schaefer, M; Strotmann, R; Schultz, G; Plant, TD			Lanthanides potentiate TRPC5 currents by an action at extracellular sites close to the pore mouth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-PERMEABLE CATION CHANNEL; CAPACITATIVE CA2+ ENTRY; OPERATED HTRP3 CHANNELS; FUNCTIONAL-CHARACTERIZATION; STORE DEPLETION; INTRACELLULAR CA2+; XENOPUS OOCYTES; HEK293 CELLS; G-PROTEIN; RECEPTOR	Mammalian members of the classical transient receptor potential channel (TRPC) subfamily (TRPC1-7) are Ca2+-permeable cation channels involved in receptor-mediated increases in intracellular Ca2+. Unlike most other TRP-related channels, which are inhibited by La3+ and Gd3+, currents through TRPC4 and TRPC5 are potentiated by La3+. Because these differential effects of lanthanides on TRPC subtypes may be useful for clarifying the role of different TRPCs in native tissues, we characterized the potentiating effect in detail and localized the molecular determinants of potentiation by mutagenesis. Whole cell currents through TRPC5 were reversibly potentiated by micromolar concentrations of La3+ or Gd3+, whereas millimolar concentrations were inhibitory. By comparison, TRPC6 was blocked to a similar extent by La3+ or Gd3+ at micromolar concentrations and showed no potentiation. Dual effects of lanthanides on TRPC5 were also observed in outside-out patches. Even at micromolar concentrations, the single channel conductance was reduced by La3+, but reduction in conductance was accompanied by a dramatic increase in channel open probability, leading to larger integral currents. Neutralization of the negatively charged amino acids Glu(543) and Glu(595)/Glu(598), situated close to the extracellular mouth of the channel pore, resulted in a loss of potentiation, and, for Glu(595)/Glu(598) in a modification of channel inhibition. We conclude that in the micromolar range, the lanthanide ions La3+ and Gd3+ have opposite effects on whole cell currents through TRPC5 and TRPC6 channels. The potentiation of TRPC4 and TRPC5 by micromolar La3+ at extracellular sites close to the pore mouth is a promising tool for identifying the involvement of these isoforms in receptor-operated cation conductances of native cells.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Plant, TD (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.							BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Halaszovich CR, 2000, J BIOL CHEM, V275, P37423, DOI 10.1074/jbc.M007010200; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 2000, BIOCHEM J, V351, P115, DOI 10.1042/0264-6021:3510115; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Inoue Ryuji, 1998, Journal of Smooth Muscle Research, V34, P69; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kinoshita M, 2000, CELL CALCIUM, V28, P151, DOI 10.1054/ceca.2000.0143; Kiselyov K, 1999, TRENDS NEUROSCI, V22, P334, DOI 10.1016/S0166-2236(99)01426-5; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Montell C., 2001, SCI STKE; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; RAMANAN SV, 1992, J NEUROSCI METH, V42, P91, DOI 10.1016/0165-0270(92)90139-5; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Walker RL, 2001, AM J PHYSIOL-CELL PH, V280, pC1184, DOI 10.1152/ajpcell.2001.280.5.C1184; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Yamada H, 2000, NEUROSCI LETT, V285, P111, DOI 10.1016/S0304-3940(00)01033-8; Zhang L, 2001, J BIOL CHEM, V276, P13331, DOI 10.1074/jbc.M008914200; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	49	213	224	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3562	3571		10.1074/jbc.M211484200	http://dx.doi.org/10.1074/jbc.M211484200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12456670	hybrid			2022-12-25	WOS:000180869700009
J	Masumoto, J; Zhou, WB; Chen, FF; Su, FY; Kuwada, JY; Hidaka, E; Katsuyama, T; Sagara, J; Taniguchi, S; Ngo-Hazelett, P; Postlethwait, JH; Nunez, G; Inohara, N				Masumoto, J; Zhou, WB; Chen, FF; Su, FY; Kuwada, JY; Hidaka, E; Katsuyama, T; Sagara, J; Taniguchi, S; Ngo-Hazelett, P; Postlethwait, JH; Nunez, G; Inohara, N			Caspy, a zebrafish caspase, activated by ASC oligomerization is required for pharyngeal arch development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED-PROXIMITY MODEL; DOMAIN-CONTAINING PROTEIN; DEATH-EFFECTOR DOMAIN; NF-KAPPA-B; CYTOCHROME-C; PYRIN DOMAIN; RECRUITMENT DOMAIN; MOLECULAR-CLONING; STRUCTURAL BASIS; FAMILY MEMBER	The pyrin domain was identified recently in multiple proteins that are associated with apoptosis and/or inflammation, but the physiological and molecular function of these proteins remain poorly understood. We have identified Caspy and Caspy2, two zebrafish caspases containing N-terminal pyrin domains. Expression of Caspy and Caspy2 induced apoptosis in mammalian cells that were inhibited by general caspase inhibitors. Biochemical analysis revealed that both Caspy and Caspy2 are active caspases, but they exhibit different substrate specificity. Caspy, but not Caspy2, interacted with the zebrafish orthologue of ASC (zAsc), a pyrin- and caspase recruitment domain-containing protein identified previously in mammals. The pyrin domains of both Caspy and zAsc were required for their interaction. Furthermore, zAsc and Caspy co-localized to the "speck" when co-transfected into mammalian cells. Enforced oligomerization of zAsc, but not simple interaction with zAsc, induced specific proteolytic activation of Caspy and enhanced Caspy-dependent apoptosis. Injection of zebrafish embryos with a morpholino antisense oligonucleotide corresponding to caspy resulted in an "open mouth" phenotype associated with defective formation of the cartilaginous pharyngeal skeleton. These studies suggest that zAsc mediates the activation of Caspy, a caspase that plays an important role in the morphogenesis of the jaw and gill-bearing arches.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Shinshu Univ, Sch Med, Dept Lab Med, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Mol Oncol & Angiol, Res Ctr Aging & Adaptat, Matsumoto, Nagano 3908621, Japan; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Shinshu University; Shinshu University; University of Oregon	Inohara, N (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Kuwada, John Y/B-1447-2009; Nuñez, Gabriel/A-7160-2014		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K04CA064421, R01CA064556] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR010715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060421] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556, CA-64421] Funding Source: Medline; NCRR NIH HHS [R01 RR10715] Funding Source: Medline; NICHD NIH HHS [P01HD22486] Funding Source: Medline; NIGMS NIH HHS [GM-60421] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aksentijevich I, 1997, CELL, V90, P797; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Inohara N, 2000, CELL DEATH DIFFER, V7, P509, DOI 10.1038/sj.cdd.4400679; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Masumoto J, 2001, BIOCHEM BIOPH RES CO, V280, P652, DOI 10.1006/bbrc.2000.4190; Masumoto J, 2001, EXP CELL RES, V262, P128, DOI 10.1006/excr.2000.5078; Masumoto J, 2001, J HISTOCHEM CYTOCHEM, V49, P1269, DOI 10.1177/002215540104901009; Miller CT, 2000, DEVELOPMENT, V127, P3815; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Piotrowski T, 1996, DEVELOPMENT, V123, P345; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schilling TF, 1996, DEVELOPMENT, V123, P329; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Thornberry NA, 2000, METHOD ENZYMOL, V322, P100; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Woods IG, 2000, GENOME RES, V10, P1903, DOI 10.1101/gr.10.12.1903; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yee CS, 1999, BRAIN RES BULL, V48, P581, DOI 10.1016/S0361-9230(99)00038-6; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265	50	86	92	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4268	4276		10.1074/jbc.M203944200	http://dx.doi.org/10.1074/jbc.M203944200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12464617	hybrid			2022-12-25	WOS:000180869700094
J	Vullhorst, D; Buonanno, A				Vullhorst, D; Buonanno, A			Characterization of general transcription factor 3, a transcription factor involved in slow muscle-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILLIAMS-BEUREN-SYNDROME; SYNDROME CRITICAL REGION; TFII-I; FIBER-TYPE; TRANSGENIC MICE; DEPENDENT REGULATION; BINDING PROTEIN; SONIC HEDGEHOG; IDENTIFICATION; SEQUENCES	General transcription factor 3 (GTF3) binds specifically to the bicoid-like motif of the troponin I-slow upstream enhancer. This motif is part of a sequence that restricts enhancer activity to slow muscle fibers. GTF3 contains multiple helix-loop-helix domains and an amino-terminal leucine zipper motif. Here we show that helix-loop-helix domain 4 is necessary and sufficient for binding the bicoid-like motif. Moreover, the affinity of this interaction is enhanced upon removal of amino-terminal sequences including domains 1 and 2, suggesting that an unmasking of the DNA binding surface may be a precondition for GTF3 to bind DNA in vivo. We have also investigated the interactions of six GTF3 splice variants of the mouse, three of which were identified in this study, with the troponin enhancer. The gamma-isoform lacking exon 23, and exons 26-28 that encode domain 6, interacted most avidly with the bicoid-like motif, the alpha- and beta- isoforms that include these exons fail to bind in gel retardation assays. We also show that GTF3 polypeptides associate with each other via the leucine zipper. We speculate that cells can generate a large number of GTF3 proteins with distinct DNA binding properties by alternative splicing and combinatorial association of GTF3 polypeptides.	NICHD, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Buonanno, A (corresponding author), NICHD, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA.			Vullhorst, Detlef/0000-0002-7947-8044	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000711] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000711] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Atchley WR, 2000, MOL BIOL EVOL, V17, P164, DOI 10.1093/oxfordjournals.molbev.a026229; BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; Bayarsaihan D, 2002, GENOMICS, V79, P137, DOI 10.1006/geno.2001.6674; Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; Blagden CS, 1997, GENE DEV, V11, P2163, DOI 10.1101/gad.11.17.2163; Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001; Cann GM, 1999, ANAT EMBRYOL, V200, P239, DOI 10.1007/s004290050276; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Cheriyath V, 2001, J BIOL CHEM, V276, P8377, DOI 10.1074/jbc.M008411200; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; Du SJ, 1997, J CELL BIOL, V139, P145, DOI 10.1083/jcb.139.1.145; EMERSON CP, 1997, METHODS CELL BIOL ME, V52, P85; Francke U, 1999, HUM MOL GENET, V8, P1947, DOI 10.1093/hmg/8.10.1947; Franke Y, 1999, CYTOGENET CELL GENET, V86, P296, DOI 10.1159/000015322; HALLAUER PL, 1988, MOL CELL BIOL, V8, P5072, DOI 10.1128/MCB.8.12.5072; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Jerkovic R, 1997, J MUSCLE RES CELL M, V18, P369, DOI 10.1023/A:1018630311208; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lupa-Kimball VA, 1998, AM J PHYSIOL-CELL PH, V274, pC229, DOI 10.1152/ajpcell.1998.274.1.C229; McCarthy JJ, 1997, AM J PHYSIOL-REG I, V272, pR1552, DOI 10.1152/ajpregu.1997.272.5.R1552; Merla G, 2002, HUM GENET, V110, P429, DOI 10.1007/s00439-002-0710-x; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; Osborne LR, 1999, GENOMICS, V57, P279, DOI 10.1006/geno.1999.5784; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; SALMINEN M, 1994, MOL CELL BIOL, V14, P6797, DOI 10.1128/MCB.14.10.6797; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Shield MA, 1996, MOL CELL BIOL, V16, P5058; SOUTHERN JA, 1991, J GEN VIROL, V72, P1551, DOI 10.1099/0022-1317-72-7-1551; Spitz F, 1997, MOL CELL BIOL, V17, P656, DOI 10.1128/MCB.17.2.656; Tassabehji M, 1999, EUR J HUM GENET, V7, P737, DOI 10.1038/sj.ejhg.5200396; Torgan CE, 2001, MOL BIOL CELL, V12, P1499, DOI 10.1091/mbc.12.5.1499; Tussie-Luna MI, 2001, P NATL ACAD SCI USA, V98, P7789, DOI 10.1073/pnas.141222298; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749; ZHU L, 1995, DEV BIOL, V169, P487, DOI 10.1006/dbio.1995.1163	45	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8370	8379		10.1074/jbc.M209361200	http://dx.doi.org/10.1074/jbc.M209361200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12475981	hybrid			2022-12-25	WOS:000181466800082
J	Brossier, F; Jewettt, TJ; Lovett, JL; Sibley, LD				Brossier, F; Jewettt, TJ; Lovett, JL; Sibley, LD			C-terminal processing of the toxoplasma protein MIC2 is essential for invasion into host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; GLIDING MOTILITY; SPOROZOITE INVASION; MICRONEME DISCHARGE; MAMMALIAN-CELLS; A-DOMAIN; GONDII; TRAP; CLEAVAGE; SURFACE	Host cell invasion by apicomplexan parasites is accompanied by the rapid, polarized secretion of parasite proteins that are involved in cell attachment. The Toxoplasma gondii micronemal protein MIC2 contains several extracellular adhesive domains, a transmembrane domain, and a short cytoplasmic tail. Following apical secretion, MIC2 is transiently present on the parasite surface before being translocated backward and released by proteolytic cleavage. Mutations in the extracellular domain of MIC2, directly upstream of the transmembrane domain, prevented processing and release of the soluble protein into the supernatant. A conserved basic residue in MIC2 was essential for cleavage, and basic residues are similarly positioned in other microneme proteins. Following the induction of secretion, MIC2 processing mutants were stably expressed on the surface of the parasite. Surface MIC2-expressing mutants showed increased adhesion to host cells, yet were impaired in their capacity to invade. These data demonstrate that proteolysis is essential for releasing cell surface adhesins prior to cell entry by apicomplexan parasites.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Sibley, LD (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	sibley@borcim.wustl.edu	Sibley, L. David/C-4616-2008; Lovett, Jennie/S-2996-2016	Lovett, Jennie/0000-0002-3710-9400	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034036] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI034036, AI010172, AI34036] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blackman Michael J., 2000, Current Drug Targets, V1, P59, DOI 10.2174/1389450003349461; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Carruthers VB, 2000, INFECT IMMUN, V68, P4005, DOI 10.1128/IAI.68.7.4005-4011.2000; Cerede O, 2002, EMBO J, V21, P2526, DOI 10.1093/emboj/21.11.2526; Dessens JT, 1999, EMBO J, V18, P6221, DOI 10.1093/emboj/18.22.6221; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; Donahue CG, 2000, MOL BIOCHEM PARASIT, V111, P15, DOI 10.1016/S0166-6851(00)00289-9; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; HOLDER AA, 1992, MEM I OSWALDO CRUZ, V87, P37, DOI 10.1590/S0074-02761992000700004; Howell SA, 2001, J BIOL CHEM, V276, P31311, DOI 10.1074/jbc.M103076200; Ireton K, 1998, CURR OPIN CELL BIOL, V10, P276, DOI 10.1016/S0955-0674(98)80151-8; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Matuschewski K, 2002, EMBO J, V21, P1597, DOI 10.1093/emboj/21.7.1597; McCormick CJ, 1999, MOL BIOCHEM PARASIT, V100, P111, DOI 10.1016/S0166-6851(99)00052-3; Menard R, 2001, CELL MICROBIOL, V3, P63, DOI 10.1046/j.1462-5822.2001.00097.x; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; Opitz C, 2002, EMBO J, V21, P1577, DOI 10.1093/emboj/21.7.1577; Ortega-Barria E, 1999, J BIOL CHEM, V274, P1267, DOI 10.1074/jbc.274.3.1267; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Sibley LD, 1998, CURR BIOL, V8, pR12, DOI 10.1016/S0960-9822(98)70008-9; Soldati D, 2001, INT J PARASITOL, V31, P1293, DOI 10.1016/S0020-7519(01)00257-0; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; Uthaipibull C, 2001, J MOL BIOL, V307, P1381, DOI 10.1006/jmbi.2001.4574; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X; Wengelnik K, 1999, EMBO J, V18, P5195, DOI 10.1093/emboj/18.19.5195; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Yuda M, 1999, J EXP MED, V190, P1711, DOI 10.1084/jem.190.11.1711	37	70	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6229	6234		10.1074/jbc.M209837200	http://dx.doi.org/10.1074/jbc.M209837200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471033	hybrid			2022-12-25	WOS:000181129400093
J	Bollan, K; King, D; Robertson, LA; Brown, K; Taylor, PM; Moss, SJ; Connolly, CN				Bollan, K; King, D; Robertson, LA; Brown, K; Taylor, PM; Moss, SJ; Connolly, CN			GABA(A) receptor composition is determined by distinct assembly signals within alpha and beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST BINDING-SITE; AMINO-ACID-RESIDUES; A RECEPTORS; DELTA-SUBUNIT; INTERSUBUNIT CONTACTS; IDENTIFICATION; STOICHIOMETRY; EXPRESSION; SUBTYPES; LOCALIZATION	Key to understanding how receptor diversity is achieved and controlled is the identification of selective assembly signals capable of distinguishing between other subunit partners. We have identified that the beta1-3 subunits exhibit distinct assembly capabilities with the gamma2L subunit. Similarly, analysis of an assembly box in alpha1-(57-68) has revealed an absolute requirement for this region in the assembly of alphabeta receptors. Furthermore, a selective requirement for a single amino acid (Arg-66), previously shown to be essential for the formation of the low affinity GABA binding site, is observed. This residue is critical for the assembly of alpha1beta2 but not alpha1beta1 or alpha1beta3 receptors. We have confirmed the ability of the previously identified GKER signal in beta3 to direct the assembly of betagamma receptors. The GKER signal is also involved in driving assembly with the alpha1 subunit, conferring the ability to assemble with alpha1(R66A) on the beta2 subunit. Although this signal is sufficient to permit the formation of beta2gamma2 receptors, it is not necessary for beta3gamma2 receptor formation, suggesting the existence of alternative assembly signals. These findings support the belief that GABA(A) receptor assembly occurs via defined pathways to limit the receptor diversity.	Univ Dundee, Ninewells Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England	University of Dundee; University of London; University College London	Connolly, CN (corresponding author), Univ Dundee, Ninewells Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland.	c.n.connolly@dundee.ac.uk		Connolly, Christopher/0000-0002-0445-8874				ANGELOTTI TP, 1993, J NEUROSCI, V13, P1418; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; Chang YC, 1996, J NEUROSCI, V16, P5415; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; Eertmoed AL, 1999, J NEUROSCI, V19, P6298; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; Gardiol A, 1999, J NEUROSCI, V19, P168, DOI 10.1523/JNEUROSCI.19-01-00168.1999; Hackam AS, 1998, J NEUROCHEM, V70, P40; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; JONES A, 1994, J NEUROCHEM, V63, P371; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; KORPI ER, 1994, J NEUROCHEM, V63, P1167; Korpi ER, 2002, NEUROSCIENCE, V109, P733, DOI 10.1016/S0306-4522(01)00527-9; Koulen P, 1998, EUR J NEUROSCI, V10, P115, DOI 10.1046/j.1460-9568.1998.00005.x; Krishek BJ, 1996, MOL PHARMACOL, V49, P494; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; Newell JG, 2000, J BIOL CHEM, V275, P14198, DOI 10.1074/jbc.275.19.14198; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Sarto I, 2002, J BIOL CHEM, V277, P30656, DOI 10.1074/jbc.M203597200; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; SIGEL E, 1989, FEBS LETT, V257, P377, DOI 10.1016/0014-5793(89)81576-5; Smith GB, 2000, NEUROPHARMACOLOGY, V39, P55, DOI 10.1016/S0028-3908(99)00104-5; Smith SS, 1998, J NEUROSCI, V18, P5275, DOI 10.1523/JNEUROSCI.18-14-05275.1998; Srinivasan S, 1999, J BIOL CHEM, V274, P26633, DOI 10.1074/jbc.274.38.26633; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Torres VI, 2002, J BIOL CHEM, V277, P43741, DOI 10.1074/jbc.M202007200; Tretter V, 2001, J BIOL CHEM, V276, P10532, DOI 10.1074/jbc.M011054200; Tretter V, 1997, J NEUROSCI, V17, P2728; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; Wohlfarth KM, 2002, J NEUROSCI, V22, P1541, DOI 10.1523/JNEUROSCI.22-05-01541.2002; Wooltorton JRA, 1997, EUR J NEUROSCI, V9, P2225, DOI 10.1111/j.1460-9568.1997.tb01641.x	44	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4747	4755		10.1074/jbc.M210229200	http://dx.doi.org/10.1074/jbc.M210229200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12471031	hybrid			2022-12-25	WOS:000180968900052
J	Pramanik, R; Qi, XM; Borowicz, S; Choubey, D; Schultz, RM; Han, JH; Chen, G				Pramanik, R; Qi, XM; Borowicz, S; Choubey, D; Schultz, RM; Han, JH; Chen, G			p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun - The determinant role of the isoforms in the p38 MAPK signal specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; VITAMIN-D-RECEPTOR; GENE-EXPRESSION; SELECTIVE ACTIVATION; CELL-PROLIFERATION; PATHWAYS COOPERATE; CYCLIN D1; STRESS; RAS; FOS	p38 MAPK pathway signaling is known to participate in cell proliferation, apoptosis, and differentiation, in a manner dependent on the cellular context. The factors that determine the specific biological response in a given cell type, however, remain largely unknown. We report opposite effects of the p38 isoforms on regulation of AP-1-dependent activities by p38 activators MAPK kinase 6 (MKK6) and/or arsenite in human breast cancer cells. The p38beta isoform increases the activation of AP-1 transcriptional activities by MKK6 and/or arsenite, whereas p38gamma/p38delta inhibits or has no effect on the stimulation. The p38beta does so by increasing the levels of phosphorylated c-Jun, whereas the p38gamma and -delta isoforms may act by regulating the c-jun transcription. AP-1-dependent processes such as vitamin D receptor gene promoter activation and cellular proliferation were similarly activated by the p38beta or inhibited by the p38gamma and/or -delta isoforms. Whereas the human breast cancer cells express all four isoforms, mouse NIH 3T3 and EMT-6 cells express only some of the p38 family members, with p38beta higher in 3T3 cells but p38beta only detected in the EMT-6 line. Consistent with the positive and negative roles of p38beta and p38beta in AP-1 regulation, MKK6 stimulates AP-1-dependent transcription in NIH 3T3 but not EMT-6 cells. In support of a role of c-Jun regulation by p38 isoforms in determining A-P-1 activity, the levels of endogenous c-Jun and its phosphorylated form on p38 activation are higher in NIH 3T3 cells. These results demonstrate the contrasting activities of the different p38 isoforms in transmitting the upstream signal to AP-1 and show that the expression profile of p38 isoforms determines whether the p38 signal pathway activates or inhibits AP-1-dependent processes.	Loyola Univ, Dept Radiat Oncol, Maywood, IL 60153 USA; Loyola Univ, Div Biochem, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Loyola University Chicago; Loyola University Chicago; Scripps Research Institute	Chen, G (corresponding author), Loyola Univ, Dept Radiat Oncol, 114-B Bldg 1 Hines,2160 S 1st Ave, Maywood, IL 60153 USA.	gchen1@lumc.edu	Choubey, Divaker/A-4771-2008; Han, J/G-4671-2010		NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER; NCI NIH HHS [CA91576] Funding Source: Medline; NIGMS NIH HHS [GM51417] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen G, 1998, INT J CANCER, V75, P303, DOI 10.1002/(SICI)1097-0215(19980119)75:2<303::AID-IJC21>3.0.CO;2-C; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chen G, 1999, ONCOGENE, V18, P7149, DOI 10.1038/sj.onc.1203149; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; GALANG CK, 1994, ONCOGENE, V9, P2913; Guo YL, 2001, J CELL BIOCHEM, V82, P556, DOI 10.1002/jcb.1180; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1993, J BIOL CHEM, V268, P25009; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jehan F, 2000, ARCH BIOCHEM BIOPHYS, V377, P273, DOI 10.1006/abbi.2000.1788; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Qi XM, 1997, ONCOGENE, V15, P2849, DOI 10.1038/sj.onc.1201463; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Weston CR, 2002, SCIENCE, V296, P2345, DOI 10.1126/science.1073344; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamagishi S, 2001, J BIOL CHEM, V276, P5129, DOI 10.1074/jbc.M007258200; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhao M, 1999, MOL CELL BIOL, V19, P21	65	122	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4831	4839		10.1074/jbc.M207732200	http://dx.doi.org/10.1074/jbc.M207732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12475989	hybrid			2022-12-25	WOS:000180968900064
J	Van Doorslaer, S; Dewilde, S; Kiger, L; Nistor, SV; Goovaerts, E; Marden, MC; Moens, L				Van Doorslaer, S; Dewilde, S; Kiger, L; Nistor, SV; Goovaerts, E; Marden, MC; Moens, L			Nitric oxide binding properties of neuroglobin - A characterization by EPR and flash photolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; NUCLEAR DOUBLE-RESONANCE; HORSE HEART MYOGLOBIN; ESCHERICHIA-COLI; NITROSATIVE STRESS; FERRIC HEME; VITREOSCILLA HEMOGLOBIN; COORDINATION STRUCTURE; TRUNCATED HEMOGLOBINS; CRYSTAL-STRUCTURE	Neuroglobin is a recently discovered member of the globin superfamily. Combined electron paramagnetic resonance and optical measurements show that, in Escherichia coli cell cultures with low O-2 concentration overexpressing wild-type mouse recombinant neuroglobin, the heme protein is mainly in a hexacoordinated deoxy ferrous form (F8His-Fe2+-E7His), whereby for a small fraction of the protein the endogenous protein ligand is replaced by NO. Analogous studies for mutated neuroglobin (mutation of E7-His to Leu, Val, or Gin) reveal the predominant presence of the nitrosyl ferrous form. After sonication of the cells wild-type neuroglobin oxidizes rapidly to the hexacoordinated ferric form, whereas NO ligation initially protects the mutants from oxidation. Flash photolysis studies of wild-type neuroglobin and its E7 mutants show high recombination rates (k(on)) and low dissociation rates (k(off)) for NO, indicating a high intrinsic affinity for this ligand similar to that of other hemoglobins. Since the rate-limiting step in ligand combination with the deoxy-hexacoordinated wild-type form involves the dissociation of the protein ligand, NO binding is slower than for the related mutants. Structural and kinetic characteristics of neuroglobin and its mutants are analyzed. NO production in rapidly growing E. coli cell cultures is discussed.	Univ Instelling Antwerp, Dept Phys, B-2610 Antwerp, Belgium; Univ Instelling Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Hop Bicetre, INSERM, U473, F-94275 Le Kremlin Bicetre, France; Natl Inst Mat Phys, Magurele Bucuresti, Romania	University of Antwerp; University of Antwerp; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; National Institute of Materials Physics - Romania	Dewilde, S (corresponding author), Univ Instelling Antwerp, Dept Phys, Univ Plein 1, B-2610 Antwerp, Belgium.	Sabine.VanDoorslaer@ua.ae.be	Marden, Michael/AAA-5923-2020; Kiger, Laurent/Q-1686-2018; Van Doorslaer, Sabine/E-5050-2017; Marden, Michael C/G-3139-2012; Nistor, Sergiu V./C-2733-2011; Goovaerts, Etienne/AAA-4212-2020; Goovaerts, Etienne/C-9630-2012	Van Doorslaer, Sabine/0000-0002-1685-9202; Marden, Michael C/0000-0002-5254-6385; Goovaerts, Etienne/0000-0002-8613-4856				Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; Brucker EA, 1998, PROTEINS, V30, P352, DOI 10.1002/(SICI)1097-0134(19980301)30:4<352::AID-PROT2>3.0.CO;2-L; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Das TK, 1999, BIOCHEMISTRY-US, V38, P15360, DOI 10.1021/bi991237e; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; EICH RF, 1997, THESIS RICE U HOUSTO; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Flores M, 1997, BIOPHYS J, V73, P3225, DOI 10.1016/S0006-3495(97)78347-4; Flores M, 2000, BIOPHYS J, V78, P2107, DOI 10.1016/S0006-3495(00)76757-9; Gardner AM, 2002, J BIOL CHEM, V277, P8166, DOI 10.1074/jbc.M110470200; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Geckil H, 2001, J BIOTECHNOL, V85, P57, DOI 10.1016/S0168-1656(00)00384-9; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; HOHN M, 1983, J AM CHEM SOC, V105, P109; HORI H, 1981, J BIOL CHEM, V256, P7849; Hutchings MI, 2000, J BACTERIOL, V182, P6434, DOI 10.1128/JB.182.22.6434-6439.2000; HUTTERMANN J, 1994, J CHEM SOC FARADAY T, V90, P3077, DOI 10.1039/ft9949003077; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; JI XB, 1988, BIOCHEM BIOPH RES CO, V157, P106, DOI 10.1016/S0006-291X(88)80018-4; JI XB, 1988, APPL ENVIRON MICROB, V54, P1791, DOI 10.1128/AEM.54.7.1791-1794.1988; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kallio PT, 1996, BIOTECHNOL PROGR, V12, P751, DOI 10.1021/bp960071v; KAPPL R, 1989, ISRAEL J CHEM, V29, P73; Kaur R, 2002, APPL ENVIRON MICROB, V68, P152, DOI 10.1128/AEM.68.1.152-160.2002; KHOSLA C, 1990, BIO-TECHNOL, V8, P849, DOI 10.1038/nbt0990-849; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; LOBRUTTO R, 1983, J BIOL CHEM, V258, P7437; MERXMW, 2001, FASEB J, V15, P1077; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MORSE RH, 1980, J BIOL CHEM, V255, P7876; Nistor SV, 2002, CHEM PHYS LETT, V361, P355, DOI 10.1016/S0009-2614(02)00961-2; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Patchkovskii S, 2000, INORG CHEM, V39, P5354, DOI 10.1021/ic0005691; PEISACH J, 1971, J BIOL CHEM, V246, P3342; PEISACH J, 1971, J BIOL CHEM, V246, P5877; Reynolds MF, 2000, BIOCHEMISTRY-US, V39, P388, DOI 10.1021/bi991378g; Schmidt PP, 2001, APPL MAGN RESON, V21, P423, DOI 10.1007/BF03162418; Sowa AW, 1998, P NATL ACAD SCI USA, V95, P10317, DOI 10.1073/pnas.95.17.10317; Svistunenko DA, 2000, BIOCHEM J, V351, P595, DOI 10.1042/0264-6021:3510595; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Tyryshkin AM, 1999, J AM CHEM SOC, V121, P3396, DOI 10.1021/ja982085y; Walker FA, 1999, COORDIN CHEM REV, V185-6, P471, DOI 10.1016/S0010-8545(99)00029-6; Watts RA, 2001, P NATL ACAD SCI USA, V98, P10119, DOI 10.1073/pnas.191349198; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Witting PK, 2001, J BIOL CHEM, V276, P3991, DOI 10.1074/jbc.M005758200; Zhang CG, 2002, BIOCHEM BIOPH RES CO, V290, P1411, DOI 10.1006/bbrc.2002.6360	56	112	114	3	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4919	4925		10.1074/jbc.M210617200	http://dx.doi.org/10.1074/jbc.M210617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12480932	hybrid			2022-12-25	WOS:000180968900075
J	Waditee, R; Tanaka, Y; Aoki, K; Hibino, T; Jikuya, H; Takano, J; Takabe, T; Takabe, T				Waditee, R; Tanaka, Y; Aoki, K; Hibino, T; Jikuya, H; Takano, J; Takabe, T; Takabe, T			Isolation and functional characterization of N-methyltransferases that catalyze betaine synthesis from glycine in a halotolerant photosynthetic organism Aphanothece halophytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE MONOOXYGENASE; ALDEHYDE DEHYDROGENASE; NA+/H+ ANTIPORTER; BINDING-PROTEIN; CYANOBACTERIUM; PURIFICATION; ENZYME; ACCUMULATION; TOLERANCE; SEQUENCE	Glycine betaine (N,N,N-trimethylglycine) is an important osmoprotectant and is synthesized in response to abiotic stresses. Although almost all known biosynthetic pathways of betaine are two-step oxidation of choline, here we isolated two N-methyltransferase genes from a halotolerant cyanobacterium Aphanothece halophytica. One of gene products (ORFI) catalyzed the methylation reactions of glycine and sarcosine with S-adenosylmethionine acting as the methyl donor. The other one (ORF2) specifically catalyzed the methylation of dimethylglycine to betaine. Both enzymes are active as monomers. Betaine, a final product, did not show the feed back inhibition for the methyltransferases even in the presence of 2 m. A reaction product, S-adenosyl homocysteine, inhibited the methylation reactions with relatively low affinities. The co-expressing of two enzymes in Escherichia coli increased the betaine level and enhanced the growth rates. Immunoblot analysis revealed that the accumulation levels of both enzymes in A. halophytica cells increased with increasing the salinity. These results indicate that A. halophytica cells synthesize betaine from glycine by a three-step methylation. The changes of amino acids Arg-169 to Lys or Glu in ORF1 and Pro-171 to Gln and/or Met-172 to Arg in ORF2 significantly decreased V-max and increased K-m for methyl acceptors (glycine, sarcosine, and dimethylglycine) but modestly affected K-m for S-adenosylmethionine, indicating the importance of these amino acids for the binding of methyl acceptors. Physiological and functional properties of methyltransferases were discussed.	Meijo Univ, Inst Res, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; Meijo Univ, Inst Res, Grad Sch Environm & Human Sci, Nagoya, Aichi 4688502, Japan; Shimadzu Co, Nakagyo Ku, Kyoto 6048511, Japan; Nagoya Univ, Grad Sch Agr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Meijo University; Meijo University; Shimadzu Corporation; Nagoya University	Takabe, T (corresponding author), Meijo Univ, Inst Res, Tenpaku Ku, Nagoya, Aichi 4688502, Japan.	takabe@ccmfs.meijo-u.ac.jp						ARONDEL V, 1993, J BIOL CHEM, V268, P16002; Boch J, 1996, J BACTERIOL, V178, P5121, DOI 10.1128/jb.178.17.5121-5129.1996; BURNET M, 1995, PLANT PHYSIOL, V108, P581, DOI 10.1104/pp.108.2.581; Chen THH, 2002, CURR OPIN PLANT BIOL, V5, P250, DOI 10.1016/S1369-5266(02)00255-8; CHERN MK, 1995, BIOCHEM BIOPH RES CO, V213, P561, DOI 10.1006/bbrc.1995.2168; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; FALKENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1034, P253, DOI 10.1016/0304-4165(90)90046-Y; GALINSKI EA, 1994, FEMS MICROBIOL REV, V15, P95, DOI 10.1111/j.1574-6976.1994.tb00128.x; Hibino T, 2002, J BIOL CHEM, V277, P41352, DOI 10.1074/jbc.M205965200; Hibino T, 1999, PLANT MOL BIOL, V40, P409, DOI 10.1023/A:1006273124726; INCHAROENSAKDI A, 1986, PLANT PHYSIOL, V81, P1044, DOI 10.1104/pp.81.4.1044; ISHITANI M, 1993, AUST J PLANT PHYSIOL, V20, P693, DOI 10.1071/PP9930693; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KAI MC, 1999, APPL ENVIRON MICROB, V65, P828; Kanipes MI, 1997, BBA-LIPID LIPID MET, V1348, P134, DOI 10.1016/S0005-2760(97)00121-5; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; Lee BH, 1997, PLANT MOL BIOL, V35, P763, DOI 10.1023/A:1005867420619; Mukherjee S, 1995, NEUROCHEM RES, V20, P1233, DOI 10.1007/BF00995388; Nuccio ML, 2000, J BIOL CHEM, V275, P14095, DOI 10.1074/jbc.275.19.14095; Nyyssola A, 2000, J BIOL CHEM, V275, P22196, DOI 10.1074/jbc.M910111199; Nyyssola A, 2001, APPL ENVIRON MICROB, V67, P2044, DOI 10.1128/AEM.67.5.2044-2050.2001; Ogawa H, 1998, INT J BIOCHEM CELL B, V30, P13, DOI 10.1016/S1357-2725(97)00105-2; RAHA A, 1994, J BIOL CHEM, V269, P5750; Rathinasabapathi B, 1997, P NATL ACAD SCI USA, V94, P3454, DOI 10.1073/pnas.94.7.3454; REED RH, 1996, FEMS MICROBIOL REV, V39, P51; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; Rontein D, 2002, METAB ENG, V4, P49, DOI 10.1006/mben.2001.0208; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; Takabe T, 1998, STRESS RESPONSES OF PHOTOSYNTHETIC ORGANISMS, P115; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Waditee R, 2002, P NATL ACAD SCI USA, V99, P4109, DOI 10.1073/pnas.052576899; Waditee R, 2001, J BIOL CHEM, V276, P36931, DOI 10.1074/jbc.M103650200; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; YAMADA H, 1979, AGR BIOL CHEM TOKYO, V43, P2173, DOI 10.1080/00021369.1979.10863769	35	90	101	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4932	4942		10.1074/jbc.M210970200	http://dx.doi.org/10.1074/jbc.M210970200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466265	hybrid			2022-12-25	WOS:000180968900077
J	Nukui, M; Taylor, KB; McPherson, DT; Shigenaga, MK; Jedrzejas, MJ				Nukui, M; Taylor, KB; McPherson, DT; Shigenaga, MK; Jedrzejas, MJ			The function of hydrophobic residues in the catalytic cleft of Streptococcus pneumoniae hyaluronate lyase - Kinetic characterization of mutant enzyme forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGRADATION; PURIFICATION; MECHANISM; BINDING; ACID; REFINEMENT; SUBSTRATE; PROTEINS; COMPLEX	Streptococcus pneumoniae hyaluronate lyase is a surface antigen of this Gram-positive human bacterial pathogen. The primary function of this enzyme is the degradation of hyaluronan, which is a major component of the extracellular matrix of the tissues of vertebrates and of some bacteria. The enzyme degrades its substrate through a beta-elimination process called proton acceptance and donation. The inherent part of this degradation is a processive mode of action of the enzyme degrading hyaluronan into unsaturated disaccharide hyaluronic acid blocks from the reducing to the nonreducing end of the polymer following the initial random endolytic binding to the substrate. The final degradation product is the unsaturated disaccharide hyaluronic acid. The residues of the enzyme that are involved in various aspects of such degradation were identified based on the three-dimensional structures of the native enzyme and its complexes with hyaluronan substrates of various lengths. The catalytic residues were identified to be Asn(349), His(399), and Tyr(408). The residues responsible for the release of the product of the reaction were identified as Glu(388), ASp(398), and and they were termed negative patch. The hydrophobic residues Trp(291), Trp(292), and Phe(343) were found to be responsible for the precise positioning of the substrate for enzyme catalysis and named hydrophobic patch. The comparison of the specific activities and kinetic properties of the wild type and the mutant enzymes involving the hydrophobic patch residues W292A, F343V, W291A/W292A, W292A/F343V, and W291A/W292A/F343V allowed for the characterization of every mutant and for the correlation of the activity and kinetic properties of the enzyme with its structure as well as the mechanism of catalysis.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Alabama Birmingham, Ctr AIDS Res Mol Biol Core Facil, Birmingham, AL 35294 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of Alabama System; University of Alabama Birmingham	Jedrzejas, MJ (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	MJedrzejas@chori.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSTRIAN R, 1982, PNEUMOCOCCUS PNEUMOC, P191; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERRY AM, 1994, INFECT IMMUN, V62, P1101, DOI 10.1128/IAI.62.3.1101-1108.1994; BOULNOIS GJ, 1992, J GEN MICROBIOL, V138, P249, DOI 10.1099/00221287-138-2-249; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; COMPER WD, 1978, PHYSIOL REV, V58, P255, DOI 10.1152/physrev.1978.58.1.255; FRASER JRE, 1989, TURNOVER METABOLISM, P42; Jedrzejas MJ, 2000, CRIT REV BIOCHEM MOL, V35, P221, DOI 10.1080/10409230091169195; Jedrzejas MJ, 1998, J STRUCT BIOL, V121, P73, DOI 10.1006/jsbi.1998.3963; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2000, ACTA CRYSTALLOGR D, V56, P460, DOI 10.1107/S0907444900000706; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly SJ, 2001, GLYCOBIOLOGY, V11, P297, DOI 10.1093/glycob/11.4.297; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurent T.C, 1970, CHEM MOL BIOL INTERC, P703; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; LINKER A, 1956, J BIOL CHEM, V219, P13; Maniatis T., 1982, MOL CLONING LAB MANU; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; MUFSON MA, 1990, PRINCIPLES PRACTICE, P1539; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Price KN, 1997, CARBOHYD RES, V303, P303, DOI 10.1016/S0008-6215(97)00171-7; PRITCHARD DG, 1994, ARCH BIOCHEM BIOPHYS, V315, P431, DOI 10.1006/abbi.1994.1521; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; WINTER WT, 1977, J MOL BIOL, V117, P761, DOI 10.1016/0022-2836(77)90068-7; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	41	37	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3079	3088		10.1074/jbc.M204999200	http://dx.doi.org/10.1074/jbc.M204999200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446724	hybrid, Green Submitted			2022-12-25	WOS:000180915000041
J	Kalaitzidis, D; Davis, RE; Rosenwald, A; Staudt, LM; Gilmore, TD				Kalaitzidis, D; Davis, RE; Rosenwald, A; Staudt, LM; Gilmore, TD			The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappa B signal transduction pathway	ONCOGENE			English	Article						RC-K8; c-Rel; Rel; Rel-nrg; NF-kappa B; I kappa B	C-REL; GASTROINTESTINAL-TRACT; TRANSCRIPTION FACTORS; HODGKINS-DISEASE; ALPHA-GENE; V-REL; MUTATIONS; EXPRESSION; PHOSPHORYLATION; TRANSFORMATION	The human large B-cell lymphoma cell line RC-K8 has a rearranged REL locus that directs the production of a chimeric protein, termed REL-NRG (Non-Rel Gene). In this study, we show that RC-K8 cells have constitutively nuclear heterodimeric and homodimeric DNA-binding complexes that consist of p50, REL, and REL-NRG. In vitro, IkappaBalpha can block the DNA-binding activity of wildtype REL homodimers but not REL-NRG homodimers. In vivo, REL-NRG cannot activate transcription of a kappaB site reporter plasmid, suggesting that it is a transcription repressing or blocking REL protein. By Western blotting, no IkappaBalpha protein can be detected in extracts of RC-K8 cells. The absence of IkappaBalpha protein in RC-K8 cells appears to be due to mutations that cause premature termination of translation in three of the four copies of the IKBA gene in RC-K8 cells. Re-expression of wild-type IkappaBalpha or a super-repressor form of IkappaBalpha in RC-K8 cells is cytotoxic; in contrast, expression of a dominant-negative form of IkappaB kinase does not affect the growth of RC-K8 cells. By cDNA microarray analysis, a number of previously identified Rel/NF-kappaB target genes are overexpressed in RC-K8 cells, consistent with there being transcriptionally active REL complexes. Taken together, our results suggest that the growth of RC-K8 cells is dependent on the activity of nuclear wild-type REL dimers, while the contribution of REL-NRG to the transformed state of RC-K8 cells is less clear. Nevertheless, the RC-K8 cell line is the first tumor cell line identified with mutations in genes encoding multiple proteins in the Rel/NF-kappaB signal transduction pathway.	Boston Univ, Dept Biol, Boston, MA 02215 USA; NCI, Metab Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.		Staudt, Louis/AAC-5324-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007387] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline; NICHD NIH HHS [T32-HD07387] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Den Dunnen JT, 1999, HUM MUTAT, V14, P95, DOI 10.1002/(SICI)1098-1004(1999)14:2<95::AID-HUMU1>3.0.CO;2-G; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Houldsworth J, 1996, BLOOD, V87, P25; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; LU D, 1991, ONCOGENE, V6, P1235; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palanisamy N, 2002, GENE CHROMOSOME CANC, V33, P114, DOI 10.1002/gcc.10016; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106	45	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8759	8768		10.1038/sj.onc.1206033	http://dx.doi.org/10.1038/sj.onc.1206033			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483529				2022-12-25	WOS:000179734400010
J	Kraus, AC; Ferber, I; Bachmann, SO; Specht, H; Wimmel, A; Gross, MW; Schlegel, J; Suske, G; Schuermann, M				Kraus, AC; Ferber, I; Bachmann, SO; Specht, H; Wimmel, A; Gross, MW; Schlegel, J; Suske, G; Schuermann, M			In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways	ONCOGENE			English	Article						lung cancer; Akt; chemoresistance; radioresistance; adhesion	NF-KAPPA-B; INDUCED APOPTOSIS; MULTIDRUG-RESISTANCE; TUMOR-CELLS; IN-VIVO; EXPRESSION; PROTEIN; GROWTH; CARCINOMA; LINES	Most small cell lung cancer (SCLC) patients relapse within 12 months of starting combination chemotherapy plus radio-therapy, due to the development of acquired chemo- and radio-resistance. This phenomenon relates to the induction of tumour differentiation, resulting in apoptosis-resistant, morphologically variant (v-SCLC) cells, which lack the neuroendocrine expression of classic (c-) SCLC cells. In this study spontaneously adherent SCLC sublines were shown by differential gene expression analysis to provide an in vitro model of variant differentiation in SCLC, with down-regulation of neuroendocrine markers and up-regulation of epithelial differentiation markers cyclin D1, endothelin, the cell adhesion molecules CD 44 and integrin subunits alpha2, beta3 and beta4. The sensitivity of adherent SCLC sublines to etoposide, cyclophosphamide and gamma radiation was significantly diminished relative to parent suspension cell lines. Western blot analysis using phosphorylation-specific antibodies to Akt and MAP kinase revealed markedly elevated activation in adherent SCLC sublines, paralleled by increased levels of phosphorylated Bad protein and activated NF-kappaB. Subcultivation of the adherent sublines on uncoated surfaces reversed their adherent phenotype immediately and under these conditions Akt activity reverted to low levels. These results suggest that c-SCLC cells can differentiate spontaneously to v-SCLC and that the associated cellular adhesion may trigger Akt-dependent inhibition of apoptosis in SCLC cells, thus leading to acquired chemo-and radio-resistance.	Univ Marburg, Univ Hosp, Inst Mol Biol & Tumour Res, D-35033 Marburg, Germany; Univ Marburg, Univ Hosp, Dept Neuropathol, D-35033 Marburg, Germany; Univ Marburg, Univ Hosp, Dept Radiotherapy & Radio Oncol, D-35033 Marburg, Germany; Univ Marburg, Univ Hosp, Ctr Internal Med, Dept Haematol & Oncol, D-35033 Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; Philipps University Marburg	Schuermann, M (corresponding author), Univ Marburg, Klinikum, Zentrum Innere Med, Baldingerstr, D-35033 Marburg, Germany.	schuermann@mailer.uni-marburg.de		Suske, Guntram/0000-0002-4807-0513; Schlegel, Jurgen/0000-0002-5544-2717				Abe Y, 1996, BRIT J CANCER, V74, P1929, DOI 10.1038/bjc.1996.655; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; BRAMBILLA E, 1991, J CLIN ONCOL, V9, P50, DOI 10.1200/JCO.1991.9.1.50; BRODIN O, 1995, LUNG CANCER-J IASLC, V12, P183, DOI 10.1016/0169-5002(95)00444-6; CARNEY DN, 1985, CANCER RES, V45, P2913; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dingemans AMC, 1996, ANN ONCOL, V7, P625; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fushimi H, 1996, CANCER, V77, P278, DOI 10.1002/(SICI)1097-0142(19960115)77:2<278::AID-CNCR9>3.0.CO;2-I; GAZDAR AF, 1985, CANCER RES, V45, P2924; Gazdar AF, 1996, J CELL BIOCHEM, P1; Grossi F, 2001, CRIT REV ONCOL HEMAT, V37, P61, DOI 10.1016/S1040-8428(00)00098-6; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; KLUG J, 1994, MOL CELL BIOL, V14, P6208, DOI 10.1128/MCB.14.9.6208; Moore SM, 1998, CANCER RES, V58, P5239; Nakashio A, 2000, CANCER RES, V60, P5303; Okada S, 2001, INT J RADIAT ONCOL, V49, P1149, DOI 10.1016/S0360-3016(00)01429-2; Ozes ON, 1999, NATURE, V401, P82; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; RADICE PA, 1982, CANCER-AM CANCER SOC, V50, P2894, DOI 10.1002/1097-0142(19821215)50:12<2894::AID-CNCR2820501232>3.0.CO;2-G; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; Salge U, 2001, J CANCER RES CLIN, V127, P139, DOI 10.1007/s004320000210; Savaraj N, 1997, AM J CLIN ONCOL-CANC, V20, P398, DOI 10.1097/00000421-199708000-00016; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Schlegel J, 2000, CANCER LETT, V158, P103, DOI 10.1016/S0304-3835(00)00515-2; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; SUPINO R, 1993, INT J CANCER, V54, P309, DOI 10.1002/ijc.2910540224; Thiede C, 2001, LEUKEMIA, V15, P293, DOI 10.1038/sj.leu.2401953; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wimmel A, 1997, LUNG CANCER, V16, P151, DOI 10.1016/S0169-5002(96)00625-3; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Worden FP, 2000, EXPERT OPIN INV DRUG, V9, P565, DOI 10.1517/13543784.9.3.565; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	40	110	117	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8683	8695		10.1038/sj.onc.1205939	http://dx.doi.org/10.1038/sj.onc.1205939			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483521				2022-12-25	WOS:000179734400002
J	Garcia, MA; Guerra, S; Gil, JS; Jimenez, V; Esteban, M				Garcia, MA; Guerra, S; Gil, JS; Jimenez, V; Esteban, M			Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L	ONCOGENE			English	Article						E3L; vaccinia virus; dsRNA; PKR; tumor apoptosis	DOUBLE-STRANDED-RNA; NF-KAPPA-B; TETRATRICOPEPTIDE REPEAT PROTEIN; BROAD SPECIES-SPECIFICITY; TUMOR-SUPPRESSOR P53; KINASE PKR; INFECTED CELLS; INTERFERON RESISTANCE; ACTIVATION; GENE	The vaccinia virus (VV) E3L gene encodes a dsRNA binding protein that inhibits activation of the IFN-induced, dsRNA-dependent protein kinase, (PKR), the 2-5A synthetases/RNase L system and other dsRNA dependent pathways, thus leading to efficient VV replication. To analyse E3L effects over cellular metabolism in a virus-free system, we have generated stable mouse 3T3 cell lines expressing E3L. Expression of E3L in NIH3T3 cells results in inhibition of eIF-2alpha phosphorylation and IkappaBalpha degradation in response to dsRNA. Antiviral responses induced by IFN-alpha/beta were partially impaired in 3T3-E3L cells, as determined by a viability assay upon VSV infection. E3L expression also confers resistance to dsRNA-triggered apoptosis. Interestingly, cells expressing E3L grew faster than control cells, and showed increased expression of cyclin A and decreased levels of P27(Kip1). E3L cooperated with H-ras in a focus formation assay, and NIH3T3 E3L cells formed solid tumors when injected in nude mice. Overall, our findings reveal that interference of E3L protein with several cellular pathways, results in promotion of cellular growth, impairment of antiviral activity and resistance to apoptosis.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, Madrid 28049, Spain.		Garcia, Maria Angel MA/I-5116-2016; Gil, Jesus/C-7739-2012; guerra, susana/K-5972-2014	Garcia, Maria Angel MA/0000-0003-2003-3769; Gil, Jesus/0000-0002-4303-6260; guerra, susana/0000-0001-9067-2991; ESTEBAN, MARIANO/0000-0003-0846-2827				ALCAMI A, 1995, J VIROL, V69, P4633; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BEATTIE E, 1995, J VIROL, V69, P499, DOI 10.1128/JVI.69.1.499-505.1995; Beattie E, 1996, VIRUS GENES, V12, P89, DOI 10.1007/BF00370005; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Brandt TA, 2001, J VIROL, V75, P850, DOI 10.1128/JVI.75.2.850-856.2001; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEURS EF, 1993, CELL, V62, P379; Murcia-Nicolas A, 1999, VIRUS RES, V59, P1, DOI 10.1016/S0168-1702(98)00114-2; PAEZ E, 1984, VIROLOGY, V134, P12, DOI 10.1016/0042-6822(84)90268-X; PARK H, 1994, P NATL ACAD SCI USA, V11, P4713; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; Rivas C, 1998, VIROLOGY, V243, P406, DOI 10.1006/viro.1998.9072; Romano PR, 1998, MOL CELL BIOL, V18, P7304, DOI 10.1128/MCB.18.12.7304; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; SEN GC, 1992, J BIOL CHEM, V267, P5017; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; Smith Geoffrey L., 1994, Trends in Microbiology, V2, P81, DOI 10.1016/0966-842X(94)90539-8; Smith GL, 1997, IMMUNOL REV, V159, P137, DOI 10.1111/j.1600-065X.1997.tb01012.x; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Tang NM, 1999, MOL CELL BIOL, V19, P4757; WATSON JC, 1991, VIROLOGY, V185, P206, DOI 10.1016/0042-6822(91)90768-7; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; YUWEN H, 1993, VIROLOGY, V195, P732, DOI 10.1006/viro.1993.1424; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	64	48	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8379	8387		10.1038/sj.onc.1206036	http://dx.doi.org/10.1038/sj.onc.1206036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466958	Bronze			2022-12-25	WOS:000179480100001
J	Span, PN; Manders, P; Heuvel, JJ; Thomas, CMG; Bosch, RR; Beex, LV; Sweep, CGJ				Span, PN; Manders, P; Heuvel, JJ; Thomas, CMG; Bosch, RR; Beex, LV; Sweep, CGJ			Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer	ONCOGENE			English	Article						breast neoplasms; quantitative real-time RT-PCR; gene expression regulation; oncogene; angiogenesis; extracellular matrix	PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; TRANSFORMING GENE; MESSENGER-RNA; MATRIX; UROKINASE; CARCINOMA; PHENOTYPE	The transcription factor Ets-1 regulates the expression of several angiogenic and extracellular matrix remodeling factors, and might be implicated in disease progression of breast cancer. In the present study, the prognostic value of Ets-1 expression was assessed by quantitative real-time fluorescence RT-PCR in 123 sporadic primary breast cancer samples of patients with a median follow-up time of 62 months. Ets-1 expression levels correlated significantly with VEGF and PAI-1 in the same tissue. In univariate (P = 0.0011) and multivariate (P = 0.005) analyses, Ets-1 expression showed significant prognostic value for relapse-free survival. Ets-1 is a strong, independent predictor of poor prognosis in breast cancer. This seems - at least in part - to be attributable to its role in transcriptional regulation of factors involved in angiogenesis (VEGF), and extracellular matrix remodeling (PAI-1).	Univ Nijmegen, Med Ctr, Dept Chem Endocrinol 530, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Obstet & Gynecol, Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Endocrinol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Span, PN (corresponding author), Univ Nijmegen, Med Ctr, Dept Chem Endocrinol 530, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Manders, P./L-4501-2015; Span, Paul/G-4710-2012; Sweep, C.G.J./H-8096-2014; Span, Paul N./A-3143-2009; Thomas, C.M.G./L-4687-2015	Span, Paul/0000-0002-1930-6638; Sweep, C.G.J./0000-0003-1103-3070; 				Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Benz CC, 1998, ENDOCR-RELAT CANCER, V5, P271, DOI 10.1677/erc.0.0050271; COX DR, 1972, J R STAT SOC B, V34, P187; Davidson B, 2001, CLIN CANCER RES, V7, P551; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Janicke F, 2001, J NATL CANCER I, V93, P913, DOI 10.1093/jnci/93.12.913; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; PERSYN JP, 1980, EUR J CANCER, V16, P1513; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294	18	108	110	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8506	8509		10.1038/sj.onc.1206040	http://dx.doi.org/10.1038/sj.onc.1206040			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466970				2022-12-25	WOS:000179480100013
J	Galman, C; Ostlund-Lindqvist, AM; Bjorquist, A; Schreyer, S; Svensson, L; Angelin, B; Rudling, M				Galman, C; Ostlund-Lindqvist, AM; Bjorquist, A; Schreyer, S; Svensson, L; Angelin, B; Rudling, M			Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency	FASEB JOURNAL			English	Article						lipoproteins; hyperlipidemia; cholesterol 7 alpha-hydroxylase; statins; resins	DENSITY-LIPOPROTEIN RECEPTOR; SERUM-CHOLESTEROL; GROWTH-HORMONE; MICE LACKING; 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; ABSORPTION; PROTEINS; S-8921; ASSAY; RATS	Reduction of plasma cholesterol by statins is fundamental to prevent coronary heart disease. Such therapy is often sub-optimal, however, particularly in patients with reduced LDL receptors (familial hypercholesterolemia), and novel or adjuvant therapies are therefore warranted. Cholesterol elimination is profoundly influenced by the rate of its conversion to bile acids (BA), regulated by the enzyme Cyp7a1. Induced fecal loss of BA by resin treatment reduces plasma cholesterol, presumably through induction of hepatic LDL receptors (LDLR). We here describe the effect of PR835, a drug belonging to a new class of lipid-lowering agents that inhibit the Slc10a2 protein, the intestinal transporter responsible for active uptake of BA. Treatment reduced plasma cholesterol by 40% in mice devoid of both the LDLR and its ligand, apoE, while triglycerides and HDL cholesterol were unchanged. Cyp7a1 enzyme activity and mRNA were induced several-fold, and hepatic HMG CoA reductase mRNA increased, mirroring an induced synthesis of BA and cholesterol. The addition of a statin potentiated the effect, leading to reductions of plasma total and LDL cholesterol by 64% and 70%, respectively. These effects could not be attributed to induction of other known hepatic lipoprotein receptors and indicate the presence of new points of targeting in lipid-lowering therapy.	Huddinge Univ Hosp, Karolinska Inst, CME, Dept Med,Metab Unit, S-14186 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Novum, Ctr Nutr & Toxicol,Mol Nutr Unit, Stockholm, Sweden; Astra Zeneca R&D, Mol Biol Cell Biol & Biochem, Molndal, Sweden	Karolinska Institutet; Karolinska Institutet; AstraZeneca	Rudling, M (corresponding author), Huddinge Univ Hosp, Karolinska Inst, CME, Dept Med,Metab Unit, M63, S-14186 Stockholm, Sweden.	mats.rudling@cnt.ki.se						Angelin B, 1999, CURR OPIN LIPIDOL, V10, P269, DOI 10.1097/00041433-199906000-00009; AXELSON M, 1988, FEBS LETT, V239, P324, DOI 10.1016/0014-5793(88)80944-X; Bonge H, 2000, ANAL BIOCHEM, V282, P94, DOI 10.1006/abio.2000.4600; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; Edwards PA, 2002, J LIPID RES, V43, P2; EINARSSON K, 1986, J LIPID RES, V27, P82; Grundy SM, 1998, CIRCULATION, V97, P1436; Higaki J, 1998, ARTERIOSCL THROM VAS, V18, P1304, DOI 10.1161/01.ATV.18.8.1304; Ichihashi T, 1998, J PHARMACOL EXP THER, V284, P43; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; LEWIS MC, 1995, J LIPID RES, V36, P1098; Love MW, 1998, CURR OPIN LIPIDOL, V9, P225, DOI 10.1097/00041433-199806000-00007; PETTERSSON L, 1994, J CHROMATOGR B, V657, P31, DOI 10.1016/0378-4347(94)80066-9; Rader DJ, 2001, NAT MED, V7, P1282, DOI 10.1038/nm1201-1282; Root C, 2002, J LIPID RES, V43, P1320, DOI 10.1194/jlr.M200121-JLR200; Rudling M, 2001, FASEB J, V15, P1350, DOI 10.1096/fj.00-0715com; Rudling M, 1998, AM J PATHOL, V153, P1923, DOI 10.1016/S0002-9440(10)65706-9; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; RUDLING MJ, 1990, P NATL ACAD SCI USA, V87, P3469, DOI 10.1073/pnas.87.9.3469; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sartipy P, 1999, J BIOL CHEM, V274, P25913, DOI 10.1074/jbc.274.36.25913; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109	25	20	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					265	+		10.1096/fj.0341fje	http://dx.doi.org/10.1096/fj.0341fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475897				2022-12-25	WOS:000180574300018
J	Podesta, M; Pitto, A; Figari, O; Bacigalupo, A; Bruzzone, S; Guida, L; Franco, L; De Flora, A; Zocchi, E				Podesta, M; Pitto, A; Figari, O; Bacigalupo, A; Bruzzone, S; Guida, L; Franco, L; De Flora, A; Zocchi, E			Cyclic ADP-ribose generation by CD38 improves human hemopoietic stem cell engraftment into NOD/SCID mice	FASEB JOURNAL			English	Article						bone marrow; hemopoietic progenitors; mononuclear cells	INTRACELLULAR CALCIUM; PERIPHERAL-BLOOD; BONE-MARROW; EXPRESSION; MOLECULE; NAD+	Cyclic ADP-ribose (cADPR) is a potent and universal intracellular calcium mobilizer, recently shown to behave as a new hemopoietic cytokine stimulating the in vitro proliferation of both committed and uncommitted human hemopoietic progenitors (HP). Here, we investigated the effects of cADPR on engraftment of hemopoietic stem cells (HSC) into irradiated NOD/SCID mice. Two different protocols were used: i) a 24 h in vitro priming of cord blood-derived mononuclear cells (MNC) with micromolar cADPR, followed by their infusion into irradiated mice (both primary and secondary transplants); and ii) co-infusion of MNC with CD38-transfected, cADPR-generating, irradiated murine 3T3 fibroblasts. We demonstrated a dual effect of cADPR on human HP in vivo: i) enhanced proliferation of committed progenitors, responsible for improvement of short-term engraftment; ii) expansion of HSC, with increased long-term human engraftment into secondary recipients and a significantly higher expansion factor of CD34(+) progenitors in mice co-infused with MNC and CD38(+) 3T3 fibroblasts. These results hold promise for the possible therapeutic use of cADPR, and of cADPR-producing stroma, to achieve long-term expansion of human HSC, that is, those HP capable of self-renewal and responsible for repopulation of the bone marrow.	San Martino Hosp, Dept Hematol, Div 2, Genoa, Italy; Univ Genoa, Dept Expt Med, Biochem Sect, I-16126 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16126 Genoa, Italy; G Gaslini Inst Children, Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini	Podesta, M (corresponding author), San Martino Hosp, Dept Hematol, Div 2, Genoa, Italy.	marina.podesta@hsanmartino.liguria.it	Podestà, Marina/K-3875-2016; Bruzzone, Santina/A-4264-2015	Podestà, Marina/0000-0002-6755-613X; Bruzzone, Santina/0000-0003-2034-3716				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Bruzzone S, 2001, FASEB J, V15, P10; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Cashman J, 1997, BRIT J HAEMATOL, V98, P1026, DOI 10.1046/j.1365-2141.1997.3233140.x; Childs R, 1999, BLOOD, V94, P3234, DOI 10.1182/blood.V94.9.3234.421k16_3234_3241; CLINE MJ, 1979, NATURE, V277, P177, DOI 10.1038/277177a0; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1999, BLOOD, V94, P2545, DOI 10.1182/blood.V94.8.2545.420k45_2545_2547; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; KRAUSE DS, 1994, BLOOD, V84, P691; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; METCALF R. L., 1971, Pesticides in the environment. Volume 1, Part I., V1, P1; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; Rice AM, 2000, TRANSPLANTATION, V69, P927; Sirard C, 1996, BLOOD, V87, P1539, DOI 10.1182/blood.V87.4.1539.bloodjournal8741539; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; van Hennik PB, 1999, BLOOD, V94, P3055, DOI 10.1182/blood.V94.9.3055.421k05_3055_3061; Wong L, 1999, BBA-GEN SUBJECTS, V1472, P555, DOI 10.1016/S0304-4165(99)00161-0; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 2001, FASEB J, V15, P1610, DOI 10.1096/fj.00-0803fje	29	20	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					310	+		10.1096/fj.02-0520fje	http://dx.doi.org/10.1096/fj.02-0520fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475890				2022-12-25	WOS:000180574300021
J	Linden, A; Mayans, O; Meyer-Klaucke, W; Antranikian, G; Wilmanns, M				Linden, A; Mayans, O; Meyer-Klaucke, W; Antranikian, G; Wilmanns, M			Differential regulation of a hyperthermophilic alpha-amylase with a novel (Ca,Zn) two-metal center by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; PYROCOCCUS-FURIOSUS; CRYSTAL-STRUCTURE; METHANOL DEHYDROGENASE; MOLECULAR-STRUCTURE; ACTIVE-SITE; ENZYMES; EXPRESSION; CALCIUM; PURIFICATION	The crystal structure of the alpha-amylase from the hyper-thermophilic archaeon Pyrococcus woesei was solved in the presence of three inhibitors: acarbose, Tris, and zinc. In the absence of exogenous metals, this a-amylase bound 1 and 4 molar eq of zinc and calcium, respectively. The structure reveals a novel, activating, two-metal (Ca,Zn)-binding site and a second inhibitory zinc-binding site that is found in the -1 sugar-binding pocket within the active site. The data resolve the apparent paradox between the zinc requirement for catalytic activity and its strong inhibitory effect when added in molar excess. They provide a rationale as to why this alpha-amylase, in contrast to commercially available alpha-amylases, does not require the addition of metal ions for full catalytic activity, suggesting it as an ideal target to maximize the efficiency of industrial processes like liquefaction of starch.	DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Tech Univ Hamburg, Dept Tech Microbiol, D-21073 Hamburg, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Hamburg University of Technology	Wilmanns, M (corresponding author), DESY, European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.	wilmanns@embl-hamburg.de	Meyer-Klaucke, Wolfram/G-1148-2010; Mayans, Olga/A-3954-2008	Wilmanns, Matthias/0000-0002-4643-5435; Mayans, Olga/0000-0001-6876-8532				Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; Aghajari N, 2002, BIOCHEMISTRY-US, V41, P4273, DOI 10.1021/bi0160516; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; Bertoldo C, 2002, CURR OPIN CHEM BIOL, V6, P151, DOI 10.1016/S1367-5931(02)00311-3; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; Brayer GD, 2000, BIOCHEMISTRY-US, V39, P4778, DOI 10.1021/bi9921182; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; Butz T, 2000, NUCL INSTRUM METH B, V161, P323, DOI 10.1016/S0168-583X(99)00898-8; Dauter Z, 1999, BIOCHEMISTRY-US, V38, P8385, DOI 10.1021/bi990256l; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dong GQ, 1997, APPL ENVIRON MICROB, V63, P3569, DOI 10.1128/AEM.63.9.3569-3576.1997; Eichler J, 2001, BIOTECHNOL ADV, V19, P261, DOI 10.1016/S0734-9750(01)00061-1; Feese MD, 2000, J MOL BIOL, V301, P451, DOI 10.1006/jmbi.2000.3977; GHOSH M, 1995, STRUCTURE, V3, P177, DOI 10.1016/S0969-2126(01)00148-4; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gilles C, 1996, EUR J BIOCHEM, V238, P561, DOI 10.1111/j.1432-1033.1996.0561z.x; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HONDA S, 1987, J CHROMATOGR-BIOMED, V419, P51, DOI 10.1016/0378-4347(87)80265-7; IRSHAD M, 1981, PHYTOCHEMISTRY, V20, P2123, DOI 10.1016/0031-9422(81)80097-0; Janecek S, 1999, J MOL EVOL, V48, P421, DOI 10.1007/PL00006486; Janecek S, 1997, PROG BIOPHYS MOL BIO, V67, P67, DOI 10.1016/S0079-6107(97)00015-1; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen S, 1997, J BIOL CHEM, V272, P16335, DOI 10.1074/jbc.272.26.16335; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; Keitel T, 2000, J MOL BIOL, V297, P961, DOI 10.1006/jmbi.2000.3603; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; Linden A, 2000, J CHROMATOGR B, V737, P253, DOI 10.1016/S0378-4347(99)00364-3; Machius M, 1998, STRUCTURE, V6, P281, DOI 10.1016/S0969-2126(98)00032-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niehaus F, 1999, APPL MICROBIOL BIOT, V51, P711, DOI 10.1007/s002530051456; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Pujadas G, 2001, MOL BIOL EVOL, V18, P38, DOI 10.1093/oxfordjournals.molbev.a003718; Savchenko A, 2002, BIOCHEMISTRY-US, V41, P6193, DOI 10.1021/bi012106s; Sevcik J, 1998, ACTA CRYSTALLOGR D, V54, P854, DOI 10.1107/S0907444998002005; Skov LK, 2001, J BIOL CHEM, V276, P25273, DOI 10.1074/jbc.M010998200; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VALLEE BL, 1959, J BIOL CHEM, V234, P2901; Vallee F, 1998, STRUCTURE, V6, P649, DOI 10.1016/S0969-2126(98)00066-5; van der Maarel MJEC, 2002, J BIOTECHNOL, V94, P137, DOI 10.1016/S0168-1656(01)00407-2; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; WANG LH, 1976, APPL ENVIRON MICROB, V31, P108, DOI 10.1128/AEM.31.1.108-118.1976	51	86	96	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9875	9884		10.1074/jbc.M211339200	http://dx.doi.org/10.1074/jbc.M211339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12482867	hybrid			2022-12-25	WOS:000181524000134
J	Rosengren, KJ; Daly, NL; Plan, MR; Waine, C; Craik, DJ				Rosengren, KJ; Daly, NL; Plan, MR; Waine, C; Craik, DJ			Twists, knots, and rings in proteins - Structural definition of the cyclotide framework	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN COUPLING-CONSTANTS; CYSTINE KNOT; MACROCYCLIC PEPTIDES; PLANT CYCLOTIDES; 3-DIMENSIONAL STRUCTURE; BETA-SHEET; NMR; POLYPEPTIDES; CIRCULIN; COSY	In recent years an increasing number of miniproteins containing an amide-cyclized backbone have been discovered. The cyclotide family is the largest group of such proteins and is characterized by a circular protein backbone and six conserved cysteine residues linked by disulfide bonds in a tight core of the molecule. These form a cystine knot in which an embedded ring formed by two of the disulfide bonds and the connecting backbone segment is threaded by a third disulfide bond. In the current study we have undertaken high resolution structural analysis of two prototypic cyclotides, kalata B1 and cycloviolacin O1, to define the role of the conserved residues in the sequence. We provide the first comprehensive analysis of the topological features in this unique family of proteins, namely rings (a circular backbone), twists (a cis-peptide bond in the Mobius cyclotides) and knots (a knotted arrangement of the disulfide bonds).	Univ Queensland, Australian Council Special Res Ctr Funct & Appl G, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland		d.craik@imb.uq.edu.au	Craik, David/B-1695-2010; Daly, Norelle L/D-4302-2013; Rosengren, K. Johan/P-4450-2016	Craik, David/0000-0003-0007-6796; Daly, Norelle L/0000-0002-4697-6602; Rosengren, K. Johan/0000-0002-5007-8434				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bokesch HR, 2001, J NAT PROD, V64, P249, DOI 10.1021/np000372l; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Broussalis AM, 2001, PHYTOCHEMISTRY, V58, P47, DOI 10.1016/S0031-9422(01)00173-X; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Cierpicki T, 2001, J BIOMOL NMR, V21, P249, DOI 10.1023/A:1012911329730; Claeson P, 1998, J NAT PROD, V61, P77, DOI 10.1021/np970342r; COOKE RM, 1992, PROTEIN ENG, V5, P473, DOI 10.1093/protein/5.6.473; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P1809, DOI 10.1016/S0041-0101(01)00129-5; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Daly NL, 2000, J BIOL CHEM, V275, P19068, DOI 10.1074/jbc.M000450200; Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200; Goransson U, 1999, J NAT PROD, V62, P283, DOI 10.1021/np9803878; Gran L, 2000, J ETHNOPHARMACOL, V70, P197, DOI 10.1016/S0378-8741(99)00175-0; Gran L., 1970, MEDD NOR FARM SELSK, V12, P173; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Gustafson KR, 2000, J NAT PROD, V63, P176, DOI 10.1021/np990432r; Hallock YF, 2000, J ORG CHEM, V65, P124, DOI 10.1021/jo990952r; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; Schoepke T., 1993, SCI PHARM, V61, P145; Skjeldal L, 2002, ARCH BIOCHEM BIOPHYS, V399, P142, DOI 10.1006/abbi.2002.2769; Sletten K., 1973, MEDD FARM SELSK, V7, P69; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Trabi M, 2001, BIOCHEMISTRY-US, V40, P4211, DOI 10.1021/bi002028t; Tran D, 2002, J BIOL CHEM, V277, P3079, DOI 10.1074/jbc.M109117200; WAGNER G, 1990, PROG NUCL MAG RES SP, V22, P101, DOI 10.1016/0079-6565(90)80003-Z; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002	44	271	276	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8606	8616		10.1074/jbc.M211147200	http://dx.doi.org/10.1074/jbc.M211147200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12482868	hybrid			2022-12-25	WOS:000181466800111
J	Moon, YA; Horton, JD				Moon, YA; Horton, JD			Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; ACID ELONGATION; LIPID-SYNTHESIS; STEROID 5-ALPHA-REDUCTASE; ADIPOSE-TISSUE; MESSENGER-RNA; GENE FAMILY; LIVER; CHOLESTEROL	The de novo synthesis of fatty acids occurs in two distinct cellular compartments. Palmitate (16:0) is synthesized from acetyl-CoA and malonyl-CoA in the cytoplasm by the enzymes acetyl-CoA carboxylase 1 and fatty acid synthase. The synthesis of fatty acids longer than 16 carbons takes place in microsomes and utilizes malonyl-CoA as the carbon source. Each two-carbon addition requires four sequential reactions: condensation, reduction, dehydration, and a final reduction to form the elongated fatty acyl-CoA. The initial condensation reaction is the regulated and rate-controlling step in microsomal fatty acyl elongation. We previously reported the cDNA cloning and characterization of a murine long chain fatty acyl elongase.(LCE) (1). Overexpression of LCE in cells resulted in the enhanced addition of two-carbon units to C12-C16 fatty acids, and evidence was provided that LCE catalyzed the initial condensation reaction of long chain fatty acid elongation. The remaining three enzymes in the elongation reaction have not been identified in mammals. Here, we report the identification and characterization of two mammalian enzymes that catalyze the 3-ketoacyl-CoA and trans-2,3-enoyl-CoA reduction reactions in long and very long chain fatty acid elongation, respectively.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Moon, YA (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NHLBI NIH HHS [HL-20948, HL-38049] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL038049] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; APRAHAMIAN SA, 1982, COMP BIOCH PHYSL B, V71, P557; Beaudoin F, 2002, J BIOL CHEM, V277, P11481, DOI 10.1074/jbc.M111441200; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; GEISSLER WM, 1994, NAT GENET, V7, P34, DOI 10.1038/ng0594-34; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; Han GS, 2002, J BIOL CHEM, V277, P35440, DOI 10.1074/jbc.M205620200; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JOHNSTON IG, 1992, J NEUROSCI RES, V32, P159, DOI 10.1002/jnr.490320205; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Knoll A, 1999, NEUROCHEM INT, V34, P255, DOI 10.1016/S0197-0186(99)00005-4; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Matsuzaka T, 2002, J LIPID RES, V43, P911; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; NUGTEREN DH, 1965, BIOCHIM BIOPHYS ACTA, V106, P280, DOI 10.1016/0005-2760(65)90036-6; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SUNEJA SK, 1990, BIOCHIM BIOPHYS ACTA, V1042, P81, DOI 10.1016/0005-2760(90)90059-7; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817	34	165	175	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7335	7343		10.1074/jbc.M211684200	http://dx.doi.org/10.1074/jbc.M211684200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482854	hybrid			2022-12-25	WOS:000181195100091
J	Han, D; Antunes, F; Canali, R; Rettori, D; Cadenas, E				Han, D; Antunes, F; Canali, R; Rettori, D; Cadenas, E			Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; RAT-LIVER; CU,ZN-SUPEROXIDE DISMUTASE; INTERMEMBRANE SPACE; HEART-MITOCHONDRIA; RESPIRATORY-CHAIN; MEMBRANE CHANNEL; OUTER-MEMBRANE; CYTOCHROME-C; HEPG2 CELLS	Several reactions in biological systems contribute to maintain the steady-state concentrations of superoxide anion (O-2(radical anion)) and hydrogen peroxide (H2O2). The electron transfer chain of mitochondria is a well documented source of H2O2; however, the release of O-2(radical) (anion) from mito chondria into cytosol has not been unequivocally established. This study was aimed at validating mitochondria as sources of cytosolic O-2(radical anion) elucidating the mechanisms underlying the release of W from mitochondria into cytosol, and assessing the role of outer membrane voltage-dependent anion channels (VDACs) in this process. Isolated rat heart mitochondria supplemented with complex I or II substrates generate an EPR signal ascribed to O-2(radical anion) Inhibition of the signal in a concentration-depend ent manner by both manganese-superoxide dismutase and cytochrome c proteins that cannot cross the mitochondrial membrane supports the extramitochondrial location of the spin adduct. Basal rates of O-2(radical anion) release from mitochondria were estimated at similar to0.04 nmol/ min/mg protein, a value increased similar to8-fold by the complex III inhibitor, antimycin A. These estimates, obtained by quantitative spin-trapping EPR, were confirmed by fluorescence techniques, mainly hydroethidine oxidation and horseradish peroxidase-based p-hydroxyphylacetate dimerization. Inhibitors of VDAC, 4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS), and dextran sulfate (in a voltage-dependent manner) inhibited O-2(radical anion) production from mitochondria by similar to55%, thus suggesting that a large portion of O-2(radical anion) exited mito chondria via these channels. These findings are discussed in terms of competitive decay pathways for O-2(radical anion) in the intermembrane space and cytosol as well as the implications of these processes for modulating cell signaling pathways in these compartments.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Res Ctr Liver Dis, Los Angeles, CA 90089 USA; Univ Lisbon, Fac Ciencias, Dept Quim & Bioquim, P-174906 Lisbon, Portugal	University of Southern California; University of Southern California; Universidade de Lisboa	Cadenas, E (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave, Los Angeles, CA 90089 USA.	cadenas@usc.edu	Antunes, Fernando/A-1030-2009; Rettori, Daniel/F-4596-2012; Canali, Raffaella/AAA-3965-2020	Antunes, Fernando/0000-0002-4192-2840; Canali, Raffaella/0000-0003-0012-4831	NIA NIH HHS [R01 AG 16718] Funding Source: Medline; NIEHS NIH HHS [R01 ES 11342] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016718] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antos N, 2001, J BIOENERG BIOMEMBR, V33, P119, DOI 10.1023/A:1010748431000; Antunes F, 1996, FREE RADICAL BIO MED, V21, P917, DOI 10.1016/S0891-5849(96)00185-2; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Bai JX, 2000, J BIOL CHEM, V275, P19241, DOI 10.1074/jbc.M000438200; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; Boveris A, 1977, Adv Exp Med Biol, V78, P67; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Boveris A, 1997, OXYGEN GENE EXPRESSI, P1; BUTLER J, 1982, J BIOL CHEM, V257, P747; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; COLOMBINI M, 1987, J BIOENERG BIOMEMBR, V19, P309, DOI 10.1007/BF00768534; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DEVRIES S, 1986, J BIOENERG BIOMEMBR, V18, P195, DOI 10.1007/BF00743464; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FORMAN HJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P396, DOI 10.1016/0003-9861(73)90636-X; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GELLER BL, 1982, J BIOL CHEM, V257, P8945; GUSKOVA RA, 1984, BIOCHIM BIOPHYS ACTA, V778, P579, DOI 10.1016/0005-2736(84)90409-7; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; Inarrea P, 2002, METHOD ENZYMOL, V349, P106, DOI 10.1016/S0076-6879(02)49326-3; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; LENAZ G, 1988, J MEMBRANE BIOL, V104, P193, DOI 10.1007/BF01872322; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MANGAN PS, 1987, P NATL ACAD SCI USA, V84, P4896, DOI 10.1073/pnas.84.14.4896; Mannella CA, 1998, J STRUCT BIOL, V121, P207, DOI 10.1006/jsbi.1997.3954; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Perkins GA, 1997, J STRUCT BIOL, V120, P219, DOI 10.1006/jsbi.1997.3920; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Shafir I, 1998, J BIOENERG BIOMEMBR, V30, P499, DOI 10.1023/A:1020598315287; Sharp RE, 1999, J BIOENERG BIOMEMBR, V31, P225, DOI 10.1023/A:1005467628660; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V28, P127; STUART RA, 1990, J BIOL CHEM, V265, P20210; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793	55	541	557	3	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5557	5563		10.1074/jbc.M210269200	http://dx.doi.org/10.1074/jbc.M210269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482755	hybrid			2022-12-25	WOS:000181129400012
J	Louis, JM; Ishima, R; Nesheiwat, I; Pannell, LK; Lynch, SM; Torchia, DA; Gronenborn, AM				Louis, JM; Ishima, R; Nesheiwat, I; Pannell, LK; Lynch, SM; Torchia, DA; Gronenborn, AM			Revisiting monomeric HIV-1 protease - Characterization and redesign for improved properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 PROTEASE; HUMAN-IMMUNODEFICIENCY; PROTEINASES; SUBSTRATE; SEQUENCES; STABILITY; COMPLEX	Interactions between the C-terminal interface residues (96-99) of the mature HIV-1 protease were shown to be essential for dimerization, whereas the N-terminal residues (1-4) and Arg(87) contribute to dimer stability (Ishima, R., Ghirlando, R., Tozser, J., Gronenborn, A. M., Torchia, D. A., and Louis, J. M. (2001) J. Biol. Chem. 276, 49110-49116). Here we show that the intramonomer interaction between the side chains of Asp(29) and Arg(87) influences dimerization significantly more than the intermonomer interaction between Asp29 and Arg8'. Several mutants, including T26A, destablize the dimer, exhibit a monomer fold, and are prone to aggregation. To alleviate this undesirable property, we designed proteins in which the N- and C-terminal regions can be linked intramolecularly by disulfide bonds. In particular, cysteine residues were introduced at positions 2 and 97 or 98. A procedure for the efficient preparation of intrachain-linked polypeptides is presented, and it is demonstrated that the Q2C/L97C variant exhibits a native-like single subunit fold. It is anticipated that monomeric proteases of this kind will aid in the discovery of novel inhibitors aimed at binding to the monomer at the dimerization interface. This extends the target area of current inhibitors, all of which bind across the active site formed by both subunits in the active dimer.	NIDCR, Struct Mol Biol Unit, NIH, Bethesda, MD 20892 USA; NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ishima, R (corresponding author), NIDCR, Struct Mol Biol Unit, NIH, Bldg 30,Rm 109, Bethesda, MD 20892 USA.	rishima@dir.nidcr.nih.gov		Louis, John M/0000-0002-0052-1899; Gronenborn, Angela M/0000-0001-9072-3525	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029022, Z01DK029025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cartas M, 2001, DNA CELL BIOL, V20, P797, DOI 10.1089/104454901753438615; Condra JH, 1998, HAEMOPHILIA, V4, P610, DOI 10.1046/j.1365-2516.1998.440610.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRANT SK, 1992, BIOCHEMISTRY-US, V31, P9491, DOI 10.1021/bi00154a023; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Ishima R, 2001, J BIOL CHEM, V276, P49110, DOI 10.1074/jbc.M108136200; Kuiken C, 2001, HIV SEQUENCE COMPEND; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; Louis JM, 1999, NAT STRUCT BIOL, V6, P868; LOUIS JM, 1989, BIOCHEM BIOPH RES CO, V164, P30, DOI 10.1016/0006-291X(89)91678-1; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; Schramm HJ, 1996, ANTIVIR RES, V30, P155, DOI 10.1016/0166-3542(96)00940-0; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; Tozser J, 2001, ANN NY ACAD SCI, V946, P145, DOI 10.1111/j.1749-6632.2001.tb03909.x; Vondrasek J, 1997, NAT STRUCT BIOL, V4, P8, DOI 10.1038/nsb0197-8; WEBER IT, 1990, J BIOL CHEM, V265, P10492; Wondrak EM, 1996, BIOCHEMISTRY-US, V35, P12957, DOI 10.1021/bi960984y	25	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6085	6092		10.1074/jbc.M209726200	http://dx.doi.org/10.1074/jbc.M209726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12468541	hybrid			2022-12-25	WOS:000181129400075
J	Shen, H; Smith, DE; Keep, RF; Xiang, JM; Brosius, FC				Shen, H; Smith, DE; Keep, RF; Xiang, JM; Brosius, FC			Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in choroid plexus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; PEPTIDE/HISTIDINE TRANSPORTER; GLYCYLSARCOSINE TRANSPORT; EXPRESSION CLONING; ACE-INHIBITORS; KIDNEY; INTESTINE	The presence of multiple oligopeptide transporters in brain has generated considerable interest as to their physiological role in neuropeptide homeostasis, pharmacologic importance, and potential as a target for drug delivery through the blood-brain and blood-cerebrospinal fluid barriers. To understand further the purpose of specific peptide transporters in brain, we have generated PEPT2-deficient mice by targeted gene disruption. Homozygous PepT2 null mice lacked expression of PEPT2 mRNA and protein in choroid plexus and kidney, tissues in which PepT2 is normally expressed, whereas heterozygous mice displayed PepT2 expression levels that were intermediate between those of wild-type and homozygous null animals. Mutant PepT2 null mice were found to be viable, grew to normal size and weight, and were without obvious kidney or brain abnormalities. Notwithstanding the lack of apparent biological effects, the proton-stimulated uptake of 1.9 mum glycylsarcosine (a model, hydrolysis-resistant dipeptide) in isolated choroid plexus was essentially ablated (ie. residual activity of 10.9 and 3.9% at 5 and 30 min, respectively). These novel findings provide strong evidence that, under the experimental conditions of this study, PEPT2 is the primary member of the peptide transporter family responsible for dipeptide uptake in choroid plexus tissue.	Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Smith, DE (corresponding author), Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 4302A Upjohn Ctr,1310 E Catherine St, Ann Arbor, MI 48109 USA.	smithb@umich.edu		Keep, Richard/0000-0001-6441-5334	NHLBI NIH HHS [P01 HL018575] Funding Source: Medline; NIGMS NIH HHS [R01 GM035498] Funding Source: Medline; NINDS NIH HHS [R01 NS034709] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034709] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akarawut W, 1998, J PHARMACOL EXP THER, V287, P684; Berger UV, 1999, ANAT EMBRYOL, V199, P439, DOI 10.1007/s004290050242; Boll M, 1996, P NATL ACAD SCI USA, V93, P284, DOI 10.1073/pnas.93.1.284; Daniel H, 1996, J MEMBRANE BIOL, V154, P197, DOI 10.1007/s002329900144; Daniel H, 1997, AM J PHYSIOL-RENAL, V273, pF1, DOI 10.1152/ajprenal.1997.273.1.F1; Fei YJ, 2000, BBA-GENE STRUCT EXPR, V1492, P145, DOI 10.1016/S0167-4781(00)00101-9; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Ganapathy ME, 1998, BIOCHEM BIOPH RES CO, V246, P470, DOI 10.1006/bbrc.1998.8628; GhersiEgea JF, 1995, TOXICOL LETT, V82-3, P645, DOI 10.1016/0378-4274(95)03510-9; Hakvoort A, 1998, J NEUROCHEM, V71, P1141; Johanson CE, 1999, ENCY NEUROSCIENCE, V1, P384; Laterra John, 1999, P671; Leibach FH, 1996, ANNU REV NUTR, V16, P99, DOI 10.1146/annurev.nu.16.070196.000531; Lin CJ, 1999, PHARM RES-DORDR, V16, P609, DOI 10.1023/A:1018847818766; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; Novotny A, 2000, J NEUROCHEM, V75, P321, DOI 10.1046/j.1471-4159.2000.0750321.x; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Rubio-Aliaga I, 2000, BIOCHEM BIOPH RES CO, V276, P734, DOI 10.1006/bbrc.2000.3546; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; Saito H, 1995, J PHARMACOL EXP THER, V275, P1631; Sakata K, 2001, BIOCHEM J, V356, P53, DOI 10.1042/0264-6021:3560053; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Shen H, 2001, PEDIATR RES, V49, P789, DOI 10.1203/00006450-200106000-00013; Shen H, 1999, AM J PHYSIOL-RENAL, V276, pF658, DOI 10.1152/ajprenal.1999.276.5.F658; Shu C, 2002, J PHARMACOL EXP THER, V301, P820, DOI 10.1124/jpet.301.3.820; Smith DE, 1998, PHARM RES-DORDR, V15, P1244, DOI 10.1023/A:1011996009332; Strazielle N, 1999, J NEUROSCI, V19, P6275; Sugawara M, 2000, J PHARM SCI-US, V89, P781, DOI 10.1002/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7; Teuscher NS, 2000, J PHARMACOL EXP THER, V294, P494; Teuscher NS, 2001, PHARMACEUT RES, V18, P807, DOI 10.1023/A:1011088413043; Wang H, 1998, AM J PHYSIOL-CELL PH, V275, pC967, DOI 10.1152/ajpcell.1998.275.4.C967; Yamashita T, 1997, J BIOL CHEM, V272, P10205; Zhu T, 2000, PHARM RES-DORDR, V17, P526, DOI 10.1023/A:1007556630189; [No title captured]	34	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4786	4791		10.1074/jbc.M207397200	http://dx.doi.org/10.1074/jbc.M207397200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473671	hybrid			2022-12-25	WOS:000180968900057
J	Stedman, TT; Sussmann, AR; Joiner, KA				Stedman, TT; Sussmann, AR; Joiner, KA			Toxoplasma gondii Rab6 mediates a retrograde pathway for sorting of constitutively secreted proteins to the Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE GRANULE PROTEINS; KINESIN-LIKE PROTEIN; GTP-BINDING PROTEIN; TRANS-GOLGI; SACCHAROMYCES-CEREVISIAE; PARASITOPHOROUS VACUOLE; ENDOPLASMIC-RETICULUM; YPT6P; MECHANISMS; CELL	Toxoplasma gondii relies on protein secretion from specialized organelles for invasion of host cells and establishment of a parasitophorous vacuole. We identify T. gondii Rab6 as a regulator of protein transport between post-Golgi dense granule organelles and the Golgi. Toxoplasma Rab6 was localized to cisternal rims of the late Golgi and trans-Golgi network, associated transport vesicles, and microdomains of dense granule and endosomal membranes. Overexpression of wildtype Rab6 or GTP-activated Rab6(Q70L) rerouted soluble dense granule secretory proteins to the Golgi and endoplasmic reticulum and augmented the effect of brefeldin A on Golgi resorption to the endoplasmic reticulum. Parasites expressing a nucleotide-free (Rab6(N124I)) or a GDP-bound (Rab6(T25N)) mutant accumulated dense granule proteins in the Golgi and associated transport vesicles and displayed reduced secretion of GRA4 and a delay in glycosylation of GRA2. Activated Rab6 on Golgi membranes colocalized with centrin during mitosis, and parasite clones expressing Rab6 mutants displayed a partial shift in cytokinesis from endodyogeny (formation of two daughter cells) to endopolygeny (multiple daughter cells). We propose that Toxoplasma Rab6 regulates retrograde transport from post-Golgi secretory granules to the parasite Golgi.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Stedman, TT (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,LCI 808,POB 208022, New Haven, CT 06520 USA.		Joiner, Keith/AAH-1059-2021	Stedman, Timothy/0000-0002-5847-7931; Joiner, Keith/0000-0003-3062-823X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009938, R01AI030060] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI30060, 1F32 AI09938-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHBAROU A, 1991, PARASITOLOGY, V103, P321, DOI 10.1017/S0031182000059837; Bensen ES, 2001, MOL BIOL CELL, V12, P13, DOI 10.1091/mbc.12.1.13; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chaturvedi S, 1999, J BIOL CHEM, V274, P2424, DOI 10.1074/jbc.274.4.2424; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; DERETIC D, 1993, J CELL SCI, V106, P803; Di Cristina M, 2000, MOL CELL BIOL, V20, P7332, DOI 10.1128/MCB.20.19.7332-7341.2000; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; Echard A, 2000, MOL BIOL CELL, V11, P3819, DOI 10.1091/mbc.11.11.3819; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Fontijn RD, 2001, MOL CELL BIOL, V21, P2944, DOI 10.1128/MCB.21.8.2944-2955.2001; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; Gotte M, 2000, Subcell Biochem, V34, P133; Hager KM, 1999, J CELL SCI, V112, P2631; Hill E, 2000, EMBO J, V19, P5711, DOI 10.1093/emboj/19.21.5711; Hoppe HC, 2000, NAT CELL BIOL, V2, P449, DOI 10.1038/35017090; Hu K, 2002, MOL BIOL CELL, V13, P593, DOI 10.1091/mbc.01-06-0309; Iida H, 1997, AM J PHYSIOL-CELL PH, V272, pC1594, DOI 10.1152/ajpcell.1997.272.5.C1594; Joiner KA, 2002, J CELL BIOL, V157, P557, DOI 10.1083/jcb.200112144; Karsten V, 1998, J CELL BIOL, V141, P1323, DOI 10.1083/jcb.141.6.1323; Karsten V, 1997, METHODS, V13, P103, DOI 10.1006/meth.1997.0503; Labruyere E, 1999, MOL BIOCHEM PARASIT, V102, P311, DOI 10.1016/S0166-6851(99)00092-4; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; Lecordier L, 1999, MOL BIOL CELL, V10, P1277, DOI 10.1091/mbc.10.4.1277; Li BJ, 1998, YEAST, V14, P915, DOI 10.1002/(SICI)1097-0061(199807)14:10<915::AID-YEA291>3.3.CO;2-P; Li BJ, 1996, J BIOL CHEM, V271, P16813, DOI 10.1074/jbc.271.28.16813; Liendo A, 2001, J BIOL CHEM, V276, P18272, DOI 10.1074/jbc.M008352200; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mercier C, 1998, J CELL SCI, V111, P2171; Robibaro B, 2002, CELL MICROBIOL, V4, P139, DOI 10.1046/j.1462-5822.2002.00178.x; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Sambrook J., 2002, MOL CLONING LAB MANU; Shaw MK, 2000, J CELL SCI, V113, P1241; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; Stedman TT, 1999, ADV CELL MOL BIOL ME, V6, P233, DOI 10.1016/S1874-5172(99)80014-5; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; TIXIERVIDAL A, 1993, J CELL SCI, V105, P935; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; Tsukada M, 1996, J CELL SCI, V109, P2471; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; Zinecker CF, 1998, MOL BIOCHEM PARASIT, V97, P241, DOI 10.1016/S0166-6851(98)00136-4	47	30	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5433	5443		10.1074/jbc.M209390200	http://dx.doi.org/10.1074/jbc.M209390200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468555	hybrid			2022-12-25	WOS:000180968900136
J	Sumanasekera, WK; Tien, ES; Turpey, R; Vanden Heuvel, JP; Perdew, GH				Sumanasekera, WK; Tien, ES; Turpey, R; Vanden Heuvel, JP; Perdew, GH			Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; THYROID-HORMONE RECEPTOR; GLUCOCORTICOID RECEPTOR; AH RECEPTOR; PROGESTERONE-RECEPTOR; NUCLEAR RECEPTORS; CYCLOSPORINE-A; CORE COMPLEX; IN-VIVO; HSP90	The peroxisome proliferator-activated receptor a (PPARalpha) is a ligand-inducible transcription factor, which belongs to the nuclear receptor superfamily. PPARalpha mediates the carcinogenic effects of peroxisome proliferators in rodents. In humans, PPARalpha plays a fundamental role in regulating energy homeostasis via control of lipid metabolism. To study the possible role of chaperone proteins in the regulation of PPARalpha activity, a monoclonal antibody (mAb) was made against PPARalpha and designated as 3B6/PPAR. The specificity of mAb 3B6/PPAR in recognizing PPARalpha was tested in immuno-precipitations using in vitro translated PPAR subtypes. The mAb 3B6/PPAR recognized PPARalpha, failed to bind to PPARbeta or PPARgamma, and is efficient in both immunoprecipitating and visualizing the receptor on protein blots. The immunoprecipitation of PPARalpha in mouse liver cytosol using mAb 3B6/PPAR has resulted in the detection of two co-immunoprecipitated proteins, which are heat shock protein 90 (hsp90) and the hepatitis B virus X-associated protein 2 (XAP2). The concomitant depletion of PPARalpha in hsp90-depleted mouse liver cytosol was also detected. Complex formation between XAP2 and PPARalpha/FLAG was also demonstrated in an in vitro translation binding assay. hsp90 interacts with PPARalpha in a mammalian two-hybrid assay and binds to the E/F domain. Transient expression of XAP2 co-expressed with PPARalpha resulted in down-regulation of a peroxisome proliferator response element-driven reporter gene activity. Taken together, these results indicate that PPARalpha is in a complex with hsp90 and XAP2, and XAP2 appears to function as a repressor. This is the first demonstration that PPARalpha is stably associated with other proteins in tissue extracts and the first nuclear receptor shown to functionally interact with XAP2.	Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Fenske Lab 226, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Grad Program Mol Toxicol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Perdew, GH (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Fenske Lab 226, University Pk, PA 16802 USA.				NIEHS NIH HHS [ES07799] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007799] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASHBY J, 1994, HUM EXP TOXICOL S2, V13, P1; Auwerx J, 1999, CELL, V97, P161; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Cattley RC, 1998, REGUL TOXICOL PHARM, V27, P47, DOI 10.1006/rtph.1997.1163; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; HORD NG, 1994, MOL PHARMACOL, V46, P618; HUANG Q, 1994, J BIOL CHEM, V269, P8493; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; Kashuba E, 2000, ONCOGENE, V19, P1801, DOI 10.1038/sj.onc.1203501; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 2000, CELL STRESS CHAPERON, V5, P243, DOI 10.1379/1466-1268(2000)005<0243:AHARLA>2.0.CO;2; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; MILAD M, 1995, MOL ENDOCRINOL, V9, P838, DOI 10.1210/me.9.7.838; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Perdew GH, 1996, BIOCHEM MOL BIOL INT, V39, P589; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Petrulis JR, 2000, J BIOL CHEM, V275, P37448, DOI 10.1074/jbc.M006873200; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PRIVALSKY ML, 1991, J BIOL CHEM, V266, P1456; Rao J, 2001, J BIOL CHEM, V276, P5814, DOI 10.1074/jbc.M007385200; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; SANCHEZ ER, 1987, MOL ENDOCRINOL, V1, P908, DOI 10.1210/mend-1-12-908; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Sladek R, 2000, ADV PHARMACOL, V47, P23; SMITH DF, 1993, J BIOL CHEM, V268, P18365; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; Willhite CC, 2001, TOXICOLOGY, V160, P219, DOI 10.1016/S0300-483X(00)00451-0; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	51	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4467	4473		10.1074/jbc.M211261200	http://dx.doi.org/10.1074/jbc.M211261200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12482853	hybrid			2022-12-25	WOS:000180968900016
J	Xie, Y; Zhong, R; Chen, CM; Calderwood, SK				Xie, Y; Zhong, R; Chen, CM; Calderwood, SK			Heat shock factor 1 contains two functional domains that mediate transcriptional repression of the c-fos and c-fms genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROINTERLEUKIN 1-BETA GENE; DNA-BINDING ABILITY; NF-KAPPA-B; C/EBP-BETA; FACTOR-I; ACTIVATION; PROTEIN; STRESS; EXPRESSION; PHOSPHORYLATION	Heat shock factor I (HSF1), in addition to its pivotal role as a regulator of the heat shock response, functions as a versatile gene repressor. We have investigated the structural domains involved in gene repression using mutational analysis of the hsf1 gene. Our studies indicate that HSF1 contains two adjacent sequences located within the N-terminal half of the protein that mediate the repression of c-fos and c-fins. One region (NF) appears to be involved in quenching transcriptional activation factors on target promoters and binds to the basic zipper transcription factor NF-IL6 required for activation of c-fins and IL-1beta. The NF domain encompasses the leucine zipper 1 and 2 sequences as well as the linker domain between the DNA binding and leucine zipper regions. The function of this domain in gene repression is highly specific for HSF1, and the homologous region from conserved family member HSF2 does not restore repressive function in HSF2/HSF1 chimeras. In addition, HSF2 is not capable of binding to NF-IL6. The NF domain, although necessary for repression, is not sufficient, and a second region (REP) occupying a portion of the regulatory domain is required for repression. Neither domain functions independently, and both are required for repression. Furthermore, we constructed dominant inhibitors of c-fos repression by HSF1, which also blocked the repression of c-fins and IL-1beta, suggesting a shared mechanism for repression of these genes by HSF1. Our studies suggest a complex mechanism for gene repression by HSF1 involving the binding to and quenching of activating factors on target promoters. Mapping the structural domains involved in this process should permit further characterization of molecular mechanisms that mediate repression.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Mol & Cellular Biol Lab, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Calderwood, SK (corresponding author), Boston Univ, Sch Med, Ctr Mol Stress Response, 88 E Newton St, Boston, MA 02118 USA.				NCI NIH HHS [CA31303, CA50642, CA47407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050642, P01CA031303, R01CA047407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Bruce JL, 1999, CELL STRESS CHAPERON, V4, P36, DOI 10.1054/csac.1999.0005; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Cahill CM, 1997, ADV EXP MED BIOL, V400, P625; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; GREEN M, 1995, MOL CELL BIOL, V15, P3354; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; He HY, 2000, CELL STRESS CHAPERON, V5, P406, DOI 10.1379/1466-1268(2000)005<0406:HAHSFC>2.0.CO;2; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; MCKNIGHT SL, 1992, TRANSCRIPTIONAL REGU, V2, P771; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Newton EM, 1996, MOL CELL BIOL, V16, P839; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Peteranderl R, 1999, BIOCHEMISTRY-US, V38, P3559, DOI 10.1021/bi981774j; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; Xie Y, 2002, BIOCHEM BIOPH RES CO, V291, P1071, DOI 10.1006/bbrc.2002.6562; Xie Y, 2001, CURR TOP BIOCH RES, V4, P81; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	52	41	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4687	4698		10.1074/jbc.M210189200	http://dx.doi.org/10.1074/jbc.M210189200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468538	hybrid			2022-12-25	WOS:000180968900044
J	Andersson, KB; Kowenz-Leutz, E; Brendeford, EM; Tygsett, AHH; Leutz, A; Gabrielsen, OS				Andersson, KB; Kowenz-Leutz, E; Brendeford, EM; Tygsett, AHH; Leutz, A; Gabrielsen, OS			Phosphorylation-dependent down-regulation of c-Myb DNA binding is abrogated by a point mutation in the v-myb oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED TRANSCRIPTION ACTIVATION; AVIAN MYELOMONOCYTIC CELLS; PROTEIN-KINASE; NF-M; GENE-PRODUCT; MIM-1 GENE; IN-VITRO; HEMATOPOIETIC-CELLS; AUTOCRINE GROWTH; CHICK-EMBRYO	The viral Myb (v-Myb) oncoprotein of the avian myeloblastosis virus (AMV) is an activated form of the cellular transcription factor c-Myb causing acute monoblastic leukemia in chicken. Oncogenic v-Myb alterations include N- and C-terminal deletions as well as point mutations. Whereas truncations in Myb cause loss of various protein modifications, none of the point mutations in v-Myb has been directly linked to protein modifications. Here we show that the DNA-binding domain of c-Myb can be phosphorylated on serine 116 by the catalytic subunit of protein kinase A. Phosphorylation of Ser(116) differentially destabilizes a subtype of c-Myb-DNA complexes. The V117D mutation of the AMV v-Myb oncoprotein abolishes phosphorylation of the adjacent Ser(116) residue. Modification of Ser(116) was also detected in live cells in c-Myb, but not in AMV v-Myb. Phosphorylation-mimicking mutants of c-Myb failed to activate the resident mim-1 gene. Our data imply that protein kinase A or a kinase with similar specificity negatively regulates c-Myb function, including collaboration with C/EBP, and that the leukemogenic AMV v-Myb version evades inactivation by a point mutation that abolishes a phosphoacceptor consensus site. This suggests a novel link between Myb, a signal transduction pathway, cooperativity with C/EBP, and a point mutation in the myb oncogene.	Univ Oslo, Dept Biochem, N-0316 Oslo, Norway; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	University of Oslo; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gabrielsen, OS (corresponding author), Univ Oslo, Dept Biochem, POB 1041, N-0316 Oslo, Norway.	O.S.Gabrielsen@biokjemi.uio.no	Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X				Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Andersson KB, 1999, J BIOL CHEM, V274, P21986, DOI 10.1074/jbc.274.31.21986; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bergholtz S, 2001, NUCLEIC ACIDS RES, V29, P3546, DOI 10.1093/nar/29.17.3546; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; Brendeford EM, 1997, J BIOL CHEM, V272, P4436, DOI 10.1074/jbc.272.7.4436; BUCHER P, 1994, ISMB, V2, P53; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Clarke D, 2000, ONCOGENE, V19, P3343, DOI 10.1038/sj.onc.1203661; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GABRIELSEN OS, 2000, PROTEIN OLIGONUCLEOT, P5997; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Gupta MP, 2000, NUCLEIC ACIDS RES, V28, P3168, DOI 10.1093/nar/28.16.3168; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Husi H, 2001, TRENDS NEUROSCI, V24, P259, DOI 10.1016/S0166-2236(00)01792-6; Introna M, 1999, LEUKEMIA, V13, P1301, DOI 10.1038/sj.leu.2401492; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Labastie MC, 1998, BLOOD, V92, P3624, DOI 10.1182/blood.V92.10.3624.422k17_3624_3635; Lalli E, 1996, EMBO J, V15, P528, DOI 10.1002/j.1460-2075.1996.tb00385.x; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lipsick JS, 1996, ONCOGENE, V13, P223; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960-9822(99)80368-6; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Ording E, 1996, ONCOGENE, V13, P1043; QUEVA C, 1992, DEVELOPMENT, V114, P125; RAMSAY RG, 1995, ONCOGENE, V11, P2113; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Rosinski JA, 1998, J MOL EVOL, V46, P74, DOI 10.1007/PL00006285; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; STERNECK E, 1992, MOL CELL BIOL, V12, P1728, DOI 10.1128/MCB.12.4.1728; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Vorbrueggen G, 1996, BIOL CHEM, V377, P721, DOI 10.1515/bchm3.1996.377.11.721; Wang QF, 2000, MOL CELL BIOL, V20, P9203, DOI 10.1128/MCB.20.24.9203-9211.2000; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; Zargarian L, 1999, BIOCHEMISTRY-US, V38, P1921, DOI 10.1021/bi981199j; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zorbas M, 1999, ONCOGENE, V18, P5821, DOI 10.1038/sj.onc.1202971	69	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3816	3824		10.1074/jbc.M209404200	http://dx.doi.org/10.1074/jbc.M209404200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12456674	hybrid			2022-12-25	WOS:000180869700039
J	Jiang, HB; Wang, Y; Yu, XQ; Kanost, MR				Jiang, HB; Wang, Y; Yu, XQ; Kanost, MR			Prophenoloxidase-activating proteinase-2 from hemolymph of Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; HOLOTRICHIA-DIOMPHALIA LARVAE; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; TOBACCO HORNWORM; IMMUNE-RESPONSES; INSECT IMMUNITY; PURIFICATION; BACTERIA; COLEOPTERAN	Proteolytic activation of prophenoloxidase in insects is a component of the host defense system against invading pathogens and parasites. We have purified from hemolymph of the tobacco hornworm, Manduca sexta, a new serine proteinase that cleaves prophenoloxidase. This enzyme, designated prophenoloxidase-activating proteinase-2 (PAP-2), differs from another PAP, previously isolated from integuments of the same insect (PAP-1). PAP-2 contains two clip domains at its amino terminus and a catalytic domain at its carboxyl terminus, whereas PAP-1 has only one clip domain. Purified PAP-2 cleaved prophenoloxidase at Arg(51) but yielded a product that has little phenoloxidase activity. However, in the presence of two serine proteinase homologs, active phenoloxidase was generated at a much higher level, and it formed covalently linked, high molecular weight oligomers. The serine proteinase homologs associate with a bacteria-binding lectin in M. sexta hemolymph, indicating that they may be important for ensuring that the activation of prophenoloxidase occurs only in the vicinity of invading microorganisms. PAP-2 mRNA was not detected in naive larval fat body or hemocytes, but it became abundant in these tissues after the insects were injected with bacteria.	Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA; Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Kansas State University	Jiang, HB (corresponding author), Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA.		YU, XiaoQiang/GRJ-1077-2022; Jiang, Haobo/A-6519-2008; YU, XIAO-QIANG/AAL-1797-2021	YU, XIAO-QIANG/0000-0003-1419-9009; Kanost, Michael/0000-0002-6827-0061; Jiang, Haobo/0000-0003-1357-1315	NIGMS NIH HHS [R37 GM041247, GM41247, GM58634] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247, R01GM041247, R01GM058634, R29GM041247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashida M., 1990, P239; Ashida Masaaki, 1998, P135; Beck G, 1996, J BIOL CHEM, V271, P11035, DOI 10.1074/jbc.271.19.11035; CAESIUM N, 1999, FEBS LETT, V443, P139; Chen CL, 1999, COMP BIOCHEM PHYS B, V122, P309, DOI 10.1016/S0305-0491(99)00020-6; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Gorman MJ, 2001, INSECT BIOCHEM MOLEC, V31, P257, DOI 10.1016/S0965-1748(00)00145-4; Jiang H, 1996, INSECT MOL BIOL, V5, P31, DOI 10.1111/j.1365-2583.1996.tb00038.x; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P835, DOI 10.1016/S0965-1748(97)00066-0; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kanost MR, 2001, ADV EXP MED BIOL, V484, P319; Kanost MR, 1999, DEV COMP IMMUNOL, V23, P291, DOI 10.1016/S0145-305X(99)00012-9; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; NIGAM Y, 1996, NEW DIRECTIONS INVER, P399; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; Soderhall Kenneth, 1996, P229; SUGUMARAN M, 1993, PARASITES PATHOGENS, V1, P317; Sugumaran Manickam, 1996, P355; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; Vasta Gerardo R., 1996, P189; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; WANG Y, 1995, INSECT MOL BIOL, V4, P113, DOI 10.1111/j.1365-2583.1995.tb00015.x; Wang Y, 2001, PROTEIN EXPRES PURIF, V23, P328, DOI 10.1006/prep.2001.1517; Yu XQ, 2001, ADV EXP MED BIOL, V484, P191; Yu XQ, 2000, J BIOL CHEM, V275, P37373, DOI 10.1074/jbc.M003021200; YU XQ, 2003, IN PRESS INSECT BIOC; [No title captured]	36	173	183	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3552	3561		10.1074/jbc.M205743200	http://dx.doi.org/10.1074/jbc.M205743200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12456683	hybrid			2022-12-25	WOS:000180869700008
J	Kneidinger, B; O'Riordan, K; Li, JJ; Brisson, JR; Lee, JC; Lam, JS				Kneidinger, B; O'Riordan, K; Li, JJ; Brisson, JR; Lee, JC; Lam, JS			Three highly conserved proteins catalyze the conversion of UDP-N-acetyl-D-glucosamine to precursors for the biosynthesis of O antigen in Pseudomonas aeruginosa 011 and capsule in Staphylococcus aureus type 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SOMATIC ANTIGENS; MOLECULAR CHARACTERIZATION; GDP-MANNOSE; LIPOPOLYSACCHARIDE; POLYSACCHARIDE; STRAINS; CLONING; VECTORS; PHAGE; IDENTIFICATION	N-Acetyl-L-fucosamine is a constituent of surface polysaccharide structures of Pseudomonas aeruginosa and Staphylococcus aureus. The three P. aeruginosa enzymes WbjB, WbjC, and WbjD, as well as the S. aureus homologs Cap5E, Cap5F, and Cap5G, involved in the biosynthesis of N-acetyl-L-fucosamine have been overexpressed and purified to near homogeneity. Capillary electrophoresis (CE), mass spectroscopy (MS), and nuclear magnetic resonance spectroscopy have been used to elucidate the biosynthesis pathway, which proceeds in five reaction steps. WbjB/ Cap5E catalyzed 4,6-dehydration of UDP-N-acetyl-n-glucosamine and 3- and 5-epimerization to yield a mixture of three keto-deoxy-sugars. The third intermediate compound was subsequently reduced at C-4 to UDP-2-acetamido-2,6-dideoxy-L-talose by WbjC/Cap5F. Incubation of UDP-2-acetamido-2,6-dideoxy-L-talose (UDP-TalNAC) with WbjD/Cap5G resulted in a new peak separable by CE that demonstrated identical mass and fragmentation patterns by CE-MS/MS to UDP-TalNAc. These results are consistent with WbjD/Cap5G-mediated 2-epimerization of UDP-TalNAC to UDP-FucNAc. A non-polar gene knockout of wbjB, the first of the genes associated with this pathway, was constructed in P. aeruginosa serotype 011 strain PA103. The corresponding mutant produced rough lipopolysaccharide devoid of B-band O antigen. This lipopolysaccharide deficiency could be complemented with P. aeruginosa wbjB or with the S. aureus homolog cap5E. Insertional inactivation of either the cap5G or cap5F genes abolished capsule polysaccharide production in the S. aureus strain Newman. Providing the appropriate gene in trans, thereby complementing these mutants, fully restored the capsular polysaccharide phenotype.	Univ Guelph, Dept Microbiol, Canadian Bacterial Dis Network, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA	University of Guelph; National Research Council Canada; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Lam, JS (corresponding author), Univ Guelph, Dept Microbiol, Canadian Bacterial Dis Network, Guelph, ON N1G 2W1, Canada.	jlam@uoguelph.ca		Lee, Jean/0000-0002-8094-5180	PHS HHS [A129040] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alpern ER, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e23; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bhasin N, 1998, MOL MICROBIOL, V27, P9, DOI 10.1046/j.1365-2958.1998.00646.x; Bisso A, 1999, FEBS LETT, V456, P370, DOI 10.1016/S0014-5793(99)00982-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; BULET P, 1984, EUR J BIOCHEM, V144, P255, DOI 10.1111/j.1432-1033.1984.tb08458.x; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P565; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2001, MOL MICROBIOL, V41, P1295, DOI 10.1046/j.1365-2958.2001.02589.x; CRYZ SJ, 1984, INFECT IMMUN, V44, P508, DOI 10.1128/IAI.44.2.508-513.1984; FOMSGAARD A, 1990, J CLIN MICROBIOL, V28, P2627, DOI 10.1128/JCM.28.12.2627-2631.1990; FOURNIER JM, 1984, INFECT IMMUN, V45, P87, DOI 10.1128/IAI.45.1.87-93.1984; Graninger M, 1999, J BIOL CHEM, V274, P25069, DOI 10.1074/jbc.274.35.25069; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; JANSSON PE, 1985, CARBOHYD RES, V140, P101, DOI 10.1016/0008-6215(85)85053-9; Jiang SM, 2001, INFECT IMMUN, V69, P1244, DOI 10.1128/IAI.69.3.1244-1255.2001; JONES C, 1991, CARBOHYD RES, V221, P95, DOI 10.1016/0008-6215(91)80051-N; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; KASATIYA SS, 1967, CAN J MICROBIOL, V13, P1079, DOI 10.1139/m67-144; KASPER DL, 1983, J BACTERIOL, V153, P991, DOI 10.1128/JB.153.2.991-997.1983; Kiser KB, 1999, J BACTERIOL, V181, P4818, DOI 10.1128/JB.181.16.4818-4824.1999; Kneidinger B, 2001, J BIOL CHEM, V276, P5577, DOI 10.1074/jbc.M010027200; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; Koplin R, 1997, J BIOL CHEM, V272, P4121, DOI 10.1074/jbc.272.7.4121; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM JS, 1987, INFECT IMMUN, V55, P1051, DOI 10.1128/IAI.55.5.1051-1057.1987; LAM MYC, 1989, J CLIN MICROBIOL, V27, P962, DOI 10.1128/JCM.27.5.962-967.1989; LEE CY, 1991, GENE, V103, P101, DOI 10.1016/0378-1119(91)90399-V; Lee J C, 1995, Methods Mol Biol, V47, P209; LEE JC, 1990, J CLIN MICROBIOL, V28, P2612, DOI 10.1128/JCM.28.12.2612-2615.1990; Lee JC, 1999, GENETICS OF BACTERIALS POLYSACCHARIDES, P185; LIU PHV, 1990, J CLIN MICROBIOL, V28, P922, DOI 10.1128/JCM.28.5.922-925.1990; LIU PV, 1983, INT J SYST BACTERIOL, V33, P256, DOI 10.1099/00207713-33-2-256; LIU PV, 1973, J INFECT DIS, V128, P506, DOI 10.1093/infdis/128.4.506; Lowary TL, 2002, CAN J CHEM, V80, P1112, DOI 10.1139/V02-118; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Manca MC, 1996, CARBOHYD RES, V281, P155, DOI 10.1016/0008-6215(95)00333-9; MOREAU M, 1990, CARBOHYD RES, V201, P285, DOI 10.1016/0008-6215(90)84244-O; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; PAVLOVSKIS OR, 1977, INFECT IMMUN, V18, P596, DOI 10.1128/IAI.18.3.596-602.1977; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; PITT TL, 1988, EUR J CLIN MICROBIOL, V7, P238, DOI 10.1007/BF01963095; Portoles M, 2001, INFECT IMMUN, V69, P917, DOI 10.1128/IAI.69.2.917-923.2001; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sau S, 1997, J BACTERIOL, V179, P1614, DOI 10.1128/jb.179.5.1614-1621.1997; SCHWEIZER HP, 1995, GENE, V158, P15, DOI 10.1016/0378-1119(95)00055-B; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SOMPOLINSKY D, 1985, J CLIN MICROBIOL, V22, P828, DOI 10.1128/JCM.22.5.828-834.1985; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Thakker M, 1998, INFECT IMMUN, V66, P5183, DOI 10.1128/IAI.66.11.5183-5189.1998; Wann ER, 1999, FEMS MICROBIOL LETT, V170, P97; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	60	78	84	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3615	3627		10.1074/jbc.M203867200	http://dx.doi.org/10.1074/jbc.M203867200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12464616	hybrid			2022-12-25	WOS:000180869700015
J	Rowley, M; Van Ness, B				Rowley, M; Van Ness, B			Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response	ONCOGENE			English	Article						Ras; myeloma; therapeutic response	MULTIPLE-MYELOMA; GROWTH-FACTOR; APOPTOSIS; DEXAMETHASONE; MUTATIONS; DIFFERENTIATION; ONCOGENES; PROTEINS; COMPLEX; ANBL6	Ras is a major signaling molecule activated by interleukin-6. There have been no published reports, however, that specifically examine the kinetics and percentage of Ras activation in response to IL-6. Model cell lines were used to study activation of N- and K-ras induced by IL-6. All of the myeloma cell lines we tested express both N-ras and K-ras, but not H-ras. GTP-bound Ras was measured and the percentage of the total Ras pool that was activated in response to IL-6 was calculated. IL-6 is able to transiently activate both Nand K-ras in the ANBL6 cell tine. In addition, increasing concentrations of IL-6 are able to activate increasing levels of both N- and K-ras. One ng/ml of IL-6 is able to activate approximately 10% of the N-ras pool and 18% of the K-ras pool. The amount of Ras-GTP in the cells correlates with the level of proliferation at low levels, but proliferation plateaus when higher levels of Ras-GTP are present. Protection from dexamethasone-induced apoptosis correlates with IL-6 concentration and Ras activation. However, IL-6 enhances apoptosis induced by doxorubicin. Interestingly, the ANBL6 cell line transfected with an N-ras12 or a K-ras12 gene is protected from doxorubicin-induced apoptosis.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Grad Program Mol Cellular Dev Biol & Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Van Ness, B (corresponding author), Canc Ctr Res Bldg,Mayo Mail Code 806, Minneapolis, MN 55455 USA.				NCI NIH HHS [P01CA62242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; Billadeau D, 1997, CANCER RES, V57, P2268; BILLADEAU D, 1995, CANCER RES, V55, P3640; Brownell HL, 1997, DNA CELL BIOL, V16, P103, DOI 10.1089/dna.1997.16.103; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; CORRADINI P, 1993, EMBO J, V16, P6439; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HARDIN J, 1994, BLOOD, V84, P3063; HATA Y, 1993, ONCOL RES, V5, P161; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KLEIN B, 1989, BLOOD, V73, P517; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; MCCLOSKEY TW, 1994, CLIN IMMUNOL IMMUNOP, V71, P14, DOI 10.1006/clin.1994.1045; McCormick F, 1996, NAT STRUCT BIOL, V3, P653, DOI 10.1038/nsb0896-653; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PORTIER M, 1992, ONCOGENE, V7, P2539; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9	25	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8769	8775		10.1038/sj.onc.1205387	http://dx.doi.org/10.1038/sj.onc.1205387			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483530				2022-12-25	WOS:000179734400011
J	Miranda, C; Zanotti, G; Pagliardinil, S; Ponzetto, C; Pierotti, MA; Greco, A				Miranda, C; Zanotti, G; Pagliardinil, S; Ponzetto, C; Pierotti, MA; Greco, A			Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity	ONCOGENE			English	Article						tyrosine kinase receptors; NTRK1; oncogenic; activation	RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; LIGAND-INDEPENDENT ACTIVATION; PROTOONCOGENE C-KIT; CONGENITAL INSENSITIVITY; POINT MUTATION; DOMAIN; CELLS; TRK; IDENTIFICATION	Activation of tyrosine kinase receptors is associated with human tumors. Tumorigenic versions of several RTKs, such as Ret, Kit and Met carry activating mutations at highly conserved residues of the tyrosine kinase domain. We have investigated the effect of some of these mutations on the NTRK1/NGF receptor, for which no naturally occurring activating point mutations have been so far detected. We introduced the following mutations in NTRK1 tyrosine kinase domain: (i) D668N equivalent to Met D1246N associated to HPRC; (ii) D668V modelled on Kit D816V found in mastocytosis; (iii) M688T corresponding to Ret M918T associated to the cancer syndrome MEN2B. The Met-like mutation rendered the NTRK1 receptor more responsive to ligand, as observed for the corresponding mutation in Met. On the contrary the Kit-like D668V resulted as neutral mutation. Surprisingly, the MEN213-like M688T completely abrogated NTRK1 receptor activity, resulting as a loss of function mutation. Our results show that the mutations tested, although involving conserved amino acids in highly homologous regions, exert distinct effects in different receptors, and suggest a very peculiar auto-inhibitory mechanism for NTRK1.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Turin, Dept Anat & Pharmacol, I-10126 Turin, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Padua; University of Turin	Greco, A (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349; Zanotti, Giuseppe/0000-0002-0945-6501				CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 2000, J CELL PHYSIOL, V182, P127, DOI 10.1002/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Indo Y, 2001, HUM MUTAT, V18, P462, DOI 10.1002/humu.1224; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Miranda C, 2002, J BIOL CHEM, V277, P6455, DOI 10.1074/jbc.M110016200; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tagliabue E, 1999, INT J BIOL MARKER, V14, P68, DOI 10.1177/172460089901400203; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Weeraratna AT, 2001, CLIN CANCER RES, V7, P2237	24	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8334	8339		10.1038/sj.onc.1206052	http://dx.doi.org/10.1038/sj.onc.1206052			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447696				2022-12-25	WOS:000179323900011
J	Hornstra, IK; Birge, S; Starcher, B; Bailey, AJ; Mecham, RP; Shapiro, SD				Hornstra, IK; Birge, S; Starcher, B; Bailey, AJ; Mecham, RP; Shapiro, SD			Lysyl oxidase is required for vascular and diaphragmatic development in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE TYROSYLQUINONE COFACTOR; CROSS-LINKS; MOLECULAR-CLONING; GENE; MAPS; COLLAGEN; ELASTIN; PROTEIN; ASSAY; SKIN	Lysyl oxidase (LOX) is an enzyme responsible for the cross-linking of collagen and elastin both in vitro and in vivo. The unique functions of the individual members of this multigene family have been difficult to ascertain because of highly conserved catalytic domains and overlapping tissue expression patterns. To address this problem of functional and structural redundancy and to determine the role of LOX in the development of tissue integrity, Lox gene expression was deleted by targeted mutagenesis in mice. Lox-targeted mice (LOX-/-) died soon after parturition, exhibiting cardiovascular instability with ruptured arterial aneurysms and diaphragmatic rupture. Microscopic analysis of the aorta demonstrated fragmented elastic fiber architecture in homozygous mutant null mice. LOX activity, as assessed by desmosine (elastin cross-link) analysis, was reduced by similar to60% in the aorta and lungs of homozygous mutant animals compared with wild type mice. Immature collagen cross-links were decreased but to a lesser degree than elastin cross-links in LOX-/- mice. Thus, lysyl oxidase appears critical during, embryogenesis for structural stability of the aorta and diaphragm and connective tissue development.	Washington Univ, Dept Med, Div Dermatol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Texas, Hlth Sci Ctr, Tyler, TX 75708 USA; Univ Bristol, Collagen Res Grp, Langford B540 5DS, England; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); University of Bristol; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Hornstra, IK (corresponding author), Washington Univ, Dept Med, Div Dermatol, Sch Med, 660 S Euclid Ave,Campus Box 8123, St Louis, MO 63110 USA.	ihornstr@im.wustl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL053325, R37HL053325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002059] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 29594, HL53325] Funding Source: Medline; NIAMS NIH HHS [K08 AR02059] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akagawa M, 2001, BIOCHEM BIOPH RES CO, V281, P193, DOI 10.1006/bbrc.2001.4315; Asuncion L, 2001, MATRIX BIOL, V20, P487, DOI 10.1016/S0945-053X(01)00161-5; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; CHANG YS, 1993, CYTOGENET CELL GENET, V63, P47, DOI 10.1159/000133500; Dietz HC, 2000, MATRIX BIOL, V19, P481, DOI 10.1016/S0945-053X(00)00101-3; HAMALAINEN ER, 1995, J BIOL CHEM, V270, P21590, DOI 10.1074/jbc.270.37.21590; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; Ito H, 2001, J BIOL CHEM, V276, P24023, DOI 10.1074/jbc.M100861200; Jordan R E, 1977, Adv Exp Med Biol, V79, P531; Jourdan-Le Saux C, 2000, MATRIX BIOL, V19, P179, DOI 10.1016/S0945-053X(00)00061-5; Jourdan-Le Saux C, 1998, GENOMICS, V51, P305, DOI 10.1006/geno.1998.5356; Jourdan-Le Saux C, 1999, J BIOL CHEM, V274, P12939; Jourdan-Le Saux C, 2001, GENOMICS, V74, P211, DOI 10.1006/geno.2001.6545; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KENYON K, 1993, J BIOL CHEM, V268, P18435; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; LAYMAN DL, 1972, ARCH BIOCHEM BIOPHYS, V149, P97, DOI 10.1016/0003-9861(72)90302-5; Li DY, 1998, J CLIN INVEST, V102, P1783, DOI 10.1172/JCI4487; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; LIGHT ND, 1982, METHOD ENZYMOL, V82, P360; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; LOSSIE AC, 1993, MAMM GENOME, V4, P177, DOI 10.1007/BF00352234; Maki JM, 2001, BIOCHEM J, V355, P381, DOI 10.1042/0264-6021:3550381; Maki JM, 2001, MATRIX BIOL, V20, P493, DOI 10.1016/S0945-053X(01)00157-3; Mao JR, 2001, J CLIN INVEST, V107, P1063, DOI 10.1172/JCI12881; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; MELET J, 1977, ANAL BIOCHEM, V77, P141, DOI 10.1016/0003-2697(77)90298-6; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; MOCK BA, 1992, GENOMICS, V14, P822, DOI 10.1016/S0888-7543(05)80201-0; NARAYANAN AS, 1972, BIOCHEM BIOPH RES CO, V46, P745; NICHOLS DG, 1995, CRITICAL HEART DIS I, P18; OAKES BW, 1976, EXP MOL PATHOL, V25, P82, DOI 10.1016/0014-4800(76)90019-8; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; PASQUALIRONCHETTI I, 1994, EXP MOL PATHOL, V61, P36, DOI 10.1006/exmp.1994.1024; Sambrook J, 2001, MOL CLONING LAB MANU; SIEGEL RC, 1976, J BIOL CHEM, V251, P5786; SIMS TJ, 1992, J CHROMATOGR-BIOMED, V582, P49, DOI 10.1016/0378-4347(92)80301-6; STARCHER B, 1995, RESPIRATION, V62, P252; Starcher B, 2001, ANAL BIOCHEM, V292, P125, DOI 10.1006/abio.2001.5050; TANG SS, 1983, J BIOL CHEM, V258, P4331; Tchernev VT, 1997, MAMM GENOME, V8, P621, DOI 10.1007/s003359900520; Uauy R, 1998, AM J CLIN NUTR, V67, p952S, DOI 10.1093/ajcn/67.5.952S; Wang SX, 1997, J BIOL CHEM, V272, P28841, DOI 10.1074/jbc.272.46.28841; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WEAVER AL, 1967, ARTHRITIS RHEUM-US, V10, P470, DOI 10.1002/art.1780100510; Wydner KS, 1997, GENOMICS, V40, P342, DOI 10.1006/geno.1996.4574	48	243	257	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14387	14393		10.1074/jbc.M210144200	http://dx.doi.org/10.1074/jbc.M210144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12473682	hybrid, Green Submitted			2022-12-25	WOS:000182405000104
J	Daikoku, T; Matsumoto, H; Gupta, RA; Das, SK; Gassmann, M; Dubois, RN; Dey, SK				Daikoku, T; Matsumoto, H; Gupta, RA; Das, SK; Gassmann, M; Dubois, RN; Dey, SK			Expression of hypoxia-inducible factors in the peri-implantation mouse uterus is regulated in a cell-specific and ovarian steroid hormone-dependent manner - Evidence for differential function of HIFs during early pregnancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ESTROGEN-RECEPTOR-ALPHA; FACTOR 1-ALPHA; MESSENGER-RNA; IN-VIVO; DEVELOPMENTAL EXPRESSION; VASCULAR-PERMEABILITY; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; DEFICIENT MICE	Increased uterine vascular permeability and angiogenesis are hallmarks of implantation and placentation. These events are profoundly influenced by vascular endothelial growth factor (VEGF). We previously showed that VEGF isoforms and VEGF receptors are expressed in the uterus, suggesting the role of VEGF in uterine vascular permeability and angiogenesis required for implantation and decidualization. We have recently shown that estrogen promotes uterine vascular permeability but inhibits angiogenesis, whereas progesterone stimulates angiogenesis with little effect on vascular permeability. However, the mechanism of differential steroid hormonal regulation of uterine angiogenesis remains unresolved. Oxygen homeostasis is essential for cell survival and is primarily mediated by hypoxia-inducible factors (HIFs). These factors are intimately associated with vascular events and induce VEGF expression by binding to the hypoxia response element in the VEGF promoter. HIFalpha isoforms function by forming heterodimers with the aryl hydrocarbon nuclear translocator (ARNT) (HIF-beta) family members. There is very limited information on the relationship among HIFs, ARNTs, and VEGF in the uterus during early pregnancy, although the role of HIFs in regulating VEGF and angiogenesis in cancers is well documented. Using molecular and physiological approaches, we here show that uterine expression of HIFs and ARNTs does not correlate with VEGF expression during the preimplantation period (days 1-4) in mice. In contrast, their expression follows the localization of uterine VEGF expression with increasing angiogenesis during the postimplantation period (days 5-8). This disparate pattern of uterine HIFs, ARNTs, and VEGF expression on days 1-4 of pregnancy suggests HIFs have multiple roles in addition to the regulation of angiogenesis during the peri-implantation period. Using pharmacological, molecular, and genetic approaches, we also observed that although progesterone primarily up-regulates uterine HIF-1alpha expression, estrogen transiently stimulates that of HIF-2alpha.	Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Tohoku Univ, Lab Anim Reprod, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan; Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland	Vanderbilt University; Vanderbilt University; Vanderbilt University; Tohoku University; University of Zurich	Dey, SK (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.	sk.dey@vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020	Gassmann, Max/0000-0003-2750-8878	NICHD NIH HHS [HD12304, HD33994, HD37830] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012304, R01HD012304, R01HD037830] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adelman DM, 2000, GENE DEV, V14, P3191, DOI 10.1101/gad.853700; Bonazzi A, 2000, J BIOL CHEM, V275, P2837, DOI 10.1074/jbc.275.4.2837; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; CHAKRABORTY I, 1995, J ENDOCRINOL, V147, P339, DOI 10.1677/joe.0.1470339; Cowden KD, 2002, BIOCHEM BIOPH RES CO, V290, P1228, DOI 10.1006/bbrc.2001.6309; Das SK, 2000, J BIOL CHEM, V275, P28834, DOI 10.1074/jbc.M003827200; Das SK, 1997, P NATL ACAD SCI USA, V94, P12786, DOI 10.1073/pnas.94.24.12786; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Elson DA, 2000, CANCER RES, V60, P6189; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; FINN CA, 1975, UTERUS CELLS TISSUES, V1, P18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Halder JB, 2000, GENESIS, V26, P213, DOI 10.1002/(SICI)1526-968X(200003)26:3<213::AID-GENE7>3.0.CO;2-M; Hofer T, 2002, PFLUG ARCH EUR J PHY, V443, P503, DOI 10.1007/s00424-001-0759-8; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hosoya T, 2001, GENES CELLS, V6, P361, DOI 10.1046/j.1365-2443.2001.00421.x; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1683, DOI 10.1210/endo-125-3-1683; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kietzmann T, 2001, EUR ARCH PSY CLIN N, V251, P170, DOI 10.1007/s004060170037; Kietzmann T, 2001, BIOCHEM J, V354, P531, DOI 10.1042/0264-6021:3540531; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Korgun ET, 2001, BIOL REPROD, V65, P1364, DOI 10.1095/biolreprod65.5.1364; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Ma W, 2001, MOL ENDOCRINOL, V15, P1983, DOI 10.1210/me.15.11.1983; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Matsumoto H, 2002, DEV BIOL, V245, P280, DOI 10.1006/dbio.2002.0645; Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Paria BC, 1999, DEV BIOL, V208, P488, DOI 10.1006/dbio.1999.9206; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Tan J, 1999, ENDOCRINOLOGY, V140, P5310, DOI 10.1210/en.140.11.5310; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Welch RD, 1999, ENDOCRINOLOGY, V140, P3602, DOI 10.1210/en.140.8.3602; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 1997, EUR J BIOCHEM, V246, P155, DOI 10.1111/j.1432-1033.1997.t01-1-00155.x; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199; Zhong H, 1999, CANCER RES, V59, P5830	64	88	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7683	7691		10.1074/jbc.M211390200	http://dx.doi.org/10.1074/jbc.M211390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482866	hybrid			2022-12-25	WOS:000181195100133
J	Hermey, G; Keat, SJ; Madsen, P; Jacobsen, C; Petersen, CM; Gliemann, J				Hermey, G; Keat, SJ; Madsen, P; Jacobsen, C; Petersen, CM; Gliemann, J			Characterization of sorCS1, an alternatively spliced receptor with completely different cytoplasmic domains that mediate different trafficking in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORTING RECEPTOR; SORTILIN/NEUROTENSIN RECEPTOR-3; GGA PROTEINS; IDENTIFICATION; SEQUENCES; FAMILY; MEMBER; BINDS; PROPEPTIDE; TRANSPORT	We previously isolated and sequenced murine sorCS1, a type 1 receptor containing a Vps10p-domain and a leucine-rich domain. We now show that human sorCS1 has three isoforms, sorCS1a-c, with completely different cytoplasmic tails and differential expression in tissues. The b tail shows high identity with that of murine sorCS1b, whereas the a and c tails have no reported counterparts. Like the Vps10p-domain receptor family members sortilin and sorLA, sorCS1 is synthesized as a proreceptor that is converted in late Golgi compartments by furin-mediated cleavage. Mature sorCS1 bound its own propeptide with low affinity but none of the ligands previously shown to interact with sortilin and sorLA. In transfected cells, about 10% of sorCS1a was expressed on the cell surface and proved capable of rapid endocytosis in complex with specific antibody, whereas sorCS1b presented a high cell surface expression but essentially no endocytosis, and sorCS1c was intermediate. This is an unusual example of an alternatively spliced single transmembrane receptor with completely different cytoplasmic domains that mediate different trafficking in cells.	Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus C, Denmark	Aarhus University	Hermey, G (corresponding author), Aarhus Univ, Dept Biochem Med, Ole Worms Alle Bldg 170, DK-8000 Aarhus C, Denmark.	ghermey@biokemi.au.dk	Hermey, Guido/AAC-5565-2020	Hermey, Guido/0000-0003-4762-5262; Madsen, Peder Sondergaard/0000-0002-8845-4802				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Boman AL, 2001, J CELL SCI, V114, P3413; Brandes C, 1997, GENOMICS, V42, P185, DOI 10.1006/geno.1997.4702; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; Do H, 2002, J BIOL CHEM, V277, P29737, DOI 10.1074/jbc.M202369200; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Hermey G, 2000, BBA-GENE STRUCT EXPR, V1491, P350, DOI 10.1016/S0167-4781(00)00044-0; Hermey G, 2001, NEUROSCI LETT, V313, P83, DOI 10.1016/S0304-3940(01)02252-2; Hermey G, 2001, NEUROREPORT, V12, P29, DOI 10.1097/00001756-200101220-00014; Hermey G, 1999, BIOCHEM BIOPH RES CO, V266, P347, DOI 10.1006/bbrc.1999.1822; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; Jacobsen L, 2001, J BIOL CHEM, V276, P22788, DOI 10.1074/jbc.M100857200; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Kirchhausen T, 2002, NAT STRUCT BIOL, V9, P241, DOI 10.1038/nsb0402-241; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nielsen MS, 1999, J BIOL CHEM, V274, P8832, DOI 10.1074/jbc.274.13.8832; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Petersen CM, 1999, EMBO J, V18, P595, DOI 10.1093/emboj/18.3.595; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Rezgaoui M, 2001, MECH DEVELOP, V100, P335, DOI 10.1016/S0925-4773(00)00523-2; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	34	37	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7390	7396		10.1074/jbc.M210851200	http://dx.doi.org/10.1074/jbc.M210851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482870	hybrid			2022-12-25	WOS:000181195100098
J	Kanki, T; Young, MT; Sakaguchi, M; Hamasaki, N; Tanner, MJA				Kanki, T; Young, MT; Sakaguchi, M; Hamasaki, N; Tanner, MJA			The N-terminal region of the transmembrane domain of human erythrocyte band 3 - Residues critical for membrane insertion and transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOUTHEAST-ASIAN OVALOCYTOSIS; ANION-EXCHANGER BAND-3; XENOPUS-OOCYTES; HEREDITARY OVALOCYTOSIS; GLYCOPHORIN-A; PROTEIN; AE1; EXPRESSION; DELETION; SEGMENTS	We studied the role of the N-terminal region of the transmembrane domain of the human erythrocyte anion exchanger (band 3; residues 361-408) in the insertion, folding, and assembly of the first transmembrane span (TM1) to give rise to a transport-active molecule. We focused on the sequence around the 9-amino acid region deleted in Southeast Asian ovalocytosis (Ala-400 to Ala-408), which gives rise to nonfunctional band 3, and also on the portion of the protein N-terminal to the transmembrane domain (amino acids 361-396). We examined the effects of mutations in these regions on endoplasmic reticulum. insertion (using cell-free translation), chloride transport, and cell-surface movement in Xenopus oocytes. We found that the hydrophobic length of TM1 was critical for membrane insertion and that formation of a transport-active structure also depended on the presence of specific amino acid sequences in TM1. Deletions of 2 or 3 amino acids including Pro-403 retained transport activity provided that a polar residue was located 2 or 3 amino acids on the C-terminal side of Asp-399. Finally, deletion of the cytoplasmic surface sequence G(381) LVRD abolished chloride transport, but not surface expression, indicating that this sequence makes an essential structural contribution to the anion transport site of band 3.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Biol Mol, Fukuoka 8128582, Japan	University of Bristol; Kyushu University; Kyushu University	Tanner, MJA (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.		Young, Mark T/E-8928-2010; Kanki, Tomotake/H-7250-2012	Young, Mark T/0000-0002-9615-9002; Kanki, Tomotake/0000-0001-9646-5379				BOOTH PB, 1977, VOX SANG, V32, P99, DOI 10.1111/j.1423-0410.1977.tb00612.x; Chambers EJ, 1999, J MOL BIOL, V285, P1289, DOI 10.1006/jmbi.1998.2392; CHERNOVA MN, 1995, J MEMBRANE BIOL, V148, P203; GENTON B, 1995, NATURE, V378, P564, DOI 10.1038/378564a0; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; GROVES JD, 1992, J BIOL CHEM, V267, P22163; Groves JD, 1999, BIOCHEM J, V344, P699, DOI 10.1042/0264-6021:3440699; GROVES JD, 1993, FEBS LETT, V330, P186, DOI 10.1016/0014-5793(93)80270-5; Hamasaki N, 1998, BIOCHEM CELL BIOL, V76, P729, DOI 10.1139/bcb-76-5-729; Hamasaki N, 1997, J BIOCHEM-TOKYO, V122, P577; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P289, DOI 10.1111/j.1432-1033.1983.tb07262.x; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; Kuma H, 1998, J BIOCHEM-TOKYO, V124, P509, DOI 10.1093/oxfordjournals.jbchem.a022142; Kuma H, 2002, BIOCHEMISTRY-US, V41, P3311, DOI 10.1021/bi011678+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SC, 1994, BLOOD, V84, P3590; MOHANDAS N, 1992, J CLIN INVEST, V89, P686, DOI 10.1172/JCI115636; MORIYAMA R, 1992, J BIOL CHEM, V267, P25792; OKUBO K, 1994, J BIOL CHEM, V269, P1918; Ota K, 1998, J BIOL CHEM, V273, P28286, DOI 10.1074/jbc.273.43.28286; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; REITHMEIER RAF, 1993, SOC GEN PHY, V48, P161; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SARABIA VE, 1993, J BIOL CHEM, V268, P10676; SCHOFIELD AE, 1992, J MOL BIOL, V223, P949, DOI 10.1016/0022-2836(92)90254-H; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SERJEANTSON S, 1977, HUM GENET, V37, P161, DOI 10.1007/BF00393579; SMYTHE JS, 1995, BLOOD, V85, P2929, DOI 10.1182/blood.V85.10.2929.bloodjournal85102929; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WANG DN, 1994, FEBS LETT, V346, P26, DOI 10.1016/0014-5793(94)00468-4	34	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5564	5573		10.1074/jbc.M211662200	http://dx.doi.org/10.1074/jbc.M211662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482865	hybrid			2022-12-25	WOS:000181129400013
J	Umashankar, M; Murthy, MRN; Savithri, HS				Umashankar, M; Murthy, MRN; Savithri, HS			Mutation of interfacial residues disrupts subunit folding and particle assembly of Physalis mottle tymovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS; PROTEIN; POLYMERASE; DNA	Virus-like particles (VLPs) serve as excellent model systems to identify the pathways of virus assembly. To gain insights into the assembly mechanisms of the Physalis mottle tymovirus (PhAW), six interfacial residues, identified based on the crystal structure of the native and recombinant capsids, were targeted for mutagenesis. The Q37E, Y67A, R68Q, D83A, I123A, and S145A mutants of the PhMV recombinant coat protein (rCP) expressed in Escherichia coli were soluble. However, except for the S145A mutant, which assembled into VLPs similar to that of wild type rCP capsids, all the other mutants failed to assemble into VLPs. Furthermore, the purified Q37E, Y67A, R68Q, D83A, and I123A rCP mutants existed essentially as partially folded monomers as revealed by Sucrose density gradient analysis, circular dichroism, fluorescence, thermal, and urea denaturation studies. The rCP mutants locked into such conformations probably lack the structural signals/features that would allow them to assemble into capsids. Thus, the mutation of residues involved in inter-subunit interactions in PhMV disrupts both subunit folding and particle assembly.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Savithri, HS (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.							HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; KAPER JM, 1975, CHEM BASIS VIRUS STR, V39; KATOUZIANSAFADI M, 1980, EUR J BIOCHEM, V112, P479; KATOUZIANSAFADI M, 1983, EUR J BIOCHEM, V137, P47, DOI 10.1111/j.1432-1033.1983.tb07793.x; KEKUDA R, 1993, VIROLOGY, V193, P959, DOI 10.1006/viro.1993.1205; Kirkitadze MD, 1998, J VIROL, V72, P10066, DOI 10.1128/JVI.72.12.10066-10072.1998; Krishna S, 1999, J MOL BIOL, V289, P919, DOI 10.1006/jmbi.1999.2787; Krishna SS, 2001, J MOL BIOL, V307, P1035, DOI 10.1006/jmbi.2001.4533; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS REF, 1991, PLANT VIROLOGY, P231; Oliveira AC, 2000, J BIOL CHEM, V275, P16037, DOI 10.1074/jbc.M910145199; Ranjith-Kumar CT, 1998, ARCH VIROL, V143, P1489, DOI 10.1007/s007050050392; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sastri M, 1997, J MOL BIOL, V272, P541, DOI 10.1006/jmbi.1997.1258; Sastri M, 1999, J MOL BIOL, V289, P905, DOI 10.1006/jmbi.1999.2786; SAVITHRI HS, 1987, J GEN VIROL, V68, P1533, DOI 10.1099/0022-1317-68-6-1533; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6	19	7	7	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6145	6152		10.1074/jbc.M207992200	http://dx.doi.org/10.1074/jbc.M207992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12477730	hybrid			2022-12-25	WOS:000181129400082
J	Geetha, T; Wooten, MW				Geetha, T; Wooten, MW			Association of the atypical protein kinase C-interacting protein p62/ZIP with nerve growth factor receptor TrkA regulates receptor trafficking and Erk5 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; TYROSINE PHOSPHORYLATION; CELL-SURVIVAL; IDENTIFICATION; TRANSDUCTION; BINDING; MEDIATE; P62; LOCALIZATION; ENDOSOMES	Previous work demonstrated an essential role for the atypical protein kinase C interacting protein, p62, in neurotrophin survival and differentiation signaling. Here we show that p62 interacts not only with TrkA but also with TrkB and TrkC, which are the primary receptors for brain-derived neurotrophic factor and neurotrophin-3. The interaction of p62 with TrkA requires the kinase activity of TrkA. Mapping analysis indicates that p62 does not compete with Shc for binding to TrkA, and p62 association was confined to the juxtamembrane region of TrkA amino acids 472-493. By immunofluorescence the colocalization of p62 and TrkA was observed 30 min post-nerve growth factor treatment within overlapping vesicular structures. Upon subcellular fractionation, activated TrkA colocalized to an endosomal compartment and p62 was coassociated with the receptor post-nerve growth factor stimulation. Moreover, an absence of p62 blocked internalization of TrkA without an effect on phosphorylation of either TrkA or MAPK, however, Erk5 signaling was selectively abrogated. We propose that p62 plays a novel role in connecting receptor signals with the endosomal signaling network required for mediating TrkA-induced differentiation.	Auburn Univ, Dept Biol Sci, Program Cellular & Mol Biosci, Auburn, AL 36849 USA	Auburn University System; Auburn University	Wooten, MW (corresponding author), Auburn Univ, Dept Biol Sci, Program Cellular & Mol Biosci, 331 Funchess Hall, Auburn, AL 36849 USA.	mwwooten@acesag.auburn.edu	Thangiah, Geetha/W-6796-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033661] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 33661] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BERG MM, 1992, J BIOL CHEM, V267, P13; BUXSER S, 1990, J BIOL CHEM, V265, P12701; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; EVELETH DD, 1992, J CELL BIOL, V117, P291, DOI 10.1083/jcb.117.2.291; Fan GH, 2002, J BIOL CHEM, V277, P6590, DOI 10.1074/jbc.M110588200; Foehr ED, 2000, J NEUROSCI, V20, P7556; Grimes ML, 1997, P NATL ACAD SCI USA, V94, P9909, DOI 10.1073/pnas.94.18.9909; Grimes ML, 1996, J NEUROSCI, V16, P7950; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Jullien J, 2002, J BIOL CHEM, V277, P38700, DOI 10.1074/jbc.M202348200; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Raffioni S, 1999, P NATL ACAD SCI USA, V96, P7178, DOI 10.1073/pnas.96.13.7178; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Samuels IS, 2001, J CELL BIOCHEM, V82, P452, DOI 10.1002/jcb.1177; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Shao YF, 2002, J CELL BIOL, V157, P679, DOI 10.1083/jcb.200201063; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUTTER A, 1979, J BIOL CHEM, V254, P5972; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; Tisi MA, 2000, J NEUROBIOL, V42, P477, DOI 10.1002/(SICI)1097-4695(200003)42:4<477::AID-NEU8>3.0.CO;2-B; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Zapf-Colby A, 1998, ENDOCRINOLOGY, V139, P3232, DOI 10.1210/en.139.7.3232; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	38	43	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4730	4739		10.1074/jbc.M208468200	http://dx.doi.org/10.1074/jbc.M208468200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12471037	hybrid			2022-12-25	WOS:000180968900050
J	Humrich, J; Bermel, C; Grubel, T; Quitterer, U; Lohse, MJ				Humrich, J; Bermel, C; Grubel, T; Quitterer, U; Lohse, MJ			Regulation of phosducin-like protein by casein kinase 2 and N-terminal splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; COUPLED RECEPTOR; PARATHYROID-HORMONE; PHOSPHORYLATION; BINDING; EXPRESSION; INHIBITION; TRANSDUCIN; CELLS; PURIFICATION	Phosducin-like protein (PhLP) is a member of the phosducin family of G-protein betagamma-regulators and exists in two splice variants. The long isoform PhLPL and the short isoform PhLPS differ by the presence or absence of an 83-amino acid N terminus. In isolated biochemical assay systems, PhLPL is the more potent Gbetagamma-inhibitor, whereas the functional role of PhLPS is still unclear. We now report that in intact HEK 293 cells, PhLPS inhibited Gbetagamma-induced inositol phosphate generation with similar to20-fold greater potency than PhLPL. Radiolabeling of transfected HEK 293 cells with [P-32] revealed that PhLPL is constitutively phosphorylated, whereas PhLPS is not. Because PhLPL has several consensus sites for the constitutively active kinase casein kinase 2 (CK2) in its N terminus, we tested the phosphorylation of the recombinant proteins by either HEK cell cytosol in the presence or absence of kinase inhibitors or by purified CK2. PhLPL was a good CK2 substrate, whereas PhLPS and phosducin were not. Progressive truncation and serine/threonine to alanine mutations of the PhLPL N terminus identified a serine/threonine cluster (Ser-18/ Thr-19/Ser-20) within a small N-terminal region of PhLPL (amino acids 5-28) as the site in which PhLPL function was modified in HEK 293 cells. In native tissue, PhLPL also seems to be regulated by phosphorylation because phosphorylated and non-phosphorylated forms of PhLPL were detected in mouse brain and adrenal gland. Moreover, the alternatively spliced isoform PhLPS was also found in adrenal tissue. Therefore, the physiological control of G-protein regulation by PhLP seems to involve phosphorylation by CK2 and alternative splicing of the regulator.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany	University of Wurzburg	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bauer PH, 1998, N-S ARCH PHARMACOL, V357, P371, DOI 10.1007/PL00005181; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BILLMAN GE, 1993, AM J PHYSIOL, V265, pH1529, DOI 10.1152/ajpheart.1993.265.5.H1529; Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gensse M, 2000, FEBS LETT, V480, P184, DOI 10.1016/S0014-5793(00)01926-8; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V234, P681, DOI 10.1006/bbrc.1997.6699; Kim YM, 2002, J BIOL CHEM, V277, P16837, DOI 10.1074/jbc.M201379200; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Schroder S, 2000, N-S ARCH PHARMACOL, V362, P435, DOI 10.1007/s002100000298; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; Schulz K, 1996, J BIOL CHEM, V271, P22546, DOI 10.1074/jbc.271.37.22546; Thibault C, 1999, BBA-GENE STRUCT EXPR, V1444, P346, DOI 10.1016/S0167-4781(99)00006-8; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469; ZHUO S, 1993, J BIOL CHEM, V268, P17754	36	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4474	4481		10.1074/jbc.M206347200	http://dx.doi.org/10.1074/jbc.M206347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466282	hybrid			2022-12-25	WOS:000180968900017
J	Kortylewski, M; Feld, F; Kruger, KD; Bahrenberg, G; Roth, RA; Joost, HG; Heinrich, PC; Behrmann, I; Barthel, A				Kortylewski, M; Feld, F; Kruger, KD; Bahrenberg, G; Roth, RA; Joost, HG; Heinrich, PC; Behrmann, I; Barthel, A			Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; PROTEIN-KINASE-B; PAX3-FKHR FUSION PROTEIN; ACUTE-PHASE RESPONSE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; ALVEOLAR RHABDOMYOSARCOMA; NUCLEAR TRANSLOCATION; CYTOKINE RECEPTORS; MELANOMA-CELLS	The phosphatidylinositol 3-kinase/Akt pathway plays an important role in the signaling of insulin and other growth factors, which reportedly attenuate the interleukin-6 (IL-6)-mediated stimulation of acute phase plasma protein genes. We investigated the effect of the protein kinase Akt on IL-6-mediated transcriptional activation. The transient expression of constitutively active Akt inhibited the IL-6-dependent activity of the alpha(2)-macroglobulin promoter in HepG2 cells, whereas expression of an inactive mutant of phosphatidylinositol-dependent kinase 1 had the opposite effect. Since Akt is known to regulate gene expression through inactivation of the transcription factor FKHR (forkhead in rhabdomyosarcoma), we examined the effect of FKHR on STAT3-mediated transcriptional regulation. Indeed, the overexpression of FKHR specifically enhanced the activity of STAT3-dependent promoters but not that of a STAT5-responsive promoter. The effect of FKHR required the presence of functional STAT3 and was abrogated by the expression of dominant negative STAT3 mutants. Furthermore, FKHR and STAT3 were shown to communoprecipitate and to colocalize in the nuclear regions of IL-6-treated HepG2 cells. Our results indicate that FKHR can modulate the IL-6-induced transcriptional activity by acting as a coactivator of STAT3.	Univ Dusseldorf, Abt Endokrinol, D-40225 Dusseldorf, Germany; Rhein Westfal TH Aachen, Inst Biochem, D-52057 Aachen, Germany; Rhein Westfal TH Aachen, Inst Pharmakol & Toxikol, D-52057 Aachen, Germany; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33613 USA; Deutsch Int Ernahrungsforsch, D-14558 Potsdam, Germany	Heinrich Heine University Dusseldorf; RWTH Aachen University; RWTH Aachen University; Stanford University; H Lee Moffitt Cancer Center & Research Institute	Barthel, A (corresponding author), Univ Dusseldorf, Abt Endokrinol, Moorenstr 5, D-40225 Dusseldorf, Germany.		Kortylewski, Marcin/H-8052-2019; Joost, Hans-Georg/J-4462-2013	Kortylewski, Marcin/0000-0002-6003-1816; Joost, Hans-Georg/0000-0002-5860-606X; Behrmann, Iris/0000-0003-3688-3645	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34926] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Leu JI, 2001, MOL CELL BIOL, V21, P414, DOI 10.1128/MCB.21.2.414-424.2001; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; MILLAND J, 1990, AM J PHYSIOL, V259, P340; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Siewert E, 2000, HEPATOLOGY, V32, P49, DOI 10.1053/jhep.2000.8532; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; Tu YP, 2000, CANCER RES, V60, P6763; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657	45	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5242	5249		10.1074/jbc.M205403200	http://dx.doi.org/10.1074/jbc.M205403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12456685	hybrid			2022-12-25	WOS:000180968900113
J	Temel, RE; Parks, JS; Williams, DL				Temel, RE; Parks, JS; Williams, DL			Enhancement of scavenger receptor class B type I-mediated selective cholesteryl ester uptake from apoA-I-/- high density lipoprotein (HDL) by apolipoprotein A-I requires HDL reorganization by lecithin cholesterol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; PLASMA LECITHIN; HEART-DISEASE; BINDING; MECHANISM; CELLS; PHOSPHATIDYLCHOLINE; ATHEROSCLEROSIS; IDENTIFICATION; METABOLISM	The severe depletion of cholesteryl ester (CE) in adrenocortical cells of apoA-I-/- mice suggests that apolipoprotein (apo) A-I plays an important role in the high density lipoprotein (HDL) CE selective uptake process mediated by scavenger receptor BI (SR-BI) in vivo. A recent study showed that apoA-I-/- HDL binds to SR-BI with the same affinity as apoA-I+/+ HDL, but apoA-I-/- HDL has a decreased V,.,,. for CE transfer from the HDL particle to adrenal cells. The present study was designed to determine the basis for the reduced selective uptake of CE from apoA-I-/- HDL. Variations in apoA-I-/- HDL particle diameter, free cholesterol or phospholipid content, or the apoE or apoA-H content of apoA-I-/- HDL had little effect on HDL CE selective uptake into Y1-BS1 adrenal cells. Lecithin cholesterol acyltransferase treatment alone or addition of apoA-I to apoA-I-/- HDL alone also had little effect. However, addition of apoA-I to apoA-I-/- HDL in the presence of lecithin cholesterol acyltransferase reorganized the large heterogeneous apoA-I-/- HDL to a more discrete particle with enhanced CE selective uptake activity. These results show a unique role for apoA-I in HDL CE selective uptake that is distinct from its role as a ligand for HDL binding to SR-BI. These data suggest that the conformation of apoA-I at the HDL surface is important for the efficient transfer of CE to the cell.	SUNY Stony Brook, Ctr Med, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Wake Forest University	Williams, DL (corresponding author), SUNY Stony Brook, Ctr Med, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	dave@pharm.sunysb.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058012, R01HL032868, R01HL054176, P01HL049373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32868, HL 54176, HL 49373, HL 58012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Chisholm JW, 1999, J LIPID RES, V40, P1512; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Connelly MA, 2001, BIOCHEMISTRY-US, V40, P5249, DOI 10.1021/bi002825r; Corsico B, 2001, J BIOL CHEM, V276, P16978, DOI 10.1074/jbc.M011533200; de Beer MC, 2001, J LIPID RES, V42, P309; de Beer MC, 2001, J BIOL CHEM, V276, P15832, DOI 10.1074/jbc.M100228200; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; EMMANUEL F, 1994, J BIOL CHEM, V269, P29883; GLASS C, 1985, J BIOL CHEM, V260, P744; GLASS CK, 1983, J BIOL CHEM, V258, P7161; GLOMSET JA, 1968, J LIPID RES, V9, P155; GONG EL, 1994, BBA-LIPID LIPID MET, V1213, P335, DOI 10.1016/0005-2760(94)00062-X; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; Liu T, 2002, J BIOL CHEM, V277, P21576, DOI 10.1074/jbc.M112103200; Mahley RW, 1999, J LIPID RES, V40, P1; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; PARKS JS, 1995, J LIPID RES, V36, P349; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Plump AS, 1997, J LIPID RES, V38, P1033; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; RICHARD BM, 1993, J LIPID RES, V34, P571; Rinninger F, 1998, BBA-LIPID LIPID MET, V1393, P277, DOI 10.1016/S0005-2760(98)00082-4; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Rye KA, 1997, J BIOL CHEM, V272, P3953, DOI 10.1074/jbc.272.7.3953; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; Temel RE, 2002, J BIOL CHEM, V277, P26565, DOI 10.1074/jbc.M203014200; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134	43	19	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4792	4799		10.1074/jbc.M208160200	http://dx.doi.org/10.1074/jbc.M208160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473673	hybrid			2022-12-25	WOS:000180968900058
J	Wu, PY; Qiu, C; Sohail, A; Zhang, X; Bhagwat, AS; Cheng, XD				Wu, PY; Qiu, C; Sohail, A; Zhang, X; Bhagwat, AS; Cheng, XD			Mismatch repair in methylated DNA - Structure and activity of the mismatch-specific thymine glycosylase domain of methyl-CpG-binding protein MBD4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION; CRYSTAL-STRUCTURE; N-GLYCOSYLASE; MED1 MBD4; ENDONUCLEASE; 8-OXOGUANINE; SUPERFAMILY; CHROMATIN; SUBSTRATE; COMPLEX	MBD4 is a member of the methyl-CpG-binding protein family. It contains two DNA binding domains, an amino-proximal methyl-CpG binding domain (MBD) and a C-terminal mismatch-specific glycosylase domain. Limited in vitro proteolysis of mouse MBD4 yields two stable fragments: a 139-residue fragment including the MBD, and the other 155-residue fragment including the glycosylase domain. Here we show that the latter fragment is active as a glycosylase on a DNA duplex containing a G:T mismatch within a CpG sequence context. The crystal structure confirmed the C-terminal domain is a member of the helix-hairpin-helix DNA glycosylase superfamily. The MBD4 active site is situated in a cleft that likely orients and binds DNA. Modeling studies suggest the mismatched target nucleotide will be flipped out into the active site where candidate residues for catalysis and substrate specificity are present.	Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Emory University; Emory University; Wayne State University	Cheng, XD (corresponding author), Emory Univ, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.		Bhagwat, Ashok/ABA-3861-2020; Hu, Ruogu/B-2203-2008; Bhagwat, Ashok/AAU-4186-2021	Bhagwat, Ashok/0000-0003-1188-0579; Sohail, Anjum/0000-0001-5567-9645	NIGMS NIH HHS [R01 GM049245-11, R01 GM057200, R01 GM049245, GM57200, GM49245] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057200, R01GM049245] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Beletskii A, 2000, J MOL BIOL, V300, P1057, DOI 10.1006/jmbi.2000.3944; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Drohat AC, 2002, NAT STRUCT BIOL, V9, P659, DOI 10.1038/nsb829; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Mol CD, 2002, J MOL BIOL, V315, P373, DOI 10.1006/jmbi.2001.5264; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Ohki I, 1999, EMBO J, V18, P6653, DOI 10.1093/emboj/18.23.6653; Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157	37	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5285	5291		10.1074/jbc.M210884200	http://dx.doi.org/10.1074/jbc.M210884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12456671	hybrid, Green Accepted			2022-12-25	WOS:000180968900119
J	Li, CJ; Iosef, C; Jia, CYH; Han, VKM; Li, SSC				Li, CJ; Iosef, C; Jia, CYH; Han, VKM; Li, SSC			Dual functional roles for the X-linked lymphoproliferative syndrome gene product SAP/SH2D1A in signaling through the signaling lymphocyte activation molecule (SLAM) family of immune receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; CUTTING EDGE; SH2 DOMAIN; TYROSINE-PHOSPHATASE; ENCODING GENE; PROTEIN SAP; DISEASE; 2B4; NK; MUTATIONS	The X-linked lymphoproliferative (XLP) syndrome gene encodes a protein named SAP or SH2D1A that is composed of a single Src homology 2 (SH2) domain. Two models have been proposed for its function in lymphocyte signaling. One postulates that it acts as an inhibitor of interactions between the phosphatase SHP-2 and the immune receptor SLAM. The other suggests that it functions as an adaptor to promote the recruitment of a kinase, FynT, to SLAM. Here, we provide evidence in support of both roles for SAP. Using an array of peptides derived from the SLAM family of receptors, we demonstrate that SAP binds with comparable affinities to the same sites in these receptors as do the SH2 domains of SHP-2 and SHIP, suggesting that these three proteins may compete against one another in binding to a given SLAM family receptor. Furthermore, in vitro and in vivo binding studies indicate that SAP is capable of binding directly to FynT, an interaction mediated by the FynT SH3 domain. In cells, FynT was shown to be indispensable for SLAM tyrosine phosphorylation, which, in turn, was drastically enhanced by SAP. Because SAP also blocked the recruitment of SHP-2 to SLAM in these cells, we propose a dual functional role for SAP in SLAM signaling by acting both as an adaptor for FynT and an inhibitor to SHP-2 binding. The physiological relevance of the dual functional role for SAP is underscored by the observation that disease-causing SAP mutants exhibited significantly reduced affinities to both FynT and SLAM.	Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada; Child Hlth Res Inst, London, ON N6C 2V5, Canada	Western University (University of Western Ontario)	Li, SSC (corresponding author), Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada.							Benoit L, 2000, J IMMUNOL, V165, P3549, DOI 10.4049/jimmunol.165.7.3549; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; delaFuente MA, 1997, BLOOD, V90, P2398; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; Fraser CC, 2002, IMMUNOGENETICS, V53, P843, DOI 10.1007/s00251-001-0415-7; HARADA S, 1982, J IMMUNOL, V129, P2532; Hwang PM, 2002, EMBO J, V21, P314, DOI 10.1093/emboj/21.3.314; Latour S, 2001, NAT IMMUNOL, V2, P681, DOI 10.1038/90615; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Morra M, 2001, EMBO J, V20, P5840, DOI 10.1093/emboj/20.21.5840; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Morra M, 2001, J BIOL CHEM, V276, P36809, DOI 10.1074/jbc.M101305200; Nakajima H, 2000, EUR J IMMUNOL, V30, P3309, DOI 10.1002/1521-4141(200011)30:11<3309::AID-IMMU3309>3.0.CO;2-3; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; PURTILO D T, 1975, Lancet, V1, P935; PURTILO DT, 1978, LANCET, V1, P798; Sayos J, 2001, BLOOD, V97, P3867, DOI 10.1182/blood.V97.12.3867; Sayos J, 2000, INT IMMUNOL, V12, P1749, DOI 10.1093/intimm/12.12.1749; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Tangye SG, 2000, J IMMUNOL, V165, P2932, DOI 10.4049/jimmunol.165.6.2932; Tangye SG, 1999, J IMMUNOL, V162, P6981; Tovar V, 2000, IMMUNOGENETICS, V51, P788, DOI 10.1007/s002510000209	30	69	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3852	3859		10.1074/jbc.M206649200	http://dx.doi.org/10.1074/jbc.M206649200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458214	hybrid			2022-12-25	WOS:000180869700044
J	Eckman, EA; Watson, M; Marlow, L; Sambamurti, K; Eckman, CB				Eckman, EA; Watson, M; Marlow, L; Sambamurti, K; Eckman, CB			Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; TRANSGENIC MICE; A-BETA; EXTRACELLULAR LEVELS; HUMAN TISSUES; IN-VITRO; PROTEIN; BRAIN; DEGRADATION; PRESENILIN-1	The abnormal accumulation of beta-amyloid (Abeta) in the brain is an early and invariant feature in Alzheimer's disease (AD) and is believed to play a pivotal role in the etiology and pathogenesis of the disease. As such, a major focus of AD research has been the elucidation of the mechanisms responsible for the generation of Abeta. As with any peptide, however, the degree of Abeta accumulation is dependent not only on its production but also on its removal. In cell-based and in vitro models we have previously characterized endothelin-converting enzyme-1 (ECE-1) as an Abeta-degrading enzyme that appears to act intracellularly, thus limiting the amount of Abeta available for secretion. To determine the physiological significance of this activity, we analyzed Abeta levels in the brains of mice deficient for ECE-1 and a closely related enzyme, ECE-2. Significant increases in the levels of both Abeta40 and Abeta42 were found in the brains of these animals when compared with age-matched littermate controls. The increase in Abeta levels in the ECE-deficient mice provides the first direct evidence for a physiological role for both ECE-1 and ECE-2 in limiting Abeta accumulation in the brain and also provides further insight into the factors involved in Abeta clearance in vivo.	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA	Mayo Clinic	Eckman, EA (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd,Birdsall Bldg,Rm 256, Jacksonville, FL 32224 USA.		Eckman, Elizabeth/AAL-7316-2021; Sambamurti, Kumar/A-1620-2012	Sambamurti, Kumar/0000-0001-9507-9214; Marlow, Laura/0000-0002-4726-9889; Eckman, Elizabeth/0000-0002-5391-4960				Backstrom JR, 1996, J NEUROSCI, V16, P7910; Barnes K, 1997, J NEUROCHEM, V68, P570; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Chesneau V, 2000, BIOCHEM J, V351, P509, DOI 10.1042/0264-6021:3510509; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Davenport AP, 1998, HISTOCHEM J, V30, P359, DOI 10.1023/A:1003236628701; De Jonghe C, 1999, HUM MOL GENET, V8, P1529, DOI 10.1093/hmg/8.8.1529; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Exley C, 2001, NEUROREPORT, V12, P2967, DOI 10.1097/00001756-200109170-00042; Flood DG, 2002, NEUROBIOL AGING, V23, P335, DOI 10.1016/S0197-4580(01)00330-X; Gray GA, 1996, PHARMACOL THERAPEUT, V72, P109, DOI 10.1016/S0163-7258(96)00101-5; Hoang MV, 1997, BIOCHEM J, V327, P23, DOI 10.1042/bj3270023; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; Kitas EA, 2002, BIOORG MED CHEM LETT, V12, P1727, DOI 10.1016/S0960-894X(02)00254-8; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; Ledesma MD, 2000, EMBO REP, V1, P530; Loffler BM, 2000, J CARDIOVASC PHARM, V35, pS79; Lorenzo MN, 2001, BBA-GENE STRUCT EXPR, V1522, P46, DOI 10.1016/S0167-4781(01)00283-4; Nakagomi S, 2000, NEUROSCIENCE, V101, P441, DOI 10.1016/S0306-4522(00)00345-6; Nakano Y, 1999, EUR J NEUROSCI, V11, P2577, DOI 10.1046/j.1460-9568.1999.00698.x; Petanceska SS, 2000, NEUROLOGY, V54, P2212, DOI 10.1212/WNL.54.12.2212; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Poduslo SE, 1999, HUM GENET, V105, P32, DOI 10.1007/s004390051060; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Sluck JM, 1999, NEUROSCIENCE, V91, P1483, DOI 10.1016/S0306-4522(98)00692-7; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Telemaque S, 1998, J CARDIOVASC PHARM, V31, pS548, DOI 10.1097/00005344-199800001-00158; Tucker HM, 2002, J NEUROSCI RES, V70, P249, DOI 10.1002/jnr.10417; Tucker HM, 2000, J NEUROSCI, V20, P3937; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; Van Nostrand WE, 1999, BIOCHEMISTRY-US, V38, P11570, DOI 10.1021/bi990610f; Vekrellis K, 2000, J NEUROSCI, V20, P1657; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yanagisawa H, 2000, J CLIN INVEST, V105, P1373, DOI 10.1172/JCI7447	46	208	220	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2081	2084		10.1074/jbc.C200642200	http://dx.doi.org/10.1074/jbc.C200642200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12464614	hybrid			2022-12-25	WOS:000180562000001
J	Segawa, T; Nau, ME; Xu, LL; Chilukuri, RN; Makarem, M; Zhang, W; Petrovics, G; Sesterhenn, IA; McLeod, DG; Moul, JW; Vahey, M; Srivastava, S				Segawa, T; Nau, ME; Xu, LL; Chilukuri, RN; Makarem, M; Zhang, W; Petrovics, G; Sesterhenn, IA; McLeod, DG; Moul, JW; Vahey, M; Srivastava, S			Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen regulated genes; gene chip; endoplasmic reticulum stress response	UNFOLDED PROTEIN RESPONSE; FATTY-ACID SYNTHASE; RECEPTOR GENE; ORNITHINE DECARBOXYLASE; POLYAMINE LEVELS; CARCINOMA-CELLS; GROWTH-FACTOR; IN-VIVO; PROGRESSION; MODEL	Evaluations of androgen regulated gene (ARG) repertoire provide new insights into the androgen receptor (AR) mediated signaling at the transcriptional level. Definition of ARGs having critical functions in the biology of normal and malignant prostate should aid in identifying new bio-markers and therapeutic targets for prostate cancer (CaP). Using Affymetrix HuGene FL oligonucleotide arrays, temporal expression profiles of ARGs in widely used hormone responsive LNCaP cells, were analysed by hierarchical clustering methods and functional classification. ARGs in response to different androgen concentrations showed temporal co-regulation of genes involved in specific biochemical pathways. This study focuses on our new observations of the coordinated androgen induction of genes (NDRG1, PDIR, HERPUD1, ORP150) involved in the endoplasmic reticulum (ER) stress response pathway. Expression analysis of the two selected ER stress responsive genes, NDRG1 and HERPUD1 in primary CaPs revealed a significantly reduced tumor associated expression. Intriguing linkage of the androgen signaling to ER stress responsive genes, a protective response to protein unfolding or protein damage resulting from cellular stress signals, suggests that androgens may induce such stress signals in CaP cells. Decreased CaP associated expression of two ER stress responsive genes also suggests that possible abrogation of this pathway in prostate tumorigenesis.	Uniformed Serv Univ Hlth Sci, Ctr Prostrate Dis Res, Dept Surg, Rockville, MD 20852 USA; Walter Reed Army Med Ctr, Urol Serv, Washington, DC 20307 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20307 USA; Walter Reed Army Inst Res, Div Retrovirol, Affymetrix Gene Array Lab, Rockville, MD 20850 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Srivastava, S (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostrate Dis Res, Dept Surg, 1530 E Jefferson St, Rockville, MD 20852 USA.	ssrivastava@cpdr.org		Petrovics, Gyorgy/0000-0003-3732-284X				Amler LC, 2000, CANCER RES, V60, P6134; Augustus M, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P321; Bettuzzi S, 2000, CANCER RES, V60, P1472; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; COFFEY DS, 1992, CAMPBELLS UROLOGY, V1, P221; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; CULIG Z, 1994, CANCER RES, V54, P5474; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FJOSNE HE, 1990, PROSTATE, V17, P1, DOI 10.1002/pros.2990170102; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Greeve I, 2000, J NEUROSCI, V20, P7345; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Guang RJ, 2000, CANCER RES, V60, P749; Hakimi JM, 1996, WORLD J UROL, V14, P329; Hardy DO, 1996, J CLIN ENDOCR METAB, V81, P4400, DOI 10.1210/jc.81.12.4400; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kanai S, 1998, J MOL EVOL, V47, P200, DOI 10.1007/PL00006377; Koike C, 1999, CANCER RES, V59, P6109; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lin BY, 2000, CANCER RES, V60, P858; Lin BY, 2001, CANCER RES, V61, P1611; Messing EM, 1999, J NATL CANCER I, V91, P1416, DOI 10.1093/jnci/91.16.1416; Mohan RR, 1999, CLIN CANCER RES, V5, P143; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mousses S, 2002, CANCER RES, V62, P1256; Myers RB, 2001, J UROLOGY, V165, P1027, DOI 10.1016/S0022-5347(05)66596-2; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nau ME, 2000, J CLIN MICROBIOL, V38, P1901, DOI 10.1128/JCM.38.5.1901-1908.2000; NOBLE RL, 1977, CANCER RES, V37, P1929; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Pollard M, 1998, PROSTATE, V37, P1, DOI 10.1002/(SICI)1097-0045(19980915)37:1<1::AID-PROS1>3.0.CO;2-L; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; ROSS R, 1986, JNCI-J NATL CANCER I, V76, P45; Segawa T, 1998, CANCER RES, V58, P2282; Simoneau AR, 2001, JNCI-J NATL CANCER I, V93, P57, DOI 10.1093/jnci/93.1.57; SMITH RC, 1995, NAT MED, V1, P1040, DOI 10.1038/nm1095-1040; Stanford JL, 1997, CANCER RES, V57, P1194; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Tindall DJ, 1999, PROSTATE, V38, P166, DOI 10.1002/(SICI)1097-0045(19990201)38:2<166::AID-PROS11>3.0.CO;2-A; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; Vaarala MH, 2000, LAB INVEST, V80, P1259, DOI 10.1038/labinvest.3780134; van Laar T, 2000, FEBS LETT, V469, P123, DOI 10.1016/S0014-5793(00)01253-9; vanBelzen N, 1997, LAB INVEST, V77, P85; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Xu LL, 2000, CANCER RES, V60, P6568; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196	59	115	116	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8749	8758		10.1038/sj.onc.1205992	http://dx.doi.org/10.1038/sj.onc.1205992			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483528				2022-12-25	WOS:000179734400009
J	Viard-Leveugle, I; Bullani, RR; Meda, P; Micheau, O; Limat, A; Saurat, JH; Tschopp, J; French, LE				Viard-Leveugle, I; Bullani, RR; Meda, P; Micheau, O; Limat, A; Saurat, JH; Tschopp, J; French, LE			Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; MONOCLONAL-ANTIBODY; T-CELLS; APOPTOSIS; EXPRESSION; ANTIGEN; DOMAIN; PROTEIN; CD95; CONTRIBUTES	Acquired Fas ligand (FasL)-mediated cytolytic activity of human keratinocytes causes the massive keratinocyte cell death that occurs during toxic epidermal necrolysis, a deadly adverse drug eruption. Under normal conditions keratinocyte apoptosis is a rare event in the epidermis although keratinocytes express the death receptor Fas and its ligand. Here we have investigated why this is so. We show that Fas, FasL, Fas-associated death domain, and caspase-8 mRNA are detectable in the epidermis, primary keratinocyte cultures, and keratinocyte cell line and that Fas protein is expressed in keratinocytes of all subcorneal layers of the epidermis, whereas FasL is only expressed in the basal and first suprabasal layers. Coexpression of Fas and FasL therefore occurs in basal and suprabasal keratinocytes. In vitro, keratinocytes are killed by recombinant FasL in a dose-dependent manner, but they are unable to kill Fas-sensitive target cells despite FasL expression. Analysis of keratinocyte culture supernatants and treatment of keratinocytes with metalloproteinase inhibitors excluded cell surface expression of FasL and rapid metalloproteinase-mediated cleavage of cell surface FasL. Fluorescence-activated cell sorter, confocal microscopical, and electron microscopical analysis revealed that keratinocyte FasL is localized intracellularly predominantly associated to intermediate filaments. These data suggest that the observed inability of keratinocyte FasL to induce apoptosis under physiological conditions is due to its cellular localization and also indicate that intermediate filaments may be involved in regulating the subcellular localization of FasL.	Univ Geneva, Sch Med, Dept Dermatol, CH-1211 Geneva 14, Switzerland; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Geneva; University of Geneva; University of Lausanne	French, LE (corresponding author), Univ Geneva, Sch Med, Dept Dermatol, CH-1211 Geneva 14, Switzerland.		French, Lars/AAL-5977-2020; micheau, olivier/C-3574-2011	French, Lars/0000-0002-4629-1486; micheau, olivier/0000-0001-8499-7984				Arnold R, 1999, J IMMUNOL, V162, P7140; Baker MB, 1996, J EXP MED, V183, P2645, DOI 10.1084/jem.183.6.2645; Berthou C, 1997, J IMMUNOL, V159, P5293; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KANTOR RRS, 1987, J BIOL CHEM, V262, P15158; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; LIMAT A, 1989, J INVEST DERMATOL, V92, P758, DOI 10.1111/1523-1747.ep12722530; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MATSUE H, 1995, ARCH DERMATOL RES, V287, P315, DOI 10.1007/BF01105085; MCCALL CA, 1991, J INVEST DERMATOL, V97, P111, DOI 10.1111/1523-1747.ep12478519; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OISHI M, 1994, ARCH DERMATOL RES, V286, P396, DOI 10.1007/BF00371800; SAYAMA K, 1994, DERMATOLOGY, V188, P305, DOI 10.1159/000247172; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x	30	52	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16183	16188		10.1074/jbc.M212188200	http://dx.doi.org/10.1074/jbc.M212188200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12473659	hybrid			2022-12-25	WOS:000182680000092
J	Carrasco, YR; Navarro, MN; Toribio, ML				Carrasco, YR; Navarro, MN; Toribio, ML			A role for the cytoplasmic tail of the pre-T cell receptor (TCR) alpha chain in promoting constitutive internalization degradation of the pre-TCR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; THYMOCYTE DEVELOPMENT; SURFACE EXPRESSION; ANTIGEN RECEPTOR; MEMBRANE DOMAINS; COMPLEXES; ENGAGEMENT; MODULATION; ENDOSOMES; SUBUNIT	Engagement of the alphabeta T cell receptor (TCR) by its ligand results in the down-modulation of TCR cell surface expression, which is thought to be a central event in T cell activation. On the other hand, pre-TCR signaling is a key process in alphabeta T cell development, which appears to proceed in a constitutive and ligand-independent manner. Here, comparative analyses on the dynamics of pre-TCR and TCR cell surface expression show that unligated pre-TCR complexes expressed on human pre-T cells behave as engaged TCR complexes, ie. they are rapidly internalized and degraded in lysosomes and proteasomes but do not recycle back to the cell surface. Thus, pre-TCR down-regulation takes place constitutively without the need for extracellular ligation. By using TCRalpha/pTalpha chain chimeras, we demonstrate that prevention of recycling and induction of degradation are unique pre-TCR properties conferred by the cytoplasmic domain of the pTalpha chain. Finally, we show that pre-TCR internalization is a protein kinase C-independent process that involves the combination of src kinase-dependent and -independent pathways. These data suggest that constitutive pre-TCR down-modulation regulates pre-TCR surface expression levels and hence the extent of ligand-independent signaling through the pre-TCR.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cientificas, Fac Biol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Toribio, ML (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cientificas, Fac Biol, E-28049 Madrid, Spain.		Carrasco, Yolanda/X-2629-2019; Toribio, Maria L/C-2039-2017	Navarro, Maria N./0000-0003-3977-812X; Carrasco, Yolanda R./0000-0003-2148-1926; Toribio, Maria L/0000-0002-8637-0373				Aifantis I, 2002, NAT IMMUNOL, V3, P483, DOI 10.1038/ni779; Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Berger MA, 1997, J EXP MED, V186, P1461, DOI 10.1084/jem.186.9.1461; Borst J, 1996, CURR OPIN IMMUNOL, V8, P181, DOI 10.1016/S0952-7915(96)80056-2; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; Carrasco YR, 2001, J EXP MED, V193, P1045, DOI 10.1084/jem.193.9.1045; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; Irving BA, 1998, SCIENCE, V280, P905, DOI 10.1126/science.280.5365.905; Itoh Y, 1999, J IMMUNOL, V162, P2073; Jacobs H, 1996, ONCOGENE, V12, P2089; Jacobs H, 1996, J EXP MED, V184, P1833, DOI 10.1084/jem.184.5.1833; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; Malissen B, 1999, ADV IMMUNOL, V72, P103, DOI 10.1016/S0065-2776(08)60018-8; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NIEDERGANG F, 1995, J BIOL CHEM, V270, P12839, DOI 10.1074/jbc.270.21.12839; OShea CC, 1997, IMMUNITY, V7, P591, DOI 10.1016/S1074-7613(00)80380-5; PANIGADA M, J EXP MED, V195, P1585; Ramiro AR, 2001, J IMMUNOL, V167, P5106, DOI 10.4049/jimmunol.167.9.5106; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; Trigueros C, 1998, J EXP MED, V188, P1401, DOI 10.1084/jem.188.8.1401; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; von Essen M, 2002, J IMMUNOL, V168, P4519, DOI 10.4049/jimmunol.168.9.4519; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; ZANDERS ED, 1983, NATURE, V303, P625, DOI 10.1038/303625a0	34	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14507	14513		10.1074/jbc.M204944200	http://dx.doi.org/10.1074/jbc.M204944200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12473666	hybrid			2022-12-25	WOS:000182405000118
J	Scherz-Shouval, R; Sagiv, Y; Shorer, H; Elazar, Z				Scherz-Shouval, R; Sagiv, Y; Shorer, H; Elazar, Z			The COOH terminus of GATE-16, an intra-Golgi transport modulator, is cleaved by the human cysteine protease HsApg4A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; FUSION PROTEIN; AUTOPHAGOSOME; HOMOLOG; GABARAP; ENZYME; NSF; SPECIFICITY; DISSECTION; ACTIVATION	Docking of a vesicle at the appropriate target membrane involves an interaction between integral membrane proteins located on the vesicle (v-SNAREs) and those located on the target membrane (t-SNAREs). GATE-16 (Golgi-associated ATPase enhancer of 16 kDa) was shown to modulate the activity of SNAREs in the Golgi apparatus and is therefore an essential component of intra-Golgi transport and post-mitotic Golgi re-assembly. GATE-16 contains a ubiquitin fold subdomain, which is terminated at the carboxyl end by an additional amino acid after a conserved glycine residue. In the present study we tested whether the COOH terminus of GATE-16 undergoes post-translational cleavage by a protease which exposes the glycine 116 residue. We describe the isolation and characterization of HsApg4A as a human protease of GATE-16. We show that GATE-16 undergoes COOH-terminal cleavage both in vivo and in vitro, only when the conserved glycine 116 is present. We then utilize an in vitro assay to show that pure HsApg4A is sufficient to cleave GATE-16. The characterization of this protease may give new insights into the mechanism of action of GATE-16 and its other family members.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmzevi@wicc.weizmann.ac.il		scherz-shouval, ruth/0000-0002-4570-121X				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; BAKER RT, 1991, NUCLEIC ACIDS RES, V19, P1035, DOI 10.1093/nar/19.5.1035; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Thumm M, 2001, MOL GENET GENOMICS, V266, P657, DOI 10.1007/s004380100585; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543	30	62	65	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14053	14058		10.1074/jbc.M212108200	http://dx.doi.org/10.1074/jbc.M212108200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12473658	hybrid			2022-12-25	WOS:000182405000064
J	Rosenthal, DS; Velena, A; Chou, FP; Schlegel, R; Ray, R; Benton, B; Anderson, D; Smith, WJ; Simbulan-Rosenthal, CM				Rosenthal, DS; Velena, A; Chou, FP; Schlegel, R; Ray, R; Benton, B; Anderson, D; Smith, WJ; Simbulan-Rosenthal, CM			Expression of dominant-negative Fas-associated death domain blocks human keratinocyte apoptosis and vesication induced by sulfur mustard	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HUMAN-PAPILLOMAVIRUS TYPE-16; SIGNALING COMPLEX DISC; POLY(ADP-RIBOSE) POLYMERASE; ICE/CED-3 PROTEASE; DEPENDENT PATHWAY; ENDOTHELIAL-CELLS; SUNBURN CELLS; ACTIVATION; CD95	DNA damaging agents up-regulate levels of the Fas receptor or its ligand, resulting in recruitment of Fas-associated death domain (FADD) and autocatalytic activation of caspase-8, consequently activating the executioner caspases-3, -6, and -7. We found that human epidermal keratinocytes exposed to a vesicating dose (300 pm) of sulfur mustard (SM) exhibit a dose-dependent increase in the levels of Fas receptor and Fas ligand. Immunoblot analysis revealed that the upstream caspases-8 and -9 are both activated in a time-dependent fashion, and caspase-8 is cleaved prior to caspase-9. These results are consistent with the activation of both death receptor (caspase-8) and mitochondrial (caspase-9) pathways by SM. Pretreatment of keratinocytes with a peptide inhibitor of caspase-3 (Ac-DEVD-CHO) suppressed SM-induced downstream markers of apoptosis. To further analyze the importance of the death receptor pathway in SM toxicity, we utilized Fas- or tumor necrosis factor receptor-neutralizing antibodies or constructs expressing a dominant-negative FADD (FADD-DN) to inhibit the recruitment of FADD to the death receptor complex and block the Fast tumor necrosis factor receptor pathway following SM exposure. Keratinocytes pretreated with Fas-blocking antibody or stably expressing FADD-DN and exhibiting reduced levels of FADD signaling demonstrated markedly decreased caspase-3 activity when treated with SM. In addition, the processing of procaspases-3, -7, and -8 into their active forms was observed in SM-treated control keratinocytes, but not in FADD-DN cells. Blocking the death receptor complex by expression of FADD-DN additionally inhibited SM-induced internucleosomal DNA cleavage and caspase-6-mediated nuclear lamin cleavage. Significantly, we further found that altering the death receptor pathway by expressing FADD-DN in human skin grafted onto nude mice reduces vesication and tissue injury in response to SM. These results indicate that the death receptor pathway plays a pivotal role in SM-induced apoptosis and is therefore a target for therapeutic intervention to reduce SM injury.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20007 USA; USA, Med Res Inst Chem Def, Aberdeen Proving Ground, MD 21010 USA	Georgetown University; Georgetown University; Research Institute of Chemical Defense - China	Rosenthal, DS (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	rosenthd@georgetown.edu	Simbulan-Rosenthal, Cynthia M./W-8429-2019; Feng-Pai, Chou/AGS-4250-2022; Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NATIONAL CANCER INSTITUTE [R01CA100443] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100443-05, R01 CA100443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Aringer M, 2002, LUPUS, V11, P102, DOI 10.1191/0961203302lu160oa; Arroyo CM, 2000, J APPL TOXICOL, V21, pS63; Borges VM, 2002, AM J RESP CELL MOL, V27, P78, DOI 10.1165/ajrcmb.27.1.4717; Butler DM, 1995, EUR CYTOKINE NETW, V6, P225; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Dabrowska MI, 1996, TOXICOL APPL PHARM, V141, P568, DOI 10.1006/taap.1996.0324; Feister AJ., 1991, MED DEFENSE MUSTARD; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GROSS CL, 1988, P M NATO RES STUD GR; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hinshaw DB, 1999, TOXICOL APPL PHARM, V156, P17, DOI 10.1006/taap.1999.8634; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Mang R, 2002, DERMATOLOGY, V204, P156, DOI 10.1159/000051840; MCLEAN WHI, 1994, J INVEST DERMATOL, V102, P24, DOI 10.1111/1523-1747.ep12371726; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meier HL, 1998, BBA-MOL CELL RES, V1404, P367, DOI 10.1016/S0167-4889(98)00078-0; MEIER HL, 1984, P 4 ANN CHEM DEF BIO; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; O'Quinn RP, 2002, ARCH DERMATOL, V138, P644, DOI 10.1001/archderm.138.5.644; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PETRALI JP, 1990, J TOXICOL-CUTAN OCUL, V9, P193, DOI 10.3109/15569529009036325; Rosenthal DS, 1998, J INVEST DERMATOL, V111, P64, DOI 10.1046/j.1523-1747.1998.00250.x; Rosenthal DS, 2001, J INVEST DERMATOL, V117, P1566, DOI 10.1046/j.0022-202x.2001.01578.x; Rosenthal DS, 2000, J APPL TOXICOL, V21, pS43; ROSENTHAL DS, 1995, J INVEST DERMATOL, V105, P38, DOI 10.1111/1523-1747.ep12312525; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Scallon B, 2002, J PHARMACOL EXP THER, V301, P418, DOI 10.1124/jpet.301.2.418; Schopf RE, 2002, J AM ACAD DERMATOL, V46, P886, DOI 10.1067/mjd.2002.120472; Schwarz A, 1997, EXP DERMATOL, V6, P1, DOI 10.1111/j.1600-0625.1997.tb00138.x; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; SMITH WJ, 1990, CELL BIOL TOXICOL, V6, P285, DOI 10.1007/BF02443803; SMITH WJ, 1991, ARCH DERMATOL, V127, P1207, DOI 10.1001/archderm.127.8.1207; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Sun J, 1999, ACTA PHARMACOL SIN, V20, P445; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VANGENDEREN J, 1985, FUND APPL TOXICOL, V5, pS98, DOI 10.1016/0272-0590(85)90119-8; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Zhou ZX, 2001, AM J PATHOL, V159, P329, DOI 10.1016/S0002-9440(10)61699-9; Zhuang LH, 1999, J IMMUNOL, V162, P1440; Zhuang LH, 2000, J INTERF CYTOK RES, V20, P445, DOI 10.1089/10799900050023852	48	51	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8531	8540		10.1074/jbc.M209549200	http://dx.doi.org/10.1074/jbc.M209549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12482751	hybrid			2022-12-25	WOS:000181466800102
J	Li, YM; Syvitski, RT; Chu, GC; Ikeda-Saito, M; La Mar, GN				Li, YM; Syvitski, RT; Chu, GC; Ikeda-Saito, M; La Mar, GN			Solution H-1 NMR investigation of the active site molecular and electronic structures of substrate-bound, cyanide-inhibited HmuO, a bacterial heme oxygenase from Corynebacterium diphtheriae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; OXIDATIVE CLEAVAGE; AQUEOUS-SOLUTIONS; SOLUTION H-1-NMR; IRON SOURCES; COMPLEX; IDENTIFICATION; SPECTROSCOPY; DEGRADATION; MECHANISM	The molecular structure and dynamic properties of the active site environment of HmuO, a heme oxygenase (HO) from the pathogenic bacterium Corynebacterium diphtheriae, have been investigated by H-1 NMR spectroscopy using the human HO (hHO) complex as a homology model. It is demonstrated that not only the spatial contacts among residues and between residues and heme, but the magnetic axes that can be related to the direction and magnitude of the steric tilt of the FeCN unit are strongly conserved in the two HO complexes. The results indicate that very similar contributions of steric blockage of several meso positions and steric tilt of the attacking ligand are operative. A distal H-bond network that involves numerous very strong H-bonds and immobilized water molecules is identified in HmuO that is analogous to that previously identified in hHO (Li, Y., Syvitski, R. T., Auclair, K., Wilks, A., Ortiz de Montellano, P. R., and La Mar, G. N. (2002) J. Biol. Chem. 277, 33018-33031). The NMR results are completely consistent with the very recent crystal structure of the HmuO-substrate complex. The H-bond network/ordered water molecules are proposed to orient the distal water molecule near the catalytically key Asp(136) (Asp(140) in hHO) that stabilizes the hydroperoxy intermediate. The dynamic stability of this H-bond network in HmuO is significantly greater than in hHO and may account for the slower catalytic rate in bacterial HO compared with mammalian HO.	Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	University of California System; University of California Davis; Case Western Reserve University; Tohoku University	La Mar, GN (corresponding author), Univ Calif Davis, Dept Chem, 1 Shields Ave, Davis, CA 95616 USA.		Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057272] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62380, GM57272] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Beale S. I., 1994, MOL BIOL CYANOBACTER, P519; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; Chu GC, 1999, J STRUCT BIOL, V126, P171, DOI 10.1006/jsbi.1999.4122; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; Chu GC, 2000, J BIOL CHEM, V275, P17494, DOI 10.1074/jbc.M000830200; CROSS KJ, 1985, J MAGN RESON, V64, P220, DOI 10.1016/0022-2364(85)90346-4; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; de Montellano PRO, 2000, CURR OPIN CHEM BIOL, V4, P221; DEMONTELLANO PRO, 2003, IN PRESS PORPHYRIN H; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Gorst CM, 1998, J AM CHEM SOC, V120, P8875, DOI 10.1021/ja9815475; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jeffery G.A., 1997, INTRO HYDROGEN BONDI; La Mar G.N., 2000, PORPHYRIN HDB, V5, P185; La Mar GN, 2001, J BIOL CHEM, V276, P15676, DOI 10.1074/jbc.M009974200; Li YM, 2002, J BIOL CHEM, V277, P33018, DOI 10.1074/jbc.M204216200; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Nguyen BD, 1999, J AM CHEM SOC, V121, P208, DOI 10.1021/ja982555o; Otting G, 1997, PROG NUCL MAG RES SP, V31, P259, DOI 10.1016/S0079-6565(97)00012-5; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; SCHULLER DJ, 2001, HDB METALLOPROTEINS, V1, P317; SMITH RM, 1983, NEUROBIOLOGY TRACE E, V1, P1; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2002, J BIOL CHEM, V277, P45086, DOI 10.1074/jbc.M207267200; Syvitski RT, 2002, J AM CHEM SOC, V124, P14296, DOI 10.1021/ja028108x; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Wilks A, 2000, J BIOL CHEM, V275, P11686, DOI 10.1074/jbc.275.16.11686; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000; Zhu WM, 2000, J BACTERIOL, V182, P439, DOI 10.1128/JB.182.2.439-447.2000	46	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6651	6663		10.1074/jbc.M211249200	http://dx.doi.org/10.1074/jbc.M211249200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12480929	hybrid			2022-12-25	WOS:000181195100005
J	Moody, AM; North, SJ; Reinhold, B; Van Dyken, SJ; Rogers, ME; Panico, M; Dell, A; Morris, HR; Marth, JD; Reinherz, EL				Moody, AM; North, SJ; Reinhold, B; Van Dyken, SJ; Rogers, ME; Panico, M; Dell, A; Morris, HR; Marth, JD; Reinherz, EL			Sialic acid capping of CD8 beta core 1-O-glycans controls thymocyte major histocompatibility complex class I interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD8 CORECEPTOR FUNCTION; T-CELL ACTIVATION; PEANUT AGGLUTININ; POSITIVE SELECTION; MASS-SPECTROMETRY; MHC CLASS; GLYCOSYLATION; EXPRESSION; BINDING; DIFFERENTIATION	Bidentate interaction of a T-cell receptor and CD8alphabeta heterodimer with a peptide-MHCI complex is required for the generation of cytotoxic T-lymphocytes. During thymic development, the modification of CD8beta glycans influences major histocompatibility complex class I binding to T-cell precursors called thymocytes. ES mass spectrometry (MS) and tandem MS/MS analysis were used to identify the changes occurring in the CD8beta-glycopeptides during T-cell development. Several threonine residues proximal to the CD8beta Ig headpiece are glycosylated with core-type 1 O-glycans. Non-sialylated glycoforms are present in immature thymocytes ut are virtually absent in mature thymocytes. These results suggest how sialylation in a discrete segment of the CD8beta stalk by ST3Gal-1 sialyltransferase creates a molecular developmental switch that affects ligan binding.	Dana Farber Canc Inst, Immunobiol Lab, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Med, Boston, MA 02115 USA; Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AY, England; MSCAN Res & Training Ctr, Ascot SL5 7PZ, Berks, England; MSCAN Inc, W Chester, PA 19380 USA; Univ Calif San Diego, Howard Hughes Med Inst, Dept Cellular & Mol Med, San Diego, CA 92093 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Imperial College London; Howard Hughes Medical Institute; University of California System; University of California San Diego	Reinherz, EL (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.			Van Dyken, Steven/0000-0002-9787-0883	NIAID NIH HHS [AI45022] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI045022, R01AI045022, R21AI045022] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Baum LG, 2002, IMMUNITY, V16, P5, DOI 10.1016/S1074-7613(02)00265-0; Bosselut R, 2000, IMMUNITY, V12, P409, DOI 10.1016/S1074-7613(00)80193-4; CASABO LG, 1994, J IMMUNOL, V152, P397; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; CROOKS MEC, 1994, IMMUNITY, V1, P277; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; Dell A, 2001, SCIENCE, V291, P2351, DOI 10.1126/science.1058890; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DISANTO JP, 1988, EMBO J, V7, P3465, DOI 10.1002/j.1460-2075.1988.tb03221.x; Galvan M, 2000, J BIOL CHEM, V275, P16730, DOI 10.1074/jbc.M001117200; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Gascoigne NRJ, 2002, CURR BIOL, V12, pR99, DOI 10.1016/S0960-9822(02)00671-1; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; Leffler H, 2001, Results Probl Cell Differ, V33, P57; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Nguyen JT, 2001, J IMMUNOL, V167, P5697, DOI 10.4049/jimmunol.167.10.5697; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; PEREIRA MEA, 1976, CARBOHYD RES, V51, P107; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; Varki A., 1999, ESSENTIALS GLYCOBIOL; Wu WY, 1996, J EXP MED, V184, P759, DOI 10.1084/jem.184.2.759	34	67	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7240	7246		10.1074/jbc.M210468200	http://dx.doi.org/10.1074/jbc.M210468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12459555	hybrid			2022-12-25	WOS:000181195100079
J	De, M; Jayarapu, K; Elenich, L; Monaco, JJ; Colbert, RA; Griffin, TA				De, M; Jayarapu, K; Elenich, L; Monaco, JJ; Colbert, RA; Griffin, TA			beta 2 subunit propeptides influence cooperative proteasome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PROTEIN-DEGRADATION; 20S PROTEASOME; INTERFERON-GAMMA; PEPTIDASE ACTIVITIES; PRECURSOR COMPLEXES; CELL-PROTEINS; LMP2; EXPRESSION; GENERATION; MATURATION	Vertebrate proteasomes are structurally heterogeneous, consisting of both "constitutive" (or "standard") proteasomes and "immunoproteasomes." Constitutive proteasomes contain three ubiquitously expressed catalytic subunits, Delta (beta1), Z (beta2), and X (beta5), whereas immunoproteasomes contain three interferon-gamma-inducible catalytic subunits, LMP2 (beta1i), MECL (beta2i), and LMP7 (beta5i). We recently have demonstrated that proteasome assembly is biased to promote immunoproteasome homogeneity when both types of catalytic subunits are expressed in the same cell. This cooperative assembly is due in part to differences between the LMP7 (beta5i) and X (beta5) propeptides. In the current study we demonstrate that differences between the MECL (beta2i) and Z (beta2) propeptides also influence cooperative assembly. Specifically, replacing the MECL propeptide with that of Z enables MECL incorporation into otherwise constitutive (Delta(+)/X+) proteasomes and facilitates X incorporation into otherwise immunoproteasomes (MECL+/LMP2(+)). We also show, using MECL-/- mice, that LMP2 incorporation does not require MECL, in contrast with previous suggestions that their incorporation is mutually codependent. These results enable us to refine our model for cooperative proteasome assembly by determining which combinations of inducible and constitutive subunits are favored over others, and we propose a mechanism for how propeptides mediate cooperative assembly.	Cincinnati Childrens Hosp, Med Ctr, William S Rowe Div Rheumatol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Griffin, TA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, William S Rowe Div Rheumatol, Cincinnati, OH 45229 USA.	grift0@cchmc.org			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002013] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02013] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Baumeister W, 1997, BIOL CHEM, V378, P121; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dahlmann B, 1999, ARCH BIOCHEM BIOPHYS, V363, P296, DOI 10.1006/abbi.1999.1104; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; Griffin Thomas A., 2000, Molecular Cell Biology Research Communications, V3, P212, DOI 10.1006/mcbr.2000.0213; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Groettrup M, 1997, P NATL ACAD SCI USA, V94, P8970, DOI 10.1073/pnas.94.17.8970; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Kingsbury DJ, 2000, J BIOL CHEM, V275, P24156, DOI 10.1074/jbc.M001742200; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; Mayr U, 1998, J STRUCT BIOL, V124, P179, DOI 10.1006/jsbi.1998.4068; Monaco JJ, 1995, ANNU REV GENET, V29, P729, DOI 10.1146/annurev.ge.29.120195.003501; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; VAN KL, 1994, IMMUNITY, V1, P533; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	37	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6153	6159		10.1074/jbc.M209292200	http://dx.doi.org/10.1074/jbc.M209292200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12456675	hybrid			2022-12-25	WOS:000181129400083
J	Felix, G; Boller, T				Felix, G; Boller, T			Molecular sensing of bacteria in plants - The highly conserved RNA-binding motif RNP-1 of bacterial cold shock proteins is recognized as an elicitor signal in tobacco	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-RESPONSE; ESCHERICHIA-COLI; HYPERSENSITIVE REACTION; ARABIDOPSIS-THALIANA; DEFENSE RESPONSES; CRYSTAL-STRUCTURE; OXIDATIVE BURST; TOMATO CELLS; PERCEPTION; FLAGELLIN	To detect microbial infection multicellular organisms have evolved sensing systems for pathogen-associated molecular patterns (PAMPs). Here, we identify bacterial cold shock protein (CSP) as a new such PAMP that acts as a highly active elicitor of defense responses in tobacco. Tobacco cells perceive a conserved domain of CSP and synthetic peptides representing 15 amino acids of this domain-induced responses at subnanomolar concentrations. Central to the elicitor-active domain is the RNP-1 motif KGFGFITP, a motif conserved also in many RNA- and DNA-binding proteins of eukaryotes. Csp15-Nsyl, a peptide representing the domain with highest homology to csp15 in a protein of Nicotiana sylvestris exhibited only weak activity in tobacco cells. Crystallographic and genetic data from the literature show that the RNP-1 domain of bacterial CSPs resides on a protruding loop and exposes a series of aromatic and basic side chains to the surface that are essential for the nucleotide-binding activity of CSPs. Similarly, these side chains were also essential for elicitor activity and replacement of single residues in csp15 with Ala strongly reduced or abolished activity. Most strikingly, csp15-Ala10, a peptide with the RNP-1 motif modified to KGAGFITP, lacked elicitor activity but acted as a competitive antagonist for CSP-related elicitors. Bacteria commonly have a small family of CSP-like proteins including both cold-inducible and noninducible members, and Csp-related elicitor activity was detected in extracts from all bacteria tested. Thus, the CSP domain containing the RNP-1 motif provides a structure characteristic for bacteria in general, and tobacco plants have evolved a highly sensitive chemoperception system to detect this bacterial PAMP.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Felix, G (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.		poinssot, benoit/B-2569-2009; Boller, Thomas/G-3500-2012	poinssot, benoit/0000-0001-5890-4318; Boller, Thomas/0000-0001-6768-7503				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; ATKINSON M, 1993, MOL PLANT MICROBE IN, V6, P253, DOI 10.1094/MPMI-6-253; ATKINSON MM, 1985, PLANT PHYSIOL, V79, P843, DOI 10.1104/pp.79.3.843; Bae WH, 2000, P NATL ACAD SCI USA, V97, P7784, DOI 10.1073/pnas.97.14.7784; Bauer Z, 2001, J BIOL CHEM, V276, P45669, DOI 10.1074/jbc.M102390200; Berrier C, 2000, J BACTERIOL, V182, P248, DOI 10.1128/JB.182.1.248-251.2000; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; FELIX G, 1987, PLANTA, V172, P386, DOI 10.1007/BF00398668; FELIX G, 1993, PLANT J, V4, P307, DOI 10.1046/j.1365-313X.1993.04020307.x; FELIX G, 1995, PLANT J, V7, P381, DOI 10.1046/j.1365-313X.1995.7030381.x; Gilmour SJ, 1996, PLANT PHYSIOL, V111, P293, DOI 10.1104/pp.111.1.293; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155; Hahn MG, 1996, ANNU REV PHYTOPATHOL, V34, P387, DOI 10.1146/annurev.phyto.34.1.387; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heath MC, 2000, CURR OPIN PLANT BIOL, V3, P315, DOI 10.1016/S1369-5266(00)00087-X; JAKOBEK JL, 1993, PLANT CELL, V5, P49, DOI 10.1105/tpc.5.1.49; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; KEPPLER LD, 1989, PHYTOPATHOLOGY, V79, P974, DOI 10.1094/Phyto-79-974; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg Arthur M., 2002, Trends in Immunology, V23, P64, DOI 10.1016/S1471-4906(01)02150-0; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Meindl T, 2000, PLANT CELL, V12, P1783, DOI 10.1105/tpc.12.9.1783; Meindl T, 1998, PLANT CELL, V10, P1561, DOI 10.1105/tpc.10.9.1561; Meyer A, 2001, PLANTA, V213, P214, DOI 10.1007/s004250000493; Nurnberger T, 2001, TRENDS PLANT SCI, V6, P372, DOI 10.1016/S1360-1385(01)02019-2; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Pearce G, 2001, P NATL ACAD SCI USA, V98, P12843, DOI 10.1073/pnas.201416998; PEARCE G, 1993, J BIOL CHEM, V268, P212; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Schneider DS, 2002, CELL, V109, P537, DOI 10.1016/S0092-8674(02)00764-X; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; Schweizer P, 1996, PLANT J, V10, P331, DOI 10.1046/j.1365-313X.1996.10020331.x; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; Thieringer HA, 1998, BIOESSAYS, V20, P49; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621	43	155	169	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6201	6208		10.1074/jbc.M209880200	http://dx.doi.org/10.1074/jbc.M209880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471032	hybrid			2022-12-25	WOS:000181129400090
J	Ishizaki, T; Yoshie, M; Yaginuma, Y; Tanaka, T; Ogawa, K				Ishizaki, T; Yoshie, M; Yaginuma, Y; Tanaka, T; Ogawa, K			Loss of Igf2 imprinting in monoclonal mouse hepatic tumor cells is not associated with abnormal methylation patterns for the H19, Igf2, and Kvlqt1 differentially methylated regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; WILMS-TUMOR; HEPATOCELLULAR-CARCINOMA; BIALLELIC EXPRESSION; COLORECTAL-CANCER; GENE; CTCF; DELETION; LOCUS	IGFII, the peptide encoded by the Igf2 gene, is a broad spectrum mitogen with important roles in prenatal growth as well as cancer progression. Igf2 is transcribed from the paternally inherited allele, whereas the linked H19 is transcribed from the maternal allele. Igf2 imprinting is thought to be maintained by differentially methylated regions (DMRs) located at multiple sites such as upstream of H19 and Igf2 and within Knulqt1 loci. Biallelic expression (loss of imprinting (LOI)) of Igf2 is frequently observed in cancers, and a subset of Wilms' and intestinal tumors have been shown to exhibit abnormal methylation at H19DMR associated with loss of maternal H19 expression, but it is not known whether such changes are common in other neoplasms. Because cancers consist of diverse cell populations with and without Igf2 LOI, we established four independent monoclonal cell lines with Igf2 LOI from mouse hepatic tumors. We here demonstrate retention of normal differential methylation at H19, Igf2, or Knulqt1 DMR by all of the cell lines. Furthermore, H19 was found to be expressed exclusively from the maternal allele, and levels of CTCF, a multifunctional nuclear factor that has an important role in the Igf2 imprinting, were comparable with those in normal hepatic tissues with no mutational changes detected. These data indicate that Igf2 LOI in tumor cells is not necessarily linked to abnormal methylation at H19, Igf2, or Knulqt1 loci.	Asahikawa Med Coll, Dept Pathol, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Neurosurg, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Ogawa, K (corresponding author), Asahikawa Med Coll, Dept Pathol, 2-1-1-1 East, Asahikawa, Hokkaido 0788510, Japan.							Ainscough JFX, 2000, DEVELOPMENT, V127, P3923; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bliek J, 2001, HUM MOL GENET, V10, P467, DOI 10.1093/hmg/10.5.467; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2001, CANCER RES, V61, P4947; Dao D, 1999, HUM MOL GENET, V8, P1337, DOI 10.1093/hmg/8.7.1337; Davies K, 2002, DEVELOPMENT, V129, P1657; DeBaun MR, 2002, AM J HUM GENET, V70, P604, DOI 10.1086/338934; DoucRasy S, 1996, ONCOGENE, V12, P423; Drewell RA, 2002, DEVELOPMENT, V129, P1205; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; FEIL R, 1994, DEVELOPMENT, V120, P2933; Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392; Ferguson-Smith AC, 2000, CURR BIOL, V10, pR872, DOI 10.1016/S0960-9822(00)00817-4; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; Hashimoto K, 1997, HUM PATHOL, V28, P862, DOI 10.1016/S0046-8177(97)90162-3; Hofmann WK, 2002, EXP HEMATOL, V30, P318, DOI 10.1016/S0301-472X(01)00797-4; Hu JF, 1997, J BIOL CHEM, V272, P20715, DOI 10.1074/jbc.272.33.20715; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kim KS, 1997, CANCER LETT, V119, P143, DOI 10.1016/S0304-3835(97)00264-4; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Mannens M, 1999, ANN MED, V31, P4, DOI 10.3109/07853899909019258; MAW MA, 1992, CANCER RES, V52, P3094; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Ohlsson R, 1999, CANCER RES, V59, P3889; Ooasa T, 1998, MOL CARCINOGEN, V23, P248, DOI 10.1002/(SICI)1098-2744(199812)23:4<248::AID-MC8>3.0.CO;2-6; Rasko JEJ, 2001, CANCER RES, V61, P6002; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Schofield PN, 2001, TOXICOL LETT, V120, P151, DOI 10.1016/S0378-4274(01)00294-6; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096; Szabo PE, 2000, CURR BIOL, V10, P607, DOI 10.1016/S0960-9822(00)00489-9; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; Ungaro P, 1997, MOL CELL ENDOCRINOL, V135, P153, DOI 10.1016/S0303-7207(97)00201-3; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; Ward Andrew, 1997, Genes and Function, V1, P25; Yoshie M, 1998, CARCINOGENESIS, V19, P1103, DOI 10.1093/carcin/19.6.1103	53	8	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6222	6228		10.1074/jbc.M207627200	http://dx.doi.org/10.1074/jbc.M207627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12475990	Green Submitted, hybrid			2022-12-25	WOS:000181129400092
J	Kiela, PR; LeSueur, J; Collins, JF; Ghishan, FK				Kiela, PR; LeSueur, J; Collins, JF; Ghishan, FK			Transcriptional regulation of the rat NHE3 gene - Functional interactions between GATA-5 and Sp family transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ EXCHANGER; MOLECULAR-CLONING; INTESTINAL NA; MICE LACKING; EXPRESSION; PROMOTER; ACTIVATION; INITIATOR; PROTEIN; BINDING	Expression of sodium-hydrogen exchanger isoform. 3 (NHE3) in the intestinal and renal epithelium plays a critical role in sodium absorption and acid/base homeostasis. To decipher rat NHE3 gene regulation, its cis-acting regulatory elements and associated transcription factors were characterized by transient transfection of Caco-2, IEC-6, Qt6, and Drosophila SL2 cells. Deletion and mutational analyses demonstrated that the atypical TATA box located at bp -26/-31 was not necessary for promoter activity, and that a -20/+8-bp fragment represents a functional initiator. Within the 81-bp upstream region, three Sp transcription factor binding sites were critical because their mutation drastically reduced promoter activity. The roles of Sp1 and Sp3 were further demonstrated by electromobility shift assay and by transactivation of the NHE3 promoter in SL2 cells by forced expression of Sp1 and Sp3. Both of these transcription factors were found to act synergistically with GATA-5 bound to a GATA box in exon 1 (+20/+23 bp). These studies demonstrate that rat NHE3 promoter is initiator-driven and controlled mainly by Sp1 and Sp3, which functionally interact with GATA-5. This interaction represents a novel regulatory mechanism, which is likely to participate in a gradient of intestinal gene expression along the crypt-villus axis.	Univ Arizona, Arizona Hlth Sci Ctr, Steele Mem Childrens Res Ctr, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Arizona Hlth Sci Ctr, Steele Mem Childrens Res Ctr, Dept Physiol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	Ghishan, FK (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Steele Mem Childrens Res Ctr, Dept Pediat, 1501 N Campbell Ave, Tucson, AZ 85724 USA.		Kiela, Pawel/AAF-5320-2020	Kiela, Pawel/0000-0002-0014-3517	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041274] Funding Source: NIH RePORTER; NIDDK NIH HHS [2R01DK041274-1F] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alrefai WA, 2001, AM J PHYSIOL-CELL PH, V281, pC1551, DOI 10.1152/ajpcell.2001.281.5.C1551; Cano A, 1999, AM J PHYSIOL-CELL PH, V276, pC102, DOI 10.1152/ajpcell.1999.276.1.C102; Cano A, 1996, AM J PHYSIOL-RENAL, V271, pF629, DOI 10.1152/ajprenal.1996.271.3.F629; Chu JS, 2002, AM J PHYSIOL-CELL PH, V283, pC358, DOI 10.1152/ajpcell.01380.2000; Collins JF, 1997, AM J PHYSIOL-CELL PH, V273, pC1937, DOI 10.1152/ajpcell.1997.273.6.C1937; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOWITZ M, 1986, ANNU REV PHYSIOL, V48, P135, DOI 10.1146/annurev.ph.48.030186.001031; DONOWITZ M, 2000, MOL PHYSL INTESTINAL, V50, P437; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Gawenis LR, 2002, AM J PHYSIOL-GASTR L, V282, pG776, DOI 10.1152/ajpgi.00297.2001; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; ICARDLIEPKALNS C, 1993, BIOCHEM BIOPH RES CO, V193, P453, DOI 10.1006/bbrc.1993.1645; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; Kandasamy RA, 1996, J BIOL CHEM, V271, P10551, DOI 10.1074/jbc.271.18.10551; Kiela PR, 2001, AM J PHYSIOL-GASTR L, V281, pG947, DOI 10.1152/ajpgi.2001.281.4.G947; Kiela PR, 2000, AM J PHYSIOL-CELL PH, V278, pC629, DOI 10.1152/ajpcell.2000.278.4.C629; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LECOINTE N, 1994, ONCOGENE, V9, P2623; Ledoussal C, 2001, AM J PHYSIOL-RENAL, V281, pF718, DOI 10.1152/ajprenal.2001.281.4.F718; LEWIS ED, 1985, MOL CELL BIOL, V5, P2433, DOI 10.1128/MCB.5.9.2433; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Musch MW, 2001, AM J PHYSIOL-GASTR L, V280, pG687, DOI 10.1152/ajpgi.2001.280.4.G687; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; van Wering HM, 2002, J BIOL CHEM, V277, P27659, DOI 10.1074/jbc.M203645200; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yang XJ, 2000, AM J PHYSIOL-CELL PH, V279, pC410, DOI 10.1152/ajpcell.2000.279.2.C410; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	38	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5659	5668		10.1074/jbc.M209473200	http://dx.doi.org/10.1074/jbc.M209473200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12464626	hybrid			2022-12-25	WOS:000181129400024
J	Loovers, HM; Veenstra, K; Snippe, H; Pesesse, X; Erneux, C; van Haastert, PJM				Loovers, HM; Veenstra, K; Snippe, H; Pesesse, X; Erneux, C; van Haastert, PJM			A diverse family of inositol 5-phosphatases playing a role in growth and development in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; POLYPHOSPHATE 5-PHOSPHATASE; CHROMOSOME CONDENSATION; MEMBRANE LOCALIZATION; ACTIN CYTOSKELETON; CRYSTAL-STRUCTURE; CHEMOTAXIS; IDENTIFICATION; DOMAINS; RCC1	Inositol phosphate-containing molecules play an important role in a broad range of cellular processes. Inositol 5-phosphatases participate in the regulation of these signaling molecules. We have identified four inositol 5-phosphatases in Dictyostelium discoideum, Dd5P1-4, showing a high diversity in domain composition. Dd5P1 possesses only a inositol 5-phosphatase catalytic domain. An unique domain composition is present in Dd5P2 containing a RCC1-like domain. RCC1 has a seven-bladed propeller structure and interacts with G-proteins. Dd5P3 and Dd5P4 have a domain composition similar to human Synaptojanin with a SacI domain and OCRL with a RhoGAP domain, respectively. We have expressed the catalytic domains and show that these inositol 5-phosphatases have different substrate preferences. Single and double gene inactivation suggest a functional redundancy for Dd5P1, Dd5P2, and Dd5P3. Inactivation of the gene coding for Dd5P4 leads to defects in growth and development. These defects are restored by the expression of the complete protein but not by the 5-phosphatase catalytic domain.	Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands; Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium	University of Groningen; Universite Libre de Bruxelles; Vrije Universiteit Brussel	van Haastert, PJM (corresponding author), Univ Groningen, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	P.J.M.van.Haastert@chem.rug.nl						ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Brauweiler A, 2000, J EXP MED, V191, P1545, DOI 10.1084/jem.191.9.1545; Buczynski G, 1997, J CELL BIOL, V136, P1271, DOI 10.1083/jcb.136.6.1271; Cantrell DA, 2001, J CELL SCI, V114, P1439; Communi D, 1996, J BIOL CHEM, V271, P11676, DOI 10.1074/jbc.271.20.11676; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; ERNEUX C, 1994, METHODS NEUROSCI, V18, P312; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; Graham DL, 1999, BIOCHEMISTRY-US, V38, P985, DOI 10.1021/bi9821770; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Harris TW, 2000, J CELL BIOL, V150, P589, DOI 10.1083/jcb.150.3.589; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hughes WE, 2000, BIOCHEM J, V350, P337, DOI 10.1042/0264-6021:3500337; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KONIJN TM, 1970, EXPERIENTIA, V26, P367, DOI 10.1007/BF01896891; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Matzaris M, 1998, J BIOL CHEM, V273, P8256, DOI 10.1074/jbc.273.14.8256; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Peracino B, 1998, J CELL BIOL, V141, P1529, DOI 10.1083/jcb.141.7.1529; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Seastone DJ, 1999, MOL BIOL CELL, V10, P393, DOI 10.1091/mbc.10.2.393; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Stolz LE, 1998, GENETICS, V148, P1715; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	42	25	25	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5652	5658		10.1074/jbc.M208396200	http://dx.doi.org/10.1074/jbc.M208396200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12464622	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000181129400023
J	McClintock, KA; Shaw, GS				McClintock, KA; Shaw, GS			A novel S100 target conformation is revealed by the solution structure of the Ca2+-S100B-TRTK-12 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN RESONANCES; PROTEIN KINASE-C; CRYSTAL-STRUCTURE; BACKBONE AMIDE; BINDING; PEPTIDE; PHOSPHORYLATION; IDENTIFICATION; CALMODULIN; DOMAIN	The Alzheimer-linked neural protein S100B is a signaling molecule shown to control the assembly of intermediate filament proteins in a calcium-sensitive manner. Upon binding calcium, a conformational change occurs in S100B exposing a hydrophobic surface for target protein interactions. The synthetic peptide TRTK-12 (TRTKIDWNKILS), derived from random bacteriophage fibrary screening, bears sequence similarity to several intermediate filament proteins and has the highest calcium-dependent affinity of any target molecule for S100B to date (K-d <1 muM). In this work, the three-dimensional structure of the Ca2+-S100B-TRTK-12 complex has been determined by NMR spectroscopy. The structure reveals an extended, contiguous hydrophobic surface is formed on Ca2+-S100B for target interaction. The TRTK-12 peptide adopts a coiled structure that fits into a portion of this surface, anchored at Trp(7), and interacts with multiple hydrophobic contacts in helices III and IV of Ca2+-S100B. This interaction is strikingly different from the alpha-helical structures found for other S100 target peptides. By using the TRTK-12 interaction as a guide, in combination with other available S100 target structures, a recognition site on helix I is identified that may act in concert with the TRTK-12-binding site from helices III and IV. This would provide a larger, more complex site to interact with full-length target proteins and would account for the promiscuity observed for S100B target protein interactions.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Western Ontario, Mclaughlin Macromol Struct Facil, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Shaw, GS (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.		Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625				Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; Bianchi R, 1996, BBA-MOL CELL RES, V1313, P258, DOI 10.1016/0167-4889(96)00098-5; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DONATO R, 1988, J BIOL CHEM, V263, P106; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; LIN LH, 1994, MOL BRAIN RES, V25, P297, DOI 10.1016/0169-328X(94)90165-1; McClintock KA, 2000, PROTEIN SCI, V9, P2043, DOI 10.1110/ps.9.10.2043; McClintock KA, 2002, BIOCHEMISTRY-US, V41, P5421, DOI 10.1021/bi011732m; Otterbein LR, 2002, STRUCTURE, V10, P557, DOI 10.1016/S0969-2126(02)00740-2; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; Smith SP, 1997, J BIOMOL NMR, V10, P77, DOI 10.1023/A:1018397213369; Smith SP, 1996, BIOCHEMISTRY-US, V35, P8805, DOI 10.1021/bi952698c; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Smith SP, 1997, PROTEIN SCI, V6, P1110, DOI 10.1002/pro.5560060518; Snapes Dr., 1991, GIRLFRENZY; VANELDIK LJ, 1994, BBA-MOL CELL RES, V1223, P398, DOI 10.1016/0167-4889(94)90101-5; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wittekind M., 1993, J MAGN RESON SER B, V101, P171, DOI 10.1006/jmrb.1993.1033; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	37	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6251	6257		10.1074/jbc.M210622200	http://dx.doi.org/10.1074/jbc.M210622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480931	hybrid			2022-12-25	WOS:000181129400096
J	Sun, Y; Hao, MM; Luo, Y; Liang, CP; Silver, DL; Cheng, C; Maxfield, FR; Tall, AR				Sun, Y; Hao, MM; Luo, Y; Liang, CP; Silver, DL; Cheng, C; Maxfield, FR; Tall, AR			Stearoyl-CoA desaturase inhibits ATP-binding cassette transporter A1-mediated cholesterol efflux and modulates membrane domain structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR CHOLESTEROL; TANGIER-DISEASE; RAT-LIVER; RECEPTOR; GENE; MACROPHAGES; MECHANISM; SREBP-1C; ABCA1; RAFTS	Liver X receptor/retinoid X receptor (LXR/RXR) transcription factors have been found to induce a number of genes involved in the regulation of cellular cholesterol efflux, including the ATP-binding cassette transporter A1 (ABCA1), which mediates the active efflux of cellular cholesterol and phospholipids to extracellular acceptors, such as apolipoprotein A-I (apoA-I). In a screen for macrophage LXR/RXR target genes, we identified stearoyl-CoA desaturases 1 and 2 (Scd1 and Scd2), and subsequently tested the hypothesis that SCD activity might modulate cellular cholesterol efflux. In HEK 293 cells co-transfection of ABCA1 with either SCD1 or SCD2 inhibited ABCA1-mediated cholesterol efflux but not phospholipid efflux. In Chinese hamster ovary (CHO) cells with moderate stable overexpression of SCD1, cholesterol efflux to apoA-I was inhibited by 73%, whereas phospholipid efflux and ABCA1 protein levels were unchanged. In contrast, cholesterol efflux to HDL2, which is not dependent on ABCA1, was increased 2-fold in CHO-SCD1 cells. The effect of SCD on cholesterol efflux to apoA-I was independent of acyl-CoA;cholesterol acyltransferase (ACAT) activity. SCD activity led to an increased content of plasma membrane monounsaturated fatty acids (18:1) at the expense of saturated fatty acids (18:0). As shown by confocal microscopy, SCD overexpression led to a decrease of Triton X-100-resistant domains in the plasma membrane, indicating a decrease in membrane-ordered regions. The data suggest that SCD changes membrane organization and depletes a specific pool of membrane cholesterol supporting ABCA1-mediated efflux, whereas increasing availability of cholesterol for passive efflux by HDL2. ABCA1-mediated cholesterol and phospholipid efflux may be uncoupled in pathological states associated with high SCD activity, as in hyperinsulinemic obese mice, or in animals treated with LXR activators.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Columbia University; Cornell University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021; Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; Silver, David/0000-0002-7289-9890	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022682, R37HL022682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027083, R37DK027083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 22682] Funding Source: Medline; NIDDK NIH HHS [DK27083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Costet P, 2000, J BIOL CHEM, V275, P28240; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gillotte-Taylor K, 2002, J BIOL CHEM, V277, P11811, DOI 10.1074/jbc.M108268200; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; LEPAGE G, 1986, J LIPID RES, V27, P114; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; Liang CP, 2001, J BIOL CHEM, V276, P49066, DOI 10.1074/jbc.M107250200; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1996, J LIPID RES, V37, P2473; OSHINO N, 1972, ARCH BIOCHEM BIOPHYS, V149, P369, DOI 10.1016/0003-9861(72)90335-9; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seo T, 2002, BIOCHEMISTRY-US, V41, P7885, DOI 10.1021/bi011949g; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	49	108	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5813	5820		10.1074/jbc.M208687200	http://dx.doi.org/10.1074/jbc.M208687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482877	hybrid			2022-12-25	WOS:000181129400042
J	Abdelghany, HM; Bailey, S; Blackburn, GM; Rafferty, JB; McLennan, AG				Abdelghany, HM; Bailey, S; Blackburn, GM; Rafferty, JB; McLennan, AG			Analysis of the catalytic and binding residues of the diadenosine tetraphosphate pyrophosphohydrolase from Caenorhabditis elegans by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; MUTT MOTIF FAMILY; BARTONELLA-BACILLIFORMIS; P-1,P-4-BIS(5'-ADENOSYL) TETRAPHOSPHATE; FUNCTIONAL-SIGNIFICANCE; LUPINUS-ANGUSTIFOLIUS; CONSERVED RESIDUES; NUDIX HYDROLASE; MECHANISM; PROTEIN	The contributions to substrate binding and catalysis of 13 amino acid residues of the Caenorhabditis elegans diadenosine tetraphosphate pyrophosphohydrolase (Ap(4)A hydrolase) predicted from the crystal structure of an enzyme-inhibitor complex have been investigated by site-directed mutagenesis. Sixteen glutathione S-transferase-Ap(4)A hydrolase fusion proteins were expressed and their k(cat) and K-m values determined after removal of the glutathione S-transferase domain. As expected for a Nudix hydrolase, the wild type k(cat) of 23 s(-1) was reduced by 10(5)-, 10(3)-, and 30-fold, respectively, by replacement of the conserved P-phosphate-binding catalytic residues Glu(56), Glu(52), and Glu(103) by Gln. K-m values were not affected, indicating a lack of importance for substrate binding. In contrast, mutating His(31) to Val or Ala and Lys(83) to Met produced 10- and 16-fold increases in K. compared with the wild type value of 8.8 muM. These residues stabilize the P-1-phosphate. H31V and H31A had a normal kcat but K83M showed a 37-fold reduction in k(cat). Lys(36) also stabilizes the P-1-phosphate and a K36M mutant had a 10-fold reduced kcat but a relatively normal K-m. Thus both Lys(36) and Lys(83) may play a role in catalysis. The previously suggested roles of Tyr(27), His(38), Lys(79), and Lys(81) in stabilizing the P-2 and P-3-phosphates were not confirmed by mutagenesis, indicating the absence of phosphate-specific binding contacts in this region. Also, mutating both Tyr(76) and Tyr(121), which clamp one substrate adenosine moiety between them in the crystal structure, to Ala only increased K-m 4-fold. It is concluded that interactions with the P-1- and P-4-phosphates are minimum and sufficient requirements for substrate binding by this class of enzyme, indicating that it may have a much wider substrate range then previously believed.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Krebs Inst Biomol Res, Dept Chem, Sheffield S3 7HF, S Yorkshire, England	University of Liverpool; University of Sheffield	Bailey, S (corresponding author), Univ Liverpool, Sch Biol Sci, Biosci Bldg,POB 147, Liverpool L69 7ZB, Merseyside, England.	agmclen@liv.ac.uk		Rafferty, John/0000-0003-1183-7474				Abdelghany HM, 2001, BBA-PROTEIN STRUCT M, V1550, P27, DOI 10.1016/S0167-4838(01)00263-1; Badger JL, 2000, MOL MICROBIOL, V36, P174, DOI 10.1046/j.1365-2958.2000.01840.x; Bailey S, 2002, STRUCTURE, V10, P589, DOI 10.1016/S0969-2126(02)00746-3; Bailey S, 2002, ACTA CRYSTALLOGR D, V58, P526, DOI 10.1107/S0907444902000768; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Bessman MJ, 2001, J BIOL CHEM, V276, P37834; BLACKBURN GM, 1987, NUCLEIC ACIDS RES, V15, P6991, DOI 10.1093/nar/15.17.6991; Cai JP, 1997, NUCLEIC ACIDS RES, V25, P1170, DOI 10.1093/nar/25.6.1170; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; Conyers GB, 2000, BIOCHEMISTRY-US, V39, P2347, DOI 10.1021/bi992458n; DIXON RM, 1989, J BIOL CHEM, V264, P2069; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Fisher DI, 2002, J BIOL CHEM, V277, P47313, DOI 10.1074/jbc.M209795200; Fletcher JI, 2002, STRUCTURE, V10, P205, DOI 10.1016/S0969-2126(02)00696-2; FRICK DN, 1995, BIOCHEMISTRY-US, V34, P5577, DOI 10.1021/bi00016a032; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; Gabelli SB, 2002, BIOCHEMISTRY-US, V41, P9279, DOI 10.1021/bi0259296; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; GURANOWSKI A, 1994, BIOCHEMISTRY-US, V33, P235, DOI 10.1021/bi00167a031; Guranowski A, 2000, PHARMACOL THERAPEUT, V87, P117, DOI 10.1016/S0163-7258(00)00046-2; GURANOWSKI A, 1992, AP4A OTHER DINUCLEOS, P81; Harris TK, 2000, BIOCHEMISTRY-US, V39, P1655, DOI 10.1021/bi9918745; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; Maksel D, 2001, BIOCHEM J, V357, P399, DOI 10.1042/0264-6021:3570399; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; McLennan AG, 1999, INT J MOL MED, V4, P79; MCLENNAN AG, 1989, BIOCHEMISTRY-US, V28, P3868, DOI 10.1021/bi00435a036; McLennan AG, 2000, ADV EXP MED BIOL, V486, P115; MCLENNAN AG, 1989, BIOMED ENVIRON MASS, V18, P450, DOI 10.1002/bms.1200180615; Mildvan AS, 1999, ADV ENZYMOL RAMB, V73, P183, DOI 10.1002/9780470123195.ch6; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Shimokawa H, 2000, NUCLEIC ACIDS RES, V28, P3240, DOI 10.1093/nar/28.17.3240; Swarbrick JD, 2000, J MOL BIOL, V302, P1165, DOI 10.1006/jmbi.2000.4085; Yang XN, 1999, J BIOL CHEM, V274, P35434, DOI 10.1074/jbc.274.50.35434	36	16	18	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4435	4439		10.1074/jbc.M211983200	http://dx.doi.org/10.1074/jbc.M211983200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12475970	hybrid			2022-12-25	WOS:000180968900012
J	Hashimoto, M; Sibata, T; Wasada, H; Toyokuni, S; Uchida, K				Hashimoto, M; Sibata, T; Wasada, H; Toyokuni, S; Uchida, K			Structural basis of protein-bound endogenous aldehydes - Chemical and immunochemical characterizations of configurational isomers of a 4-hydroxy-2-nonenal-histidine adduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL CARCINOMA; FERRIC NITRILOTRIACETATE; LIPID-PEROXIDATION; OXIDATIVE STRESS; LIVER; MICE; ATHEROSCLEROSIS; IDENTIFICATION; NEPHROTOXICITY; CARCINOGENESIS	4-Hydroxy-2-nonenal (HNE), a major racemic product of lipid peroxidation, reacts with histidine to form a stable HNE-histidine Michael addition-type adduct possessing three chiral centers in the cyclic hemiacetal structure. In the present study, we characterized configurational isomers of a HNE-Nalpha-acetylhistidine adduct by NMR spectroscopy and by molecular orbital calculations. In addition, we raised monoclonal antibodies against (R)-HNE-histidine and (S)-HNE-histidine adducts, characterized their specificities, and examined in vivo localizations of each adduct under oxidative stress. To facilitate structural characterization of the configurational isomers of an HNE-histidine adduct, we prepared the (R)-HNE-histidine and (S)-HNE-histidine adducts by incubating N-alpha-acetylhistidine with each HNE enantiomer, both of which provided two peaks (Ra and Rb from (R)-HNE-histidine and Sa and Sb from (S)-HNE-histidine adducts) in reversed-phase high-performance liquid chromatography. The NMR analysis showed that each peak was a mixture of two diastereomers. In addition, the analysis of the nuclear Overhauser effect enabled the determination of configurations of the eight isomers. The relative amounts of these isomers in the NMR analysis correlated with the relative energies calculated by molecular orbital methods. On the other hand, using (R)-HNE-modified and (S)-HNE-modified keyhole limpet hemocyanins as the antigens, we raised the monoclonal antibodies, mAbR310 and mAbS412, which enantioselectively recognized the (R)-HNE-histidine and (S)-HNE-histidine adducts, respectively. Among the mixtures (Ra, Rb, Sa, and Sb) of diastereomers, mAbR310 showed the highest immunoreactivity to Rb (the mixture of 2R,4S,5R and 2S,4S,5R isomers), whereas mAbS412 preferentially recognized Sa (the mixture of 2R,4S,5S and 2S,4S,5S isomers). The presence of (R)-HNE and (S)-HNE epitopes in vivo was immunohistochemically examined in the kidney of rats exposed to the renal carcinogen, ferric nitrilotriatcetate, by which nuclear and cytosolic stainings with mAbR310 and mAbS412, respectively, were detected.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Gifu Univ, Fac Reg Studies, Gifu 5011193, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 606, Japan	Nagoya University; Gifu University; Kyoto University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.		Toyokuni, Shinya/ABE-7714-2021; Toyokuni, Shinya/C-1358-2010; Shibata, Takahiro/I-6872-2014	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109; Shibata, Takahiro/0000-0003-3194-607X; Uchida, Koji/0000-0003-3894-5299				ALLEVI P, 1993, J ORG CHEM, V58, P5000, DOI 10.1021/jo00070a043; AWAI M, 1979, AM J PATHOL, V95, P663; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; BENEDETTI A, 1986, BIOCHIM BIOPHYS ACTA, V876, P658, DOI 10.1016/0005-2760(86)90055-X; De Montarby L., 1988, TETRAHEDRON LETT, V29, P3895; EBINA Y, 1986, J NATL CANCER I, V76, P107; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1982, BIOCHEM J, V208, P129, DOI 10.1042/bj2080129; ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466; Ichihashi K, 2001, J BIOL CHEM, V276, P23903, DOI 10.1074/jbc.M101947200; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JL, 1987, CANCER RES, V47, P1867; NADKARNI DV, 1995, CHEM RES TOXICOL, V8, P284, DOI 10.1021/tx00044a014; Nakamura K, 2002, CIRCULATION, V105, P2867, DOI 10.1161/01.CIR.0000018605.14470.DD; Oberley TD, 1999, FREE RADICAL BIO MED, V27, P695, DOI 10.1016/S0891-5849(99)00117-3; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; SCHAUENSTEIN E, 1971, MONATSH CHEM, V102, P517, DOI 10.1007/BF00909348; Schauenstein E, 1978, Ciba Found Symp, P225; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; TOYOKUNI S, 1990, CANCER RES, V50, P5574; TOYOKUNI S, 1995, FEBS LETT, V359, P189, DOI 10.1016/0014-5793(95)00033-6; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; Toyokuni S, 1997, LAB INVEST, V76, P365; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; Toyokuni S, 2000, ANTIOXID REDOX SIGN, V2, P681, DOI 10.1089/ars.2000.2.4-681; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; UCHIDA K, 1995, ARCH BIOCHEM BIOPHYS, V317, P405, DOI 10.1006/abbi.1995.1181; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016	37	78	82	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5044	5051		10.1074/jbc.M210129200	http://dx.doi.org/10.1074/jbc.M210129200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473681	hybrid			2022-12-25	WOS:000180968900090
J	Hermand, P; Gane, P; Huet, M; Jallu, V; Kaplan, C; Sonneborn, HH; Cartron, JP; Bailly, P				Hermand, P; Gane, P; Huet, M; Jallu, V; Kaplan, C; Sonneborn, HH; Cartron, JP; Bailly, P			Red cell ICAM-4 is a novel ligand for platelet-activated alpha(IIIb)beta(3) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE; BLOOD-GROUP ANTIGENS; RECEPTOR; ERYTHROCYTES; BINDS; EXPRESSION; GLYCOPROTEIN; INTEGRINS; LUTHERAN; PROTEIN	ICAM-4 (LW blood group glycoprotein) is an erythroid-specific membrane component that belongs to the family of intercellular adhesion molecules and interacts in vitro with different members of the integrin family, suggesting a potential role in adhesion or cell interaction events, including hemostasis and thrombosis. To evaluate the capacity of ICAM-4 to interact with platelets, we have immobilized red blood cells (RBCs), platelets, and ICAM-Fc fusion proteins to a plastic surface and analyzed their interaction in cell adhesion assays with RBCs and platelets from normal individuals and patients, as well as with cell transfectants expressing the alpha(IIb)beta(3) integrin. The platelet fibrinogen receptor OZ11A (platelet GPIIb-IIIa) in a high affinity state following GRGDSP peptide activation was identified for the first time as the receptor for RBC ICAM-4. The specificity of the interaction was demonstrated by showing that: W activated platelets adhered less efficiently to immobilized ICAM-4-negative than to ICAM-4-positive RBCs, (ii) monoclonal antibodies specific for the beta(3)-chain alone and for a complex-specific epitope of the alpha(IIb)beta(3) integrin, and specific for ICAM-4 to a lesser extent, inhibited platelet adhesion, whereas monoclonal antibodies to GPIb, CD36, and CD47 did not, (iii) activated platelets from two unrelated type-I glanzmann's thrombasthenia patients did not bind to coated ICAM-4. Further support to RBC-platelet interaction was provided by showing that dithiothreitol-activated alpha(IIb)beta(3)-Chinese hamster ovary transfectants strongly adhere to coated ICAM-4-Fc protein but not to ICAM-1-Fc and was inhibitable by specific antibodies. Deletion of individual Ig domains of ICAM-4 and inhibition by synthetic peptides showed that the alpha(IIb)beta(3) integrin binding site encompassed the first and second Ig domains and that the G65-V74 sequence of domain D1 might play a role in this interaction. Although normal RBCs are considered passively entrapped in fibrin polymers during thrombus, these studies identify ICAM-4 as the first RBC protein ligand of platelets that may have relevant physiological significance.	Inst Natl Transfus Sanguine, INSERM, U76, Paris, France; Inst Natl Transfus Sanguine, Unite Immunol Plaquettaire, F-75015 Paris, France; Biotest AG, D-63276 Dreieich, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Biotest	Cartron, JP (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, Paris, France.	cartron@idf.inserm.fr		HERMAND, Patricia/0000-0003-0628-9733				ABRAMS CS, 1990, BLOOD, V75, P128; Altieri DC, 1999, THROMB HAEMOSTASIS, V82, P781; Andrews D A, 1999, Curr Opin Hematol, V6, P76, DOI 10.1097/00062752-199903000-00004; BAILLY P, 1994, P NATL ACAD SCI USA, V91, P5306, DOI 10.1073/pnas.91.12.5306; Bailly P, 1995, EUR J IMMUNOL, V25, P3316, DOI 10.1002/eji.1830251217; BERNSTEIN E, 1971, SCIENCE, V173, P765; Bony V, 1999, BRIT J HAEMATOL, V107, P263, DOI 10.1046/j.1365-2141.1999.01721.x; Bratosin D, 1998, BIOCHIMIE, V80, P173, DOI 10.1016/S0300-9084(98)80024-2; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Cartron JP, 2001, TRANSFUS CLIN BIOL, V8, P163, DOI 10.1016/S1246-7820(01)00142-2; Chan JYH, 2001, BRIT J HAEMATOL, V112, P541, DOI 10.1046/j.1365-2141.2001.02439.x; Cines DB, 1998, BLOOD, V91, P3527; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; El Nemer W, 1998, J BIOL CHEM, V273, P16686; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; Goel MS, 2002, BLOOD, V100, P3797, DOI 10.1182/blood-2002-03-0712; GREENWALT DE, 1992, BLOOD, V80, P1105; Hanspal M, 1997, Curr Opin Hematol, V4, P142; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; Hebbel Robert P., 1994, P217; Hebbel RP, 1997, J CLIN INVEST, V99, P2561, DOI 10.1172/JCI119442; HERMAND P, 1995, BLOOD, V86, P1590, DOI 10.1182/blood.V86.4.1590.bloodjournal8641590; Hermand P, 2000, J BIOL CHEM, V275, P26002, DOI 10.1074/jbc.M002823200; Hillery CA, 1996, BLOOD, V87, P4879, DOI 10.1182/blood.V87.11.4879.bloodjournal87114879; JOSEPH R, 1989, THROMB RES, V53, P485, DOI 10.1016/0049-3848(89)90203-X; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MARCUS AJ, 1993, FASEB J, V7, P516, DOI 10.1096/fasebj.7.6.8472890; Minetti G, 1997, Curr Opin Hematol, V4, P116; MorelKopp MC, 1997, BLOOD, V90, P669, DOI 10.1182/blood.V90.2.669.669_669_677; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Oh S S, 1997, Curr Opin Hematol, V4, P148; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Parsons SF, 1999, BEST PRACT RES CL HA, V12, P729, DOI 10.1053/beha.1999.0050; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; SANIABADI AR, 1985, THROMB RES, V38, P225, DOI 10.1016/0049-3848(85)90150-1; Schmidt AM, 2000, SEMIN THROMB HEMOST, V26, P485, DOI 10.1055/s-2000-13204; Serjeant GR, 1997, LANCET, V350, P725, DOI 10.1016/S0140-6736(97)07330-3; Sirolli V, 2001, THROMB HAEMOSTASIS, V86, P834, DOI 10.1055/s-0037-1616140; SONNEBORN HH, 1994, VOX SANGUINIS S2, V67, P114; Southcott MJG, 1999, BLOOD, V93, P4425, DOI 10.1182/blood.V93.12.4425.412k22_4425_4435; Spring FA, 2000, TRANSFUS MED REV, V14, P351, DOI 10.1053/tmrv.2000.16231; Spring FA, 2001, BLOOD, V98, P458, DOI 10.1182/blood.V98.2.458; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Telen MJ, 2000, SEMIN HEMATOL, V37, P130, DOI 10.1016/S0037-1963(00)90038-6; Tsakadze NL, 2002, TRENDS CARDIOVAS MED, V12, P101, DOI 10.1016/S1050-1738(01)00157-8; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; Valles J, 2002, BLOOD, V99, P3978, DOI 10.1182/blood.V99.11.3978; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; VERFAILLIE C, 1994, CRIT REV ONCOL HEMAT, V16, P201, DOI 10.1016/1040-8428(94)90071-X; WARD GE, 1994, BAILLIERE CLIN INF D, V1, P155; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; Wick T M, 1996, Curr Opin Hematol, V3, P118; Wun T, 1997, J LAB CLIN MED, V129, P507, DOI 10.1016/S0022-2143(97)90005-6; Wun T, 1999, J INVEST MED, V47, P121; XIA ZM, 1994, BIOPHYS J, V66, P2190, DOI 10.1016/S0006-3495(94)81015-X; ZUCKER MB, 1984, THROMB HAEMOSTASIS, V51, P119	62	69	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4892	4898		10.1074/jbc.M211282200	http://dx.doi.org/10.1074/jbc.M211282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12477717	hybrid			2022-12-25	WOS:000180968900071
J	Kawachi, K; Masuyama, N; Nishida, E				Kawachi, K; Masuyama, N; Nishida, E			Essential role of the transcription factor ETS-2 in Xenopus early development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYME CELL-DIFFERENTIATION; SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE CASCADE; MESODERM INDUCTION; ZEBRAFISH HOMOLOG; GENE-EXPRESSION; BRACHYURY GENE; T-GENE; ACTIVATION; EMBRYOS	The fibroblast growth factor (FGF)/MAPK pathway plays an important role in early Xenopus developmental processes, including mesoderm patterning. The activation of the MAPK pathway leads to induction of Xenopus Brachyury (Xbra), which regulates the transcription of downstream mesoderm-specific genes in mesoderm patterning. However, the link between the FGF/MAPK pathway and the induction of Xbra has not been fully understood. Here we present evidence suggesting that Ets-2 is involved in the induction of Xbra and thus in the development of posterior mesoderm during early embryonic development. Overexpression of Ets-2 caused posteriorized embryos and led to the induction of mesoderm in ectodermal explants. Expression of a dominant-negative form of Ets-2 or injection of antisense morpholino oligonucleotides against Ets-2 inhibited the formation of the trunk and tail structures. Overexpression of Ets-2 resulted in the induction of Xbra, and expression of the dominant-negative Ets-2 inhibited FGF-or constitutively active MEK-induced Xbra expression. Moreover, overexpression of Ets-2 up-regulated the transcription from Xbra promoter reporter gene constructs. Ets-2 bound to the Xbra promoter region in vitro. These results taken together indicate that Xenopus Ets-2 plays an essential role in mesoderm patterning, lying between the FGF/MAPK pathway and the Xbra transcription.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.							AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Artinger M, 1997, MECH DEVELOP, V65, P187, DOI 10.1016/S0925-4773(97)00073-7; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Chen YL, 1999, MECH DEVELOP, V80, P67, DOI 10.1016/S0925-4773(98)00194-4; Conlon FL, 1996, DEVELOPMENT, V122, P2427; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; Hanafusa H, 2000, EMBO REP, V1, P32, DOI 10.1093/embo-reports/kvd008; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Isaacs HV, 1998, EMBO J, V17, P3413, DOI 10.1093/emboj/17.12.3413; Kim J, 1998, J BIOL CHEM, V273, P1542, DOI 10.1074/jbc.273.3.1542; KISPERT A, 1995, DEV BIOL, V168, P406, DOI 10.1006/dbio.1995.1090; Kurokawa D, 2000, ZYGOTE, V8, pS33; Kurokawa D, 1999, MECH DEVELOP, V80, P41, DOI 10.1016/S0925-4773(98)00192-0; Kusakabe M, 2001, EMBO REP, V2, P727, DOI 10.1093/embo-reports/kve152; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LATINKIE BV, 1997, GENE DEV, V23, P3265; Lerchner W, 2000, DEVELOPMENT, V127, P2729; Ma XJ, 1997, J BIOL CHEM, V272, P10389; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Meyer D, 1997, INT J DEV BIOL, V41, P607; Mullick J, 2001, J BIOL CHEM, V276, P18007, DOI 10.1074/jbc.M100671200; Munchberg SR, 1999, MECH DEVELOP, V80, P53, DOI 10.1016/S0925-4773(98)00193-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Panitz F, 1998, EMBO J, V17, P4414, DOI 10.1093/emboj/17.15.4414; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Pownall ME, 1996, DEVELOPMENT, V122, P3881; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; SIVE HL, 1993, GENE DEV, V1, P1; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Tada M, 1997, DEVELOPMENT, V124, P2225; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	47	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5473	5477		10.1074/jbc.M211054200	http://dx.doi.org/10.1074/jbc.M211054200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468533	hybrid			2022-12-25	WOS:000180968900140
J	Lavictoire, SJ; Parolin, DAE; Klimowicz, AC; Kelly, JF; Lorimer, IAJ				Lavictoire, SJ; Parolin, DAE; Klimowicz, AC; Kelly, JF; Lorimer, IAJ			Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYL BETA-HYDROXYLASE; MOLECULAR CHAPERONE HSP90; ANTIBODY VARIABLE DOMAIN; EGF RECEPTOR; SIGNAL-TRANSDUCTION; HUMAN GLIOBLASTOMAS; PROTEIN-KINASE; GENE AMPLIFICATION; TYROSINE KINASE; CDC37	EGFRvIII is a mutant epidermal growth factor that promotes aggressive growth of glioblastomas. We made a plasmid that directed the expression of an EGFRvIII with three copies of the Flag epitope at its amino terminus. Flag-tagged EGFRvIII was expressed at the same levels as unmodified EGFRvIII, and showed the same subcellular localization. However, the Flag epitope could only be detected on EGFRvIII present in the endoplasmic reticulum; the epitope was covalently modified during trafficking of the receptor through the Golgi so that it was no longer recognized by anti-Flag antibody. This property was exploited to selectively purify nascent EGFRvIII from glioblastoma cells. Nascent EGFRvIII was found to copurify with a set of other proteins, identified by mass spectrometry as the two endoplasmic reticulum chaperones Grp94 and BiP, and the two cytosolic chaperones Hsc70 and Hsp90. The Hsp90-associated chaperone Cdc37 also co-purified with EGFRvIII, suggesting that Hsp90 binds EGFRvIII as a complex with this protein. Geldanamycin and radicicol, two chemically unrelated inhibitors of Hsp90, decreased the expression of EGFRvIII in glioblastoma cells. These studies show that nascent EGFRvIII in the endoplasmic reticulum. associates with Hsp90 and Cdc37, and that the Hsp90 association is necessary to maintain expression of EGFRvIII.	Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; National Research Council Canada	Lorimer, IAJ (corresponding author), Ottawa Reg Canc Ctr, Ctr Canc Therapeut, 3rd Floor,503 Smyth Rd, Ottawa, ON K1H 1C4, Canada.							Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Feldkamp MM, 1999, NEUROSURGERY, V45, P1442, DOI 10.1097/00006123-199912000-00034; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; Frederick L, 2000, CANCER RES, V60, P1383; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; Han YC, 1996, CANCER RES, V56, P3859; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Landry RC, 2001, J MOL BIOL, V308, P883, DOI 10.1006/jmbi.2001.4628; Lorimer IAJ, 2002, CURR CANCER DRUG TAR, V2, P91, DOI 10.2174/1568009023333926; Lorimer IAJ, 2000, J IMMUNOL METHODS, V237, P147, DOI 10.1016/S0022-1759(99)00219-7; Lorimer IAJ, 1996, P NATL ACAD SCI USA, V93, P14815, DOI 10.1073/pnas.93.25.14815; Lorimer IAJ, 2001, BBA-MOL CELL RES, V1538, P1, DOI 10.1016/S0167-4889(00)00129-4; Matsuda S, 1999, J BIOL CHEM, V274, P34515, DOI 10.1074/jbc.274.49.34515; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane Motoo, 2001, Cancer Letters, V162, pS17, DOI 10.1016/S0304-3835(00)00648-0; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Neckers L, 1999, DRUG RESIST UPDATE, V2, P165, DOI 10.1054/drup.1999.0082; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Scholz GM, 2001, CELL GROWTH DIFFER, V12, P409; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 2000, ONCOGENE, V19, P2186, DOI 10.1038/sj.onc.1203561; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; WANG QP, 1991, J BIOL CHEM, V266, P14004; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Worm K, 1999, HUM PATHOL, V30, P222, DOI 10.1016/S0046-8177(99)90280-0; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x	53	63	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5292	5299		10.1074/jbc.M209494200	http://dx.doi.org/10.1074/jbc.M209494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12471035	hybrid			2022-12-25	WOS:000180968900120
J	Otsuki, Y; Tanaka, M; Kamo, T; Kitanaka, C; Kuchino, Y; Sugimura, H				Otsuki, Y; Tanaka, M; Kamo, T; Kitanaka, C; Kuchino, Y; Sugimura, H			Guanine nucleotide exchange factor, Tiam1, directly binds to c-Myc and interferes with c-Myc-mediated apoptosis in rat-1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; RHO-FAMILY; SIGNALING PATHWAY; T-LYMPHOCYTES; PROTEIN; ACTIVATION; GTPASE; EXPRESSION; ALPHA; RAC	The transcription factor c-Myc is important for the control of cell growth, cell cycle progression, neoplasia, and apoptotic cell death. Recently, c-Myc-binding proteins, which bind either to the N-terminal domain or the C-terminal domain of c-Myc, have been proposed as the key molecules to realize the mechanisms of these multiple c-Myc functions. We report in the present study on another protein, Tiam1, which is a specific guanine nucleotide exchange factor of Rac1 and which binds to c-Myc and modulates several of its biological functions. We were able to detect the direct binding and in vivo association between c-Myc and Tiam1. The necessary role in this interaction of the Myc box 11 of c-Myc was revealed in the cell extracts. The additional discovery of the intranuclear localization of Tiam1 in Rat1 cells and in neuronal cells of the mouse brain suggests this interaction may occur in the nucleus. Overexpression of Tiam1 repressed the luciferase activity of c-Myc and also inhibited the c-Myc apoptotic activity through this protein-protein interaction. Taken together, we concluded that Tiam1 is another c-Myc regulator, working in the nuclei to control c-Myc-related apoptosis.	Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 4313192, Japan; Natl Canc Ctr, Res Inst, Div Biophys, Tokyo 1140045, Japan	Hamamatsu University School of Medicine; National Cancer Center - Japan	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol 1, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hsugimur@hama-med.ac.jp		Otsuki, Yoshiro/0000-0002-0568-3811				ASKEW DS, 1991, ONCOGENE, V6, P1915; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kawazoe N, 1999, ONCOGENE, V18, P2413, DOI 10.1038/sj.onc.1202555; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; Na SQ, 1999, ONCOGENE, V18, P7966, DOI 10.1038/sj.onc.1203122; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Qi HW, 2001, CELL GROWTH DIFFER, V12, P603; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Thiriet N, 2001, MOL BRAIN RES, V90, P202, DOI 10.1016/S0169-328X(01)00093-6; Toenjes KA, 1999, CURR BIOL, V9, P1183, DOI 10.1016/S0960-9822(00)80022-6; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001	49	25	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5132	5140		10.1074/jbc.M206733200	http://dx.doi.org/10.1074/jbc.M206733200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12446731	hybrid			2022-12-25	WOS:000180968900100
J	Barthwal, MK; Sathyanarayana, P; Kundu, CN; Rana, B; Pradeep, A; Sharma, C; Woodgett, JR; Rana, A				Barthwal, MK; Sathyanarayana, P; Kundu, CN; Rana, B; Pradeep, A; Sharma, C; Woodgett, JR; Rana, A			Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; STRESS; ACTIVATION; PHOSPHORYLATES; APOPTOSIS; PKB/AKT; DEATH; JNK	Mixed lineage kinase 3 (MLK3) is a mitogen-activated protein kinase kinase kinase (MAPKKK) that activates c-jun N-terminal kinase (JNK) and can induce cell death in neurons. By contrast, the activation of phosphatidylinositol 3-kinase and AKT/protein kinase B (PKB) acts to suppress neuronal apoptosis. Here, we report a functional interaction between MLK3 and AKT1/PKBalpha. Endogenous MLK3 and AKT1 interact in HepG2 cells, and this interaction is regulated by insulin. The interaction domain maps to the C-terminal half of MLK3 (amino acids 511-847), and this region also contains a putative AKT phosphorylation consensus sequence. Endogenous JNK, MKK7, and MLK3 kinase activities in HepG2 cells are significantly attenuated by insulin treatment, whereas the phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin reversed the effect. Finally, MLK3-mediated JNK activation is inhibited by AKT1. AKT phosphorylates MLK3 on serine 674 both in vitro and in vivo. Furthermore, the expression of activated AKT1 inhibits MLK3-mediated cell death in a manner dependent on serine 674 phosphorylation. Thus, these data provide the first direct link between MLK3-mediated cell death and its regulation by a cell survival signaling protein, AKT1.	Texas A&M Univ Syst, Hlth Sci Ctr, Inst Cardiovasc Res, Div Mol Cardiol,Coll Med, Temple, TX 76504 USA; Univ Toronto, Dept Expt Therapeut, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 3M9, Canada	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Rana, A (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Inst Cardiovasc Res, Div Mol Cardiol,Coll Med, 1901 S 1st St,Bldg 162, Temple, TX 76504 USA.	arana@medicine.tamu.edu	Rana, Ajay/ABE-3739-2020; Woodgett, Jim/F-1087-2010	Rana, Ajay/0000-0003-0951-2566; Woodgett, Jim/0000-0003-3731-5797; Barthwal, Dr.Manoj/0000-0001-7574-482X; Kundu, Chanakya/0000-0003-0297-1030	NIGMS NIH HHS [GM55853] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Mielke K, 2002, MOL CELL NEUROSCI, V20, P211, DOI 10.1006/mcne.2002.1132; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Nicholas RS, 2002, J NEUROIMMUNOL, V124, P36, DOI 10.1016/S0165-5728(02)00011-5; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001	21	119	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3897	3902		10.1074/jbc.M211598200	http://dx.doi.org/10.1074/jbc.M211598200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458207	hybrid			2022-12-25	WOS:000180869700050
J	Kirschke, CP; Huang, LP				Kirschke, CP; Huang, LP			ZnT7, a novel mammalian zinc transporter, accumulates zinc in the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LETHAL MILK; FUNCTIONAL-CHARACTERIZATION; CONFERS RESISTANCE; GENE ENCODES; EXPRESSION; PROTEIN; FAMILY; CLONING; MEMBER; LOCALIZATION	ZnT7, a novel member of the zinc transporter (ZnT) family, was identified by searching the expressed sequence tag (EST) databases with the amino acid sequence of ZnT1. Like the other ZnT proteins, the protein (387 amino acids) predicted from this gene contains six transmembrane domains and a histidine-rich loop between transmembrane domains IV and V. We show that Znt7 is widely transcribed in mouse tissues with abundant expression in the liver and small intestine and moderate expression in the kidney, spleen, brain, and lung. An affinity-purified antibody raised against the amino acids 299-315 of mouse ZnT7 specifically reacted with the proteins with apparent molecular masses of 85, 43, and 65 kDa in small intestine and lung tissues by Western blot analysis. Immunofluorescence microscope analysis reveals that ZnT7 is localized in the Golgi apparatus and cytoplasmic vesicles. Exposure of the ZnT7-expressing Chinese hamster ovary (CHO) cells to zinc causes an accumulation of zinc in the Golgi apparatus, suggesting that ZnT7 facilitates zinc transport from the cytoplasm into the Golgi apparatus.	Univ Calif Davis, Rowe Program Genet, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutrit, Davis, CA 95616 USA; Univ Calif Davis, USDA ARS, Western Human Nutr Res Ctr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; United States Department of Agriculture (USDA); University of California System; University of California Davis	Huang, LP (corresponding author), Univ Calif Davis, Rowe Program Genet, 1 Shields Ave, Davis, CA 95616 USA.	lhuang@whnrc.usda.gov						ACKLAND ML, 1992, J NUTR, V122, P1214, DOI 10.1093/jn/122.6.1214; APONTE GW, 1991, P NATL ACAD SCI USA, V88, P5282, DOI 10.1073/pnas.88.12.5282; BURGUNDER JM, 1984, J HERED, V75, P480; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Inoue K, 2002, HUM MOL GENET, V11, P1775, DOI 10.1093/hmg/11.15.1775; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Kelleher SL, 2002, J NUTR, V132, P3280, DOI 10.1093/jn/132.11.3280; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Lioumi M, 1999, GENOMICS, V62, P272, DOI 10.1006/geno.1999.5993; Liuzzi JP, 2001, J NUTR, V131, P46, DOI 10.1093/jn/131.1.46; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Milon B, 2001, FEBS LETT, V507, P241, DOI 10.1016/S0014-5793(01)02950-7; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PILETZ JE, 1978, SCIENCE, V199, P181, DOI 10.1126/science.619449; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; WILDMAN REC, 2000, ADV HUMAN NUTR, P254; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	32	223	235	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4096	4102		10.1074/jbc.M207644200	http://dx.doi.org/10.1074/jbc.M207644200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446736	hybrid			2022-12-25	WOS:000180869700075
J	Mundt, B; Kuhnel, F; Zender, L; Paul, Y; Tillmann, H; Trautwein, C; Manns, MP; Kubicka, S				Mundt, B; Kuhnel, F; Zender, L; Paul, Y; Tillmann, H; Trautwein, C; Manns, MP; Kubicka, S			Involvement of TRAIL and its receptors in viral hepatitis	FASEB JOURNAL			English	Article						Fas (CD95); apoptosis; hepatitis B; hepatitis C; acute liver failure	NF-KAPPA-B; TUMORICIDAL ACTIVITY; MEDIATED APOPTOSIS; ANTITUMOR-ACTIVITY; FAS LIGAND; LIVER; EXPRESSION; FAMILY; MEMBER; GENE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is able to kill a broad spectrum of tumor cells but appears to be nontoxic to most normal cells. Because there are conflicting data about the hepatotoxicity of TRAIL, we investigated the physiological function of TRAIL and its receptors in the liver. Hepatocytes are sensitive for FasL- and TRAIL-mediated apoptosis in vitro, but TRAIL induces no apoptosis in healthy livers in vivo. Using mouse models of adenoviral hepatitis and livers of patients with hepatitis infection, we could demonstrate that apoptosis in virally infected hepatocytes is mediated by TRAIL receptor DR5 and TRAIL. In contrast to FasL, TRAIL-mediated apoptosis of hepatocytes in vivo is triggered through viral infection. The TRAIL receptor/ligand system enables the organisms to specifically kill virus-infected hepatocytes, whereas normal uninfected hepatocytes in vivo are resistant to TRAIL-mediated apoptosis. Overexpression of TRAIL in the liver after viral infection is not dependent on lymphocytes, natural killer, or Kupffer cells, which indicates that the TRAIL receptor/ligand system is a paracrine mechanism of hepatocytes against virally infected cells. Our results suggest that TRAIL might be used not only for cancer therapy but also for therapy of patients with viral hepatitis to selectively eliminate infected hepatocytes and limit viral replication.	Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany	Hannover Medical School	Kubicka, S (corresponding author), Hannover Med Sch, Dept Gastroenterol & Hepatol, Carl Neubergstr 1, D-30625 Hannover, Germany.	Kubicka.stefan@mh-hannover.de						Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chirmule N, 1999, HUM GENE THER, V10, P259, DOI 10.1089/10430349950019048; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Dejosez M, 2000, CELL DEATH DIFFER, V7, P1127, DOI 10.1038/sj.cdd.4400746; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Gallop JR, 1995, CERN REPORT, V95, P1; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; HARDONK MJ, 1992, J LEUKOCYTE BIOL, V52, P296, DOI 10.1002/jlb.52.3.296; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lieber A, 1997, J VIROL, V71, P8798, DOI 10.1128/JVI.71.11.8798-8807.1997; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OGASAWARA J, 1993, NATURE, V365, P568, DOI 10.1038/365568a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Sedger LM, 1999, J IMMUNOL, V163, P920; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strater J, 2002, GASTROENTEROLOGY, V122, P659, DOI 10.1053/gast.2002.31889; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375	43	125	134	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					94	+		10.1096/fj.02-0537fje	http://dx.doi.org/10.1096/fj.02-0537fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475902				2022-12-25	WOS:000180218500019
J	Higashibata, H; Kikuchi, H; Kawarabayasi, Y; Matsui, I				Higashibata, H; Kikuchi, H; Kawarabayasi, Y; Matsui, I			Helicase and nuclease activities of hyperthermophile Pyrococcus horikoshii Dna2 inhibited by substrates with RNA segments at 5 '-end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEIN; THERMOAUTOTROPHICUM DELTA-H; COMPLETE GENOME SEQUENCE; DEPENDENT ADENOSINETRIPHOSPHATASE-B; REPLICATION FORK; ENDONUCLEASE; ARCHAEON; REPAIR; HELICASE/ENDONUCLEASE; RECOMBINATION	Dna2 protein plays an important role in Okazaki fragment maturation on the lagging strand and also participates in DNA repair in Eukarya. Herein, we report the first biochemical characterization of a Dna2 homologue from Archaea, the hyperthermophile Pyrococcus horikoshii (Dna2Pho). Dna2Pho has both a RecB-like nuclease motif and seven conserved helicase motifs similar to Dna2 from Saccharomyces cerevisiae. Dna2Pho has single-stranded (ss) DNA-stimulated ATPase activity, DNA helicase activity (5' to 3' direction) requiring ATP, and nuclease activity, which prefers free W-ends of ssDNA as substrate. These activities depend on MgCl2 concentrations. Dna2Pho requires a higher concentration of MgCl2 for the nuclease than helicase activity. Both the helicase and nuclease activities of Dna2Pho were inhibited by substrates with RNA segments at the W-end of flap DNA, whereas the nuclease activity of Dna2 from S. cerevisiae was reported to be stimulated by RNA segments in the 5'-tail.	Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Technol & Evaluat, Shibuya Ku, Nishihara, Okinawa 1510066, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Higashi 1-1, Tsukuba, Ibaraki 3058566, Japan.	ik-matsui@aist.go.jp		HIGASHIBATA, Hiroki/0000-0001-7416-5316				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bae SH, 2002, J BIOL CHEM, V277, P26632, DOI 10.1074/jbc.M111026200; Bae SH, 2001, NUCLEIC ACIDS RES, V29, P3069, DOI 10.1093/nar/29.14.3069; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bohlke K, 2002, EXTREMOPHILES, V6, P1, DOI 10.1007/s007920100222; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cann IKO, 1999, GENETICS, V152, P1249; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; IMANAKA T, 1981, J BACTERIOL, V147, P776, DOI 10.1128/JB.147.3.776-786.1981; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kelman Z, 2000, TRENDS BIOCHEM SCI, V25, P521, DOI 10.1016/S0968-0004(00)01687-X; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Liu LD, 2001, J BIOL CHEM, V276, P45484, DOI 10.1074/jbc.M106391200; MacNeill SA, 2001, MOL MICROBIOL, V40, P520, DOI 10.1046/j.1365-2958.2001.02390.x; MacNeill SA, 2001, CURR BIOL, V11, pR842, DOI 10.1016/S0960-9822(01)00500-0; Matsui E, 1999, J BIOL CHEM, V274, P18297, DOI 10.1074/jbc.274.26.18297; MATSUI I, 2000, EXTR 2000 3 INT C EX, P209; Myllykallio H, 2000, SCIENCE, V288, P2212, DOI 10.1126/science.288.5474.2212; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEKI M, 1987, BIOCHEMISTRY-US, V26, P2924, DOI 10.1021/bi00384a038; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Shen YL, 2001, J BIOL CHEM, V276, P27376, DOI 10.1074/jbc.M011762200; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; WULFING C, 1994, J BIOL CHEM, V269, P2895	45	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15983	15990		10.1074/jbc.M207748200	http://dx.doi.org/10.1074/jbc.M207748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12473672	hybrid			2022-12-25	WOS:000182680000068
J	Ball, S; Bella, J; Kielty, C; Shuttleworth, A				Ball, S; Bella, J; Kielty, C; Shuttleworth, A			Structural basis of type VI collagen dimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; INTEGRIN ALPHA-2-BETA-1 VLA-2; AMINO-ACID-SEQUENCE; I-DOMAIN; LIGAND-BINDING; A-DOMAINS; VONWILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; GLOBULAR DOMAINS; ALPHA(2)BETA(1)	We have determined the interactive sites required for dimer formation in type VI collagen. Despite the fact that type VI collagen is a heterotrimer composed of alpha1(VI), alpha2(VI), and alpha3(VI) chains, the formation of dimers is determined principally by interactions of the alpha2(VI) chain. Key components of this interaction are the metal ion-dependent adhesion site (MIDAS) motif of the alpha2C2 A-domain and the GER sequence in the helical domain of another a2(VI) chain. Replacement of the alpha2(VI) C2 domain with the alpha3(VI) domain abolished dimer formation, whereas alterations in the cd(VI) C1 domain did not disrupt dimer formation. When the helical sequences were investigated, replacement of the alpha2(VI) sequence GSPGERGDQ with the alpha3(VI) sequence GEKGERGDV abolished dimer formation. Mutating the Pro-108 to a Lys-108 in this alpha2(VI) sequence did not influence dimer formation and suggests that, unlike the integrin I-domain/triple-helix interaction, hydroxyproline is not required in collagen VI A-domain/helix interaction. These results demonstrate that the alpha2(VI) chain position in the assembled triple-helical molecule is critical for antiparallel dimer formation and identify the interacting collagenous and MIDAS sequences involved. These interactions underpin the subsequent assembly of type VI collagen.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Shuttleworth, A (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	ashuttle@fs1.seg.man.ac.uk	Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562				AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; Ball SG, 2001, J BIOL CHEM, V276, P7422, DOI 10.1074/jbc.M002816200; Bella J, 2000, STRUCTURE, V8, pR121, DOI 10.1016/S0969-2126(00)00153-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; KERN A, 1994, J BIOL CHEM, V269, P22811; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knupp C, 2001, EMBO J, V20, P372, DOI 10.1093/emboj/20.3.372; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MCGUIRE SL, 1995, J BIOL CHEM, V170, P25266; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Romijn RAP, 2001, J BIOL CHEM, V276, P9985, DOI 10.1074/jbc.M006548200; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; van der Plas RM, 2000, THROMB HAEMOSTASIS, V84, P1005; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200	35	40	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15326	15332		10.1074/jbc.M209977200	http://dx.doi.org/10.1074/jbc.M209977200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12473679	hybrid			2022-12-25	WOS:000182516100097
J	Kitazume, S; Tachida, Y; Oka, R; Kotani, N; Ogawa, K; Suzuki, M; Dohmae, N; Takio, K; Saido, TC; Hashimoto, Y				Kitazume, S; Tachida, Y; Oka, R; Kotani, N; Ogawa, K; Suzuki, M; Dohmae, N; Takio, K; Saido, TC; Hashimoto, Y			Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta-secretase (BACE1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CLEAVING ENZYME; PRESENILIN-1; INHIBITOR; GENERATION; PROTEASES; PEPTIDES; DISEASE; DOMAIN; NOTCH	BACE1 is a membrane-bound aspartic protease that cleaves the amyloid precursor protein (APP) at the beta-secretase site, a critical step in the Alzheimer disease pathogenesis. We previously found that BACE1 also cleaved a membrane-bound sialyltransferase, ST6Gal I. By BACE1 overexpression in COS cells, the secretion of ST6Gal I markedly increased, and the amino terminus of the secreted ST6Gal I started at Glu41. Here we report that BACE1-Fc chimera protein cleaved the A-ST6Gal I fusion protein, or ST6Gal I-derived peptide, between Leu(37) and Gln(38), suggesting that an initial cleavage product by BACE1 was three amino acids longer than the secreted ST6Gal I. The three amino acids, Gln(38)-Ala(39)-Lys(40), were found to be truncated by exopeptidase activity, which was detected in detergent extracts of Golgi-derived membrane fraction. These results suggest that ST6Gal I is cleaved initially between Leu(37) and Gln(38) by BACE1, and then the three-amino acid sequence at the NH2 terminus is removed by exopeptidase(s) before secretion from the cells.	RIKEN, Frontier Res Syst, Supra Biomol Syst Grp, Glyco Chain Funct Lab, Wako, Saitama 3510198, Japan; RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Proteolyt Neurosci Lab, Wako, Saitama 3510198, Japan; RIKEN, Dept Biomol Characterizat, Wako, Saitama 3510198, Japan	RIKEN; RIKEN; RIKEN	Hashimoto, Y (corresponding author), RIKEN, Frontier Res Syst, Supra Biomol Syst Grp, Glyco Chain Funct Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015; Dohmae, Naoshi/C-2040-2011	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903; Dohmae, Naoshi/0000-0002-5242-9410; Kotani, Norihiro/0000-0003-3739-6478				Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; Kitazume-Kawaguchi S, 1999, GLYCOBIOLOGY, V9, P1397; Komlosh A, 2001, J BIOL CHEM, V276, P30050, DOI 10.1074/jbc.M103177200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Marcinkeviciene J, 2001, J BIOL CHEM, V276, P23790, DOI 10.1074/jbc.M101896200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Stoltze L, 2000, NAT IMMUNOL, V1, P413, DOI 10.1038/80852; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	32	97	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14865	14871		10.1074/jbc.M206262200	http://dx.doi.org/10.1074/jbc.M206262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12473667	hybrid			2022-12-25	WOS:000182516100038
J	Braastad, CD; Han, ZY; Hendrickson, EA				Braastad, CD; Han, ZY; Hendrickson, EA			Constitutive DNase I hypersensitivity of p53-regulated promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ATM-DEPENDENT PHOSPHORYLATION; TRANSCRIPTION FACTOR-BINDING; HEAT-SHOCK PROMOTER; WILD-TYPE P53; CHROMATIN STRUCTURE; GENE-EXPRESSION; NUCLEOSOMAL TEMPLATES; DROSOPHILA-HSP26 GENE; GAMMA-INDUCTION	The ability of p53 to alter, at the transcriptional level, the gene expression of downstream targets is critical for its role as a tumor suppressor. Most models of p53 activation postulate the stepwise recruitment by p53 of coactivators, histone acetyltransferases, and/or chromatin remodeling factors to a promoter region to facilitate the subsequent access of the general transcriptional machinery required for transcriptional induction. We demonstrate here, however, that the promoter regions for the p53 target genes, p21, 14-3-3sigma, and KARP-1, exist in a constitutively open conformation that is readily accessible to DNase I. This conformation was not altered by DNA damage or by whether p53 was present or absent in the cell. In contrast, p53 response elements, which resided outside the immediate promoter regions, existed within DNase I-resistant chromatin domains. Thus, p53 activation of downstream target genes occurs without p53 inducing chromatin alterations detectable by DNase I accessibility at either the promoter or the response element. As such, these data support models of p53 activation that do not require extensive chromatin alterations to support cognate gene expression.	Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Brown Univ, Dept Mol Biol Cellular Biol & Biochem, Providence, RI 02912 USA	University of Minnesota System; University of Minnesota Twin Cities; Brown University	Hendrickson, EA (corresponding author), Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.	hendr064@tc.umn.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035763] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35763] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Braastad CD, 2002, NUCLEIC ACIDS RES, V30, P1713, DOI 10.1093/nar/30.8.1713; Brown RC, 2002, MOL CELL BIOL, V22, P161, DOI 10.1128/MCB.22.1.161-170.2002; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen C, 2001, MOL CELL BIOL, V21, P7682, DOI 10.1128/MCB.21.22.7682-7695.2001; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fry CJ, 2002, SCIENCE, V295, P1847, DOI 10.1126/science.1070260; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; GONCZY P, 1989, MOL CELL BIOL, V9, P296; Graunke DM, 1999, NUCLEIC ACIDS RES, V27, P3881, DOI 10.1093/nar/27.19.3881; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hecht A, 1999, METH MOL B, V119, P469; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Krebs JE, 2000, CRIT REV EUKAR GENE, V10, P1; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Langst G, 2001, J CELL SCI, V114, P2561; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Li Y, 2001, ONCOGENE, V20, P726, DOI 10.1038/sj.onc.1204147; LIN D, 1988, SOMAT CELL MOLEC GEN, V14, P261, DOI 10.1007/BF01534587; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Litt MD, 1997, J BIOL CHEM, V272, P14921, DOI 10.1074/jbc.272.23.14921; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu YG, 2001, CARCINOGENESIS, V22, P851, DOI 10.1093/carcin/22.6.851; LU Q, 1992, J MOL BIOL, V225, P985, DOI 10.1016/0022-2836(92)90099-6; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; LU YM, 1994, ONCOGENE, V9, P1015; Mai X, 2000, MOL CELL BIOL, V20, P6668, DOI 10.1128/MCB.20.18.6668-6676.2000; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Myung K, 1997, EMBO J, V16, P3172, DOI 10.1093/emboj/16.11.3172; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; OwenHughes T, 1996, EMBO J, V15, P4702, DOI 10.1002/j.1460-2075.1996.tb00847.x; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PLET A, 1995, ONCOGENE, V10, P319; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Roberts SGE, 2000, CELL MOL LIFE SCI, V57, P1149, DOI 10.1007/PL00000755; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; WU C, 1989, METHOD ENZYMOL, V170, P269; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	85	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8261	8268		10.1074/jbc.M204256200	http://dx.doi.org/10.1074/jbc.M204256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12475992	hybrid			2022-12-25	WOS:000181466800068
J	Flynn, J; Fang, JY; Mikovits, JA; Reich, NO				Flynn, J; Fang, JY; Mikovits, JA; Reich, NO			A potent cell-active allosteric inhibitor of murine DNA cytosine C-5 methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN DNA; DE-NOVO; STEADY-STATE; METHYLATION; MAINTENANCE; EXPRESSION; BINDING; ACTIVATION; SEQUENCES; CPG	The major DNA cytosine methyltransferase isoform in mouse erythroleukemia cells, Dnmt1, exhibits potent dead-end inhibition with a single-stranded nucleic acid by binding to an allosteric site on the enzyme. The previously reported substrate inhibition with double-stranded substrates also involves binding to an allosteric site. Thus, both forms of inhibition involve ternary enzyme-DNA-DNA complexes. The inhibition potency of the single-stranded nucleic acid is determined by the sequence, length, and most appreciably the presence of a single 5-methyleytosine residue. A single-stranded phosphorothioate derivative inhibits DNA methylation activity in nuclear extracts. Mouse erythroleukemia cells treated with the phosphorothioate inhibitor show a significant decrease in global genomic methylation levels. Inhibitor treatment of human colon cancer cells causes demethylation of the p16 tumor suppressor gene and subsequent p16 re-expression. Allosteric inhibitors of mammalian DNA cytosine methyltransferases, representing a new class of molecules with potential therapeutic applications, may be used to elucidate novel epigenetic mechanisms that control development.	Univ Calif Santa Barbara, Dept Biochem & Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA; Shanghai Inst Digest Dis, Shanghai, Peoples R China; EpiGenX Pharmaceut, Pacific Technol Ctr, Santa Barbara, CA 93111 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Reich, NO (corresponding author), Univ Calif Santa Barbara, Dept Biochem & Chem, Santa Barbara, CA 93106 USA.	reich@mail.chem.ucsb.edu						Aniello F, 1996, GENE, V178, P57, DOI 10.1016/0378-1119(96)00334-4; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; Bacolla A, 2001, J BIOL CHEM, V276, P18605, DOI 10.1074/jbc.M100404200; BAKER DJ, 1994, J MOL BIOL, V243, P143; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bestor TH, 2000, J CLIN INVEST, V105, P409, DOI 10.1172/JCI9459; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594; BOLDEN A, 1984, J BIOL CHEM, V259, P2437; Brown R, 2002, TRENDS MOL MED, V8, pS43, DOI 10.1016/S1471-4914(02)02314-6; Carotti D, 1998, BIOCHEMISTRY-US, V37, P1101, DOI 10.1021/bi971031i; CEDAR H, 1979, NUCLEIC ACIDS RES, V6, P2125, DOI 10.1093/nar/6.6.2125; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2001, J CLIN ONCOL, V19, P299, DOI 10.1200/JCO.2001.19.2.299; Fatemi M, 2001, J MOL BIOL, V309, P1189, DOI 10.1006/jmbi.2001.4709; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Flynn J, 1998, J MOL BIOL, V279, P101, DOI 10.1006/jmbi.1998.1761; FLYNN J, 1966, BIOCHEMISTRY-US, V35, P7308; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Glickman JF, 1997, J BIOL CHEM, V272, P17851, DOI 10.1074/jbc.272.28.17851; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HITT MM, 1988, J BIOL CHEM, V263, P4392; Jeltsch A, 1999, J BIOL CHEM, V274, P19538, DOI 10.1074/jbc.274.28.19538; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1983, RECENT RES CANCER, V84, P202; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; Kimura H, 1996, J BIOCHEM, V120, P1182; Laiho P, 2002, CANCER RES, V62, P1166; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Martienssen R, 1998, TRENDS GENET, V14, P263, DOI 10.1016/S0168-9525(98)01518-2; Nakao M, 2001, GENE, V278, P25, DOI 10.1016/S0378-1119(01)00721-1; OREND G, 1991, J VIROL, V65, P4301, DOI 10.1128/JVI.65.8.4301-4308.1991; Paz MF, 2002, CANCER RES, V62, P4519; PEDRALINOY G, 1986, J BIOL CHEM, V261, P7600; Phan J, 2001, J BIOL CHEM, V276, P14170, DOI 10.1074/jbc.M009493200; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; REICH NO, 1990, J BIOL CHEM, V265, P8966; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Segel I.H., 1975, ENZYME KINETICS; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; SPECTOR T, 1981, BIOCHEM PHARMACOL, V30, P1, DOI 10.1016/0006-2952(81)90277-X; Strathdee G, 2002, EXPERT OPIN INV DRUG, V11, P747; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; SZYF M, 1997, P NATL ACAD SCI USA, V94, P684; TAJIMA S, 1995, J BIOCHEM-TOKYO, V117, P1050, DOI 10.1093/oxfordjournals.jbchem.a124805; Tollefsbol TO, 1997, J MOL BIOL, V269, P494, DOI 10.1006/jmbi.1997.1064; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003; Wolffe AP, 1999, P NATL ACAD SCI USA, V96, P5894, DOI 10.1073/pnas.96.11.5894; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	55	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8238	8243		10.1074/jbc.M209839200	http://dx.doi.org/10.1074/jbc.M209839200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12477724	hybrid			2022-12-25	WOS:000181466800064
J	Zhang, X; Zhu, T; Chen, Y; Mertani, HC; Lee, KO; Lobie, PE				Zhang, X; Zhu, T; Chen, Y; Mertani, HC; Lee, KO; Lobie, PE			Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; CYCLIN D1 OVEREXPRESSION; GENE-EXPRESSION; CELL-PROLIFERATION; GLAND DEVELOPMENT; TRANSGENIC MICE; P53 EXPRESSION; HOMEOBOX GENES; REDUCED GROWTH; BCL-2	Increased mammary epithelial expression of the human growth hormone (hGH) gene is associated with the acquisition of pathological proliferation. We report here that autocrine hGH production by human mammary carcinoma cells increased the expression and transcriptional activity of the homeobox domain containing protein HOXA1. Forced expression of HOXA1 in human mammary carcinoma cells resulted in increased total cell number primarily by the promotion of cell survival mediated by the transcriptional up-regulation of Bcl-2. HOYA1 also abrogated the apoptotic response of mammary carcinoma cells to doxorubicin. Forced expression of HOXA1 in mammary carcinoma cells, in a Bcl-2-dependent manner, resulted in dramatic enhancement of anchorage-independent proliferation and colony formation in soft agar. Finally, forced expression of HOXA1 was sufficient to result in the oncogenic transformation of immortalized human mammary epithelial cells with aggressive in vivo tumor formation. Herein, we have therefore provided a molecular mechanism by which autocrine hGH stimulation of human mammary epithelial cells may result in oncogenic transformation.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Dept Med, Singapore 117609, Singapore; Univ Lyon 1, CNRS UMR 5578, Lyon, France	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Lobie, PE (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		MERTANI, Hichem-Claude/AAR-6415-2020; Lee, Kok-Onn/E-9874-2011	Lee, Kok-Onn/0000-0002-3040-1185				Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Barrow JR, 2000, DEVELOPMENT, V127, P933; BCHINI O, 1991, ENDOCRINOLOGY, V128, P539, DOI 10.1210/endo-128-1-539; Bonetti A, 1998, CLIN CANCER RES, V4, P2331; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; CELETTI A, 1993, INT J CANCER, V53, P237, DOI 10.1002/ijc.2910530211; Chariot A, 1996, BIOCHEM BIOPH RES CO, V222, P292, DOI 10.1006/bbrc.1996.0737; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Chi KN, 2000, BREAST CANCER RES TR, V63, P199, DOI 10.1023/A:1017371013487; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; Clark GJ, 1996, ONCOGENE, V12, P169; Decaudin D, 1997, CANCER RES, V57, P62; Del Bino G, 1999, CELL PROLIFERAT, V32, P25, DOI 10.1046/j.1365-2184.1999.00130.x; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; FREI E., 2000, CANC MED, P556; FRIEDMANN Y, 1994, CANCER RES, V54, P5981; Fuchs EJ, 1997, CANCER RES, V57, P2550; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; Graichen R, 2002, J BIOL CHEM, V277, P26662, DOI 10.1074/jbc.M109931200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUTRIERREZPUENT.Y, 2002, SEMIN ONCOL      S11, V29, P71; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayakawa K, 2000, ONCOL REP, V7, P267; HONG YS, 1995, GENE, V159, P209, DOI 10.1016/0378-1119(95)92712-G; Hull KL, 2001, J ENDOCRINOL, V168, P1, DOI 10.1677/joe.0.1680001; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kleinberg DL, 1997, J MAMMARY GLAND BIOL, V2, P49, DOI 10.1023/A:1026373513521; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Liu ND, 1997, EXP CELL RES, V237, P196, DOI 10.1006/excr.1997.3789; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Mertani HC, 1998, INT J CANCER, V79, P202; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Musgrove EA, 1996, J MAMMARY GLAND BIOL, V1, P153, DOI 10.1007/BF02013639; NAGASAWA H, 1985, EUR J CANCER CLIN ON, V21, P1547, DOI 10.1016/0277-5379(85)90250-0; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; Okada S, 2001, TRENDS MOL MED, V7, P126, DOI 10.1016/S1471-4914(01)01933-5; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172; Pavelic K, 2001, J MOL MED, V79, P566, DOI 10.1007/s001090100256; Pegram M, 2000, SEMIN ONCOL, V27, P13; Raccurt M, 2002, J ENDOCRINOL, V175, P307, DOI 10.1677/joe.0.1750307; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Schally AV, 2001, FRONT NEUROENDOCRIN, V22, P248, DOI 10.1006/frne.2001.0217; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Sesmilo G, 2002, J CLIN ENDOCR METAB, V87, P1692, DOI 10.1210/jc.87.4.1692; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; SOULE HD, 1990, CANCER RES, V50, P6075; Stavrou S, 2001, ENDOCRIN METAB CLIN, V30, P545, DOI 10.1016/S0889-8529(05)70201-2; Swanson SM, 2002, CARCINOGENESIS, V23, P977, DOI 10.1093/carcin/23.6.977; TORNELL J, 1991, INT J CANCER, V49, P114, DOI 10.1002/ijc.2910490121; Walden PD, 1998, ENDOCRINOLOGY, V139, P659, DOI 10.1210/en.139.2.659; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yang XF, 1996, CANCER RES, V56, P1509; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhou Q, 2000, BREAST CANCER RES TR, V59, P27, DOI 10.1023/A:1006370603147	69	122	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7580	7590		10.1074/jbc.M212050200	http://dx.doi.org/10.1074/jbc.M212050200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482855	hybrid			2022-12-25	WOS:000181195100121
J	Cashel, M; Hsu, LM; Hernandez, VJ				Cashel, M; Hsu, LM; Hernandez, VJ			Changes in conserved region 3 of Escherichia coli sigma(70) reduce abortive transcription and enhance promoter escape	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE HOLOENZYME; OPEN-COMPLEX-FORMATION; PROTEIN P4; IN-VIVO; INITIATION; DNA; ACTIVATION; CLEARANCE; SEQUENCE; SUBUNIT	Mutations within the Escherichia coli rpoD gene encoding amino acid substitutions in conserved region 3 of the (70)(sigma) subunit of E. coli RNA polymerase restore normal stress responsiveness to strains devoid of the stress alarmone, guanosine-3',5'-(bis)pyrophosphate (ppGpp). The presence of a mutant protein, either sigma(70)(P504L) or sigma(70)(S506F), suppresses the physiological defects in strains devoid of ppGpp. In vitro, when reconstituted into RNA polymerase holoenzyme, these a mutants confer unique transcriptional properties, namely they reduce the probabilities of forming abortive RNAs. Here we investigated the behavior of these mutant enzymes during transcription of the highly abortive cellular promoter, gal P2. No differences between mutant and wildtype enzymes were observed prior to and including open complex formation. Remarkably, the mutant enzymes produced drastically reduced levels of gal P2 abortive RNAs and increased production of full-length gal P2 RNAs relative to the wild-type enzyme, leading to greatly reduced ratios of abortive to productive RNAs. These results are attributed mainly to a decreased formation of unproductive initial transcribing complexes with the mutant polymerases and increased rates of promoter escape. Altered transcription properties of these mutant polymerases arise from an alternative structure of the sigma(70) region 3.2 segment that permits efficient positioning of the nascent RNA into the RNA exit channel displacing sigma and facilitating a release.	SUNY Buffalo, Dept Microbiol, Ctr Microbial Pathogenesis, Buffalo, NY 14214 USA; NICHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA; Mt Holyoke Coll, Programs Biochem, S Hadley, MA 01075 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Mount Holyoke College	Hernandez, VJ (corresponding author), SUNY Buffalo, Dept Microbiol, Ctr Microbial Pathogenesis, Buffalo, NY 14214 USA.	vjh@buffalo.edu			NIGMS NIH HHS [GM57189] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057189] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOROWIEC JA, 1985, J MOL BIOL, V184, P587, DOI 10.1016/0022-2836(85)90305-5; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARPOUSIS AJ, 1982, J MOL BIOL, V157, P619, DOI 10.1016/0022-2836(82)90502-2; CHAN B, 1989, GENE, V84, P227, DOI 10.1016/0378-1119(89)90496-4; Chan CL, 2001, J BIOL CHEM, V276, P38201; CHOY HE, 1993, P NATL ACAD SCI USA, V90, P472, DOI 10.1073/pnas.90.2.472; ELLINGER T, 1994, J MOL BIOL, V239, P466, DOI 10.1006/jmbi.1994.1389; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HERBERT M, 1986, P NATL ACAD SCI USA, V83, P2807, DOI 10.1073/pnas.83.9.2807; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; Hsu LM, 2002, BBA-GENE STRUCT EXPR, V1577, P191, DOI 10.1016/S0167-4781(02)00452-9; Hsu LM, 1996, METHOD ENZYMOL, V273, P59; JIN DJ, 1994, J BIOL CHEM, V269, P17221; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; JOHNSTON DE, 1976, RNA POLYM, P101; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; Ko DC, 1998, GENE DEV, V12, P3276, DOI 10.1101/gad.12.20.3276; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; LIU CG, 1994, GENE DEV, V8, P2904, DOI 10.1101/gad.8.23.2904; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MCALLISTER CF, 1988, J BIOL CHEM, V263, P11743; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; Monsalve M, 1996, EMBO J, V15, P383, DOI 10.1002/j.1460-2075.1996.tb00368.x; Monsalve M, 1996, P NATL ACAD SCI USA, V93, P8913, DOI 10.1073/pnas.93.17.8913; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; PONNAMBALAM S, 1988, MOL MICROBIOL, V2, P165, DOI 10.1111/j.1365-2958.1988.tb00018.x; Roberts CW, 1996, CELL, V86, P495; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; Sen R, 2001, GENES CELLS, V6, P389, DOI 10.1046/j.1365-2443.2001.00436.x; Sen R, 1998, J BIOL CHEM, V273, P9872, DOI 10.1074/jbc.273.16.9872; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; STEFANO JE, 1979, BIOCHEMISTRY-US, V18, P1063, DOI 10.1021/bi00573a020; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; XIAO H, 1991, J BIOL CHEM, V266, P5980	45	24	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5539	5547		10.1074/jbc.M211430200	http://dx.doi.org/10.1074/jbc.M211430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12477716	hybrid			2022-12-25	WOS:000181129400010
J	Collier, JJ; Doan, TTT; Daniels, MC; Schurr, JR; Kolls, JK; Scott, DK				Collier, JJ; Doan, TTT; Daniels, MC; Schurr, JR; Kolls, JK; Scott, DK			c-Myc is required for the glucose-mediated induction of metabolic enzyme genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; PYRUVATE-KINASE GENE; GLUCOSE-6-PHOSPHATASE GENE; TRANSCRIPTION FACTOR; BINDING PROTEIN; MOLECULAR PHYSIOLOGY; RESPONSE ELEMENT; TRANSGENIC MICE; DNA-BINDING; EXPRESSION	Glucose exerts powerful effects on hepatocyte gene transcription by mechanisms that are incompletely understood. c-Myc regulates hepatic glucose metabolism by increasing glycolytic enzyme gene transcription while concomitantly decreasing gluconeogenic and ketogenic enzyme gene expression. However, the molecular mechanisms by which c-Myc exerts these effects is not known. In this study, the glucose-mediated induction of L-type pyruvate kinase and glucose-6-phosphatase mRNA levels was diminished by maneuvers involving recombinant adenoviral vectors that interfere with (i) c-Myc protein levels by antisense expression or (ii) c-Myc function through a dominant-negative Max protein. These results were obtained using both HL1C rat hepatoma cells and primary rat hepatocytes. Furthermore, a decrease in c-Myc abundance reduced glucose production in HL1C cells, presumably by decreasing glucose-6-phosphatase activity. The repression of hormone-activated phosphoenolpyruvate carboxykinase gene transcription by glucose was not affected by a reduction in c-Myc levels. The basal mRNA levels for L-pyruvate kinase and glucose-6-phosphatase were not altered to any significant degree by adenoviral treatment. Furthermore, adenoviral overexpression of the c-Myc protein induced glucose-6-phosphatase mRNA in the absence of glucose stimulation. We conclude that multiple mechanisms exist to communicate the glucose-derived signal and that c-Myc has a key role in the hepatic glucose signaling pathway.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Scott, DK (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.		Collier, James/N-1958-2017; Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304				Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Cairo S, 2001, HUM MOL GENET, V10, P617, DOI 10.1093/hmg/10.6.617; Cournarie F, 1999, FEBS LETT, V460, P527, DOI 10.1016/S0014-5793(99)01407-6; Dang CV, 1999, MOL CELL BIOL, V19, P1; DEACIUC IV, 1986, AM J PHYSIOL, V251, pR984, DOI 10.1152/ajpregu.1986.251.5.R984; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; Jonas JC, 2001, J BIOL CHEM, V276, P35375, DOI 10.1074/jbc.M105020200; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Massillon D, 2001, J BIOL CHEM, V276, P4055, DOI 10.1074/jbc.M007939200; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Riu E, 1996, P NATL ACAD SCI USA, V93, P2198, DOI 10.1073/pnas.93.5.2198; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298	41	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6588	6595		10.1074/jbc.M208011200	http://dx.doi.org/10.1074/jbc.M208011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480946	hybrid			2022-12-25	WOS:000181129400137
J	Denko, N; Wernke-Dollries, K; Johnson, AB; Hammond, E; Chiang, CM; Barton, MC				Denko, N; Wernke-Dollries, K; Johnson, AB; Hammond, E; Chiang, CM; Barton, MC			Hypoxia actively represses transcription by inducing negative cofactor 2 (Dr1/DrAP1) and blocking preinitiation complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; C-TERMINAL DOMAIN; P53-MEDIATED REPRESSION; GENE-EXPRESSION; HIF-ALPHA; TATA BOX; NC2; BINDING; PHOSPHORYLATION; HOLOENZYME	Hypoxia is a growth inhibitory stress associated with multiple disease states. We find that hypoxic stress actively regulates transcription not only by activation of specific genes but also by selective repression. We reconstituted this bimodal response to hypoxia in vitro and determined a mechanism for hypoxia-mediated repression of transcription. Hypoxic cell extracts are competent for transcript elongation, but cannot assemble a functional preinitiation complex (PIC) at a subset of promoters. PIC assembly and RNA polymerase II C-terminal domain (CTD) phosphorylation were blocked by hypoxic induction and core promoter binding of negative cofactor 2 protein (NIC2alpha/beta, Dr1/DrAP1). Immunodepletion of NC2beta/Dr1 protein complexes rescued hypoxic-repressed transcription without alteration of normoxic transcription. Physiological regulation of NC2 activity may represent an active means of conserving energy in response to hypoxic stress.	Univ Cincinnati, Med Ctr, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Stanford Univ, Sch Med, Div Radiat & Canc Biol, Dept Radiat Oncol, Stanford, CA 94305 USA; Univ Texas, MD Anderson Canc Ctr, Ctr Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	University System of Ohio; University of Cincinnati; Stanford University; University of Texas System; UTMD Anderson Cancer Center; Case Western Reserve University	Barton, MC (corresponding author), Univ Cincinnati, Med Ctr, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.	mbarton@odin.mdace.tmc.edu	denko, nicholas/F-8444-2010	Barton, Michelle/0000-0002-4042-1374; Hammond, Ester/0000-0002-2335-3146				Brown JM, 1998, CANCER RES, V58, P1408; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Cang Y, 2002, P NATL ACAD SCI USA, V99, P12727, DOI 10.1073/pnas.202236699; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Geisberg JV, 2001, MOL CELL BIOL, V21, P2736, DOI 10.1128/MCB.21.8.2736-2742.2001; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; GOLDBERG I, 2002, J BIOL CHEM, V7, P7; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; INOSTROZA JA, 1992, CELL, V70, P477; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lemaire M, 2000, MOL MICROBIOL, V36, P163, DOI 10.1046/j.1365-2958.2000.01839.x; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Ogden SK, 2000, J BIOL CHEM, V275, P27806; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	40	36	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5744	5749		10.1074/jbc.M212534200	http://dx.doi.org/10.1074/jbc.M212534200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12477712	hybrid			2022-12-25	WOS:000181129400034
J	Touz, MC; Lujan, HD; Hayes, SF; Nash, TE				Touz, MC; Lujan, HD; Hayes, SF; Nash, TE			Sorting of encystation-specific cysteine protease to lysosome-like peripheral vacuoles in Giardia lamblia requires a conserved tyrosine-based motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; SURFACE PROTEIN; PRIMITIVE EUKARYOTE; WALL PROTEINS; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; ACID-PHOSPHATASE; EXPRESSION; LOCALIZATION; DIFFERENTIATION	Encystation-specific cysteine protease (ESCP) was the first membrane-associated protein described to be part of the lysosome-like peripheral vacuoles in the intestinal parasite Giardia lamblia. ESCP is homologous to cathepsin C enzymes of higher eukaryotes, but is distinguished from other lysosomal cysteine proteases because it possesses a transmembrane domain and a short cytoplasmic tail. Tyrosine-based motifs within tails of membrane proteins are known to participate in endosomal/lysosomal protein sorting in higher eukaryotes. In this study, we show that a YRPI motif within the ESCP cytoplasmic tail is necessary and sufficient to mediate ESCP sorting to peripheral vacuoles in Giardia. Deletion and point mutation analysis demonstrated that the tyrosine residue is critical for ESCP sorting, whereas amino acids located at the Y+1 (Arg), Y+2 (Pro), and Y+3 (lie) positions show minimal effect. Loss of the motif resulted in surface localization, whereas addition of the motif to a variant-specific surface protein resulted in lysosomal localization. Although Giardia trophozoites lack a morphologically discernible Golgi apparatus, our findings indicate that this parasite directs proteins to the lysosomes using a conserved sorting signal similar to that used by yeast and mammalian cells. Because Giardia is one of the earliest branching protist, these results demonstrate that sorting motifs for specific protein traffic developed very early during eukaryotic evolution.	NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Univ Nacl Cordoba, Fac Ciencias Med, Catedra Bioquim & Biol Mol, RA-5000 Cordoba, Argentina; NIAID, Rocky Mt Lab, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National University of Cordoba; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Touz, MC (corresponding author), NIAID, Parasit Dis Lab, NIH, Bldg 4,Rm B1-06,900 Rockville Pike, Bethesda, MD 20892 USA.	mtouz@niaid.nih.gov		TOUZ, MARIA/0000-0002-6769-6896	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000161, Z01AI000161] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam RD, 2000, INT J PARASITOL, V30, P475, DOI 10.1016/S0020-7519(99)00191-5; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BOUCHER SEM, 1990, INFECT IMMUN, V58, P3516, DOI 10.1128/IAI.58.11.3516-3522.1990; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Dell'Angelica EC, 2001, CELL, V106, P395, DOI 10.1016/S0092-8674(01)00470-6; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; FEELY DE, 1987, J PROTOZOOL, V34, P80, DOI 10.1111/j.1550-7408.1987.tb03137.x; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; Gu F, 2001, CELL MOL LIFE SCI, V58, P1067, DOI 10.1007/PL00000922; Hayman JR, 2001, INFECT IMMUN, V69, P7057, DOI 10.1128/IAI.69.11.7057-7066.2001; Honsho M, 1998, J BIOL CHEM, V273, P20860, DOI 10.1074/jbc.273.33.20860; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; ITIN C, 1995, BIOCHEM SOC T, V23, P541, DOI 10.1042/bst0230541; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Lanfredi-Rangel A, 1998, J STRUCT BIOL, V123, P225, DOI 10.1006/jsbi.1998.4035; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; LINDMARK DG, 1988, EXP PARASITOL, V65, P141, DOI 10.1016/0014-4894(88)90116-6; Lujan HD, 1996, BIOL CELL, V86, P11, DOI 10.1016/0248-4900(96)89519-0; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; LUJAN HD, 1995, J BIOL CHEM, V270, P13807, DOI 10.1074/jbc.270.23.13807; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Marti M, 2002, INFECT IMMUN, V70, P1014, DOI 10.1128/IAI.70.2.1014-1016.2002; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P236, DOI 10.1006/expr.1994.1087; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; NASH TE, 1992, MOL BIOCHEM PARASIT, V51, P219, DOI 10.1016/0166-6851(92)90072-R; NASH TE, 1995, J EUKARYOT MICROBIOL, V42, P604, DOI 10.1111/j.1550-7408.1995.tb05914.x; NASH TE, 1988, J IMMUNOL, V141, P636; Nash TE, 2001, INFECT IMMUN, V69, P1922, DOI 10.1128/IAI.69.3.1922-1923.2001; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Papanastasiou P, 1997, BIOCHEM J, V322, P49, DOI 10.1042/bj3220049; Papanastasiou P, 1997, MOL BIOCHEM PARASIT, V86, P13, DOI 10.1016/S0166-6851(97)90002-5; REINER DS, 1990, EUR J CELL BIOL, V53, P142; Reiner DS, 2001, CELL MICROBIOL, V3, P459, DOI 10.1046/j.1462-5822.2001.00129.x; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Singer SM, 1998, MOL BIOCHEM PARASIT, V92, P59, DOI 10.1016/S0166-6851(97)00225-9; Slavin I, 2002, MOL BIOCHEM PARASIT, V122, P95, DOI 10.1016/S0166-6851(02)00065-8; Touz MC, 2002, BIOCHEM J, V364, P703, DOI 10.1042/BJ20020025; Touz MC, 2002, J BIOL CHEM, V277, P50557, DOI 10.1074/jbc.M202558200; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Ward W, 1997, CELL, V89, P437, DOI 10.1016/S0092-8674(00)80224-X; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; YEE J, 1995, P NATL ACAD SCI USA, V92, P5615, DOI 10.1073/pnas.92.12.5615	49	45	48	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6420	6426		10.1074/jbc.M208354200	http://dx.doi.org/10.1074/jbc.M208354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12466276	hybrid			2022-12-25	WOS:000181129400115
J	Blanpain, C; Doranz, BJ; Bondue, A; Govaerts, C; De Leener, A; Vassart, G; Doms, RW; Proudfoot, A; Parmentier, M				Blanpain, C; Doranz, BJ; Bondue, A; Govaerts, C; De Leener, A; Vassart, G; Doms, RW; Proudfoot, A; Parmentier, M			The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-1; HIV-1 INFECTION; COUPLED RECEPTORS; MCP-1 RECEPTOR; ACTIVATION; RESIDUES; IDENTIFICATION; C5A; DETERMINANTS; INDIVIDUALS	CCR5 is a functional receptor for various inflammatory CC-chemokines, including macrophage inflammatory protein (MIP)-1alpha and RANTES (regulated on activation normal T cell expressed and secreted), and is the main coreceptor of human immunodeficiency viruses. The second extracellular loop and amino-terminal domain of CCR5 are critical for chemokine binding, whereas the transmembrane helix bundle is involved in receptor activation. Chemokine domains and residues important for CCR5 binding and/or activation have also been identified. However, the precise way by which chemokines interact with And activate CCR5 is presently unknown. In this study, we have compared the binding and functional properties of chemokine variants onto wild-type CCR5 and CCR5 point mutants. Several mutations in CCR5 extracellular domains (E172A, R168A, K191A, and D276A) strongly affected MIP-1alpha binding but had little effect on RANTES binding. However, a MIP/RANTES chimera, containing the MIP-1alpha N terminus and the RANTES core, bound to these mutants with an affinity similar to that of RANTES. Several CCR5 mutants affecting transmembrane helices 2 and 3 (L104F, L104F/F109H/F112Y, F85L/L104F) reduced the potency of MIP-1alpha by 10-100 fold with little effect on activation by RANTES. However, the MIP/RANTES chimera activated these mutants with a potency similar to that of MIP-1alpha. In contrast, LD78beta, a natural MIP-1alpha variant, which, like RANTES, contains a proline at position 2, activated these mutants as well as RANTES. Altogether, these results suggest that the core domains of MIP-1alpha and RANTES bind distinct residues in CCR5 extracellular domains, whereas the N terminus of chemokines mediates receptor activation by interacting with the transmembrane helix bundle.	Free Univ Brussels, IRIBHN, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium; Free Univ Brussels, Lab Cytol & Cancerol Expt, B-1070 Brussels, Belgium; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Pennsylvania	Parmentier, M (corresponding author), Free Univ Brussels, IRIBHN, Inst Interdisciplinary Res, 808 Route Lennik,Campus Erasme, B-1070 Brussels, Belgium.		Blanpain, Cedric/ABD-8392-2021	Parmentier, Marc/0000-0001-8081-4685				Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645; Blanpain C, 2002, MOL BIOL CELL, V13, P723, DOI 10.1091/mbc.01-03-0129; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Blanpain C, 2001, J LEUKOCYTE BIOL, V69, P977; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bondue A, 2002, BIOCHEMISTRY-US, V41, P13548, DOI 10.1021/bi026087d; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Detheux M, 2000, J EXP MED, V192, P1501, DOI 10.1084/jem.192.10.1501; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Fischereder M, 2001, LANCET, V357, P1758, DOI 10.1016/S0140-6736(00)04898-4; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; Govaerts C, 2001, J BIOL CHEM, V276, P13217, DOI 10.1074/jbc.M011670200; GOVAERTS C, 1993, J BIOL CHEM, V278, P1892; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; Mayer MR, 2001, J BIOL CHEM, V276, P13911, DOI 10.1074/jbc.M011202200; Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; Ylisastigui L, 1998, AIDS, V12, P977, DOI 10.1097/00002030-199809000-00003	43	131	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5179	5187		10.1074/jbc.M205684200	http://dx.doi.org/10.1074/jbc.M205684200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466283	hybrid			2022-12-25	WOS:000180968900106
J	Bouschet, T; Perez, V; Fernandez, C; Bockaert, J; Eychene, A; Journot, L				Bouschet, T; Perez, V; Fernandez, C; Bockaert, J; Eychene, A; Journot, L			Stimulation of the ERK pathway by GTP-loaded Rap1 requires the concomitant activation of ras, protein kinase C, and protein kinase A in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; NERVE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; ADENYLATE-CYCLASE; MAP KINASE; PHOSPHOLIPASE-C; PC12 CELLS; B-RAF; CALCIUM INFLUX; CYCLIC-AMP	The small GTPases Ras or Rap1 were suggested to mediate the stimulatory effect of some G protein-coupled receptors on ERK activity in neuronal cells. Accordingly, we reported here that pituitary adenylate cyclase-activating polypeptide (PACAP), whose G protein-coupled receptor triggers neuronal differentiation of the PC12 cell line via ERK1/2 activation, transiently activated Ras and induced the sustained GTP loading of Rapl. Ras mediated peak stimulation of ERK by PACAP, whereas Rapl was necessary for the sustained activation phase. However, PACAP-induced GTP-loading of Rapl was not sufficient to account for ERK activation by PACAP because 1) PACAP-elicited Rapl GTP-loading depended only on phospholipase C, whereas maximal stimulation of ERK by PACAP also required the activity of protein kinase A (PKA), protein kinase C (PKC), and calcium-dependent signaling;, and 2) constitutively active mutants of Rapl, RaplA-V12, and Rap1B-V12 only minimally stimulated the ERK pathway compared with Ras-V12. The effect of Rap1A-V12 was dramatically potentiated by the concurrent activation of PKC, the cAMP pathway, and Ras, and this potentiation was blocked by dominant-negative mutants of Ras and Raf. Thus, this set of data indicated that GPCR-elicited GTP loading of Rapl was not sufficient to stimulate efficiently ERK in PC12 cells and required the permissive co-stimulation of PKA, PKC, or Ras.	CNRS, CCIPE 141, UPR 9023, F-34094 Montpellier 05, France; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Journot, L (corresponding author), CNRS, CCIPE 141, UPR 9023, Rue Cardonille, F-34094 Montpellier 05, France.	journot@montp.inserm.fr	Eychene, Alain/M-8838-2017; Bouschet, Tristan/C-8265-2019; Journot, Laurent/T-9652-2018	Bouschet, Tristan/0000-0002-7858-6115; Journot, Laurent/0000-0003-3499-8887; EYCHENE, Alain/0000-0002-6818-7225				ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Barsacchi R, 1999, FEBS LETT, V461, P273, DOI 10.1016/S0014-5793(99)01468-4; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CAREY KD, 2002, J BIOL CHEM; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Daniel PB, 2001, J BIOL CHEM, V276, P12938, DOI 10.1074/jbc.M009941200; Dautzenberg FM, 1999, J NEUROENDOCRINOL, V11, P941; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; Egea J, 1998, J NEUROCHEM, V70, P2554; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FRODIN M, 1994, J BIOL CHEM, V269, P6207; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Gonzalez BJ, 1997, NEUROSCIENCE, V78, P419, DOI 10.1016/S0306-4522(96)00617-3; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Huang NK, 2001, J BIOL CHEM, V276, P13838, DOI 10.1074/jbc.M008589200; Iida N, 2001, J NEUROSCI, V21, P6459, DOI 10.1523/JNEUROSCI.21-17-06459.2001; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lazarovici P, 1998, MOL PHARMACOL, V54, P547, DOI 10.1124/mol.54.3.547; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVIMONTALCINI R, 1965, ARCH ITAL BIOL, V103, P832; Lioudyno M, 1998, J NEUROSCI RES, V51, P243, DOI 10.1002/(SICI)1097-4547(19980115)51:2<243::AID-JNR13>3.0.CO;2-9; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357; Lu NR, 1998, J NEUROSCI RES, V53, P651, DOI 10.1002/(SICI)1097-4547(19980915)53:6<651::AID-JNR3>3.0.CO;2-4; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nicot A, 2001, P NATL ACAD SCI USA, V98, P4758, DOI 10.1073/pnas.071465398; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Suh JH, 2001, NAT NEUROSCI, V4, P123, DOI 10.1038/83936; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6; Zhong HY, 1999, J NEUROCHEM, V72, P2388, DOI 10.1046/j.1471-4159.1999.0722388.x	58	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4778	4785		10.1074/jbc.M204652200	http://dx.doi.org/10.1074/jbc.M204652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473665	hybrid			2022-12-25	WOS:000180968900056
J	Lee, RC; Hrmova, M; Burton, RA; Lahnstein, J; Fincher, GB				Lee, RC; Hrmova, M; Burton, RA; Lahnstein, J; Fincher, GB			Bifunctional family 3 glycoside hydrolases from barley with alpha-L-arabinofuranosidase and beta-D-xylosidase activity - Characterization, primary structures, and COOH-terminal processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-STERCORARIUM; 3-DIMENSIONAL STRUCTURES; NUCLEOTIDE-SEQUENCE; TRICHODERMA-REESEI; GERMINATED BARLEY; ASPERGILLUS-NIGER; ALEURONE LAYERS; CELL-WALLS; PROTEIN; GENE	An alpha-L-arabinofuranosidase and a beta-D-xylosidase, designated ARA-I and XYL, respectively, have been purified about 1,000-fold from extracts of 5-day-old barley (Hordeum vulgare L.) seedlings using ammonium sulfate fractional precipitation, ion exchange chromatography, chromatofocusing, and size-exclusion chromatography. The ARA-I has an apparent molecular mass of 67 kDa and an isoelectric point of 5.5, and its catalytic efficiency during hydrolysis of 4'-nitrophenyl alpha-L-arabinofuranoside is only slightly higher than during hydrolysis of 4'-nitrophenyl beta-D-xyloside. Thus, the enzyme is actually a bifunctional alpha-L-arabinofuranosidase/beta-D-xylosidase. In contrast, the XYL enzyme, which also has an apparent molecular mass of 67 kDa and an isoelectric point of 6.7, preferentially hydrolyzes 4'-nitrophenyl beta-D-xyloside, with a catalytic efficiency similar to30-fold higher than with 4'-nitrophenyl alpha-L-arabinofuranoside. The enzymes hydrolyze wheat flour arabinoxylan slowly but rapidly hydrolyze oligosaccharide products released from this polysaccharide by (1 --> 4)-beta-D-xylan endohydrolase. Both enzymes hydrolyze (1 --> 4)-beta-D-xylopentaose, and ARA-I can also degrade (1 --> 5)-alpha-L-arabinofuranohexaose. ARA-I and XYL cDNAs encode mature proteins of 748 amino acid residues which have calculated molecular masses of 79.2 and 80.5 kDa, respectively. Both are family 3 glycoside hydrolases. The discrepancies between the apparent molecular masses obtained for the purified enzymes and those predicted from the cDNAs are attributable to COOH-terminal processing, through which about 130 amino acid residues are removed from the primary translation product. The genes encoding the ARA-I and XYL have been mapped to chromosomes 2H and 611, respectively. ARA-I transcripts are most abundant in young roots, young leaves, and developing grain, whereas XYL mRNA is detected in most barley tissues.	Univ Adelaide, Dept Plant Sci, Glen Osmond, SA 5064, Australia	University of Adelaide	Fincher, GB (corresponding author), Univ Adelaide, Dept Plant Sci, Waite Campus, Glen Osmond, SA 5064, Australia.	geoff.fincher@adelaide.edu.au	Hrmova, Maria/AAH-3951-2020; Burton, Rachel A/C-4441-2011	Burton, Rachel A/0000-0002-0638-4709; Hrmova, Maria/0000-0002-3545-0605				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREWARTHA KA, 1979, CARBOHYD RES, V77, P191, DOI 10.1016/S0008-6215(00)83805-7; Banik M, 1997, MOL GEN GENET, V253, P599, DOI 10.1007/s004380050362; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Carpita NC, 1996, ANNU REV PLANT PHYS, V47, P445, DOI 10.1146/annurev.arplant.47.1.445; Caspers MPM, 2001, PLANT J, V26, P191, DOI 10.1046/j.0960-7412.2001.01019.x; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; DASHEK WV, 1977, PLANTA, V134, P251, DOI 10.1007/BF00384189; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOAN NP, 1988, J BIOL CHEM, V263, P11106; Ferre H, 2000, EUR J BIOCHEM, V267, P6633, DOI 10.1046/j.1432-1327.2000.01758.x; Fincher G. B., 1992, Barley: genetics, biochemistry, molecular biology and biotechnology., P413; FINCHER G B, 1974, Australian Journal of Plant Physiology, V1, P297; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIBEAUT DM, 1991, PLANT PHYSIOL, V97, P551, DOI 10.1104/pp.97.2.551; Gielkens MMC, 1997, CURR GENET, V31, P22, DOI 10.1007/s002940050172; Harvey AJ, 2000, PROTEINS, V41, P257, DOI 10.1002/1097-0134(20001101)41:2<257::AID-PROT100>3.0.CO;2-C; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; Herrmann MC, 1997, BIOCHEM J, V321, P375, DOI 10.1042/bj3210375; HEYN ANJ, 1986, PLANT SCI, V45, P77, DOI 10.1016/0168-9452(86)90040-3; Hrmova M, 1997, CARBOHYD RES, V305, P209, DOI 10.1016/S0008-6215(97)00257-7; Hrmova M, 2002, PLANT CELL, V14, P1033, DOI 10.1105/tpc.010442; Hrmova M, 1996, J BIOL CHEM, V271, P5277, DOI 10.1074/jbc.271.9.5277; HRMOVA M, 1993, BIOCHEM J, V289, P453, DOI 10.1042/bj2890453; Hrmova M, 2001, STRUCTURE, V9, P1005, DOI 10.1016/S0969-2126(01)00673-6; IIYAMA K, 1994, PLANT PHYSIOL, V104, P315, DOI 10.1104/pp.104.2.315; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kitamoto N, 1999, APPL ENVIRON MICROB, V65, P20; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANGRIDGE P, 1995, MOL BREEDING, V1, P389, DOI 10.1007/BF01248416; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leatherbarrow R. J., 1998, GRAFIT VERSION 4 0; Lee RC, 2001, BIOCHEM J, V356, P181, DOI 10.1042/0264-6021:3560181; Li YK, 2000, J BIOCHEM-TOKYO, V127, P315, DOI 10.1093/oxfordjournals.jbchem.a022609; MargollesClark E, 1996, APPL ENVIRON MICROB, V62, P3840, DOI 10.1128/AEM.62.10.3840-3846.1996; Matsuo N, 2000, BIOCHEM J, V346, P9, DOI 10.1042/0264-6021:3460009; McKie VA, 1997, BIOCHEM J, V323, P547, DOI 10.1042/bj3230547; Nelson N, 1944, J BIOL CHEM, V153, P375; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pitson SM, 1996, FEBS LETT, V398, P7, DOI 10.1016/S0014-5793(96)01153-2; ROBINSON AB, 1973, J AM CHEM SOC, V95, P8156, DOI 10.1021/ja00805a032; SAKKA K, 1993, BIOSCI BIOTECH BIOCH, V57, P268, DOI 10.1271/bbb.57.268; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMPSON DJ, 2002, J CEREAL SCI, V35, P1; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; STAM P, 1993, PLANT J, V3, P739, DOI 10.1111/j.1365-313X.1993.00739.x; TAIZ L, 1976, PLANT PHYSIOL, V58, P380, DOI 10.1104/pp.58.3.380; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tramontano A, 1998, METHODS, V14, P293, DOI 10.1006/meth.1998.0585; UTT EA, 1991, APPL ENVIRON MICROB, V57, P1227, DOI 10.1128/AEM.57.4.1227-1234.1991; vanPeij NNME, 1997, EUR J BIOCHEM, V245, P164; Varghese JN, 1999, STRUCTURE, V7, P179, DOI 10.1016/S0969-2126(99)80024-0; VIETOR RJ, 1994, CARBOHYD POLYM, V24, P113, DOI 10.1016/0144-8617(94)90020-5; Vincent P, 1997, BIOCHEM J, V322, P845, DOI 10.1042/bj3220845; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VROEMEN S, 1995, MOL GEN GENET, V246, P465, DOI 10.1007/BF00290450; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; Wilkie K. C. B., 1979, Advances in Carbohydrate Chemistry and Biochemistry, V36, P215; Zverlov VV, 1998, FEMS MICROBIOL LETT, V164, P337, DOI 10.1016/S0378-1097(98)00236-5	65	145	155	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5377	5387		10.1074/jbc.M210627200	http://dx.doi.org/10.1074/jbc.M210627200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12464603	hybrid			2022-12-25	WOS:000180968900130
J	Bosoy, D; Peng, Y; Mian, IS; Lue, NF				Bosoy, D; Peng, Y; Mian, IS; Lue, NF			Conserved N-terminal motifs of telomerase reverse transcriptase required for ribonucleoprotein assembly in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERASE; CATALYTIC SUBUNIT GENE; TETRAHYMENA-TELOMERASE; YEAST TELOMERASE; MAMMALIAN TELOMERASE; TERT GENE; IN-VITRO; RNA; PROTEIN; COMPONENT	Telomerase is a ribonucleoprotein (RNP) reverse transcriptase responsible for the maintenance of one strand of the telomere terminal repeats. The key protein subunit of the telomerase complex, known as TERT, possesses reverse transcriptase (RT)-like motifs that directly mediate nucleotide addition. The RT motifs are located in the C-terminal region of the polypeptide. Sequence alignments also revealed the existence of four conserved motifs (named GQ, CP, QFP, and T) in the N-terminal region of TERT. The GQ motif of yeast TERT has been demonstrated previously to be essential for telomerase catalysis and may participate in RNP formation. In this report, we show that substitution of conserved residues in the CP, QFP, and T motifs of yeast TERT also impairs both telomere maintenance and telomerase activity, thus confirming the validity of the sequence alignment. The extent of telomere shortening correlates with the extent of reduction in the level of telomerase activity, TERT protein, and TERT-associated TLC1 RNA. Overexpression of the mutant proteins does not result in telomere shortening, implying that assembly rather than catalytic function was affected. This notion was further supported by comparing the efficiency of RNP formation in the wild type and the overexpression strains. Taken together, our results show that three of the four N-terminal motifs are required for efficient telomerase RNP formation in vivo but not for the enzymatic function of telomerase. We also show that the majority of telomerase-associated TLC1 RNA has a more upstream 3' end than previously reported, consistent with additional processing events during RNP maturation.	Cornell Univ, Weill Med Coll, WR Hearst Microbiol Res Ctr, Dept Microbiol & Immunol, New York, NY 10021 USA; Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Cornell University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Lue, NF (corresponding author), Cornell Univ, Weill Med Coll, WR Hearst Microbiol Res Ctr, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.		Lue, Neal/AAO-6759-2020	Lue, Neal/0000-0001-9700-6895	NIGMS NIH HHS [R01 GM62631-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062631] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Bachand F, 2001, MOL CELL BIOL, V21, P1888, DOI 10.1128/MCB.21.5.1888-1897.2001; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Bosoy D, 2001, J BIOL CHEM, V276, P46305, DOI 10.1074/jbc.M108168200; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Chapon C, 1997, RNA, V3, P1337; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Guo WT, 2001, BBA-GENE STRUCT EXPR, V1517, P398, DOI 10.1016/S0167-4781(00)00306-7; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Heller-Uszynska K, 2002, PLANT J, V31, P75, DOI 10.1046/j.1365-313X.2001.01337.x; Hinkley CS, 1998, NUCLEIC ACIDS RES, V26, P532, DOI 10.1093/nar/26.2.532; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kuramoto M, 2001, GENE, V277, P101, DOI 10.1016/S0378-1119(01)00684-9; Lai CK, 2002, GENE DEV, V16, P415, DOI 10.1101/gad.962602; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1495, DOI 10.1093/nar/26.6.1495; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1487, DOI 10.1093/nar/26.6.1487; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Malik HS, 2000, GENE, V251, P101, DOI 10.1016/S0378-1119(00)00207-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller MC, 2000, EMBO J, V19, P4412, DOI 10.1093/emboj/19.16.4412; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oguchi K, 1999, FEBS LETT, V457, P465, DOI 10.1016/S0014-5793(99)01083-2; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Takenaka Y, 2001, GENE, V264, P153, DOI 10.1016/S0378-1119(01)00337-7; Teixeira MT, 2002, EMBO REP, V3, P652, DOI 10.1093/embo-reports/kvf133; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Wang LB, 2002, NUCLEIC ACIDS RES, V30, P4032, DOI 10.1093/nar/gkf513; WEINRICH SL, 1997, NAT GENET, V17, P198; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; Yang YH, 2002, EXP CELL RES, V277, P201, DOI 10.1006/excr.2002.5541; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	64	67	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3882	3890		10.1074/jbc.M210645200	http://dx.doi.org/10.1074/jbc.M210645200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458198	hybrid			2022-12-25	WOS:000180869700048
J	Cheng, P; Yang, YH; Wang, LX; He, QY; Liu, Y				Cheng, P; Yang, YH; Wang, LX; He, QY; Liu, Y			WHITE COLLAR-1, a multifunctional Neurospora protein involved in the circadian feedback loops, light sensing, and transcription repression of Wc-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOCK PROTEIN; SIGNAL-TRANSDUCTION; CRASSA; RHYTHMS; PAS; FREQUENCY; GENETICS; PHOSPHORYLATION; TRANSLATION; COMPONENTS	WHITE COLLAR-1 (WC-1) and WC-2, the two PAS domain-containing transcription factors, are the positive elements of the circadian feedback loops in Neurospora. In addition, both proteins are essential components for the light input of various blue light responses, including the light entrainment of the circadian clock. Recently, we identified WC-1 as the blue light photoreceptor responsible for these light responses. In this study, we show that the formation of the FRQ-WC complex in vivo, a step critical in closing the circadian negative feedback loop, requires WC-1. In addition, we show that WC-1 negatively regulates the expression of wc-2 at the level of the transcription, forming another interacting loop. In a wc-1 mutant, we demonstrate that there is alternative protein initiation of WC-1, and the requirements of WC-1 for the light induction of frq and other genes differ significantly, suggesting the existence of different WC complexes in the cell. Consistent with this interpretation, our results show that there are at least two different types of WC-1/WC-2 complexes in vivo, and that the larger WC-1/WC-2 complex contains more than one WC-1 molecule. Using a series of wc-1 mutants, we show that the WC-1 PASC domain and its C-terminal region are essential for the formation of the WC-1/WC-2 complex. Functional analyses reveal that the DNA-binding domain of WC-1 is required only for the activation of frq in the dark and not for the light function of the protein, confirming that WC-1 is a multifunctional protein with separable protein domains.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Liu, Y (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Rm L4-235,5323 Harry Hines Blvd, Dallas, TX 75390 USA.		He, qiyang/GQA-4070-2022; He, qiyang/AAT-5826-2021					Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Bae K, 2000, J NEUROSCI, V20, P1746; Ballario P, 1998, MOL MICROBIOL, V29, P719, DOI 10.1046/j.1365-2958.1998.00955.x; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; Cheng P, 2002, MOL CELL BIOL, V22, P517, DOI 10.1128/MCB.22.2.517-524.2002; Cheng P, 2001, P NATL ACAD SCI USA, V98, P7408, DOI 10.1073/pnas.121170298; Cheng P, 2001, EMBO J, V20, P101, DOI 10.1093/emboj/20.1.101; Collett MA, 2002, GENETICS, V160, P149; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Denault DL, 2001, EMBO J, V20, P109, DOI 10.1093/emboj/20.1.109; Dragovic Z, 2002, EMBO J, V21, P3643, DOI 10.1093/emboj/cdf377; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Froehlich AC, 2002, SCIENCE, V297, P815, DOI 10.1126/science.1073681; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; He QY, 2002, SCIENCE, V297, P840, DOI 10.1126/science.1072795; Heintzen C, 2001, CELL, V104, P453, DOI 10.1016/S0092-8674(01)00232-X; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LAKINTHOMAS PL, 1990, CRIT REV MICROBIOL, V17, P365, DOI 10.3109/10408419009114762; Lee K, 2000, SCIENCE, V289, P107, DOI 10.1126/science.289.5476.107; Lewis ZA, 2002, MOL MICROBIOL, V45, P917, DOI 10.1046/j.1365-2958.2002.03074.x; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; Loros JJ, 2001, ANNU REV PHYSIOL, V63, P757, DOI 10.1146/annurev.physiol.63.1.757; Merrow M, 2001, EMBO J, V20, P307, DOI 10.1093/emboj/20.3.307; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Schwerdtfeger C, 2000, EUR J BIOCHEM, V267, P414, DOI 10.1046/j.1432-1327.2000.01016.x; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Talora C, 1999, EMBO J, V18, P4961, DOI 10.1093/emboj/18.18.4961; Toyota K, 2002, MOL GENET GENOMICS, V268, P56, DOI 10.1007/s00438-002-0722-1; Yang YH, 2002, GENE DEV, V16, P994, DOI 10.1101/gad.965102; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	39	111	117	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3801	3808		10.1074/jbc.M209592200	http://dx.doi.org/10.1074/jbc.M209592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12454012	hybrid			2022-12-25	WOS:000180869700037
J	Potter, JJ; Rennie-Tankersley, L; Mezey, E				Potter, JJ; Rennie-Tankersley, L; Mezey, E			Endotoxin enhances liver alcohol dehydrogenase by action through upstream stimulatory factor but not by nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; RAT-LIVER; GENE; CELLS; TRANSCRIPTION; EXPRESSION; ACTIVATION; BINDING	Liver alcohol dehydrogenase (ADH) is increased by physiological stress and by chronic administration of growth hormone (GH). Endotoxin plays a role in the pathogenesis of alcoholic liver disease. The effect of lipopolysaccharide (LPS), the endotoxin component of Gram-negative bacteria, was determined on liver ADH. LPS given daily to rats for 3 days increased ADH mRNA, ADH protein, and ADH activity. Nuclear factor-kappaB (NF-kappaB) in the liver nuclear extracts bound to an oligonucleotide specifying region -226 to -194 of the ADH promoter, whereas upstream stimulatory factor (USF) was shown previously to bind to a more proximal site. LPS increased NF-kappaB and USF binding to the ADH promoter. The NF-kappaB (p65) and NF-kappaB (p50) expression vectors inhibited the transfected ADH promoter activity, which contrasts with the previously demonstrated stimulation by an USF expression vector. The binding activities of STAT5b and of C/EBPbeta, which mediate the effect of GH on ADH, were not changed or decreased, respectively, by LPS, indicating that GH plays no intermediary role in the effect of LPS. This study shows that LPS increases ADH and that this effect is mediated by increased binding of USF to the ADH promoter and not by NF-kappaB, which has an inhibitory action.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Mezey, E (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 921 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.				NIAAA NIH HHS [AA00626] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA000626] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		An MR, 1996, MOL CELL BIOL, V16, P2295; AUSUBEL FM, 1995, CURRENT PROTOCOL S29, V1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bergad PL, 2000, AM J PHYSIOL-CELL PH, V279, pC1906, DOI 10.1152/ajpcell.2000.279.6.C1906; Briard N, 2000, J ENDOCRINOL, V164, P361, DOI 10.1677/joe.0.1640361; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROW KE, 1977, ALCOHOL CLIN EXP RES, V1, P43, DOI 10.1111/j.1530-0277.1977.tb05765.x; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Goldring CEP, 2000, FASEB J, V14, P2393; Iber H, 2000, ARCH BIOCHEM BIOPHYS, V377, P187, DOI 10.1006/abbi.2000.1772; Jokelainen K, 1998, BIOCHEM BIOPH RES CO, V253, P834, DOI 10.1006/bbrc.1998.9863; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsukawa T, 2001, ENDOCRINOLOGY, V142, P4643, DOI 10.1210/en.142.11.4643; McCann SM, 2000, ANN NY ACAD SCI, V917, P4, DOI 10.1111/j.1749-6632.2000.tb05368.x; Mezey E, 1993, Alcohol Alcohol Suppl, V2, P57; MEZEY E, 1979, BIOCHEM PHARMACOL, V28, P657, DOI 10.1016/0006-2952(79)90151-5; PLAGEMANN PGW, 1960, J BIOL CHEM, V235, P2288; POTTER JJ, 1993, BIOCHEM BIOPH RES CO, V191, P1040, DOI 10.1006/bbrc.1993.1322; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; Potter JJ, 2001, ARCH BIOCHEM BIOPHYS, V391, P41, DOI 10.1006/abbi.2001.2393; POTTER JJ, 1989, ARCH BIOCHEM BIOPHYS, V274, P548, DOI 10.1016/0003-9861(89)90469-4; POTTER JJ, 1991, ARCH BIOCHEM BIOPHYS, V95, P360; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Thurman RG, 1998, AM J PHYSIOL-GASTR L, V275, pG605, DOI 10.1152/ajpgi.1998.275.4.G605; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P543; YAMAUCHI M, 1988, GASTROENTEROLOGY, V94, P163, DOI 10.1016/0016-5085(88)90625-7; Ye XB, 2001, BIOCHEM BIOPH RES CO, V288, P927, DOI 10.1006/bbrc.2001.5883; Yin M, 2001, HEPATOLOGY, V34, P935, DOI 10.1053/jhep.2001.28888	29	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4353	4357		10.1074/jbc.M210097200	http://dx.doi.org/10.1074/jbc.M210097200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12454009	hybrid			2022-12-25	WOS:000180869700104
J	Stegmuller, J; Werner, H; Nave, KA; Trotter, J				Stegmuller, J; Werner, H; Nave, KA; Trotter, J			The proteoglycan NG2 is complexed with alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors by the PDZ glutamate receptor interaction protein (GRIP) in glial progenitor cells - Implications for glial-neuronal signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGODENDROCYTE PRECURSOR CELLS; MEMBRANE-SPANNING PROTEOGLYCAN; CENTRAL-NERVOUS-SYSTEM; EXCITATORY SYNAPSES; ADHESION MOLECULES; CHANNEL EXPRESSION; MOUSE HIPPOCAMPUS; OPTIC-NERVE; IN-VITRO; DOMAIN	The proteoglycan NG2 is expressed by immature glial cells in the developing and adult central nervous system. Using the COOH-terminal region of NG2 as bait in a yeast two-hybrid screen, we identified the glutamate receptor interaction protein GRIP1, a multi-PDZ domain protein, as an interacting partner. NG2 exhibits a PDZ binding motif at the extreme COOH terminus which binds to the seventh PDZ domain of GRIPl. In addition to the published expression in neurons, GRIPl is expressed by immature glial cells. GRIPl is known to bind to the GluRB subunit of the AMPA glutamate receptor expressed by subpopulations of neurons and immature glial cells. In cultures of primary oligodendrocytes, cells coexpress GluRB and NG2. A complex of NG2, GRIP1, and GluRB can be precipitated from transfected mammalian cells and from cultures of primary oligodendrocytes. Furthermore, NG2 and GRIP can be coprecipitated from developing brain tissue. These data suggest that GRIPl acts as a scaffolding molecule clustering NG2 and AMPA receptors in immature glia. In view of the presence of synaptic contacts between neurons and NG2-positive glial cells in the hippocampus and the close association of NG2-expressing glial cells with axons, we suggest a role for the NG2-AMPA receptor complex in glial-neuronal recognition and signaling.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ Mainz, Dept Zool, Unit Mol Cell Biol, D-55099 Mainz, Germany	Ruprecht Karls University Heidelberg; Max Planck Society; Johannes Gutenberg University of Mainz	Trotter, J (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Nave, Klaus-Armin/C-8883-2011	Werner, Hauke/0000-0002-7710-5738				Araque A, 2001, ANNU REV PHYSIOL, V63, P795, DOI 10.1146/annurev.physiol.63.1.795; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Benson DL, 2000, TRENDS CELL BIOL, V10, P473, DOI 10.1016/S0962-8924(00)01838-9; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; Butt AM, 1999, GLIA, V26, P84, DOI 10.1002/(SICI)1098-1136(199903)26:1<84::AID-GLIA9>3.3.CO;2-C; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; Diers-Fenger M, 2001, GLIA, V34, P213, DOI 10.1002/glia.1055; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Dou CL, 1997, J NEUROCHEM, V68, P1021; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; FULTON BP, 1992, J NEUROSCI, V12, P4816; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; Hata Y, 1996, J NEUROSCI, V16, P2488; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; Knutson P, 1997, J NEUROSCI, V17, P2669, DOI 10.1523/jneurosci.17-08-02669.1997; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LEVINE JM, 1993, GLIA, V7, P307, DOI 10.1002/glia.440070406; Martin S, 2001, J NEUROSCI, V21, P8119, DOI 10.1523/JNEUROSCI.21-20-08119.2001; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Missler M, 1998, J BIOL CHEM, V273, P34716, DOI 10.1074/jbc.273.52.34716; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Niehaus A, 1999, J NEUROSCI, V19, P4948; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Ong WY, 1999, NEUROSCIENCE, V92, P83, DOI 10.1016/S0306-4522(98)00751-9; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Schneider S, 2001, J NEUROSCI, V21, P920, DOI 10.1523/JNEUROSCI.21-03-00920.2001; SEIFERT G, 1995, EUR J NEUROSCI, V7, P1872, DOI 10.1111/j.1460-9568.1995.tb00708.x; Seifert G, 1997, MOL BRAIN RES, V47, P286, DOI 10.1016/S0169-328X(97)00059-4; Seifert G, 1997, J NEUROPHYSIOL, V78, P2916, DOI 10.1152/jn.1997.78.6.2916; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 1999, ANN NY ACAD SCI, V868, P483, DOI 10.1111/j.1749-6632.1999.tb11317.x; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 2000, J CELL BIOL, V151, P143, DOI 10.1083/jcb.151.1.143; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SONTHEIMER H, 1989, NEURON, V2, P1135, DOI 10.1016/0896-6273(89)90180-3; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; TROTTER J, 1989, J NEUROSCI RES, V22, P369, DOI 10.1002/jnr.490220402; TROTTER J, 1989, DEV BRAIN RES, V46, P115, DOI 10.1016/0165-3806(89)90148-X; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Wyszynski M, 1998, NEUROPHARMACOLOGY, V37, P1335, DOI 10.1016/S0028-3908(98)00120-8; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Yuan XQ, 1998, DEVELOPMENT, V125, P2901; Zhou M, 2001, J NEUROSCI, V21, P7901, DOI 10.1523/JNEUROSCI.21-20-07901.2001	66	78	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3590	3598		10.1074/jbc.M210010200	http://dx.doi.org/10.1074/jbc.M210010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458226	hybrid			2022-12-25	WOS:000180869700012
J	Zhu, GH; Lenzi, M; Schwartz, EL				Zhu, GH; Lenzi, M; Schwartz, EL			The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells	ONCOGENE			English	Article						thymidine phosphorylase; angiogenic factor; transcription regulation; colorectal cancer	ENDOTHELIAL GROWTH-FACTOR; MURINE URIDINE PHOSPHORYLASE; HUMAN COLORECTAL-CARCINOMA; NF-KAPPA-B; FACTOR-ALPHA; FACTOR GENE; DEPENDENT INDUCTION; GASTRIC-CARCINOMA; INTERFERON-GAMMA; LUNG-CANCER	Thymidine phosphorylase (TP; also known as platelet-derived endothelial cell growth factor, PD-ECGF) is an angiogenic factor that is chemotactic for endothelial cells and has been found to induce neovascularization in vivo. TP is frequently overexpressed in human solid tumors, where its expression has been correlated with increased tumor microvessel density, invasion, and metastasis, and shorter patient survival. In this report, TP activity in the WiDr colon carcinoma cell line was found to be induced 100-fold by tumor necrosis factor (TNFalpha), a secretory product of activated macrophages that has indirect angiogenic activities. Increased TP activity was accompanied by increased TP mRNA levels and without an increase in mRNA stability. TNFalpha-induced TP mRNA levels were reduced by mithramycin, a DNA-binding transcription inhibitor specific for GC-rich sequences. Transcriptional regulation by TNFa was confirmed by transient transfection of WiDr with upstream TP sequences in a luciferase reporter construct. Deletion analysis of the reporter pinpointed two regions of the TP promoter with regulatory elements for both TNFalpha-inducible and basal expression, and they contained, respectively, three and one consensus binding sites for the Sp1-family of transcription factors. One additional region contributed only to basal TP expression, and it contained three Sp1 sites. TNFalpha-induced TP expression decreased when point mutations were made in three of the four Sp1 sites postulated to contribute to both basal and TNFalpha-inducible expression. Electrophoretic mobility shift assays further demonstrated binding of nuclear Sp1 to these three sites. Sp1-binding activity was also increased in cells treated with TNFalpha. These studies establish a role for Sp1 in the regulation of expression of the angiogenic factor TP in colon cancer WiDr cells.	Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Schwartz, EL (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.				NATIONAL CANCER INSTITUTE [R01CA054422, R01CA089352] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89352, P01-CA13330, R01-CA54422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; Cakouros D, 2001, J IMMUNOL, V167, P302, DOI 10.4049/jimmunol.167.1.302; Cao DL, 1999, CANCER RES, V59, P4997; Cheng N, 2001, J BIOL CHEM, V276, P13771, DOI 10.1074/jbc.M009147200; EDA H, 1993, JPN J CANCER RES, V84, P341, DOI 10.1111/j.1349-7006.1993.tb02876.x; EDA H, 1993, CANCER CHEMOTH PHARM, V32, P333, DOI 10.1007/BF00735915; Engels K, 1997, J PATHOL, V182, P414, DOI 10.1002/(SICI)1096-9896(199708)182:4<414::AID-PATH897>3.0.CO;2-Q; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FINNIS C, 1993, EUR J BIOCHEM, V212, P201, DOI 10.1111/j.1432-1033.1993.tb17651.x; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Goto H, 2001, CANCER RES, V61, P469; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Griffiths L, 1997, CANCER RES, V57, P570; HAGIWARA K, 1991, MOL CELL BIOL, V11, P2125, DOI 10.1128/MCB.11.4.2125; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Kim I, 2000, BIOCHEM BIOPH RES CO, V269, P361, DOI 10.1006/bbrc.2000.2296; Koukourakis MI, 1998, BRIT J CANCER, V77, P1696, DOI 10.1038/bjc.1998.280; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; Lee AHS, 1999, J PATHOL, V187, P285; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Maeda K, 1996, BRIT J CANCER, V73, P884, DOI 10.1038/bjc.1996.177; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; O'Byrne KJ, 2000, BRIT J CANCER, V82, P1427, DOI 10.1054/bjoc.1999.1129; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; POLVERINI PJ, 1984, LAB INVEST, V51, P635; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROSENBAUM JT, 1988, AM J PATHOL, V133, P47; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SATO N, 1986, JNCI-J NATL CANCER I, V76, P1113; SATO N, 1987, J NATL CANCER I, V79, P1383; Sawada N, 1998, CLIN CANCER RES, V4, P1013; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz EL, 1998, CANCER RES, V58, P1551; SCHWARTZ EL, 1995, J BIOL CHEM, V270, P19073, DOI 10.1074/jbc.270.32.19073; Seki N, 2000, EUR J CANCER, V36, P68, DOI 10.1016/S0959-8049(99)00201-4; Shimaoka S, 2000, CANCER, V88, P2220, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2220::AID-CNCR4>3.3.CO;2-3; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SUMIZAWA T, 1993, J BIOCHEM-TOKYO, V114, P9, DOI 10.1093/oxfordjournals.jbchem.a124146; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahashi Y, 1998, CLIN CANCER RES, V4, P429; Takahashi Y, 1996, J NATL CANCER I, V88, P1146, DOI 10.1093/jnci/88.16.1146; TAKEBAYASHI Y, 1995, CANCER LETT, V95, P57, DOI 10.1016/0304-3835(95)03865-T; Takebayashi Y, 1996, JNCI-J NATL CANCER I, V88, P1110, DOI 10.1093/jnci/88.16.1110; TEVAEARAI HT, 1992, EUR J CANCER, V28A, P368, DOI 10.1016/S0959-8049(05)80055-3; van Triest B, 2000, CLIN CANCER RES, V6, P1063; WATANABE SI, 1995, J BIOL CHEM, V270, P12191, DOI 10.1074/jbc.270.20.12191; WATANABE SI, 1995, BIOCHEM BIOPH RES CO, V216, P265, DOI 10.1006/bbrc.1995.2619; Zhang DK, 2001, CANCER RES, V61, P6899; ZIMMERMAN M, 1964, J BIOL CHEM, V239, P2618	58	62	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8477	8485		10.1038/sj.onc.1206030	http://dx.doi.org/10.1038/sj.onc.1206030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466967				2022-12-25	WOS:000179480100010
J	Sciacca, L; Mineo, R; Pandini, G; Murabito, A; Vigneri, R; Belfiore, A				Sciacca, L; Mineo, R; Pandini, G; Murabito, A; Vigneri, R; Belfiore, A			In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A	ONCOGENE			English	Article						insulin; isoforms; IGF-I receptor; IGF-II; cell invasion; apoptosis	GROWTH-FACTOR-II; BREAST-CANCER CELLS; MONOCLONAL-ANTIBODIES; AUTOPHOSPHORYLATION; ACTIVATION; MECHANISM; MIGRATION; PATHWAYS; TUMORS	One of the two isoforms of the human insulin receptor (isoform A or IR-A) binds IGF-II with high affinity and is predominantly expressed in fetal tissues and malignant cells. We evaluated the biological relevance of IR-A in human myosarcoma cells. Six myosarcoma cell lines were studied. All produced high amounts of IGF-II and five of them predominantly expressed IR-A. SKUT-1 leiomyosarcoma cells, that do not express the IGF-IR, were identified as a suitable model to study the effects of IR-A in the absence of the interference of IGF-IR. In these cells, which express high levels of IR with an IR-A relative abundance of approximate to95%, IGF-II elicits biological effects exclusively via IR-A activation and IGF-I is almost ineffective. Blockade of autocrine IGF-II reduced unstimulated cell viability and migration. Although both insulin and IGF-II activate IR-A, these two ligands showed a different ability to activate different intracellular signaling pathways and to elicit different biological effects. Insulin was more potent than IGF-II in activating the PI3-K/Akt pathway and in protecting cells from apoptosis. In contrast, IGF-II was more potent than insulin in activating the Shc/ERK pathway and in stimulating cell migration. These data indicate that IGF-II sensitive IR-A is the predominant IR isoform in a variety of myosarcoma cells. In SKUT-1 leiomyoma cells this fetal IR isoform may vicariate the IGF-IR for cell response to both insulin and IGF-II. Acting on the same IR-A receptor IGF-II is more potent than insulin in stimulating cancer cell migration.	Univ Catanzaro, Cattedra Endocrinol, Dipartimento Med Clin & Sperimentale, Policlin Mater Domini, I-88100 Catanzaro, Italy; Univ Catania, Dipartimento Med Interna & Med Specialist, Osped Garibaldi, I-95123 Catania, Italy; Ist Mediterraneo Oncol, IMO, Catania, Italy	Magna Graecia University of Catanzaro; University of Catania; Mediterranean Institute of Oncology	Belfiore, A (corresponding author), Univ Catanzaro, Cattedra Endocrinol, Dipartimento Med Clin & Sperimentale, Policlin Mater Domini, Via T Campanella 115, I-88100 Catanzaro, Italy.		Pandini, Giuseppe/AAB-9650-2019; Sciacca, Laura/B-9368-2014; SCIACCA, Laura/AAS-2896-2020; Belfiore, Antonino/B-4652-2011; Vigneri, Riccardo/M-3968-2017	Pandini, Giuseppe/0000-0003-3747-7649; Sciacca, Laura/0000-0002-3258-7200; SCIACCA, Laura/0000-0002-3258-7200; Belfiore, Antonino/0000-0002-6181-4193; Vigneri, Riccardo/0000-0002-4401-3140				BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Bartucci M, 2001, CANCER RES, V61, P6747; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; Cullen K J, 1992, Cancer Treat Res, V61, P413; CULLEN KJ, 1992, BREAST CANCER RES TR, V22, P21, DOI 10.1007/BF01833330; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; HEO DS, 1990, CANCER RES, V50, P3681; Hiromura K, 2002, KIDNEY INT, V61, P1312, DOI 10.1046/j.1523-1755.2002.00257.x; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; KULL FC, 1983, J BIOL CHEM, V258, P6561; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; ROTH RA, 1982, P NATL ACAD SCI-BIOL, V79, P7312, DOI 10.1073/pnas.79.23.7312; RUBIN R, 1995, LAB INVEST, V73, P311; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; STRAUSS G, 1994, J INTERN MED, V236, P97, DOI 10.1111/j.1365-2796.1994.tb01127.x; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Vella V, 2002, J CLIN ENDOCR METAB, V87, P245, DOI 10.1210/jc.87.1.245; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670	28	130	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8240	8250		10.1038/sj.onc.1206058	http://dx.doi.org/10.1038/sj.onc.1206058			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447687				2022-12-25	WOS:000179323900002
J	Scarlett, DJG; McCaughan, KK; Wilson, DN; Tate, WP				Scarlett, DJG; McCaughan, KK; Wilson, DN; Tate, WP			Mapping functionally important motifs SPF and GGQ of the decoding release factor RF2 to the Escherichia coli ribosome by hydroxyl radical footprinting - Implications for macromolecular mimicry and structural changes in RF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE CENTER; TRANSFER-RNA HYDROLYSIS; FACTOR-I; TRANSLATION TERMINATION; PROTEIN-SYNTHESIS; CHAIN TERMINATION; BOND FORMATION; MESSENGER-RNA; CROSS-LINKING; STOP CODONS	The function of the decoding release factor (RF) in translation termination is to couple cognate recognition of the stop codon in the mRNA with hydrolysis of the completed polypeptide from its covalently linked tRNA. For this to occur, the RF must interact with specific A-site components of the active centers within both the small and large ribosomal subunits. In this work, we have used directed hydroxyl radical foot-printing to map the ribosomal binding site of the Escherichia coli class I release factor RF2, during translation termination. In the presence of the cognate UGA stop codon, residues flanking the universally conserved (250)GGQ(252) motif of RF2 were each shown to footprint to the large ribosomal subunit, specifically to conserved elements of the peptidyltransferase and GTPase-associated centers. In contrast, residues that flank the putative "peptide anticodon" of RF2, (SPF207)-S-205, were shown to make a footprint in the small ribosomal subunit at positions within well characterized 16 S rRNA motifs in the vicinity of the decoding center. Within the recently solved crystal structure of E. coli RF2, the GGQ and SPF motifs are separated by 23 Angstrom only, a distance that is incompatible. with the observed cleavage sites that are up to 100 Angstrom apart. Our data suggest that RF2 may undergo gross conformational changes upon ribosome binding, the implications of which are discussed in terms of the mechanism of RF-mediated termination.	Univ Otago, Dept Biochem, Dunedin, New Zealand; Univ Otago, Ctr Gene Res, Dunedin, New Zealand; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	University of Otago; University of Otago; Max Planck Society	Tate, WP (corresponding author), Univ Otago, Dept Biochem, POB 56, Dunedin, New Zealand.	warren.tate@stonebow.otago.ac.nz	Wilson, Daniel/AAE-8504-2019	Wilson, Daniel/0000-0003-3816-3828				Arkov AL, 2000, BIOCHIMIE, V82, P671, DOI 10.1016/S0300-9084(00)01162-7; Arkov AL, 1998, EMBO J, V17, P1507, DOI 10.1093/emboj/17.5.1507; Askarian-Amiri ME, 2000, J BIOL CHEM, V275, P17241, DOI 10.1074/jbc.M910448199; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BROWN CM, 1993, NUCLEIC ACIDS RES, V21, P2109, DOI 10.1093/nar/21.9.2109; Culver GM, 1999, J MOL BIOL, V286, P355, DOI 10.1006/jmbi.1998.2483; Culver GM, 2000, METHOD ENZYMOL, V318, P461; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; DERIEMER LH, 1981, J LABELLED COMPD RAD, V18, P1517, DOI 10.1002/jlcr.2580181017; Dincbas-Renqvist V, 2000, EMBO J, V19, P6900, DOI 10.1093/emboj/19.24.6900; DONLY BC, 1990, BIOCHEM INT, V20, P437; ELLIOTT T, 1991, J BACTERIOL, V173, P4144, DOI 10.1128/jb.173.13.4144-4154.1991; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Green R, 1997, J MOL BIOL, V266, P40, DOI 10.1006/jmbi.1996.0780; Green R, 1998, SCIENCE, V280, P286, DOI 10.1126/science.280.5361.286; Green R, 2002, CELL, V110, P665, DOI 10.1016/S0092-8674(02)00965-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hansen JL, 2002, P NATL ACAD SCI USA, V99, P11670, DOI 10.1073/pnas.172404099; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Holmberg L, 1999, J MOL BIOL, V289, P223, DOI 10.1006/jmbi.1999.2706; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Ito K, 1998, P NATL ACAD SCI USA, V95, P8165, DOI 10.1073/pnas.95.14.8165; Jemiolo DK, 1995, P NATL ACAD SCI USA, V92, P12309, DOI 10.1073/pnas.92.26.12309; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; Joseph S, 1997, SCIENCE, V278, P1093, DOI 10.1126/science.278.5340.1093; KASTNER B, 1990, J MOL BIOL, V212, P241, DOI 10.1016/0022-2836(90)90120-B; Kisselev LL, 1999, MOL BIOL+, V33, P932; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Lancaster L, 2000, RNA, V6, P717, DOI 10.1017/S1355838200000303; Lieberman KR, 2000, J MOL BIOL, V297, P1129, DOI 10.1006/jmbi.2000.3621; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOFFAT JG, 1994, J BIOL CHEM, V269, P18899; MOFFAT JG, 1993, EUR J BIOCHEM, V213, P749, DOI 10.1111/j.1432-1033.1993.tb17816.x; Murgola EJ, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P509; MURGOLA EJ, 1988, P NATL ACAD SCI USA, V85, P4162, DOI 10.1073/pnas.85.12.4162; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Nissen P, 2000, EMBO J, V19, P489, DOI 10.1093/emboj/19.4.489; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P4423, DOI 10.1093/nar/20.17.4423; Poole E, 2000, BBA-GENE STRUCT EXPR, V1493, P1, DOI 10.1016/S0167-4781(00)00162-7; Porse BT, 1996, J MOL BIOL, V264, P472, DOI 10.1006/jmbi.1996.0655; Porse BT, 1999, P NATL ACAD SCI USA, V96, P9003, DOI 10.1073/pnas.96.16.9003; PORSE BT, 1995, J MOL BIOL, V249, P1, DOI 10.1006/jmbi.1995.0276; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; RINKEAPPEL J, 1993, NUCLEIC ACIDS RES, V21, P2853, DOI 10.1093/nar/21.12.2853; RYDEN SM, 1984, MOL GEN GENET, V193, P38, DOI 10.1007/BF00327411; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4693; Schmeing TM, 2002, NAT STRUCT BIOL, V9, P225, DOI 10.1038/nsb758; SCOLNICK EM, 1969, P NATL ACAD SCI USA, V64, P1235, DOI 10.1073/pnas.64.4.1235; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; TATE WP, 1983, J BIOL CHEM, V258, P2816; TATE WP, 1984, J BIOL CHEM, V259, P7317; TATE WP, 1986, J BIOL CHEM, V261, P2289; TATE WP, 1990, RIBOSOMES PROTEIN SY, P81; Uno M, 1996, BIOCHIMIE, V78, P935, DOI 10.1016/S0300-9084(97)86715-6; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; Van de Peer Y, 1998, NUCLEIC ACIDS RES, V26, P179, DOI 10.1093/nar/26.1.179; Van Dyke N, 2002, J MOL BIOL, V319, P329, DOI 10.1016/S0022-2836(02)00304-2; Vestergaard B, 2001, MOL CELL, V8, P1375, DOI 10.1016/S1097-2765(01)00415-4; Wilson DN, 2000, RNA, V6, P1704, DOI 10.1017/S135583820000131X; Wilson KS, 2000, NAT STRUCT BIOL, V7, P866, DOI 10.1038/82818; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Xu WB, 2002, J BACTERIOL, V184, P1200, DOI 10.1128/jb.184.4.1200-1203.2002	71	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15095	15104		10.1074/jbc.M211024200	http://dx.doi.org/10.1074/jbc.M211024200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12458201	hybrid			2022-12-25	WOS:000182516100067
J	Kuraoka, I; Endou, M; Yamaguchi, Y; Wada, T; Handa, H; Tanaka, K				Kuraoka, I; Endou, M; Yamaguchi, Y; Wada, T; Handa, H; Tanaka, K			Effects of endogenous DNA base lesions on transcription elongation by mammalian RNA polymerase II - Implications for transcription-coupled DNA repair and transcriptional mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCKAYNE-SYNDROME; MUTT PROTEIN; NUCLEOTIDE; OXIDATION; COMPLEX; STRAND	The blockage of transcription elongation by RNA polymerase II (pol II) is thought to be a trigger for transcription-coupled repair in the pathway of nucleotide excision repair. Purified pol H and oligo(dC)-tailed templates containing a single non-bulky DNA lesion on the transcribed strand such as an apurinic/apyrimidinic (AP) site, uracil, or 8-oxoguanine (8-oxoG) were used for transcription elongation assays. In this system pol II could bypass both the AP site and uracil without pausing and insert cytosine opposite the AP site and either guanine or adenine opposite to uracil. Thus, the AP site on the DNA templates could lead to correct transcription only if depurination at guanine occurred, whereas uracil generated either the correct transcriptional product or an incorrect one with a G:C to A:T transition. In the case of 8-oxoG, pol II stalled at the lesion, but sometimes bypassed it and inserted a cytosine residue or the incorrect adenine residue leading to a G:C to T:A transversion. These findings indicate that 8-oxoG lesions caused a blockage of transcription elongation and/or the misincorporation of a ribonucleotide by pol 11, implying the initiation of transcription-coupled repair of 8-oxoG and/or transcriptional mutagenesis.	Osaka Univ, Lab Organismal Biosyst, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Yokohama, Kanagawa 2268501, Japan	Osaka University; Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Tokyo Institute of Technology	Tanaka, K (corresponding author), Osaka Univ, Lab Organismal Biosyst, Grad Sch Frontier Biosci, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	ktanaka@fbs.osaka-u.ac.jp	Yamaguchi, Yuki/B-9390-2015	Yamaguchi, Yuki/0000-0002-0197-614X; Kuraoka, Isao/0000-0001-6391-3411				CHEN YH, 1993, J BIOL CHEM, V268, P5849; Citterio E, 2000, CELL, V101, P447, DOI 10.1016/S0092-8674(00)80854-5; Cooke MS, 1998, FREE RADICAL RES, V28, P459, DOI 10.3109/10715769809066883; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Dukan S, 2000, P NATL ACAD SCI USA, V97, P5746, DOI 10.1073/pnas.100422497; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; Kunkel T A, 1999, Trends Genet, V15, P93, DOI 10.1016/S0168-9525(98)01664-3; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shivji MKK, 1999, METH MOL B, V113, P373; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Tornaletti S, 2001, J BIOL CHEM, V276, P45367, DOI 10.1074/jbc.M105282200; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; Viswanathan A, 1999, SCIENCE, V284, P159, DOI 10.1126/science.284.5411.159; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	29	105	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7294	7299		10.1074/jbc.M208102200	http://dx.doi.org/10.1074/jbc.M208102200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12466278	hybrid			2022-12-25	WOS:000181195100086
J	Xu, Y; Clark, JC; Aronow, BJ; Dey, CR; Liu, C; Wooldridge, JL; Whitsett, JA				Xu, Y; Clark, JC; Aronow, BJ; Dey, CR; Liu, C; Wooldridge, JL; Whitsett, JA			Transcriptional adaptation to cystic fibrosis transmembrane conductance regulator deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PSEUDOMONAS-AERUGINOSA; GENE-EXPRESSION; ACTIVATION; FAMILY; INFLAMMATION; PROTEASOME; PROTEIN; MICE; CFTR	Cystic fibrosis, the most commonly inherited lethal pulmonary disorder in Caucasians, is caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR). To identify genomic responses to the presence or absence of CFTR in pulmonary tissues in vivo, microarray analyses of lung mRNAs were performed on whole lung tissue from mice lacking (CFTR(-)) or expressing mouse CFTR (CFTR(+)). Whereas the histology of lungs from CFTR(-) an CFTR(+) mice was indistinguishable, statistically significant increases in the relative abundance of 29 and decreases in 25 RNAs were identified by RNA microarray analysis. Of RNAs whose expression was consistently altered by the absence of CFTR, functional classes of genes influencing gene transcription, inflammation, intracellular trafficking, signal transduction, and ion transport were identified. IRNAs encoding the transcription factor CCAAT enhancei-binding protein (CEBP) 5 and interleukin (IL) 1beta, both known to regulate CFTR expression, were induced, perhaps indicating adaptation to the lack of CFTR. RNAs mediating lung inflammation including calgranulin-S100 family members, IL-1beta and IL-4, were increased. Likewise, expression of several membrane transport proteins that interact directly with CFTR were increased, suggesting that CFTR-protein complexes initiate genomic responses. Absence of CFTR influenced the expression of genes modulating diverse pulmonary cell functions that may ameliorate or contribute to the pathogenesis of CF.	Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp, Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp, Med Ctr, Div Pediat Informat, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp, Med Ctr, Div Pulm Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Neonatol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@chmec.org	Aronow, Bruce J/F-8438-2012	, Yan/0000-0003-2025-027X	NHLBI NIH HHS [HL56387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056387, P01HL056387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Biwersi J, 1996, P NATL ACAD SCI USA, V93, P12484, DOI 10.1073/pnas.93.22.12484; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; Chanson M, 2001, AM J PATHOL, V158, P1775, DOI 10.1016/S0002-9440(10)64133-8; Chatterjee PK, 1999, EXP NEPHROL, V7, P438; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Chroneos ZC, 2000, J IMMUNOL, V165, P3941, DOI 10.4049/jimmunol.165.7.3941; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DENAMUR E, 1994, HUM MOL GENET, V3, P1089, DOI 10.1093/hmg/3.7.1089; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Elmer HL, 1999, AM J PHYSIOL-LUNG C, V276, pL466, DOI 10.1152/ajplung.1999.276.3.L466; ENGELHARDT JF, 1994, J CLIN INVEST, V93, P737, DOI 10.1172/JCI117028; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARY CA, 1993, AM J PHYSIOL, V265, pL598, DOI 10.1152/ajplung.1993.265.6.L598; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Ho K, 1998, CURR OPIN NEPHROL HY, V7, P49, DOI 10.1097/00041552-199801000-00009; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kelley TJ, 1997, P NATL ACAD SCI USA, V94, P2604, DOI 10.1073/pnas.94.6.2604; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; Leblais V, 1999, J BIOL CHEM, V274, P6107, DOI 10.1074/jbc.274.10.6107; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Notterman DA, 2001, CANCER RES, V61, P3124; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; Poschet JF, 2002, J BIOL CHEM, V277, P13959, DOI 10.1074/jbc.M105441200; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schroeder TH, 2002, P NATL ACAD SCI USA, V99, P6907, DOI 10.1073/pnas.092160899; SHEN BQ, 1993, J BIOL CHEM, V268, P19070; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Thiery E, 2000, MECH DEVELOP, V95, P313, DOI 10.1016/S0925-4773(00)00364-6; Thomas GR, 2000, J IMMUNOL, V164, P3870, DOI 10.4049/jimmunol.164.7.3870; WEBBER SE, 1992, BRIT J PHARMACOL, V105, P857, DOI 10.1111/j.1476-5381.1992.tb09068.x; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Whitsett JA, 2002, J BIOL CHEM, V277, P22743, DOI 10.1074/jbc.M202253200; WILKINS MR, 1993, J ENDOCRINOL, V137, P347, DOI 10.1677/joe.0.1370347; Xu K, 2000, J IMMUNOL, V164, P4916, DOI 10.4049/jimmunol.164.9.4916; ZHOU L, 1994, SCIENCE, V266, P1705, DOI 10.1126/science.7527588	47	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7674	7682		10.1074/jbc.M210277200	http://dx.doi.org/10.1074/jbc.M210277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482874	hybrid			2022-12-25	WOS:000181195100132
J	Clabby, ML; Robinson, TA; Quigley, HF; Wilson, DB; Kelly, DP				Clabby, ML; Robinson, TA; Quigley, HF; Wilson, DB; Kelly, DP			Retinoid X receptor a represses GATA-4-mediated transcription via a retinoid-dependent interaction with the cardiac-enriched repressor FOG-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; FACTOR GATA-4; HEART MORPHOGENESIS; GENE-EXPRESSION; ACID SYNTHESIS; ALPHA; MUSCLE; MOUSE; RXR; HYPERTROPHY	Dietary vitamin A and its derivatives, retinoids, regulate cardiac growth and development. To delineate mechanisms involved in retinoid-mediated control of cardiac gene expression, the regulatory effects of the retinoid X receptor alpha(RXRalpha) on atrial naturietic factor (ANF) gene transcription was investigated. The transcriptional activity of an ANF promoter-reporter in rat neonatal ventricular myocytes was repressed by RXRalpha in the presence of 9-cis-RA and by the constitutively active mutant RXRalphaF318A indicating that liganded RXR confers the regulatory effect. The RXRalpha-mediated repression mapped to the proximal 147 bp of the rat ANF promoter, a region lacking a consensus retinoid response element but containing several known cardiogenic cis elements including a well characterized GATA response element. Glutathione S-transferase "pull-down" assays revealed that RXRalpha interacts directly with GATA-4, in a ligand-independent manner, via the DNA binding domain of RXRalpha and the second zinc finger of GATA-4. Liganded RXRalpha repressed the activity of a heterologous promoter-reporter construct containing GATA-response element recognition sites in cardiac myocytes but not in several other cell types, suggesting that additional cardiac-enriched factors participate in the repression complex. Co-transfection of liganded RXRalpha and the known cardiac-enriched GATA-4 repressor, FOG-2, resulted in additive repression of GATA-4 activity in ventricular myocytes. In addition, RXRalpha was found to bind FOG-2, in a 9-cis-RA-dependent manner. These data reveal a novel mechanism by which retinoids regulate cardiogenic gene expression through direct interaction with GATA-4 and its co-repressor, FOG-2.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kelly, DP (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, 660 S Euclid Ave,Campus Box 8086, St Louis, MO 63110 USA.		Wilson, David/K-7433-2014; Kelly, Daniel/ABG-2056-2021	Wilson, David/0000-0002-1826-7745; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003829, P50HL061006, R01HL058493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, P30DK056341] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL61006, R01 HL58493, KO8 HL03829] Funding Source: Medline; NIDDK NIH HHS [P30 DK56341, P30 DK52574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; BUCKINGHAM ME, 1994, CURR OPIN GENET DEV, V4, P745, DOI 10.1016/0959-437X(94)90142-P; Chang AN, 2002, P NATL ACAD SCI USA, V99, P9237, DOI 10.1073/pnas.142302099; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Doevendans PA, 1996, INT J BIOCHEM CELL B, V28, P387, DOI 10.1016/1357-2725(95)00145-X; Dong S, 2002, BLOOD, V99, P2637, DOI 10.1182/blood.V99.8.2637; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Gonzalez MM, 2002, J BIOL CHEM, V277, P18501, DOI 10.1074/jbc.M200205200; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; Huggins GS, 2001, J BIOL CHEM, V276, P28029, DOI 10.1074/jbc.M103577200; Kersten S, 1998, J MOL BIOL, V284, P21, DOI 10.1006/jmbi.1998.2168; Kim SW, 2001, ONCOGENE, V20, P6638, DOI 10.1038/sj.onc.1204695; Kostetskii I, 1999, DEV BIOL, V206, P206, DOI 10.1006/dbio.1998.9139; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Levin ER, 1998, NEW ENGL J MED, V339, P321; LI Q, 1994, J BIOL CHEM, V269, P4934; Lien CL, 1999, DEVELOPMENT, V126, P75; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Mascrez B, 1998, DEVELOPMENT, V125, P4691; McWhinney CD, 2000, MOL CELL BIOCHEM, V214, P111, DOI 10.1023/A:1007129723949; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 2001, DEVELOPMENT, V128, P1019; OSMOND MK, 1991, DEVELOPMENT, V113, P1405; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; TUNNACLIFFE A, 1983, EMBO J, V2, P1577, DOI 10.1002/j.1460-2075.1983.tb01627.x; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; WU J, 1995, AM J PHYSIOL-ENDOC M, V268, pE1108, DOI 10.1152/ajpendo.1995.268.6.E1108; Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	48	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5760	5767		10.1074/jbc.M208173200	http://dx.doi.org/10.1074/jbc.M208173200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480945	hybrid			2022-12-25	WOS:000181129400036
J	Deschenes-Furry, J; Belanger, G; Perrone-Bizzozero, N; Jasmin, BJ				Deschenes-Furry, J; Belanger, G; Perrone-Bizzozero, N; Jasmin, BJ			Post-transcriptional regulation of acetylcholinesterase mRNAs in nerve growth factor-treated PC12 cells by the RNA-binding protein HuD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; GAP-43 MESSENGER-RNA; TISSUE-SPECIFIC EXPRESSION; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; NEURITE OUTGROWTH; SKELETAL-MUSCLE; MOLECULAR-FORMS; RAT-BRAIN; POSTTRANSCRIPTIONAL REGULATION	Expression of acetylcholinesterase (AChE) is greatly enhanced during neuronal differentiation, but the nature of the molecular mechanisms remains to be fully defined. In this study, we observed that nerve growth factor treatment of PC12 cells leads to a progressive increase in the expression of AChE transcripts, reaching similar to3.5-fold by 72 h. Given that the AChE 3'-untranslated region (UTR) contains an AU-rich element, we focused on the potential role of the RNA-binding protein HuD in mediating the increase in AChE mRNA seen in differentiating neurons. Using PC12 cells engineered to stably express HuD or an antisense to HuD, our studies indicate that HuD can regulate the abundance of AChE transcripts in neuronal cells. Furthermore, transfection of a reporter construct containing the AChE 3'-UTR showed that this 3'-UTR can increase expression of the reporter gene product in cells expressing HuD but not in cells expressing the antisense. RNA gel shifts and Northwestern blots revealed an increase in the binding of several protein complexes in differentiated neurons. Immunoprecipitation experiments demonstrated that HuD can bind directly AChE transcripts. These results show the importance of post-transcriptional mechanisms in regulating AChE expression in differentiating neurons and implicate HuD as a key trans-acting factor in these events.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Ctr Neuromuscular Dis, Ottawa, ON K1H 8M5, Canada; Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA	University of Ottawa; University of Ottawa; University of New Mexico	Jasmin, BJ (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.				NINDS NIH HHS [NS-30255] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030255, R29NS030255] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alterio J, 2001, MOL CELL NEUROSCI, V17, P179, DOI 10.1006/mcne.2000.0930; Anderson KD, 2001, EXP NEUROL, V168, P250, DOI 10.1006/exnr.2000.7599; Angus LM, 2001, J BIOL CHEM, V276, P17603, DOI 10.1074/jbc.M100916200; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; BERNARD V, 1995, NEUROSCIENCE, V64, P995, DOI 10.1016/0306-4522(94)00497-S; Blasina MF, 2000, CELL TISSUE RES, V299, P173, DOI 10.1007/s004419900117; Boudreau-Lariviere C, 1999, FEBS LETT, V444, P22, DOI 10.1016/S0014-5793(99)00015-0; Boudreau-Lariviere C, 2000, J NEUROCHEM, V74, P2250, DOI 10.1046/j.1471-4159.2000.0742250.x; BoudreauLariviere C, 1996, NEUROSCIENCE, V73, P613, DOI 10.1016/0306-4522(96)00033-4; Brimijoin S, 1996, NEUROSCIENCE, V71, P555, DOI 10.1016/0306-4522(95)00457-2; Chan RYY, 1998, J BIOL CHEM, V273, P9727, DOI 10.1074/jbc.273.16.9727; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; Coleman BA, 1996, J BIOL CHEM, V271, P4410; Cuadrado A, 2002, NUCLEIC ACIDS RES, V30, P2202, DOI 10.1093/nar/30.10.2202; Dobashi Y, 1998, BIOCHEM BIOPH RES CO, V244, P226, DOI 10.1006/bbrc.1998.8247; Dupree JL, 1996, J NEUROCYTOL, V25, P439, DOI 10.1007/BF02284814; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Erondu NE, 1999, MOL ENDOCRINOL, V13, P495, DOI 10.1210/me.13.3.495; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; Fernandes KJL, 1998, J NEUROSCI, V18, P9936; FORSTER E, 1993, NEUROSCI LETT, V155, P216, DOI 10.1016/0304-3940(93)90711-S; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1981, J BIOL CHEM, V256, P6363; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HAMMOND P, 1994, P NATL ACAD SCI USA, V91, P10933, DOI 10.1073/pnas.91.23.10933; Hew Y, 2000, J BIOL CHEM, V275, P24857, DOI 10.1074/jbc.M002776200; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; INESTROSA NC, 1981, J NEUROSCI, V1, P1260; JASMIN BJ, 1993, NEURON, V11, P467, DOI 10.1016/0896-6273(93)90151-G; JASMIN BJ, 1990, J NEUROSCI, V10, P1444; JONES SA, 1995, CELL TISSUE RES, V279, P323, DOI 10.1007/BF00318488; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Koenigsberger C, 1997, J NEUROCHEM, V69, P1389; Krejci E, 1999, J NEUROSCI, V19, P10672, DOI 10.1523/JNEUROSCI.19-24-10672.1999; LANDWEHRMEYER B, 1993, NEUROSCIENCE, V57, P615, DOI 10.1016/0306-4522(93)90010-D; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LAYER PG, 1995, PROG HISTOCHEM CYTOC, V29, P1; Legay C, 2000, MICROSC RES TECHNIQ, V49, P56, DOI 10.1002/(SICI)1097-0029(20000401)49:1<56::AID-JEMT7>3.0.CO;2-R; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; LI Y, 1993, J BIOL CHEM, V268, P5790; Li YK, 2000, J NEUROSCI, V20, P149, DOI 10.1523/JNEUROSCI.20-01-00149.2000; LUCAS CA, 1980, NEUROSCI LETT, V18, P333, DOI 10.1016/0304-3940(80)90307-9; Luo ZD, 1999, MOL PHARMACOL, V56, P886, DOI 10.1124/mol.56.5.886; LUO ZG, 1994, J BIOL CHEM, V269, P27216; Malter JS, 2001, J NEUROSCI RES, V66, P311, DOI 10.1002/jnr.10021; Manohar CF, 2002, J BIOL CHEM, V277, P1967, DOI 10.1074/jbc.M106966200; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; Mobarak CD, 2000, MOL BIOL CELL, V11, P3191, DOI 10.1091/mbc.11.9.3191; PALACIOS G, 1994, MOL BRAIN RES, V24, P107, DOI 10.1016/0169-328X(94)90122-8; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; PERRONE-BIZZOZERO N I, 1991, Molecular and Cellular Neuroscience, V2, P402; PERRONEBIZZOZER, 2002, J NEUROSCI RES, V68, P121; Pregelj P, 2002, J NEUROSCI RES, V67, P114, DOI 10.1002/jnr.3000; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; Rimer M, 1999, BIOCHEM BIOPH RES CO, V260, P251, DOI 10.1006/bbrc.1999.0893; ROBERTSON RT, 1993, NEWS PHYSIOL SCI, V8, P266; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Sagesser R, 1997, NUCLEIC ACIDS RES, V25, P3816, DOI 10.1093/nar/25.19.3816; Sharma KV, 1998, J NEUROSCI RES, V53, P454, DOI 10.1002/(SICI)1097-4547(19980815)53:4<454::AID-JNR7>3.3.CO;2-E; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; Sketelj J, 1998, J NEUROSCI, V18, P1944; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Srivatsan M, 1997, NEUROSCIENCE, V77, P921, DOI 10.1016/S0306-4522(96)00458-7; Sternfeld M, 1998, J NEUROSCI, V18, P1240; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; TETZLAFF W, 1989, J NEUROSCI, V9, P1303; Tsai KC, 1997, J NEUROSCI, V17, P1950; Wan DCC, 2000, NEUROSCI LETT, V288, P81, DOI 10.1016/S0304-3940(00)01200-3; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200	81	52	52	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5710	5717		10.1074/jbc.M209383200	http://dx.doi.org/10.1074/jbc.M209383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12468554	hybrid			2022-12-25	WOS:000181129400030
J	Fransson, A; Ruusala, A; Aspenstrom, P				Fransson, A; Ruusala, A; Aspenstrom, P			Atypical Rho GTPases have roles in mitochondrial homeostasis and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; FAMILY; PROTEIN; BINDING; CDC42; GROWTH; CYTOSKELETON; MEMBER; RAC	The human genomic sequencing effort has revealed the presence of a large number of Rho GTPases encoded by the human genome. Here we report the characterization of a new family of Rho GTPases with atypical features. These proteins, which were called Miro-1 and Miro-2 (for mitochondrial Rho), have tandem GTP-binding domains separated by a linker region containing putative calcium-binding EF hand motifs. Genes encoding Miro-like proteins were found in several eukaryotic organisms from Saccharomyces cerevisiae, Caenorhabditis elegans, and Drosophila melanogaster to mammals, indicating that these genes evolved early during evolution. Immunolocalization. experiments, in which transfected NIH3T3 and COS 7 cells were stained for ectopically expressed Miro as well as for the endogenous Miro-1 protein, showed that Miro was present in mitochondria. Interestingly, overexpression. of a constitutively active mutant of Miro-1 (Miro-1/Val-13) induced an aggregation of the mitochondrial network and resulted in an increased apoptotic rate of the cells expressing activated Miro-1. These data indicate a novel role for Rho-like GTPases in mitochondrial homeostasis and apoptosis.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Aspenstrom, P (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.	pontus.aspenstrom@LICR.uu.se						Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Ellis S, 2000, CURR BIOL, V10, P1387, DOI 10.1016/S0960-9822(00)00777-6; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li XY, 2002, MOL CELL BIOL, V22, P1158, DOI 10.1128/MCB.22.4.1158-1171.2002; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Parone PA, 2002, BIOCHIMIE, V84, P105, DOI 10.1016/S0300-9084(02)01380-9; Richnau N, 2001, J BIOL CHEM, V276, P35060, DOI 10.1074/jbc.M103540200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rivero F, 2001, NUCLEIC ACIDS RES, V29, P1068, DOI 10.1093/nar/29.5.1068; Santel A, 2001, J CELL SCI, V114, P867; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Tu S, 2001, J BIOL CHEM, V276, P19656, DOI 10.1074/jbc.M009838200; van der Bliek AM, 2000, J CELL BIOL, V151, pF1, DOI 10.1083/jcb.151.2.F1; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; Westermann B, 2002, EMBO REP, V3, P527, DOI 10.1093/embo-reports/kvf113; Zalcman G, 1999, Prog Mol Subcell Biol, V22, P85; ZHEN GY, 2001, TRENDS BIOCHEM SCI, V26, P724	35	282	291	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6495	6502		10.1074/jbc.M208609200	http://dx.doi.org/10.1074/jbc.M208609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482879	hybrid			2022-12-25	WOS:000181129400125
J	Castro, C; Diez-Juan, A; Cortes, MJ; Andres, V				Castro, C; Diez-Juan, A; Cortes, MJ; Andres, V			Distinct regulation of mitogen-activated protein kinases and p27(Kip1) in smooth muscle cells from different vascular beds - A potential role in establishing regional phenotypic variance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; CYCLIN-DEPENDENT KINASES; INHIBITOR P27(KIP1); SIGNALING PATHWAY; CAROTID ARTERIES; EXPRESSION; PROLIFERATION; INJURY; ATHEROSCLEROSIS; MECHANISMS	Excessive proliferation and migration of vascular smooth muscle cells (SMCs) participate in atherosclerotic plaque growth. In this study, we investigated whether SMCs from vessels with different atherogenicity exhibit distinct growth and migratory potential and investigated the underlying mechanisms. In fat-fed rabbits, we found increased cell proliferation and atheroma formation in the aortic arch versus the femoral artery. When examined in culture, SMCs isolated from the aortic arch (ASMCs) displayed a greater capacity for inducible proliferation and migration than paired cultures of femoral artery SMCs. Two lines of evidence suggested that distinct regulation of the growth suppressor p27(Kip1) (p27) contributes to establishing these phenotypic dissimilarities. First, p27 expression was comparably lower in ASMCs, which exhibited a higher fraction of p27 phosphorylated on Thr-187 and ubiquitinated. Second, forced p27 overexpression in ASMCs impaired their proliferative and migratory potential. We found that platelet-derived growth factor-BB-dependent induction of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway was comparably higher in ASMCs. Importantly, pharmacological inhibition of MAPKs increased p27 expression and attenuated ASMC proliferation and migration. In contrast, forced MAPK activation diminished p27 expression and markedly augmented femoral artery SMC proliferation and migration. We propose that intrinsic differences in the regulation of MAPKs and p27 play an important role in creating variance in the proliferative and migratory capacity of vascular SMCs, which might in turn contribute to establishing regional variability in atherogenicity.	CSIC, Spanish Concil Sci Res, Inst Biomed Valencia,Lab Vasc Biol, Dept Mol & Cellular Pathol & Therapy, Valencia 46010, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Andres, V (corresponding author), CSIC, Spanish Concil Sci Res, Inst Biomed Valencia,Lab Vasc Biol, Dept Mol & Cellular Pathol & Therapy, Jaime Roig 11, Valencia 46010, Spain.	vandres@ibv.csic.es	Diez Juan, Antonio/D-3695-2018; Andres, Vicente/I-6440-2014; Diez-Juan, Antonio/H-5464-2015	Andres, Vicente/0000-0002-0125-7209; Diez-Juan, Antonio/0000-0002-0166-1869				Bauters C, 1997, PROG CARDIOVASC DIS, V40, P107, DOI 10.1016/S0033-0620(97)80003-5; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; BochatonPiallat ML, 1996, ARTERIOSCL THROM VAS, V16, P815, DOI 10.1161/01.ATV.16.6.815; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; CHAMLEYCAMPBELL JH, 1981, J CELL BIOL, V89, P379, DOI 10.1083/jcb.89.2.379; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Chen DH, 2000, ARTERIOSCL THROM VAS, V20, P629, DOI 10.1161/01.ATV.20.3.629; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Delmas C, 2001, J BIOL CHEM, V276, P34958, DOI 10.1074/jbc.M101714200; Diez-Juan A, 2001, FASEB J, V15, P1989, DOI 10.1096/fj.01-0130com; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Goukassian D, 2001, FASEB J, V15, P1877, DOI 10.1096/fj.01-0065com; Haq S, 2001, CIRCULATION, V103, P670; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hu YH, 2000, ARTERIOSCL THROM VAS, V20, P18, DOI 10.1161/01.ATV.20.1.18; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Ihling C, 1999, ATHEROSCLEROSIS, V144, P7, DOI 10.1016/S0021-9150(99)00032-5; Koh KN, 1998, J MOL CELL CARDIOL, V30, P463, DOI 10.1006/jmcc.1997.0611; Kolodgie FD, 1996, ARTERIOSCL THROM VAS, V16, P1454, DOI 10.1161/01.ATV.16.12.1454; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Koyama H, 1998, CIRC RES, V82, P713, DOI 10.1161/01.RES.82.6.713; Li SH, 2001, CIRC RES, V89, P517, DOI 10.1161/hh1801.097165; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Majack RA, 1996, J CELL PHYSIOL, V167, P106, DOI 10.1002/(SICI)1097-4652(199604)167:1<106::AID-JCP12>3.0.CO;2-9; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Olson NE, 2000, J BIOL CHEM, V275, P11270, DOI 10.1074/jbc.275.15.11270; OLSON NE, 1992, AM J PATHOL, V140, P1017; OWENS GK, 1995, PHYSIOL REV, V75, P487; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Poolman RA, 1999, CIRC RES, V85, P117, DOI 10.1161/01.RES.85.2.117; Pyles JM, 1997, CIRC RES, V81, P904; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Taylor John M., 1997, Frontiers in Bioscience (online), V2, pD298; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; VERBEUREN TJ, 1986, CIRC RES, V58, P552, DOI 10.1161/01.RES.58.4.552; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Yang ZH, 1998, CIRCULATION, V97, P181, DOI 10.1161/01.CIR.97.2.181; Zou YP, 1998, INT J MOL MED, V1, P827	53	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4482	4490		10.1074/jbc.M204716200	http://dx.doi.org/10.1074/jbc.M204716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12477734	hybrid			2022-12-25	WOS:000180968900018
J	Tamas, P; Solti, Z; Bauer, P; Illes, A; Sipeki, S; Bauer, A; Farago, A; Downward, J; Buday, L				Tamas, P; Solti, Z; Bauer, P; Illes, A; Sipeki, S; Bauer, A; Farago, A; Downward, J; Buday, L			Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; PLECKSTRIN HOMOLOGY; ACTIN CYTOSKELETON; FACTOR RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; FOCAL ADHESIONS; EGF RECEPTOR	Vav2 is a member of the Vav family that serves as a guanine nucleotide exchange factor for the Rho family of Ras-related GTPases. Unlike Vav1, whose expression is restricted to cells of hematopoietic origin, Vav2 is broadly expressed. Recently, Vav2 has been identified as a substrate for the epidermal growth factor (EGF) receptor; however, the mechanism by which Vav2 is activated in EGF-treated cells is unclear. By the means of an in vitro protein kinase assay, we show here that purified and activated EGF receptor phosphorylates Vav2 exclusively on its N-terminal domain. Furthermore, EGF receptor phosphorylates Vav2 on all three possible phosphorylation sites, Tyr-142, Tyr-159, and Tyr-172. In intact cells we also show that Vav2 associates with the activated EGF receptor in an Src homology 2 domain-dependent manner, with Vav2 Src homology 2 domain binding preferentially to autophosphorylation sites Tyr-992 and Tyr-1148 of the EGF receptor. Treatment of cells with EGF results in stimulation of exchange activity of Vav2 as measured on Rac; however, the intensity of the exchange activity does not show any correlation with the level of Vav2 tyrosine phosphorylation. Introducing a point mutation into the Vav2 pleckstrin homology domain or treatment of cells with the phosphatidylinositol 3-kinase inhibitor LY294002 prior to EGF stimulation inhibits Vav2 exchange activity. Although phosphorylation mutants of Vav2 can readily induce actin rearrangement in COS7 cells, pleckstrin homology domain mutant does not stimulate membrane ruffling. These results suggest that EGF regulates Vav2 activity basically through phosphatidylinositol 3-kinase activation, whereas tyrosine phosphorylation of Vav2 may rather be necessary for mediating protein-protein interactions.	Semmelweis Univ, Sch Med, Dept Med Chem, H-1088 Budapest, Hungary; Canc Res UK, London WC2A 3PX, England	Semmelweis University; Cancer Research UK	Buday, L (corresponding author), Semmelweis Univ, Sch Med, Dept Med Chem, 9 Puskin St, H-1088 Budapest, Hungary.	buday@puskin.sote.hu	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729; Sipeki, Szabolcs/0000-0002-9678-6743				Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NOBES CD, 1995, J CELL SCI, V108, P225; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; VAN AL, 1997, GENE DEV, V11, P2295; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xie H, 1998, J CELL SCI, V111, P615; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zeng ZZ, 2002, J BIOL CHEM, V277, P41213, DOI 10.1074/jbc.M204508200	41	91	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5163	5171		10.1074/jbc.M207555200	http://dx.doi.org/10.1074/jbc.M207555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12454019	hybrid			2022-12-25	WOS:000180968900104
J	Ogut, O; Hossain, MM; Jin, JP				Ogut, O; Hossain, MM; Jin, JP			Interactions between nebulin-like motifs and thin filament regulatory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; TROPONIN-T; Z-LINE; VARIABLE REGION; ACTIN-BINDING; F-ACTIN; FRAGMENTS; EXPRESSION; NEBULETTE; SEQUENCE	Nebulin (600-900 kDa) and nebulette (107-109 kDa) are two homologous thin filament-associated proteins in skeletal and cardiac muscles, respectively. Both proteins are capped with a unique region at the amino terminus as well as a serine-rich linker domain and SH3 domains at the COOH terminus. Their significant size difference is attributed to the length of the central region wherein both proteins are primarily composed of similar to35 amino acid repeats termed nebulin-like repeats or motifs. These motifs are marked by a conserved SXXXY sequence and high affinity binding to F-actin. To further characterize the effects that nebulin-like proteins may have on the striated muscle thin filament, we have cloned, expressed, and purified a five-motif chicken nebulette fragment and tested its interaction with the thin filament regulatory proteins. Both tropomyosin and troponin T individually bound the nebulette fragment, although the affinity of this interaction was significantly increased when tropomyosin-troponin T was tested as a binary complex. The addition of troponin I to the tropomyosin-troponin T complex decreased the binding to the nebulette fragment, indicating an involvement of the conserved T2 region of troponin T in this interaction. F-actin cosedimentation demonstrated that the nebulette fragment was able to significantly increase the affinity of the tropomyosin-troponin assembly for F-actin. The relationships provide a means for nebulin-like motifs to participate in the allosteric regulation of striated muscle contraction.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Jin, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.			Jin, JP/0000-0001-9932-1063				BABU A, 1987, J BIOL CHEM, V262, P5815; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; Gao JM, 1996, BIOCHEM BIOPH RES CO, V218, P292, DOI 10.1006/bbrc.1996.0051; Geeves MA, 2000, BIOCHEMISTRY-US, V39, P9345, DOI 10.1021/bi0002232; GRANZIER HLM, 1993, ELECTROPHORESIS, V14, P56, DOI 10.1002/elps.1150140110; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Jin JP, 1998, BIOCHEM BIOPH RES CO, V242, P540, DOI 10.1006/bbrc.1997.8006; JIN JP, 1991, J BIOL CHEM, V266, P21215; JIN JP, 1995, J BIOL CHEM, V270, P6908; JIN JP, 1990, HYBRIDOMA, V9, P597, DOI 10.1089/hyb.1990.9.597; KRUEGER M, 1991, J CELL BIOL, V115, P97; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; Lukoyanova N, 2002, CURR BIOL, V12, P383, DOI 10.1016/S0960-9822(02)00678-4; McElhinny AS, 2001, J BIOL CHEM, V276, P583, DOI 10.1074/jbc.M005693200; Millevoi S, 1998, J MOL BIOL, V282, P111, DOI 10.1006/jmbi.1998.1999; Moncman CL, 1999, CELL MOTIL CYTOSKEL, V44, P1, DOI 10.1002/(SICI)1097-0169(199909)44:1<1::AID-CM1>3.0.CO;2-8; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; MULLERSEITZ M, 1993, GENOMICS, V18, P559, DOI 10.1016/S0888-7543(05)80356-8; NAVE R, 1990, FEBS LETT, V269, P163, DOI 10.1016/0014-5793(90)81144-D; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Ogut O, 2000, J BIOL CHEM, V275, P26089, DOI 10.1074/jbc.M910360199; Ojima K, 2000, J CELL BIOL, V150, P553, DOI 10.1083/jcb.150.3.553; ROOT DD, 1994, BIOCHEMISTRY-US, V33, P12581, DOI 10.1021/bi00208a008; Root DD, 2001, BIOCHEMISTRY-US, V40, P1171, DOI 10.1021/bi0015010; SWEITZER NK, 1990, J GEN PHYSIOL, V96, P1221, DOI 10.1085/jgp.96.6.1221; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; WANG K, 1980, P NATL ACAD SCI-BIOL, V77, P3254, DOI 10.1073/pnas.77.6.3254; Wang K, 1996, J BIOL CHEM, V271, P4304; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; Zhang JQ, 1998, BIOPHYS J, V74, P349, DOI 10.1016/S0006-3495(98)77792-6	32	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3089	3097		10.1074/jbc.M205853200	http://dx.doi.org/10.1074/jbc.M205853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446728	hybrid			2022-12-25	WOS:000180915000042
J	Benhar, M; Engelberg, D; Levitzki, A				Benhar, M; Engelberg, D; Levitzki, A			Cisplatin-induced activation of the EGF receptor	ONCOGENE			English	Article						cisplatin; EGF receptor; Src; glioblastoma; DNA damage	GROWTH-FACTOR RECEPTOR; N-TERMINAL KINASE; BCL-X-L; C-SRC; INDUCED APOPTOSIS; TYROSINE KINASES; PROTEIN-KINASE; HYDROGEN-PEROXIDE; EPITHELIAL-CELLS; PHOSPHORYLATION	Cisplatin (CDDP) is an efficient DNA-damaging antitumor agent employed for the treatment of various human cancers. CDDP activates nuclear as well as cytoplasmatic signaling pathways involved in regulation of the cell cycle, damage repair and programmed cell death. Here we report that CDDP also activates a membrane-integrated protein, the epidermal growth factor receptor (EGFR). We show that EGFR is activated in response to CDDP in various types of cells that overexpress the receptor, including transformed human glioma cells and human breast tumor cells. CDDP-induced EGFR activation requires its kinase activity, as it can be blocked by an EGFR kinase inhibitor or by expression of a kinase dead receptor. We also show that CDDP-induced EGFR activation is independent of receptor ligand. CDDP induces the activation of c-Src, and EGFR activation is blocked by Src-family inhibitor PP1, suggesting that Src kinases mediate CDDP-induced EGFR activation. We propose that EGFR activation in response to CDDP is a survival response, since inhibition of EGFR activation enhances CDDP-induced death. These findings show that signals generated by DNA damage can modulate EGFR activity, and argue that interfering with CDDP-induced EGFR activation in tumor cells might be a useful approach to sensitize these cells to genotoxic agents.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il	Benhar, Moran/AAV-5764-2020	Benhar, Moran/0000-0002-7094-3456				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Gebauer G, 2000, INT J ONCOL, V16, P321; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; KITAGAWA D, 2001, J BIOL CHEM, V2, P2; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Miyajima A, 1997, BRIT J CANCER, V76, P206, DOI 10.1038/bjc.1997.363; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Persons DL, 1999, CLIN CANCER RES, V5, P1007; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	43	116	121	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8723	8731		10.1038/sj.onc.1205980	http://dx.doi.org/10.1038/sj.onc.1205980			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483525				2022-12-25	WOS:000179734400006
J	Jin, SQ; Tong, T; Fan, WH; Fan, FY; Antinore, MJ; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM				Jin, SQ; Tong, T; Fan, WH; Fan, FY; Antinore, MJ; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM			GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity	ONCOGENE			English	Article						p53; GADD45; G2-M arrest; cyclin B1	P53-REGULATED PROTEIN GADD45; HUMAN CANCER-CELLS; DNA-DAMAGE; IONIZING-RADIATION; DEPENDENT KINASES; MAMMALIAN G(1); GROWTH ARREST; HELA-CELLS; P53; CHECKPOINTS	In response to DNA damage, the cell cycle checkpoint is an important biological event in maintaining genomic fidelity. Gadd45, a p53-regulated and DNA damage inducible protein, has recently been demonstrated to play a role in the G2-M checkpoint in response to DNA damage. In the current study, we further investigated the biochemical mechanism(s) involved in the GADD45-activated cell cycle G2-M arrest. Using the tetracycline-controlled system (tet-off), we established GADD45-inducible lines in HCT116 (wild-type p53) and Hela (inactivated p53 status) cells. Following inducible expression of the Gadd45 protein, cell growth was strongly suppressed in both HCT116 and Hela cells. Interestingly, HCT116 cells revealed a significant G2-M arrest but Hela cells failed to arrest at the G2-M phases, indicating that the GADD45-activated G2-M arrest requires normal p53 function. The GADD45-induced G2-M arrest was observed independent of p38 kinase activity. Importantly, induction of Gadd45 protein resulted in a reduction of nuclear cyclin B1 protein, whose nuclear localization is critical for the completion of G2-M transition. The reduced nuclear cyclin B1 levels correlated with inhibition of Cdc2/cyclin 131 kinase activity. Additionally, overexpression of cyclin B1 substantially abrogated the GADD45-induced cell growth suppression. Therefore, GADD45 inhibition of Cdc2 kinase activity through alteration of cyclin B1 subcellular localization may be an essential step in the GADD45-induced cell cycle G2-M arrest and growth suppression.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.			mazzacurati, lucia/0000-0002-8336-8032	NATIONAL CANCER INSTITUTE [R01CA083874] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-83874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen IT, 1996, ONCOGENE, V12, P595; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; O'Connor P M, 1992, Semin Cancer Biol, V3, P409; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; OConnor PM, 1997, CANCER SURV, V29, P151; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Soria JC, 2000, CANCER RES, V60, P4000; STEWART N, 1995, ONCOGENE, V10, P109; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu M, 2002, MOL IMMUNOL, V38, P981, DOI 10.1016/S0161-5890(02)00026-3; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHANG H, 1994, COLD SPRING HARB SYM, V59, P21, DOI 10.1101/SQB.1994.059.01.005; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	48	154	165	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8696	8704		10.1038/sj.onc.1206034	http://dx.doi.org/10.1038/sj.onc.1206034			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483522				2022-12-25	WOS:000179734400003
J	Chesire, DR; Isaacs, WB				Chesire, DR; Isaacs, WB			Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor	ONCOGENE			English	Article						androgen receptor; beta-catenin; TCF/LEF; prostate; nuclear signaling	HUMAN-PROSTATE-CANCER; GROWTH-FACTOR-BETA; CREB-BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; WNT/BETA-CATENIN; CARCINOMA-CELLS; TUMOR-SUPPRESSOR; MAMMARY-GLAND; TARGET GENES; CYCLIN D1	beta-catenin signaling may contribute to prostate cancer (CaP) progression. Although beta-catenin is known to upregulate T cell factor (TCF) target gene expression in CaP cells, recent evidence demonstrates its capacity to enhance ligand-dependent androgen receptor (AR) function. Thus, we wished to further understand the interaction between these two pathways. We find in both CaP cells (CWR22-Rv1, LAPC-4, DU145) and non-CaP cells (HEK-293, TSU, SW480, HCT-116) that beta-catenin/TCF-related transcription (CRT), as measured by activation of a synthetic promoter and that of cyclin D1, is inhibited by androgen treatment. This inhibition is AR-dependent, as it only occurs in cells expressing AR endogenously or transiently, and is abrogated by AR antagonists. Additional analyses convey that the ligand-dependent nature of CRT suppression depends on transactivation-competent AR in the nucleus, but not on indirect effects stemming from AR target gene expression. Given the recent work identifying an AR/beta-catenin interaction, and from our finding that liganded AR does not prompt gross changes in the constitutive nuclear localization of TCF4 or mutant beta-catenin, we hypothesized that transcription factor (i.e. AR and TCF) competition for beta-catenin recruitment may explain, in part, androgen-induced suppression of CRT. To address this idea, we expressed an AR mutant lacking its DNA-binding domain (DBD). This receptor could not orchestrate ligand-dependent CRT repression, thereby providing support for those recent data implicating the AR DBD/LBD as necessary for beta-catenin interaction. Further supporting this hypothesis, TCF/LEF overexpression counteracts androgen-induced suppression of CRT, and requires beta-catenin binding activity to do so. Interestingly, TCF4 over-expression potently antagonizes AR function; however, this inhibition may occur independently of beta-catenin/TCF4 interaction. These results from TCF4 over-expression analyses, taken together, provide further evidence that AR-mediated suppression of CRT is a consequence of limiting amounts of beta-catenin, and not AR target gene expression. Our analyses point to a reciprocal balance between AR and CRT function that may shape critical processes during normal prostate development and tumor progression.	Johns Hopkins Med Inst, Brady Urol Inst, Res Labs, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Isaacs, WB (corresponding author), Johns Hopkins Univ Hosp, Dept Urol, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.	wisaacs@jhmi.edu			NCI NIH HHS [CA58236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Brisken C, 2000, GENE DEV, V14, P650; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Cude KJ, 1999, J MOL MED, V77, P419, DOI 10.1007/s001090050372; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; CULIG Z, 1994, CANCER RES, V54, P5474; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hobisch A, 1998, CANCER RES, V58, P4640; HOBISCH A, 1995, CANCER RES, V55, P3068; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; HUSMANN DA, 1990, ENDOCRINOLOGY, V126, P2359, DOI 10.1210/endo-126-5-2359; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Knudsen KE, 1999, CANCER RES, V59, P2297; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Linja MJ, 2001, CANCER RES, V61, P3550; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MacLean HE, 1997, J STEROID BIOCHEM, V62, P233, DOI 10.1016/S0960-0760(97)00049-6; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; McDonald S, 2000, CANCER RES, V60, P2317; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Park JJ, 2000, CANCER RES, V60, P5946; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Samowitz WS, 1999, CANCER RES, V59, P1442; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tindall DJ, 1999, PROSTATE, V38, P166, DOI 10.1002/(SICI)1097-0045(19990201)38:2<166::AID-PROS11>3.0.CO;2-A; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Truica CI, 2000, CANCER RES, V60, P4709; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; van Bokhoven A, 2001, CANCER RES, V61, P6340; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Voeller HJ, 1998, CANCER RES, V58, P2520; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; Wen Y, 2000, CANCER RES, V60, P6841; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yu DC, 1999, CANCER RES, V59, P1498; Yuan X, 2001, J BIOL CHEM, V276, P46647, DOI 10.1074/jbc.M108404200; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	95	129	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8453	8469		10.1038/sj.onc.1206049	http://dx.doi.org/10.1038/sj.onc.1206049			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466965				2022-12-25	WOS:000179480100008
J	Park, WY; Hwang, CI; Im, CN; Kang, MJ; Woo, JH; Kim, JH; Kim, YS; Kim, JH; Kim, H; Kim, KA; Yu, HJ; Lee, SJ; Lee, YS; Seo, JS				Park, WY; Hwang, CI; Im, CN; Kang, MJ; Woo, JH; Kim, JH; Kim, YS; Kim, JH; Kim, H; Kim, KA; Yu, HJ; Lee, SJ; Lee, YS; Seo, JS			Identification of radiation-specific responses from gene expression profile	ONCOGENE			English	Article						gamma-irradiation; cDNA microarray; p53; cytoplasmic epoxide hydrolase; phospholipase C gamma 2	T-CELL RECEPTOR; IONIZING-RADIATION; GENOTOXIC STRESS; DNA-DAMAGE; KAPPA-B; IN-VITRO; P53; APOPTOSIS; IRRADIATION; CANCER	The responses to ionizing radiation (IR) in tumors are dependent on cellular context. We investigated radiation-related expression patterns in Jurkat T cells with nonsense mutation in p53 using cDNA microarray. Expression of 2400 genes in gamma-irradiated cells was distinct from other stimulations like anti-CD3, phetohemagglutinin (PHA) and concanavalin A (ConA) in unsupervised clustering analysis. Among them, 384 genes were selected for their IR-specific changes to make 'RadChip'. In spite of p53 status, every type of cells showed similar patterns in expression of these genes upon gamma-radiation. Moreover, radiation-induced responses were clearly separated from the responses to other genotoxic stress like UV radiation, cisplatin and doxorubicin. We focused on two IR-related genes, phospholipase Cgamma2 (PLCG2) and cytosolic epoxide hydrolase (EPHX2), which were increased at 12 h after gamma-radiation in RT-PCR. TPCK could suppress the induction of these two genes in either of Jurkat T cells and PBMCs, which might suggest the transcriptional regulation of PLCG2 and EPHX2 by NF-gammaB upon gamma-radiation. From these results, we could identify the IR-specific genes from expression profiling, which can be used as radiation biomarkers to screen radiation exposure as well as probing the mechanism of cellular responses to ionizing radiation.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chongnogu, Seoul 110799, South Korea; Seoul Natl Univ, Ilchun Mol Med Inst, Seoul, South Korea; Seoul Natl Univ, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Seoul Natl Univ, Grad Sch Publ Hlth, Dept Biostat, Seoul, South Korea; Macrogen Inc, Seoul, South Korea; Korea Canc Ctr Hosp, Lab Radiat Effect, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Macrogen, Inc.; National Cancer Center - Korea (NCC)	Seo, JS (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chongnogu, 28 Yongondong, Seoul 110799, South Korea.		Kim, Ho/AAS-2402-2021; park, woongyang/D-5727-2012; Kim, Ju Han/E-5983-2012; Seo, Jeong-Sun/J-2763-2012; Kim, Yon Su/J-2743-2012	Kim, Ho/0000-0001-7472-3752; Hwang, Chang-il/0000-0002-5710-7672; Im, Chang-Nim/0000-0002-7566-7075				Abraham RT, 2000, IMMUNOL RES, V22, P95, DOI 10.1385/IR:22:2-3:95; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Amundson SA, 2001, COMP BIOCHEM PHYS B, V129, P703, DOI 10.1016/S1096-4959(01)00389-X; Backlund MG, 2001, CANCER RES, V61, P6577; Cemerski S, 2002, J BIOL CHEM, V277, P19585, DOI 10.1074/jbc.M111451200; DENEKAMP J, 1973, BRIT J RADIOL, V46, P381, DOI 10.1259/0007-1285-46-545-381; DENT P, 1995, MOL CELL BIOL, V15, P4125; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gong BD, 2000, CANCER RES, V60, P5754; Green JA, 2001, LANCET, V358, P781, DOI 10.1016/S0140-6736(01)05965-7; Iwamoto KS, 1996, CANCER RES, V56, P3862; Kang JS, 1996, FEBS LETT, V399, P14, DOI 10.1016/S0014-5793(96)01276-8; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; Kawabe T, 2002, ONCOGENE, V21, P1717, DOI 10.1038/sj.onc.1205229; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim SG, 1997, MOL PHARMACOL, V51, P225, DOI 10.1124/mol.51.2.225; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LuHesselmann J, 1997, RADIAT RES, V148, P531, DOI 10.2307/3579728; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MORETTA A, 1987, P NATL ACAD SCI USA, V84, P1654, DOI 10.1073/pnas.84.6.1654; NOGAMI M, 1994, RADIAT RES, V139, P47, DOI 10.2307/3578731; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park WY, 2001, BIOCHEM BIOPH RES CO, V282, P934, DOI 10.1006/bbrc.2001.4632; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Roth JA, 2001, ACTA ONCOL, V40, P739; Safwat A, 2000, RADIAT RES, V153, P599, DOI 10.1667/0033-7587(2000)153[0599:TIOLDT]2.0.CO;2; SALLY AA, 1999, ONCOGENE, V18, P3666; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Seidegard J, 1997, ENVIRON HEALTH PERSP, V105, P791, DOI 10.2307/3433285; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Vigorito E, 1999, HEMATOL CELL THER, V41, P153, DOI 10.1007/s00282-999-0153-0; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Zhan QM, 1996, ONCOGENE, V13, P2287	41	96	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8521	8528		10.1038/sj.onc.1205977	http://dx.doi.org/10.1038/sj.onc.1205977			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466973				2022-12-25	WOS:000179480100016
J	Costa, C; Brokaw, JL; Wang, Y; Fodor, WL				Costa, C; Brokaw, JL; Wang, Y; Fodor, WL			Delayed rejection of porcine cartilage is averted by transgenic expression of alpha 1,2-fucosyltransferase	FASEB JOURNAL			English	Article						Gal alpha 1,3-Gal antigen; H-transferase; xenoantibody response; xenotransplantation; tissue engineering	ALPHA-GAL EPITOPES; CYNOMOLGUS MONKEY; DOWN-REGULATION; TRANSPLANTS; PIG; XENOGRAFTS; CELLS; MICE; ALPHA(1,2)-FUCOSYL-TRANSFERASE; ALLOGRAFTS	The use of xenogeneic cells or tissues for tissue engineering applications may lead to advances in biomedical research. Hyperacute and delayed rejection are immunologic hurdles that must be addressed to achieve xenograft survival in the pig-to-primate setting. Expression of human alpha1,2-fucosyltransferase (HT) in the donor cell or tissue protects from hyperacute rejection (HAR) by reducing expression of Galalpha1,3-Gal epitope, the major xenoantigen recognized by human natural antibodies. We hypothesized that Gal 1,3-Gal antigen contributes to delayed tissue rejection. To test this hypothesis, we transplanted control or HT-transgenic engineered porcine cartilage s.c. into alpha1,3-galactosyltransferase knockout (Gal KO) mice. Control porcine cartilage grafted in Gal KO mice was not susceptible to HAR but was rejected in several wk by a prominent cellular immune infiltrate and elevated antibody titers. In contrast, Gal KO mice receiving the HT engineered cartilage showed a markedly reduced anti-pig antibody response and no anti-Galalpha1,3-Gal-elicited antibody response. The HT implants had a mild cellular infiltrate that was confined to the graft periphery. Our study demonstrates that a marked reduction of Galalpha1,3-Gal antigen in HT-transgenic porcine cartilage confers resistance to a process of delayed rejection. Further development of tissue engineering applications that use genetically modified porcine tissues is encouraged.	Alexion Pharmaceut Inc, Dept Mol Sci, Cheshire, CT 06410 USA; Alexion Pharmaceut Inc, Dept Cellular Sci, Cheshire, CT 06410 USA		Costa, C (corresponding author), Alexion Pharmaceut Inc, Dept Mol Sci, 352 Knotter Dr, Cheshire, CT 06410 USA.	costac@alxn.com	Costa, Cristina/AAP-4005-2020	Costa, Cristina/0000-0002-1837-4268	NICHD NIH HHS [R44 HD095784] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alwayn IPJ, 1999, XENOTRANSPLANTATION, V6, P157, DOI 10.1034/j.1399-3089.1999.00030.x; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808; Bondioli K, 2001, MOL REPROD DEV, V60, P189, DOI 10.1002/mrd.1076; Bracy JL, 1998, SCIENCE, V281, P1845, DOI 10.1126/science.281.5384.1845; BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401; Chen, 1996, Mol Diagn, V1, P65, DOI 10.1016/S1084-8592(96)70023-1; Chen CG, 1996, XENOTRANSPLANTATION, V3, P69, DOI 10.1111/j.1399-3089.1996.tb00121.x; Cohney S, 1997, TRANSPLANTATION, V64, P495, DOI 10.1097/00007890-199708150-00020; Costa C, 1999, XENOTRANSPLANTATION, V6, P6, DOI 10.1034/j.1399-3089.1999.00004.x; Costa C, 2002, J IMMUNOL, V168, P3808, DOI 10.4049/jimmunol.168.8.3808; Cozzi E., 1997, XENOTRANSPLANTATION, P665; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; Edge ASB, 1998, CELL TRANSPLANT, V7, P525, DOI 10.1016/S0963-6897(98)00043-8; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; Galili U, 1997, XENOTRANSPLANTATION, V4, P127, DOI 10.1111/j.1399-3089.1997.tb00175.x; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; GOODMAN DJ, 1997, XENOTRANSPLANTATION, P95; HAYES CE, 1974, J BIOL CHEM, V249, P1904; Inverardi L, 1997, TRANSPLANTATION, V63, P1318, DOI 10.1097/00007890-199705150-00021; KANDEL RA, 1995, ARTIF CELL BLOOD SUB, V23, P565, DOI 10.3109/10731199509117971; Kobayashi T, 1997, TRANSPLANTATION, V64, P1255, DOI 10.1097/00007890-199711150-00005; Koike C, 1996, XENOTRANSPLANTATION, V3, P81, DOI 10.1111/j.1399-3089.1996.tb00123.x; Kozlowski T, 1999, TRANSPLANTATION, V67, P18, DOI 10.1097/00007890-199901150-00004; Kwiatkowski P, 1999, TRANSPLANTATION, V67, P219, DOI 10.1097/00007890-199901270-00006; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Lambrigts D, 1998, TRANSPLANTATION, V66, P547, DOI 10.1097/00007890-199809150-00001; Larsson LC, 1999, TRANSPLANTATION, V68, P1153, DOI 10.1097/00007890-199910270-00016; LaTemple DC, 1998, XENOTRANSPLANTATION, V5, P191, DOI 10.1111/j.1399-3089.1998.tb00027.x; Lin SS, 2000, TRANSPLANTATION, V70, P1667, DOI 10.1097/00007890-200012270-00002; Marchetti P, 1996, TRANSPLANTATION, V61, P1100, DOI 10.1097/00007890-199604150-00019; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; McKenzie IFC, 2000, TRANSPLANTATION, V70, P1205, DOI 10.1097/00007890-200010270-00014; Naziruddin B, 2001, XENOTRANSPLANTATION, V8, P26; Ohdan H, 2000, J IMMUNOL, V165, P5518, DOI 10.4049/jimmunol.165.10.5518; PIERSON RN, 1989, J EXP MED, V170, P991, DOI 10.1084/jem.170.3.991; Platt JL, 1998, XENOTRANSPLANTATION, V5, P169, DOI 10.1111/j.1399-3089.1998.tb00024.x; Platt JL, 1998, NATURE, V392, P11; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; Sirlin CB, 2001, RADIOLOGY, V219, P35, DOI 10.1148/radiology.219.1.r01ap0435; Stock UA, 2001, ANNU REV MED, V52, P443, DOI 10.1146/annurev.med.52.1.443; Stone KR, 1998, TRANSPLANTATION, V65, P1577, DOI 10.1097/00007890-199806270-00007; Stone KR, 1997, TRANSPLANTATION, V63, P640, DOI 10.1097/00007890-199703150-00005; Tanemura M, 2000, J CLIN INVEST, V105, P301, DOI 10.1172/JCI7358; Uchida T, 1999, TRANSPLANTATION, V68, P1721, DOI 10.1097/00007890-199912150-00016; VOLKOV MV, 1976, CLIN ORTHOP RELAT R, V114, P192; Wang H, 2000, NAT MED, V6, P549, DOI 10.1038/75029; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Yang YG, 1998, J EXP MED, V187, P1335, DOI 10.1084/jem.187.8.1335; Zhong R, 2001, XENOTRANSPLANTATION, V8, P25	52	24	25	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					109	+		10.1096/fj.02-0630fje	http://dx.doi.org/10.1096/fj.02-0630fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475900				2022-12-25	WOS:000180218500025
J	Kontush, A; Chancharme, L; Escargueil-Blanc, I; Therond, P; Salvayre, R; Negre-Salvayre, A; Chapman, MJ				Kontush, A; Chancharme, L; Escargueil-Blanc, I; Therond, P; Salvayre, R; Negre-Salvayre, A; Chapman, MJ			Mildly oxidized LDL particle subspecies are distinct in their capacity to induce apoptosis in endothelial cells: role of lipid hydroperoxides	FASEB JOURNAL			English	Article						atherosclerosis; dense LDL; light LDL; LOOH; cytotoxicity	LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; SHED MEMBRANE MICROPARTICLES; ATHEROSCLEROTIC LESIONS; DNA FRAGMENTATION; PLASMA; BLOOD; DEATH; HETEROGENEITY; ACCUMULATION	The risk of atherosclerosis is intimately related to the heterogeneity of low-density lipoprotein (LDL) particles. The potential relationship between oxidative modification of distinct LDL subspecies and induction of apoptosis in arterial wall cells is indeterminate. The capacity of light LDL3 versus dense LDL5 to induce cytotoxicity in endothelial cells as a function of the degree of copper-mediated oxidation was compared. Mildly oxidized LDL3 (oxLDL3) exerted potent cytotoxicity, which was intimately related to both the degree of oxidation and the oxLDL3 concentration based on either cholesterol content or particle number. In contrast, dense LDL5 particles exerted a minor effect on cell viability. Cells incubated with oxLDL3 exhibited apoptotic features, with cytoplasmic condensation, cell or nuclear fragmentation, and accumulation of DNA fragments. OxLDL3-induced apoptosis involved cytoplasmic release of cytochrome c, with a concomitant increase in caspase-3-like protease activity. OxLDL3 particles were uniquely distinct from oxLDL5 particles in their elevated content of lipid hydroperoxides. Hydroperoxide removal by NaBH4 markedly reduced oxLDL3-induced cytotoxicity, leading to an increase in cell viability. Lipid hydroperoxide content of oxidatively modified LDL subclasses is therefore a major determinant of the induction of apoptosis in endothelial cells. These data are highly relevant to atherogenic hypercholesterolemia, in which the LDL phenotype is dominated by elevated concentrations of light LDL3.	Hop La Pitie Salpetriere, INSERM, U551, F-75651 Paris 13, France; CHU Rangueil, INSERM, U466, F-34054 Toulouse, France; CHU Kremlin Bicetre, INSERM, U347, F-94276 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Chapman, MJ (corresponding author), Hop La Pitie Salpetriere, INSERM, U551, Pavillon Benjamin Delessert, F-75651 Paris 13, France.	chapman@infobiogen.fr	Kontush, Anatol/J-2198-2016; chapman, john/Y-2742-2019	Negre-Salvayre, Anne/0000-0003-2136-5706				Alcouffe J, 1999, J LIPID RES, V40, P1200; Anber V, 1996, ATHEROSCLEROSIS, V124, P261, DOI 10.1016/0021-9150(96)05842-X; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; Bjorkerud S, 1996, AM J PATHOL, V149, P367; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; CAMPOS H, 1995, ARTERIOSCL THROM VAS, V15, P1043, DOI 10.1161/01.ATV.15.8.1043; Chancharme L, 1999, ARTERIOSCL THROM VAS, V19, P810, DOI 10.1161/01.ATV.19.3.810; Chancharme L, 2002, J LIPID RES, V43, P453; Chapman M. J., 1999, ADV VASC BIOL, P69; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; CHAPMAN MJ, 1981, J LIPID RES, V22, P339; Claise C, 1999, ATHEROSCLEROSIS, V147, P95, DOI 10.1016/S0021-9150(99)00170-7; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Dimmeler S, 1997, CIRCULATION, V95, P1760; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FREI B, 1988, ANAL BIOCHEM, V175, P120, DOI 10.1016/0003-2697(88)90369-7; GENG YJ, 1995, AM J PATHOL, V147, P251; Girotti AW, 1998, J LIPID RES, V39, P1529; HAN DKM, 1995, AM J PATHOL, V147, P267; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; Hsieh CC, 2000, ATHEROSCLEROSIS, V151, P481, DOI 10.1016/S0021-9150(00)00453-6; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P2225, DOI 10.1161/01.ATV.17.10.2225; Karten B, 1997, CHEM PHYS LIPIDS, V88, P83, DOI 10.1016/S0009-3084(97)00038-8; Kotamraju S, 2001, J BIOL CHEM, V276, P17316, DOI 10.1074/jbc.M011731200; Krauss Ronald M., 1994, Current Opinion in Lipidology, V5, P339, DOI 10.1097/00041433-199410000-00005; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; LUC G, 1988, ATHEROSCLEROSIS, V71, P143, DOI 10.1016/0021-9150(88)90138-4; Lund-Katz S, 1998, BIOCHEMISTRY-US, V37, P12867, DOI 10.1021/bi980828m; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; Meilhac O, 1999, FASEB J, V13, P485, DOI 10.1096/fasebj.13.3.485; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NIGON F, 1991, J LIPID RES, V32, P1741; Nishio E, 1996, BIOCHEM BIOPH RES CO, V223, P413, DOI 10.1006/bbrc.1996.0907; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PRICE P, 1990, CANCER RES, V50, P1392; Roland A, 2001, ARTERIOSCL THROM VAS, V21, P594, DOI 10.1161/01.ATV.21.4.594; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Siow RCM, 1999, ARTERIOSCL THROM VAS, V19, P2387, DOI 10.1161/01.ATV.19.10.2387; Smalley DM, 1997, ARTERIOSCL THROM VAS, V17, P3469, DOI 10.1161/01.ATV.17.12.3469; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; Suc I, 1997, ARTERIOSCL THROM VAS, V17, P2158, DOI 10.1161/01.ATV.17.10.2158; THEROND P, 1993, LIPIDS, V28, P245, DOI 10.1007/BF02536647; Tricot O, 2000, CIRCULATION, V101, P2450, DOI 10.1161/01.CIR.101.21.2450; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yla-Herttuala S, 1998, CURR OPIN LIPIDOL, V9, P337	53	20	21	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					88	+		10.1096/fj.02-0293fje	http://dx.doi.org/10.1096/fj.02-0293fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475909				2022-12-25	WOS:000180218500018
J	Gimferrer, I; Farnos, M; Calvo, M; Mittelbrunn, M; Enrich, C; Sanchez-Madrid, F; Vives, J; Lozano, F				Gimferrer, I; Farnos, M; Calvo, M; Mittelbrunn, M; Enrich, C; Sanchez-Madrid, F; Vives, J; Lozano, F			The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CD6 MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR COMPLEX; HUMAN LYMPHOCYTES-T; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; CYTOPLASMIC DOMAIN; B-CELLS; ACTIVATION; SURFACE	CD5 and CD6 are closely related lymphocyte surface receptors of the scavenger receptor cysteine-rich superfamily, which show highly homologous extracellular regions but little conserved cytoplasmic tails. Both molecules are expressed on the same lymphocyte populations (thymocytes, mature T cells, and B1a cells) and share similar co-stimulatory properties on mature T cells. Although several works have been reported on the molecular associations and the signaling pathway mediated by CD5, very limited information is available for CD6 in this regard. Here we show the physical association of CD5 and CD6 at the cell membrane of lymphocytes, as well as their localization at the immunological synapse. CD5 and CD6 co-immunoprecipitate from Brij 96 but not Nonidet P-40 cell lysates, independently of both the co-expression of other lymphocyte surface receptors and the integrity of CD5 cytoplasmic region. Fluorescence resonance energy transfer analysis, co-capping, and co-modulation experiments demonstrate the physical in vivo association of CD5 and CD6. Analysis of T cell/antigen-presenting cells conjugates shows the accumulation of both molecules at the immunological synapse. These results indicate that CD5 and CD6 are structurally and physically related receptors, which may be functionally linked to provide either similar or complementary accessory signals during T cell activation and/or differentiation.	Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer, Inst Clin Infecc & Immunol, Serv Immunol, Barcelona 08036, Spain; Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Serv Cient Tecn, Fac Med, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Fac Med, Dept Cellular Biol, E-08036 Barcelona, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Autonomous University of Madrid; Hospital de La Princesa	Lozano, F (corresponding author), Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer, Inst Clin Infecc & Immunol, Serv Immunol, Villarroel 170, Barcelona 08036, Spain.	lozano@medicina.ub.es	LOZANO, FRANCISCO/AAB-7888-2019; Lozano-Soto, Francisco/AAB-7930-2019; Calvo, Maria/I-1872-2015; Mittelbrunn, Maria/I-5882-2015; Sanchez-Madrid, Francisco/M-7889-2016; Mittelbrunn, Maria/J-9146-2019	LOZANO, FRANCISCO/0000-0003-1119-4368; Lozano-Soto, Francisco/0000-0003-3714-2304; Calvo, Maria/0000-0002-7473-0474; Mittelbrunn, Maria/0000-0003-3487-8762; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Mittelbrunn, Maria/0000-0003-3487-8762; Enrich, Carlos/0000-0003-0382-2993; Gimferrer, Idoia/0000-0002-5535-352X				ALBEROLAILA J, 1992, J IMMUNOL, V148, P1287; ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; Azzam HS, 2001, J IMMUNOL, V166, P5464, DOI 10.4049/jimmunol.166.9.5464; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; Bhandoola A, 2002, EUR J IMMUNOL, V32, P1811, DOI 10.1002/1521-4141(200206)32:6<1811::AID-IMMU1811>3.0.CO;2-G; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; BOTT CM, 1993, INT IMMUNOL, V5, P783, DOI 10.1093/intimm/5.7.783; BOTT CM, 1994, J IMMUNOL, V153, P1; Bowen MA, 1997, J IMMUNOL, V158, P1149; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Calvo J, 1999, TISSUE ANTIGENS, V54, P128, DOI 10.1034/j.1399-0039.1999.540203.x; Calvo J, 1999, EUR J IMMUNOL, V29, P2119, DOI 10.1002/(SICI)1521-4141(199907)29:07<2119::AID-IMMU2119>3.3.CO;2-6; CARDENAS L, 1990, J IMMUNOL, V145, P1450; Carmo AM, 1999, J IMMUNOL, V163, P4238; CARRERA AC, 1989, J BIOL CHEM, V264, P15650; Castro MAA, 2002, EUR J IMMUNOL, V32, P1509, DOI 10.1002/1521-4141(200205)32:5<1509::AID-IMMU1509>3.0.CO;2-T; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; Cibotti R, 1997, IMMUNITY, V6, P245, DOI 10.1016/S1074-7613(00)80327-1; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GANGEMI RMR, 1989, J IMMUNOL, V143, P2439; Gary-Gouy H, 2000, J BIOL CHEM, V275, P548, DOI 10.1074/jbc.275.1.548; GODING JW, 1976, J IMMUNOL METHODS, V13, P215, DOI 10.1016/0022-1759(76)90068-5; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; Kobarg J, 1997, EUR J IMMUNOL, V27, P2971, DOI 10.1002/eji.1830271133; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P812, DOI 10.1002/eji.1830240406; LEDBETTER JA, 1989, MOL IMMUNOL, V26, P137, DOI 10.1016/0161-5890(89)90095-3; Lozano F, 2000, CRIT REV IMMUNOL, V20, P347; MORIMOTO C, 1988, J IMMUNOL, V140, P2165; Niedergang F, 1997, J IMMUNOL, V159, P1703; OSMAN N, 1993, EUR J IMMUNOL, V23, P1173, DOI 10.1002/eji.1830230530; OSMAN N, 1992, EUR J IMMUNOL, V22, P2995, DOI 10.1002/eji.1830221135; OSORIO LM, 1994, CELL IMMUNOL, V154, P123, DOI 10.1006/cimm.1994.1062; Osorio LM, 1997, BLOOD, V89, P2833, DOI 10.1182/blood.V89.8.2833; Osorio LM, 1998, IMMUNOLOGY, V93, P358; Padilla O, 2000, IMMUNOGENETICS, V51, P993, DOI 10.1007/s002510000235; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; Pena-Rossi C, 1999, J IMMUNOL, V163, P6494; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; ROBINSON WH, 1995, EUR J IMMUNOL, V25, P2765, DOI 10.1002/eji.1830251008; Simarro M, 1997, J IMMUNOL, V159, P4307; Singer NG, 2002, INT IMMUNOL, V14, P585, DOI 10.1093/intimm/dxf025; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; SWACK JA, 1989, MOL IMMUNOL, V26, P1037, DOI 10.1016/0161-5890(89)90068-0; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; Teh SJ, 1997, BLOOD, V89, P1308, DOI 10.1182/blood.V89.4.1308; Toyo-oka K, 1999, INT IMMUNOL, V11, P2043, DOI 10.1093/intimm/11.12.2043; VERWILGHEN J, 1993, J IMMUNOL, V150, P835; Vila J. M., 2000, Inmunologia, V19, P105; WEE SF, 1993, J EXP MED, V177, P219, DOI 10.1084/jem.177.1.219; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Zhou XY, 2000, J IMMUNOL, V164, P1260, DOI 10.4049/jimmunol.164.3.1260	57	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8564	8571		10.1074/jbc.M209591200	http://dx.doi.org/10.1074/jbc.M209591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12473675	hybrid			2022-12-25	WOS:000181466800106
J	Tirosh, B; Furman, MH; Tortorella, D; Ploegh, HL				Tirosh, B; Furman, MH; Tortorella, D; Ploegh, HL			Protein unfolding is not a prerequisite for endoplasmic reticulum-to-cytosol dislocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I HEAVY-CHAINS; MEMBRANE-PROTEIN; DIHYDROFOLATE-REDUCTASE; ER MEMBRANE; TRANSLOCATION; IMPORT; DEGRADATION; PROTEASOME; TRANSPORT; INTERMEDIATE	We examined the effects of protein folding on endoplasmic reticulum. (ER)-to-cytosol transport (dislocation) by exploiting the well-characterized dihydrofolate reductase (DHFR) domain. DHFR retains the capacity to bind folate analogues in the lumen of microsomes and in the ER of intact cells, upon which it acquires a conformation resistant to proteinase K digestion. Here we show that a Class I major histocompatibility complex heavy chain fused to DHFR is still recognized by the human cytomegalovirus-encoded glycoproteins US2 and US11, resulting in dislocation of the fusion protein from the ER in vitro and in vivo. A folded state of the DHFR domain does not impair dislocation of Class I MHC heavy chains in vitro or in living cells. In fact, a slight acceleration of the dislocation of DHFR heavy chain fusion was observed in vitro in the presence of a folate analogue. These results suggest that one or more of the channels used for dislocation can accommodate polypeptides that contain a tightly folded domain of considerable size. Our data raise the possibility that the See61 channel can be modified to accommodate a folded DHFR domain for dislocation, but not for translocation into the ER, or that a channel altogether distinct from Sec61 is used for dislocation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave,Armenise Bldg,Rm 137, Boston, MA 02115 USA.			Tortorella, Domenico/0000-0003-0961-3535	NIAID NIH HHS [5R37-AI33456] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033456] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ENDO T, 1994, EUR J BIOCHEM, V225, P403, DOI 10.1111/j.1432-1033.1994.00403.x; Fiebiger E, 2002, EMBO J, V21, P1041, DOI 10.1093/emboj/21.5.1041; Furman MH, 2002, J BIOL CHEM, V277, P3258, DOI 10.1074/jbc.M109765200; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; JOHNSTON JA, 1995, J BIOL CHEM, V270, P8172, DOI 10.1074/jbc.270.14.8172; Jones TR, 1997, J VIROL, V71, P2970, DOI 10.1128/JVI.71.4.2970-2979.1997; Kowarik M, 2002, MOL CELL, V10, P769, DOI 10.1016/S1097-2765(02)00685-8; Mingarro I, 2000, BMC Cell Biol, V1, P3, DOI 10.1186/1471-2121-1-3; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Piper JR, 1996, J MED CHEM, V39, P1271, DOI 10.1021/jm950760y; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Salvador N, 2000, J BIOL CHEM, V275, P27447; SASSO SP, 1994, BBA-PROTEIN STRUCT M, V1207, P74, DOI 10.1016/0167-4838(94)90053-1; SCHLENSTEDT G, 1994, FEBS LETT, V340, P139, DOI 10.1016/0014-5793(94)80189-4; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	35	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6664	6672		10.1074/jbc.M210158200	http://dx.doi.org/10.1074/jbc.M210158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482753	hybrid			2022-12-25	WOS:000181195100006
J	Podar, K; Tai, YT; Cole, CE; Hideshima, T; Sattler, M; Hamblin, A; Mitsiades, N; Schlossman, RL; Davies, FE; Morgan, GJ; Munshi, NC; Chauhan, D; Anderson, KC				Podar, K; Tai, YT; Cole, CE; Hideshima, T; Sattler, M; Hamblin, A; Mitsiades, N; Schlossman, RL; Davies, FE; Morgan, GJ; Munshi, NC; Chauhan, D; Anderson, KC			Essential role of caveolae in interleukin-6-and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE DOMAINS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; RECEPTOR SUBSTRATE-1; PROTEIN-COMPONENT; PROSTATE-CANCER; EXPRESSION; CHOLESTEROL; KINASE	Caveolae, specialized flask-shaped lipid rafts on the cell surface, are composed of cholesterol, sphingolipids, and structural proteins termed caveolins; functionally, these plasma membrane microdomains have been implicated in signal transduction and transmembrane transport. In the present study, we examined the role of caveolin-1 in multiple myeloma cells. We show for the first time that caveolin-1, which is usually absent in blood cells, is expressed in multiple myeloma cells. Analysis of myeloma cell-derived plasma membrane fractions shows that caveolin-1 is co-localized with interleukin-6 receptor signal transducing chain gp130 and with insulin-like growth factor-I receptor. Cholesterol depletion by beta-cyclodextrin results in the loss of caveola structure in myeloma cells, as shown by transmission electron microscopy, and loss of caveolin-1 function. Interleukin-6 and insulin-like growth factor-I, growth and survival factors in multiple myeloma, induce caveolin-1 phosphorylation, which is abrogated by pre-treatment with beta-cyclodextrin. Importantly, inhibition of caveolin-1 phosphorylation blocks both interleukin-6-induced protein complex formation with caveolin-1 and downstream activation of the phosphatidylinositol 3-kinase/ Akt-1 pathway. beta-Cyclodextrin also blocks insulin-like growth factor-I-induced tyrosine phosphorylation of insulin-responsive substrate-1 and downstream activation of the phosphatidylinositol 3-kinase/Akt-1 pathway. Therefore, cholesterol depletion by beta-cyclodextrin abrogates both interleukin-6- and insulin-like growth factor-I-triggered multiple myeloma cell survival via negative regulation of caveolin-1. Taken together, this study identifies caveolin-1 and other structural membrane components as potential new therapeutic targets in multiple myeloma.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Univ Michigan, Ctr Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Leeds Gen Infirm, Leeds 3EX LSI, W Yorkshire, England; Vet Affairs Hlth Care Ctr, Brockton, MA 02401 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Michigan System; University of Michigan; Leeds General Infirmary	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.	Anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021; Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632; Davies, Faith/0000-0002-3971-2393; morgan, gareth/0000-0002-4271-6360	PHS HHS [P0-1 78378] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brown LM, 1999, CANCER, V85, P2385; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Chauhan D, 2001, APOPTOSIS, V6, P47, DOI 10.1023/A:1009620027205; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Ge NL, 2000, BLOOD, V96, P2856; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hailstones D, 1998, J LIPID RES, V39, P369; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hatanaka M, 1998, BIOCHEM BIOPH RES CO, V253, P382, DOI 10.1006/bbrc.1998.9744; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, SEMIN ONCOL, V28, P607, DOI 10.1053/sonc.2001.28608; ITO Y, 2000, BRIT J CANCER, V86, P912; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin B, 2002, CANCER RES, V62, P5019; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Maggi D, 2002, BIOCHEM BIOPH RES CO, V295, P1085, DOI 10.1016/S0006-291X(02)00809-4; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Michaud DS, 2001, CANCER CAUSE CONTROL, V12, P557, DOI 10.1023/A:1011256201044; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Ogata A, 1997, J IMMUNOL, V159, P2212; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Rajjayabun PH, 2001, UROLOGY, V58, P811, DOI 10.1016/S0090-4295(01)01337-1; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SATO JD, 1987, J EXP MED, V165, P1761, DOI 10.1084/jem.165.6.1761; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smith GD, 1998, LANCET, V351, P934, DOI 10.1016/S0140-6736(05)60603-4; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stahlhut M, 2000, EXP CELL RES, V261, P111, DOI 10.1006/excr.2000.4960; Tai YT, 2000, J IMMUNOL METHODS, V235, P11, DOI 10.1016/S0022-1759(99)00199-4; Tai YT, 2000, J IMMUNOL, V165, P6347, DOI 10.4049/jimmunol.165.11.6347; Thompson TC, 1998, CANCER METAST REV, V17, P439, DOI 10.1023/A:1006110326366; Trombetta L D, 1981, Cellule, V73, P237; Tu YP, 2000, CANCER RES, V60, P6763; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; van de Donk NWCJ, 2002, LEUKEMIA, V16, P1362, DOI 10.1038/sj.leu.2402501; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Yang G, 1998, CLIN CANCER RES, V4, P1873; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	69	122	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5794	5801		10.1074/jbc.M208636200	http://dx.doi.org/10.1074/jbc.M208636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482878	hybrid			2022-12-25	WOS:000181129400040
J	Thomenius, MJ; Wang, NS; Reineks, EZ; Wang, ZQ; Distelhorst, CW				Thomenius, MJ; Wang, NS; Reineks, EZ; Wang, ZQ; Distelhorst, CW			Bcl-2 on the endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; CYTOCHROME-C RELEASE; CELL-DEATH; SUBCELLULAR LOCATION; BH3 DOMAIN; APOPTOSIS; FAMILY; SURVIVAL; OLIGOMERIZATION; PREVENTS	Bcl-2 family members have been shown to be key mediators of apoptosis as either pro- or anti-apoptotic factors. It is thought that both classes of Bcl-2 family members act at the level of the mitochondria to regulate apoptosis, although the founding anti-apoptotic family member, Bcl-2 is localized to the endoplasmic reticulum (ER), mitochondrial, and nuclear membranes. In order to better understand the effect of Bcl-2 localization on its activity, we have utilized a Bcl-2 mutant that localizes only to the ER membrane, designated Bcl-2Cb5. Bcl-2Cb5 was expressed in MDA-MB-468 cells, which protected against apoptosis induced by the kinase inhibitor, staurosporine. Data presented here show that Bcl-2Cb5 inhibits this process by blocking Bax activation and cytochrome c release. Furthermore, we show that Bcl-2Cb5 can inhibit the activation of a constitutively mitochondrial mutant of Bax, indicating that an intermediate between Bcl-2 on the ER and Bax on the mitochondria must exist. We demonstrate that this intermediate is likely a BH3-only subfamily member. Data presented here show that Bcl-2Cb5 can sequester a constitutively active form of Bad (Bad3A) from the mitochondria and prevent it from activating Bax. These data suggest that Bcl-2 indirectly protects mitochondrial membranes from Bax, via BH3-only proteins.	Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Div Hematol Oncol,Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Div Hematol Oncol,Dept Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	cwd@po.ewru.edu			NATIONAL CANCER INSTITUTE [T32CA073515, P30CA043703, R01CA085804] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85804, T32 CA73515, CA43703, P30 CA43703-12] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakayama T, 2000, IPAP CONFERENCE SER, V1, P7, DOI 10.1109/ROMAN.2000.892461; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	43	79	82	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6243	6250		10.1074/jbc.M208878200	http://dx.doi.org/10.1074/jbc.M208878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12477729	hybrid			2022-12-25	WOS:000181129400095
J	Nelson, EJ; Hellevuo, K; Yoshimura, M; Tabakoff, B				Nelson, EJ; Hellevuo, K; Yoshimura, M; Tabakoff, B			Ethanol-induced phosphorylation and potentiation of the activity of type 7 adenylyl cyclase - Involvement of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINERGIC MODULATION; CYCLIC-AMP; CAMP; RECEPTOR; ACTIVATION; BINDING; CELLS; PKC; STIMULATION; INHIBITION	Ethanol can enhance G(salpha)-stimulated adenylyl cyclase (AC) activity. Of the nine isoforms of AC, type 7 (AC7) is the most sensitive to ethanol. The potentiation of AC7 by ethanol is dependent on protein kinase C (PKC). We designed studies to determine which PKC isotype(s) are involved in the potentiation of Galpha(s)-activated AC7 activity by ethanol and to investigate the direct phosphorylation of AC7 by PKC. AC7 was phosphorylated in vitro by the catalytic subunits of PKCs. The addition of ethanol to AC7-transfected HEK 293 cells increased the endogenous phosphorylation of AC7, as indicated by a decreased "back-phosphorylation" of AC7 by PKC in vitro. The potentiation of Galpha(s)-stimulated AC7 activity by either phorbol 12,13-dibutyrate or ethanol, in HEL cells endogenously expressing AC7, was not through the Ca2+-sensitive conventional PKCdelta. However, the potentiation of AC7 activity by ethanol or phorbol 12,13-dibutyrate was found to be reduced by the selective inhibitor of PKCS (rottlerin), a PKCdelta-specific inhibitory peptide (deltaV1-1), and the expression of the dominant negative form of PKCdelta. Immunoprecipitation data indicated that PKCdelta could bind and directly phosphorylate AC7. The results indicate that the potentiation of AC7 activity by ethanol involves phosphorylation of AC7 that is mediated by PKCdelta.	Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Tabakoff, B (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pharmacol, 4200 E 9th Ave,C236, Denver, CO 80262 USA.		Tabakoff, Boris/AAX-1204-2021		NIAAA NIH HHS [AA 9014, R01 AA013148, R01 AA013148-01A1] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009014, R01AA013148] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bol GF, 1997, BBA-MOL CELL RES, V1358, P307, DOI 10.1016/S0167-4889(97)00073-6; Chakrabarti S, 1998, MOL PHARMACOL, V54, P655; Chen CH, 2001, J MOL CELL CARDIOL, V33, P581, DOI 10.1006/jmcc.2000.1330; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; Dar MS, 1997, BRAIN RES, V749, P263, DOI 10.1016/S0006-8993(96)01263-2; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; Feoktistov I, 1997, BIOCHEM PHARMACOL, V54, P917, DOI 10.1016/S0006-2952(97)00288-8; GERMANO P, 1994, J BIOL CHEM, V269, P23102; Gerstin EH, 1998, J BIOL CHEM, V273, P16409, DOI 10.1074/jbc.273.26.16409; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Inagaki K, 2000, CIRCULATION, V101, P797, DOI 10.1161/01.CIR.101.7.797; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LIN YF, 1994, NEURON, V13, P1421, DOI 10.1016/0896-6273(94)90427-8; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; Meng ZH, 1998, NEUROSCIENCE, V85, P919, DOI 10.1016/S0306-4522(97)00627-1; Menninger JA, 1998, ALCOHOL CLIN EXP RES, V22, P1955, DOI 10.1111/j.1530-0277.1998.tb05903.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1998, Patent No. 5783405; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Rabbani M, 1999, ALCOHOL CLIN EXP RES, V23, P77, DOI 10.1111/j.1530-0277.1999.tb04026.x; Ratsma JE, 1999, ALCOHOL CLIN EXP RES, V23, P600, DOI 10.1111/j.1530-0277.1999.tb04160.x; SAITO T, 1985, J NEUROCHEM, V44, P1037, DOI 10.1111/j.1471-4159.1985.tb08722.x; Smit Martine J., 1998, V32, P1; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SZABO G, 1988, LIFE SCI, V42, P615, DOI 10.1016/0024-3205(88)90452-3; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; Villalba M, 1999, J IMMUNOL, V163, P5813; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; Yoshimura M, 1999, ALCOHOL CLIN EXP RES, V23, P1457, DOI 10.1097/00000374-199909000-00006; Yoshimura M, 1995, ALCOHOL CLIN EXP RES, V19, P1435, DOI 10.1111/j.1530-0277.1995.tb01004.x; Zimmermann G, 1996, J BIOL CHEM, V271, P27161, DOI 10.1074/jbc.271.43.27161	48	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4552	4560		10.1074/jbc.M210386200	http://dx.doi.org/10.1074/jbc.M210386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12454008	hybrid			2022-12-25	WOS:000180968900027
J	Ferrand, M; Le Fourn, V; Franc, JL				Ferrand, M; Le Fourn, V; Franc, JL			Increasing diversity of human thyroperoxidase generated by alternative splicing - Characterization by molecular cloning of new transcripts with single- and multispliced mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROID PEROXIDASE; INTRACELLULAR TRAFFICKING; MESSENGER-RNAS; MYELOPEROXIDASE; EXPRESSION; FORM; GENE; DISEASE; CELLS; CDNA	The human thyroperoxidase (hTPO) gene is composed of 17 exons. The longest complete cDNA sequence determined so far contains a full-length hTPO (TPO1) encoding a 933-amino acid polypeptide. Several mRNA species encoding for hTPO isoforms are present in normal thyroid tissues, including TPO2 with exon 10 deleted and TPOzanelli with exon 16 deleted. In the present study, we established the existence of two new single-spliced transcripts, TPO4 and TPO5, lacking exons 14 and 8, respectively. Upon transfecting the TPO4 cDNA into Chinese hamster ovary cells, it was observed that TPO4 is able to reach the cell surface, is enzymatically active, and is able to be recognized by a panel of 12 monoclonal antibodies directed against hTPO, whereas TPO5 does not fold correctly and is unable to reach the cell surface. In normal tissues, the expression of TPO4 mRNA was examined by performing quantitative reverse transcription PCR. This deleted TPO mRNA amounted to 32 +/- 11% of the total TPO mRNAs. In the same tissues, the TPO2, TPOzanelli, and TPO5 amounted to 35 +/- 12%, 36 +/- 14%, and similar to10%, respectively. The sum of these four species (not including TPO1) was more than 100%, possibly due to the presence of multispliced mRNAs. This possibility was tested, and three new variants were identified: TPO2/3, lacking exons 10 and 16, TPO2/4, lacking exons 10 and 14, and an unexpected variant, TPO6, corresponding to the deletion of exons 10, 12, 13, 14, and 16. In conclusion, these results indicate the existence of five new transcripts. One of them, TPO4, codes for an enzymatically active protein, whereas TPO5 is unable to fold correctly. The functional significance of the other newly spliced mRNA variants still remains to be elucidated, but these results might help to explain the heterogeneity of the hTPO purified from the thyroid gland.	Univ Mediterranee, Fac Med, INSERM, U555, F-13385 Marseille 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Franc, JL (corresponding author), Univ Mediterranee, Fac Med, INSERM, U555, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.		Franc, Jean-Louis/C-8861-2009	Franc, Jean-Louis/0000-0002-2900-5468				Cetani F, 1995, MOL CELL ENDOCRINOL, V115, P125, DOI 10.1016/0303-7207(95)03680-6; ELISEI R, 1991, J CLIN ENDOCR METAB, V72, P700, DOI 10.1210/jcem-72-3-700; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Gardas A, 1997, J CLIN ENDOCR METAB, V82, P3752, DOI 10.1210/jc.82.11.3752; GIRAUD A, 1992, J ENDOCRINOL, V132, P317, DOI 10.1677/joe.0.1320317; Guo J, 2002, J BIOL CHEM, V277, P40189, DOI 10.1074/jbc.M205524200; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HOSOKAWA Y, 1993, LEUKEMIA, V7, P441; KAUFMAN KD, 1989, J CLIN INVEST, V84, P394, DOI 10.1172/JCI114179; KIMURA S, 1989, BIOCHEMISTRY-US, V28, P4481, DOI 10.1021/bi00436a054; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; LEFOURN V, 2002, J ENDOCRINOL INVEST, V25, P138; LIBERT F, 1987, EMBO J, V6, P4193, DOI 10.1002/j.1460-2075.1987.tb02766.x; MAGNUSSON RP, 1987, MOL ENDOCRINOL, V1, P856, DOI 10.1210/mend-1-11-856; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; NAGAYAMA Y, 1990, J CLIN ENDOCR METAB, V71, P384, DOI 10.1210/jcem-71-2-384; Niccoli P, 1997, J BIOL CHEM, V272, P29487, DOI 10.1074/jbc.272.47.29487; Niccoli-Sire P, 2001, BIOCHEMISTRY-US, V40, P2572, DOI 10.1021/bi0026324; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; Spencer WE, 1999, BIOTECHNIQUES, V27, P1044, DOI 10.2144/99275rr04; Taurog A, 1999, BIOCHIMIE, V81, P557, DOI 10.1016/S0300-9084(99)80110-2; Wang J, 2000, BIOTECHNIQUES, V29, P976, DOI 10.2144/00295bm09; ZANELLI E, 1990, BIOCHEM BIOPH RES CO, V170, P735, DOI 10.1016/0006-291X(90)92152-P; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	26	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3793	3800		10.1074/jbc.M209513200	http://dx.doi.org/10.1074/jbc.M209513200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12454013	hybrid			2022-12-25	WOS:000180869700036
J	Marathe, GK; Zimmerman, GA; McIntyre, TM				Marathe, GK; Zimmerman, GA; McIntyre, TM			Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SERUM PARAOXONASE; OXYHEMOGLOBIN-INDUCED PEROXIDATION; HUMAN-PLASMA; STRUCTURAL IDENTIFICATION; CIGARETTE-SMOKING; ACTIVE-SITE; IN-VIVO; OXIDATION; PHOSPHATIDYLCHOLINES; ATHEROSCLEROSIS	Paraoxonase-1 (PON1), an high density lipoprotein (HDL)-associated organophosphate triesterase, suppresses atherosclerosis in an unknown way. Purified PON1 protects lipoprotein particles from oxidative modification and hydrolyzes pro-atherogenic oxidized phospholipids and the inflammatory mediator platelet-activating factor (PAF). We find human PON1 acted as a phospholipase A(2) but not as a phospholipase C or D through cleavage of phosphodiester bonds as expected. PON1 requires divalent cations, but EDTA did not block the phospholipase A(2) activity of PON1. In contrast, a serine esterase inhibitor abolished phospholipase activity even though PON1 has no active-site serine residues. PAF acetylhydrolase, an oxidized phospholipid phospholipase A(2), is a serine esterase associated with specific HDL particles. Western blotting did not reveal detectable amounts of PAF acetylhydrolase in PON1 preparations, although very low amounts of PAF acetylhydrolase might still account for PON1 phospholipase A(2) activity. We revised the standard PON1 purification by first depleting HDL of PAF acetylhydrolase to find PON1 purified in this way. no longer hydrolyzed oxidized phospholipids or PAF. Serum from a donor with an inactivating mutation in the PAF acetylhydrolase gene did not hydrolyze oxidized phospholipids or PAF, yet displayed full paraoxonase activity. We conclude that PAF acetylhydrolase is the sole phospholipase A(2) of HDL and that PON1 has no phospholipase activity toward PAF or pro-atherogenic oxidized phospholipids.	Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Expt Pathol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntyre, TM (corresponding author), Univ Utah, Dept Med, 4130 EIHG,2030 E 15 N, Salt Lake City, UT 84112 USA.			Marathe, Gopal/0000-0002-0025-6677	NHLBI NIH HHS [HL 44525, HL 44513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL044525, R01HL044513, R01HL044525] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmed Z, 2002, BIOCHEM BIOPH RES CO, V290, P391, DOI 10.1006/bbrc.2001.6150; Ahmed Z, 2001, J BIOL CHEM, V276, P24473, DOI 10.1074/jbc.M010459200; Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510; Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; Cao HB, 1999, J LIPID RES, V40, P133; Costa LG, 1999, CHEM-BIOL INTERACT, V119, P429, DOI 10.1016/S0009-2797(99)00055-1; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Dentan C, 1996, BBA-LIPID LIPID MET, V1299, P353, DOI 10.1016/0005-2760(95)00226-X; DOUSSET N, 1981, BIOCHIM BIOPHYS ACTA, V641, P1, DOI 10.1016/0005-2736(81)90564-2; Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473; Furlong CE, 2002, PHARMACOGENOMICS, V3, P341, DOI 10.1517/14622416.3.3.341; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; IMAIZUMI TA, 1991, ATHEROSCLEROSIS, V87, P47, DOI 10.1016/0021-9150(91)90231-Q; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V961, P13; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; JOSSE D, 2001, J APPL TOXICOL S1, V21, P7, DOI DOI 10.1002/JAT.789; KUO CL, 1995, DRUG METAB DISPOS, V23, P935; La Du BN, 1992, PHARMACOGENETICS DRU, P51; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness MI, 1996, CURR OPIN LIPIDOL, V7, P69, DOI 10.1097/00041433-199604000-00004; Mackness MI, 1998, ATHEROSCLEROSIS, V136, P195, DOI 10.1016/S0021-9150(97)00197-4; Marathe GK, 2001, J LIPID RES, V42, P1430; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Navab M, 2000, J LIPID RES, V41, P1495; Oda MN, 2002, BIOCHEM BIOPH RES CO, V290, P921, DOI 10.1006/bbrc.2001.6295; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Quarck R, 2001, CIRCULATION, V103, P2495; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Shih DM, 1996, J CLIN INVEST, V97, P1630, DOI 10.1172/JCI118589; Silva AR, 2002, J IMMUNOL, V168, P4112, DOI 10.4049/jimmunol.168.8.4112; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SMOLEN A, 1991, DRUG METAB DISPOS, V19, P107; SORENSON RC, 1995, P NATL ACAD SCI USA, V92, P7187, DOI 10.1073/pnas.92.16.7187; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Subbanagounder G, 1999, CIRC RES, V85, P311, DOI 10.1161/01.RES.85.4.311; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; Tokumura A, 2000, J LIPID RES, V41, P953; Tward A, 2002, CIRCULATION, V106, P484, DOI 10.1161/01.CIR.0000023623.87083.4F; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	55	147	153	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3937	3947		10.1074/jbc.M211126200	http://dx.doi.org/10.1074/jbc.M211126200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12466264	hybrid			2022-12-25	WOS:000180869700055
J	Stitham, J; Stojanovic, A; Merenick, BL; O'Hara, KA; Hwa, J				Stitham, J; Stojanovic, A; Merenick, BL; O'Hara, KA; Hwa, J			The unique ligand-binding pocket for the human prostacyclin receptor - Site-directed mutagenesis and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE TERTIARY STRUCTURE; DISULFIDE BOND FORMATION; PROSTANOID RECEPTORS; PULMONARY-HYPERTENSION; TRANSMEMBRANE DOMAIN; CYTOPLASMIC DOMAIN; AGONIST BINDING; ACTIVATION; RHODOPSIN; IDENTIFICATION	The human prostacyclin receptor is a seven-transmembrane a-helical G-protein coupled receptor, which plays important roles in both vascular smooth muscle relaxation as well as prevention of blood coagulation. The position of the native ligand-binding pocket for prostacyclin as well as other derivatives of the 20-carbon eicosanoid, arachidonic acid, has yet to be determined. Through the use of prostanoid receptor sequence alignments, site-directed mutagenesis, and the 2.8-Angstrom x-ray crystallographic structure of bovine rhodopsin, we have developed a three-dimensional model of the agonist-binding pocket within the seven-transmembrane (TM) domains of the human prostacyclin receptor. Upon mutation to alanine, 11 of 29 candidate residues within TM domains II, III, IV, V, and VII exhibited a marked decrease in agonist binding. Of this group, four amino acids, Arg-279 (TMVII), Phe-278 (TMVII), Tyr-75 (TMII), and Phe-95 (TMIII), were identified (via receptor amino acid sequence alignment, ligand structural comparison, and computer-assisted homology modeling) as having direct molecular interactions with ligand side-chain constituents. This binding pocket is distinct from that of the biogenic amine receptors and rhodopsin where the native ligands (also composed of a carbon ring and a carbon chain) are accommodated in an opposing direction. These findings should assist in the development of novel and highly specific ligands including selective antagonists for further molecular pharmacogenetic studies of the human prostacyclin receptor.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Hwa, J (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.							Abramovitz M, 2000, BBA-MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388-1981(99)00164-X; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Armstrong RA, 1996, PHARMACOL THERAPEUT, V72, P171, DOI 10.1016/S0163-7258(96)00103-9; Bley KR, 1998, TRENDS PHARMACOL SCI, V19, P141, DOI 10.1016/S0165-6147(98)01185-7; BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; Cai KW, 2001, BIOCHEMISTRY-US, V40, P12479, DOI 10.1021/bi010747h; Chang CS, 1997, BIOCHEM J, V322, P597, DOI 10.1042/bj3220597; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jones RL, 1997, CLIN EXP PHARMACOL P, V24, P969, DOI 10.1111/j.1440-1681.1997.tb02730.x; Kedzie KM, 1998, MOL PHARMACOL, V54, P584, DOI 10.1124/mol.54.3.584; Keith RL, 2002, CANCER RES, V62, P734; Klein-Seetharaman J, 2001, BIOCHEMISTRY-US, V40, P12472, DOI 10.1021/bi010746p; Kobayashi T, 2000, J BIOL CHEM, V275, P24294, DOI 10.1074/jbc.M002437200; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; Maruyama I, 1998, LUPUS, V7, pS41, DOI 10.1177/096120339800700210; Nagaya N, 1999, J AM COLL CARDIOL, V34, P1188, DOI 10.1016/S0735-1097(99)00312-5; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; Olschewski H, 2000, ANN INTERN MED, V132, P435, DOI 10.7326/0003-4819-132-6-200003210-00003; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; Schiffrin EL, 1998, J CARDIOVASC PHARM, V32, pS2; Schneider MR, 1996, BREAST CANCER RES TR, V38, P133, DOI 10.1007/BF01803791; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Stitham J, 2002, J BIOL CHEM, V277, P15439, DOI 10.1074/jbc.M201187200; Stitham J, 2002, MOL PHARMACOL, V61, P1202, DOI 10.1124/mol.61.5.1202; STRADER CD, 1989, J BIOL CHEM, V264, P13572; TSAI AL, 1991, J COMPUT AID MOL DES, V5, P135, DOI 10.1007/BF00129752; Ungrin MD, 2001, MOL PHARMACOL, V59, P1446, DOI 10.1124/mol.59.6.1446; Watanabe K, 1999, CANCER RES, V59, P5093; Zhang ZB, 2001, MOL PHARMACOL, V60, P480	39	49	49	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4250	4257		10.1074/jbc.M207420200	http://dx.doi.org/10.1074/jbc.M207420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446735	hybrid			2022-12-25	WOS:000180869700092
J	Yasuda, S; Nishijima, M; Hanada, K				Yasuda, S; Nishijima, M; Hanada, K			Localization, topology, and function of the LCB1 subunit of serine palmitolyltransferase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY SENSORY NEUROPATHY; SPHINGOLIPID SYNTHESIS; 8-AMINO-7-OXONONANOATE SYNTHASE; PALMITOYLTRANSFERASE ACTIVITY; ENDOPLASMIC-RETICULUM; BASE SYNTHESIS; ACYL-COA; PROTEIN; ENZYME; CLONING	Serine palmitoyltransferase (SPT), the enzyme catalyzing the initial step in the biosynthesis of sphingolipids, comprises two different subunits, LCB1 and LCB2. LCB1 has a single highly hydrophobic domain near the N terminus. Chinese hamster ovary cell mutant LY-B cells are defective in SPT activity because of the lack of expression of an endogenous LCB1 subunit. Stable expression of LCB1 having an epitope tag at either the N or C terminus restored SPT activity of LY-B cells, suggesting that the epitope tag did not affect the localization or topology of LCB1. Indirect immunostaining showed that the N- and C-terminal epitopes are oriented toward the lumenal and cytosol side, respectively, at the endoplasmic reticulum. Interestingly, there was far less LCB2 in LY-B cells than in wild-type cells, and the amount of LCB2 in LY-B cells was restored to the wild-type level by transfection with LCB1 eDNA. In addition, overproduction of the LCB2 subunit required co-overproduction of the LCB1 subunit. These results indicated that the LCB1 subunit is most likely an integral protein having a single transmembrane domain with a lumenal orientation of its N terminus in the endoplasmic reticulum and that the LCB1 subunit is indispensable for the maintenance of the LCB2 subunit in mammalian cells.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1,Toyama, Tokyo 1628640, Japan.			YASUDA, Satoshi/0000-0002-1011-0815; Hanada, Kentaro/0000-0003-1383-2781				Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Bejaoui K, 2001, NAT GENET, V27, P261, DOI 10.1038/85817; Bejaoui K, 2002, J CLIN INVEST, V110, P1301, DOI 10.1172/JCI200216450; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Chen Chien Peter, 2002, Appl Bioinformatics, V1, P21; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Farrell AM, 1998, J LIPID RES, V39, P2031; Gable K, 2002, J BIOL CHEM, V277, P10194, DOI 10.1074/jbc.M107873200; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hanada K, 2000, J BIOL CHEM, V275, P8409, DOI 10.1074/jbc.275.12.8409; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Ott CM, 2002, J CELL SCI, V115, P2003; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Rost B, 1996, METHOD ENZYMOL, V266, P525; Webster SP, 2000, BIOCHEMISTRY-US, V39, P516, DOI 10.1021/bi991620j; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; ZHAO C, 1994, J BIOL CHEM, V269, P21480; [No title captured]	31	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4176	4183		10.1074/jbc.M209602200	http://dx.doi.org/10.1074/jbc.M209602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12464627	hybrid			2022-12-25	WOS:000180869700085
J	Jang, BC; Munoz-Najar, U; Paik, JH; Claffey, K; Yoshida, M; Hla, T				Jang, BC; Munoz-Najar, U; Paik, JH; Claffey, K; Yoshida, M; Hla, T			Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE-2 MESSENGER-RNA; FISSION YEAST; PROTEIN; CELLS; STABILIZATION; BIOLOGY; GENE; MICE	Cyclooxygenase (COX)-2, the inducible prostaglandin synthase, is overexpressed in cancer and chronic inflammatory diseases. Post-transcriptional regulation of COX-2 mRNA is important in controlling the expression of the COX-2 gene. Here, we report that leptomycin B (LMB), a specific inhibitor of the nuclear export factor CRM1 potently inhibits the stabilization of COX-2 mRNA in MDA-MB-231 human mammary cancer cells. However, COX-2 promoter-driven reporter gene expression is not inhibited by LMB, suggesting that LMB acts at the post-transcriptional level. Subcellular fractionation experiments indicate that LMB inhibited the time-dependent export of COX-2 mRNA into the membrane-bound polysomal compartment at the endoplasmic reticulum. LMB suppressed COX-2 expression by interleukin-1beta in HT-29 human colon cancer cells and in human umbilical vein endothelial cells but had no effect on COX-2 expression induced by Escherichia coli lipopolysaccharide in monocytic THP-1 cells. These data suggest that the nuclear export of COX-2 mRNA may be rate-liming in a cell-specific manner. LMB may be useful to control COX-2 expression in various human diseases in which COX-2 plays a pathogenetic role.	Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA; RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan	University of Connecticut; RIKEN	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, 263 Farmington Ave, Farmington, CT 06030 USA.		Yoshida, Minoru/C-8049-2014; Hla, Timothy/G-5873-2012	Yoshida, Minoru/0000-0002-4376-5674; Hla, Timothy/0000-0001-8355-4065	NHLBI NIH HHS [HL49094] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; Hawk ET, 2002, JNCI-J NATL CANCER I, V94, P545; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; KOMIYAMA K, 1985, J ANTIBIOT, V38, P427, DOI 10.7164/antibiotics.38.427; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; Moore MJ, 2001, SCIENCE, V294, P1841, DOI 10.1126/science.1067676; NISHI K, 1994, J BIOL CHEM, V269, P6320; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Watanabe M, 1999, GENES CELLS, V4, P291, DOI 10.1046/j.1365-2443.1999.00259.x; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	22	94	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					2773	2776		10.1074/jbc.C200620200	http://dx.doi.org/10.1074/jbc.C200620200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12468543	hybrid			2022-12-25	WOS:000180915000001
J	Eda, S; Maseda, H; Nakae, T				Eda, S; Maseda, H; Nakae, T			An elegant means of self-protection in gram-negative bacteria by recognizing and extruding xenobiotics from the periplasmic space	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX PUMPS; SUBSTRATE-SPECIFICITY; PSEUDOMONAS-AERUGINOSA; ANTIBIOTIC EXTRUSION; ESCHERICHIA-COLI; DRUG EXTRUSION; TRANSPORTER; RESISTANCE; VECTORS; SUBUNIT	Infection of Pseudomonas aeruginosa in cystic fibrosis patients is a major cause of mortality. This organism shows wide ranging antibiotic resistance that is largely attributable to the expression of xenobiotic efflux pump(s). Here, we show a novel mechanism by which the resistance-nodulation-division-type xenobiotic transporter expels potential hazards and protects the interior of the cells. The xenobiotic transporters MexB and MexY preferentially export beta-lactam and aminoglycoside antibiotics, respectively. When two large extramembrane loops of MexY were replaced by the corresponding loops of MexB, the hybrid protein exhibited P-lactam selectivity (MexB-type), but failed to recognize aminoglycoside. As the transmembrane segment of MexB was replaced with a corresponding transmembrane segment of MexY, one-by-one for all 12 segments, all the hybrid proteins showed MexB-type antibiotic selectivity. These results clearly demonstrated that the resistance-nodulation-division-type efflux pump in P. aeruginosa selects and transports substrates via the domains that largely protrude over the cytoplasmic membrane. The transmerabrane segments were unlikely to have been involved in substrate selectivity. These observations led us to propose a novel mechanism by which the xenobiotic transporters in Gram-negative bacteria select and expel substrates from the periplasmic space before potential hazards penetrate into the cytoplasmic membrane.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan	Tokai University	Nakae, T (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	nakae@is.icc.u-tokai.ac.jp						Bibi E, 2001, J MOL MICROB BIOTECH, V3, P171; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Elkins CA, 2002, J BACTERIOL, V184, P6490, DOI 10.1128/JB.184.23.6490-6499.2002; Gotoh N, 1999, FEBS LETT, V458, P32, DOI 10.1016/S0014-5793(99)01116-3; Guan L, 1999, J BIOL CHEM, V274, P10517, DOI 10.1074/jbc.274.15.10517; Guan L, 2001, J BACTERIOL, V183, P1734, DOI 10.1128/JB.183.5.1734-1739.2001; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; Klyachko KA, 1997, J BACTERIOL, V179, P2189, DOI 10.1128/jb.179.7.2189-2193.1997; Mao WM, 2002, MOL MICROBIOL, V46, P889, DOI 10.1046/j.1365-2958.2002.03223.x; Masuda N, 2000, ANTIMICROB AGENTS CH, V44, P3322, DOI 10.1128/AAC.44.12.3322-3327.2000; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Nakae Taiji, 1997, J Infect Chemother, V3, P173, DOI 10.1007/BF02490031; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ocaktan A, 1997, J BIOL CHEM, V272, P21964, DOI 10.1074/jbc.272.35.21964; Poole K, 2001, J MOL MICROB BIOTECH, V3, P255; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; SIMON R, 1986, METHOD ENZYMOL, V118, P640; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506	23	47	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2085	2088		10.1074/jbc.C200661200	http://dx.doi.org/10.1074/jbc.C200661200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12460990	hybrid			2022-12-25	WOS:000180562000002
J	Devarajan, E; Sahin, AA; Chen, JS; Krishnamurthy, RR; Aggarwal, N; Brun, AM; Sapino, A; Zhang, F; Sharma, D; Yang, XH; Tora, AD; Mehta, K				Devarajan, E; Sahin, AA; Chen, JS; Krishnamurthy, RR; Aggarwal, N; Brun, AM; Sapino, A; Zhang, F; Sharma, D; Yang, XH; Tora, AD; Mehta, K			Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance	ONCOGENE			English	Article						apoptosis; cyteine-proteases; drug-resistance; caspases; breast cancer	FAS-MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR GENE; DRUG-RESISTANCE; CELL-LINES; P53; PROTEASES; DNA; AMPLIFICATION; EXPRESSION; INHIBITION	Caspase-3 is a member of the cysteine protease family, which plays a crucial role in apoptotic pathways by cleaving a variety of key cellular proteins. Caspase-3 can be activated by diverse death-inducing signals, including the chemotherapeutic agents. The purpose of this study was to determine the levels of caspase-3 expression in breast tumor samples and to determine whether alterations in its expression can affect their ability to undergo apoptosis. Primary breast tumor and normal breast parenchyma samples were obtained from patients undergoing breast surgery and the expression of caspases-3 was studied. Similarly, normal mammary epithelial cells and several established mammary cancer cell lines were studied for caspases-3 expression by reverse transcriptase-polymerase chain reaction, Northern blot analysis, and Western blot analysis. Approximately 75% of the tumor as well as morphologically normal peritumoral tissue samples lacked the caspase-3 transcript and caspase-3 protein expression. In addition, the caspases-3 mRNA levels in commercially available total RNA samples from breast, ovarian, and cervical tumors were either undetectable (breast and cervical) or substantially decreased (ovarian). Despite the complete loss of caspase-3, the expression levels of other caspases, such as caspase-8 and caspase-9, were normal in all of the tumor samples studied. The sensitivity of caspase-3-deficient breast cancer (MCF-7) cells to undergo apoptosis in response to doxorubicin and other apoptotic stimuli could be augmented by reconstituting caspase-3 expression. These results suggest that the loss of caspases-3 expression may represent an important cell survival mechanism in breast cancer patients.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ N Texas, Hlth Sci Ctr, Dept Pathol, Ft Worth, TX 76107 USA; Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy; Northwestern Univ, Sch Med, Dept Pathol, Evanston, IL 60201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of North Texas System; University of North Texas Health Science Center; University of Turin; Northwestern University	Mehta, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Yang, Jim/B-3776-2010; Sapino, Anna/AGY-9901-2022; Sapino, Anna/J-4113-2018	Sapino, Anna/0000-0003-3542-9571; Sapino, Anna/0000-0003-3542-9571				Ahmad M, 1998, CANCER RES, V58, P5201; BAGASRA O, 1993, J IMMUNOL METHODS, V158, P131, DOI 10.1016/0022-1759(93)90265-9; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Chen XM, 2000, JNCI-J NATL CANCER I, V92, P1999, DOI 10.1093/jnci/92.24.1999; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Clynes M, 1998, CRIT REV ONCOL HEMAT, V28, P181, DOI 10.1016/S1040-8428(98)00018-3; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Devarajan E, 2002, INT J ONCOL, V20, P913; Eck-Enriquez K, 2000, BREAST CANCER RES TR, V61, P229, DOI 10.1023/A:1006442017658; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V277, P655, DOI 10.1006/bbrc.2000.3698; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Guo YP, 1999, CANCER RES, V59, P1366; Haidar MA, 2000, INT J ONCOL, V16, P561; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; Hasegawa J, 1996, CANCER RES, V56, P1713; Hickman JA, 1996, EUR J CANCER, V32A, P921, DOI 10.1016/0959-8049(96)00080-9; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Huang YH, 2001, BIOCHEM BIOPH RES CO, V283, P762, DOI 10.1006/bbrc.2001.4871; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; Nakopoulou L, 2001, PATHOBIOLOGY, V69, P266, DOI 10.1159/000064337; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Pirnia F, 2000, J NATL CANCER I, V92, P1535, DOI 10.1093/jnci/92.18.1535; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ueki T, 2001, INT J CANCER, V91, P673, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1113>3.0.CO;2-U; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Winter RN, 2001, CANCER RES, V61, P1227; Yang XH, 2001, CANCER RES, V61, P348; Yuan YF, 2001, CANCER RES, V61, P5558	40	332	345	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8843	8851		10.1038/sj.onc.1206044	http://dx.doi.org/10.1038/sj.onc.1206044			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483536				2022-12-25	WOS:000179734400017
J	Kim, SH; Gunnery, S; Choe, JK; Mathews, MB				Kim, SH; Gunnery, S; Choe, JK; Mathews, MB			Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR	ONCOGENE			English	Article						PKR; interferon; melanoma; colon; cancer	SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; MALIGNANT TRANSFORMATION; HEPATOCELLULAR-CARCINOMA; CUTANEOUS MELANOMA; CATALYTIC DOMAIN; TUMOR-SUPPRESSOR; C-MYC; ACTIVATION; P68	The interferon-inducible, double-stranded RNA (dsRNA)-activated protein kinase, PKR, plays key roles in regulation of cell growth and differentiation, and has been postulated as a tumor suppressor. Downstream effectors of PKR include the translation initiation factor, eIF2alpha, and the transcription factor, NF-kappaB. We found elevated levels of PKR protein, dsRNA-dependent PKR autophosphorylation activity, and phosphorylated eIF2a in melanoma cells compared to nontransformed melanocytes in culture. Treatment with interferon-alpha2b further induced PKR expression and activity. Immunohistochemical analysis of primary melanomas demonstrated minimal PKR immunoreactivity, but melanoma lymph node metastases expressed a high level of PKR protein. Furthermore, analysis of colon cancer specimens revealed that transformation from normal mucosa to adenomas and carcinomas was coincident with an increase in PKR expression. These data do not support the concept of PKR as a classic tumor suppressor but instead suggest that PKR upregulation occurs at defined steps in cancer progression, probably as a cellular response to neoplasia.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; VA New Jersey Healthcare Syst, Pathol & Lab Med Serv, E Orange, NJ 07018 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; VA New Jersey Healthcare Syst, Surg Serv, E Orange, NJ 07018 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; New Jersey Department of Health & Senior Services; Rutgers State University New Brunswick; Rutgers State University Medical Center; New Jersey Department of Health & Senior Services	Kim, SH (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.				NIAID NIH HHS [AI34552] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HAINES GK, 1993, VIRCHOWS ARCH B, V63, P289, DOI 10.1007/BF02899275; HAINES GK, 1992, VIRCHOWS ARCH B, V62, P151, DOI 10.1007/BF02899677; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; HAINES GK, 1993, ARCH OTOLARYNGOL, V119, P1142; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; KIM SH, 1998, CUTANEOUS ONCOLOGY, P303; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mathews Michael B., 2001, Trends in Biochemical Sciences, V26, P585, DOI 10.1016/S0968-0004(01)01971-5; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; Pataer A, 2002, CANCER RES, V62, P2239; Pehamberger H, 1998, J CLIN ONCOL, V16, P1425, DOI 10.1200/JCO.1998.16.4.1425; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; Shimada A, 1998, CANCER RES, V58, P4434; Sieber OM, 2000, MOL MED TODAY, V6, P462; SINGH C, 1995, TUMOR BIOL, V16, P281, DOI 10.1159/000217945; Sudhakar A, 2000, BIOCHEMISTRY-US, V39, P12929, DOI 10.1021/bi0008682; Terada T, 2000, HUM PATHOL, V31, P817, DOI 10.1053/hupa.2000.8443; Terada W, 2000, LIVER, V20, P450, DOI 10.1034/j.1600-0676.2000.020006450.x; WILLIAMS BR, 2001, SCI STKE RE, V2; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; Zhou U, 1998, EUR J CANCER, V34, P2046, DOI 10.1016/S0959-8049(98)00292-5	50	76	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8741	8748		10.1038/sj.onc.1205987	http://dx.doi.org/10.1038/sj.onc.1205987			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483527				2022-12-25	WOS:000179734400008
J	Chadee, DN; Peltier, CP; Davie, JR				Chadee, DN; Peltier, CP; Davie, JR			Histone H1(S)-3 phosphorylation in Ha-ras oncogene-transformed mouse fibroblasts	ONCOGENE			English	Article						histone Hl; ras oncogene; Cdk2	NIH 3T3 CELLS; G1 PHASE; SER-10 PHOSPHORYLATION; MAMMALIAN-CELLS; GENE-EXPRESSION; H1; KINASE; PROGRESSION; CHROMATIN; CYCLE	Phosphorylation of linker histone H1(S)-3 (previously named H1b) and core histone H3 is elevated in mouse fibroblasts transformed with oncogenes or constitutively active mitogen-activated protein kinase (MAPK) kinase (MEK). H1(S)-3 phosphorylation is the only histone modification known to be dependent upon transcription and replication. Our results show that the increased amounts of phosphorylated H1(S)-3 in the oncogene Ha-ras-transformed mouse fibroblasts was a consequence of an elevated Cdk2 activity rather than the reduced activity of a H1 phosphatase, which our studies suggest is PP1. Induction of oncogenic ras expression results in an increase in H1(S)-3 and H3 phosphorylation. However, in contrast to the phosphorylation of H3, which occurred immediately following the onset of Ras expression, there was a lag of several hours before H1(S)-3 phosphorylation levels increased. We found that there was a transient increase in the levels of P21(cip1), which inhibited the HI kinase activity of Cdk2. Cdk2 activity and H1(S)-3 phosphorylated levels increased after p21(cip1) levels declined. Our studies suggest that persistent activation of the Ras-MAPK signal transduction pathway in oncogene-transformed cells results in deregulated activity of kinases phosphorylating H3 and H1(S)-3 associated with transcribed genes. The chromatin remodelling actions of these modified histones may result in aberrant gene expression.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada		Davie, JR (corresponding author), Manitoba Inst Cell Biol, 675 McDeermot Ave, Winnipeg, MB R3E 0V9, Canada.	Davie@cc.umanitoba.ca		Davie, James/0000-0002-0420-6888				Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; HALIOTIS T, 1990, INT J CANCER, V45, P1177, DOI 10.1002/ijc.2910450631; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; KRAEMER PM, 1993, EXP CELL RES, V207, P206, DOI 10.1006/excr.1993.1183; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; LAITINEN J, 1995, J CELL BIOCHEM, V57, P1, DOI 10.1002/jcb.240570102; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LU MJ, 1994, CHROMOSOMA, V103, P111; Maharizi M, 1999, J OPTOELECTRON ADV M, V1, P65; MELLO MLS, 1994, ANAL QUANT CYTOL, V16, P113; Parseghian MH, 2000, CHROMOSOME RES, V8, P405, DOI 10.1023/A:1009262819961; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; Paulson JR, 1996, J CELL SCI, V109, P1437; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Strelkov IS, 2002, CANCER RES, V62, P75; TAN KB, 1982, J BIOL CHEM, V257, P5337; Taylor WR, 1995, FEBS LETT, V377, P51, DOI 10.1016/0014-5793(95)01314-8; TUCK AB, 1991, J NATL CANCER I, V83, P485; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247	29	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8397	8403		10.1038/sj.onc.1206029	http://dx.doi.org/10.1038/sj.onc.1206029			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466960				2022-12-25	WOS:000179480100003
J	Flamant, M; Tharaux, PL; Placier, S; Henrion, D; Coffman, T; Chatziantoniou, C; Dussaule, JC				Flamant, M; Tharaux, PL; Placier, S; Henrion, D; Coffman, T; Chatziantoniou, C; Dussaule, JC			Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice	FASEB JOURNAL			English	Article						EGF receptor; MAP kinase; fibrosis; vasoconstriction	ACTIVATED PROTEIN-KINASE; ANGIOTENSIN-II; EGF RECEPTOR; HYPERTENSIVE-RATS; COLLAGEN GENE; MITOGEN; INHIBITION; EXPRESSION; HYPERTROPHY; ANTAGONIST	Vascular remodeling and rearrangement of the extracellular matrix formation are among the major adaptive mechanisms in response to a chronic blood pressure increase. Vasoactive peptides, such as endothelin, participate in hypertension-associated vascular fibrosis by stimulating collagen I formation and increasing contractility of arterial wall. In the present study, we tested the hypothesis that activation of the epidermal growth factor (EGF) receptor pathway mediates these events. Experiments were performed in transgenic mice harboring the luciferase gene under the control of the collagen I-alpha2 chain promoter. Endothelin induced a rapid phosphorylation of the mitogen-activated protein kinase (MAPK)/ERK and increased collagen I gene activity in freshly isolated aortas. This effect of endothelin was totally inhibited by an endothelin receptor antagonist, an EGF receptor phosphorylation inhibitor, and a blocker of the MAPK/ERK cascade. In parallel experiments, inhibition of EGF receptor phosphorylation decreased the endothelin-induced pressor effect in isolated aortic rings and in anesthetized animals in vivo. In addition, the endothelin-induced increase of blood pressure was blunted in the waved-2 mice, a strain expressing functionally impaired EGF receptors. Our results provide the first evidence that the EGF receptor mediates at least two of the major actions of endothelin in the vascular tissue: contractility and fibrogenesis.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Hop Lariboisiere, INSERM, U541, F-75010 Paris, France; VA Med Ctr, Div Nephrol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Nephrol, Durham, NC 27710 USA; CHU St Antoine, Serv Physiol, AP HP, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Duke University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Dussaule, JC (corresponding author), INSERM, U489, F-75020 Paris, France.	jean-claude.dussaule@sat.ap-hop-paris.fr	Henrion, Daniel/J-8141-2015; Tharaux, Pierre-Louis/A-9155-2009; Chatziantoniou, Christos/L-2501-2016; Henrion, Daniel/AAK-1995-2021; Henrion, Daniel/N-7023-2015	Henrion, Daniel/0000-0003-1094-0285; Tharaux, Pierre-Louis/0000-0002-6062-5905; Henrion, Daniel/0000-0003-1094-0285; Henrion, Daniel/0000-0003-1094-0285				Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BERK BC, 1985, J CLIN INVEST, V75, P1083, DOI 10.1172/JCI111772; Boffa JJ, 1999, CIRCULATION, V100, P1901, DOI 10.1161/01.CIR.100.18.1901; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Bouriquet N, 1996, HYPERTENSION, V27, P382, DOI 10.1161/01.HYP.27.3.382; Brilla CG, 2000, CIRCULATION, V102, P1388, DOI 10.1161/01.CIR.102.12.1388; Buist A, 1998, BIOCHEM BIOPH RES CO, V251, P6, DOI 10.1006/bbrc.1998.9405; Chatziantoniou C, 1998, J CLIN INVEST, V101, P2780, DOI 10.1172/JCI2132; CHUA BHL, 1992, AM J PHYSIOL, V262, pE412, DOI 10.1152/ajpendo.1992.262.4.E412; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dussaule JC, 2000, J AM SOC NEPHROL, V11, pS124; Fakhouri F, 2001, J AM SOC NEPHROL, V12, P2701, DOI 10.1681/ASN.V12122701; Florian JA, 2001, AM J PHYSIOL-REG I, V281, pR878, DOI 10.1152/ajpregu.2001.281.3.R878; Florian JA, 1999, AM J PHYSIOL-HEART C, V276, pH976, DOI 10.1152/ajpheart.1999.276.3.H976; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Guo X, 1996, Hypertens Res, V19, P23, DOI 10.1291/hypres.19.23; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; Hocher B, 1997, J CLIN INVEST, V99, P1380, DOI 10.1172/JCI119297; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; IWASAKI H, J CARDIOVASC PHAR S1, V31, pS182; Kodama H, 2002, J MOL CELL CARDIOL, V34, P139, DOI 10.1006/jmcc.2001.1496; Kubo T, 1998, EUR J PHARMACOL, V347, P337, DOI 10.1016/S0014-2999(98)00111-3; LI JS, 1994, HYPERTENSION, V24, P183, DOI 10.1161/01.HYP.24.2.183; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Moreau P, 1997, CIRCULATION, V96, P1593, DOI 10.1161/01.CIR.96.5.1593; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; NAKAMURA T, 1995, KIDNEY INT, V47, P481, DOI 10.1038/ki.1995.61; Northcott C, 2001, HYPERTENSION, V38, P1337, DOI 10.1161/hy1201.096815; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RIPPETOE PE, 1989, AM REV RESPIR DIS, V140, P821, DOI 10.1164/ajrccm/140.3.821; RIVZI M, 1997, J MOL CELL CARDIOL, V29, P1779; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; Takemoto M, 1997, HYPERTENSION, V30, P1621, DOI 10.1161/01.HYP.30.6.1621; Tharaux PL, 2000, HYPERTENSION, V36, P330, DOI 10.1161/01.HYP.36.3.330; WANG Y, 1992, BIOCHEM J, V15, P587; WEBER KT, 1989, J AM COLL CARDIOL, V13, P1637, DOI 10.1016/0735-1097(89)90360-4	37	73	77	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					327	+		10.1096/fj.02-0115fje	http://dx.doi.org/10.1096/fj.02-0115fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475899				2022-12-25	WOS:000180574300026
J	Drobna, Z; Jaspers, I; Thomas, DJ; Styblo, M				Drobna, Z; Jaspers, I; Thomas, DJ; Styblo, M			Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals	FASEB JOURNAL			English	Article						arsenic; methylation; ERK; JNK; cancer	SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; MONOMETHYLARSONOUS ACID MMA(III); DNA-BINDING; IN-VITRO; C-JUN; PROTEIN EXPRESSION; GENE-EXPRESSION; TRIVALENT; PHOSPHORYLATION	Chronic exposures to inorganic arsenic (iAs) have been linked to increased incidences of various cancers, including cancer of the urinary bladder. Mechanisms by which iAs promotes cancer may include stimulation of activator protein-1 (AP-1) DNA binding through increased expression and/or phosphorylation of the AP-1 constituents. However, the role of methylated metabolites of iAs in AP-1 activation has not been thoroughly examined. In this study, we show that short-time exposures to 0.1-5 muM arsenite (iAs(III)) or the methylated trivalent arsenicals methylarsine oxide ((MAsO)-O-III), or iododimethylarsine ((DMAsI)-I-III) induce phosphorylation of c-Jun and increase AP-1 DNA binding activity in human bladder epithelial cells. (DMAsI)-I-III and especially (MAsO)-O-III are considerably more potent than iAs(III) as inducers of c-Jun phosphorylation and AP-1 activation. Phosphorylated c-Jun, JunB, JunD, and Fra-1, but not c-Fos, FosB, or ATF-2, are detected in the AP-1-DNA binding complex in cells exposed to trivalent arsenicals. In cells transiently transfected with an AP-1-dependent promoter-reporter construct, (MAsO)-O-III was more potent than iAs(III) in inducing the AP-1-dependent gene transcription. Exposures to trivalent arsenicals induce phosphorylation of extracellular signal-regulated kinase (ERK), but not c-Jun N-terminal kinases or p38 kinases. These results indicate that an ERK-dependent signal transduction pathway is at least partially responsible for c-Jun phosphorylation and AP-1 activation in UROtsa cells exposed to inorganic or methylated trivalent arsenicals.	Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; US EPA, Pharmacokinet Branch, Expt Toxicol Div, Natl Hlth & Environm Effects Res Lan,Off Res & De, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; United States Environmental Protection Agency	Styblo, M (corresponding author), Univ N Carolina, Dept Pediat, CB 7220,535 Burnett Womack Clin Sci Bldg, Chapel Hill, NC 27599 USA.	styblo@med.unc.edu	Jaspers, Ilona/AAZ-5035-2020					ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; [Anonymous], 1987, IARC MON EV CARC S7, V1-42, P100; Aposhian HV, 2000, CHEM RES TOXICOL, V13, P693, DOI 10.1021/tx000114o; Aposhian HV, 1997, ANNU REV PHARMACOL, V37, P397, DOI 10.1146/annurev.pharmtox.37.1.397; Barchowsky A, 1996, FREE RADICAL BIO MED, V21, P783, DOI 10.1016/0891-5849(96)00174-8; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; BATES MN, 1992, AM J EPIDEMIOL, V135, P462, DOI 10.1093/oxfordjournals.aje.a116313; Burleson FG, 1996, RES COMMUN MOL PATH, V93, P131; CARMICHAEL J, 1987, CANCER RES, V47, P936; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chung YW, 2002, BIOCHEM BIOPH RES CO, V293, P1248; Cullen W.R., 1989, APPL ORGANOMET CHEM, V3, P71; CULLEN WR, 1984, J INORG BIOCHEM, V21, P179, DOI 10.1016/0162-0134(84)83002-0; Del Razo LM, 2001, TOXICOL APPL PHARM, V174, P282, DOI 10.1006/taap.2001.9226; *ENV PROT AG, 1988, RISK ASS FOR SPEC RE; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GRUDA MC, 1994, ONCOGENE, V9, P2537; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Irgolic Kurt J., 1994, P51; Jaspers I, 1999, J BIOL CHEM, V274, P31025, DOI 10.1074/jbc.274.43.31025; Kaltreider RC, 1999, MOL CARCINOGEN, V25, P219; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kitchin KT, 2001, TOXICOL APPL PHARM, V172, P249, DOI 10.1006/taap.2001.9157; Le XC, 2000, ANAL CHEM, V72, P5172, DOI 10.1021/ac000527u; Le XC, 2000, ENVIRON HEALTH PERSP, V108, P1015, DOI 10.2307/3434951; Lin S, 1999, CHEM RES TOXICOL, V12, P924, DOI 10.1021/tx9900775; Lin S, 2002, J BIOL CHEM, V277, P10795, DOI 10.1074/jbc.M110246200; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Mandal BK, 2001, CHEM RES TOXICOL, V14, P371, DOI 10.1021/tx000246h; Mass MJ, 2001, CHEM RES TOXICOL, V14, P355, DOI 10.1021/tx000251l; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Petrick JS, 2000, TOXICOL APPL PHARM, V163, P203, DOI 10.1006/taap.1999.8872; Petrick JS, 2001, CHEM RES TOXICOL, V14, P651, DOI 10.1021/tx000264z; PETZOLDT JL, 1994, UROL RES, V22, P67, DOI 10.1007/BF00310994; Petzoldt JL, 1995, UROL RES, V23, P377, DOI 10.1007/BF00698738; Porter AC, 1999, ONCOGENE, V18, P7794, DOI 10.1038/sj.onc.1203214; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; Salazar AM, 1997, MUTAT RES-FUND MOL M, V381, P259, DOI 10.1016/S0027-5107(97)00207-8; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simeonova Petia P., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P281; Simeonova PP, 2002, J BIOL CHEM, V277, P2945, DOI 10.1074/jbc.M109136200; Simeonova PP, 2001, TOXICOL SCI, V60, P279, DOI 10.1093/toxsci/60.2.279; Simeonova PP, 2000, CANCER RES, V60, P3445; Styblo M, 1995, TOXICOL APPL PHARM, V135, P172, DOI 10.1006/taap.1995.1220; Styblo M, 1997, CHEM RES TOXICOL, V10, P27, DOI 10.1021/tx960139g; Styblo M, 2000, ARCH TOXICOL, V74, P289, DOI 10.1007/s002040000134; Styblo M, 1999, ARSENIC EXPOSURE AND HEALTH EFFECTS, P311, DOI 10.1016/B978-008043648-7/50035-2; Thomas DJ, 2001, TOXICOL APPL PHARM, V176, P127, DOI 10.1006/taap.2001.9258; Trouba KJ, 2000, TOXICOL APPL PHARM, V164, P161, DOI 10.1006/taap.1999.8873; VAHTER M, 1994, APPL ORGANOMET CHEM, V8, P175, DOI 10.1002/aoc.590080304; Vahter Marie, 1999, Science Progress, V82, P69; Vega L, 2001, TOXICOL APPL PHARM, V172, P225, DOI 10.1006/taap.2001.9152; Vogt BL, 2001, MUTAT RES-FUND MOL M, V478, P159, DOI 10.1016/S0027-5107(01)00137-3; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wiencke JK, 1997, MUTAT RES-REV MUTAT, V386, P335, DOI 10.1016/S1383-5742(97)00016-1; Wijeweera JB, 2001, TOXICOL SCI, V61, P283, DOI 10.1093/toxsci/61.2.283; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	59	69	71	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					67	+		10.1096/fj.02-0287fje	http://dx.doi.org/10.1096/fj.02-0287fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475910				2022-12-25	WOS:000180218500015
J	Nucifora, FC; Ellerby, LM; Wellington, CL; Wood, JD; Herring, WJ; Sawa, A; Hayden, MR; Dawson, VL; Dawson, TM; Ross, CA				Nucifora, FC; Ellerby, LM; Wellington, CL; Wood, JD; Herring, WJ; Sawa, A; Hayden, MR; Dawson, VL; Dawson, TM; Ross, CA			Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; NEURONAL INTRANUCLEAR INCLUSIONS; N-TERMINAL FRAGMENTS; HUNTINGTONS-DISEASE; MUTANT HUNTINGTIN; GENE-PRODUCT; TRIPLET-REPEAT; CAG REPEAT; DRPLA PROTEIN; MOUSE MODEL	Dentatorubral and pallidoluysian atrophy (DRPLA) is an autosomal dominant neurodegenerative disorder similar to Huntington's disease, with clinical manifestations including chorea, incoordination, ataxia, and dementia. It is caused by an expansion of a CAG trinucleotide repeat encoding polyglutamine in the atrophin-1 gene. Both patients and DRPLA transgenic mice have nuclear accumulation of atrophin-1, especially an similar to120 kDa fragment, which appears to represent a cleavage product. We now show that this is an N-terminal fragment that does not correspond to the previously described caspase-3 fragment, or any other known caspase cleavage product. The atrophin-1 sequence contains a putative nuclear localization signal in the N terminus of the protein and a putative nuclear export signal in the C terminus. We have tested the hypothesis that endogenous localization signals are functional in atrophin-1, and that nuclear localization and proteolytic cleavage contribute to atrophin-1 cell toxicity. In transient cell transfection experiments using a neuroblastoma cell line, full-length atrophin-1 with 26 (normal) or 65 (expanded) glutamines localized to both nucleus and cytoplasm, with no significant difference in toxicity between the normal and mutant proteins. A construct with 65 glutamine repeats encoding an N-terminal fragment (which removes an NES) of atrophin-1 similar in size to the truncation product in DRPLA patient tissue, showed increased nuclear labeling, and an increase in cellular toxicity, compared with a similar fragment with 26 glutamines. Full-length atrophin-1 with 65 polyglutamine repeats and mutations inactivating the NES also yielded increased nuclear localization and increased toxicity. These data suggest that truncation enhances cellular toxicity of the mutant protein, and that the NES is a relevant region deleted during truncation. Furthermore, mutating the NLS in the truncated protein shifted atrophin-1 more to the cytoplasm and eliminated the increased toxicity, consistent with the idea that nuclear localization enhances toxicity. In none of the experiments were inclusions visible in the nucleus or cytoplasm suggesting that inclusion formation is unrelated to cell death. These data indicate that truncation of atrophin-1 may alter its ability to shuttle between the nucleus and cytoplasm, leading to abnormal nuclear interactions and cell toxicity.	Johns Hopkins Univ, Sch Med, Div Neurobiol, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Buck Inst Age Res, Novato, CA 94945 USA; Univ British Columbia, Ctr Mol Med & Therapeut, Dept Med Genet, Vancouver, BC V5H 4H4, Canada; Womens & Childrens Hosp, Vancouver, BC V5H 4H4, Canada; Univ Sheffield, Sch Med, Acad Neurol Unit, Sheffield S10 2RX, S Yorkshire, England	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Buck Institute for Research on Aging; University of British Columbia; University of Sheffield	Ross, CA (corresponding author), Ross Res Bldg,Rm 618,720 Rutland Ave, Baltimore, MD 21205 USA.	caross@jhu.edu	Wood, Jonathan D/A-5060-2009; NUCIFORA, FREDERICK/X-2364-2019; Hayden, Michael R/D-8581-2011; Dawson, Valina/Y-9757-2019; Ross, Christopher A/H-8395-2013	Hayden, Michael R/0000-0001-5159-1419; Dawson, Valina/0000-0002-2915-3970	NINDS NIH HHS [NS16375, NS38144, NS34172, NS37090] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016375, P01NS016375, R01NS037090, R01NS038144, R01NS034172] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Becher MW, 1998, MOVEMENT DISORD, V13, P852; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Davies SW, 1998, LANCET, V351, P131, DOI 10.1016/S0140-6736(97)08360-8; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Dyer RB, 2001, NAT GENET, V29, P270, DOI 10.1038/ng745; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Ellis RJ, 2002, NATURE, V416, P483, DOI 10.1038/416483a; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Hackam AS, 1999, HUM MOL GENET, V8, P25, DOI 10.1093/hmg/8.1.25; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; HOUSMAN D, 1995, NAT GENET, V10, P3, DOI 10.1038/ng0595-3; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; IKEUCHI T, 1995, ANN NEUROL, V37, P769, DOI 10.1002/ana.410370610; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Knight SP, 1997, J NEUROL SCI, V146, P19, DOI 10.1016/S0022-510X(96)00266-3; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KOMURE O, 1995, NEUROLOGY, V45, P143, DOI 10.1212/WNL.45.1.143; Li H, 2000, NAT GENET, V25, P385, DOI 10.1038/78054; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Luthi-Carter R, 2002, HUM MOL GENET, V11, P1927, DOI 10.1093/hmg/11.17.1927; MacDonald ME, 1996, CURR OPIN NEUROBIOL, V6, P638, DOI 10.1016/S0959-4388(96)80097-3; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Margolis RL, 1996, MOL BRAIN RES, V36, P219, DOI 10.1016/0169-328X(95)00241-J; Mende-Mueller LM, 2001, J NEUROSCI, V21, P1830, DOI 10.1523/JNEUROSCI.21-06-01830.2001; Miyashita T, 1997, J BIOL CHEM, V272, P29238, DOI 10.1074/jbc.272.46.29238; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NAITO H, 1982, NEUROLOGY, V32, P798, DOI 10.1212/WNL.32.8.798; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Okamura-Oho Y, 1999, HUM MOL GENET, V8, P947, DOI 10.1093/hmg/8.6.947; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; Ross CA, 1997, MEDICINE, V76, P305, DOI 10.1097/00005792-199709000-00001; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Sato A, 1999, HUM MOL GENET, V8, P997, DOI 10.1093/hmg/8.6.997; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Shahbazian MD, 2001, NEUROBIOL DIS, V8, P974, DOI 10.1006/nbdi.2001.0444; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SMITH JK, 1958, NEUROLOGY, V8, P205, DOI 10.1212/WNL.8.3.205; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Sun B, 2002, NEUROBIOL DIS, V11, P111, DOI 10.1006/nbdi.2002.0539; TANAKA Y, 2001, SOC NEUR ABSTR; Waerner T, 2001, CELL GROWTH DIFFER, V12, P201; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wheeler VC, 1999, HUM MOL GENET, V8, P115, DOI 10.1093/hmg/8.1.115; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Yamada M, 2001, AM J PATHOL, V159, P1785, DOI 10.1016/S0002-9440(10)63025-8; Yamada M, 2001, ANN NEUROL, V49, P14, DOI 10.1002/1531-8249(200101)49:1<14::AID-ANA5>3.0.CO;2-X; YAZAWA I, 1995, NAT GENET, V10, P99, DOI 10.1038/ng0595-99; Yazawa I, 1997, NEUROSCI LETT, V225, P53, DOI 10.1016/S0304-3940(97)00189-4; Yazawa I, 2000, BIOCHEM J, V351, P587, DOI 10.1042/0264-6021:3510587; Zhang S, 2002, CELL, V108, P45, DOI 10.1016/S0092-8674(01)00630-4; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	70	64	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13047	13055		10.1074/jbc.M211224200	http://dx.doi.org/10.1074/jbc.M211224200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12464607	hybrid			2022-12-25	WOS:000182189500059
J	Grober, J; Lucas, S; Sorhede-Winzell, M; Zaghini, I; Mairal, A; Contreras, JA; Besnard, P; Holm, C; Langin, D				Grober, J; Lucas, S; Sorhede-Winzell, M; Zaghini, I; Mairal, A; Contreras, JA; Besnard, P; Holm, C; Langin, D			Hormone-sensitive lipase is a cholesterol esterase of the intestinal mucosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT-STIMULATED LIPASE; DIETARY-CHOLESTEROL; DEPENDENT LIPASE; GENE; EXPRESSION; SECRETION; IDENTIFICATION; PROTEIN; ACETYLCHOLINESTERASE; PHOSPHORYLATION	The identity of the enzymes responsible for lipase and cholesterol esterase activities in the small intestinal mucosa is not known. Because hormone-sensitive lipase (HSL) catalyzes the hydrolysis of acylglycerols and cholesteryl esters, we sought to determine whether HSL could be involved. HSL mRNA and protein were detected in all segments of the small intestine by Northern and Western blot analyses, respectively. Immunocytochemistry experiments revealed that HSL was expressed in the differentiated enterocytes of the villi and was absent in the undifferentiated cells of the crypt. Diacylglycerol lipase and cholesterol esterase activities were found in the different segments. Analysis of gut from HSL-null mice showed that diacylglycerol lipase activity was unchanged in the duodenum and reduced in jejunum. Neutral cholesterol esterase activity was totally abolished in duodenum, jejunum, and ileum of HSL-null mice. Analysis of HSL mRNA structure showed two types of transcripts expressed in equal amounts with alternative 5'-ends transcribed from two exons. This work demonstrates that HSL is expressed in the mucosa of the small intestine. The results also reveal that the enzyme participates in acylglycerol hydrolysis in jejunal enterocytes and cholesteryl ester hydrolysis throughout the small intestine.	Lund Univ, Dept Cell & Mol Biol, Sect Mol Signaling, S-22184 Lund, Sweden; Univ Toulouse 3, Ctr Hosp Univ, Inst Luis Bugnard, INSERM,Unite Rech Obes, F-31403 Toulouse, France; Univ Bourgogne 1, Ecole Natl Super Biol Appl Nutr & Alimentat, Lab Physiol Nutr, FRE2328 CNRS, F-21000 Dijon, France	Lund University; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Bourgogne	Langin, D (corresponding author), CHU Rangueil, INSERM U317, Batiment L3, F-31403 Toulouse 4, France.	Dominique.Langin@toulouse.inserm.fr		Langin, Dominique/0000-0002-2669-7825; LUCAS, Stephanie/0000-0001-7530-7486				Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Blaise R, 2001, J BIOL CHEM, V276, P5109, DOI 10.1074/jbc.M009103200; Bruneau N, 1998, J CELL SCI, V111, P2665; Bruneau N, 2001, EXP CELL RES, V271, P94, DOI 10.1006/excr.2001.5361; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; DELEON MP, 1985, DIGEST DIS SCI, V30, P1053, DOI 10.1007/BF01315603; Dolinsky VW, 2001, BBA-MOL CELL BIOL L, V1532, P162, DOI 10.1016/S1388-1981(01)00133-0; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; FIELD FJ, 1984, J LIPID RES, V25, P389; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Grober J, 1997, BIOCHEM J, V328, P453, DOI 10.1042/bj3280453; HEMILA H, 1994, BBA-LIPID LIPID MET, V1210, P249, DOI 10.1016/0005-2760(94)90129-5; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; Holm C, 2000, METH MOL B, V155, P97; Holst LS, 1996, GENOMICS, V35, P441, DOI 10.1006/geno.1996.0383; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; LANGIN D, 1993, TRENDS BIOCHEM SCI, V18, P466, DOI 10.1016/0968-0004(93)90007-A; Laurin NN, 2000, MAMM GENOME, V11, P972, DOI 10.1007/s003350010185; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; MAHAN JT, 2001, AM J PHYSIOL, V280, pF1187; Mairal A, 2002, BIOCHEM BIOPH RES CO, V291, P286, DOI 10.1006/bbrc.2002.6427; MANSBACH CM, 1985, AM J PHYSIOL, V249, pG642, DOI 10.1152/ajpgi.1985.249.5.G642; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; RAO RH, 1993, ARCH BIOCHEM BIOPHYS, V304, P483, DOI 10.1006/abbi.1993.1379; RAO RH, 1990, BIOCHIM BIOPHYS ACTA, V1043, P273, DOI 10.1016/0005-2760(90)90027-U; REMAURY A, 1995, BIOCHEM BIOPH RES CO, V207, P175, DOI 10.1006/bbrc.1995.1169; SABESIN SM, 1977, J LIPID RES, V18, P496; Shen H, 2001, ADV DRUG DELIVER REV, V50, pS103, DOI 10.1016/S0169-409X(01)00181-8; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 2001, J BIOL CHEM, V276, P49443, DOI 10.1074/jbc.M104095200; Smih F, 2002, DIABETES, V51, P293, DOI 10.2337/diabetes.51.2.293; Talts JF, 1999, METH MOL B, V129, P153; TIPTON AD, 1989, AM J PHYSIOL, V257, pG871, DOI 10.1152/ajpgi.1989.257.6.G871; Wei YY, 1999, NAT STRUCT BIOL, V6, P340; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	42	48	49	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6510	6515		10.1074/jbc.M208513200	http://dx.doi.org/10.1074/jbc.M208513200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482847	hybrid			2022-12-25	WOS:000181129400127
J	Mahabeleshwar, GH; Kundu, GC				Mahabeleshwar, GH; Kundu, GC			Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; MATRIX-METALLOPROTEINASE; HEMATOPOIETIC-CELLS; EPITHELIAL-CELLS; UP-REGULATION; GROWTH; REQUIREMENT; INDUCTION; RECEPTOR; SUBUNIT	Tumor growth and metastasis are multifaceted processes that mainly involve cell adhesion, proteolytic degradation of the extracellular matrix, and cell migration. Syk is a member of a tyrosine kinase family that is expressed mostly in hematopoietic cells. Syk is expressed in cell lines of epithelial origin, but its function in these cells remains unknown. Here we report that Syk is expressed in MCF-7 cells but not in MDA-MB-231 cells. The overexpression of wild type Syk kinase but not kinase-negative Syk suppressed cell motility and inhibited the activation of phosphatidylinositol (PI) W-kinase in MDA-MB-231 cells. In contrast, when Syk-specific antisense S-oligonucleotide but not the sense S-oligonucleotide was transfected to MCF-7 cells the level of PI W-kinase activity as well as cell motility were increased. The MDA-MB-231 cells transfected with wild type Syk cDNA followed by treatment with piceatannol, a Syk inhibitor, enhanced cell motility and PI W-kinase activity. Pervanadate, a phosphotyrosine phosphatase inhibitor, induced PI W-kinase activity and stimulated the interaction between the inhibitor of nuclear factor kappaBalpha (IkappaBalpha) and the p85alpha domain of PI 3'-kinase through tyrosine phosphorylation of the IkappaBalpha, which ultimately resulted in nuclear factor kappaB (NFkappaB) activation. Pervanadate had no effect on the activation of Syk in these cells. However, Syk suppressed the NFkappa3 transcriptional activation and interaction between IkappaBalpha and PI W-kinase by inhibiting the tyrosine phosphorylation of IkappaBalpha. Syk, PI 3'-kinase inhibitors, and NFkappaB inhibitory peptide inhibited urokinase type plasminogen activator WPM secretion and cell motility in these cells. To our knowledge, this is the first report that Syk suppresses the cell motility and inhibits the PI T-kinase activity and uPA secretion by blocking NFkappaB activity through tyrosine phosphorylation of IkappaBalpha. These data further demonstrate a functional molecular link between Syk-regulated PI W-kinase activity and NFkappaB-mediated uPA secretion, and all of these ultimately control the motility of breast cancer cells.	NCCS, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), NCCS, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; FLUCK M, 1995, BIOCHEM BIOPH RES CO, V213, P273, DOI 10.1006/bbrc.1995.2126; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; LIOTTA LA, 1992, CELL, V71, P411; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; RIZZO MT, 1994, CANCER RES, V54, P2611; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SHEELA S, 1982, CARCINOGENESIS, V3, P363, DOI 10.1093/carcin/3.4.363; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S	39	62	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6209	6221		10.1074/jbc.M208905200	http://dx.doi.org/10.1074/jbc.M208905200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12477728	hybrid			2022-12-25	WOS:000181129400091
J	Tiwari, A; Hayward, LJ				Tiwari, A; Hayward, LJ			Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOTOR-NEURONS; CU,ZN-SUPEROXIDE DISMUTASE; SUBUNIT STRUCTURE; PROTEIN; SOD1; MICE; MUTATIONS; DEGENERATION; STABILITY	We observed that 14 biologically metallated mutants of copper/zinc superoxide dismutase (SOD1) associated with familial amyotrophic lateral sclerosis all exhibited aberrantly accelerated mobility during partially denaturing PAGE and increased sensitivity to proteolytic digestion compared with wild type SOD1. Decreased metal binding site occupancy and exposure to the disulfide-reducing agents dithiothreitol, Tris(2-carboxyethyl)phosphine (TCEP), or reduced glutathione increased the fraction of anomalously migrating mutant SOD1 proteins. Furthermore, the incubation of mutant SOD1s with TCEP increased the accessibility to iodoacetamide of cysteine residues that normally participate in the formation of the intrasubunit disulfide bond (Cys-57 to Cys-146) or are buried within the core of the beta-barrel (Cys-6). SOD1 enzymes in spinal cord lysates from G85R and G93A mutant but not wild type SOD1 transgenic mice also exhibited abnormal vulnerability to TCEP, which exposed normally inaccessible cysteine residues to modification by maleimide conjugated to polyethylene glycol. These results implicate SOD1 destabilization under cellular disulfide-reducing conditions at physiological pH and temperature as a shared property that may be relevant to amyotrophic lateral sclerosis mutant neurotoxicity.	Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Hayward, LJ (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, 55 Lake Ave N, Worcester, MA 01655 USA.		Tiwari, Ashutosh/A-7458-2008	Tiwari, Ashutosh/0000-0001-7373-349X; Hayward, Lawrence/0000-0003-0579-0358	NINDS NIH HHS [R01 NS44170, R01 NS044170] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044170] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERNETHY JL, 1974, J BIOL CHEM, V249, P7339; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; Banci L, 1999, J BIOL INORG CHEM, V4, P795, DOI 10.1007/s007750050353; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; Banci L, 2002, EUR J BIOCHEM, V269, P1905, DOI 10.1046/j.1432-1033.2002.02840.x; Battistoni A, 1999, FEBS LETT, V443, P313, DOI 10.1016/S0014-5793(98)01725-6; Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BEYER WF, 1987, J BIOL CHEM, V262, P11182; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Brown RH, 1995, CURR OPIN NEUROBIOL, V5, P841, DOI 10.1016/0959-4388(95)80114-6; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DalCanto MC, 1997, ACTA NEUROPATHOL, V93, P537; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FISHER CL, 1994, PROTEINS, V19, P24, DOI 10.1002/prot.340190105; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Goto JJ, 1998, J BIOL CHEM, V273, P30104, DOI 10.1074/jbc.273.46.30104; Goto JJ, 2000, J BIOL CHEM, V275, P1007, DOI 10.1074/jbc.275.2.1007; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Jaarsma D, 2000, NEUROBIOL DIS, V7, P623, DOI 10.1006/nbdi.2000.0299; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; KEELE BB, 1971, J BIOL CHEM, V246, P2875; Kong JM, 1998, J NEUROSCI, V18, P3241; Krezel A, 2001, J INORG BIOCHEM, V84, P77, DOI 10.1016/S0162-0134(00)00212-9; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lapko VN, 2000, J MASS SPECTROM, V35, P572, DOI 10.1002/(SICI)1096-9888(200004)35:4<572::AID-JMS971>3.0.CO;2-2; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; Makmura L, 2001, ANTIOXID REDOX SIGN, V3, P1105, DOI 10.1089/152308601317203611; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P5055, DOI 10.1021/bi00590a005; Oeda T, 2001, HUM MOL GENET, V10, P2013, DOI 10.1093/hmg/10.19.2013; Ogawa Y, 1997, BIOCHEM BIOPH RES CO, V241, P251, DOI 10.1006/bbrc.1997.7804; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Schinina ME, 1996, EUR J BIOCHEM, V237, P433, DOI 10.1111/j.1432-1033.1996.0433k.x; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; Williams RJP, 2000, COORDIN CHEM REV, V200, P247, DOI 10.1016/S0010-8545(00)00324-6; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yen TY, 2002, J MASS SPECTROM, V37, P15, DOI 10.1002/jms.241; Zu JS, 1997, NEUROGENETICS, V1, P65, DOI 10.1007/s100480050010	64	176	179	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5984	5992		10.1074/jbc.M210419200	http://dx.doi.org/10.1074/jbc.M210419200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12458194	hybrid			2022-12-25	WOS:000181129400063
J	Parolini, C; Chiesa, G; Zhu, YW; Forte, T; Caligari, S; Gianazza, E; Sacco, MG; Sirtori, CR; Rubin, EM				Parolini, C; Chiesa, G; Zhu, YW; Forte, T; Caligari, S; Gianazza, E; Sacco, MG; Sirtori, CR; Rubin, EM			Targeted replacement of mouse apolipoprotein A-I with human ApoA-I or the mutant ApoA-l(Milano) - Evidence of APOA-I-M impaired hepatic secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; CORONARY-ARTERY DISEASE; LOW HDL CHOLESTEROL; TRANSGENIC MICE; INVIVO METABOLISM; ANIMAL-MODEL; VA-HIT; PLASMA; ATHEROSCLEROSIS	Despite a pro-atherogenic profile, individuals carrying the molecular variant (R173C) of apolipoprotein (apo)A-I, named apoA-I-Milano (apoA-I-M), appear to be at reduced risk for cardiovascular disease. To develop an in vivo system to explore, in a controlled manner, the effects of apoA-I-M on lipid metabolism, we have used the gene targeting technology, or "gene knock-in" (gene k-in), to replace the murine apoA-I gene with either human apoA-I or apoA-I-M genes in embryonic stem cells. As in human carriers, mice expressing apoA-I-M (A-I-M k-in) are characterized by low concentrations of the human apolipoprotein and reduced high density lipoprotein cholesterol levels, compared with A-I k-in animals. The aim of the present study was to investigate the basic mechanisms of hypoalphalipoproteinemia associated with the apoA-I-M mutation. ApoA-I and apoA-I-M mRNA expression, as assessed by Northern blot analysis and quantitative real time reverse transcription-PCR, did not exhibit significant differences in either liver or intestine. Moreover, human apolipoprotein synthesis rates were similar in the k-in lines. When the secretion rate of the human apoli-poproteins was assessed in cultured hepatocytes from the mouse lines, secretion from apoA-I-M-expressing cells was markedly reduced (42% for A-I-M k-in and 36% for A-I/A-I-M k-in mice) as compared with that of A-I k-in hepatocytes. These results provide the first evidence that the hypoalphalipoproteinemia in apoA-I-M human carriers may be partially explained by impaired apoA-I-M secretion.	Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; CNR, Ist Tecnol, I-20090 Milan, Italy; Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	University of Milan; Consiglio Nazionale delle Ricerche (CNR); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Parolini, C (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.		Sirtori, Cesare/F-4658-2012; Parolini, Cinzia/G-8984-2012; Chiesa, Giulia/G-8987-2012	Parolini, Cinzia/0000-0002-5699-0918; Chiesa, Giulia/0000-0001-5553-1210	NHLBI NIH HHS [HL55493, HL18574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055493, P01HL018574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ASSMANN G, 1993, CIRCULATION, V87, P28; AZROLAN N, 1995, J BIOL CHEM, V270, P19833, DOI 10.1074/jbc.270.34.19833; BADIMON JJ, 1992, CIRCULATION, V86, P86; Bielicki JK, 1997, J LIPID RES, V38, P2314; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Calabresi L, 1997, BIOCHEM BIOPH RES CO, V232, P345, DOI 10.1006/bbrc.1997.6286; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chiesa G, 1998, ATHEROSCLEROSIS, V136, P139, DOI 10.1016/S0021-9150(97)00195-0; Chiesa G, 2002, CIRC RES, V90, P974, DOI 10.1161/01.RES.0000018422.31717.EE; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cockerill GW, 2001, CIRCULATION, V103, P108; COLYVAS N, 1992, CIRCULATION, V85, P1286, DOI 10.1161/01.CIR.85.4.1286; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCESCHINI G, 1987, ARTERIOSCLEROSIS, V7, P426, DOI 10.1161/01.ATV.7.4.426; FRANCESCHINI G, 1990, BIOCHIM BIOPHYS ACTA, V1043, P1, DOI 10.1016/0005-2760(90)90102-4; Franceschini G, 1996, EUR J CLIN INVEST, V26, P733, DOI 10.1046/j.1365-2362.1996.2120536.x; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GHISELLI G, 1985, J BIOL CHEM, V260, P5662; GIANAZZA E, 1985, ELECTROPHORESIS, V6, P53, DOI 10.1002/elps.1150060113; GIANAZZA E, 2002, PROTEIN PROTOCOL HDB, P169; GORG A, 1987, ELECTROPHORESIS, V8, P122, DOI 10.1002/elps.1150080207; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; GUALANDRI V, 1985, AM J HUM GENET, V37, P1083; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAYEK T, 1993, J CLIN INVEST, V91, P1665, DOI 10.1172/JCI116375; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Kuivenhoven JA, 1997, ARTERIOSCL THROM VAS, V17, P560, DOI 10.1161/01.ATV.17.3.560; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez D, 1999, ENDOCRINOLOGY, V140, P3034, DOI 10.1210/en.140.7.3034; MarzalCasacuberta A, 1996, J BIOL CHEM, V271, P6720, DOI 10.1074/jbc.271.12.6720; McManus DC, 2001, J BIOL CHEM, V276, P21292, DOI 10.1074/jbc.M100463200; MIYAZAKI A, 1995, ARTERIOSCL THROM VAS, V15, P1882, DOI 10.1161/01.ATV.15.11.1882; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; Perez-Mendez O, 2000, ATHEROSCLEROSIS, V148, P317, DOI 10.1016/S0021-9150(99)00279-8; RADER DJ, 1992, J LIPID RES, V33, P755; RADER DJ, 1993, LANCET, V342, P1455, DOI 10.1016/0140-6736(93)92933-K; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; ROMA P, 1993, J CLIN INVEST, V91, P1445, DOI 10.1172/JCI116349; Rubins HB, 2001, CIRCULATION, V103, P2828; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; Sirtori CR, 2001, CIRCULATION, V103, P1949; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; Stein O, 1999, ATHEROSCLEROSIS, V144, P285, DOI 10.1016/S0021-9150(99)00065-9; TALMUD P, 1982, GENET EPIDEMIOL, V45, P161; TillyKiesi M, 1997, ARTERIOSCL THROM VAS, V17, P873, DOI 10.1161/01.ATV.17.5.873; WALSH A, 1989, J BIOL CHEM, V264, P6488; WEISGRABER KH, 1980, J CLIN INVEST, V66, P901, DOI 10.1172/JCI109957; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134	56	29	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4740	4746		10.1074/jbc.M207335200	http://dx.doi.org/10.1074/jbc.M207335200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12471038	hybrid, Green Published			2022-12-25	WOS:000180968900051
J	Schneider, P; Olson, D; Tardivel, A; Browning, B; Lugovskoy, A; Gong, DH; Dobles, M; Hertig, S; Hofmann, K; Van Vlijmen, H; Hsu, YM; Burkly, LC; Tschopp, J; Zheng, TS				Schneider, P; Olson, D; Tardivel, A; Browning, B; Lugovskoy, A; Gong, DH; Dobles, M; Hertig, S; Hofmann, K; Van Vlijmen, H; Hsu, YM; Burkly, LC; Tschopp, J; Zheng, TS			Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-RECEPTOR; DEATH DOMAIN; TUMORICIDAL ACTIVITY; FUNCTIONAL-ANALYSIS; CRYSTAL-STRUCTURE; DEFICIENT MICE; DECOY RECEPTOR; COMPLEX; OSTEOPROTEGERIN; PROTEINS	Tumor necrosis factor (TNF) ligand and receptor superfamily members play critical roles in diverse developmental and pathological settings. In search for novel TNF superfamily members, we identified a murine chromosomal locus that contains three new TNF receptor-related genes. Sequence alignments suggest that the ligand binding regions of these murine TNF receptor homologues, mTNFRH1, -2 and -3, are most homologous to those of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors. By using a number of in vitro ligand-receptor binding assays, we demonstrate that mTNFRH1 and -2, but not mTNFRH3, bind murine TRAIL, suggesting that they are indeed TRAIL receptors. This notion is further supported by our demonstration that both mTNFRH1:Fc and mTNFRH2:Fc fusion proteins inhibited mTRAIL-induced apoptosis of Jurkat cells. Unlike the only other known murine TRAIL receptor mTRAILR2, however, neither mTNFRH2 nor mTNFRH3 has a cytoplasmic region containing the well characterized death domain motif. Coupled with our observation that overexpression of mTNFRH1 and -2 in 293T cells neither induces apoptosis nor triggers NFkappaB activation, we propose that the mTnfrh1 and mTnfrh2 genes encode the first described murine decoy receptors for TRAIL, and we renamed them mDcTrailr1 and -r2, respectively. Interestingly, the overall sequence structures of mDcTRAILR1 and -R2 are quite distinct from those of the known human decoy TRAIL receptors, suggesting that the presence of TRAIL decoy receptors represents a more recent evolutionary event.	Biogen Inc, Dept Exploratory Sci, Cambridge, MA 02142 USA; Biogen Inc, Dept Struct Informat, Cambridge, MA 02142 USA; Biogen Inc, Dept Prot Chem, Cambridge, MA 02142 USA; Biogen Inc, Dept Transgen, Cambridge, MA 02142 USA; Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland; MEMOREC Stoffel GMBH, D-50829 Cologne, Germany	Biogen; Biogen; Biogen; Biogen; University of Lausanne	Zheng, TS (corresponding author), Biogen Inc, Dept Exploratory Sci, 12 Cambridge Ctr, Cambridge, MA 02142 USA.		Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083; Schneider, Pascal/0000-0003-0677-9409				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Engemann S, 2000, HUM MOL GENET, V9, P2691, DOI 10.1093/hmg/9.18.2691; Griffith TS, 1999, J IMMUNOL, V162, P2597; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; SALI A, 1995, MODELLER IMPLEMENTIN; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 2000, METHOD ENZYMOL, V322, P325; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; TAGUCHI R, 1984, J BIOCHEM-TOKYO, V96, P437, DOI 10.1093/oxfordjournals.jbchem.a134855; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Taylor PC, 2001, CURR OPIN RHEUMATOL, V13, P164, DOI 10.1097/00002281-200105000-00003; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; UDENFRIEND S, 1995, METHOD ENZYMOL, V250, P571; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wu GS, 1999, CANCER RES, V59, P2770	42	96	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5444	5454		10.1074/jbc.M210783200	http://dx.doi.org/10.1074/jbc.M210783200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466268	Green Published, hybrid			2022-12-25	WOS:000180968900137
J	Balciunas, D; Hallberg, M; Bjorklund, S; Ronne, H				Balciunas, D; Hallberg, M; Bjorklund, S; Ronne, H			Functional interactions within yeast mediator and evidence of differential subunit modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; PYRUVATE DECARBOXYLASE; CYC8-TUP1 COREPRESSOR; REPEAT DOMAIN; HOLOENZYME; RECRUITMENT; COMPLEX; GENES	It is possible to recruit RNA polymerase II to a target promoter and, thus, activate transcription by fusing Mediator subunits to a DNA binding domain. To investigate functional interactions within Mediator, we have tested such fusions of the lexA DNA binding domain to Med1, Med2, Gal11, Srb7, and Srb10 in wild type, med1, med2, gal11, sin4, srb8, srb10, and srb11 strains. We found that lexA-Med2 and lexA-Gal11 are strong activators that are independent of all Mediator subunits tested. lexA-Srb10 is a weak activator that depends on Srb8 and Srb11. lexA-Med1 and lexA-Srb7 are both cryptic activators that become active in the absence of Srb8, Srb10, Srb11, or Sin4. An unexpected finding was that lexA-VP16 differs from Gal4-vP16 in that it is independent of the activator binding Mediator module. Both lexA-Med1 and lexA-Srb7 are stably associated with Med4 and Med8, which suggests that they are incorporated into Mediator. Med4 and Med8 exist in two mobility forms that differ in their association with lexA-Med1 and lexA-Srb7. Within purified Mediator, Med4 is present as a phosphorylated lower mobility form. Taken together, these results suggest that assembly of Mediator is a multistep process that involves conversion of both Med4 and Med8 to their low mobility forms.	Swedish Univ Agr Sci, Dept Plant Biol, Uppsala Genet Ctr, S-75007 Uppsala, Sweden; Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Swedish University of Agricultural Sciences; Uppsala University; Umea University	Ronne, H (corresponding author), Swedish Univ Agr Sci, Dept Plant Biol, Uppsala Genet Ctr, Box 7080, S-75007 Uppsala, Sweden.		Balciunas, Darius/AAD-1420-2019	Ronne, Hans/0000-0002-1645-6091				Balciunas D, 1999, P NATL ACAD SCI USA, V96, P376, DOI 10.1073/pnas.96.2.376; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; Balciunas D, 1999, MOL GEN GENET, V262, P589; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bi EF, 1996, MOL CELL BIOL, V16, P5264; BJORKLUND S, 2002, IN PRESS ADV PROTEIN; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gaudreau L, 1999, P NATL ACAD SCI USA, V96, P2668, DOI 10.1073/pnas.96.6.2668; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; Gustafsson CM, 1998, J BIOL CHEM, V273, P30851, DOI 10.1074/jbc.273.47.30851; Han SJ, 1999, MOL CELL BIOL, V19, P979; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HOHMANN S, 1993, MOL GEN GENET, V241, P657, DOI 10.1007/BF00279908; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; KAMENS J, 1991, NEW BIOL, V3, P1005; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Lee M, 2000, GENETICS, V155, P1535; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Li Y, 1996, METHOD ENZYMOL, V273, P172; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; NONET ML, 1989, GENETICS, V123, P715; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ostling J, 1998, EUR J BIOCHEM, V252, P162, DOI 10.1046/j.1432-1327.1998.2520162.x; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMITT HD, 1983, MOL GEN GENET, V192, P247, DOI 10.1007/BF00327674; THOMAS BJ, 1989, CELL, V56, P4961; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; Yu YX, 1996, MOL CELL BIOL, V16, P5254	54	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3831	3839		10.1074/jbc.M206946200	http://dx.doi.org/10.1074/jbc.M206946200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12468546	hybrid			2022-12-25	WOS:000180869700041
J	Maki, H; Matsuura, K; Shimada, K; Nagashima, KVP				Maki, H; Matsuura, K; Shimada, K; Nagashima, KVP			Chimeric photosynthetic reaction center complex of purple bacteria composed of the core subunits of Rubrivivax gelatinosus and the cytochrome subunit of Blastochloris viridis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; SITE-DIRECTED MUTAGENESIS; RHODOPSEUDOMONAS-VIRIDIS; ELECTRON-TRANSFER; RHODOCYCLUS-GELATINOSUS; C SUBUNIT; HEMES; GENES; BACTERIOCHLOROPHYLL; RESOLUTION	A gene coding for the photosynthetic reaction center-bound cytochrome subunit, pules', of Blastochloris viridis, which belongs to the a-purple bacteria, was introduced into Rubrivivax gelatinosus, which belongs to the beta-purple bacteria. The cytochrome subunit of B. viridis was synthesized in the R. gelatinosus cells, in which the native pufC gene was knocked out, and formed a chimeric reaction center (RC) complex together with other subunits of R. gelatinosus. The transformant was able to grow photosynthetically. Rapid photo-oxidization of the hemes in the cytochrome subunit was observed in the membrane of the transformant. The soluble electron carrier, cytochrome c(2), isolated from B. viridis was a good electron donor to the chimeric RC. The redox midpoint potentials and the redox difference spectra of four hemes in the cytochrome subunit of the chimeric RC were almost identical with those in the B. viridis RC. The cytochrome subunit of B. viridis seems to retain its structure and function in the R. gelatinosus cell. The chimeric RC and its mutagenesis system should be useful for further studies about the cytochrome subunit of B. viridis.	Tokyo Metropolitan Univ, Dept Biol, Hachioji, Tokyo 1920397, Japan	Tokyo Metropolitan University	Nagashima, KVP (corresponding author), Tokyo Metropolitan Univ, Dept Biol, Minamiohsawa 1-1, Hachioji, Tokyo 1920397, Japan.		Nagashima, Kenji V. P./M-2208-2017	Nagashima, Kenji V. P./0000-0002-4526-6625				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P258, DOI 10.1016/S0005-2728(05)80108-2; Chen IP, 2000, BIOCHEMISTRY-US, V39, P3592, DOI 10.1021/bi992443p; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DRACHEVA SM, 1988, EUR J BIOCHEM, V171, P253, DOI 10.1111/j.1432-1033.1988.tb13784.x; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; FRITZ F, 1992, FEBS LETT, V297, P167, DOI 10.1016/0014-5793(92)80352-H; FRITZSCH G, 1989, BIOCHIM BIOPHYS ACTA, V977, P157, DOI 10.1016/S0005-2728(89)80066-0; FUKUSHIMA A, 1988, BIOCHIM BIOPHYS ACTA, V933, P399, DOI 10.1016/0005-2728(88)90074-6; GRISSHAMMER R, 1991, BIOCHIM BIOPHYS ACTA, V1088, P183, DOI 10.1016/0167-4781(91)90053-O; Hiraishi A, 1997, INT J SYST BACTERIOL, V47, P217, DOI 10.1099/00207713-47-1-217; KNAFF DB, 1991, BIOCHEMISTRY-US, V30, P1303, DOI 10.1021/bi00219a021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lancaster C. R. D., 1995, ANOXYGENIC PHOTOSYNT, P503; LAUSSERMAIR E, 1992, EMBO J, V11, P777, DOI 10.1002/j.1460-2075.1992.tb05111.x; Masuda S, 1999, J BIOL CHEM, V274, P10795, DOI 10.1074/jbc.274.16.10795; MATSUURA K, 1986, BIOCHIM BIOPHYS ACTA, V852, P9, DOI 10.1016/0005-2728(86)90050-2; Menin L, 1999, BIOCHEMISTRY-US, V38, P15238, DOI 10.1021/bi991146h; Meyer TE, 1995, ANOXYGENIC PHOTOSYNT, P725; MICHEL H, 1982, J MOL BIOL, V158, P567, DOI 10.1016/0022-2836(82)90216-9; Nagashima KVP, 1997, J MOL EVOL, V45, P131, DOI 10.1007/PL00006212; Nagashima KVP, 1996, FEBS LETT, V385, P209, DOI 10.1016/0014-5793(96)00382-1; NAGASHIMA KVP, 1994, J BIOL CHEM, V269, P2477; Nagashima KVP, 1998, PHOTOSYNTH RES, V55, P349, DOI 10.1023/A:1005912810674; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1100, P49; NITSCHKE W, 1989, BIOCHEMISTRY-US, V28, P3161, DOI 10.1021/bi00434a008; Nitschke W., 1995, ANOXYGENIC PHOTOSYNT, P775; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P15779, DOI 10.1021/bi990907d; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P2861, DOI 10.1021/bi982747w; Osyczka A, 1998, BIOCHEMISTRY-US, V37, P11732, DOI 10.1021/bi980910h; Osyczka A, 2001, J BIOL CHEM, V276, P24108, DOI 10.1074/jbc.M101141200; Osyczka A, 1997, BBA-BIOENERGETICS, V1321, P93, DOI 10.1016/S0005-2728(97)00041-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOEPP B, 1995, BIOCHEMISTRY-US, V34, P11736, DOI 10.1021/bi00037a010; SHINKAREV VP, 1990, FEBS LETT, V261, P11, DOI 10.1016/0014-5793(90)80624-R; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; WEYER KA, 1987, BIOCHEMISTRY-US, V26, P2909, DOI 10.1021/bi00384a036; WEYER KA, 1987, EMBO J, V6, P2197, DOI 10.1002/j.1460-2075.1987.tb02490.x; WOESE CR, 1984, SYST APPL MICROBIOL, V5, P315, DOI 10.1016/S0723-2020(84)80034-X	39	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3921	3928		10.1074/jbc.M209069200	http://dx.doi.org/10.1074/jbc.M209069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12464624	hybrid			2022-12-25	WOS:000180869700053
J	Delhommeau, FO; Thierry, A; Feneux, D; Lauret, E; Leclercq, E; Courtier, MH; Sainteny, F; Vainchenker, W; Bennaceur-Griscelli, A				Delhommeau, FO; Thierry, A; Feneux, D; Lauret, E; Leclercq, E; Courtier, MH; Sainteny, F; Vainchenker, W; Bennaceur-Griscelli, A			Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant	ONCOGENE			English	Article						telomere; telomerase; leukemia; retrovirus; cell death; therapy	REVERSE-TRANSCRIPTASE GENE; HUMAN TUMOR-CELLS; IONIZING-RADIATION; CATALYTIC SUBUNIT; HUMAN-CHROMOSOMES; TTAGGG REPEATS; LIFE-SPAN; LENGTH; APOPTOSIS; ENDS	As activation of telomerase represents a key step in the malignant transformation process, experimental models to develop anti-telomerase drugs provide a rational basis for anticancer strategies. We analysed the short and longterm efficacy of a stably expressed dominant-negative mutant (DN) of the telomerase catalytic unit (hTERT) in UT-7 and U937 human leukemia cell lines by using an IRES-e-GFP retrovirus. As expected, telomerase inactivation resulted in drastic telomere shortening, cytogenetic instability and cell growth inhibition in all e-GFP positive DN clones after 15-35 days of culture. However, despite this initial response, 50% of e-GFP positive DN clones with short telomeres escaped from crisis after 35 days of culture and recovered a proliferation rate similar to the control cells. This rescue was associated with a telomerase reactivation inducing telomere lengthening. We identified two pathways, one involving the loss of the DN transgene expression and the other the transcriptional up-regulation of endogenous hTERT with persistence of the DN transgene expression. Although this second mechanism appears to be a very rare event (one clone), these findings suggest that genomic instability induced by short telomeres after telomerase inhibition might enhance the probability of activation or selection of telomere maintenance mechanisms dependent on hTERT transcription.	Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Hop Bicetre, Serv Hematol & Cytogenet, F-94270 Le Kremlin Bicetre, France; Inst Gustave Roussy, Dept Clin Biol, Serv Hematol Biol, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Bennaceur-Griscelli, A (corresponding author), Inst Gustave Roussy, INSERM, U362, PR-1,39-53 Rue Camille Desmoulins, F-94805 Villejuif, France.	abenna@igr.fr	LAURET, Evelyne/P-4929-2017	LAURET, Evelyne/0000-0003-4643-6857; bennaceur griscelli, annelise/0000-0002-3557-4499; Vainchenker, William/0000-0003-4705-202X; Delhommeau, Francois/0000-0002-4915-0734				Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; di Fagagna FD, 1999, NAT GENET, V23, P76; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hou M, 2001, CLIN CHEM, V47, P519; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KOMATSU N, 1991, CANCER RES, V51, P341; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morin GB, 1997, EXP GERONTOL, V32, P375, DOI 10.1016/S0531-5565(96)00164-7; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Raymond E, 1996, CURR OPIN BIOTECH, V7, P583, DOI 10.1016/S0958-1669(96)80068-1; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Sachsinger J, 2001, CANCER RES, V61, P5580; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wright WE, 1996, DEV GENET, V18, P173; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	51	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8262	8271		10.1038/sj.onc.1206054	http://dx.doi.org/10.1038/sj.onc.1206054			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447689				2022-12-25	WOS:000179323900004
J	Yu, WS; Murray, NR; Weems, C; Chen, L; Guo, HP; Ethridge, R; Ceci, JD; Evers, BM; Thompson, EA; Fields, AP				Yu, WS; Murray, NR; Weems, C; Chen, L; Guo, HP; Ethridge, R; Ceci, JD; Evers, BM; Thompson, EA; Fields, AP			Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; RECEPTOR SUBTYPE EP1; ABERRANT CRYPT FOCI; FATTY-ACIDS; FISH-OIL; PROSTAGLANDIN; EXPRESSION; PROLIFERATION; INHIBITION; GROWTH	Elevated expression of protein kinase C betaII (PKCPH) is an early promotive event in colon carcinogenesis (Gokmen-Polar, Y., Murray, N. R., Velasco, M. A., Gatalica, Z., and Fields, A. P. (2001) Cancer Res. 61,13751381). Expression of PKCPH in the colon of transgenic mice leads to hyperproliferation and increased susceptibility to colon carcinogenesis due, at least in part, to repression of transforming growth factor beta type II receptor (TGF-betaRII) expression (Murray, N. R., Davidson, L. A., Chapkin, R. S., Gustafson, W. C., Schattenberg, D. G., and Fields, A. P. (1999) J. Cell Biol., 145, 699-711). Here we report that PKCbetaII induces the expression of cyclooxygenase type 2 (Cox-2) in rat intestinal epithelial (RIE) cells in vitro and in transgenic PKCbetaII mice in vivo. Cox-2 mRNA increases more than 10-fold with corresponding increases in Cox-2 protein and PGE2 production in RIE/PKCbetaII cells. PKCPH activates the Cox-2 promoter by 2- to 3-fold and stabilizes Cox-2 mRNA by at least 4-fold. The selective Cox-2 inhibitor Celecoxib restores expression of TGF-betaRII both in vitro and in vivo and restores TGFbeta-mediated transcription in RIE/PKCbetaII cells. Likewise, the omega-3 fatty acid eicosapentaenoic acid (EPA), which inhibits PKCbetaII activity and colon carcinogenesis, causes inhibition of Cox-2 protein expression, re-expression of TGF-/3RII, and restoration of TGF-beta1-mediated transcription in RIE/PKCbetaII cells. Our data demonstrate that PKCbetaII promotes colon cancer, at least in part, through induction of Cox-2, suppression of TGF-beta signaling, and establishment of a TGF-beta-resistant, hyperproliferative state in the colonic epithelium. Our data define a procarcinogemc PKCbetaII - Cox-2 - TGF-beta signaling axis within the colonic epithelium, and provide a molecular mechanism by which dietary omega-3 fatty acids and nonsteroidal antiinflammatory agents such as Celecoxib suppress colon carcinogenesis.	Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Fields, AP (corresponding author), Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, 301 Univ Blvd,MRB 9104, Galveston, TX 77555 USA.	afields@utmb.edu			NCI NIH HHS [CA81436, CA56869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869, R01CA081436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANG HO, 1976, ACTA MED SCAND, V200, P69; Bartsch H, 1999, CARCINOGENESIS, V20, P2209, DOI 10.1093/carcin/20.12.2209; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Caygill CPJ, 1996, BRIT J CANCER, V74, P159, DOI 10.1038/bjc.1996.332; CAYGILL CPJ, 1995, EUR J CANCER PREV, V4, P329, DOI 10.1097/00008469-199508000-00008; Chang WCL, 1997, CARCINOGENESIS, V18, P721, DOI 10.1093/carcin/18.4.721; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESCHNER EE, 1990, CANCER, V66, P2350, DOI 10.1002/1097-0142(19901201)66:11&lt;2350::AID-CNCR2820661117&gt;3.0.CO;2-6; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GERWIN BI, 1990, AM J PHYSIOL, V259, pL262, DOI 10.1152/ajplung.1990.259.4.L262; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; Hansen-Petrik MB, 2002, CANCER RES, V62, P403; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawamori T, 2001, ANTICANCER RES, V21, P3865; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Murray NR, 2002, J CELL BIOL, V157, P915, DOI 10.1083/jcb.200201127; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; MURRAY NR, 1997, MOL B INT U, P97; Mutoh M, 2002, CANCER RES, V62, P28; O'Mahony CA, 1999, SURGERY, V126, P364, DOI 10.1016/S0039-6060(99)70178-9; Obata T, 1999, CLIN EXP ALLERGY, V29, P1129; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; REDDY BS, 1991, CANCER RES, V51, P487; Ringbom T, 2001, J NAT PROD, V64, P745, DOI 10.1021/np000620d; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Singh J, 1997, CANCER RES, V57, P3465; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; TAKAHASHI M, 1993, CANCER RES, V53, P2786; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; WALI RK, 1995, CANCER RES, V55, P5257; Watanabe K, 1999, CANCER RES, V59, P5093; Watanabe K, 2000, CANCER LETT, V156, P57, DOI 10.1016/S0304-3835(00)00440-7; WEINSTEIN IB, 1991, ENVIRON HEALTH PERSP, V93, P175, DOI 10.2307/3431186; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117	45	66	69	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11167	11174		10.1074/jbc.M211424200	http://dx.doi.org/10.1074/jbc.M211424200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12480928	hybrid			2022-12-25	WOS:000181855400041
J	Dinadayala, P; Laval, F; Raynaud, C; Lemassu, A; Laneelle, MA; Laneelle, G; Daffe, M				Dinadayala, P; Laval, F; Raynaud, C; Lemassu, A; Laneelle, MA; Laneelle, G; Daffe, M			Tracking the putative biosynthetic precursors of oxygenated mycolates of Mycobacterium tuberculosis - Structural analysis of fatty acids of a mutant strain devoid of methoxy- and ketomycolates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACIDS; TARGET; INHA; VIRULENCE; FORTUITUM; ENVELOPE; LOCATION; GROWTH	Disruption of the mma4 gene (renamed hma) of Mycobacterium tuberculosis has yielded a mutant strain defective in the synthesis of both keto- and methoxymycolates, with an altered cell-wall permeability to small molecules and a decreased virulence in the mouse model of infection (Dubnau, E., Chan, J., Raynaud, C., Mohan, V. P., Laneelle, M. A., Yu, K., Quemard, A., Smith, I., and Daffe, M. (2000) Mol. Microbiol. 36, 630-637). Assuming that the mutant would accumulate the putative precursors of the oxygenated mycolates of M. tuberculosis, a detailed structural analysis of mycolates from the hma-inactivated strain was performed using a combination of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, proton NMR spectroscopy, and chemical degradation techniques. These consisted most exclusively of alpha-mycolates, composed of equal amounts of C-76-C-82 dicyclopropanated (alpha(1)) and of C-77-C-79 monoethylenic monocyclopropanated (alpha(2)) mycolates, the double bond being located at the "distal" position. In addition, small amounts of cis-epoxymycolates, structurally related to alpha(2)-mycolates, was produced by the mutant strain. Complementation of the hma-inactivated mutant with the wild-type gene resulted in the disappearance of the newly identified mycolates and the production of keto- and methoxymycolates of M. tuberculosis. Introduction of the hma gene in Mycobacterium smegmatis led to the lowering of diethylenic a mycolates of the recipient strain and the production of keto- and hydroxymycolates. These data indicate that long-chain ethylenic compounds may be the precursors of the oxygenated mycolates of M. tuberculosis. Because the lack of production of several methyltransferases involved in the biosynthesis of mycolates is known to decrease the virulence of the tubercle bacillus, the identification of the substrates of these enzymes should help in the design of inhibitors of the growth of M. tuberculosis.	Univ Toulouse 3, Dept Mecanismes Mol Infect Mycobacteriennes, Inst Pharmacol & Biol Struct, CNRS,UMR 5089, F-31077 Toulouse 04, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Daffe, M (corresponding author), Univ Toulouse 3, Dept Mecanismes Mol Infect Mycobacteriennes, Inst Pharmacol & Biol Struct, CNRS,UMR 5089, 205 Route Narbonne, F-31077 Toulouse 04, France.		LAUZERAL-VIZCAINO, Françoise/W-8898-2019	LAUZERAL-VIZCAINO, Françoise/0000-0002-9741-3252; Lemassu, Anne/0000-0002-9323-2497				ASSELINEAU C, 1981, ANN INST PASTEUR MIC, VA132, P19; Asselineau C, 2002, PROG LIPID RES, V41, P501, DOI 10.1016/S0163-7827(02)00008-5; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DAFFE M, 1981, TETRAHEDRON LETT, V22, P4515, DOI 10.1016/S0040-4039(01)93029-1; DAFFE M, 1988, EUR J BIOCHEM, V177, P339, DOI 10.1111/j.1432-1033.1988.tb14381.x; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DAFFE M, 1983, ANN MICROBIOL I PA B, V132, P3; DAFFE M, 1983, ANN MICROBIOL I PAST, V134, P367; DAVIDSON LA, 1982, J GEN MICROBIOL, V128, P823; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; DRAPER P, 1982, ANN INST PASTEUR MIC, VB133, P39; Dubnau E, 1997, MOL MICROBIOL, V23, P313, DOI 10.1046/j.1365-2958.1997.2301589.x; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Goren M. B., 1979, TUBERCULOSIS, P63; Huang CC, 2002, J BIOL CHEM, V277, P11559, DOI 10.1074/jbc.M111698200; HUANG HC, 1982, J ORG CHEM, V47, P4018, DOI 10.1021/jo00142a003; Kremer L, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P173; LACAVE C, 1987, EUR J BIOCHEM, V163, P369, DOI 10.1111/j.1432-1033.1987.tb10809.x; LACAVE C, 1989, EUR J BIOCHEM, V181, P459, DOI 10.1111/j.1432-1033.1989.tb14747.x; Laneelle G, 1989, Acta Leprol, V7 Suppl 1, P65; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; LEDERER E, 1969, Q REV CHEM SOC, V23, P453, DOI 10.1039/qr9692300453; Marrakchi H, 2000, MICROBIOL-UK, V146, P289, DOI 10.1099/00221287-146-2-289; MINNIKIN DE, 1982, BIOCHIM BIOPHYS ACTA, V712, P616, DOI 10.1016/0005-2760(82)90290-9; MINNIKIN DE, 1984, ARCH MICROBIOL, V139, P225, DOI 10.1007/BF00402005; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; Quemard A, 1997, EUR J BIOCHEM, V250, P758, DOI 10.1111/j.1432-1033.1997.00758.x; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Schroeder BG, 2001, BIOORG CHEM, V29, P164, DOI 10.1006/bioo.2001.1207; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TOUBIANA R, 1979, J BACTERIOL, V139, P205, DOI 10.1128/JB.139.1.205-211.1979; VONRUDLOFF E, 1956, CAN J CHEM, V34, P1413; Watanabe M, 2002, MICROBIOL-SGM, V148, P1881, DOI 10.1099/00221287-148-6-1881; Watanabe M, 2001, MICROBIOL-SGM, V147, P1825, DOI 10.1099/00221287-147-7-1825; WINDER F G, 1970, Journal of General Microbiology, V63, P41; Yuan Y, 1998, MOL MICROBIOL, V29, P1449, DOI 10.1046/j.1365-2958.1998.01026.x; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828	41	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7310	7319		10.1074/jbc.M210501200	http://dx.doi.org/10.1074/jbc.M210501200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12473649	hybrid			2022-12-25	WOS:000181195100088
J	Kao, HY; Han, CC; Korma, AA; Evans, RM				Kao, HY; Han, CC; Korma, AA; Evans, RM			Co-repressor release but not ligand binding is a prerequisite for transcription activation by human retinoid acid receptor alpha ligand-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; HISTONE DEACETYLASE; CRYSTAL-STRUCTURE; N-COR; FOLDING NUCLEUS; COACTIVATOR; COMPLEX; DETERMINANTS; CONSERVATION; SPECIFICITY	Nuclear hormone receptors coordinately regulate the activity of genetic networks through the recruitment of transcriptional co-regulators, including co-repressors and co-activators. Allosteric modulation of the ligand-binding domain by hormonal activators shifts the cofactor binding preference by defined structural changes in overlapping docking sites. We report here that mutations at conserved residues within the docking motif of the retinoic acid receptor alpha cause defects in dimerization, co-regulator association, and transcriptional regulation. Furthermore, although a minimal co-repressor receptor interaction domain is sufficient for receptor binding, Ranking sequences appear to stabilize this interaction without interfering with ligand sensitivity. However, ligand sensitivity is changed by the K262A mutation, which requires much higher concentrations of all-trans-retinoic acid to promote co-repressor dissociation. Consequently, K262A functions as a dominant-negative mutant at low concentrations of all-trans-retinoic acid. As a result, transcriptional activation is mechanistically linked to co-repressor release.	Case Western Reserve Univ, Dept Biochem, Sch Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Howard Hughes Medical Institute; Salk Institute	Evans, RM (corresponding author), Case Western Reserve Univ, Dept Biochem, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Komar, Anton/0000-0003-4188-0633	NICHD NIH HHS [HD27183] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kao HY, 2000, GENE DEV, V14, P55; Leo C, 2001, J BIOL CHEM, V276, P23127, DOI 10.1074/jbc.M100462200; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mirny L, 2001, J MOL BIOL, V308, P123, DOI 10.1006/jmbi.2001.4602; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ONATE SA, 1995, SCIENCE, V270, P1354; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; Ting KLH, 2002, J MOL EVOL, V54, P425, DOI 10.1007/s00239-001-0033-x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	31	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7366	7373		10.1074/jbc.M207569200	http://dx.doi.org/10.1074/jbc.M207569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12468549	hybrid			2022-12-25	WOS:000181195100095
J	Kim, DY; Kim, DR; Ha, SC; Lokanath, NK; Lee, CJ; Hwang, HY; Kim, KK				Kim, DY; Kim, DR; Ha, SC; Lokanath, NK; Lee, CJ; Hwang, HY; Kim, KK			Crystal structure of the protease domain of a heat-shock protein HtrA from Thermotoga maritima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SERINE-PROTEASE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; DEPENDENT PROTEASES; REGULATORY SUBUNITS; DEGRADATION; CHAPERONE; BACTERIAL; SPECIFICITY; ALIGNMENT	HtrA (high temperature requirement A), a periplasmic heat-shock protein, functions as a molecular chaperone at low temperatures, and its proteolytic activity is turned on at elevated temperatures. To investigate the mechanism of functional switch to protease, we determined the crystal structure of the NH2-terminal protease domain (PD) of HtrA from Thermotoga maritima, which was shown to retain both proteolytic and chaperone-like activities. Three subunits of HtrA PD compose a trimer, and multimerization architecture is similar to that found in the crystal structures of intact HtrA hexamer from Escherichia coli and human HtrA2 trimer. HtrA PD shares the same fold with chymotrypsin-like serine proteases, but it contains an additional lid that blocks access the of substrates to the active site. A corresponding lid found in E. coli HtrA is a long loop that also blocks the active site of another subunit. These results suggest that the activation of the proteolytic function of HtrA at elevated temperatures might occur by a conformational change, which includes the opening of the helical lid to expose the active site and subsequent rearrangement of a catalytic triad and an oxyanion hole.	Sungkyunkwan Univ, Sch Med, SBRI, Ctr Mol Med,Dept Mol Cell Biol, Suwon 440746, South Korea; KSBC, R&D Ctr, PENGEN Biotech, Suwon 442270, South Korea; Bioneer Corp, Taejon 306220, South Korea	Samsung; Sungkyunkwan University (SKKU); Samsung	Kim, KK (corresponding author), Sungkyunkwan Univ, Sch Med, SBRI, Ctr Mol Med,Dept Mol Cell Biol, Suwon 440746, South Korea.	kkim@med.skku.ac.kr		Kim, Dong Young/0000-0001-7594-9083				Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Cambillau C, 1996, CURR OPIN STRUC BIOL, V6, P449, DOI 10.1016/S0959-440X(96)80108-4; Cavarelli J, 1997, STRUCTURE, V5, P813, DOI 10.1016/S0969-2126(97)00235-9; Derman AI, 2000, NAT STRUCT BIOL, V7, P394; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Jones CH, 2001, INFECT IMMUN, V69, P5538, DOI 10.1128/IAI.69.9.5538-5545.2001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim DY, 2002, ACTA CRYSTALLOGR D, V58, P170, DOI 10.1107/S0907444901018248; Kim KI, 1999, J MOL BIOL, V294, P1363, DOI 10.1006/jmbi.1999.3320; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; Misra R, 2000, J BACTERIOL, V182, P4882, DOI 10.1128/JB.182.17.4882-4888.2000; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Savopoulos JW, 2000, PROTEIN EXPRES PURIF, V19, P227, DOI 10.1006/prep.2000.1240; SKORKOGLONEK J, 1995, J BIOL CHEM, V270, P11140, DOI 10.1074/jbc.270.19.11140; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888	38	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6543	6551		10.1074/jbc.M208148200	http://dx.doi.org/10.1074/jbc.M208148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12458220	hybrid			2022-12-25	WOS:000181129400131
J	Kimura, H; Shiota, K				Kimura, H; Shiota, K			Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; REPRESS TRANSCRIPTION; CHROMOSOMAL PROTEIN; GENE-EXPRESSION; COMPLEX; CELLS; LOCALIZATION; REPLICATION; MUTATION; SEQUENCE	During mammalian cell division, DNA methylation patterns are transferred accurately to the newly synthesized DNA strand. This depends on maintenance DNA methyltransferase activity. DNA methylation can affect chromatin organization and gene expression by recruitment of histone deacetylases (HDACs). Here we show that the methyl-CpG binding protein, MeCP2, interacts directly with the maintenance DNA methyltransferase, Dnmt1. The region of MeCP2 that interacts with Dnmt1 corresponds to the transcription repressor domain which can also recruit HDACs via a corepressor, mSin3A. Dnmt1 can form complexes with HDACs as well as MeCP2. Surprisingly, the MeCP2-Dnmt1 complex does not contain the histone deacetylase, HDAC1. Thus, Dnmt1 takes the place of the mSin3A-HDAC1 complex, indicating that the MeCP2-interacting Dnmt1 does not bind to HDAC1. Further, we demonstrate that MeCP2 can form a complex with hemimethylated as well as fully methylated DNA. Immunoprecipitated MeCP2 complexes show DNA methyltransferase activity to hemimethylated DNA. These results suggest that Dnmt1 associates with MeCP2 in order to perform maintenance methylation in vivo. We propose that genome-wide and/or -specific local DNA methylation may be maintained by the Dnmt1-MeCP2 complexes, bound to hemimethylated DNA. Dnmt1 may be recruited to targeted regions via multiple steps that may or may not involve histone deacetylases.	Univ Tokyo, Dept Anim Resource Sci Vet Med Sci, Lab Cellular Biochem, Tokyo, Japan	University of Tokyo	Shiota, K (corresponding author), Univ Tokyo, Dept Anim Resource Sci Vet Med Sci, Lab Cellular Biochem, Tokyo, Japan.							Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Coy JF, 1999, HUM MOL GENET, V8, P1253, DOI 10.1093/hmg/8.7.1253; DEsposito M, 1996, MAMM GENOME, V7, P533, DOI 10.1007/s003359900157; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kimura H, 1998, BIOCHEM BIOPH RES CO, V253, P495, DOI 10.1006/bbrc.1998.9802; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Shiota K, 2002, DIFFERENTIATION, V69, P162, DOI 10.1046/j.1432-0436.2002.690406.x; SZYF M, 1991, J BIOL CHEM, V266, P10027; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008	36	235	248	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4806	4812		10.1074/jbc.M209923200	http://dx.doi.org/10.1074/jbc.M209923200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473678	hybrid			2022-12-25	WOS:000180968900060
J	Liaw, SH; Chen, SJ; Ko, TP; Hsu, CS; Chen, CJ; Wang, AHJ; Tsai, YC				Liaw, SH; Chen, SJ; Ko, TP; Hsu, CS; Chen, CJ; Wang, AHJ; Tsai, YC			Crystal structure of D-aminoacylase from Alcaligenes faecalis DA1 - A novel subset of amidohydrolases and insights into the enzyme mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-BETA-LACTAMASE; XYLOSOXYDANS A-6; BACILLUS-PASTEURII; ESCHERICHIA-COLI; ACTIVE-SITE; RESOLUTION; PROTEIN; UREASE; PURIFICATION; CATALYSIS	D-Aminoacylase is an attractive candidate for commercial production Of D-amino acids through its catalysis in the hydrolysis of N-acyl-D-amino acids. We report here the first D-aminoacylase crystal structure from A. faecalis at 1.5-Angstrom resolution. The protein comprises a small beta-barrel, and a catalytic (betaalpha),(8)-barrel with a 63-residue insertion. The enzyme structure shares significant similarity to the alpha/beta-barrel amidohydrolase superfamily, in which the beta-strands in both barrels superimpose well. Unexpectedly, the enzyme binds two zinc ions with widely different affinities, although only the tightly bound zinc ion is required for activity. One zinc ion is coordinated by Cys(96), His(220), and His(250), while the other is loosely chelated by His(67), His(69), and Cys(96.) This is the first example of the metal ion coordination by a cysteine residue in the superfamily. Therefore, D-aminoacylase defines a novel subset and is a mononuclear zinc metalloenzyme but containing a binuclear active site. The preferred substrate was modeled into a hydrophobic pocket, revealing the substrate specificity and enzyme catalysis. The 63-residue insertion containing substrate-interacting residues may act as a gate controlling access to the active site, revealing that the substrate binding would induce a closed conformation to sequester the catalysis from solvent.	Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; Natl Yang Ming Med Coll, Inst Biochem, Taipei 11221, Taiwan; Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan; Synchrotron Radiat Res Ctr, Xray Struct Biol Grp, Hsinchu 30077, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Synchrotron Radiation Research Center	Wang, AHJ (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan.	ahjwang@gate.sinica.edu.tw; shliaw@ym.edu.tw	Chen, Chun-Jung/A-6880-2011	Chen, Chun-Jung/0000-0002-5157-4288				Abendroth J, 2002, J MOL BIOL, V320, P143, DOI 10.1016/S0022-2836(02)00422-9; Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Benini S, 1998, J BIOL INORG CHEM, V3, P268, DOI 10.1007/s007750050231; Benning MM, 2001, BIOCHEMISTRY-US, V40, P2712, DOI 10.1021/bi002661e; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchbinder JL, 1998, BIOCHEMISTRY-US, V37, P5096, DOI 10.1021/bi971707+; Chantalat L, 2000, PROTEIN SCI, V9, P1402, DOI 10.1110/ps.9.7.1402; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Hsu CS, 2002, PROTEIN SCI, V11, P2545, DOI 10.1110/ps.0220902; Hsu CS, 2002, ACTA CRYSTALLOGR D, V58, P1482, DOI 10.1107/S0907444902011046; Ireton GC, 2002, J MOL BIOL, V315, P687, DOI 10.1006/jmbi.2001.5277; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MORIGUCHI M, 1993, BIOSCI BIOTECH BIOCH, V57, P1149, DOI 10.1271/bbb.57.1149; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; SAKAI K, 1991, J FERMENT BIOENG, V71, P79, DOI 10.1016/0922-338X(91)90227-8; SUGIE M, 1978, AGR BIOL CHEM TOKYO, V42, P107, DOI 10.1080/00021369.1978.10862932; Thoden JB, 2001, BIOCHEMISTRY-US, V40, P6989, DOI 10.1021/bi010682i; TSAI YC, 1992, ENZYME MICROB TECH, V14, P384, DOI 10.1016/0141-0229(92)90007-B; VALLEE BL, 1993, P NATL ACAD SCI USA, V90, P2715, DOI 10.1073/pnas.90.7.2715; WAKAYAMA M, 1995, BIOSCI BIOTECH BIOCH, V59, P2115, DOI 10.1271/bbb.59.2115; WAKAYAMA M, 1995, J FERMENT BIOENG, V80, P311, DOI 10.1016/0922-338X(95)94197-Y; WAKAYAMA M, 1995, J BIOCHEM-TOKYO, V118, P204, DOI 10.1093/oxfordjournals.jbchem.a124879; Wakayama M, 2000, BIOSCI BIOTECH BIOCH, V64, P1, DOI 10.1271/bbb.64.1; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YANG YB, 1992, BIOSCI BIOTECH BIOCH, V56, P1392, DOI 10.1271/bbb.56.1392; YANG YB, 1991, APPL ENVIRON MICROB, V57, P1259, DOI 10.1128/AEM.57.4.1259-1260.1991	31	56	57	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4957	4962		10.1074/jbc.M210795200	http://dx.doi.org/10.1074/jbc.M210795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12454005	hybrid			2022-12-25	WOS:000180968900080
J	Luo, J; Sun, YB; Lin, H; Qian, Y; Li, Z; Leonard, SS; Huang, CS; Shi, XL				Luo, J; Sun, YB; Lin, H; Qian, Y; Li, Z; Leonard, SS; Huang, CS; Shi, XL			Activation of JNK by vanadate induces a Fas-associated death domain (FADD)-dependent death of cerebellar granule progenitors in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; NF-KAPPA-B; PHOSPHOTYROSINE PHOSPHATASE INHIBITORS; TERMINAL KINASE PATHWAY; NERVE GROWTH-FACTOR; INDUCED APOPTOSIS; PROTEIN-KINASE; CD95 FAS/APO-1; CYTOCHROME-C; NEURONAL APOPTOSIS	Apoptosis is a highly regulated process that plays a critical role in neuronal development as well as the homeostasis of the adult nervous system. Vanadate, an environmental toxicant, causes developmental defects in the central nervous system. Here, we demonstrated that vanadate induced apoptosis in cultured cerebellar granule progenitors (CGPs). Treatment of cultured CGPs with vanadate activated ERKs and JNKs but not p38 MAPK and also induced c-Jun phosphorylation. In addition, vanadate induced FasL production, Fas (CD95) aggregation, and its association with the Fas-associated death domain (FADD), as well as the activation of caspase-8. Furthermore, vanadate generated reactive oxygen species (ROS) in CGPs; however, ROS was not involved in vanadate-mediated MAPK activation. Vanadate-induced FasL expression was ROS-dependent but JNK-independent. In contrast, vanadate-elicited Fas aggregation and Fas-FADD association, as well as caspase-8 activation, were dependent on JNK activation but were minimally regulated by ROS generation. The hydrogen peroxide scavenger, catalase, blocked vanadate-induced FasL expression and partially mitigated vanadate-induced cell death. On the other hand, dominant negative FADD and caspase-8 inhibitor completely eliminated vanadate-induced apoptosis. Thus, JNK signaling plays a major role in vanadate-mediated activation of the Fas-FADD-caspase-8 pathway that accounts for vanadate-induced apoptosis of CGPs.	W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; NIOSH, Pathol & Physiol Res Branch, NIH, Morgantown, WV 26506 USA; NYU, Med Ctr, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA	West Virginia University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; New York University	Luo, J (corresponding author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.	jluo@hsc.wvu.edu	Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096; Luo, Jia/0000-0002-6968-3618	NCI NIH HHS [CA90385] Funding Source: Medline; NIAAA NIH HHS [AA12968] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA012968] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Blanchard DA, 2000, ONCOGENE, V19, P4184, DOI 10.1038/sj.onc.1203761; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Boyd D W, 1984, Adv Inorg Biochem, V6, P311; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381; Camandola S, 2000, J NEUROCHEM, V74, P159, DOI 10.1046/j.1471-4159.2000.0740159.x; Cardozo J, 1998, Invest Clin, V39 Suppl 1, P49; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; CATALAN RE, 1987, LIFE SCI, V40, P799, DOI 10.1016/0024-3205(87)90308-0; Chen CY, 2001, CELL GROWTH DIFFER, V12, P297; Chen F, 1999, J BIOL CHEM, V274, P20307, DOI 10.1074/jbc.274.29.20307; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COHEN MD, 1992, MUTAT RES, V269, P141, DOI 10.1016/0027-5107(92)90169-3; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Cui H, 1998, DEV BRAIN RES, V106, P129, DOI 10.1016/S0165-3806(97)00204-6; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; DERODRIGUEZ CF, 1998, INVEST CLIN S1, V39, P55; Domingo JL, 1996, REPROD TOXICOL, V10, P175, DOI 10.1016/0890-6238(96)00019-6; ERDMANN E, 1984, BIOCHEM PHARMACOL, V33, P945, DOI 10.1016/0006-2952(84)90498-2; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Figiel I, 1997, NEUROREPORT, V8, P2465, DOI 10.1097/00001756-199707280-00011; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Honig LS, 2000, AM J MED, V108, P317, DOI 10.1016/S0002-9343(00)00291-6; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Ishiyama S, 1998, J IMMUNOL, V161, P4695; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KUNIMOTO M, 1994, BIOCHEM BIOPH RES CO, V204, P310, DOI 10.1006/bbrc.1994.2461; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEONARD A, 1994, MUTAT RES, V317, P81, DOI 10.1016/0165-1110(94)90013-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Z, 2001, DEV BRAIN RES, V132, P47, DOI 10.1016/S0165-3806(01)00294-2; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1108; Luo J, 1997, BRAIN RES, V770, P139, DOI 10.1016/S0006-8993(97)00762-2; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Mandell JW, 1998, J NEUROBIOL, V35, P17, DOI 10.1002/(SICI)1097-4695(199804)35:1<17::AID-NEU2>3.0.CO;2-E; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Miyazawa K, 2000, J NEUROSCI, V20, P5756, DOI 10.1523/JNEUROSCI.20-15-05756.2000; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; NRIAGU JO, 1988, NATURE, V333, P134, DOI 10.1038/333134a0; Oberto A, 1996, J PHARMACOL EXP THER, V279, P435; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Oppenheim RW, 2000, J NEUROSCI, V20, P6117, DOI 10.1523/JNEUROSCI.20-16-06117.2000; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; SHI XL, 1991, ARCH BIOCHEM BIOPHYS, V289, P355, DOI 10.1016/0003-9861(91)90423-G; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; Stefanis L, 1997, CURR OPIN NEUROL, V10, P299, DOI 10.1097/00019052-199708000-00004; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; STERN A, 1993, BIOCHEM CELL BIOL, V71, P103, DOI 10.1139/o93-018; Sun YB, 2002, J CELL PHYSIOL, V192, P225, DOI 10.1002/jcp.10132; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woodin MA, 2000, AM J IND MED, V37, P353, DOI 10.1002/(SICI)1097-0274(200004)37:4<353::AID-AJIM5>3.3.CO;2-C; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585; Ye JP, 1999, MOL CELL BIOCHEM, V198, P193, DOI 10.1023/A:1006969008056; YOUNES M, 1991, TOXICOLOGY, V70, P141, DOI 10.1016/0300-483X(91)90041-X; YUKAWA M, 1980, ARCH ENVIRON HEALTH, V35, P36, DOI 10.1080/00039896.1980.10667459; Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464	93	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4542	4551		10.1074/jbc.M208295200	http://dx.doi.org/10.1074/jbc.M208295200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12454017	hybrid, Green Submitted			2022-12-25	WOS:000180968900026
J	Asada, M; Irie, K; Morimoto, K; Yamada, A; Ikeda, W; Takeuchi, M; Takai, Y				Asada, M; Irie, K; Morimoto, K; Yamada, A; Ikeda, W; Takeuchi, M; Takai, Y			ADIP, a novel afadin- and alpha-actinin-binding protein localized at cell-cell adherens junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; ASH1 MESSENGER-RNA; TIGHT-JUNCTION; ADHESION MOLECULE; CHROMOSOMAL LOCALIZATION; CADHERIN SUPERFAMILY; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; GLYCOPROTEIN-D	Afadin is an actin filament (F-actin)-binding protein that is associated with the cytoplasmic tail of nectin, a Ca2+-independent immunoglobulin-like cell-cell adhesion molecule. Nectin and afadin strictly localize at cell-cell adherens junctions (AJs) undercoated with F-actin bundles and are involved in the formation of AJs in cooperation with E-cadherin in epithelial cells. In epithelial cells of afadin (-/-) mice and (-/-) embryoid bodies, the proper organization of AJs is markedly impaired. However, the molecular mechanism of how the nectin-afadin system is associated with the E-cadherin-catenin system or functions in the formation of AJs has not yet been fully understood. Here we identified a novel afadin-binding protein, named ADIP (afadin DIL domain-interacting protein). ADIP consists of 615 amino acids with a calculated M-r of 70,954 and has three coiled-coil domains. Northern and Western blot analyses in mouse tissues indicated that ADIP was widely distributed. Immunofluorescence and immunoelectron microscopy revealed that ADIP strictly localized at cell-cell AJs undercoated with F-actin bundles in small intestine absorptive epithelial cells. This localization pattern was the same as those of afadin and nectin. ADIP was undetectable at cell-matrix AJs. ADIP furthermore bound alpha-actinin, an F-actin-bundling protein known to be indirectly associated with E-cadherin through its direct binding to alpha-catenin. These results indicate that ADIP is an afadin- and alpha-actinin-binding protein that localizes at cell-cell AJs and may have two functions. ADIP may connect the nectin-afadin and E-cadherin-catenin systems through alpha-actinin, and ADIP may be involved in organization of the actin cytoskeleton at AJs through afadin and alpha-actinin.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; AOKI J, 1994, J BIOL CHEM, V269, P8431; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bohl F, 2000, EMBO J, V19, P5514, DOI 10.1093/emboj/19.20.5514; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Ebnet K, 2000, J BIOL CHEM, V275, P27979; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; HONDA T, 2003, IN PRESS GENES CELLS; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; James P, 1996, GENETICS, V144, P1425; Kaiser C., 1994, METHODS YEAST GENETI; Kawabe H, 2001, J BIOL CHEM, V276, P48350, DOI 10.1074/jbc.M107335200; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Long RM, 2000, EMBO J, V19, P6592, DOI 10.1093/emboj/19.23.6592; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Maniatis T., 1989, MOL CLONING LAB MAN; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pokutta S, 2002, J BIOL CHEM, V277, P18868, DOI 10.1074/jbc.M201463200; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; PRASAD R, 1993, CANCER RES, V53, P5624; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takeichi M, 2000, PHILOS T ROY SOC B, V355, P885, DOI 10.1098/rstb.2000.0624; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; TERRACIO L, 1990, J CELL PHYSIOL, V145, P78, DOI 10.1002/jcp.1041450112; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Yagi T, 2000, GENE DEV, V14, P1169; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	84	78	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4103	4111		10.1074/jbc.M209832200	http://dx.doi.org/10.1074/jbc.M209832200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446711	hybrid			2022-12-25	WOS:000180869700076
J	Nevins, TA; Harder, ZM; Korneluk, RG; Holcik, M				Nevins, TA; Harder, ZM; Korneluk, RG; Holcik, M			Distinct regulation of internal ribosome entry site-mediated translation following cellular stress is mediated by apoptotic fragments of eIF4G translation initiation factor family members eIF4GI and p97lDAP5/NAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; C-MYC; PROTEIN-SYNTHESIS; ALTERNATIVE TRANSLATION; CLEAVAGE; CONTAINS; XIAP; AVAILABILITY; INHIBITION; CELLS	Many cellular stresses lead to the inhibition of protein synthesis. Despite this, some cellular mRNAs are selectively translated under these conditions. It was suggested that the presence of internal ribosome entry site (IRES) sequences in the 5'-untranslated regions allow these mRNAs to be actively translated despite the overall cessation of protein synthesis. Here we tested the hypothesis that the IRES elements of genes that are involved in the control of cell survival are distinctly regulated by cellular stresses. We show that the transient conditions of cellular stress favor the translation of pro-survival IRES, while the severe apoptotic conditions support translation of pro-death IRES elements. Furthermore, activation of pro-death IRES during the etoposide-induced apoptosis is caspase-dependent and correlates with the expression of apoptotic fragments of two members of the eIF4G translation initiation factor family, p97/DAP5/NAT1 and eIF4GI. Our results suggest that the regulation of IRES translation during stress contributes to the fine-tuning of cell fate.	Childrens Hosp Eastern Ontario, Res Inst, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Pediat, Ottawa, ON K1H 8L1, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa	Holcik, M (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Solange Gauthier Karsh Mol Genet Lab, 401 Smyth Rd,Rm R-306, Ottawa, ON K1H 8L1, Canada.	martin@mgcheo.med.uottawa.ca	Holcik, Martin/A-9768-2008; Holcik, Martin/E-5372-2011; Holcik, Martin/AAC-6660-2019	Holcik, Martin/0000-0002-1922-5299				Bernstein J, 1997, J BIOL CHEM, V272, P9356; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; De Gregorio E, 1998, RNA, V4, P828, DOI 10.1017/S1355838298980372; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Marissen WE, 2000, CELL DEATH DIFFER, V7, P1234, DOI 10.1038/sj.cdd.4400750; Martinez-Salas E, 2001, J GEN VIROL, V82, P973, DOI 10.1099/0022-1317-82-5-973; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Sehgal A, 2000, ONCOGENE, V19, P2836, DOI 10.1038/sj.onc.1203601; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35	34	116	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3572	3579		10.1074/jbc.M206781200	http://dx.doi.org/10.1074/jbc.M206781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458215	hybrid			2022-12-25	WOS:000180869700010
J	Sasaki, A; Inagaki-Ohara, K; Yoshida, T; Yamanaka, A; Sasaki, M; Yasukawa, H; Koromilas, AE; Yoshimura, A				Sasaki, A; Inagaki-Ohara, K; Yoshida, T; Yamanaka, A; Sasaki, M; Yasukawa, H; Koromilas, AE; Yoshimura, A			The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JANUS TYROSINE KINASE; SIGNAL-TRANSDUCTION; ACTIVATION; PROTEINS; RECEPTOR; BINDING; TRANSCRIPTION; SUPPRESSORS; EXPRESSION; REGULATORS	The suppressor of cytokine signaling-3 (SOCS3/ClS-33/ SSI-3) is an important negative regulator of cytokine signaling. Here, we show that an N-terminal truncated isoform (DeltaN-SOCS3) translated from the internal AUG codon 12 was profoundly induced by endoplasmic reticulum. (ER) stress- or active double-stranded RNA-activated protein kinase PKR, as a result of induction of eukaryotic initiation factor 2alpha phosphorylation. DeltaN-SOCS3 exhibited a stronger cytokine-inhibitory activity and a higher stability than WT-SOCS3 in Ba/F3 hematopoietic cells. A potential ubiquitination residue, Lys-6, at the N terminus is evolutionary conserved among SOCS3 species. The K6Q-SOCS3 mutant showed a much longer half-life than WT-SOCS3 in Ba/F3 cells. Furthermore, inhibition of the 26 S proteasome pathway increased both ubiquitination and protein levels of WT-SOCS3 but had no effect on K6Q-SOCS3. SOCS3 mutant lacking the carboxyl-terminal SOCS-box exhibited the same stability as K6Q-SOCS3. These observations suggest that the short form of SOCS3 is a naturally occurring stabilized inhibitory protein, whereas WT-SOCS3 is a short-lived protein modulated by Lys-6 ubiquitination and proteasome-dependent degradation. Our findings provide strong evidence for the first time that translational control plays an important role in stabilization and function of SOCS3.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; Kurume Univ, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan	Kyushu University; Lady Davis Institute; McGill University; Kurume University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Yamanaka, Atsushi/0000-0002-4025-8650; Sasaki, Atsuo/0000-0003-2963-4501				Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Clemens MJ, 2001, PROG MOLEC, V27, P57; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li SY, 2001, J BIOL CHEM, V276, P13881, DOI 10.1074/jbc.M008140200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	34	80	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2432	2436		10.1074/jbc.C200608200	http://dx.doi.org/10.1074/jbc.C200608200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12459551	hybrid			2022-12-25	WOS:000180562000050
J	Duyndam, MCA; Hulscher, STM; van der Wall, E; Pinedo, HM; Boven, E				Duyndam, MCA; Hulscher, STM; van der Wall, E; Pinedo, HM; Boven, E			Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; UBIQUITIN-PROTEASOME PATHWAY; FACTOR 1-ALPHA HIF-1-ALPHA; SMOOTH-MUSCLE CELLS; C-JUN; SIGNALING PATHWAY; NITRIC-OXIDE; FACTOR GENE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL REGULATION	Recently we have demonstrated that sodium arsenite induces the expression of hypoxia-inducible factor la (HIF-1alpha) protein and vascular endothelial growth factor (VEGF) in OVCAR-3 human ovarian cancer cells. We now show that arsenic trioxide, an experimental anticancer drug, exerts the same effects. The involvement of phosphatidylinositol 3-kinase and mitogen-activated protein kinase (MAPK) pathways in the effects of sodium arsenite was investigated. By using kinase inhibitors in OVCAR-3 cells, both effects of sodium arsenite were found to be independent of phosphatidylinositol 3-kinase and p44/p42 MAPKS but were attenuated by inhibition of p38 MAPK. A role for p38 in the regulation of HIF-1a and VEGF expression was supported further by analysis of activation kinetics. Experiments in mouse fibroblast cell lines, lacking expression of c-Jun N-terminal kinases 1 and 2, suggested that these kinases are not required for induction of HIF-1alpha protein and VEGF mRNA. Unexpectedly, sodium arsenite did not activate a HIF-1-dependent reporter gene in OVCAR-3 cells, indicating that functional HIF-1 was not induced. In agreement with this hypothesis, up-regulation of VEGF mRNA was not reduced in HIF-1alpha(-/-) mouse fibroblast cell lines. Altogether, these data suggest that not HIF-1, but rather p38, mediates induction of VEGF mRNA expression by sodium arsenite.	Free Univ Amsterdam, Ctr Med, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Duyndam, MCA (corresponding author), Free Univ Amsterdam, Ctr Med, Dept Med Oncol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.							Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Blancher C, 2001, CANCER RES, V61, P7349; Bode A, 2000, DRUG RESIST UPDATE, V3, P21, DOI 10.1054/drup.2000.0114; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; Duyndam MCA, 2002, AM J PATHOL, V160, P537, DOI 10.1016/S0002-9440(10)64873-0; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; Feldser D, 1999, CANCER RES, V59, P3915; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1996, CANCER RES, V56, P3436; McDowell HE, 1997, EUR J BIOCHEM, V247, P306, DOI 10.1111/j.1432-1033.1997.00306.x; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8; Murgo AJ, 2001, ONCOLOGIST, V6, P22, DOI 10.1634/theoncologist.6-suppl_2-22; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Richard DE, 1999, BIOCHEM BIOPH RES CO, V266, P718, DOI 10.1006/bbrc.1999.1889; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Robinson CJ, 2001, J CELL SCI, V114, P853; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Shibata T, 2000, GENE THER, V7, P493, DOI 10.1038/sj.gt.3301124; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sodhi A, 2000, CANCER RES, V60, P4873; Sugihara T, 1998, J BIOL CHEM, V273, P3033, DOI 10.1074/jbc.273.5.3033; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Uslu R, 2000, CLIN CANCER RES, V6, P4957; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XM, 1997, BIOCHEM BIOPH RES CO, V238, P207, DOI 10.1006/bbrc.1997.7273; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	64	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6885	6895		10.1074/jbc.M206320200	http://dx.doi.org/10.1074/jbc.M206320200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482858	hybrid, Green Published			2022-12-25	WOS:000181195100034
J	Kovacs, J; Low, P; Pacz, A; Horvath, I; Olah, J; Ovadi, J				Kovacs, J; Low, P; Pacz, A; Horvath, I; Olah, J; Ovadi, J			Phosphoenolpyruvate-dependent tubulin-pyruvate kinase interaction at different organizational levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE; POLYMERIZATION; GLYCOLYSIS; BINDING	Evidence for the direct binding of pyruvate kinase to tubulin/microtubule and for the inhibitory effect of phosphoenolpyruvate on tubulin-enzyme hetero-association were provided by surface plasmon resonance and pelleting experiments. Electron microscopy revealed that pyruvate kinase induces depolymerization of paclitaxel-stabilized microtubules into large oligomeric aggregates and bundles the tubules in a salt concentration-dependent manner. The C-terminal "tail"-free microtubules did not bind pyruvate kinase, suggesting the crucial role of the C-terminal segments in the binding of kinase. Immunoblotting and polymerization experiments with cell-free brain extract revealed that pyruvate kinase specifically binds to microtubules, the binding of pyruvate kinase impedes microtubule assembly, and phosphoenolpyruvate counteracts the destabilization of microtubules induced by pyruvate kinase. We also showed by immunostaining the juxtanuclear localization of pyruvate kinase in intact L929 cells and that this localization was influenced by treatments with paclitaxel or vinblastine. These findings suggest that the distribution of the enzyme may be controlled by the microtubular network in vivo.	Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Dept Gen Zool, H-1445 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University	Ovadi, J (corresponding author), Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, POB 7, H-1518 Budapest, Hungary.	ovadi@enzim.hu	Low, Peter/A-3379-2013; Horvath, Istvan/B-1889-2009	Low, Peter/0000-0003-2450-7087; Horvath, Istvan/0000-0003-4262-1430; Ovadi, Judit/0000-0002-3420-682X; Olah, Judit/0000-0002-2470-8631				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Liliom K, 2000, EUR J BIOCHEM, V267, P4731, DOI 10.1046/j.1432-1327.2000.01526.x; NA GC, 1986, BIOCHEMISTRY-US, V25, P6214, DOI 10.1021/bi00368a057; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; Orosz F, 1999, BIOCHEMISTRY-US, V38, P1857, DOI 10.1021/bi981350p; Ottaway J H, 1977, Curr Top Cell Regul, V12, P107; OVADI J, 1996, CHANNELLING INTERMED, P237; *PHARM BIOS AB, 1994, BIAT HDB; Srere PA, 1998, TRENDS BIOCHEM SCI, V23, P319, DOI 10.1016/S0968-0004(98)01262-6; TRACEY DE, 1976, BIOCHEMISTRY-US, V15, P624, DOI 10.1021/bi00648a027; Vertessy BG, 1999, BIOCHEM BIOPH RES CO, V254, P430, DOI 10.1006/bbrc.1998.9957; VOLKER KW, 1993, J MOL RECOGNIT, V6, P167, DOI 10.1002/jmr.300060405; Wagner G, 2001, FEBS LETT, V509, P81, DOI 10.1016/S0014-5793(01)03136-2; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9; Wang ZH, 2000, BIOPHYS J, V78, P1955, DOI 10.1016/S0006-3495(00)76743-9; Wojtas K, 1997, MOL BIOL CELL, V8, P1665, DOI 10.1091/mbc.8.9.1665	17	20	21	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7126	7130		10.1074/jbc.M210244200	http://dx.doi.org/10.1074/jbc.M210244200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482859	hybrid			2022-12-25	WOS:000181195100064
J	Sollerbrant, K; Raschperger, E; Mirza, M; Engstrom, U; Philipson, L; Ljungdahl, PO; Pettersson, RF				Sollerbrant, K; Raschperger, E; Mirza, M; Engstrom, U; Philipson, L; Ljungdahl, PO; Pettersson, RF			Coxsackievirus and adenovirus receptor (CAR) forms a complex with the PDZ domain-containing protein ligand-of-numb protein-x (LNX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL FATE; EXPRESSION; DIVISION; MATURATION	The Coxsackievirus and adenovirus receptor (CAR) functions as a virus receptor, but its primary biological function is unknown. A yeast two-hybrid screen was used to identify Ligand-of-Numb protein-X (LNX) as a binding partner to the intracellular tail of CAR. LNX harbors several protein-protein interacting domains, including four PDZ domains, and was previously shown to bind to and regulate the expression level of the cell-fate determinant Numb. CAR was able to bind LNX both in vivo and in vitro. Efficient binding to LNX required not only the consensus PDZ domain binding motif in the C terminus of CAR but also upstream sequences. The CAR binding region in LNX was mapped to the second PDZ domain. CAR and LNX were also shown to colocalize in vivo in mammalian cells. We speculate that CAR and LNX are part of a larger protein complex that might have important functions at discrete subcellular localizations in the cell.	Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden; Ludwig Inst Canc Res, Uppsala Branch, SE-75124 Uppsala, Sweden; Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Karolinska Institutet	Sollerbrant, K (corresponding author), Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, Box 240, SE-17177 Stockholm, Sweden.		Ljungdahl, Per O/M-5258-2013	Ljungdahl, Per O/0000-0002-6625-3540				Andersson AM, 1997, J VIROL, V71, P4717, DOI 10.1128/JVI.71.6.4717-4727.1997; ANDERSSON B, 2000, GENE FUNCT DIS, V2, P11; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Carson SD, 1999, J VIROL, V73, P7077, DOI 10.1128/JVI.73.8.7077-7079.1999; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Fechner H, 1999, GENE THER, V6, P1520, DOI 10.1038/sj.gt.3301030; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Hutchin ME, 2000, HUM GENE THER, V11, P2365, DOI 10.1089/104303400750038471; Ito M, 2000, CIRC RES, V86, P275, DOI 10.1161/01.RES.86.3.275; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; Nalbantoglu J, 1999, HUM GENE THER, V10, P1009, DOI 10.1089/10430349950018409; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; Okegawa T, 2000, CANCER RES, V60, P5031; PHILIPSON L, 2003, IN PRESS CURR TOP MI; Rebel VI, 2000, STEM CELLS, V18, P176, DOI 10.1634/stemcells.18-3-176; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rice DS, 2001, MOL CELL NEUROSCI, V18, P525, DOI 10.1006/mcne.2001.1024; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tomko RP, 2000, EXP CELL RES, V255, P47, DOI 10.1006/excr.1999.4761; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0	25	79	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7439	7444		10.1074/jbc.M205927200	http://dx.doi.org/10.1074/jbc.M205927200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12468544	hybrid			2022-12-25	WOS:000181195100104
J	Correia, SS; Duarte, CB; Faro, CJ; Pires, EV; Carvalho, AL				Correia, SS; Duarte, CB; Faro, CJ; Pires, EV; Carvalho, AL			Protein kinase C gamma associates directly with the GluR4 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subunit - Effect on receptor phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTORS; GLUTAMATE RECEPTORS; PICK1 INTERACTS; BINDING; CHANNELS; POTENTIATION; SYNAPSES; SYNTENIN; RELEASE; GABA	Ionotropic glutamate receptors mediate the majority of excitatory synaptic transmission in the brain and are thought to be involved in learning and memory formation. The activity of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)-type glutamate receptors can be regulated by direct phosphorylation of their subunits, which affects the electrophysiological properties of the receptor, and the receptor association with numerous proteins that modulate membrane traffic and synaptic targeting of the receptor. In the present study we investigated the association of protein kinase C (PKC) gamma isoform with the GluR4 AMPA receptor subunit. PKCgamma was co-immunoprecipitated with GluR4 AMPA receptor subunit in rat cerebellum and in cultured chick retina cell extracts, and immunocytochemistry experiments showed co-localization of GluR4 and PKCgamma in cultured chick retinal neurons. Pull-down assays showed that native PKCgamma binds the GIuR4 C-terminal membrane-proximal region, and recombinant PKCgamma was retained by GST-GluR4 C-terminal fusion protein, suggesting that the kinase binds directly to GluR4. Furthermore, GST-GluR4 C-terminal protein was phosphorylated on GluR4 Ser-482 by bound kinases, retained by the fusion protein, including PKCgamma. The GluR4 C-terminal segment that interacts with PKCgamma, which lacks the PKC phosphorylation sites, inhibited histone H1 phosphorylation by PKC, to the same extent as the PKC pseudosubstrate peptide 19-31, indicating that PKCgamma bound to GluR4 preferentially phosphorylates GluR4 to the detriment of other substrates. Additionally, PKCgamma expression in GluR4 transfected human embryonic kidney 293T cells increased the amount of plasma membrane-associated GluR4. Our results suggest that PKCgamma binds directly to GluR4, thereby modulating the function of GluR4-containing AMPA receptors.	Univ Coimbra, Dept Zool, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal; Univ Coimbra, Dept Biochem, P-3004517 Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra	Carvalho, AL (corresponding author), Univ Coimbra, Dept Zool, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal.	alc@imagem.ibili.uc.pt	Duarte, Carlos B/K-6358-2013; Carvalho, Ana Luisa/K-6367-2013	Duarte, Carlos B/0000-0002-1474-0208; Carvalho, Ana Luisa/0000-0001-8368-6666				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Carvalho AL, 2000, NEUROCHEM RES, V25, P1245, DOI 10.1023/A:1007644128886; Carvalho AL, 1999, J NEUROSCI, V19, P4748; Carvalho AL, 1998, J NEUROCHEM, V70, P2112; Carvalho AL, 2002, EUR J NEUROSCI, V15, P465, DOI 10.1046/j.0953-816x.2001.01881.x; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chung HJ, 2000, J NEUROSCI, V20, P7258; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; CONDORELLI DF, 1993, J NEUROSCI RES, V36, P344, DOI 10.1002/jnr.490360312; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dev KK, 2000, J NEUROSCI, V20, P7252; DUARTE CB, 1992, BRAIN RES, V591, P27, DOI 10.1016/0006-8993(92)90974-E; ESTEBAN JA, 2001, SOC NEUR 31 ANN M NO; Ghosh KK, 2001, J NEUROSCI, V21, P8636, DOI 10.1523/JNEUROSCI.21-21-08636.2001; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Grunder T, 2000, INVEST OPHTH VIS SCI, V41, P3600; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Hollmann M, 1999, HANDB EXP PHARM, V141, P3; HOUSE C, 1989, FEBS LETT, V249, P243, DOI 10.1016/0014-5793(89)80632-5; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; ORR JW, 1994, J BIOL CHEM, V269, P8383; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Ravindranathan A, 2000, J PHYSIOL-LONDON, V523, P667, DOI 10.1111/j.1469-7793.2000.00667.x; Robert A, 2001, J NEUROSCI, V21, P5574, DOI 10.1523/JNEUROSCI.21-15-05574.2001; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Santos PF, 1998, EUR J NEUROSCI, V10, P2723, DOI 10.1046/j.1460-9568.1998.00281.x; Shen L, 2000, J NEUROSCI, V20, P7932; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Vandenberghe W, 2001, EUR J NEUROSCI, V14, P305, DOI 10.1046/j.0953-816x.2001.01648.x; VANDERZEE EA, 1992, J NEUROSCI, V12, P4808; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Zhu JJ, 2000, NAT NEUROSCI, V3, P1098, DOI 10.1038/80614	50	42	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6307	6313		10.1074/jbc.M205587200	http://dx.doi.org/10.1074/jbc.M205587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471040	Green Published, hybrid			2022-12-25	WOS:000181129400103
J	Despouy, G; Bastie, JN; Deshaies, S; Balitrand, N; Mazharian, A; Rochette-Egly, C; Chomienne, C; Delva, L				Despouy, G; Bastie, JN; Deshaies, S; Balitrand, N; Mazharian, A; Rochette-Egly, C; Chomienne, C; Delva, L			Cyclin D3 is a cofactor of retinoic acid receptors, modulating their activity in the presence of cellular retinoic acid-binding protein II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; DEPENDENT KINASES; RAR-ALPHA; GRANULOCYTIC DIFFERENTIATION; RETINOBLASTOMA PROTEIN; POSITIVE REGULATOR; NUCLEAR RECEPTORS; CELLS; D1; EXPRESSION	Ligand-induced transcription activation of retinoic acid (RA) target genes by nuclear receptors (retinoic acid (RAR) and retinoid X (RXR) receptors) depends on the recruitment of coactivators. We have previously demonstrated that the small 15-kDa cellular RA-binding protein II (CRABPII) is a coactivator present in the RA-dependent nuclear complex. As identifying cell-specific partners of CRABPII might help to understand the novel control of RA signaling, we performed a yeast two-hybrid screen of a hematopoietic HL-60 cDNA library using human CRABPII as bait and have subsequently identified human cyclin D3 as a partner of CRABII. Cyclin D3 interacted with CRABPII in a ligand-independent manner and equally bound RARalpha, but not RXRalpha, and only in the presence of RA. We further show that cyclin D3 positively modulated RA-mediated transcription through CRABPII. Therefore, cyclin D3 may be part of a ternary complex with CRABPII and RAR. Finally, we show that cyclin D3 expression paralleled HL-60 differentiation and arrest of cell growth. These findings led us to speculate that control of cell proliferation during induction of differentiation may directly involve, at the transcriptional level, nuclear receptors, coactivators, and proteins of the cell cycle in a cell- and nuclear receptor-specific manner.	Hop St Louis, Inst Univ Hematol, Equipe Mixte INSERM 00 03, Lab Biol Cellulaire Hematopoiet, F-75010 Paris, France; Unite Mixte Rech, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chomienne, C (corresponding author), Hop St Louis, Inst Univ Hematol, Equipe Mixte INSERM 00 03, Lab Biol Cellulaire Hematopoiet, 1 Ave Claude Vellefaux, F-75010 Paris, France.	lbch@chu-stlouis.fr	Despouy, Gilles/ABE-1702-2021	Gilles, Despouy/0000-0001-9250-9821; Mazharian, Alexandra/0000-0002-0204-3325; DELVA, Laurent/0000-0002-1086-3964; CHOMIENNE, Christine/0000-0001-5513-5752				Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bastie JN, 2001, FEBS LETT, V507, P67, DOI 10.1016/S0014-5793(01)02938-6; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Bommer M, 2002, J BIOL CHEM, V277, P37961, DOI 10.1074/jbc.M206001200; Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Delva L, 1999, MOL CELL BIOL, V19, P7158; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Dong D, 1999, J BIOL CHEM, V274, P23695, DOI 10.1074/jbc.274.34.23695; Gaub MP, 1998, J HISTOCHEM CYTOCHEM, V46, P1103, DOI 10.1177/002215549804601002; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Glass CK, 2000, GENE DEV, V14, P121; HARPER JW, 1993, CELL, V75, P805; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; Jing YK, 1997, CANCER RES, V57, P1668; KIESS M, 1995, ONCOGENE, V10, P159; KIZAKI M, 1993, BLOOD, V82, P3592; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Li Y, 1999, EXP CELL RES, V253, P372, DOI 10.1006/excr.1999.4664; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Ratajczak T, 2001, REPROD FERT DEVELOP, V13, P221, DOI 10.1071/RD01023; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shimizu T, 2000, ONCOGENE, V19, P4640, DOI 10.1038/sj.onc.1203821; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolf G, 2000, NUTR REV, V58, P151, DOI 10.1111/j.1753-4887.2000.tb01851.x; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	45	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6355	6362		10.1074/jbc.M210697200	http://dx.doi.org/10.1074/jbc.M210697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12482873	hybrid			2022-12-25	WOS:000181129400109
J	Harris, SP; Heller, WT; Greaser, ML; Moss, RL; Trewhella, J				Harris, SP; Heller, WT; Greaser, ML; Moss, RL; Trewhella, J			Solution structure of heavy meromyosin by small-angle scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-BRIDGE ATTACHMENT; SMOOTH-MUSCLE MYOSIN; X-RAY-DIFFRACTION; THICK FILAMENTS; SKELETAL-MUSCLE; TAIL JUNCTION; SHAPE CHANGES; TROPONIN-C; 2 HEADS; ACTIN	Elucidation of x-ray crystal structures for the S1 subfragment of myosin afforded atomic resolution of the nucleotide and actin binding sites of the enzyme. The structures have led to more detailed hypotheses regarding the mechanisms by which force generation is coupled to ATP hydrolysis. However, the three-dimensional structure of double-headed myosin consisting of two S1 subfragments has not yet been solved. Therefore, to investigate the overall shape and relative orientations of the two heads of myosin, we performed small-angle x-ray and neutron scattering measurements of heavy meromyosin containing all three light chains (LC1-3) in solution. The resulting small-angle scattering intensity profiles were best fit by models of the heavy meromyosin head-tail junction in which the angular separation between heads was less than 180 degrees. The S1 heads of the best fit models are not related by an axis of symmetry, and one of the two S-1 heads is bent back along the rod. These results provide new information on the structure of the head-tail junction of myosin and indicate that combining scattering measurements with high resolution structural modeling is a feasible approach for investigating myosin head-head interactions in solution.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA; Univ Wisconsin, Meat Sci & Muscle Biol Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Wisconsin System; University of Wisconsin Madison	Harris, SP (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA.	spharris@physiology.wisc.edu	Greaser, Marion L/C-6147-2012; Heller, William/ABE-1104-2020	Greaser, Marion L/0000-0002-6583-9566; Heller, William/0000-0001-6456-2975; Trewhella, Jill/0000-0002-8555-6766	NHLBI NIH HHS [HL10161-02, P01-HL47053] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047053, F32HL010161] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amann KJ, 1999, J BIOL CHEM, V274, P35375, DOI 10.1074/jbc.274.50.35375; Burgess SA, 1997, J CELL BIOL, V139, P675, DOI 10.1083/jcb.139.3.675; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; FARUQI AR, 1991, J CELL SCI, P23; FRADO LLY, 1992, J MUSCLE RES CELL M, V13, P436; Gallagher SC, 1999, BIOCHEMISTRY-US, V38, P6752, DOI 10.1021/bi982991n; GARRIGOS M, 1992, BIOPHYS J, V63, P1462, DOI 10.1016/S0006-3495(92)81743-5; Gu J, 2002, BIOPHYS J, V82, P2123, DOI 10.1016/S0006-3495(02)75559-8; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; HAMMOUDA B, 1996, SMALL ANGLE NEUTRON; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; Heller WT, 2002, BIOCHEMISTRY-US, V41, P15654, DOI 10.1021/bi026687c; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; Juanhuix J, 2001, BIOPHYS J, V80, P1429, DOI 10.1016/S0006-3495(01)76115-2; Katayama E, 1998, ADV EXP MED BIOL, V453, P37; KNIGHT P, 1984, J MOL BIOL, V177, P461, DOI 10.1016/0022-2836(84)90295-X; Knight PJ, 1996, J MOL BIOL, V255, P269, DOI 10.1006/jmbi.1996.0022; KRIGBAUM WR, 1970, BIOCHEMISTRY-US, V9, P1216, DOI 10.1021/bi00807a024; Levine R, 2001, BIOPHYS J, V81, P1070, DOI 10.1016/S0006-3495(01)75764-5; Linari M, 2000, J PHYSIOL-LONDON, V526, P589, DOI 10.1111/j.1469-7793.2000.00589.x; LU RC, 1980, P NATL ACAD SCI-BIOL, V77, P2010, DOI 10.1073/pnas.77.4.2010; MENDELSON RA, 1984, J MOL BIOL, V177, P153, DOI 10.1016/0022-2836(84)90062-7; MENDELSON RA, 1973, BIOCHEMISTRY-US, V12, P2250, DOI 10.1021/bi00736a011; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; OFFER G, 1978, NATURE, V271, P325, DOI 10.1038/271325a0; Offer G, 1996, J MOL BIOL, V256, P407, DOI 10.1006/jmbi.1996.0096; Padron R, 1998, J MOL BIOL, V275, P35, DOI 10.1006/jmbi.1997.1448; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RIMM DL, 1989, J CELL BIOL, V108, P1783, DOI 10.1083/jcb.108.5.1783; SCHAUB MC, 1981, BIOCHIMIE, V63, P291, DOI 10.1016/S0300-9084(81)80117-4; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SLAYTER HS, 1967, P NATL ACAD SCI USA, V58, P1611, DOI 10.1073/pnas.58.4.1611; Squire J, 1998, J STRUCT BIOL, V122, P128, DOI 10.1006/jsbi.1998.3995; SVERGUN DI, 1991, J APPL CRYSTALLOGR, V24, P485, DOI 10.1107/S0021889891001280; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; SVERGUN DI, 1987, DOKL AKAD NAUK SSSR+, V297, P1373; TAYLOR KA, 1993, J MOL BIOL, V233, P86, DOI 10.1006/jmbi.1993.1487; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; WAGNER PD, 1981, J BIOL CHEM, V256, P2647; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; Wall ME, 2000, ANNU REV PHYS CHEM, V51, P355, DOI 10.1146/annurev.physchem.51.1.355; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; Xu S, 1999, BIOPHYS J, V77, P2665, DOI 10.1016/S0006-3495(99)77101-8	49	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6034	6040		10.1074/jbc.M210558200	http://dx.doi.org/10.1074/jbc.M210558200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12466269	hybrid			2022-12-25	WOS:000181129400069
J	Komatsu, N; Watanabe, T; Uchida, M; Mori, M; Kirito, K; Kikuchi, S; Liu, QF; Tauchi, T; Miyazawa, K; Endo, H; Nagai, T; Ozawa, K				Komatsu, N; Watanabe, T; Uchida, M; Mori, M; Kirito, K; Kikuchi, S; Liu, QF; Tauchi, T; Miyazawa, K; Endo, H; Nagai, T; Ozawa, K			A member of forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; KINASE INHIBITOR; HEMATOPOIETIC-CELLS; BH3-ONLY MEMBER; DOWN-REGULATION; FAMILY-MEMBER; PHOSPHORYLATION; TRANSFORMATION; P27(KIP1); SURVIVAL	A member of the Forkhead transcription factor family, FKHRL1, lies downstream of the phosphatidylinositol 3-kinase-Akt activation pathway in cytokine signaling. Because the phosphatidylinositol 3-kinase-Akt activation pathway is required for BCR-ABL-mediated transformation and survival signaling in chronic myelogenous leukemia (CML), in this study we examined the involvement of FKHRL1 in the BCR-ABL-mediated signaling pathway. FKHRL1 was constitutively phosphorylated in BCR-ABL-expressing cell lines KCL22 and KU812, and its phosphorylation was inhibited by treatment with STI571, a specific inhibitor of BCR-ABL tyrosine kinase. Concomitantly, ST1571 induced cell cycle arrest at the G(0)/G(1) phase, accompanied by up-regulation of a cyclin-dependent kinase inhibitor p27/Kip1 in KCL22 cells. In addition, FKHRL1 was constitutively phosphorylated in the TF-1/bcr-abl cell line ectopically expressing BCR-ABL but not in the parent TF-1 cell line. Considering several lines of evidence that phosphorylated FKHRL1 has lost transcriptional activity and that p27/Kip1 expression is positively regulated by dephosphorylated "active" FKHRL1, BCR-ABL may down-regulate p27/Kip1 expression via the loss of FKHRL1 function as a transcription factor. To demonstrate this hypothesis, we generated a tamoxifen-inducible "active FKHRL1" FKHRL1-TM (a triple mutant of FKHRL1, in which all three Akt phosphorylation sites have been mutated), estrogen receptor system in the KCL22 cell line. The addition of tamoxifen inhibited the cell growth indicating that overexpression of FKHRL1 in the nucleus antagonized deregulated proliferation of CML cells. Collectively, FKHRL1 regulates the expression of p27/Kip1 as a downstream molecule of BCR-ABL signaling in CAM cells. BCR-ABL-induced loss of FKHRL1 function may be involved in oncogenic transformation of CAM partially via the down-regulation of p27/Kip1 proteins.	Jichi Med Sch, Dept Med, Div Hematol, Kawachi, Tochigi 3290498, Japan; Tokyo Med Univ, Dept Internal Med 1, Tokyo 1608402, Japan; Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University; Tokyo Medical University; Jichi Medical University	Komatsu, N (corresponding author), Jichi Med Sch, Dept Med, Div Hematol, Kawachi, Tochigi 3290498, Japan.	nkomatsu@jichi.ac.jp	Kirito, Keita/AEO-6802-2022					Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; KUBONISHI I, 1983, International Journal of Cell Cloning, V1, P105; Kuribara R, 2000, BLOOD, V96, p347A; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 2000, CURR BIOL, V10, P1201; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TAUCHI T, 1995, INT J HEMATOL, V61, P105; Woods YL, 2002, BIOCHEM SOC T, V30, P391, DOI 10.1042/bst0300391; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200	48	92	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6411	6419		10.1074/jbc.M211562200	http://dx.doi.org/10.1074/jbc.M211562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12456669	hybrid			2022-12-25	WOS:000181129400114
J	Nassar, T; Sachais, BS; Akkawi, S; Kowalska, MA; Bdeir, H; Leitersdorf, E; Hiss, E; Ziporen, L; Aviram, M; Cines, D; Poncz, M; Higazi, AAR				Nassar, T; Sachais, BS; Akkawi, S; Kowalska, MA; Bdeir, H; Leitersdorf, E; Hiss, E; Ziporen, L; Aviram, M; Cines, D; Poncz, M; Higazi, AAR			Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; CHEMOKINE PLATELET-FACTOR-4; ATHEROSCLEROTIC LESIONS; PLASMINOGEN-ACTIVATOR; OXIDATIVE STRESS; SMOOTH-MUSCLE; PROTEIN-C; FACTOR-IV; HEPARIN; ATHEROGENESIS	Accumulation of low-density lipoprotein (LDL)-derived cholesterol by macrophages in vessel walls is a pathogenomic feature of atherosclerotic lesions. Platelets contribute to lipid uptake by macrophages through mechanisms that are only partially understood. We have previously shown that platelet factor 4 (PF4) inhibits the binding and degradation of LDL through its receptor, a process that could promote the formation of oxidized LDL (ox-LDL). We have now characterized the effect of PF4 on the binding of ox-LDL to vascular cells and macrophages and on the accumulation of cholesterol esters. PF4 bound to ox-LDL directly and also increased ox-LDL binding to vascular cells and macrophages. PF4 did not stimulate ox-LDL binding to cells that do not synthesize glycosaminoglycans or after enzymatic cleavage of cell surface heparan and chondroitin sulfates. The effect of PF4 on binding ox-LDL was dependent on specific lysine residues in its C terminus. Addition of PF4 also caused an similar to10-fold increase in the amount of ox-LDL esterified by macrophages. Furthermore, PF4 and ox-LDL co-localize in atherosclerotic lesion, especially in macrophage-derived foam cells. These observations offer a potential mechanism by which platelet activation at sites of vascular injury may promote the accumulation of deleterious lipoproteins and offer a new focus for pharmacological intervention in the development of atherosclerosis.	Hadassah Univ Hosp, Ctr Res Prevent & Treatment Atherosclerosis, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Ctr Res Prevent & Treatment Atherosclerosis, Dept Med, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91120 Jerusalem, Israel; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Inst Autoimmune Dis, IL-69978 Tel Aviv, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Lipid Res Lab, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Pennsylvania; University of Pennsylvania; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Poncz, M (corresponding author), Childrens Hosp Philadelphia, ARC, 1 Civ Ctr,Rm 317, Philadelphia, PA 19104 USA.		Sachais, Bruce/D-1236-2009					Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; AVIRAM M, 1995, THROMB HAEMOSTASIS, V74, P560; Aviram M, 2000, AM J CLIN NUTR, V71, P1062; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1978, J SUPRAMOL STR CELL, V8, P223, DOI 10.1002/jss.400080302; BUEGE JA, 1978, METHOD ENZYMOL, V52, P301; CHESTERMAN CN, 1986, CLIN HAEMATOL, V15, P323; CURTISS LK, 1987, J CLIN INVEST, V80, P367, DOI 10.1172/JCI113081; Davies MJ, 1996, THROMB RES, V82, P1, DOI 10.1016/0049-3848(96)00035-7; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; Dudek AZ, 1997, J BIOL CHEM, V272, P31785, DOI 10.1074/jbc.272.50.31785; ELSAADANI M, 1989, J LIPID RES, V30, P627; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Gawaz M, 1998, CIRCULATION, V98, P1164, DOI 10.1161/01.CIR.98.12.1164; GOLDBERG ID, 1980, SCIENCE, V209, P611, DOI 10.1126/science.6994228; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HAWIGER J, 1995, THROMB HAEMOSTASIS, V74, P369; Higazi AAR, 1996, J BIOL CHEM, V271, P17650, DOI 10.1074/jbc.271.30.17650; Holvoet P, 1997, CURR OPIN LIPIDOL, V8, P320, DOI 10.1097/00041433-199710000-00012; HUSSEIN O, 1993, ISRAEL J MED SCI, V29, P453; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Keidar S, 1996, ARTERIOSCL THROM VAS, V16, P97, DOI 10.1161/01.ATV.16.1.97; KRUTH HS, 1985, SCIENCE, V227, P1243, DOI 10.1126/science.3975612; KRUTH HS, 1994, J BIOL CHEM, V269, P12420; Lecomte-Raclet L, 1998, BLOOD, V91, P2772, DOI 10.1182/blood.V91.8.2772.2772_2772_2780; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MOORE S, 1976, THROMB HAEMOSTASIS, V35, P70; NATH N, 1975, BLOOD, V45, P537; OBRIEN JR, 1984, THROMB HAEMOSTASIS, V51, P354; Osterud B, 1997, THROMB RES, V85, P1, DOI 10.1016/S0049-3848(96)00205-8; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; PONCZ M, 1987, BLOOD, V69, P219; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUCINSKI B, 1990, THROMB HAEMOSTASIS, V63, P493; Sachais BS, 2002, BLOOD, V99, P3613, DOI 10.1182/blood.V99.10.3613; Scheuerer B, 2000, BLOOD, V95, P1158, DOI 10.1182/blood.V95.4.1158.004k31_1158_1166; SEVITT S, 1986, ATHEROSCLEROSIS, V61, P107, DOI 10.1016/0021-9150(86)90069-9; SLUNGAARD A, 1994, J BIOL CHEM, V269, P25549; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STERN D, 1985, J CLIN INVEST, V75, P272, DOI 10.1172/JCI111685; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; Thomas DP, 1993, HEMOSTASIS THROMBOSI, P167; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WOOLF N, 1967, AM J PATHOL, V51, P373; YAN ZQ, 1994, BLOOD, V84, P2329; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025; Ziporen L, 1998, BLOOD, V92, P3250, DOI 10.1182/blood.V92.9.3250.421k23_3250_3259	54	116	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6187	6193		10.1074/jbc.M208894200	http://dx.doi.org/10.1074/jbc.M208894200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12466273	hybrid			2022-12-25	WOS:000181129400088
J	Waters, C; Sambi, B; Kong, KC; Thompson, D; Pitson, SM; Pyne, S; Pyne, NJ				Waters, C; Sambi, B; Kong, KC; Thompson, D; Pitson, SM; Pyne, S; Pyne, NJ			Sphingosine 1-phosphate and platelet-derived growth factor (PDGF) act via PDGF beta receptor-sphingosine 1-phosphate receptor complexes in airway smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MEDIATED TYROSINE PHOSPHORYLATION; COUPLED RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; G(BETA-GAMMA) SUBUNITS; FACTOR STIMULATION; MOLECULAR-CLONING; MAMMALIAN-CELLS; EDG-1; PATHWAY	Platelet-derived growth factor (PDGF) and sphingosine 1-phosphate (SIP) act via PDGFbeta receptor-S1P(1) receptor complexes in airway smooth muscle cells to promote mitogenic signaling. Several lines of evidence support this conclusion. First, both receptors were co-immunoprecipitated from cell lysates with specific anti-SIP, antibodies, indicating that they form a complex. Second, treatment of airway smooth muscle cells with PDGF stimulated the phosphorylation of p42/p44 MAPK, and this phosphorylated p42/p44 MAPK associates with the PDGFbeta receptor-S1P(1) receptor complex. Third, treatment of cells with antisense S1P(1) receptor plasmid construct reduced the PDGF- and S1P-dependent activation of p42/p44 MAPK. Fourth, SIP and/or PDGF induced the formation of endocytic vesicles containing both PDGFbeta receptors and S1P(1) receptors, which was required for activation of the p42/ p44 MAPK pathway. PDGF does not induce the release of S1P(1) suggesting the absence of a sequential mechanism. However, sphingosine kinase 1 is constitutively exported from cells and supports activation of p42/p44 MAPK by exogenous sphingosine. Thus, the presentation of sphingosine from other cell types and its conversion to SIP by the kinase exported from airway smooth muscle cells might enable SIP to act with PDGF on the PDGFbeta receptor-S1P(1) receptor complex to induce biological responses in vivo. These data provide further evidence for a novel mechanism for G-protein-coupled receptor and receptor tyrosine kinase signal integration that is distinct from the transactivation of receptor tyrosine kinases by G-protein-coupled receptor agonists and/or sequential release and action of SIP in response to PDGF.	Univ Strathclyde, Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland; Inst Med & Vet Sci, Hanson Inst, Div Human Immunol, Adelaide, SA 5000, Australia	University of Strathclyde; Hanson Institute; Institute Medical & Veterinary Science Australia	Pyne, NJ (corresponding author), Univ Strathclyde, Inst Biomed Sci, Dept Physiol & Pharmacol, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.		Pitson, Stuart/B-9342-2009; Pyne, Susan/AAF-5001-2019	Pitson, Stuart/0000-0002-9527-2740; Pyne, Susan/0000-0002-6608-9584; Pyne, Nigel/0000-0002-5657-4578				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; Glickman M, 1999, MOL CELL NEUROSCI, V14, P141, DOI 10.1006/mcne.1999.0776; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; HLA T, 1990, J BIOL CHEM, V265, P9308; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; PYNE S, 1993, BIOCHEM PHARMACOL, V45, P593, DOI 10.1016/0006-2952(93)90132-G; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; Tolan D, 1999, CELL SIGNAL, V11, P349, DOI 10.1016/S0898-6568(99)00005-4; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Watterson KR, 2002, J BIOL CHEM, V277, P5767, DOI 10.1074/jbc.M110647200; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162	34	119	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6282	6290		10.1074/jbc.M208560200	http://dx.doi.org/10.1074/jbc.M208560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480944	hybrid			2022-12-25	WOS:000181129400100
J	Baumann, RG; Black, LW				Baumann, RG; Black, LW			Isolation and characterization of T4 bacteriophage gp17 terminase, a large subunit multimer with enhanced ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFINED INVITRO SYSTEM; DNA PACKAGING REACTION; GENE-PRODUCT-A; LAMBDA TERMINASE; FUNCTIONAL DOMAINS; PURIFICATION; PROTEINS; ENDONUCLEASE; AMPLIFICATION; MACHINE	Phage T4 terminase is a two-subunit enzyme that binds to the prohead portal protein and cuts and packages a headful of concatameric DNA. To characterize the T4 terminase large subunit, gp17 (70 kDa), gene 17 was cloned and expressed as a chitin-binding fusion protein. Following cleavage and release of gp17 from chitin, two additional column steps completed purification. The purification yielded (i) homogeneous soluble gp17 highly active in in vitro DNA packaging (similar to10% efficiency, > 10(8) phage/ml of extract); (ii) gp17 lacking endonuclease and contaminating protease activities; and (iii) a DNA-independent ATPase activity stimulated > 100-fold by the terminase small subunit, gp16 (18 kDa), and modestly by portal gp20 and single-stranded binding protein gp32 multimers. Analyses revealed a preparation of highly active and slightly active gp17 forms, and the latter could be removed by immunoprecipitation using antiserum raised against a denatured form of the gp17 protein, leaving a terminase with the increased specific activity (similar to400 ATPs/gp17 monomer/min) required for DNA packaging. Analysis of gp17 complexes separated from gp16 on glycerol gradients showed that a prolonged enhanced ATPase activity persisted after exposure to gp16, suggesting that constant interaction of the two proteins may not be required during packaging.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Black, LW (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.				NIAID NIH HHS [AI11676] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI011676, R01AI011676, R21AI011676] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUMANN RG, 1999, 16 BIENN C VIR PHAG; BAUMANN RG, 2002, THESIS U MARYLAND SC; BAZINET C, 1985, ANNU REV MICROBIOL, V39, P109; BHATTACHARYYA SP, 1994, GENE, V146, P67, DOI 10.1016/0378-1119(94)90834-6; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BLACK LW, 1981, VIROLOGY, V113, P336, DOI 10.1016/0042-6822(81)90160-4; Bright JN, 2001, PROG BIOPHYS MOL BIO, V76, P131, DOI 10.1016/S0079-6107(01)00012-8; Catalano CE, 2000, CELL MOL LIFE SCI, V57, P128, DOI 10.1007/s000180050503; DRIEDONKS RA, 1981, J MOL BIOL, V152, P641, DOI 10.1016/0022-2836(81)90121-2; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; FRACKMAN S, 1984, J MOL BIOL, V180, P283, DOI 10.1016/S0022-2836(84)80005-4; FUJISAWA H, 1991, VIROLOGY, V185, P788, DOI 10.1016/0042-6822(91)90550-U; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; Golz S, 1999, J MOL BIOL, V285, P1131, DOI 10.1006/jmbi.1998.2399; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAMADA K, 1987, VIROLOGY, V159, P244, DOI 10.1016/0042-6822(87)90461-2; HAMADA K, 1984, VIROLOGY, V139, P251, DOI 10.1016/0042-6822(84)90372-6; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HWANG Y, 1995, VIROLOGY, V211, P367, DOI 10.1006/viro.1995.1419; Ibarra B, 2001, NUCLEIC ACIDS RES, V29, P4264, DOI 10.1093/nar/29.21.4264; Leffers G, 2000, J BIOL CHEM, V275, P37127, DOI 10.1074/jbc.M003357200; Lin H, 1997, J BIOL CHEM, V272, P3495, DOI 10.1074/jbc.272.6.3495; LIN H, 1996, THESIS U MARYLAND SC; Lin HC, 1999, J MOL BIOL, V289, P249, DOI 10.1006/jmbi.1999.2781; Malys N, 2002, J MOL BIOL, V319, P289, DOI 10.1016/S0022-2836(02)00298-X; Maniatis T., 1982, MOL CLONING LAB MANU; MANNE V, 1982, J BIOL CHEM, V257, P13223; MORITA M, 1994, J MOL BIOL, V235, P248, DOI 10.1016/S0022-2836(05)80031-2; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; PARRIS W, 1994, J BIOL CHEM, V269, P13564; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; Rao VB, 2001, J MOL BIOL, V314, P401, DOI 10.1006/jmbi.2001.5169; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; Sambrook J., 2002, MOL CLONING LAB MANU; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; SPRINGER TA, 1991, CURRENT PROTOCOLS MO; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; WU CHH, 1995, J MOL BIOL, V247, P523; WU CHH, 1995, J MOL BIOL, V247, P604	40	63	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4618	4627		10.1074/jbc.M208574200	http://dx.doi.org/10.1074/jbc.M208574200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466275	hybrid			2022-12-25	WOS:000180968900036
J	del Valle, LJ; Ramon, E; Canavate, X; Dias, P; Garriga, P				del Valle, LJ; Ramon, E; Canavate, X; Dias, P; Garriga, P			Zinc-induced decrease of the thermal stability and regeneration of rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; METARHODOPSIN-II; RETINITIS-PIGMENTOSA; ANTAGONIST-BINDING; BOVINE RHODOPSIN; PH-DEPENDENCE; TEMPERATURE; SWITCH; SITE; LOCALIZATION	Zinc is present at high concentrations in the photoreceptor cells of the retina where it has been proposed to play a role in the visual phototransduction process. In order to obtain more information about this role, the study of the effect of zinc on several properties of the visual photoreceptor rhodopsin has been investigated. A specific effect of Zn2+ on the thermal stability of rhodopsin, obtained from bovine retinas and solubilized in dodecyl maltoside detergent, in the dark is reported. The thermal stability of rhodopsin in its ground state (dark state) is clearly reduced with increasing Zn2+ concentrations (0-50 mum Zn2+). The thermal bleaching process is accelerated in the presence of Zn2+ with k rate constants, at 55 degreesC, of 0.028 +/- 0.002 min(-1) (0 mum Zn2+) and 0.056 +/- 0.003 min(-1) (50 muM Zn2+), corresponding to t(1/2) values of 24.4 +/- 1.6 min and 11.8 +/- 0.1 min, respectively. Thermodynamic parameters derived from Arrhenius plots show a significant E-a increase at 50 muM Zn2+ for the process, with DeltaG(double dagger) decrease and increase in DeltaH(double dagger) and DeltaS(double dagger) possibly reflecting conformational rearrangements and reordering of water molecules. The stability of the metarhodopsin IT intermediate is also decreased and changes in the metarhodopsin II decay pathway are also detected. The extent of rhodopsin regeneration in vitro is also reduced by zinc. These effects, specific for zinc, are also seen for rhodopsin in native disc membranes, and may be relevant to the suggested role of Zn2+ in normal and pathological retinal function.	Univ Politecn Cataluna, CEBIM, Dept Engn Quim, Terrassa 08222, Catalonia, Spain	Universitat Politecnica de Catalunya	Garriga, P (corresponding author), Univ Politecn Cataluna, CEBIM, Dept Engn Quim, Colom 1, Terrassa 08222, Catalonia, Spain.	pere.garriga@upc.es	Cañavate, Javier/L-1670-2019; Del Valle, Luis J./I-1342-2015; Garriga, Pere/C-1949-2017	Cañavate, Javier/0000-0002-1502-6962; Del Valle, Luis J./0000-0001-9916-1741; Garriga, Pere/0000-0003-4234-8382				ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; BALDWIN PA, 1985, BIOCHEMISTRY-US, V24, P2624, DOI 10.1021/bi00332a006; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DeLange F, 1997, EUR J BIOCHEM, V243, P174, DOI 10.1111/j.1432-1033.1997.0174a.x; DRYJA TP, 1995, INVEST OPHTH VIS SCI, V36, P1197; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; Farrar GJ, 2002, EMBO J, V21, P857, DOI 10.1093/emboj/21.5.857; Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3; HE B, 1995, J PROTEIN CHEM, V14, P349, DOI 10.1007/BF01886792; He F, 2000, J BIOL CHEM, V275, P20572, DOI 10.1074/jbc.M000440200; HIRAYAMA Y, 1990, ACTA HISTOCHEM, V89, P107, DOI 10.1016/S0065-1281(11)80328-4; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; Lu ZL, 2000, J BIOL CHEM, V275, P5682, DOI 10.1074/jbc.275.8.5682; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MCCORMICK LD, 1985, BIOPHYS J, V47, P381, DOI 10.1016/S0006-3495(85)83929-1; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Mombelli E, 1997, BIOCHEMISTRY-US, V36, P8733, DOI 10.1021/bi970467v; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PADROS E, 1984, TRENDS BIOCHEM SCI, V9, P508, DOI 10.1016/0968-0004(84)90272-X; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; Pepe IM, 2001, PROG RETIN EYE RES, V20, P733, DOI 10.1016/S1350-9462(01)00013-1; RAFFERTY CN, 1980, BIOCHEMISTRY-US, V19, P2145, DOI 10.1021/bi00551a023; Schetz JA, 1999, J PHARMACOL EXP THER, V289, P956; Schetz JA, 1997, J NEUROCHEM, V68, P1990; SCHETZ JA, 1999, REC BIOCH M, P121; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shuster TA, 1996, CURR EYE RES, V15, P1019, DOI 10.3109/02713689609017650; SHUSTER TA, 1992, BIOCHEM J, V282, P123, DOI 10.1042/bj2820123; TAM SW, 1976, BIOCHEM BIOPH RES CO, V72, P302, DOI 10.1016/0006-291X(76)90994-3; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vogel R, 2001, BIOCHEMISTRY-US, V40, P483, DOI 10.1021/bi001855r; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WU SM, 1993, VISION RES, V33, P2611, DOI 10.1016/0042-6989(93)90219-M	45	31	32	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4719	4724		10.1074/jbc.M210760200	http://dx.doi.org/10.1074/jbc.M210760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12482872	hybrid			2022-12-25	WOS:000180968900048
J	Deng, WG; Zhu, Y; Wu, KK				Deng, WG; Zhu, Y; Wu, KK			Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; COLON-CANCER CELLS; TRANSCRIPTION FACTOR; HUMAN FIBROBLASTS; PROTEIN P300; DNA-BINDING; EXPRESSION; GENE; BETA	It is well established that p300 plays an important role in mediating gene expressions. However, it is less clear how its binding is influenced by physiological stimuli and how its altered binding affects transactivator acetylation. and binding. In this study, we determined p300 binding to a core cyclooxygenase-2 (COX-2) promoter region by chromatin immunoprecipitation and streptavidin-agarose pull-down assays in basal and tumor necrosis factor-a (TNFalpha)-treated human foreskin fibroblasts. We found basal binding of p300, p50/p65 NF-kappaB,. cyclic AMP regulatory element-binding protein-2, CCAAT/enhancer-binding protein beta, and c-Jun. p50/p65 and p300 binding was selectively increased by TNFa. Immunoprecipitation confirmed direct interaction of p300 with NF-kappaB and the other involved transactivators. p50 acetylation was detected in resting cells and was increased by TNFalpha or lipopolysaccharide. Overexpression of p300 augmented p50 acetylation, which was attenuated by deletion of its histone acetyltransferase domain. Enhanced p50 acetylation correlated with increased p50 binding to COX-2 promoter and transcriptional activation. Co-transfection of E1A with p300 abrogated p50 acetylation and p50 binding. These findings suggest that up-regulation of p300 binding and its acetylation of NF-kappaB occupies a central position in COX-2 promoter activation.	Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Inst Mol Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Hematol, Dept Internal Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Wu, KK (corresponding author), Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Inst Mol Med, 6431 Fannin, Houston, TX 77030 USA.		Wu, Kenneth Kun-Yu/B-1070-2010	Deng, wuguo/0000-0002-1193-1500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-50675] Funding Source: Medline; NINDS NIH HHS [P50 NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; CILES RH, 1998, TRENDS GENET, V14, P178; Deng WG, 2002, FASEB J, V16, P1286, DOI 10.1096/fj.01-0844fje; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; OGRYZKO VV, 1996, CELL, V87, P9553; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; Saunders MA, 2001, J BIOL CHEM, V276, P18897, DOI 10.1074/jbc.M011147200; SCHROR, 2002, CIRCULATION, V105, P2760; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SIEBERT K, 1994, P NATL ACAD SCI USA, V91, P12013; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 2002, CANCER RES, V62, P2522; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	29	123	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4770	4777		10.1074/jbc.M209286200	http://dx.doi.org/10.1074/jbc.M209286200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12471036	hybrid			2022-12-25	WOS:000180968900055
J	Mizuta, R; Iwai, K; Shigeno, M; Mizuta, M; Uemura, T; Ushiki, T; Kitamura, D				Mizuta, R; Iwai, K; Shigeno, M; Mizuta, M; Uemura, T; Ushiki, T; Kitamura, D			Molecular visualization of immunoglobulin switch region RNA/DNA complex by atomic force microscope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; TRANSCRIPTION; RECOMBINATION	Immunoglobulin heavy-chain (IgH) class switch recombination (CSR) is initiated by DNA breakage in the switch (S) region featuring tandem repetitive nucleotide sequences. Various studies have demonstrated that S-region transcription and splicing proceed to genomic recombination and are indispensable for CSR in vivo, although the precise molecular mechanism is largely unknown. Here, we show the novel physical property of the in vitro transcribed S-region RNA by direct visualization using an atomic force microscope (AFM). The S-region sense RNA, but not the antisense RNA, forms a persistent hybrid with the template plasmid DNA and changes the plasmid conformation from supercoil to open circle in the presence of spermidine. In addition, the S-region transcripts generate globular forms and are assembled on the template DNA into a large aggregate that may stall replication and increase the recombinogenicity of the S-region DNA.	Sci Univ Tokyo, Res Inst Biol Sci, Noda, Chiba 2780022, Japan; Sci Univ Tokyo, Genome & Drug Res Ctr, Noda, Chiba 2780022, Japan; Niigata Univ, Fac Med, Dept Anat & Histol, Niigata 9518510, Japan; Seiko Instruments, Chiba 2702222, Japan	Tokyo University of Science; Tokyo University of Science; Niigata University; Seiko Instruments Inc.	Mizuta, R (corresponding author), Sci Univ Tokyo, Res Inst Biol Sci, 2669 Yamazaki, Noda, Chiba 2780022, Japan.		Ushiki, Tatsuo/ABD-6831-2021					Bettuzzi S, 1999, FEBS LETT, V446, P18, DOI 10.1016/S0014-5793(99)00182-9; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; Hein K, 1998, J EXP MED, V188, P2369, DOI 10.1084/jem.188.12.2369; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Krasilnikova MM, 1998, EMBO J, V17, P5095, DOI 10.1093/emboj/17.17.5095; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; LUNDGREN M, 1995, EUR J IMMUNOL, V25, P2042, DOI 10.1002/eji.1830250736; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; REABAN ME, 1994, J BIOL CHEM, V269, P21850; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Stavnezer J, 2000, CURR TOP MICROBIOL, V245, P127; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; Tashiro J, 2001, INT IMMUNOL, V13, P495, DOI 10.1093/intimm/13.4.495; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; Ushiki T, 1996, ARCH HISTOL CYTOL, V59, P421	19	37	37	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4431	4434		10.1074/jbc.M209262200	http://dx.doi.org/10.1074/jbc.M209262200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12475983	hybrid			2022-12-25	WOS:000180968900011
J	Park, EI; Manzella, SM; Baenziger, JU				Park, EI; Manzella, SM; Baenziger, JU			Rapid clearance of sialylated glycoproteins by the asialoglycoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; ASPARAGINE-LINKED OLIGOSACCHARIDES; N-ACETYLGALACTOSAMINE; LUTROPIN; EXPRESSION; SUBUNIT; BOVINE; LIVER; GLYCOSYLATION; ENDOCYTOSIS	The asialoglycoprotein-receptor (ASGP-R) located on liver parenchymal cells was originally identified and characterized on the basis of its ability to bind glycoproteins bearing terminal galactose (Gal) or N-acetylgalac-tosamine (GalNAc); however, endogenous ligands for the ASGP-R have not to date been definitively identified. We have determined that the rat ASGP-R specifically binds oligosaccharides terminating with the sequence Siaalpha2,6GalNAcbeta1,4GlcNAcbeta1,2Man. Bovine serum albumin chemically modified with 10-15 tetrasaccharides with the sequence Siaalpha2,6GalNAcbeta1,4GlcNAcbeta1,2Man is cleared from the blood of the rat with a half-life of < 1 min by a receptor located in the liver. We have isolated the receptor and identified it as the ASGP-R. Furthermore, we have determined that subunit 1 of the ASGP-R accounts for the binding of terminal Siaalpha2,6GalNAcbeta. Based on the newly defined specificity of the rat ASGP-R we hypothesize that glycoproteins bearing structures that are selectively modified with terminal Siaalpha2,6GalNAcbeta and are released into the blood may be endogenous ligands for the rat ASGP-R.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	Baenziger, JU (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.		Baenziger, Jacques U/E-9430-2012		NATIONAL CANCER INSTITUTE [R37CA021923, T32CA009547] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA21923, T32-CA09547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; Clark GF, 1996, HUM REPROD, V11, P467, DOI 10.1093/HUMREP/11.3.467; COLLINS JC, 1984, HEPATOLOGY, V4, P80, DOI 10.1002/hep.1840040114; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1989, TRENDS BIOCHEM SCI, V14, P168, DOI 10.1016/0968-0004(89)90267-3; HUBER BE, 1992, MOL PHARMACOL, V41, P639; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Manzella SM, 1997, J BIOL CHEM, V272, P4775, DOI 10.1074/jbc.272.8.4775; Meier M, 2000, J MOL BIOL, V300, P857, DOI 10.1006/jmbi.2000.3853; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; MORELL AG, 1971, J BIOL CHEM, V246, P1461; Roseman DS, 2000, P NATL ACAD SCI USA, V97, P9949, DOI 10.1073/pnas.170184597; Roseman DS, 2001, J BIOL CHEM, V276, P17052, DOI 10.1074/jbc.M101027200; SCHWARTZ AL, 1980, J BIOL CHEM, V255, P9033; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SMEDSROD B, 1985, J LEUKOCYTE BIOL, V38, P213, DOI 10.1002/jlb.38.2.213; TOLLESHAUG H, 1977, BIOCHIM BIOPHYS ACTA, V499, P73, DOI 10.1016/0304-4165(77)90230-6; Tozawa R, 2001, J BIOL CHEM, V276, P12624, DOI 10.1074/jbc.M011063200; VANDENEIJNDEN DH, 1995, BIOCHEM SOC T, V23, P175, DOI 10.1042/bst0230175; VANDENHA.CJ, 1970, J BIOL CHEM, V245, P4397; vanSeeventer PB, 1997, CARBOHYD RES, V300, P127, DOI 10.1016/S0008-6215(97)00012-8; WEIGEL PH, 1994, BIOESSAYS, V16, P519, DOI 10.1002/bies.950160713; WEIGEL PH, 1980, J BIOL CHEM, V255, P6111; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200	32	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4597	4602		10.1074/jbc.M210612200	http://dx.doi.org/10.1074/jbc.M210612200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12464602	hybrid			2022-12-25	WOS:000180968900033
J	Wahlstrom, JL; Randall, MA; Lawson, JD; Lyons, DE; Siems, WF; Crouch, GJ; Barr, R; Facemyer, KC; Cremo, CR				Wahlstrom, JL; Randall, MA; Lawson, JD; Lyons, DE; Siems, WF; Crouch, GJ; Barr, R; Facemyer, KC; Cremo, CR			Structural model of the regulatory domain of smooth muscle heavy meromyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; ESSENTIAL LIGHT-CHAIN; SKELETAL-MUSCLE; MYOSIN MOTOR; HYPERTROPHIC CARDIOMYOPATHY; 2-HEADED STRUCTURE; SCALLOP MYOSIN; MUTATIONS; CONFORMATION; PROBES	The goal of this study was to provide structural information about the regulatory domains of double-headed smooth muscle heavy meromyosin, including the N terminus of the regulatory light chain, in both the phosphorylated and unphosphorylated states. We extended our previous photo-cross-linking studies (Wu, X., Clack, B. A., Zhi, G., Stull, J. T., and Cremo, C. R. (1999) J. BioL Chem. 274, 20328-20335) to determine regions of the regulatory light chain that are cross-linked by a crosslinker attached to Cys(108) on the partner regulatory light chain. For this purpose, we have synthesized two new biotinylated sulfhydryl reactive photo-cross-linking reagents, benzophenone, 4-(N-iodoacetamido)-4'-(N-biotinylamido) and benzophenone, 4-(N-maleimido)-4'-(N-biotinylamido). Cross-linked peptides were purified by avidin affinity chromatography and characterized by Edman sequencing and mass spectrometry. Labeled Cys(108) from one regulatory light chain cross-linked to (71)GMMSEAPGPIN(81), a loop in the N-terminal half of the regulatory light chain, and to (4)RAKAKTTKKRPQR(16), a region for which there is no atomic resolution data. Both cross-links were to the partner regulatory light chain and occurred in unphosphorylated but not phosphorylated heavy meromyosin. Using these data, data from our previous study, and atomic coordinates from various myosin isoforms, we have constructed a structural model of the regulatory domain in an unphosphorylated double-headed molecule that predicts the general location of the N terminus. The implications for the structural basis of the phosphorylation-mediated regulatory mechanism are discussed.	Univ Nevada, Dept Biochem 330, Reno, NV 89557 USA; Washington State Univ, Dept Chem, Pullman, WA 99164 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Washington State University	Cremo, CR (corresponding author), Univ Nevada, Dept Biochem 330, 1664 N Virginia St, Reno, NV 89557 USA.			Wahlstrom, Jan/0000-0002-9434-1302; Lawson, J David/0000-0002-5232-4539				CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; Epstein ND, 1998, ADV EXP MED BIOL, V453, P105; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; Flavigny J, 1998, J MOL MED-JMM, V76, P208, DOI 10.1007/s001090050210; GILBERT BA, 1995, J AM CHEM SOC, V117, P8061, DOI 10.1021/ja00136a002; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1991, J BIOL CHEM, V266, P21339; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; Konishi K, 1998, J BIOCHEM-TOKYO, V124, P163, DOI 10.1093/oxfordjournals.jbchem.a022075; Konishi K, 2001, J BIOCHEM-TOKYO, V129, P365, DOI 10.1093/oxfordjournals.jbchem.a002866; Lauzon AM, 2001, BIOPHYS J, V80, P1900, DOI 10.1016/S0006-3495(01)76159-0; Luo Y, 1999, BIOCHEMISTRY-US, V38, P6678, DOI 10.1021/bi9824341; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Means G.E., 1971, CHEM MODIFICATION PR, P214; Offer G, 1996, J MOL BIOL, V256, P407, DOI 10.1006/jmbi.1996.0096; Olney JJ, 1996, J BIOL CHEM, V271, P20375, DOI 10.1074/jbc.271.34.20375; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; STULL JT, 1990, PROG CLIN BIOL RES, V327, P107; Sweeney HL, 1998, AM J RESP CRIT CARE, V158, pS95, DOI 10.1164/ajrccm.158.supplement_2.13tac400; TOHTONG R, 1995, NATURE, V374, P650, DOI 10.1038/374650a0; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; WHITE HD, 1985, J BIOL CHEM, V260, P982; Wu XD, 1999, J BIOL CHEM, V274, P20328, DOI 10.1074/jbc.274.29.20328; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANG ZH, 1995, J BIOL CHEM, V270, P24646, DOI 10.1074/jbc.270.42.24646	43	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5123	5131		10.1074/jbc.M206963200	http://dx.doi.org/10.1074/jbc.M206963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12446732	hybrid			2022-12-25	WOS:000180968900099
J	Pikkarainen, S; Tokola, H; Kerkela, R; Majalahti-Palviainen, T; Vuolteenaho, O; Ruskoaho, H				Pikkarainen, S; Tokola, H; Kerkela, R; Majalahti-Palviainen, T; Vuolteenaho, O; Ruskoaho, H			Endothelin-1-specific activation of B-type natriuretic peptide gene via p38 mitogen-activated protein kinase and nuclear ETS factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING MOTIF; C-FOS GENE; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; CARDIAC MYOCYTES; RESPONSE ELEMENT; COUPLED RECEPTOR; HEART-FAILURE; GROWTH-FACTOR; MURINE ETS-1	Terminally differentiated cardiac myocytes adapt to mechanical and neurohumoral stress via morphological changes of individual cells accompanied by reactivation of fetal pattern of gene expression. Endothelin-1, a powerful paracrine mediator of myocyte growth, induces similar changes in cultured cardiac myocytes as those seen in hypertrophied heart in vivo. By using rat B-type natriuretic peptide promoter, we identified a novel ETS binding sequence, on which nuclear protein binding is activated in endothelin-1-treated cultured cardiac myocytes. This sequence binds ETS-like gene-1 transcription factor and mediates endothelin-1-specific activation of transcription, but not responses to increased calcium signaling via L-type calcium channels, angiotensin II treatment, or mechanical stretch of myocytes. Interestingly, endothelin-1 activated signaling converges via p38 mitogen-activated protein kinase-dependent mechanism on ETS binding site, whereas this element inhibits extracellular signal-regulated kinase activated transcription. In conclusion, given the fundamental role of the interaction of mitogen-activated protein kinases and ETS factors in regulation of eukaryotic cell differentiation, growth, and oncogenesis, these results provide the unique evidence of a endothelin-1- and mitogen-activated protein kinase-regulated ETS factor pathway for cardiac myocytes.	Univ Oulu, Bioctr, Dept Pharmacol & Toxicol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr, Dept Physiol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu	Ruskoaho, H (corresponding author), Univ Oulu, Bioctr, Dept Pharmacol & Toxicol, POB 5000, FIN-90014 Oulu, Finland.	heikki.ruskoaho@oulu.fi						AOYAGI T, 1993, J BIOL CHEM, V268, P27176; ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; AwaneIgata Y, 1997, BRIT J PHARMACOL, V120, P516, DOI 10.1038/sj.bjp.0700925; Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; BECHEM M, 1993, PFLUG ARCH EUR J PHY, V424, P343, DOI 10.1007/BF00384362; Cain AE, 2002, HYPERTENSION, V39, P543, DOI 10.1161/hy0202.103129; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clerk A, 1999, AM J CARDIOL, V83, p64H; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; Cowley DO, 2000, GENE DEV, V14, P366; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Gupta M, 1998, MOL CELL BIOL, V18, P7243, DOI 10.1128/MCB.18.12.7243; Hafizi S, 1999, ATHEROSCLEROSIS, V146, P351, DOI 10.1016/S0021-9150(99)00178-1; Haq S, 2001, CIRCULATION, V103, P670; Hautala N, 2001, CIRCULATION, V103, P730; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kakita T, 2001, CIRC RES, V88, P1239, DOI 10.1161/hh1201.091794; Kappel A, 2000, BLOOD, V96, P3078; Kerkela R, 2002, J BIOL CHEM, V277, P13752, DOI 10.1074/jbc.M105736200; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Levin ER, 1998, NEW ENGL J MED, V339, P321; Liang FQ, 2000, HYPERTENSION, V35, P188, DOI 10.1161/01.HYP.35.1.188; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Lorell BH, 2000, CIRCULATION, V102, P470; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORGAN JP, 1991, NEW ENGL J MED, V325, P625; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Murat A, 2000, J BIOL CHEM, V275, P40867, DOI 10.1074/jbc.M008071200; Naito S, 1998, AM J PHYSIOL-CELL PH, V274, pC472, DOI 10.1152/ajpcell.1998.274.2.C472; Nicol RL, 2000, ANNU REV GENOM HUM G, V1, P179, DOI 10.1146/annurev.genom.1.1.179; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Pacher R, 1996, J AM COLL CARDIOL, V27, P633, DOI 10.1016/0735-1097(95)00520-X; Pikkarainen S, 2002, J MOL MED, V80, P51, DOI 10.1007/s001090100278; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; Salani D, 2000, AM J PATHOL, V157, P1537, DOI 10.1016/S0002-9440(10)64791-8; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Stephenson J, 2001, JAMA-J AM MED ASSOC, V286, P34, DOI 10.1001/jama.286.1.34; SUGDEN PH, 1995, CARDIOVASC RES, V30, P478, DOI 10.1016/S0008-6363(95)00096-8; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Thuerauf DJ, 1997, J BIOL CHEM, V272, P7464, DOI 10.1074/jbc.272.11.7464; Tokola H, 2001, CAN J PHYSIOL PHARM, V79, P646, DOI 10.1139/cjpp-79-8-646; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239	60	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3969	3975		10.1074/jbc.M205616200	http://dx.doi.org/10.1074/jbc.M205616200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446726	hybrid			2022-12-25	WOS:000180869700058
J	Becker, NA; Thorland, EC; Denison, SR; Phillips, LA; Smith, DI				Becker, NA; Thorland, EC; Denison, SR; Phillips, LA; Smith, DI			Evidence that instability within the FRA3B region extends four megabases	ONCOGENE			English	Article						common fragile sites; FRA3B; human papillomavirus; cervical cancer; viral integration	COMMON FRAGILE SITE; CELL CARCINOMA; FHIT GENE; VIRAL INTEGRATION; CERVICAL-CANCER; BROAD REGION; EXPRESSION; CLONING; DNA; METHYLATION	FRA3B is the most frequently expressed common fragile site localized within human chromosomal band 3p14.2, which is frequently deleted in many different cancers, including cervical cancer. Previous reports indicate aphidicolin-induced FRA3B instability occurs over similar to500 kb which is spanned by the 1.5 Mb fragile histidine triad (FHIT) gene. Recently an HPV16 cervical tumor integration, 2 Mb centromeric to the published FRA3B region, has been identified. FISH-based analysis with a BAC spanning the integration has demonstrated this integration occurs within the FRA3B region of instability. These data suggest that the unstable FRA3B region is much larger than previously reported. FISH-based analysis of aphidicolin-induced metaphase chromosomes allowed for a complete characterization of instability associated with FRA3B. This analysis indicates that fragility extends for 4 Mb. Within this region are a total of five genes, including FHIT. FRA3B gene expression analysis on a panel of cervical tumor-derived cell lines revealed that three of the five genes within FRA3B were aberrantly regulated. A similar analysis of genes outside of FRA3B indicated that the surrounding genes were not aberrantly expressed. These data provide additional support that regions of instability associated with CFSs and the genes contained within them, may play an important role in cancer development.	Mayo Clin & Mayo Fdn, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol, 200 1St St Sw,Hilton 800, Rochester, MN 55905 USA.	smith.david@mayo.edu			NCI NIH HHS [CA 48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; CHOO KR, 1998, GENETIC BASIS HUMAN, P631; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Connolly DC, 2000, CLIN CANCER RES, V6, P3505; Cool D E, 1993, Semin Cell Biol, V4, P443, DOI 10.1006/scel.1993.1052; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Corbin S, 2002, CANCER RES, V62, P3477; Druck T, 1998, ONCOL RES, V10, P341; Fang JM, 2001, GENE CHROMOSOME CANC, V30, P292, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1095>3.0.CO;2-F; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, CANCER GENET CYTOGEN, V31, P69, DOI 10.1016/0165-4608(88)90013-1; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Gonzalez MV, 1998, J CLIN PATHOL, V51, P520, DOI 10.1136/jcp.51.7.520; Gostout BS, 1998, AM J OBSTET GYNECOL, V179, P56, DOI 10.1016/S0002-9378(98)70251-0; Greenspan DL, 1997, CANCER RES, V57, P4692; Hendricks DT, 1997, CANCER RES, V57, P2112; Herzog CR, 2001, MOL CARCINOGEN, V30, P159, DOI 10.1002/mc.1024; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kastury K, 1996, GENOMICS, V32, P225, DOI 10.1006/geno.1996.0109; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; POPESCU NC, 1990, HUM GENET, V84, P383; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; SANDBERG AA, 1990, CHROMOSOME HUMAN CAN; Sarkar G, 1993, PCR Methods Appl, V2, P318; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; Tanaka H, 1998, CANCER RES, V58, P3429; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Thorland EC, 2000, CANCER RES, V60, P5916; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VERMA RS, 1989, HUMAN CHROMOSOMES MA; VERTINO PM, 1993, CANCER RES, V53, P1684; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Zimonjic DB, 1997, CANCER RES, V57, P1166; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	48	52	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8713	8722		10.1038/sj.onc.1205950	http://dx.doi.org/10.1038/sj.onc.1205950			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483524				2022-12-25	WOS:000179734400005
J	Stevnsner, T; Nyaga, S; de Souza-Pinto, NC; van der Horst, GTJ; Gorgels, TGMF; Hogue, BA; Thorslund, T; Bohr, VA				Stevnsner, T; Nyaga, S; de Souza-Pinto, NC; van der Horst, GTJ; Gorgels, TGMF; Hogue, BA; Thorslund, T; Bohr, VA			Mitochondrial repair of 8-oxoguanine is deficient in Cockayne syndrome group B	ONCOGENE			English	Article						base excision repair; oxidative damage; mitochondria; Cockayne syndrome	RNA-POLYMERASE-II; TRANSCRIPTION-COUPLED REPAIR; OXIDATIVE BASE DAMAGE; HAMSTER OVARY CELLS; INDUCED DNA-DAMAGE; ACTIVE GENES; PREFERENTIAL REPAIR; INDUCED APOPTOSIS; FACTOR CSB/ERCC6; EXCISION-REPAIR	Reactive oxygen species, which are prevalent in mitochondria, cause oxidative DNA damage including the mutagenic DNA lesion 7,8-dihydroxyguanine (8-oxoG). Oxidative damage to mitochondrial DNA has been implicated as a causative factor in a wide variety of degenerative diseases, and in cancer and aging. 8-oxoG is repaired efficiently in mammalian mitochondrial DNA by enzymes in the base excision repair pathway, including the 8-oxoguanine glycosylase (OGG1), which incizes the lesion in the first step of repair. Cockayne syndrome (CS) is a segmental premature aging syndrome in humans that has two complementation groups, CSA and CSB. Previous studies showed that CSB-deficient cells have reduced capacity to repair 8-oxoG. This study examines the role of the CSB gene in regulating repair of 8-oxoG in mitochondrial DNA in human and mouse cells. 8-oxoG repair was measured in liver cells from CSB deficient mice and in human CS-B cells carrying expression vectors for wild type or mutant forms of the human CSB gene. For the first time we report that CSB stimulates repair of 8-oxoG in mammalian mitochondrial DNA. Furthermore, evidence is presented to support the hypothesis that wild type CSB regulates expression of OGG1.	NIA, Lab Mol Gerontol, IRP, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Mol Biol, Danish Ctr Mol Gerontol, DK-8000 Aarhus C, Denmark; Erasmus Univ, Ctr Biomed Genet, Ctr Genet Med, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; Erasmus University Rotterdam	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, IRP, NIH, Box 1,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Souza-Pinto, Nadja/T-3050-2019; Souza-Pinto, Nadja C./C-3462-2013; Bohr, Vilhelm/AAP-5931-2020; van der Horst, Gijsbertus TJ/E-3661-2015	Souza-Pinto, Nadja/0000-0003-4206-964X; Souza-Pinto, Nadja C./0000-0003-4206-964X; van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Thorslund, Tina/0000-0001-9207-0070; Stevnsner, Tinna/0000-0003-1007-0427	NATIONAL INSTITUTE ON AGING [ZIAAG000733, Z01AG000733, Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aburatani H, 1997, CANCER RES, V57, P2151; Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Balajee AS, 2000, ONCOGENE, V19, P477, DOI 10.1038/sj.onc.1203372; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOHR VA, 1988, NUCLEIC ACIDS RES, V16, P7397, DOI 10.1093/nar/16.15.7397; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; Ljungman M, 1996, ONCOGENE, V13, P823; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MAYNE LV, 1982, CANCER RES, V42, P1473; MAYNE LV, 1984, AM J HUM GENET, V36, P311; MAYNE LV, 1982, MUTAT RES, V106, P179, DOI 10.1016/0027-5107(82)90200-7; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SCHNEIDER JE, 1990, NUCLEIC ACIDS RES, V18, P631, DOI 10.1093/nar/18.3.631; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; Selzer RR, 2002, NUCLEIC ACIDS RES, V30, P782, DOI 10.1093/nar/30.3.782; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TUO J, 2002, IN PRESS DNA REPAIR; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WADE MH, 1979, MUTAT RES, V59, P49, DOI 10.1016/0027-5107(79)90194-5; Wallace Douglas C., 1998, Biofactors, V7, P187	48	88	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8675	8682		10.1038/sj.onc.1205994	http://dx.doi.org/10.1038/sj.onc.1205994			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483520				2022-12-25	WOS:000179734400001
J	Ling, MT; Wang, XH; Ouyang, XS; Lee, TK; Fan, TY; Xu, KX; Tsao, SW; Wong, Y				Ling, MT; Wang, XH; Ouyang, XS; Lee, TK; Fan, TY; Xu, KX; Tsao, SW; Wong, Y			Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth	ONCOGENE			English	Article						Id-1; prostate cancer; MAPK; cell growth	LOOP-HELIX PROTEINS; HUMAN KERATINOCYTES; PANCREATIC-CANCER; G(1) PROGRESSION; SENESCENCE; EXPRESSION; GENES; ID1; P16/INK4A; CARCINOMA	The helix-loop-helix protein Id-1 has been suggested to play a positive role in cell proliferation and tumorigenesis of many types of human cancers. However, little is known about the molecular mechanism involved in the function of Id-1. In this study, using four stable Id-1 transfectant clones, we investigated the involvement of MAPK signaling pathway in the Id-1 induced serum independent prostate cancer cell growth. Our results demonstrated that both transient and stable ectopic Id-1 expression in prostate cancer LNCaP cells led to activation of the Raf/MEK1/2 signaling pathway. In addition, inhibition of MEK1/2 phosphorylation by one of its inhibitors, PD098059, resulted in the decreased cell cycle S phase fraction and cell growth rate, suggesting that activation of MAPK signaling pathway is essential for Id-1 induced prostate cancer cell proliferation. Furthermore, treatment with antisense oligonucleotide complementary to Id-1 mRNA in PC-3 and DU145 cells resulted in a decreased Id-1 expression which was accompanied by decreased Egr-1 protein. Our results suggest for the first time that the function of Id-1 is associated with MAPK signaling pathway activation and indicate a possible novel mechanism in which Id-1 regulates prostate cancer cell growth and tumorigenesis.	Univ Hong Kong, Dept Anat, Fac Med, Lab Block,Canc Biol Lab, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Cent Lab, Inst Mol Technol Drug Discovery & Synthesis, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Wong, Y (corresponding author), Univ Hong Kong, Dept Anat, Fac Med, Lab Block,Canc Biol Lab, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.		Tsao, George/C-4422-2009	Lee, Kin Wah/0000-0003-0682-322X				Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eid MA, 1998, CANCER RES, V58, P2461; Fan MY, 2000, CANCER RES, V60, P6403; Gioeli D, 1999, CANCER RES, V59, P279; HARA E, 1994, J BIOL CHEM, V269, P2139; Kawashita Y, 1999, HUM GENE THER, V10, P1509, DOI 10.1089/10430349950017842; Kleeff J, 1998, CANCER RES, V58, P3769; Langlands K, 2000, CANCER RES, V60, P5929; Lin CQ, 2000, CANCER RES, V60, P1332; Ling MT, 2001, J ENDOCRINOL, V170, P287, DOI 10.1677/joe.0.1700287; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Ouyang XS, 2002, J UROLOGY, V167, P2598, DOI 10.1016/S0022-5347(05)65044-6; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Polsky D, 2001, CANCER RES, V61, P6008; Ristow HJ, 1996, GROWTH REGULAT, V6, P96; Sakurai D, 2001, BIOCHEM BIOPH RES CO, V284, P436, DOI 10.1006/bbrc.2001.4974; Schindl M, 2001, CANCER RES, V61, P5703; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	29	89	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8498	8505		10.1038/sj.onc.1206007	http://dx.doi.org/10.1038/sj.onc.1206007			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466969	Green Submitted			2022-12-25	WOS:000179480100012
J	Joussen, AM; Poulaki, V; Mitsiades, N; Cai, WY; Suzuma, I; Pak, J; Ju, ST; Rook, SL; Esser, P; Mitsiades, C; Kirchhof, B; Adamis, AP; Aiello, LP				Joussen, AM; Poulaki, V; Mitsiades, N; Cai, WY; Suzuma, I; Pak, J; Ju, ST; Rook, SL; Esser, P; Mitsiades, C; Kirchhof, B; Adamis, AP; Aiello, LP			Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes	FASEB JOURNAL			English	Article						diabetic retinopathy; apoptosis; leukocyte adhesion	ADHESION MOLECULE-1; VASCULAR-PERMEABILITY; DOWN-REGULATION; LIGAND; EXPRESSION; DEATH; LEUKOSTASIS; MECHANISM; MEMBER	Diabetic macular edema, resulting from increased microvascular permeability, is the most prevalent cause of vision loss in diabetes. The mechanisms underlying this complication remain poorly understood. In the current study, diabetic vascular permeability (blood-retinal barrier breakdown) is demonstrated to result from a leukocyte-mediated Fas-FasL-dependent apoptosis of the retinal vasculature. Following the onset of streptozotocin-induced diabetes, FasL expression was increased in rat neutrophils (P<0.005) and was accompanied by a simultaneous increase in Fas expression in the retinal vasculature. Static adhesion assays demonstrated that neutrophils from diabetic, but not control, rats induced endothelial cell apoptosis in vitro (P<0.005). The latter was inhibited via an antibody-based FasL blockade (P<0.005). In vivo, the inhibition of FasL potently reduced retinal vascular endothelial cell injury, apoptosis, and blood-retinal barrier breakdown (P<0.0001) but did not diminish leukocyte adhesion to the diabetic retinal vasculature. Taken together, these data are the first to identify leukocyte-mediated Fas-FasL-dependent retinal endothelial cell apoptosis as a major cause of blood-retinal barrier breakdown in early diabetes. These data imply that the targeting of the Fas-FasL pathway may prove beneficial in the treatment of diabetic retinopathy.	Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med ZMMK, D-50931 Cologne, Germany; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Inst, Boston, MA 02114 USA; Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Surg Res Labs, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA	University of Cologne; University of Cologne; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Joussen, AM (corresponding author), Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	JoussenA@aol.com; tony_adamis@meei.harvard.edu	Joussen, Antonia/AAA-6901-2022					Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; Cardier JE, 1999, FASEB J, V13, P1950, DOI 10.1096/fasebj.13.14.1950; Carley William W., 1996, Microcirculation (Philadelphia), V3, P359, DOI 10.3109/10739689609148308; Choi C, 1999, J IMMUNOL, V162, P1889; DODGE AB, 1991, COMP BIOCHEM PHYS B, V98, P461, DOI 10.1016/0305-0491(91)90240-E; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1; Koeplinger KA, 2000, PROTEIN EXPRES PURIF, V18, P378, DOI 10.1006/prep.2000.1205; Kraling BM, 1998, IN VITRO CELL DEV-AN, V34, P308; MCLEOD DS, 1995, AM J PATHOL, V147, P642; Mitsiades N, 1998, J CLIN ENDOCR METAB, V83, P2199, DOI 10.1210/jc.83.6.2199; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Nakayama M, 2002, DIABETES, V51, P1391, DOI 10.2337/diabetes.51.5.1391; Ohta N, 1999, J DIABETES COMPLICAT, V13, P151, DOI 10.1016/S1056-8727(99)00040-9; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; POULAKI V, 2002, IN PRESS EXP EYE RES; Rawson RA, 1943, AM J PHYSIOL, V138, P0708, DOI 10.1152/ajplegacy.1943.138.5.708; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; SCHRODER S, 1991, AM J PATHOL, V139, P81; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Walsh K, 1999, MOL MED TODAY, V5, P61, DOI 10.1016/S1357-4310(98)01415-4	29	138	159	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					76	+		10.1096/fj.02-0157fje	http://dx.doi.org/10.1096/fj.02-0157fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475915				2022-12-25	WOS:000180218500021
J	Bubacco, L; van Gastel, M; Groenen, EJJ; Vijgenboom, E; Canters, GW				Bubacco, L; van Gastel, M; Groenen, EJJ; Vijgenboom, E; Canters, GW			Spectroscopic characterization of the electronic changes in the active site of Streptomyces antibioticus tyrosinase upon binding of transition state analogue inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN-ECHO ENVELOPE; CRYSTAL-STRUCTURE; NUCLEAR MODULATION; COPPER SITE; HEMOCYANIN; IMIDAZOLE; COMPLEXES; PROTEINS; CU(II); MODEL	The dinuclear copper enzyme tyrosinase (Ty) from genetically engineered Streptomyces antibioticus has been investigated in its paramagnetic half-met form [Cu(I)-Cu(II)]. The cw EPR, pulsed EPR, and hyperfine sublevel correlation spectroscopy (HYSCORE) experiments on the half-met-Ty and on its complexes with three different types of competitive inhibitor are reported. The first type includes p-nitrophenol, a very poor substrate for the monooxygenase activity of Ty. The second type comprises hydroxyquinones, such as kojic acid and L-mimosine, and the third type of inhibitor is represented by toluic acid. The electronic and structural differences of the half-met-Ty form induced at the cupric site by the different inhibitors have been determined. Probes of structural effects are the hyperfine coupling constants of the non coordinating Ndelta histidyl nitrogens. By using the available crystal structures of hemocyanin as a template in combination with the spectroscopic results, a structural model for the active site of half-met-Ty is obtained and a model for the binding modes of both mono- and diphenols could be proposed.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Univ Padua, Dept Biol, I-35121 Padua, Italy; Leiden Univ, Huygens Lab, Dept Mol Phys, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; University of Padua; Leiden University; Leiden University - Excl LUMC	Canters, GW (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, POB 9502, NL-2300 RA Leiden, Netherlands.		Bubacco, Luigi/B-5602-2012; van Gastel, Maurice/G-8572-2012	Bubacco, Luigi/0000-0001-7927-9208; van Gastel, Maurice/0000-0002-1547-6365; Vijgenboom, Erik/0000-0002-5059-069X				Abragam A., 1970, ELECT PARAMAGNETIC R; ABUHIJLEH AL, 1993, INORG CHIM ACTA, V209, P187, DOI 10.1016/S0020-1693(00)85140-3; BARTA G, 1992, INORG CHEM, V31, P1575; Bhalla R, 1997, INORG CHEM, V36, P2944, DOI 10.1021/ic961204c; Bubacco L, 1999, FEBS LETT, V442, P215, DOI 10.1016/S0014-5793(98)01662-7; Bubacco L, 2000, J MOL CATAL B-ENZYM, V8, P27, DOI 10.1016/S1381-1177(99)00064-8; BUBACCO L, 1995, BIOCHEMISTRY-US, V34, P1524, DOI 10.1021/bi00005a008; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Colaneri MJ, 2000, BIOCHEMISTRY-US, V39, P584, DOI 10.1021/bi991613v; CONRAD JS, 1994, BIOCHEMISTRY-US, V33, P5739, DOI 10.1021/bi00185a010; Coremans JWA, 1996, J AM CHEM SOC, V118, P12141, DOI 10.1021/ja962076u; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Decker H, 2000, ANGEW CHEM INT EDIT, V39, P1591, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1591::AID-ANIE1591>3.0.CO;2-H; DECKER H, 2000, TRENDS BIOCH, V25; DISSELHORST JAJM, 1995, J MAGN RESON SER A, V115, P183, DOI 10.1006/jmra.1995.1165; HAZES B, 1993, PROTEIN SCI, V2, P597; HAZES B, 1992, PROTEINS, V12, P278, DOI 10.1002/prot.340120306; HIMMELWRIGHT RS, 1980, J AM CHEM SOC, V102, P7339, DOI 10.1021/ja00544a031; JACKMAN MP, 1991, BIOCHEM J, V274, P707, DOI 10.1042/bj2740707; JIANG F, 1990, J AM CHEM SOC, V112, P9035, DOI 10.1021/ja00181a002; JOLLEY RL, 1974, J BIOL CHEM, V249, P335; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KITAJIMA N, 1992, J AM CHEM SOC, V114, P1277, DOI 10.1021/ja00030a025; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; LERCH K, 1972, EUR J BIOCHEM, V31, P427, DOI 10.1111/j.1432-1033.1972.tb02549.x; MAGLIOZZO RS, 1995, BIOCHEMISTRY-US, V34, P1513, DOI 10.1021/bi00005a007; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MIMS WB, 1978, J CHEM PHYS, V69, P4921, DOI 10.1063/1.436479; MIMS WB, 1977, J CHEM PHYS, V66, P5536, DOI 10.1063/1.433875; MONDOVI B, 1977, BIOCHEMISTRY-US, V16, P4189; NEESE F, 1995, QCPE B, V15, P5; Olesen K, 1998, BIOCHEMISTRY-US, V37, P6086, DOI 10.1021/bi971603z; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; REINHARD H, 1994, J PHYS CHEM-US, V98, P8806, DOI 10.1021/j100086a035; ROSENBERG RC, 1975, J AM CHEM SOC, V97, P2092, DOI 10.1021/ja00841a016; SAKAGUCHI JCS, 1978, J CHEM SOC DA, P600; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; van Gastel M, 2000, FEBS LETT, V474, P228, DOI 10.1016/S0014-5793(00)01609-4; van Gastel M, 1998, J PHYS CHEM A, V102, P4462, DOI 10.1021/jp980584f; VOLBEDA A, 1989, J MOL BIOL, V206, P531, DOI 10.1016/0022-2836(89)90499-3; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; WINKLER ME, 1981, J AM CHEM SOC, V103, P7001, DOI 10.1021/ja00413a055; WOOLERY GL, 1984, BIOCHIM BIOPHYS ACTA, V788, P155, DOI 10.1016/0167-4838(84)90257-7	45	34	34	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7381	7389		10.1074/jbc.M206394200	http://dx.doi.org/10.1074/jbc.M206394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12473668	Green Published, hybrid			2022-12-25	WOS:000181195100097
J	Hillebrand, H; Schmidt, A; Krauth-Siegel, RL				Hillebrand, H; Schmidt, A; Krauth-Siegel, RL			A second class of peroxidases linked to the trypanothione metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; TRYPANOSOMA-BRUCEI; OXIDATIVE STRESS; BLOOD-STREAM; HUMAN PLASMA; TRYPAREDOXIN; REDUCTASE; CRUZI; GENE; MITOCHONDRIAL	Trypanosoma brucei, the causative agent of African sleeping sickness, has three nearly identical genes encoding cysteine homologues of classical selenocysteine-containing glutathione peroxidases. The proteins are expressed in the mammalian and insect stages of the parasite. One of the genes, which contains a mitochondrial as well as a glycosomal targeting signal has been overexpressed. The recombinant T. brucei peroxidase has a high preference for the trypanothione/tryparedoxin couple as electron donor for the reduction of different hydroperoxides but accepts also T. brucei thioredoxin. The apparent rate constants k(2)' for the regeneration of the reduced enzyme are 2 X 10(5) m(-1) s(-1) with tryparedoxin and 5 x 10(3) m(-1) s(-1) with thioredoxin. No saturation kinetics was observed and the rate-limiting step of the overall reaction is reduction of the hydroperoxide. With glutathione, the peroxidase has marginal activity and reduction of the enzymes becomes limiting with a k(2)' value of 3 m(-1) s(-1). The T. brucei peroxidase, in contrast to the related Trypanosoma cruzi enzyme, also accepts hydrogen peroxide as substrate. The catalytic efficiency of the peroxidase studied here is comparable with that of the peroxiredoxin-like tryparedoxin peroxidases, which shows that trypanosomes possess two distinct peroxidase systems both dependent on the unique dithiol trypanothione.	Univ Heidelberg, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Univ Heidelberg, Biochem Zentrum Heidelberg, Neuenheimer Feld 504, D-69120 Heidelberg, Germany.		Hillebrand, Helmut/I-1717-2014	Hillebrand, Helmut/0000-0001-7449-1613				Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Augustyns K, 2001, CURR PHARM DESIGN, V7, P1117, DOI 10.2174/1381612013397564; Aumann KD, 1997, BIOMED ENVIRON SCI, V10, P136; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; Brigelius-Flohe R, 2002, METHOD ENZYMOL, V347, P101; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P27670; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; Flohe L, 2002, METHOD ENZYMOL, V347, P244; FLOHE L, 1971, H-S Z PHYSIOL CHEM, V352, P159, DOI 10.1515/bchm2.1971.352.1.159; FORSTROM JW, 1979, ARCH BIOCHEM BIOPHYS, V193, P51, DOI 10.1016/0003-9861(79)90007-9; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; Hausler T, 1997, EUR J CELL BIOL, V73, P240; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; KORNBLATT MJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P25, DOI 10.1016/0003-9861(92)90360-9; KrauthSiegel RL, 1996, MOL BIOCHEM PARASIT, V80, P203, DOI 10.1016/0166-6851(96)02689-8; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; Melville SE, 2000, MOL BIOCHEM PARASIT, V111, P261, DOI 10.1016/S0166-6851(00)00316-9; Mukhopadhyay R, 1996, P NATL ACAD SCI USA, V93, P10383, DOI 10.1073/pnas.93.19.10383; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Ren B, 1997, J MOL BIOL, V268, P869, DOI 10.1006/jmbi.1997.1005; Schmidt Armin, 2002, Current Topics in Medicinal Chemistry, V2, P1239, DOI 10.2174/1568026023393048; Schoneck R, 1997, EUR J BIOCHEM, V243, P739, DOI 10.1111/j.1432-1033.1997.00739.x; Shahi SK, 2002, MOL MICROBIOL, V43, P1129, DOI 10.1046/j.1365-2958.2002.02831.x; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; Steinert P, 2000, BIOL CHEM, V381, P211, DOI 10.1515/BC.2000.028; Sugimoto M, 1997, GENES GENET SYST, V72, P311, DOI 10.1266/ggs.72.311; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; Sztajer H, 2001, J BIOL CHEM, V276, P7397, DOI 10.1074/jbc.M008631200; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; TURNER CMR, 1990, PARASITOLOGY, V101, P377, DOI 10.1017/S0031182000060571; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P1; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; Wilkinson SR, 2000, BIOCHEM J, V352, P755, DOI 10.1042/0264-6021:3520755; WILLIAMS DL, 1992, MOL BIOCHEM PARASIT, V52, P127, DOI 10.1016/0166-6851(92)90042-I	44	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6809	6815		10.1074/jbc.M210392200	http://dx.doi.org/10.1074/jbc.M210392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12466271	hybrid			2022-12-25	WOS:000181195100024
J	Zhou, J; Scholes, J; Hsieh, JT				Zhou, J; Scholes, J; Hsieh, JT			Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; TYROSINE KINASE HCK; CRYSTAL-STRUCTURE; SH3 DOMAIN; CARCINOMA-CELLS; PROTEIN; BINDING; PHOSPHORYLATION; INHIBITION; MECHANISM	DOC-2/DAB2 is a potent tumor suppressor in many cancer types including prostate cancer. In prostate cancer, expression of DOC-2/DAB2 can inhibit its growth. Our recent studies demonstrate that DOC-2/DAB2 can suppress both protein kinase C and peptide growth factor-elicited signal pathways via the Ras-mitogen-activated protein kinase pathway. In this study, we further showed that the proline-rich domain of DOC-2/DAB2 could also interact with proteins containing the Src homology 3 domain, such as Src and Fgr. The binding of c-Src to DOC-2/DAB2 was enhanced in cells treated with growth factor, and this interaction resulted in c-Src inactivation. The c-Src inactivation was evidenced by the decreased tyrosine 416 phosphorylation of c-Src and reduced downstream effector activation. It appears that DOC-2/DAB2 can bind to Src homology 3 domain of c-Src and maintain it in an inactive conformation. Thus, this study provides a new mechanism for modulating c-Src in prostatic epithelium and cancer.	Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hsieh, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Urol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	JT.Hsieh@UTSouthwestern.edu			NIDDK NIH HHS [DK 47657] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047657] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Mayer BJ, 1997, CURR BIOL, V7, pR295, DOI 10.1016/S0960-9822(06)00141-2; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Potts W M, 1988, Oncogene Res, V3, P343; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	29	52	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6936	6941		10.1074/jbc.M210628200	http://dx.doi.org/10.1074/jbc.M210628200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12473651	hybrid			2022-12-25	WOS:000181195100040
J	Bar, I; Tissir, F; de Rouvroit, CL; De Backer, O; Goffinet, AM				Bar, I; Tissir, F; de Rouvroit, CL; De Backer, O; Goffinet, AM			The gene encoding Disabled-1 (DAB1), the intracellular adaptor of the reelin pathway, reveals unusual complexity in human and mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL MIGRATION; MESSENGER-RNA; TYROSINE PHOSPHORYLATION; BRAIN-DEVELOPMENT; VLDL RECEPTOR; SPINAL-CORD; CELL-CYCLE; MICE; EXPRESSION; BINDING	The Disabled-1 (Dab1) gene encodes a key regulator of Reelin signaling. Reelin is a large glycoprotein secreted by neurons of the developing brain, particularly Cajal-Retzius cells. The DAB1 protein docks to the intracellular part of the Reelin very low density lipoprotein receptor and apoE receptor type 2 and becomes tyrosine-phosphorylated following binding of Reelin to cortical neurons. In mice, mutations of Dab1 and Reelin generate identical phenotypes. In humans, Reelin mutations are associated with brain malformations and mental retardation; mutations in DAB1 have not been identified. Here, we define the organization of Dab1, which is similar in human and mouse. The Dab1 gene spreads over 1100 kb of genomic DNA and is composed of 14 exons encoding the major protein form, some alternative internal exons, and multiple 5'-exons. Alternative polyadenylation and splicing events generate DAB1 isoforms. Several 5'-untranslated regions (UTRs) correspond to different promoters. Two 5'-UTRs (1A and 1B) are predominantly used in the developing brain. 5'-UTR 1B is composed of 10 small exons spread over 800 kb. With a genomic length of 1.1 Mbp for a coding region of 5.5 kb, Dab1 provides a rare example of genomic complexity, which will impede the identification of human mutations.	Univ Namur, Sch Med, Neurobiol Unit, B-5000 Namur, Belgium; Catholic Univ Louvain, Sch Med, Dev Genet Unit, B-1200 Brussels, Belgium	University of Namur; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Bar, I (corresponding author), Univ Namur, Sch Med, Neurobiol Unit, 61 Rue Bruxelles, B-5000 Namur, Belgium.	Isabelle.Bar@fundp.ac.be	bar, isabelle/AAQ-7795-2020	Tissir, Fadel/0000-0002-9292-6622				Bernier B, 1999, J COMP NEUROL, V413, P463, DOI 10.1002/(SICI)1096-9861(19991025)413:3<463::AID-CNE8>3.0.CO;2-F; Carroll P, 2001, MOL CELL NEUROSCI, V17, P611, DOI 10.1006/mcne.2001.0966; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; de Rouvroit CL, 2001, MECH DEVELOP, V105, P47, DOI 10.1016/S0925-4773(01)00396-3; Feng YY, 2001, NAT REV NEUROSCI, V2, P408, DOI 10.1038/35077559; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Herrick TM, 2002, DEVELOPMENT, V129, P787; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Kojima T, 2000, MOL BRAIN RES, V75, P121, DOI 10.1016/S0169-328X(99)00313-7; Lambert de Rouvroit C, 1998, Adv Anat Embryol Cell Biol, V150, P1; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Monuki ES, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn752; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Pesole G, 2002, NUCLEIC ACIDS RES, V30, P335, DOI 10.1093/nar/30.1.335; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Redina OE, 1998, GENE, V222, P53, DOI 10.1016/S0378-1119(98)00465-X; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 2000, J COMP NEUROL, V424, P327, DOI 10.1002/1096-9861(20000821)424:2<327::AID-CNE10>3.0.CO;2-6; Scherer SW, 1997, GENOMICS, V44, P232, DOI 10.1006/geno.1997.4842; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng ZJ, 2001, GENE, V268, P31, DOI 10.1016/S0378-1119(01)00401-2; Sheng ZJ, 2000, GENOMICS, V70, P381, DOI 10.1006/geno.2000.6383; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; TAKAHASHI T, 1995, J NEUROSCI, V15, P6046; TENNYSON CN, 1995, NAT GENET, V9, P184, DOI 10.1038/ng0295-184; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Valent A, 1997, EUR J HUM GENET, V5, P102, DOI 10.1159/000484742; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Yip JW, 2000, P NATL ACAD SCI USA, V97, P8612, DOI 10.1073/pnas.150040497	40	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5802	5812		10.1074/jbc.M207178200	http://dx.doi.org/10.1074/jbc.M207178200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12446734	hybrid			2022-12-25	WOS:000181129400041
J	Ramon, E; del Valle, LJ; Garriga, P				Ramon, E; del Valle, LJ; Garriga, P			Unusual thermal and conformational properties of the rhodopsin congenital night blindness mutant Thr-94 -> Ile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINITIS-PIGMENTOSA; BOVINE RHODOPSIN; SCHIFF-BASE; INTRADISCAL DOMAIN; PEPTIDE BACKBONE; POINT MUTANTS; MUTATION; GENE; EXPRESSION; ACTIVATION	Naturally occurring point mutations in the opsin gene cause the retinal diseases retinitis pigmentosa and congenital night blindness. Although these diseases involve similar mutations in very close locations in rhodopsin, their progression is very different, with retinitis pigmentosa being severe and causing retinal degeneration. We report on the expression and characterization of the recently found T94I mutation associated with congenital night blindness, in the second transmembrane helix or rhodopsin, and mutations at the same site. T94I mutant rhodopsin folded properly and was able to bind 11-cis-retinal to form chromophore, but it showed a blue-shifted visible band at 478 nm and reduced molar extinction coefficient. Furthermore, T94I showed dramatically reduced thermal stability, extremely long lived metarhodopsin 11 intermediate, and highly increased reactivity toward hydroxylamine in the dark, when compared with wild type rhodopsin. The results are consistent with the location of Thr-94 in close proximity to Glu-113 counterion in the vicinity of the Schiff base linkage and suggest a role for this residue in maintaining the correct dark inactive conformation of the receptor. The reported results, together with previously published data on the other two known congenital night blindness mutants, suggest that the molecular mechanism underlying this disease may not be structural misfolding, as proposed for retinitis pigmentosa mutants, but abnormal functioning of the receptor by decreased thermal stability and/or constitutive activity.	Univ Politecn Catalunya, Dept Engn Quim, Catalonia 08222, Spain	Universitat Politecnica de Catalunya	Garriga, P (corresponding author), Univ Politecn Catalunya, Dept Engn Quim, Colom 1, Catalonia 08222, Spain.		Del Valle, Luis J./I-1342-2015; Garriga, Pere/C-1949-2017	Del Valle, Luis J./0000-0001-9916-1741; Garriga, Pere/0000-0003-4234-8382				al-Jandal N, 1999, HUM MUTAT, V13, P75, DOI 10.1002/(SICI)1098-1004(1999)13:1<75::AID-HUMU9>3.0.CO;2-4; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; DENG H, 1994, BIOPHYS J, V66, P1129, DOI 10.1016/S0006-3495(94)80893-8; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; Eilers M, 1999, P NATL ACAD SCI USA, V96, P487, DOI 10.1073/pnas.96.2.487; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; Farrar GJ, 2002, EMBO J, V21, P857, DOI 10.1093/emboj/21.5.857; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; Garriga P, 2002, FEBS LETT, V528, P17, DOI 10.1016/S0014-5793(02)03241-6; Garriga P, 1996, P NATL ACAD SCI USA, V93, P4560, DOI 10.1073/pnas.93.10.4560; Han M, 2000, METHOD ENZYMOL, V315, P251; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Inglehearn CF, 1998, EYE, V12, P571, DOI 10.1038/eye.1998.147; JAGER S, 1996, BIOCHEMISTRY-US, V35, P2908; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; LIU RSH, 1982, METHOD ENZYMOL, V88, P506; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; Nagata T, 1997, BIOCHEMISTRY-US, V36, P6164, DOI 10.1021/bi962920t; Nagata T, 1998, BIOCHEMISTRY-US, V37, P17216, DOI 10.1021/bi9810149; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Peralvarez A, 2001, FEBS LETT, V508, P399, DOI 10.1016/S0014-5793(01)03080-0; POGOZHEVA ID, 1997, BIOPHYS J, V70, P1963; Rao VR, 1996, ANNU REV BIOPH BIOM, V25, P287; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SIEVING PA, 1995, P NATL ACAD SCI USA, V92, P880, DOI 10.1073/pnas.92.3.880; Sieving PA, 2001, J NEUROSCI, V21, P5449, DOI 10.1523/JNEUROSCI.21-15-05449.2001; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0	36	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6427	6432		10.1074/jbc.M210929200	http://dx.doi.org/10.1074/jbc.M210929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12466267	hybrid			2022-12-25	WOS:000181129400116
J	Skouboe, C; Bjergbaek, L; Oestergaard, VH; Larsen, MK; Knudsen, BR; Andersen, AH				Skouboe, C; Bjergbaek, L; Oestergaard, VH; Larsen, MK; Knudsen, BR; Andersen, AH			A human topoisomerase II alpha heterodimer with only one ATP binding site can go through successive catalytic cycles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TRANSPORT; SACCHAROMYCES-CEREVISIAE; ANTINEOPLASTIC DRUGS; PROTEIN CLAMP; STEADY-STATE; ENZYME; DOMAIN; MECHANISM; BISDIOXOPIPERAZINES; COMMUNICATION	Eukaryotic DNA topoisomerase II is a dimeric nuclear enzyme essential for DNA metabolism and chromosome dynamics. It changes the topology of DNA by coupling binding and hydrolysis of two ATP molecules to the transport of one DNA duplex through a temporary break introduced in another. During this process the structurally and functionally complex enzyme passes through a cascade of conformational changes, which requires intra- and intersubunit communication. To study the importance of ATP binding and hydrolysis in relation to DNA strand transfer, we have purified and characterized a human topoisomerase IIalpha heterodimer with only one ATP binding site. The heterodimer was able to relax supercoiled DNA, although less efficiently than the wild type enzyme. It furthermore possessed a functional N-terminal clamp and was sensitive to ICRF-187. This demonstrates that human topoisomerase IIalpha can pass through all the conformations required for DNA strand passage and enzyme resetting with binding and hydrolysis of only one ATP. However, the heterodimer lacked the normal stimulatory effect of DNA on ATP binding and hydrolysis as well as the stimulatory effect of ATP on DNA cleavage. The results can be explained in a model, where efficient catalysis requires an extensive communication between the second ATP and the DNA segment to be cleaved.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, AH (corresponding author), Aarhus Univ, Dept Mol Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.		Bjergbæk, Lotte/AAW-6302-2021; Andersen, Anni/O-1162-2017; Oestergaard, Vibe Hallundbæk/B-7254-2015	Oestergaard, Vibe Hallundbæk/0000-0002-1633-0560; Bjergbaek, Lotte/0000-0002-8233-3356; Knudsen, Birgitta Ruth/0000-0002-3484-3802; Andersen, Anni/0000-0001-7194-3258				Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Baird CL, 2001, J BIOL CHEM, V276, P27893, DOI 10.1074/jbc.M102544200; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Biersack H, 1996, P NATL ACAD SCI USA, V93, P8288, DOI 10.1073/pnas.93.16.8288; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chang S, 1998, J BIOL CHEM, V273, P19822, DOI 10.1074/jbc.273.31.19822; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Jensen S, 1996, MOL CELL BIOL, V16, P3866; JENSEN TH, 1995, GENE, V162, P235, DOI 10.1016/0378-1119(95)00328-4; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Morris SK, 2000, J BIOL CHEM, V275, P2613, DOI 10.1074/jbc.275.4.2613; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; ODea MH, 1996, J BIOL CHEM, V271, P9723, DOI 10.1074/jbc.271.16.9723; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Patel S, 2000, MOL PHARMACOL, V58, P560, DOI 10.1124/mol.58.3.560; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sehested M, 1998, CANCER RES, V58, P1460; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wessel I, 1999, CANCER RES, V59, P3442; Wessel I, 2002, FEBS LETT, V520, P161, DOI 10.1016/S0014-5793(02)02805-3; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	31	24	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5768	5774		10.1074/jbc.M210332200	http://dx.doi.org/10.1074/jbc.M210332200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480934	hybrid			2022-12-25	WOS:000181129400037
J	Davey, MJ; Indiani, C; O'Donnell, M				Davey, MJ; Indiani, C; O'Donnell, M			Reconstitution of the Mcm2-7p Heterohexamer, subunit arrangement, and ATP site architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE ACTIVITY; MINICHROMOSOME MAINTENANCE PROTEIN; SINGLE-STRANDED-DNA; MCM-PROTEINS; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SCHIZOSACCHAROMYCES-POMBE; NUCLEOTIDE-BINDING; COMPLEX-FORMATION	The Mcm2-7p heterohexamer is the presumed replicative helicase in eukaryotic cells. Each of the six subunits is required for replication. We have purified the six Saccharomyces cerevisiae MCM proteins as recombinant proteins in Escherichia coli and have reconstituted the Mcm2-7p complex from individual subunits. Study of MCM ATPase activity demonstrates that no MCM protein hydrolyzes ATP efficiently. ATP hydrolysis requires a combination of two MCM proteins. The fifteen possible pairwise mixtures of MCM proteins yield only three pairs of MCM proteins that produce ATPase activity. Study of the Mcm3/7p ATPase shows that an essential arginine in Mcm3p is required for hydrolysis of the ATP bound to Mcm7p. Study of the pairwise interactions between MCM proteins connects the remaining MCM proteins to the Mcm3/7p pair. The data predict which subunits in the ATPase pairs bind the ATP that is hydrolyzed and indicate the arrangement of subunits in the Mcm2-7p heterohexamer.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	O'Donnell, M (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.		Davey, Megan/B-4066-2012	O'Donnell, Michael/0000-0001-9002-4214	PHS HHS [38839] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BURKE D, 1998, METHODS YEAST GENETI; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Cann IKO, 1999, GENETICS, V152, P1249; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Ishimi Y, 2001, J BIOL CHEM, V276, P42744, DOI 10.1074/jbc.M106861200; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Neuwald AF, 1999, GENOME RES, V9, P27; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PATEL SS, 1995, BIOPHYS J, V68, pS186; PATEL SS, 1995, BIOPHYS J, V68, P189; Prokhorova TA, 2000, J BIOL CHEM, V275, P2491, DOI 10.1074/jbc.275.4.2491; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	48	142	143	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4491	4499		10.1074/jbc.M210511200	http://dx.doi.org/10.1074/jbc.M210511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12480933	hybrid			2022-12-25	WOS:000180968900019
J	Kim, SJ; Beard, WA; Harvey, J; Shock, DD; Knutson, JR; Wilson, SH				Kim, SJ; Beard, WA; Harvey, J; Shock, DD; Knutson, JR; Wilson, SH			Rapid segmental and subdomain motions of DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; TRYPTOPHAN RESIDUES; STOCHASTIC SIMULATION; CATALYTIC MECHANISM; CRYSTAL-STRUCTURES; RNA-POLYMERASE; DOMAIN; SITE; COMPLEXES; DYNAMICS	DNA polymerase (pol) beta is a two-domain DNA repair enzyme that undergoes structural transitions upon binding substrates. Crystallographic structures indicate that these transitions include movement of the amino-terminal 8-kDa lyase domain relative to the 31-kDa polymerase domain. Additionally, a polymerase subdomain moves toward the nucleotide-binding pocket after nucleotide binding, resulting in critical contacts between alpha-helix N and the nascent base pair. Kinetic and structural characterization of pol beta has suggested that these conformational changes participate in stabilizing the ternary enzyme-substrate complex facilitating chemistry. To probe the microenvironment and dynamics of both the lyase domain and alpha-helix N in the polymerase domain, the single native tryptophan (Trp-325) of wild-type enzyme was replaced with alanine, and tryptophan was strategically substituted for residues in the lyase domain (F25W/W325A) or near the end of alpha-helix N (L287W/W325A). Influences of substrate on the fluorescence anisotropy decay of these single tryptophan forms of pol beta were determined. The results revealed that the segmental motion of alpha-helix N was rapid (similar to1 ns) and far more rapid than the step that limits chemistry. Binding of Mg2+ and/or gapped DNA did not cause a noticeable change in the rotational correlation time or angular amplitude of tryptophan in alpha-helix N. More important, binding of a correct nucleotide significantly limited the angular range of the nanosecond motion within alpha-helix N. In contrast, the segmental motion of the 8-kDa domain was "frozen" upon DNA binding alone, and this restriction did not increase further upon nucleotide binding. The dynamics of alpha-helix N are discussed from the perspective of the "open" to "closed" conformational change of pol beta deduced from crystallography, and the results are more generally discussed in the context of reaction cycle-regulated flexibility for proteins acting as molecular motors.	NHLBI, NIH, Biophys Chem Lab, Bethesda, MD 20892 USA; NIEHS, Struct Biol Lab, NIEHS, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NHLBI, NIH, Biophys Chem Lab, Bethesda, MD 20892 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001452, ZIAHL001452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050158, Z01ES050158] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j; Beard WA, 2002, J BIOL CHEM, V277, P8235, DOI 10.1074/jbc.M107286200; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; BRAND L, 1985, SPECTROSCOPY DYNAMIC; Brokaw CJ, 2000, CELL MOTIL CYTOSKEL, V47, P108, DOI 10.1002/1097-0169(200010)47:2<108::AID-CM2>3.3.CO;2-Z; Brokaw CJ, 2001, BIOPHYS J, V81, P1333, DOI 10.1016/S0006-3495(01)75790-6; CASASFINET JR, 1991, J MOL BIOL, V221, P693, DOI 10.1016/0022-2836(91)80081-5; CHUANG TJ, 1972, J CHEM PHYS, V57, P5094, DOI 10.1063/1.1678194; Clayton AHA, 2000, BIOPHYS J, V79, P1066, DOI 10.1016/S0006-3495(00)76360-0; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; Deterding LJ, 2000, J BIOL CHEM, V275, P10463, DOI 10.1074/jbc.275.14.10463; Dunlap CA, 2002, BIOCHEMISTRY-US, V41, P11226, DOI 10.1021/bi025837g; Gangal M, 1998, BIOCHEMISTRY-US, V37, P13728, DOI 10.1021/bi980560z; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Kemple MD, 1997, BIOCHEMISTRY-US, V36, P1678, DOI 10.1021/bi962146+; KIM SJ, 1994, J MOL BIOL, V244, P224, DOI 10.1006/jmbi.1994.1720; KNUTSON JR, 1982, BIOCHEMISTRY-US, V21, P4671, DOI 10.1021/bi00262a024; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; Kungl AJ, 1998, BIOCHEMISTRY-US, V37, P2778, DOI 10.1021/bi971654w; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Liu DJ, 1996, BIOCHEMISTRY-US, V35, P6188, DOI 10.1021/bi952656o; MUNRO I, 1979, P NATL ACAD SCI USA, V76, P56, DOI 10.1073/pnas.76.1.56; Nishimoto E, 1998, BIOCHEMISTRY-US, V37, P5599, DOI 10.1021/bi9718651; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; PRASAD R, 1994, TECHNIQUES PROTEIN C, V5, P359; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SEMISOTNOV GV, 1981, BIOPOLYMERS, V20, P2287, DOI 10.1002/bip.1981.360201102; She MD, 1997, BIOPHYS J, V73, P1042, DOI 10.1016/S0006-3495(97)78137-2; Shen F, 1996, J BIOL CHEM, V271, P4827; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Storch EM, 1999, BIOCHEMISTRY-US, V38, P5065, DOI 10.1021/bi982159i; TANFORD C, 1967, PHYSICAL CHEM MACROM, P432; Tcherkasskaya O, 2000, BIOCHEMISTRY-US, V39, P1879, DOI 10.1021/bi992117+; WAHL P, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P417, DOI 10.1073/pnas.65.2.417; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; WEBER G, 1969, BIOCHEMISTRY-US, V8, P361, DOI 10.1021/bi00829a050; Yang LJ, 2002, J MOL BIOL, V317, P651, DOI 10.1006/jmbi.2002.5450; Yguerabide J, 1972, Methods Enzymol, V26, P498; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124	48	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5072	5081		10.1074/jbc.M208472200	http://dx.doi.org/10.1074/jbc.M208472200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458221	hybrid			2022-12-25	WOS:000180968900093
J	Roy, A; Wonderlin, WF				Roy, A; Wonderlin, WF			The permeability of the endoplasmic reticulum is dynamically coupled to protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER MEMBRANE; CONDUCTING CHANNEL; TRANSLOCON; INHIBITION; INITIATION; APOPTOSIS; RIBOSOME	Proteins synthesized by the rough endoplasmic reticulum (RER) co-translationally cross the membrane through the pore of a ribosome-bound translocon (RBT) complex. Although this pore is also permeable to small molecules, it is generally thought that barriers to their permeation prevent the cyclical process of protein translation from affecting the permeability of the RER. We tested this hypothesis by culturing Chinese hamster ovary-S cells with inhibitors of protein translation that affect the occupancy of RBTs by nascent proteins and then permeabilizing the plasma membrane and measuring the permeability of the RER to a small molecule, 4-methyl-umbelliferyl-alpha-D-glucopyranoside (4-MalphaG). The premature or normal release of nascent proteins by puromycin or pactamycin, respectively, increased the permeability of the RER to 4-MaG by 20-30%. In contrast, inhibition of elongation and the release of nascent proteins by cycloheximide did not increase the permeability, but it prevented the increase in permeability by pactamycin. We conclude that the permeability of the RER is coupled to protein translation by a simple gating mechanism whereby a nascent protein blocks the pore of a RBT during translation, but after release of the nascent protein the pore is permeable to small molecules as long as an empty ribosome remains bound to the translocon.	W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA	West Virginia University	Wonderlin, WF (corresponding author), W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA.							ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; BALIGA BS, 1969, J BIOL CHEM, V244, P4480; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; CHOW SC, 1995, EXP CELL RES, V216, P149, DOI 10.1006/excr.1995.1019; FAWCET DW, 1981, CELL, P321; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Heritage D, 2001, J BIOL CHEM, V276, P22655, DOI 10.1074/jbc.M102409200; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Ioannou M, 1998, MOL PHARMACOL, V53, P1089; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; KELLEY LL, 1992, J CELL PHYSIOL, V151, P487, DOI 10.1002/jcp.1041510307; LODISH HF, 1971, BIOCHEMISTRY-US, V10, P2348, DOI 10.1021/bi00788a027; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MADEN BEH, 1968, EUR J BIOCHEM, V6, P309, DOI 10.1111/j.1432-1033.1968.tb00450.x; MEISSNER G, 1981, J BIOL CHEM, V256, P6413; Musat-Marcu S, 1999, J MOL CELL CARDIOL, V31, P1073, DOI 10.1006/jmcc.1999.0939; PESTKA S, 1972, P NATL ACAD SCI USA, V69, P624, DOI 10.1073/pnas.69.3.624; Pestka S, 1974, Methods Enzymol, V30, P261; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; Romisch K, 1999, J CELL SCI, V112, P4185; Seiser RM, 2000, J BIOL CHEM, V275, P33820, DOI 10.1074/jbc.M004462200; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STEWARTBLAIR ML, 1971, BIOCHEMISTRY-US, V10, P4198, DOI 10.1021/bi00799a007	25	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4397	4403		10.1074/jbc.M207295200	http://dx.doi.org/10.1074/jbc.M207295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458217	Green Published, hybrid			2022-12-25	WOS:000180968900006
J	Smith, IF; Boyle, JP; Plant, LD; Pearson, HA; Peers, C				Smith, IF; Boyle, JP; Plant, LD; Pearson, HA; Peers, C			Hypoxic remodeling of Ca2+ stores in type I cortical astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL CALCIUM ACCUMULATION; GENE-EXPRESSION; GLIAL-CELLS; NEURONS; BRADYKININ; GLUTAMATE; DEMENTIA; RELEASE; STROKE; BRAIN	Prolonged periods of hypoxia are deleterious to higher brain functions and increase the likelihood of developing dementias. Here, we have used fluorimetric techniques to investigate the effects of chronic hypoxia (2.5% O-2, 24 h) on Ca2+ stores in type I cortical astrocytes, because such stores are crucial to various astrocyte functions, including Ca2+-dependent modulation of neuronal activity. Rises of [Ca2+](i) evoked by exposure of astrocytes to bradykinin were enhanced following chronic hypoxia, as were transient increases in [Ca2+](i) recorded in Ca2+-free perfusate. The enhanced responses were due partly to impaired plasmalemmal Na+/Ca2+ exchange following chronic hypoxia. More importantly, chronic hypoxia increased the Ca2+ content of mitochondria (as determined by exposing cells to mitochondrial inhibitors), such that they were unable to act as Ca2+ buffers following bradykinin-evoked Ca2+ release from the endoplasmic reticulum. Hypoxic enhancement of mitochondrial Ca2+ content was also observed in confocal images of cells loaded with the mitochondrial Ca2+ indicator, Rhod-2. Confocal imaging of cells loaded with tetramethylrhodamine ethyl ester, an indicator of mitochondrial membrane potential, indicated that mitochondria were hyperpolarized in astrocytes following chronic hypoxia. Our findings indicate that hypoxia disturbs Ca2+ signaling in type I astrocytes, primarily by causing mitochondrial Ca2+ overload.	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Peers, C (corresponding author), Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England.		smith, ian/E-7528-2011; Boyle, John/N-4868-2016	Peers, Chris/0000-0002-8354-346X				Alvarez-Maubecin V, 2000, J NEUROSCI, V20, P4091; Araque A, 2001, ANNU REV PHYSIOL, V63, P795, DOI 10.1146/annurev.physiol.63.1.795; Barrett EF, 2001, J GEN PHYSIOL, V118, P79, DOI 10.1085/jgp.118.1.79; BeitnerJohnson D, 1997, RESP PHYSIOL, V110, P87, DOI 10.1016/S0034-5687(97)00075-3; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Bezzi P, 2001, Prog Brain Res, V132, P255; Budd SL, 1998, PHARMACOL THERAPEUT, V80, P203, DOI 10.1016/S0163-7258(98)00029-1; Carmignoto G, 2000, PROG NEUROBIOL, V62, P561, DOI 10.1016/S0301-0082(00)00029-0; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 2000, J APPL PHYSIOL, V88, P1880, DOI 10.1152/jappl.2000.88.5.1880; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Deitmer JW, 1998, CELL CALCIUM, V24, P405, DOI 10.1016/S0143-4160(98)90063-X; Fam SR, 2000, J NEUROSCI, V20, P2800; Giaume C, 1998, GLIA, V24, P50, DOI 10.1002/(SICI)1098-1136(199809)24:1<50::AID-GLIA6>3.0.CO;2-4; GIMPL G, 1992, NEUROSCI LETT, V144, P139, DOI 10.1016/0304-3940(92)90735-P; Grosche J, 1999, NAT NEUROSCI, V2, P139, DOI 10.1038/5692; Hohler B, 1999, FEBS LETT, V457, P53, DOI 10.1016/S0014-5793(99)00999-0; INCALZI RA, 1993, AM REV RESPIR DIS, V148, P418, DOI 10.1164/ajrccm/148.2.418; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; Koistinaho J, 1996, NEUROREPORT, V7, P2727, DOI 10.1097/00001756-199611040-00064; Kokmen E, 1996, NEUROLOGY, V46, P154, DOI 10.1212/WNL.46.1.154; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lee I, 2001, BIOL CHEM, V382, P1629, DOI 10.1515/BC.2001.198; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; Moroney JT, 1996, STROKE, V27, P1283, DOI 10.1161/01.STR.27.8.1283; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Opuni K, 2000, J BIOL CHEM, V275, P21549, DOI 10.1074/jbc.M003158200; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; Sergeeva M, 2000, NEUROSCIENCE, V97, P765, DOI 10.1016/S0306-4522(00)00062-2; Smith IF, 2001, J NEUROCHEM, V79, P877, DOI 10.1046/j.1471-4159.2001.00620.x; STEPHENS GJ, 1993, GLIA, V9, P269, DOI 10.1002/glia.440090405; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; TSIEN RY, 1994, HDB CONFOCAL MICROSC, P267; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Wang YX, 2000, FASEB J, V14, P1731, DOI 10.1096/fj.99-0859com; Waypa GB, 2001, CIRC RES, V88, P1259, DOI 10.1161/hh1201.091960	45	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4875	4881		10.1074/jbc.M209206200	http://dx.doi.org/10.1074/jbc.M209206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12477727	hybrid			2022-12-25	WOS:000180968900069
J	Sugatani, T; Alvarez, U; Hruska, KA				Sugatani, T; Alvarez, U; Hruska, KA			PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FOCAL ADHESION KINASE; TUMOR-SUPPRESSOR PTEN; BONE-RESORPTION; RECEPTOR ACTIVATOR; MIGRATION; PROTEIN; SURVIVAL; AKT; PHOSPHORYLATION	PTEN (also known as MMAC-1 or TEP-1) is a frequently mutated tumor suppressor gene in human cancer. PTEN functions have been identified in the regulation of cell survival, growth, adhesion, migration, and invasiveness. Here, we characterize the diverse signaling networks modulated by PTEN in osteoclast precursors stimulated by RANKL and osteopontin (OPN). RANKL dose-dependently stimulated transient activation of Akt before activation of PTEN, consistent with a role for PTEN in decreasing Akt activity. PTEN overexpression blocked RANKL-activated Akt stimulated survival and osteopontin-stimulated cell migration while a dominant-negative PTEN increased the actions of RANKL and OPN. PTEN overexpression suppressed RANKL-mediated osteoclast differentiation and OPN-stimulated cell migration. The PTEN dominant-negative constitutively induced osteoclast differentiation and cell migration. Our data demonstrate multiple roles for PTEN in RANKL-induced osteoclast differentiation and OPN-stimulated cell migration in RAW 264.7 osteoclast precursors.	Washington Univ, Sch Med, Dept Pewdiat, Cell & Mol Biol Unit, St Louis, MO 63110 USA; Mie Univ, Sch Med, Dept Oral & Maxillofacial Surg, Tsu, Mie 5148507, Japan	Washington University (WUSTL); Mie University	Hruska, KA (corresponding author), Washington Univ, Sch Med, Dept Pediat Med & Cell & Mol Biol, 5th Floor McDonnell Pediat Res Bldg,Campus Box 82, St Louis, MO 63110 USA.				NIAMS NIH HHS [AR41677] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041677] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Chambers TJ, 2000, J PATHOL, V192, P4; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; Huxford T, 1999, COLD SPRING HARB SYM, V64, P533, DOI 10.1101/sqb.1999.64.533; Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Ory S, 2000, J CELL SCI, V113, P1177; Razzouk S, 1999, EUR J CELL BIOL, V78, P249, DOI 10.1016/S0171-9335(99)80058-2; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stokoe D, 2001, CURR BIOL, V11, pR502, DOI 10.1016/S0960-9822(01)00303-7; Suda T, 1997, METHOD ENZYMOL, V282, P223; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; VAN AL, 1997, GENE DEV, V11, P2295; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; Yamada KM, 2001, J CELL SCI, V114, P2375; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156; ZHANG D, 1995, J CELL SCI, V108, P2285; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	53	83	91	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5001	5008		10.1074/jbc.M209299200	http://dx.doi.org/10.1074/jbc.M209299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12460992	hybrid			2022-12-25	WOS:000180968900085
J	Shaw-Reid, CA; Munshi, V; Graham, P; Wolfe, A; Witmer, M; Danzeisen, R; Olsen, DB; Carroll, SS; Embrey, M; Wai, JS; Miller, MD; Cole, JL; Hazuda, DJ				Shaw-Reid, CA; Munshi, V; Graham, P; Wolfe, A; Witmer, M; Danzeisen, R; Olsen, DB; Carroll, SS; Embrey, M; Wai, JS; Miller, MD; Cole, JL; Hazuda, DJ			Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 REVERSE-TRANSCRIPTASE; STRAND TRANSFER-REACTIONS; PYRIDINONE DERIVATIVES; VIRAL REPLICATION; DNA-POLYMERASE; SEQUENCE; DOMAIN	Human immunodeficiency virus-type 1 (HIV-1) reverse transcriptase (RT) coordinates DNA polymerization and ribonuclease H (RNase H) activities using two discrete active sites embedded within a single heterodimeric polyprotein. We have identified a novel thiophene diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid, that selectively inhibits polymerase-independent RNase H cleavage (IC50 = 3.2 mum) but has no effect on DNA polymerization (IC50 > 50 mum). The activity profile of the diketo acid is shown to be distinct from previously described compounds, including the polymerase inhibitor foscarnet and the putative RNase H inhibitor 4-chlorophenylhydrazone. Both foscarnet and the hydrazone inhibit RNase H cleavage and DNA polymerization activities of RT, yet neither inhibits the RNase H activity of RT containing a mutation in the polymerase active site (D185N) or an isolated HIV-1 RNase H domain chimera containing the alpha-C helix from Escherichia coli RNase HI, suggesting these compounds affect RNase H indirectly. In contrast, the diketo acid inhibits the RNase H activity of the isolated RNase H domain as well as full-length RT, and inhibition is not affected by the polymerase active site mutation. In isothermal titration calorimetry studies using the isolated RNase H domain, binding of the diketo acid is independent of nucleic acid but strictly requires Mn2+ implying a direct interaction between the inhibitor and the RNase H active site. These studies demonstrate that inhibition of HIV-1 RNase H may occur by either direct or indirect mechanisms, and they provide a framework for identifying novel agents such as 4-[5-(benzoylamino)thien2-yl]-2,4-dioxobutanoic acid that specifically targets RNase H.	Merck & Co Inc, Dept Biol Chem, Merck Res Labs, W Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA	Merck & Company; Merck & Company	Shaw-Reid, CA (corresponding author), Merck & Co Inc, Dept Biol Chem, Merck Res Labs, WP42-300,POB 4, W Point, PA 19486 USA.		Cole, James/G-2586-2011	olsen, david/0000-0001-5521-0206				Arion D, 2002, J BIOL CHEM, V277, P1370, DOI 10.1074/jbc.M110254200; BARBER HJ, 1961, J CHEM SOC, P2828, DOI 10.1039/jr9610002828; Borkow G, 1997, BIOCHEMISTRY-US, V36, P3179, DOI 10.1021/bi9624696; CARROLL SS, 1993, J BIOL CHEM, V268, P276; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; Davis WR, 2000, BIOCHEMISTRY-US, V39, P14279, DOI 10.1021/bi0015764; Gabbara S, 1999, BIOCHEMISTRY-US, V38, P13070, DOI 10.1021/bi991085n; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; KECK JL, 1995, P NATL ACAD SCI USA, V92, P2740, DOI 10.1073/pnas.92.7.2740; LOYA S, 1990, ANTIMICROB AGENTS CH, V34, P2009, DOI 10.1128/AAC.34.10.2009; Min BS, 2002, PHYTOTHER RES, V16, pS57, DOI 10.1002/ptr.808; MOHAN P, 1994, J MED CHEM, V37, P2513, DOI 10.1021/jm00042a004; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; Parniak M A, 2000, Adv Pharmacol, V49, P67; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; SCHATZ O, 1989, GENE REGULATION AIDS, P293; Sluis-Cremer N, 2002, MOL PHARMACOL, V62, P398, DOI 10.1124/mol.62.2.398; STAHL SJ, 1994, PROTEIN ENG, V7, P1103, DOI 10.1093/protein/7.9.1103; STAHLHUT M, 1994, PROTEIN EXPRES PURIF, V5, P614, DOI 10.1006/prep.1994.1084; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; YOUNG SD, 2000, Patent No. 6262055	24	146	152	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					2777	2780		10.1074/jbc.C200621200	http://dx.doi.org/10.1074/jbc.C200621200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12480948	hybrid			2022-12-25	WOS:000180915000002
J	Hobbs, SS; Coffing, SL; Le, AT; Cameron, EM; Williams, EE; Andrew, M; Blommel, EN; Hammer, RP; Chang, H; Riese, DJ				Hobbs, SS; Coffing, SL; Le, AT; Cameron, EM; Williams, EE; Andrew, M; Blommel, EN; Hammer, RP; Chang, H; Riese, DJ			Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation	ONCOGENE			English	Article						heregulins; neuregulins; ErbB3; ErbB4; HER3; HER4	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASES; SIGNALING NETWORK; CELLULAR-RESPONSE; BETA-RECEPTOR; EGF DOMAIN; HEREGULIN; PROTEIN; LIGAND	During the last decade, several novel members of the Epidermal Growth Factor family of peptide growth factors have been identified. Most prominent among these are the Neuregulins or Heregulins. To date, four different Neuregulin genes have been identified (Neuregulin1-4) and several different splicing isoforms have been identified for :at least two of these genes (Neuregulin1 and Neuregulin2). While Neuregulin1 isoforms have been extensively studied, comparatively little is known about Neuregulin3, Neuregulin4, or the Neuregulin2 isoforms. Indeed, there has been no systematic comparison of the activities of these molecules. Here we demonstrate that Neuregulin2alpha and Neuregulin2beta stimulate ErbB3 tyrosine phosphorylation and coupling to biological responses. In contrast, Neuregulin3 and Neuregulin4 fail to activate ErbB3 signaling. Furthermore, Neuregulin2beta, but not Neuregulin2alpha, stimulates ErbB4 tyrosine phosphorylation and coupling to biological responses. Finally, both Neuregulin3 and Neuregulin4 stimulate modest amounts of ErbB4 tyrosine phosphorylation. However, whereas Neuregulin3 stimulates a modest amount of ErbB4 coupling to biological responses, Neuregulin4 fails to stimulate ErbB4 coupling to biological responses. This suggests that there are qualitative as well as quantitative differences in ErbB family receptor activation by Neuregulin isoforms.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Louisiana State University System; Louisiana State University; Bristol-Myers Squibb	Riese, DJ (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, 1333 RHPH,Room 224D, W Lafayette, IN 47907 USA.		Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802	NCI NIH HHS [F33CA085049, R21CA080770] Funding Source: Medline; NIGMS NIH HHS [T32GM008737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F33CA085049, R21CA080770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; DrummondBarbosa D, 1997, BBA-REV CANCER, V1332, pM1, DOI 10.1016/S0304-419X(96)00034-0; Feroz K, 2002, CELL SIGNAL, V14, P793, DOI 10.1016/S0898-6568(02)00019-0; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Gullick WJ, 2001, ENDOCR-RELAT CANCER, V8, P75, DOI 10.1677/erc.0.0080075; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Hijazi MM, 1998, INT J ONCOL, V13, P1061; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Kumar R, 2000, J CLIN LIGAND ASSAY, V23, P233; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Ozawa F, 2001, TERATOGEN CARCIN MUT, V21, P27, DOI 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; Pinkas-Kramarski R, 1999, MOL CELL BIOL, V19, P8695; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; SWEENEYCROVELLO C, 1998, J BIOL CHEM, V273, P26954; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	39	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8442	8452		10.1038/sj.onc.1205960	http://dx.doi.org/10.1038/sj.onc.1205960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466964				2022-12-25	WOS:000179480100007
J	Perri, P; Longo, L; Cusano, R; McConville, CM; Rees, SA; Devoto, M; Conte, M; Ferrara, GB; Seri, M; Romeo, G; Tonini, GP				Perri, P; Longo, L; Cusano, R; McConville, CM; Rees, SA; Devoto, M; Conte, M; Ferrara, GB; Seri, M; Romeo, G; Tonini, GP			Weak linkage at 4p16 to predisposition for human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; chromosome 4p; LOH; linkage analysis; tumor suppressor genes	COMPARATIVE GENOMIC HYBRIDIZATION; TUMORS; MUTATION; DELETION; CANCER; REGION; LOCUS; MYC	The most frequent genetic alterations described in neuroblastoma (NB) are amplification of MYCN oncogene and deletion of chromosome 1p, although somatic deletions have been demonstrated at other chromosomal intervals. Since loss of heterozygosity (LOH) at distal 4p has been observed in about 20-29% of neuroblastomas, we have evaluated deletions in 41 Italian NB samples by LOH analysis at loci mapping to 4p as follows: pter-D4S2936-D4S412-D4S2957MS432-D4S3023-MS431-cen. Our analysis showed allele losses in eight out of 41 samples (19.5%) and allowed the identification of a smallest region of overlapping deletion (SRO) of 3.0 cM, delimited by D4S412 and D4S3023. Two of these tumors with 4p LOH are from patients belonging to a family with recurrent NB. Interestingly the genotyping of this family revealed an identical haplotype that includes the nonrecombinant loci D4S412, D4S2957 and D4S432 shared by all affected children and demonstrated that this haplotype is retained in the two tumors carrying somatic deletions from patients of this family. Furthermore linkage analysis was performed in two NB families and yielded an overall lod-score of 3.0 in the interval including the haplotype. This provides a confirmatory indication that the region delimited by D4S2936 and D4S3023, which also includes the new defined SRO, may harbor NB predisposing gene/s.	Natl Inst Canc Res, IST, Lab Populat Genet, I-16132 Genoa, Italy; Adv Biotechnol Ctr, Lab Neuroblastoma Res, I-16132 Genoa, Italy; Gaslini Childrens Hosp, Mol Genet Lab, I-16148 Genoa, Italy; Univ Birmingham, Dept Paediat & Child Hlth, Birmingham B15 2TT, W Midlands, England; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; AI duPont Hosp Children, Dept Res, Wilmington, DE 19899 USA; Gaslini Childrens Hosp, Dept Hematol & Oncol, I-16148 Genoa, Italy; Natl Inst Canc Res, IST, Immunogenet Lab, I-16132 Genoa, Italy; Univ Bologna, Dept Internal Med Cardioangiol & Hepatol, I-40138 Bologna, Italy	University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Birmingham; University of Genoa; Nemours Alfred I. duPont Hospital for Children; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS AOU San Martino IST; University of Bologna	Tonini, GP (corresponding author), Natl Inst Canc Res, IST, Lab Populat Genet, Lgo R Benzi 10, I-16132 Genoa, Italy.		conte, massimo/K-2049-2016; conte, massimo/AAA-8044-2019; Devoto, Marcella/AAP-7595-2021; Longo, Luca/K-6156-2018; Perri, Patrizia/I-8124-2018; Perri, Patrizia/AFV-5794-2022; Eva, Alessandra/J-8268-2016; Seri, Marco/A-4339-2014	conte, massimo/0000-0001-9405-7339; conte, massimo/0000-0001-9405-7339; Longo, Luca/0000-0002-5153-4243; Perri, Patrizia/0000-0003-2538-8278; Perri, Patrizia/0000-0003-2538-8278; Eva, Alessandra/0000-0003-2949-078X; DEVOTO, MARCELLA/0000-0002-4431-5114; Seri, Marco/0000-0003-2425-2176; Cusano, Roberto/0000-0001-5543-7881				Altura RA, 1997, GENE CHROMOSOME CANC, V19, P176, DOI 10.1002/(SICI)1098-2264(199707)19:3<176::AID-GCC7>3.0.CO;2-V; Bown N, 2001, MED PEDIATR ONCOL, V36, P14, DOI 10.1002/1096-911X(20010101)36:1<14::AID-MPO1005>3.3.CO;2-7; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Caron H, 1996, HUM GENET, V97, P834; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Lo Cunsolo C, 2000, BRIT J CANCER, V83, P1295, DOI 10.1054/bjoc.2000.1432; Luttikhuis MEMO, 2001, BRIT J CANCER, V85, P531, DOI 10.1054/bjoc.2001.1960; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Perri P, 1997, EUR J CANCER, V33, P1949, DOI 10.1016/S0959-8049(97)00286-4; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; TAKITA J, 1995, ONCOGENE, V11, P1829; Vandesompele J, 2001, MED PEDIATR ONCOL, V36, P5, DOI 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E; Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	20	30	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8356	8360		10.1038/sj.onc.1206009	http://dx.doi.org/10.1038/sj.onc.1206009			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447700				2022-12-25	WOS:000179323900015
J	Tamura, Y; Adachi, H; Osuga, J; Ohashi, K; Yahagi, N; Sekiya, M; Okazaki, H; Tomita, S; Iizuka, Y; Shimano, H; Nagai, R; Kimura, S; Tsujimoto, M; Ishibashi, S				Tamura, Y; Adachi, H; Osuga, J; Ohashi, K; Yahagi, N; Sekiya, M; Okazaki, H; Tomita, S; Iizuka, Y; Shimano, H; Nagai, R; Kimura, S; Tsujimoto, M; Ishibashi, S			FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER-RECEPTOR; ENDOTHELIAL RECEPTOR; GLYCOSYLATION; EXPRESSION; BINDING; CELLS; ATHEROSCLEROSIS; DEGRADATION; ENDPRODUCTS; PROTEIN	Advanced glycation end products (AGEs) are nonenzymatically glycosylated proteins, which accumulate in vascular tissues in aging and diabetes. Receptors for AGEs include scavenger receptors, which recognize acetylated low density lipoproteins (Ac-LDL) such as scavenger receptor class AI/AII (SR-A), cell surface glycoprotein CD36, scavenger receptor class B type I (SRBI), and lectin-like oxidized low density lipoprotein receptor-1. The broad ligand repertoire of these receptors as well as the diversity of the receptors for AGEs have prompted us to examine whether AGEs are also recognized by the novel scavenger receptors, which we have recently isolated from a cDNA library prepared from human umbilical vein endothelial cells, such as the scavenger receptor expressed by endothelial cells-I (SREC-I); the fasciclin EGF-like, laminin-type EGF-like, and link domain-containing scavenger receptor-1 (FEEL-1); and its paralogous protein, FEEL-2. At 4 degreesC, I-125-AGE-bovine serum albumin (BSA) exhibited high affinity specific binding to Chinese hamster ovary (CHO) cells overexpressing FEEL-1 (CHO-FEEL-1) and FEEL-2 (CHO-FEEL-2) with K-d of 2.55 and 1.68 mug/ml, respectively, but not to CHO cells expressing SREC (CHO-SREC) and parent CHO cells. At 37 degreesC, I-125-AGE-BSA was taken up and degraded by CHO-FEEL-1 and CHO-FEEL-2 cells but not by CHO-SREC and parent CHO cells. Thus, the ability to bind Ac-LDL is not necessarily a prerequisite to bind AGEs. The I-125-AGE-BSA binding to CHO-FEEL-1 and CHO-FEEL-2 cells was effectively inhibited by Ac-LDL and polyanionic SR-A inhibitors such as fucoidan, polyinosinic acids, and dextran sulfate but not by native LDL, oxidized LDL, or HDL. FEEL-1, which is expressed by the liver and vascular tissues, may recognize AGEs, thereby contributing to the development of diabetic vascular complications and atherosclerosis.	Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, Kawachi, Tochigi 3290498, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Infect Dis, Bunkyo Ku, Tokyo 1138655, Japan; RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Univ Tsukuba, Inst Clin Med, Dept Metab, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Endocrinol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Atherosclerosis, Tsukuba, Ibaraki 3058575, Japan	Jichi Medical University; University of Tokyo; University of Tokyo; University of Tokyo; RIKEN; University of Tsukuba; University of Tsukuba; University of Tsukuba	Ishibashi, S (corresponding author), Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, 3311-1 Yakushiji,Minamikawachi Machi, Kawachi, Tochigi 3290498, Japan.	ishibash@jichi.ac.jp	Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572; 				Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Adachi H, 2002, J BIOL CHEM, V277, P34264, DOI 10.1074/jbc.M204277200; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Hansen B, 2002, DIABETOLOGIA, V45, P1379, DOI 10.1007/s00125-002-0912-8; Higashi T, 1997, DIABETES, V46, P463, DOI 10.2337/diabetes.46.3.463; Ichikawa K, 1998, ATHEROSCLEROSIS, V136, P281, DOI 10.1016/S0021-9150(97)00221-9; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHII J, 2002, J BIOL CHEM, V277, P24014; Jono T, 2002, FEBS LETT, V511, P170, DOI 10.1016/S0014-5793(01)03325-7; LI YM, 1995, NAT MED, V1, P1057, DOI 10.1038/nm1095-1057; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; Matsumoto K, 2000, BIOCHEM J, V352, P233, DOI 10.1042/0264-6021:3520233; NAKAMURA Y, 1993, AM J PATHOL, V143, P1649; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Niwa T, 1997, J CLIN INVEST, V99, P1272, DOI 10.1172/JCI119285; Ohgami N, 2001, J BIOL CHEM, V276, P13348, DOI 10.1074/jbc.M011613200; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Perrey S, 2001, ATHEROSCLEROSIS, V154, P51, DOI 10.1016/S0021-9150(00)00457-3; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Pugliese G, 2001, FASEB J, V15, P2471, DOI 10.1096/fj.01-0006com; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; Smedsrod B, 1997, BIOCHEM J, V322, P567, DOI 10.1042/bj3220567; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; Vlassara H, 2002, J INTERN MED, V251, P87, DOI 10.1046/j.1365-2796.2002.00932.x; YAN SD, 1994, J BIOL CHEM, V269, P9889	30	143	145	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12613	12617		10.1074/jbc.M210211200	http://dx.doi.org/10.1074/jbc.M210211200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12473645	hybrid			2022-12-25	WOS:000182189500005
J	Abbink, TEM; Berkhout, B				Abbink, TEM; Berkhout, B			A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SPLICE DONOR; PACKAGING SIGNAL; TAR RNA; STEM-LOOP; REVERSE TRANSCRIPTION; NUCLEOCAPSID PROTEIN; SECONDARY STRUCTURE; HIV-1(LAI) RNA; BINDING-SITES; DIMERIZATION	The 5'-untranslated region (5'-UTR) is the most conserved part of the HIV-1 RNA genome, and it contains regulatory motifs that mediate various steps in the viral life cycle. Previous work showed that the 5'-terminal 290 nucleotides of HIV-1 RNA adopt two mutually exclusive secondary structures, long distance interaction (LDI) and branched multiple hairpin (BMH). BMH has multiple hairpins, including the dimer initiation signal (DIS) hairpin that mediates RNA dimerization. LDI contains a long distance base-pairing interaction that occludes the DIS region. Consequently, the two conformations differ in their ability to form RNA dimers. In this study, we have presented evidence that the full-length 5'-UTR also adopts the LDI and BMH conformations. The downstream 290-352 region, including the Gag start codon, folds differently in the context of the LDI and BMH structures. These nucleotides form an extended hairpin structure in the LDI conformation, but the same sequences create a novel long distance interaction with upstream U5 sequences in the BMH conformation. The presence of this U5-AUG duplex was confirmed by computer-assisted RNA structure prediction, biochemical analyses, and a phylogenetic survey of different virus isolates. The U5-AUG duplex may influence translation of the Gag protein because it occludes the start codon of the Gag open reading frame.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	b.berkhout@amc.uva.nl	Abbink, Truus/N-4990-2018					AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974; ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; Amarasinghe GK, 2001, J MOL BIOL, V314, P961, DOI 10.1006/jmbi.2000.5182; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; Berkhout B, 1997, NUCLEIC ACIDS RES, V25, P940, DOI 10.1093/nar/25.5.940; BERKHOUT B, 1995, J MOL BIOL, V252, P59, DOI 10.1006/jmbi.1994.0475; BERKHOUT B, 1992, NUCLEIC ACIDS RES, V20, P27, DOI 10.1093/nar/20.1.27; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Berkhout B, 1996, J VIROL, V70, P6723, DOI 10.1128/JVI.70.10.6723-6732.1996; Berkhout B, 2000, Adv Pharmacol, V48, P29; Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684; Butsch M, 2002, J VIROL, V76, P3089, DOI 10.1128/jvi.76.7.3089-3094.2002; CLAVEL F, 1990, J VIROL, V64, P5230, DOI 10.1128/JVI.64.10.5230-5234.1990; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; Damgaard CK, 1998, NUCLEIC ACIDS RES, V26, P3667, DOI 10.1093/nar/26.16.3667; Das AT, 1997, J VIROL, V71, P2346, DOI 10.1128/JVI.71.3.2346-2356.1997; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; Doherty EA, 2001, NAT STRUCT BIOL, V8, P339, DOI 10.1038/86221; Fletcher SP, 2002, J VIROL, V76, P5024, DOI 10.1128/JVI.76.10.5024-5033.2002; Greatorex J, 2002, J MOL BIOL, V322, P543, DOI 10.1016/S0022-2836(02)00776-3; Haddrick M, 1996, J MOL BIOL, V259, P58, DOI 10.1006/jmbi.1996.0301; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; HAYASHI T, 1993, FEBS LETT, V327, P213, DOI 10.1016/0014-5793(93)80172-Q; HAYASHI T, 1992, VIROLOGY, V188, P590, DOI 10.1016/0042-6822(92)90513-O; Hemmings-Mieszczak M, 1998, RNA, V4, P101; HemmingsMieszczak M, 1997, J MOL BIOL, V267, P1075, DOI 10.1006/jmbi.1997.0929; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Huthoff H, 2002, BIOCHEMISTRY-US, V41, P10439, DOI 10.1021/bi025993n; Huthoff H, 2001, NUCLEIC ACIDS RES, V29, P2594, DOI 10.1093/nar/29.12.2594; Huynen MA, 1996, J COMPUT BIOL, V3, P253, DOI 10.1089/cmb.1996.3.253; Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819; Kerwood DJ, 2001, BIOCHEMISTRY-US, V40, P14518, DOI 10.1021/bi0111909; Klasens BIF, 1998, NUCLEIC ACIDS RES, V26, P1870, DOI 10.1093/nar/26.8.1870; Klasens BIF, 1999, NUCLEIC ACIDS RES, V27, P446, DOI 10.1093/nar/27.2.446; KLAVER B, 1994, EMBO J, V13, P2650, DOI 10.1002/j.1460-2075.1994.tb06555.x; KLAVER B, 1994, J VIROL, V68, P3830, DOI 10.1128/JVI.68.6.3830-3840.1994; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Laughrea M, 1996, BIOCHEMISTRY-US, V35, P9366, DOI 10.1021/bi960395s; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209; Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s; OREILLY MM, 1995, VIROLOGY, V213, P373, DOI 10.1006/viro.1995.0010; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; RICHARDSON JH, 1993, J VIROL, V67, P3997, DOI 10.1128/JVI.67.7.3997-4005.1993; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; VICENZI E, 1994, J VIROL, V68, P7879, DOI 10.1128/JVI.68.12.7879-7890.1994; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Zeffman A, 2000, J MOL BIOL, V297, P877, DOI 10.1006/jmbi.2000.3611; Zuker M, 1999, ALGORITHMS THERMODYN, P11, DOI 10.1007/978-94-011-4485-8_2	61	149	152	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11601	11611		10.1074/jbc.M210291200	http://dx.doi.org/10.1074/jbc.M210291200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12458192	hybrid			2022-12-25	WOS:000181855400093
J	Michelotti, GA; Bauman, MJ; Smith, MP; Schwinn, DA				Michelotti, GA; Bauman, MJ; Smith, MP; Schwinn, DA			Cloning and characterization of the rat ala-adrenergic receptor gene promoter - Demonstration of cell specificity and regulation by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; SUBTYPE MESSENGER-RNAS; CARDIAC MYOCYTES; TRANSCRIPTIONAL REGULATION; PROXIMAL PROMOTER; IN-VIVO; EXPRESSION; HYPERTROPHY; ALPHA(1B); SEQUENCE	Recent studies reveal important and distinct roles for cardiac alpha(1a) adrenergic receptors (alpha(1a)ARs). Surprisingly, given their importance in myocardial ischemia/reperfusion, hypoxia, and hypertrophy as well as frequent use of rat cardiomyocyte model systems, the rat alpha(1a)AR gene promoter has never been characterized. Therefore, we isolated 3.9 kb of rat alpha(1a)AR 5'-untranslated region and 5'-regulatory sequences and identified multiple transcription initiation sites. One proximal (P1) and several clustered upstream distal promoters (P2, P3, and P4) were delineated. Sequences surrounding both proximal and distal promoters lack typical TATA or CCAAT boxes but contain cis-elements for multiple myocardium-relevant nuclear regulators including Sp1, GATA, and CREB, findings consistent with enhanced cardiac basal alpha(1a)AR expression seen in Northern blots and reporter constructs. Promoter analysis using deletion reporter constructs reveals, in addition to a powerful upstream enhancer, a key region (-558/-542) important in regulating all alpha(1a)AR promoters with hypoxic stress. Gel shift analysis of this 14-bp region confirms a hypoxia-induced shift independent of direct hypoxia-inducible factor binding. Mutational analysis of this sequence identifies a novel 9-bp hypoxia response element, the loss of which severely attenuates hypoxia-mediated repression of alpha(1a)AR transcription. These findings for the alpha(1a) gene should facilitate elucidation of alpha(1)AR-mediated mechanisms involved in distinct myocardial pathologies.	Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Schwinn, DA (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.			Schwinn, Debra/0000-0002-9696-5231; Michelotti, Gregory/0000-0002-7908-1979	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049103, R37HL049103] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49103] Funding Source: Medline; NIA NIH HHS [AG00745] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANYUKHOVSKY EP, 1994, CIRC RES, V74, P937, DOI 10.1161/01.RES.74.5.937; Autelitano DJ, 1998, J MOL CELL CARDIOL, V30, P1515, DOI 10.1006/jmcc.1998.0717; Beitner-Johnson D, 2000, ADV EXP MED BIOL, V475, P143; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; Brodde OE, 1999, PHARMACOL REV, V51, P651; Burashnikov A, 1999, CARDIOVASC RES, V43, P901, DOI 10.1016/S0008-6363(99)00124-8; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; D'Alonzo RC, 2002, J BIOL CHEM, V277, P24788, DOI 10.1074/jbc.M202604200; Dao N, 1998, BIOCHEM BIOPH RES CO, V253, P804, DOI 10.1006/bbrc.1998.9860; Deng XF, 2000, CIRC RES, V87, P781, DOI 10.1161/01.RES.87.9.781; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Flesch M, 2001, CARDIOVASC RES, V50, P3, DOI 10.1016/S0008-6363(01)00218-8; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; Hampel C, 2002, J UROLOGY, V167, P1513, DOI 10.1016/S0022-5347(05)65355-4; KAMBAYASHI M, 1992, CIRCULATION, V86, P1935, DOI 10.1161/01.CIR.86.6.1935; Kirigiti P, 2001, MOL PHARMACOL, V60, P1308, DOI 10.1124/mol.60.6.1308; Korner K, 2000, J BIOL CHEM, V275, P18676, DOI 10.1074/jbc.M001110200; LECH K, 1999, CURRENT PROTOCOLS MO, V1; Leech CJ, 1996, AM J PHYSIOL-HEART C, V270, pH710, DOI 10.1152/ajpheart.1996.270.2.H710; Leon-Velarde F, 2001, AM J PHYSIOL-REG I, V280, pR274, DOI 10.1152/ajpregu.2001.280.1.R274; LI HT, 1995, CIRCULATION, V92, P919; Lin G, 2001, CIRC RES, V89, P343, DOI 10.1161/hh1601.095912; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Michel G, 2000, J BIOMOL STRUCT DYN, V18, P169, DOI 10.1080/07391102.2000.10506656; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 2000, PHARMACOL THERAPEUT, V88, P281, DOI 10.1016/S0163-7258(00)00092-9; Muller FU, 2000, MOL CELL BIOCHEM, V212, P11, DOI 10.1023/A:1007176030884; O'Connell TD, 2001, MOL PHARMACOL, V59, P1225, DOI 10.1124/mol.59.5.1225; PRICE DT, 1994, MOL PHARMACOL, V45, P171; PRICE DT, 1994, MOL PHARMACOL, V46, P221; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Razik MA, 1997, J BIOL CHEM, V272, P28237, DOI 10.1074/jbc.272.45.28237; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; Rustighi A, 2002, BIOCHEMISTRY-US, V41, P1229, DOI 10.1021/bi011666o; Sabri A, 2000, CIRC RES, V86, P1047, DOI 10.1161/01.RES.86.10.1047; Salvi S, 2001, CHEST, V119, P1242, DOI 10.1378/chest.119.4.1242; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; STEWART AFR, 1994, CIRC RES, V75, P796, DOI 10.1161/01.RES.75.4.796; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Taylor CT, 1999, J BIOL CHEM, V274, P19447, DOI 10.1074/jbc.274.27.19447; TRIEZENBERG SJ, 1999, CURRENT PROTOCOLS MO, V1; VALCARCEL J, 1997, CURR BIOL, V7, P705; Varma DR, 2000, CAN J PHYSIOL PHARM, V78, P267, DOI 10.1139/cjpp-78-4-267; Wang BH, 2000, AM J PHYSIOL-HEART C, V279, pH1079, DOI 10.1152/ajpheart.2000.279.3.H1079; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Xin XH, 1999, MOL PHARMACOL, V56, P1152, DOI 10.1124/mol.56.6.1152; Zuscik MJ, 1999, MOL PHARMACOL, V56, P1288, DOI 10.1124/mol.56.6.1288	47	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8693	8705		10.1074/jbc.M211986200	http://dx.doi.org/10.1074/jbc.M211986200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12471020	hybrid			2022-12-25	WOS:000181466800122
J	Grabner, GK; Switzer, RL				Grabner, GK; Switzer, RL			Kinetic studies of the uracil phosphoribosyltransferase reaction catalyzed by the Bacillus subtilis pyrimidine attenuation regulatory protein PyrR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE ANALOG INHIBITOR; 2.0 ANGSTROM STRUCTURE; MESSENGER-RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; TRANSCRIPTIONAL ATTENUATION; TRANSITION-STATE; SALMONELLA-TYPHIMURIUM; BIOSYNTHETIC OPERON; CRYSTAL-STRUCTURE; BINDING	The PyrR protein from Bacillus subtilis and many other bacteria is a bifunctional protein. Its primary function is the regulation of expression of pyrimidine biosynthetic (pyr) genes by binding to specific sites on pyr mRNA in a uridine nucleotide-dependent manner and altering the folding of downstream RNA to promote termination of transcription. PyrR also catalyzes the uracil phosphoribosyltransferase (UPRTase) reaction even though it bears little amino acid sequence similarity to other bacterial UPRTases. The PyrR-catalyzed UPRTase reaction obeyed a Ping Pong steady state kinetic pattern under all conditions examined, but no catalysis of [C-14]uracil-UMP and [P-32]PPi-phosphoribosylpyrophosphate exchange reactions could be detected. Steady state equations for Ordered Bi Bi mechanisms for PyrR that include a kinetically irreversible conformational change after binding of PRPP but before uracil binding were shown to account for the Ping Pong pattern of the enzyme. This mechanism was supported by the following experimental observations. The reverse reaction was extremely slow with a catalytic rate constant 3300 times smaller than for the forward reaction. Patterns of product inhibition of the forward reaction were consistent with a version of the irreversible conformational change model in which PyrR returns to the unliganded conformation before dissociation of UMP and were inconsistent with several other kinetic mechanisms. UMP and phosphoribosylpyrophosphate were shown by equilibrium dialysis to bind to free PyrR (dissociation constants of 27 +/- 3 and 18 +/- 2 mum, respectively), but uracil and PPi did not bind at equilibrium concentrations up to 750 pm. We propose that the conformational change kinetic model developed for PyrR can also account for numerous other reports of Ping Pong kinetics for various phosphoribosyltransferases that do not form the phosphoribosyl-enzyme intermediate predicted by classic Ping Pong kinetics.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Grabner, GK (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.							BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; Bonner ER, 2001, NUCLEIC ACIDS RES, V29, P4851, DOI 10.1093/nar/29.23.4851; BRASHEAR WT, 1975, J BIOL CHEM, V250, P6885; Cleland W W, 1979, Methods Enzymol, V63, P103; Eads JC, 1997, STRUCTURE, V5, P47, DOI 10.1016/S0969-2126(97)00165-2; Focia PJ, 1998, BIOCHEMISTRY-US, V37, P17120, DOI 10.1021/bi9821465; GHIM SY, 1994, J BACTERIOL, V176, P3698, DOI 10.1128/JB.176.12.3698-3707.1994; GIBSON KJ, 1982, J BIOL CHEM, V257, P2391; GRABNER GK, 2002, THESIS U ILLINOIS UR; HENDERSO.JF, 1968, J BIOL CHEM, V243, P2514; HORI M, 1966, J BIOL CHEM, V241, P3404; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; KRENITSKY TA, 1969, J BIOL CHEM, V244, P1271; Lu Y, 1996, J BACTERIOL, V178, P7206, DOI 10.1128/jb.178.24.7206-7211.1996; LU Y, 1995, J BACTERIOL, V177, P1315, DOI 10.1128/jb.177.5.1315-1325.1995; Lu Y, 1996, P NATL ACAD SCI USA, V93, P14462, DOI 10.1073/pnas.93.25.14462; Lundegaard C, 1999, BIOCHEMISTRY-US, V38, P3327, DOI 10.1021/bi982279q; MARTIN RG, 1963, J BIOL CHEM, V238, P257; MARTINUSSEN J, 1995, J BACTERIOL, V177, P271, DOI 10.1128/jb.177.1.271-274.1995; MCIVOR RS, 1983, J BACTERIOL, V156, P192, DOI 10.1128/JB.156.1.192-197.1983; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; NATALINI P, 1979, J BIOL CHEM, V254, P1558; NOSAL JM, 1993, J BIOL CHEM, V268, P10168; Savacool HK, 2002, J BACTERIOL, V184, P2521, DOI 10.1128/JB.184.9.2521-2528.2002; SEGEL IH, 1975, ENZYME KINETICS BEHA, P653; Shi WX, 1999, NAT STRUCT BIOL, V6, P588; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Sinha SC, 2001, CURR OPIN STRUC BIOL, V11, P733, DOI 10.1016/S0959-440X(01)00274-3; Switzer RL, 1999, PROG NUCLEIC ACID RE, V62, P329; Tomchick DR, 1998, STRUCTURE, V6, P337, DOI 10.1016/S0969-2126(98)00036-7; Turner RJ, 1998, J BIOL CHEM, V273, P5932, DOI 10.1074/jbc.273.10.5932; VICTOR J, 1979, J BIOL CHEM, V254, P2647; Witte JF, 1999, ARCH BIOCHEM BIOPHYS, V361, P106, DOI 10.1006/abbi.1998.0971; Xu YM, 1997, BIOCHEMISTRY-US, V36, P3700, DOI 10.1021/bi9616007; ZIMMERMAN SB, 1963, METHOD ENZYMOL, V6, P258, DOI 10.1016/0076-6879(63)06170-X	36	12	13	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6921	6927		10.1074/jbc.M211111200	http://dx.doi.org/10.1074/jbc.M211111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482852	hybrid			2022-12-25	WOS:000181195100038
J	Herold, S; Rock, G				Herold, S; Rock, G			Reactions of deoxy-, oxy-, and methemoglobin with nitrogen monoxide - Mechanistic studies of the S-nitrosothiol formation under different mixing conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SOLUTIONS; REGIONAL BLOOD-FLOW; PHYSIOLOGICAL CONDITIONS; LIGAND-BINDING; ERYTHROCYTE CONSUMPTION; OXIDATIVE REACTIONS; REVERSIBLE BINDING; HUMAN HEMOGLOBIN; HEME-PROTEINS; NEUTRAL-PH	The reaction between hemoglobin (Hb) and NO. has been investigated thoroughly in recent years, but its mechanism is still a matter of substantial controversy. We have carried out a systematic study of the influence of the following factors on the yield of S-nitrosohemoglobin (SNO-Hb) generated from the reaction of NO. with oxy-, deoxy-, and metHb:1) the volumetric ratio of the protein and the NO. solutions; 2) the rate of addition of the NO. solution to the protein solution; 3) the amount of NO. added; and 4) the concentration of the phosphate buffer. Our results suggest that. the highest SNO-Hb yields are mostly obtained by very slow addition of sub-stoichiometric amounts of NO. from a diluted solution. Possible pathways of SNO-Hb formation from the reaction of NO. with oxy-, deoxy-, and metHb are described Our data strongly suggest that, because of mixing artifacts, care should be taken to use results from in vitro experiments to draw conclusion on the mechanism of the reaction in vivo.	ETH Honggerberg, Anorgan Chem Lab, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Herold, S (corresponding author), ETH Honggerberg, Anorgan Chem Lab, HCI H 215, CH-8093 Zurich, Switzerland.	herold@inorg.chem.ethz.ch						ANDERSEN HJ, 1992, J AGR FOOD CHEM, V40, P1741, DOI 10.1021/jf00022a004; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Arnold EV, 1996, METHOD ENZYMOL, V269, P41; BECKMAN JS, 1996, NITRIC OXIDE PRINCIP, P1, DOI DOI 10.1016/B978-012435555-2/50002-4; BENESCH RE, 1973, ANAL BIOCHEM, V55, P245, DOI 10.1016/0003-2697(73)90309-6; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; Chan NL, 1998, BIOCHEMISTRY-US, V37, P16459, DOI 10.1021/bi9816711; CHIODI H, 1985, ENVIRON RES, V37, P355, DOI 10.1016/0013-9351(85)90116-1; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; Coupe PJ, 2001, J CHEM SOC PERK T 2, P1595, DOI 10.1039/b103100g; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; Ford PC, 2002, CHEM REV, V102, P993, DOI 10.1021/cr0000271; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; Gross SS, 2001, NATURE, V409, P577, DOI 10.1038/35054661; Han TH, 2002, P NATL ACAD SCI USA, V99, P7763, DOI 10.1073/pnas.122118299; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Hoshino M, 1996, J AM CHEM SOC, V118, P5702, DOI 10.1021/ja953311w; HOSHINO M, 1993, J AM CHEM SOC, V115, P9568, DOI 10.1021/ja00074a023; Huang Z, 2001, BBA-GEN SUBJECTS, V1568, P252, DOI 10.1016/S0304-4165(01)00227-6; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699; Jourd'heuil D, 1998, NITRIC OXIDE-BIOL CH, V2, P37, DOI 10.1006/niox.1998.0167; Keshive M, 1996, CHEM RES TOXICOL, V9, P988, DOI 10.1021/tx960036y; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; Laverman LE, 2001, J AM CHEM SOC, V123, P285, DOI 10.1021/ja001696z; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Merx Marc W., 2001, FASEB Journal, V15, P1077; Miller LM, 1997, BIOCHEMISTRY-US, V36, P12199, DOI 10.1021/bi962744o; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Rathore R, 2000, ANGEW CHEM INT EDIT, V39, P2123, DOI 10.1002/1521-3773(20000616)39:12<2123::AID-ANIE2123>3.0.CO;2-4; Rathore R, 1998, ANGEW CHEM INT EDIT, V37, P1585, DOI 10.1002/(SICI)1521-3773(19980619)37:11<1585::AID-ANIE1585>3.0.CO;2-W; Reichenbach G, 2001, NITRIC OXIDE-BIOL CH, V5, P395, DOI 10.1006/niox.2001.0365; Romeo AA, 2001, J AM CHEM SOC, V123, P1782, DOI 10.1021/ja005612y; Sampath V, 2001, J BIOL CHEM, V276, P13635, DOI 10.1074/jbc.M006588200; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Tsikas D, 2001, J CHROMATOGR A, V915, P107, DOI 10.1016/S0021-9673(01)00634-3; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; Vaughn MW, 2000, J BIOL CHEM, V275, P2342, DOI 10.1074/jbc.275.4.2342; Vaughn MW, 2001, NITRIC OXIDE-BIOL CH, V5, P18, DOI 10.1006/niox.2000.0328; WADE RS, 1990, CHEM RES TOXICOL, V3, P289, DOI 10.1021/tx00016a002; Wade RS, 1996, CHEM RES TOXICOL, V9, P1382, DOI 10.1021/tx9600457; Wang YN, 1996, J AM CHEM SOC, V118, P3972, DOI 10.1021/ja9538647; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; Zhang Y, 2002, FREE RADICAL BIO MED, V32, P1212, DOI 10.1016/S0891-5849(02)00829-8	72	87	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6623	6634		10.1074/jbc.M210275200	http://dx.doi.org/10.1074/jbc.M210275200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12468537	hybrid			2022-12-25	WOS:000181195100002
J	Webb, P; Nguyen, P; Kushner, PJ				Webb, P; Nguyen, P; Kushner, PJ			Differential SERM effects on corepressor binding dictate ER alpha activity in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; ACTIVATOR PROTEIN-1 ACTIVITY; BREAST-CANCER CELLS; N-COR; TRANSCRIPTIONAL ACTIVITY; MOLECULAR DETERMINANTS; NUCLEAR RECEPTORS; STRUCTURAL BASIS; PARTIAL AGONIST; LIGAND	Selective estrogen receptor modulators (SERMs) show differential effects upon ERalpha activation function 1 (AF-1). Tamoxifen allows strong ERalpha AF-1 activity, whereas raloxifene allows less and ICI 182,780 (ICI) allows none. Here, we show that blockade of corepressor histone deacetylase (HDAC) activity reverses the differential inhibitory effect of SERMs upon AF-1 activity in MCF-7 cells. This suggests that differential SERM repression of AF-1 involves HDAC-dependent corepressors. Consistent with this, ICI and raloxifene are more potent than tamoxifen in promoting ERalpha-dependent sequestration of progesterone receptor-associated corepressors. Moreover, ICI and raloxifene are more efficient than tamoxifen in promoting ERalpha binding to the corepressor N-CoR in vivo and in vitro. An ERalpha mutation (537X) that increases N-CoR binding in the presence of all SERMs blocks AF-1 activity. An ERalpha mutation (L379R) that decreases N-CoR binding increases AF-1 activity in the presence of ICI and raloxifene and reverses the effect of the 537X mutation. The 537X and L379R mutations also alter the ligand preference of ERalpha action at AP-1 sites and C3 complement, an action that also involves AF-1. Together, our results suggest that differential SERM effects on corepressor binding can explain differences in SERM effects on ERalpha activity. We propose a model for differential effects of SERMs on N-CoR binding.	Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kushner, PJ (corresponding author), Univ Calif San Francisco, Dept Med, 2200 Post St,Rm C442, San Francisco, CA 94115 USA.	kushner@itsa.ucsf.edu			NCI NIH HHS [CA80210] Funding Source: Medline; NIDDK NIH HHS [DK51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aumais JP, 1997, J BIOL CHEM, V272, P12229, DOI 10.1074/jbc.272.18.12229; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Burke LJ, 1998, MOL ENDOCRINOL, V12, P248, DOI 10.1210/me.12.2.248; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Feng WJ, 2001, MOL ENDOCRINOL, V15, P32, DOI 10.1210/me.15.1.32; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Glass CK, 2000, GENE DEV, V14, P121; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jordan VC, 2001, J NATL CANCER I, V93, P1449, DOI 10.1093/jnci/93.19.1449; Jordan VC, 2002, CANCER CELL, V1, P215, DOI 10.1016/S1535-6108(02)00050-8; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Kushner P J, 2000, Novartis Found Symp, V230, P20, DOI 10.1002/0470870818.ch3; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Lopez GN, 1999, MOL ENDOCRINOL, V13, P897, DOI 10.1210/me.13.6.897; Mak HY, 1999, MOL CELL BIOL, V19, P3895; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nguyen NH, 2002, J MED CHEM, V45, P3310, DOI 10.1021/jm0201013; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Parker MG, 1998, BIOCHEM SOC SYMP, P45; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Planas-Silva MD, 2001, CANCER RES, V61, P3858; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sibonga JD, 1998, ENDOCRINOLOGY, V139, P3736, DOI 10.1210/en.139.9.3736; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wakeling AE, 2000, ENDOCR-RELAT CANCER, V7, P17, DOI 10.1677/erc.0.0070017; Weatherman RV, 2001, J BIOL CHEM, V276, P3827, DOI 10.1074/jbc.M005414200; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; Webb P, 2000, J BIOL CHEM, V275, P37552, DOI 10.1074/jbc.M007435200; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Willson TM, 1997, ENDOCRINOLOGY, V138, P3901, DOI 10.1210/en.138.9.3901; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	62	112	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6912	6920		10.1074/jbc.M208501200	http://dx.doi.org/10.1074/jbc.M208501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482846	hybrid			2022-12-25	WOS:000181195100037
J	Whitby, MC; Osman, F; Dixon, J				Whitby, MC; Osman, F; Dixon, J			Cleavage of model replication forks by fission yeast Mus81-Eme1 and budding yeast Mus81-Mms4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; HOLLIDAY JUNCTION RESOLVASE; DNA-REPLICATION; ESCHERICHIA-COLI; BLOOMS-SYNDROME; IN-VITRO; REPAIR; RECOMBINATION; CHECKPOINT; ARREST	The blockage of replication forks can result in the disassembly of the replicative apparatus and reversal of the fork to form a DNA junction that must be processed in order for replication to restart and sister chromatids to segregate at mitosis. Fission yeast Mus81-Emel and budding yeast Mus81-Mms4 are endonucleases that have been implicated in the processing of aberrant DNA junctions formed at stalled replication forks. Here we have investigated the activity of purified Mus81-Emel and Mus81-Mms4 on substrates that resemble DNA junctions that are expected to form when a replication fork reverses. Both enzymes cleave Holliday junctions and substrates that resemble normal replication forks poorly or not at all. However, forks where the equivalents of either both the leading and lagging strands or just the lagging strand are juxtaposed at the junction point, or where either the leading or lagging strand has been unwound to produce a fork with a single-stranded tail, are cleaved well. Cleavage sites map predominantly between 3 and 6 bp 5' of the junction point. For most substrates the leading strand template is cleaved. The sole exception is a fork with a 5' single-stranded tail, which is cleaved in the lagging strand template.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Whitby, MC (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.			Whitby, Matthew/0000-0003-0951-3374				Berdichevsky A, 2002, MOL CELL, V10, P917, DOI 10.1016/S1097-2765(02)00679-2; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Doe CL, 2000, EMBO J, V19, P2751, DOI 10.1093/emboj/19.11.2751; Doe CL, 2002, J BIOL CHEM, V277, P32753, DOI 10.1074/jbc.M202120200; Enzlin JH, 2002, EMBO J, V21, P2045, DOI 10.1093/emboj/21.8.2045; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Hartsuiker E, 2001, EMBO J, V20, P6660, DOI 10.1093/emboj/20.23.6660; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; Seigneur M, 2000, MOL MICROBIOL, V38, P565, DOI 10.1046/j.1365-2958.2000.02152.x; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; Whitby MC, 1998, J BIOL CHEM, V273, P35063, DOI 10.1074/jbc.273.52.35063	38	100	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6928	6935		10.1074/jbc.M210006200	http://dx.doi.org/10.1074/jbc.M210006200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12473680	hybrid			2022-12-25	WOS:000181195100039
J	Cawley, NX; Chino, M; Maldonado, A; Rodriguez, YM; Loh, YP; Ellman, JA				Cawley, NX; Chino, M; Maldonado, A; Rodriguez, YM; Loh, YP; Ellman, JA			Synthesis and characterization of the first potent inhibitor of yapsin 1 - Implications for the study of yapsin-like enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ASPARTIC PROTEASE-3; OPIOMELANOCORTIN-CONVERTING ENZYME; HUMAN PARATHYROID-HORMONE; CANDIDA-ALBICANS; YEAST-ASPARTIC-PROTEASE-3 YAP3; IN-VIVO; GENE; PURIFICATION; EXPRESSION; SECRETION	The potent peptidic inhibitor, Y1, of the basic residue-specific yeast aspartyl protease, yapsin 1, was synthesized and characterized. The inhibitor was based on the peptide sequence of a cholecystokinin(13-33) analog that yapsin 1 cleaved with an efficiency of 5.2 x 10(5) M-1 S-1 (Olsen, V., Guruprasad, K., Cawley, N. X., Chen, H. C., Blundell, T. L., and Loh, Y. P. (1998) Biochemistry 37, 2768-2777). The apparent K-i of Y1 for the inhibition of yapsin 1 was determined to be 64.5 nm, and the mechanism is competitive. Y2 was also developed as an analog of Y1 for coupling to agarose beads. The resulting inhibitor-coupled agarose beads were successfully used to purify yapsin I to apparent homogeneity from conditioned medium of a yeast expression system. Utilization of this new reagent greatly facilitates the purification of yapsin 1 and should also enable the identification of new yapsin-like enzymes from mammalian and nonmammalian sources. In this regard, Y1 also efficiently inhibited Sap9p, a secreted aspartyl protease from the human pathogen, Candida albicans, which has specificity for basic residues similar to yapsin 1 and might provide the basis for the prevention or control of its virulence. A single-step purification of Sap9p from conditioned medium was also accomplished with the inhibitor column. N-terminal amino acid sequence analysis yielded two sequences indicating that Sap9p is composed of two subunits, designated here as alpha and beta, similar to yapsin 1.	NICHD, Cellular Neurobiol Sect, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA; Univ Calif Berkeley, Combinatorial Chem Dept, Berkeley, CA 94704 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Berkeley	Cawley, NX (corresponding author), 49 Convent Dr,MSC 4480,Bldg 49-5A38, Bethesda, MD 20892 USA.		Ellman, Jonathan A/C-7732-2013		NIGMS NIH HHS [GM54051] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000056] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; ASH J, 1995, J BIOL CHEM, V270, P20847, DOI 10.1074/jbc.270.35.20847; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; BAKKER AV, 1990, BIOCHEM J, V271, P559, DOI 10.1042/bj2710559; Borg-von Zepelin M, 1998, MOL MICROBIOL, V28, P543, DOI 10.1046/j.1365-2958.1998.00815.x; Bourbonnais Y, 2000, PROTEIN EXPRES PURIF, V20, P485, DOI 10.1006/prep.2000.1338; Cawley N.X., 1995, THESIS UNIFORMED SER; Cawley NX, 1996, J BIOL CHEM, V271, P4168; Cawley NX, 1998, J BIOL CHEM, V273, P584, DOI 10.1074/jbc.273.1.584; CAWLEY NX, 1995, BIOCHEMISTRY-US, V34, P7430, DOI 10.1021/bi00022a016; CAWLEY NX, 2003, IN PRESS HDB PROTEOL; Copley KS, 1998, BIOCHEM J, V330, P1333; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; FernandezGarcia C, 1995, TETRAHEDRON-ASYMMETR, V6, P2905, DOI 10.1016/0957-4166(95)00382-7; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kang HA, 1998, APPL MICROBIOL BIOT, V50, P187, DOI 10.1007/s002530051275; Kerry-Williams SM, 1998, YEAST, V14, P161, DOI 10.1002/(SICI)1097-0061(19980130)14:2<161::AID-YEA208>3.0.CO;2-Y; KICK EK, 1995, J MED CHEM, V38, P1427, DOI 10.1021/jm00009a002; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; LEDGERWOOD EC, 1995, BIOCHEM J, V308, P321, DOI 10.1042/bj3080321; Ledgerwood EC, 1996, FEBS LETT, V383, P67, DOI 10.1016/0014-5793(96)00219-0; Lindberg I., 1995, METH NEUROSCI, V23, P94; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOH YP, 2003, IN PRESS HDB PROTEOL; Monod M, 1998, MICROBIOL-UK, V144, P2731, DOI 10.1099/00221287-144-10-2731; Naglik JR, 1999, INFECT IMMUN, V67, P2482, DOI 10.1128/IAI.67.5.2482-2490.1999; Newport G, 1997, J BIOL CHEM, V272, P28954, DOI 10.1074/jbc.272.46.28954; Olsen V, 1998, BIOCHEMISTRY-US, V37, P2768, DOI 10.1021/bi9724826; Olsen V, 1999, BIOCHEM J, V339, P407, DOI 10.1042/0264-6021:3390407; Song GY, 2000, PROCESS BIOCHEM, V35, P503, DOI 10.1016/S0032-9592(99)00097-7; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7	33	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5523	5530		10.1074/jbc.M207230200	http://dx.doi.org/10.1074/jbc.M207230200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12468548	hybrid			2022-12-25	WOS:000181129400008
J	Huang, ZS; Su, WH; Wang, JL; Wu, HN				Huang, ZS; Su, WH; Wang, JL; Wu, HN			Selective strand annealing and selective strand exchange promoted by the N-terminal domain of hepatitis delta antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMMERHEAD RIBOZYME CATALYSIS; ACID-CHAPERONE ACTIVITY; VIRUS-RNA REPLICATION; NUCLEOCAPSID PROTEIN; VIRAL GENOME; IN-VITRO; IDENTIFICATION; TRANSCRIPTION; VIVO; A1	We have previously shown that the N-terminal domain of hepatitis delta virus (NdAg) has an RNA chaperone activity in vitro (Huang, Z. S., and Wu, H. N. (1998) J. BioL Chem. 273, 26455-26461). Here we investigate further the basis of the stimulatory effect of NdAg on RNA structural rearrangement: mainly the formation and breakage of base pairs. Duplex dissociation, strand annealing, and exchange of complementary RNA oligonucleotides; the hybridization of yeast U4 and U6 small nuclear RNAs and of hammerhead ribozymes and cognate substrates; and the cis-cleavage reaction of hepatitis delta ribozymes were used to determine directly the role of NdAg in RNA-mediated processes. The results showed that NdAg could accelerate the annealing of complementary sequences in a selective fashion and promote strand exchange for the formation of a more extended duplex. These activities would prohibit NdAg from modifying the structure of a stable RNA, but allow NdAg to facilitate a trans-acting hammerhead ribozyme to find a more extensively matched target in cognate substrate. These and other results suggest that hepatitis delta antigen may have a biological role as an RNA chaperone, modulating the folding of viral RNA for replication and transcription.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Wu, HN (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.		Wu, Huey Nan/ABA-4484-2021	Wu, Huey Nan/0000-0002-1538-7776				Beard MR, 1996, J VIROL, V70, P4986, DOI 10.1128/JVI.70.8.4986-4995.1996; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; CAROLINE G, 2001, J BIOL CHEM, V276, P19301; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; Filipovska J, 2000, RNA, V6, P41, DOI 10.1017/S1355838200991167; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Huang ZS, 1998, J BIOL CHEM, V273, P26455, DOI 10.1074/jbc.273.41.26455; Jeng KS, 1996, J VIROL, V70, P2403, DOI 10.1128/JVI.70.4.2403-2410.1996; Jeng KS, 1996, J VIROL, V70, P4205, DOI 10.1128/JVI.70.7.4205-4209.1996; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; Lee CB, 1996, BIOCHEMISTRY-US, V35, P12303, DOI 10.1021/bi961219m; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; MACNAUGHTON TB, 1993, J VIROL, V67, P2228, DOI 10.1128/JVI.67.4.2228-2234.1993; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; Modahl LE, 2000, MOL CELL BIOL, V20, P6030, DOI 10.1128/MCB.20.16.6030-6039.2000; Modahl LE, 1998, J VIROL, V72, P5449, DOI 10.1128/JVI.72.7.5449-5456.1998; PERROTTA AT, 1991, NATURE, V350, P433; POISSON F, 1993, J GEN VIROL, V74, P2473, DOI 10.1099/0022-1317-74-11-2473; PONTIUS BW, 1992, J BIOL CHEM, V267, P13815; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; ROSENSTEIN SP, 1991, NUCLEIC ACIDS RES, V19, P5409, DOI 10.1093/nar/19.19.5409; Skabkin MA, 2001, J BIOL CHEM, V276, P44841, DOI 10.1074/jbc.M107581200; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Wang HW, 1997, VIROLOGY, V239, P119, DOI 10.1006/viro.1997.8818; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; Wu TT, 1997, J VIROL, V71, P5408, DOI 10.1128/JVI.71.7.5408-5414.1997; Zuccola HJ, 1998, STRUCTURE, V6, P821, DOI 10.1016/S0969-2126(98)00084-7	34	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5685	5693		10.1074/jbc.M207938200	http://dx.doi.org/10.1074/jbc.M207938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12466279	hybrid			2022-12-25	WOS:000181129400027
J	McIntosh, AL; Gallegos, AM; Atshaves, BP; Storey, SM; Kannoju, D; Schroeder, F				McIntosh, AL; Gallegos, AM; Atshaves, BP; Storey, SM; Kannoju, D; Schroeder, F			Fluorescence and multiphoton imaging resolve unique structural forms of sterol in membranes of living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN-2 EXPRESSION; SYNAPTIC PLASMA-MEMBRANES; PHOSPHOLIPID-BILAYERS; CHOLESTEROL DYNAMICS; LIPID-COMPOSITION; ALTERS; DOMAINS; RAFTS; PHOSPHATIDYLCHOLINE; DEHYDROERGOSTEROL	Although cholesterol is an essential component of mammalian membranes, resolution of cholesterol organization in membranes and organelles (i.e. lysosomes) of living cells is hampered by the paucity of nondestructive, nonperturbing methods providing real time structural information. Advantage was taken of the fact that the emission maxima of a naturally occurring fluorescent sterol (dehydroergosterol) were resolvable into two structural forms, monomeric (356 and 375 nm) and crystalline (403 and 426 nm). Model membranes (sterol:phospholipid ratios in the physiological range, e.g. 0.5-1.0), subcellular membrane fractions (plasma membranes, lysosomal membranes, microsomes, and mitochondrial membranes), and lipid rafts/caveolae (plasma membrane cholesterol-rich microdomain purified by a non-detergent method) contained primarily monomeric sterol and only small quantities (i.e. 1-5%) of the crystalline form. In contrast, the majority of sterol in isolated lysosomes was crystalline. However, addition of sterol carrier protein-2 in vitro significantly reduced the proportion of crystalline dehydroergosterol in the isolated lysosomes. Multiphoton laser scanning microscopy (MPLSM) of living L-cell fibroblasts cultured with dehydroergosterol for the first time provided real time images showing the presence of monomeric sterol in plasma membranes, as well as other intracellular membrane structures of living cells. Furthermore, MPLSM confirmed that crystalline sterol colocalized in highest amounts with LysoTracker Green, a lysosomal marker dye. Although crystalline sterol was also detected in the cytoplasm, the extralysosomal crystalline sterol did not colocalize with BODIPY FL C-5-ceramide, a Golgi marker, and crystals were not associated with the cell surface membrane. These noninvasive, nonperturbing methods demonstrated for the first time that multiple structural forms of sterol normally occurred within membranes, membrane microdomains (lipid rafts/ caveolae), and intracellular organelles of living cells, both in vitro and visualized in real time by MPLSM.	Texas A&M Univ, Dept Physiol & Pharmacol, Texas Vet Med Ctr, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Schroeder, F (corresponding author), Texas A&M Univ, Dept Physiol & Pharmacol, Texas Vet Med Ctr, College Stn, TX 77843 USA.	Fschroeder@cvm.tamu.edu			PHS HHS [GTM31651] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; Avdulov NA, 1997, J NEUROCHEM, V68, P2086; BAN T, 1991, ARTERY, V18, P54; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; BOURGES M, 1967, BIOCHIM BIOPHYS ACTA, V137, P157, DOI 10.1016/0005-2760(67)90019-7; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CASTANHO MARB, 1992, BIOPHYS J, V63, P1455, DOI 10.1016/S0006-3495(92)81733-2; CHEN M, 1995, BBA-MOL BASIS DIS, V1272, P101, DOI 10.1016/0925-4439(95)00073-D; Chong P.L., 1996, J FLUORESC, V6, P221; CHUNG DS, 1993, P NATL ACAD SCI USA, V90, P11341, DOI 10.1073/pnas.90.23.11341; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DRAB M, 2001, SCI EXPRESS, V10, P1; Fielding CJ, 1997, J LIPID RES, V38, P1503; FISCHER R T, 1985, Journal of Biological Physics, V13, P13, DOI 10.1007/BF01872877; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; Frank PG, 2001, BIOCHEMISTRY-US, V40, P10892, DOI 10.1021/bi0106437; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Gallegos AM, 2002, CHEM PHYS LIPIDS, V116, P19, DOI 10.1016/S0009-3084(02)00018-X; Gallegos AM, 2001, BIOCHEMISTRY-US, V40, P6493, DOI 10.1021/bi010217l; Gallegos AM, 2000, CHEM PHYS LIPIDS, V105, P9, DOI 10.1016/S0009-3084(99)00128-0; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; GLEASON MM, 1991, CIRC RES, V69, P216, DOI 10.1161/01.RES.69.1.216; Guo W, 2000, ARTERIOSCL THROM VAS, V20, P1630, DOI 10.1161/01.ATV.20.6.1630; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HIRAI A, 1994, J CLIN INVEST, V94, P2215, DOI 10.1172/JCI117583; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Huang H, 1999, BIOCHEM J, V344, P593, DOI 10.1042/0264-6021:3440593; Huang JY, 1999, BBA-BIOMEMBRANES, V1417, P89, DOI 10.1016/S0005-2736(98)00260-0; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; LOOMIS CR, 1979, J LIPID RES, V20, P525; Loura LMS, 1997, BIOPHYS J, V72, P2226, DOI 10.1016/S0006-3495(97)78866-0; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; MANTRIPRAGADA B, 1991, P NATL ACAD SCI USA, V88, P8689; MARTIN RB, 1978, LIPIDS, V13, P594, DOI 10.1007/BF02535821; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; Moncecchi D, 1996, BBA-LIPID LIPID MET, V1302, P110, DOI 10.1016/0005-2760(96)00044-6; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; NEMECZ G, 1988, BIOCHIM BIOPHYS ACTA, V943, P511, DOI 10.1016/0005-2736(88)90384-7; Ohvo-Rekila H, 2000, CHEM PHYS LIPIDS, V105, P167, DOI 10.1016/S0009-3084(00)00122-5; Pope M., 1999, ELECT PROCESSES ORGA, V2nd, P1; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Razani B, 2001, J BIOL CHEM, V276, P38121; RENSHAW PF, 1983, J LIPID RES, V24, P47; RICE PA, 1989, P NATL ACAD SCI USA, V86, P6445, DOI 10.1073/pnas.86.17.6445; SANKARAM MB, 1994, BIOPHYS J, V66, P1959, DOI 10.1016/S0006-3495(94)80989-0; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schoer JK, 2000, BIOCHEMISTRY-US, V39, P7662, DOI 10.1021/bi992686h; SCHROEDER F, 1984, PROG LIPID RES, V23, P97, DOI 10.1016/0163-7827(84)90009-2; SCHROEDER F, 1987, BIOCHEMISTRY-US, V26, P2441, DOI 10.1021/bi00383a007; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1983, J IMMUNOL METHODS, V57, P363, DOI 10.1016/0022-1759(83)90096-0; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; Schroeder F, 2001, EXP BIOL MED, V226, P873, DOI 10.1177/153537020122601002; SCHROEDER F, 1983, J BIOCHEM BIOPH METH, V8, P15, DOI 10.1016/0165-022X(83)90017-9; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P47; SCHROEDER F, 1988, ADV BIOTECHNOLOGY ME, P183; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMALL DM, 1974, SCIENCE, V185, P222, DOI 10.1126/science.185.4147.222; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P253; SMUTZER G, 1986, BIOCHIM BIOPHYS ACTA, V862, P361, DOI 10.1016/0005-2736(86)90239-7; SOKOL J, 1988, J BIOL CHEM, V263, P3411; Tabas I, 1997, TRENDS CARDIOVAS MED, V7, P256, DOI 10.1016/S1050-1738(97)00086-8; TANGIRALA RK, 1994, J LIPID RES, V35, P93; Thompson T. E., 1974, CELL SURFACE DEV, P1; Tulenko TN, 1998, J LIPID RES, V39, P947; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; Xu, 2002, T FLUOR SP, P471; YEAGLE PL, 1990, ADV CHOLESTEROL RES, P111	75	51	53	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6384	6403		10.1074/jbc.M205472200	http://dx.doi.org/10.1074/jbc.M205472200			20	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12456684	hybrid			2022-12-25	WOS:000181129400112
J	Braun, L; Christophe, T; Boulay, F				Braun, L; Christophe, T; Boulay, F			Phosphorylation of key serine residues is required for internalization of the complement 5a (C5a) anaphylatoxin receptor via a beta-arrestin, dynamin, and clathrin-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; N-FORMYL PEPTIDE; MUSCARINIC ACETYLCHOLINE-RECEPTOR; GREEN FLUORESCENT PROTEIN; CHEMOATTRACTANT RECEPTORS; MEDIATED ENDOCYTOSIS; ADRENERGIC-RECEPTOR; TRAFFICKING; MODULATION; EXPRESSION	The human complement 5a (C5a) anaphylatoxin receptor (CD88) is a G protein-coupled receptor involved in innate host defense and inflammation. Upon agonist binding, C5a receptor (C5aR) undergoes rapid phosphorylation on the six serine residues present in the C-terminal region followed by desensitization and internalization. Using confocal immunofluorescence microscopy and green fluorescent protein-tagged beta-arrestins (beta-arr 1- and beta-arr 2-EGFP) we show a persistent complex between C5aR and beta-arrestins to endosomal compartments. Serine residues in the C5aR C terminus were identified that control the intracellular trafficking of the C5aR-arrestin complex in response to C5a. Two phosphorylation mutants C5aR-A(314,317,327,332) and C5aR-A(314,317,332,334), which are phosphorylated only on Ser(334)/ Ser(338) and Ser(327)/Ser(338), respectively, recruited beta-arr 1 and were internalized. In contrast, the phosphorylation-deficient receptors C5aR-A(334,338) and C5aR-A(332,334,338) were not internalized even though observations by confocal microscopy indicated that beta-arr 1-EGFP and/or beta-arr 2-EGFP could be recruited to the plasma membrane. Altogether the results indicate that C5aR activation is able to promote a loose association with beta-arrestins, but phosphorylation of either Ser(334)/Ser(338) or Ser(327)/Ser(338) is necessary and sufficient for the formation of a persistent complex. In addition, it was observed that C5aR endocytosis was inhibited by the expression of the dominant negative mutants of dynamin (K44E) and beta-arrestin 1 (beta-arr 1-(319-418)-EGFP). Thus, the results suggest that the C5aR is internalized via a pathway dependent on beta-arrestin, clathrin, and dynamin.	Univ Grenoble 1, CEA, CNRS, UMR 5092,Dept Reponse & Dynam Cellulaires Biochim, F-38054 Grenoble 9, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Boulay, F (corresponding author), Univ Grenoble 1, CEA, CNRS, UMR 5092,Dept Reponse & Dynam Cellulaires Biochim, 17 Rue Martyrs, F-38054 Grenoble 9, France.	fboulay@cea.fr	BRAUN, Laurence/M-7111-2014	BRAUN, Laurence/0000-0002-0568-3571				Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; LANG JC, 1993, EMBO J, V12, P2671, DOI 10.1002/j.1460-2075.1993.tb05928.x; Langkabel P, 1999, EUR J IMMUNOL, V29, P3035, DOI 10.1002/(SICI)1521-4141(199909)29:09<3035::AID-IMMU3035>3.0.CO;2-Z; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; MERY L, 1994, J BIOL CHEM, V269, P3457; Naik N, 1997, J CELL SCI, V110, P2381; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; Roseberry AG, 2001, J CELL SCI, V114, P739; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; TARDIF M, 1993, J IMMUNOL, V150, P3534; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	43	50	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4277	4285		10.1074/jbc.M210120200	http://dx.doi.org/10.1074/jbc.M210120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12464600	hybrid			2022-12-25	WOS:000180869700095
J	Dawson, CW; Tramountanis, G; Eliopoulos, AG; Young, LS				Dawson, CW; Tramountanis, G; Eliopoulos, AG; Young, LS			Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; MIDDLE T-ANTIGEN; PHOSPHOINOSITIDE 3-KINASE; NASOPHARYNGEAL CARCINOMA; EPITHELIAL-CELLS; KINASE-B; MEMBRANE-PROTEIN-1; PROLIFERATION; AKT	The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is an integral membrane protein that functions as a constitutively activated member of the tumor necrosis factor receptor family. Whereas LMP1 has been shown to activate the NF-kappaB and mitogen-activated protein kinase pathways, these effects alone are unable to account for the profound oncogenic properties of LMP1. Here we show that LMP1 can activate phosphatidylinositol 3-kinase (PI3K), a lipid kinase responsible for activating a diverse range of cellular processes in response to extracellular stimuli. LMP1 was found to stimulate PI3K activity inducing phosphorylation and subsequent activation of Akt, a downstream target of PI3K responsible for promoting cell survival. Treatment of LMP1-expressing cells with the PI3K inhibitor LY294002 resulted in decreased cell survival. The tumor necrosis factor receptor-associated factor-binding domain of LMP1 was found to be responsible for PI3K activation. The ability of LMP1 to induce actin stress-fiber formation, a Rho GTPase-mediated phenomenon, was also dependent on PI3K activation. These data implicate PI3K activation in many of the LMP1-induced phenotypic effects associated with transformation and suggests that this pathway contributes both to the oncogenicity of this molecule and its role in the establishment of persistent EBV infection.	Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.		Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/ABI-6632-2020; ELIOPOULOS, ARISTIDES/R-9449-2018	Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Brennan P, 2002, ONCOGENE, V21, P1263, DOI 10.1038/sj.onc.1205182; Cantrell DA, 2001, J CELL SCI, V114, P1439; Coffer PJ, 1998, BIOCHEM J, V335, P1; Dahl J, 1998, J VIROL, V72, P3221, DOI 10.1128/JVI.72.4.3221-3226.1998; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; FAHRAEUS R, 1992, INT J CANCER, V52, P834, DOI 10.1002/ijc.2910520527; Fruman DA, 1999, BIOCHEM SOC T, V27, P624, DOI 10.1042/bst0270624; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Horikawa T, 2001, AM J PATHOL, V159, P27, DOI 10.1016/S0002-9440(10)61669-0; Horikawa T, 2000, CANCER-AM CANCER SOC, V89, P715, DOI 10.1002/1097-0142(20000815)89:4<715::AID-CNCR1>3.0.CO;2-9; HU LF, 1995, EUR J CANCER, V31A, P658, DOI 10.1016/0959-8049(94)00468-K; HUEN DS, 1995, ONCOGENE, V10, P549; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Izumi KM, 1999, J VIROL, V73, P9908, DOI 10.1128/JVI.73.12.9908-9916.1999; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kilpatrick LE, 2002, AM J PHYSIOL-CELL PH, V283, pC48, DOI 10.1152/ajpcell.00385.2001; Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lawlor MA, 2001, J CELL SCI, V114, P2903; Ozes ON, 1999, NATURE, V401, P82; Puls A, 1999, J CELL SCI, V112, P2983; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Rickinson AB, 1996, VIROLOGY, P2397; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Tarlinton D, 1998, CURR BIOL, V8, pR753, DOI 10.1016/S0960-9822(07)00478-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; VAN AL, 1997, GENE DEV, V11, P2295; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Westerberg L, 2001, BLOOD, V98, P1086, DOI 10.1182/blood.V98.4.1086; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4	51	222	242	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3694	3704		10.1074/jbc.M209840200	http://dx.doi.org/10.1074/jbc.M209840200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446712	hybrid			2022-12-25	WOS:000180869700024
J	Kanner, BI				Kanner, BI			Transmembrane domain I of the gamma-aminobutyric acid transporter GAT-1 plays a crucial role in the transition between cation leak and transport modes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL GLUTAMATE TRANSPORTER; NA+CL COTRANSPORT FUNCTION; SEROTONIN TRANSPORTER; RAT-BRAIN; DOPAMINE TRANSPORTER; GABA TRANSPORTER; XENOPUS OOCYTES; EXPRESSION; SODIUM; FLUXES	The sodium- and chloride-dependent gamma-aminobutyric acid (GABA) transporter is essential for synaptic transmission by this neurotransmitter. GAT-1 expressed in Xenopus laevis oocytes exhibits sodium-dependent GABA-induced inward currents reflecting electrogenic sodium-coupled transport. In lithium-containing medium, GAT-1 mediates GABA-independent currents, the relationship of which to the physiological transport process is poorly understood. In this study, mutants are described that appear to be locked in this cation leak mode. When Gly(63), located in the middle of the highly conserved transmembrane domain I, was mutated to serine or cysteine, sodium-dependent GABA currents were abolished. Strikingly, these mutants exhibited robust inward currents in lithium- as well as potassium-containing media. Membrane-impermeant sulfhydryl reagents inhibited these currents of the cysteine but not of the serine mutant, indicating that this position was accessible to the external aqueous medium. The cation leak currents mediated by wild-type GAT-1 were inhibited by low millimolar sodium concentrations in a noncompetitive manner. Mutations at other positions of transmembrane domain I increased or decreased the apparent sodium affinity, as monitored by the sodium-dependent steady-state GABA currents or transient currents. In parallel, the ability of sodium to inhibit the cation leak currents was increased or decreased, respectively. Thus, transmembrane domain I of GAT-1 contains determinants controlling both sodium-coupled GABA flux and the cation leak pathway as well as the interconversion of these distinct modes. Our observations suggest the possibility that the permeation pathway in both modes shares common structural elements.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.							Barker EL, 1999, J NEUROSCI, V19, P4705; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Bennett ER, 2000, J BIOL CHEM, V275, P34106, DOI 10.1074/jbc.M004229200; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Borre L, 2002, J BIOL CHEM, V277, P13501, DOI 10.1074/jbc.M110861200; Borre L, 2001, J BIOL CHEM, V276, P40396, DOI 10.1074/jbc.M104926200; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MacAulay N, 2002, J PHYSIOL-LONDON, V544, P447, DOI 10.1113/jphysiol.2002.022897; MacAulay N, 2001, J BIOL CHEM, V276, P40476, DOI 10.1074/jbc.M105578200; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MAGER S, 1996, J NEUROSCI, V16, P5404; Nelson N, 1998, J NEUROCHEM, V71, P1785; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RADIAN R, 1986, J BIOL CHEM, V261, P5437; Ryan RM, 2002, J BIOL CHEM, V277, P13494, DOI 10.1074/jbc.M109970200; Seal RP, 2001, P NATL ACAD SCI USA, V98, P15324, DOI 10.1073/pnas.011400198; Sonders MS, 1997, J NEUROSCI, V17, P960; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WANG JB, 1995, J NEUROCHEM, V64, P1416	40	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3705	3712		10.1074/jbc.M210525200	http://dx.doi.org/10.1074/jbc.M210525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446715	hybrid			2022-12-25	WOS:000180869700025
J	Modregger, J; Schmidt, AA; Ritter, B; Huttner, WB; Plomann, M				Modregger, J; Schmidt, AA; Ritter, B; Huttner, WB; Plomann, M			Characterization of endophilin B1b, a brain-specific membrane-associated lysophosphatidic acid acyl transferase with properties distinct from endophilin A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; SH3 DOMAIN; CONTAINING PROTEIN; BINDING PARTNERS; RAT-BRAIN; DYNAMIN; HUNTINGTIN; FAMILY; CELLS; SRC	We have characterized mammalian endophilin B1, a novel member of the endophilins and a representative of their B subgroup. The endophilins B show the same domain organization as the endophilins A, which contain an N-terminal domain responsible for lipid binding and lysophosphatidic acid acyl transferase activity, a central coiled-coil domain for oligomerization, a less conserved linker region, and a C-terminal Src homology 3 (SH3) domain. The endophilin B1 gene gives rise to at least three splice variants, endophilin B1a, which shows a widespread tissue distribution, and endophilins B1b and B1c, which appear to be brain-specific. Endophilin B1, like endophilins A, binds to palmitoyl-CoA, exhibits lysophosphatidic acid acyl transferase activity, and interacts with dynamin, amphiphysins 1 and 2, and huntingtin. However, in contrast to endophilins A, endophilin B1 does not bind to synaptojanin 1 and synapsin 1, and overexpression of its SH3 domain does not inhibit transferrin endocytosis. Consistent with this, immunofluorescence analysis of endophilin B1b transfected into fibroblasts shows an intracellular reticular staining, which in part overlaps with that of endogenous dynamin. Upon subcellular fractionation of brain and transfected fibroblasts, endophilin B1 is largely recovered in association with membranes. Together, our results suggest that the action of the endophilins is not confined to the formation of endocytic vesicles from the plasma membrane, with endophilin B1 being associated with, and presumably exerting a functional role at, intracellular membranes.	Univ Cologne, Fac Med, Ctr Biochem 2, D-50931 Cologne, Germany; CNRS, Inst Propre Rech, Inst Biol Physicochim, F-75005 Paris, France; Max Planck Inst Moll Cell Biol & Genet, D-01307 Dresden, Germany	University of Cologne; Centre National de la Recherche Scientifique (CNRS); Max Planck Society	Plomann, M (corresponding author), Univ Cologne, Fac Med, Ctr Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.		Huttner, Wieland B./P-4080-2018	Ritter, Brigitte/0000-0002-0094-0460; Schmidt, Anne/0000-0002-8326-0937; Modregger, Jan/0000-0001-6209-5891				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel F, 1997, SHORT PROTOCOLS MOL; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; GRAY EG, 1962, J ANAT, V96, P79; Guichet A, 2002, EMBO J, V21, P1661, DOI 10.1093/emboj/21.7.1661; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Huttner WB, 2002, TRENDS CELL BIOL, V12, P155, DOI 10.1016/S0962-8924(02)02252-3; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Modregger J, 2000, J CELL SCI, V113, P4511; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378; Plomann M, 1998, EUR J BIOCHEM, V256, P201, DOI 10.1046/j.1432-1327.1998.2560201.x; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Schmidt A, 1998, METHODS, V16, P160, DOI 10.1006/meth.1998.0663; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Torrey T, 1998, MAMM GENOME, V9, P74, DOI 10.1007/s003359900683; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Wood JD, 1996, HUM MOL GENET, V5, P481, DOI 10.1093/hmg/5.4.481	38	53	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4160	4167		10.1074/jbc.M208568200	http://dx.doi.org/10.1074/jbc.M208568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12456676	hybrid			2022-12-25	WOS:000180869700083
J	Moon, SY; Zang, HS; Zheng, Y				Moon, SY; Zang, HS; Zheng, Y			Characterization of a brain-specific Rho GTPase-activating protein, p200RhoGAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; C-SRC; ACTIN CYTOSKELETON; ADHESION KINASE; FAMILY GTPASES; CDC42 GTPASE; HUMAN GENOME; P190 RHOGAP; BINDING; TRANSFORMATION	The Rho GTPase-activating proteins (RhoGAPs) are a family of. multifunctional molecules that transduce diverse intracellular, signals by regulating Rho GTPase activities. A novel RhoGAP family member, p200RhoGAP, is cloned in human and mouse. The murine p200RhoGAP shares 86% sequence identity with the human homolog. In addition to a conserved RhoGAP domain at the N terminus, multiple proline-rich motifs are found in the C-terminal region of the molecules. Northern blot analysis revealed a brain-specific expression pattern of p200RhoGAP. The RhoGAP domain of p200RhoGAP stimulated the GTPase activities of Rac1 and RhoA an vitro and in vivo, and the conserved catalytic arginine residue (Arg-58) contributed to the GAP activity. Expression of the RhoGAP domain of p200RhoGAP in Swiss 3T3 fibroblasts inhibited actin stress fiber formation stimulated by lysophosphatidic acid and platelet-derived growth factor-induced membrane ruffling but not Bradykinin-induced filopodia formation. Endogenous p200RhoGAP was localized to cortical actin in naive N1E-115 neuroblastoma cells and to the edges of extended neurites of differentiated N1E-115 cells. Transient expression of the RhoGAP domain and the full-length molecule, but not the catalytic arginine mutants, readily induced a differentiation phenotype in N1E-115 cells. Finally, p200RhoGAP was capable of binding to the Src homology 3 domains of Src, Crk, and phospholipase Cgamma in vitro and became tyrosine-phosphorylated upon association with activated Src in cells. These results suggest that p200RhoGAP is involved in the regulation of neurite outgrowth by exerting its RhoGAP activity and that its cellular activity may be regulated through interaction with Src-like tyrosine kinases.	Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Tennessee System; University of Tennessee Health Science Center	Zheng, Y (corresponding author), Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM60523] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Billuart P, 2001, CELL, V107, P195, DOI 10.1016/S0092-8674(01)00522-0; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fincham VJ, 1999, J CELL SCI, V112, P947; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harada A, 2000, J BIOL CHEM, V275, P36885, DOI 10.1074/jbc.M004069200; Haskell MD, 2001, J CELL SCI, V114, P1699; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; LEWIN B, 2000, GENES, V7, P688; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; VAN AL, 1997, GENE DEV, V11, P2295; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	36	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4151	4159		10.1074/jbc.M207789200	http://dx.doi.org/10.1074/jbc.M207789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12454018	hybrid			2022-12-25	WOS:000180869700082
J	Vijayan, KV; Liu, Y; Dong, JF; Bray, PF				Vijayan, KV; Liu, Y; Dong, JF; Bray, PF			Enhanced activation of mitogen-activated protein kinase and myosin light chain kinase by the Pro(33) polymorphism of integrin beta 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET SHAPE CHANGE; MAP KINASE; OUTSIDE-IN; SIGNALING PATHWAY; MEGAKARYOCYTIC DIFFERENTIATION; PL(A2) POLYMORPHISM; CYTOPLASMIC DOMAIN; PHOSPHOLIPASE A(2); BETA(3); CELLS	Integrin beta(3) is polymorphic at residue 33 (Leu(33) or Pro(33)), and the Pro 33 variant exhibits increased outside-in signaling to focal adhesion kinase and greater actin reorganization. Because focal adhesion kinase activation and an intact cytoskeleton are critical links for integrin-mediated signaling to MAPK, we explored the role of integrin alpha(IIb)beta3 in this signaling using Chinese hamster ovary and human kidney 293 cell lines expressing either the Leu(33) or Pro(33) isoform of beta(3). Compared with Leu33 cells, Pro33 cells demonstrated substantially greater activation of ERK2 (but not MAPK family members JNK and p38) upon adhesion to immobilized fibrinogen (but not fibronectin) and upon integrin cross-linking. ERK2 activation was mediated through MAPK kinase and required phosphoinositide 3-kinase signaling and an intact actin cytoskeleton. Human platelets and Chinese hamster ovary cells expressing the Pro 33 isoform showed enhanced activation of the ERK2 substrate myosin light chain kinase (MLCK) upon adhering to fibrinogen. Furthermore, compared with platelets and cells expressing the Leu33 isoform, the Pro33 variant showed greater a-granule release, clot retraction, and adhesion to fibrinogen under shear stress, and these functional differences were abolished by MLCK and MAPK kinase inhibition. Post-integrin occupancy signaling through MAPK and MLCK after alpha(IIb)beta(3) cross-linking may explain in part the increased adhesive properties of the Pro(33) variant of integrin beta(3).	Baylor Coll Med, Thrombosis Res Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Bray, PF (corresponding author), Baylor Coll Med, Thrombosis Res Sect, 1 Baylor Plaza,BCM 286, Houston, TX 77030 USA.	pbray@bcm.tmc.edu			NHLBI NIH HHS [HL65967, HL57488] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL065967, R01HL057488] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett JS, 2001, BLOOD, V97, P3093, DOI 10.1182/blood.V97.10.3093; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; Brunton VG, 2001, NEOPLASIA, V3, P215, DOI 10.1038/sj.neo.7900149; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN YP, 1994, BLOOD, V84, P1857; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cooke GE, 1998, LANCET, V351, P1253, DOI 10.1016/S0140-6736(05)79320-X; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dorsey JF, 2002, BLOOD, V99, P1388, DOI 10.1182/blood.V99.4.1388; Feng DL, 1999, ARTERIOSCL THROM VAS, V19, P1142, DOI 10.1161/01.ATV.19.4.1142; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fredrickson BJ, 1998, BLOOD, V92, P3684, DOI 10.1182/blood.V92.10.3684.422k39_3684_3693; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; IKEBE M, 1985, J BIOL CHEM, V260, P27; Jiang F, 2002, BLOOD, V99, P3579, DOI 10.1182/blood.V99.10.3579; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; McNicol A, 1998, BIOCHEM PHARMACOL, V55, P1759, DOI 10.1016/S0006-2952(97)00632-1; Miao H, 2002, J CELL SCI, V115, P2199; Michelson AD, 2000, CIRCULATION, V101, P1013, DOI 10.1161/01.CIR.101.9.1013; Phillips DR, 2001, THROMB HAEMOSTASIS, V86, P246; Ratcliffe MJ, 1999, BIOCHEM J, V338, P471, DOI 10.1042/0264-6021:3380471; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; Sajid M, 2002, ARTERIOSCL THROM VAS, V22, P1984, DOI 10.1161/01.ATV.0000043664.48689.7F; Sato T, 1999, J BIOCHEM, V125, P96, DOI 10.1093/oxfordjournals.jbchem.a022275; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; Stockton RA, 2001, MOL BIOL CELL, V12, P1937, DOI 10.1091/mbc.12.7.1937; Undas A, 1999, LANCET, V353, P982, DOI 10.1016/S0140-6736(98)05054-5; Valentin N, 1994, Curr Opin Hematol, V1, P381; Vijayan KV, 2000, J CLIN INVEST, V105, P793, DOI 10.1172/JCI6982; Vijayan KV, 1998, BLOOD, V92, p343A; Wang RG, 1997, J CLIN INVEST, V100, P2393, DOI 10.1172/JCI119780; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Wilde JI, 2000, PLATELETS, V11, P286; Williams MS, 2001, EXP BIOL MED, V226, P409, DOI 10.1177/153537020122600504; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	49	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3860	3867		10.1074/jbc.M208680200	http://dx.doi.org/10.1074/jbc.M208680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12460991	hybrid			2022-12-25	WOS:000180869700045
J	Yujiri, T; Nawata, R; Takahashi, T; Sato, Y; Tanizawa, Y; Kitamura, T; Oka, Y				Yujiri, T; Nawata, R; Takahashi, T; Sato, Y; Tanizawa, Y; Kitamura, T; Oka, Y			MEK kinase 1 interacts with focal adhesion kinase and regulates insulin receptor substrate-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GENE DISRUPTION; CELL-MIGRATION; ACTIVATION; CASCADE; DOMAIN; JNK; ASSOCIATION; COMPONENTS; PATHWAY	MEK kinase 1 (MEKK1) has been shown to contribute to the regulation of cell migration, whereas focal adhesion kinase (FAK) is a major player involved in both cell migration and integrin signaling. Here we show that MEKK1 and FAK are co-immunoprecipitated from mouse fibroblasts. Moreover, the association between MEKK1 and FAK appears to be physiologically relevant, as it is enhanced by treatment with epidermal growth factor (EGF). Targeting FAK to the membrane also enhanced its association with MEKK1, indicating that MEKK1 is localized to a membrane-related subcellular domain, perhaps focal adhesions. Interestingly, the expression of insulin receptor substrate-1 (IRS-1) was diminished in MEKK1-deficient fibroblasts, which is similar to an earlier finding in FAK-deficient fibroblasts. Insulin-like growth factor 1 (IGF-1)-induced ERK activation was diminished in MEKK1-deficient cells, but phosphatidylinositol 3-kinase/Akt activation was not. Although integrin reportedly regulates the transcription of the IRS-1 gene via FAK-mediated JNK activation, no impairment of fibronectin-stimulated activation of FAK, ERK, or JNK was observed in MEKK1-deficient cells. Reconstitution of MEKK1 expression restored IRS-1 expression as well as IGF-1-induced ERK activation. Taken together, these findings indicate that MEKK1 interacts with FAK in focal adhesions and regulates IRS-1 expression.	Yamaguchi Univ, Grad Sch Med, Dept Bio Signal Anal, Yamaguchi 7558505, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy, Tokyo 1088639, Japan; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Mol Metabol & Diabet, Sendai, Miyagi 9808575, Japan	Yamaguchi University; University of Tokyo; Tohoku University	Yujiri, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Bio Signal Anal, Yamaguchi 7558505, Japan.		Kitamura, Toshio/AAA-2071-2021; Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARY LA, 1999, FRONT BIOSCI, V4, P102; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Lebrun P, 2000, J BIOL CHEM, V275, P38371, DOI 10.1074/jbc.M006162200; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Onishi M, 1996, EXP HEMATOL, V24, P324; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Winnay JN, 2000, J BIOL CHEM, V275, P10545, DOI 10.1074/jbc.275.14.10545; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	28	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3846	3851		10.1074/jbc.M206087200	http://dx.doi.org/10.1074/jbc.M206087200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458213	hybrid			2022-12-25	WOS:000180869700043
J	Christopoulos, A; Christopoulos, G; Morfis, M; Udawela, M; Laburthe, M; Couvineau, A; Kuwasako, K; Tilakaratne, N; Sexton, PM				Christopoulos, A; Christopoulos, G; Morfis, M; Udawela, M; Laburthe, M; Couvineau, A; Kuwasako, K; Tilakaratne, N; Sexton, PM			Novel receptor partners and function of receptor activity-modifying proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCITONIN-RECEPTOR; AMYLIN RECEPTOR; EXPRESSION; PEPTIDE; CLONING; IDENTIFICATION; HORMONE; RAMPS	The receptor activity-modifying proteins (RAMPs) comprise a family of three accessory proteins that heterodimerize with the calcitonin receptor-like receptor (CL receptor) or with the calcitonin receptor (CTR) to generate different receptor phenotypes. However, RAMPs are more widely distributed across cell and tissue types than the CTR and CL receptor, suggesting additional roles for RAMPs in cellular processes. We have investigated the potential for RAMP interaction with a number of Class H G protein-coupled receptors (GPCRs) in addition to the CL receptor and the CTR. Using immunofluorescence confocal microscopy, we demonstrate, for the first time, that RAMPs interact with at least four additional receptors, the VPAC1 vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor with all three RAMPs; the glucagon and PTH1 parathyroid hormone receptors with RAMP2; and the PTH2 receptor with RAMP3. Unlike the interaction of RAMPs with the CL receptor or the CTR, VPAC1R-RAMP complexes do not show altered phenotypic behavior compared with the VPAC1R alone, as determined using radioligand binding in COS-7 cells. However, the VPAC1R-RAMP2 heterodimer displays a significant enhancement of agonist-mediated phosphoinositide hydrolysis with no change in cAMP stimulation compared with the VPAC1R alone. Our findings identify a new functional consequence of RAMP-receptor interaction, suggesting that RAMPs play a more general role in modulating cell signaling through other GPCRs than is currently appreciated.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia; Univ Paris 07, INSERM, U410, Dept Neuroendocrinol & Cell Biol, F-75018 Paris, France; Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Miyazaki	Sexton, PM (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia.		Kuwasako, Kenji/H-8065-2016; Sexton, Patrick M/B-1319-2008; couvineau, alain/G-3641-2013; LABURTHE, Marc/C-1875-2012; Christopoulos, Arthur/B-6207-2013; couvineau, alain/T-3466-2019	Sexton, Patrick M/0000-0001-8902-2473; couvineau, alain/0000-0003-2912-5168; Christopoulos, Arthur/0000-0003-4442-3294; couvineau, alain/0000-0003-2912-5168; Udawela, Madhara/0000-0001-6258-0408				Armour SL, 1999, J PHARMACOL TOXICOL, V42, P217, DOI 10.1016/S1056-8719(00)00074-5; Christopoulos A, 2001, J PHARMACOL EXP THER, V298, P1260; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; COUVINEAU A, 1985, BIOCHEM J, V231, P139, DOI 10.1042/bj2310139; Flahaut M, 2002, J BIOL CHEM, V277, P14731, DOI 10.1074/jbc.M112084200; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; GAYLINN BD, 1993, MOL ENDOCRINOL, V7, P77, DOI 10.1210/me.7.1.77; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; Husmann K, 2000, MOL CELL ENDOCRINOL, V162, P35, DOI 10.1016/S0303-7207(00)00212-4; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924; Nicole P, 1998, J PHARMACOL EXP THER, V284, P744; Oliver KR, 2001, EUR J NEUROSCI, V14, P618, DOI 10.1046/j.0953-816x.2001.01688.x; PINES M, 1994, ENDOCRINOLOGY, V135, P1713, DOI 10.1210/en.135.4.1713; Sexton P M, 1999, Curr Opin Drug Discov Devel, V2, P440; Tilakaratne N, 2000, J PHARMACOL EXP THER, V294, P61; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455	21	380	387	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3293	3297		10.1074/jbc.C200629200	http://dx.doi.org/10.1074/jbc.C200629200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446722	hybrid			2022-12-25	WOS:000180915000067
J	Gutwein, P; Mechtersheimer, S; Riedle, S; Stoeck, A; Gast, D; Joumaa, S; Zentgraf, H; Fogel, M; Altevogt, P				Gutwein, P; Mechtersheimer, S; Riedle, S; Stoeck, A; Gast, D; Joumaa, S; Zentgraf, H; Fogel, M; Altevogt, P			ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles	FASEB JOURNAL			English	Article						shedding; cholesterol; methyl-beta-cyclodextrin; Golgi apparatus	AMYLOID PRECURSOR PROTEIN; CHOLESTEROL DEPLETION; MATRIX METALLOPROTEINASES; INTRACELLULAR DOMAIN; MEDIATED RELEASE; BETA-SECRETASE; ECTODOMAIN; BINDING; DISINTEGRIN; ENDOCYTOSIS	Cells can release membrane components in a soluble form and as membrane vesicles. L1, an important molecule for cell migration of neural and tumor cells, is released by membrane-proximal cleavage, and soluble L1 promotes cell migration. Release of L1 is enhanced by shedding inducers such as phorbol ester and pervanadate, but it is also enhanced by depletion of cellular cholesterol with methyl-beta-cyclodextrin (MCD). How such different compounds can induce shedding is presently unknown. We show here that ADAM10 is involved in L1 cleavage, which occurs at the cell surface and in the Golgi apparatus. MCD and pervanadate treatment induced the release of microvesicles containing full-length L1 and the active form of ADAM10. L1 cleavage occurred in isolated vesicles. L1-containing microvesicles could trigger haptotactic cell migration. Only the neural L1 form carrying the RSLE signal for clathrin-dependent endocytosis was recruited and cleaved in vesicles. Phorbol ester treatment activated L1 cleavage predominantly at the cell surface. Our results provide evidence for two pathways of L1 cleavage, based on ADAM10 localization, that can be activated differentially: 1) direct cleavage at the cell surface, and 2) release and cleavage in secretory vesicles most likely derived from the Golgi apparatus. The findings establish a novel role for ADAM10 as a vesicle-based protease.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; Kaplan Hosp, Dept Pathol, IL-76100 Rehovot, Israel	Helmholtz Association; German Cancer Research Center (DKFZ); Hebrew University of Jerusalem; Kaplan Medical Center	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, G0100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	P.Altevogt@dkfz.de						Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Angelucci A, 2000, CLIN EXP METASTAS, V18, P163, DOI 10.1023/A:1006778000173; Beer S, 1999, J CELL SCI, V112, P2667; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen TT, 1999, MAR BIOTECHNOL, V1, P1; Chubinskaya S, 2001, J HISTOCHEM CYTOCHEM, V49, P1165, DOI 10.1177/002215540104900910; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Denzer K, 2000, J CELL SCI, V113, P3365; Dolo V, 1998, CANCER RES, V58, P4468; Duczmal A, 1997, BIOCHEM BIOPH RES CO, V232, P236, DOI 10.1006/bbrc.1997.6265; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Ginestra A, 1998, ANTICANCER RES, V18, P3433; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 2001, J NEUROSCI, V21, P9194, DOI 10.1523/JNEUROSCI.21-23-09194.2001; Kenwrick S, 2000, HUM MOL GENET, V9, P879, DOI 10.1093/hmg/9.6.879; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Long KE, 2001, J BIOL CHEM, V276, P1285, DOI 10.1074/jbc.M006658200; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Millichip MI, 1998, BIOCHEM BIOPH RES CO, V245, P594, DOI 10.1006/bbrc.1998.8485; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nayeem N, 1999, J CELL SCI, V112, P4739; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schmid RS, 2000, J NEUROSCI, V20, P4177; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0; Turner AJ, 1999, BIOCHEM SOC T, V27, P255, DOI 10.1042/bst0270255; Urban S, 2000, EMBO J, V19, P1217, DOI 10.1093/emboj/19.6.1217; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; Walev I, 2000, J LEUKOCYTE BIOL, V68, P865; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	62	185	192	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					292	+		10.1096/fj.02-0430fje	http://dx.doi.org/10.1096/fj.02-0430fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475894				2022-12-25	WOS:000180574300014
J	Bae, JY; Donigian, JR; Hsueh, AJW				Bae, JY; Donigian, JR; Hsueh, AJW			Tankyrase 1 interacts with Mcl-1 proteins and inhibits their regulation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; MOTOR COMPLEX; UP-REGULATION; GENE-PRODUCT; IN-VIVO; BCL-2; FAMILY; MEMBER; EXPRESSION	Mcl-1L (myeloid cell leukemia-1 long) is an antiapoptotic Bcl-2 family protein discovered as an early induction gene during leukemia cell differentiation. Previously, we identified Mcl-1S (short) as a short splicing variant of the Mcl-1 gene with proapoptotic activity. To identify Mcl-1-interacting proteins, we performed yeast two-hybrid screening and found cDNAs encoding tankyrase 1. This protein possesses poly(ADP-ribose) polymerase activity and presumably facilitates the turnover of substrates following ADP-ribosylation. In yeast and mammalian cells, tankyrase 1 interacts with both Mcl-1L and Mcl-1S, but does not bind to other Bcl-2 family proteins tested. Analysis of truncated tankyrase 1 mutants indicated that the first 10 ankyrin repeats are involved in interaction with Mcl-1. In the N terminus of Mcl-1, a stretch of 25 amino acids is sufficient for binding to tankyrase 1. Overexpression of tankyrase 1 antagonizes both Mcl-1L-mediated cell survival and Mel-1S-induced cell death. Furthermore, coexpression of tankyrase I with Mcl-1L or Mcl-1S decreased the levels of Mcl-1 proteins. Although tankyrase 1 down-regulates Mcl-1 protein expression, no ADP-ribosylation of Mcl-1 was detected. In contrast, overexpression of Mcl-1 proteins suppressed the ADP-ribosylation of the telonteric repeat binding factor 1, another tankyrase 1-interacting protein. Thus, interaction of McI-1L and McI-1S with tankyrase 1 could serve as a unique mechanism to decrease the expression of these Bcl-2 family proteins, thereby leading to the modulation of the apoptosis pathway.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA; Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA	Stanford University; Rockefeller University	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.			bae, jeehyeon/0000-0003-1995-1378	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031566] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31566] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bennett V, 2001, CURR OPIN CELL BIOL, V13, P61, DOI 10.1016/S0955-0674(00)00175-7; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Burkle A, 2000, BIOGERONTOLOGY, V1, P41, DOI 10.1023/A:1010089924898; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Kaipia A, 1997, ENDOCRINOLOGY, V138, P5497, DOI 10.1210/en.138.12.5497; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kuimov AN, 2001, GENES IMMUN, V2, P52, DOI 10.1038/sj.gene.6363722; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Puthier D, 2001, BRIT J HAEMATOL, V112, P358, DOI 10.1046/j.1365-2141.2001.02575.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rubtsov AM, 2000, FEBS LETT, V482, P1, DOI 10.1016/S0014-5793(00)01924-4; Sbodio JI, 2002, BIOCHEM J, V361, P451, DOI 10.1042/0264-6021:3610451; Seimiya H, 2002, J BIOL CHEM, V277, P14116, DOI 10.1074/jbc.M112266200; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	39	60	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5195	5204		10.1074/jbc.M201988200	http://dx.doi.org/10.1074/jbc.M201988200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12475993	hybrid			2022-12-25	WOS:000180968900108
J	Liu, SH; Leppla, SH				Liu, SH; Leppla, SH			Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE PLASMINOGEN-ACTIVATOR; PROTECTIVE ANTIGEN; LETHAL FACTOR; DIPHTHERIA-TOXIN; MAMMALIAN-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; EUKARYOTIC CELLS; MACROPHAGES; RECEPTOR; FURIN	The interaction of anthrax toxin protective antigen (PA) and target cells was assessed, and the importance of the cytosolic domain of tumor endothelium marker 8 (TEM8) in its function as a cellular receptor for PA was evaluated. PA binding and proteolytic processing on the Chinese hamster ovary cell surface occurred rapidly, with both processes nearly reaching steady state in 5 min. Remarkably, the resulting PA63 fragment was present on the cell surface only as an oligomer, and furthermore, the oligomer was the only PA species internalized, suggesting that oligomerization of PA63 triggers receptor-mediated endocytosis. Following internalization, the PA63 oligomer was rapidly and irreversibly transformed to an SDS/heat-resistant form, in a process requiring an acidic compartment. This conformational change was functionally correlated with membrane insertion, channel formation, and translocation of lethal factor into the cytosol. To explore the role of the TEMS cytosolic tail, a series of truncated TEM8 mutants was transfected into a PA receptor-deficient Chinese hamster ovary cell line. Interestingly, all of the cytosolic tail truncated TEMS mutants functioned as PA receptors, as determined by PA binding, processing, oligomer formation, and translocation of an lethal factor fusion toxin into the cytosol. Moreover, cells transfected with a TEM8 construct truncated before the predicted transmembrane domain failed to bind PA, demonstrating that residues 321-343 are needed for cell surface anchoring. Further evidence that the cytosolic domain plays no essential role in anthrax toxin action was obtained by showing that TEMS anchored by a glycosylphosphatidylinositol tail also functioned as a PA receptor.	NIAID, Microbial Pathogenesis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Leppla, SH (corresponding author), NIAID, Microbial Pathogenesis Sect, NIH, Bldg 30, Rm 303,MSC 4350, Bethesda, MD 20892 USA.	Leppla@nih.gov		Liu, Shihui/0000-0003-3444-1069	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000929, Z01AI000929] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARORA N, 1994, INFECT IMMUN, V62, P4955, DOI 10.1128/IAI.62.11.4955-4961.1994; BEALL FA, 1962, J BACTERIOL, V83, P1274, DOI 10.1128/JB.83.6.1274-1280.1962; Beauregard KE, 1997, J EXP MED, V186, P1159, DOI 10.1084/jem.186.7.1159; Beauregard KE, 2000, CELL MICROBIOL, V2, P251, DOI 10.1046/j.1462-5822.2000.00052.x; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; EZZELL JW, 1984, INFECT IMMUN, V45, P761, DOI 10.1128/IAI.45.3.761-767.1984; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; Gottesman M M, 1987, Methods Enzymol, V151, P3, DOI 10.1016/S0076-6879(87)51004-7; HANNA PC, 1992, MOL BIOL CELL, V3, P1269, DOI 10.1091/mbc.3.11.1269; Kim BY, 2001, J BIOL CHEM, V276, P29393, DOI 10.1074/jbc.M101778200; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1999, COMPREHENSIVE SOURCE, P243; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; Liu SH, 2000, CANCER RES, V60, P6061; Liu SH, 2001, J BIOL CHEM, V276, P17976, DOI 10.1074/jbc.M011085200; LOW MG, 1987, BIOCHEM J, V244, P1; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; NOVAK JM, 1992, J BIOL CHEM, V267, P17186; OBRIEN J, 1985, INFECT IMMUN, V47, P306, DOI 10.1128/IAI.47.1.306-310.1985; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PLOUG M, 1991, J BIOL CHEM, V266, P1926; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; Singh Y, 1999, INFECT IMMUN, V67, P1853; SINGH Y, 1994, J BIOL CHEM, V269, P29039; SMITH H, 1962, J GEN MICROBIOL, V29, P517, DOI 10.1099/00221287-29-3-517; St Croix B, 2000, SCIENCE, V289, P1197; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	41	123	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5227	5234		10.1074/jbc.M210321200	http://dx.doi.org/10.1074/jbc.M210321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468536	hybrid			2022-12-25	WOS:000180968900111
J	Ukomadu, C; Dutta, A				Ukomadu, C; Dutta, A			Inhibition of cdk2 activating phosphorylation by mevastatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; S-PHASE; KINASE; LOVASTATIN; CAK; P21; PROTEASOME; REDUCTASE; GROWTH; ARREST	Phosphorylation of cdk2 on threonine 160 is essential for kinase activity. Mevastatin, an inhibitor of cholesterol synthesis, inhibits cell growth through inhibition of cdk2 and this has been suggested to be due to enhancement of p21 levels. In a prostate cancer cell line, PC3, mevastatin treatment led to elevated levels of p21 and caused a small increase in the p21 associated with cdk2. However, this increase in the associated p21 appeared out of proportion with the resulting dramatic inhibition of kinase activity. Using RNA interference we show that mevastatin inhibits cdk2 activity despite lack of induction of p21, p27, and p57. Instead the kinase was inhibited due to a decrease in activating phosphorylation. Phosphorylation of cdk2 from mevastatin-treated cells with exogenous cyclin-dependent kinase (cdk)-activating enzymes restored its functional activity. The only known mammalian cyclin H.cdk7.mat1 complex (cdk2-activating kinase, Cak), was not inhibited by mevastatin, suggesting either that a different CAK is responsible for cdk2 phosphorylation in vivo or that the regulation is at the level of substrate accessibility or of cdk2 dephosphorylation. These results suggest that mevastatin inhibits cdk2 activity in PC3 cells through the inhibition of Thr-160 phosphorylation of cdk2, providing a novel example of regulation of cdk2 at this level.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA089406] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89406] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; DECLUE JE, 1991, CANCER RES, V51, P712; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Garrett S, 2001, MOL CELL BIOL, V21, P88, DOI 10.1128/MCB.21.1.88-99.2001; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Retterstol K, 1996, AM J CARDIOL, V78, P1369, DOI 10.1016/S0002-9149(96)00649-2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yamaguchi R, 2000, EXP CELL RES, V261, P271, DOI 10.1006/excr.2000.5053	24	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4840	4846		10.1074/jbc.M208658200	http://dx.doi.org/10.1074/jbc.M208658200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12475985	hybrid			2022-12-25	WOS:000180968900065
J	Zhou, JZ; Fariss, RN; Zelenka, PS				Zhou, JZ; Fariss, RN; Zelenka, PS			Synergy of epidermal growth factor and 12(S)-hydroxyeicosatetraenoate on protein kinase C activation in lens epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE; FACTOR RECEPTORS; IN-VIVO; PHOSPHORYLATION; ACID; TRANSLOCATION; 12(S)-HETE; ISOZYMES; PATHWAYS; ISOTYPES	12(S)-Hydroxyeicosatetraenoic acid (12(S)HETE) is a bioactive metabolite of arachidonic acid synthesized by 12-lipoxygenase. The 12-lipoxygenase blocker, baicalein, prevents epidermal growth factor (EGF)-induced activation of protein kinase C (PKC) alpha and beta in lens epithelial cells, whereas supplementation with 12(S)HETE reverses this effect, suggesting that EGF and 12(S)HETE may work together to activate PKC. This study investigates the mechanism of PKCbeta activation by EGF and 12(S)HETE. 12(S)HETE alone directed translocation of PKCbeta through the C1 rather than the C2 domain, without activating phosphoinositide 3-kinase (PI3K) or MAPK signaling or increasing intracellular calcium concentration. In the presence of baicalein, EGF triggered an asymmetric phosphorylation of the EGF receptor initiating signaling through PI3K and MAPK, but not PLCgamma. Together, 12(S)HETE and EGF synergistically increased phosphorylation of PKCbeta in the activation loop and C terminus as well as PKCbeta-specific activity. PI3K inhibitors blocked phosphorylation, but MEK1 inhibitors did not. Microvesicles containing phosphatidylinositol 3,4,5-trisphosphate mimicked the action of EGF on PKCbeta activity in the presence of 12(S)HETE. Kinase-inactive PKCbeta mutations in either activation loop or C terminus were effectively translocated by 12(S)HETE, as was PKCbeta in the presence of chelerythrine or Go-6983. These findings indicate that unphosphorylated PKCbeta is translocated to the membrane by 12(S)HETE and phosphorylated by EGF-dependent PI3K signaling, to generate catalytically competent PKCbeta.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NEI, Lab Mech Ocular Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Zelenka, PS (corresponding author), NEI, Mol & Dev Biol Lab, NIH, Bldg 6,Rm 214,6 Ctr Dr,MSC 2730, Bethesda, MD 20892 USA.	zelenkap@nei.nih.gov	Fariss, Robert/ABI-1771-2020	Fariss, Robert/0000-0003-3227-7170	NATIONAL EYE INSTITUTE [ZIAEY000238, Z01EY000238] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alpert SE, 1999, AM J PHYSIOL-LUNG C, V277, pL457, DOI 10.1152/ajplung.1999.277.3.L457; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Arora JK, 1996, INVEST OPHTH VIS SCI, V37, P1411; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Haque MSR, 1999, MOL VIS, V5, pU1; HURST JS, 1991, J BIOL CHEM, V266, P6726; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU B, 1995, P NATL ACAD SCI USA, V92, P9323, DOI 10.1073/pnas.92.20.9323; LUO JH, 1993, J BIOL CHEM, V268, P23580; LYSZ TW, 1992, EXP EYE RES, V54, P769, DOI 10.1016/0014-4835(92)90032-N; LYSZ TW, 1994, CELL GROWTH DIFFER, V5, P1069; Negash S, 2002, J CELL SCI, V115, P2109; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nie DT, 2001, CANCER METAST REV, V20, P195, DOI 10.1023/A:1015579209850; O'Flaherty JT, 2001, J BIOL CHEM, V276, P24743, DOI 10.1074/jbc.M101093200; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; OLIW EH, 1993, ACTA PHYSIOL SCAND, V147, P117, DOI 10.1111/j.1748-1716.1993.tb09479.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1994, J BIOL CHEM, V269, P27715; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Seth RK, 2001, INVEST OPHTH VIS SCI, V42, P3239; Slater SJ, 2002, J BIOL CHEM, V277, P15277, DOI 10.1074/jbc.M112207200; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; Szekeres CK, 2000, BIOCHEM BIOPH RES CO, V275, P690, DOI 10.1006/bbrc.2000.3348; Szekeres CK, 2000, J BIOL CHEM, V275, P38831, DOI 10.1074/jbc.M002673200; Tari AM, 2001, SEMIN ONCOL, V28, P142, DOI 10.1053/sonc.2001.28555; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Zakaroff-Girard A, 1999, LIFE SCI, V64, P2135, DOI 10.1016/S0024-3205(99)00164-2; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	44	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5388	5398		10.1074/jbc.M209695200	http://dx.doi.org/10.1074/jbc.M209695200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12464613	hybrid			2022-12-25	WOS:000180968900131
J	Banfi, B; Clark, RA; Steger, K; Krause, KH				Banfi, B; Clark, RA; Steger, K; Krause, KH			Two novel proteins activate superoxide generation by the NADPH oxidase NOX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H OXIDASE; DOMAIN; PHOSPHORYLATION; SUBUNIT; CELLS; IDENTIFICATION; EXPRESSION; P67(PHOX); P47(PHOX); HOMOLOG	NOX1, an NADPH oxidase expressed predominantly in colon epithelium, shows a high degree of similarity to the phagocyte NADPH oxidase. However, superoxide generation by NOX1 has been difficult to demonstrate. Here we show that NOX1 generates superoxide when co-expressed with the p47(phox) and p67(phox) subunits of the phagocyte NADPH oxidase but not when expressed by itself. Since p47(phox) and p67(phox) are restricted mainly to myeloid cells, we searched for their homologues and identified two novel cDNAs. The mRNAs of both homologues were found predominantly in colon epithelium. Differences between the homologues and the phagocyte NADPH oxidase subunits included the lack of the auto-inhibitory domain and the protein kinase C phosphorylation sites in the p47(phox) homologue as well as the absence of the first Src homology 3 domain and the presence of a hydrophobic stretch in the p67(phox) homologue. Co-expression of NOX1 with the two novel proteins led to stimulus-independent high level superoxide generation. Stimulus dependence of NOX1 was restored when p47(phox) was used to replace its homologue. In conclusion, NOX1 is a superoxide-generating enzyme that is activated by two novel proteins, which we propose to name NOXO1 (NOX organizer 1) and NOXA1 (NOX activator 1).	Univ Hosp Geneva, Dept Geriatr, Biol Ageing Lab, CH-1225 Geneva, Switzerland; Inst Vet Anat, D-35392 Giessen, Germany; S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA	University of Geneva; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio	Banfi, B (corresponding author), Univ Hosp Geneva, Dept Geriatr, Biol Ageing Lab, 2 Ch Petit Bel Air, CH-1225 Geneva, Switzerland.		Krause, Karl-Heinz/E-8030-2011; Clark, Robert/Q-6764-2019	Krause, Karl-Heinz/0000-0002-9033-6768; Clark, Robert/0000-0002-4892-3619; Banfi, Botond/0000-0001-9273-1318	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020866, R37AI020866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019519] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI020866, R01 AI020866, AI20866] Funding Source: Medline; NIA NIH HHS [R01 AG019519, AG19519] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Biberstine-Kinkade KJ, 2001, J BIOL CHEM, V276, P31105, DOI 10.1074/jbc.M103327200; Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lavigne MC, 2001, CIRCULATION, V104, P79, DOI 10.1161/01.CIR.104.1.79; Lerm M, 2002, INFECT IMMUN, V70, P4053, DOI 10.1128/IAI.70.8.4053-4058.2002; Maturana A, 2001, J BIOL CHEM, V276, P30277, DOI 10.1074/jbc.M010438200; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459	27	389	405	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3510	3513		10.1074/jbc.C200613200	http://dx.doi.org/10.1074/jbc.C200613200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12473664	hybrid, Green Published			2022-12-25	WOS:000180869700002
J	Defais, M; Phez, E; Johnson, NP				Defais, M; Phez, E; Johnson, NP			Kinetic mechanism for the formation of the presynaptic complex of the bacterial recombinase RecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PROMOTED ATP HYDROLYSIS; NON-COOPERATIVE BINDING; ESCHERICHIA-COLI; NUCLEOPROTEIN FILAMENTS; GENETIC-RECOMBINATION; PROTEIN INTERACTIONS; LARGE LIGANDS; EXCHANGE; VISUALIZATION	RecA protein from Escherichia coli catalyzes DNA strand exchange during homologous recombination in a reaction that requires nucleoside triphosphate cofactor. In the first step of this reaction RecA protein polymerizes on single-stranded DNA to form a filament with a stoichiometry of three nucleotides/RecA monomer called the presynaptic complex. We have used fluorescence anisotropy of a fluorescein-labeled oligonucleotide to investigate presynaptic complex formation. RecA-ATPgammaS bound to oligonucleotide by a two-step process. Kinetic studies revealed an intermediate in the polymerization reaction that had greater mobility, than the final product filament. The intermediate was transformed into the final product by a process that was independent of filament concentration and temperature, k = 0.3 +/- 0.1 min(-1). This process had the same rate as that reported for a step in the isomerization of presynaptic complex by ATPgammaS (Paulus, B. F., and Bryant, F. R. (1997) Biochemistry 36, 7832-7838). Judging from anisotropy measurements, the intermediate had hydrodynamic properties similar to a mixed filament containing RecA monomers with and without ATPgammaS. These results show that the presynaptic complex can assume conformations with different segmental mobilities that could play a role in homologous recombination.	CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Johnson, NP (corresponding author), CNRS, UMR 5089, Inst Pharmacol & Biol Struct, 205,Route Narbonne, F-31077 Toulouse, France.	Neil.Johnson@ipbs.fr						Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; Canet D, 2001, BIOPHYS J, V80, P1996, DOI 10.1016/S0006-3495(01)76169-3; Cazaux C, 1998, J BIOL CHEM, V273, P28799, DOI 10.1074/jbc.273.44.28799; CAZENAVE C, 1983, EMBO J, V2, P2247, DOI 10.1002/j.1460-2075.1983.tb01730.x; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; COX MM, 1983, J BIOL CHEM, V258, P2586; DUNN K, 1982, CELL, V28, P757, DOI 10.1016/0092-8674(82)90055-1; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; FLORY J, 1982, CELL, V28, P747, DOI 10.1016/0092-8674(82)90054-X; Gourves AS, 2001, J BIOL CHEM, V276, P9613, DOI 10.1074/jbc.M004855200; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; Logan KM, 2001, BIOCHEMISTRY-US, V40, P11382, DOI 10.1021/bi011081u; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MORRICAL SW, 1985, BIOCHEMISTRY-US, V24, P760, DOI 10.1021/bi00324a034; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Paulus BF, 1997, BIOCHEMISTRY-US, V36, P7832, DOI 10.1021/bi970576+; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; TAKAHASHI M, 1989, J BIOL CHEM, V264, P288; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; ZLOTNICK A, 1993, J BIOL CHEM, V268, P22525	32	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3545	3551		10.1074/jbc.M204341200	http://dx.doi.org/10.1074/jbc.M204341200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12456687	hybrid			2022-12-25	WOS:000180869700007
J	Zhang, BY; Liu, M; Arvan, P				Zhang, BY; Liu, M; Arvan, P			Behavior in the eukaryotic secretory pathway of insulin-containing fusion proteins and single-chain insulins bearing various B-chain mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PANCREATIC BETA-CELLS; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; SORTING RECEPTOR; FOLDING PATHWAY; YEAST; PROINSULIN; MUTANT	In the secretory pathway, endoproteolytic cleavage of the insulin precursor protein promotes a change in the biophysical properties of the processed insulin product, and this may be relevant for its intracellular trafficking. We have now studied several independent point mutants contained within the insulin B-chain, S9D, H10D, V12E (called B9D, B10D, and B12E), as well as the double point mutant P28K,K29P (B28K,B29P), that have been reported to inhibit insulin oligomerization. In yeast cells, the unprocessed precursor of each of these mutants is secreted, whereas >90% of the endoproteolytically released single-chain insulin moiety is retained intracellularly; a large portion of the B9D, B10D, and B12E single-chain insulins exhibit abnormally slow mobility upon nonreducing SDS-PAGE, despite normal mobility upon reducing SDS-PAGE. Although no free thiols can be detected, each of these mutants exhibits increased disulfide accessibility to dithiothreitol. After dithiothreitol treatment, a portion of the molecules can reoxidize to a form more compact than the original single-chain insulin mutants formed in vivo (indicating initial disulfide mispairing). Disulfide mispairing of a fraction of B9D, B10D, and B12E mutants also occurs in the context of single-chain insulin and even in authentic proinsulin expressed within the secretory pathway of mammalian cells. We conclude that analyses of the intracellular trafficking of certain oligomerization-defective insulin mutants is complicated by the formation of disulfide isomers in the secretory pathway.	Yeshiva Univ Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; ARVAN P, 1991, J BIOL CHEM, V266, P14171; Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; Arvan P, 2002, CURR OPIN CELL BIOL, V14, P448, DOI 10.1016/S0955-0674(02)00344-7; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; Bullesbach EE, 2001, J PEPT RES, V57, P77, DOI 10.1034/j.1399-3011.2001.00832.x; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P8943, DOI 10.1073/pnas.85.23.8943; CHAN SJ, 1987, P NATL ACAD SCI USA, V84, P2194, DOI 10.1073/pnas.84.8.2194; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; CISZAK E, 1995, STRUCTURE, V3, P615, DOI 10.1016/S0969-2126(01)00195-2; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; ELLIOTT S, 1990, J PROTEIN CHEM, V9, P95, DOI 10.1007/BF01024990; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FRANK BH, 1968, BIOCHEM BIOPH RES CO, V32, P155, DOI 10.1016/0006-291X(68)90362-8; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; GRANT PT, 1972, BIOCHEM J, V126, P433, DOI 10.1042/bj1260433; GRUPPUSO PA, 1984, NEW ENGL J MED, V311, P629, DOI 10.1056/NEJM198409063111003; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P1556, DOI 10.1021/bi011166v; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P10585, DOI 10.1021/bi020165f; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; Hober S, 1999, FEBS LETT, V443, P271, DOI 10.1016/S0014-5793(98)01737-2; Holkeri H, 1998, FEBS LETT, V429, P162, DOI 10.1016/S0014-5793(98)00586-9; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; Hua QX, 1998, J MOL BIOL, V277, P103, DOI 10.1006/jmbi.1997.1574; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HUANG XF, 1995, J BIOL CHEM, V270, P20417, DOI 10.1074/jbc.270.35.20417; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; JORGENSEN AMM, 1992, J MOL BIOL, V227, P1146, DOI 10.1016/0022-2836(92)90527-Q; Jorgensen MU, 1999, EUR J BIOCHEM, V260, P461, DOI 10.1046/j.1432-1327.1999.00176.x; KAARSHOLM NC, 1989, BIOCHEMISTRY-US, V28, P4427, DOI 10.1021/bi00436a046; Kjeldsen T, 2000, APPL MICROBIOL BIOT, V54, P277, DOI 10.1007/s002530000402; Kjeldsen T, 2001, Biotechnol Genet Eng Rev, V18, P89; Kowarik M, 2002, MOL CELL, V10, P769, DOI 10.1016/S1097-2765(02)00685-8; Kuliawat R, 2000, MOL BIOL CELL, V11, P1959, DOI 10.1091/mbc.11.6.1959; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Lee HC, 2000, NATURE, V408, P483, DOI 10.1038/35044106; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Milner SJ, 1999, BIOTECHNOL BIOENG, V62, P693; NARHI LO, 1993, BIOCHEMISTRY-US, V32, P5214, DOI 10.1021/bi00070a033; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; ROSENFELD RD, 1993, J PROTEIN CHEM, V12, P247, DOI 10.1007/BF01028187; Rowling P J, 1993, Subcell Biochem, V21, P41; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; SIEBER P, 1978, H-S Z PHYSIOL CHEM, V359, P113; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH MC, 1989, J BIOL CHEM, V264, P9314; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; STEINER DF, 1992, DIABETOLOGIA, V35, pS41, DOI 10.1007/BF00586278; STEUBE K, 1991, EUR J BIOCHEM, V198, P651, DOI 10.1111/j.1432-1033.1991.tb16063.x; TANG JG, 1988, BIOCHEM J, V255, P451, DOI 10.1042/bj2550451; Weiss MA, 2002, J MOL BIOL, V315, P103, DOI 10.1006/jmbi.2001.5224; Weiss MA, 2001, J BIOL CHEM, V276, P40018, DOI 10.1074/jbc.M104634200; Winter J, 2002, J BIOL CHEM, V277, P310, DOI 10.1074/jbc.M107832200; Yao ZP, 1999, ACTA CRYSTALLOGR D, V55, P1524, DOI 10.1107/S0907444999008562; Yuan Y, 1999, BIOCHEM J, V343, P139, DOI 10.1042/0264-6021:3430139; Zhang BY, 2001, J CELL BIOL, V153, P1187, DOI 10.1083/jcb.153.6.1187; Zhang YS, 2002, ACTA CRYSTALLOGR D, V58, P186, DOI 10.1107/S0907444901018455	66	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3687	3693		10.1074/jbc.M209474200	http://dx.doi.org/10.1074/jbc.M209474200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446709	hybrid			2022-12-25	WOS:000180869700023
J	Curino, A; Mitola, DJ; Aaronson, H; McMahon, GA; Raja, K; Keegan, AD; Lawrence, DA; Bugge, TH				Curino, A; Mitola, DJ; Aaronson, H; McMahon, GA; Raja, K; Keegan, AD; Lawrence, DA; Bugge, TH			Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages	ONCOGENE			English	Review						fibrosarcoma; tumor-infiltrating macrophages; plasminogen activator; stroma	RECEPTOR-BOUND UROKINASE; LEWIS LUNG-CARCINOMA; SPONTANEOUS METASTASIS MODEL; SQUAMOUS-CELL CARCINOMA; GENE-INACTIVATED MICE; HUMAN COLON-CANCER; LATENT TGF-BETA; ACTIVATOR INHIBITOR-1; DEFICIENT MICE; BREAST-CANCER	The specific functions of plasminogen, stromal plasminogen activator, stromal plasminogen activator receptor, and stromal plasminogen activator inhibitor in the progression of the murine soft tissue sarcoma, T241 were investigated. Negation of plasminogen to the tumor blunted the orthotopic growth of the sarcoma in syngeneic mice. The reduced tumor growth was associated with a dramatic increase in tumor-infiltrating F4/80-positive macrophages and a diminution of vessel density, but not with obvious differences in fibrin and collagen deposition, or invasiveness of the tumor. Ablation of plasminogen activation by the tumor stroma only modestly impaired the prolonged growth of the sarcoma, suggesting that tumor cell-produced plasminogen activator is sufficient to mediate productive plasminogen activation. Plasminogen facilitated sarcoma progression, angiogenesis, and suppression of macrophage infiltration in the absence of either stromal urokinase plasminogen activator receptor or stromal plasminogen activator inhibitor. These data demonstrate that tumor cell-produced plasminogen activator and host plasminogen cooperate to facilitate soft tissue sarcoma growth and suppress the accumulation of tumor-infiltrating macrophages.	Natl Inst Dent Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Amer Red Cross, Dept Immunol, Rockville, MD 20855 USA; Amer Red Cross, Dept Vasc Biol, Rockville, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); American Red Cross; American Red Cross	Bugge, TH (corresponding author), Natl Inst Dent Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr, Bethesda, MD 20892 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL055747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55747, P01 HL54710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEVA DG, 1994, J IMMUNOL, V153, P1674; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BAKER MS, 1990, CANCER RES, V50, P4676; Beck JM, 1999, INFECT IMMUN, V67, P879, DOI 10.1128/IAI.67.2.879-884.1999; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; Bugge TH, 1997, BLOOD, V90, P4522; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chapman HA, 2001, THROMB HAEMOSTASIS, V86, P124; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; De Petro G, 1998, CANCER RES, V58, P2234; DECLERCK PJ, 1995, THROMB HAEMOSTASIS, V74, P1305; DECLERCK PJ, 1995, J BIOL CHEM, V270, P8397, DOI 10.1074/jbc.270.15.8397; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; DiNapoli MR, 1996, J EXP MED, V183, P1323, DOI 10.1084/jem.183.4.1323; Dublin E, 2000, AM J PATHOL, V157, P1219, DOI 10.1016/S0002-9440(10)64637-8; DUFFY MJ, 1990, CANCER RES, V50, P6827; Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; FOEKENS JA, 1992, CANCER RES, V52, P6101; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GANESH S, 1994, CANCER RES, V54, P4065; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Goguen JD, 2000, METHODS, V21, P179, DOI 10.1006/meth.2000.0989; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Gutierrez LS, 2000, CANCER RES, V60, P5839; HALL SW, 1991, J BIOL CHEM, V266, P12329; HEARING VJ, 1988, CANCER RES, V48, P1270; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; HIENERT G, 1988, J UROLOGY, V140, P1466, DOI 10.1016/S0022-5347(17)42074-X; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hudson MA, 1997, J NATL CANCER I, V89, P709, DOI 10.1093/jnci/89.10.709; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; Kono K, 1996, EUR J IMMUNOL, V26, P1308, DOI 10.1002/eji.1830260620; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lanza F, 1998, BRIT J HAEMATOL, V103, P110; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Leek RD, 2000, J PATHOL, V190, P430, DOI 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6; Leek RD, 1996, CANCER RES, V56, P4625; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; List K, 2000, BIOCHEMISTRY-US, V39, P508, DOI 10.1021/bi991701f; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Martin DC, 1999, J CELL BIOL, V146, P881, DOI 10.1083/jcb.146.4.881; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Min HY, 1996, CANCER RES, V56, P2428; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morita S, 1998, INT J CANCER, V78, P286, DOI 10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; NEKARDA H, 1994, LANCET, V343, P117, DOI 10.1016/S0140-6736(94)90845-1; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Nielsen BS, 1996, LAB INVEST, V74, P168; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OHMORI T, 1995, HISTOL HISTOPATHOL, V10, P789; OKA T, 1991, CANCER RES, V51, P3522; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PEDERSEN H, 1994, CANCER RES, V54, P4671; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; PLESNER T, 1994, AM J CLIN PATHOL, V102, P835, DOI 10.1093/ajcp/102.6.835; PLOW EF, 1986, J IMMUNOL, V137, P1910; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; PYKE C, 1994, HISTOPATHOLOGY, V24, P131, DOI 10.1111/j.1365-2559.1994.tb01291.x; PYKE C, 1993, CANCER RES, V53, P1911; PYKE C, 1991, AM J PATHOL, V138, P1059; Rabbani SA, 1995, INT J CANCER, V63, P840, DOI 10.1002/ijc.2910630615; Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x; Rogove AD, 1999, J CELL SCI, V112, P4007; Romisch J, 1999, HAEMOSTASIS, V29, P292; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SAWAYA R, 1988, J NEUROSURG, V68, P73, DOI 10.3171/jns.1988.68.1.0073; Schmidt M, 2000, HEAD NECK-J SCI SPEC, V22, P498, DOI 10.1002/1097-0347(200008)22:5<498::AID-HED9>3.0.CO;2-W; Shapiro RL, 1996, CANCER RES, V56, P3597; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sier CFM, 1998, CANCER RES, V58, P1843; SIMON DI, 1993, BLOOD, V82, P2414; SKRIVER L, 1984, Journal of Cell Biology, V99, P752; Solberg H, 2001, J HISTOCHEM CYTOCHEM, V49, P237, DOI 10.1177/002215540104900211; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Taniguchi T, 1998, CANCER RES, V58, P4461; Wahl LM, 1998, J NATL CANCER I, V90, P1583, DOI 10.1093/jnci/90.21.1583; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; YU H, 1990, CANCER RES, V50, P7623	113	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8830	8842		10.1038/sj.onc.1205951	http://dx.doi.org/10.1038/sj.onc.1205951			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483535				2022-12-25	WOS:000179734400016
J	Perry, C; Sklan, EH; Birikh, K; Shapira, M; Trejo, L; Eldor, A; Soreq, H				Perry, C; Sklan, EH; Birikh, K; Shapira, M; Trejo, L; Eldor, A; Soreq, H			Complex regulation of acetylcholinesterase gene expression in human brain tumors	ONCOGENE			English	Article						acetylcholinesterase; human brain tumors; Runx1; AML1	TISSUE-SPECIFIC EXPRESSION; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; NEURONAL DIFFERENTIATION; SPLICE VARIANTS; CELL-GROWTH; BUTYRYLCHOLINESTERASE; PROTEIN; LEUKEMIA; FORMS	To study the regulation of acetylcholinesterase (AChE) gene expression in human brain tumors, 3' splice variants of AChE mRNA and potentially relevant transcription factor mRNAs were labeled in primary astrocytomas and melanomas. AChE-S and AChE-R mRNA, as well as Runx1/AML1 mRNA accumulated in astrocytomas in correlation with tumor aggressiveness, but neither HNF3beta nor c-fos mRNA was observed in melanoma and astrocytomas. immunohistochemistry demonstrated nuclear Runx1/AML1 and cellular AChE-S and AChE-R in melanomas, however, only AChE-S, and not the secreted AChE-R variant, was retained in astrocyte tumor cells. Runx1/AML1 revealed weak linkage with ACHE promoter sequences, yet enhanced ACHE gene expression in co-transfected COS1 cells. The p300 coactivator and the ACHE promoter's distal enhancer facilitated this effect, which was independent of much of the Runx1/AML1 trans-activation domain. Surprisingly, GASP, a fusion product of green fluorescence protein (GFP) and ASP(67), a peptide composed of the 67 C-terminal amino acid residues of AChE-S, localized to COS1 cell nuclei. However, GARP, the corresponding fusion product of GFP with a peptide having the 51 C-terminal residues of AChE-E or GFP alone, remained cytoplasmic. Runx1/AML1 exhibited improved nuclear retention in GASP-expressing COS1 cells, suggesting modulated nuclear localization processes. Together, these findings reveal brain tumor-specific regulation of both expression and cellular retention of variant ACHE gene products.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, IL-64239 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Pathol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, IL-64239 Tel Aviv, Israel; RAS, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117799, Russia	Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il	Birikh, Klara/AAO-4069-2021	Birikh, Klara/0000-0001-6124-447X; Soreq, Hermona/0000-0002-0955-526X				ACHESON AL, 1984, J NEUROSCI, V4, P1771; ALOYA RB, 1993, P NATL ACAD SCI USA, V90, P2471; Barbosa M, 2001, SURG NEUROL, V55, P106, DOI 10.1016/S0090-3019(01)00351-2; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; Ben Aziz-Aloya R, 1998, CELL DEATH DIFFER, V5, P765, DOI 10.1038/sj.cdd.4400415; BERGER R, 1985, CYTOGENET CELL GENET, V40, P490, DOI 10.1159/000132181; Bigbee JW, 1999, ENVIRON HEALTH PERSP, V107, P81, DOI 10.2307/3434475; BROWN LM, 1990, CANCER RES, V50, P6585; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; Coleman BA, 1996, J BIOL CHEM, V271, P4410; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EHRLICH G, 1992, GENOMICS, V13, P1192, DOI 10.1016/0888-7543(92)90037-S; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; GETMAN DK, 1992, AM J HUM GENET, V51, P170; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Goodman RH, 2000, GENE DEV, V14, P1553; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grisaru D, 1999, MOL CELL BIOL, V19, P788; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Grisaru D, 2001, MOL MED, V7, P93, DOI 10.1007/BF03401943; Haas R, 1996, BIOCHEM J, V314, P817, DOI 10.1042/bj3140817; Karpel R, 1996, J NEUROCHEM, V66, P114; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitange G, 1999, MODERN PATHOL, V12, P618; Koenigsberger C, 1997, J NEUROCHEM, V69, P1389; LAPIDOTLIFSON Y, 1989, P NATL ACAD SCI USA, V86, P4715, DOI 10.1073/pnas.86.12.4715; LeBeau MM, 1996, BLOOD, V88, P1930; LI Y, 1991, J BIOL CHEM, V266, P23083; Li YK, 2000, J NEUROSCI, V20, P149, DOI 10.1523/JNEUROSCI.20-01-00149.2000; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Neskovic-Konstantinovic Z, 1999, J EXP CLIN CANC RES, V18, P347; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Perry C, 2002, LEUKEMIA RES, V26, P221, DOI 10.1016/S0145-2126(01)00128-X; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAZON N, 1984, EXP NEUROL, V84, P681, DOI 10.1016/0014-4886(84)90215-2; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; SaezValero J, 1996, BBA-MOL BASIS DIS, V1317, P210, DOI 10.1016/S0925-4439(96)00061-0; SaezValero J, 1996, NEUROSCI LETT, V206, P173, DOI 10.1016/S0304-3940(96)12452-6; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; SOREQ H, 1984, EMBO J, V3, P1371, DOI 10.1002/j.1460-2075.1984.tb01979.x; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Valter MM, 1999, CANCER RES, V59, P5608; VELAN B, 1994, J BIOL CHEM, V269, P22719; Welker P, 2000, BRIT J CANCER, V82, P1453, DOI 10.1054/bjoc.1999.1076; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yamada M, 1996, J NEUROSCI RES, V43, P355, DOI 10.1002/(SICI)1097-4547(19960201)43:3<355::AID-JNR10>3.0.CO;2-4; ZAKUT H, 1988, CANCER, V61, P727, DOI 10.1002/1097-0142(19880215)61:4<727::AID-CNCR2820610416>3.0.CO;2-L; Zhang HT, 2000, BRIT J CANCER, V83, P63	61	72	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8428	8441		10.1038/sj.onc.1205945	http://dx.doi.org/10.1038/sj.onc.1205945			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466963				2022-12-25	WOS:000179480100006
J	Graeler, M; Goetzl, EJ				Graeler, M; Goetzl, EJ			Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells	FASEB JOURNAL			English	Article						immunity; chemokine; lysophospholipid; receptor; G-protein	MODEL BASEMENT-MEMBRANE; LYSOPHOSPHATIDIC ACID; LYMPHOCYTES; MIGRATION; FTY720	Sphingosine 1-phosphate (S1P) from platelets and macrophages stimulates migration and enhances survival of T cells. Mouse spleen CD4 and CD8 T cells are shown to express predominantly S1P(1) (Edg-1) and S1P(4) (Edg-6) G-protein-coupled receptors with only minimal representation of S1P(2), S1P(3), and S1P(5). At and below plasma concentrations of healthy mammals (1 nM-1 muM), S1P evokes trans-Matrigel chemotaxis of mouse CD4 and CD8 T cells and recruits T cells into subcutaneous air pouches. T cell receptor-mediated activation of CD4 T cells suppresses expression of S1P(1) and S1P(4) receptors and eliminates their chemotactic responses to S1P. The immunoregulator FTY720, a structural homologue of S1P, lacks T cell chemotactic activity and competitively inhibits T cell chemotactic responses to S1P in vitro and in vivo. S1P may be a distinctive contributor to compartmental immunity by attracting naive and memory T cells preferentially over activated effector T cells.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, UB8B,UC Box 0711,533 Parnassus & 4th, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; HLA T, 1990, J BIOL CHEM, V265, P9308; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Xia MH, 1996, J IMMUNOL, V156, P160; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317; Zheng YH, 2000, FASEB J, V14, P2387	14	183	187	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					1874	1878		10.1096/fj.02-0548com	http://dx.doi.org/10.1096/fj.02-0548com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468451				2022-12-25	WOS:000180574300007
J	Nishimori, H; Sasaki, Y; Yoshida, K; Irifune, H; Zembutsu, H; Tanaka, T; Aoyama, T; Hosaka, T; Kawaguchi, S; Wada, T; Hata, J; Toguchida, J; Nakamura, Y; Tokino, T				Nishimori, H; Sasaki, Y; Yoshida, K; Irifune, H; Zembutsu, H; Tanaka, T; Aoyama, T; Hosaka, T; Kawaguchi, S; Wada, T; Hata, J; Toguchida, J; Nakamura, Y; Tokino, T			The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors	ONCOGENE			English	Article						ld2; EWS-ETS; Ewing family tumor	DNA-BINDING; CHROMOSOME-TRANSLOCATION; SARCOMA TRANSLOCATION; MOLECULAR ANALYSIS; CDNA MICROARRAY; CELLS; EXPRESSION; CANCER; FUSES; ERG	We report here that the Id2 (inhibitor of DNA binding 2) gene is a novel target of transcriptional activation by EWS-FLI1 and EWS-ERG, two fusion proteins that characterize Ewing family tumors (EFTs). To identify downstream targets of these EWS-ETS fusion proteins, we introduced EWS-ETS fusion constructs into a human fibrosarcoma cell line by retroviral transduction. cDNA microarray analysis revealed that Id2 expression was up-regulated by introducing the EWS-ETS fusion gene but not by the normal full-length ETS gene. An Id2 promoter-luciferase reporter assay showed that transactivation by EWS-ETS involves the minimal Id2 promoter and may function in cooperation with c-Myc within the full-length regulatory region. A chromatin immunoprecipitation assay revealed direct interaction between the Id2 promoter and EWS-FLI1 fusion protein in vivo. Significantly higher expression of Id2 and c-Myc was observed in all of the six EFT cell lines examined compared to six other sarcoma cell lines. Moreover, high levels of Id2 expression were also observed in five of the six primary tumors examined. Id2 is generally thought to affect the balance between cell differentiation and proliferation in development and is highly expressed in several cancer types. Considering these previous studies, our data suggest that the oncogenic effect of EWS-ETS may be mediated in part by up-regulating Id2 expression.	Sapporo Med Univ, Sch Med, Inst Canc Res, Dept Mol Biol,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Orthoped Surg, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, Tokyo 1088639, Japan; Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Orthoped Surg, Sakyo Ku, Kyoto 6068507, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan	Sapporo Medical University; Sapporo Medical University; University of Tokyo; Kyoto University; Kyoto University; Keio University	Tokino, T (corresponding author), Sapporo Med Univ, Sch Med, Inst Canc Res, Dept Mol Biol,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.		Tanaka, Toshihiro/J-9310-2014; Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Tanaka, Toshihiro/0000-0001-6201-9784; Sasaki, Yasushi/0000-0002-3500-8059; 				Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kihara C, 2001, CANCER RES, V61, P6474; Kleeff J, 1998, CANCER RES, V58, P3769; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lopez-Guerrero JA, 2001, LAB INVEST, V81, P803, DOI 10.1038/labinvest.3780290; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Ono K, 2000, CANCER RES, V60, P5007; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Thompson AD, 1996, ONCOGENE, V13, P2649; Urano F, 1998, JPN J CANCER RES, V89, P703, DOI 10.1111/j.1349-7006.1998.tb03274.x; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WEI G, 2000, CANCER, V89, P783; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	38	85	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8302	8309		10.1038/sj.onc.1206025	http://dx.doi.org/10.1038/sj.onc.1206025			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447693				2022-12-25	WOS:000179323900008
J	Veitch, DP; Nokelainen, P; McGowan, KA; Nguyen, TT; Nguyen, NE; Stephenson, R; Pappano, WN; Keene, DR; Spong, SM; Greenspan, DS; Findell, PR; Marinkovich, PM				Veitch, DP; Nokelainen, P; McGowan, KA; Nguyen, TT; Nguyen, NE; Stephenson, R; Pappano, WN; Keene, DR; Spong, SM; Greenspan, DS; Findell, PR; Marinkovich, PM			Mammalian tolloid metalloproteinase, and not matrix metalloprotease 2 or membrane type 1 metalloprotease, processes laminin-5 in keratinocytes and skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROCOLLAGEN C-PROTEINASE; EPITHELIAL-CELL MIGRATION; IV COLLAGENASE EXPRESSION; GAMMA-2 CHAIN; ALPHA-3 CHAIN; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; SHORT ARM; ADHESION	Laminin-5, a major adhesive ligand for epithelial cells, undergoes processing of its gamma2 and alpha3 chains. This study investigated the mechanism of laminin-5 processing by keratinocytes. BI-1 (BMP-1 isoenzyme inhibitor-1), a selective inhibitor of a small group of astacin-like metalloproteinases, which includes bone morphogenetic protein I (BMP-1), mammalian Tolloid (mTLD), mammalian Tolloid-like 1 (mTLL-1), and mammalian Tolloid-like 2 (mTLL-2), inhibited the processing of laminin-5 gamma2 and a3 chains in keratinocyte cultures in a dose-dependent manner. In a proteinase survey, all BMP-1 isoenzymes processed human laminin-5/2 and alpha3 chains to 105- and 165-kDa fragments, respectively. In contrast, MT1-MMP and MMP-2 did not cleave the gamma2 chain of human laminin-5 but processed the rat laminin gamma2 chain to an 80kDa fragment. An immunoblot and quantitative PCR survey of the BMP-1 isoenzymes revealed expression of mTLD in primary keratinocyte cultures but little or no expression of BW-1, mTLL-1, or mTLL-2. mTLD was shown to cleave the gamma2 chain at the same site as the previously identified BMP-1 cleavage site. In addition, mTLD/BMP-1 null mice were shown to have deficient laminin-5 processing. Together, these data identify laminin-5 as a substrate for mTLD, suggesting a role for laminin-5 processing by mTLD in the skin.	Stanford Univ, Program Epithelial Biol, Stanford, CA 94305 USA; FibroGen Inc, San Francisco, CA 94080 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Shriners Hosp Crippled Children, Imaging Ctr, Portland, OR 97201 USA; Vet Affairs Med Ctr, Dermatol Serv, Palo Alto, CA 94304 USA	Stanford University; FibroGen; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Marinkovich, PM (corresponding author), Stanford Univ, Program Epithelial Biol, 269 Campus Dr,Rm 2145, Stanford, CA 94305 USA.			Greenspan, Daniel/0000-0001-8096-7446; Pappano, William/0000-0003-2848-2219	NIAMS NIH HHS [P01 AR 44012-01, R01 AR 47223-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044012, R01AR047223] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Baker SE, 1996, J CELL SCI, V109, P2509; Baumann P, 2000, BRIT J CANCER, V83, P1387, DOI 10.1054/bjoc.2000.1454; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; CARTER BZ, 1991, LAB INVEST, V65, P610; Decline F, 2001, J CELL SCI, V114, P811; FIBROGEN INC, 1998, Patent No. 5807981; Gagnoux-Palacios L, 2001, J CELL BIOL, V153, P835, DOI 10.1083/jcb.153.4.835; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gilles C, 2001, J CELL SCI, V114, P2967; Keene DR, 1997, MICROSC RES TECHNIQ, V38, P394, DOI 10.1002/(SICI)1097-0029(19970815)38:4<394::AID-JEMT7>3.0.CO;2-J; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LANGHOFER M, 1993, J CELL SCI, V105, P753; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; MARINKOVICH MP, 1993, LAB INVEST, V69, P295; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; Miquel C, 1996, EXP CELL RES, V224, P279, DOI 10.1006/excr.1996.0138; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; NORMAND J, 1995, IN VITRO CELL DEV-AN, V31, P447; Ono Y, 1999, CANCER, V85, P2315, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2315::AID-CNCR3>3.0.CO;2-Y; PYKE C, 1995, CANCER RES, V55, P4132; Quaranta V, 2000, J CELL BIOL, V149, P1167, DOI 10.1083/jcb.149.6.1167; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; RIDDELLE KS, 1991, J CELL BIOL, V112, P159, DOI 10.1083/jcb.112.1.159; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SALO T, 1991, J BIOL CHEM, V266, P11436; Sasaki T, 2001, J MOL BIOL, V314, P751, DOI 10.1006/jmbi.2001.5176; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; SONNENBERG A, 1993, J CELL SCI, V106, P1083; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Tani T, 1997, AM J PATHOL, V151, P1289; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; UITTO VJ, 1994, ANN NY ACAD SCI, V732, P140, DOI 10.1111/j.1749-6632.1994.tb24731.x; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	48	121	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15661	15668		10.1074/jbc.M210588200	http://dx.doi.org/10.1074/jbc.M210588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12473650	hybrid			2022-12-25	WOS:000182680000027
J	Borges-Walmsley, MI; Beauchamp, J; Kelly, SM; Jumel, K; Candlish, D; Harding, SE; Price, NC; Walmsley, AR				Borges-Walmsley, MI; Beauchamp, J; Kelly, SM; Jumel, K; Candlish, D; Harding, SE; Price, NC; Walmsley, AR			Identification of oligomerization and drug-binding domains of the membrane fusion protein EmrA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX PUMP; ESCHERICHIA-COLI; STRUCTURE PREDICTION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; TUNNEL ENTRANCE; COILED COILS; RESISTANCE; EXPORT; ACRB	Many pathogenic Gram-negative bacteria possess tripartite transporters that catalyze drug extrusion across the inner and outer membranes, thereby conferring resistance. These transporters consist of inner (IMP) and outer (OMP) membrane proteins, which are coupled by a periplasmic membrane fusion (MFP) protein. However, it is not know whether the MFP translocates the drug between the membranes, by acting as a channel, or whether it brings the IMP and OMP together, facilitating drug transfer. The MFP EmrA has an elongated periplasmic domain, which binds transported drugs, and is anchored to the inner membrane by a single a-helix, which contains a leucine zipper dimerization domain. Consistent with CD and hydrodynamic analyses, the periplasmic domain is predicted to be composed of a beta-sheet subdomain and an a-helical coiled-coil. We propose that EmrA forms a trimer in which the coiled-coils radiate across the periplasm, where they could sequester the OMP ToIC. The "free" leucine zipper in the EmrA trimer might stabilize the interaction with the IMP EmrB, which also possesses leucine zipper motifs in the putative N- and C-terminal helices. The beta-sheet subdomain of EmrA would sit at the membrane surface adjacent to the EmrB, from which it receives the transported drug, inducing a conformational change that triggers the interaction with the OMP.	Univ Durham, Wolfson Res Inst, Ctr Infect Dis, Stockton On Tees TS17 6BH, England; Univ Glasgow, Div Infect & Immun, Glasgow G11 6NU, Lanark, Scotland; Univ Glasgow, Div Biochem & Mol Biol, Glasgow G11 6NU, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland; Univ Glasgow, Dept Chem, Glasgow G11 6NU, Lanark, Scotland; Univ Nottingham, Sch Biosci, Natl Ctr Macromol Hydrodynam, Loughborough LE12 5RD, England	Durham University; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Nottingham	Walmsley, AR (corresponding author), Univ Durham, Wolfson Res Inst, Ctr Infect Dis, Queens Campus, Stockton On Tees TS17 6BH, England.		Kelly, Sharon/K-4611-2013	Harding, Stephen E./0000-0002-7798-9692; Kelly, Sharon/0000-0002-3516-1387	Biotechnology and Biological Sciences Research Council [B18660] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alonso A, 2000, ANTIMICROB AGENTS CH, V44, P3079, DOI 10.1128/AAC.44.11.3079-3086.2000; Andersen C, 2000, EMBO REP, V1, P313, DOI 10.1093/embo-reports/kvd075; Andersen C, 2002, MOL MICROBIOL, V44, P1131, DOI 10.1046/j.1365-2958.2002.02898.x; Andersen C, 2002, P NATL ACAD SCI USA, V99, P11103, DOI 10.1073/pnas.162039399; Balakrishnan L, 2001, J MOL BIOL, V313, P501, DOI 10.1006/jmbi.2001.5038; Borges-Walmsley MI, 2001, TRENDS MICROBIOL, V9, P71, DOI 10.1016/S0966-842X(00)01920-X; Brooun A, 1999, J BACTERIOL, V181, P5131, DOI 10.1128/JB.181.16.5131-5133.1999; Chuanchuen R, 2002, J BACTERIOL, V184, P5036, DOI 10.1128/JB.184.18.5036-5044.2002; Colmer JA, 1998, MOL MICROBIOL, V27, P63, DOI 10.1046/j.1365-2958.1998.00657.x; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DUBOCHET J, 1983, J BACTERIOL, V155, P381, DOI 10.1128/JB.155.1.381-390.1983; Eftink MR, 1991, TOPICS FLUORESCENCE, V2, P53; Elkins CA, 2002, J BACTERIOL, V184, P6490, DOI 10.1128/JB.184.23.6490-6499.2002; GRAHAM LL, 1991, J BACTERIOL, V173, P1623, DOI 10.1128/jb.173.5.1623-1633.1991; HUNT AG, 1986, METHOD ENZYMOL, V125, P302; Johnson JM, 1999, J MOL BIOL, V287, P695, DOI 10.1006/jmbi.1999.2630; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee EH, 1999, MOL MICROBIOL, V33, P839, DOI 10.1046/j.1365-2958.1999.01530.x; Lin J, 2002, ANTIMICROB AGENTS CH, V46, P2124, DOI 10.1128/AAC.46.7.2124-2131.2002; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; National Committee for Clinical Laboratory Standards, 1990, M7A2 NAT COMM CLIN L; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Sharff A, 2001, EUR J BIOCHEM, V268, P5011, DOI 10.1046/j.0014-2956.2001.02442.x; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SZABO AG, 2000, SPECTROPHOTOMETRY SP, P62; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000; Zgurskaya HI, 1999, J MOL BIOL, V285, P409, DOI 10.1006/jmbi.1998.2313	36	43	48	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12903	12912		10.1074/jbc.M209457200	http://dx.doi.org/10.1074/jbc.M209457200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12482849	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000182189500041
J	Hashimoto, W; Nankai, H; Mikami, B; Murata, K				Hashimoto, W; Nankai, H; Mikami, B; Murata, K			Crystal structure of Bacillus sp GL1 xanthan lyase, which acts on the side chains of xanthan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PNEUMONIAE HYALURONATE LYASE; POLYSACCHARIDE LYASE; PECTATE LYASE; 3-DIMENSIONAL STRUCTURE; MOLECULAR-CLONING; PROTEIN; MECHANISM; DEGRADATION; PROGRAM; COMPLEX	Xanthan lyase, a member of polysaccharide lyase family 8, is a key enzyme for complete depolymerization of a bacterial heteropolysaccharide, xanthan, in Bacillus sp. GL1. The enzyme acts exolytically on the side chains of the polysaccharide. The x-ray crystallographic structure of xanthan lyase was determined by the multiple isomorphous replacement method. The crystal structures of xanthan lyase and its complex with the product (pyruvylated mannose) were refined at 2.3 and 2.4 Angstrom resolution with final R-factors of 17.5 and 16.9%, respectively. The refined structure of the product-free enzyme comprises 752 amino acid residues, 248 water molecules, and one calcium ion. The enzyme consists of N-terminal alpha-helical and C-terminal beta-sheet domains, which constitute incomplete alpha(5)/alpha(5)-barrel and anti-parallel beta-sheet structures, respectively. A deep cleft is located in the N-terminal a-helical domain facing the interface between the two domains. Although the overall structure of the enzyme is basically the same as that of the family 8 lyases for hyaluronate and chondroitin AC, significant differences were observed in the loop structure over the cleft. The crystal structure of the xanthan lyase complexed with pyruvylated mannose indicates that the sugar-binding site is located in the deep cleft, where aromatic and positively charged amino acid residues are involved in the binding. The Arg(313) and Tyr(315) residues in the loop from the N-terminal domain and the Arg(612) residue in the loop from the C-terminal domain directly bind to the pyruvate moiety of the product through the formation of hydrogen bonds, thus determining the substrate specificity of the enzyme.	Kyoto Univ, Dept Basic & Appl Mol Biotechnol, Div Food & Biol Sci, Grad Sch Agr, Uji, Kyoto 6110011, Japan; Kyoto Univ, Lab Qual Design Exploitat, Div Agron & Hort Sci, Grad Sch Agr, Uji, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Murata, K (corresponding author), Kyoto Univ, Dept Basic & Appl Mol Biotechnol, Div Food & Biol Sci, Grad Sch Agr, Uji, Kyoto 6110011, Japan.	murata@food2.food.kyoto-u.ac.jp						Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Becker A, 1998, APPL MICROBIOL BIOT, V50, P145, DOI 10.1007/s002530051269; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Capila I, 2002, BBA-PROTEIN STRUCT M, V1597, P260, DOI 10.1016/S0167-4838(02)00304-7; Davies GJ, 2002, BIOCHEM SOC T, V30, P291, DOI 10.1042/BST0300291; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; Hashimoto W, 2001, APPL ENVIRON MICROB, V67, P713, DOI 10.1128/AEM.67.2.713-720.2001; Hashimoto W, 1998, ARCH BIOCHEM BIOPHYS, V354, P31, DOI 10.1006/abbi.1998.0674; Hashimoto W, 1998, APPL ENVIRON MICROB, V64, P3765; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Itoh T, 2000, J MOL BIOL, V303, P733, DOI 10.1006/jmbi.2000.4188; JANSSON PE, 1975, CARBOHYD RES, V45, P275, DOI 10.1016/S0008-6215(00)85885-1; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nankai H, 1999, APPL ENVIRON MICROB, V65, P2520; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROGOVIN SP, 1961, J BIOCHEM MICROBIOL, V3, P51, DOI 10.1002/jbmte.390030107; Sakon J, 1997, NAT STRUCT BIOL, V4, P810, DOI 10.1038/nsb1097-810; Sandford P. A., 1977, ACS SYM SER, V45, P192; Sevcik J, 1998, ACTA CRYSTALLOGR D, V54, P854, DOI 10.1107/S0907444998002005; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vitali J, 1998, PLANT PHYSIOL, V116, P69, DOI 10.1104/pp.116.1.69; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; Yoon HJ, 2000, PROTEIN EXPRES PURIF, V19, P84, DOI 10.1006/prep.2000.1226; Yoon HJ, 1999, J MOL BIOL, V290, P505, DOI 10.1006/jmbi.1999.2883; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	52	42	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7663	7673		10.1074/jbc.M208100200	http://dx.doi.org/10.1074/jbc.M208100200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12475987	hybrid			2022-12-25	WOS:000181195100131
J	Gautreau, A; Fievet, BT; Brault, E; Antony, C; Houdusse, A; Louvard, D; Arpin, M				Gautreau, A; Fievet, BT; Brault, E; Antony, C; Houdusse, A; Louvard, D; Arpin, M			Isolation and characterization of an aggresome determinant in the NF2 tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN AGGREGATION; TERMINAL DOMAIN; PLASMA-MEMBRANE; MERLIN; EZRIN; BINDING; EXPRESSION; ACTIN; CYTOSKELETON; PROTEASOME	Schwannomin (Sch) is the product of the NF2 tumor suppressor gene. The NF2 gene is mutated in patients affected by neurofibromatosis type 2, a syndrome associated with multiple tumors of the nervous system. Here we found that Sch, when its N-terminal FERM domain was misfolded by the pathogenetic mutation DeltaF118, formed aggresomes, i.e. aggregates that cluster at the centrosome as a result of microtubule-dependent transport. Strikingly the related protein ezrin affected by the same mutation did not form aggresomes even though its FERM domain was similarly misfolded. By studying ezrin/Sch chimeras, we delineated a sequence of 61 amino acids in the C terminus of Sch that determined the formation of aggresomes. Aggresome formation by these chimeras was independent from their rate of degradation. Sch(535-595) was sufficient to induce aggresomes of a green fluorescent fusion protein in vivo and aggregates of a glutathione S-transferase fusion protein in vitro. Taken together, these results suggest that aggresome formation is controlled primarily by aggresome determinants, which are distinct from degradation determinants, or from misfolding, through which aggresome determinants might be exposed.	Inst Curie, UMR144 CNRS, Paris 05, France; Ctr Etud Polymorphisme Humain, INSERM U434, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Arpin, M (corresponding author), Inst Curie, UMR144 CNRS, 26 Rue Ulm, Paris 05, France.		antony, claude/K-5342-2013; Gautreau, Alexis/AAT-2751-2020	Gautreau, Alexis/0000-0002-2369-4362				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Brault E, 2001, J CELL SCI, V114, P1901; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Deguen B, 1998, INT J CANCER, V77, P554, DOI 10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; FRANCK Z, 1993, J CELL SCI, V105, P219; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gronholm M, 1999, J CELL SCI, V112, P895; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maeda M, 1999, ONCOGENE, V18, P4788, DOI 10.1038/sj.onc.1202871; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wigley WC, 1999, J CELL BIOL, V145, P481	31	8	8	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6235	6242		10.1074/jbc.M210639200	http://dx.doi.org/10.1074/jbc.M210639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471027	hybrid			2022-12-25	WOS:000181129400094
J	Casarosa, P; Menge, WM; Minisini, R; Otto, C; van Heteren, J; Jongejan, A; Timmerman, H; Moepps, B; Kirchhoff, F; Mertens, T; Smit, MJ; Leurs, R				Casarosa, P; Menge, WM; Minisini, R; Otto, C; van Heteren, J; Jongejan, A; Timmerman, H; Moepps, B; Kirchhoff, F; Mertens, T; Smit, MJ; Leurs, R			Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN CYTOMEGALOVIRUS; CHEMOKINE RECEPTOR; HIV-1 ENTRY; HIGH-AFFINITY; BINDING-SITE; US28; ACTIVATION; CELLS; ANTAGONIST	Human cytomegalovirus (HCMV) encodes a G protein-coupled receptor (GPCR), named US28, which shows homology to chemokine receptors and binds several chemokines with high affinity. US28 induces migration of smooth muscle cells, a feature essential for the development of atherosclerosis, and may serve as a co-receptor for human immunodeficiency virus-type 1 entry into cells. Previously, we have shown that HCMV-encoded US28 displays constitutive activity, whereas its mammalian homologs do not. In this study we have identified a small nonpeptidergic molecule (VUF2274) that inhibits US28-mediated phospholipase C activation in transiently transfected COS-7 cells and in HCMV-infected fibroblasts. Moreover, VUF2274 inhibits US28-mediated HIV entry into cells. In addition, VUF2274 fully displaces radiolabeled RANTES (regulated on activation normal T cell expressed and secreted) binding at US28, apparently with a noncompetitive behavior. Different analogues of VUF2274 have been synthesized and pharmacologically characterized, to understand which features are important for its inverse agonistic activity. Finally, by means of mutational analysis of US28, we have identified a glutamic acid in transmembrane 7 (TM 7), which is highly conserved among chemokine receptors, as a critical residue for VUF2274 binding to US28. The identification of a full inverse agonist provides an important tool to investigate the relevance of US28 constitutive activity in viral pathogenesis.	Free Univ Amsterdam, Fac Chem, Div Med Chem, Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands; Univ Clin Ulm, Dept Virol, D-89081 Ulm, Germany; Univ Clin Ulm, Dept Pharmacol & Toxicol, D-89081 Ulm, Germany	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Ulm University; Ulm University	Leurs, R (corresponding author), Free Univ Amsterdam, Fac Chem, Div Med Chem, Leiden Amsterdam Ctr Drug Res, De Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.		Mertens, Thomas M/E-9826-2013; Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021; Minisini, Rosalba/ABF-9724-2021; Kirchhoff, Frank/O-8367-2018	Leurs, Rob/0000-0003-1354-2848; Kirchhoff, Frank/0000-0002-7052-2360; Smit, Martine/0000-0003-2713-0238				ABUBAKAR S, 1990, BIOCHEM BIOPH RES CO, V166, P953, DOI 10.1016/0006-291X(90)90903-Z; ALBRECHT T, 1990, INTERVIROLOGY, V31, P68, DOI 10.1159/000150140; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; Beisser PS, 2001, J VIROL, V75, P5949, DOI 10.1128/JVI.75.13.5949-5957.2001; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Brandt SM, 2002, J BIOL CHEM, V277, P17291, DOI 10.1074/jbc.M108232200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cascieri MA, 1999, J BIOL CHEM, V274, P8694, DOI 10.1074/jbc.274.13.8694; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; FINKLE C, 1991, J ACQ IMMUN DEF SYND, V4, P735; GAO JL, 1994, J BIOL CHEM, V269, P28539; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Kovacs A, 1999, NEW ENGL J MED, V341, P77, DOI 10.1056/NEJM199907083410203; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; MELNICK JL, 1994, J MED VIROL, V42, P170, DOI 10.1002/jmv.1890420213; Melnick Joseph L., 1996, Archivum Immunologiae et Therapiae Experimentalis, V44, P297; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; Okada T, 2000, J STRUCT BIOL, V130, P73, DOI 10.1006/jsbi.1999.4209; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Shibutani T, 1997, J CLIN INVEST, V100, P2054, DOI 10.1172/JCI119738; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; SWEET C, 1990, PATHOGENICITY VIRUSE; VALYINAGY T, 1988, ARCH VIROL, V101, P199, DOI 10.1007/BF01311001; van der Meer P, 2000, EXP MOL PATHOL, V69, P192, DOI 10.1006/exmp.2000.2336; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; WEBSTER A, 1991, J ACQ IMMUN DEF SYND, V4, pS47; Wieland K, 1999, J BIOL CHEM, V274, P29994, DOI 10.1074/jbc.274.42.29994; Zipeto D, 1999, J GEN VIROL, V80, P543, DOI 10.1099/0022-1317-80-3-543	45	79	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5172	5178		10.1074/jbc.M210033200	http://dx.doi.org/10.1074/jbc.M210033200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12456673	hybrid, Green Published			2022-12-25	WOS:000180968900105
J	Priet, S; Navarro, JM; Gros, N; Querat, G; Sire, J				Priet, S; Navarro, JM; Gros, N; Querat, G; Sire, J			Functional role of HIV-1 virion-associated uracil DNA glycosylase 2 in the correction of G : U Mispairs to G : C pairs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC ENDONUCLEASE APE1; DEOXYURIDINE-TRIPHOSPHATASE; MUTATION FREQUENCY; PROTEIN BINDS; REPAIR ENZYME; UNG GENE; IN-VIVO; VIRUS; REPLICATION; DUTPASE	Human monocytes/macrophages are target cells for HIV-1 infection. As other non-dividing cells, they are characterized by low and imbalanced intracellular dNTP pool levels and an excess of dUTP. The replication of HIV-1 in this cellular context favors misincorporation of uracil residues into viral DNA because of the use of dUTP in place of dCTP. We have previously reported that the host uracil DNA glycosylase enzyme UNG2 is packaged into HIV-1 viral particles via a specific association with the integrase domain of the Gag-Pol precursor. In this study, we investigated whether virion-associated UNG2 plays a role similar to that of its cellular counterpart. We show that the L172A mutation of integrase impaired the packaging of UNG2 into viral particles. Using a primer-template DNA substrate containing G:U mispairs, we demonstrate that wild-type viral lysate has the ability to repair G:U mismatched pairs to G:C matched pairs, in contrast to UNG2-deficient viral lysate. Moreover, no correction of G:T mispairs by wildtype HIV-1 viral lysate was observed, which argues for the specificity of the repair process. We also show that UNG2 physically associates with the viral reverse transcriptase enzyme. Altogether our data indicate for the first time that a uracil repair pathway is specifically associated with HIV-1 viral particles. However, the molecular mechanism of this process remains to be characterized further.	INSERM, U372, F-13276 Marseille 09, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Sire, J (corresponding author), INSERM, U372, 163 Ave Luminy,BP 178, F-13276 Marseille 09, France.		Querat, Gilles/E-9577-2014; Priet, Stéphane/ABD-4869-2020; Priet, Stéphane/N-7952-2017	Querat, Gilles/0000-0003-1897-8210; Priet, Stéphane/0000-0001-7102-3654; Priet, Stéphane/0000-0001-7102-3654				Bess JW, 1997, VIROLOGY, V230, P134, DOI 10.1006/viro.1997.8499; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; Courcelle CT, 2001, J VIROL, V75, P7592, DOI 10.1128/JVI.75.16.7592-7601.2001; ELDER JH, 1992, J VIROL, V66, P1791, DOI 10.1128/JVI.66.3.1791-1794.1992; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; KamathLoeb AS, 1997, EUR J BIOCHEM, V250, P492, DOI 10.1111/j.1432-1033.1997.0492a.x; Krokan HE, 1997, BIOCHEM J, V325, P1; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LICHTENSTEIN DL, 1995, J VIROL, V69, P2881, DOI 10.1128/JVI.69.5.2881-2888.1995; Mansky LM, 2000, J VIROL, V74, P7039, DOI 10.1128/JVI.74.15.7039-7047.2000; MARTINEZ MA, 1994, P NATL ACAD SCI USA, V91, P11787, DOI 10.1073/pnas.91.25.11787; Masuda Y, 1998, J BIOL CHEM, V273, P30360, DOI 10.1074/jbc.273.46.30360; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MEYERHANS A, 1994, J VIROL, V68, P535, DOI 10.1128/JVI.68.1.535-540.1994; MULLER SJ, 1993, J BIOL CHEM, V268, P1310; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Prichard MN, 1996, J VIROL, V70, P3018, DOI 10.1128/JVI.70.5.3018-3025.1996; PYLES RB, 1994, J VIROL, V68, P4514, DOI 10.1128/JVI.68.7.4514-4524.1994; ROIZMAN B, 1990, VIROLOGY, V2, P1795; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; STEAGALL WK, 1995, VIROLOGY, V210, P302, DOI 10.1006/viro.1995.1347; TERAI C, 1991, EXP CELL RES, V193, P375, DOI 10.1016/0014-4827(91)90110-G; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; Turelli P, 1996, J VIROL, V70, P1213, DOI 10.1128/JVI.70.2.1213-1217.1996; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113	33	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4566	4571		10.1074/jbc.M209311200	http://dx.doi.org/10.1074/jbc.M209311200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458223	hybrid			2022-12-25	WOS:000180968900029
J	Hanson, EM; Dickensheets, H; Qu, CK; Donnelly, RP; Keegan, AD				Hanson, EM; Dickensheets, H; Qu, CK; Donnelly, RP; Keegan, AD			Regulation of the dephosphorylation of Stat6 - Participation of TYR-713 in the interleukin-4 receptor alpha, the tyrosine phosphatase SHP-1, and the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; NUCLEAR-LOCALIZATION; NEGATIVE REGULATION; GENE-EXPRESSION; IL-4 RECEPTOR; CUTTING EDGE; MOTH-EATEN; T-CELLS; B-CELLS; PROTEIN	Signal transducer and activator of transcription 6 (Stat6) plays an important role in interleukin (IL)-4-induced responses. To analyze the regulation of Stat6 phosphorylation, cells were cultured in the continuous presence of IL-4 or after a pulse and washout. In the continual presence of IL-4, Stat6 remained phosphorylated for an extended period. After IL-4 removal and inhibition of the Janus family kinase, tyrosine-phosphorylated Stat6 decayed at a rate dependent upon the length of IL-4 stimulation. The decay of tyrosine-phosphorylated Stat6 was similar in the presence or absence of either cycloheximide or actinomycin D. In the absence of functional Src homology-containing phosphatase-1 (SHP-1), the early loss of tyrosine-phosphorylated Stat6 was substantially reduced. Furthermore, the rate of loss of tyrosine-phosphorylated Stat6 in cells expressing a mutation of the human IL-4 receptor a in the immunoreceptor tyrosine-based inhibitory motif sequence (Y5F) was dramatically decreased compared with wild-type cells. The early rate of decay was similar in the presence or absence of MG132, an inhibitor of the proteasome, but the later rate of decay was decreased 5-fold. These results suggest that the loss of tyrosine phosphorylation of Stat6 is regulated by the action of SHP-1 and the proteasome but is not dependent on new protein synthesis.	Amer Red Cross, Holland Lab, Dept Immunol, Rockville, MD 20855 USA; Amer Red Cross, Holland Lab, Dept Hematopoiesis, Rockville, MD 20855 USA; Fed Drug Adm, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; George Washington Univ, Ctr Med, Inst Biomed Sci, Bethesda, MD 20892 USA	American Red Cross; American Red Cross; US Food & Drug Administration (FDA); George Washington University	Keegan, AD (corresponding author), Amer Red Cross, Holland Lab, Dept Immunol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Donnelly, Raymond P./AFT-8600-2022	Donnelly, Raymond P./0000-0002-0695-5276	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038985, R01AI038985] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38985] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; Dickensheets HL, 1999, P NATL ACAD SCI USA, V96, P10800, DOI 10.1073/pnas.96.19.10800; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FLORES E, 1994, MOL CELL BIOL, V14, P4938, DOI 10.1128/MCB.14.7.4938; GREINER DL, 1986, J EXP MED, V164, P1129, DOI 10.1084/jem.164.4.1129; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Huang H, 2000, J IMMUNOL, V164, P1211, DOI 10.4049/jimmunol.164.3.1211; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Losman JA, 1999, J IMMUNOL, V162, P3770; Lu BF, 1997, J IMMUNOL, V159, P1255; Migone TS, 2001, BLOOD, V98, P1935, DOI 10.1182/blood.V98.6.1935; MUTA T, 1994, NATURE, V369, P340, DOI 10.1038/369340a0; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; POO WJ, 1988, NATURE, V332, P378, DOI 10.1038/332378a0; RABIN EM, 1986, J EXP MED, V164, P517, DOI 10.1084/jem.164.2.517; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wang HY, 1999, J IMMUNOL, V162, P4385; White ED, 2001, J LEUKOCYTE BIOL, V69, P825; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Zamorano J, 1998, J IMMUNOL, V161, P859	50	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3903	3911		10.1074/jbc.M211747200	http://dx.doi.org/10.1074/jbc.M211747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12459556	hybrid			2022-12-25	WOS:000180869700051
J	Laitinen, OH; Nordlund, HR; Hytonen, VP; Uotila, STH; Marttila, AT; Savolainen, J; Airenne, KJ; Livnah, O; Bayer, EA; Wilchek, M; Kulomaa, MS				Laitinen, OH; Nordlund, HR; Hytonen, VP; Uotila, STH; Marttila, AT; Savolainen, J; Airenne, KJ; Livnah, O; Bayer, EA; Wilchek, M; Kulomaa, MS			Rational design of an active avidin monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SITE-DIRECTED MUTAGENESIS; INFECTED INSECT CELLS; BIOTIN BINDING; HIGH-AFFINITY; SUBUNIT ASSOCIATION; CHICKEN AVIDIN; STREPTAVIDIN; COMPLEX; TRYPTOPHAN	Homotetrameric chicken avidin that binds four molecules of biotin was converted to a monomeric form (monoavidin) by mutations of two interface residues: tryptophan 110 in the 1-->2 interface was mutated to lysine and asparagine 54 in the 1-->4 interface was converted to alanine. The affinity for biotin binding of the mutant decreased from K-d similar to10(-15) M of the wild-type tetramer to K-d similar to10(-7) M, which was studied by an optical biosensor IAsys and by a fluorescence spectroscopical method in solution. The binding was completely reversible. Conversion of the tetramer to a monomer results in increased sensitivity to proteinase K digestion. The antigenic properties of the mutated protein were changed, such that monoavidin was only partially recognized by a polyclonal antibody whereas two different monoclonal antibodies entirely failed to recognize the avidin monomer. This new monomeric avidin, which binds biotin reversibly, may be useful for applications both in vitro and in vivo. It may also shed light on the effect of inter-subunit interactions on the binding of ligands.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40014 Jyvaskyla, Finland; Univ Jyvaskyla, Dept Chem, FIN-40014 Jyvaskyla, Finland; Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland; Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	University of Jyvaskyla; University of Jyvaskyla; University of Eastern Finland; Hebrew University of Jerusalem; Weizmann Institute of Science	Kulomaa, MS (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35 YAB, FIN-40014 Jyvaskyla, Finland.		Savolainen, Janne/F-4318-2010; Kulomaa, Markku S/C-9063-2014; Laitinen, Olli H/A-6618-2016; Hytonen, Vesa P./E-8855-2013	Savolainen, Janne/0000-0001-6905-5905; Laitinen, Olli H/0000-0002-3751-9952; Hytonen, Vesa P./0000-0002-9357-1480				Airenne KJ, 1997, PROTEIN EXPRES PURIF, V9, P100, DOI 10.1006/prep.1996.0660; Airenne KJ, 1999, PROTEIN EXPRES PURIF, V17, P139, DOI 10.1006/prep.1999.1123; Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; BISGROVE BW, 1995, J MOL EVOL, V41, P34; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; Freitag S, 1999, BIOMOL ENG, V16, P13, DOI 10.1016/S1050-3862(99)00048-0; FUDEMGOLDIN B, 1990, METHOD ENZYMOL, V184, P167; GREEN NM, 1973, BIOCHEM J, V133, P687, DOI 10.1042/bj1330687; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HENRIKSON KP, 1979, ANAL BIOCHEM, V94, P366, DOI 10.1016/0003-2697(79)90374-9; Karisola P, 2002, J BIOL CHEM, V277, P22656, DOI 10.1074/jbc.M201076200; KOHANSKI RA, 1990, METHOD ENZYMOL, V184, P194; KURZBAN GP, 1991, J BIOL CHEM, V266, P14470; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Laitinen OH, 2002, BIOCHEM J, V363, P609, DOI 10.1042/0264-6021:3630609; Laitinen OH, 2001, J BIOL CHEM, V276, P8219, DOI 10.1074/jbc.M007930200; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Marttila AT, 1998, FEBS LETT, V441, P313, DOI 10.1016/S0014-5793(98)01570-1; Marttila AT, 2000, FEBS LETT, V467, P31, DOI 10.1016/S0014-5793(00)01119-4; Perez-Luna VH, 1999, J AM CHEM SOC, V121, P6469, DOI 10.1021/ja983984p; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; Qureshi MH, 2001, J BIOL CHEM, V276, P46422, DOI 10.1074/jbc.M107398200; Sano T, 1997, P NATL ACAD SCI USA, V94, P6153, DOI 10.1073/pnas.94.12.6153; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; Schultz J, 2000, CANCER RES, V60, P6663; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wilchek M, 1999, BIOMOL ENG, V16, P1	32	58	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4010	4014		10.1074/jbc.M205844200	http://dx.doi.org/10.1074/jbc.M205844200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458212	hybrid			2022-12-25	WOS:000180869700063
J	Spafford, JD; Munno, DW; van Nierop, P; Feng, ZP; Jarvis, SE; Gallin, WJ; Smit, AB; Zamponi, GW; Syed, NI				Spafford, JD; Munno, DW; van Nierop, P; Feng, ZP; Jarvis, SE; Gallin, WJ; Smit, AB; Zamponi, GW; Syed, NI			Calcium channel structural determinants of synaptic transmission between identified invertebrate neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-INTERACTION SITE; N-TYPE; NEUROTRANSMITTER RELEASE; LYMNAEA NEURONS; CA2+ CHANNELS; SYNTAXIN 1A; BINDING; ORGANIZATION; INHIBITION; DISRUPTION	We report here that unlike what was suggested for many vertebrate neurons, synaptic transmission in Lymnaea stagnalis occurs independent of a physical interaction between presynaptic calcium channels and a functional complement of SNARE proteins. Instead, synaptic transmission in Lymnaea requires the expression of a C-terminal splice variant of the Lymnaea homolog to mammalian N- and P/Q-type calcium channels. We show that the alternately spliced region physically interacts with the scaffolding proteins Mint1 and CASK, and that synaptic transmission is abolished following RNA interference knockdown of CASK or after the injection of peptide sequences designed to disrupt the calcium channel-Mint1 interactions. Our data suggest that Mint1 and CASK may serve to localize the non-L-type channels at the active zone and that synaptic transmission in invertebrate neurons utilizes a mechanism for optimizing calcium entry, which occurs independently of a physical association between calcium channels and SNARE proteins.	Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Vrije Univ Amsterdam, Dept Mol & Cellular Neurobiol, NL-108 HV Amsterdam, Netherlands; Univ Calgary, Dept Anat & Cell Biol, Calgary, AB T2N 4N1, Canada; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 1E9, Canada	University of Calgary; Vrije Universiteit Amsterdam; University of Calgary; University of Alberta	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, 3330 Hosp Dr,NW, Calgary, AB T2N 4N1, Canada.	Zamponi@ucalgary.ca	Smit, August B/E-8410-2011; Gallin, Warren/A-2640-2014	Zamponi, Gerald W./0000-0002-0644-9066; Gallin, Warren/0000-0002-9937-3880				Atwood HL, 2002, NAT REV NEUROSCI, V3, P497, DOI 10.1038/nrn876; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Feng ZP, 1997, J NEUROSCI, V17, P7839; Feng ZP, 2002, J PHYSIOL-LONDON, V539, P53, DOI 10.1113/jphysiol.2001.013125; Fergestad T, 2001, J NEUROSCI, V21, P9142, DOI 10.1523/JNEUROSCI.21-23-09142.2001; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jarvis SE, 2001, TRENDS PHARMACOL SCI, V22, P519, DOI 10.1016/S0165-6147(00)01800-9; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; Kaneko S, 2002, J NEUROSCI, V22, P82, DOI 10.1523/JNEUROSCI.22-01-00082.2002; Kawasaki F, 2000, J NEUROSCI, V20, P4885; Laverty HG, 1998, GENOMICS, V53, P29, DOI 10.1006/geno.1998.5479; Lee JH, 1999, FEBS LETT, V445, P231, DOI 10.1016/S0014-5793(99)00082-4; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Lloyd TE, 2000, NEURON, V26, P45, DOI 10.1016/S0896-6273(00)81136-8; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; Maximov A, 2002, J NEUROSCI, V22, P6939; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; Mochida S, 1998, P NATL ACAD SCI USA, V95, P14523, DOI 10.1073/pnas.95.24.14523; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Rettig J, 1997, J NEUROSCI, V17, P6647; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Smith LA, 1996, J NEUROSCI, V16, P7868; Spencer GE, 2000, J NEUROSCI, V20, P8077; Stanley EF, 1997, TRENDS NEUROSCI, V20, P404, DOI 10.1016/S0166-2236(97)01091-6; Tabuchi K, 2002, J NEUROSCI, V22, P4264, DOI 10.1523/JNEUROSCI.22-11-04264.2002; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; van Kesteren RE, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0004.2001; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9	38	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4258	4267		10.1074/jbc.M211076200	http://dx.doi.org/10.1074/jbc.M211076200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458203	hybrid, Green Published			2022-12-25	WOS:000180869700093
J	Zhu, QS; Lee, DWK; Casey, JR				Zhu, QS; Lee, DWK; Casey, JR			Novel topology in C-terminal region of the human plasma membrane anion exchanger, AE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; N-GLYCOSYLATION MUTAGENESIS; PROTEOLYTIC CLEAVAGE SITES; ERYTHROCYTE BAND-3 PROTEIN; TRANSPORT PROTEIN; MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDES; CYTOPLASMIC SIDE; LYSINE RESIDUES; DOMAIN	Human AE1 performs electroneutral exchange of Cl- for HCO3- across the erythrocyte membrane. We examined the topology of the AE1 C-terminal region using cysteine-scanning mutagenesis and sulfhydryl-specific chemistry. Eighty individual cysteine residues, introduced into an otherwise cysteine-less mutant between Phe(806) and Cys(885), were expressed by transient transfection of HEK293 cells. Topology of the region was determined by comparing cysteine labeling with the membrane-permeant cysteine-directed reagent biotin maleimide, with or without prior labeling with the membrane-impermeant reagents, bromotrimethylammoniumbimane bromide (qBBr) and lucifer yellow iodoacetamide (LYIA). Phe(806)-Leu(835), Ser(852)-Ala(855), and Ile(872)- Cys(885). were labeled by biotin maleimide, suggesting their location in an aqueous environment. In contrast, Phe(836)-Lys(851) and Ser(851)-Arg(871) were not labeled by biotin maleimide and therefore localize to the plane of the bilayer, as transmembrane segments (TM). Labeling by qBBr revealed that Pro(815)-Lys(829) and Ser(852)-Ala(855) are accessible to the extracellular medium. Pro(815)-Lys(829) mutants were also labeled with LYIA. Mutants Ile(872)-Cys(885) were inaccessible to the extracellular medium and thus localized to the intracellular surface of AE1 Functional assays revealed that one face of each of two AE1 TMs was sensitive to mutation. Based on these results, we propose a topology model for the C-terminal region of the membrane domain of human AE1.	Univ Alberta, Dept Physiol, Canadian Inst Hlth Res Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Canadian Inst Hlth Res Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				Askin D, 1998, BIOCHEMISTRY-US, V37, P11670, DOI 10.1021/bi973158d; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BRUCE LJ, 1993, BIOCHEM J, V293, P317, DOI 10.1042/bj2930317; BRUCE LJ, 1994, J BIOL CHEM, V269, P16155; Bruce LJ, 1999, BEST PRACT RES CL HA, V12, P637, DOI 10.1053/beha.1999.0046; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; CRANDALL I, 1993, P NATL ACAD SCI USA, V90, P4703, DOI 10.1073/pnas.90.10.4703; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fujinaga J, 1999, J BIOL CHEM, V274, P6626, DOI 10.1074/jbc.274.10.6626; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; Groves JD, 1999, BIOCHEM J, V344, P699, DOI 10.1042/0264-6021:3440699; Hamasaki N, 1997, J BIOCHEM-TOKYO, V122, P577; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; Jay DG, 1996, CELL, V86, P853, DOI 10.1016/S0092-8674(00)80160-9; JENNINGS ML, 1982, J BIOL CHEM, V257, P7554; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KAY MMB, 1994, ANN NY ACAD SCI, V719, P419, DOI 10.1111/j.1749-6632.1994.tb56847.x; KAY MMB, 1990, GERONTOLOGY, V36, P293; KAY MMB, 1990, P NATL ACAD SCI USA, V87, P5734, DOI 10.1073/pnas.87.15.5734; Kimura-Someya T, 2000, J BIOL CHEM, V275, P18692, DOI 10.1074/jbc.M000354200; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOSOWER NS, 1979, P NATL ACAD SCI USA, V76, P3382, DOI 10.1073/pnas.76.7.3382; Kuma H, 2002, BIOCHEMISTRY-US, V41, P3380, DOI 10.1021/bi015879p; Kuma H, 2002, BIOCHEMISTRY-US, V41, P3311, DOI 10.1021/bi011678+; LEE BS, 1991, J BIOL CHEM, V266, P11448; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; NEWTON GL, 1992, ANAL BIOCHEM, V201, P30, DOI 10.1016/0003-2697(92)90170-C; OKUBO K, 1994, J BIOL CHEM, V269, P1918; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Popov M, 1999, BIOCHEM J, V339, P269, DOI 10.1042/0264-6021:3390269; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Quilty JA, 2000, TRAFFIC, V1, P987, DOI 10.1034/j.1600-0854.2000.011208.x; Reithmeier RAF, 2001, BLOOD CELL MOL DIS, V27, P85, DOI 10.1006/bcmd.2000.0353; REITHMEIER RAF, 1992, STRUCTURE BIOL MEMBR, P337; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; TANNER MJA, 1989, METHOD ENZYMOL, V173, P423; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Toye AM, 2002, BLOOD, V99, P342, DOI 10.1182/blood.V99.1.342; WAINWRIGHT SD, 1990, BIOCHEM J, V272, P265, DOI 10.1042/bj2720265; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; Zhang DC, 2000, BLOOD, V96, P2925	46	129	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3112	3120		10.1074/jbc.M207797200	http://dx.doi.org/10.1074/jbc.M207797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446737	hybrid			2022-12-25	WOS:000180915000045
J	Lee, S; Kim, H; Ryu, S; Kim, H; Kim, B; Kim, D; Lim, C; Jung, H; Lee, D; Kim, H				Lee, S; Kim, H; Ryu, S; Kim, H; Kim, B; Kim, D; Lim, C; Jung, H; Lee, D; Kim, H			Effects of chronic polyphenol or vitamin ingestion on antioxidative activity during exercise in rats	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2003 Meeting	APR 11-15, 2003	SAN DIEGO, CALIFORNIA						Lab Exercise Nutr, Taegu 702701, South Korea										0	61	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 14	2003	17	4	1	S			A326	A326		10.1096/fj.02-0570fje	http://dx.doi.org/10.1096/fj.02-0570fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	658QZ	12475887				2022-12-25	WOS:000181733101552
J	Shirafuji, Y; Tanabe, H; Satchell, DP; Henschen-Edman, A; Wilson, CL; Ouellette, AJ				Shirafuji, Y; Tanabe, H; Satchell, DP; Henschen-Edman, A; Wilson, CL; Ouellette, AJ			Structural determinants of procryptdin recognition and cleavage by matrix metalloproteinase-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; CELL ALPHA-DEFENSINS; PANETH CELL; HOST-DEFENSE; EPITHELIAL-CELLS; ANTIMICROBIAL PEPTIDES; MATRILYSIN; LOCALIZATION; ACTIVATION	The bactericidal activity of mouse Paneth cell alpha-defensins, or cryptdins, is dependent on processing of cryptdin precursors (pro-Crps) by matrix metallo-proteinase-7 (MMP-7) (Wilson, C. L., Ouellette, A. J., Satchell, D. P., Ayabe, T., Lopez-Boado, Y. S., Stratman, J. L., Hultgren, S. J., Matrisian, L. M., and Parks, W. C. (1999) Science 286, 113-117). To investigate the mechanisms of pro-Crp processing by this enzyme, recombinant pro-Crp4, a His-tagged chimeric pro-Crp (pro-CC), and site-directed mutant precursors of each were digested with MMP-7, and the cleavage products were analyzed by NH2-terminal peptide sequencing. Proteolysis of pro-Crp4 with MMP-7 activated in vitro bactericidal activity to the level of the mature Crp4 peptide by cleaving pro-Crp4 at Ser43 down arrow Ile(44) and Ala(53) down arrow Leu(54) in the proregion and near the Crp4 peptide NH2 terminus between Ser(58) down arrow Leu(59). Because the Crp4 NH2 terminus occurs at Gly(61), not Leu(59), AMP-7 is necessary but insufficient to complete the processing of Crp4. Crp activating proteolysis at S58 down arrow L59 was unaffected by 144S/144D or L54S/L54D loss-of-function mutations in pro-Crp4, and a (L59S)-pro-CC mutant was cleaved normally at Ser(43) down arrow Val(44) and Ser(53) down arrow Leu(54) sites but not at the peptide NH2 terminus. C57BL/6 mice contain an abundant (L59S)-Crp4 mutant peptide with Leu(54) at its NH2 terminus resulting from Ala(53) down arrow Leu(54) cleavage and loss-of-function at the Ser(58) down arrow Ser(59) cleavage site. Thus, a-defensins resulting from mutations at AMP-7 cleavage sites exist in mouse populations. A pro-CC substrate containing both L54S and L59S mutations resisted cleavage at Ser(43) down arrow Val(44) completely, showing that cleavage at one or both downstream sites must precede proteolysis at Ser(43) down arrow Val(44). These findings show that NHdP-7 activation of pro-Crps can occur without proteolysis of the proregion, and prosegment fragmentation depends, at least in part, on the release of the Crp peptide from the precursor.	Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA	Washington University (WUSTL); University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Ouellette, AJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA.				NIDCR NIH HHS [DE14040] Funding Source: Medline; NIDDK NIH HHS [DK44632, DK10184] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE014040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044632, F32DK010184, R55DK044632] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Cunliffe RN, 2001, GUT, V48, P176, DOI 10.1136/gut.48.2.176; GANZ T, 1993, BLOOD, V82, P641; Ghosh D, 2002, NAT IMMUNOL, V3, P583, DOI 10.1038/ni797; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; Huttner KM, 1999, PEDIATR RES, V45, P785, DOI 10.1203/00006450-199906000-00001; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Lopez-Boado YS, 2001, J BIOL CHEM, V276, P41417, DOI 10.1074/jbc.M107121200; MICHAELSON D, 1992, J LEUKOCYTE BIOL, V51, P634, DOI 10.1002/jlb.51.6.634; Ouellette AJ, 1999, INFECT IMMUN, V67, P6643; Ouellette AJ, 2000, J BIOL CHEM, V275, P33969, DOI 10.1074/jbc.M004062200; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; PEETERS TL, 1976, EXPERIENTIA, V32, P1125, DOI 10.1007/BF01927581; Porter EM, 1997, INFECT IMMUN, V65, P2389, DOI 10.1128/IAI.65.6.2389-2395.1997; Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z; Porter EM, 1998, FEBS LETT, V434, P272, DOI 10.1016/S0014-5793(98)00994-6; Putsep K, 2000, J BIOL CHEM, V275, P40478, DOI 10.1074/jbc.M007816200; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1993, GENETIC ENG PRINCIPL; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; VALORE EV, 1992, BLOOD, V79, P1538; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113	26	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7910	7919		10.1074/jbc.M210600200	http://dx.doi.org/10.1074/jbc.M210600200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12482850	hybrid			2022-12-25	WOS:000181466800023
J	Cheng, NH; Hirschi, KD				Cheng, NH; Hirschi, KD			Cloning and characterization of CXIP1, a novel PICOT domain-containing Arabidopsis protein that associates with CAX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CALCIUM HOMEOSTASIS; INTERACTING PROTEIN; CA2+/H+ ANTIPORTER; H+/CA2+ ANTIPORTER; EXPRESSION; GLUTAREDOXIN; TOBACCO; KINASE; IDENTIFICATION	Regulation of Ca2+ transporters is a vital component of signaling. The Arabidopsis H+/Ca2+ exchanger CAX1 contains an N-terminal autoinhibitory domain that prevents Ca2+ transport when CAX1 is heterologously expressed in yeast. Using a yeast screen, we have identified three different proteins that activate CAX1. One of these, CXIP1 (CAX-interacting protein-1; 19.3 kDa) has amino acid similarity to the C terminus of PICOT (protein kinase C-interacting cousin of thioredoxin) proteins. Although PICOT proteins are found in a variety of organisms, a function has not been previously ascribed to a plant PICOT protein. We demonstrate that CXIP1 activated the CAX1 homolog CAX4, but not CAX2 or CAX3. An Arabidopsis homolog of CXIP1 (CXIP2) weakly activated CAX4, but not CAX1. In a yeast two-hybrid assay, CXIP1 interacted with the N terminus of CAX1. In competition analysis, CXIP1 and a CAX1 N-terminal peptide appeared to bind to similar N-terminal domains of CAX1. Chimeric CAX3 constructs containing the N terminus of CAX1 were activated by CXIP1. In Arabidopsis, CXIP1 transcripts, like CAX1, accumulated in response to different metal conditions. This work thus characterizes a new class of signaling molecules in plants that may regulate CAX transporters in vivo.	Baylor Coll Med, USDA, ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA; Texas A&M Univ, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station	Hirschi, KD (corresponding author), Baylor Coll Med, USDA, ARS, Childrens Nutr Res Ctr, 1100 Bates St, Houston, TX 77030 USA.	kendalh@bcm.tmc.edu	hirschi, kendal/GNP-0351-2022		NHLBI NIH HHS [CHRC 5 P30] Funding Source: Medline; NIGMS NIH HHS [1R01 GM57427] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057427] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balmer Y, 2002, TRENDS PLANT SCI, V7, P191, DOI 10.1016/S1360-1385(02)02263-X; Cheng NH, 2002, PLANT PHYSIOL, V128, P1245, DOI 10.1104/pp.010857; CHENG NH, 2003, IN PRESS PLANT CELL; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Harper JF, 2001, TRENDS PLANT SCI, V6, P395, DOI 10.1016/S1360-1385(01)02023-4; HARPER JW, 1993, CELL, V75, P805; Hirschi K, 2001, TRENDS PLANT SCI, V6, P100, DOI 10.1016/S1360-1385(00)01863-X; Hirschi KD, 2000, PLANT PHYSIOL, V124, P125, DOI 10.1104/pp.124.1.125; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; Hirschi KD, 1999, PLANT CELL, V11, P2113, DOI 10.1105/tpc.11.11.2113; Hwang I, 2000, PLANT PHYSIOL, V122, P157, DOI 10.1104/pp.122.1.157; Hwang I, 2000, P NATL ACAD SCI USA, V97, P6224, DOI 10.1073/pnas.97.11.6224; Isakov N, 2000, TRENDS BIOCHEM SCI, V25, P537, DOI 10.1016/S0968-0004(00)01685-6; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Long JC, 1998, PLANT CELL, V10, P2077, DOI 10.1105/tpc.10.12.2077; Luan S, 1996, P NATL ACAD SCI USA, V93, P6964, DOI 10.1073/pnas.93.14.6964; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; MINET M, 1992, PLANT J, V2, P417; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; Pittman JK, 2002, J BIOL CHEM, V277, P26452, DOI 10.1074/jbc.M202563200; Pittman JK, 2002, PLANT PHYSIOL, V130, P1054, DOI 10.1104/pp.008193; Pittman JK, 2001, PLANT PHYSIOL, V127, P1020, DOI 10.1104/pp.010409; Quintero FJ, 2002, P NATL ACAD SCI USA, V99, P9061, DOI 10.1073/pnas.132092099; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Sanders D, 2002, PLANT CELL, V14, pS401, DOI 10.1105/tpc.002899; Shaul O, 1999, EMBO J, V18, P3973, DOI 10.1093/emboj/18.14.3973; Sherman F., 1986, METHODS YEAST GENETI; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Shigaki T, 2001, ANAL BIOCHEM, V298, P118, DOI 10.1006/abio.2001.5341; Sze H, 2000, ANNU REV PLANT PHYS, V51, P433, DOI 10.1146/annurev.arplant.51.1.433; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueoka-Nakanishi H, 2000, EUR J BIOCHEM, V267, P3090, DOI 10.1046/j.1432-1033.2000.01343.x; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Zhu JK, 2001, CURR OPIN PLANT BIOL, V4, P401, DOI 10.1016/S1369-5266(00)00192-8	36	56	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6503	6509		10.1074/jbc.M210883200	http://dx.doi.org/10.1074/jbc.M210883200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480930	hybrid			2022-12-25	WOS:000181129400126
J	Gilchrist, CA; Leo, M; Line, CG; Mann, BJ; Petri, WA				Gilchrist, CA; Leo, M; Line, CG; Mann, BJ; Petri, WA			Calcium modulates promoter occupancy by the Entamoeba histolytica Ca2+-binding transcription factor URE3-BP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT MUTANT; BINDING PROTEIN; DNA-BINDING; GAL/GALNAC LECTIN; SEQUENCE-ANALYSIS; FERREDOXIN GENE; CA2+ ENTRY; HGL5 GENE; EXPRESSION; CULTIVATION	The Entamoeba histolytica upstream regulatory element 3-binding protein (URE3-BP) binds to the URE3 sequence of the Gal/GalNAc-inhibitable lectin hgl5 and ferredoxin I (fdx) gene promoters. This binding can be inhibited in vitro by addition of calcium. Two EF-hand motifs, which are associated with the ability to bind calcium, are present in the amino acid sequence of LTRE3-BP. Mutation of the second EF-hand motif in URE3-BP resulted in the loss of calcium inhibition of DNA binding as monitored by electrophoretic mobility shift assay. Chromatin immunoprecipitation assays revealed that URE3-BP was physically bound to the hgl5 and fdx promoters in vivo. Parasite intracellular calcium concentrations were altered by changes in extracellular calcium. Promoter occupancy was lost when intracellular calcium levels were increased by coordinate increases in extracellular calcium. Increased intracellular calcium also resulted in decreased levels of URE3-BP mRNA. Together these results demonstrate that changes in extracellular calcium result in changes in URE3-BP mRNA and in the ability of URE3-BP to bind to URE3-containing promoters. Modulation of URE3-BP by calcium may represent an important mechanism of control of gene expression in E. histolytica.	Univ Virginia, Hlth Syst, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Petri, WA (corresponding author), Univ Virginia, Hlth Syst, Dept Internal Med, MR4 Bldg,Rm 2115,POB 801340, Charlottesville, VA 22908 USA.		Petri, William A./D-3639-2019; Petri, William/AAL-3642-2020	Petri, William/0000-0002-7268-1218	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037941] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37941] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; AYALA P, 1990, EXP PARASITOL, V71, P169, DOI 10.1016/0014-4894(90)90019-9; Ayeh-Kumi PF, 2001, EXP PARASITOL, V99, P80, DOI 10.1006/expr.2001.4652; Bruchhaus I, 2002, MOL MICROBIOL, V44, P1063, DOI 10.1046/j.1365-2958.2002.02941.x; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carbajal ME, 1996, EXP PARASITOL, V82, P11, DOI 10.1006/expr.1996.0002; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Civitelli R., 1994, PHYSL GASTROINTESTIN, P2173; Densmore JJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1494, DOI 10.1152/ajpcell.1996.271.5.C1494; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; Gilchrist CA, 2001, J BIOL CHEM, V276, P11838, DOI 10.1074/jbc.M007375200; Gilchrist CA, 1995, MOL BIOCHEM PARASIT, V74, P1, DOI 10.1016/0166-6851(95)02474-3; Gilchrist CA, 1998, INFECT IMMUN, V66, P2383, DOI 10.1128/IAI.66.5.2383-2386.1998; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; Giri B, 1996, FEBS LETT, V393, P109, DOI 10.1016/0014-5793(96)00866-6; Gomez C, 1998, J BIOL CHEM, V273, P7277, DOI 10.1074/jbc.273.13.7277; Haverstick DM, 2000, CANCER RES, V60, P1002; Haverstick DM, 1998, CELL CALCIUM, V23, P361, DOI 10.1016/S0143-4160(98)90092-6; HUBER M, 1988, MOL BIOCHEM PARASIT, V31, P27, DOI 10.1016/0166-6851(88)90142-9; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P297; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lilliehook C, 2002, MOL CELL NEUROSCI, V19, P552, DOI 10.1006/mcne.2001.1096; Linderson Y, 2001, GENE, V262, P107, DOI 10.1016/S0378-1119(00)00546-1; Marchat LA, 2002, CELL MICROBIOL, V4, P725, DOI 10.1046/j.1462-5822.2002.00220.x; NELLANS HN, 1990, MINER ELECTROL METAB, V16, P101; Nickel R, 2000, FEBS LETT, V486, P112, DOI 10.1016/S0014-5793(00)02245-6; Osawa M, 2001, J BIOL CHEM, V276, P41005, DOI 10.1074/jbc.M105842200; Padilla-Vaca F, 1999, INFECT IMMUN, V67, P2096, DOI 10.1128/IAI.67.5.2096-2102.1999; Perez DG, 1998, J BIOL CHEM, V273, P7285, DOI 10.1074/jbc.273.13.7285; Perez E, 1998, FEMS MICROBIOL LETT, V159, P187, DOI 10.1016/S0378-1097(97)00565-X; PRASAD J, 1992, MOL BIOCHEM PARASIT, V52, P137, DOI 10.1016/0166-6851(92)90044-K; Purdy JE, 1996, MOL BIOCHEM PARASIT, V78, P91, DOI 10.1016/S0166-6851(96)02614-X; Ramakrishnan G, 1996, MOL MICROBIOL, V19, P91, DOI 10.1046/j.1365-2958.1996.356885.x; Singh U, 1997, P NATL ACAD SCI USA, V94, P8812, DOI 10.1073/pnas.94.16.8812; Singh U, 2002, MOL BIOCHEM PARASIT, V120, P107, DOI 10.1016/S0166-6851(01)00441-8; Singh U, 1998, J BIOL CHEM, V273, P21663, DOI 10.1074/jbc.273.34.21663; Wassmann C, 1999, J BIOL CHEM, V274, P26051, DOI 10.1074/jbc.274.37.26051; WILLIAMS RJP, 1977, CALCIUM BINDING PROT, P3; Zhang JH, 1997, GENOME RES, V7, P649, DOI 10.1101/gr.7.6.649	41	26	26	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4646	4653		10.1074/jbc.M211271200	http://dx.doi.org/10.1074/jbc.M211271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466263	hybrid			2022-12-25	WOS:000180968900039
J	Luo, WT; Chen, XM; Fang, H; Green, N				Luo, WT; Chen, XM; Fang, H; Green, N			Factors governing nonoverlapping substrate specificity by mitochondrial inner membrane peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; BACTERIAL SIGNAL PEPTIDASE; CLEAVAGE SITES; NUCLEAR GENE; SACCHAROMYCES-CEREVISIAE; PROTEIN; PRECURSOR; COMPLEX; CYTOCHROME-C1; SEQUENCES	At least three peptidases are involved in cleaving pre-sequences from imported mitochondrial proteins. One of the peptidase, the inner membrane peptidase, has two catalytic subunits, Imp1p and Imp2p, which are structurally related but functionally distinct in the yeast Saccharomyces cerevisiae. Whereas both subunits are members of the type I signal peptidase family, they exhibit nonoverlapping substrate specificities. A clue to the substrate specificity mechanism has come from our discovery of the importance not only of the -1 and -3 residues in the signal peptides cleaved by Imp1p and Imp2p but also the +1 cargo residues attached to the signal peptides. We specifically find that Imp1p prefers substrates having a negatively charged residue (Asp or Glu) at the +1 position, whereas Imp2p prefers substrates having the Met residue at the +1 position. We further suggest that the conformation of the cargo is important for substrate recognition by Imp2p. A role for the cargo in presequence recognition distinguishes Imp1p and Imp2p from other type I signal peptidases.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Luo, WT (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37232 USA.							Allsop A, 1996, J ANTIBIOT, V49, P921, DOI 10.7164/antibiotics.49.921; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Chen XM, 1999, J BIOL CHEM, V274, P37750, DOI 10.1074/jbc.274.53.37750; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; Esser K, 1996, MOL GEN GENET, V252, P437, DOI 10.1007/s004380050248; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FOLZ RJ, 1988, J BIOL CHEM, V264, P3979; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; Jan PS, 2000, MOL GEN GENET, V263, P483, DOI 10.1007/s004380051192; Karamyshev AL, 1998, J MOL BIOL, V277, P859, DOI 10.1006/jmbi.1997.1617; MORGANHUGHES JA, 1994, MYOLOGY BASIC CLIN, V2, P1610; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; OHASHI A, 1982, J BIOL CHEM, V257, P3042; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; PAETZEL M, 1995, PROTEINS, V23, P122, DOI 10.1002/prot.340230115; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; PRATJE E, 1983, EMBO J, V2, P1079; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	30	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4943	4948		10.1074/jbc.M210916200	http://dx.doi.org/10.1074/jbc.M210916200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12482857	hybrid			2022-12-25	WOS:000180968900078
J	Yuan, JZ; Slice, LW; Gu, J; Rozengurt, E				Yuan, JZ; Slice, LW; Gu, J; Rozengurt, E			Cooperation of G(q), G(i), and G(12/13) in protein kinase D activation and phosphorylation induced by lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; COUPLED RECEPTOR AGONISTS; GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; GTP-BINDING PROTEIN; PHORBOL ESTERS; ALPHA-SUBUNIT; D PKD; TYROSINE PHOSPHORYLATION; CELLULAR-RESPONSES	To examine the contribution of different G-protein pathways to lysophosphatidic acid (LPA)-induced protein kinase D (PKD) activation, we tested the effect of LPA on PKD activity in murine embryonic cell lines deficient in Galpha(q/11) (Galpha(q/11) KO cells) or Galpha(12/13) (Galpha(12/13) KO cells) and used cells lacking rhodopsin kinase (RK cells) as a control. In RK and Ga-12/13 KO cells, LPA induced PKD activation through a phospholipase C/protein kinase C pathway in a concentration-dependent fashion with maximal stimulation (6-fold for RK cells and 4-fold for Ga-12/13 KO cells in autophosphorylation activity) achieved at 3 muM. In contrast, LPA did not induce any significant increase in PKD activity in Galpha(q/11) KO cells. However, LPA induced a significantly increased PKD activity when Galpha(q/11) KO cells were transfected with Galpha(q). LPA-induced PKD activation was modestly attenuated by prior exposure of RK cells to pertussis toxin (PTx) but abolished by the combination treatments of PTx and Clostridium difficile toxin B. Surprisingly, PTx alone strikingly inhibited LPA-induced PKD activation in a concentration-dependent fashion in Ga-12/13 KO cells. Similar results were obtained when activation loop phosphorylation at Ser-744 was determined using an antibody that detects the phosphorylated state of this residue. Our results indicate that G(q) is necessary but not sufficient to mediate LPA-induced PKD activation. In addition to G(q), LPA requires additional G-protein pathways to elicit a maximal response with G(i) playing a critical role in Ga-12/13 KO cells. We conclude that LPA induces PKD activation through G(q) G(i), and G(12) and propose that PKD activation is a point of convergence in the action of multiple G-protein pathways.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; California Institute of Technology	Rozengurt, E (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 900 Veterans Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NCI NIH HHS [F32 CA84658-01A1, P50 CA 90388-01] Funding Source: Medline; NIDDK NIH HHS [DK 17294, DK 55003, DK56930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388, F32CA084658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, R37DK017294, R01DK017294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Offermanns S, 1996, CANCER SURV, V27, P177; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Paolucci L, 1999, CANCER RES, V59, P572; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Slater SJ, 2001, BIOCHEMISTRY-US, V40, P4437, DOI 10.1021/bi001654n; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Strassheim D, 1998, MOL PHARMACOL, V53, P1047; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; Yang AH, 2002, BBA-MOL CELL BIOL L, V1582, P197, DOI 10.1016/S1388-1981(02)00172-5; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	73	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4882	4891		10.1074/jbc.M211175200	http://dx.doi.org/10.1074/jbc.M211175200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12477719	hybrid			2022-12-25	WOS:000180968900070
J	Tsutsumi, R; Higashi, H; Higuchi, M; Okada, M; Hatakeyama, M				Tsutsumi, R; Higashi, H; Higuchi, M; Okada, M; Hatakeyama, M			Attenuation of Helicobacter pylori CagA-SHP-2 signaling by interaction betwwen CagA and C-terminal Src kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; PROTEIN-TYROSINE KINASE; IV SECRETION; PEPTIC-ULCERATION; FAMILY KINASES; APOPTOSIS; INFECTION; PHOSPHATASE; STRAINS; CSK	diseases ranging from gastritis to cancer. The CagA protein is the product of the cagA gene carried among virulent H. pylori strains and is associated with severe disease outcomes, most notably gastric carcinoma. CagA is injected from the attached H. pylori into gastric epithelial cells and undergoes tyrosine phosphorylation. The phosphorylated CagA binds and activates SHP-2 phosphatase and thereby induces a growth factor-like morphological change termed the "humming-bird phenotype." In this work, we demonstrate that CagA is also capable of interacting with C-terminal Src kinase (Csk). As is the case with SHP-2, Csk selectively binds tyrosine-phosphorylated CagA via its SH2 domain. Upon complex formation, CagA stimulates Csk, which in turn inactivates the Src family of protein-tyrosine kinases. Because Src family kinases are responsible for CagA phosphorylation, an essential prerequisite of CagA.SHP-2 complex formation and subsequent induction of the hummingbird phenotype, our results indicate that CagA-Csk interaction down-regulates CagA.SHP-2 signaling by both competitively inhibiting CagA.SHP-2 complex formation and reducing levels of CagA phosphorylation. We further demonstrate that CagA.SHP-2 signaling eventually induces apoptosis in AGS cells. Our results thus indicate that CagA-Csk interaction prevents excess cell damage caused by deregulated activation of SHP-2. Attenuation of CagA activity by Csk may enable cagA-positive H. pylori to persistently infect the human stomach for decades while avoiding excess CagA toxicity to the host.	Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Sapporo, Hokkaido 0600185, Japan; Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600185, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Oncogene Res, Suita, Osaka 5650871, Japan	Hokkaido University; Hokkaido University; Osaka University	Hatakeyama, M (corresponding author), Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@imm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012	Tsutsumi, Ryouhei/0000-0002-1704-0362				Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; BLASER MJ, 1995, CANCER RES, V55, P2111; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Cover TL, 1999, GASTROENTEROLOGY, V117, P257, DOI 10.1016/S0016-5085(99)70575-5; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; Eck M, 1997, GASTROENTEROLOGY, V112, P1482, DOI 10.1016/S0016-5085(97)70028-3; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Gregorieff A, 1998, J BIOL CHEM, V273, P13217, DOI 10.1074/jbc.273.21.13217; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Jones NL, 1999, INFECT IMMUN, V67, P4237, DOI 10.1128/IAI.67.8.4237-4242.1999; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Liu HS, 1998, BRIT J CANCER, V77, P1777, DOI 10.1038/bjc.1998.296; MARSHALL BJ, 1984, LANCET, V1, P1311; Moss SF, 2001, CANCER RES, V61, P1406; Murakami K, 1999, SCAND J GASTROENTERO, V34, P474, DOI 10.1080/003655299750026191; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nardone G, 1999, GUT, V44, P789, DOI 10.1136/gut.44.6.789; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Neu B, 2002, AM J PHYSIOL-GASTR L, V283, pG309, DOI 10.1152/ajpgi.00546.2001; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peek RM, 1999, CANCER RES, V59, P6124; Peek RM, 1997, JNCI-J NATL CANCER I, V89, P863, DOI 10.1093/jnci/89.12.863; Rokkas T, 1999, DIGEST DIS SCI, V44, P487, DOI 10.1023/A:1026636803101; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; Yamaoka Y, 1999, GASTROENTEROLOGY, V117, P342, DOI 10.1053/gast.1999.0029900342; Yamaoka Y, 1998, J CLIN MICROBIOL, V36, P2258, DOI 10.1128/JCM.36.8.2258-2263.1998; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	52	221	233	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3664	3670		10.1074/jbc.M208155200	http://dx.doi.org/10.1074/jbc.M208155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446738	hybrid			2022-12-25	WOS:000180869700020
J	Bao, KK; Wang, H; Miller, JK; Erie, DA; Skalka, AM; Wong, I				Bao, KK; Wang, H; Miller, JK; Erie, DA; Skalka, AM; Wong, I			Functional oligomeric state of avian sarcoma virus integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRAL DNA INTEGRATION; TYPE-1 INTEGRASE; HIV-1 INTEGRASE; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; TERMINAL DOMAINS; IN-VITRO; PROTEIN; CORE	Retroviral integrase, one of only three enzymes encoded by the virus, catalyzes the essential step of inserting a DNA copy of the viral genome into the host during infection. Using the avian sarcoma virus integrase, we demonstrate that the enzyme functions as a tetramer. In presteady-state active site titrations, four integrase protomers were required for a single catalytic turnover. Volumetric determination of integrase-DNA complexes imaged by atomic force microscopy during the initial turnover additionally revealed substrate-induced assembly of a tetramer. These results suggest that tetramer formation may be a requisite step during catalysis with ramifications for antiviral design strategies targeting the structurally homologous human immunodeficiency virus, type 1 (HIV-1) integrase.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Oregon State University; University of North Carolina; University of North Carolina Chapel Hill; Fox Chase Cancer Center	Wong, I (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 ALS Bldg, Corvallis, OR 97331 USA.	wongis@onid.orst.edu	Wang, Hong/F-3164-2014	Wang, Hong/0000-0003-0165-3559	NIGMS NIH HHS [GM58771] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058771] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; Bao KK, 2002, J BIOL CHEM, V277, P12099, DOI 10.1074/jbc.M111314200; Bao KK, 2002, J BIOL CHEM, V277, P12089, DOI 10.1074/jbc.M111315200; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; JENKINS TM, 1995, P NATL ACAD SCI USA, V92, P6057, DOI 10.1073/pnas.92.13.6057; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; LUTZKE RAP, 1995, P NATL ACAD SCI USA, V92, P11456, DOI 10.1073/pnas.92.25.11456; Mazumder A, 1996, J MED CHEM, V39, P2472, DOI 10.1021/jm960074e; Melek M, 2002, P NATL ACAD SCI USA, V99, P134, DOI 10.1073/pnas.012610699; Ratcliff GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/ja005750n; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463	30	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1323	1327		10.1074/jbc.C200550200	http://dx.doi.org/10.1074/jbc.C200550200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12446721	Green Published, hybrid			2022-12-25	WOS:000180321900081
J	Tanaka, SM; Alam, I; Turner, CH				Tanaka, SM; Alam, I; Turner, CH			Stochastic resonance in osteogenic response to mechanical loading	FASEB JOURNAL			English	Article						biomechanics; bone formation; osteoporosis; mechanotransduction	SIGNAL-TRANSDUCTION; BONE; STRAIN; ENHANCEMENT; VIBRATION	Stochastic resonance, in which noise enhances the response of a nonlinear system to a weak signal, has been observed in various biological sensory systems. We speculated that bone formation in response to mechanical loading could be enhanced by adding noise (vibration) to a standard exercise regimen. To test this hypothesis, three different loading regimens were applied to the ulnae of mice: (1) high amplitude, low frequency sinusoidal loading at 2 Hz with an amplitude of 3 N to simulate exercise; (2) low amplitude, broad frequency vibration with frequency components 0-50 Hz and 0.3 N of mean amplitude; (3) the sinusoidal wave combined with vibration (S+V) to invoke stochastic resonance. The simulated exercise regimen induced new bone formation on the periosteal surface of the ulna, however the addition of vibration noise with exercise enhanced the osteogenic response by almost 4-fold. Vibration by itself had no effect on bone formation. It was concluded that adding low magnitude vibration greatly enhanced bone formation in response to loading, suggesting a contribution of stochastic resonance in the osteogenic response.	Indiana Univ, Sch Med, Dept Orthoped Surg, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Turner, CH (corresponding author), Indiana Univ, Sch Med, Dept Orthoped Surg, 541 Clin Dr,Room 600, Indianapolis, IN 46202 USA.	turnerch@iupui.edu	Tanaka, Shigeo/E-7098-2015	Tanaka, Shigeo/0000-0002-1262-3876				BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BEZRUKOV SM, 1995, NATURE, V378, P362, DOI 10.1038/378362a0; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; Collins JJ, 1997, PHYS REV E, V56, P923, DOI 10.1103/PhysRevE.56.923; Duncan RL, 1998, SEMIN NEPHROL, V18, P178; Fritton SP, 2000, J BIOMECH, V33, P317, DOI 10.1016/S0021-9290(99)00210-9; Huang RP, 1999, J GERONTOL A-BIOL, V54, pB352, DOI 10.1093/gerona/54.8.B352; Khan K, 2000, J Sci Med Sport, V3, P150, DOI 10.1016/S1440-2440(00)80077-8; Rubin C, 2002, J BONE MINER RES, V17, P349, DOI 10.1359/jbmr.2002.17.2.349; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756-3282(01)00689-5; RUBIN CT, 1990, J BIOMECH, V23, P43, DOI 10.1016/0021-9290(90)90040-A; Tanaka S, 2001, J BONE MINER RES, V16, pS481; TURNER CH, 1995, J BIOMECH, V28, P39, DOI 10.1016/0021-9290(95)80005-0; TURNER CH, 1995, J BONE MINER RES, V10, P1544; USUI Y, 1989, J ORTHOPAED RES, V7, P559, DOI 10.1002/jor.1100070414	21	52	60	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					313	+		10.1096/fj.02-0561fje	http://dx.doi.org/10.1096/fj.02-0561fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475888				2022-12-25	WOS:000180574300017
J	Chhabra, SR; Shockley, KR; Conners, SB; Scott, KL; Wolfinger, RD; Kelly, RM				Chhabra, SR; Shockley, KR; Conners, SB; Scott, KL; Wolfinger, RD; Kelly, RM			Carbohydrate-induced differential gene expression patterns in the hyperthermophilic bacterium Thermotoga maritima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATORS; CATABOLITE REPRESSION; GLYCOSYL HYDROLASES; RECOMBINANT ENZYMES; ALPHA-GLUCURONIDASE; SUGAR UTILIZATION; SEQUENCE-ANALYSIS; TRANSPORT-SYSTEM	The hyperthermophilic bacterium Thermotoga maritima MSB8 was grown on a variety of carbohydrates to determine the influence of carbon and energy source on differential gene expression. Despite the fact that T. maritima has been phylogenetically characterized as a primitive microorganism from an evolutionary perspective, results here suggest that it has versatile and discriminating mechanisms for regulating and effecting complex carbohydrate utilization. Growth of T. maritima on monosaccharides was found to be slower than growth on polysaccharides, although growth to cell densities of 10(8) to 10(9) cells/ml was observed on all carbohydrates tested. Differential expression of genes encoding carbohydrate-active proteins encoded in the T. maritima genome was followed using a targeted cDNA microarray in conjunction with mixed model statistical analysis. Coordinated regulation of genes responding to specific carbohydrates was noted. Although glucose generally repressed expression of all glycoside hydrolase genes, other sugars induced or repressed these genes to varying extents. Expression profiles of most endo-acting glycoside hydrolase genes correlated well with their reported biochemical properties, although exo-acting glycoside hydrolase genes displayed less specific expression patterns. Genes encoding selected putative ABC sugar transporters were found to respond to specific carbohydrates, and in some cases putative oligopeptide transporter genes were also found to respond to specific sugar substrates. Several genes encoding putative transcriptional regulators were expressed during growth on specific sugars, thus suggesting functional assignments. The transcriptional response of T. maritima to specific carbohydrate growth substrates indicated that sugar backbone- and linkage-specific regulatory networks are operational in this organism during the uptake and utilization of carbohydrate substrates. Furthermore, the wide ranging collection of such networks in T. maritima suggests that this organism is capable of adapting to a variety of growth environments containing carbohydrate growth substrates.	N Carolina State Univ, Dept Chem Engn, Riddick Lab 113, Raleigh, NC 27695 USA; SAS Inst Inc, Cary, NC 27513 USA	University of North Carolina; North Carolina State University; SAS Institute Inc	Kelly, RM (corresponding author), N Carolina State Univ, Dept Chem Engn, Riddick Lab 113, Box 7905, Raleigh, NC 27695 USA.	rmkelly@eos.ncsu.edu		Kelly, Robert/0000-0002-0639-3592				ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLAMEY JM, 1994, BIOCHEMISTRY-US, V33, P1000, DOI 10.1021/bi00170a019; BRONNENMEIER K, 1995, APPL ENVIRON MICROB, V61, P1399, DOI 10.1128/AEM.61.4.1399-1407.1995; Bruckner R, 2002, FEMS MICROBIOL LETT, V209, P141; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Chhabra S, 2001, METHOD ENZYMOL, V330, P224; Chhabra SR, 2002, FEBS LETT, V531, P375, DOI 10.1016/S0014-5793(02)03493-2; Chhabra SR, 2002, APPL ENVIRON MICROB, V68, P545, DOI 10.1128/AEM.68.2.545-554.2002; COHEN SP, 1993, J BACTERIOL, V175, P1484, DOI 10.1128/JB.175.5.1484-1492.1993; de Vos WM, 1998, EXTREMOPHILES, V2, P201, DOI 10.1007/s007920050061; DIORIO C, 1995, J BACTERIOL, V177, P2050, DOI 10.1128/jb.177.8.2050-2056.1995; FUJITA Y, 1995, MOL MICROBIOL, V17, P953, DOI 10.1111/j.1365-2958.1995.mmi_17050953.x; Galperin MY, 1996, APPL ENVIRON MICROB, V62, P2915; Galperin MY, 1997, APPL ENVIRON MICROB, V63, P969; Hardham JM, 1997, GENE, V197, P47, DOI 10.1016/S0378-1119(97)00234-5; HASSEMAN J, 2001, TIGR MICROARRAY PROT; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Henrissat B, 2001, METHOD ENZYMOL, V330, P183; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Jin W, 2001, NAT GENET, V29, P389, DOI 10.1038/ng766; Kerr MK, 2001, GENET RES, V77, P123; KREUZER P, 1989, J BACTERIOL, V171, P3840, DOI 10.1128/jb.171.7.3840-3845.1989; Lee MH, 2002, BIOCHEM BIOPH RES CO, V295, P818, DOI 10.1016/S0006-291X(02)00748-9; Liebl W, 2001, METHOD ENZYMOL, V330, P290; Liebl W, 1996, MICROBIOL-SGM, V142, P2533, DOI 10.1099/00221287-142-9-2533; Martin RG, 2001, CURR OPIN MICROBIOL, V4, P132, DOI 10.1016/S1369-5274(00)00178-8; McGuire AM, 2000, GENOME RES, V10, P744, DOI 10.1101/gr.10.6.744; Mirny LA, 2002, J MOL BIOL, V321, P7, DOI 10.1016/S0022-2836(02)00587-9; Mirny LA, 2002, NUCLEIC ACIDS RES, V30, P1704, DOI 10.1093/nar/30.7.1704; MIWA Y, 1988, J BIOL CHEM, V263, P13252; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Nesbo CL, 2002, J BACTERIOL, V184, P4475, DOI 10.1128/JB.184.16.4475-4488.2002; Nguyen TN, 2001, FEMS MICROBIOL LETT, V195, P79, DOI 10.1111/j.1574-6968.2001.tb10501.x; Nikolskaya AN, 2002, NUCLEIC ACIDS RES, V30, P2453, DOI 10.1093/nar/30.11.2453; Parker KN, 2001, BIOTECHNOL BIOENG, V75, P322, DOI 10.1002/bit.10020; Phadtare S, 1999, CURR OPIN MICROBIOL, V2, P175, DOI 10.1016/S1369-5274(99)80031-9; Plumbridge J, 2001, J MOL MICROB BIOTECH, V3, P371; Rodionov DA, 2001, FEMS MICROBIOL LETT, V205, P305, DOI 10.1111/j.1574-6968.2001.tb10965.x; Ruile P, 1997, MOL MICROBIOL, V23, P267, DOI 10.1046/j.1365-2958.1997.2011568.x; Shulami S, 1999, J BACTERIOL, V181, P3695, DOI 10.1128/JB.181.12.3695-3704.1999; Song SG, 1998, FEMS MICROBIOL LETT, V163, P255, DOI 10.1111/j.1574-6968.1998.tb13054.x; Song SG, 1997, J BACTERIOL, V179, P7025, DOI 10.1128/jb.179.22.7025-7032.1997; Sorensen KI, 1996, J BACTERIOL, V178, P1003, DOI 10.1128/jb.178.4.1003-1011.1996; Suresh C, 2002, FEBS LETT, V517, P159, DOI 10.1016/S0014-5793(02)02611-X; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; TITGEMEYER F, 1993, J CELL BIOCHEM, V51, P69, DOI 10.1002/jcb.240510113; Vargas M, 1996, MICROBIOL-UK, V142, P139, DOI 10.1099/13500872-142-1-139; Wolfinger RD, 2001, J COMPUT BIOL, V8, P625, DOI 10.1089/106652701753307520; Yernool DA, 2000, J BACTERIOL, V182, P5172, DOI 10.1128/JB.182.18.5172-5179.2000; Zeng XM, 2000, J BACTERIOL, V182, P1916, DOI 10.1128/JB.182.7.1916-1922.2000; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200	53	106	109	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7540	7552		10.1074/jbc.M211748200	http://dx.doi.org/10.1074/jbc.M211748200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12475972	hybrid			2022-12-25	WOS:000181195100116
J	Lee, Y; Nazar, RN				Lee, Y; Nazar, RN			Terminal structure mediates 5 S rRNA stability and integration during ribosome biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; PROTEIN-BINDING-SITE; SACCHAROMYCES-CEREVISIAE; 5-S RNA; ANGSTROM RESOLUTION; XENOPUS-OOCYTES; LA PROTEIN; YEAST; PRECURSOR; MATURATION	Formation of the eukaryotic ribosomal 5 S RNA-protein complex has been shown to be critical to ribosome biogenesis and has been speculated to contribute to a quality control mechanism that helps ensure that only normal precursors are processed and assembled into active ribosomes. To study the structural basis of these observations, the RNA-protein interface in the 5 S RNA-protein complex of the yeast (Saccharomyces cerevisiae) ribosome was examined based on a systematic introduction of targeted base substitutions in the RNA sequence. Most base substitutions had little or no effect on the efficiency of complex formation, but large effects were observed when changes disrupted helix 1, the secondary structure formed between the interacting termini. Again, only modest effects were evident when the extended 3' end of the mature RNA molecule was altered, but essentially no complex was formed when the 5' end of the mature 5 S RNA sequence was artificially extended by one nucleotide. In vitro analyses demonstrated that this extension also dramatically altered the maturation of 5 S rRNA precursor molecules as well as the stability of the mature 5 S rRNA. Taken together, the results indicate that in the course of RNA maturation, the 5 S, RNA-binding protein binds precisely over or "caps" the termini in a critical manner that protects the RNA from further degradation.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Guelph	Nazar, RN (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	rnnazar@uoguelph.ca						ARIS JP, 1991, METHOD ENZYMOL, V194, P735; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; BROW DA, 1987, J BIOL CHEM, V262, P13959; Chaconas G, 1980, Methods Enzymol, V65, P75; DESHMUKH M, 1993, MOL CELL BIOL, V13, P2835, DOI 10.1128/MCB.13.5.2835; DOUTHWAITE S, 1982, BIOCHEMISTRY-US, V21, P2313, DOI 10.1021/bi00539a007; FOX GE, 1975, NATURE, V256, P505, DOI 10.1038/256505a0; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; GARRETT RA, 1979, J MOL BIOL, V132, P637, DOI 10.1016/0022-2836(79)90379-6; GARRETT RA, 1979, INT REV BIOCHEM, V25, P121; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; Kufel J, 2003, J BIOL CHEM, V278, P2147, DOI 10.1074/jbc.M208856200; Kufel J, 2002, MOL CELL BIOL, V22, P5248, DOI 10.1128/MCB.22.14.5248-5256.2002; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lalev AI, 1998, J MOL BIOL, V284, P1341, DOI 10.1006/jmbi.1998.2222; LEE Y, 1995, J BIOL CHEM, V270, P28003; Lee Y, 1997, J BIOL CHEM, V272, P15206, DOI 10.1074/jbc.272.24.15206; Maraia RJ, 2002, GENE EXPRESSION, V10, P41; MCDOUGALL J, 1983, J BIOL CHEM, V258, P5256; MCDOUGALL J, 1987, NUCLEIC ACIDS RES, V15, P161, DOI 10.1093/nar/15.1.161; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; NAZAR RN, 1979, EUR J BIOCHEM, V102, P573, DOI 10.1111/j.1432-1033.1979.tb04274.x; NAZAR RN, 1991, J BIOL CHEM, V266, P4562; NAZAR RN, 1979, J BIOL CHEM, V254, P7724; NAZAR RN, 1983, NUCLEIC ACIDS RES, V11, P3155, DOI 10.1093/nar/11.10.3155; PEACOCK AC, 1967, BIOCHEMISTRY-US, V6, P1818, DOI 10.1021/bi00858a033; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERCIVALSMITH A, 1987, MOL CELL BIOL, V7, P2484, DOI 10.1128/MCB.7.7.2484; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PREISER PR, 1991, J BIOL CHEM, V260, P7509; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; SZOSTAK JW, 1979, PLASMID, V2, P536, DOI 10.1016/0147-619X(79)90053-2; TANG BZ, 1992, J BIOL CHEM, V267, P17738; TANG BZ, 1991, J BIOL CHEM, V266, P6120; VANRYK DI, 1990, J BIOL CHEM, V265, P8377; VANRYK DI, 1992, J BIOL CHEM, V267, P16177; VANRYK DI, 1992, J MOL BIOL, V226, P1027, DOI 10.1016/0022-2836(92)91050-Y; VASISHT V, 1994, J BIOL CHEM, V269, P18468; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	51	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6635	6641		10.1074/jbc.M212220200	http://dx.doi.org/10.1074/jbc.M212220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12471019	hybrid			2022-12-25	WOS:000181195100003
J	NDong, C; Anzellotti, D; Ibrahim, RK; Huner, NPA; Sarhan, F				NDong, C; Anzellotti, D; Ibrahim, RK; Huner, NPA; Sarhan, F			Daphnetin methylation by a novel O-methyltransferase is associated with cold acclimation and photosystem II excitation pressure in rye	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-TEMPERATURE; FREEZING TOLERANCE; GENE-EXPRESSION; WINTER RYE; LIGNIN; PLANTS; PURIFICATION; CLONING; BINDING; PROTEIN	In plants, O-methylation of phenolic compounds plays an important role in such processes as lignin synthesis, flower pigmentation, chemical defense, and signaling. However, apart from phenylpropanoids and flavonoids, very few enzymes involved in coumarin biosynthesis have been identified. We report here the molecular and biochemical characterization of a gene encoding a novel O-methyltransferase that catalyzes the methylation of 7,8-dihydroxycoumarin, daphnetin. The recombinant protein displayed an exclusive methylation of position 8 of daphnetin. The identity of the methylated product was unambiguously identified as 7-hydroxy-8-methoxycoumarin by co-chromatography on cellulose TLC and coelution from high performance liquid chromatography, with authentic synthetic samples, as well as by UV, mass spectroscopy, H-1 NMR spectral analysis, and NOE correlation signals of the relevant protons. Northern blot analysis and enzyme activity assays revealed that the transcript and corresponding enzyme activity are up-regulated by both low temperature and photosystem II excitation pressure. Using various phenylpropanoid and flavonoid substrates, we demonstrate that cold acclimation of rye leaves increases O-methyltransferase activity not only for daphnetin but also for the lignin precursors, caffeic acid, and 5-hydroxyferulic acid. The significance of this novel enzyme and daphnetin O-methylation is discussed in relation to its putative role in modulating cold acclimation and photosystem II excitation pressure.	Univ Quebec, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada; Concordia Univ, Plant Biochem Lab, Montreal, PQ H3G 1M8, Canada; Concordia Univ, Ctr Struct Funct Genom, Montreal, PQ H3G 1M8, Canada; Univ Western Ontario, Dept Plant Sci, London, ON N6A 5B7, Canada	University of Quebec; University of Quebec Montreal; Concordia University - Canada; Concordia University - Canada; Western University (University of Western Ontario)	Sarhan, F (corresponding author), Univ Quebec, Dept Sci Biol, CP 8888 Succursale Centre Ville, Montreal, PQ H3C 3P8, Canada.							BOHM BA, 1961, CAN J BIOCHEM PHYS, V39, P1389, DOI 10.1139/o61-148; BUGOS RC, 1991, PLANT MOL BIOL, V17, P1203, DOI 10.1007/BF00028736; Chun JU, 1998, EUPHYTICA, V102, P219, DOI 10.1023/A:1018333730936; DELUCA V, 1985, ARCH BIOCHEM BIOPHYS, V238, P596, DOI 10.1016/0003-9861(85)90205-X; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Gilmour SJ, 1998, PLANT J, V16, P433, DOI 10.1046/j.1365-313x.1998.00310.x; GOWRI G, 1991, PLANT PHYSIOL, V97, P7, DOI 10.1104/pp.97.1.7; Gray GR, 1997, PLANT PHYSIOL, V114, P467, DOI 10.1104/pp.114.2.467; Gray GR, 1996, PLANT PHYSIOL, V110, P61, DOI 10.1104/pp.110.1.61; Grayer RJ, 2000, PHYTOCHEM ANALYSIS, V11, P257, DOI 10.1002/1099-1565(200007/08)11:4&lt;257::AID-PCA521&gt;3.0.CO;2-A; Hatfield R, 2001, PLANT PHYSIOL, V126, P1351, DOI 10.1104/pp.126.4.1351; Hughes MA, 1996, J EXP BOT, V47, P291, DOI 10.1093/jxb/47.3.291; HUNER NPA, 1993, PHOTOSYNTH RES, V37, P19, DOI 10.1007/BF02185436; Huner NPA, 1998, TRENDS PLANT SCI, V3, P224, DOI 10.1016/S1360-1385(98)01248-5; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Ibrahim RK, 1997, TRENDS PLANT SCI, V2, P249, DOI 10.1016/S1360-1385(97)86345-5; JONES PG, 1994, MOL MICROBIOL, V11, P811, DOI 10.1111/j.1365-2958.1994.tb00359.x; LEGRAND M, 1978, PLANTA, V144, P101, DOI 10.1007/BF00385014; LEWIS NG, 1990, ANNU REV PLANT PHYS, V41, P455, DOI 10.1146/annurev.pp.41.060190.002323; LIN-GEN Z, 1982, Planta Medica, V45, P172, DOI 10.1055/s-2007-971368; LOIS R, 1992, Z NATURFORSCH C, V47, P90; Matern U., 1999, COMPREHENSIVE NATURA, V1, P623; MOLYNEUX RJ, 1974, AUST J CHEM, V27, P2697, DOI 10.1071/CH9742697; Murray R. D. H., 1982, NATURAL COUMARINS OC; Ndong C, 2001, PLANT MOL BIOL, V45, P691, DOI 10.1023/A:1010684719225; Nishida I, 1996, ANNU REV PLANT PHYS, V47, P541, DOI 10.1146/annurev.arplant.47.1.541; Pastori G, 2000, J EXP BOT, V51, P107, DOI 10.1093/jexbot/51.342.107; PAYA M, 1992, BIOCHEM PHARMACOL, V44, P205, DOI 10.1016/0006-2952(92)90002-Z; PAYA M, 1994, BIOCHEM PHARMACOL, V48, P445, DOI 10.1016/0006-2952(94)90273-9; Sambrook J., 2002, MOL CLONING LAB MANU; Scott-Craig JS, 1998, PLANT PHYSIOL, V116, P1083, DOI 10.1104/pp.116.3.1083; Seguin J, 1998, PHYTOCHEMISTRY, V49, P319; SHARMA SK, 1979, Z NATURFORSCH C, V34, P387; SYED SK, 1993, BIOCHEMISTRY-US, V32, P2242, DOI 10.1021/bi00060a016; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; TSANG YF, 1979, PHYTOCHEMISTRY, V18, P1131, DOI 10.1016/0031-9422(79)80120-X; Vazquez-Tello A, 1998, MOL GEN GENET, V257, P157, DOI 10.1007/s004380050635; Wang M. S., 1980, CHIN TRAD HERB DRUGS, V11, P49; Yang EB, 1999, BIOCHEM BIOPH RES CO, V260, P682, DOI 10.1006/bbrc.1999.0958; YANG YZ, 1992, AM J TROP MED HYG, V46, P15, DOI 10.4269/ajtmh.1992.46.15; Yesilada E, 2001, CYTOKINE, V13, P359, DOI 10.1006/cyto.2001.0838; [No title captured]	42	27	31	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6854	6861		10.1074/jbc.M209439200	http://dx.doi.org/10.1074/jbc.M209439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12480941	hybrid			2022-12-25	WOS:000181195100030
J	Spasojevic, I; Batinic-Haberle, I; Reboucas, JS; Idemori, YM; Fridovich, I				Spasojevic, I; Batinic-Haberle, I; Reboucas, JS; Idemori, YM; Fridovich, I			Electrostatic contribution in the catalysis of O-2((center dot)over-bar) dismutation by superoxide dismutase mimics - (MnTE)-T-III-2-PyP5+ VERSUS (MnBr8T)-Br-III-2-PyP+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION POTENTIALS; METAL-ION SPECIFICITY; MANGANESE PORPHYRINS; POTENTIOMETRIC TITRATIONS; REACTION-MECHANISM; REDOX POTENTIALS; AQUEOUS-MEDIA; COMPLEXES; COPPER; SITE	The Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)-porphyrin ((MnTE)-T-III-2-PyP5+) is a potent superoxide dismutase (SOD) mimic in vitro and was beneficial in rodent models of oxidative stress pathologies. Its high activity has been ascribed to both the favorable redox potential of its metal center and to the electrostatic facilitation assured by the four positive charges encircling the metal center. Its comparison with the non-alkylated, singly charged analogue Mn(III) beta-octabromo meso-tetrakis(2-pyridyl)porphyrin (Mn(III)Br(8)T2-PYP+) enabled us to evaluate the electrostatic contribution to the catalysis of O-2. dismutation. Both compounds exhibit nearly identical metal-centered redox potential for Mn-III/Mn-II redox couple: +228 mV for (MnTE)-T-III-2-PyP5+ and +219 mV versus NHE for (MnBr8T)-Br-III-2-PyP+. The eight electron-withdrawing beta pyrrolic bromines contribute equally to the redox properties of the parent (MnT)-T-III-2-PyP+ as do four quaternized cationic meso ortho pyridyl nitrogens. However, the SOD-like activity of the highly charged (MnTE)-T-III-2-PyP5+ is >100-fold higher (log k(cat) = 7.76) than that of the singly charged (MnBr8T)-Br-III-2-PyP+ (log k(cat) = 5.63). The kinetic salt effect showed that the catalytic rate constants of the (MnTE)-T-III-2-PyP5+ and of its methyl analogue, (MnTM)-T-III-2-PyP5+, are exactly 5-fold more sensitive to ionic strength than is the k(cat) of (MnBr8T)-Br-III-2-PyP+, which parallels the charge ratio of these compounds. Interestingly, only a small effect of ionic strength on the rate constant was found in the case of penta-charged para ((MnTM)-T-III-4-PyP5+) and meta isomers ((MnTM)-T-III-3-PyP5+), indicating that the placement of the positive charges in the close proximity of the metal center (ortho position) is essential for the electrostatic facilitation of O-2. dismutation.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Fed Minas Gerais, ICEx, Dept Quim, BR-31270901 Belo Horizonte, MG, Brazil	Duke University; Universidade Federal de Minas Gerais	Spasojevic, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	ivan@chem.duke.edu	Reboucas, Julio/B-6827-2008	Reboucas, Julio/0000-0003-3818-029X				Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; BARRETTE WC, 1983, BIOCHEMISTRY-US, V22, P624, DOI 10.1021/bi00272a015; Batinic-Haberle I, 1999, INORG CHEM, V38, P4011, DOI 10.1021/ic990118k; Batinic-Haberle I, 2002, FREE RADICAL BIO MED, V33, pS125; Batinic-Haberle I., 2001, International Journal of Radiation Oncology Biology Physics, V51, P235, DOI 10.1016/S0360-3016(01)02253-2; Batinic-Haberle I, 1998, J BIOL CHEM, V273, P24521, DOI 10.1074/jbc.273.38.24521; Batinic-Haberle I, 2002, J CHEM SOC DALTON, P2689, DOI 10.1039/b201057g; Batinic-Haberle I, 2002, METHOD ENZYMOL, V349, P223, DOI 10.1016/S0076-6879(02)49337-8; BatinicHaberle I, 1997, ARCH BIOCHEM BIOPHYS, V343, P225, DOI 10.1006/abbi.1997.0157; BENNETT LE, 1973, PROGR INORG CHEM, V18, P1; BHYRAPPA P, 1991, INORG CHEM, V30, P239, DOI 10.1021/ic00002a018; Bottino R, 2002, DIABETES, V51, P2561, DOI 10.2337/diabetes.51.8.2561; BOUCHER LJ, 1972, COORDIN CHEM REV, V7, P289, DOI 10.1016/S0010-8545(00)80024-7; BUTLER J, 1982, J BIOL CHEM, V257, P747; CARNIERI N, 1982, J CHEM SOC DALTON, P931, DOI 10.1039/dt9820000931; CHEN SM, 1990, J ELECTROANAL CHEM, V294, P151, DOI 10.1016/0022-0728(90)87142-7; Choudhury SB, 1999, BIOCHEMISTRY-US, V38, P3744, DOI 10.1021/bi982537j; CUDD A, 1982, J BIOL CHEM, V257, P1443; CUDD A, 1982, FEBS LETT, V144, P181, DOI 10.1016/0014-5793(82)80596-6; D'Souza F, 1998, INORG CHEM, V37, P4567, DOI 10.1021/ic980336y; DESIDERI A, 1988, FREE RADICAL BIO MED, V5, P313, DOI 10.1016/0891-5849(88)90102-5; DSOUZA F, 1993, INORG CHEM, V32, P4042, DOI 10.1021/ic00071a012; Edward RA, 1998, J AM CHEM SOC, V120, P9684, DOI 10.1021/ja981072h; Ellerby LM, 1996, J AM CHEM SOC, V118, P6556, DOI 10.1021/ja953845x; Espenson J.H., 1981, CHEM KINETICS REACTI, P172; FARAGGI M, 1984, OXYGEN RADICALS CHEM, P419; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GIRAUDEAU A, 1979, J AM CHEM SOC, V101, P3857, DOI 10.1021/ja00508a024; Han WG, 2002, INORG CHEM, V41, P205, DOI 10.1021/ic010355z; Hariprasad G, 1996, J CHEM SOC DALTON, P3429, DOI 10.1039/dt9960003429; HARRIMAN A, 1979, J CHEM SOC FARAD T 2, V75, P1543, DOI 10.1039/f29797501543; Jackson TA, 2002, J AM CHEM SOC, V124, P10833, DOI 10.1021/ja0266058; Jin N, 1999, J AM CHEM SOC, V121, P2923, DOI 10.1021/ja984429q; JORDAN RB, 1998, REACTION MECH INORGA, P188; Kachadourian R, 1999, INORG CHEM, V38, P391, DOI 10.1021/ic9808854; Kachadourian R, 1998, FREE RADICAL BIO MED, V25, pS17; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; Kolthoff IM, 1935, J PHYS CHEM-US, V39, P945, DOI 10.1021/j150367a004; Koppenol W.H., 1981, OXYGEN OXYRADICALS C, P671; LAWRENCE GD, 1979, BIOCHEMISTRY-US, V18, P3045, DOI 10.1021/bi00581a021; Liu MH, 1997, J ELECTROANAL CHEM, V426, P197, DOI 10.1016/S0022-0728(96)04968-6; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Piganelli JD, 2002, DIABETES, V51, P347, DOI 10.2337/diabetes.51.2.347; Reboucas JS, 2002, J PORPHYR PHTHALOCYA, V6, P50, DOI 10.1142/S1088424602000087; REDDY D, 1993, J CHEM SOC DALTON, P3575, DOI 10.1039/dt9930003575; RODGERS KR, 1992, INORG CHEM, V31, P2688, DOI 10.1021/ic00039a007; Schwartz AL, 2000, J INORG BIOCHEM, V80, P247, DOI 10.1016/S0162-0134(00)00086-6; Sheng HX, 2002, FREE RADICAL BIO MED, V33, pS436; Sheng HX, 2002, FREE RADICAL BIO MED, V33, P947, DOI 10.1016/S0891-5849(02)00979-6; SINES JJ, 1990, BIOCHEMISTRY-US, V29, P9403, DOI 10.1021/bi00492a014; Spasojevic I, 2002, INORG CHEM, V41, P5874, DOI 10.1021/ic025556x; Spasojevic I, 2001, INORG CHEM, V40, P726, DOI 10.1021/ic0004986; Spasojevic I, 2001, INORG CHIM ACTA, V317, P230, DOI 10.1016/S0020-1693(01)00365-6; Vance CK, 2001, BIOCHEMISTRY-US, V40, P13079, DOI 10.1021/bi0113317; Vance CK, 1998, J AM CHEM SOC, V120, P461, DOI 10.1021/ja972060j; Vujaskovic Z, 2002, FREE RADICAL BIO MED, V33, P857, DOI 10.1016/S0891-5849(02)00980-2; Vujaskovic Z, 2001, FREE RADICAL BIO MED, V31, pS128; VUJASKOVIC Z, 2001, P 48 ANN M RAD RES S, P161; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3; WOOD PM, 1988, BIOCHEM J, V253, P287, DOI 10.1042/bj2530287; Xie J, 2002, J AM CHEM SOC, V124, P3769, DOI 10.1021/ja016254h; Yikilmaz E, 2002, J AM CHEM SOC, V124, P3482, DOI 10.1021/ja011220v; Zhou HX, 1997, P NATL ACAD SCI USA, V94, P12372, DOI 10.1073/pnas.94.23.12372	66	65	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6831	6837		10.1074/jbc.M211346200	http://dx.doi.org/10.1074/jbc.M211346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12475974	hybrid			2022-12-25	WOS:000181195100027
J	Allen, S; Heath, PR; Kirby, J; Wharton, SB; Cookson, MR; Menzies, FM; Banks, RE; Shaw, PJ				Allen, S; Heath, PR; Kirby, J; Wharton, SB; Cookson, MR; Menzies, FM; Banks, RE; Shaw, PJ			Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MOUSE MODEL; SUPEROXIDE-DISMUTASE; SPINAL-CORD; DEPENDENT APOPTOSIS; OXIDATIVE STRESS; MOTOR-NEURONS; IN-VIVO; CU,ZN-SUPEROXIDE DISMUTASE; CEREBROSPINAL-FLUID; TYROSINE NITRATION	Injury to motor neurons associated with mutant Cu,Zn-superoxide dismutase (SOD1)-related familial amyotrophic lateral sclerosis (FALS) results from a toxic gain-of-function of the enzyme. The mechanisms by which alterations to SOD1 elicit neuronal death remain uncertain despite intensive research effort. Analysis of the cellular proteins that are differentially expressed in the presence of mutant SOD1 represents a novel approach to investigate further this toxic gain-of-function. By using the motor neuron-like cell line NSC34 stably transfected with wild-type, G93A, or G37R mutant human SOD1, we investigated the effects of mutant human SOD1 on protein expression using proteomic approaches. Seven up-regulated proteins were identified as argininosuccinate synthase, argininosuccinate lyase, neuronal nitric-oxide synthase, RNA-binding motif protein 3, peroxiredoxin 1, proteasome subunit 65 (X), and glutathione S-transferase (GST) Alpha 2. Seven downregulated proteins were identified as GST Mu 1, GST Mu 2, GST Mu 5, a hypothetical GST Mu, GST Pi B, leukotriene B-4 12-hydroxydehydrogenase, and proteasome subunit beta5i (LMP7). GST assays demonstrated a significant reduction in the total GST activity of cells expressing mutant human SOD1. Proteasome assays demonstrated significant reductions in chymotrypsin-like, trypsin-like, and post-glutamyl-hydrolase proteasome activities. Laser capture microdissection of spinal cord motor neurons from human FALS cases, in conjunction with reverse transcriptase-PCR, demonstrated decreased levels of mRNA encoding GST Mu 1, leukotriene 134 12-hydroxydehydrogenase, and LMP7. These combined approaches provide further evidence for involvement of alterations in antioxidant defenses, proteasome function, and nitric oxide metabolism in the pathophysiology of FALS.	Univ Sheffield, Div Genom Med, Acad Unit Neurol, Sheffield S10 2RX, S Yorkshire, England; Univ Sheffield, Div Genom Med, Acad Unit Pathol, Sheffield S10 2RX, S Yorkshire, England; NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; St James Univ Hosp, Ctr Clin Canc, Leeds LS9 7TF, W Yorkshire, England	University of Sheffield; University of Sheffield; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Saint James's University Hospital	Allen, S (corresponding author), Univ Sheffield, Div Genom Med, Acad Unit Neurol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.		Wharton, Stephen B/B-5117-2009; Kirby, Janine/B-3980-2009; Cookson, Mark/AAW-2516-2021; Shaw, Pamela J/A-7620-2010; Shaw, Pamela/E-6193-2010; Shaw, Pamela J/A-5215-2009	Wharton, Stephen B/0000-0003-2785-333X; Kirby, Janine/0000-0002-7468-5917; Cookson, Mark/0000-0002-1058-3831; Shaw, Pamela/0000-0002-8925-2567; Banks, Rosamonde/0000-0002-0042-8715	NATIONAL INSTITUTE ON AGING [ZIAAG000953, Z01AG000953] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Almer G, 1999, J NEUROCHEM, V72, P2415, DOI 10.1046/j.1471-4159.1999.0722415.x; ANDERSON JW, 1983, PLANTA, V158, P442, DOI 10.1007/BF00397738; Arnott D, 1998, ANAL BIOCHEM, V258, P1, DOI 10.1006/abio.1998.2566; Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Beckman JS, 2001, TRENDS NEUROSCI, V24, pS15, DOI 10.1016/S0166-2236(00)01981-0; Beyette J, 1998, BIOCHEM J, V332, P315, DOI 10.1042/bj3320315; Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Cookson MR, 2002, AMYOTROPH LATERAL SC, V3, P75, DOI 10.1080/146608202760196048; Crow JP, 1997, J NEUROCHEM, V69, P1936; Dick RA, 2001, J BIOL CHEM, V276, P40803, DOI 10.1074/jbc.M105487200; Ding QX, 2002, J BIOL CHEM, V277, P13935, DOI 10.1074/jbc.M107706200; Doroudchi MM, 2001, NEUROREPORT, V12, P1239, DOI 10.1097/00001756-200105080-00037; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Engidawork E, 2001, J NEURAL TRANSM-SUPP, P117; Estevez AG, 1998, J NEUROSCI, V18, P923; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Facchinetti F, 1999, NEUROSCIENCE, V90, P1483, DOI 10.1016/S0306-4522(98)00492-8; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Ghadge GD, 1997, J NEUROSCI, V17, P8756; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; KASHIWADO K, 2002, BIOL PSYCHIAT, V26, P163; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kingsbury DJ, 2000, J BIOL CHEM, V275, P24156, DOI 10.1074/jbc.M001742200; Kirby J, 2002, HUM MOL GENET, V11, P2061, DOI 10.1093/hmg/11.17.2061; Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Linnebank M, 2000, J INHERIT METAB DIS, V23, P308, DOI 10.1023/A:1005690005439; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; MATHER K, 1993, NEUROPATH APPL NEURO, V19, P141, DOI 10.1111/j.1365-2990.1993.tb00419.x; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; Mitsumoto A, 2001, FREE RADICAL BIO MED, V30, P625, DOI 10.1016/S0891-5849(00)00503-7; Mori M, 2000, BIOCHEM BIOPH RES CO, V275, P715, DOI 10.1006/bbrc.2000.3169; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; Olsen MK, 2001, ANN NEUROL, V50, P730, DOI 10.1002/ana.1252; Paxinou E, 2001, P NATL ACAD SCI USA, V98, P11575, DOI 10.1073/pnas.201293198; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Phul RK, 2000, AMYOTROPH LATERAL SC, V1, P259, DOI 10.1080/14660820050515089; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rabilloud T, 2001, PROTEOMICS, V1, P1105, DOI 10.1002/1615-9861(200109)1:9<1105::AID-PROT1105>3.0.CO;2-M; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sathasivam S, 2001, NEUROPATH APPL NEURO, V27, P257, DOI 10.1046/j.0305-1846.2001.00332.x; SHAW PJ, 1995, ANN NEUROL, V38, P691, DOI 10.1002/ana.410380424; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shibata N, 2000, ACTA NEUROPATHOL, V100, P275, DOI 10.1007/s004019900173; Smith RG, 1998, ANN NEUROL, V44, P696, DOI 10.1002/ana.410440419; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tohgi H, 1999, ANN NEUROL, V46, P129, DOI 10.1002/1531-8249(199907)46:1<129::AID-ANA21>3.0.CO;2-Y; Upton-Rice MN, 1999, ANN NEUROL, V45, P413, DOI 10.1002/1531-8249(199903)45:3<413::AID-ANA24>3.0.CO;2-5; Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xie CS, 1998, FREE RADICAL BIO MED, V25, P979, DOI 10.1016/S0891-5849(98)00186-5; Xie CS, 2001, FREE RADICAL BIO MED, V31, P73, DOI 10.1016/S0891-5849(01)00553-6; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x	74	91	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6371	6383		10.1074/jbc.M209915200	http://dx.doi.org/10.1074/jbc.M209915200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12475980	hybrid			2022-12-25	WOS:000181129400111
J	Bessho, T				Bessho, T			Induction of DNA replication-mediated double strand breaks by psoralen DNA interstrand cross-links	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; RECOMBINATION; INITIATION; XPF-ERCC1; ERCC1-XPF; NUCLEASES; PROMOTES; DAMAGE	The effect of DNA interstrand cross-links (cross-links) on DNA replication was examined with a cell-free SV40 origin-dependent DNA replication system. A defined template DNA with a single psoralen cross-link and the SV40 origin of replication was replicated by HeLa cell-free extract in the presence of SV40 large T antigen. The psoralen cross-link inhibited DNA replication by terminating chain elongation at 1-50 nucleotides before the cross-linked sites. The termination of DNA replication by the cross-links mediated the generation of double strand breaks near the cross-linked sites. These results are the first biochemical evidence of the generation of double strand breaks by DNA replication.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Bessho, T (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	besshot@uthscsa.edu						Adair GR, 2000, EMBO J, V19, P5552, DOI 10.1093/emboj/19.20.5552; Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Bessho T, 1997, MOL CELL BIOL, V17, P6822, DOI 10.1128/MCB.17.12.6822; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; CHENG S, 1988, J BIOL CHEM, V263, P15110; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Li L, 1999, MOL CELL BIOL, V19, P5619; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; Niedernhofer LJ, 2001, EMBO J, V20, P6540, DOI 10.1093/emboj/20.22.6540; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Thompson LH, 1996, MUTAT RES-DNA REPAIR, V363, P77, DOI 10.1016/0921-8777(96)00008-0; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; Zhang NX, 2002, MOL CELL BIOL, V22, P2388, DOI 10.1128/MCB.22.7.2388-2397.2002	27	75	76	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5250	5254		10.1074/jbc.M212323200	http://dx.doi.org/10.1074/jbc.M212323200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473662	hybrid			2022-12-25	WOS:000180968900114
J	Inoue, A; Ikebe, M				Inoue, A; Ikebe, M			Characterization of the motor activity of mammalian myosin VIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; REGULATORY LIGHT-CHAIN; ACTIN-BASED MOTOR; USHER 1B SYNDROME; UNCONVENTIONAL MYOSIN; SENSORY EPITHELIA; GENE-PRODUCT; DEAFNESS; EXPRESSION; COMPLEX	Myosin VIIA was cloned from rat kidney, and the construct (M7IQ5) containing the motor domain, IQ domain, and the coiled-coil domain as well as the full-length myosin VIIA (M7full) was expressed. The M7IQ5 contained five calmodulins. Based upon native gel electrophoresis and gel filtration, it was found that M7IQ5 was single-headed, whereas M7full was two-headed, suggesting that the tail domain contributes to form the two-headed structure. M7IQ5 had Mg2+-ATPase activity that was markedly activated by actin with K-actin of 33 mum and V-max of 0.53 s(-1) head(-1). Myosin VIIA required an extremely high ATP concentration for ATPase activity, ATP-induced dissociation from actin, and in vitro actin-translocating activity. ADP markedly inhibited the actin-activated ATPase activity. ADP also significantly inhibited the ATP-induced dissociation of myosin VIIA from actin. Consistently, ADP decreased K-actin of the actin-activated ATPase. ADP decreased the actin gliding velocity, although ADP did not stop the actin gliding even at high concentration. These results suggest that myosin VIIA has slow ATP binding or low affinity for ATP and relatively high affinity for ADP. The directionality of myosin VIIA was determined by using the polarity-marked dual fluorescence-labeled actin filaments. It was found that myosin VIIA is a plus-directed motor.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60381] Funding Source: Medline; NIAMS NIH HHS [AR 41653] Funding Source: Medline; NIGMS NIH HHS [GM 58834] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker JP, 1997, J MOL BIOL, V272, P523, DOI 10.1006/jmbi.1997.1232; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; CHEN TL, 1991, J CELL BIOL, V115, P330; Chen ZY, 1996, GENOMICS, V36, P440, DOI 10.1006/geno.1996.0489; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Ernest S, 2000, HUM MOL GENET, V9, P2189, DOI 10.1093/hmg/9.14.2189; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Hodge T, 2000, J CELL SCI, V113, P3353; HOH JFY, 1976, BIOCHEM J, V157, P87, DOI 10.1042/bj1570087; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Inoue A, 2000, MOL BIOL CELL, V11, p375A; Kussel-Andermann P, 2000, EMBO J, V19, P6020, DOI 10.1093/emboj/19.22.6020; Kussel-Andermann P, 2000, J BIOL CHEM, V275, P29654, DOI 10.1074/jbc.M004393200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Sahly I, 1997, ANAT EMBRYOL, V196, P159, DOI 10.1007/s004290050088; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Solc CK, 1994, AUDIT NEUROSCI, V1, P63; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Todorov PT, 2001, BIOCHEM J, V354, P267, DOI 10.1042/0264-6021:3540267; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; Udovichenko IP, 2002, J CELL SCI, V115, P445; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Wolfrum U, 1998, CELL MOTIL CYTOSKEL, V40, P261, DOI 10.1002/(SICI)1097-0169(1998)40:3<261::AID-CM5>3.3.CO;2-#; Yamashita RA, 2000, J MUSCLE RES CELL M, V21, P491, DOI 10.1023/A:1026589626422; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	56	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5478	5487		10.1074/jbc.M210489200	http://dx.doi.org/10.1074/jbc.M210489200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466270	hybrid			2022-12-25	WOS:000180968900141
J	Suh, MH; Pulakat, L; Gavini, N				Suh, MH; Pulakat, L; Gavini, N			Functional expression of a fusion-dimeric MoFe protein of nitrogenase in Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-IRON PROTEIN; CRYSTALLOGRAPHIC STRUCTURE; MUTATIONAL ANALYSIS; COFACTOR SYNTHESIS; ELECTRON-TRANSFER; CLUSTER; FIXATION; COMPLEX; CENTERS; GENES	The MoFe protein component of the complex metalloenzyme nitrogenase is an alpha2beta2 tetramer encoded by the nifD and the nifK genes. In nitrogen fixing organisms, the alpha and beta subunits are translated as separate polypeptides and then assembled into tetrameric MoFe protein complex that includes two types of metal centers, the P cluster and the FeMo cofactor. In Azotobacter vinelandii, the NifEN complex, the site for biosynthesis of the FeMo cofactor, is an alpha2beta2 tetramer that is structurally similar to the MoFe protein and encoded as two separate polypeptides by the nifE and the nifN genes. In Anabaena variabilis it was shown that a NifE-N fusion protein encoded by translationally fused nifE and nifN genes can support biological nitrogen fixation. The structural similarity between the MoFe protein and the NifEN complex prompted us to test whether the MoFe protein could also be functional when synthesized as a single protein encoded by nifD-K translational fusion. Here we report that the NifD-K fusion protein encoded by nifD-K translational fusion in A. vinelandii is a large protein (as determined by Western blot analysis) and is capable of supporting biological nitrogen fixation. These results imply that the MoFe protein is flexible in that it can accommodate major structural changes and remain functional.	Bowling Green State Univ, Dept Biol Sci, Bowling Green, OH 43403 USA	University System of Ohio; Bowling Green State University	Gavini, N (corresponding author), Bowling Green State Univ, Dept Biol Sci, Bowling Green, OH 43403 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM057636] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57636] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CHEN L, 1994, J BIOL CHEM, V269, P3290; Christiansen J, 2001, ANNU REV PLANT PHYS, V52, P269, DOI 10.1146/annurev.arplant.52.1.269; CHRISTIANSEN J, 2000, USE AMINO ACID SUBST, P101; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; Fani R, 2000, J MOL EVOL, V51, P1; Gavini N, 1997, BIOCHEM BIOPH RES CO, V240, P153, DOI 10.1006/bbrc.1997.7545; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; HOWARD JB, 2000, STRUCTURE NITROGENAS, P43; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PETERS JW, 1995, J BIOL CHEM, V270, P27007, DOI 10.1074/jbc.270.45.27007; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; Pulakat L, 1996, J BIOL CHEM, V271, P1884, DOI 10.1074/jbc.271.4.1884; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Sambrook J., 2002, MOL CLONING LAB MANU; Suh MH, 2002, BIOCHEM BIOPH RES CO, V299, P233, DOI 10.1016/S0006-291X(02)02620-7; Suh MH, 2000, GENETICA, V110, P101, DOI 10.1023/A:1017976920135; THIEL T, 1995, P NATL ACAD SCI USA, V92, P9358, DOI 10.1073/pnas.92.20.9358	35	10	11	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5353	5360		10.1074/jbc.M208969200	http://dx.doi.org/10.1074/jbc.M208969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12468552	hybrid			2022-12-25	WOS:000180968900127
J	Ghelli, A; Zanna, C; Porcelli, AM; Schapira, AHV; Martinuzzi, A; Carelli, V; Rugolo, M				Ghelli, A; Zanna, C; Porcelli, AM; Schapira, AHV; Martinuzzi, A; Carelli, V; Rugolo, M			Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; DNA; PROTEIN; DEGENERATION; DYSFUNCTION; EXPRESSION; DEFECTS; CALCIUM; PATHWAY; GROWTH	Leber's hereditary optic neuropathy (LHON), a maternally inherited form of central vision loss, is associated with mitochondrial DNA pathogenic point mutations affecting different subunits of complex I. We here report that osteosarcoma-derived cytoplasmic hybrids (cybrid) cell lines harboring one of the three most frequent LHON pathogenic mutations, at positions 11778/ND4, 3460/ND1, and 14484/ND6, undergo cell death when galactose replaces glucose in the medium, contrary to control cybrids that maintain some growth capabilities. This is a well known way to produce a metabolic stress, forcing the cells to rely on the mitochondrial respiratory chain to produce ATP. We demonstrate that LHON cybrid cell death is apoptotic, showing chromatin condensation and nuclear DNA laddering. Moreover, we also document the mitochondrial involvement in the activation of the apoptotic cascade, as shown by the increased release of cytochrome c into the cytosol in LHON cybrid cells as compared with controls. Cybrids bearing the 3460/ND1 and 14484/ND6 mutations seemed more readily prone to undergo apoptosis as compared with the 11778/ND4 mutation. In conclusion, LHON cybrid cells forced by the reduced rate of glycolytic flux to utilize oxidative metabolism are sensitized to an apoptotic death through a mechanism involving mitochondria.	Univ Bologna, Dipartimento Biol Evolutionist Speriementale, I-40126 Bologna, Italy; Univ London, Royal Free & Univ Coll Med Sch, Dept Clin Neurosci, London NW3 2PF, England; IRCCS E Meda, I-31015 Treviso, Italy; Univ Bologna, Dipartimento Sci Neurol, I-40123 Bologna, Italy	University of Bologna; University of London; University College London; University of Bologna	Ghelli, A (corresponding author), Univ Bologna, Dipartimento Biol Evolutionist Speriementale, Via Irnerio 42, I-40126 Bologna, Italy.	ghelli@alma.unibo.it	Zanna, Claudia/GVT-1932-2022; Rugolo, Michela/AAY-8640-2020; Schapira, Anthony H V/A-1245-2010; Martinuzzi, Andrea/AAC-3127-2022; Martinuzzi, Andrea/K-3887-2016	Schapira, Anthony H V/0000-0002-3018-3966; Martinuzzi, Andrea/0000-0002-0319-3579; Porcelli, Anna Maria/0000-0002-6209-0692; CARELLI, VALERIO/0000-0003-4923-6404; Rugolo, Michela/0000-0002-4597-0452; GHELLI, ANNA MARIA/0000-0003-0830-0000	Telethon [GGP02323] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BERRIDGE MV, 1996, BIOCHEMICA, V4, P15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8; Brown MD, 1999, J NEUROL SCI, V165, P1, DOI 10.1016/S0022-510X(99)00087-8; Brown MD, 2000, J BIOL CHEM, V275, P39831, DOI 10.1074/jbc.M006476200; Carelli V, 2002, BBA-MOL BASIS DIS, V1588, P7, DOI 10.1016/S0925-4439(02)00097-2; Carelli V, 1999, ANN NEUROL, V45, P320, DOI 10.1002/1531-8249(199903)45:3<320::AID-ANA7>3.0.CO;2-L; Carelli V, 2002, NEUROLOGY, V58, pA507; Carelli V, 1997, NEUROLOGY, V48, P1623, DOI 10.1212/WNL.48.6.1623; Carelli V, 2002, NEUROCHEM INT, V40, P573, DOI 10.1016/S0197-0186(01)00129-2; Carelli V, 2002, MITOCHONDRIAL DISORD, V26, P115; Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209; Cock HR, 1998, ANN NEUROL, V44, P187, DOI 10.1002/ana.410440208; Danielson SR, 2002, J BIOL CHEM, V277, P5810, DOI 10.1074/jbc.M110119200; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Gorman A., 1996, TECHNIQUES APOPTOSIS, P2; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; HOLLEY RW, 1974, P NATL ACAD SCI USA, V71, P2942, DOI 10.1073/pnas.71.8.2942; Howell N, 1997, J BIOENERG BIOMEMBR, V29, P165, DOI 10.1023/A:1022690030664; Howell N, 1999, INT REV CYTOL, V186, P49; Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010; Kim JY, 2002, ANN NEUROL, V51, P630, DOI 10.1002/ana.10177; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MURGIA M, 1992, J BIOL CHEM, V267, P10939; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Porcelli AM, 2001, METHOD CELL BIOL, V65, P353, DOI 10.1016/S0091-679X(01)65021-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Robinson B H, 1996, Methods Enzymol, V264, P454, DOI 10.1016/S0076-6879(96)64041-5; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Valentino ML, 2002, ANN NEUROL, V51, P774, DOI 10.1002/ana.10193; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VERGANI L, 1995, BIOCHEM BIOPH RES CO, V210, P880, DOI 10.1006/bbrc.1995.1740; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431; Wong A, 1997, BIOCHEM BIOPH RES CO, V239, P139, DOI 10.1006/bbrc.1997.7443	44	153	158	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4145	4150		10.1074/jbc.M210285200	http://dx.doi.org/10.1074/jbc.M210285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12446713	hybrid			2022-12-25	WOS:000180869700081
J	Granboulan, M; Lankar, D; Raposo, G; Bonnerot, C; Hivroz, C				Granboulan, M; Lankar, D; Raposo, G; Bonnerot, C; Hivroz, C			Phosphoinositide 3-kinase activation by Ig beta controls de Novo formation of an antigen-processing compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; RECEPTOR; CELL; COMPLEX; ALPHA; IMMUNOGLOBULIN	Antigens that bind B cell antigen receptor (BCR) are preferentially and rapidly processed for antigen presentation. The BCR is a multimeric complex containing a signaling module composed of Igalpha and Igbeta. Signaling pathways implicated in antigen presentation through the BCR are ill defined. Here we demonstrate that phosphoinositide 3-kinase (PI3K) inhibitors preclude antigen presentation induced by BCR or Igbeta but not Iga. Unraveling the mechanisms responsible for this inhibition, we show that PI3K inhibitors block neither antigen internalization nor degradation. Rather PI3K inhibitors block de novo formation of a multivesicular antigen processing compartment, which is induced by triggering of the BCR or Igbeta. Strikingly, we found using fluorescent probes binding specifically to PI3K products that BCR and Igbeta but not Iga induce PI3K activation in endocytic compartments wherein antigen is transported. Altogether, these results strongly suggest that Igbeta couples the BCR to PI3K activation that is instrumental for de novo formation of the antigen processing compartment and efficient antigen presentation.	Inst Curie, INSERM U520, F-75248 Paris 05, France; Inst Curie, UMR 144, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Hivroz, C (corresponding author), Inst Curie, INSERM U520, 26 Rue Ulm, F-75248 Paris 05, France.	claire.hivroz@curie.fr	Hivroz, Claire/H-2711-2014	Hivroz, Claire/0000-0002-6794-2890				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Barois N, 1997, J BIOL CHEM, V272, P3641, DOI 10.1074/jbc.272.6.3641; Boeddinghaus C, 2002, J CELL BIOL, V157, P79, DOI 10.1083/jcb.200112098; BONNEROT C, 1995, IMMUNITY, V3, P335, DOI 10.1016/1074-7613(95)90118-3; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; Cassard S, 1998, J IMMUNOL, V160, P1767; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; Drake JR, 1997, J EXP MED, V186, P1299, DOI 10.1084/jem.186.8.1299; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; GOLD MR, 1992, J IMMUNOL, V148, P2012; Jacob A, 2002, J BIOL CHEM, V277, P23420, DOI 10.1074/jbc.M202485200; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Lang ML, 2001, J IMMUNOL, V166, P5585, DOI 10.4049/jimmunol.166.9.5585; Lankar D, 1998, J EXP MED, V188, P819, DOI 10.1084/jem.188.5.819; Lankar D, 2002, J EXP MED, V195, P461, DOI 10.1084/jem.20011543; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; Mellman I, 1998, TRENDS CELL BIOL, V8, P231, DOI 10.1016/S0962-8924(98)01276-8; MITCHELL RN, 1995, J EXP MED, V181, P1705, DOI 10.1084/jem.181.5.1705; Okkenhaug K, 2002, SCIENCE, V297, P1031; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; Raposo G, 1997, HDB EXPT IMMUNOLOGY, V4, P1; Reaves BJ, 1996, J CELL SCI, V109, P749; Schamel WWA, 2000, IMMUNITY, V13, P5, DOI 10.1016/S1074-7613(00)00003-0; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; Siemasko K, 2002, J IMMUNOL, V168, P2127, DOI 10.4049/jimmunol.168.5.2127; Siemasko K, 1998, J IMMUNOL, V160, P5203; Song WX, 1997, INT IMMUNOL, V9, P1709, DOI 10.1093/intimm/9.11.1709; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	46	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4331	4338		10.1074/jbc.M209885200	http://dx.doi.org/10.1074/jbc.M209885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12459553	hybrid			2022-12-25	WOS:000180869700101
J	Jaiswal, AS; Marlow, BP; Gupta, N; Narayan, S				Jaiswal, AS; Marlow, BP; Gupta, N; Narayan, S			beta-Catenin-mediated transactivation and cell - cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells	ONCOGENE			English	Article						curcumin; caspase-3; beta-catenin; c-Myc; cell-cell adhesion; G(2)/M arrest; apoptosis	C-MYC; ADENOMATOUS POLYPOSIS; CARCINOMA-CELLS; IN-VITRO; P53-DEPENDENT APOPTOSIS; ADHERENS JUNCTIONS; DIETARY CURCUMIN; CYCLE ARREST; APC PROTEIN; E-CADHERIN	The development of nontoxic natural agents with chemopreventive activity against colon cancer is the focus of investigation in many laboratories. Curcumin (feruylmethane), a natural plant product, possesses such chemopreventive activity, but the mechanisms by which it prevents cancer growth are not well understood. In the present study, we examined the mechanisms by which curcumin treatment affects the growth of colon cancer cells in vitro. Results showed that curcumin treatment causes p53- and p21-independent G(2)/M phase arrest and apoptosis in HCT-116(p53(+/+)), HCT-116(p53(-/-)) and HCT-116(p21(-/-)) cell lines. We further investigated the association of the beta-catenin-mediated c-Myc expression and the cell-cell adhesion pathways in curcumin-induced G(2)/M arrest and apoptosis in HCT-116 cells. Results described a caspase-3-mediated cleavage of beta-catenin, decreased transactivation of beta-catenin/Tcf-Lef, decreased promoter DNA binding activity of the beta-catenin/Tcf-Lef complex, and decreased levels of c-Myc protein. These activities were linked with decreased Cdc2/cyclin B1 kinase activity, a function of the G2/M phase arrest. The decreased transactivation of beta-catenin in curcumin-treated HCT-116 cells was unpreventable by caspase-3 inhibitor Z-DEVD-fmk, even though the curcumin-induced cleavage of beta-catenin was blocked in Z-DEVD-fmk pretreated cells. The curcumin treatment also induced caspase-3-mediated degradation of cell-cell adhesion proteins beta-catenin, E-cadherin and APC, which were linked with apoptosis, and this degradation was prevented with the caspase-3 inhibitor. Our results suggest that curcumin treatment impairs both Wnt signaling and cell-cell adhesion pathways, resulting in G(2)/M phase arrest and apoptosis in HCT-116 cells.	Univ Florida, UF Shands Canc Ctr, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, UF Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Narayan, S (corresponding author), Univ Florida, Coll Med, UF Shands Canc Ctr, Acad Res Bldg,Room R4-216,POB 100232, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu			NCI NIH HHS [CA77721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bordonaro M, 1999, CELL GROWTH DIFFER, V10, P713; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; BROWNE SJ, 1994, INT J CANCER, V59, P56, DOI 10.1002/ijc.2910590113; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; BUSH JA, 2001, ONCOGENE, V20, P7597; Chan TA, 2000, GENE DEV, V14, P1584; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Citro G, 1998, CANCER RES, V58, P283; Clement MV, 1998, BLOOD, V92, P996; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Goel A, 2001, CANCER LETT, V172, P111, DOI 10.1016/S0304-3835(01)00655-3; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heatwole V M, 1999, Methods Mol Biol, V115, P141; Huang MT, 1997, J CELL BIOCHEM, P26; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; INOUE M, 1994, BIOCHEM BIOPH RES CO, V204, P898, DOI 10.1006/bbrc.1994.2544; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523-1747.1998.00352.x; Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468; Kawamori T, 1999, CANCER RES, V59, P597; KELLOFF GJ, 1994, CANCER RES, V54, pS2015; Kelloff GJ, 1996, J CELL BIOCHEM, P54, DOI 10.1002/jcb.240630705; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KUTTAN R, 1987, TUMORI, V73, P29, DOI 10.1177/030089168707300105; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; Ling YH, 2001, MOL PHARMACOL, V59, P593, DOI 10.1124/mol.59.3.593; Mahmoud NN, 2000, CARCINOGENESIS, V21, P921, DOI 10.1093/carcin/21.5.921; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Manson MM, 2000, TOXICOL LETT, V112, P499, DOI 10.1016/S0378-4274(99)00211-8; McCarty MF, 2001, MED HYPOTHESES, V56, P137, DOI 10.1054/mehy.2000.1126; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Moragoda L, 2001, ANTICANCER RES, V21, P873; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2001, BRIT J CANCER, V85, P898, DOI 10.1054/bjoc.2001.2002; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Pereira MA, 1999, ADV EXP MED BIOL, V470, P55; Phan TT, 2001, J TRAUMA, V51, P927, DOI 10.1097/00005373-200111000-00017; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Polakis P, 2000, GENE DEV, V14, P1837; RAO CV, 1995, CANCER RES, V55, P259; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Schmeiser K, 1999, CELL DEATH DIFFER, V6, P377, DOI 10.1038/sj.cdd.4400504; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Sharma RA, 2001, CLIN CANCER RES, V7, P1894; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wargovich MJ, 1997, CANCER LETT, V114, P11, DOI 10.1016/S0304-3835(97)04616-8; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	70	293	317	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8414	8427		10.1038/sj.onc.1205947	http://dx.doi.org/10.1038/sj.onc.1205947			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466962				2022-12-25	WOS:000179480100005
J	Karpowich, NK; Huang, HH; Smith, PC; Hunt, JF				Karpowich, NK; Huang, HH; Smith, PC; Hunt, JF			Crystal structures of the BtuF periplasmic-binding protein for vitamin B12 suggest a functionally important reduction in protein mobility upon ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREPONEMA-PALLIDUM TROA; ACTIVE-TRANSPORT; ATP-BINDING; BIOSYNTHESIS; RESOLUTION; MECHANISM; MOLSCRIPT; REVEALS; PROGRAM; DOMAINS	BtuF is the periplasmic binding protein (PBP) for the vitamin B12 transporter BtuCD, a member of the ATP-binding cassette (ABC) transporter superfamily of transmembrane pumps. We have determined crystal structures of Escherichia coli BtuF in the apo state at 3.0 A resolution and with vitamin B12 bound at 2.0 Angstrom resolution. The structure of BtuF is similar to that of the FhuD and TroA PBPs and is composed of two alpha/beta domains linked by a rigid alpha-helix. B12 is bound in the "base-on" or vitamin conformation in a wide acidic cleft located between these domains. The C-terminal domain shares structural homology to a B12-binding domain found in a variety of enzymes. The same surface of this domain interacts with opposite surfaces of B12 when comparing ligand-bound structures of BtuF and the homologous enzymes, a change that is probably caused by the obstruction of the face that typically interacts with this domain by the base-on conformation of vitamin B12 bound to BtuF. There is no apparent pseudo-symmetry in the surface properties of the BtuF domains flanking its B12 binding site even though the presumed transport site in the previously reported crystal structure of BtuCD is located in an intersubunit interface with 2-fold symmetry. Unwinding of an alpha-helix in the C-terminal domain of BtuF appears to be part of conformational change involving a general increase in the mobility of this domain in the apo structure compared with the B12-bound structure. As this helix is located on the surface likely to interact with BtuC, unwinding of the helix upon binding to BtuC could play a role in triggering release of B12 into the transport cavity. Furthermore, the high mobility of this domain in free BtuF could provide an entropic driving force for the subsequent release of BtuF required to complete the transport cycle.	Columbia Univ, Dept Biol Sci, Fairchild Ctr 702A, New York, NY 10027 USA	Columbia University	Hunt, JF (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild Ctr 702A, MC2434, New York, NY 10027 USA.	hunt@sid.bio.columbia.edu		Smith, Paul/0000-0003-4098-4588				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASSFORD PJ, 1977, J BACTERIOL, V132, P796, DOI 10.1128/JB.132.3.796-805.1977; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Cadieux N, 2002, J BACTERIOL, V184, P706, DOI 10.1128/JB.184.3.706-717.2002; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Drenth J, 1994, PRINCIPLES PROTEIN X; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; Lee YH, 2002, J BACTERIOL, V184, P2300, DOI 10.1128/JB.184.8.2300-2304.2002; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Martens JH, 2002, APPL MICROBIOL BIOT, V58, P275, DOI 10.1007/s00253-001-0902-7; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3213; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; Raux E, 2000, CELL MOL LIFE SCI, V57, P1880, DOI 10.1007/PL00000670; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wolf A, 1996, J BIOL CHEM, V271, P21243, DOI 10.1074/jbc.271.35.21243	39	124	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8429	8434		10.1074/jbc.M212239200	http://dx.doi.org/10.1074/jbc.M212239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12468528	hybrid			2022-12-25	WOS:000181466800089
J	Wheeler, MD; Thurman, RG				Wheeler, MD; Thurman, RG			Up-regulation of CD14 in liver caused by acute ethanol involves oxidant-dependent AP-1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTOR-4; KUPFFER CELLS; BACTERIAL LIPOPOLYSACCHARIDE; PROTEIN-KINASE; ALCOHOL; GENE; TRANSCRIPTION; ENDOTOXIN; SENSITIZATION	Ethanol is known to cause both tolerance and sensitization to endotoxin (lipopolysaccharide). It is also known that ethanol modulates the expression and activity of several intracellular signaling molecules and transcription factors in monocytes and Kupffer cells, the resident hepatic macrophages. Expression of CD14, the endotoxin receptor, is up-regulated following chronic exposure to endotoxin and ethanol. Ethanol-induced oxidative stress is important in the regulation of transcription factor activation and cytokine production by Kupffer cells. Thus, it was hypothesized that acute ethanol increases CD14 expression through a mechanism dependent upon oxidant production. This hypothesis was tested by overexpression of superoxide dismutase via recombinant adenovirus. Mice were infected with adenovirus (3 X 10(9) plaque-forming units, intravenously) containing either Cu,Zn superoxide dismutase (Ad.SOD1) or beta-galactosidase (Ad.lacZ), which caused significant expression of Cu,Zn-SOD in hepatocytes and Kupffer cells. Three days post-infection, mice were given saline or ethanol (5 g/kg, intragastrically). A significant increase in CD14 mRNA was observed 3 h after ethanol, and this increase was almost completely blocked in mice overexpressing Cu,Zn-SOD. Additionally, overexpression of SOD also blunted ethanol-induced activation of redox-sensitive transcription factors NFkappaB and AP-1 and production of cytokines. However, only inhibition of AP-1 with dominant-negative TAK1 but not NFkappaB by dominant-negative IkappaBalpha significantly blunted ethanol-induced increases in CD14, suggesting that AP-1 is important for CD14 transcriptional regulation. It is also shown here that NADPH oxidase is important in the increase in CD14 due to ethanol. Moreover, these data suggest that acute ethanol causes sensitization to endotoxin through mechanisms dependent upon oxidative stress.	Univ N Carolina, Dept Pharmacol, Hepatobiol & Toxicol Curriculum Toxicol Lab, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Wheeler, MD (corresponding author), Univ N Carolina, Dept Pharmacol, Hepatobiol & Toxicol Curriculum Toxicol Lab, CB 7365,Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	wheelmi@med.unc.edu						Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Enomoto N, 2001, ALCOHOL CLIN EXP RES, V25, p51S, DOI 10.1097/00000374-200106001-00012; Enomoto N, 1998, GASTROENTEROLOGY, V115, P443, DOI 10.1016/S0016-5085(98)70211-2; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; HAZIOT A, 1988, J IMMUNOL, V141, P547; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Jarvelainen HA, 2001, HEPATOLOGY, V33, P1148, DOI 10.1053/jhep.2001.24236; Kishore R, 2002, AM J PHYSIOL-GASTR L, V282, pG6, DOI 10.1152/ajpgi.00328.2001; Kono H, 2000, AM J PHYSIOL-GASTR L, V278, pG652, DOI 10.1152/ajpgi.2000.278.4.G652; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liu SB, 2000, GENE, V250, P137, DOI 10.1016/S0378-1119(00)00179-7; Mandrekar P, 1997, ALCOHOL CLIN EXP RES, V21, P988, DOI 10.1111/j.1530-0277.1997.tb04242.x; MATSUURA K, 1992, J BIOL CHEM, V267, P21787; RIGBY PWJ, 1983, J GEN VIROL, V64, P255, DOI 10.1099/0022-1317-64-2-255; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; Rusyn I, 1998, CARCINOGENESIS, V19, P1217, DOI 10.1093/carcin/19.7.1217; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMEDSROD B, 1985, J LEUKOCYTE BIOL, V38, P213, DOI 10.1002/jlb.38.2.213; Tewes F, 1997, EUR J IMMUNOL, V27, P3015, DOI 10.1002/eji.1830271139; Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270-2276.2001; Wheeler MD, 2001, J LEUKOCYTE BIOL, V69, P622; Yamashina S, 2000, BIOCHEM BIOPH RES CO, V277, P686, DOI 10.1006/bbrc.2000.3738; Yin M, 2001, J IMMUNOL, V166, P4737, DOI 10.4049/jimmunol.166.7.4737; Yoshimura A, 1999, J IMMUNOL, V163, P1; ZABEL U, 1991, J BIOL CHEM, V266, P252	29	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8435	8441		10.1074/jbc.M212076200	http://dx.doi.org/10.1074/jbc.M212076200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12482856	hybrid, Green Published			2022-12-25	WOS:000181466800090
J	Borza, T; Iancu, CV; Pike, E; Honzatko, RB; Fromm, HJ				Borza, T; Iancu, CV; Pike, E; Honzatko, RB; Fromm, HJ			Variations in the response of mouse isozymes of adenylosuccinate synthetase to inhibitors of physiological relevance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOTIDE CYCLE; HUMAN SKELETAL-MUSCLE; AMMONIA PRODUCTION; MOLECULAR-CLONING; AMP DEAMINATION; IMP REAMINATION; ACTIVE-SITE; PURIFICATION; COMPLEXES; BINDING	Vertebrates have acidic and basic isozymes of adenylosuceinate synthetase, which participate in the first committed step of de novo AMP biosynthesis and/or the purine nucleotide cycle. These isozymes differ in their kinetic properties and N-leader sequences, and their regulation may vary with tissue type. Recombinant acidic and basic synthetases from mouse, in the presence of active site ligands,. behave in analytical ultracentrifugation as dimers. Active, site ligands enhance thermal stability of both isozymes. Truncated forms of both isozymes retain the kinetic parameters and the oligomerization status of the full-length proteins. AMP potently inhibits the acidic isozyme competitively with respect to IMP. In contrast, AMP weakly inhibits the basic isozyme noncompetitively with respect to all substrates. IMP inhibition of the acidic isozyme is competitive, and that of the basic isozyme noncompetitive, with respect to GTP. Fructose 1,6-bisphosphate potently inhibits both isozymes competitively with respect to IMP but becomes noncompetitive at saturating substrate concentrations. The above, coupled with structural information, suggests antagonistic interactions between the active sites of the basic isozyme, whereas active sites of the acidic isozyme seem functionally independent. Fructose 1,6-bisphosphate and IMP together may be dynamic regulators of the basic isozyme in muscle, causing potent inhibition of the synthetase under conditions of high AMP deaminase activity.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Mol Biol Bldg, Ames, IA 50011 USA.	hjfromm@iastate.edu	Borza, Tudor/A-8510-2012; Borza, Tudor/M-4937-2019	Borza, Tudor/0000-0002-2527-6551; Borza, Tudor/0000-0002-2527-6551	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARABADJIS PG, 1993, AM J PHYSIOL, V264, pC1246, DOI 10.1152/ajpcell.1993.264.5.C1246; BAUGHER BW, 1980, BIOCHEM BIOPH RES CO, V94, P123, DOI 10.1016/S0006-291X(80)80196-3; BOGUSKY RT, 1976, J CLIN INVEST, V58, P326, DOI 10.1172/JCI108476; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choe JY, 1999, BIOCHEMISTRY-US, V38, P6953, DOI 10.1021/bi990159s; CLARK SW, 1976, BIOCHIM BIOPHYS ACTA, V437, P87, DOI 10.1016/0304-4165(76)90349-4; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Fischer H E, 1978, Methods Enzymol, V51, P207; FonnePfister R, 1996, P NATL ACAD SCI USA, V93, P9431, DOI 10.1073/pnas.93.18.9431; GOODMAN MN, 1977, J BIOL CHEM, V252, P5054; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; Hellsten Y, 1999, J PHYSIOL-LONDON, V520, P909, DOI 10.1111/j.1469-7793.1999.00909.x; Hisatome I, 1998, AM J PHYSIOL-CELL PH, V275, pC870, DOI 10.1152/ajpcell.1998.275.3.C870; Honzatko RB, 1999, ADV ENZYMOL RAMB, V73, P57, DOI 10.1002/9780470123195.ch3; Iancu CV, 2002, J BIOL CHEM, V277, P40536, DOI 10.1074/jbc.M204952200; Iancu CV, 2002, J BIOL CHEM, V277, P26779, DOI 10.1074/jbc.M203730200; Iancu CV, 2001, J BIOL CHEM, V276, P42146, DOI 10.1074/jbc.M106294200; Kang C, 1996, J BIOL CHEM, V271, P29722, DOI 10.1074/jbc.271.47.29722; KANG CH, 1995, J BIOL CHEM, V270, P15539, DOI 10.1074/jbc.270.26.15539; Kang CH, 1997, J BIOL CHEM, V272, P11881, DOI 10.1074/jbc.272.18.11881; Knecht K, 2001, J NEUROSCI RES, V66, P941, DOI 10.1002/jnr.10059; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREBS HA, 1978, BIOCHEM J, V176, P733, DOI 10.1042/bj1760733; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; LEE AD, 1989, BIOCHEM J, V258, P915, DOI 10.1042/bj2580915; Lipps G, 1999, BIOCHEM J, V341, P537, DOI 10.1042/0264-6021:3410537; MANFREDI JP, 1989, AM J PHYSIOL, V257, pC29, DOI 10.1152/ajpcell.1989.257.1.C29; MARYNISSEN G, 1992, BIOCHEM MED METAB B, V48, P127, DOI 10.1016/0885-4505(92)90057-6; MATSUDA Y, 1980, BIOCHIM BIOPHYS ACTA, V616, P340, DOI 10.1016/0005-2744(80)90151-5; MATSUDA Y, 1977, BIOCHEM BIOPH RES CO, V78, P766, DOI 10.1016/0006-291X(77)90245-5; MEYER RA, 1980, AM J PHYSIOL, V239, pC32, DOI 10.1152/ajpcell.1980.239.1.C32; Moe OA, 1996, BIOCHEMISTRY-US, V35, P9024, DOI 10.1021/bi960426j; MOMMSEN TP, 1988, METABOLISM, V37, P552, DOI 10.1016/0026-0495(88)90170-9; MOSS KM, 1975, BIOCHEM J, V150, P162; MUIRHEAD KM, 1974, J BIOL CHEM, V249, P459; Norman B, 2001, J APPL PHYSIOL, V91, P258, DOI 10.1152/jappl.2001.91.1.258; OGAWA H, 1977, J BIOCHEM, V81, P859, DOI 10.1093/oxfordjournals.jbchem.a131550; OGAWA H, 1976, BIOCHEM BIOPH RES CO, V68, P524, DOI 10.1016/0006-291X(76)91177-3; OGAWA H, 1978, EUR J BIOCHEM, V85, P331, DOI 10.1111/j.1432-1033.1978.tb12243.x; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; Prade L, 2000, J MOL BIOL, V296, P569, DOI 10.1006/jmbi.1999.3473; RAZ I, 1991, AM J PHYSIOL, V260, pE430, DOI 10.1152/ajpendo.1991.260.3.E430; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; RUNDELL KW, 1992, AM J PHYSIOL, V263, pC294, DOI 10.1152/ajpcell.1992.263.2.C294; SCHULTZ V, 1976, J BIOL CHEM, V251, P485; SPECTOR T, 1976, BIOCHIM BIOPHYS ACTA, V445, P509, DOI 10.1016/0005-2744(76)90104-2; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; Tarnopolsky MA, 2001, J PHYSIOL-LONDON, V533, P881, DOI 10.1111/j.1469-7793.2001.t01-1-00881.x; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; TORNHEIM K, 1972, J BIOL CHEM, V247, P162; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TULLSON PC, 1995, J APPL PHYSIOL, V78, P146, DOI 10.1152/jappl.1995.78.1.146; Tullson PC, 1996, AM J PHYSIOL-CELL PH, V270, pC1067; TULLSON PC, 1991, AM J PHYSIOL, V261, pC342, DOI 10.1152/ajpcell.1991.261.2.C342; VANDERWE.MB, 1974, J BIOL CHEM, V249, P7282; Wang WY, 1997, J BIOL CHEM, V272, P7078, DOI 10.1074/jbc.272.11.7078	61	14	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6673	6679		10.1074/jbc.M210838200	http://dx.doi.org/10.1074/jbc.M210838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12482871	hybrid			2022-12-25	WOS:000181195100007
J	Abell, BM; Jung, M; Oliver, JD; Knight, BC; Tyedmers, J; Zimmermann, R; High, S				Abell, BM; Jung, M; Oliver, JD; Knight, BC; Tyedmers, J; Zimmermann, R; High, S			Tail-anchored and signal-anchored proteins utilize overlapping pathways during membrane insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ER MEMBRANE; POSTTRANSLATIONAL TRANSPORT; TRANSLOCATION COMPLEX; MICROSOMAL-MEMBRANES; CONDUCTING CHANNEL; DOCKING PROTEIN; SEC61 COMPLEX; INTEGRATION; SEQUENCES	Tail-anchored proteins are a distinct class of membrane proteins that are characterized by a C-terminal membrane insertion sequence and a capacity for post-translational integration. Although it is now clear that tail-anchored proteins are inserted into the membrane at the endoplasmic reticulum. (ER), the molecular basis for their integration is poorly understood. We have used a cross-linking approach to identify ER components that may be involved in the membrane insertion of tail-anchored proteins. We find that several newly synthesized tail-anchored proteins are transiently associated with a defined subset of cellular components. Among these, we identify several ER proteins, including subunits of the Sec61 translocon, Sec62p, Sec63p, and the 25-kDa subunit of the signal peptidase complex. When we analyze the cotranslational membrane insertion of a comparable signal-anchored protein we find the nascent polypeptide associated with a similar set of ER components. We conclude that the pathways for the integration of tail-anchored and signal-anchored membrane proteins at the ER exhibit a substantial degree of overlap, and we propose that this reflects similarities between co- and post-translational membrane insertion.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Saarland, D-66421 Homburg, Germany	University of Manchester; Saarland University	High, S (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	stephen.high@man.ac.uk	Jung, Martin/AAM-4547-2021; Jung, Martin/D-2207-2012	Jung, Martin/0000-0002-1482-7020; Jung, Martin/0000-0002-1482-7020; Abell, Ben/0000-0002-0953-0046; High, Stephen/0000-0002-4532-8152	Biotechnology and Biological Sciences Research Council [SF16973] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Behrens TW, 1996, J BIOL CHEM, V271, P23528, DOI 10.1074/jbc.271.38.23528; Borgese N, 2001, MOL BIOL CELL, V12, P2482, DOI 10.1091/mbc.12.8.2482; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; High S, 1997, TRENDS CELL BIOL, V7, P206; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Kim PK, 1999, J BIOL CHEM, V274, P36876, DOI 10.1074/jbc.274.52.36876; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; KLAPPA P, 1994, FEBS LETT, V341, P281, DOI 10.1016/0014-5793(94)80473-7; Knight BC, 1998, BIOCHEM J, V331, P161, DOI 10.1042/bj3310161; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Martoglio B, 1996, TRENDS CELL BIOL, V6, P142, DOI 10.1016/0962-8924(96)10001-5; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Meacock SL, 2000, ESSAYS BIOCHEM, V36, P1; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Meyer HA, 2000, J BIOL CHEM, V275, P14550, DOI 10.1074/jbc.275.19.14550; MULLER G, 1987, EMBO J, V6, P2099, DOI 10.1002/j.1460-2075.1987.tb02476.x; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Nilsson I, 2002, FEBS LETT, V516, P106, DOI 10.1016/S0014-5793(02)02511-5; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Plath K, 2000, J CELL BIOL, V151, P167, DOI 10.1083/jcb.151.1.167; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Romisch K, 1999, J CELL SCI, V112, P4185; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; Tyedmers J, 2000, P NATL ACAD SCI USA, V97, P7214, DOI 10.1073/pnas.97.13.7214; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wattenberg B, 2001, TRAFFIC, V2, P66, DOI 10.1034/j.1600-0854.2001.20108.x; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262; Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	48	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5669	5678		10.1074/jbc.M209968200	http://dx.doi.org/10.1074/jbc.M209968200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12464599	hybrid			2022-12-25	WOS:000181129400025
J	Angevine, CM; Fillingame, RH				Angevine, CM; Fillingame, RH			Aqueous access channels in subunit a of rotary ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-ACCESSIBILITY METHOD; ESCHERICHIA-COLI; PROTON TRANSLOCATION; ALPHA-SUBUNIT; DIRECTED MUTAGENESIS; STRUCTURAL CHEMISTRY; SUPPRESSOR MUTATIONS; SCANNING MUTAGENESIS; CROSS-LINKING; ION-CHANNEL	The role of subunit a in proton translocation by the Escherichia coli F1F0. ATP synthase is poorly understood. In the membrane-bound F-o sector of the enzyme, H+ binding and release occurs at Asp(61) in the middle of the second transmembrane helix (TMH) of subunit c. Protons are thought to reach Asp(61) via an aqueous access pathway formed at least in part by one or more of the five TMHs of subunit a. In this report, we have substituted Cys into a 19-residue span of the fourth TMH of subunit a and used chemical modification to obtain information about the aqueous accessibility of residues along this helix. Residues 206, 210, and 214 are N-ethyl-maleimide-accessible from the cytoplasmic side of the membrane and may lie on the H+ transport route. Residues 215 and 218 on TMH4, as well as residue 245 on TMH5, are Ag+-accessible but N-ethylmalcimide-inaccessible and may form part of an aqueous pocket extending from Asp(61) of subunit c to the periplasmic surface.	Univ Wisconsin, Dept Biomol Chem, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med, 587 Med Sci Bldg, Madison, WI 53706 USA.				NIGMS NIH HHS [GM23105, 5T32 GM08349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023105, R37GM023105, T32GM008349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; [Anonymous], 1973, CHEM BIOCH SULFHYDRY; Barik S, 1996, Methods Mol Biol, V57, P203; Bass RB, 1999, BIOCHEMISTRY-US, V38, P9317, DOI 10.1021/bi9908179; Bell RA, 1999, ENVIRON TOXICOL CHEM, V18, P9, DOI [10.1897/1551-5028(1999)018&lt;0009:SCAGOS&gt;2.3.CO;2, 10.1002/etc.5620180103]; BENNETT MA, 1962, CHEM REV, V62, P611, DOI 10.1021/cr60220a006; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; DANCE IG, 1986, POLYHEDRON, V5, P1037, DOI 10.1016/S0277-5387(00)84307-7; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; Dimroth P, 2000, BBA-BIOENERGETICS, V1458, P374, DOI 10.1016/S0005-2728(00)00088-8; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Egan TM, 1998, J NEUROSCI, V18, P2350; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 2000, J EXP BIOL, V203, P9; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; Fillingame RH, 2000, J BIOENERG BIOMEMBR, V32, P433, DOI 10.1023/A:1005604722178; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRAGA D, 1994, J BIOL CHEM, V269, P2562; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P2187, DOI 10.1093/nar/9.9.2187; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; GORIN G, 1966, ARCH BIOCHEM BIOPHYS, V115, P593, DOI 10.1016/0003-9861(66)90079-8; Groth G, 2002, P NATL ACAD SCI USA, V99, P3464, DOI 10.1073/pnas.052546099; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HOWITT SM, 1988, BIOCHIM BIOPHYS ACTA, V936, P74, DOI 10.1016/0005-2728(88)90253-8; HUSSAIN S, 1994, BBA-BIOMEMBRANES, V1190, P402, DOI 10.1016/0005-2736(94)90100-7; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Kaim G, 2001, BBA-BIOENERGETICS, V1505, P94, DOI 10.1016/S0005-2728(00)00280-2; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kinosita K, 2000, PHILOS T R SOC B, V355, P473, DOI 10.1098/rstb.2000.0589; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kriegler S, 1999, J BIOL CHEM, V274, P3934, DOI 10.1074/jbc.274.7.3934; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; Kwaw I, 2001, BIOCHEMISTRY-US, V40, P10491, DOI 10.1021/bi010866x; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; Li J, 2002, P NATL ACAD SCI USA, V99, P11605, DOI 10.1073/pnas.192439299; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; MORRIS LJ, 1966, J LIPID RES, V7, P717; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; WEAST RC, 1982, CRC HDB CHEM PHYSICS, pF179; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; ZHANG Y, 1994, J BIOL CHEM, V269, P5473; ZHANG Y, 1995, J BIOL CHEM, V270, P87, DOI 10.1074/jbc.270.1.87	77	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6066	6074		10.1074/jbc.M210199200	http://dx.doi.org/10.1074/jbc.M210199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12473663	hybrid			2022-12-25	WOS:000181129400073
J	Fei, YJ; Inoue, K; Ganapathy, V				Fei, YJ; Inoue, K; Ganapathy, V			Structural and functional characteristics of two sodium-coupled dicarboxylate transporters (ceNaDC1 and ceNaDC2) from Caenorhabditis elegans and their relevance to life span	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC ORGANIZATION; CITRATE TRANSPORTER; CALORIC RESTRICTION; EXPRESSION; CLONING	We have cloned and functionally characterized two Na+-coupled dicarboxylate transporters, namely ceNaDC1 and ceNaDC2, from Caenorhabditis elegans. These two transporters show significant sequence homology with the product of the Indy gene identified in Drosophila melanogaster and with the Na+-coupled dicarboxylate transporters NaDC1 and NaDC3 identified in mammals. In a mammalian cell heterologous expression system, the cloned ceNaDC1 and ceNaDC2 mediate Na+-coupled transport of various dicarboxylates. With succinate as the substrate, ceNaDC1 exhibits much lower affinity compared with ceNaDC2. Thus, ceNaDC1 and ceNaDC2 correspond at the functional level to the mammalian NaDC1 and NaDC3, respectively. The nadc1 and nadc2 genes are not expressed at the embryonic stage, but the expression is detectable all through the early larva stage to the adult stage. Tissue-specific expression pattern studies using a reporter gene fusion approach in transgenic C. elegans show that both genes are co-expressed in the intestinal tract, an organ responsible for not only the digestion and absorption of nutrients but also for the storage of energy in this organism. Independent knockdown of the function of these two transporters in C. elegans using the strategy of RNA interference suggests that NaDC1 is not associated with the regulation of average life span in this organism, whereas the knockdown of NaDC2 function leads to a significant increase in the average life span. Disruption of the function of the high affinity Na+-coupled dicarboxylate transporter NaDC2 in C. elegans may lead to decreased availability of dicarboxylates for cellular production of metabolic energy, thus creating a biological state similar to that of caloric restriction, and consequently leading to life span extension.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Fei, YJ (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	yjfei@mail.mcg.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33347] Funding Source: Medline; NIDA NIH HHS [DA10065] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Anderson P, 1995, METHOD CELL BIOL, V48, P31; AVERY L, 1997, C ELEGANS, V2, P679, DOI [10.1101/087969532.33.679, DOI 10.1101/087969532.33.679]; Chen XM, 1999, J CLIN INVEST, V103, P1159, DOI 10.1172/JCI5392; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Davies JP, 1996, EMBO J, V15, P2150, DOI 10.1002/j.1460-2075.1996.tb00568.x; Fei YJ, 1998, BIOCHEM J, V332, P565, DOI 10.1042/bj3320565; Fei YJ, 2000, J BIOL CHEM, V275, P9563, DOI 10.1074/jbc.275.13.9563; Huang W, 2000, J PHARMACOL EXP THER, V295, P392; Inoue K, 2002, BIOCHEM BIOPH RES CO, V299, P465, DOI 10.1016/S0006-291X(02)02669-4; Inoue K, 2002, J BIOL CHEM, V277, P39469, DOI 10.1074/jbc.M207072200; Inoue K, 2002, BIOCHEM J, V367, P313, DOI 10.1042/BJ20021132; Kekuda R, 1999, J BIOL CHEM, V274, P3422, DOI 10.1074/jbc.274.6.3422; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Knauf F, 2002, P NATL ACAD SCI USA, V99, P14315, DOI 10.1073/pnas.222531899; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Miller DM, 1999, BIOTECHNIQUES, V26, P914, DOI 10.2144/99265rr01; Pajor AM, 2000, J MEMBRANE BIOL, V175, P1, DOI 10.1007/s002320001049; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Russel FGM, 2002, ANNU REV PHYSIOL, V64, P563, DOI 10.1146/annurev.physiol.64.081501.155913; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Sekine T, 1998, AM J PHYSIOL-RENAL, V275, pF298, DOI 10.1152/ajprenal.1998.275.2.F298; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Wood WB, 1988, NEMATODE CAENORHABDI, P587	30	56	68	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6136	6144		10.1074/jbc.M208763200	http://dx.doi.org/10.1074/jbc.M208763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12480943	hybrid			2022-12-25	WOS:000181129400081
J	Gentzsch, M; Cui, LY; Mengos, A; Chang, XB; Chen, JH; Riordan, JR				Gentzsch, M; Cui, LY; Mengos, A; Chang, XB; Chen, JH; Riordan, JR			The PDZ-binding chloride channel ClC-3B localizes to the golgi and associates with cystic fibrosis transmembrane conductance regulator-interacting PDZ proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR; PROTEASOME; DOMAINS; PARTNER	CIC chloride channels are widely distributed in organisms across the evolutionary spectrum, and members of the mammalian family play crucial roles in cellular function and are mutated in several human diseases (Jentsch, T. J., Stein, V., Weinreich, F., and Zdebik, A. A. (2002) Physiol. Rev. 82, 503-568). Within the CIC-3, -4, -5 branch of the family that are intracellular channels, two alternatively spliced CIC-3 isoforms were recognized recently (Ogura, T., Furukawa, T., Toyozaki, T., Yamada, K., Zheng, Y. J., Katayama, Y., Nakaya, H., and Inagaki, N. (2002) FASEB J. 16, 863-865). CIC-3A resides in late endosomes where it serves as an anion shunt during acidification. We show here that the CIC-3B PDZ-binding isoform resides in the Golgi where it co-localizes with a small amount of the other known PDZ-binding chloride channel, CFTR (cystic fibrosis transmembrane conductance regulator). Both channel proteins bind the Golgi PDZ protein, GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein). Interestingly, however, when overexpressed, GOPC, which is thought to influence traffic in the endocytic/secretory pathway, causes a large reduction in the amounts of both channels, probably by leading them to the degradative end of this pathway. CIC-3B as well as CFTR also binds EBP50 (ERM-binding phosphoprotein 50) and PDZK1, which are concentrated at the plasma membrane. However, only PDZK1 was found to promote interaction between the two channels, perhaps because they were able to bind to two different PDZ domains in PDZK1. Thus while small portions of the populations of CIC-3B and CFTR may associate and co-localize, the bulk of the two populations reside in different organelles of cells where they are expressed heterologously or endogenously, and therefore their cellular functions are likely to be distinct and not primarily related.	Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Riordan, JR (corresponding author), Mayo Clin Scottsdale, SC Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.		Gentzsch, Martina/AAY-1815-2021					Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; Biederer T, 2002, J NEUROSCI, V22, P7340; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Estevez R, 2002, CURR OPIN STRUC BIOL, V12, P531, DOI 10.1016/S0959-440X(02)00358-5; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; FIRZELL RA, 1999, PHYSL CYSTIC FIBROSI, V79; HANRAHAN JW, 2002, ABC PROTEINS BACTERI, P589; HERMOSO M, 2002, J BIOL CHEM; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Iyer R, 2002, NATURE, V419, P715, DOI 10.1038/nature01000; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Liu TF, 2001, J BIOL CHEM, V276, P35768, DOI 10.1074/jbc.M103585200; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Mohammad-Panah R, 2002, J BIOL CHEM, V277, P566, DOI 10.1074/jbc.M106968200; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Schwake M, 2001, J BIOL CHEM, V276, P12049, DOI 10.1074/jbc.M010642200; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9	37	111	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6440	6449		10.1074/jbc.M211050200	http://dx.doi.org/10.1074/jbc.M211050200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471024	hybrid			2022-12-25	WOS:000181129400118
J	Gotthardt, M; Hammer, RE; Hubner, N; Monti, J; Witt, CC; McNabb, M; Richardson, JA; Granzier, H; Labeit, S; Herz, J				Gotthardt, M; Hammer, RE; Hubner, N; Monti, J; Witt, CC; McNabb, M; Richardson, JA; Granzier, H; Labeit, S; Herz, J			Conditional expression of mutant M-line titins results in cardiomyopathy with altered sarcomere structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL DILATED CARDIOMYOPATHY; ANKYRIN-REPEAT PROTEIN; LIGHT-CHAIN KINASE; IMMUNOELECTRON MICROSCOPY; CRE RECOMBINASE; C-ELEGANS; MUSCLE; GENE; ELASTICITY; DROSOPHILA	Titin is a giant protein responsible for muscle elasticity and provides a scaffold for several sarcomeric proteins, including the novel titin-binding protein MURF-1, which binds near the titin M-line region. Another unique feature of titin is the presence of a serine/threonine kinase-like domain at the edge of the M-line region of the sarcomere, for which no physiological catalytic function has yet been shown. To investigate the role(s) of the titin M-line segment, we have conditionally deleted the exons MEx1 and MEx2 (encoding the kinase domain plus Ranking sequences) at different stages of embryonic development. Our data demonstrate an important role for MEx1 and MEx2 in early cardiac development (embryonic lethality) as well as postnatally when disruption of M-line titin leads to muscle weakness and death at similar to5 weeks of age. Myopathic changes include pale M-lines devoid of MURF-1, and gradual sarcomeric disassembly. The animal model presented here indicates a critical role for the M-line region of titin in maintaining the structural integrity of the sarcomere.	Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Pullman, WA 99164 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Max Delbruck Ctr Mol Med, Klin Genet Herz Kreislauferkrankungen, D-13122 Berlin, Germany; Univ Klinikum, Inst Anasthesiol & Operat Intens Med, D-68131 Mannheim, Germany	Washington State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ruprecht Karls University Heidelberg	Gotthardt, M (corresponding author), Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Wegner Hall,Rm 205, Pullman, WA 99164 USA.	Gotthard@vetmed.wsu.edu	Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Hammer, Robert E./0000-0001-5487-7551	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Ayme-Southgate A, 2000, ADV EXP MED BIOL, V481, P251; AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; Bang ML, 2001, J CELL BIOL, V153, P413, DOI 10.1083/jcb.153.2.413; Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Centner T, 2000, ADV EXP MED BIOL, V481, P35; Champagne MB, 2000, J MOL BIOL, V300, P759, DOI 10.1006/jmbi.2000.3802; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Flaherty DB, 2002, J MOL BIOL, V323, P533, DOI 10.1016/S0022-2836(02)00970-1; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Granzier H, 2002, J PHYSIOL-LONDON, V541, P335, DOI 10.1113/jphysiol.2001.014381; Granzier H, 1996, BIOPHYS J, V70, P430, DOI 10.1016/S0006-3495(96)79586-3; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; HACKMAN P, 2002, IN PRESS AM J HUM GE; Herz J, 2000, CURR OPIN LIPIDOL, V11, P161, DOI 10.1097/00041433-200004000-00009; Kaul A, 2000, CELL, V102, P17, DOI 10.1016/S0092-8674(00)00006-4; Kemp TJ, 2000, GENOMICS, V66, P229, DOI 10.1006/geno.2000.6213; Kolmerer B, 1996, J MOL BIOL, V256, P556, DOI 10.1006/jmbi.1996.0108; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; Maruyama K, 1999, REV PHYSIOL BIOCH P, V138, P1, DOI 10.1007/BF02346658; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; McElhinny AS, 2002, J CELL BIOL, V157, P125, DOI 10.1083/jcb.200108089; Minamino T, 2001, CIRC RES, V88, P587, DOI 10.1161/01.RES.88.6.587; Obermann WMJ, 1996, J CELL BIOL, V134, P1441, DOI 10.1083/jcb.134.6.1441; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; Sambrook J, 2001, MOL CLONING LAB MANU; Siu BL, 1999, CIRCULATION, V99, P1022, DOI 10.1161/01.CIR.99.8.1022; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; Trinick J, 1999, TRENDS CELL BIOL, V9, P377, DOI 10.1016/S0962-8924(99)01641-4; Trombitas K, 1998, J CELL BIOL, V140, P853, DOI 10.1083/jcb.140.4.853; Wang K, 1996, ADV BIOPHYS, V33, P123; WILLNOW TE, 1994, METHOD CELL BIOL, V43, P305; Zou YM, 1997, DEVELOPMENT, V124, P793	42	112	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6059	6065		10.1074/jbc.M211723200	http://dx.doi.org/10.1074/jbc.M211723200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12464612	hybrid			2022-12-25	WOS:000181129400072
J	Otsuki, M; Itoh, T; Takenawa, T				Otsuki, M; Itoh, T; Takenawa, T			Neural Wiskott-Aldrich syndrome protein is recruited to rafts and associates with endophilin A in response to epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLE ENDOCYTOSIS; STIMULATED GLUT4 TRANSLOCATION; ACTIN-DEPOLYMERIZING PROTEIN; POLARIZED EPITHELIAL-CELLS; N-WASP; INTERNALIZATION STEP; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CYTOSKELETAL REARRANGEMENT; INTRACELLULAR-TRANSPORT	Neural Wiskott-Aldrich syndrome protein (N-WASP) has been implicated in endocytosis; however, little is known about how it interacts functionally with the endocytic machinery. Sucrose gradient fractionation experiments and immunofluorescence studies with anti-N-WASP antibody revealed that N-WASP is recruited together with clathrin and dynamin, which play essential roles in clathrin-mediated endocytosis, to lipid rafts in an epidermal growth factor (EGF)-dependent manner. Endophilin A (EA) binds to dynamin and plays an essential role in the fission step of clathrin-mediated endocytosis. In the present study, we show that the Src homology 3 (SH3) domain of EA associates with the proline-rich domain of N-WASP and dynamin in vitro. Co-immunoprecipitation assays with anti-N-WASP antibody revealed that EGF induces association of N-WASP with EA. In addition, EA enhances N-WASP-induced actin-related protein 2/3 (Arp2/3) complex activation in vitro. Immunofluorescence studies revealed that actin accumulates at sites where N-WASP and EA are co-localized after EGF stimulation. Furthermore, studies of overexpression of the SH3 domain of EA indicate that EA may regulate EGF-induced recruitment of N-WASP to lipid rafts. These results suggest that, upon EGF stimulation, N-WASP interacts with EA through its proline-rich domain to induce the fission step of clathrin-mediated endocytosis.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp						BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Czech MP, 2000, NATURE, V407, P147, DOI 10.1038/35025183; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Modregger J, 2000, J CELL SCI, V113, P4511; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Naqvi SN, 1998, CURR BIOL, V8, P959, DOI 10.1016/S0960-9822(98)70396-3; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scales SJ, 1999, NATURE, V401, P123, DOI 10.1038/43582; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Sever S, 2000, TRAFFIC, V1, P385, DOI 10.1034/j.1600-0854.2000.010503.x; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sorkin A, 2000, J CELL SCI, V113, P4375; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329	59	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6461	6469		10.1074/jbc.M207433200	http://dx.doi.org/10.1074/jbc.M207433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12477732	hybrid			2022-12-25	WOS:000181129400121
J	Matallanas, D; Arozarena, I; Berciano, MT; Aaronson, DS; Pellicer, A; Lafarga, M; Crespo, P				Matallanas, D; Arozarena, I; Berciano, MT; Aaronson, DS; Pellicer, A; Lafarga, M; Crespo, P			Differences on the inhibitory Specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane Microlocalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PLASMA-MEMBRANE; CELL-CYCLE; HYPERVARIABLE REGION; DEPENDENT ACTIVATION; POLYBASIC DOMAIN; CAAX MOTIF; GROWTH; MOUSE; GENE	Ras GTPases include the isoforms H-Ras, K-Ras, and N-Ras. Despite their great biochemical and biological similarities, evidence is mounting suggesting that Ras proteins may not be functionally redundant. A widespread strategy for studying small GTPases is the utilization of dominant inhibitory mutants that specifically block the activation of their respective wild-type proteins. As such, H-Ras N17 has proved to be extremely valuable as a tool to probe Ras functions. However, a comparative study on the inhibitory specificities of H-, K-, and N-Ras N17 mutants has not been approached thus far. Herein, we demonstrate that H-, K-, and N-Ras N17 mutants exhibit markedly distinct inhibitory effects toward H-, K-, and N-Ras. H-Ras N17 can effectively inhibit the activation of all three isoforms. K-Ras N17 completely blocks the activation of K-Ras and is only slightly inhibitory on H-Ras. N-Ras N17 can mainly inhibit N-Ras activation. In light of the recent data on the compartmentalization of H-Ras and K-Ras in the plasma membrane, here we present for the first time a description of N-Ras cellular microlocalization. Overall, our results on Ras N17 mutants specificities exhibit a marked correlation with the localization of the Ras isoforms to distinct membrane microdomains.	Consejo Super Invest Centif, Inst Invest Biomed, Madrid 28029, Spain; Univ Cantabria, Dept Biol Mol, Santander 39011, Spain; Univ Cantabria, Dept Anat & Biol Celular, Santander 39011, Spain; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	Universidad de Cantabria; Universidad de Cantabria; New York University; New York University	Crespo, P (corresponding author), Consejo Super Invest Centif, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.	pcrespo@iib.uam.es	Lafarga, Miguel/K-3733-2014; gomez, david/U-9465-2019; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Arozarena, Imanol/A-5981-2017; Crespo, Piero/M-3273-2014	gomez, david/0000-0002-2360-3141; Arozarena, Imanol/0000-0001-6349-2442; Pellicer, Angel/0000-0002-5062-0692; Crespo, Piero/0000-0003-2825-7783; Berciano, Maria T./0000-0002-8225-6995; Lafarga, Miguel/0000-0003-3402-1152	NCI NIH HHS [CA-36327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036327, R01CA036327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arozarena I, 2001, J BIOL CHEM, V276, P21878, DOI 10.1074/jbc.M011383200; Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOS JL, 1989, CANCER RES, V49, P4682; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIORUCCI G, 1986, BIOCHIM BIOPHYS ACTA, V950, P81; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jaumot M, 2002, J BIOL CHEM, V277, P272, DOI 10.1074/jbc.M108423200; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHER J, 1995, ONCOGENE, V11, P1639; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MULLER R, 1983, MOL CELL BIOL, V3, P1062; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Prior IA, 2001, J CELL SCI, V114, P1603; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rebollo A, 1999, ONCOGENE, V18, P4930, DOI 10.1038/sj.onc.1202875; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Welman A, 2000, ONCOGENE, V19, P4582, DOI 10.1038/sj.onc.1203818; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	56	90	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4572	4581		10.1074/jbc.M209807200	http://dx.doi.org/10.1074/jbc.M209807200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458225	hybrid			2022-12-25	WOS:000180968900030
J	Wei, Y; Renard, CA; Labalette, C; Wu, YF; Levy, L; Neuveut, C; Prieur, X; Flajolet, M; Prigent, S; Buendia, MA				Wei, Y; Renard, CA; Labalette, C; Wu, YF; Levy, L; Neuveut, C; Prieur, X; Flajolet, M; Prigent, S; Buendia, MA			Identification of the LIM protein FHL2 as a coactivator of beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1; TRANSCRIPTIONAL COACTIVATORS; ANDROGEN RECEPTOR; GENE; ACTIVATION; EXPRESSION; APC; PATHWAY; TARGET; CANCER	beta-Catenin is a key mediator of the Wnt pathway, which plays a critical role in embryogenesis and oncogenesis. As a transcriptional activator, beta-catenin binds the transcription factors, T-cell factor and lymphoid enhancer factor, and regulates gene expression in response to Wnt signaling. Abnormal activation of beta-catenin has been linked to various types of cancer. In a yeast two-hybrid screen, we identified the four and a half of LIM-only protein 2 (FHL2) as a novel beta-catenin-interacting protein. Here we show specific interaction of FHL2 with beta-catenin, which requires the intact structure of.FHL2 and armadillo repeats 1-9 of beta-catenin. FHL2 cooperated with beta-catenin to activate T-cell factor/lymphoid enhancer factor-dependent transcription from a synthetic reporter and the cyclin D1 and interleukin-8 promoters in kidney and colon cell lines. In contrast, coexpression of beta-catenin and FHL2 had no synergistic effect on androgen receptor-mediated transcription, whereas each of these two coactivators independently stimulated AR transcriptional activity. Thus, the ability of FHL2 to stimulate the trans-activating function of beta-catenin might be dependent on the promoter context. The detection of increased FHL2 expression in hepatoblastoma, a liver tumor harboring frequent beta-catenin mutations, suggests that FHL2 might enforce beta-catenin transactivation activity in cancer cells. These findings reveal a new function of the LIM coactivator FHL2 in transcriptional activation of Wnt-responsive genes.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Wei, Y (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75015 Paris, France.		Prieur, Xavier/D-4760-2015; LEVY, Laurence/AAF-5672-2021; Wei, Yu/A-7289-2016	Prieur, Xavier/0000-0003-0215-5447; Neuveut, Christine/0000-0001-6520-271X				Barker N, 2000, ADV CANCER RES, V77, P1; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Koch A, 1999, CANCER RES, V59, P269; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takayasu H, 2001, CLIN CANCER RES, V7, P901; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; Truica CI, 2000, CANCER RES, V60, P4709; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200	40	117	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					5188	5194		10.1074/jbc.M207216200	http://dx.doi.org/10.1074/jbc.M207216200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12466281	hybrid			2022-12-25	WOS:000180968900107
J	Bougie, I; Charpentier, S; Bisaillon, M				Bougie, I; Charpentier, S; Bisaillon, M			Characterization of the metal ion binding properties of the hepatitis C virus RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEIN 5B; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; REVERSE-TRANSCRIPTASE; VIRAL-RNA; IDENTIFICATION; REPLICATION; SITE; REQUIREMENTS; INHIBITION	The hepatitis C virus nonstructural 513 protein (NS5B) protein has been shown to require either magnesium or manganese for its RNA-dependent RNA polymerase activity. As a first step toward elucidating the nature and the role(s) of the metal ions in the reaction chemistry, we have utilized endogenous tryptophan fluorescence to quantitate the interactions of magnesium and manganese ions with this protein. The association of either Mg2+ or Mn2+ ions with the enzyme resulted in a decrease in the intensity of the tryptophan emission spectrum. This decrease was used to determine the apparent dissociation constants for both ions. The apparent K-d values for the binding of Mg2+ and Mn2+ ions to the free enzyme were 3.1 and 0.3 mm, respectively. Dual ligand titration experiments demonstrated that both ions bind to a single common site, for which they compete. The kinetics of real time metal ion binding to the NS5B protein were also investigated. Based on the results of our fluorescence and near-UV circular dichroism experiments, we show that NS5B undergoes conformational changes upon the binding of metal ions. However, this process does not significantly stimulate the binding to the RNA or NTP substrates. We envisage that the ion-induced conformational change is a prerequisite for catalytic activity by both correctly positioning the side chains of the residues located in the active site of the enzyme and also contributing to the stabilization of the intermediate transition state.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Bisaillon, M (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12e Ave, Sherbrooke, PQ J1H 5N4, Canada.							Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Al RH, 1998, VIRUS RES, V53, P141, DOI 10.1016/S0168-1702(97)00147-0; ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; Bartenschlager R, 1997, ANTIVIR CHEM CHEMOTH, V8, P281, DOI 10.1177/095632029700800401; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; Cheney IW, 2002, VIROLOGY, V297, P298, DOI 10.1006/viro.2002.1461; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; DeFrancesco R, 1996, METHOD ENZYMOL, V275, P58; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; HOUGHTON M, 1996, VIROLOGY; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson RB, 2000, ARCH BIOCHEM BIOPHYS, V377, P129, DOI 10.1006/abbi.2000.1749; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kim M, 2002, J VIROL, V76, P6944, DOI 10.1128/JVI.76.14.6944-6956.2002; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lohmann V, 2000, J VIRAL HEPATITIS, V7, P167; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sarbah SA, 2000, J CLIN GASTROENTEROL, V30, P125, DOI 10.1097/00004836-200003000-00005; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; Uchiyama Y, 2002, HEPATOL RES, V23, P90, DOI 10.1016/S1386-6346(01)00167-X; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000; Zhu CX, 1997, J BIOL CHEM, V272, P16206, DOI 10.1074/jbc.272.26.16206	43	41	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3868	3875		10.1074/jbc.M209785200	http://dx.doi.org/10.1074/jbc.M209785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458224	hybrid			2022-12-25	WOS:000180869700046
J	Chen, H; Toyooka, S; Gazdar, AF; Hsieh, JT				Chen, H; Toyooka, S; Gazdar, AF; Hsieh, JT			Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; REPRESS TRANSCRIPTION; CO-REPRESSOR; CHROMATIN; BINDING; PROTEIN; ACETYLATION; INHIBITION; PROMOTER	hDAB21P (human DAB2 (also known as DOC-2) interactive protein) is a novel GTPase-activating protein for modulating the Ras-mediated signal pathway. We demonstrate that the down-regulation of hDAB2IP mRNA in prostate cancer (PCa) cells is regulated by transcriptional levels. Analysis of the hDAB2IP promoter revealed that it is a typical TATA-less promoter containing many GC-rich sequences. In this study, we delineated the potential impact of the epigenetic control of the hDAB2IP promoter on its gene regulation in PCa. Acetylhistone H3 was associated with the hDAB2IP promoter, and CpG islands remained almost unmethylated in normal prostatic epithelia, but not in PCa cell lines. Our data further indicated that trichostatin A (histone deacetylase inhibitor) and 5'-aza-2'-deoxycytidine (DNA hypomethylation agent) acted cooperatively in modulating hDAB2IP gene expression in PCa, whereas histone acetylation played a more significant role in this event. Moreover, a core promoter sequence from the hDAB2IP gene responsible for these treatments was identified. We therefore conclude that epigenetic regulation plays a potential role in regulating hDAB2IP expression in PCa and that these results also provide a new therapeutic strategy for PCa patients.	Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Human Ctr Therapeut Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hsieh, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Urol, 5323 Harry Hiens Blvd, Dallas, TX 75390 USA.	JT.Hsieh@UTSouthwestern.edu			NIDDK NIH HHS [DK-47657] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047657] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kubota T, 2001, BRAIN DEV-JPN, V23, pS177, DOI 10.1016/S0387-7604(01)00361-8; Leonhardt H, 2000, J CELL BIOCHEM, P78; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lorincz MC, 2001, MOL CELL BIOL, V21, P7913, DOI 10.1128/MCB.21.23.7913-7922.2001; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Santourlidis S, 2001, MOL CARCINOGEN, V32, P36, DOI 10.1002/mc.1062; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; Soria JC, 2002, CANCER RES, V62, P351; Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Torres L, 2000, FASEB J, V14, P95, DOI 10.1096/fasebj.14.1.95; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Tycko B, 1997, MUTAT RES-REV MUTAT, V386, P131, DOI 10.1016/S1383-5742(96)00049-X; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Wolffe AP, 2000, BIOCHEM SOC T, V28, P379, DOI 10.1042/0300-5127:0280379; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	55	116	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3121	3130		10.1074/jbc.M208230200	http://dx.doi.org/10.1074/jbc.M208230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446720	hybrid			2022-12-25	WOS:000180915000046
J	Zhou, H; Liu, LL; Lee, KY; Qin, XS; Grasso, AW; Kung, HJ; Willis, JE; Kern, J; Wagner, T; Gerson, SL				Zhou, H; Liu, LL; Lee, KY; Qin, XS; Grasso, AW; Kung, HJ; Willis, JE; Kern, J; Wagner, T; Gerson, SL			Lung tumorigenesis associated with erb-B-2 and erb-B-3 overexpression in human erb-B-3 transgenic mice is enhanced by methylnitrosourea	ONCOGENE			English	Article						transgenic mice; erb-B-2; erb-B-3; lung tumor; methylnitrosourea; K-ras	HUMAN MGMT; CELL-LINES; EXPRESSION; GENE; RECEPTOR; HEREGULIN; CANCER; MOUSE; ALKYLTRANSFERASE; EPITHELIUM	Erb-B-3 overexpression is associated with poor prognosis in non-small cell lung cancer and is often overexpressed in breast cancers. MMTVhuman-erb-B-3 transgenic mice were generated to evaluate the impact of erb-B-3 overexpression on lung and mammary gland tumorigenesis. These transgenic mice developed a high incidence of lung adenocarcinomas but not mammary gland tumors. The tumors overexpressed transgenic human [h]-erb-B-3 but also overexpressed endogenous erb-B-2, indicating that the heterodimer of h-erb-B-3-erb-B-2 was required for proliferative signal transduction to the nucleus. Lung tumor latency was shorter and the incidence higher in erb-B-3 transgenic mice treated with the methylating agent, methylnitrosourea [MNU]. In MNU treated mice, K-ras activating point mutations in codon 12, synergized with h-erb-B-3 in lung tumorogenesis. In bitransgenic MMTVrat-erb-B2/MMTV-human-erb-B-3 mice, lung tumor latency was also significantly shortened. Unlike over-expression of rat-erb-B-2, overexpression of h-erb-B-3 did not alter the incidence or latency of mammary tumors. Coupled erb-B-2 and erb-B-3 overexpression as well as K-ras activation induced signaling through mitogen-activated protein kinase (MAPK). This animal model links erb-B-3 with lung cancer, suggests that erbB-2 and erb-B-3 heterodimerization is a necessary intermediate, and documents latency shortening by methylating agent-induced mutation of K-ras. This erb-B-3 mouse lung cancer model will help dissect genetic changes in lung tumorigenesis and may be useful for chemoprevention studies.	Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Greenville Hosp Syst, Oncol Res Inst, Greenville, SC 29605 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95819 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Div Pulm Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Microbiol & Mol Biol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Greenville Health System; University of California System; University of California Davis; University Hospitals of Cleveland; Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University	Gerson, SL (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, BRB-3W,10900 Euclid Ave, Cleveland, OH 44106 USA.	slg5@po.cwru.edu		Kern, Jeffrey/0000-0001-9709-9622	NATIONAL CANCER INSTITUTE [P30CA043703, R01CA073062, R01CA063193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA73062, R01CA63193, P30CA43703] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamson ED, 1997, CURR TOP DEV BIOL, V35, P71, DOI 10.1016/S0070-2153(08)60257-4; Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Al Moustafa AE, 1999, ANTICANCER RES, V19, P481; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hung MC, 1999, SEMIN ONCOL, V26, P51; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kiguchi K, 2000, ONCOGENE, V19, P4243, DOI 10.1038/sj.onc.1203778; Kristiansen G, 2001, EUR J CANCER, V37, P1089, DOI 10.1016/S0959-8049(01)00096-X; Liu LL, 1999, CARCINOGENESIS, V20, P279, DOI 10.1093/carcin/20.2.279; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Patel NV, 2000, AM J RESP CELL MOL, V22, P432, DOI 10.1165/ajrcmb.22.4.3854; Peterson LA, 2001, CANCER RES, V61, P5757; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Polosa R, 2000, J ALLERGY CLIN IMMUN, V106, P1124; Qin XS, 1999, ONCOGENE, V18, P4394, DOI 10.1038/sj.onc.1202798; Qin XS, 1999, CARCINOGENESIS, V20, P1667, DOI 10.1093/carcin/20.9.1667; Reese JS, 2001, ONCOGENE, V20, P5258, DOI 10.1038/sj.onc.1204700; Reinmuth N, 2000, EUR RESPIR J, V16, P991, DOI 10.1183/09031936.00.16599100; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Sundaresan S, 1998, ENDOCRINOLOGY, V139, P4756, DOI 10.1210/en.139.12.4756; Weinstein EJ, 2000, CANCER RES, V60, P3856; Yi ES, 1997, MODERN PATHOL, V10, P142; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zhou H, 2001, ONCOGENE, V20, P6009, DOI 10.1038/sj.onc.1204830	29	18	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8732	8740		10.1038/sj.onc.1205984	http://dx.doi.org/10.1038/sj.onc.1205984			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483526				2022-12-25	WOS:000179734400007
J	Okada, M; Yan, SF; Pinsky, DJ				Okada, M; Yan, SF; Pinsky, DJ			Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets	FASEB JOURNAL			English	Article						ischemia; reperfusion; early growth response-1; troglitazone	RENAL ISCHEMIA/REPERFUSION INJURY; TRANSCRIPTION FACTOR; VITAMIN-E; REPERFUSION; ADIPOGENESIS; CHEMOKINES; EXPRESSION; CYTOKINES; REGULATOR; HYPOXIA	The peroxisome proliferator-activated receptor (PPAR) is a nuclear receptor whose activation regulates metabolism and inflammation. Recent data indicate that the zinc finger transcription factor early growth response gene-1 (Egr-1) acts as a master switch for the inflammatory response in ischemic vessels. Experiments tested the hypothesis that activation of endogenous PPAR-gamma inhibits induction of Egr-1. Egr-1 is rapidly induced in murine lungs after ischemia-reperfusion, as well as in alveolar mononuclear phagocytes deprived of oxygen as an ischemic model. In vitro, the natural PPAR-gamma ligand (15-deoxy-Delta(12,14)-prostaglandin J(2)) and a PPAR-gamma activator (troglitazone), but not a PPAR-gamma activator (bezafibrate), strikingly diminished Egr-1 mRNA and protein expression and nuclear DNA binding activity corresponding to Egr-1. In vivo, treatment with troglitazone before ischemia prevented induction of Egr-1 and its target genes such as interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-2. As a consequence of PPAR-gamma activation, pulmonary leukostasis was decreased and oxygenation and overall survival were improved. Activation of PPAR-gamma suppresses activation of Egr-1 and its inflammatory gene targets and provides potent protection against ischemic pulmonary injury. These data reveal a new mechanism whereby PPAR-gamma activation may decrease tissue inflammation in response to an ischemic insult.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Pinsky, DJ (corresponding author), Columbia Univ Coll Phys & Surg, PH 10 Stem,630 W 168th St, New York, NY 10032 USA.	djp5@columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060900, R01HL059488, R01HL055397] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55397, HL60900, HL59488] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FURIE MB, 1995, AM J PATHOL, V146, P1287; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOLDBLUM SE, 1985, J APPL PHYSIOL, V59, P1978, DOI 10.1152/jappl.1985.59.6.1978; Heemann U, 2000, AM J PATHOL, V156, P287, DOI 10.1016/S0002-9440(10)64729-3; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Miura M, 2001, AM J PATHOL, V159, P2137, DOI 10.1016/S0002-9440(10)63065-9; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Okada M, 2001, FASEB J, V15, P2757, DOI 10.1096/fj.01-0490fje; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Venditti P, 1999, ARCH PHYSIOL BIOCHEM, V107, P27, DOI 10.1076/apab.107.1.27.4355; Venditti P, 2000, LIFE SCI, V66, P697, DOI 10.1016/S0024-3205(99)00641-4; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	25	101	110	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					1861	1868		10.1096/fj.02-0503com	http://dx.doi.org/10.1096/fj.02-0503com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468449				2022-12-25	WOS:000180574300005
J	Gendelman, R; Burton-Wurster, NI; MacLeod, JN; Lust, G				Gendelman, R; Burton-Wurster, NI; MacLeod, JN; Lust, G			The cartilage-specific fibronectin isoform has a high affinity binding site for the small proteoglycan decorin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; PLASMA FIBRONECTIN; CELL-ADHESION; CHONDROITIN SULFATE; ARTICULAR-CARTILAGE; SYNTHETIC PEPTIDES; HEPARIN; EXPRESSION; INTEGRIN; SEGMENT	Binding of fibronectin to the small proteoglycan decorin plays an important role in cell differentiation and cell migration. The cartilage-specific (V+C)(-) fibronectin isoform, in which nucleotides that normally encode the protein segments V, III15, and I-10 are spliced out, is one of the major splice variants present in cartilage matrices. Full-length and truncated cDNA constructs were used to express recombinant versions of fibronectin. Results demonstrated that the (V+C)(-) isoform has a higher affinity for decorin. Dissociation constants for decorin and fibronectin interaction were calculated to be 93 nm for the V+C+ isoform and 24 nM and 223 nm for (V+C)(-) fibronectin. Because heparin competed with decorin competitively, binding of decorin to fibronectin likely occurs at a heparin-binding region. We propose that alternative splicing of the V and C regions changes the global conformation of fibronectin in such a way that it opens an additional decorin-binding site. This conformational change is responsible for the higher affinity of the (V+C)(-) fibronectin isoform for decorin.	Cornell Univ, Coll Vet Med, James A Baker Inst Anim Hlth, Ithaca, NY 14853 USA	Cornell University	Burton-Wurster, NI (corresponding author), Cornell Univ, Coll Vet Med, James A Baker Inst Anim Hlth, Ithaca, NY 14853 USA.	niw1@cornell.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044340] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44340] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AN SSA, 1992, BIOCHEMISTRY-US, V31, P9927, DOI 10.1021/bi00156a010; BARKALOW FJ, 1994, J BIOL CHEM, V269, P3957; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; Barry F, 2001, EXP CELL RES, V268, P189, DOI 10.1006/excr.2001.5278; Burton-Wurster N, 1998, MATRIX BIOL, V17, P193, DOI 10.1016/S0945-053X(98)90058-0; Burton-Wurster N, 1999, BIOCHEM J, V341, P555, DOI 10.1042/0264-6021:3410555; Chen H, 2002, J BIOL CHEM, V277, P20095, DOI 10.1074/jbc.M201238200; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DRAKE SL, 1993, J BIOL CHEM, V268, P15859; GRINNELL F, 1982, AM J DERMATOPATH, V4, P185, DOI 10.1097/00000372-198204000-00014; Hari SP, 2000, BIOCHEMISTRY-US, V39, P3763, DOI 10.1021/bi9926734; HASCALL VC, 1970, J BIOL CHEM, V245, P4920; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HUEBSCH JC, 1995, CIRC RES, V77, P43, DOI 10.1161/01.RES.77.1.43; Hynes RO, 1990, FIBRONECTINS; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; Kapila YL, 1999, J BIOL CHEM, V274, P30906, DOI 10.1074/jbc.274.43.30906; KAR L, 1993, J BIOL CHEM, V268, P8580; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; MacLeod JN, 1996, J BIOL CHEM, V271, P18954, DOI 10.1074/jbc.271.31.18954; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; Merle B, 1999, J CELL BIOCHEM, V75, P538; MOORADIAN DL, 1992, INVEST OPHTH VIS SCI, V33, P3034; MOULD AP, 1991, J BIOL CHEM, V266, P3579; Moyano JV, 1997, J BIOL CHEM, V272, P24832, DOI 10.1074/jbc.272.40.24832; O'Reilly D., 1994, BACULOVIRUS EXPRESSI, P124; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; Poulouin L, 1999, PROTEIN EXPRES PURIF, V17, P146, DOI 10.1006/prep.1999.1103; Sachchidanand, 2002, J BIOL CHEM, V277, P50629, DOI 10.1074/jbc.M208956200; Santas AJ, 2002, J BIOL CHEM, V277, P13650, DOI 10.1074/jbc.M111361200; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WURSTER NB, 1982, BIOCHEM BIOPH RES CO, V109, P1094, DOI 10.1016/0006-291X(82)91889-7; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; YANAGISHITA M, 1983, J BIOL CHEM, V258, P2847	45	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11175	11181		10.1074/jbc.M211799200	http://dx.doi.org/10.1074/jbc.M211799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12482864	hybrid			2022-12-25	WOS:000181855400042
J	Gamage, NU; Duggleby, RG; Barnett, AC; Tresillian, M; Latham, CF; Liyou, NE; McManus, ME; Martin, JL				Gamage, NU; Duggleby, RG; Barnett, AC; Tresillian, M; Latham, CF; Liyou, NE; McManus, ME; Martin, JL			Structure of a human carcinogen-converting enzyme, SULT1A1 - Structural and kinetic implications of substrate inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE SULFOTRANSFERASE; CRYSTAL-STRUCTURE; PHENOL SULFOTRANSFERASE; HUMAN LIVER; CYTOSOLIC SULFOTRANSFERASES; ESTROGEN SULFOTRANSFERASE; BACTERIAL EXPRESSION; SULFATING FORM; SPECIFICITY; CANCER	Sulfonation catalyzed by sulfotransferase enzymes plays an important role in chemical defense mechanisms against various xenobiotics but also bioactivates carcinogens. A major human sulfotransferase, SULT1A1, metabolizes and/or bioactivates many endogenous compounds and is implicated in a range of cancers because of its ability to modify diverse promutagen and procarcinogen xenobiotics. The crystal structure of human SULT1A1 reported here is the first sulfotransferase structure complexed with a xenobiotic substrate. An unexpected finding is that the enzyme accommodates not one but two molecules of the xenobiotic model substrate p-nitrophenol in the active site. This result is supported by kinetic data for SULT1A1 that show substrate inhibition for this small xenobiotic. The extended active site of SULT1A1 is consistent with binding of diiodothyronine but cannot easily accommodate beta-estradiol, although both are known substrates. This observation, together with evidence for a disorder-order transition in SULT1A1, suggests that the active site is flexible and can adapt its architecture to accept diverse hydrophobic substrates with varying sizes, shapes and flexibility. Thus the crystal structure of SULT1A1 provides the molecular basis for substrate inhibition and reveals the first clues as to how the enzyme sulfonates a wide variety of lipophilic compounds.	Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Queensland, Inst Mol Biosci, Special Res Ctr Funct & Appl Genom, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem & Mol Biol, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland; University of Queensland	Martin, JL (corresponding author), Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.		Martin, Jennifer L./A-6039-2010	Martin, Jennifer L./0000-0002-9225-8863	LSPPPO CDC HHS [1LS6] Funding Source: Medline	LSPPPO CDC HHS		Adjei AA, 2002, BIOCHEM BIOPH RES CO, V292, P402, DOI 10.1006/bbrc.2002.6658; Bamber DE, 2001, PHARMACOGENETICS, V11, P679, DOI 10.1097/00008571-200111000-00006; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; Brix LA, 1999, BIOCHEMISTRY-US, V38, P10474, DOI 10.1021/bi990795q; Brix LA, 1999, BIOCHEM J, V337, P337, DOI 10.1042/0264-6021:3370337; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dajani R, 1998, MOL PHARMACOL, V54, P942, DOI 10.1124/mol.54.6.942; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; DEBAUN JR, 1970, CANCER RES, V30, P115; Falany CN, 1997, FASEB J, V11, P1; FOLDES A, 1973, BIOCHIM BIOPHYS ACTA, V327, P365, DOI 10.1016/0005-2744(73)90419-1; Gaedigk A, 1998, CHEM-BIOL INTERACT, V109, P43, DOI 10.1016/S0009-2797(97)00119-1; GANGULY TC, 1995, DRUG METAB DISPOS, V23, P945; Glatt H, 1997, FASEB J, V11, P314, DOI 10.1096/fasebj.11.5.9141497; Glatt H, 2001, MUTAT RES-FUND MOL M, V482, P27, DOI 10.1016/S0027-5107(01)00207-X; Honma W, 2001, DRUG METAB DISPOS, V29, P274; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P940; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis AJ, 1996, DRUG METAB DISPOS, V24, P1180; Li X, 2001, J ENDOCRINOL, V171, P525, DOI 10.1677/joe.0.1710525; Liu MC, 2000, J BIOL CHEM, V275, P13460, DOI 10.1074/jbc.275.18.13460; Lu GG, 2000, EUR J BIOCHEM, V267, P861, DOI 10.1046/j.1432-1327.2000.01070.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; PANG SS, 2002, J BIOL CHEM     1220; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Raftogianis RB, 1999, BIOCHEM PHARMACOL, V58, P605, DOI 10.1016/S0006-2952(99)00145-8; Rehse PH, 2002, BIOCHEM J, V364, P165, DOI 10.1042/bj3640165; REITER C, 1983, N-S ARCH PHARMACOL, V324, P140, DOI 10.1007/BF00497020; SCHREUDER HA, 1993, P NATL ACAD SCI USA, V90, P9968, DOI 10.1073/pnas.90.21.9968; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; Seth P, 2000, CANCER RES, V60, P6859; Stanley EL, 2001, J CLIN ENDOCR METAB, V86, P5944, DOI 10.1210/jc.86.12.5944; VERONESE ME, 1994, BIOCHEM J, V302, P497, DOI 10.1042/bj3020497; Wang J, 1998, MOL PHARMACOL, V53, P274, DOI 10.1124/mol.53.2.274; Wang YF, 2002, LUNG CANCER, V35, P137, DOI 10.1016/S0169-5002(01)00406-8; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Zhang HP, 1998, J BIOL CHEM, V273, P10888, DOI 10.1074/jbc.273.18.10888	45	125	132	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7655	7662		10.1074/jbc.M207246200	http://dx.doi.org/10.1074/jbc.M207246200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12471039	hybrid, Green Published			2022-12-25	WOS:000181195100130
J	Serra, V; von Zglinicki, T; Lorenz, M; Saretzki, G				Serra, V; von Zglinicki, T; Lorenz, M; Saretzki, G			Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; LIFE-SPAN; IN-VITRO; LIPOFUSCIN ACCUMULATION; OXYGEN CONCENTRATION; BJ FIBROBLASTS; SENESCENCE; EXPRESSION; MICE; IMPAIRMENT	There is good evidence that telomere shortening acts as a biological clock in human fibroblasts, limiting the number of population doublings a culture can achieve. Oxidative stress also limits the growth potential of human cells, and recent data show that the effect of mild oxidative stress is mediated by a stress-related increased rate of telomere shortening. Thus, fibroblast strains have donor-specific antioxidant defense, telomere shortening rate, and growth potential. We used low-density gene expression array analysis of fibroblast strains with different antioxidant potentials and telomere shortening rates to identify gene products responsible for these differences. Extracellular superoxide dismutase was identified as the strongest candidate, a correlation that was confirmed by Northern blotting. Over-expression of this gene in human fibroblasts with low antioxidant capacity increased total cellular superoxide dismutase activity, decreased the intracellular peroxide content, slowed the telomere shortening rate, and elongated the life span of these cells under normoxia and hyperoxia. These results identify extracellular superoxide dismutase as an important antioxidant gene product in human fibroblasts, confirm the causal role of oxidative stress for telomere shortening, and strongly suggest that the senescence-like arrest under mild oxidative stress is telomere-driven.	Univ Newcastle, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Charite Hosp, Inst Pathol, D-10098 Berlin, Germany; Charite Hosp, Res Lab Cardiol, D-10098 Berlin, Germany	Newcastle University - UK; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	von Zglinicki, T (corresponding author), Univ Newcastle, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	t.vonzglinicki@ncl.ac.uk	Saretzki, Gabriele Christine/I-7175-2019; Serra, Violeta/AAG-8328-2019	Saretzki, Gabriele Christine/0000-0003-2100-8223; Lorenz, Mario/0000-0001-5267-4101; von Zglinicki, Thomas/0000-0002-5939-0248; Serra, Violeta/0000-0001-6620-1065				Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; BALIN AK, 1977, J CELL BIOL, V74, P58, DOI 10.1083/jcb.74.1.58; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; de Grey ADNJ, 2000, ARCH BIOCHEM BIOPHYS, V373, P295, DOI 10.1006/abbi.1999.1509; Duguet M, 1997, J CELL SCI, V110, P1345; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; KIM RA, 1995, P NATL ACAD SCI USA, V92, P2667, DOI 10.1073/pnas.92.7.2667; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Levin ED, 2002, BEHAV GENET, V32, P119, DOI 10.1023/A:1015201823417; Levin ED, 1998, BEHAV GENET, V28, P381, DOI 10.1023/A:1021673703129; Liu L, 2002, AGING CELL, V1, P40, DOI 10.1046/j.1474-9728.2002.00004.x; Lorenz M, 2001, FREE RADICAL BIO MED, V31, P824, DOI 10.1016/S0891-5849(01)00664-5; Ludwig A, 2001, CANCER RES, V61, P3053; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Petersen S, 1998, EXP CELL RES, V239, P152, DOI 10.1006/excr.1997.3893; Saretzki G, 1998, J GERONTOL A-BIOL, V53, pB438, DOI 10.1093/gerona/53A.6.B438; Sentman ML, 2002, FREE RADICAL BIO MED, V32, P975, DOI 10.1016/S0891-5849(02)00790-6; Serra V, 2000, ANN NY ACAD SCI, V908, P327; Serra V, 2002, FEBS LETT, V516, P71, DOI 10.1016/S0014-5793(02)02504-8; Sheng H, 2000, EXP NEUROL, V163, P392, DOI 10.1006/exnr.2000.7363; SHENG H, 1999, NEUROSCI LETT, V267; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Sitte N, 2001, EXP GERONTOL, V36, P475, DOI 10.1016/S0531-5565(00)00253-9; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; SOHAL RS, 1989, FREE RADICAL BIO MED, V6, P23, DOI 10.1016/0891-5849(89)90155-X; STRALIN P, 1994, BIOCHEM J, V298, P347, DOI 10.1042/bj2980347; Thiels E, 2000, J NEUROSCI, V20, P7631; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; von Zglinicki T, 2000, LAB INVEST, V80, P1739, DOI 10.1038/labinvest.3780184; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; Von Zglinicki T, 2000, ANN NY ACAD SCI, V908, P99, DOI 10.1111/j.1749-6632.2000.tb06639.x; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Yoon HJ, 1998, BBA-GENE STRUCT EXPR, V1395, P110, DOI 10.1016/S0167-4781(97)00139-5	42	182	192	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6824	6830		10.1074/jbc.M207939200	http://dx.doi.org/10.1074/jbc.M207939200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12475988	hybrid			2022-12-25	WOS:000181195100026
J	Tsai, PW; Shiah, SG; Lin, MT; Wu, CW; Kuo, ML				Tsai, PW; Shiah, SG; Lin, MT; Wu, CW; Kuo, ML			Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; LYMPH-NODE METASTASIS; FACTORS VEGF-B; TUMOR-CELLS; MAP KINASE; PROINFLAMMATORY CYTOKINES; SIGNALING PATHWAYS; EPITHELIAL-CELLS	Vascular endothelial growth factor C (VEGF-C) is a critical activator of tumor lymphangiogenesis that recently has been strongly implicated in the tumor metastasis process. In this study, we identified that HRG-beta1 stimulated up-regulation of VEGF-C mRNA and protein of human breast cancer cells in a dosage- and time-dependent manner and that this up-regulation was de novo RNA synthesis-dependent. The HRG-beta1-induced increase in VEGF-C expression was effectively reduced by treatment with Herceptin, an antibody specifically against HER2. Also, when HER2 was overexpressed in MCF-7 cells that resulted in an evident increase in the VEGF-C level, suggesting an essential role of HER2 in mediating VEGF-C up-regulation by HRG-beta1. NF-kappaB has been shown to be probably involved in interleukin-1beta-or tumor necrosis factor-alpha-induced VEGF-C mRNA expression in human fibroblasts. Here we found that HRG-beta1 could stimulate NF-kappaB nuclear translocation and DNA-binding activity via the IkappaBalpha phosphorylation-degradation mechanism. Blockage of the NF-kappaB activation cascade caused a complete inhibition of the HRG-beta1-induced elevation of VEGF-C. In promoter-reporter assay, the luciferase activities of the reporter constructs, including the putative NF-kappaB site deleted and mutated form were significantly reduced after HRG-beta1 treatment as compared with the 1.5-kb VEGF-C promoter. Although investigating the upstream kinase pathway(s) involved in HRG-beta1-elicited NF-kappaB activation and VEGF-C up-regulation, we found that HRG-beta1 could activate extracellular signal-regulated protein kinase 1/2, phosphatidylinositol 3'-kinase, and p38 mitogen-activated protein kinase (MAPK) in MCF-7. However, only SB203580 (a specific inhibitor of p38 MAPK), not PD98059 nor LY294002, blocked the up-regulation of VEGF-C by HRG-beta1. A similar inhibition in VEGF-C expression was obtained by cell transfection with dominant-negative p38 (p38AF). Interestingly, the HRG-beta1-induced NF-kappaB activation cascade was also effectively blocked by SB203580 treatment or p38AF transfection. Our data thus suggests that HRG-beta1 stimulated a NF-kappaB-dependent up-regulation of VEGF-C through the p38 MAPK signaling pathway in human breast cancer cells.	Natl Taiwan Univ, Coll Med, Lab Mol & Cellular Toxicol, Inst Toxicol, Taipei 110, Taiwan; Natl Hlth Res Inst, Presidents Lab, Taipei 115, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 110, Taiwan	National Taiwan University; National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University Hospital	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Lab Mol & Cellular Toxicol, Inst Toxicol, 1,Sec 1,Jeni Ai Rd, Taipei 110, Taiwan.		Kuo, Min-Liang/C-4872-2009; Shiah, Shine-Gwo/D-2087-2010	LIN, MING-TSAN/0000-0001-7313-7057; KUO, MIN-LIANG/0000-0002-7139-0144; Shiah, Shine-Gwo/0000-0002-1003-973X				Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Adam L, 2001, CANCER RES, V61, P81; Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; BORG JP, 1995, ONCOGENE, V10, P973; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; Hoffmann M, 1998, CANCER IMMUNOL IMMUN, V47, P167, DOI 10.1007/s002620050517; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2; Karpanen T, 2001, CANCER RES, V61, P1786; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lessor T, 1998, J CELL BIOCHEM, V70, P587, DOI 10.1002/(SICI)1097-4644(19980915)70:4<587::AID-JCB14>3.0.CO;2-E; Lewis GD, 1996, CANCER RES, V56, P1457; Li XR, 2001, INT J BIOCHEM CELL B, V33, P421, DOI 10.1016/S1357-2725(01)00027-9; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; MARTE BM, 1995, ONCOGENE, V10, P167; Mattila MMT, 2002, INT J CANCER, V98, P946, DOI 10.1002/ijc.10283; Mazumdar A, 2001, CANCER RES, V61, P400; Mochida-Nishimura K, 2001, MOL MED, V7, P177, DOI 10.1007/BF03401951; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Niki T, 2000, CLIN CANCER RES, V6, P2431; Ohta Y, 2000, J THORAC CARDIOV SUR, V119, P804, DOI 10.1016/S0022-5223(00)70017-1; Olofsson B, 1999, CURR OPIN BIOTECH, V10, P528, DOI 10.1016/S0958-1669(99)00024-5; Ozes ON, 1999, NATURE, V401, P82; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Plate KH, 2001, NAT MED, V7, P151, DOI 10.1038/84579; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Romano MF, 2000, GENE THER, V7, P1234, DOI 10.1038/sj.gt.3301216; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Talukder AH, 2000, CANCER RES, V60, P474; Tang CK, 1996, CANCER RES, V56, P3350; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Vadlamudi R, 1999, CANCER RES, V59, P2843; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Weinstein EJ, 2000, CANCER RES, V60, P3856; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; Weldon CB, 2001, SURGERY, V130, P143, DOI 10.1067/msy.2001.115512; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiong SB, 2001, CANCER RES, V61, P1727; Yang WT, 2002, CANCER, V94, P2855, DOI 10.1002/cncr.10553; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823	64	128	147	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5750	5759		10.1074/jbc.M204863200	http://dx.doi.org/10.1074/jbc.M204863200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12471041	hybrid			2022-12-25	WOS:000181129400035
J	Walker, AK; Blackwell, TK				Walker, AK; Blackwell, TK			A broad but restricted requirement for TAF-5 (Human TAF(II)100) for embryonic transcription in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; C-ELEGANS; IN-VIVO; ACETYLASE COMPLEX; SAGA COMPLEXES; YEAST; DROSOPHILA; DISTINCT; SUBUNIT; TBP	As conserved components of the transcription factor (TF) IID- and TFTC/SAGA-related complexes, TATA-binding protein-associated factors (TAF(II)s) are important for eukaryotic mRNA transcription. In yeast, genetic analyses suggest that, although some individual TAF(II)s are required for transcription of most genes, others have highly specialized functions. Much less is known about the functions of TAF(II)s in metazoans, which have more complex genomes that include many tissue-specific genes. TAF-5 (human (h) TAF(II)100) is of particular interest because it is predicted to have an important structural role. Here we describe the first genetics-based analysis of TAF-5 in a metazoan. By performing RNA interference in Caenorhabditis elegans embryos, which can survive for several cell generations without transcription, we found that taf-5 is important for a significant fraction of transcription. However, TAF-5 is apparently not essential for the expression of multiple developmental and other metazoan-specific genes. This phenotype remarkably resembles the previously described effects of similarly depleting two C. elegans histone fold TAF(II)s, TAF-9 (hTAF(II)31/32) and TAF-10 (hTAF(II)130), but is distinct from the widespread transcription block caused by TAF-4 (hTAF(II)130) depletion. Our findings suggest that TAF-5, TAF-9, and TAF-10 are part of a functional module of TFIID- and TFTC/SAGA-related complexes that can be bypassed in many metazoan-specific genes.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Blackwell, TK (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.				NIGMS NIH HHS [R01 GM062891, GM62891] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062891] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Andel F, 1999, SCIENCE, V286, P2153, DOI 10.1126/science.286.5447.2153; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Bellier S, 1997, MOL CELL BIOL, V17, P1434, DOI 10.1128/MCB.17.3.1434; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Calvo D, 2001, EMBO J, V20, P7197, DOI 10.1093/emboj/20.24.7197; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; Durso RJ, 2001, MOL CELL BIOL, V21, P7331, DOI 10.1128/MCB.21.21.7331-7344.2001; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Mitsuzawa H, 2002, NUCLEIC ACIDS RES, V30, P1952, DOI 10.1093/nar/30.9.1952; Newman-Smith ED, 1998, CURR OPIN GENET DEV, V8, P472, DOI 10.1016/S0959-437X(98)80120-2; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; Rubin GM, 2001, NATURE, V409, P820, DOI 10.1038/35057277; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Seydoux G, 1997, DEVELOPMENT, V124, P2191; Shim EY, 2002, J BIOL CHEM, V277, P30413, DOI 10.1074/jbc.C200305200; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wassarman DA, 2000, P NATL ACAD SCI USA, V97, P1154, DOI 10.1073/pnas.97.3.1154; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	51	9	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6181	6186		10.1074/jbc.M211056200	http://dx.doi.org/10.1074/jbc.M211056200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12458202	hybrid			2022-12-25	WOS:000181129400087
J	Haouz, A; Vanheusden, V; Munier-Lehmann, H; Froeyen, M; Herdewijn, P; Van Calenbergh, S; Delarue, M				Haouz, A; Vanheusden, V; Munier-Lehmann, H; Froeyen, M; Herdewijn, P; Van Calenbergh, S; Delarue, M			Enzymatic and structural analysis of inhibitors designed against Mycobacterium tuberculosis thymidylate kinase - New insights into the phosphoryl transfer mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 THYMIDINE KINASE; SIMPLEX-VIRUS TYPE-1; CRYSTAL-STRUCTURE; COMPLEX; CRYSTALLOGRAPHY; MONOPHOSPHATE; RESOLUTION; CATALYSIS; BINDING; ASSAY	The chemical synthesis of new compounds designed as inhibitors of Mycobacterium tuberculosis TMP kinase (TMPK) is reported. The synthesis concerns TMP analogues modified at the 5-position of the thymine ring as well as a novel compound with a six-membered sugar ring. The binding properties of the analogues are compared with the known inhibitor azido-TMP, which is postulated here to work by excluding the TMP-bound Mg2+ ion. The crystallographic structure of the complex of one of the compounds, 5-CH2OH-dUMP, with TMPK has been determined at 2.0 Angstrom. It reveals a major conformation for the hydroxyl group in contact with a water molecule and a minor conformation pointing toward Ser(99). Looking for a role for Ser(99), we have identified an unusual catalytic triad, or a proton wire, made of strictly conserved residues (including Glu(6), Ser(99), Arg, and Asp(9)) that probably serves to protonate the transferred PO3 group. The crystallographic structure of the commercially available bisubstrate analogue P-1-(adenosine-5')-P-5-(thymidine-5')-pentaphosphate bound to TMPK is also reported at 2.45 Angstrom and reveals an alternative binding pocket for the adenine moiety of the molecule compared with what is observed either in the Escherichia coli or in the yeast enzyme structures. This alternative binding pocket opens a way for the design of a new family of specific inhibitors.	Inst Pasteur, CNRS, URA 2185, Unite Biochim Struct, F-75015 Paris, France; Inst Pasteur, CNRS, URA 2185, Lab Chim Struct Macromol, F-75015 Paris, France; Univ Ghent, Fac Pharmaceut Sci, Med Chem Lab, B-9000 Ghent, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, Med Chem Lab, B-3000 Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ghent University; KU Leuven	Delarue, M (corresponding author), Inst Pasteur, CNRS, URA 2185, Unite Biochim Struct, 25 Rue Dr Roux, F-75015 Paris, France.	marc.delarue@pasteur.fr	Munier-Lehmann, Hélène/Q-1867-2019; Froeyen, Mathy MC/I-1665-2014; Munier-Lehmann, Helene/N-9889-2017; Van Calenbergh, Serge/A-3167-2008	Munier-Lehmann, Hélène/0000-0001-7579-8561; Froeyen, Mathy MC/0000-0002-8675-6540; Munier-Lehmann, Helene/0000-0001-7579-8561; Van Calenbergh, Serge/0000-0002-4201-1264; HAOUZ, Ahmed/0000-0003-1196-1635; Herdewijn, Piet/0000-0003-3589-8503				Anderson E. P., 1973, ENZYMES, V8, P49; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bennett MS, 1999, FEBS LETT, V443, P121, DOI 10.1016/S0014-5793(98)01619-6; BLONDIN C, 1994, ANAL BIOCHEM, V220, P219, DOI 10.1006/abio.1994.1326; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Champness JN, 1998, PROTEINS, V32, P350, DOI 10.1002/(SICI)1097-0134(19980815)32:3<350::AID-PROT10>3.0.CO;2-8; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; CLINE RE, 1959, J AM CHEM SOC, V81, P2521, DOI 10.1021/ja01519a056; Cole Stewart T., 1994, Trends in Microbiology, V2, P411, DOI 10.1016/0966-842X(94)90621-1; DABRY GK, 1995, ANTIVIR CHEM CHEMOTH, V6, P54; de la Sierra IL, 2000, ACTA CRYSTALLOGR D, V56, P226, DOI 10.1107/S0907444999016212; de la Sierra IL, 2001, J MOL BIOL, V311, P87, DOI 10.1006/jmbi.2001.4843; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; GRIFFITHS PD, 1995, ANTIVIR CHEM CHEMOTH, V6, P191, DOI 10.1177/095632029500600401; GUPTA VS, 1971, CAN J CHEMISTRY, V49, P719, DOI 10.1139/v71-121; HAOUZ A, 1994, ENZYME MICROB TECH, V16, P292, DOI 10.1016/0141-0229(94)90169-4; Hutter MC, 2000, PROTEIN SCI, V9, P2225, DOI 10.1110/ps.9.11.2225; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavie A, 1997, NAT STRUCT BIOL, V4, P601, DOI 10.1038/nsb0897-601; Lavie A, 1998, P NATL ACAD SCI USA, V95, P14045, DOI 10.1073/pnas.95.24.14045; Lavie A, 1998, BIOCHEMISTRY-US, V37, P3677, DOI 10.1021/bi9720787; Manallack DT, 2002, J ENZYM INHIB MED CH, V17, P167, DOI 10.1080/14756360290032949; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; Munier-Lehmann H, 2001, PROTEIN SCI, V10, P1195, DOI 10.1110/ps.45701; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ostermann N, 2000, J MOL BIOL, V304, P43, DOI 10.1006/jmbi.2000.4175; Ostermann N, 2000, STRUCTURE, V8, P629, DOI 10.1016/S0969-2126(00)00149-0; Ostrowski T, 1998, J MED CHEM, V41, P4343, DOI 10.1021/jm980287z; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Scheffzek K, 1996, BIOCHEMISTRY-US, V35, P9716, DOI 10.1021/bi960642s; SCHEIT KH, 1966, CHEM BER-RECL, V99, P3884, DOI 10.1002/cber.19660991221; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; Segel I.H, 1993, ENZYME KINETICS; Shaw A, 2002, J MOL BIOL, V320, P303, DOI 10.1016/S0022-2836(02)00387-X; Sheng XR, 1999, J BIOL CHEM, V274, P22238, DOI 10.1074/jbc.274.32.22238; Stokstad E, 2000, SCIENCE, V287, P2391; Tona R, 2000, ORG LETT, V2, P1693, DOI 10.1021/ol005797d; Tsuyuguchi I, 2001, TUBERCULOSIS, V81, P221, DOI 10.1054/tube.2001.0286; Vanheusden V, 2002, BIOORG MED CHEM LETT, V12, P2695, DOI 10.1016/S0960-894X(02)00551-6; Vastmans K, 2001, NUCLEIC ACIDS RES, V29, P3154, DOI 10.1093/nar/29.15.3154; Vogt J, 2000, PROTEINS, V41, P545, DOI 10.1002/1097-0134(20001201)41:4<545::AID-PROT110>3.0.CO;2-8; WIGERINCK P, 1991, J MED CHEM, V34, P2383, DOI 10.1021/jm00112a011; Wild K, 1997, PROTEIN SCI, V6, P2097	49	84	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4963	4971		10.1074/jbc.M209630200	http://dx.doi.org/10.1074/jbc.M209630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12454011	Green Published, hybrid			2022-12-25	WOS:000180968900081
J	Losman, JA; Chen, XP; Vuong, BQ; Fay, S; Rothman, PB				Losman, JA; Chen, XP; Vuong, BQ; Fay, S; Rothman, PB			Protein phosphatase 2A regulates the stability of pim protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOCS-BOX MOTIF; C-MYC; TRANSGENIC MICE; MESSENGER-RNA; CELL-LINES; PROTEASOME; EXPRESSION; DEGRADATION; GENE; PHOSPHORYLATION	The pint family of proto-oncogenes encodes three serine-threonine kinases that have been implicated in the development of malignancies in mice and in humans. Expression of the Pint protein kinases is tightly regulated at the transcriptional, post-transcriptional, and translational levels. Dysregulation of pim transcription and pim mRNA stability have been implicated in Pim-mediated transformation. The data presented herein demonstrate that expression of the Pim kinases is additionally regulated at the post-translational level, by the serine-threonine phosphatase protein phosphatase 2A (PP2A). The catalytic subunit of PP2A associates with the Pim kinases in vivo, and the Pint kinases are substrates of PP2A phosphatase activity in vitro. Furthermore, overexpression of PP2A reduces the levels of the Pim proteins, whereas inhibition of PP2A activity by the protein phosphatase inhibitor okadaic acid stabilizes the Pint proteins. Finally, the effects of PP2A on the expression of the Pint proteins can affect Pint function. Taken together, these data suggest that PP2A activity is important for the regulation of the stability and function of the Pim kinases.	Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Integrated Program Mol Cellular & Biophys Studies, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Rothman, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Surg, 630 W 168th St, New York, NY 10032 USA.			Vuong, Bao/0000-0001-5416-9635	NIAID NIH HHS [T32 AI 07525, P01 AI 50514] Funding Source: Medline; NIGMS NIH HHS [GM 07367] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050514, T32AI007525] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; DOMEN J, 1993, BLOOD, V82, P1445; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; ETLINGER JD, 1993, ENZYME PROTEIN, V47, P325, DOI 10.1159/000468690; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Konietzko U, 1999, EMBO J, V18, P3359, DOI 10.1093/emboj/18.12.3359; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Liang H, 1996, ARCH BIOCHEM BIOPHYS, V330, P259, DOI 10.1006/abbi.1996.0251; Losman JA, 1999, J IMMUNOL, V162, P3770; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; NAGARAJAN L, 1993, BIOCHEM BIOPH RES CO, V190, P435, DOI 10.1006/bbrc.1993.1066; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P2556, DOI 10.1073/pnas.83.8.2556; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Umeda M, 1997, FEBS LETT, V403, P313, DOI 10.1016/S0014-5793(97)00073-2; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VONLINDERN M, 1989, ONCOGENE, V4, P75; Wingett D, 1996, J IMMUNOL, V156, P549; WINGETT D, 1991, J IMMUNOL, V147, P3653; YIPSCHNEIDER MT, 1995, BLOOD, V85, P3494, DOI 10.1182/blood.V85.12.3494.bloodjournal85123494; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	38	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4800	4805		10.1074/jbc.M208246200	http://dx.doi.org/10.1074/jbc.M208246200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12473674	hybrid			2022-12-25	WOS:000180968900059
J	Toulokhonova, L; Metzler, WJ; Witmer, MR; Copeland, RA; Marcinkeviciene, J				Toulokhonova, L; Metzler, WJ; Witmer, MR; Copeland, RA; Marcinkeviciene, J			Kinetic studies on beta-Site amyloid precursor protein-cleaving enzyme (BACE) - Confirmation of an iso-mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARRIER HYDROGEN-BONDS; PORCINE PEPSIN; ASPARTIC PROTEINASE; FRACTIONATION FACTORS; GAMMA-SECRETASE; INHIBITION; ENDOTHIAPEPSIN; SPECIFICITY; COMPLEXES; RENIN	The steady-state kinetic mechanism of beta-amyloid precursor protein-cleaving enzyme (BACE)-catalyzed proteolytic cleavage was evaluated using product and statine- (Stat(V)) or hydroxyethylene-containing (OM99-2) peptide inhibition data, solvent kinetic isotope effects, and proton NMR spectroscopy. The noncompetitive inhibition pattern observed for both cleavage products, together with the independence of Stat(V) inhibition on substrate concentration, suggests a uni-bi-iso kinetic mechanism. According to this mechanism, the enzyme undergoes multiple conformation changes during the catalytic cycle. If any of these steps are rate-limiting to turnover, an enzyme form preceding the rate-limiting conformational change should accumulate. An insignificant solvent kinetic isotope effect (SKIE) on k(cat)/K-m, a large inverse solvent kinetic isotope effect on k(cat), and the absence of any SKIE on the inhibition onset by Stat(V) during catalysis together indicate that the rate-limiting iso-step occurs after formation of a tetrahedral intermediate. A moderately short and strong hydrogen bond (at delta 13.0 ppm and phi of 0.6) has been observed by NMR spectroscopy in the enzyme-hydroxyethylene peptide (OM99-2) complex that presumably mimics the tetrahedral intermediate of catalysis. Collapse of this intermediate, involving multiple steps and interconversion of enzyme forms, has been suggested to impose a rate limitation, which is manifested in a significant SKIE on k(cat). Multiple enzyme forms and their distribution during catalysis were evaluated by measuring the SKIE on the noncompetitive (mixed) inhibition constants for the C-terminal reaction product. Large, normal SKIE values were observed for these inhibition constants, suggesting that both kinetic and thermodynamic components contribute to the K-ii and K-is expressions, as has been suggested for other iso-mechanism featuring enzymes. We propose that a conformational change related to the reprotonation of aspartates during or after the bond-breaking event is the rate-limiting segment in the catalytic reaction of beta-amyloid precursor protein-cleaving enzyme, and ligands binding to other than the ground-state forms of the enzyme might provide inhibitors of greater pharmacological relevance.	Bristol Myers Squibb Co, Dept Chem Enzymol, Wilmington, DE 19880 USA; Dept Macromol Struct, Princeton, NJ 08543 USA; Dept Biopharmaceut Sci & Technol, Princeton, NJ 08543 USA	Bristol-Myers Squibb	Marcinkeviciene, J (corresponding author), Bristol Myers Squibb Co, Dept Chem Enzymol, POB 80400, Wilmington, DE 19880 USA.	jovita.marcinkeviciene@bms.com						ALBERY WJ, 1986, BIOCHEMISTRY-US, V25, P2572, DOI 10.1021/bi00357a043; Cassidy CS, 1997, BIOCHEMISTRY-US, V36, P4576, DOI 10.1021/bi962013o; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHO YK, 1994, BIOCHEMISTRY-US, V33, P9637, DOI 10.1021/bi00198a032; CHOU TC, 1974, MOL PHARMACOL, V10, P235; Citron M, 2000, MOL MED TODAY, V6, P392, DOI 10.1016/S1357-4310(00)01759-7; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland WW, 2000, ARCH BIOCHEM BIOPHYS, V382, P1, DOI 10.1006/abbi.2000.2011; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Coates L, 2001, BIOCHEMISTRY-US, V40, P13149, DOI 10.1021/bi010626h; Coates L, 2002, J MOL BIOL, V318, P1405, DOI 10.1016/S0022-2836(02)00197-3; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; FRASER ME, 1992, BIOCHEMISTRY-US, V31, P5201, DOI 10.1021/bi00137a016; Ghosh AK, 2000, J AM CHEM SOC, V122, P3522, DOI 10.1021/ja000300g; GREEN DW, 1990, BIOCHEMISTRY-US, V29, P3126, DOI 10.1021/bi00464a032; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; HORE PJ, 1983, J MAGN RESON, V55, P283, DOI 10.1016/0022-2364(83)90240-8; HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; KREEVOY MM, 1980, J AM CHEM SOC, V102, P3315, DOI 10.1021/ja00530a002; Kumar GA, 1998, J ORG CHEM, V63, P6968, DOI 10.1021/jo980759h; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LOH SN, 1994, BIOCHEMISTRY-US, V33, P1029, DOI 10.1021/bi00170a023; MACGREGOR GA, 1981, NATURE, V291, P329, DOI 10.1038/291329a0; Mallender WD, 2001, MOL PHARMACOL, V59, P619, DOI 10.1124/mol.59.3.619; Marcinkeviciene J, 2002, J BIOL CHEM, V277, P28677, DOI 10.1074/jbc.M203120200; Marcinkeviciene J, 2001, J BIOL CHEM, V276, P23790, DOI 10.1074/jbc.M101896200; Markley JL, 1996, BIOCHEMISTRY-US, V35, P11092, DOI 10.1021/bi961366k; Northrop DB, 2001, ACCOUNTS CHEM RES, V34, P790, DOI 10.1021/ar000184m; Northrop DB, 1997, ARCH BIOCHEM BIOPHYS, V342, P317, DOI 10.1006/abbi.1997.0131; Oefner C, 1999, CHEM BIOL, V6, P127, DOI 10.1016/S1074-5521(99)89004-8; Piana S, 2000, PROTEINS, V39, P26, DOI 10.1002/(SICI)1097-0134(20000401)39:1<26::AID-PROT3>3.0.CO;2-N; QUINN DM, 1991, ENZYME MECH ISOTOPE, P73; REBHOLZ KL, 1995, METHOD ENZYMOL, V249, P211; REBHOLZ KL, 1994, ARCH BIOCHEM BIOPHYS, V312, P227, DOI 10.1006/abbi.1994.1303; REBHOLZ KL, 1991, BIOCHEM BIOPH RES CO, V176, P65, DOI 10.1016/0006-291X(91)90890-J; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; STEIN RL, 1985, J AM CHEM SOC, V107, P6039, DOI 10.1021/ja00307a035; SUGUNA K, 1987, P NATL ACAD SCI USA, V84, P7009, DOI 10.1073/pnas.84.20.7009; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WANG MS, 1975, BIOORG CHEM, V4, P392, DOI 10.1016/0045-2068(75)90050-4; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	48	38	38	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4582	4589		10.1074/jbc.M210471200	http://dx.doi.org/10.1074/jbc.M210471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12458195	hybrid			2022-12-25	WOS:000180968900031
J	Yoon-Robarts, M; Linden, RM				Yoon-Robarts, M; Linden, RM			Identification of active site residues of the adeno-associated virus type 2 Rep endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE ACTIVITY; ADENOASSOCIATED VIRUS; MUTATIONAL ANALYSIS; IN-VITRO; V(D)J RECOMBINATION; GENE-THERAPY; PROTEIN; INTEGRATION; AAV; BINDING	Adeno-associated virus type 2 Rep endonuclease activity is necessary for both viral DNA replication and site-specific integration of the viral genome into human chromosome 19. The biochemical activities required for site-specific endonuclease activity (namely specific DNA binding and transesterification. activity) have been mapped to the amino-terminal domain of the AAV2 Rep protein. The amino-terminal 208 amino acids are alone sufficient for site-specific endonuclease activity, and nicking by this domain is metal-dependent. To identify this metal-binding site, we have employed a cysteine mutagenesis approach that targets conserved acidic amino acids. By using this technique, we provide functional biochemical data supporting a role for glutamate 83 in the coordination of metal ions in the context of Rep endonuclease activity. In addition, our biochemical data suggest that glutamate 164, although not involved in the coordination of metal ions, is closely associated with the active site. Thus, in lieu of a crystal structure for the AAV type 2 amino-terminal domain, our data corroborate the recently published structural studies of the AAV type 5 endonuclease and suggest that although the two enzymes are not highly conserved with respect to the AAV family, their active sites are highly conserved.	CUNY Mt Sinai Sch Med, Carl C Icahn Inst Gene Therapy & Mol Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Linden, RM (corresponding author), CUNY Mt Sinai Sch Med, Carl C Icahn Inst Gene Therapy & Mol Med, New York, NY 10029 USA.				NIAID NIH HHS [T32AI07647] Funding Source: Medline; NICHD NIH HHS [T32HD07105] Funding Source: Medline; NIGMS NIH HHS [GM/AI62234] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062234] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allingham JS, 2002, J MOL BIOL, V319, P53, DOI 10.1016/S0022-2836(02)00297-8; Allingham JS, 1999, J MOL BIOL, V289, P1195, DOI 10.1006/jmbi.1999.2837; BERNS KI, 1975, VIROLOGY, V68, P556, DOI 10.1016/0042-6822(75)90298-6; BERNS KI, 1995, BIOESSAYS, V17, P237, DOI 10.1002/bies.950170310; Brister JR, 1999, J VIROL, V73, P9325, DOI 10.1128/JVI.73.11.9325-9336.1999; Cathomen T, 2000, J VIROL, V74, P2372, DOI 10.1128/JVI.74.5.2372-2382.2000; CHEUNG AKM, 1980, J VIROL, V33, P739, DOI 10.1128/JVI.33.2.739-748.1980; Chiorini JA, 1999, J VIROL, V73, P4293, DOI 10.1128/JVI.73.5.4293-4298.1999; Chiorini JA, 1999, J VIROL, V73, P1309, DOI 10.1128/JVI.73.2.1309-1319.1999; Davis MD, 2000, J VIROL, V74, P2936, DOI 10.1128/JVI.74.6.2936-2942.2000; Davis MD, 1999, J VIROL, V73, P2084, DOI 10.1128/JVI.73.3.2084-2093.1999; Dutheil N, 2000, P NATL ACAD SCI USA, V97, P4862, DOI 10.1073/pnas.080079397; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; Galburt EA, 2002, BIOCHEMISTRY-US, V41, P13851, DOI 10.1021/bi020467h; Hickman AB, 2002, MOL CELL, V10, P327, DOI 10.1016/S1097-2765(02)00592-0; HORER M, 1995, J VIROL, V69, P5485; IM DS, 1992, J VIROL, V66, P1119, DOI 10.1128/JVI.66.2.1119-1128.1992; IM DS, 1990, CELL, V61, P447, DOI 10.1016/0092-8674(90)90526-K; KOONIN EV, 1993, BIOSYSTEMS, V30, P241, DOI 10.1016/0303-2647(93)90074-M; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; KOTIN RM, 1992, EMBO J, V11, P5071, DOI 10.1002/j.1460-2075.1992.tb05614.x; KOTIN RM, 1994, HUM GENE THER, V5, P793, DOI 10.1089/hum.1994.5.7-793; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; Linden RM, 1996, P NATL ACAD SCI USA, V93, P7966, DOI 10.1073/pnas.93.15.7966; Linden RM, 1996, P NATL ACAD SCI USA, V93, P11288, DOI 10.1073/pnas.93.21.11288; Linden RM, 2000, CONTRIB MICROBIOL, V4, P68; Linden RM, 1997, GENE THER, V4, P4, DOI 10.1038/sj.gt.3300357; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; Santagata S, 1998, J BIOL CHEM, V273, P16325, DOI 10.1074/jbc.273.26.16325; Sarnovsky RJ, 1996, EMBO J, V15, P6348, DOI 10.1002/j.1460-2075.1996.tb01024.x; Smith DH, 1999, J VIROL, V73, P2930, DOI 10.1128/JVI.73.4.2930-2937.1999; Smith RH, 2000, J VIROL, V74, P3122, DOI 10.1128/JVI.74.7.3122-3129.2000; Smith RH, 1998, J VIROL, V72, P4874, DOI 10.1128/JVI.72.6.4874-4881.1998; SNYDER RO, 1990, J VIROL, V64, P6204, DOI 10.1128/JVI.64.12.6204-6213.1990; Urabe M, 1999, J VIROL, V73, P2682, DOI 10.1128/JVI.73.4.2682-2693.1999; Walker SL, 1997, J VIROL, V71, P6996, DOI 10.1128/JVI.71.9.6996-7004.1997; WARD P, 1995, VIROLOGY, V209, P692, DOI 10.1006/viro.1995.1306; Yoon M, 2001, J VIROL, V75, P3230, DOI 10.1128/JVI.75.7.3230-3239.2001; Zhou XH, 1999, J VIROL, V73, P1580, DOI 10.1128/JVI.73.2.1580-1590.1999; Zhu CX, 1997, J BIOL CHEM, V272, P16206, DOI 10.1074/jbc.272.26.16206; Zhu CX, 2000, J BIOL CHEM, V275, P5318, DOI 10.1074/jbc.275.8.5318; [No title captured]	44	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4912	4918		10.1074/jbc.M209750200	http://dx.doi.org/10.1074/jbc.M209750200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12480938	hybrid			2022-12-25	WOS:000180968900074
J	Haro, A; Velez, M; Goormaghtigh, E; Lago, S; Vazquez, J; Andreu, D; Gasset, M				Haro, A; Velez, M; Goormaghtigh, E; Lago, S; Vazquez, J; Andreu, D; Gasset, M			Reconstitution of holin activity with a synthetic peptide containing the 1-32 sequence region of edh, the EJ-1 phage holin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; TRANSMEMBRANE DOMAINS; BACTERIOPHAGE LYSIS; CIRCULAR-DICHROISM; LACTOCOCCUS-LACTIS; LIPID BILAYERS; LAMBDA-HOLIN; MECHANISM; MEMBRANE; ORIENTATION	Pneumococcal EJ-1 phage holin (EJh) is a hydrophobic polypeptide of 85 amino acid residues displaying lethal inner membrane disruption activity. To get an insight into holin structure and function, several peptides representing the different topological regions predicted by sequence analysis have been synthesized. Peptides were structurally characterized in both aqueous buffer and membrane environments, and their potential to induce membrane perturbation was determined. Among them, only the N-terminal predicted transmembrane helix increased the membrane permeability. This segment, only when flanked by the positive charged residues on its N-terminal side, which are present in the sequence of the full-length protein, folds into a major alpha-helix structure with a transmembrane preferential orientation. Fluorescein quenching experiments of N-terminal-labeled peptide evidenced the formation of oligomers of variable size depending on the peptide-to-lipid molar ratio. The self-assembling tendency correlated with the formation of transmembrane pores that permit the release of encapsulated dextrans of various sizes. When analyzed by atomic force microscopy, peptide-induced membrane lesions are visualized as transbilayer holes. These findings are the first evidence for a lytic domain in holins and for the nature of membrane lesions caused by them.	CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; CSIC, Ctr Biol Mol Severo Ochoa, E-28006 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias 100 16, E-28049 Madrid, Spain; Free Univ Brussels, B-1050 Brussels, Belgium; Univ Pablo de Olavide, Fac Ciencias Expt, Seville 41013, Spain; Univ Pompeu Fabra, Dept Ciencias Expt & Salud, Barcelona 08003, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universidad Pablo de Olavide; Pompeu Fabra University	Gasset, M (corresponding author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.		Andreu, David/I-4359-2014; Lago, Santiago/K-3517-2012; Gasset, Maria/I-2050-2014; Gasset, Maria/K-4339-2012; Velez, Marisela/F-2900-2013; Vazquez, Jesus/B-7697-2015	Andreu, David/0000-0002-6317-6666; Gasset, Maria/0000-0001-6436-4055; Gasset, Maria/0000-0001-6436-4055; Velez, Marisela/0000-0002-9424-510X; Vazquez, Jesus/0000-0003-1461-5092; Goormaghtigh, Erik/0000-0002-2071-2262				Aggeli A, 1996, BIOCHEMISTRY-US, V35, P16213, DOI 10.1021/bi960891g; Alewood P, 1997, METHOD ENZYMOL, V289, P14; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; Blasi U, 1996, MOL MICROBIOL, V21, P675, DOI 10.1046/j.1365-2958.1996.331395.x; Blasi U, 1999, J BACTERIOL, V181, P2922; Boden N, 1997, BIOPHYS CHEM, V65, P205, DOI 10.1016/S0301-4622(96)02260-0; BOHRER MP, 1979, J GEN PHYSIOL, V74, P583, DOI 10.1085/jgp.74.5.583; Corbin J, 1998, J BIOL CHEM, V273, P771, DOI 10.1074/jbc.273.2.771; deRuyter PGGA, 1997, NAT BIOTECHNOL, V15, P976, DOI 10.1038/nbt1097-976; Diaz E, 1996, MOL MICROBIOL, V19, P667, DOI 10.1046/j.1365-2958.1996.399929.x; Ding FX, 2001, BIOCHEMISTRY-US, V40, P8945, DOI 10.1021/bi010394m; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; Fernandez-Tornero C, 2002, J MOL BIOL, V321, P163, DOI 10.1016/S0022-2836(02)00596-X; Fominaya J, 2000, J GENE MED, V2, P455, DOI 10.1002/1521-2254(200011/12)2:6<455::AID-JGM145>3.0.CO;2-O; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; Gasset M, 1997, EUR J BIOCHEM, V250, P735, DOI 10.1111/j.1432-1033.1997.00735.x; Gindreau E, 1999, FEMS MICROBIOL LETT, V171, P231, DOI 10.1016/S0378-1097(99)00006-3; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; Grundling A, 2000, J BIOL CHEM, V275, P769, DOI 10.1074/jbc.275.2.769; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15156, DOI 10.1021/bi970146j; Jass J, 2000, BIOPHYS J, V79, P3153, DOI 10.1016/S0006-3495(00)76549-0; JOHNSONBOAZ R, 1994, MOL MICROBIOL, V13, P495, DOI 10.1111/j.1365-2958.1994.tb00444.x; LADHOKIN AS, 1997, BIOPHYS J, V72, P794; LADHOKIN AS, 1997, BIOPHYS J, V72, P1762; LINDBLOM G, 1991, BIOCHEMISTRY-US, V30, P10938, DOI 10.1021/bi00109a019; Marsh D, 1997, BIOPHYS J, V72, P2710, DOI 10.1016/S0006-3495(97)78914-8; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; RAAB R, 1986, J BACTERIOL, V167, P1035, DOI 10.1128/jb.167.3.1035-1042.1986; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Rinia HA, 2001, FEBS LETT, V504, P194, DOI 10.1016/S0014-5793(01)02704-1; Saiz JL, 2002, PROTEIN SCI, V11, P1788, DOI 10.1110/ps.4680102; Sanders JW, 1997, APPL ENVIRON MICROB, V63, P4877, DOI 10.1128/AEM.63.12.4877-4882.1997; Schneider J, 2000, BIOPHYS J, V79, P1107, DOI 10.1016/S0006-3495(00)76364-8; Smith DL, 1998, J BACTERIOL, V180, P2531, DOI 10.1128/JB.180.9.2531-2540.1998; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; TYRREL JW, 2001, PHYS REV LETT, V87, P17614; Wang IN, 2000, ANNU REV MICROBIOL, V54, P799, DOI 10.1146/annurev.micro.54.1.799; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575; YOUNG R, 1995, FEMS MICROBIOL REV, V17, P191, DOI 10.1016/0168-6445(94)00079-4; Young R, 2002, J MOL MICROB BIOTECH, V4, P21; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992; ZAGOTTA MT, 1990, J BACTERIOL, V172, P191	45	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3929	3936		10.1074/jbc.M211334200	http://dx.doi.org/10.1074/jbc.M211334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12464609	hybrid			2022-12-25	WOS:000180869700054
J	Hou, YX; Riordan, JR; Chang, XB				Hou, YX; Riordan, JR; Chang, XB			ATP binding, not hydrolysis, at the first nucleotide-binding domain of multidrug resistance-associated protein MRP1 enhances ADP-Vi trapping at the second domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; CANCER CELL-LINE; LEUKOTRIENE C-4; CATALYTIC CYCLE; CONJUGATE TRANSPORT; GENE; SITES; OVEREXPRESSION; TURNOVER	Multidrug resistance-associated protein (MRP1) transports solutes in an ATP-dependent manner by utilizing its two nonequivalent nucleotide binding domains (NBDs) to bind and hydrolyze ATP. We found that ATP binding to the first NBD of MRP1 increases binding and trapping of ADP at the second domain (Hou, Y., Cui, L., Riordan, J. R., and Chang, X. (2002) J. Biol. Chem. 277, 5110-5119). These results were interpreted as indicating that the binding of ATP at NBD1 causes a conformational change in the molecule and increases the affinity for ATP at NBD2. However, we did not distinguish between the possibilities that the enhancement of ADP trapping might be caused by either ATP binding alone or hydrolysis. We now report the following. 1) ATP has a much lesser effect at 0 C than at 37 C. 2) After hexokinase treatment, the nonhydrolyzable ATP analogue, adenyl 5'-(yl iminodiphosphate), does not enhance ADP trapping. 3) Another nonhydrolyzable ATP analogue, adenosine 5'-(beta,gamma-methylene)triphosphate, whether hexokinase-treated or not, causes a slight enhancement. 4) In contrast, the hexokinase-treated poorly hydrolyzable ATP analogue, adenosine 5'-O-(thiotriphosphate) (ATPgammaS), enhances ADP trapping to a similar extent as ATP under conditions in which ATPgammaS should not be hydrolyzed. We conclude that: 1) ATP hydrolysis is not required to enhance ADP trapping by MRP1 protein; 2) with nucleotides having appropriate structure such as ATP or ATPgammaS, binding alone can enhance ADP trapping by MRP1; 3) the stimulatory effect on ADP trapping is greatly diminished when the MRP1 protein is in a "fiozen state" (0 degreesC); and 4) the steric structure of the nucleotide gamma-phosphate is crucial in determining whether binding of the nucleotide to NBD1 of MRP1 protein can induce the conformational change that influences nucleotide trapping at NBD2.	Mayo Clin & Mayo Fdn, S C Johnson Med Res Ctr, Mayo Clin Scottsdale, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix	Chang, XB (corresponding author), Mayo Clin & Mayo Fdn, S C Johnson Med Res Ctr, Mayo Clin Scottsdale, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	xbchang@mayo.edu			NATIONAL CANCER INSTITUTE [R01CA089078] Funding Source: NIH RePORTER; NCI NIH HHS [CA89078] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui LY, 2001, ARCH BIOCHEM BIOPHYS, V392, P153, DOI 10.1006/abbi.2001.2441; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GEORGES E, 1993, J BIOL CHEM, V268, P1792; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Keppler D, 1996, ADV ENZYME REGUL, V36, P17, DOI 10.1016/0065-2571(95)00011-9; Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Manciu L, 2000, BIOCHEMISTRY-US, V39, P13026, DOI 10.1021/bi001043v; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; MIRSKI SEL, 1987, CANCER RES, V47, P2594; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Senior AE, 1998, METHOD ENZYMOL, V292, P514; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Vigano C, 2002, J BIOL CHEM, V277, P5008, DOI 10.1074/jbc.M107928200; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1	41	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3599	3605		10.1074/jbc.M210480200	http://dx.doi.org/10.1074/jbc.M210480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12458196	hybrid			2022-12-25	WOS:000180869700013
J	Rousseau, V; Goupille, O; Morin, N; Barnier, JV				Rousseau, V; Goupille, O; Morin, N; Barnier, JV			A new constitutively active brain PAK3 isoform displays modified specificities toward Rac and Cdc42 GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED KINASE PAK1; BREAST-CANCER CELLS; PROTEIN-KINASE; MENTAL-RETARDATION; RHO GTPASES; ACTIVATION; FAMILY; MEMBRANE; ORGANIZATION; EXPRESSION	p21-activated kinases (PAK) are involved in the control of cytoskeleton dynamics and cell cycle progression. Here we report the characterization of a new mammalian PAK3 mRNA that contains a 45-bp alternatively spliced exon. This exon encodes for 15 amino acids that are inserted in the regulatory domain, inside the auto-inhibitory domain but outside the Cdc42 and Rac interactive binding domain. The transcript of the 68-kDa new isoform named PAK3b is expressed in various areas of the adult mouse brain. In contrast to PAK3 without the exon b (PAK3a), whose basal kinase activity is weak in resting cells, PAK3b displays a high kinase activity in starved cells that is not further stimulated by active GTPases. Indeed, we demonstrate that the autoinhibitory domain of PAK3b no longer inhibits the kinase activity of PAK3. Moreover, we show that the 15-amino acid insertion within the autoinhibitory domain impedes the ability of PAK3b to bind to the GTPases Rac and Cdc42 and changes its specificity toward the GTPases. Altogether, our results show that the new PAK3b isoform has unique properties and would signal differently from PAK3a in neurons.	CNRS, Neurobiol Cellulaire & Mol Lab, F-91198 Gif Sur Yvette, France; CNRS, Ctr Rech Biochim Macromol, F-34033 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Barnier, JV (corresponding author), CNRS, Neurobiol Cellulaire & Mol Lab, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.		Goupille, Olivier/AAO-2716-2020	Morin, Nathalie/0000-0001-8677-1401				Allen KM, 1998, GENOMICS, V52, P214, DOI 10.1006/geno.1998.5424; Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Bienvenu T, 2000, AM J MED GENET, V93, P294, DOI 10.1002/1096-8628(20000814)93:4<294::AID-AJMG8>3.0.CO;2-F; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cau J, 2000, J BIOL CHEM, V275, P2367, DOI 10.1074/jbc.275.4.2367; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Ellis S, 2000, CURR BIOL, V10, P1387, DOI 10.1016/S0960-9822(00)00777-6; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Reeder MK, 2001, J BIOL CHEM, V276, P40606, DOI 10.1074/jbc.M103925200; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Tu H, 1999, MOL CELL BIOL, V19, P602; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	57	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3912	3920		10.1074/jbc.M207251200	http://dx.doi.org/10.1074/jbc.M207251200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12464619	hybrid, Green Published			2022-12-25	WOS:000180869700052
J	Schneider, D; Engelman, DM				Schneider, D; Engelman, DM			GALLEX, a measurement of heterologous association of transmembrane helices in a biological membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; ESCHERICHIA-COLI; GENETIC SYSTEM; ALPHA-HELICES; DNA-BINDING; IN-VIVO; DIMERIZATION; MOTIF; LEXA; GLYCOPHORIN	Whereas a variety of two-hybrid systems are available to measure the interaction of soluble proteins, related methods are significantly less developed for the measurement of membrane protein interactions. Here we present a two-hybrid system to follow the heterodimerization of membrane proteins in the Escherichia coli inner membrane. The method is based on the repression of a reporter gene activity by two LexA DNA binding domains with different DNA binding specificities. When coupled to transmembrane domains, heterodimeric association is reported by repression of beta-galactosidase synthesis. The LexA-transmembrane chimeric proteins were found to correctly insert into the membrane, and reproducible signals were obtained measuring the homodimerization as well as heterodimerization of wildtype and mutant glycophorin A transmembrane helices. The GALLEX data were compared with data recently gained by other methods and discussed in the general context of heteroassociation of single TM helices. Additionally, the formation of heterodimers between the TM domains of the alpha(4) and the beta(7) integrin subunits were tested. The results show that both homo- and heterodimerization of membrane proteins can be measured accurately using the GALLEX system.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Engelman, DM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114, New Haven, CT 06520 USA.				NIGMS NIH HHS [P01 GM54160] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM054160] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brosig B, 1998, PROTEIN SCI, V7, P1052; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; Daines DA, 2000, J BACTERIOL, V182, P5267, DOI 10.1128/JB.182.18.5267-5270.2000; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Dmitrova M, 1998, MOL GEN GENET, V257, P205; Dunnwald M, 1999, MOL BIOL CELL, V10, P329, DOI 10.1091/mbc.10.2.329; Ehrhard KN, 2000, NAT BIOTECHNOL, V18, P1075, DOI 10.1038/80274; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fleishman SJ, 2002, J MOL BIOL, V321, P363, DOI 10.1016/S0022-2836(02)00590-9; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; KOLMAR H, 1995, EMBO J, V14, P3895, DOI 10.1002/j.1460-2075.1995.tb00061.x; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; Leeds JA, 2001, J MOL BIOL, V313, P181, DOI 10.1006/jmbi.2001.5007; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Massaad MJ, 2001, J CELL SCI, V114, P4629; PORTE D, 1995, J BIOL CHEM, V270, P22721, DOI 10.1074/jbc.270.39.22721; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNARR M, 1991, BIOCHIMIE, V73, P423, DOI 10.1016/0300-9084(91)90109-E; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	31	105	107	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3105	3111		10.1074/jbc.M206287200	http://dx.doi.org/10.1074/jbc.M206287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12446730	hybrid			2022-12-25	WOS:000180915000044
J	Elkins, JM; Hewitson, KS; McNeill, LA; Seibel, JF; Schlemminger, I; Pugh, CW; Ratcliffe, PJ; Schofield, CJ				Elkins, JM; Hewitson, KS; McNeill, LA; Seibel, JF; Schlemminger, I; Pugh, CW; Ratcliffe, PJ; Schofield, CJ			Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN; RECOGNITION; COMPLEX; ALPHA; HYDROXYPROLINE; HYDROXYLASE; MOLSCRIPT; FAMILY; ENZYME	The activity of the transcription factor hypoxia-inducible factor (HIF) is regulated by oxygen-dependent hydroxylation. Under normoxic conditions, hydroxylation of proline residues triggers destruction of its a-subunit while hydroxylation of Asn(803) in the C-terminal transactivation domain of HIF-1alpha (CAD) prevents its interaction with p300. Here we report crystal structures of the asparagine hydroxylase (factor-inhibiting HIF, FIH) complexed with Fe-(II), 2-oxoglutarate cosubstrate, and CAD fragments, which reveal the structural basis of HIF modification. CAD binding to FIH occurs via an induced fit process at two distinct interaction sites. At the hydroxylation site CAD adopts a loop conformation, contrasting with a helical conformation for the same residues when bound to p300. Asn(803) of CAD is buried and precisely orientated in the active site such that hydroxylation occurs at its beta-carbon. Together with structures with the inhibitors Zn-(II) and N-oxaloylglycine, analysis of the FIH-CAD complexes will assist design of hydroxylase inhibitors with proangiogenic properties. Conserved structural motifs within FIH imply it is one of an extended family of Fe-(II) oxygenases involved in gene regulation.	Univ Oxford, Oxford Ctr Mol Sci, Dyson Perrins Lab, Oxford OX1 3QY, England; Cellular Physiol Grp, Oxford OX3 7BN, England	University of Oxford; University of Oxford	Hewitson, KS (corresponding author), Univ Oxford, Oxford Ctr Mol Sci, Dyson Perrins Lab, S Parks Rd, Oxford OX1 3QY, England.	kirsty.hewitson@chem.ox.ac.uk; christopher.schofield@chem.ox.ac.uk	Seibel, Juergen/A-6908-2015	Seibel, Juergen/0000-0002-8036-4853; Schofield, Christopher/0000-0002-0290-6565; Pugh, Chris/0000-0002-5170-1662; Elkins, Jon/0000-0003-2858-8929; Ratcliffe, Peter/0000-0002-2853-806X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Fusetti F, 2002, STRUCTURE, V10, P259, DOI 10.1016/S0969-2126(02)00704-9; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6; Zhou J, 2001, J AM CHEM SOC, V123, P7388, DOI 10.1021/ja004025+	29	317	331	4	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1802	1806		10.1074/jbc.C200644200	http://dx.doi.org/10.1074/jbc.C200644200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12446723	hybrid			2022-12-25	WOS:000180462200058
J	Wandall, HH; Pedersen, JW; Park, C; Levery, SB; Pizette, S; Cohen, SM; Schwientek, T; Clausen, H				Wandall, HH; Pedersen, JW; Park, C; Levery, SB; Pizette, S; Cohen, SM; Schwientek, T; Clausen, H			Drosophila egghead encodes beta 1,4-mannosyltransferase predicted to form the immediate precursor glycosphingolipid substrate for brainiac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; COMPLEX GANGLIOSIDES; FRINGE; GLYCOSYLATION; CLONING; ALPHA; NOTCH; MICE; GLYCOSYLTRANSFERASES; MELANOGASTER	The neurogenic Drosophila genes brainiac and egghead are essential for epithelial development in the embryo and in oogenesis. Analysis of egghead and brainiac mutants has led to the suggestion that the two genes function in a common signaling pathway. Recently, brainiac was shown to encode a UDP-N-acetylglucosamine:betaManbeta1,3-N-acetylglucosaminyltransferase (beta3GlcNAc-transferase) tentatively assigned a key role in biosynthesis of arthroseries glycosphingolipids and forming the trihexosylceramide, GlcNAcbeta1-3Manbeta1-4Glc:beta1-1Cer. In the present study we demonstrate that egghead encodes a Golgi-located GDP-mannose:betaGlcbeta1,4-mannosyltransferase tentatively assigned a biosynthetic role to form the precursor arthroseries glycosphingolipid substrate for Brainiac, Manbeta1-4Glcbeta1-1Cer. Egghead is unique among eukaryotic glycosyltransferase genes in that homologous genes are limited to invertebrates, which correlates with the exclusive existence of arthroseries glycolipids in invertebrates. We propose that brainiac and egghead function in a common biosynthetic pathway and that inactivating mutations in either lead to sufficiently early termination of glycolipid biosynthesis to inactivate essential functions mediated by glycosphingolipids.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Copenhagen; University System Of New Hampshire; University of New Hampshire; European Molecular Biology Laboratory (EMBL)	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.		Cohen, Stephen M/G-9930-2011; clausen, henrik/AAD-8016-2021	Cohen, Stephen M/0000-0003-2858-9163; Wandall, Hans H./0000-0003-0240-9232; Clausen, Henrik/0000-0002-0915-5055	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016459, P41RR005351] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR05351, P20 RR16459] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bulik DA, 2002, BBA-GEN SUBJECTS, V1573, P247, DOI 10.1016/S0304-4165(02)00391-4; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Chiavegatto S, 2000, EXP NEUROL, V166, P227, DOI 10.1006/exnr.2000.7504; GOODE S, 1992, DEVELOPMENT, V116, P177; Goode S, 1996, DEVELOPMENT, V122, P3863; Goode S, 1996, DEV BIOL, V178, P35, DOI 10.1006/dbio.1996.0196; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; Hellberg A, 2002, J BIOL CHEM, V277, P29455, DOI 10.1074/jbc.M203047200; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Inoue M, 2002, J BIOL CHEM, V277, P29881, DOI 10.1074/jbc.M201631200; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Lee JH, 2001, J BIOL CHEM, V276, P13924, DOI 10.1074/jbc.M010046200; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Muller R, 2002, J BIOL CHEM, V277, P32417, DOI 10.1074/jbc.C200381200; Okada M, 2002, J BIOL CHEM, V277, P1633, DOI 10.1074/jbc.C100395200; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Rubsam R, 1998, MECH DEVELOP, V72, P131, DOI 10.1016/S0925-4773(98)00023-9; Schwientek T, 2002, J BIOL CHEM, V277, P32421, DOI 10.1074/jbc.M206213200; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8	31	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1411	1414		10.1074/jbc.C200619200	http://dx.doi.org/10.1074/jbc.C200619200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12454022	hybrid			2022-12-25	WOS:000180462200007
J	Rahaman, SO; Harbor, PC; Chernova, O; Barnett, GH; Vogelbaum, MA; Haque, SJ				Rahaman, SO; Harbor, PC; Chernova, O; Barnett, GH; Vogelbaum, MA; Haque, SJ			Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells	ONCOGENE			English	Article						glioblastoma; Jak-Stat signal transduction; apoptosis; IL-6; Stat3	HUMAN-BRAIN; CONFERS RESISTANCE; MALIGNANT GLIOMA; IL-6 FAMILY; JAK-STAT; ACTIVATION; RECEPTOR; GENE; PROTEIN; GROWTH	Glioblastoma multiforme (GBM), the most common and malignant central nervous system tumor in humans, is highly proliferative and resistant to apoptosis. Stat3, a latent transcription factor being activated by aberrant cytokine or growth factor signaling, acts as a suppressor of apoptosis in a number of cancer cells. Here we report that GBM tumors and cell lines contain high levels of constitutively activated Stat3 when compared with normal human astrocytes, white matter, and normal tissue adjacent to tumor. The persistent activation of Stat3 is in part, attributable to an autocrine action of interleukin-6 in the GBM cell tine U251. Janus kinase inhibitor AG490 inhibits Stat3 activation with a concomitant reduction in steady-state levels of Bcl-X-L, Bcl-2 and Mel-1 proteins and induces apoptosis in U251 cells as revealed by Poly (ADP-ribose) polymerase cleavage and Annexin-V staining. Expression of a dominant negative mutant Stat3 protein or treatment with AG490 markedly reduces the proliferation of U251 cells by inhibiting the constitutive activation of Stat3. These results provide evidence that constitutive activation of Stat3 contributes to the pathogenesis of glioblastoma by promoting both proliferation and survival of GBM cells. Therefore, targeting Stat3 signaling may provide a potential therapeutic intervention for GBM.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Haque, SJ (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, NB-40,9500 Euclid Ave, Cleveland, OH 44195 USA.	haquej@ccf.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060533] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM60533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badache A, 2001, CANCER RES, V61, P383; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Goswami S, 1998, J NEUROCHEM, V71, P1837; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Halfter H, 2000, MOL BRAIN RES, V80, P198, DOI 10.1016/S0169-328X(00)00162-5; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Ichimura K, 2000, CANCER RES, V60, P417; Ivanchuk SM, 2001, J NEURO-ONCOL, V51, P219, DOI 10.1023/A:1010632309113; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levin Victor A., 1997, P2022; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lilja A, 2001, INT J ONCOL, V19, P495; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Paillaud E, 2002, J NEUROSCI RES, V67, P670, DOI 10.1002/jnr.10110; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Prados Michael D., 2000, Seminars in Oncology, V27, P1; Rahaman SO, 2002, CANCER RES, V62, P1103; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun S, 2002, J GEN VIROL, V83, P1651, DOI 10.1099/0022-1317-83-7-1651; Tchirkov A, 2001, BRIT J CANCER, V85, P518, DOI 10.1054/bjoc.2001.1942; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN MEIR E, 1990, CANCER RES, V50, P6683; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	51	298	324	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8404	8413		10.1038/sj.onc.1206047	http://dx.doi.org/10.1038/sj.onc.1206047			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466961				2022-12-25	WOS:000179480100004
J	Cadoret, A; Ovejero, C; Terris, B; Souil, E; Levy, L; Lamers, WH; Kitajewski, J; Kahn, A; Perret, C				Cadoret, A; Ovejero, C; Terris, B; Souil, E; Levy, L; Lamers, WH; Kitajewski, J; Kahn, A; Perret, C			New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism	ONCOGENE			English	Article						beta-catenin; hepatocellular carcinoma; glutamine synthetase; ornithine aminotransferase; glutamate transporter GLT-1	HEPATOCELLULAR CARCINOMAS; TRANSGENIC MICE; T-ANTIGEN; C-MYC; SYNTHETASE; CANCER; CELLS; EXPRESSION; MUTATIONS; GENE	Inappropriate activation of the Wnt/beta-catenin signaling has been implicated in the development of hepatocellular carcinoma (HCC), but exactly how beta-catenin works remains to be elucidated. To identify, in vivo, the target genes of beta-catenin in the liver, we have used the suppression subtractive hybridization technique and transgenic mice expressing an activated beta-catenin in the liver that developed hepatomegaly. We identified three genes involved in glutamine metabolism, encoding glutamine synthetase (GS), ornithine aminotransferase (OAT) and the glutamate transporter GLT-1. By Northern blot and immunohistochemical analysis we demonstrated that these three genes were specifically induced by activation of the beta-catenin pathway in the liver. In different mouse models bearing an activated beta-catenin signaling in the liver known to be associated with hepatocellular proliferation we observed a marked up-regulation of these three genes. The cellular distribution of GS and GLT-1 parallels beta-catenin activity. By contrast no up-regulation of these three genes was observed in the liver in which hepatocyte proliferation was induced by a signal-independent of beta-catenin. In addition, the GS promoter was activated in the liver of GS(+/LacZ) mice by adenovirus vector-mediated beta-catenin overexpression. Strikingly, the overexpression of the GS gene in human HCC samples was strongly correlated with beta-catenin activation. Together, our results indicate that GS is a target of the Wnt/beta-catenin pathway in the liver. Because a linkage of the glutamine pathway to hepatocarcinogenesis has already been demonstrated, we propose that regulation of these three genes of glutamine metabolism by beta-catenin is a contributing factor to liver carcinogenesis.	Univ Paris 05, Dept Genet Dev & Pathol Mol, INSERM U567, CNRS UMR 8104,Inst Cochin, F-75014 Paris, France; Hop Cochin, Serv Anatomopathol, F-75014 Paris, France; Inst Pasteur, INSERM, U163, F-75015 Paris, France; Univ Amsterdam, Acad Med Ctr, AMC Liver Ctr, NL-1105 BK Amsterdam, Netherlands; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Amsterdam; Academic Medical Center Amsterdam; Columbia University; Columbia University	Perret, C (corresponding author), Univ Paris 05, Dept Genet Dev & Pathol Mol, INSERM U567, CNRS UMR 8104,Inst Cochin, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Perret-Mayeux, Christine/L-3297-2017; Cadoret, Axelle/L-2529-2017; Terris, Benoit/P-1497-2017; LEVY, Laurence/AAF-5672-2021; Lamers, Wouter H./D-2965-2012	Cadoret, Axelle/0000-0002-4283-6864; perret, christine/0000-0003-4710-7051				Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cadoret A, 2001, CANCER RES, V61, P3245; CHRISTA L, 1994, GASTROENTEROLOGY, V106, P1312, DOI 10.1016/0016-5085(94)90024-8; de la Coste A, 1999, CANCER RES, V59, P5017; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Ferry N, 1998, HUM GENE THER, V9, P1975, DOI 10.1089/hum.1998.9.14-1975; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; GEBHARDT R, 1995, CARCINOGENESIS, V16, P1673; Harada N, 2002, CANCER RES, V62, P1971; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Koch A, 1999, CANCER RES, V59, P269; KOVACEVIC Z, 1983, PHYSIOL REV, V63, P547, DOI 10.1152/physrev.1983.63.2.547; KUO FC, 1991, MOL CELL BIOL, V11, P6050, DOI 10.1128/MCB.11.12.6050; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Osada T, 2000, J HEPATOL, V33, P247, DOI 10.1016/S0168-8278(00)80365-7; Palos TP, 1999, J NEUROCHEM, V73, P1012, DOI 10.1046/j.1471-4159.1999.0731012.x; Polakis P, 2000, GENE DEV, V14, P1837; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umeda T, 2000, INT J ONCOL, V16, P1133; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	26	315	328	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8293	8301		10.1038/sj.onc.1206118	http://dx.doi.org/10.1038/sj.onc.1206118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447692				2022-12-25	WOS:000179323900007
J	Liu, LT; Chang, HC; Chiang, LC; Hung, WC				Liu, LT; Chang, HC; Chiang, LC; Hung, WC			Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells	ONCOGENE			English	Article						RECK; NSAIDs; lung cancer	MATRIX METALLOPROTEINASES; GENE-EXPRESSION; INHIBITORS; INVASION; ASPIRIN; METASTASIS; TISSUE; COLON	Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to exert anti-angiogenic and anti-metastatic activity both in vitro and in vivo. Block of angiogenesis and metastasis by NSAlDs has been found to be mediated partly via suppression of matrix metalloproteinase (MMP) activity. However, the molecular mechanism of this inhibitory action has not been well defined. Recent works demonstrated that a membrane-anchored MMP inhibitor RECK may potently suppress MMP-2 and -9 activity to inhibit angiogenesis and metastasis in vitro and in vivo. In this study, we test the possibility that NSAlDs may up-regutate RECK to inhibit MMP activity. RT-PCR analyses showed that NS398 and aspirin up-regulated RECK mRNA level in CL-1 human lung cancer cells. Additionally, NSAIDs increased RECK protein level as detected by immuno-blotting. Since RECK is a membrane-anchored glycoprotein, we also performed immunofluorescent staining to assess the expression of RECK on cell surface. Our results showed that fluorescent intensity of RECK was obviously increased after NSAID treatment. Moreover, induction of RECK by NSAlDs was associated with reduction of MMP-2 activity. We also found that NSAID-activated RECK expression might not be mediated via inhibition of cyclo-oxygenases (COXs) because addition of prostaglandin E-2 (PGE(2)) could not counteract the effect of NSAIDs and overexpression of COX-2 could not down-regulate RECK. Taken together, our results suggest that induction of RECK expression may be one of the mechanisms by which NSAlDs suppress MMP activity to block angiogenesis and metastasis.	Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Physiol, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Microbiol, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.		Chiang, Lien-Chai/A-1327-2010	Liu, Li-Teh/0000-0002-7993-7263				Akhmedkhanov A, 2002, BRIT J CANCER, V87, P49, DOI 10.1038/sj.bjc.6600370; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chen JJW, 2001, CANCER RES, V61, P5223; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048; FUTAKI N, 1993, J PHARM PHARMACOL, V45, P753, DOI 10.1111/j.2042-7158.1993.tb07103.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Masferrer JL, 2000, CANCER RES, V60, P1306; MEREDITH TJ, 1992, THERAPEUTIC APPL NSA, P67; NELSON C, 1995, J NATL CANCER I, V87, P567, DOI 10.1093/jnci/87.8.567; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Pan MR, 2001, FEBS LETT, V508, P365, DOI 10.1016/S0014-5793(01)03118-0; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400	23	29	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8347	8350		10.1038/sj.onc.1206017	http://dx.doi.org/10.1038/sj.onc.1206017			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447698				2022-12-25	WOS:000179323900013
J	Yatabe, Y; Osada, H; Tatematsu, Y; Mitsudomi, T; Takahashi, T				Yatabe, Y; Osada, H; Tatematsu, Y; Mitsudomi, T; Takahashi, T			Decreased expression of 14-3-3 sigma in neuroendocrine tumors is independent of origin and malignant potential	ONCOGENE			English	Article						14-3-3 sigma; stratifin; small cell lung cancer; carcinoid; stem cell	CELL LUNG-CANCER; BREAST-CANCER; CARCINOID-TUMORS; P53 MUTATIONS; PROGNOSTIC-SIGNIFICANCE; TRANSGENIC MICE; GENE-MUTATIONS; DNA-DAMAGE; STEM-CELLS; P73 GENE	We recently reported that 14-3-3sigma is frequently inactivated in small cell lung cancer (SCLC) and a part of large cell carcinomas. Subsequent studies revealed that the large cell carcinomas could be morphologically categorized as large cell neuroendocrine carcinomas (LCNEC). The present study therefore examines 14-3-3sigma expression in a spectrum of neuroendocrine lung tumors, which had varied p53 status, proliferative activity and clinical aggressiveness. The expression of 14-3-3sigma was decreased in all four categories of the spectrum, (5 out of 5 typical carcinoids, 2 out of 2 atypical carcinoids, 5 out of 7 LCNECs and 15 out of 18 SCLCs). In sharp contrast, the level of 14-3-3sigma expression in 75 non-small cell lung cancers (NSCLCs) was the same as that in normal lung tissue, with only one exception. The expression status of neuroendocrine tumors and NSCLCs was not affected by p53 status, but dense promoter hypermethylation of the 14-3-3sigma gene was specifically observed in neuroendocrine tumors, suggesting that methylation plays a regulatory role in 14-3-3sigma expression in vivo as well as in vitro. Furthermore, the expression was not only down-regulated in pulmonary neuroendocrine tumors, but also in neuroendocrine tumors arising from various other organs, through examination of 123 non-pulmonary tumors. Since various carcinogenic machineries are involved in the neuroendocrine tumors, a reduced expression of 14-3-3sigma might be required for the development of neuroendocrine tumors. Constitutive 14-3-3sigma expression was distributed exclusively in putative stem cells of the normal lung, namely the basal cells of the bronchus, and type 11 pneumocytes. Notably, 14-3-3sigma expression was up-regulated during the regeneration of type 11 pneumocytes, suggesting that 14-3-3sigma plays a biological role when a regenerative and/or differentiating drive is activated, facilitating exit from stem cells.	Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Yatabe, Y (corresponding author), Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Anbazhagan R, 1999, CANCER RES, V59, P5119; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Boers JE, 1998, AM J RESP CRIT CARE, V157, P2000, DOI 10.1164/ajrccm.157.6.9707011; Brambilla E, 1996, AM J PATHOL, V149, P1941; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; COLBY TV, 1995, TUMORS LOWER RESP TR; Corn PG, 1999, CANCER RES, V59, P3352; Debelenko LV, 2000, GENE CHROMOSOME CANC, V28, P58, DOI 10.1002/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2; Debelenko LV, 1997, GASTROENTEROLOGY, V113, P773, DOI 10.1016/S0016-5085(97)70171-9; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; DELLAMBRA E, 1995, J CELL SCI, V108, P3569; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Dosaka-Akita H, 2000, CANCER, V88, P550, DOI 10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D; Endl E, 2001, J PATHOL, V195, P457, DOI 10.1002/path.978; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Galanis E, 1997, CANCER-AM CANCER SOC, V79, P1729, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1729::AID-CNCR14>3.0.CO;2-#; GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Gruvberger S, 2001, CANCER RES, V61, P5979; Haruki N, 2000, JPN J CANCER RES, V91, P317, DOI 10.1111/j.1349-7006.2000.tb00947.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hida T, 1998, CANCER RES, V58, P3761; Hoos A, 2001, LAB INVEST, V81, P1331, DOI 10.1038/labinvest.3780347; HORIO Y, 1993, CANCER RES, V53, P1; IBRAHIM NBN, 1984, CANCER-AM CANCER SOC, V54, P1645, DOI 10.1002/1097-0142(19841015)54:8<1645::AID-CNCR2820540828>3.0.CO;2-Q; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Konishi H, 2002, CANCER RES, V62, P271; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; LOHMANN DR, 1993, CANCER RES, V53, P5797; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MILLER CW, 1992, CANCER RES, V52, P1695; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURREN J, 2001, CANC PRINCIPLES PRAC, P1010; Nishio M, 1997, CLIN CANCER RES, V3, P1051; Nomoto S, 1998, CANCER RES, V58, P1380; Onuki N, 1999, CANCER, V85, P600, DOI 10.1002/(SICI)1097-0142(19990201)85:3<600::AID-CNCR10>3.0.CO;2-W; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Ostergaard M, 1997, CANCER RES, V57, P4111; Padberg BC, 1996, AM J SURG PATHOL, V20, P815, DOI 10.1097/00000478-199607000-00004; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Przygodzki RM, 1996, AM J PATHOL, V148, P1531; Ramnani DM, 1999, MODERN PATHOL, V12, P443; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sampietro G, 2000, APPL IMMUNOHISTO M M, V8, P49, DOI 10.1097/00022744-200003000-00008; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sturm N, 2002, HUM PATHOL, V33, P175, DOI 10.1053/hupa.2002.31299; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; Travis W, 1999, HISTOLOGICAL TYPING, P7; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; VERHAGEN APM, 1992, CANCER RES, V52, P6182; WILLIAMS ED, 1963, LANCET, V1, P238; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998; Yatabe Y, 1998, CANCER RES, V58, P1042; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	70	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8310	8319		10.1038/sj.onc.1206014	http://dx.doi.org/10.1038/sj.onc.1206014			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447694				2022-12-25	WOS:000179323900009
J	Soderdahl, T; Enoksson, M; Lundberg, M; Holmgren, A; Ottersen, OP; Orrenius, S; Bolcsfoldi, G; Cotgreave, IA				Soderdahl, T; Enoksson, M; Lundberg, M; Holmgren, A; Ottersen, OP; Orrenius, S; Bolcsfoldi, G; Cotgreave, IA			Visualization of the compartmentalization of glutathione and protein-glutathione mixed disulfides in cultured cells	FASEB JOURNAL			English	Article						confocal microscopy; FACS; mitochondria; nucleus; diamide	S-THIOLATION; OXIDATIVE STRESS; HEPATOCYTES; MITOCHONDRIAL; SULFHYDRYLS; MENADIONE; DEPLETION	Fluorescence microscopy of A549 cells stained with a glutathione (L-gamma-glutamyl-L-cysteinylglycine, GSH)-specific polyclonal antibody displayed uniform staining of the perinuclear cytosol, with the nuclear region apparently lacking GSH staining. This discontinuous staining was confirmed in other cell types and also corroborated in A549 cells stained with the thiol-reactive dye mercury orange. The selectivity of antibody binding was confirmed by buthionine sulfoximine (BSO)-dependent inhibition of GSH synthesis. However, confocal visualization of antibody-stained A549 cells in the z-plane revealed the majority of the perinuclear staining intensity in the upper half of the cell to be associated with mitochondria, as confirmed by double staining for cytochrome oxidase. Integration of the confocal signals from the nuclear and cytosolic regions halfway down the z-plane showed that the GSH concentrations of these compartments are close to equilibrium. Confirmation of the relatively high levels of mitochondrial glutathione was provided in cells treated with BSO and visualized in z-section, revealing the mitochondrial GSH content of these cells to be well preserved in apposition to near-complete depletion of cytosolic/nuclear GSH. Localized gradients within the cytosolic compartment were also visible, particularly in the z-plane. The antibody also provided initial visualization of the compartmentalization of protein-GSH mixed disulfides formed in A549 cells exposed to diamide. Discontinuous staining was again evident, with heavy staining in membrane blebs and in the nuclear region. Using FACS analysis of anti-GSH antibody-stained Jurkat T lymhocytes, we also demonstrated population variations in the cellular compliment of GSH and protein-GSH mixed disulfides, formed in response to diamide. In addition, we showed cell-cycle variation in GSH content of the cells, with the highest levels of GSH associated with the G2/M mitotic phase of the cell cycle, using double staining with propidium iodide. Similar FACS analyses performed in isolated mitochondria presented a considerable variation in GSH content within mitochondria of uniform granularity from the same preparation.	Karolinska Inst, Inst Environm Med, Div Biochem Toxicol, S-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Div Toxicol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, Div Biochem, S-17177 Stockholm, Sweden; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway; AstraZeneca R&D Sodertalje, Safety Assessment, Dept Genet Toxicol, S-15185 Sodertalje, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Oslo; AstraZeneca	Cotgreave, IA (corresponding author), Karolinska Inst, Inst Environm Med, Div Biochem Toxicol, Box 210, S-17177 Stockholm, Sweden.	Ian.Cotgreave@Imm.ki.se						ATZORI L, 1990, J CELL PHYSIOL, V143, P165, DOI 10.1002/jcp.1041430123; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; BRITTEN RA, 1991, BIOCHEM PHARMACOL, V41, P647, DOI 10.1016/0006-2952(91)90642-I; BRIVIBA K, 1993, BIOCHEM J, V294, P631, DOI 10.1042/bj2940631; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHAI YC, 1991, ARCH BIOCHEM BIOPHYS, V284, P270, DOI 10.1016/0003-9861(91)90295-T; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; Cotgreave IA, 2002, FASEB J, V16, P435, DOI 10.1096/fj.01-0685fje; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; HJELLE OP, 1994, EUR J NEUROSCI, V6, P793, DOI 10.1111/j.1460-9568.1994.tb00990.x; Huster D, 1998, ANAT EMBRYOL, V198, P277, DOI 10.1007/s004290050184; JEVTOVICTODOROVIC V, 1992, BIOCHEM PHARMACOL, V44, P1383, DOI 10.1016/0006-2952(92)90540-Y; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEREDITH MJ, 1982, J BIOL CHEM, V257, P3747; MIRABELLI F, 1988, ARCH BIOCHEM BIOPHYS, V264, P261, DOI 10.1016/0003-9861(88)90593-0; Ramirez-Leon V, 1999, EUR J NEUROSCI, V11, P2935, DOI 10.1046/j.1460-9568.1999.00710.x; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; ROMERO FJ, 1984, EXPERIENTIA, V40, P365, DOI 10.1007/BF01952555; ROMERO FJ, 1984, BIOCHEM BIOPH RES CO, V123, P1116, DOI 10.1016/S0006-291X(84)80248-X; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SCHUPPEKOISTINE.I, 1995, ENDOTHELIUM, V3, P301; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; TAYLOR CW, 1973, EXP CELL RES, V82, P215, DOI 10.1016/0014-4827(73)90264-4; THOMAS M, 1995, BRIT J CANCER, V72, P45, DOI 10.1038/bjc.1995.275; TIRMENSTEIN MA, 1988, BIOCHEM BIOPH RES CO, V155, P956, DOI 10.1016/S0006-291X(88)80589-8; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956	29	86	88	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					124	+		10.1096/fj.02-0259fje	http://dx.doi.org/10.1096/fj.02-0259fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475911				2022-12-25	WOS:000180218500016
J	Varani, K; Abbracchio, MP; Cannella, M; Cislaghi, G; Giallonardo, P; Mariotti, C; Cattabriga, E; Cattabeni, F; Borea, PA; Squitieri, F; Cattaneo, E				Varani, K; Abbracchio, MP; Cannella, M; Cislaghi, G; Giallonardo, P; Mariotti, C; Cattabriga, E; Cattabeni, F; Borea, PA; Squitieri, F; Cattaneo, E			Aberrant A(2A) receptor function in peripheral blood cells in Huntington's disease	FASEB JOURNAL			English	Article						A(2A) adenosine receptor; blood circulating cells; Huntington's disease; biomarker	ADENOSINE RECEPTORS; LIGAND-BINDING; BIOCHEMICAL-CHARACTERIZATION; NEURODEGENERATIVE DISEASE; MEMBRANES; LYMPHOCYTES; MECHANISM; STRIATUM; SYSTEMS; MODELS	A(2A) adenosine receptors specifically found on striatal medium spiny neurons play a major role in sensory motor function and may also be involved in neuropsychiatric and neurodegenerative disorders. One hypothesis concerning Huntington's disease (HD) proposes that an imbalance of the cortico-striatal pathway, due to the mutation in the HD gene, leads to striatal vulnerability. An A(2A) receptor dysfunction has been previously demonstrated in striatal cells engineered to express mutant huntingtin. Here we tested whether a similar dysfunction (i.e., the binding and functional parameters of A(2A) adenosine receptors) is present in peripheral blood cells (platelets, lymphocytes, and neutrophils) of subjects carrying the mutant gene. This study involved 48 heterozygous and three homozygous patients compared with 58 healthy subjects. Moreover, we selected seven at-risk mutation carriers. A(2A) receptor density and function are substantially increased in peripheral blood cells from both patients and subjects at the presymptomatic stage. In the neutrophils of the three homozygous HD subjects receptor dysfunction was higher than in heterozygotes. These data indicate the existence of an aberrant A(2A) receptor phenotype in the peripheral blood cells of subjects carrying the HD mutation. Future studies will assess whether this parameter can be exploited as a peripheral biomarker of Huntington's disease.	IRCCS Neuromed, Neurogenet Unit, I-86077 Pozzilli, IS, Italy; Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, I-44100 Ferrara, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Fornaroli Hosp, Neurol Sect, Magenta, MI, Italy; IRCCS C Besta, Neurogenet Sect, Milan, Italy	IRCCS Neuromed; University of Ferrara; University of Milan; University of Milan	Squitieri, F (corresponding author), IRCCS Neuromed, Neurogenet Unit, Local Camerelle, I-86077 Pozzilli, IS, Italy.	neurogen@neuromed.it; elena.cattaneo@unimi.it	Squitieri, Ferdinando/N-1852-2019; Cannella, Milena/G-8291-2011; Mariotti, Caterina/AAP-9425-2021; Abbracchio, Maria Pia/B-9342-2014	Squitieri, Ferdinando/0000-0002-7397-1727; Mariotti, Caterina/0000-0003-2405-3564; Abbracchio, Maria Pia/0000-0002-7833-3388; CANNELLA, Milena/0000-0001-6284-9374; CATTANEO, ELENA/0000-0002-0755-4917	Telethon [GGP02185] Funding Source: Medline	Telethon(Fondazione Telethon)		Abbracchio MP, 1999, ANN NY ACAD SCI, V890, P79, DOI 10.1111/j.1749-6632.1999.tb07983.x; Barbanti P, 2000, CEPHALALGIA, V20, P15, DOI 10.1046/j.1468-2982.2000.00001.x; BENJAMIN CM, 1994, AM J HUM GENET, V55, P606; BLUM D, 2003, LANCET, V362, P366; Cannella M, 2001, NEUROL SCI, V22, P55, DOI 10.1007/s100720170044; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Cha JHJ, 1999, PHILOS T R SOC B, V354, P981, DOI 10.1098/rstb.1999.0449; Di Luca M, 1998, ARCH NEUROL-CHICAGO, V55, P1195, DOI 10.1001/archneur.55.9.1195; Draper N.R., 1998, APPL REGRESSION ANAL, P79; FERRE S, 1993, J NEUROSCI, V13, P5402, DOI 10.1523/JNEUROSCI.13-12-05402.1993; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Ilani T, 2001, P NATL ACAD SCI USA, V98, P625, DOI 10.1073/pnas.021535398; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; Lawrence AD, 1998, BRAIN, V121, P1343, DOI 10.1093/brain/121.7.1343; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAGGI R, 1993, PHARMACOL RES, V28, P351, DOI 10.1006/phrs.1993.1137; MARTINEZMIR MI, 1991, NEUROSCIENCE, V42, P697, DOI 10.1016/0306-4522(91)90038-P; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARSONS B, 1995, J NEUROCHEM, V65, P2057; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Rovati GE, 1998, TRENDS PHARMACOL SCI, V19, P365; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Seubert CN, 2000, ANESTHESIOLOGY, V92, P567, DOI 10.1097/00000542-200002000-00041; Sipione S, 2001, MOL NEUROBIOL, V23, P21; Squitieri F, 2001, BRAIN RES BULL, V56, P233, DOI 10.1016/S0361-9230(01)00648-7; SQUITIERI F, 1994, HUM MOL GENET, V3, P2103, DOI 10.1093/hmg/3.12.2103; Squitieri F, 2003, BRAIN, V126, P946, DOI 10.1093/brain/awg077; Ujfalusi A, 1998, LIFE SCI, V64, pPL19, DOI 10.1016/S0024-3205(98)00547-5; Varani K, 2000, MOL PHARMACOL, V57, P968; Varani K, 1998, BRIT J PHARMACOL, V123, P1723, DOI 10.1038/sj.bjp.0701758; Varani K, 1996, BRIT J PHARMACOL, V117, P1693, DOI 10.1111/j.1476-5381.1996.tb15341.x; Varani K, 1999, BRIT J CLIN PHARMACO, V47, P167, DOI 10.1046/j.1365-2125.1999.00866.x; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Varani K, 2001, FASEB J, V15, P1245, DOI 10.1096/fj.00-0730fje; Varani K, 1997, BRIT J PHARMACOL, V122, P386, DOI 10.1038/sj.bjp.0701378; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369	39	122	126	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2148	+		10.1096/fj.03-0079fje	http://dx.doi.org/10.1096/fj.03-0079fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958155				2022-12-25	WOS:000185925100018
